PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Richardson, DS; Komdeur, J; Burke, T				Richardson, DS; Komdeur, J; Burke, T			Altruism and infidelity among warblers	NATURE			English	Article							ACROCEPHALUS-SECHELLENSIS; SEYCHELLES		Univ Sheffield, Dept Anim & Plant Sci, Sheffield S10 2TN, S Yorkshire, England; Lund Univ, Dept Anim Ecol, S-22362 Lund, Sweden; Univ Groningen, Zool Lab, NL-9750 AA Haren, Netherlands; Univ Melbourne, Dept Zool, Parkville, Vic 3010, Australia	University of Sheffield; Lund University; University of Groningen; University of Melbourne	Richardson, DS (corresponding author), Univ Sheffield, Dept Anim & Plant Sci, Sheffield S10 2TN, S Yorkshire, England.		Komdeur, Jan/X-1261-2019; Richardson, David S/A-5082-2010; Burke, Terry/B-3196-2011	Komdeur, Jan/0000-0002-9241-0124; Richardson, David S/0000-0001-7226-9074; Burke, Terry/0000-0003-3848-1244				EMLEN ST, 1995, P NATL ACAD SCI USA, V92, P8092, DOI 10.1073/pnas.92.18.8092; Goodnight KF, 1999, MOL ECOL, V8, P1231, DOI 10.1046/j.1365-294x.1999.00664.x; HAMILTON WD, 1964, J THEOR BIOL, V7, P1, DOI [10.1016/0022-5193(64)90038-4, 10.1016/0022-5193(64)90039-6]; Hatchwell BJ, 2001, P ROY SOC B-BIOL SCI, V268, P885, DOI 10.1098/rspb.2001.1598; Komdeur J, 1996, P ROY SOC B-BIOL SCI, V263, P661, DOI 10.1098/rspb.1996.0099; KOMDEUR J, 1994, P ROY SOC B-BIOL SCI, V256, P47, DOI 10.1098/rspb.1994.0047; KOMDEUR J, 1994, BEHAV ECOL SOCIOBIOL, V34, P175, DOI 10.1007/BF00167742; Richardson DS, 2001, MOL ECOL, V10, P2263, DOI 10.1046/j.0962-1083.2001.01355.x; Richardson DS, 2002, EVOLUTION, V56, P2313; Russell AF, 2001, P ROY SOC B-BIOL SCI, V268, P2169, DOI 10.1098/rspb.2001.1790	10	49	50	0	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 10	2003	422	6932					580	580		10.1038/422580a	http://dx.doi.org/10.1038/422580a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	665GN	12686989	Green Published			2022-12-28	WOS:000182111400029
J	Lusk, C				Lusk, C			Tree-species competition and coexistence	NATURE			English	Article							NEOTROPICAL FOREST; NEW-ZEALAND; HISTORY		Univ Concepcion, Dept Bot, Concepcion, Chile	Universidad de Concepcion	Lusk, C (corresponding author), Univ Concepcion, Dept Bot, Casilla 160-C, Concepcion, Chile.	clusk@udec.cl	Komdeur, Jan/X-1261-2019; Richardson, David S/A-5082-2010; Burke, Terry/B-3196-2011	Komdeur, Jan/0000-0002-9241-0124; Richardson, David S/0000-0001-7226-9074; Burke, Terry/0000-0003-3848-1244				CHESSON PL, 1981, AM NAT, V117, P923, DOI 10.1086/283778; Harms KE, 2001, J ECOL, V89, P947, DOI 10.1111/j.1365-2745.2001.00615.x; Harper J. L, 1977, POPULATION BIOL PLAN; Hubbell SP, 1999, SCIENCE, V283, P554, DOI 10.1126/science.283.5401.554; Kelly CK, 2002, NATURE, V417, P437, DOI 10.1038/417437a; LIEBERMAN M, 1995, J TROP ECOL, V11, P161, DOI 10.1017/S0266467400008609; LORIMER CG, 1985, CAN J FOREST RES, V15, P200, DOI 10.1139/x85-038; LUSK C, 1992, J ECOL, V80, P379, DOI 10.2307/2260684; OGDEN J, 1981, J BIOGEOGR, V8, P405, DOI 10.2307/2844759; STEWART GH, 1990, VEGETATIO, V87, P101, DOI 10.1007/BF00042947	10	49	50	0	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 10	2003	422	6932					580	581		10.1038/422580b	http://dx.doi.org/10.1038/422580b			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	665GN	12686989				2022-12-28	WOS:000182111400030
J	Foy, E; Li, K; Wang, CF; Sumpter, R; Ikeda, M; Lemon, SM; Gale, M				Foy, E; Li, K; Wang, CF; Sumpter, R; Ikeda, M; Lemon, SM; Gale, M			Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease	SCIENCE			English	Article							IRF-3; PHOSPHORYLATION; TRANSACTIVATION; LOCALIZATION; INFECTION; DISTINCT; THERAPY; KINASE; PKR	Persistent infections with hepatitis C virus (HCV) are likely to depend on viral inhibition of host defenses. We show that the HCV NS3/4A serine protease blocks the phosphorylation and effector action of interferon regulatory factor -3 (IRF-3), a key cellular antiviral signaling molecule. Disruption of NS3/4A protease function by mutation or a ketoamide peptidomimetic inhibitor relieved this blockade and restored IRF-3 phosphorylation after cellular challenge with an unrelated virus. Furthermore, dominant-negative or constitutively active IRF-3 mutants, respectively, enhanced or suppressed HCV RNA replication in hepatoma cells. Thus, the NS3/4A protease represents a dual therapeutic target, the inhibition of which may both block viral replication and restore IRF-3 control of HCV infection.	Univ Texas, SW Med Ctr, Dept Microbiol, Dallas, TX 75390 USA; Univ Texas, Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Medical Branch Galveston	Gale, M (corresponding author), Univ Texas, SW Med Ctr, Dept Microbiol, Dallas, TX 75390 USA.	Michael.Gale@UTSouthwestern.edu	IKEDA, Masanori/B-2279-2011; Sumpter, Jr., Rhea/N-8152-2018	Gale, Michael/0000-0002-6332-7436	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI048235, U19AI040035] Funding Source: NIH RePORTER; NIAID NIH HHS [U01-AI48235, U19-AI40035] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Barnes B, 2002, J INTERF CYTOK RES, V22, P59, DOI 10.1089/107999002753452665; Blight KJ, 2000, SCIENCE, V290, P1972, DOI 10.1126/science.290.5498.1972; De Francesco R, 2000, CURR TOP MICROBIOL, V242, P149; Farci P, 2002, P NATL ACAD SCI USA, V99, P3081, DOI 10.1073/pnas.052712599; Forns X, 1999, Clin Liver Dis, V3, P693, DOI 10.1016/S1089-3261(05)70234-8; Fredericksen B, 2002, VIRAL IMMUNOL, V15, P29, DOI 10.1089/088282402317340215; Fried MW, 2002, NEW ENGL J MED, V347, P975, DOI 10.1056/NEJMoa020047; Grandvaux N, 2002, J VIROL, V76, P5532, DOI 10.1128/JVI.76.11.5532-5539.2002; Ikeda M, 2002, J VIROL, V76, P2997, DOI 10.1128/JVI.76.6.2997-3006.2002; Katze MG, 2002, NAT REV IMMUNOL, V2, P675, DOI 10.1038/nri888; LEMON SM, UNPUB; Lin RT, 1999, MOL CELL BIOL, V19, P2465; Lin RT, 1998, MOL CELL BIOL, V18, P2986, DOI 10.1128/MCB.18.5.2986; Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110; McHutchison JG, 2002, HEPATOLOGY, V36, pS245, DOI 10.1053/jhep.2002.36795; Nakaya T, 2001, BIOCHEM BIOPH RES CO, V283, P1150, DOI 10.1006/bbrc.2001.4913; Pflugheber J, 2002, P NATL ACAD SCI USA, V99, P4650, DOI 10.1073/pnas.062055699; Reed KE, 1998, CURR STUD HEMATOL BL, P1; Reich NC, 2002, J INTERF CYTOK RES, V22, P103, DOI 10.1089/107999002753452719; Sato M, 2000, IMMUNITY, V13, P539, DOI 10.1016/S1074-7613(00)00053-4; SCHERING CORP CORVAS, 2002, Patent No. 0208244; Sen GC, 2001, ANNU REV MICROBIOL, V55, P255, DOI 10.1146/annurev.micro.55.1.255; Servant MJ, 2001, J BIOL CHEM, V276, P355, DOI 10.1074/jbc.M007790200; Smith EJ, 2001, J BIOL CHEM, V276, P8951, DOI 10.1074/jbc.M008717200; Tai CL, 2001, J VIROL, V75, P8289, DOI 10.1128/JVI.75.17.8289-8297.2001; Taylor DR, 1999, SCIENCE, V285, P107, DOI 10.1126/science.285.5424.107; Yoneyama M, 1998, EMBO J, V17, P1087, DOI 10.1093/emboj/17.4.1087; Zhu NL, 2001, VIROLOGY, V283, P178, DOI 10.1006/viro.2001.0896	28	636	691	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 16	2003	300	5622					1145	1148		10.1126/science.1082604	http://dx.doi.org/10.1126/science.1082604			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678VC	12702807	Green Submitted			2022-12-28	WOS:000182886500046
J	Dunnigan, MG; Pollock, AM				Dunnigan, MG; Pollock, AM			Downsizing of acute inpatient beds associated with private finance initiative: Scotland's case study	BRITISH MEDICAL JOURNAL			English	Article							NHS	Objectives To evaluate whether the projected 24% reduction in acute bed numbers in Lothian hospitals, which formed part of the private finance initiative (PFI) plans for the replacement Royal Infirmary of Edinburgh, is being compensated for by improvements in efficiency and greater use of community facilities, and to ascertain whether there is an independent PFI effect by comparing clinical activity and performance in acute specialties in Lothian hospitals with other NHS hospitals in Scotland. Design Comparison of projected and actual trends in acute bed capacity and inpatient and day case admissions in the first five years (1995-6 to 2000-1) of Lothian Health Board's integrated healthcare plan. Population study of trends in bed rate, hospital activity, length of stay, and throughput in Lothian hospitals compared with the rest of Scotland from 1990-1 to 2000-1. Main outcome measures Staffed bed rates, admission rates, mean lengths of stay, occupancy, and throughput in four adult acute specialty groups in 1990-1,1995-6, and 2000-1. Results By 2000-1, rates for inpatient admission in all acute, medical, surgical, and intensive therapy specialties in Lothian hospitals were respectively 20%, 6%, 28%, and 38% below those in the rest of Scotland. Day case rates in all acute and acute surgical specialties were 13% and 33% lower. The proportion of delayed discharges in staffed acute and post-acute NHS beds in Lothian hospitals exceeded the Scottish average (15% and 12% respectively; P < 0.001). Conclusion The planning targets and increase in clinical activity in acute specialties in Lothian hospitals associated with PFI had not been achieved by 2000-1. The effect on clinical activity has been a steeper decline in the number of acute beds and rates of admission in Lothian hospitals compared with the rest of Scotland between 1995-6 and 2000-1.	UCL, Publ Hlth Policy Unit, Sch Publ Policy, London WC1H 9QU, England	University of London; University College London	Pollock, AM (corresponding author), UCL, Publ Hlth Policy Unit, Sch Publ Policy, London WC1H 9QU, England.	allyson.pollock@ucl.ac.uk		pollock, allyson/0000-0002-7388-3110				*AUD GEN SCOTL, 2003, OV NHS SCOTL; Breslow NE, 1987, STAT METH CANC RES, V2; COATES P, 2000, PUBLIC FINANCE  0825, P16; *COUNT DURH DARL N, 2001, INP WAIT LIST OUTP W; Department of Health, 2000, SHAP FUT NHS LONG TE; DUNNIGAN MG, 1999, HERALD          0301; Gaffney D, 1999, BMJ-BRIT MED J, V319, P48, DOI 10.1136/bmj.319.7201.48; Gaffney D, 1999, BRIT MED J, V319, P116, DOI 10.1136/bmj.319.7202.116; Gaffney D, 1999, BRIT MED J, V319, P249, DOI 10.1136/bmj.319.7204.249; GALBRAITH S, 1999, HERALD          0220; *LOTH HLTH, 1992, AC SERV STRAT PROF C; *LOTH HLTH BOARD, 2000, INT HEALTHC PLAN 199; *LOTH HLTH BOARD, 1996, INT HEALTHC PLAN 199; *MANCH HLTH SERV M, 1996, FUT HEALTHC WORK FOR; MUNRO A, 1994, HLTH B EDINBURGH, V52, P35; Pollock AM, 2000, BRIT MED J, V320, P461, DOI 10.1136/bmj.320.7233.461; Pollock AM, 1999, BMJ-BRIT MED J, V319, P179, DOI 10.1136/bmj.319.7203.179; Pollock AM, 1997, BRIT MED J, V314, P1266, DOI 10.1136/bmj.314.7089.1266; RHIND G, 1999, HERALD          0523; RHIND G, 1999, HERALD          0223; SCAIFE G, 1993, ACCOUNTABILITY REV P; SMITH CA, 1999, MAKING SENSE PRIVATE, P140; WARNER M, 1994, CLOSER HOME HEALTHCA, P1	23	21	21	0	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 26	2003	326	7395					905	908A		10.1136/bmj.326.7395.905	http://dx.doi.org/10.1136/bmj.326.7395.905			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	673WQ	12714469	Bronze, Green Published, Green Accepted			2022-12-28	WOS:000182603600015
J	Smith, G; Wolf, CR; Deeni, YY; Dawe, RS; Evans, AT; Comrie, MM; Ferguson, J; Ibbotson, SH				Smith, G; Wolf, CR; Deeni, YY; Dawe, RS; Evans, AT; Comrie, MM; Ferguson, J; Ibbotson, SH			Cutaneous expression of cytochrome P450CYP2S1: individuality in regulation by therapeutic agents for psoriasis and other skin diseases	LANCET			English	Article							ARYL-HYDROCARBON HYDROXYLASE; RETINOIC ACID; COAL-TAR; GENE-EXPRESSION; THYROID-HORMONE; P450; IDENTIFICATION; INDUCTION; ENZYMES; PHARMACOGENETICS	Background Treatment of common skin diseases such as psoriasis is complicated by differences between individuals in response to topical drug treatment and photochemotherapy. Individuality in hepatic expression of drug-metabolising enzymes is an important determinant of systemic drug handling; we investigated whether similar variation in cutaneous gene expression contributes to individuality in response to topical therapies. Methods We used quantitative real-time RT-PCR to demonstrate the expression in skin of a recently identified cytochrome P450, CYP2S1, in healthy volunteers (n=27) and patients with psoriasis (n=29). We also investigated regulation of CYP2S1 by ultraviolet radiation, psoralen-ultraviolet A (PUVA), and topical drugs used to treat psoriasis. Findings We found that CYP2S1 is expressed in skin and showed pronounced individuality in constitutive expression of the enzyme and its induction after ultraviolet irradiation or topical drug treatment. Cutaneous expression of CYP2S1 was induced by ultraviolet radiation, PUVA, coal tar, and all-trans retinoic acid; expression was significantly higher in lesional psoriatic skin than in adjacent non-lesional skin (geometric mean 3.38 [95% CI 2.64-4.34] times higher; p<0.0001), which implies that topical drugs are differentially metabolised in psoriatic plaque and non-lesional skin. We showed that all-trans retinoic acid is metabolised by CYP2S1, which has higher cutaneous expression than CYP26, previously described as the specific cutaneous P450 retinoic-acid-metabolising enzyme. Interpretation These findings increase our understanding of the interaction between therapeutic agents and the skin and suggest a functional role for CYP2S1 in the metabolism of topical drugs and in mediating the response to photochemotherapy in psoriasis.	Univ Dundee, Ninewells Hosp & Med Sch, Photobiol Unit, Dundee DD1 9SY, Scotland; Univ Dundee, Ninewells Hosp & Med Sch, Biomed Res Ctr, Dundee DD1 9SY, Scotland; Univ Dundee, Ninewells Hosp & Med Sch, Dept Mol & Cellular Pathol, Dundee DD1 9SY, Scotland	University of Dundee; University of Dundee; University of Dundee	Ibbotson, SH (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Photobiol Unit, Dundee DD1 9SY, Scotland.		Dawe, Robert S./H-6830-2019; Ibbotson, Sally H/H-7061-2019	Dawe, Robert S./0000-0002-4732-071X; Ibbotson, Sally H/0000-0001-5685-752X; Deeni, Yusuf Y./0000-0002-8529-7469; Smith, Gillian/0000-0001-9288-7566; Wolf, Charles Roland/0000-0002-6969-0113				Allen RG, 2000, FREE RADICAL BIO MED, V28, P463, DOI 10.1016/S0891-5849(99)00242-7; Baron JM, 2001, J INVEST DERMATOL, V116, P541, DOI 10.1046/j.1523-1747.2001.01298.x; BAUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141; BICKERS DR, 1978, J CLIN INVEST, V62, P1061, DOI 10.1172/JCI109211; CHAMBON P, 1996, FASEB J, V10, P195; FISCHER T, 1977, ACTA DERM-VENEREOL, V57, P345; Fisher GJ, 1997, NEW ENGL J MED, V337, P1419, DOI 10.1056/NEJM199711133372003; GIBSON GG, 1994, INTRO DRUG METABOLIS; Glass CK, 1996, J ENDOCRINOL, V150, P349, DOI 10.1677/joe.0.1500349; GONZALEZ FJ, 1993, PHARMACOGENETICS, V3, P51, DOI 10.1097/00008571-199302000-00006; Gonzalez MC, 2001, BRIT J DERMATOL, V145, P749, DOI 10.1046/j.1365-2133.2001.04490.x; Goodwin B, 1999, MOL PHARMACOL, V56, P1329, DOI 10.1124/mol.56.6.1329; Hoffman SMG, 2001, PHARMACOGENETICS, V11, P687, DOI 10.1097/00008571-200111000-00007; Janmohamed A, 2001, BIOCHEM PHARMACOL, V62, P777, DOI 10.1016/S0006-2952(01)00718-3; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Katiyar SK, 2000, J INVEST DERMATOL, V114, P328, DOI 10.1046/j.1523-1747.2000.00876.x; LAWRENCE CM, 1984, BRIT J DERMATOL, V110, P671, DOI 10.1111/j.1365-2133.1984.tb04703.x; LI XY, 1995, CARCINOGENESIS, V16, P519, DOI 10.1093/carcin/16.3.519; Marill J, 2000, MOL PHARMACOL, V58, P1341, DOI 10.1124/mol.58.6.1341; MCCORMICK A, 1995, MORBIDITY STAT GEN P, P54; Morgan ET, 2001, DRUG METAB DISPOS, V29, P207; Nebert DW, 2000, CLIN CHEM LAB MED, V38, P857, DOI 10.1515/CCLM.2000.124; Pritchard MP, 1998, PHARMACOGENETICS, V8, P33, DOI 10.1097/00008571-199802000-00005; Rivera SP, 2002, MOL PHARMACOL, V61, P255, DOI 10.1124/mol.61.2.255; Rylander T, 2001, BIOCHEM BIOPH RES CO, V281, P529, DOI 10.1006/bbrc.2001.4390; STOUGHTON RB, 1978, ARCH DERMATOL, V114, P43, DOI 10.1001/archderm.114.1.43; Tanaka E, 1998, J CLIN PHARM THER, V23, P403, DOI 10.1046/j.1365-2710.1998.00086.x; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; Welter JF, 1995, ONCOGENE, V11, P2681; White JA, 1997, J BIOL CHEM, V272, P18538, DOI 10.1074/jbc.272.30.18538; Whitlock JP, 1999, ANNU REV PHARMACOL, V39, P103, DOI 10.1146/annurev.pharmtox.39.1.103; Wingender E, 2000, NUCLEIC ACIDS RES, V28, P316, DOI 10.1093/nar/28.1.316; Wolf CR, 1999, BRIT MED BULL, V55, P366, DOI 10.1258/0007142991902439; Wolf CR, 2000, BRIT MED J, V320, P987, DOI 10.1136/bmj.320.7240.987	34	109	113	1	12	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 19	2003	361	9366					1336	1343		10.1016/S0140-6736(03)13081-4	http://dx.doi.org/10.1016/S0140-6736(03)13081-4			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	669HP	12711469				2022-12-28	WOS:000182346100011
J	Thorpe, A; Neal, D				Thorpe, A; Neal, D			Benign prostatic hyperplasia	LANCET			English	Review							TRANSURETHRAL NEEDLE ABLATION; INTENSITY FOCUSED ULTRASOUND; URINARY-TRACT SYMPTOMS; SUSTAINED-RELEASE ALFUZOSIN; COMMUNITY-BASED SAMPLE; QUALITY-OF-LIFE; NATURAL-HISTORY; MEDICAL THERAPY; PRESSURE-FLOW; HOLMIUM LASER	In both ageing men and women, lower urinary tract symptoms (LUTS) are increasing. These infections have many possible causes, including smooth muscle dysfunction, neurological factors and benign prostatic hyperplasia. Up to 15% to 25% of men aged 50-65 years have LUTS of sufficient severity to interfere with their quality of life. Although benign prostatic hyperplasia is an important cause of these symptoms, and can have serious consequences, clinicians should be aware of these other causes so that the appropriate diagnosis Is made before invasive treatments are started. New medical treatments, Including alpha-adrenergic blocking agents and 5 alpha-reductase inhibitors mean that many men without complications such as infection, bleeding, or chronic retention, and with mild to moderate symptoms, should be managed in primary care. Combined local protocols between primary and secondary care will help to establish which men with persistent symptoms or complications need referral for a urological opinion to determine the need for further investigation and more invasive forms of management. We review the pathophysiology of the disease, and current approaches to investigation and management of this common problem.	Addenbrookes Hosp, Dept Surg, Ctr Oncol, Cambridge CB2 2QQ, England; Addenbrookes Hosp, Dept Canc Res, Ctr Oncol, Cambridge CB2 2QQ, England; Freeman Rd Hosp, Dept Urol, Newcastle Upon Tyne NE7 7DN, Tyne & Wear, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Newcastle Freeman Hospital; Newcastle University - UK	Neal, D (corresponding author), Addenbrookes Hosp, Dept Surg, Ctr Oncol, Hills Rd, Cambridge CB2 2QQ, England.	den22@medschl.cam.ac.uk		Neal, David/0000-0002-6033-5086				Abrams P, 2002, NEUROUROL URODYNAM, V21, P167, DOI 10.1002/nau.10052; ABRAMS P, 1978, URODYNAMIC FINDINGS, P1258; ABRAMS PH, 1978, UROL INT, V33, P171, DOI 10.1159/000280194; [Anonymous], 2000, EUR UROL, V37, P680; Arai Y, 2000, J UROLOGY, V164, P1206, DOI 10.1016/S0022-5347(05)67142-X; ARAKI H, 1983, PROSTATE, V4, P253, DOI 10.1002/pros.2990040305; BARRY MJ, 1990, PROSTATE, P61; BARRY MJ, 1990, UROL CLIN N AM, V17, P495; Bartsch G, 2000, EUR UROL, V37, P367, DOI 10.1159/000020181; BERRY SJ, 1984, J UROLOGY, V132, P474, DOI 10.1016/S0022-5347(17)49698-4; BLANDY JP, 1986, PROSTATE, P51; BLANDY JP, 1986, PROSTATE, P12; Borth CS, 2001, UROLOGY, V57, P1082, DOI 10.1016/S0090-4295(01)01018-4; BOSCH JLHR, 1995, BRIT J UROL, V75, P622, DOI 10.1111/j.1464-410X.1995.tb07421.x; Boyarsky S, 1976, Trans Am Assoc Genitourin Surg, V68, P29; BOYARSKY S, 1983, BENIGN PROSTATIC HYP, P766; Boyle P, 2000, UROLOGY, V55, P533, DOI 10.1016/S0090-4295(99)00593-2; Boyle PP, 2002, J UROLOGY, V167, P372; BROOKES ST, 2002, SEXUAL DYSFUNCTION M, P1059; Buck AC, 1996, BRIT J UROL, V78, P325, DOI 10.1046/j.1464-410X.1996.00104.x; Burney TL, 1996, J ENDOUROL, V10, P469, DOI 10.1089/end.1996.10.469; Byrne RL, 1996, BRIT J UROL, V77, P627, DOI 10.1046/j.1464-410X.1996.09721.x; Cazares LH, 2002, CLIN CANCER RES, V8, P2541; Chapple C R, 2001, Curr Opin Urol, V11, P9, DOI 10.1097/00042307-200101000-00002; Chapple CR, 1998, EUR UROL, V34, P10, DOI 10.1159/000052283; CHAPPLE CR, 1994, BRIT J UROL, V74, P585, DOI 10.1111/j.1464-410X.1994.tb09188.x; Clifford GM, 2000, EUR UROL, V38, P2, DOI 10.1159/000020246; CONRAD S, 1996, J UROLOGY, V155, P704; Cuellar D C, 2001, Curr Opin Urol, V11, P27, DOI 10.1097/00042307-200101000-00004; DAncona FCH, 1997, J UROLOGY, V158, P120, DOI 10.1097/00005392-199707000-00035; de la Rosette JJMCH, 1998, NEUROUROL URODYNAM, V17, P99, DOI 10.1002/(SICI)1520-6777(1998)17:2<99::AID-NAU3>3.3.CO;2-5; De La Rosette JJMCH, 2000, CURR OPIN UROL, V10, P1; Debruyne FMJ, 1998, EUR UROL, V34, P169, DOI 10.1159/000019706; delaRosette JJMCH, 1997, J UROLOGY, V157, P430, DOI 10.1016/S0022-5347(01)65164-4; Desautel MG, 1998, UROLOGY, V51, P1013, DOI 10.1016/S0090-4295(98)00102-2; DeWildt MJAM, 1996, BRIT J UROL, V77, P221, DOI 10.1046/j.1464-410X.1996.82511.x; Di Silverio F, 1998, PROSTATE, V36, P1, DOI 10.1002/(SICI)1097-0045(19980615)36:1<1::AID-PROS1>3.0.CO;2-M; Djavan B, 2002, J UROLOGY, V167, P268; Donovan J L, 1999, Curr Opin Urol, V9, P3, DOI 10.1097/00042307-199901000-00002; Donovan JL, 2000, J UROLOGY, V164, P65, DOI 10.1016/S0022-5347(05)67450-2; Donovan JL, 1996, BRIT J UROL, V77, P554, DOI 10.1046/j.1464-410X.1996.93013.x; Emberton M, 1996, BRIT J UROL, V77, P233, DOI 10.1046/j.1464-410X.1996.88213.x; Flanigan RC, 1998, J UROLOGY, V160, P12, DOI 10.1016/S0022-5347(01)63011-8; FORRAY C, 1994, MOL PHARMACOL, V45, P703; FREYER P, 1912, 1000 CASES TOTAL ENU, P2; Fuller E., 1985, J CUTAN GENITOURIN D, V13, P229; GARRAWAY WM, 1991, LANCET, V338, P469, DOI 10.1016/0140-6736(91)90543-X; Gilling PJ, 1999, J UROLOGY, V162, P1640, DOI 10.1016/S0022-5347(05)68186-4; GILLING PJ, 2002, BJU INT, V90, P12; Girman CJ, 1998, UROLOGY, V51, P8, DOI 10.1016/S0090-4295(98)00049-1; Griffiths D, 1997, NEUROUROL URODYNAM, V16, P1, DOI 10.1002/(SICI)1520-6777(1997)16:1<1::AID-NAU1>3.0.CO;2-I; HALD T, 1989, PROSTATE, P69; HARVARD BM, 1954, LOW TRANSVESICAL SUP; Hill B, 2002, J UROLOGY, V167, P294; Holtgrewe HL, 2000, J UROLOGY, V164, P71, DOI 10.1016/S0022-5347(05)67451-4; HOUDELETTE DM, 1994, J UROLOGY, V151, P415; HUNTER DJW, 1995, UROLOGY, V45, P962, DOI 10.1016/S0090-4295(99)80116-2; ISAACS JT, 1989, PROSTATE, P33; Jacobsen SJ, 1996, J UROLOGY, V155, P595, DOI 10.1016/S0022-5347(01)66461-9; JACOBSEN SJ, J UROL, V162, P1301; Jensen KME, 1998, SCAND J UROL NEPHROL, V32, P26; KABELIN JN, 1998, HOLMIUM YTTRIUM ALUM; KAPLAN SA, 1995, J UROLOGY, V154, P1785, DOI 10.1016/S0022-5347(01)66784-3; KIRBY RS, 1987, BR J UROL, V50, P12; Kyprianou N, 2000, Curr Urol Rep, V1, P89, DOI 10.1007/s11934-000-0042-0; Kyprianou N, 1998, J UROLOGY, V159, P1810, DOI 10.1016/S0022-5347(01)63162-8; Lepor H, 1996, NEW ENGL J MED, V335, P533, DOI 10.1056/NEJM199608223350801; Loran Oleg, 2000, Journal of Urology, V163, P218; LYTTON B, 1968, J UROLOGY, V99, P639, DOI 10.1016/S0022-5347(17)62763-0; Madersbacher S, 1996, EUR UROL, V30, P437; MADSEN PO, 1983, BENIGN PROSTATIC HYP, P763; Matsuoka K, 2000, J UROLOGY, V163, P515, DOI 10.1016/S0022-5347(05)67914-1; McConnell JD, 2002, J UROLOGY, V167, P265; MCGUIRE EJ, 1986, PROSTATE, P23; McNeill SA, 1999, BJU INT, V84, P622; McVary Kevin T, 2002, Curr Urol Rep, V3, P269, DOI 10.1007/s11934-002-0047-y; MEBUST W, 1991, P INT CONS BEN PROST, P51; MEBUST WK, 1989, J UROLOGY, V141, P243, DOI 10.1016/S0022-5347(17)40731-2; Millin TJ, 1947, RETROPUBIC URINARY S; MILROY E, 1988, PRACTITIONER, V232, P1141; Mulligan ED, 1997, BRIT J UROL, V79, P177, DOI 10.1046/j.1464-410X.1997.03286.x; Nakamura K, 1997, J ENDOUROL, V11, P197, DOI 10.1089/end.1997.11.197; NEAL DE, 1989, BRIT MED J, V299, P762, DOI 10.1136/bmj.299.6702.762; Neal DE, 1997, LANCET, V350, P305, DOI 10.1016/S0140-6736(05)63382-X; NEAL DE, BENIGN PROSTATIC HYP; NIELSEN K T, 1988, Comprehensive Therapy, V14, P21; OCONOR VJ, 1982, J UROLOGY, V127, P448, DOI 10.1016/S0022-5347(17)53859-8; Pannek J, 1998, NEUROUROL URODYNAM, V17, P9, DOI 10.1002/(SICI)1520-6777(1998)17:1<9::AID-NAU3>3.0.CO;2-H; PARAGUY EP, 2002, COMMUNICATION; PERSKY L, 1983, BENIGN PROSTATIC HYP, P714; Pickard R, 1998, BRIT J UROL, V81, P712; Prakash K, 2002, P NATL ACAD SCI USA, V99, P7598, DOI 10.1073/pnas.112191399; Ramon J, 1997, BRIT J UROL, V80, P128, DOI 10.1046/j.1464-410X.1997.00245.x; Rhodes T, 2002, J UROLOGY, V167, P269; Roberts RO, 1997, J UROLOGY, V157, P1711, DOI 10.1016/S0022-5347(01)64842-0; Robertson AS, 1996, J UROLOGY, V155, P506, DOI 10.1016/S0022-5347(01)66435-8; Roehrborn CG, 2000, EUR UROL, V37, P528, DOI 10.1159/000020189; Roehrborn CG, 1998, UROLOGY, V51, P415, DOI 10.1016/S0090-4295(97)00682-1; ROERHRBORN C, 2000, J UROLOGY, V163, P309; ROOS NP, 1987, J UROLOGY, V137, P1184, DOI 10.1016/S0022-5347(17)44442-9; ROOS NP, 1989, NEW ENGL J MED, V320, P1120, DOI 10.1056/NEJM198904273201705; Schatzl G, 2000, EUR UROL, V37, P695, DOI 10.1159/000020220; SCHULMAN CC, 1995, UROLOGY, V45, P28, DOI 10.1016/S0090-4295(95)96260-3; Selley S., 1997, HLTH TECHNOLOGY ASSE, V1, P1, DOI DOI 10.3310/HTA1020; SIDNEY S, 1991, UROLOGY, V38, P13, DOI 10.1016/0090-4295(91)80193-B; SMITH RA, 1988, POSTGRAD MED, V83, P79, DOI 10.1080/00325481.1988.11700255; Speakman M, 2002, J UROLOGY, V167, P375; STEYN M, 1988, FAM PRACT, V5, P193, DOI 10.1093/fampra/5.3.193; STYLES RA, 1991, J UROLOGY, V146, P1029, DOI 10.1016/S0022-5347(17)37994-6; Thalmann GN, 2002, J UROLOGY, V167, P2496, DOI 10.1016/S0022-5347(05)65013-6; THORPE AC, 1995, BRIT J UROL, V76, P446, DOI 10.1111/j.1464-410X.1995.tb07743.x; THORPE AC, 1994, BRIT J UROL, V74, P559, DOI 10.1111/j.1464-410X.1994.tb09184.x; Tornblom M, 1999, UROLOGY, V53, P945, DOI 10.1016/S0090-4295(98)00640-2; TUBARO A, 2000, EUROPEAN UROLOGY S, V7, P7; TUT V, 2002, BJU INT, V90, P26; van Kerrebroeck P, 2002, NEUROUROL URODYNAM, V21, P179, DOI 10.1002/nau.10053; Walden M, 1998, SCAND J UROL NEPHROL, V32, P204; WALSH A, 1989, PROSTATE, P137; Walsh P C, 1984, Prog Clin Biol Res, V145, P1; WALSH PC, 1990, J UROLOGY, V143, P1203, DOI 10.1016/S0022-5347(17)40225-4; WALSH TN, 1989, PROSTATE, P143; WILLIAMS A, 1990, HEALTH POLICY, V16, P199; WILT TJ, 2002, TREATMENT OPTIONS BE, P1047	123	210	232	2	26	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 19	2003	361	9366					1359	1367		10.1016/S0140-6736(03)13073-5	http://dx.doi.org/10.1016/S0140-6736(03)13073-5			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	669HP	12711484				2022-12-28	WOS:000182346100025
J	Morillon, A; O'Sullivan, J; Azad, A; Proudfoot, N; Mellor, J				Morillon, A; O'Sullivan, J; Azad, A; Proudfoot, N; Mellor, J			Regulation of elongating RNA polymerase II by forkhead transcription factors in yeast	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; ENVIRONMENTAL-CHANGES; PROCESSING FACTORS; TERMINAL DOMAIN; GENE-EXPRESSION; INITIATION; PROMOTER; KINASE; FKH1P	The elongation phase of transcription by RNA polymerase II (RNAPII) is highly regulated and tightly linked to pre-messenger RNA (pre-mRNA) processing. Recent studies have implicated an early elongation checkpoint that facilitates the link to pre-mRNA processing. Here we show that the yeast forkhead transcription factors, Fkh1p and Fkh2p, associate with the coding regions of active genes and influence, in opposing ways, transcriptional elongation and termination. These events are coordinated with serine-5 and -2 phosphorylation of the heptad repeat of the carboxy-terminal domain (CTD) of RNAPII. Our results suggest that, in addition to their documented promoter function, Fkh1p and Fkh2p coordinate early transcription elongation and pre-mRNA processing. This may reflect a general feature of gene regulation in eukaryotes.	Univ Oxford, Dept Biochem, Oxford OX1 3QU, England; Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England	University of Oxford; University of Oxford	Mellor, J (corresponding author), Univ Oxford, Dept Biochem, S Parks Rd, Oxford OX1 3QU, England.		O'Sullivan, Justin/HDO-1639-2022; Pillay, Nischalan/F-9536-2012; Morillon, Antonin/M-4751-2017	O'Sullivan, Justin/0000-0003-2927-450X; Morillon, Antonin/0000-0002-0575-5264; Proudfoot, Nicholas/0000-0001-8646-3222				Carlsson P, 2002, DEV BIOL, V250, P1, DOI 10.1006/dbio.2002.0780; Causton HC, 2001, MOL BIOL CELL, V12, P323, DOI 10.1091/mbc.12.2.323; Cho EJ, 2001, GENE DEV, V15, P3319, DOI 10.1101/gad.935901; Cirillo LA, 1998, EMBO J, V17, P244, DOI 10.1093/emboj/17.1.244; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; Dye MJ, 1999, MOL CELL, V3, P371, DOI 10.1016/S1097-2765(00)80464-5; EXINGER F, 1992, CURR GENET, V22, P9, DOI 10.1007/BF00351735; Fish RN, 2002, BBA-GENE STRUCT EXPR, V1577, P287, DOI 10.1016/S0167-4781(02)00459-1; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Greger IH, 1998, EMBO J, V17, P4771, DOI 10.1093/emboj/17.16.4771; Greger IH, 2000, P NATL ACAD SCI USA, V97, P8415, DOI 10.1073/pnas.140217697; Hartzog GA, 1998, GENE DEV, V12, P357, DOI 10.1101/gad.12.3.357; Hollenhorst PC, 2000, GENETICS, V154, P1533; Hollenhorst PC, 2001, GENE DEV, V15, P2445, DOI 10.1101/gad.906201; Komarnitsky P, 2000, GENE DEV, V14, P2452, DOI 10.1101/gad.824700; Koranda M, 2000, NATURE, V406, P94, DOI 10.1038/35017589; Kumar R, 2000, CURR BIOL, V10, P896, DOI 10.1016/S0960-9822(00)00618-7; Lee TI, 2002, SCIENCE, V298, P799, DOI 10.1126/science.1075090; Licatalosi DD, 2002, MOL CELL, V9, P1101, DOI 10.1016/S1097-2765(02)00518-X; Orphanides G, 2002, CELL, V108, P439, DOI 10.1016/S0092-8674(02)00655-4; Pic A, 2000, EMBO J, V19, P3750, DOI 10.1093/emboj/19.14.3750; Pokholok DK, 2002, MOL CELL, V9, P799, DOI 10.1016/S1097-2765(02)00502-6; Rodriguez CR, 2000, MOL CELL BIOL, V20, P104, DOI 10.1128/MCB.20.1.104-112.2000; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Shaw RJ, 2000, MOL CELL BIOL, V20, P7427, DOI 10.1128/MCB.20.20.7427-7437.2000; Simon I, 2001, CELL, V106, P697, DOI 10.1016/S0092-8674(01)00494-9; Zhu GF, 2000, NATURE, V406, P90, DOI 10.1038/35017581	27	56	56	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 18	2003	300	5618					492	495		10.1126/science.1081379	http://dx.doi.org/10.1126/science.1081379			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	668LR	12702877				2022-12-28	WOS:000182295900042
J	Campbell, SM; Braspenning, J; Hutchinson, A; Marshall, MN				Campbell, SM; Braspenning, J; Hutchinson, A; Marshall, MN			Improving the quality of health care - Research methods used in developing and applying quality indicators in primary care	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE; CONSENSUS METHODS; CRITERIA; IMPROVEMENT; GUIDELINES; ANGINA; ASTHMA		Univ Manchester, Natl Primary Care Res & Dev Ctr, Manchester M13 9PL, Lancs, England; UMC St Radboud, WOK, Ctr Qual Care Res, NL-6500 HB Nijmegen, Netherlands; Univ Sheffield, Sect Publ Hlth, Sheffield S1 4DA, S Yorkshire, England	University of Manchester; Radboud University Nijmegen; University of Sheffield	Campbell, SM (corresponding author), Univ Manchester, Natl Primary Care Res & Dev Ctr, Manchester M13 9PL, Lancs, England.		Braspenning, Jozé/AAG-7612-2021; Braspenning, Jozé CC/D-4268-2009	Braspenning, Jozé/0000-0003-0800-0630; Braspenning, Jozé CC/0000-0003-0800-0630; Campbell, Stephen/0000-0002-2328-4136				Black N, 1999, J Health Serv Res Policy, V4, P236; BRASPENNING J, 2001, KWALITEITS DOELMATIG; Brook R H, 1986, Int J Technol Assess Health Care, V2, P53; Brook RH, 2000, INT J QUAL HEALTH C, V12, P281, DOI 10.1093/intqhc/12.4.281; Buck D, 1996, 150 U YORK CTR HLTH; Campbell SM, 2002, QUAL SAF HEALTH CARE, V11, P125, DOI 10.1136/qhc.11.2.125; Campbell SM, 1999, QUAL HEALTH CARE, V8, P6, DOI 10.1136/qshc.8.1.6; Donabedian A., 1982, EXPLORATIONS QUALITY, VII; Donabedian A, 1980, EXPLORATIONS QUALITY, V1; Ferlie EB, 2001, MILBANK Q, V79, P281, DOI 10.1111/1468-0009.00206; FINK A, 1984, AM J PUBLIC HEALTH, V74, P979, DOI 10.2105/AJPH.74.9.979; GRIMSHAW JM, 1993, LANCET, V342, P1317, DOI 10.1016/0140-6736(93)92244-N; Hearnshaw HM, 2001, QUAL HEALTH CARE, V10, P173, DOI 10.1136/qhc.0100173..; JONES J, 1995, BRIT MED J, V311, P376, DOI 10.1136/bmj.311.7001.376; Lawrence M., 1997, EUR J GEN PRACT, V3, P103, DOI DOI 10.3109/13814789709160336; Marshall M, 2002, QUALITY INDICATORS G; MCCALL A, 1998, BRIT MED J, V317, P1354; McGlynn EA, 1998, AM J PREV MED, V14, P14, DOI 10.1016/S0749-3797(97)00032-9; Murphy MK, 1998, HLTH TECHNOL ASSESS, V2, P1; NAYLOR CD, 1995, LANCET, V345, P840, DOI 10.1016/S0140-6736(95)92969-X; Pringle M, 2000, BRIT MED J, V321, P737, DOI 10.1136/bmj.321.7263.737; Pringle M, 1998, BMJ-BRIT MED J, V317, P1120; Seddon ME, 2001, QUAL HEALTH CARE, V10, P152, DOI 10.1136/qhc.0100152..; Streiner DL., 1995, HLTH MEASUREMENT SCA, V2nd ed.	24	412	421	4	39	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 12	2003	326	7393					816	819		10.1136/bmj.326.7393.816	http://dx.doi.org/10.1136/bmj.326.7393.816			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	670BE	12689983	Green Published			2022-12-28	WOS:000182386700031
J	Mowat, AM				Mowat, AM			Coeliac disease - a meeting point for genetics, immunology, and protein chemistry	LANCET			English	Review							T-CELL RESPONSE; CELIAC-DISEASE; TISSUE TRANSGLUTAMINASE; ORAL TOLERANCE; GLIADIN; INTOLERANCE; PEPTIDES; GLUTENIN		Univ Glasgow, Western Infirm, Dept Bacteriol & Immunol, Glasgow G11 6NT, Lanark, Scotland	University of Glasgow	Mowat, AM (corresponding author), Univ Glasgow, Western Infirm, Dept Bacteriol & Immunol, Glasgow G11 6NT, Lanark, Scotland.		Mowat, Allan M/H-7932-2016	Mowat, Allan M/0000-0001-9389-3079				Anderson RP, 2000, NAT MED, V6, P337, DOI 10.1038/73200; Arentz-Hansen H, 2000, J EXP MED, V191, P603, DOI 10.1084/jem.191.4.603; Arentz-Hansen H, 2002, GASTROENTEROLOGY, V123, P803, DOI 10.1053/gast.2002.35381; Greco L, 2002, GUT, V50, P624, DOI 10.1136/gut.50.5.624; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.iy.12.040194.005015; Molberg O, 1998, NAT MED, V4, P713, DOI 10.1038/nm0698-713; Mowat AM, 1999, CURR OPIN GASTROEN, V15, P546, DOI 10.1097/00001574-199911000-00016; NILSEN EM, 1995, GUT, V37, P766, DOI 10.1136/gut.37.6.766; POLANCO I, 1992, J PEDIATR-US, V121, pS108, DOI 10.1016/S0022-3476(05)81417-9; Shan L, 2002, SCIENCE, V297, P2275, DOI 10.1126/science.1074129; Sollid LM, 2002, NAT REV IMMUNOL, V2, P647, DOI 10.1038/nri885; SOLLID LM, 1989, J EXP MED, V169, P345, DOI 10.1084/jem.169.1.345; Vader LW, 2002, J EXP MED, V195, P643, DOI 10.1084/jem.20012028; Vader W, 2002, GASTROENTEROLOGY, V122, P1729, DOI 10.1053/gast.2002.33606; van Belzen MJ, 2001, AM J GASTROENTEROL, V96, P3337, DOI 10.1016/S0002-9270(01)03897-7; van de Wal Y, 1999, EUR J IMMUNOL, V29, P3133, DOI 10.1002/(SICI)1521-4141(199910)29:10&lt;3133::AID-IMMU3133&gt;3.0.CO;2-G; Viney JL, 1998, J IMMUNOL, V160, P5815	17	75	79	0	10	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 12	2003	361	9365					1290	1292						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	666DM	12699968				2022-12-28	WOS:000182161600023
J	Elbaz, D; Cesarsky, CJ				Elbaz, D; Cesarsky, CJ			A fossil record of galaxy encounters	SCIENCE			English	Review							ULTRALUMINOUS INFRARED GALAXIES; STAR-FORMATION RATE; DEEP FIELD-SOUTH; X-RAY; REDSHIFT SURVEY; RADIO-EMISSION; POWER SPECTRUM; LOCKMAN HOLE; MU-M; EVOLUTION	The cosmic infrared background (CIRB) is a record of a large fraction of the emission of light by stars and galaxies over time. The bulk of this emission has been resolved by the Infrared Space Observatory camera. The dominant contributors are bright starburst galaxies with redshift z similar to 0.8; that is, in the same redshift range as the active galactic nuclei responsible for the bulk of the x-ray background. At the longest wavelengths, sources of redshift z greater than or equal to 2 tend to dominate the CIRB. It appears that the majority of present-day stars have been formed in dusty starbursts triggered by galaxy-galaxy interactions and the buildup of large-scale structures.	Ctr Etud Saclay, CEA, Serv Astrophys, F-91191 Gif Sur Yvette, France; European So Observ, D-85748 Garching, Germany	CEA; UDICE-French Research Universities; Universite Paris Saclay; European Southern Observatory	Elbaz, D (corresponding author), Ctr Etud Saclay, CEA, Serv Astrophys, F-91191 Gif Sur Yvette, France.	delbaz@cea.fr	Elbaz, David/AAB-4141-2020	Elbaz, David/0000-0002-7631-647X				Aghanim N, 1996, ASTRON ASTROPHYS, V311, P1; Aharonian F, 2002, ASTRON ASTROPHYS, V384, pL23, DOI 10.1051/0004-6361:20020206; Almaini O, 2003, MON NOT R ASTRON SOC, V338, P303, DOI 10.1046/j.1365-8711.2003.05989.x; ALMAINI O, IN PRESS ASTRON NACH; Aussel H, 1999, ASTRON ASTROPHYS, V342, P313; AUSSEL H, UNPUB; Barger AJ, 2002, ASTRON J, V124, P1839, DOI 10.1086/342448; Bernstein RA, 2002, ASTROPHYS J, V571, P56, DOI 10.1086/339422; Brandt WN, 2001, ASTRON J, V122, P2810, DOI 10.1086/324105; Cardiel N, 2003, ASTROPHYS J, V584, P76, DOI 10.1086/345594; Chary R, 2001, ASTROPHYS J, V556, P562, DOI 10.1086/321609; Cohen JG, 2000, ASTROPHYS J, V538, P29, DOI 10.1086/309096; CONDON JJ, 1992, ANNU REV ASTRON ASTR, V30, P575, DOI 10.1146/annurev.aa.30.090192.003043; Dannerbauer H, 2002, ASTROPHYS J, V573, P473, DOI 10.1086/340762; DICKINSON M, 2001, SPRINGER VERLAG ESO, P324; Dole H, 2001, ASTRON ASTROPHYS, V372, P364, DOI 10.1051/0004-6361:20010449; Elbaz D, 1999, ASTRON ASTROPHYS, V351, pL37; Elbaz D, 2002, ASTRON ASTROPHYS, V384, P848, DOI 10.1051/0004-6361:20020106; ELBAZ D, UNPUB; Fadda D, 2002, ASTRON ASTROPHYS, V383, P838, DOI 10.1051/0004-6361:20011842; Flores H, 1999, ASTROPHYS J, V517, P148, DOI 10.1086/307172; FLORES H, UNPUB; Franceschini A, 2001, ASTRON ASTROPHYS, V378, P1, DOI 10.1051/0004-6361:20011175; FRANCESCHINI A, IN PRESS ASTRON ASTR; Gear WK, 2000, MON NOT R ASTRON SOC, V316, pL51, DOI 10.1046/j.1365-8711.2000.03822.x; Genzel R, 1998, ASTROPHYS J, V498, P579, DOI 10.1086/305576; Genzel R, 2000, ANNU REV ASTRON ASTR, V38, P761, DOI 10.1146/annurev.astro.38.1.761; Genzel R, 2001, ASTROPHYS J, V563, P527, DOI 10.1086/323772; Gispert R, 2000, ASTRON ASTROPHYS, V360, P1; Gould A, 1996, ASTROPHYS J, V465, P759, DOI 10.1086/177460; Hasinger G, 1998, ASTRON ASTROPHYS, V329, P482; HASINGER G, 2002, ESO MESSENGER, V108, P11; Hauser MG, 2001, ANNU REV ASTRON ASTR, V39, P249, DOI 10.1146/annurev.astro.39.1.249; Hughes DH, 1998, NATURE, V394, P241, DOI 10.1038/28328; ISHIDA CM, 2002, THESIS U HAWAII; Ivison RJ, 2002, MON NOT R ASTRON SOC, V337, P1, DOI 10.1046/j.1365-8711.2002.05900.x; Kawara K, 1998, ASTRON ASTROPHYS, V336, pL9; Komossa S, 2003, ASTROPHYS J, V582, pL15, DOI 10.1086/346145; Lagache G, 2000, ASTRON ASTROPHYS, V355, P17; Lagache G, 2003, MON NOT R ASTRON SOC, V338, P555, DOI 10.1046/j.1365-8711.2003.05971.x; LEGER A, 1984, ASTRON ASTROPHYS, V137, pL5; Lemke D, 1996, ASTRON ASTROPHYS, V315, pL64; Lutz D, 2001, ASTRON ASTROPHYS, V378, P70, DOI 10.1051/0004-6361:20011120; Madau P, 2000, MON NOT R ASTRON SOC, V312, pL9, DOI 10.1046/j.1365-8711.2000.03268.x; Matsuhara H, 2000, ASTRON ASTROPHYS, V361, P407; Miville-Deschenes MA, 2002, ASTRON ASTROPHYS, V393, P749, DOI 10.1051/0004-6361:20020929; PARTRIDGE RB, 1967, ASTROPHYS J, V148, P377, DOI 10.1086/149161; Plante S, 2002, ASTRON J, V124, P1995, DOI 10.1086/342445; Renault C, 2001, ASTRON ASTROPHYS, V371, P771, DOI 10.1051/0004-6361:20010448; Richards EA, 2000, ASTROPHYS J, V533, P611, DOI 10.1086/308684; Rigopoulou D, 2000, ASTROPHYS J, V537, pL85, DOI 10.1086/312774; Rosati P, 2002, ASTROPHYS J, V566, P667, DOI 10.1086/338339; SANDERS DB, 1988, ASTROPHYS J, V325, P74, DOI 10.1086/165983; Sanders DB, 1996, ANNU REV ASTRON ASTR, V34, P749, DOI 10.1146/annurev.astro.34.1.749; Severgnini P, 2000, ASTRON ASTROPHYS, V360, P457; Smail I, 2002, MON NOT R ASTRON SOC, V331, P495, DOI 10.1046/j.1365-8711.2002.05203.x; STANEV T, 1998, APJ, V494, P159; Tacconi LJ, 2002, ASTROPHYS J, V580, P73, DOI 10.1086/343075; Thuan TX, 1999, ASTROPHYS J, V516, P783, DOI 10.1086/307152; Tran QD, 2001, ASTROPHYS J, V552, P527, DOI 10.1086/320543; Veilleux S, 2002, ASTROPHYS J SUPPL S, V143, P315, DOI 10.1086/343844	61	67	67	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 11	2003	300	5617					270	274		10.1126/science.1081525	http://dx.doi.org/10.1126/science.1081525			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	665RQ	12690183	Green Submitted			2022-12-28	WOS:000182135400039
J	Kaech, SM; Ahmed, R				Kaech, SM; Ahmed, R			Immunology - CD8 T cells remember with a little help	SCIENCE			English	Editorial Material							CUTTING EDGE; MEMORY; DIFFERENTIATION; EXPRESSION; INFECTION; MICE		Emory Univ, Sch Med, Emory Vaccine Ctr, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Microbiol & Immunol, Atlanta, GA 30322 USA	Emory University; Emory University	Kaech, SM (corresponding author), Emory Univ, Sch Med, Emory Vaccine Ctr, 1510 Clifton Rd, Atlanta, GA 30322 USA.							Belz GT, 2002, J VIROL, V76, P12388, DOI 10.1128/JVI.76.23.12388-12393.2002; Bourgeois C, 2002, SCIENCE, V297, P2060, DOI 10.1126/science.1072615; Grayson JM, 2000, J IMMUNOL, V164, P3950, DOI 10.4049/jimmunol.164.8.3950; Janssen EM, 2003, NATURE, V421, P852, DOI 10.1038/nature01441; Kaech SM, 2001, NAT IMMUNOL, V2, P415, DOI 10.1038/87720; Kaech SM, 2002, CELL, V111, P837, DOI 10.1016/S0092-8674(02)01139-X; MATLOUBIAN M, 1994, J VIROL, V68, P8056, DOI 10.1128/JVI.68.12.8056-8063.1994; Mercado R, 2000, J IMMUNOL, V165, P6833, DOI 10.4049/jimmunol.165.12.6833; Shedlock DJ, 2003, J IMMUNOL, V170, P2053, DOI 10.4049/jimmunol.170.4.2053; Shedlock DJ, 2003, SCIENCE, V300, P337, DOI 10.1126/science.1082305; Sun JC, 2003, SCIENCE, V300, P339, DOI 10.1126/science.1083317; van Stipdonk MJB, 2001, NAT IMMUNOL, V2, P423, DOI 10.1038/87730; vonHerrath MG, 1996, J VIROL, V70, P1072, DOI 10.1128/JVI.70.2.1072-1079.1996; Wherry EJ, 2003, NAT IMMUNOL, V4, P225, DOI 10.1038/ni889; Wong P, 2001, J IMMUNOL, V166, P5864, DOI 10.4049/jimmunol.166.10.5864; Zajac AJ, 1998, J EXP MED, V188, P2205, DOI 10.1084/jem.188.12.2205	16	106	106	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 11	2003	300	5617					263	265		10.1126/science.1084511	http://dx.doi.org/10.1126/science.1084511			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	665RQ	12690179				2022-12-28	WOS:000182135400035
J	Annas, GJ				Annas, GJ			HIPAA regulations - A new era of medical-record privacy?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							RULE		Boston Univ, Sch Publ Hlth, Hlth Law Dept, Boston, MA 02215 USA	Boston University	Annas, GJ (corresponding author), Boston Univ, Sch Publ Hlth, Hlth Law Dept, Boston, MA 02215 USA.			Annas, George/0000-0001-5836-7831				ANNAS G, 1989, RIGHTS PATIENTS; Annas GJ, 2002, NEW ENGL J MED, V346, P216, DOI 10.1056/NEJM200201173460320; *DEP HLTH HUM SERV, 2002, STAND PRIV IND ID HL, P25; Federman D.D., 2003, RESPONSIBLE RES; Gordon Susan M., 2002, DEL LAW REV, V5, P23; Jacobson PD, 2002, MINN LAW REV, V86, P1497; Kulynych J, 2002, NEW ENGL J MED, V347, P1133, DOI 10.1056/NEJMp020113; Kulynych J, 2002, NEW ENGL J MED, V346, P201, DOI 10.1056/NEJM200201173460312; LADINE B, 2002, BOSTON GLOBE    0810, pA1; Office of Civil Rights Department of Health and Human Services, 2002, FED REGISTER, V67, P53182; *PRIV PROT STUC CO, 1977, PERS PRIV INF SOC; SIEGLER M, 1982, NEW ENGL J MED, V307, P1518, DOI 10.1056/NEJM198212093072411; Zoeller Brian, 2002, Brandeis Law J, V40, P1065; 1991, FED REG         0618, V56, P28003	14	137	138	3	6	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 10	2003	348	15					1486	1490		10.1056/NEJMlim035027	http://dx.doi.org/10.1056/NEJMlim035027			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	665CU	12686707	Green Published			2022-12-28	WOS:000182102700012
J	Keusch, GT; Medlin, CA				Keusch, GT; Medlin, CA			Tapping the power of small institutions - Now is the time to create a virtual, global network for health research.	NATURE			English	Editorial Material							SCIENCE; EUROPE		NIH, Fogarty Int Ctr, Bethesda, MD 20892 USA; Univ Calif San Francisco, Inst Global Hlth, San Francisco, CA 94105 USA	National Institutes of Health (NIH) - USA; NIH Fogarty International Center (FIC); University of California System; University of California San Francisco	Keusch, GT (corresponding author), NIH, Fogarty Int Ctr, Bldg 10, Bethesda, MD 20892 USA.			/0000-0001-5724-2965				Annan K, 2003, SCIENCE, V299, P1485, DOI 10.1126/science.299.5612.1485; Feachem RGA, 2002, NATURE, V417, P695, DOI 10.1038/417695a; Global Forum for Health Research, 2002, 10 90 REP HLTH RES 2; Nossal GJ, 2003, IMMUNOL CELL BIOL, V81, P20, DOI 10.1046/j.0818-9641.2002.01139.x; Radda G, 2002, SCIENCE, V295, P445, DOI 10.1126/science.1069179; Winnacker EL, 2002, SCIENCE, V295, P446, DOI 10.1126/science.1068921; World Bank, 1993, WORLD DEV REP INV HL; World Health Organization, 1996, INV HLTH RES DEV REP; World Health Organization, 2001, MACR HLTH INV HLTH E	9	13	13	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 10	2003	422	6932					561	562		10.1038/422561a	http://dx.doi.org/10.1038/422561a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	665GN	12686973				2022-12-28	WOS:000182111400017
J	Sweeney, A; Jiggins, C; Johnsen, S				Sweeney, A; Jiggins, C; Johnsen, S			Insect communication: Polarized light as a butterfly mating signal	NATURE			English	Article							COLOR		Duke Univ, Dept Biol, Durham, NC 27708 USA; Smithsonian Trop Res Inst, Balboa, Panama; Univ Edinburgh, Inst Cell Anim & Populat Biol, Edinburgh EH9 3JT, Midlothian, Scotland	Duke University; Smithsonian Institution; Smithsonian Tropical Research Institute; University of Edinburgh	Sweeney, A (corresponding author), Duke Univ, Dept Biol, Durham, NC 27708 USA.		Jiggins, Chris/T-4296-2019; Jiggins, Chris D/B-9960-2008	Jiggins, Chris/0000-0002-7809-062X; Jiggins, Chris D/0000-0002-7809-062X				[Anonymous], 2002, AQUACULTURE, V235, P13, DOI [10.1016/j.aquaculture.2003.11.035, DOI 10.1016/J.AQUACULTURE.2003.11.035, DOI 10.1016/S1369-7021(02)00929-X]; Beltran M, 2002, MOL BIOL EVOL, V19, P2176, DOI 10.1093/oxfordjournals.molbev.a004042; ENDLER JA, 1993, ECOL MONOGR, V63, P1, DOI 10.2307/2937121; Estrada C, 2002, ECOL ENTOMOL, V27, P448, DOI 10.1046/j.1365-2311.2002.00434.x; Jiggins CD, 2001, NATURE, V411, P302, DOI 10.1038/35077075; Kelber A, 1999, NATURE, V402, P251, DOI 10.1038/46204; Kemp DJ, 2002, TRENDS ECOL EVOL, V17, P298, DOI 10.1016/S0169-5347(02)02516-8; Kinoshita M, 1997, NATURWISSENSCHAFTEN, V84, P199, DOI 10.1007/s001140050377; Shashar N, 1998, BIOTROPICA, V30, P275, DOI 10.1111/j.1744-7429.1998.tb00061.x; Shashar N, 2000, VISION RES, V40, P71, DOI 10.1016/S0042-6989(99)00158-3; Vukusic P, 2000, NATURE, V404, P457, DOI 10.1038/35006561; Vukusic P, 2002, P ROY SOC B-BIOL SCI, V269, P7, DOI 10.1098/rspb.2001.1836	12	188	197	3	78	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 1	2003	423	6935					31	32		10.1038/423031a	http://dx.doi.org/10.1038/423031a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	673CG	12721616				2022-12-28	WOS:000182561600030
J	Armstrong, PW				Armstrong, PW			Two hard lessons	LANCET			English	Editorial Material									Univ Alberta, Edmonton, AB T6G 2H7, Canada	University of Alberta	Armstrong, PW (corresponding author), Univ Alberta, 251 Med Sci Bldg, Edmonton, AB T6G 2H7, Canada.			Armstrong, Paul/0000-0002-0460-3445					0	1	1	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 26	2003	361	9367					1417	1417		10.1016/S0140-6736(03)13133-9	http://dx.doi.org/10.1016/S0140-6736(03)13133-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	672HZ	12727394				2022-12-28	WOS:000182516300009
J	Chen, SH; Chen, WR; Mallamace, F				Chen, SH; Chen, WR; Mallamace, F			The glass-to-glass transition and its end point in a copolymer micellar system	SCIENCE			English	Article							DYNAMIC LIGHT-SCATTERING; COLLOIDAL SUSPENSIONS; RELAXATION; MODEL	We present experimental evidence, obtained from small-angle neutron scattering and photon correlation measurements, indicating the existence of two types of structurally arrested (glassy) states in a copolymer micellar system with a short-range interparticle attractive interaction. Within a certain range of micellar volume fractions, a sharp transition between these two types of glass is observed by varying the temperature. Furthermore, we found an end point of this transition line beyond which the two glasses become identical in their local structure and their long-time dynamics. These findings confirm the recent mode-coupling theory predictions regarding the phase behavior of the structurally arrested states for this type of system.	MIT, Dept Nucl Engn, Cambridge, MA 02139 USA; Univ Messina, Dipartimento Fis, I-98100 Messina, Italy; Univ Messina, Inst Nazl Fis Mat, I-98100 Messina, Italy	Massachusetts Institute of Technology (MIT); University of Messina; University of Messina	Chen, SH (corresponding author), MIT, Dept Nucl Engn, Cambridge, MA 02139 USA.	sowhsin@mit.edu		Mallamace, Francesco/0000-0003-4098-174X				BARTSCH E, 1992, J CHEM PHYS, V97, P3950, DOI 10.1063/1.462934; Bartsch E, 2002, J NON-CRYST SOLIDS, V307, P802, DOI 10.1016/S0022-3093(02)01523-5; Bergenholtz J, 1999, PHYS REV E, V59, P5706, DOI 10.1103/PhysRevE.59.5706; Bergenholtz J, 1999, J PHYS-CONDENS MAT, V11, P10171, DOI 10.1088/0953-8984/11/50/310; CHEN SH, 1999, COLLOID SURF A, V95, P183; Chen W., UNPUB; Chen WR, 2002, PHYS REV E, V66, DOI 10.1103/PhysRevE.66.021403; Dawson K, 2001, PHYS REV E, V63, DOI 10.1103/PhysRevE.63.011401; Eckert T, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.125701; Fabbian L, 1999, PHYS REV E, V59, pR1347, DOI 10.1103/PhysRevE.59.R1347; Fuchs M., 1995, Transport Theory and Statistical Physics, V24, P855, DOI 10.1080/00411459508203937; GOTZE W, 1991, LES HOUCH S, V51, P287; GOTZE W, 1992, REP PROG PHYS, V55, P241, DOI 10.1088/0034-4885/55/3/001; Liao CY, 2000, J APPL CRYSTALLOGR, V33, P677, DOI 10.1107/S0021889899013205; Lobry L, 1999, PHYS REV E, V60, P7076, DOI 10.1103/PhysRevE.60.7076; Mallamace F, 2000, PHYS REV LETT, V84, P5431, DOI 10.1103/PhysRevLett.84.5431; Pham KN, 2002, SCIENCE, V296, P104, DOI 10.1126/science.1068238; PONYATOVSKY EG, 1992, MATER SCI REP, V8, P147, DOI 10.1016/0920-2307(92)90007-N; PUSEY PN, 1987, PHYS REV LETT, V59, P2083, DOI 10.1103/PhysRevLett.59.2083; Russel W.B., 1992, COLLOIDAL DISPERSION; Segre PN, 2001, PHYS REV LETT, V86, P6042, DOI 10.1103/PhysRevLett.86.6042; VANMEGEN W, 1994, PHYS REV E, V49, P4206, DOI 10.1103/PhysRevE.49.4206; VANMEGEN W, 1991, PHYS REV A, V43, P5429, DOI 10.1103/PhysRevA.43.5429; Weeks ER, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.095704; Weeks ER, 2000, SCIENCE, V287, P627, DOI 10.1126/science.287.5453.627; Zaccarelli E, 2001, PHYS REV E, V63, DOI 10.1103/PhysRevE.63.031501; ZHANG KW, 1995, LANGMUIR, V11, P538, DOI 10.1021/la00002a029	27	127	128	0	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 25	2003	300	5619					619	622		10.1126/science.1082364	http://dx.doi.org/10.1126/science.1082364			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	671FB	12714739				2022-12-28	WOS:000182453700035
J	Collins, FS; Green, ED; Guttmacher, AE; Guyer, MS				Collins, FS; Green, ED; Guttmacher, AE; Guyer, MS			A vision for the future of genomics research	NATURE			English	Article							GENETIC INFORMATION; SEQUENCE; DNA; PRIVACY		NHGRI, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Collins, FS (corresponding author), NHGRI, NIH, Bethesda, MD 20892 USA.							Anderlik MR, 2001, ANNU REV GENOM HUM G, V2, P401, DOI 10.1146/annurev.genom.2.1.401; Aparicio S, 2002, SCIENCE, V297, P1301, DOI 10.1126/science.1072104; Avery OT, 1944, J EXP MED, V79, P137, DOI 10.1084/jem.79.2.137; Banerjee N, 2002, CURR OPIN MICROBIOL, V5, P313, DOI 10.1016/S1369-5274(02)00322-3; COHEN SN, 1973, P NATL ACAD SCI USA, V70, P3240, DOI 10.1073/pnas.70.11.3240; COLLINS F, 1993, SCIENCE, V262, P43, DOI 10.1126/science.8211127; Collins FS, 1998, SCIENCE, V282, P682, DOI 10.1126/science.282.5389.682; Drews J, 1997, NAT BIOTECHNOL, V15, P1318, DOI 10.1038/nbt1297-1318; Druker BJ, 2003, SEMIN HEMATOL, V40, P50, DOI 10.1053/shem.2003.50000; Fuller BP, 1999, SCIENCE, V285, P1359, DOI 10.1126/science.285.5432.1359; Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Golub TR, 2001, CURR OPIN HEMATOL, V8, P252, DOI 10.1097/00062752-200107000-00012; GUTTMACHER AE, 2000, NEW ENGL J MED, V347, P1512; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Hilbert D., 1902, B AM MATH SOC, V8, P437, DOI [DOI 10.1090/S0002-9904-1902-00923-3, 10.1090/S0002-9904-1902-00923-3]; Hirschhorn JN, 2002, GENET MED, V4, P45, DOI 10.1097/00125817-200203000-00002; Holt RA, 2002, SCIENCE, V298, P129, DOI 10.1126/science.1076181; HUDSON KL, 1995, SCIENCE, V270, P391, DOI 10.1126/science.270.5235.391; JACKSON DA, 1972, P NATL ACAD SCI USA, V69, P2904, DOI 10.1073/pnas.69.10.2904; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lynch HT, 2003, NEW ENGL J MED, V348, P919, DOI 10.1056/NEJMra012242; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; Mendel G., 1866, VERHAND NATURF VER B, V4, P3, DOI DOI 10.5962/BHL.TITLE.61004; Miller P S, 2000, J Health Care Law Policy, V3, P225; Natl. Res. Council, 1988, MAPP SEQ HUM GEN; NIRENBERG MW, 1963, SCI AM, V208, P80, DOI 10.1038/scientificamerican0363-80; Reich DE, 2001, TRENDS GENET, V17, P502, DOI 10.1016/S0168-9525(01)02410-6; Rothenberg K, 1997, SCIENCE, V275, P1755, DOI 10.1126/science.275.5307.1755; Sachidanandam R, 2001, NATURE, V409, P928, DOI 10.1038/35057149; SANGER F, 1975, J MOL BIOL, V94, P441, DOI 10.1016/0022-2836(75)90213-2; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Sidow A, 2002, CELL, V111, P13, DOI 10.1016/S0092-8674(02)01003-6; SMITH LM, 1986, NATURE, V321, P674, DOI 10.1038/321674a0; Stockwell BR, 2000, NAT REV GENET, V1, P116, DOI 10.1038/35038557; Tyson JJ, 2001, NAT REV MOL CELL BIO, V2, P908, DOI 10.1038/35103078; *US DEP HHS US DOE, 1990, US DEP HHS US DOE NI; Van der Weyden L, 2002, PHYSIOL GENOMICS, V11, P133, DOI 10.1152/physiolgenomics.00074.2002; Wagner KR, 2002, NEUROL CLIN, V20, P645, DOI 10.1016/S0733-8619(02)00002-6; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; WATSON JD, 1953, NATURE, V171, P737, DOI 10.1038/171737a0; Zhang MQ, 2002, NAT REV GENET, V3, P698, DOI 10.1038/nrg890; 2002, NATURE GENET, V32, P461	44	1215	1308	6	133	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 24	2003	422	6934					835	847		10.1038/nature01626	http://dx.doi.org/10.1038/nature01626			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	670WR	12695777				2022-12-28	WOS:000182432600044
J	McGill, BJ				McGill, BJ			A test of the unified neutral theory of biodiversity	NATURE			English	Article							RAIN-FOREST; ABUNDANCE; COMMUNITIES; DIVERSITY; PATTERNS	One of the fundamental questions of ecology is what controls biodiversity. Recent theory suggests that biodiversity is controlled predominantly by neutral drift of species abundances(1-4). This theory has generated considerable controversy(5-12), because it claims that many mechanisms that have long been studied by ecologists (such as niches) have little involvement in structuring communities. The theory predicts that the species abundance distribution within a community should follow a zero-sum multinomial distribution (ZSM), but this has not, so far, been rigorously tested. Specifically, it remains to be shown that the ZSM fits the data significantly better than reasonable null models. Here I test whether the ZSM fits several empirical data sets better than the lognormal distribution. It does not. Not only does the ZSM fail to fit empirical data better than the lognormal distribution 95% of the time, it also fails to fit empirical data better even a majority of the time. This means that there is no evidence that the ZSM predicts abundances better than the much more parsimonious null hypothesis.	Univ Arizona, Dept Ecol & Evolut Biol, Tucson, AZ 85721 USA	University of Arizona	McGill, BJ (corresponding author), Univ Arizona, Dept Ecol & Evolut Biol, Tucson, AZ 85721 USA.	mail@brianmcgill.org	McGill, Brian J/A-3476-2008	McGill, Brian J/0000-0002-0850-1913				Abrams PA, 2001, NATURE, V412, P858, DOI 10.1038/35091120; Bell G, 2001, SCIENCE, V293, P2413, DOI 10.1126/science.293.5539.2413; Burslem DFRP, 2000, J ECOL, V88, P1063, DOI 10.1046/j.1365-2745.2000.00517.x; Condit R, 2002, SCIENCE, V295, P666, DOI 10.1126/science.1066854; de Mazancourt C, 2001, SCIENCE, V293, P1772; Dewdney AK, 2000, BIOL BULL-US, V198, P152, DOI 10.2307/1542811; Enquist BJ, 2002, SCIENCE, V295, P1835; Gaston K.J., 2000, PATTERN PROCESS MACR, DOI [10.1002/9780470999592, DOI 10.1002/9780470999592]; Grimmett G., 1992, PROBABILITY RANDOM P; Harte J, 1999, SCIENCE, V284, P334, DOI 10.1126/science.284.5412.334; Hilborn Ray, 1997, V28; HUBBELL SP, 1979, SCIENCE, V203, P1299, DOI 10.1126/science.203.4387.1299; HUBBELL SP, 1975, COMMUNITY ECOLOGY, P314; Hubbell Stephen P., 2001, V32, pi; Kimura M., 1983, NEUTRAL THEORY MOL E; Laurance WF, 1998, ECOLOGY, V79, P2032, DOI 10.1890/0012-9658(1998)079[2032:RFFATD]2.0.CO;2; Levine JM, 2002, TRENDS ECOL EVOL, V17, P99; May R.M., 1975, P81; MCGILL BJ, IN PRESS OIKOS; PIELOU E C, 1969, P286; PRICE J, 1995, SUMMER ATLAS N AM BI; Pyke CR, 2001, J VEG SCI, V12, P553, DOI 10.2307/3237007; ROBBINS C. S., 1986, RESOURCE PUBLICATION, V157, piii; SAUER JR, 2001, N AM BREEDINB BIRD S; Terborgh J, 1996, ECOLOGY, V77, P561, DOI 10.2307/2265630; TOKESHI M, 1993, ADV ECOL RES, V24, P111, DOI 10.1016/S0065-2504(08)60042-2; Yu DW, 1998, ECOL LETT, V1, P193; Yu DW, 2002, TRENDS ECOL EVOL, V17, P353, DOI 10.1016/S0169-5347(02)02575-2	28	347	374	4	174	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 24	2003	422	6934					881	885		10.1038/nature01583	http://dx.doi.org/10.1038/nature01583			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	670WR	12692564				2022-12-28	WOS:000182432600052
J	Kusminsky, RE				Kusminsky, RE			One more time	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 23	2003	289	16					2037	2038		10.1001/jama.289.16.2037	http://dx.doi.org/10.1001/jama.289.16.2037			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	669WW	12709445				2022-12-28	WOS:000182374300001
J	Wilson, BJ; Watson, MS; Prescott, GJ; Sunderland, S; Campbell, DM; Hannaford, P; Smith, WCS				Wilson, BJ; Watson, MS; Prescott, GJ; Sunderland, S; Campbell, DM; Hannaford, P; Smith, WCS			Hypertensive diseases of pregnancy and risk of hypertension and stroke in later life: results from cohort study	BRITISH MEDICAL JOURNAL			English	Article							CORONARY DEATHS; HEART-DISEASE; FOLLOW-UP; HEALTH; WOMEN; PREECLAMPSIA; ECLAMPSIA; PROGNOSIS; MOTHERS; RECALL	Objective To examine the association between hypertensive diseases of pregnancy (gestational hypertension and pre-eclampsia) and the development of circulatory diseases in later life. Design Cohort study of women who had pre-eclampsia during their first singleton pregnancy. Two comparison groups were matched for age and year of delivery, one with gestational hypertension and one with no history of raised blood pressure. Setting Maternity services. in the Grampian region of Scotland. Participants Women selected from the Aberdeen maternity and neonatal databank who were resident in Aberdeen and who delivered a first, live singleton from 1951 to 1970. Main outcome measures Current vital and cardiovascular health status ascertained through postal questionnaire survey, clinical examination, linkage to hospital discharge, and mortality data. Results There were significant positive associations between pre-eclampsia/eclampsia or gestational hypertension and later hypertension in all measures. The adjusted relative risks varied from 1.13-3.72 for gestational hypertension and 1.40-3.98 for pre-eclampsia or eclampsia. The adjusted incident rate ratio for death from stroke for the pre-eclampsia/eclampsia group was 3.59 (95% confidence interval 1.04 to 12.4). Conclusions Hypertensive diseases of pregnancy seem to be associated in later life with diseases related to hypertension. If greater awareness of this association leads to earlier diagnosis and improved management, there may be scope for reducing a proportion of the morbidity and mortality from such diseases.	Univ Aberdeen, Dept Publ Hlth, Aberdeen AB25 2ZD, Scotland; Univ Aberdeen, Dept Obstet & Gynaecol, Aberdeen AB9 1FX, Scotland; Univ Aberdeen, Dept Gen Practice & Primary Care, Aberdeen AB9 1FX, Scotland	University of Aberdeen; University of Aberdeen; University of Aberdeen	Smith, WCS (corresponding author), Univ Aberdeen, Dept Publ Hlth, Aberdeen AB25 2ZD, Scotland.		Hannaford, Philip C/B-7867-2012	Prescott, Gordon/0000-0002-9156-2361				ADAMS EM, 1961, LANCET, V2, P1373; BERAL V, 1985, J EPIDEMIOL COMMUN H, V39, P343, DOI 10.1136/jech.39.4.343; CAMPBELL DM, 2000, HDB HYPERTENSION, V20; CARELTON H, 1988, AM J OBSTET GYNECOL, V159, P156; CARLETON H, 1988, AM J OBSTET GYNECOL, V159, P156, DOI 10.1016/0002-9378(88)90513-3; DUFFUS GM, 1968, LANCET, V1, P994; GIBSON GB, 1959, BRIT MED J, V2, P159, DOI 10.1136/bmj.2.5145.159; HAKIM RB, 1992, AM J EPIDEMIOL, V136, P566, DOI 10.1093/oxfordjournals.aje.a116534; Hall MH, 1992, EFFECTS SMOKING FETU, P81; Hannaford P, 1997, HEART, V77, P154, DOI 10.1136/hrt.77.2.154; Irgens HU, 2001, BRIT MED J, V323, P1213, DOI 10.1136/bmj.323.7323.1213; Kendrick Stephen, 1993, Health Bulletin (Edinburgh), V51, P72; KOTCHEN JM, 1982, AM J EPIDEMIOL, V115, P861, DOI 10.1093/oxfordjournals.aje.a113373; LINDEBERG S, 1988, ACTA OBSTET GYN SCAN, V67, P605, DOI 10.3109/00016348809004272; *NAT HIGH BLOOD PR, REP HIGH BLOOD PRESS; NEUGEBAUER R, 1990, J CLIN EPIDEMIOL, V43, P1337, DOI 10.1016/0895-4356(90)90100-4; *OFF POP CENS SURV, 1992, MORT STAT DH2, V19; PLESS CE, 1995, ARCH PEDIAT ADOL MED, V149, P553, DOI 10.1001/archpedi.1995.02170180083016; SAMPHIER ML, 1981, PROSPECTIVE LONGITUD; SELVAGGI L, 1988, INT J GYNECOL OBSTET, V27, P45, DOI 10.1016/0020-7292(88)90086-0; SIBAI BM, 1992, AM J OBSTET GYNECOL, V166, P1757, DOI 10.1016/0002-9378(92)91566-S; SIBAI BM, 1986, AM J OBSTET GYNECOL, V155, P1011, DOI 10.1016/0002-9378(86)90336-4; SINGH MM, 1974, J OBSTET GYN BR COMM, V81, P903; Smith GCS, 2001, LANCET, V357, P2002, DOI 10.1016/S0140-6736(00)05112-6; SMITH WCS, 1989, SCOT MED J, V34, P550, DOI 10.1177/003693308903400603; SMITH WCS, 1990, BRIT HEART J, V64, P295; Svensson A, 1983, J Hypertens Suppl, V1, P94; Todd G. F., 1969, STAT SMOKING UK; TUNSTALLPEDOE H, 1994, CIRCULATION, V90, P583, DOI 10.1161/01.CIR.90.1.583; Womersley J, 1996, J PUBLIC HEALTH MED, V18, P465, DOI 10.1093/oxfordjournals.pubmed.a024546; Yawn BP, 1998, J CLIN EPIDEMIOL, V51, P399, DOI 10.1016/S0895-4356(97)00304-1	31	460	504	2	68	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 19	2003	326	7394					845	849		10.1136/bmj.326.7394.845	http://dx.doi.org/10.1136/bmj.326.7394.845			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	670BF	12702615	Green Accepted, Bronze, Green Published			2022-12-28	WOS:000182386800015
J	Canfield, RL; Henderson, CR; Cory-Slechta, DA; Cox, C; Jusko, TA; Lanphear, BP				Canfield, RL; Henderson, CR; Cory-Slechta, DA; Cox, C; Jusko, TA; Lanphear, BP			Intellectual impairment in children with blood lead concentrations below 10 mu g per deciliter	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	21st Annual Meeting of the Behavioral-Toxicology-Society	APR 20-22, 2002	RES TRIANGLE PK, NORTH CAROLINA	Behav Toxicol Soc			PORT-PIRIE COHORT; ENVIRONMENTAL LEAD; COGNITIVE FUNCTION; NEUROPSYCHOLOGICAL DEVELOPMENT; PRESCHOOL-CHILDREN; PRIMARY PREVENTION; BONE LEAD; EXPOSURE; INTELLIGENCE; LEVEL	BACKGROUND: Despite dramatic declines in children's blood lead concentrations and a lowering of the Centers for Disease Control and Prevention's level of concern to 10 microg per deciliter (0.483 micromol per liter), little is known about children's neurobehavioral functioning at lead concentrations below this level. METHODS: We measured blood lead concentrations in 172 children at 6, 12, 18, 24, 36, 48, and 60 months of age and administered the Stanford-Binet Intelligence Scale at the ages of 3 and 5 years. The relation between IQ and blood lead concentration was estimated with the use of linear and nonlinear mixed models, with adjustment for maternal IQ, quality of the home environment, and other potential confounders. RESULTS: The blood lead concentration was inversely and significantly associated with IQ. In the linear model, each increase of 10 microg per deciliter in the lifetime average blood lead concentration was associated with a 4.6-point decrease in IQ (P=0.004), whereas for the subsample of 101 children whose maximal lead concentrations remained below 10 microg per deciliter, the change in IQ associated with a given change in lead concentration was greater. When estimated in a nonlinear model with the full sample, IQ declined by 7.4 points as lifetime average blood lead concentrations increased from 1 to 10 microg per deciliter. CONCLUSIONS: Blood lead concentrations, even those below 10 microg per deciliter, are inversely associated with children's IQ scores at three and five years of age, and associated declines in IQ are greater at these concentrations than at higher concentrations. These findings suggest that more U.S. children may be adversely affected by environmental lead than previously estimated.	Cornell Univ, Coll Human Ecol, Div Nutr Sci, Ithaca, NY 14853 USA; Cornell Univ, Coll Human Ecol, Dept Human Dev, Ithaca, NY USA; Univ Rochester, Sch Med, Dept Environm Med, Rochester, NY USA; Univ Rochester, Sch Med, Dept Biostat & Computat Biol, Rochester, NY USA; NICHHD, Div Epidemiol Stat & Prevent, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA; Univ Washington, Sch Publ Hlth & Community Med, Dept Epidemiol, Seattle, WA 98195 USA; Childrens Hosp, Med Ctr, Cincinnati Childrens Environm Hlth Ctr, Cincinnati, OH 45229 USA	Cornell University; Cornell University; University of Rochester; University of Rochester; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of Washington; University of Washington Seattle; Cincinnati Children's Hospital Medical Center	Canfield, RL (corresponding author), Cornell Univ, Coll Human Ecol, Div Nutr Sci, Ithaca, NY 14853 USA.				NIEHS NIH HHS [R01 ES08388, ES01247, R01 ES008388, P30 ES001247] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES001247, R01ES008388] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bae DS, 2001, TOXICOL SCI, V63, P132, DOI 10.1093/toxsci/63.1.132; BAGHURST PA, 1992, NEW ENGL J MED, V327, P1279, DOI 10.1056/NEJM199210293271805; BELLINGER D, 1994, PEDIATR ANN, V23, P600, DOI 10.3928/0090-4481-19941101-08; BELLINGER D, 1991, PEDIATRICS, V87, P219; BELLINGER D, 1994, PEDIATRICS, V93, pA28; BELLINGER DC, 1983, J PEDIATR-US, V102, P523, DOI 10.1016/S0022-3476(83)80178-4; BELLINGER DC, 1992, PEDIATRICS, V90, P855; BUCK SF, 1960, J ROY STAT SOC B, V22, P302; Caldwell B., 1984, HOME OBSERVATION MEA; Centers for Disease Control, 1991, PREV LEAD POIS YOUNG; Cheng YW, 2001, AM J EPIDEMIOL, V153, P164, DOI 10.1093/aje/153.2.164; CORYSLECHTA DA, 1995, ANNU REV PHARMACOL, V35, P391, DOI 10.1146/annurev.pharmtox.35.1.391; DIETRICH KN, 1993, NEUROTOXICOL TERATOL, V15, P37, DOI 10.1016/0892-0362(93)90043-N; Dietrich KN, 2001, NEUROTOXICOL TERATOL, V23, P511, DOI 10.1016/S0892-0362(01)00184-2; FULTON M, 1987, LANCET, V1, P1221; HENDERSON CR, 1982, BIOMETRICS, V38, P623, DOI 10.2307/2530044; International Programme on Chemical Safety, 1995, ENV HLTH CRIT, V165; *JM SATTL, 1992, ASS CHILDR; Langford IH, 1998, J ROY STAT SOC A STA, V161, P121, DOI 10.1111/1467-985X.00094; Lanphear BP, 2000, PUBLIC HEALTH REP, V115, P521, DOI 10.1093/phr/115.6.521; Lanphear BP, 1999, PEDIATRICS, V103, P772, DOI 10.1542/peds.103.4.772; Lanphear BP, 1998, SCIENCE, V281, P1617, DOI 10.1126/science.281.5383.1617; Lanphear BP, 1998, SCIENCE, V282, P51; Lanphear BP, 1996, AM J PUBLIC HEALTH, V86, P1416, DOI 10.2105/AJPH.86.10.1416; Lin JL, 2003, NEW ENGL J MED, V348, P277, DOI 10.1056/NEJMoa021672; Marsden PA, 2003, NEW ENGL J MED, V348, P345, DOI 10.1056/NEJMe020164; MCCROWELL KL, 1994, J PSYCHOEDUC ASSESS, V12, P126, DOI 10.1177/073428299401200202; MCMICHAEL AJ, 1992, NEUROTOXICOL TERATOL, V14, P321, DOI 10.1016/0892-0362(92)90038-C; MCMICHAEL AJ, 1988, NEW ENGL J MED, V319, P468, DOI 10.1056/NEJM198808253190803; Moss ME, 1999, JAMA-J AM MED ASSOC, V281, P2294, DOI 10.1001/jama.281.24.2294; NEEDLEMAN HL, 1990, JAMA-J AM MED ASSOC, V263, P673, DOI 10.1001/jama.263.5.673; Needleman HL, 1996, JAMA-J AM MED ASSOC, V275, P363, DOI 10.1001/jama.275.5.363; PEOPLES CE, 1995, INTELLIGENCE, V21, P69, DOI 10.1016/0160-2896(95)90039-X; POCOCK SJ, 1994, BRIT MED J, V309, P1189, DOI 10.1136/bmj.309.6963.1189; RICE DC, 1993, NEUROTOXICOLOGY, V14, P167; Rogan WJ, 2001, NEW ENGL J MED, V344, P1421, DOI 10.1056/NEJM200105103441902; Rosen JF, 2001, NEW ENGL J MED, V344, P1470, DOI 10.1056/NEJM200105103441910; Ruppert D., 2003, SEMIPARAMETRIC REGRE; SCHWARTZ J, 1995, ARCH ENVIRON HEALTH, V50, P31, DOI 10.1080/00039896.1995.9955010; SCHWARTZ J, 1994, ENVIRON RES, V65, P42, DOI 10.1006/enrs.1994.1020; SCHWARTZ J, 1993, NEUROTOXICOLOGY, V14, P237; Searle S.R., 1971, LINEAR MODELS; Segal N., 1985, HDB INTELLIGENCE THE, P391; Stone B. M., 2003, ARCH CLIN NEUROPSYCH, V613, P1; THORNDIKE RL, 1986, STANFORDBINET INTELL; Tong S, 1998, JAMA-J AM MED ASSOC, V280, P1915, DOI 10.1001/jama.280.22.1915; Tong S, 1996, BRIT MED J, V313, P198; Tong SL, 1996, BRIT MED J, V312, P1569, DOI 10.1136/bmj.312.7046.1569; Tong SL, 2001, ANN EPIDEMIOL, V11, P38, DOI 10.1016/S1047-2797(00)00176-9; Wasserman GA, 1997, ENVIRON HEALTH PERSP, V105, P956, DOI 10.1289/ehp.97105956; Wasserman GA, 2000, NEUROTOXICOL TERATOL, V22, P811, DOI 10.1016/S0892-0362(00)00106-9; Wasserman GA, 1998, AM J PUBLIC HEALTH, V88, P481, DOI 10.2105/AJPH.88.3.481; WINNEKE G, 1994, NEUROTOXICOLOGY, V15, P705	53	1483	1549	3	133	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 17	2003	348	16					1517	1526		10.1056/NEJMoa022848	http://dx.doi.org/10.1056/NEJMoa022848			10	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	667TT	12700371	Bronze, Green Accepted			2022-12-28	WOS:000182248900002
J	Chapman, SC; Blain, AW; Ivison, RJ; Smail, IR				Chapman, SC; Blain, AW; Ivison, RJ; Smail, IR			A median redshift of 2.4 for galaxies bright at submillimetre wavelengths	NATURE			English	Article							LYMAN-BREAK GALAXIES; DEEP FIELD-NORTH; STAR-FORMATION; LENSING CLUSTERS; RADIO-EMISSION; EVOLUTION	A significant fraction of the energy emitted in the early Universe came from very luminous galaxies that are largely hidden at optical wavelengths (because of interstellar dust grains); this energy now forms part of the cosmic background radiation at wavelengths near 1 mm (ref. 1). Some submillimetre (submm) galaxies have been resolved from the background radiation(2), but they have been difficult to study because of instrumental limitations(3). This has impeded the determination of their redshifts (z), which is a crucial element in understanding their nature and evolution(4). Here we report spectroscopic redshifts for ten submm galaxies that were identified using high-resolution radio observations(5-7). The median redshift for our sample is 2.4, with a quartile range of 1.9-2.8. This population therefore coexists with the peak activity of quasars, suggesting a close relationship between the growth of massive black holes and luminous dusty galaxies(8). The space density of submm galaxies at redshifts over 2 is about 1,000 times greater than that of similarly luminous galaxies in the present-day Universe, so they represent an important component of star formation at high redshifts.	CALTECH, Pasadena, CA 91125 USA; Royal Observ, Astron Technol Ctr, Edinburgh EH9 3HJ, Midlothian, Scotland; Univ Durham, Inst Computat Cosmol, Durham DH1 3LE, England	California Institute of Technology; University of Edinburgh; Durham University	Chapman, SC (corresponding author), CALTECH, Pasadena, CA 91125 USA.	schapman@irastro.caltech.edu	Smail, Ian/M-5161-2013; Smail, Ian/AAL-9018-2020; Ivison, R. J./G-4450-2011	Smail, Ian/0000-0003-3037-257X; Smail, Ian/0000-0003-3037-257X; Ivison, R. J./0000-0001-5118-1313				Barger AJ, 2000, ASTRON J, V119, P2092, DOI 10.1086/301341; Barger AJ, 2002, ASTRON J, V124, P1839, DOI 10.1086/342448; Barger AJ, 1999, ASTRON J, V117, P2656, DOI 10.1086/300890; Barger AJ, 1998, NATURE, V394, P248, DOI 10.1038/28338; Blain AW, 2002, PHYS REP, V369, P111, DOI 10.1016/S0370-1573(02)00134-5; Blain AW, 1999, MON NOT R ASTRON SOC, V302, P632, DOI 10.1046/j.1365-8711.1999.02178.x; Boyle BJ, 2000, MON NOT R ASTRON SOC, V317, P1014, DOI 10.1046/j.1365-8711.2000.03730.x; Chapman SC, 2003, ASTROPHYS J, V585, P57, DOI 10.1086/345980; Chapman SC, 2002, MON NOT R ASTRON SOC, V335, pL17, DOI 10.1046/j.1365-8711.2002.05760.x; Chapman SC, 2002, ASTROPHYS J, V570, P557, DOI 10.1086/339498; Chapman SC, 2001, ASTROPHYS J, V548, pL147, DOI 10.1086/319111; CHAPMAN SC, IN PRESS ASTROPHYS J; CONDON JJ, 1992, ANNU REV ASTRON ASTR, V30, P575, DOI 10.1146/annurev.aa.30.090192.003043; Cowie LL, 2002, ASTRON J, V123, P2197, DOI 10.1086/339978; Fixsen DJ, 1998, ASTROPHYS J, V508, P123, DOI 10.1086/306383; Fomalont EB, 2002, ASTRON J, V123, P2402, DOI 10.1086/339308; Ivison RJ, 2000, MON NOT R ASTRON SOC, V315, P209, DOI 10.1046/j.1365-8711.2000.03376.x; Ivison RJ, 1998, MON NOT R ASTRON SOC, V298, P583, DOI 10.1046/j.1365-8711.1998.01677.x; Ivison RJ, 2002, MON NOT R ASTRON SOC, V337, P1, DOI 10.1046/j.1365-8711.2002.05900.x; Kennicutt RC, 1998, ANNU REV ASTRON ASTR, V36, P189, DOI 10.1146/annurev.astro.36.1.189; OKE JB, 1995, PUBL ASTRON SOC PAC, V107, P375, DOI 10.1086/133562; Richards EA, 2000, ASTROPHYS J, V533, P611, DOI 10.1086/308684; Scott SE, 2002, MON NOT R ASTRON SOC, V331, P817, DOI 10.1046/j.1365-8711.2002.05193.x; Sheinis AI, 2002, PUBL ASTRON SOC PAC, V114, P851, DOI 10.1086/341706; Smail I, 2002, MON NOT R ASTRON SOC, V331, P495, DOI 10.1046/j.1365-8711.2002.05203.x; Smail I, 1997, ASTROPHYS J, V490, pL5, DOI 10.1086/311017; SMAIL I, IN PRESS MON NAT R A; STEIDEL C, IN PRESS ASTROPHYS J; Steidel CC, 1999, ASTROPHYS J, V519, P1, DOI 10.1086/307363	30	401	403	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 17	2003	422	6933					695	698		10.1038/nature01540	http://dx.doi.org/10.1038/nature01540			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	668CG	12700754	Green Submitted, Green Accepted			2022-12-28	WOS:000182272300033
J	Hedges, R				Hedges, R			Puzzling out the past	NATURE			English	Editorial Material									Univ Oxford, Res Lab Archaeol, Oxford OX1 3QJ, England	University of Oxford	Hedges, R (corresponding author), Univ Oxford, Res Lab Archaeol, 6 Keble Rd, Oxford OX1 3QJ, England.							COOK GT, 2002, ANTIQUITY, V76, P77; DENIRO MJ, 1987, AM SCI, V75, P182; FERGUSON CW, 1968, SCIENCE, V159, P839, DOI 10.1126/science.159.3817.839	3	1	1	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 17	2003	422	6933					667	667		10.1038/422667a	http://dx.doi.org/10.1038/422667a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	668CG	12700740				2022-12-28	WOS:000182272300021
J	Shi, YJ; Sawada, J; Sui, GC; Affar, EB; Whetstine, JR; Lan, F; Ogawa, H; Luke, MPS; Nakatani, Y; Shi, Y				Shi, YJ; Sawada, J; Sui, GC; Affar, EB; Whetstine, JR; Lan, F; Ogawa, H; Luke, MPS; Nakatani, Y; Shi, Y			Coordinated histone modifications mediated by a CtBP co-repressor complex	NATURE			English	Article							COREPRESSOR; PROTEIN; TRANSCRIPTION; TRANSFORMATION; METHYLATION; EXPRESSION; FAMILY; GENES	The transcriptional co-repressor CtBP (C-terminal binding protein) is implicated in tumorigenesis because it is targeted by the adenovirus E1A protein during oncogenic transformation(1). Genetic studies have also identified a crucial function for CtBP in animal development(2). CtBP is recruited to DNA by transcription factors that contain a PXDLS motif(3,4), but the detailed molecular events after the recruitment of CtBP to DNA and the mechanism of CtBP function in tumorigenesis are largely unknown. Here we report the identification of a CtBP complex that contains the essential components for both gene targeting and coordinated histone modifications, allowing for the effective repression of genes targeted by CtBP. Inhibiting the expression of CtBP and its associated histone-modifying activities by RNA-mediated interference resulted in alterations of histone modifications at the promoter of the tumour invasion suppressor gene E-cadherin and increased promoter activity in a reporter assay. These findings identify a molecular mechanism by which CtBP mediates transcriptional repression and provide insight into CtBP participation in oncogenesis.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Dana Farber Canc Inst, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute	Shi, Y (corresponding author), Harvard Univ, Sch Med, Dept Pathol, 200 Longwood Ave, Boston, MA 02115 USA.	yang_shi@hms.harvard.edu	Ogawa, Hidesato/A-2079-2016; Ogawa, Hidesato/M-3778-2019	Ogawa, Hidesato/0000-0001-9740-9010; Sui, Guangchao/0000-0002-8164-5585				Ballas N, 2001, NEURON, V31, P353, DOI 10.1016/S0896-6273(01)00371-3; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; Chinnadurai G, 2003, BIOESSAYS, V25, P9, DOI 10.1002/bies.10212; Chinnadurai G, 2002, MOL CELL, V9, P213, DOI 10.1016/S1097-2765(02)00443-4; Collins C, 1998, P NATL ACAD SCI USA, V95, P8703, DOI 10.1073/pnas.95.15.8703; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Grooteclaes ML, 2000, ONCOGENE, V19, P3823, DOI 10.1038/sj.onc.1203721; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kouzarides T, 2002, CURR OPIN GENET DEV, V12, P198, DOI 10.1016/S0959-437X(02)00287-3; Kumar V, 2002, MOL CELL, V10, P857, DOI 10.1016/S1097-2765(02)00650-0; Lahn BT, 1999, NAT GENET, V21, P429, DOI 10.1038/7771; Nibu Y, 1998, SCIENCE, V280, P101, DOI 10.1126/science.280.5360.101; Ogawa H, 2002, SCIENCE, V296, P1132, DOI 10.1126/science.1069861; Postigo AA, 1999, P NATL ACAD SCI USA, V96, P6683, DOI 10.1073/pnas.96.12.6683; Satijn DPE, 1997, MOL CELL BIOL, V17, P6076, DOI 10.1128/MCB.17.10.6076; Schmitz F, 2000, NEURON, V28, P857, DOI 10.1016/S0896-6273(00)00159-8; Sewalt RGAB, 1999, MOL CELL BIOL, V19, P777; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Tachibana M, 2001, J BIOL CHEM, V276, P25309, DOI 10.1074/jbc.M101914200; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; You A, 2001, P NATL ACAD SCI USA, V98, P1454, DOI 10.1073/pnas.98.4.1454; Zhang QH, 2002, SCIENCE, V295, P1895; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301	24	610	639	2	56	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 17	2003	422	6933					735	738		10.1038/nature01550	http://dx.doi.org/10.1038/nature01550			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	668CG	12700765				2022-12-28	WOS:000182272300045
J	Skelly, M; Hoffman, J; Fabbri, M; Holzman, RS; Clarkson, AB; Merali, S				Skelly, M; Hoffman, J; Fabbri, M; Holzman, RS; Clarkson, AB; Merali, S			S-adenosylmethionine concentrations in diagnosis of Pneumocystis carinii pneumonia	LANCET			English	Article								Pneumocystis carinii is unable to synthesise S-adenosylmethionine and thus scavenges this intermediate. We aimed to test whether measurement of concentrations of this metabolic intermediate in plasma could provide a new method for rapid diagnosis of Pneumocystis carinii pneumonia (PCP). We measured S-adenosylmethionine plasma concentrations in 12 healthy controls, 16 patients with confirmed or suspected PCP, and 36 patients with other infections. Median concentration in healthy controls was 106 nmol/L (range 86-128), but the protein was undetectable in eight patients with histologically proven and seven with suspected PCP, and was 8 nmol/L in another confirmed case (p<0.0001). In 36 patients with other infections, S-adenosylmethionine concentrations were much the same as in controls: IS had bacterial pneumonia, two tuberculosis, five cryptococcal meningitis, three had other infections, and eight had asymptomatic HIV-1 infection. After treatment for PCP, S-adenosylmethionine concentrations rose rapidly in all but one patient who died of the disease. Measurement of plasma S-adenosylmethlonine concentrations could prove useful for diagnosis of PCP and assessment of patients' response to treatment.	NYU, Sch Med, Dept Med & Mol Parasitol, New York, NY 10010 USA; NYU, Bellevue Hosp Ctr, Dept Med, New York, NY 10016 USA	New York University; Bellevue Hospital Center; New York University	Merali, S (corresponding author), NYU, Sch Med, Dept Med & Mol Parasitol, New York, NY 10010 USA.							Barry S M, 2001, HIV Med, V2, P123, DOI 10.1046/j.1468-1293.2001.00062.x; Chiang PK, 1996, FASEB J, V10, P471, DOI 10.1096/fasebj.10.4.8647346; Kaplan JE, 2000, CLIN INFECT DIS, V30, pS5, DOI 10.1086/313843; Merali S, 2000, J BIOL CHEM, V275, P14958, DOI 10.1074/jbc.275.20.14958; Merali S, 1999, P NATL ACAD SCI USA, V96, P2402, DOI 10.1073/pnas.96.5.2402	5	43	45	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 12	2003	361	9365					1267	1268		10.1016/S0140-6736(03)12984-4	http://dx.doi.org/10.1016/S0140-6736(03)12984-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	666DM	12699956				2022-12-28	WOS:000182161600012
J	Ewer, K; Deeks, J; Alvarez, L; Bryant, S; Waller, S; Andersen, P; Monk, P; Lalvani, A				Ewer, K; Deeks, J; Alvarez, L; Bryant, S; Waller, S; Andersen, P; Monk, P; Lalvani, A			Comparison of T-cell-based assay with tuberculin skin test for diagnosis of Mycobacterium tuberculosis infection in a school tuberculosis outbreak	LANCET			English	Article							IMMUNE-RESPONSES; BOVIS BCG; ESAT-6; ENUMERATION; ANTIGENS; PROTEIN	Background The diagnosis of latent tuberculosis infection relies on the tuberculin skin test (TST), which has many drawbacks. However, to find out whether new tests are better than TST is difficult because of the lack of a gold standard test for latent infection. We developed and assessed a sensitive enzyme-linked immunospot (ELISPOT) assay to detect T cells specific for Mycobacterium tuberculosis antigens that are absent from Mycobacterium bovis BCG and most environmental mycobacteria. We postulated that if the ELISPOT is a more accurate test of latent infection than TST, it should correlate better with degree of exposure to M tuberculosis. Methods A large tuberculosis outbreak in a UK school resulted from one infectious index case. We tested 535 students for M tuberculosis infection with TST and ELISPOT. We compared the correlation of these tests with degree of exposure to the index case and BCG vaccination. Findings Although agreement between the tests was high (89% concordance, kappa=0.72, p<0.0001), ELISPOT correlated significantly more closely with M tuberculosis exposure than did TST on the basis of measures of proximity (p=0.03) and duration of exposure (p=0.007) to the index case. TST was significantly more likely to be positive in BCG-vaccinated than in non-vaccinated students (p=0.002), whereas EUSPOT results were not associated with BCG vaccination (p=0.44). Interpretation ELISPOT offers a more accurate approach than TST for identification of individuals who have latent tuberculosis infection and could improve tuberculosis control by more precise targeting of preventive treatment.	Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Med, Oxford OX3 9DU, England; Inst Hlth Sci, Ctr Stat Med, Oxford, England; Leicestershire Area Hlth Author, Leicester, Leics, England; Statens Serum Inst, DK-2300 Copenhagen, Denmark	University of Oxford; University of Oxford; Statens Serum Institut	Lalvani, A (corresponding author), Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Med, Level 7, Oxford OX3 9DU, England.		Alvarez-Erviti, Lydia/B-4353-2011; Alvarez-Erviti, Lydia/AAW-5850-2021; Deeks, Jon/AAV-5745-2020; Ewer, Katie J/B-4328-2011	Deeks, Jon/0000-0002-8850-1971; Ewer, Katie J/0000-0001-9827-9836; Andersen, Peter/0000-0002-5869-2551; Lalvani, Ajit/0000-0002-2396-246X; Alvarez-Erviti, Lydia/0000-0002-1238-9442				Andersen P, 2000, LANCET, V356, P1099, DOI 10.1016/S0140-6736(00)02742-2; [Anonymous], 2000, AM J RESP CRIT CARE, V161, pS221; Arend SM, 2000, J INFECT DIS, V181, P1850, DOI 10.1086/315448; Barnes PF, 2001, AM J RESP CRIT CARE, V163, P807, DOI 10.1164/ajrccm.163.4.ed0201c; Black GF, 2002, LANCET, V359, P1393, DOI 10.1016/S0140-6736(02)08353-8; Brock I, 2001, INT J TUBERC LUNG D, V5, P462; Carruthers K J, 1969, Tubercle, V50, P22, DOI 10.1016/0041-3879(69)90005-1; Chapman ALN, 2002, AIDS, V16, P2285, DOI 10.1097/00002030-200211220-00008; Deeks~ JJ, 2001, SYSTEMATIC REV HLTH; Doherty TM, 2002, J CLIN MICROBIOL, V40, P704, DOI 10.1128/JCM.40.2.704-706.2002; GRZYBOWSKI S, 1975, Bulletin of the International Union Against Tuberculosis, V50, P90; Harboe M, 1996, INFECT IMMUN, V64, P16, DOI 10.1128/IAI.64.1.16-22.1996; HMSO, 1996, IMM INF DIS; HOUK VN, 1968, ARCH ENVIRON HEALTH, V16, P26, DOI 10.1080/00039896.1968.10665011; HOUK VN, 1968, ARCH ENVIRON HEALTH, V16, P4, DOI 10.1080/00039896.1968.10665007; HUEBNER RE, 1993, CLIN INFECT DIS, V17, P968, DOI 10.1093/clinids/17.6.968; Jasmer RM, 2002, NEW ENGL J MED, V347, P1860, DOI 10.1056/NEJMcp021045; Kenyon TA, 1996, NEW ENGL J MED, V334, P933, DOI 10.1056/NEJM199604113341501; Lalvani A, 1997, J EXP MED, V186, P859, DOI 10.1084/jem.186.6.859; Lalvani A, 2001, AM J RESP CRIT CARE, V163, P824, DOI 10.1164/ajrccm.163.4.2009100; Lalvani A, 2001, J INFECT DIS, V183, P469, DOI 10.1086/318081; Lalvani A, 2001, LANCET, V357, P2017, DOI 10.1016/S0140-6736(00)05115-1; Lein AD, 1999, CLIN DIAGN LAB IMMUN, V6, P606, DOI 10.1128/CDLI.6.4.606-609.1999; Mahairas GG, 1996, J BACTERIOL, V178, P1274, DOI 10.1128/jb.178.5.1274-1282.1996; Mazurek GH, 2001, JAMA-J AM MED ASSOC, V286, P1740, DOI 10.1001/jama.286.14.1740; Ormerod P, 2000, THORAX, V55, P887; Rose AMC, 2001, THORAX, V56, P173, DOI 10.1136/thorax.56.3.173; SMALL PM, 1994, NEW ENGL J MED, V330, P1703, DOI 10.1056/NEJM199406163302402; STEAD WW, 1978, JAMA-J AM MED ASSOC, V240, P2544, DOI 10.1001/jama.240.23.2544; Taylor Z, 2001, AM J RESP CRIT CARE, V163, P1; Zuber PLF, 1997, JAMA-J AM MED ASSOC, V278, P304, DOI 10.1001/jama.278.4.304	31	480	518	0	16	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 5	2003	361	9364					1168	1173		10.1016/S0140-6736(03)12950-9	http://dx.doi.org/10.1016/S0140-6736(03)12950-9			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	664ZF	12686038				2022-12-28	WOS:000182094600009
J	Lindholm, LH; Samuelsson, O				Lindholm, LH; Samuelsson, O			What are the odds at ASCOT today?	LANCET			English	Editorial Material							CHOLESTEROL LEVELS; SUBGROUP ANALYSES; EVENTS; TRIAL		Umea Univ, Dept Publ Hlth & Clin Med, SE-90185 Umea, Sweden; Univ Gothenburg, Sahlgrens Univ Hosp, Dept Nephrol, Gothenburg, Sweden	Umea University; Sahlgrenska University Hospital; University of Gothenburg	Lindholm, LH (corresponding author), Umea Univ, Dept Publ Hlth & Clin Med, SE-90185 Umea, Sweden.							AULT A, 2003, REUTERS HLTH    0319; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; Furberg CD, 2002, JAMA-J AM MED ASSOC, V288, P2981; Furberg CD, 2002, JAMA-J AM MED ASSOC, V288, P2998, DOI 10.1001/jama.288.23.2998; Goldberg RB, 1998, CIRCULATION, V98, P2513, DOI 10.1161/01.CIR.98.23.2513; Haffner SM, 1999, ARCH INTERN MED, V159, P2661, DOI 10.1001/archinte.159.22.2661; SAMUELSSON O, 1987, JAMA-J AM MED ASSOC, V258, P1768; Weber Michael A, 2003, J Clin Hypertens (Greenwich), V5, P9, DOI 10.1111/j.1524-6175.2003.02287.x; 1995, J INTERN MED S737, V238, pS1	9	10	10	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 5	2003	361	9364					1144	1145		10.1016/S0140-6736(03)12977-7	http://dx.doi.org/10.1016/S0140-6736(03)12977-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	664ZF	12686031				2022-12-28	WOS:000182094600002
J	Forsyth, JS; Willatts, P; Agostoni, C; Bissenden, J; Casaer, P; Boehm, G				Forsyth, JS; Willatts, P; Agostoni, C; Bissenden, J; Casaer, P; Boehm, G			Long chain polyunsaturated fatty acid supplementation in infant formula and blood pressure in later childhood: follow up of a randomised controlled trial	BRITISH MEDICAL JOURNAL			English	Article							DOCOSAHEXAENOIC ACID; EICOSAPENTAENOIC ACID; CARDIOVASCULAR RISK; CHILDREN; DIET; RATS	Objective To determine whether supplementation of infant formula milk with long chain polyunsaturated fatty acids (LCPUFAs) influences blood pressure in later childhood. Design Follow up of a multicentre, randomised controlled trial. Setting Four study centres in Europe. Participants 147 formula fed children, with a reference group of 88 breastfed children. Intervention In the original trial newborn infants were randomised to be fed with a formula supplemented with LCPUFAs (n=111) or a formula without LCPUFAs but otherwise nutritionally similar (n=126). In the present followup Study the blood pressure of the children at age 6 years was measured. Main outcome measures Systolic, diastolic, and mean blood pressure. Results 71 children in the LCPUFA Supplementation group (64% of he original group) and 76 children in the non-supplementation group (60%) were enrolled into the follow up study. The LCPUFA group had significantly lower mean blood pressure (mean difference -3.0 mm Hg (95% confidence interval -5.4 mm Hg to -0.5 mm Hg)) and diastolic blood pressure (mean difference -3.6 mm Hg (-6.5 mm Hg to -0.6 mm Hg)) than the non-supplementation group. The diastolic pressure of the breastfed children (n=88 (63%)) was significantly lower than that of the non-supplemented formula group but did not differ from the LCPUFA, formula group. Conclusions Dietary supplementation with LCPUFAs during infancy is associated with lower blood pressure in later childhood. Blood pressure tends to track from childhood into adult life, so early exposure to dietary LCPUFAs may reduce cardiovascular risk in adulthood.	Univ Dundee, Tayside Inst Child Hlth, Dundee DD1 9SY, Scotland; Univ Dundee, Dept Psychol, Dundee DD1 4HN, Scotland; Univ Milan, Dept Paediat, Milan, Italy; City Hosp, Dept Paediat, Birmingham B18 7QH, W Midlands, England; Katholieke Univ Leuven, Dept Paediat, Louvain, Belgium; Numico Res, Friedrichsdorf, Germany	University of Dundee; University of Dundee; University of Milan; University of Birmingham; KU Leuven; Danone Nutricia; Royal Numico N.V.	Forsyth, JS (corresponding author), Univ Dundee, Tayside Inst Child Hlth, Dundee DD1 9SY, Scotland.		Agostoni, Carlo/B-3470-2015; Agostoni, Carlo/A-9303-2012	Agostoni, Carlo/0000-0002-5006-0832; 				CLANDININ MT, 1981, EARLY HUM DEV, V5, P355, DOI 10.1016/0378-3782(81)90016-5; COOK NR, 1995, ARCH INTERN MED, V155, P701, DOI 10.1001/archinte.155.7.701; Cunnane SC, 2000, LIPIDS, V35, P105, DOI 10.1007/s11745-000-0501-6; Engler M B, 2000, Biol Res Nurs, V2, P85, DOI 10.1177/109980040000200202; Engler MM, 1999, PROSTAG LEUKOTR ESS, V61, P289, DOI 10.1054/plef.1999.0102; Forsyth JS, 1999, ARCH DIS CHILD, V81, P253, DOI 10.1136/adc.81.3.253; Koletzko B, 2001, ACTA PAEDIATR, V90, P460, DOI 10.1080/080352501750126492; LangleyEvans SC, 1996, INT J FOOD SCI NUTR, V47, P417, DOI 10.3109/09637489609006955; Makrides M, 2000, PEDIATRICS, V105, P32, DOI 10.1542/peds.105.1.32; Mori TA, 1999, HYPERTENSION, V34, P253, DOI 10.1161/01.HYP.34.2.253; Mori TA, 2000, CIRCULATION, V102, P1264, DOI 10.1161/01.CIR.102.11.1264; Mori TA, 2001, CURR OPIN LIPIDOL, V12, P11, DOI 10.1097/00041433-200102000-00003; Rose G., 1992, STRATEGY PREVENTIVE; Rousseau D, 2001, MOL CELL BIOCHEM, V225, P109, DOI 10.1023/A:1012266005428; Singhal A, 2001, LANCET, V357, P413, DOI 10.1016/S0140-6736(00)04004-6; Taittonen L, 1996, PEDIATR RES, V40, P627, DOI 10.1203/00006450-199610000-00019; Weisinger HS, 2001, NAT MED, V7, P258, DOI 10.1038/85354; WHINCUP P, 1995, BRIT MED J, V311, P773, DOI 10.1136/bmj.311.7008.773; Willatts P, 1998, LANCET, V352, P688, DOI 10.1016/S0140-6736(97)11374-5; Wilson AC, 1998, BMJ-BRIT MED J, V316, P21, DOI 10.1136/bmj.316.7124.21; Wilson S A, 1998, J Palliat Med, V1, P21, DOI 10.1089/jpm.1998.1.21	21	149	154	0	17	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 3	2003	326	7396					953	955		10.1136/bmj.326.7396.953	http://dx.doi.org/10.1136/bmj.326.7396.953			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	676JC	12727766	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000182746700014
J	Khot, UN; Novaro, GM; Popovic, ZB; Mills, RM; Thomas, JD; Tuzcu, EM; Hammer, D; Nissen, SE; Francis, GS				Khot, UN; Novaro, GM; Popovic, ZB; Mills, RM; Thomas, JD; Tuzcu, EM; Hammer, D; Nissen, SE; Francis, GS			Nitroprusside in critically ill patients with left ventricular dysfunction and aortic stenosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONGESTIVE-HEART-FAILURE; VALVE-REPLACEMENT; BALLOON VALVULOPLASTY; AREA; ECHOCARDIOGRAPHY; PROGNOSIS; INFUSION; THERAPY; ADULTS	BACKGROUND: Vasodilators are considered to be contraindicated in patients with severe aortic stenosis because of concern that they may precipitate life-threatening hypotension. However, vasodilators such as nitroprusside may improve myocardial performance if peripheral vasoconstriction is contributing to afterload. METHODS: We determined the response to intravenous nitroprusside in 25 patients with severe aortic stenosis and left ventricular systolic dysfunction. Patients were included in the study if they had been admitted to the intensive care unit for invasive hemodynamic monitoring of heart failure and if they had a depressed ejection fraction (lessthan/equal 0.35), severe aortic stenosis (aortic-valve area, lessthan/equal 1 cm(sup 2)), and a depressed cardiac index (lessthan/equal 2.2 liters per minute per square meter). Patients were excluded if they had hypotension, defined as either the need for intravenous inotropic or pressor agents or a low mean systemic arterial pressure (<60 mm Hg). Patients were enrolled irrespective of other, coexisting valve disease or coronary artery disease. RESULTS: At base line, the mean (+/-SD) ejection fraction was 0.21+/-0.08; the aortic-valve area was 0.6+/-0.2 cm(sup 2), with peak and mean gradients of 65+/-37 and 39+/-23 mm Hg, respectively; and the cardiac index was 1.60+/-0.35 liters per minute per square meter. After six hours of therapy with nitroprusside (at which time the dose had been increased to a mean of 103+/-67 microg per minute), the cardiac index had increased to 2.22+/-0.44 liters per minute per square meter (P<0.001 for the comparison with base line). After 24 hours of nitroprusside infusion (dose, 128+/-96 microg per minute), the cardiac index had increased further, to 2.52+/-0.55 liters per minute per square meter (P<0.001 for the comparison with base line). Nitroprusside was well tolerated and had minimal side effects. CONCLUSIONS: Nitroprusside rapidly and markedly improves cardiac function in patients with decompensated heart failure due to severe left ventricular systolic dysfunction and severe aortic stenosis. It provides a safe and effective bridge to aortic-valve replacement or oral vasodilator therapy in these critically ill patients.	Indiana Heart Phys, Indianapolis, IN USA; Cleveland Clin Florida, Dept Cardiol, Weston, FL USA; Cleveland Clin Fdn, Dept Cardiol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation	Khot, UN (corresponding author), Indiana Heart Phys, 112 N 17th Ave,Suite 300, Beech Grove, IN 46107 USA.			popovic, zoran/0000-0001-5692-2299				ARONOW WS, 1993, AM J CARDIOL, V72, P846, DOI 10.1016/0002-9149(93)91081-R; AWAN N, 1977, BRIT HEART J, V39, P651; AWAN NA, 1981, AM HEART J, V101, P386, DOI 10.1016/0002-8703(81)90126-5; BAIM DS, 2000, GROSSMANS CARDIAC CA, P206; Bonow RO, 1998, J AM COLL CARDIOL, V32, P1486, DOI 10.1016/S0735-1097(98)00454-9; Brown DL, 1998, CARDIAC INTENSIVE CA, P441; CARABELLO BA, 1980, CIRCULATION, V62, P42, DOI 10.1161/01.CIR.62.1.42; Carabello BA, 1998, TXB CARDIOVASCULAR M, P533; COHN JN, 1986, NEW ENGL J MED, V314, P1547, DOI 10.1056/NEJM198606123142404; COHN JN, 1991, NEW ENGL J MED, V325, P303, DOI 10.1056/NEJM199108013250502; Frances GS, 1998, TXB CARDIOVASCULAR M, P2179; GUIHA NH, 1974, NEW ENGL J MED, V291, P587, DOI 10.1056/NEJM197409192911201; HATLE L, 1980, BRIT HEART J, V43, P284; HESS OM, 1995, CARDIOVASCULAR MED, P187; Hinchman David A., 1999, Cardiology Clinics, V17, P137, DOI 10.1016/S0733-8651(05)70061-8; HOFMANN T, 1987, AM J CARDIOL, V59, P330, DOI 10.1016/0002-9149(87)90808-3; HUTTER AM, 1970, CIRCULATION, V41, P623, DOI 10.1161/01.CIR.41.4.623; IKRAM H, 1992, AM J CARDIOL, V69, P361, DOI 10.1016/0002-9149(92)90234-P; Johnson W, 2002, J AM COLL CARDIOL, V39, P1623, DOI 10.1016/S0735-1097(02)01814-4; Lin SS, 1998, AM HEART J, V136, P1010, DOI 10.1016/S0002-8703(98)70157-7; *MED EC, 2001, DRUG TOP RED BOOK, P478; MONTIELTRUJILLO A, 2000, CONGESTIVE HEART FAI, P325; MORENO PR, 1994, J AM COLL CARDIOL, V23, P1071, DOI 10.1016/0735-1097(94)90592-4; Nohria A, 2002, JAMA-J AM MED ASSOC, V287, P628, DOI 10.1001/jama.287.5.628; OH JK, 1988, J AM COLL CARDIOL, V11, P1227, DOI 10.1016/0735-1097(88)90286-0; OTTO CM, 1986, J AM COLL CARDIOL, V7, P509, DOI 10.1016/S0735-1097(86)80460-0; PEPINE CJ, 1979, J CLIN INVEST, V64, P643, DOI 10.1172/JCI109505; Pereira JJ, 2002, J AM COLL CARDIOL, V39, P1356, DOI 10.1016/S0735-1097(02)01759-X; RAHIMTOOLA SH, 1994, J AM COLL CARDIOL, V23, P1076, DOI 10.1016/0735-1097(94)90593-2; Ross J Jr, 1968, Circulation, V38, P61; SAFIAN RD, 1988, CIRCULATION, V78, P1181, DOI 10.1161/01.CIR.78.5.1181; SAFIAN RD, 1988, NEW ENGL J MED, V319, P125, DOI 10.1056/NEJM198807213190301; SMITH N, 1978, CIRCULATION, V58, P255, DOI 10.1161/01.CIR.58.2.255; STODDARD MF, 1991, AM HEART J, V122, P1415, DOI 10.1016/0002-8703(91)90585-6; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; 1988, EUR HEART J SE, V9, P65	36	146	153	0	4	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 1	2003	348	18					1756	1763		10.1056/NEJMoa022021	http://dx.doi.org/10.1056/NEJMoa022021			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	672VK	12724481				2022-12-28	WOS:000182543500004
J	Staudt, LM				Staudt, LM			Molecular diagnosis of the hematologic cancers	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CHRONIC LYMPHOCYTIC-LEUKEMIA; ACUTE MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; B-CELL LYMPHOMA; GENOMIC ABERRATIONS; CD38 EXPRESSION; MUTATION STATUS; GENE; FLT3; PREDICTION		NCI, Metab Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Staudt, LM (corresponding author), NCI, Metab Branch, Ctr Canc Res, NIH, Bldg 10,Rm 4N114,9000 Rockville Pike, Bethesda, MD 20892 USA.		Staudt, Louis/AAC-5324-2019		NATIONAL CANCER INSTITUTE [Z01SC004024] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Armstrong SA, 2003, CANCER CELL, V3, P173, DOI 10.1016/S1535-6108(03)00003-5; Armstrong SA, 2002, NAT GENET, V30, P41, DOI 10.1038/ng765; Bloomfield CD, 1998, CANCER RES, V58, P4173; Crespo M, 2003, NEW ENGL J MED, V348, P1764, DOI 10.1056/NEJMoa023143; Damle RN, 1999, BLOOD, V94, P1840, DOI 10.1182/blood.V94.6.1840; Davis RE, 2001, J EXP MED, V194, P1861, DOI 10.1084/jem.194.12.1861; DEVITA VT, 1975, LANCET, V1, P248; Dohner H, 2000, NEW ENGL J MED, V343, P1910, DOI 10.1056/NEJM200012283432602; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Ferrando AA, 2000, SEMIN HEMATOL, V37, P381, DOI 10.1016/S0037-1963(00)90018-0; Ferrando AA, 2002, CANCER CELL, V1, P75, DOI 10.1016/S1535-6108(02)00018-1; Gilliland DG, 2002, CURR OPIN HEMATOL, V9, P274, DOI 10.1097/00062752-200207000-00003; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Hamblin TJ, 1999, BLOOD, V94, P1848, DOI 10.1182/blood.V94.6.1848; Hayakawa F, 2000, ONCOGENE, V19, P624, DOI 10.1038/sj.onc.1203354; Huang JZ, 2002, BLOOD, V99, P2285, DOI 10.1182/blood.V99.7.2285; Klein U, 2001, J EXP MED, V194, P1625, DOI 10.1084/jem.194.11.1625; Krober A, 2002, BLOOD, V100, P1410, DOI 10.1182/blood.V100.4.1410.h81602001410_1410_1416; Maloney KW, 1999, LEUKEMIA, V13, P1708, DOI 10.1038/sj.leu.2401548; Mrozek K, 2001, BEST PRACT RES CL HA, V14, P19, DOI 10.1053/beha.2000.0114; Nakao M, 1996, LEUKEMIA, V10, P1911; Nowell PC, 2002, ANNU REV MED, V53, P1, DOI 10.1146/annurev.med.53.082901.103519; Oscier DG, 2002, BLOOD, V100, P1177, DOI 10.1182/blood.V100.4.1177.h81602001177_1177_1184; Pabst T, 2001, NAT GENET, V27, P263, DOI 10.1038/85820; Rosenwald A, 2001, J EXP MED, V194, P1639, DOI 10.1084/jem.194.11.1639; Rosenwald A, 2002, NEW ENGL J MED, V346, P1937, DOI 10.1056/NEJMoa012914; Rosenwald A, 2003, CANCER CELL, V3, P185, DOI 10.1016/S1535-6108(03)00028-X; Rowley JD, 1998, ANNU REV GENET, V32, P495, DOI 10.1146/annurev.genet.32.1.495; Schoch C, 2002, P NATL ACAD SCI USA, V99, P10008, DOI 10.1073/pnas.142103599; Shaffer AL, 2001, IMMUNITY, V15, P375, DOI 10.1016/S1074-7613(01)00194-7; Shipp MA, 2002, NAT MED, V8, P68, DOI 10.1038/nm0102-68; SHIPP MA, 1993, NEW ENGL J MED, V329, P987, DOI 10.1056/nejm199309303291402; Stankovic T, 2002, BLOOD, V99, P300, DOI 10.1182/blood.V99.1.300; Staudt LM, 2000, ANNU REV IMMUNOL, V18, P829, DOI 10.1146/annurev.immunol.18.1.829; Virtaneva K, 2001, P NATL ACAD SCI USA, V98, P1124, DOI 10.1073/pnas.98.3.1124; WIESTNER A, IN PRESS BLOOD; Yamamoto Y, 2001, BLOOD, V97, P2434, DOI 10.1182/blood.V97.8.2434; Yeoh EJ, 2002, CANCER CELL, V1, P133, DOI 10.1016/S1535-6108(02)00032-6; [No title captured]	40	136	149	0	5	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 1	2003	348	18					1777	1785		10.1056/NEJMra020067	http://dx.doi.org/10.1056/NEJMra020067			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	672VK	12724484				2022-12-28	WOS:000182543500007
J	Vetter, N				Vetter, N			Inappropriately delayed discharge from hospital: What do we know?	BRITISH MEDICAL JOURNAL			English	Article							APPROPRIATENESS EVALUATION PROTOCOL; CARE; HOME; BEDS		Univ Wales Coll Med, Dept Epidemiol & Stat, Cardiff CF14 4XL, S Glam, Wales; Univ Wales Coll Med, Dept Publ Hlth, Cardiff CF14 4XL, S Glam, Wales	Cardiff University; Cardiff University	Vetter, N (corresponding author), Univ Wales Coll Med, Dept Epidemiol & Stat, Heath Pk, Cardiff CF14 4XL, S Glam, Wales.							ANDERSON P, 1988, BRIT MED J, V297, P910, DOI 10.1136/bmj.297.6653.910; Chopard P, 1998, INT J EPIDEMIOL, V27, P513, DOI 10.1093/ije/27.3.513; Coast J, 1996, INT J QUAL HEALTH C, V8, P31, DOI 10.1093/intqhc/8.1.31; Epstein J, 2001, SOC WORK HEALTH CARE, V32, P43, DOI 10.1300/J010v32n04_03; FALCONE D, 1991, HEALTH SERV RES, V26, P339; GERTMAN PM, 1981, MED CARE, V19, P855, DOI 10.1097/00005650-198108000-00005; Hermans E, 1996, SCAND J CARING SCI, V10, P81, DOI 10.1111/j.1471-6712.1996.tb00316.x; HIRSCH CH, 1990, J AM GERIATR SOC, V38, P1296, DOI 10.1111/j.1532-5415.1990.tb03451.x; Hyde CJ, 2000, AGE AGEING, V29, P271, DOI 10.1093/ageing/29.3.271; LEWIS H, 1988, NEW ZEAL MED J, V101, P575; McDonagh MS, 2000, HEALTH POLICY, V53, P157, DOI 10.1016/S0168-8510(00)00092-0; Minichiello T M, 2001, Eff Clin Pract, V4, P250; Patterson CJ, 1999, CLIN REHABIL, V13, P101, DOI 10.1191/026921599677096598; STRUMWASSER I, 1990, MED CARE, V28, P95, DOI 10.1097/00005650-199002000-00001; STYRBORN K, 1993, SCAND J SOC MED, V21, P272, DOI 10.1177/140349489302100407	15	33	34	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 26	2003	326	7395					927	928		10.1136/bmj.326.7395.927	http://dx.doi.org/10.1136/bmj.326.7395.927			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	673WQ	12714477	Green Published			2022-12-28	WOS:000182603600024
J	Bloomfield, FH; Oliver, MH; Hawkins, P; Campbell, M; Phillips, DJ; Gluckman, PD; Challis, JRG; Harding, JE				Bloomfield, FH; Oliver, MH; Hawkins, P; Campbell, M; Phillips, DJ; Gluckman, PD; Challis, JRG; Harding, JE			A periconceptional nutritional origin for noninfectious preterm birth	SCIENCE			English	Article									Univ Toronto, Dept Physiol, Toronto, ON, Canada; Univ Auckland, Liggins Inst, Auckland 1, New Zealand; Monash Univ, Ctr Mol Reprod & Endocrinol, Clayton, Vic 3168, Australia	University of Toronto; University of Auckland; Monash University	Bloomfield, FH (corresponding author), Univ Toronto, Dept Physiol, Toronto, ON, Canada.	f.bloomfield@auckland.ac.nz	Phillips, David/A-5007-2009; Challis, John RG/E-7419-2014; Bloomfield, Frank/A-1374-2008; Harding, Jane E/J-5853-2015	Harding, Jane E/0000-0003-2697-1422; Oliver, Mark/0000-0002-0359-2297; Bloomfield, Frank/0000-0001-6424-6577				Challis JRG, 2000, ENDOCR REV, V21, P514, DOI 10.1210/er.21.5.514; Dole N, 2003, AM J EPIDEMIOL, V157, P14, DOI 10.1093/aje/kwf176; Fadalti M, 2000, ANN NY ACAD SCI, V900, P89; FALL CM, COMMUNICATION; Goldenberg RL, 2000, NEW ENGL J MED, V342, P1500, DOI 10.1056/NEJM200005183422007; LIGGINS GC, 1972, PEDIATRICS, V50, P515	6	202	203	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 25	2003	300	5619					606	606		10.1126/science.1080803	http://dx.doi.org/10.1126/science.1080803			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	671FB	12714735				2022-12-28	WOS:000182453700031
J	de Marcillac, P; Coron, N; Dambier, G; Leblanc, J; Moalic, JP				de Marcillac, P; Coron, N; Dambier, G; Leblanc, J; Moalic, JP			Experimental detection of alpha-particles from the radioactive decay of natural bismuth	NATURE			English	Article							SCINTILLATORS; BOLOMETER	The only naturally occurring isotope of bismuth, Bi-209, is commonly regarded as the heaviest stable isotope. But like most other heavy nuclei abundant in nature and characterized by an exceptionally long lifetime, it is metastable with respect to alpha-decay(1). However, the decay usually evades observation because the nuclear structure(2,3) of Bi-209 gives rise to an extremely low decay probability and, moreover, generates low-energy alpha-particles difficult to detect. Indeed, dedicated experiments(2-6) attempting to record the alpha-decay of Bi-209 in nuclear emulsions failed. However, scintillating bolometers(7-9) operated at temperatures below 100 mK offer improved detection efficiency and sensitivity, whereas a broad palette of targets could be available(10). Here we report the successful use of this method for the unambiguous detection of Bi-209 alpha-decay in bismuth germanate detectors cooled to 20 mK. We measure an energy release of 3,137 +/- 1 (statistical) +/-2 (systematic) keV and a half-life of (1.9 +/- 0.2) x 10(19) yr, which are in agreement with expected values.	CNRS, Inst Astrophys Spatiale, F-91405 Orsay, France; Univ Paris 11, UMR 8617, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Earth Sciences & Astronomy (INSU); UDICE-French Research Universities; Universite Paris Saclay	de Marcillac, P (corresponding author), CNRS, Inst Astrophys Spatiale, Bat 121, F-91405 Orsay, France.							Alessandrello A, 1996, PHYS LETT B, V384, P316, DOI 10.1016/0370-2693(96)00573-4; Alessandrello A, 1992, NUCL PHYS P S, V28A, P233; Audi G, 1997, NUCL PHYS A, V624, P1, DOI 10.1016/S0375-9474(97)00482-X; BARNES RGL, 1984, IEEE T NUCL SCI, V31, P249, DOI 10.1109/TNS.1984.4333256; Bobin C, 1997, NUCL INSTRUM METH A, V386, P453, DOI 10.1016/S0168-9002(96)01185-0; Cebrian S, 2003, PHYS LETT B, V556, P14, DOI 10.1016/S0370-2693(03)00123-0; Cebrian S, 2002, NUCL PHYS B-PROC SUP, V110, P97, DOI 10.1016/S0920-5632(02)01463-9; CORON N, 1985, NATURE, V314, P75, DOI 10.1038/314075a0; DEBRAECKELEER L, 1998, TUNL PROGR REP, V37, P94; DEBRAECKELEER L, 1999, TUNL PROGR REP, V38, P87; DECARVALHO HG, 1972, LETT NUOVO CIMENTO, V3, P720, DOI 10.1007/BF02824346; FARAGGI H, 1951, CR HEBD ACAD SCI, V232, P2093; FIRESTONE RB, 1996, TABLE ISOTOPES, V2, P2545; GIANNATIEMPO A, 1982, Z PHYS A-HADRON NUCL, V308, P247, DOI 10.1007/BF01418287; GONZALEZMESTRES L, 1989, NUCL INSTRUM METH A, V279, P382, DOI 10.1016/0168-9002(89)91110-8; HINCKS EP, 1958, CAN J PHYS, V36, P231, DOI 10.1139/p58-027; JENKNER K, 1949, NATURE, V164, P412, DOI 10.1038/164412a0; Moses WW, 1998, IEEE T NUCL SCI, V45, P462, DOI 10.1109/23.682427; Norman E.B., 2000, B AM PHYS SOC, V45, P30; POWELL CF, 1959, STUDY ELEMENTARY PAR, P137; RASMUSSEN JO, 1959, PHYS REV, V115, P1675, DOI 10.1103/PhysRev.115.1675; RASMUSSEN JO, 1959, PHYS REV, V113, P1593, DOI 10.1103/PhysRev.113.1593; RIEZLER W, 1952, Z NATURFORSCH A, V7, P634; Tretyak VI, 2002, ATOM DATA NUCL DATA, V80, P83, DOI 10.1006/adnd.2001.0873; ZHOU JW, 1993, NUCL INSTRUM METH A, V335, P443, DOI 10.1016/0168-9002(93)91229-G; ZHOU TQ, 1987, NUCL INSTRUM METH A, V258, P58, DOI 10.1016/0168-9002(87)90079-9; ZIEGLER JF, 1977, STOPPING RANGES IONS, V4	27	172	173	1	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 24	2003	422	6934					876	878		10.1038/nature01541	http://dx.doi.org/10.1038/nature01541			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	670WR	12712201				2022-12-28	WOS:000182432600050
J	Appel, LJ; Champagne, CM; Harsha, DW; Cooper, LS; Obarzanek, E; Elmer, PJ; Stevens, VJ; Vollmer, WM; Lin, PH; Svetkey, LP; Stedman, SW; Young, DR				Appel, LJ; Champagne, CM; Harsha, DW; Cooper, LS; Obarzanek, E; Elmer, PJ; Stevens, VJ; Vollmer, WM; Lin, PH; Svetkey, LP; Stedman, SW; Young, DR		PREMIER Collaborative Res Grp	Effects of comprehensive lifestyle modification on blood pressure - Control main results of the PREMIER clinical trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DIETARY PATTERNS; WEIGHT-LOSS; HYPERTENSION PREVENTION; SODIUM REDUCTION; RISK; INTERVENTION; POPULATION; GUIDELINES; DISEASE; HEALTH	Context Weight loss, sodium reduction, increased physical activity, and limited alcohol intake are established recommendations that reduce blood pressure (BP). The Dietary Approaches to Stop Hypertension (DASH) diet also lowers BP. To date, no trial has evaluated the effects of simultaneously implementing these lifestyle recommendations. Objective To determine the effect on BP of 2 multicomponent, behavioral interventions. Design, Setting, and Participants Randomized trial with enrollment at 4 clinical centers (January 2000-June 2001) among 810 adults (mean [SD] age, 50 [8.9] years; 62% women; 34% African American) with above-optimal BP, including stage 1 hypertension (120-159 mm Hg systolic and 80-95 mm Hg diastolic), and who were not taking anti hypertensive medications. Intervention Participants were randomized to one of 3 intervention groups: (1) "established," a behavioral intervention that implemented established recommendations (n=268); (2) "established plus DASH, "which also implemented the DASH diet (n=269); and (3) an "advice only" comparison group (n=273). Main Outcome Measures Blood pressure measurement and hypertension status at 6 months. Results Both behavioral interventions significantly reduced weight, improved fitness, and lowered sodium intake. The established plus DASH intervention also increased fruit, vegetable, and dairy intake. Across the groups, gradients in BP and hypertensive status were evident. After subtracting change in advice only, the mean net reduction in systolic BP was 3.7 mm Hg (P<.001) in the established group and 4.3 mm Hg (P<.001) in the established plus DASH group; the systolic BP difference between the established and established plus DASH groups was 0.6 mm Hg (P=.43). Compared with the baseline hypertension prevalence of 38%, the prevalence at 6 months was 26% in the advice only group, 17% in the established group (P=.01 compared with the advice only group), and 12% in the established plus DASH group (P<.001 compared with the advice only group; P=.12 compared with the established group). The prevalence of optimal BP (<120 mm Hg systolic and <80 mm Hg diastolic) was 19% in the advice only group, 30% in the established group (P=.005 compared with the advice only group), and 35% in the established plus DASH group (P<001 compared with the advice only group; P=.24 compared with the established group). Conclusion individuals with above-optimal BP, including stage 1 hypertension, can make multiple lifestyle changes that lower BP and reduce their cardiovascular disease risk.	Johns Hopkins Med Inst, Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Dept Epidemiol, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Dept Int Hlth Human Nutr, Baltimore, MD 21205 USA; Pennington Biomed Res Ctr, Baton Rouge, LA USA; NHLBI, Bethesda, MD 20892 USA; Kaiser Permanente Ctr Hlth Res, Portland, OR USA; Duke Univ, Med Ctr, Duke Hypertens Ctr, Durham, NC USA; Duke Univ, Med Ctr, Sarah W Stedman Ctr Nutr Studies, Durham, NC USA; Univ Maryland, Dept Kinesiol, College Pk, MD 20742 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Kaiser Permanente; Duke University; Duke University; University System of Maryland; University of Maryland College Park	Appel, LJ (corresponding author), Johns Hopkins Med Inst, Dept Med, 2024 E Monument St,Suite 2-645, Baltimore, MD 21205 USA.	lappel@jhmi.edu	Appel, Larry/GLT-2608-2022; Champagne, Catherine/N-1956-2017	Champagne, Catherine/0000-0001-6127-1072	NCRR NIH HHS [M01 RR00052] Funding Source: Medline; NHLBI NIH HHS [UO1 HL60574, UO1 HL62828, UO1 HL60571, UO1 HL60570, UO1 HL60573] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000052] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL060570, U01HL060574, U01HL060573, U01HL062828, U01HL060571] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aickin M, 1996, AM J PUBLIC HEALTH, V86, P726, DOI 10.2105/AJPH.86.5.726; *AM COLL SPORTS ME, 1995, ACMS GUID EX TEST PR; [Anonymous], 1993, ARCH INTERN MED, V153, P154, DOI DOI 10.1001/archinte.1993.00410020010002; [Anonymous], 1997, ARCH INTERN MED, V157, P2413; Appel LJ, 1997, NEW ENGL J MED, V336, P1117, DOI 10.1056/NEJM199704173361601; BLAIR SN, 1985, AM J EPIDEMIOL, V122, P794, DOI 10.1093/oxfordjournals.aje.a114163; BURT VL, 1995, HYPERTENSION, V25, P305, DOI 10.1161/01.HYP.25.3.305; Cushman William C, 2002, J Clin Hypertens (Greenwich), V4, P393; DATTILO AM, 1992, AM J CLIN NUTR, V56, P320, DOI 10.1093/ajcn/56.2.320; FOX TA, 1992, J AM DIET ASSOC, V92, P729; Fung TT, 2001, ARCH INTERN MED, V161, P1857, DOI 10.1001/archinte.161.15.1857; John JH, 2002, LANCET, V359, P1969, DOI 10.1016/S0140-6736(02)98858-6; Kant AK, 2000, JAMA-J AM MED ASSOC, V283, P2109, DOI 10.1001/jama.283.16.2109; Karanja NM, 1999, J AM DIET ASSOC, V99, pS19, DOI 10.1016/S0002-8223(99)00412-5; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; KUMANYIKA SK, 1993, HYPERTENSION, V22, P502, DOI 10.1161/01.HYP.22.4.502; LANGFORD HG, 1991, HYPERTENSION, V17, P210, DOI 10.1161/01.HYP.17.2.210; McCullough ML, 2000, AM J CLIN NUTR, V72, P1223; Miller ER, 2002, HYPERTENSION, V40, P612, DOI 10.1161/01.HYP.0000037217.96002.8E; Muntner P, 2002, HYPERTENSION, V39, P897, DOI 10.1161/01.HYP.0000013862.13962.1D; *NAT AC SCI I MED, 2000, ROL NUTR MAINT HLTH; ROSE G, 1977, BRIT J PREV SOC MED, V31, P42; Sacks FM, 2001, NEW ENGL J MED, V344, P3, DOI 10.1056/NEJM200101043440101; Schafer JL, 1999, STAT METHODS MED RES, V8, P3, DOI 10.1191/096228099671525676; Simons-Morton DG, 2001, JAMA-J AM MED ASSOC, V286, P677; STAMLER J, 1993, ARCH INTERN MED, V153, P598, DOI 10.1001/archinte.153.5.598; Stevens VJ, 2001, ANN INTERN MED, V134, P1, DOI 10.7326/0003-4819-134-1-200101020-00007; SVETKEY LP, IN PRESS ANN EPIDEMI; Tuomilehto J, 2001, NEW ENGL J MED, V344, P1343, DOI 10.1056/NEJM200105033441801; Vasan RS, 2002, JAMA-J AM MED ASSOC, V287, P1003, DOI 10.1001/jama.287.8.1003; Vasan RS, 2001, NEW ENGL J MED, V345, P1291, DOI 10.1056/NEJMoa003417; WHELTON PK, 1992, JAMA-J AM MED ASSOC, V267, P1213, DOI 10.1001/jama.1992.03480090061028; Whelton PK, 1998, JAMA-J AM MED ASSOC, V279, P839, DOI 10.1001/jama.279.11.839; Whelton PK, 1997, ARCH INTERN MED, V157, P657, DOI 10.1001/archinte.157.6.657	36	1011	1046	2	83	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 23	2003	289	16					2083	2093						11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	669WW	12709466				2022-12-28	WOS:000182374300024
J	Simms, C; Rowson, M				Simms, C; Rowson, M			Reassessment of health effects of the Indonesian economic crisis: donors versus the data	LANCET			English	Editorial Material									Medact, London N19 4DJ, England		Simms, C (corresponding author), 30 Somers Rd, Antigonish, NS B2G 2Z3, Canada.							[Anonymous], DEM HLTH SURV; [Anonymous], WHO VACC PREV DIS MO; *AS DEV BANK, 2000, 9 M CONS GROUP IND F; *AS DEV BANK, 1999, ASS POV IND STAT APP; *AUSAID, 1999, IMP AS CRIS CHILDR I; *BAPPENAS BPS UN D, 2001, NEW CONS DEM HUM DEV; *COMM MACR HLTH, 2001, FIN REP; LIBERMAN SS, 2001, WATCHING BRIEF; PRADHAN M, INDONESIA HLTH SECTO; SAADAH F, 1999, WATCHING BRIEF; *WORLD BANK, 2000, 21318 WORLD BANK	11	19	20	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 19	2003	361	9366					1382	1385		10.1016/S0140-6736(03)13076-0	http://dx.doi.org/10.1016/S0140-6736(03)13076-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	669HP	12711487				2022-12-28	WOS:000182346100028
J	Solomon, T; Ooi, MH; Beasley, DWC; Mallewa, M				Solomon, T; Ooi, MH; Beasley, DWC; Mallewa, M			West Nile encephalitis	BMJ-BRITISH MEDICAL JOURNAL			English	Review							NEW-YORK; VIRUS-INFECTION; JAPANESE ENCEPHALITIS; OUTBREAK; EPIDEMIC		Univ Liverpool, Dept Neurol Sci, Liverpool L9 7LJ, Merseyside, England; Univ Liverpool, Dept Med Microbiol, Liverpool L9 7LJ, Merseyside, England; Univ Malaysia Sarawak, Kota Samarahan 94300, Sarawak, Malaysia; Univ Texas, Med Branch, Dept Pathol, WHO Collaborating Ctr Trop Dis, Galveston, TX 77555 USA; Univ Liverpool, Dept Neurol Sci, Malawi Liverpool Wellcome Trust Programme Trop Me, Liverpool L69 3BX, Merseyside, England	University of Liverpool; University of Liverpool; University of Malaysia Sarawak; University of Texas System; University of Texas Medical Branch Galveston; University of Liverpool	Solomon, T (corresponding author), Univ Liverpool, Dept Neurol Sci, Liverpool L9 7LJ, Merseyside, England.	Tom.Solomon@tsolomon.liv.ac.uk	Ooi, MH/AAP-7081-2020	Solomon, Tom/0000-0001-7266-6547	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Anderson JF, 2002, EMERG INFECT DIS, V8, P107, DOI 10.3201/eid0801.010252; Asnis DS, 2000, CLIN INFECT DIS, V30, P413, DOI 10.1086/313737; Beasley DWC, 2002, VIROLOGY, V296, P17, DOI 10.1006/viro.2002.1372; Briese T, 1999, LANCET, V354, P1261, DOI 10.1016/S0140-6736(99)04576-6; Centers for Disease Control and Prevention (CDC), 2002, MMWR Morb Mortal Wkly Rep, V51, P929; Cernescu C., 1997, Romanian Journal of Virology, V48, P13; Chowers MY, 2001, EMERG INFECT DIS, V7, P675; GOLDBLUM N, 1954, AM J HYG, V59, P89, DOI 10.1093/oxfordjournals.aje.a119626; Gould EA, 1997, FACTORS IN THE EMERGENCE OF ARBOVIRUS DISEASES, P51; Lanciotti RS, 2000, J CLIN MICROBIOL, V38, P4066, DOI 10.1128/JCM.38.11.4066-4071.2000; Lanciotti RS, 1999, SCIENCE, V286, P2333, DOI 10.1126/science.286.5448.2333; Leis AA, 2002, NEW ENGL J MED, V347, P1279, DOI 10.1056/NEJM2002c021587; Mackenzie J S, 1998, Commun Dis Intell, V22, P93; Martin DA, 2002, CLIN DIAGN LAB IMMUN, V9, P544, DOI 10.1128/CDLI.9.3.544-549.2002; MCINTOSH BM, 1976, S AFR J SCI, V72, P295; MEIKLE J, 2002, GUARDIAN        1028; Misra UK, 1997, J NEUROL, V244, P299, DOI 10.1007/s004150050090; Mostashari F, 2001, LANCET, V358, P261, DOI 10.1016/S0140-6736(01)05480-0; Nash D, 2001, NEW ENGL J MED, V344, P1807, DOI 10.1056/NEJM200106143442401; Petersen LR, 2002, ANN INTERN MED, V137, P173, DOI 10.7326/0003-4819-137-3-200208060-00009; Platonov AE, 2001, EMERG INFECT DIS, V7, P128, DOI 10.3201/eid0701.010118; RAHAL J, 2002, 40 M CHIC IL, pA823; Rappole JH, 2000, EMERG INFECT DIS, V6, P319, DOI 10.3201/eid0604.000401; Shlim DR, 2002, CLIN INFECT DIS, V35, P183, DOI 10.1086/341247; Solomon T, 2000, BRIT MED J, V321, P1484, DOI 10.1136/bmj.321.7275.1484; Solomon T, 2002, CURR TOP MICROBIOL, V267, P171; Solomon T, 2000, J NEUROL NEUROSUR PS, V68, P405, DOI 10.1136/jnnp.68.4.405; Solomon T, 2003, LANCET, V361, P821, DOI 10.1016/S0140-6736(03)12709-2; SOLOMON T, IN PRESS CLIN INFECT; SPIGLAND I, 1958, Harefuah, V54, P275; TAYLOR RM, 1956, AM J TROP MED HYG, V5, P579, DOI 10.4269/ajtmh.1956.5.579; Tsai TF, 1998, LANCET, V352, P767, DOI 10.1016/S0140-6736(98)03538-7; Wasay M, 2000, ARCH NEUROL-CHICAGO, V57, P114, DOI 10.1001/archneur.57.1.114; Weiss D, 2001, EMERG INFECT DIS, V7, P654, DOI 10.3201/eid0704.010409	34	95	104	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 19	2003	326	7394					865	869		10.1136/bmj.326.7394.865	http://dx.doi.org/10.1136/bmj.326.7394.865			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	670BF	12702624	Green Published			2022-12-28	WOS:000182386800024
J	Spira, AM				Spira, AM			Preparing the traveller	LANCET			English	Review							MALARIA PREVENTION MEASURES; YELLOW-FEVER; AFRICAN TRYPANOSOMIASIS; VENOUS THROMBOEMBOLISM; ATOVAQUONE-PROGUANIL; NONIMMUNE TRAVELERS; HEALTH-PROBLEMS; HEPATITIS-A; PROPHYLAXIS; MEFLOQUINE	The four steps for giving travellers the foundation for healthy journeys are to assess their health, analyse their itineraries, select vaccines, and provide education about prevention and self-treatment of travel-related diseases. This process takes time. Since there is a risk of information overload, travellers should leave the clinic with some written advice for reinforcement. The order of these steps can be tailored to what best suits the travel clinic, but vaccinating early in the process allows monitoring for adverse reactions. Face-to-face discussion is vital for explaining the use and side-effects of medications. Those who provide a travel medicine service should be seeing many travellers and should seek specialist training. In 2003, the International Society of Travel Medicine introduced a certificate of knowledge examination in travel medicine. We cannot make travellers bullet-proof but it is possible to make them bullet-resistant. The pre-travel visit should minimise health risks specific to the journey, give travellers the capability to handle most minor medical problems, and allow them to identify when to seek local care during the trip or on return.	Travel Med Ctr, Beverly Hills, CA 90211 USA		Spira, AM (corresponding author), Travel Med Ctr, 131 N Robertson Blvd, Beverly Hills, CA 90211 USA.	travelmed@earthlink.net						ACREE F, 1968, SCIENCE, V161, P1346, DOI 10.1126/science.161.3848.1346; Adachi JA, 2000, CLIN INFECT DIS, V31, P1079, DOI 10.1086/318119; *ADV COMM IMM PRAC, 1999, MMWR-MORBID MORTAL W, V48, P16; Akasaka S, 2001, J Infect Chemother, V7, P49, DOI 10.1007/s101560170034; Alghasham AA, 2000, ANN PHARMACOTHER, V34, P347; Centers of Disease Control and Prevention, 2001, MMWR Recomm Rep, V50, P1, DOI 10.1103/PhysRevE.106.055304; [Anonymous], 1993, MMWR Recomm Rep, V42, P1; Ansdell VE, 1999, MED CLIN N AM, V83, P945; Arfvidsson B, 2000, HEMATOL ONCOL CLIN N, V14, P391, DOI 10.1016/S0889-8588(05)70140-4; Bamberger JD, 1999, AM J MED, V106, P323, DOI 10.1016/S0002-9343(99)00018-2; Banerjee D, 2001, J TRAVEL MED, V8, P173, DOI 10.2310/7060.2001.24236; Barrett PJ, 1996, BRIT MED J, V313, P525, DOI 10.1136/bmj.313.7056.525; Barros MLB, 1996, LANCET, V348, P969, DOI 10.1016/S0140-6736(05)65392-5; BARTSCH P, 1991, NEW ENGL J MED, V325, P1284, DOI 10.1056/NEJM199110313251805; Basnyat B, 2001, J TRAVEL MED, V8, P270, DOI 10.2310/7060.2001.24036; Bradley D J, 2001, Commun Dis Public Health, V4, P84; BRADLEY DJ, 1998, EUROSURVEILLANCE, V3, P4; *CDCP, 2001, HLTH INF INT TRAV 20; Centers for Disease Control and Prevention (CDC), 2002, MMWR Morb Mortal Wkly Rep, V51, P324; Centers for Disease Control and Prevention (CDC), 2001, MMWR Morb Mortal Wkly Rep, V50, P21; Centers for Disease Control and Prevention (CDC), 2001, MMWR Morb Mortal Wkly Rep, V50, P597; Cetron MS, 1996, LANCET, V348, P1274, DOI 10.1016/S0140-6736(96)01511-5; Chan RC, 2001, LANCET, V358, P121, DOI 10.1016/S0140-6736(01)05341-7; CLAUSTRAT B, 1992, BIOL PSYCHIAT, V32, P705, DOI 10.1016/0006-3223(92)90300-O; *COMM SAF MED, 2000, CURR PROBL PHARMACOV, V26, P1; dos Santos CC, 1999, CAN MED ASSOC J, V160, P195; DUPONT HL, 1990, AM J MED, V88, pS15, DOI 10.1016/0002-9343(90)90270-N; DuPont HL, 2001, CLIN INFECT DIS, V33, P1807, DOI 10.1086/323814; Ericsson, 1997, J Travel Med, V4, P3, DOI 10.1111/j.1708-8305.1997.tb00765.x; Ericsson CD, 1998, INFECT DIS CLIN N AM, V12, P285, DOI 10.1016/S0891-5520(05)70006-4; Fischer PR, 1998, INFECT DIS CLIN N AM, V12, P355, DOI 10.1016/S0891-5520(05)70009-X; Fradin MS, 1998, ANN INTERN MED, V128, P931, DOI 10.7326/0003-4819-128-11-199806010-00013; Gagneux, 1996, J Travel Med, V3, P14, DOI 10.1111/j.1708-8305.1996.tb00690.x; Grabowski P, 1996, TROP MED INT HEALTH, V1, P730; Hackett PH, 2001, NEW ENGL J MED, V345, P107, DOI 10.1056/NEJM200107123450206; HANDSZUH H, 1997, TXB TRAVEL MED HLTH; HARGARTEN SW, 1991, ANN EMERG MED, V20, P622, DOI 10.1016/S0196-0644(05)82379-0; Hill, 1996, J Travel Med, V3, P46, DOI 10.1111/j.1708-8305.1996.tb00696.x; Hill DR, 2000, J TRAVEL MED, V7, P259, DOI 10.2310/7060.2000.00075; Hogh B, 2000, LANCET, V356, P1888, DOI 10.1016/S0140-6736(00)03260-8; Houweling H, 1991, Int J STD AIDS, V2, P252; Kain KC, 1998, CLIN INFECT DIS, V27, P142, DOI 10.1086/514616; Keystone JS, 1996, LANCET, V347, P1423, DOI 10.1016/S0140-6736(96)91678-5; Keystone JS, 2001, J TRAVEL MED, V8, pS42; Knols BGJ, 1995, T ROY SOC TROP MED H, V89, P604, DOI 10.1016/0035-9203(95)90406-9; KUSCHNER RA, 1995, CLIN INFECT DIS, V21, P536, DOI 10.1093/clinids/21.3.536; LEE JM, 1995, VACCINE, V13, P743, DOI 10.1016/0264-410X(94)00079-3; Lesmana M, 2001, ANTIMICROB AGENTS CH, V45, P359, DOI 10.1128/AAC.45.1.359-362.2001; Lobel HO, 1998, AM J TROP MED HYG, V59, P129, DOI 10.4269/ajtmh.1998.59.129; LOBEL HO, 1993, LANCET, V341, P848, DOI 10.1016/0140-6736(93)93058-9; Lobel HO, 2001, J TRAVEL MED, V8, P167, DOI 10.2310/7060.2001.22206; MacArthur J. R., 2001, Morbidity and Mortality Weekly Report, V50, P25; Martin M, 2001, EMERG INFECT DIS, V7, P945, DOI 10.3201/eid0706.010605; Memish ZA, 2002, CLIN INFECT DIS, V34, P84, DOI 10.1086/323403; Mermin JH, 1998, ARCH INTERN MED, V158, P633, DOI 10.1001/archinte.158.6.633; Mileno MD, 1998, INFECT DIS CLIN N AM, V12, P369, DOI 10.1016/S0891-5520(05)70010-6; Monath TP, 2002, CLIN INFECT DIS, V34, P1369, DOI 10.1086/340104; Moore DAJ, 2002, EMERG INFECT DIS, V8, P74, DOI 10.3201/eid0801.010130; Mulhall BP, 1996, INT J STD AIDS, V7, P455, DOI 10.1258/0956462961918419; MURPHY GS, 1993, LANCET, V341, P96, DOI 10.1016/0140-6736(93)92568-E; Naylor MF, 1997, ARCH DERMATOL, V133, P1146, DOI 10.1001/archderm.133.9.1146; Nevill CG, 1996, TROP MED INT HEALTH, V1, P139; Noronha E, 2000, Rev Soc Bras Med Trop, V33, P201; Overbosch D, 2001, CLIN INFECT DIS, V33, P1015, DOI 10.1086/322694; Patton PG, 1999, J TRAVEL MED, V6, P24, DOI 10.2310/7060.1999.00006; Phillips, 1996, J Travel Med, V3, P40, DOI 10.1111/j.1708-8305.1996.tb00695.x; Plotkin SA, 2000, CLIN INFECT DIS, V30, P4, DOI 10.1086/313632; PROVIC P, 1995, MED J AUSTRALIA, V163, P27; RAEBER PA, 1994, LANCET, V344, P331, DOI 10.1016/S0140-6736(94)91368-4; Rani S, 2022, SPAT INF RES, V30, P417, DOI 10.1007/s41324-022-00442-9; REID D, 1997, TXB TRAVEL MED HLTH, P3; RIED LD, 1994, J WILDERNESS MED, V5, P34; Rigau-Perez, 1997, J Travel Med, V4, P65, DOI 10.1111/j.1708-8305.1997.tb00782.x; Salafsky B, 1999, AM J TROP MED HYG, V61, P743, DOI 10.4269/ajtmh.1999.61.743; Samuel BU, 1998, INFECT DIS CLIN N AM, V12, P325, DOI 10.1016/S0891-5520(05)70008-8; Schlagenhauf P, 1999, J TRAVEL MED, V6, P122, DOI 10.1111/j.1708-8305.1999.tb00843.x; Schlagenhauf P, 2000, J TRAVEL MED, V7, P225, DOI 10.2310/7060.2000.00069; SCHWARTZ E, 1990, ARCH INTERN MED, V150, P349, DOI 10.1001/archinte.150.2.349; SHANDERA WX, 1993, J WILDERNESS MED, V4, P40, DOI 10.1580/0953-9859-4.1.40; Shanks GD, 1999, CLIN INFECT DIS, V29, P942, DOI 10.1086/520469; Shanks GD, 1999, J TRAVEL MED, V6, pS21; Sinha A, 1999, CLIN INFECT DIS, V29, P840, DOI 10.1086/520446; STEFFEN R, 1994, J WILDERNESS MED, V5, P56, DOI 10.1580/0953-9859-5.1.56; STEFFEN R, 1987, J INFECT DIS, V156, P84, DOI 10.1093/infdis/156.1.84; STEFFEN R, 1983, JAMA-J AM MED ASSOC, V249, P1175; Steffen R, 1999, TROPICAL INFECT DIS, P106; Stratton MA, 2000, ARCH INTERN MED, V160, P334, DOI 10.1001/archinte.160.3.334; Suankratay C, 2001, J TRAVEL MED, V8, P192, DOI 10.2310/7060.2001.22179; TAKAFUJI ET, 1984, NEW ENGL J MED, V310, P497, DOI 10.1056/NEJM198402233100805; Thimasarn, 1995, J Travel Med, V2, P59, DOI 10.1111/j.1708-8305.1995.tb00627.x; Thoelen S, 1999, VACCINE, V17, P1657, DOI 10.1016/S0264-410X(98)00421-6; USHERWOOD V, 1989, J ROY COLL GEN PRACT, V39, P148; VANCREVEL R, 1994, CLIN INFECT DIS, V19, P132, DOI 10.1093/clinids/19.1.132; WEINKE T, 1991, AM J TROP MED HYG, V45, P86, DOI 10.4269/ajtmh.1991.45.86; Wellems TE, 2001, J INFECT DIS, V184, P770, DOI 10.1086/322858; WERZBERGER A, 1992, NEW ENGL J MED, V327, P453, DOI 10.1056/NEJM199208133270702; *WHO, 2002, INT TRAV HLTH; Wilks J, 1999, J TRAVEL MED, V6, P115, DOI 10.1111/j.1708-8305.1999.tb00842.x; Wittlinger, 1995, J Travel Med, V2, P154, DOI 10.1111/j.1708-8305.1995.tb00643.x; Wongsrichanalai C, 2002, LANCET INFECT DIS, V2, P209, DOI 10.1016/S1473-3099(02)00239-6; World Health Organization, 1997, WORLD HLTH REP 1996, P1; *WORLD TOUR ORG, FACTS FIG 2001 DAT; 1996, US NAVY DIVERS HDB	103	48	50	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 19	2003	361	9366					1368	1381		10.1016/S0140-6736(03)13075-9	http://dx.doi.org/10.1016/S0140-6736(03)13075-9			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	669HP	12711486				2022-12-28	WOS:000182346100027
J	Dickson, BJ				Dickson, BJ			Wiring the brain with insulin	SCIENCE			English	Editorial Material							PHOTORECEPTOR AXON GUIDANCE; DROSOPHILA; RECEPTOR; CELL		Austrian Acad Sci, Inst Mol Biotechnol, A-1010 Vienna, Austria	Austrian Academy of Sciences; Vienna Biocenter (VBC); Institute of Molecular Biotechnology (IMBA)	Dickson, BJ (corresponding author), Austrian Acad Sci, Inst Mol Biotechnol, A-1010 Vienna, Austria.	dickson@nt.imp.univie.ac.at	Dickson, Barry/AAE-7632-2019	Dickson, Barry/0000-0003-0715-892X				Bohni R, 1999, CELL, V97, P865, DOI 10.1016/S0092-8674(00)80799-0; Brogiolo W, 2001, CURR BIOL, V11, P213, DOI 10.1016/S0960-9822(01)00068-9; Campbell DS, 2001, NEURON, V32, P1013, DOI 10.1016/S0896-6273(01)00551-7; Chung CY, 2001, TRENDS BIOCHEM SCI, V26, P557, DOI 10.1016/S0968-0004(01)01934-X; Garrity PA, 1996, CELL, V85, P639, DOI 10.1016/S0092-8674(00)81231-3; Hing H, 1999, CELL, V97, P853, DOI 10.1016/S0092-8674(00)80798-9; Ming GI, 1999, NEURON, V23, P139, DOI 10.1016/S0896-6273(00)80760-6; Rulifson EJ, 2002, SCIENCE, V296, P1118, DOI 10.1126/science.1070058; Song JB, 2003, SCIENCE, V300, P502, DOI 10.1126/science.1081203	9	18	19	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 18	2003	300	5618					440	441		10.1126/science.1084513	http://dx.doi.org/10.1126/science.1084513			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	668LR	12702863				2022-12-28	WOS:000182295900024
J	Fujita, N; Jaye, DL; Kajita, M; Geigerman, C; Moreno, CS; Wade, PA				Fujita, N; Jaye, DL; Kajita, M; Geigerman, C; Moreno, CS; Wade, PA			MTA3, a Mi-2/NuRD complex subunit, an invasive growth pathway in breast	CELL			English	Article							CHROMATIN-REMODELING COMPLEX; TRANSCRIPTION FACTOR SNAIL; CELL-CELL-ADHESION; HISTONE DEACETYLASE; ESTROGEN-RECEPTOR; GENE-EXPRESSION; E-CADHERIN; MAMMARY ADENOCARCINOMA; EPITHELIAL-CELLS; DNA METHYLATION	Estrogen receptor is a key regulator of proliferation and differentiation in mammary epithelia and represents a crucial prognostic indicator and therapeutic target in breast cancer. Mechanistically, estrogen receptor induces changes in gene expression through direct gene activation and also through the biological functions of target loci. Here, we identify the product of human MTA3 as an estrogen-dependent component of the Mi-2/NuRD transcriptional corepressor in breast epithelial cells and demonstrate that MTA3 constitutes a key component of an estrogen-dependent pathway regulating growth and differentiation. The absence of estrogen receptor or of MTA3 leads to aberrant expression of the transcriptional repressor Snail, a master regulator of epithelial to mesenchymal transitions. Aberrant Snail expression results in loss of expression of the cell adhesion molecule E-cadherin, an event associated with changes in epithelial architecture and invasive growth. These results establish a mechanistic link between estrogen receptor status and invasive growth of breast cancers.	Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA	Emory University	Wade, PA (corresponding author), Emory Univ, Sch Med, Dept Pathol & Lab Med, Whitehead Biomed Res Bldg,Room 142,615 Michael St, Atlanta, GA 30322 USA.		Moreno, Carlos S/B-3863-2009; Wade, Paul A/D-2374-2019; Larue, Lionel/I-6532-2016	Moreno, Carlos S/0000-0002-5582-0028; Wade, Paul A/0000-0002-6042-357X; jaye, david/0000-0001-7977-6909	NCI NIH HHS [K22-CA96560-01] Funding Source: Medline; NICHD NIH HHS [5K22HD01238] Funding Source: Medline; NIDDK NIH HHS [DK60647] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K22HD001238] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [K22CA096560] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK060647] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams CL, 1998, CURR OPIN CELL BIOL, V10, P572, DOI 10.1016/S0955-0674(98)80031-8; Armstrong JA, 1998, CELL, V95, P93, DOI 10.1016/S0092-8674(00)81785-7; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; Blanco MJ, 2002, ONCOGENE, V21, P3241, DOI 10.1038/sj.onc.1205416; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Ch'ng Q, 1999, DEVELOPMENT, V126, P3303; Coffee B, 1999, NAT GENET, V22, P98, DOI 10.1038/8807; Couse JF, 1999, ENDOCR REV, V20, P358, DOI 10.1210/er.20.3.358; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fujita N, 2000, MOL CELL BIOL, V20, P5107, DOI 10.1128/MCB.20.14.5107-5118.2000; Gruber CJ, 2002, NEW ENGL J MED, V346, P340, DOI 10.1056/NEJMra000471; Hajra KM, 2002, CANCER RES, V62, P1613; Hajra KM, 2002, GENE CHROMOSOME CANC, V34, P255, DOI 10.1002/gcc.10083; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hirohashi S, 1998, AM J PATHOL, V153, P333, DOI 10.1016/S0002-9440(10)65575-7; IMHOF BA, 1983, CELL, V35, P667, DOI 10.1016/0092-8674(83)90099-5; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kehle J, 1998, SCIENCE, V282, P1897, DOI 10.1126/science.282.5395.1897; Kurdistani SK, 2002, NAT GENET, V31, P248, DOI 10.1038/ng907; Lapidus RG, 1998, J MAMMARY GLAND BIOL, V3, P85, DOI 10.1023/A:1018778403001; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MASOOD S, 1992, DIAGN CYTOPATHOL, V8, P475, DOI 10.1002/dc.2840080508; Mazumdar A, 2001, NAT CELL BIOL, V3, P30, DOI 10.1038/35050532; McDonnell DP, 2002, SCIENCE, V296, P1642, DOI 10.1126/science.1071884; McDonnell DP, 2002, AM J CARDIOL, V90, p35F, DOI 10.1016/S0002-9149(01)02221-4; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Nie ZQ, 2000, MOL CELL BIOL, V20, P8879, DOI 10.1128/MCB.20.23.8879-8888.2000; Nilsson S, 2001, PHYSIOL REV, V81, P1535, DOI 10.1152/physrev.2001.81.4.1535; PENCIL SD, 1993, BREAST CANCER RES TR, V25, P165, DOI 10.1007/BF00662141; Prall OWJ, 1998, J STEROID BIOCHEM, V65, P169, DOI 10.1016/S0960-0760(98)00021-1; REDDEL RR, 1984, EUR J CANCER CLIN ON, V20, P1419, DOI 10.1016/0277-5379(84)90062-2; Solari F, 1999, DEVELOPMENT, V126, P2483; Sommer S, 2001, SEMIN CANCER BIOL, V11, P339, DOI 10.1006/scbi.2001.0389; Sporn MB, 1996, LANCET, V347, P1377, DOI 10.1016/S0140-6736(96)91015-6; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Toh Y, 1997, INT J CANCER, V74, P459, DOI 10.1002/(SICI)1097-0215(19970822)74:4<459::AID-IJC18>3.3.CO;2-H; TOH Y, 1994, J BIOL CHEM, V269, P22958; Tong JK, 1998, NATURE, V395, P917, DOI 10.1038/27699; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Wade PA, 1998, CURR BIOL, V8, P843, DOI 10.1016/S0960-9822(98)70328-8; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4	47	415	448	1	26	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 18	2003	113	2					207	219		10.1016/S0092-8674(03)00234-4	http://dx.doi.org/10.1016/S0092-8674(03)00234-4			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	672EP	12705869	Bronze			2022-12-28	WOS:000182508500010
J	Gould, WS				Gould, WS			The "magic" word	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 16	2003	289	15					1899	1900		10.1001/jama.289.15.1899	http://dx.doi.org/10.1001/jama.289.15.1899			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	667VC	12697774				2022-12-28	WOS:000182253900001
J	Snyder, M; Gerstein, M				Snyder, M; Gerstein, M			Genomics - Defining genes in the genomics era	SCIENCE			English	Editorial Material							PROTEIN-CODING GENES; SACCHAROMYCES-CEREVISIAE GENOME; YEAST GENOME; TRANSCRIPTIONAL ACTIVITY; TOTAL NUMBER; PSEUDOGENES; EVOLUTION; DNA		Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA; Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA	Yale University; Yale University	Snyder, M (corresponding author), Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA.			Snyder, Michael/0000-0003-0784-7987				Blandin G, 2000, FEBS LETT, V487, P31, DOI 10.1016/S0014-5793(00)02275-4; Brown PO, 1999, NAT GENET, V21, P33, DOI 10.1038/4462; Burge CB, 1998, CURR OPIN STRUC BIOL, V8, P346, DOI 10.1016/S0959-440X(98)80069-9; Coelho PSR, 2000, CURR OPIN MICROBIOL, V3, P309, DOI 10.1016/S1369-5274(00)00095-3; Coelho PSR, 2002, GENE DEV, V16, P2755, DOI 10.1101/gad.1035002; Das M, 2001, GENOMICS, V77, P71, DOI 10.1006/geno.2001.6620; Eddy SR, 2002, CELL, V109, P137, DOI 10.1016/S0092-8674(02)00727-4; FALK R, 1986, STUD HIST PHILOS SCI, V17, P133, DOI 10.1016/0039-3681(86)90024-5; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Harrison P, 2002, J MOL BIOL, V316, P409, DOI 10.1006/jmbi.2001.5343; Harrison PM, 2002, NUCLEIC ACIDS RES, V30, P1083, DOI 10.1093/nar/30.5.1083; Harrison PM, 2002, J MOL BIOL, V318, P1155, DOI 10.1016/S0022-2836(02)00109-2; Horak Christine E, 2002, Funct Integr Genomics, V2, P171; Kapranov P, 2002, SCIENCE, V296, P916, DOI 10.1126/science.1068597; Kowalczuk M, 1999, YEAST, V15, P1031, DOI 10.1002/(SICI)1097-0061(199908)15:11<1031::AID-YEA431>3.0.CO;2-G; Kumar A, 2002, NAT BIOTECHNOL, V20, P58, DOI 10.1038/nbt0102-58; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Liu HP, 1996, GENETICS, V144, P967; Mackiewicz P, 2002, YEAST, V19, P619, DOI 10.1002/yea.865; Mewes HW, 1997, NATURE, V387, P7, DOI 10.1038/387s007; Modrek B, 2002, NAT GENET, V30, P13, DOI 10.1038/ng0102-13; Morange M, 2001, MISUNDERSTOOD GENE; Rinn JL, 2003, GENE DEV, V17, P529, DOI 10.1101/gad.1055203; Tycowski KT, 1996, NATURE, V379, P464, DOI 10.1038/379464a0; Velculescu VE, 1997, CELL, V88, P243, DOI 10.1016/S0092-8674(00)81845-0; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Zhang CT, 2000, NUCLEIC ACIDS RES, V28, P2804, DOI 10.1093/nar/28.14.2804; Zhang MQ, 2002, NAT REV GENET, V3, P698, DOI 10.1038/nrg890; Zhang ZL, 2002, GENOME RES, V12, P1466, DOI 10.1101/gr.331902	29	90	107	0	60	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 11	2003	300	5617					258	260		10.1126/science.1084354	http://dx.doi.org/10.1126/science.1084354			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	665RQ	12690176				2022-12-28	WOS:000182135400032
J	Anselmi, M; Avanzini, F; Moreira, JM; Montalvo, G; Armani, D; Prandi, R; Marquez, M; Caicedo, C; Colombo, F; Tognoni, G				Anselmi, M; Avanzini, F; Moreira, JM; Montalvo, G; Armani, D; Prandi, R; Marquez, M; Caicedo, C; Colombo, F; Tognoni, G			Treatment and control of arterial hypertension in a rural community in Ecuador	LANCET			English	Article								Cardiovascular diseases are widespread in developing countries, but little is known about cardiovascular risk profiles in rural communities. To assess the importance of arterial hypertension in a rural district of Ecuador, we screened 4284 of the 8876 adults who lived in the area. 1542 (36%) individuals had hypertension, only four (0.3%) of whom were well controlled by treatment. We monitored all deaths for 2.5 years, and noted that cardiovascular diseases were the primary cause of death in the adult population. Furthermore, of the individuals who died of a cardiovascular disease, four out of five had a history of hypertension. Our findings indicate that in this rural area of Ecuador the high prevalence of uncontrolled hypertension is a major cause of total mortality.	Mario Negri Inst Pharmacol Res, I-20157 Milan, Italy; CECOMET, Esmeraldas, Ecuador; Minist Salud Publ, Borbon, Ecuador; Osped S Cuore, Ctr Malattie Trop, Verona, Italy	Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Avanzini, F (corresponding author), Mario Negri Inst Pharmacol Res, Via Eritrea 62, I-20157 Milan, Italy.	avanzini@marionegri.it		Avanzini, Fausto/0000-0002-4029-2891				CHANDRAMOHAN D, 1994, INT J EPIDEMIOL, V23, P213, DOI 10.1093/ije/23.2.213; Cooper R, 1997, AM J PUBLIC HEALTH, V87, P160, DOI 10.2105/AJPH.87.2.160; Ordunez P, 2001, Rev Panam Salud Publica, V10, P226, DOI 10.1590/S1020-49892001001000002; Reddy KS, 1998, CIRCULATION, V97, P596; [No title captured]	5	22	23	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 5	2003	361	9364					1186	1187		10.1016/S0140-6736(03)12918-2	http://dx.doi.org/10.1016/S0140-6736(03)12918-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	664ZF	12686043				2022-12-28	WOS:000182094600014
J	Whitney, CG; Farley, MM; Hadler, J; Harrison, LH; Bennett, NM; Lynfield, R; Reingold, A; Cieslak, PR; Pilishvili, T; Jackson, D; Facklam, RR; Jorgensen, JH; Schuchat, A				Whitney, CG; Farley, MM; Hadler, J; Harrison, LH; Bennett, NM; Lynfield, R; Reingold, A; Cieslak, PR; Pilishvili, T; Jackson, D; Facklam, RR; Jorgensen, JH; Schuchat, A		Active Bacterial Core Surveillance	Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	42nd Interscience Conference on Antimicrobial Agents and Chemotherapy	SEP 26-30, 2002	SAN DIEGO, CA				STREPTOCOCCUS-PNEUMONIAE; NASOPHARYNGEAL CARRIAGE; IMMUNOGENICITY; REDUCTION; INFECTIONS; PREVENTION; PRINCIPLES; DIPHTHERIA; EFFICACY; TETANUS	BACKGROUND: In early 2000, a protein-polysaccharide conjugate vaccine targeting seven pneumococcal serotypes was licensed in the United States for use in young children. METHODS: We examined population-based data from the Active Bacterial Core Surveillance of the Centers for Disease Control and Prevention to evaluate changes in the burden of invasive disease, defined by isolation of Streptococcus pneumoniae from a normally sterile site. Serotyping and susceptibility testing of isolates were performed. We assessed trends using data from seven geographic areas with continuous participation from 1998 through 2001 (population, 16 million). RESULTS: The rate of invasive disease dropped from an average of 24.3 cases per 100,000 persons in 1998 and 1999 to 17.3 per 100,000 in 2001. The largest decline was in children under two years of age. In this group, the rate of disease was 69 percent lower in 2001 than the base-line rate (59.0 cases per 100,000 vs. 188.0 per 100,000, P<0.001); the rate of disease caused by vaccine and vaccine-related serotypes declined by 78 percent (P<0.001) and 50 percent (P<0.001), respectively. Disease rates also fell for adults; as compared with base line, the rate of disease in 2001 was 32 percent lower for adults 20 to 39 years of age (7.6 cases per 100,000 vs. 11.2 per 100,000, P<0.001), 8 percent lower for those 40 to 64 years of age (19.7 per 100,000 vs. 21.5 per 100,000, P=0.03), and 18 percent lower for those 65 years of age or more (49.5 per 100,000 vs. 60.1 per 100,000, P<0.001). The rate of disease caused by strains that were not susceptible to penicillin was 35 percent lower in 2001 than in 1999 (4.1 cases per 100,000 vs. 6.3 per 100,000, P<0.001). CONCLUSIONS: The use of the pneumococcal conjugate vaccine is preventing disease in young children, for whom the vaccine is indicated, and may be reducing the rate of disease in adults. The vaccine provides an effective new tool for reducing disease caused by drug-resistant strains.	Ctr Dis Control & Prevent, Div Bacterial & Mycot Dis, Natl Ctr Infect Dis, Atlanta, GA USA; Emory Univ, Sch Med, Atlanta, GA USA; Vet Affairs Med Ctr, Atlanta, GA 30033 USA; Connecticut Dept Publ Hlth, Hartford, CT USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA; Monroe Cty Dept Hlth, Rochester, NY USA; Univ Rochester, Rochester, NY USA; Minnesota Dept Hlth, Minneapolis, MN USA; Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA; Oregon Dept Human Serv, Hlth Div, Portland, OR USA; Univ Texas, Hlth Sci Ctr, San Antonio, TX USA	Centers for Disease Control & Prevention - USA; Emory University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Atlanta VA Health Care System; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; University of Rochester; Minnesota Department of Health (MHD); University of California System; University of California Berkeley; University of Texas System; University of Texas Health San Antonio	Whitney, CG (corresponding author), CDC Mailstop C-23,1600 Clifton Rd NE, Atlanta, GA 30333 USA.	cwhitney@cdc.gov						*ADV COMM IMM PRAC, 2001, MMWR-MORBID MORTAL W, V50, P1140; [Anonymous], 2000, MMWR Recomm Rep, V49, P1; Black S, 2000, PEDIATR INFECT DIS J, V19, P187, DOI 10.1097/00006454-200003000-00003; Black SB, 2002, PEDIATR INFECT DIS J, V21, P810, DOI 10.1097/00006454-200209000-00005; Black SB, 2001, PEDIATR INFECT DIS J, V20, P1105, DOI 10.1097/00006454-200112000-00002; Breiman RF, 2000, ARCH INTERN MED, V160, P2633, DOI 10.1001/archinte.160.17.2633; Dagan R, 2002, J INFECT DIS, V185, P927, DOI 10.1086/339525; Dagan R, 1997, PEDIATR INFECT DIS J, V16, P1060, DOI 10.1097/00006454-199711000-00011; Dagan R, 1996, J INFECT DIS, V174, P1271, DOI 10.1093/infdis/174.6.1271; DEAN A, 1995, EPI INFO VERSION 6 W; Department of Health Human Services Washington DC. Healthy People 2010 (Group) and United States Government Printing Office., 2000, HLTH PEOPL 2010; Dowell SF, 1998, PEDIATRICS, V101, P163; Eskola J, 2001, NEW ENGL J MED, V344, P403, DOI 10.1056/NEJM200102083440602; Gonzales R, 2001, ANN INTERN MED, V134, P479, DOI 10.7326/0003-4819-134-6-200103200-00013; HENDLEY JO, 1975, J INFECT DIS, V132, P55, DOI 10.1093/infdis/132.1.55; Mbelle N, 1999, J INFECT DIS, V180, P1171, DOI 10.1086/315009; *NCCLS, 2002, M100S12 NCCLS, V22; Nuorti JP, 2000, NEW ENGL J MED, V342, P681, DOI 10.1056/NEJM200003093421002; Obaro SK, 2000, PEDIATR INFECT DIS J, V19, P463, DOI 10.1097/00006454-200005000-00014; Obaro SK, 1996, LANCET, V348, P271, DOI 10.1016/S0140-6736(05)65585-7; Robinson KA, 2001, JAMA-J AM MED ASSOC, V285, P1729, DOI 10.1001/jama.285.13.1729; Whitney CG, 2000, NEW ENGL J MED, V343, P1917, DOI 10.1056/NEJM200012283432603	22	1682	1759	0	76	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 1	2003	348	18					1737	1746		10.1056/NEJMoa022823	http://dx.doi.org/10.1056/NEJMoa022823			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	672VK	12724479				2022-12-28	WOS:000182543500002
J	Mitchell, RMS; Byrne, MF; Baillie, J				Mitchell, RMS; Byrne, MF; Baillie, J			Pancreatitis	LANCET			English	Review							ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; ACUTE NECROTIZING PANCREATITIS; ALCOHOLIC CHRONIC-PANCREATITIS; CATIONIC TRYPSINOGEN GENE; POST-ERCP PANCREATITIS; CYSTIC-FIBROSIS GENE; IDIOPATHIC CHRONIC-PANCREATITIS; TOTAL PARENTERAL-NUTRITION; SERINE-PROTEASE INHIBITOR; CONTROLLED CLINICAL-TRIAL	In the past decade, our understanding of the genetic basis, pathogenesis, and natural history of pancreatitis has grown strikingly. In severe acute pancreatitis, intensive medical support and non-surgical intervention for complications keeps patients alive; surgical drainage (necrosectomy) is reserved for patients with infected necrosis for whom supportive measures have failed. Enteral feeding has largely replaced the parenteral route; controversy remains with respect to use of prophylactic antibiotics. Although gene therapy for chronic pancreatitis is years away, our understanding of the roles of gene mutations in hereditary and sporadic pancreatitis offers tantalising clues about the disorder's pathogenesis. The division between acute and chronic pancreatitis has always been blurred: now, genetics of the disorder suggest a continuous range of disease rather than two separate entities. With recognition of pancreatic intraepithelial neoplasia, we see that chronic pancreatitis is a premalignant disorder in some patients. Magnetic resonance cholangiopancreatography and endoscopic ultrasound are destined to replace endoscopic retrograde cholangiopancreatography for many diagnostic indications in pancreatic disease.	Duke Univ, Med Ctr, Div Gastroenterol, Durham, NC 27710 USA	Duke University	Baillie, J (corresponding author), Duke Univ, Med Ctr, Div Gastroenterol, Box 3189 Duke S, Durham, NC 27710 USA.	baill001@mc.duke.edu						AHEARNE PM, 1992, AM J SURG, V163, P111, DOI 10.1016/0002-9610(92)90262-P; AMMANN RW, 1987, PANCREAS, V2, P368, DOI 10.1097/00006676-198707000-00002; Ammann RW, 1997, PANCREAS, V14, P215, DOI 10.1097/00006676-199704000-00001; Ammann RW, 1999, GASTROENTEROLOGY, V116, P1132, DOI 10.1016/S0016-5085(99)70016-8; Ammann RW, 2001, INTERNAL MED, V40, P368, DOI 10.2169/internalmedicine.40.368; Baillie John, 2002, Curr Gastroenterol Rep, V4, P112, DOI 10.1007/s11894-002-0047-6; BALTHAZAR EJ, 1990, RADIOLOGY, V174, P331, DOI 10.1148/radiology.174.2.2296641; Baron TH, 1999, NEW ENGL J MED, V340, P1412, DOI 10.1056/NEJM199905063401807; Bassi C, 1998, GASTROENTEROLOGY, V115, P1513, DOI 10.1016/S0016-5085(98)70030-7; BLAMEY SL, 1984, GUT, V25, P1340, DOI 10.1136/gut.25.12.1340; BOURLIERE M, 1989, DIGEST DIS SCI, V34, P343, DOI 10.1007/BF01536253; BRADLEY EL, 1993, ARCH SURG-CHICAGO, V128, P586; BUCHLER M, 1992, GASTROENTEROLOGY, V103, P1902; BUCHLER MW, 1995, AM J SURG, V169, P65, DOI 10.1016/S0002-9610(99)80111-1; BUCHMAN AL, 1995, JPEN-PARENTER ENTER, V19, P453, DOI 10.1177/0148607195019006453; Byrne Michael F., 2002, Curr Treat Options Gastroenterol, V5, P331, DOI 10.1007/s11938-002-0021-2; Catalano MF, 1998, GASTROINTEST ENDOSC, V48, P11, DOI 10.1016/S0016-5107(98)70122-1; Cavallini G, 1996, NEW ENGL J MED, V335, P919, DOI 10.1056/NEJM199609263351302; Chen JM, 2000, J MED GENET, V37, P67, DOI 10.1136/jmg.37.1.67; CHILLON M, 1995, NEW ENGL J MED, V332, P1475, DOI 10.1056/NEJM199506013322204; CLAVIEN PA, 1989, ANN SURG, V210, P614, DOI 10.1097/00000658-198911000-00008; Cohn JA, 2002, J INVEST MED, V50, p247S, DOI 10.1136/jim-50-suppl5-01; Cohn JA, 1998, NEW ENGL J MED, V339, P653, DOI 10.1056/NEJM199809033391002; CORFIELD AP, 1985, GUT, V26, P724, DOI 10.1136/gut.26.7.724; COTTON PB, 1994, GASTROINTEST ENDOSC, V40, P514, DOI 10.1016/S0016-5107(94)70228-4; CRAIG RM, 1975, ANN INTERN MED, V83, P831, DOI 10.7326/0003-4819-83-6-831; Cylwik B, 1998, HEPATO-GASTROENTEROL, V45, P528; Czako L, 2001, PANCREAS, V23, P323, DOI 10.1097/00006676-200110000-00015; Delcenserie R, 1996, PANCREAS, V13, P198; Delhaye M, 1996, EUR J GASTROEN HEPAT, V8, P699; Dervenis C, 1999, INT J PANCREATOL, V25, P195; Deviere J, 2001, GASTROENTEROLOGY, V120, P498, DOI 10.1053/gast.2001.21172; DIMAGNO EP, 1973, NEW ENGL J MED, V288, P813, DOI 10.1056/NEJM197304192881603; Dumonceau JM, 1996, GASTROINTEST ENDOSC, V43, P547, DOI 10.1016/S0016-5107(96)81583-5; Durie PR, 2000, MED CLIN N AM, V84, P609, DOI 10.1016/S0025-7125(05)70244-3; Eatock FC, 2000, INT J PANCREATOL, V28, P23, DOI 10.1385/IJGC:28:1:23; Etemad B, 2001, GASTROENTEROLOGY, V120, P682, DOI 10.1053/gast.2001.22586; FAN ST, 1993, NEW ENGL J MED, V328, P228, DOI 10.1056/NEJM199301283280402; Ferec C, 1999, J MED GENET, V36, P228; FINCH WT, 1976, ANN SURG, V183, P667, DOI 10.1097/00000658-197606000-00008; FOITZIK T, 1995, EUR J SURG, V161, P187; Frank B, 1999, AM J GASTROENTEROL, V94, P463, DOI 10.1016/S0002-9270(98)00759-X; Freeman ML, 1996, NEW ENGL J MED, V335, P909, DOI 10.1056/NEJM199609263351301; Freeman ML, 1999, GASTROINTEST ENDOSC, V49, P580, DOI 10.1016/S0016-5107(99)70385-8; Freeman ML, 2001, GASTROINTEST ENDOSC, V54, P425, DOI 10.1067/mge.2001.117550; Golub R, 1998, J Gastrointest Surg, V2, P496, DOI 10.1016/S1091-255X(98)80048-6; Gorry MC, 1997, GASTROENTEROLOGY, V113, P1063, DOI 10.1053/gast.1997.v113.pm9322498; Gress F, 1999, AM J GASTROENTEROL, V94, P900; Gress F, 2001, AM J GASTROENTEROL, V96, P409; Gukovskaya AS, 1997, J CLIN INVEST, V100, P1853, DOI 10.1172/JCI119714; HAMOSH A, 1993, NEW ENGL J MED, V329, P1308; HAVALA T, 1989, GASTROENTEROL CLIN N, V18, P525; Hofbauer B, 1998, AM J PHYSIOL-GASTR L, V275, pG352, DOI 10.1152/ajpgi.1998.275.2.G352; HOWES R, 1975, J SURG RES, V18, P197, DOI 10.1016/0022-4804(75)90016-5; Hughes CB, 1996, AM J SURG, V171, P274, DOI 10.1016/S0002-9610(97)89568-2; HUIBREGTSE K, 1988, GASTROINTEST ENDOSC, V34, P9, DOI 10.1016/S0016-5107(88)71221-3; IZBICKI JR, 1994, BRIT J SURG, V81, P1351, DOI 10.1002/bjs.1800810932; Johnson CD, 2001, GUT, V48, P62, DOI 10.1136/gut.48.1.62; Kalady MF, 2001, AM SURGEON, V67, P478; Kalfarentzos F, 1997, BRIT J SURG, V84, P1665, DOI 10.1002/bjs.1800841207; KALFARENTZOS FE, 1991, J AM COLL NUTR, V10, P156; Keim V, 1998, PANCREAS, V16, P45, DOI 10.1097/00006676-199801000-00008; Kemppainen E, 1997, GUT, V41, P690, DOI 10.1136/gut.41.5.690; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Kusske AM, 1996, SURGERY, V120, P284, DOI 10.1016/S0039-6060(96)80299-6; LANGE JF, 1987, HEPATO-GASTROENTEROL, V34, P28; LANKISCH PG, 1993, DIGESTION, V54, P148, DOI 10.1159/000201029; LANKISCH PG, 1995, PANCREAS, V10, P338, DOI 10.1097/00006676-199505000-00003; LAYER P, 1994, GASTROENTEROLOGY, V107, P1481, DOI 10.1016/0016-5085(94)90553-3; Lecesne R, 1999, RADIOLOGY, V211, P727, DOI 10.1148/radiology.211.3.r99jn08727; Lehman GA, 1999, GASTROINTEST ENDOSC, V49, pS81, DOI 10.1016/S0016-5107(99)70533-X; LESER HG, 1991, GASTROENTEROLOGY, V101, P782, DOI 10.1016/0016-5085(91)90539-W; Libera E D, 2000, HPB Surg, V11, P333; Loperfido S, 1998, GASTROINTEST ENDOSC, V48, P1, DOI 10.1016/S0016-5107(98)70121-X; Lowenfels AB, 1997, J NATL CANCER I, V89, P442, DOI 10.1093/jnci/89.6.442; LUITEN EJT, 1995, ANN SURG, V222, P57, DOI 10.1097/00000658-199507000-00010; MALESCI A, 1995, SCAND J GASTROENTERO, V30, P392, DOI 10.3109/00365529509093296; MANN DV, 1994, BRIT J SURG, V81, P890, DOI 10.1002/bjs.1800810632; Marotta F, 1996, DIGESTION, V57, P446, DOI 10.1159/000201373; McClave SA, 1997, JPEN-PARENTER ENTER, V21, P14, DOI 10.1177/014860719702100114; Neff R, 2001, SURG CLIN N AM, V81, P399, DOI 10.1016/S0039-6109(05)70127-4; NEOPTOLEMOS JP, 1988, LANCET, V2, P979, DOI 10.1016/S0140-6736(88)90740-4; Neoptolemos JP, 2000, LANCET, V355, P1955, DOI 10.1016/S0140-6736(00)02327-8; Noone PG, 2001, GASTROENTEROLOGY, V121, P1310, DOI 10.1053/gast.2001.29673; Nordback I, 2001, J GASTROINTEST SURG, V5, P113, DOI 10.1016/S1091-255X(01)80021-4; NORMAN JG, 1995, ARCH SURG-CHICAGO, V130, P966; Oezcueruemez-Porsch M, 1998, DIGEST DIS SCI, V43, P1763, DOI 10.1023/A:1018887704337; Otani T, 1998, AM J PHYSIOL-GASTR L, V275, pG999, DOI 10.1152/ajpgi.1998.275.5.G999; PEDERZOLI P, 1993, SURG GYNECOL OBSTET, V176, P480; Perrault J, 2000, MED CLIN N AM, V84, P519, DOI 10.1016/S0025-7125(05)70237-6; PISTERS PWT, 1992, SURG GYNECOL OBSTET, V175, P275; Poon RTP, 1999, GASTROINTEST ENDOSC, V49, P593, DOI 10.1016/S0016-5107(99)70387-1; Povoski S P, 1995, Nutr Clin Pract, V10, P43, DOI 10.1177/011542659501000243; RANSON JHC, 1974, SURG GYNECOL OBSTET, V139, P69; Rongione AJ, 1997, GASTROENTEROLOGY, V112, P960, DOI 10.1053/gast.1997.v112.pm9041259; Rosenstein BJ, 1998, J PEDIATR-US, V132, P589, DOI 10.1016/S0022-3476(98)70344-0; Sahai AV, 1998, GASTROINTEST ENDOSC, V48, P18, DOI 10.1016/S0016-5107(98)70123-3; SAINIO V, 1995, LANCET, V346, P663, DOI 10.1016/S0140-6736(95)92280-6; SARLES H, 1984, CLIN GASTROENTEROL, V13, P895; Schmid SW, 1999, GUT, V45, P311, DOI 10.1136/gut.45.2.311; Scolapio JS, 1999, GASTROENTEROL CLIN N, V28, P695, DOI 10.1016/S0889-8553(05)70082-0; Seifert H, 2000, ENDOSCOPY, V32, P255, DOI 10.1055/s-2000-93; Sharer N, 1998, NEW ENGL J MED, V339, P645, DOI 10.1056/NEJM199809033391001; Simon B, 2001, DIGEST DIS, V19, P6, DOI 10.1159/000050648; SITZMANN JV, 1989, SURG GYNECOL OBSTET, V168, P311; SLAFF J, 1984, GASTROENTEROLOGY, V87, P44; SPECHLER SJ, 1983, DIGEST DIS SCI, V28, P865, DOI 10.1007/BF01317034; STEER ML, 1995, NEW ENGL J MED, V332, P1482, DOI 10.1056/NEJM199506013322206; TANAKA N, 1995, CRIT CARE MED, V23, P901, DOI 10.1097/00003246-199505000-00019; TAYLOR CJ, 1994, LANCET, V343, P615, DOI 10.1016/S0140-6736(94)92629-8; Teich N, 2000, GASTROENTEROLOGY, V119, P461, DOI 10.1053/gast.2000.9312; Teich N, 1998, HUM MUTAT, V12, P39, DOI 10.1002/(SICI)1098-1004(1998)12:1<39::AID-HUMU6>3.0.CO;2-P; Testoni PA, 1999, ENDOSCOPY, V31, P131, DOI 10.1055/s-1999-13660; Testoni PA, 2001, ALIMENT PHARM THER, V15, P965, DOI 10.1046/j.1365-2036.2001.01015.x; Threadgold J, 2002, GUT, V50, P675, DOI 10.1136/gut.50.5.675; TOSKES PP, 1990, GASTROENTEROL CLIN N, V19, P783; Truninger K, 2002, AM J GASTROENTEROL, V97, P1133; VANGOSSUM A, 1988, JPEN-PARENTER ENTER, V12, P250, DOI 10.1177/0148607188012003250; Varallyay E, 1998, BIOCHEM BIOPH RES CO, V243, P56, DOI 10.1006/bbrc.1997.8058; VENTRUCCI M, 1987, PANCREAS, V2, P506, DOI 10.1097/00006676-198709000-00003; VOLKHOLZ H, 1982, VIRCHOWS ARCH A, V396, P331, DOI 10.1007/BF00431392; Whitcomb DC, 1999, GUT, V45, P317, DOI 10.1136/gut.45.3.317; Whitcomb DC, 1996, NAT GENET, V14, P141, DOI 10.1038/ng1096-141; WIERSEMA MJ, 1993, ENDOSCOPY, V25, P555, DOI 10.1055/s-2007-1010405; WILSON C, 1989, BRIT J SURG, V76, P177, DOI 10.1002/bjs.1800760224; Windsor ACJ, 1998, GUT, V42, P431, DOI 10.1136/gut.42.3.431; Witt H, 2000, NAT GENET, V25, P213, DOI 10.1038/76088; Witt H, 1999, GASTROENTEROLOGY, V117, P7, DOI 10.1016/S0016-5085(99)70543-3	128	222	247	0	20	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 26	2003	361	9367					1447	1455		10.1016/S0140-6736(03)13139-X	http://dx.doi.org/10.1016/S0140-6736(03)13139-X			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	672HZ	12727412				2022-12-28	WOS:000182516300026
J	Griffith, CA; Owen, T; Geballe, TR; Rayner, J; Rannou, P				Griffith, CA; Owen, T; Geballe, TR; Rayner, J; Rannou, P			Evidence for the exposure of water ice on Titan's surface	SCIENCE			English	Article							5 MU-M; CARBON-MONOXIDE; JOVIAN PLANETS; ATMOSPHERE; AEROSOLS; METHANE; CLOUDS; SPECTROPHOTOMETRY; SPECTRUM; IMAGES	The smoggy stratosphere of Saturn's largest moon, Titan, veils its surface from view, except at narrow wavelengths centered at 0.83, 0.94, 1.07, 1.28, 1.58, 2.0, 2.9, and 5.0 micrometers. We derived a spectrum of Titan's surface within these "windows" and detected features characteristic of water ice. Therefore, despite the hundreds of meters of organic liquids and solids hypothesized to exist on Titan's surface, its icy bedrock lies extensively exposed.	Univ Arizona, Dept Planetary Sci, Tucson, AZ 85721 USA; Univ Hawaii, Inst Astron, Honolulu, HI 96822 USA; Gemini Observ, Hilo, HI 96720 USA; Univ Paris 06, Paris, France	University of Arizona; University of Hawaii System; UDICE-French Research Universities; Sorbonne Universite	Griffith, CA (corresponding author), Univ Arizona, Dept Planetary Sci, 1629 E Univ Blvd, Tucson, AZ 85721 USA.		RANNOU, Pascal/I-9059-2012	RANNOU, pascal/0000-0003-0836-723X				Combes M, 1997, ICARUS, V129, P482, DOI 10.1006/icar.1997.5772; COUSTENIS A, 1995, ICARUS, V118, P87, DOI 10.1006/icar.1995.1179; CRUIKSHANK DP, 1991, ICARUS, V94, P345, DOI 10.1016/0019-1035(91)90233-J; FLASAR FM, 1983, SCIENCE, V221, P55, DOI 10.1126/science.221.4605.55; Gibbard SG, 1999, ICARUS, V139, P189, DOI 10.1006/icar.1999.6095; Griffith CA, 2000, SCIENCE, V290, P509, DOI 10.1126/science.290.5491.509; GRIFFITH CA, 1993, NATURE, V364, P511, DOI 10.1038/364511a0; GRIFFITH CA, 1991, ICARUS, V93, P362, DOI 10.1016/0019-1035(91)90219-J; Griffith CA, 1998, NATURE, V395, P575, DOI 10.1038/26920; Grundy WM, 2002, ICARUS, V155, P486, DOI 10.1006/icar.2001.6726; Hidayat T, 1998, ICARUS, V133, P109, DOI 10.1006/icar.1998.5908; HUSSON N, 1991, GEISA DATA BANK 1991; KARKOSCHKA E, 1994, ICARUS, V111, P174, DOI 10.1006/icar.1994.1139; KHARE BN, 1984, ICARUS, V60, P127, DOI 10.1016/0019-1035(84)90142-8; LELLOUCH E, 1989, ICARUS, V79, P328, DOI 10.1016/0019-1035(89)90081-X; LEMMON MT, 1993, ICARUS, V103, P329, DOI 10.1006/icar.1993.1074; LUNINE JI, 1983, SCIENCE, V222, P1229, DOI 10.1126/science.222.4629.1229; LUTZ BL, 1983, SCIENCE, V220, P1374, DOI 10.1126/science.220.4604.1374; McCord TB, 1998, J GEOPHYS RES-PLANET, V103, P8603, DOI 10.1029/98JE00788; MCCORD TB, COMMUNICATION; MCKAY CP, 1989, ICARUS, V80, P23, DOI 10.1016/0019-1035(89)90160-7; McKay CP, 2001, PLANET SPACE SCI, V49, P79, DOI 10.1016/S0032-0633(00)00051-9; Meier R, 2000, ICARUS, V145, P462, DOI 10.1006/icar.2000.6360; Noll KS, 1996, ICARUS, V124, P625, DOI 10.1006/icar.1996.0236; RAGES K, 1983, J GEOPHYS RES-SPACE, V88, P8721, DOI 10.1029/JA088iA11p08721; Rannou P, 1997, J GEOPHYS RES-PLANET, V102, P10997, DOI 10.1029/97JE00719; Rannou P, 1995, ICARUS, V118, P355, DOI 10.1006/icar.1995.1196; Rayner JT, 2003, PUBL ASTRON SOC PAC, V115, P362, DOI 10.1086/367745; RICHARDSON J, UNPUB; ROUSH TL, 2002, C 33 LUN PLAN I HOUS; Smith PH, 1996, ICARUS, V119, P336, DOI 10.1006/icar.1996.0023; STAMNES K, 1988, APPL OPTICS, V27, P2502, DOI 10.1364/AO.27.002502; TOMASKO MG, 1982, ICARUS, V51, P65, DOI 10.1016/0019-1035(82)90030-6; TOMASKO MG, 1997, ESA SP PUBL, V1177, P109; TOON OB, 1992, ICARUS, V95, P24, DOI 10.1016/0019-1035(92)90188-D; WEST RA, 1991, ICARUS, V90, P330, DOI 10.1016/0019-1035(91)90113-8; WEST RA, 1983, J GEOPHYS RES-SPACE, V88, P8699, DOI 10.1029/JA088iA11p08699; YELLE RV, 1997, ESA SP PUBL, V1177, P243; YUNG YL, 1984, ASTROPHYS J SUPPL S, V55, P465, DOI 10.1086/190963	40	117	118	1	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 25	2003	300	5619					628	630		10.1126/science.1081897	http://dx.doi.org/10.1126/science.1081897			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	671FB	12714742				2022-12-28	WOS:000182453700038
J	Umeda, H; Nomoto, K				Umeda, H; Nomoto, K			First-generation black-hole-forming supernovae and the metal abundance pattern of a very iron-poor star	NATURE			English	Article							II SUPERNOVAE; 1ST STARS; NUCLEOSYNTHESIS; EVOLUTION; PECULIAR	It has been proposed(1) theoretically that the first generation of stars in the Universe (population III) would be as massive as 100 solar masses (100 M.), because of inefficient cooling(2-4) of the precursor gas clouds. Recently, the most iron-deficient (but still carbon-rich) low-mass star-HE0107-5240-was discovered(5). If this is a population III star that gained its metals (elements heavier than helium) after its formation, it would challenge the theoretical picture of the formation of the first stars. Here we report that the patterns of elemental abundance in HE0107-5240 (and other extremely metal-poor stars) are in good accord with the nucleosynthesis that occurs in stars with masses of 20-130 M. when they become supernovae if, during the explosions, the ejecta undergo substantial mixing and fall-back to form massive black holes. Such supernovae have been observed(7). The abundance patterns are not, however, consistent with enrichment by supernovae from stars in the range 130-300 M. We accordingly infer that the first-generation supernovae came mostly from explosions of similar to20-130 M. stars; some of these produced iron-poor but carbon- and oxygen-rich ejecta. Low-mass second-generation stars, like HE0107-5240, could form because the carbon and oxygen provided pathways for the gas to cool.	Univ Tokyo, Dept Astron, Sch Sci, Tokyo 1130033, Japan	University of Tokyo	Nomoto, K (corresponding author), Univ Tokyo, Dept Astron, Sch Sci, Tokyo 1130033, Japan.	nomoto@astron.s.u-tokyo.ac.jp						Abel T, 2002, SCIENCE, V295, P93, DOI 10.1126/science.1063991; Aoki W, 2002, ASTROPHYS J, V567, P1166, DOI 10.1086/338756; AUDOUZE J, 1995, ASTROPHYS J, V451, pL49, DOI 10.1086/309687; Blake LAJ, 2001, NUCL PHYS A, V688, p502C; Depagne E, 2002, ASTRON ASTROPHYS, V390, P187, DOI 10.1051/0004-6361:20020687; Fujimoto MY, 2000, ASTROPHYS J, V529, pL25, DOI 10.1086/312453; HACHISU I, 1990, ASTROPHYS J, V358, pL57, DOI 10.1086/185779; Heger A, 2002, ASTROPHYS J, V567, P532, DOI 10.1086/338487; Kifonidis K, 2000, ASTROPHYS J, V531, pL123, DOI 10.1086/312541; MAEDA K, UNPUB ASTROPHYS J; MCWILLIAM A, 1995, ASTRON J, V109, P2757, DOI 10.1086/117486; Nakamura F, 1999, ASTROPHYS J, V515, P239, DOI 10.1086/307020; NOMOTO K, 2002, ASTROPH0209064; NOMOTO K, IN PRESS MASSIVE STA; Norris JE, 2001, ASTROPHYS J, V561, P1034, DOI 10.1086/323429; Omukai K, 1998, ASTROPHYS J, V508, P141, DOI 10.1086/306395; RYAN SG, IN PRESS CNO UNIVERS; RYAN SG, 2002, ASTROPH0211608; Sackmann IJ, 1999, ASTROPHYS J, V510, P217, DOI 10.1086/306545; Schneider R, 2002, ASTROPHYS J, V571, P30, DOI 10.1086/339917; Shigeyama T, 1998, ASTROPHYS J, V507, pL135, DOI 10.1086/311699; Siess L, 2002, ASTROPHYS J, V570, P329, DOI 10.1086/339733; Turatto M, 1998, ASTROPHYS J, V498, pL129, DOI 10.1086/311324; Umeda H, 2002, ASTROPHYS J, V565, P385, DOI 10.1086/323946; YOSHII Y, 1981, ASTRON ASTROPHYS, V97, P280; Zampieri L, 2003, MON NOT R ASTRON SOC, V338, P711, DOI 10.1046/j.1365-8711.2003.06082.x	27	326	330	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 24	2003	422	6934					871	873		10.1038/nature01571	http://dx.doi.org/10.1038/nature01571			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	670WR	12712199	Green Submitted			2022-12-28	WOS:000182432600048
J	Ng, J; O'Grady, G; Pettit, T; Frith, R				Ng, J; O'Grady, G; Pettit, T; Frith, R			Nitrous oxide use in first-year students at Auckland University	LANCET			English	Article								In a recent Lancet Case report, a patient presented with subacute combined degeneration of the spinal cord after recreational use of nitrous oxide (N2O). There is very little information about use of this substance as a recreational drug. In a questionnaire-based study, we surveyed 1782 students in their first year at the University of Auckland, New Zealand. 1360 (76%) questionnaires were completed and consistent. 780 (57%) students were aware of recreational use of N2O, 158 (12%) used the substance recreationally, and 39 (3%) inhaled It at least monthly. Users were most likely to be white and to be men. Our results show a high frequency of recreational N2O use in first-year students at Auckland University. Although this study does not accurately reflect use of this substance in the wider community, the high prevalence suggests that presentations of subacute myelopathy in an otherwise fit young person should prompt an enquiry about use of N2O.	Auckland Hosp, Dept Neurol, Auckland 1001, New Zealand	Auckland City Hospital	Frith, R (corresponding author), Auckland Hosp, Dept Neurol, Auckland 1001, New Zealand.							DEACON R, 1978, LANCET, V2, P1023, DOI 10.1016/S0140-6736(78)92341-3; Ng J, 2002, LANCET, V360, P384, DOI 10.1016/S0140-6736(02)09611-3; *STAT NZ, 1998, GUID COLL COMM INF, P7	3	42	44	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 19	2003	361	9366					1349	1350		10.1016/S0140-6736(03)13045-0	http://dx.doi.org/10.1016/S0140-6736(03)13045-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	669HP	12711474				2022-12-28	WOS:000182346100016
J	Chen, DT; Miller, FG; Rosenstein, DL				Chen, DT; Miller, FG; Rosenstein, DL			Clinical research and the physician-patient relationship	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							ETHICS; TRIALS; EQUIPOISE	All practicing physicians should be prepared to respond to requests from patients for advice about participating in clinical trials research. Even physicians who choose not to conduct clinical trials but rather devote their practice to clinical care may have patients who consider volunteering for research. In advising patients about clinical research, physicians enhance the physician-patient relationship and contribute to the overall goals of evidence-based medicine. We discuss several ethical and practical challenges facing physicians who wish to help their patients make decisions about volunteering for clinical trials. in addition, We suggest how preparation for advising patients about clinical research participation can be incorporated into the medical education process.	NIMH, Dept Clin Bioeth, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Chen, DT (corresponding author), NIMH, Dept Clin Bioeth, NIH, 10 Ctr Dr,Room 10-1C118, Bethesda, MD 20892 USA.	dochen@cc.nih.gov						APPELBAUM PS, 1987, HASTINGS CENT REP, V17, P20, DOI 10.2307/3562038; Braunholtz DA, 2001, J CLIN EPIDEMIOL, V54, P217, DOI 10.1016/S0895-4356(00)00305-X; CHEN DT, IN PRESS PSYCHOPHARM; *EM CAR RES I, 2002, SHOULD I ENT CLIN TR; Emanuel EJ, 2000, JAMA-J AM MED ASSOC, V283, P2701, DOI 10.1001/jama.283.20.2701; Emanuel EJ, 2001, NEW ENGL J MED, V345, P915, DOI 10.1056/NEJM200109203451211; EMANUEL LL, 1994, ARCH INTERN MED, V154, P1785, DOI 10.1001/archinte.154.16.1785; Fleischman Alan R, 2002, Trans Am Clin Climatol Assoc, V113, P126; FREEDMAN B, 1987, NEW ENGL J MED, V317, P141, DOI 10.1056/NEJM198707163170304; FRIED C, 1974, MED EXPT PERSONAL IN, P47; Kass NE, 1996, HASTINGS CENT REP, V26, P25, DOI 10.2307/3528467; Kolata Gina, 1999, N Y Times Web, pC12; Lantos JD, 1999, J PEDIATR-US, V134, P130, DOI 10.1016/S0022-3476(99)70400-2; Lidz CW, 2002, MED CARE, V40, P55, DOI 10.1097/01.MLR.0000023956.25813.18; Lilford RJ, 2001, BMJ-BRIT MED J, V322, P795; McCray AT, 2000, ANN INTERN MED, V133, P609, DOI 10.7326/0003-4819-133-8-200010170-00013; Miller FG, 1998, JAMA-J AM MED ASSOC, V280, P1449, DOI 10.1001/jama.280.16.1449; Miller M, 2000, HASTINGS CENT REP, V30, P34, DOI 10.2307/3527646; Miller M, 2001, Int Anesthesiol Clin, V39, P13; Morin K, 2002, JAMA-J AM MED ASSOC, V287, P78, DOI 10.1001/jama.287.1.78; Novack DH, 1997, JAMA-J AM MED ASSOC, V278, P502, DOI 10.1001/jama.278.6.502; Rao JN, 2002, BRIT MED J, V325, P36, DOI 10.1136/bmj.325.7354.36; Rettig RA, 2000, HEALTH AFFAIR, V19, P129, DOI 10.1377/hlthaff.19.2.129; Stoeckle JD, 1997, J CLIN ETHIC, V8, P22; VIST GE, 2002, COCHRANE LIB; Wolf LE, 2000, AM J MED, V109, P82, DOI 10.1016/S0002-9343(00)00465-4	26	44	44	1	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	2003	138	8					669	672		10.7326/0003-4819-138-8-200304150-00015	http://dx.doi.org/10.7326/0003-4819-138-8-200304150-00015			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	666JH	12693890				2022-12-28	WOS:000182173800010
J	Katz, MH				Katz, MH			Multivariable analysis: A primer for readers of medical research	ANNALS OF INTERNAL MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; LOGISTIC-REGRESSION ANALYSIS; CORONARY-HEART-DISEASE; RISK; MODELS; INFECTION; EVENTS; TRIAL; SIMULATION; PREDICTION	Many clinical readers, especially those uncomfortable with mathematics, treat published multivariable models as a black box, accepting the author's explanation of the results. However, multivariable analysis can be understood without undue concern for the underlying mathematics. This paper reviews the basics of multivariable analysis, including what multivariable models are, why they are used, what types exist, what assumptions underlie them, how they should be interpreted, and how they can be evaluated. A deeper understanding of multivariable models enables readers to decide for themselves how much weight to give to the results of published analyses.	San Francisco Dept Publ Hlth, San Francisco, CA USA	San Francisco Department of Public Health	Katz, MH (corresponding author), 101 Grove St,Room 308, San Francisco, CA 94102 USA.	Mitch.Katz@sfdph.org						Braitman LE, 1996, ANN INTERN MED, V125, P406, DOI 10.7326/0003-4819-125-5-199609010-00008; Colford JM, 1996, AM J EPIDEMIOL, V144, P807, DOI 10.1093/oxfordjournals.aje.a009015; CONCATO J, 1993, ANN INTERN MED, V118, P201, DOI 10.7326/0003-4819-118-3-199302010-00009; Cummings SR, 1998, JAMA-J AM MED ASSOC, V280, P2077, DOI 10.1001/jama.280.24.2077; Emanuel EJ, 2000, ANN INTERN MED, V133, P527, DOI 10.7326/0003-4819-133-7-200010030-00011; Gerstein HC, 2001, JAMA-J AM MED ASSOC, V286, P421, DOI 10.1001/jama.286.4.421; GLANTZ S, 1990, PRIMER APPLIED REGRE, P110; Gronbaek M, 2000, ANN INTERN MED, V133, P411, DOI 10.7326/0003-4819-133-6-200009190-00008; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HARRELL FE, 1985, CANCER TREAT REP, V69, P1071; Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4; Hooton TM, 1996, NEW ENGL J MED, V335, P468, DOI 10.1056/NEJM199608153350703; Hosmer DW, 1997, STAT MED, V16, P965; HOSMER DW, 1989, APPL LOGISTIC REGRES, P187; HSIAO JK, 1989, ARCH GEN PSYCHIAT, V46, P664; Hujoel PP, 2000, JAMA-J AM MED ASSOC, V284, P1406, DOI 10.1001/jama.284.11.1406; Johnson JG, 2000, JAMA-J AM MED ASSOC, V284, P2348, DOI 10.1001/jama.284.18.2348; KAHN HA, 1989, STAT METHODS EPIDEMI, P193; KALBFLEISH JD, 1980, STAT ANAL FAILURE TI, P89; Katz MH, 1999, MULTIVARIABLE ANAL P; KELSEY JL, 1996, METHODS OBSERVATIONA, P130; LAWLESS JF, 1982, STAT MODELS METHODS, P394; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; McAlindon TE, 1996, ANN INTERN MED, V125, P353, DOI 10.7326/0003-4819-125-5-199609010-00001; O'Malley PG, 2000, NEW ENGL J MED, V343, P1298, DOI 10.1056/NEJM200011023431803; Peduzzi P, 1995, J CLIN EPIDEMIOL, V48, P1503, DOI 10.1016/0895-4356(95)00048-8; Peduzzi P, 1996, J CLIN EPIDEMIOL, V49, P1373, DOI 10.1016/S0895-4356(96)00236-3; Phibbs CS, 1996, JAMA-J AM MED ASSOC, V276, P1054, DOI 10.1001/jama.276.13.1054; Stevens DA, 2000, NEW ENGL J MED, V342, P756, DOI 10.1056/NEJM200003163421102; Steyerberg EW, 1999, J CLIN EPIDEMIOL, V52, P935, DOI 10.1016/S0895-4356(99)00103-1; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; Wasson JH, 1996, JAMA-J AM MED ASSOC, V275, P641, DOI 10.1001/jama.275.8.641	33	278	286	1	30	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	2003	138	8					644	650		10.7326/0003-4819-138-8-200304150-00012	http://dx.doi.org/10.7326/0003-4819-138-8-200304150-00012			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	666JH	12693887				2022-12-28	WOS:000182173800007
J	Biezeveld, MH; Kuipers, IM; Geisser, J; Lam, J; Ottenkamp, JJ; Hack, CE; Kuijpers, TW				Biezeveld, MH; Kuipers, IM; Geisser, J; Lam, J; Ottenkamp, JJ; Hack, CE; Kuijpers, TW			Association of mannose-binding lectin genotype with cardiovascular abnormalities in Kawasaki disease	LANCET			English	Article								Kawasaki disease is an acute vasculitis of possible infectious cause, which in particular affects the coronary arteries. Young children rely mostly on their innate immune system for protection against invading microorganisms, of which mannose-binding lectin is an important component. We aimed to investigate the possible role of the gene for this molecule (MBL) in white Dutch patients with Kawasaki disease. In 90 patients, frequency of mutations in the MBL gene was higher than in healthy children. In children younger than I year, those with mutations were at higher risk of development of coronary artery lesions than were those without (odds ratio 15-7, 95% CI 1.4-176.5, p=0.026). Our findings suggest that the innate immune system contributes differently to pathophysiology of Kawasaki disease at various ages.	Univ Amsterdam, Acad Med Ctr, Emma Childrens Hosp, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Netherlands Blood Transfus Serv, Cent Lab, Amsterdam, Netherlands; Univ Amsterdam, Expt & Clin Immunol Lab, Amsterdam, Netherlands	Emma Children's Hospital; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; University of Amsterdam; University of Amsterdam	Kuijpers, TW (corresponding author), Univ Amsterdam, Acad Med Ctr, Emma Childrens Hosp, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.		Levi, Marcel/AAZ-8559-2020					KAWASAKI T, 1974, PEDIATRICS, V54, P271; MADSEN HO, 1995, J IMMUNOL, V155, P3013; Rowley AH, 1999, PEDIATR CLIN N AM, V46, P313, DOI 10.1016/S0031-3955(05)70120-6; Turner M W, 2000, Rev Immunogenet, V2, P305; Zhang T, 2002, ACTA PAEDIATR, V91, P517, DOI 10.1080/080352502753711623	5	53	55	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 12	2003	361	9365					1268	1270		10.1016/S0140-6736(03)12985-6	http://dx.doi.org/10.1016/S0140-6736(03)12985-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	666DM	12699957				2022-12-28	WOS:000182161600013
J	Bligh, J; Farrow, R				Bligh, J; Farrow, R			Interactive case report - A 66 year old woman with a rash: case outcome	BRITISH MEDICAL JOURNAL			English	Article									Peninsula Med Sch, Plymouth PL6 8BX, Devon, England	University of Plymouth	Bligh, J (corresponding author), Peninsula Med Sch, Tamar Sci Pk, Plymouth PL6 8BX, Devon, England.								0	2	2	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 12	2003	326	7393					804	804		10.1136/bmj.326.7393.804	http://dx.doi.org/10.1136/bmj.326.7393.804			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	670BE	12689963	Green Published, Green Accepted			2022-12-28	WOS:000182386700022
J	van Walraven, C; Mamdani, M; Cohn, A; Katib, Y; Walker, M; Rodger, MA				van Walraven, C; Mamdani, M; Cohn, A; Katib, Y; Walker, M; Rodger, MA			Risk of subsequent thromboembolism for patients wit pre-eclampsia	BRITISH MEDICAL JOURNAL			English	Article							THROMBOPHILIA; PREECLAMPSIA		Ottawa Hlth Res Inst, Ottawa, ON K1Y 4E9, Canada; Inst Clin Evaluat Sci, Toronto, ON M4N 3N5, Canada; Univ Ottawa, Ottawa, ON K1H 8M5, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Toronto; University of Ottawa	van Walraven, C (corresponding author), Ottawa Hlth Res Inst, Ottawa, ON K1Y 4E9, Canada.			Rodger, Marc/0000-0001-8166-3487				Grandone E, 1997, THROMB HAEMOSTASIS, V77, P1052; Gris JC, 1997, THROMB HAEMOSTASIS, V77, P1096; Kupferminc MJ, 1999, NEW ENGL J MED, V340, P9, DOI 10.1056/NEJM199901073400102; REDMAN CWG, 1990, NEW ENGL J MED, V323, P478, DOI 10.1056/NEJM199008163230710; Rodeghiero F, 1997, THROMB HAEMOSTASIS, V78, P636	5	35	35	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 12	2003	326	7393					791	792		10.1136/bmj.326.7393.791	http://dx.doi.org/10.1136/bmj.326.7393.791			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	670BE	12689975	Bronze, Green Published			2022-12-28	WOS:000182386700017
J	Frommer, WB; Schulze, WX; Lalonde, S				Frommer, WB; Schulze, WX; Lalonde, S			Plant science - Hexokinase, jack-of-all-trades	SCIENCE			English	Editorial Material							SACCHAROMYCES-CEREVISIAE; SUGAR SENSOR; MEMBRANE; PII		Univ Tubingen, Zentrum Mol Biol Pflanzen, Dept Plant Physiol, D-72076 Tubingen, Germany; Univ So Denmark, Dept Biochem & Mol Biol, Prot Interact Lab, DK-5230 Odense, Denmark	Eberhard Karls University of Tubingen; University of Southern Denmark	Frommer, WB (corresponding author), Univ Tubingen, Zentrum Mol Biol Pflanzen, Dept Plant Physiol, D-72076 Tubingen, Germany.		Schulze, Waltraud X/E-9800-2011; Frommer, Wolf B/A-8256-2008; Frommer, Wolf B/K-5042-2017	Schulze, Waltraud X/0000-0001-9957-7245; Frommer, Wolf B/0000-0001-6465-0115; Frommer, Wolf B/0000-0001-6465-0115				Cesar MD, 2002, ARCH BIOCHEM BIOPHYS, V397, P106, DOI 10.1006/abbi.2001.2639; FEHR M, 2003, J BIOL CHEM     0320; Halford NG, 1999, TRENDS PLANT SCI, V4, P117, DOI 10.1016/S1360-1385(99)01377-1; Herrero P, 1998, FEBS LETT, V434, P71, DOI 10.1016/S0014-5793(98)00872-2; Jang JC, 1997, PLANT CELL, V9, P5, DOI 10.1105/tpc.9.1.5; Kuser PR, 2000, J BIOL CHEM, V275, P20814, DOI 10.1074/jbc.M910412199; Lalonde S, 1999, PLANT CELL, V11, P707, DOI 10.1105/tpc.11.4.707; Mayordomo I, 2001, YEAST, V18, P923, DOI 10.1002/yea.737; Moore B, 2003, SCIENCE, V300, P332, DOI 10.1126/science.1080585; Murata T, 1997, FEBS LETT, V406, P109, DOI 10.1016/S0014-5793(97)00253-6; Stitt M, 1999, PLANT CARBOHYDRATE B, P1; Travis AJ, 1999, J BIOL CHEM, V274, P34467, DOI 10.1074/jbc.274.48.34467; Wiese A, 1999, FEBS LETT, V461, P13, DOI 10.1016/S0014-5793(99)01417-9	13	40	41	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 11	2003	300	5617					261	+		10.1126/science.1084120	http://dx.doi.org/10.1126/science.1084120			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	665RQ	12690178				2022-12-28	WOS:000182135400034
J	Yang, WL; Brouet, V; Zhou, XJ; Choi, HJ; Louie, SG; Cohen, ML; Kellar, SA; Bogdanov, PV; Lanzara, A; Goldoni, A; Parmigiani, F; Hussain, Z; Shen, ZX				Yang, WL; Brouet, V; Zhou, XJ; Choi, HJ; Louie, SG; Cohen, ML; Kellar, SA; Bogdanov, PV; Lanzara, A; Goldoni, A; Parmigiani, F; Hussain, Z; Shen, ZX			Band structure and Fermi surface of electron-doped C-60 monolayers	SCIENCE			English	Article							PHOTOEMISSION SPECTRA; SUPERCONDUCTIVITY; K3C60; FULLERIDES; AG(111); SYSTEMS; PHONON; ENERGY; FILMS; STATE	C-60 fullerides are challenging systems because both the electron-phonon and electron-electron interactions are large on the energy scale of the expected narrow band width. We report angle-resolved photoemission data on the band dispersion for an alkali-doped C-60 monolayer and a detailed comparison with theory. Compared to the maximum bare theoretical band width of 170 meV, the observed 100-meV dispersion is within the range of renormalization by electron-phonon coupling. This dispersion is only a fraction of the integrated peak width, revealing the importance of many-body effects. Additionally, measurements on the Fermi surface indicate the robustness of the Luttinger theorem even for materials with strong interactions.	Stanford Univ, Dept Phys, Stanford, CA 94305 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Adv Light Source, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Mat Sci, Berkeley, CA 94720 USA; Stanford Univ, Dept Appl Phys, Stanford, CA 94305 USA; Stanford Univ, Stanford Synchrotron Radiat Lab, Stanford, CA 94305 USA; Univ Paris 11, Phys Solides Lab, CNRS, UMR8502, F-91405 Orsay, France; Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA; Sincrotrone Trieste SCpA, I-34012 Trieste, Italy; Univ Cattolica Sacro Cuore, Dipartimento Matemat & Fis, Ist Nazl Fis Mat, I-25121 Brescia, Italy	Stanford University; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Stanford University; Stanford University; United States Department of Energy (DOE); SLAC National Accelerator Laboratory; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); UDICE-French Research Universities; Universite Paris Saclay; University of California System; University of California Berkeley; Elettra Sincrotrone Trieste; Catholic University of the Sacred Heart; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR)	Shen, ZX (corresponding author), Stanford Univ, Dept Phys, Stanford, CA 94305 USA.		lanzara, alessandra/AAC-9535-2020; Yang, Wanli/D-7183-2011; Moreno, Gabriel/K-8537-2017; Choi, Hyoung Joon/N-8933-2015	Yang, Wanli/0000-0003-0666-8063; Choi, Hyoung Joon/0000-0001-8565-8597; GOLDONI, Andrea/0000-0001-9989-3889; Parmigiani, Fulvio/0000-0001-9529-7406				ALTMAN EI, 1993, PHYS REV B, V48, P18244, DOI 10.1103/PhysRevB.48.18244; ANTROPOV VP, 1993, PHYS REV B, V48, P7651, DOI 10.1103/PhysRevB.48.7651; Aryasetiawan F, 1997, PHYS REV B, V55, P10165, DOI 10.1103/PhysRevB.55.R10165; BENNING PJ, 1993, PHYS REV B, V47, P13843, DOI 10.1103/PhysRevB.47.13843; Bogdanov PV, 2000, PHYS REV LETT, V85, P2581, DOI 10.1103/PhysRevLett.85.2581; Burkhart GJ, 1996, PHYS REV B, V54, pR6865, DOI 10.1103/PhysRevB.54.R6865; Capone M, 2002, SCIENCE, V296, P2364, DOI 10.1126/science.1071122; Cepek C, 2000, SURF SCI, V454, P467, DOI 10.1016/S0039-6028(00)00135-7; Chuang YD, 2001, SCIENCE, V292, P1509, DOI 10.1126/science.1059255; COHEN ML, 1982, PHYS SCRIPTA, VT1, P5, DOI 10.1088/0031-8949/1982/T1/001; ERWIN SC, 1991, SCIENCE, V254, P842, DOI 10.1126/science.254.5033.842; Georges A, 1996, REV MOD PHYS, V68, P13, DOI 10.1103/RevModPhys.68.13; Goldoni A, 2000, J CHEM PHYS, V113, P8266, DOI 10.1063/1.1315588; GUNNARSSON O, 1995, PHYS REV LETT, V74, P1875, DOI 10.1103/PhysRevLett.74.1875; Gunnarsson O, 1997, REV MOD PHYS, V69, P575, DOI 10.1103/RevModPhys.69.575; HEBARD AF, 1991, NATURE, V350, P600, DOI 10.1038/350600a0; HEBARD AF, 1993, PHYS REV B, V48, P9945, DOI 10.1103/PhysRevB.48.9945; Hesper R, 1997, EUROPHYS LETT, V40, P177, DOI 10.1209/epl/i1997-00442-2; Hesper R, 2000, PHYS REV B, V62, P16046, DOI 10.1103/PhysRevB.62.16046; Hoogenboom BW, 1998, PHYS REV B, V57, P11939, DOI 10.1103/PhysRevB.57.11939; IHM J, 1979, J PHYS C SOLID STATE, V12, P4409, DOI 10.1088/0022-3719/12/21/009; KNUPFER M, 1993, PHYS REV B, V47, P13944, DOI 10.1103/PhysRevB.47.13944; Liechtenstein AI, 1996, J PHYS-CONDENS MAT, V8, P4001, DOI 10.1088/0953-8984/8/22/005; LOF RW, 1992, PHYS REV LETT, V68, P3924, DOI 10.1103/PhysRevLett.68.3924; MODESTI S, 1993, PHYS REV LETT, V71, P2469, DOI 10.1103/PhysRevLett.71.2469; SanchezPortal D, 1997, INT J QUANTUM CHEM, V65, P453, DOI 10.1002/(SICI)1097-461X(1997)65:5<453::AID-QUA9>3.0.CO;2-V; Takenobu T, 2000, PHYS REV LETT, V85, P381, DOI 10.1103/PhysRevLett.85.381; Tjeng LH, 1997, SOLID STATE COMMUN, V103, P31, DOI 10.1016/S0038-1098(97)00126-9; TROULLIER N, 1991, PHYS REV B, V43, P1993, DOI 10.1103/PhysRevB.43.1993; Zhou XJ, 1999, SCIENCE, V286, P268, DOI 10.1126/science.286.5438.268	30	99	101	1	41	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 11	2003	300	5617					303	307		10.1126/science.1082174	http://dx.doi.org/10.1126/science.1082174			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	665RQ	12690192				2022-12-28	WOS:000182135400049
J	Esposito, K; Pontillo, A; Di Palo, C; Giugliano, G; Masella, M; Marfella, R; Giugliano, D				Esposito, K; Pontillo, A; Di Palo, C; Giugliano, G; Masella, M; Marfella, R; Giugliano, D			Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women - A randomized trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							C-REACTIVE PROTEIN; SUBCUTANEOUS ADIPOSE-TISSUE; NECROSIS-FACTOR-ALPHA; INSULIN-RESISTANCE; MEDITERRANEAN DIET; INTERLEUKIN-6; PREVALENCE; DISEASE; ASSOCIATIONS; ADIPONECTIN	Context Obesity is an independent risk factor for cardiovascular disease, which may be mediated by increased secretion of proinflammatory cytokines by adipose tissue. Objective To determine the effect of a program of changes in lifestyle designed to obtain a sustained reduction of body weight on markers of systemic vascular inflammation and insulin resistance. Design and Setting Randomized single-blind trial conducted from February 1999 to February 2002 at a university hospital in Italy. Patients One hundred twenty premenopausal obese women (body mass index greater than or equal to30) aged 20 to 46 years without diabetes, hypertension, or hyperlipidemia. Interventions The 60 women randomly assigned to the intervention group received detailed advice about how to achieve a reduction of weight of 10% or more through a low-energy Mediterranean-style diet and increased physical activity. The control group (n = 60) was given general information about healthy food choices and exercise. Main Outcome Measures Lipid and glucose intake; blood pressure; homeostatic model assessment of insulin sensitivity; and circulating levels of interleukin 6 (IL-6), interleukin 18 (IL-18), C-reactive protein (CRP), and adiponectin. Results After 2 years, women in the intervention group consumed more foods rich in complex carbohydrates (9% corrected difference; P<.001), monounsaturated fat (2%; P-.009), and fiber (7 g/d; P<.001); had a lower ratio of omega-6 to omega-3 fatty acids (-5; P<.001); and had lower energy (-310 kcal/d; P<.001), saturated fat (-3.5%; P=.007), and cholesterol intake (-92 mg/d; P<.001) than controls. Body mass index decreased more in the intervention group than in controls (-4.2; P<.001), as did serum concentrations of IL-6 (-1.1 pg/mL; P=..009), IL-18 (-57 pg/mL; P=.02), and CRP (-1.6 mg/L; P=.008), while adiponectin levels increased significantly (2.2 mug/mL; P=.01). In multivariate analyses, changes in free fatty acids (P=.008), IL-6 (P=.02), and adiponectin (P=.007) levels were independently associated with changes in insulin sensitivity. Conclusion In this study, a multidisciplinary program aimed to reduce body weight in obese women through lifestyle changes was associated with a reduction in markers of vascular inflammation and insulin resistance.	Univ Naples 2, Dept Geriatr & Metab Dis, Ctr Obes Management, Naples, Italy; Univ Naples 2, Chair Plast & Reconstruct Surg, Naples, Italy; Univ Naples 2, Dept Psychiat, Naples, Italy; Univ Naples 2, Cardiovasc Res Ctr, Naples, Italy	Universita della Campania Vanvitelli; Universita della Campania Vanvitelli; Universita della Campania Vanvitelli; Universita della Campania Vanvitelli	Esposito, K (corresponding author), Policlin Univ, Dept Geriatr & Metab Dis, Ctr Obes Management, Piazza L Miraglia, I-80138 Naples, Italy.		Esposito, Katherine/AHE-2564-2022; Marfella, Raffaele/C-6899-2012; Maiorino, Maria Ida/AHE-9986-2022	Esposito, Katherine/0000-0002-3652-5154; Marfella, Raffaele/0000-0003-3960-9270; Maiorino, Maria Ida/0000-0003-4659-7546; Giugliano, Dario/0000-0002-9377-873X				Bastard JP, 2000, J CLIN ENDOCR METAB, V85, P3338, DOI 10.1210/jc.85.9.3338; Billington CJ, 2000, ARCH INTERN MED, V160, P898, DOI 10.1001/archinte.160.7.898; Blake GJ, 2001, CIRC RES, V89, P763, DOI 10.1161/hh2101.099270; Blankenberg S, 2002, CIRCULATION, V106, P24, DOI 10.1161/01.CIR.0000020546.30940.92; Corbi GM, 2002, J CLIN ENDOCR METAB, V87, P2080, DOI 10.1210/jc.87.5.2080; de Lorgeril M, 1999, CIRCULATION, V99, P779, DOI 10.1161/01.CIR.99.6.779; Egger G, 1997, BRIT MED J, V315, P477, DOI 10.1136/bmj.315.7106.477; Esposito K, 2002, J CLIN ENDOCR METAB, V87, P3864, DOI 10.1210/jc.2002-????; Flegal KM, 2002, JAMA-J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723; Freedman MR, 2001, OBES RES, V9, p1S, DOI 10.1038/oby.2001.113; Fruebis J, 2001, P NATL ACAD SCI USA, V98, P2005, DOI 10.1073/pnas.041591798; Harris TB, 1999, AM J MED, V106, P506, DOI 10.1016/S0002-9343(99)00066-2; Heilbronn LK, 2001, ARTERIOSCL THROM VAS, V21, P968, DOI 10.1161/01.ATV.21.6.968; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; Kopelman PG, 2000, NATURE, V404, P635, DOI 10.1038/35007508; Kumada M, 2003, ARTERIOSCL THROM VAS, V23, P85, DOI 10.1161/01.ATV.0000048856.22331.50; Maeda K, 1996, BIOCHEM BIOPH RES CO, V221, P286, DOI 10.1006/bbrc.1996.0587; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; Mohamed-Ali V, 1997, J CLIN ENDOCR METAB, V82, P4196, DOI 10.1210/jc.82.12.4196; Ogden CL, 2002, JAMA-J AM MED ASSOC, V288, P1728, DOI 10.1001/jama.288.14.1728; Ridker PM, 2000, NEW ENGL J MED, V342, P836, DOI 10.1056/NEJM200003233421202; Robertson RM, 2001, CIRCULATION, V103, P1821, DOI 10.1161/01.CIR.103.13.1821; Serdula MK, 1999, JAMA-J AM MED ASSOC, V282, P1353, DOI 10.1001/jama.282.14.1353; Singh RB, 2002, LANCET, V360, P1455, DOI 10.1016/S0140-6736(02)11472-3; Stefan N, 2002, HORM METAB RES, V34, P469, DOI 10.1055/s-2002-34785; STOUTHARD JML, 1995, AM J PHYSIOL-ENDOC M, V268, pE813, DOI 10.1152/ajpendo.1995.268.5.E813; Tchernof A, 2002, CIRCULATION, V105, P564, DOI 10.1161/hc0502.103331; Yang WS, 2001, J CLIN ENDOCR METAB, V86, P3815, DOI 10.1210/jc.86.8.3815; Yudkin JS, 1999, ARTERIOSCL THROM VAS, V19, P972, DOI 10.1161/01.ATV.19.4.972; Ziccardi P, 2002, CIRCULATION, V105, P804, DOI 10.1161/hc0702.104279	30	1118	1161	0	136	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 9	2003	289	14					1799	1804		10.1001/jama.289.14.1799	http://dx.doi.org/10.1001/jama.289.14.1799			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	664ZJ	12684358	Bronze			2022-12-28	WOS:000182094900025
J	Hague, WM; Davoren, PM; Oliver, J; Rowan, J				Hague, WM; Davoren, PM; Oliver, J; Rowan, J			Contraindications to use of metformin - Metformin may be useful in gestational diabetes	BMJ-BRITISH MEDICAL JOURNAL			English	Letter									Univ Adelaide, Queen Elizabeth Hosp, Dept Obstet, Woodville, SA 5011, Australia; Univ Queensland, Dept Med, Gold Coast Hosp, Southport, Qld 4215, Australia; Flinders Univ S Australia, Sch Med, Dept Physiol, Bedford Pk, SA 5042, Australia; Natl Womens Hosp, Auckland, New Zealand	University of Adelaide; Gold Coast University Hospital; University of Queensland; Flinders University South Australia	Hague, WM (corresponding author), Univ Adelaide, Queen Elizabeth Hosp, Dept Obstet, Woodville, SA 5011, Australia.							Barker DJP, 1998, MOTHERS BABIES HLTH; COETZEE EJ, 1986, DIABETES RES CLIN PR, V1, P281; Glueck CJ, 2002, FERTIL STERIL, V77, P520, DOI 10.1016/S0015-0282(01)03202-2; Hellmuth E, 2000, DIABETIC MED, V17, P507, DOI 10.1046/j.1464-5491.2000.00314.x; Jones GC, 2003, BMJ-BRIT MED J, V326, P4, DOI 10.1136/bmj.326.7379.4	5	48	52	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 5	2003	326	7392					762	763						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	665LF	12680386				2022-12-28	WOS:000182121600024
J	Sever, PS; Dahlof, B; Poulter, NR; Wedel, H; Beevers, G; Caulfield, M; Collins, R; Kjeldsen, SE; Kristinsson, A; McInnes, GT; Mehlsen, J; Nieminen, M; O'Brien, E; Ostergren, J				Sever, PS; Dahlof, B; Poulter, NR; Wedel, H; Beevers, G; Caulfield, M; Collins, R; Kjeldsen, SE; Kristinsson, A; McInnes, GT; Mehlsen, J; Nieminen, M; O'Brien, E; Ostergren, J		ASCOT Investigators	Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial	LANCET			English	Article							HEART-DISEASE; SERUM-CHOLESTEROL; BLOOD-PRESSURE; RISK; INTERVENTION; PRAVASTATIN; MORTALITY; THERAPY; PROGRAM; MEN	Background The lowering of cholesterol concentrations in individuals at high risk of cardiovascular disease improves outcome. No study, however, has assessed benefits of cholesterol lowering in the primary prevention of coronary heart disease (CHD) in hypertensive patients who are not conventionally deemed dyslipidaemic. Methods Of 19 342 hypertensive patients (aged 40-79 years with at least three other cardiovascular risk factors) randomised to one of two anti hypertensive regimens in the Anglo-Scandinavian Cardiac Outcomes Trial, 10305 with non-fasting total cholesterol concentrations 6.5 mmol/L or less were randomly assigned additional atorvastatin 10 mg or placebo. These patients formed the lipid-lowering arm of the study. We planned follow-up for an average of 5 years, the primary endpoint being non-fatal myocardial infarction and fatal CHD. Data were analysed by intention to treat. Findings Treatment was stopped after a median follow-up of 3.3 years. By that time, 100 primary events had occurred in the atorvastatin group compared with 154 events in the placebo group (hazard ratio 0.64 [95% CI 0.50-0.83], p=0.0005). This benefit emerged in the first year of follow-up. There was no significant heterogeneity among prespecified subgroups. Fatal and non-fatal stroke (89 atorvastatin vs 121 placebo, 0.73 [0.56-0.96], p=0.024), total cardiovascular events (389 vs 486, 0.79 [0.69-0.90], p=0.0005), and total coronary events (178 vs 247, 0.71 [0.59-0.86], p=0.0005) were also significantly lowered. There were 185 deaths in the atorvastatin group and 212 in the placebo group (0.87 [0.71-1.06], p=0.16). Atorvastatin lowered total serum cholesterol by about 1.3 mmol/L compared with placebo at 12 months, and by 1.1 mmol/L after 3 years of follow-up. Interpretation The reductions in major cardiovascular events with atorvastatin are large, given the short follow-up time. These findings may have implications for future lipid-lowering guidelines.	Univ London Imperial Coll Sci Technol & Med, NHLI, Fac Med, Dept Clin Pharmacol,Cardiovasc Studies Unit, London W2 1PG, England; Sahlgrens Univ Hosp, Gothenburg, Sweden; Nord Sch Publ Hlth, Gothenburg, Sweden; City Hosp, Birmingham, W Midlands, England; Queen Marys Sch Med, Barts & London, London, England; Radcliffe Infirm, Oxford OX2 6HE, England; Ulleval Hosp, Oslo, Norway; Univ Hosp, Reykjavik, Iceland; Univ Glasgow, Glasgow, Lanark, Scotland; Frederiksberg Univ Hosp, Frederiksberg, Denmark; Univ Cent Hosp, Helsinki, Finland; Beaumont Hosp, Dublin 9, Ireland; Karolinska Hosp, S-10401 Stockholm, Sweden	Imperial College London; Sahlgrenska University Hospital; University of Birmingham; University of London; Queen Mary University London; Radcliffe Infirmary; University of Oslo; Landspitali National University Hospital; University of Glasgow; University of Helsinki; Helsinki University Central Hospital; Karolinska Institutet; Karolinska University Hospital	Poulter, NR (corresponding author), Univ London Imperial Coll Sci Technol & Med, NHLI, Fac Med, Dept Clin Pharmacol,Cardiovasc Studies Unit, St Marys Campus, London W2 1PG, England.	n.poulter@imperial.ac.uk	Mehlsen, Jesper/AAA-5848-2022; Stanton, Alice V/F-4697-2012	Caulfield, Mark/0000-0001-9295-3594				*ALLHAT OFF COORD, 2002, JAMA-J AM MED ASSOC, V288, P2998, DOI DOI 10.1016/S1062-1458(03)00049-7; Athyros VG, 2002, CURR MED RES OPIN, V18, P220, DOI 10.1185/030079902125000787; Bucher HC, 1999, ARTERIOSCL THROM VAS, V19, P187, DOI 10.1161/01.ATV.19.2.187; BUCHWALD H, 1990, NEW ENGL J MED, V323, P946, DOI 10.1056/NEJM199010043231404; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; Crouse JR, 1998, ATHEROSCLEROSIS, V138, P11, DOI 10.1016/S0021-9150(98)00014-8; Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615; Executive Summary of the Third Report of the National Cholesterol Education Program Expert Panel on Detection, 2001, JAMA-J AM MED ASSOC, V285, P2487; Freeman DJ, 2001, CIRCULATION, V103, P357; Glorioso N, 1999, HYPERTENSION, V34, P1281, DOI 10.1161/01.HYP.34.6.1281; Hansson L, 1992, Blood Press, V1, P113, DOI 10.3109/08037059209077502; KANNEL WB, 1999, HYPERTENSION PHYSIOP, P888; Kotseva K, 2001, EUR HEART J, V22, P554, DOI 10.1053/euhj.2001.2610; Maron DJ, 2000, CIRCULATION, V101, P207, DOI 10.1161/01.CIR.101.2.207; MARTIN MJ, 1986, LANCET, V2, P933; PEDERSEN TR, 1994, LANCET, V344, P1383; Ramsay LE, 1996, LANCET, V348, P387, DOI 10.1016/S0140-6736(96)05516-X; Ramsay LE, 1999, J HUM HYPERTENS, V13, P569, DOI 10.1038/sj.jhh.1000917; Rodgers A, 1998, LANCET, V352, P1801; Rubins HB, 1999, NEW ENGL J MED, V341, P410, DOI 10.1056/NEJM199908053410604; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; Schwartz GG, 2001, JAMA-J AM MED ASSOC, V285, P1711, DOI 10.1001/jama.285.13.1711; Serruys PWJC, 2002, JAMA-J AM MED ASSOC, V287, P3215, DOI 10.1001/jama.287.24.3215; Sever PS, 2001, J HYPERTENS, V19, P1139, DOI 10.1097/00004872-200106000-00020; Shepherd J, 2002, LANCET, V360, P1623, DOI 10.1016/S0140-6736(02)11600-X; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; STAMLER J, 1986, JAMA-J AM MED ASSOC, V256, P2823, DOI 10.1001/jama.256.20.2823; STAMLER R, 1992, CORONARY HEART DIS E; Tonkin A, 1998, NEW ENGL J MED, V339, P1349; WHO Int Soc Hyperten Blood Press Lower, 1998, J HYPERTENS, V16, P127; Wood D, 1998, HEART, V80, pS1; WOOLF N, 1999, LIPOPROTEINS HLTH DI; ANGL SCAND CARD OUTC	33	2704	2922	5	112	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 5	2003	361	9364					1149	1158		10.1016/S0140-6736(03)12948-0	http://dx.doi.org/10.1016/S0140-6736(03)12948-0			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	664ZF	12686036				2022-12-28	WOS:000182094600007
J	Kovacs, MJ; Rodger, M; Anderson, DR; Morrow, B; Kells, G; Kovacs, J; Boyle, E; Wells, PS				Kovacs, MJ; Rodger, M; Anderson, DR; Morrow, B; Kells, G; Kovacs, J; Boyle, E; Wells, PS			Comparison of 10-mg and 5-mg warfarin initiation nomograms together with low-molecular-weight heparin for outpatient treatmeny of acute venous thromboembolism - A randomized, double-blind, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							DEEP-VEIN THROMBOSIS; ORAL ANTICOAGULATION; THERAPY; HOME	Background: The optimal means of achieving therapeutic oral anticoagulation in the outpatient setting has not been determined. Objective: To compare a 10-mg dosing nomogram with a 5-mg nomogram that has been suggested to be sufficient for warfarin initiation. Design: Randomized, controlled clinical trial. Setting: Outpatient venous thromboembolism services of four tertiary care hospitals. Patients: 201 of 210 consecutive patients with objectively confirmed diagnoses of acute venous thromboembolism. Intervention: All patients were treated with subcutaneous low-molecular-weight heparin for a minimum of 5 days until a therapeutic international normalized ratio (INR) was achieved. Patients were randomly assigned to initially receive a 10-mg or 5-mg dose of warfarin. Measurements: The primary end point was time in days to therapeutic INR. Secondary end points were the proportion of patients who had achieved a therapeutic INR by day 5, the total number of INR assessments, the number of INR measurements greater than 5.0, incidence of recurrent venous thromboembolism and major bleeding, and survival. Results: 210 consecutive patients met the inclusion criteria. Of these, 9 were excluded and 201 were randomly assigned to study groups (104 to the 10-mg group and 97 to the 5-mg group). Demographic characteristics of both groups were similar. Patients in the 10-mg group achieved therapeutic INR 1.4 days earlier than patients in the 5-mg group (P < 0.001). Eighty-three percent of patients in the 10-mg group achieved a therapeutic INR by day 5 versus 46% in the 5-mg group (P < 0.001). Fewer INR assessments were performed in the 10-mg group than in the 5-mg group (8.1 vs. 9.1; P = 0.04). There were no significant differences between the two groups in recurrent events, major bleeding, survival, and number of INR measurements greater than 5.0. Conclusion: The 10-mg warfarin initiation nomogram is superior to the 5-mg nomogram because it allows more rapid achievement of a therapeutic INR.	London Hlth Sci Ctr, Dept Hematol, London, ON N6A 4G5, Canada; Ottawa Hlth Res Inst, Ottawa, ON, Canada; Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada	London Health Sciences Centre; University of Ottawa; Ottawa Hospital Research Institute; Queen Elizabeth II Health Sciences Centre	Kovacs, MJ (corresponding author), London Hlth Sci Ctr, Dept Hematol, 800 Commissioners Rd E, London, ON N6A 4G5, Canada.	michael.kovacs@lhsc.on.ca	Boyle, Eleanor/G-4567-2016; Kovacs, Michael/G-3315-2011	Boyle, Eleanor/0000-0002-9012-9128; Rodger, Marc/0000-0001-8166-3487				Crowther MA, 1997, ANN INTERN MED, V127, P333, DOI 10.7326/0003-4819-127-4-199708150-00019; Crowther MA, 1999, ARCH INTERN MED, V159, P46, DOI 10.1001/archinte.159.1.46; Harrison L, 1997, ANN INTERN MED, V126, P133, DOI 10.7326/0003-4819-126-2-199701150-00006; Hirsh J, 2002, BLOOD, V99, P3102, DOI 10.1182/blood.V99.9.3102; Koopman MMW, 1996, NEW ENGL J MED, V334, P682, DOI 10.1056/NEJM199603143341102; Kovacs MJ, 1998, HAEMOSTASIS, V28, P62; Kovacs MJ, 2002, PATHOPHYSIOL HAEMO T, V32, P131, DOI 10.1159/000065215; Levine M, 1996, NEW ENGL J MED, V334, P677, DOI 10.1056/NEJM199603143341101; tenCate JW, 1997, NEW ENGL J MED, V337, P657; WEINMANN EE, 1994, NEW ENGL J MED, V331, P1630, DOI 10.1056/NEJM199412153312407; Wells PS, 1998, ARCH INTERN MED, V158, P1809, DOI 10.1001/archinte.158.16.1809	11	158	161	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 6	2003	138	9					714	719		10.7326/0003-4819-138-9-200305060-00007	http://dx.doi.org/10.7326/0003-4819-138-9-200305060-00007			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	674XA	12729425				2022-12-28	WOS:000182661400003
J	Martin, WA; Camenzind, E; Burkhard, PR				Martin, WA; Camenzind, E; Burkhard, PR			ECG artifact due to deep brain stimulation	LANCET			English	Editorial Material									Univ Hosp Geneva, Div Cardiol, CH-1211 Geneva, Switzerland; Univ Hosp Geneva, Div Neurol, CH-1211 Geneva, Switzerland	University of Geneva; University of Geneva	Martin, WA (corresponding author), Univ Hosp Geneva, Div Cardiol, CH-1211 Geneva, Switzerland.								0	26	27	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 26	2003	361	9367					1431	1431		10.1016/S0140-6736(03)13136-4	http://dx.doi.org/10.1016/S0140-6736(03)13136-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	672HZ	12727397	Bronze			2022-12-28	WOS:000182516300012
J	Rodger, A; Jaffar, S; Paynter, S; Hayward, A; Carless, J; Maguire, H				Rodger, A; Jaffar, S; Paynter, S; Hayward, A; Carless, J; Maguire, H			Delay in the diagnosis of pulmonary tuberculosis, London, 1998-2000: analysis of surveillance data	BRITISH MEDICAL JOURNAL			English	Article									Univ London London Sch Hyg & Trop Med, Infect Dis Epidemiol Unit, London WC1E 7HT, England; Univ London London Sch Hyg & Trop Med, European Ctr Hlth Soc Transit, London WC1E 7HT, England; UCL Royal Free & Univ Coll Med Sch, Ctr Infect Dis Epidemiol, Dept Primary Care & Populat Sci, London NW3 2PF, England; Ctr Communicable Dis Surveillance, London Reg Unit, London W2 3QR, England	University of London; London School of Hygiene & Tropical Medicine; University of London; London School of Hygiene & Tropical Medicine; University of London; University College London; UCL Medical School	Rodger, A (corresponding author), Univ London London Sch Hyg & Trop Med, Infect Dis Epidemiol Unit, Keppel St, London WC1E 7HT, England.	alison.rodger@lshtm.ac.uk	Paynter, Stuart/F-7916-2010; Hayward, Andrew C/C-3268-2013	Hayward, Andrew C/0000-0002-3549-6232; Jaffar, Shabbar/0000-0002-9615-1588				Chin DP, 2000, JAMA-J AM MED ASSOC, V283, P2968, DOI 10.1001/jama.283.22.2968; Rodrigo T, 2001, INT J TUBERC LUNG D, V5, P432; Wares DF, 1999, J PUBLIC HEALTH MED, V21, P355, DOI 10.1093/pubmed/21.3.355; WRIGHT A, 2001, COMMUNICABLE DIS SUR; Zahar JR, 2001, INTENS CARE MED, V27, P513, DOI 10.1007/s001340000849	5	48	50	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 26	2003	326	7395					909	910		10.1136/bmj.326.7395.909	http://dx.doi.org/10.1136/bmj.326.7395.909			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	673WQ	12714470	Green Published, Bronze, Green Accepted			2022-12-28	WOS:000182603600016
J	Siders, CW; Cavalleri, A				Siders, CW; Cavalleri, A			Creating transient crystal structures with light	SCIENCE			English	Editorial Material							X-RAY-DIFFRACTION; FEMTOSECOND RESOLUTION; DYNAMICS; GENERATION; PULSES		Univ Cent Florida, CREOL, Sch Opt, Orlando, FL 32816 USA; Univ Cent Florida, Florida Photon Ctr Excellence, Orlando, FL 32816 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Sci Mat, Berkeley, CA 94720 USA	State University System of Florida; University of Central Florida; State University System of Florida; University of Central Florida; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Siders, CW (corresponding author), Univ Cent Florida, CREOL, Sch Opt, Orlando, FL 32816 USA.		Siders, Craig/AFU-8557-2022					Cavalleri A, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.237401; Collet E, 2003, SCIENCE, V300, P612, DOI 10.1126/science.1082001; DeCamp MF, 2001, NATURE, V413, P825, DOI 10.1038/35101560; DOUGHERTY TP, 1992, SCIENCE, V258, P770, DOI 10.1126/science.258.5083.770; KRAUSE JL, 1993, J CHEM PHYS, V99, P6562, DOI 10.1063/1.465848; Rischel C, 1997, NATURE, V390, P490, DOI 10.1038/37317; Rousse A, 2001, NATURE, V410, P65, DOI 10.1038/35065045; ROUSSE A, 1994, PHYS REV E, V50, P2200, DOI 10.1103/PhysRevE.50.2200; Schoenlein RW, 1996, SCIENCE, V274, P236, DOI 10.1126/science.274.5285.236; Schoenlein RW, 2000, SCIENCE, V287, P2237, DOI 10.1126/science.287.5461.2237; SCHOTTE F, IN PRESS SCIENCE; Service RF, 2002, SCIENCE, V298, P1356, DOI 10.1126/science.298.5597.1356; Siders CW, 1999, SCIENCE, V286, P1340, DOI 10.1126/science.286.5443.1340; Sokolowski-Tinten K, 2003, NATURE, V422, P287, DOI 10.1038/nature01490; Srajer V, 1996, SCIENCE, V274, P1726, DOI 10.1126/science.274.5293.1726	15	10	10	1	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 25	2003	300	5619					591	592		10.1126/science.1084470	http://dx.doi.org/10.1126/science.1084470			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	671FB	12714730				2022-12-28	WOS:000182453700026
J	Bozovic, I; Logvenov, G; Verhoeven, MAJ; Caputo, P; Goldobin, E; Geballe, TH				Bozovic, I; Logvenov, G; Verhoeven, MAJ; Caputo, P; Goldobin, E; Geballe, TH			No mixing of superconductivity and antiferromagnetism in a high-temperature superconductor	NATURE			English	Article							LA2-XSRXCUO4; SEPARATION; TRANSPORT; STATE	There is still no universally accepted theory of high-temperature superconductivity. Most models assume that doping creates 'holes' in the valence band of an insulating, antiferromagnetic 'parent' compound, and that antiferromagnetism and high-temperature superconductivity are intimately related(1-8). If their respective energies are nearly equal, strong antiferromagnetic fluctuations (temporally and spatially restricted antiferromagnetic domains) would be expected in the superconductive phase, and superconducting fluctuations would be expected in the antiferromagnetic phase(7); the two states should 'mix' over an extended length scale(8). Here we report that one-unit-cell-thick antiferromagnetic La2CuO4 barrier layers remain highly insulating and completely block a supercurrent; the characteristic decay length is 1 Angstrom, indicating that the two phases do not mix. We likewise found that isolated one-unit-cell-thick layers of La1.85Sr0.15CuO4 remain superconducting. The latter further implies that, on doping, new electronic states are created near the middle of the bandgap. These two findings are in conflict with most proposed models, with a few notable exceptions that include postulated spin-charge separation(2).	Oxxel GmbH, D-28359 Bremen, Germany; Stanford Univ, Geballe Lab Adv Mat, Stanford, CA 94305 USA; Stanford Univ, Dept Appl Phys, Stanford, CA 94305 USA	Stanford University; Stanford University	Bozovic, I (corresponding author), Oxxel GmbH, Technol Pk Univ, D-28359 Bremen, Germany.	ibozovic@pacbell.net	Goldobin, Edward/A-4302-2010					Alexandrov A.S., 1995, POLARONS BIPOLARONS; Anderson P. W., 1997, THEORY SUPERCONDUCTI; ANDERSON PW, 1988, PHYS REV LETT, V60, P132, DOI 10.1103/PhysRevLett.60.132; Anderson PW, 2000, PHYSICA C, V341, P9, DOI 10.1016/S0921-4534(00)00378-6; ANDO Y, 1995, PHYS REV LETT, V75, P4662, DOI 10.1103/PhysRevLett.75.4662; BOZOVIC I, 1995, J SUPERCOND, V8, P537, DOI 10.1007/BF00727419; Bozovic I, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.107001; Bozovic I, 2001, IEEE T APPL SUPERCON, V11, P2686, DOI 10.1109/77.919617; BOZOVIC I, 1992, J SUPERCOND, V5, P19, DOI 10.1007/BF00617991; Demler E, 1998, PHYS REV LETT, V80, P2917, DOI 10.1103/PhysRevLett.80.2917; Fisher DS, 1995, PHYS REV B, V52, P17112, DOI 10.1103/PhysRevB.52.17112; Golubov AA, 1994, PHYSICA C, V235-40, P3261, DOI 10.1016/0921-4534(94)91157-6; GORKOV LP, 1987, JETP LETT+, V46, P420; KAMPF A, 1990, PHYS REV B, V41, P6399, DOI 10.1103/PhysRevB.41.6399; KIRILLOV D, 1989, J APPL PHYS, V66, P977, DOI 10.1063/1.344451; KIVELSON SA, 1987, PHYS REV B, V35, P8865, DOI 10.1103/PhysRevB.35.8865; THIO T, 1990, PHYS REV B, V42, P10800, DOI 10.1103/PhysRevB.42.10800; UCHIDA S, 1991, PHYS REV B, V43, P7942, DOI 10.1103/PhysRevB.43.7942; VARMA CM, 1990, PHYS REV LETT, V64, P497, DOI 10.1103/PhysRevLett.64.497; WOLF EL, 1989, PRINCIPLES ELECT TUN, P36; ZAANEN J, 1989, PHYS REV B, V40, P7391, DOI 10.1103/PhysRevB.40.7391; Zhang SC, 1997, SCIENCE, V275, P1089, DOI 10.1126/science.275.5303.1089	23	139	143	2	65	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 24	2003	422	6934					873	875		10.1038/nature01544	http://dx.doi.org/10.1038/nature01544			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	670WR	12712200				2022-12-28	WOS:000182432600049
J	Saveliev, A; Everett, C; Sharpe, T; Webster, Z; Festenstein, R				Saveliev, A; Everett, C; Sharpe, T; Webster, Z; Festenstein, R			DNA triplet repeats mediate heterochromatin-protein-1-sensitive variegated gene silencing	NATURE			English	Article							MYOTONIC-DYSTROPHY; TRINUCLEOTIDE REPEAT; TRANSGENIC MICE; HISTONE H3; HETEROCHROMATIN PROTEIN-1; CTG REPEAT; HIGH-LEVEL; LYSINE 9; IN-VIVO; EXPANSION	Gene repression is crucial to the maintenance of differentiated cell types in multicellular organisms, whereas aberrant silencing can lead to disease. The organization of DNA into chromatin and heterochromatin(1) is implicated in gene silencing. In chromatin, DNA wraps around histones, creating nucleosomes. Further condensation of chromatin, associated with large blocks of repetitive DNA sequences, is known as heterochromatin. Position effect variegation (PEV) occurs when a gene is located abnormally close to heterochromatin, silencing the affected gene in a proportion of cells(1). Here we show that the relatively short triplet-repeat expansions found inmyotonic dystrophy and Friedreich's ataxia confer variegation of expression on a linked transgene in mice. Silencing was correlated with a decrease in promoter accessibility and was enhanced by the classical PEV modifier heterochromatin protein 1 ( HP1). Notably, triplet-repeat-associated variegation was not restricted to classical heterochromatic regions but occurred irrespective of chromosomal location. Because the phenomenon described here shares important features with PEV, the mechanisms underlying heterochromatin-mediated silencing might have a role in gene regulation at many sites throughout the mammalian genome and modulate the extent of gene silencing and hence severity in several triplet-repeat diseases.	Univ London Imperial Coll Sci Technol & Med, Sch Med, CSC Gene Control Mechanisms & Dis Grp, Fac Med, London W12 0NN, England; MRC, Ctr Clin Sci, Transgen & Embryon Stem Cell Lab, London W12 0NN, England; Natl Hosp Neurol & Neurosurg, Inst Neurol, Dept Neurogenet, London WC1N 3BG, England	Imperial College London; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust	Festenstein, R (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sch Med, CSC Gene Control Mechanisms & Dis Grp, Fac Med, Hammersmith Campus,Du Cane Rd, London W12 0NN, England.			Saveliev, Alexander/0000-0003-0840-4774				Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; CARANGO P, 1993, GENOMICS, V18, P340, DOI 10.1006/geno.1993.1474; Carter D, 2002, NAT GENET, V32, P623, DOI 10.1038/ng1051; Davis BM, 1997, P NATL ACAD SCI USA, V94, P7388, DOI 10.1073/pnas.94.14.7388; Dillon N, 2002, TRENDS GENET, V18, P252, DOI 10.1016/S0168-9525(02)02648-3; DORER DR, 1994, CELL, V77, P993, DOI 10.1016/0092-8674(94)90439-1; Festenstein R, 1999, NAT GENET, V23, P457, DOI 10.1038/70579; Festenstein R, 1996, SCIENCE, V271, P1123, DOI 10.1126/science.271.5252.1123; Garrick D, 1998, NAT GENET, V18, P56, DOI 10.1038/ng0198-56; GREAVES DR, 1989, CELL, V56, P979, DOI 10.1016/0092-8674(89)90631-4; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; Hwang KK, 2001, P NATL ACAD SCI USA, V98, P11423, DOI 10.1073/pnas.211303598; Kioussis D, 1997, CURR OPIN GENET DEV, V7, P614, DOI 10.1016/S0959-437X(97)80008-1; Klesert TR, 1997, NAT GENET, V16, P402, DOI 10.1038/ng0897-402; Klesert TR, 2000, NAT GENET, V25, P105, DOI 10.1038/75490; KRAHE R, 1995, GENOMICS, V28, P1, DOI 10.1006/geno.1995.1099; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; LAKE RA, 1990, EMBO J, V9, P3129, DOI 10.1002/j.1460-2075.1990.tb07510.x; Litt MD, 2001, SCIENCE, V293, P2453, DOI 10.1126/science.1064413; MAHADEVAN M, 1992, SCIENCE, V255, P1253, DOI 10.1126/science.1546325; Mankodi A, 2000, SCIENCE, V289, P1769, DOI 10.1126/science.289.5485.1769; Milot E, 1996, CELL, V87, P105, DOI 10.1016/S0092-8674(00)81327-6; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Sakamoto N, 2001, J BIOL CHEM, V276, P27171, DOI 10.1074/jbc.M101879200; Sun FL, 2001, MOL CELL BIOL, V21, P2867, DOI 10.1128/MCB.21.8.2867-2879.2001; WANG YH, 1994, SCIENCE, V265, P669, DOI 10.1126/science.8036515; WELLS RD, 1988, FASEB J, V2, P2939, DOI 10.1096/fasebj.2.14.3053307; WIJGERDE M, 1995, NATURE, V377, P209, DOI 10.1038/377209a0	30	200	212	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 24	2003	422	6934					909	913		10.1038/nature01596	http://dx.doi.org/10.1038/nature01596			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	670WR	12712207				2022-12-28	WOS:000182432600059
J	Sunderland, T; Linker, G; Mirza, N; Putnam, KT; Friedman, DL; Kimmel, LH; Bergeson, J; Manetti, GJ; Zimmermann, M; Tang, B; Bartko, JJ; Cohen, RM				Sunderland, T; Linker, G; Mirza, N; Putnam, KT; Friedman, DL; Kimmel, LH; Bergeson, J; Manetti, GJ; Zimmermann, M; Tang, B; Bartko, JJ; Cohen, RM			Decreased beta-amyloid(1-42) and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AMYLOID-BETA-PROTEIN; APOLIPOPROTEIN-E GENOTYPE; CSF-TAU; BIOCHEMICAL MARKER; CLINICAL-DIAGNOSIS; FRONTOTEMPORAL DEMENTIA; INVERSE CORRELATION; PHOSPHORYLATED TAU; LARGE-SCALE; MULTICENTER	Context Alzheimer disease (AD) is characterized by pathological results at autopsy of amyloid plaques and tau-associated neurofibrillary tangles, but the clinical diagnosis of AD is determined on the basis of medical history, cognitive symptoms, and exclusionary criteria. The search for antemortem biomarkers is intense and has focused on cerebrospinal fluid (CSF) beta-amyloid(1-42) and tau proteins. Objectives To compare CSF beta-amyloid and tau levels in a new population of AD patients and controls. To perform a meta-analysis of studies of CSF beta-amyloid and tau levels in AD patients and controls. Design Cross-sectional study of the comparison of baseline CSF beta-amyloid(1-42) and tau levels in AD patients and controls. Meta-analysis involved 17 studies of CSF beta-amyloid and 34 studies of CSF tau. Setting Clinical research unit of the National Institute of Mental Health, Bethesda, Md. Patients The Geriatric Psychiatry Branch evaluated AD patients as inpatients at the National Institutes of Health Clinical Center between May 1985 and January 2001. A total of 203 patients participated in this study (131 with AD and 72 controls). None had other serious illnesses, and 31 of 131 AD cases had AD confirmed at autopsy. Meta-analysis provided an additional 3133 AD patients and 1481 controls. Main Outcome Measures Levels of CSF beta-amyloid(1-42) were measured by a sandwich enzyme-linked immunoabsorbent assay with a polyclonal capture antibody and a monoclonal detection antibody. Levels of CSF tau were measured with a standard commercial immunoassay. Results Levels of CSF beta-amyloid(1-42) were significantly lower in the AD patients vs controls (mean [SD], 183 [121] pg/mL vs 491 [245] pg/mL; P<.001). Levels of CSF tau were significantly higher in AD patients (mean [SD], 587 [365] pg/mL vs 244 [156] pg/mL; P<.001). The cutpoints of 444 pg/mL for CSF beta-amyloid(1-42) and 195 pg/mL for CSF tau gave a sensitivity and specificity of 92% and 89%, respectively, to distinguish AD patients from controls, which is comparable with rates with clinical diagnosis. Meta-analyses of studies comparing CSF beta-amyloid and tau levels in AD participants and controls confirmed an overall difference between levels in these 2 groups. Conclusions Alzheimer disease is associated with a significant decrease in CSF beta-amyloid(1-42) levels along with an increase in CSF tau levels. These findings suggest that the 2 measures are biological markers of AD pathophysiology. While these CSF measures may have a potential clinical utility as biomarkers of disease, the preliminary and retrospective nature of the findings, the absence of assay standardization, and the lack of comparison patient populations must be addressed in future studies testing the usefulness of these CSF measures for predictive, diagnostic, or treatment evaluation purposes.	NIMH, Geriatr Psychiat Branch, Bethesda, MD 20892 USA; Pfizer Inc, Cent Res, Pharmacogenom & Clin Bochem Measurements Div, Groton, CT 06340 USA; Vertex Pharmaceut, Proteom Grp, Cambridge, MA USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); Pfizer; Vertex Pharmaceuticals	Sunderland, T (corresponding author), NIMH, Geriatr Psychiat Branch, 9000 Rockville Pike, Bethesda, MD 20892 USA.	trey@helix.nih.gov			NATIONAL INSTITUTE OF MENTAL HEALTH [Z01MH000339] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Alzheimers Assoc, 1998, NEUROBIOL AGING, V19, P109; Andreasen N, 1998, J NEUROL NEUROSUR PS, V64, P298, DOI 10.1136/jnnp.64.3.298; Andreasen N, 1999, NEUROLOGY, V53, P1488, DOI 10.1212/WNL.53.7.1488; Andreasen N, 1999, ARCH NEUROL-CHICAGO, V56, P673, DOI 10.1001/archneur.56.6.673; Andreasen N, 2001, ARCH NEUROL-CHICAGO, V58, P373, DOI 10.1001/archneur.58.3.373; [Anonymous], 1997, Neurobiol Aging, V18, pS1; Arai H, 1998, NEUROSCI LETT, V256, P174, DOI 10.1016/S0304-3940(98)00781-2; Arai H, 1997, J AM GERIATR SOC, V45, P1228, DOI 10.1111/j.1532-5415.1997.tb03775.x; ARAI H, 1995, ANN NEUROL, V38, P649, DOI 10.1002/ana.410380414; Blennow K, 2001, MOL NEUROBIOL, V24, P87, DOI 10.1385/MN:24:1-3:087; Blennow K, 1995, MOL CHEM NEUROPATHOL, V26, P231, DOI 10.1007/BF02815140; Breiman L., 1984, CLASSIFICATION REGRE; Buch KBN, 1999, NEUROSCI LETT, V277, P21; Cohen J., 2013, STAT POWER ANAL BEHA, DOI DOI 10.4324/9780203771587; Csernansky JG, 2002, ALZ DIS ASSOC DIS, V16, P144, DOI 10.1097/00002093-200207000-00003; Dukoff R, 1997, AM J PSYCHIAT, V154, P1070; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Fukuyama R, 2000, EUR NEUROL, V43, P155, DOI 10.1159/000008156; Galasko D, 1998, ARCH NEUROL-CHICAGO, V55, P937, DOI 10.1001/archneur.55.7.937; Golombowski S, 1997, NEUROSCI LETT, V225, P213, DOI 10.1016/S0304-3940(97)00228-0; Green AJE, 1999, NEUROSCI LETT, V259, P133, DOI 10.1016/S0304-3940(98)00904-5; Hampel H, 1999, BRAIN RES, V823, P104, DOI 10.1016/S0006-8993(99)01146-4; Hampel H, 2001, ANN NEUROL, V49, P545, DOI 10.1002/ana.111; Hedges L.V., 1985, STAT METHODS METAANA, DOI [10.1016/C2009-0-03396-0, DOI 10.1016/C2009-0-03396-0]; HOCK C, 1995, ANN NEUROL, V37, P414, DOI 10.1002/ana.410370325; Hock C, 1998, EUR NEUROL, V39, P111, DOI 10.1159/000007917; HUGHES CP, 1982, BRIT J PSYCHIAT, V140, P566, DOI 10.1192/bjp.140.6.566; Hulstaert F, 1999, NEUROLOGY, V52, P1555, DOI 10.1212/WNL.52.8.1555; Ishiguro K, 1999, NEUROSCI LETT, V270, P91, DOI 10.1016/S0304-3940(99)00476-0; Itoh N, 2001, ANN NEUROL, V50, P150, DOI 10.1002/ana.1054; Jensen M, 1999, ANN NEUROL, V45, P504, DOI 10.1002/1531-8249(199904)45:4<504::AID-ANA12>3.0.CO;2-9; Kahle PJ, 2000, NEUROLOGY, V54, P1498, DOI 10.1212/WNL.54.7.1498; Kanai M, 1998, ANN NEUROL, V44, P17, DOI 10.1002/ana.410440108; Kanemaru K, 2000, NEUROLOGY, V54, P1875, DOI 10.1212/WNL.54.9.1875; Kapaki E, 2003, EUR J NEUROL, V10, P119, DOI 10.1046/j.1468-1331.2003.00562.x; Knopman DS, 2001, NEUROLOGY, V56, P1143, DOI 10.1212/WNL.56.9.1143; Kurz A, 1998, ALZ DIS ASSOC DIS, V12, P372, DOI 10.1097/00002093-199812000-00020; LEWIS RJ, 2002, INTRO CLASSIFICATION; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Mecocci P, 1998, ALZ DIS ASSOC DIS, V12, P211, DOI 10.1097/00002093-199809000-00015; Mehta PD, 2000, ARCH NEUROL-CHICAGO, V57, P100, DOI 10.1001/archneur.57.1.100; MENDEZ MF, 1992, ALZ DIS ASSOC DIS, V6, P35, DOI 10.1097/00002093-199205000-00004; MIRRA SS, 1991, NEUROLOGY, V41, P479, DOI 10.1212/WNL.41.4.479; Mittal VA, 2011, PSYCHIAT RES, V189, P158, DOI 10.1016/j.psychres.2011.06.006; Molina L, 1999, NEUROREPORT, V10, P3491, DOI 10.1097/00001756-199911260-00005; MORI H, 1995, NEUROSCI LETT, V186, P181, DOI 10.1016/0304-3940(95)11291-4; MOTTER R, 1995, ANN NEUROL, V38, P643, DOI 10.1002/ana.410380413; MUNROE WA, 1995, ANN CLIN LAB SCI, V25, P207; NAKAMURA T, 1994, ANN NEUROL, V36, P903, DOI 10.1002/ana.410360616; Nishimura T, 1998, METHOD FIND EXP CLIN, V20, P227; NITSCH RM, 1995, ANN NEUROL, V37, P512, DOI 10.1002/ana.410370414; Otto M, 2000, NEUROLOGY, V54, P1099, DOI 10.1212/WNL.54.5.1099; Pirttila T, 1996, ARCH NEUROL-CHICAGO, V53, P189, DOI 10.1001/archneur.1996.00550020105022; REISBERG B, 1982, AM J PSYCHIAT, V139, P1136; Riemenschneider M, 2000, NEUROSCI LETT, V284, P85, DOI 10.1016/S0304-3940(00)00976-9; ROSENTHAL R, 1978, JUDGMENT STUDIES DES, P179; Rosler N, 2001, J NEURAL TRANSM, V108, P231, DOI 10.1007/s007020170091; Sackett DL, 2002, BRIT MED J, V324, P539, DOI 10.1136/bmj.324.7336.539; Selkoe DJ, 2000, JAMA-J AM MED ASSOC, V283, P1615, DOI 10.1001/jama.283.12.1615; Shoji M, 2002, NEUROBIOL AGING, V23, P363, DOI 10.1016/S0197-4580(01)00309-8; Shoji M, 1998, J NEUROL SCI, V158, P134, DOI 10.1016/S0022-510X(98)00122-1; Sjogren M, 2000, J NEURAL TRANSM, V107, P563, DOI 10.1007/s007020070079; Sjogren M, 2002, DEMENT GERIATR COGN, V13, P112, DOI 10.1159/000048642; Sjogren M, 2001, CLIN CHEM, V47, P1776; Skoog I, 1995, NEURODEGENERATION, V4, P433, DOI 10.1006/neur.1995.0052; Skoog I, 2003, DEMENT GERIATR COGN, V15, P169, DOI 10.1159/000068478; SKOOG I, 1996, NEUROSCI LETT, V214, P163; Sunderland T, 1999, BIOL PSYCHIAT, V46, P750, DOI 10.1016/S0006-3223(99)00143-2; SUNDERLAND T, 1999, INFORMED CONSENT RES; Tamaoka A, 1997, J NEUROL SCI, V148, P41, DOI 10.1016/S0022-510X(96)00314-0; Tapiola T, 2000, NEUROBIOL AGING, V21, P735, DOI 10.1016/S0197-4580(00)00164-0; TATO RE, 1995, J NEUROL NEUROSUR PS, V59, P280, DOI 10.1136/jnnp.59.3.280; VANDERMEEREN M, 1993, J NEUROCHEM, V61, P1828, DOI 10.1111/j.1471-4159.1993.tb09823.x; Vanderstichele H, 2000, AMYLOID, V7, P245, DOI 10.3109/13506120009146438; VANGOOL WA, 1995, ANN NEUROL, V37, P277, DOI 10.1002/ana.410370221; VICTOROFF J, 1995, AM J PSYCHIAT, V152, P1476; VIGOPELFREY C, 1995, NEUROLOGY, V45, P788, DOI 10.1212/WNL.45.4.788; Winer B.J., 1991, STAT PRINCIPLES EXPT	78	492	516	3	40	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 23	2003	289	16					2094	2103		10.1001/jama.289.16.2094	http://dx.doi.org/10.1001/jama.289.16.2094			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	669WW	12709467				2022-12-28	WOS:000182374300025
J	Chaudhuri, J; Tian, M; Khuong, C; Chua, K; Pinaud, E; Alt, FW				Chaudhuri, J; Tian, M; Khuong, C; Chua, K; Pinaud, E; Alt, FW			Transcription-targeted DNA deamination by the AID antibody diversification enzyme	NATURE			English	Article							IMMUNOGLOBULIN SWITCH REGIONS; SOMATIC HYPERMUTATION; MECHANISM; RECOMBINATION; SEQUENCES; COMPLEX; REPAIR	Activation-induced cytidine deaminase (AID), which is specific to B lymphocytes, is required for class switch recombination (CSR)-a process mediating isotype switching of immunoglobulin-and somatic hypermutation-the introduction of many point mutations into the immunoglobulin variable region genes(1,2). It has been suggested that AID may function as an RNA-editing enzyme(3) or as a cytidine deaminase on DNA(4),(5). However, the precise enzymatic activity of AID has not been assessed in previous studies. Similarly, although transcription of the target immunoglobulin locus sequences is required for both CSR and somatic hypermutation, the precise role of transcription has remained speculative(6-9). Here we use two different assays to demonstrate that AID can deaminate specifically cytidines on single-stranded (ss) DNA but not double-stranded (ds) DNA substrates in vitro. However, dsDNA can be deaminated by AID in vitro when the reaction is coupled to transcription. Moreover, a synthetic dsDNA sequence, which targets CSR in vivo in a manner dependent on transcriptional orientation(10), was deaminated by AID in vitro with the same transcriptional-orientation-dependence as observed for endogenous CSR. We conclude that transcription targets the DNA deamination activity of AID to dsDNA by generating secondary structures that provide ssDNA substrates.	Childrens Hosp, Howard Hughes Med Inst, Ctr Blood Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Howard Hughes Medical Institute; Harvard University; Harvard Medical School	Alt, FW (corresponding author), Childrens Hosp, Howard Hughes Med Inst, Ctr Blood Res, Boston, MA 02115 USA.	alt@enders.tch.harvard.edu	PINAUD, Eric/O-8443-2016	PINAUD, Eric/0000-0001-7405-9273				Artsimovitch I, 2002, CELL, V109, P193, DOI 10.1016/S0092-8674(02)00724-9; Bassing CH, 2002, CELL, V109, pS45, DOI 10.1016/S0092-8674(02)00675-X; Daniels GA, 1995, NUCLEIC ACIDS RES, V23, P5006, DOI 10.1093/nar/23.24.5006; Di Noia J, 2002, NATURE, V419, P43, DOI 10.1038/nature00981; Doi T, 2003, P NATL ACAD SCI USA, V100, P2634, DOI 10.1073/pnas.0437710100; DUNNICK W, 1993, NUCLEIC ACIDS RES, V21, P365, DOI 10.1093/nar/21.3.365; Faili A, 2002, NAT IMMUNOL, V3, P815, DOI 10.1038/ni826; Honjo T, 2002, ANNU REV IMMUNOL, V20, P165, DOI 10.1146/annurev.immunol.20.090501.112049; Luby TM, 2001, J EXP MED, V193, P159, DOI 10.1084/jem.193.2.159; Manis JP, 2002, TRENDS IMMUNOL, V23, P31, DOI 10.1016/S1471-4906(01)02111-1; Martin A, 2002, NAT REV IMMUNOL, V2, P605, DOI 10.1038/nri858; Martin A, 2002, NATURE, V415, P802, DOI 10.1038/nature714; Mizuta R, 2003, J BIOL CHEM, V278, P4431, DOI 10.1074/jbc.M209262200; Muramatsu M, 1999, J BIOL CHEM, V274, P18470, DOI 10.1074/jbc.274.26.18470; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Papavasiliou FN, 2002, J EXP MED, V195, P1193, DOI 10.1084/jem.20011858; PAPAVASILIOU FN, 2002, CELL S1, V109, P35; Petersen-Mahrt SK, 2002, NATURE, V418, P99, DOI 10.1038/nature00862; Rada C, 2002, CURR BIOL, V12, P1748, DOI 10.1016/S0960-9822(02)01215-0; RAMIRO AR, IN PRESS NATURE IMMU; REABAN ME, 1990, NATURE, V348, P342, DOI 10.1038/348342a0; Revy P, 2000, CELL, V102, P565, DOI 10.1016/S0092-8674(00)00079-9; Sartori AA, 2001, J BIOL CHEM, V276, P29979, DOI 10.1074/jbc.M102985200; Shanmugam A, 2000, J EXP MED, V191, P1365, DOI 10.1084/jem.191.8.1365; SHINKUTA R, IN PRESS NATURE IMMU; Stavnezer J, 2000, CURR TOP MICROBIOL, V245, P127; Storb U, 1998, IMMUNOL REV, V162, P153; Tashiro J, 2001, INT IMMUNOL, V13, P495, DOI 10.1093/intimm/13.4.495; Tian M, 2000, J BIOL CHEM, V275, P24163, DOI 10.1074/jbc.M003343200; Yoshikawa K, 2002, SCIENCE, V296, P2033, DOI 10.1126/science.1071556; YU K, IN PRESS NATURE IMMU	31	576	586	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 17	2003	422	6933					726	730		10.1038/nature01574	http://dx.doi.org/10.1038/nature01574			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	668CG	12692563				2022-12-28	WOS:000182272300043
J	Clarke, T				Clarke, T			Infection risk puts the brakes on Canada's biomedical research	NATURE			English	News Item																			0	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 17	2003	422	6933					652	652		10.1038/422652b	http://dx.doi.org/10.1038/422652b			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	668CG	12700726	Bronze			2022-12-28	WOS:000182272300009
J	Malhotra, A; Muse, VV; Mark, EJ; Brown, R; Hales, CA; Bhan, I				Malhotra, A; Muse, VV; Mark, EJ; Brown, R; Hales, CA; Bhan, I			Case 12-2003: An 82-year-old man with dyspnea and pulmonary abnormalities - Amiodarone-induced lung disease with bronchiolitis obliterans organizing pneumonia and interstitial pneumonitis	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							POSITIVE AIRWAY PRESSURE; ERYTHROCYTE SEDIMENTATION-RATE; HEART-FAILURE; SLEEP-APNEA; TOXICITY; CLASSIFICATION; PATHOGENESIS; FIBROSIS; SURVIVAL; THERAPY		Brigham & Womens Hosp, Pulm & Crit Care Unit, Boston, MA 02115 USA; Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital	Malhotra, A (corresponding author), Brigham & Womens Hosp, Pulm & Crit Care Unit, 75 Francis St, Boston, MA 02115 USA.							ARNON R, 1988, CHEST, V93, P425, DOI 10.1378/chest.93.2.425; CAMUS P, 1989, THORAX, V44, P711, DOI 10.1136/thx.44.9.711; Carmichael LC, 1996, BRIT J CLIN PRACT, V50, P228; Collard HR, 2003, ARCH INTERN MED, V163, P17, DOI 10.1001/archinte.163.1.17; DARMANATA JI, 1984, THORAX, V39, P57, DOI 10.1136/thx.39.1.57; DEAN PJ, 1987, AM J CLIN PATHOL, V87, P7, DOI 10.1093/ajcp/87.1.7; Faling LJ, 1997, NEW ENGL J MED, V337, P1449, DOI 10.1056/NEJM199711133372008; FESSLER HE, 1988, J APPL PHYSIOL, V65, P1244, DOI 10.1152/jappl.1988.65.3.1244; FUCHS RM, 1982, AM J CARDIOL, V49, P849, DOI 10.1016/0002-9149(82)91968-3; GLEADHILL IC, 1989, AM J MED, V86, P4, DOI 10.1016/0002-9343(89)90221-0; HABER HL, 1991, NEW ENGL J MED, V324, P353, DOI 10.1056/NEJM199102073240601; Hirata Y, 2001, CARDIOVASC RES, V51, P585, DOI 10.1016/S0008-6363(01)00320-0; Imamura H, 2001, PACE, V24, P1563, DOI 10.1046/j.1460-9592.2001.01563.x; Iskander S, 1999, CATHETER CARDIO INTE, V47, P61, DOI 10.1002/(SICI)1522-726X(199905)47:1<61::AID-CCD14>3.0.CO;2-C; Jacobson W, 1997, ARCH PATHOL LAB MED, V121, P1269; Javaheri S, 2000, CIRCULATION, V101, P392, DOI 10.1161/01.CIR.101.4.392; Jellinek H, 2000, J APPL PHYSIOL, V88, P926, DOI 10.1152/jappl.2000.88.3.926; KATZENSTEIN ALA, 1994, AM J SURG PATHOL, V18, P136, DOI 10.1097/00000478-199402000-00003; Katzenstein ALA, 1998, AM J RESP CRIT CARE, V157, P1301, DOI 10.1164/ajrccm.157.4.9707039; Katzenstein ALA, 2000, AM J SURG PATHOL, V24, P1, DOI 10.1097/00000478-200001000-00001; Kaya GC, 2001, EUR J NUCL MED, V28, P346, DOI 10.1007/s002590000446; LIU FLW, 1986, THORAX, V41, P100, DOI 10.1136/thx.41.2.100; Maisel Alan, 2001, Cardiology Clinics, V19, P557, DOI 10.1016/S0733-8651(05)70243-5; MARTIN WJ, 1988, CHEST, V93, P1242, DOI 10.1378/chest.93.6.1242; MARTIN WJ, 1990, CLIN CHEST MED, V11, P131; McDonagh TA, 1998, LANCET, V351, P9, DOI 10.1016/S0140-6736(97)03034-1; MCGOVERN B, 1983, BRIT MED J, V287, P175, DOI 10.1136/bmj.287.6386.175; Moss AJ, 1996, NEW ENGL J MED, V335, P1933, DOI 10.1056/NEJM199612263352601; MYERS JL, 1987, HUM PATHOL, V18, P349, DOI 10.1016/S0046-8177(87)80164-8; Naccarelli GV, 2000, CLIN CARDIOL, V23, P73, DOI 10.1002/clc.4960230203; Nakajima M, 2000, INTERNAL MED, V39, P1097, DOI 10.2169/internalmedicine.39.1097; NAUGHTON MT, 1995, AM J RESP CRIT CARE, V152, P473, DOI 10.1164/ajrccm.152.2.7633695; Nul DR, 1997, J AM COLL CARDIOL, V29, P1199, DOI 10.1016/S0735-1097(97)00066-1; OHAR JA, 1992, CHEST, V102, P999, DOI 10.1378/chest.102.4.999; Ott MC, 2003, CHEST, V123, P646, DOI 10.1378/chest.123.2.646; PATEL SR, 2001, AM J RESP CRIT CARE, V163, pA448; ROTMENSCH HH, 1980, AM HEART J, V100, P412, DOI 10.1016/0002-8703(80)90165-9; Roy D, 2000, NEW ENGL J MED, V342, P913, DOI 10.1056/NEJM200003303421302; Selman M, 2001, ANN INTERN MED, V134, P136, DOI 10.7326/0003-4819-134-2-200101160-00015; SHARKEY SW, 1987, AM J MED, V83, P111, DOI 10.1016/0002-9343(87)90504-3; Sharma R, 2000, J AM COLL CARDIOL, V36, P523, DOI 10.1016/S0735-1097(00)00745-2; Sin DD, 2000, CIRCULATION, V102, P61, DOI 10.1161/01.CIR.102.1.61; Siniakowicz RM, 2001, J CARDIOVASC ELECTR, V12, P431, DOI 10.1046/j.1540-8167.2001.00431.x; Teboul JL, 2000, CRIT CARE MED, V28, P3631, DOI 10.1097/00003246-200011000-00014; WILSON BD, 1990, AM REV RESPIR DIS, V141, P1553, DOI 10.1164/ajrccm/141.6.1553	45	31	32	0	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 17	2003	348	16					1574	1585		10.1056/NEJMcpc030005	http://dx.doi.org/10.1056/NEJMcpc030005			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	667TT	12700378				2022-12-28	WOS:000182248900009
J	Minto, CL; Liao, LM; Woodhouse, CRJ; Ransley, PG; Creighton, SM				Minto, CL; Liao, LM; Woodhouse, CRJ; Ransley, PG; Creighton, SM			The effect of clitoral surgery on sexual outcome in individuals who have intersex conditions with ambiguous genitalia: a cross-sectional study	LANCET			English	Article							FEMINIZING GENITOPLASTY; GENDER ASSIGNMENT; HERMAPHRODITISM; RECONSTRUCTION; MANAGEMENT	Background The effects on sexual function of surgical removal of parts of the clitoris are unknown. For infants with intersex conditions and ambiguous genitalia being raised female, this surgery is often undertaken in early childhood. Our aim was to assess the effects of surgery on sexual outcome in this population. Method We did a cross-sectional study to which we recruited 39 adults who had intersex conditions with ambiguous genitalia who were living as female from clinical (n=15) and peer-support (n=24) settings. We obtained data by use of a postal questionnaire, incorporating a validated sexual function assessment inventory. We also obtained hospital notes of 36 respondents who did not want to remain anonymous, and did genital examinations of 19 women. We assessed sexual problems in relation to surgical history and compared the results for our population to those of a healthy control group. Findings Of the 39 individuals enrolled, 28 had been sexually active and all had sexual difficulties. The 18 women who had undergone clitoral surgery had higher rates of non-sensuality (78%) and of inability to achieve orgasm (39%) than did the ten who had not had surgery (20% [p=0.002] and 0% [p=0.03], respectively). Interpretation Sexual function could be compromised by clitoral surgery. Debate on the ethics of the use of this surgery in children should be promoted and further multicentre research is needed to ensure representative samples and comprehensive outcome assessment. Meanwhile, parents and patients who consent to clitoral surgery should be fully informed of the potential risks to sexual function.	UCL Hosp NHS Trust, Elizabeth Garrett Anderson Hosp, Dept Obstet & Gynaecol, London WC1E 6DH, England; UCL Hosp NHS Trust, Middlesex Hosp, Inst Urol, London, England; Great Ormond St Hosp Sick Children, London WC1N 3JH, England	University College London Hospitals NHS Foundation Trust; University of London; University College London; University College London Hospitals NHS Foundation Trust; University of London; University College London; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust	Creighton, SM (corresponding author), UCL Hosp NHS Trust, Elizabeth Garrett Anderson Hosp, Dept Obstet & Gynaecol, Huntley St, London WC1E 6DH, England.	sarah.creighton@uclh.org						Baskin LS, 1999, J UROLOGY, V162, P1015, DOI 10.1016/S0022-5347(01)68052-2; Blackless M, 2000, AM J HUM BIOL, V12, P151, DOI 10.1002/(SICI)1520-6300(200003/04)12:2<151::AID-AJHB1>3.0.CO;2-F; Costa EMF, 1997, FERTIL STERIL, V67, P229; Creighton S, 2001, BMJ-BRIT MED J, V323, P1264, DOI 10.1136/bmj.323.7324.1264; DITTMANN RW, 1992, PSYCHONEUROENDOCRINO, V17, P153, DOI 10.1016/0306-4530(92)90054-B; Glassberg KI, 1999, J UROLOGY, V161, P1308, DOI 10.1016/S0022-5347(01)61676-8; GOLOMBOK S, 1984, BR J SEX MED, V11, P171; Golombok S., 1994, GENDER DEV; GONZALEZ R, 1990, J UROLOGY, V143, P776, DOI 10.1016/S0022-5347(17)40091-7; HAMPSON JL, 1961, SEX INTERNAL SECRETI, P1401; HINDERER UT, 1989, PLAST RECONSTR SURG, V84, P325, DOI 10.1097/00006534-198908000-00022; Jones Howard Wilbur, 1958, HERMAPHRODITISM GENI; May B, 1996, J Health Psychol, V1, P479, DOI 10.1177/135910539600100406; Meyer-Bahlburg HFL, 1999, J CLIN ENDOCR METAB, V84, P3455, DOI 10.1210/jc.84.10.3455; MINTO CL, IN PRESS FERTIL STER; MONEY J, 1955, B JOHNS HOPKINS HOSP, V97, P301; MONEY J, 1955, B JOHNS HOPKINS HOSP, V97, P284; NEWMAN K, 1992, J PEDIATR SURG, V27, P180, DOI 10.1016/0022-3468(92)90308-T; O'Connell HE, 1998, J UROLOGY, V159, P1892, DOI 10.1016/S0022-5347(01)63188-4; Passerini-Glazel G, 1999, J UROLOGY, V161, P1592, DOI 10.1016/S0022-5347(05)68987-2; RAJFER J, 1982, J UROLOGY, V128, P341, DOI 10.1016/S0022-5347(17)52916-X; Rink RC, 1998, WORLD J UROL, V16, P212, DOI 10.1007/s003450050055; RUST J, 1985, BRIT J CLIN PSYCHOL, V24, P63, DOI 10.1111/j.2044-8260.1985.tb01314.x; RUST J, 1986, INTERPERSONAL DIFFIC, P51; Slijper FME, 1998, ARCH SEX BEHAV, V27, P125, DOI 10.1023/A:1018670129611; Von Prader A, 1954, HELV PEDIAT ACTA, V9, P231; Young Hugh, 1937, GENITAL ABNORMALITIE; Zucker Kenneth J, 2002, J Pediatr Adolesc Gynecol, V15, P3, DOI 10.1016/S1083-3188(01)00133-4	28	187	200	0	16	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 12	2003	361	9365					1252	1257		10.1016/S0140-6736(03)12980-7	http://dx.doi.org/10.1016/S0140-6736(03)12980-7			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	666DM	12699952				2022-12-28	WOS:000182161600009
J	Kominis, IK; Kornack, TW; Allred, JC; Romalis, MV				Kominis, IK; Kornack, TW; Allred, JC; Romalis, MV			A subfemtotesla multichannel atomic magnetometer	NATURE			English	Article							READ-OUT ELECTRONICS; BIOMAGNETIC MEASUREMENTS; HUMAN BRAIN; MAGNETOENCEPHALOGRAPHY; RESOLUTION; RESONANCE; DEVICES; NOISE	The magnetic field is one of the most fundamental and ubiquitous physical observables, carrying information about all electromagnetic phenomena. For the past 30 years, superconducting quantum interference devices (SQUIDs) operating at 4 K have been unchallenged as ultrahigh-sensitivity magnetic field detectors(1), with a sensitivity reaching down to 1 fT Hz(-1/2) (1 fT = 10(-15) T). They have enabled, for example, mapping of the magnetic fields produced by the brain, and localization of the underlying electrical activity (magnetoencephalography). Atomic magnetometers, based on detection of Larmor spin precession of optically pumped atoms, have approached similar levels of sensitivity using large measurement volumes(2,3), but have much lower sensitivity in the more compact designs required for magnetic imaging applications(4). Higher sensitivity and spatial resolution combined with non-cryogenic operation of atomic magnetometers would enable new applications, including the possibility of mapping non-invasively the cortical modules in the brain. Here we describe a new spin-exchange relaxation-free ( SERF) atomic magnetometer, and demonstrate magnetic field sensitivity of 0.54 fT Hz(-1/2) with a measurement volume of only 0.3 cm(3). Theoretical analysis shows that fundamental sensitivity limits of this device are below 0.01 fT Hz(-1/2). We also demonstrate simple multichannel operation of the magnetometer, and localization of magnetic field sources with a resolution of 2 mm.	Princeton Univ, Dept Phys, Princeton, NJ 08544 USA; Univ Washington, Dept Phys, Seattle, WA 98195 USA	Princeton University; University of Washington; University of Washington Seattle	Romalis, MV (corresponding author), Princeton Univ, Dept Phys, Princeton, NJ 08544 USA.		Kominis, Iannis/C-5515-2011; Allred, Joel/C-9550-2012	Kominis, Iannis/0000-0003-3307-2695; 				Affolderbach C, 2002, APPL PHYS B-LASERS O, V75, P605, DOI 10.1007/s00340-002-0959-8; Aleksandrov E. B., 1995, Optics and Spectroscopy, V78, P292; Alexandrov EB, 1996, LASER PHYS, V6, P244; Allred JC, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.130801; Budker D, 2002, REV MOD PHYS, V74, P1153, DOI 10.1103/RevModPhys.74.1153; Budker D, 2000, PHYS REV A, V62, DOI 10.1103/PhysRevA.62.043403; Budker D, 1998, PHYS REV LETT, V81, P5788, DOI 10.1103/PhysRevLett.81.5788; Clem TR, 1998, NAV ENG J, V110, P139, DOI 10.1111/j.1559-3584.1998.tb02393.x; Del Gratta C, 2001, REP PROG PHYS, V64, P1759, DOI 10.1088/0034-4885/64/12/204; Drung D, 2001, IEEE T APPL SUPERCON, V11, P880, DOI 10.1109/77.919485; DUPONTRO.J, 1969, PHYS LETT A, VA 28, P638, DOI 10.1016/0375-9601(69)90480-0; Greenberg YS, 1998, REV MOD PHYS, V70, P175, DOI 10.1103/RevModPhys.70.175; HAMALAINEN M, 1993, REV MOD PHYS, V65, P413, DOI 10.1103/RevModPhys.65.413; HAPPER W, 1977, PHYS REV A, V16, P1877, DOI 10.1103/PhysRevA.16.1877; Harry GM, 2000, APPL PHYS LETT, V76, P1446, DOI 10.1063/1.126059; Kandori A, 2000, REV SCI INSTRUM, V71, P2184, DOI 10.1063/1.1150603; Kirschvink JL, 1997, SCIENCE, V275, P1629, DOI 10.1126/science.275.5306.1629; McDermott R, 2002, SCIENCE, V295, P2247, DOI 10.1126/science.1069280; Nenonen J, 1996, REV SCI INSTRUM, V67, P2397, DOI 10.1063/1.1147514; Oukhanski N, 2002, PHYSICA C, V368, P166, DOI 10.1016/S0921-4534(01)01160-1; Rodriguez E, 1999, NATURE, V397, P430, DOI 10.1038/17120; Tralshawala N, 1997, APPL PHYS LETT, V71, P1573, DOI 10.1063/1.119974; TSO DY, 1990, SCIENCE, V249, P417, DOI 10.1126/science.2165630; Tsuei CC, 2000, PHYS REV LETT, V85, P182, DOI 10.1103/PhysRevLett.85.182; Weinstock H., 2012, SQUID SENSORS FUNDAM, V329; ZIMMERMAN JE, 1970, J APPL PHYS, V41, P1572, DOI 10.1063/1.1659074	27	885	949	35	283	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 10	2003	422	6932					596	599		10.1038/nature01484	http://dx.doi.org/10.1038/nature01484			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	665GN	12686995				2022-12-28	WOS:000182111400036
J	Gadde, KM; Franciscy, DM; Wagner, HR; Krishnan, KRR				Gadde, KM; Franciscy, DM; Wagner, HR; Krishnan, KRR			Zonisamide for weight loss in obese adults - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							US ADULTS; IN-VIVO; DOPAMINE; SYSTEM; ACETAZOLAMIDE; SPREAD	Context Zonisamide is a marketed antiepileptic drug that has serotonergic and dopaminergic activity in addition to blockade of sodium and calcium channels. Weight loss was an adverse effect associated with zonisamide treatment in epilepsy clinical trials. Objective To evaluate the efficacy of zonisamide for weight loss in obese adults. Design and Setting Sixteen-week randomized, double-blind, placebo-controlled trial with an optional single-blind extension of the same treatment for another 16 weeks, conducted at Duke University Medical Center from March 2001 to March 2002. Participants Fifty-five (92%) women and 5 (8%) men (mean [SE] body mass index, 36.3 [0.5]; mean age, 37.0 (1.0) years). Interventions Patients were randomly assigned to receive zonisamide (n=30) or placebo (n=30). All participants were prescribed a balanced hypocaloric diet (500 kcal/d deficit) and compliance was monitored with self-rated food diaries. Zonisamide therapy was started at 100 mg/d orally, with gradual increase to 400 mg/d and further increase to 600 mg/d for patients losing less than 5% of body weight at the end of 12 weeks. Placebo dosing was identical. Main Outcome Measure Change in body weight. Results Of the 60 randomized patients, 51 completed the 16-week acute phase. In an intent-to-treat analysis using the available data for all randomized participants with the last observation carried forward, the zonisamide group lost more body weight than the placebo group (mean [SE], 5.9 [0.8] kg [6.0% loss] vs 0.9 [0.4] kg [1.0% loss]; t=5.5; P<.001) during the 16-week period. A longitudinal mixed-model regression for weight change controlling for age, race, sex, body mass index, and percent body fat estimated that zonisamide treatment over the 16-week study duration was associated with significantly greater weight loss than was placebo (t=6.4; P<.001). Seventeen (57%) of 30 in the zonisamide group and 3 (10%) of 30 in the placebo group lost at least 5% of body weight (P<.001) by week 16. Of the 37 participants who entered the extension phase, 36 completed week 32. The zonisamide group (n=19) had a mean weight loss of 9.2 kg (1.7 kg) (9.4% loss) at week 32 compared with 1.5 kg (0.7 kg) (1.8% loss) for the placebo group (n=17) (t=4.0; P<.001). Zonisamide was tolerated well, with few adverse effects. Conclusion In this short-term, preliminary trial, zonisamide and hypocaloric diet resulted in more weight loss than placebo and hypocaloric diet in the treatment of obesity.	Duke Univ, Med Ctr, Obes Clin Trials Program, Dept Psychiat, Durham, NC 27710 USA	Duke University	Gadde, KM (corresponding author), Duke Univ, Med Ctr, Obes Clin Trials Program, Dept Psychiat, Box 3812, Durham, NC 27710 USA.		Gadde, Kishore/N-1963-2017	Gadde, Kishore/0000-0002-1856-5574; Wagner, Ryan/0000-0003-3954-6556				Blackburn GL, 1999, AM J CLIN NUTR, V69, P347; Calle EE, 1999, NEW ENGL J MED, V341, P1097, DOI 10.1056/NEJM199910073411501; DAHL H, 1984, ACTA OPHTHALMOL, V62, P739; DRAGO J, 1994, P NATL ACAD SCI USA, V91, P12564, DOI 10.1073/pnas.91.26.12564; Flegal KM, 2002, JAMA-J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723; Galuska DA, 1999, JAMA-J AM MED ASSOC, V282, P1576, DOI 10.1001/jama.282.16.1576; HASHIGUTI H, 1993, J NEURAL TRANSM-GEN, V93, P213, DOI 10.1007/BF01244998; JENSEN LB, 1994, J BONE MINER RES, V9, P459; KANEKO S, 1993, JPN J PSYCHIAT NEUR, V47, P371; KOLOTKIN RL, 1995, OBES RES, V3, P49, DOI 10.1002/j.1550-8528.1995.tb00120.x; Leppik IE, 1999, EPILEPSIA, V40, pS23, DOI 10.1111/j.1528-1157.1999.tb00916.x; MCMURDO MET, 1990, LANCET, V336, P1190, DOI 10.1016/0140-6736(90)92803-P; McNeely W, 1998, DRUGS, V56, P1093, DOI 10.2165/00003495-199856060-00019; MILLER LG, 1990, J FAM PRACTICE, V31, P199; Mokdad AH, 1999, JAMA-J AM MED ASSOC, V282, P1519, DOI 10.1001/jama.282.16.1519; Must A, 1999, JAMA-J AM MED ASSOC, V282, P1523, DOI 10.1001/jama.282.16.1523; National Heart Lung and Blood Institute, 1998, NIH PUBL, V98-4083; OKADA M, 1992, EPILEPSY RES, V13, P113, DOI 10.1016/0920-1211(92)90066-3; Okada M, 1999, EPILEPSY RES, V34, P187, DOI 10.1016/S0920-1211(98)00109-0; Okada M, 1995, EPILEPSY RES, V22, P193, DOI 10.1016/0920-1211(95)00078-X; Oommen KJ, 1999, CLIN NEUROPHARMACOL, V22, P192; Schwartz MW, 1999, AM J CLIN NUTR, V69, P584; Terry P, 1995, OBES RES, V3, pS515, DOI 10.1002/j.1550-8528.1995.tb00221.x; Wang GJ, 2001, LANCET, V357, P354, DOI 10.1016/S0140-6736(00)03643-6	24	185	204	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 9	2003	289	14					1820	1825		10.1001/jama.289.14.1820	http://dx.doi.org/10.1001/jama.289.14.1820			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	664ZJ	12684361	Bronze			2022-12-28	WOS:000182094900028
J	Shulman, KI; Rochon, P; Sykora, K; Anderson, G; Mamdani, M; Bronskill, S; Tran, CTT				Shulman, KI; Rochon, P; Sykora, K; Anderson, G; Mamdani, M; Bronskill, S; Tran, CTT			Changing prescription patterns for lithium and valproic acid in old age: shifting practice without evidence	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Univ Toronto, Fac Med, Sunnybrook & Womens Coll Hlth Sci Ctr, Dept Psychiat, Toronto, ON M4N 3M5, Canada; Sunnybrook & Womens Coll Hlth Sci Ctr, ICES, Toronto, ON, Canada; Baycrest Ctr Geriatr Care, Kunin Lunenfeld Appl Res Unit, Toronto, ON M6S 2E1, Canada	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University Toronto Affiliates; Baycrest	Shulman, KI (corresponding author), Univ Toronto, Fac Med, Sunnybrook & Womens Coll Hlth Sci Ctr, Dept Psychiat, Toronto, ON M4N 3M5, Canada.	ken.shulman@sw.ca	Rochon, Paula A/J-2918-2016	Rochon, Paula A/0000-0002-5973-4151				Baldessarini R J, 1999, Bipolar Disord, V1, P17, DOI 10.1034/j.1399-5618.1999.10106.x; Dinan TG, 2002, BRIT MED J, V324, P989, DOI 10.1136/bmj.324.7344.989; Johnson G, 1998, NEUROPSYCHOPHARMACOL, V19, P200, DOI 10.1016/S0893-133X(98)00019-0; MACRITCHIE KA, 2001, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003196; Sival RC, 2002, INT J GERIATR PSYCH, V17, P579, DOI 10.1002/gps.653	5	67	69	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 3	2003	326	7396					960	961		10.1136/bmj.326.7396.960	http://dx.doi.org/10.1136/bmj.326.7396.960			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	676JC	12727769	Green Published, Bronze			2022-12-28	WOS:000182746700017
J	Abbott, A				Abbott, A			Human fatality adds fresh impetus to fight against bird flu	NATURE			English	News Item																		2003, NATURE, V422, P247	1	10	11	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 1	2003	423	6935					5	5		10.1038/423005b	http://dx.doi.org/10.1038/423005b			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	673CG	12721589	Bronze			2022-12-28	WOS:000182561600007
J	Chacron, MJ; Doiron, B; Maler, L; Longtin, A; Bastian, J				Chacron, MJ; Doiron, B; Maler, L; Longtin, A; Bastian, J			Non-classical receptive field mediates switch in a sensory neuron's frequency tuning	NATURE			English	Article							WEAKLY ELECTRIC FISH; LATERAL-LINE LOBE; GYMNOTIFORM FISH; SPIKE TRAINS; SIGNALS; REPRESENTATION; COMMUNICATION; ORGANIZATION; MECHANISMS; AFFERENTS	Animals have developed stereotyped communication calls to which specific sensory neurons are well tuned(1,2). These communication calls must be discriminated from environmental signals such as those produced by prey. Sensory systems might have evolved neural circuitry to encode both categories. In weakly electric fish, prey and communication signals differ in their spatial extent and frequency content(3,4). Here we show that stimuli of different spatial extents mimicking prey and communication signals cause a switch in the frequency tuning and spike-timing precision of electrosensory pyramidal neurons, resulting in the selective and optimal encoding of both stimulus categories. As in other sensory systems(5), pyramidal neurons respond only to stimuli located within a restricted region of space known as the classical receptive field (CRF)(6). In some systems, stimulation outside the CRF but within a non-classical receptive field (nCRF) can modulate the neural response to CRF stimulation even though nCRF stimulation alone fails to elicit responses(7,8). We show that pyramidal neurons possess a nCRF and that it can modulate the response to CRF stimuli to induce this neurobiological switch in frequency tuning.	Univ Ottawa, Dept Phys, Ottawa, ON K1N 6N5, Canada; Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON K1H 8M5, Canada; Univ Oklahoma, Dept Zool, Norman, OK 73019 USA	University of Ottawa; University of Ottawa; University of Oklahoma System; University of Oklahoma - Norman	Chacron, MJ (corresponding author), Univ Ottawa, Dept Phys, Ottawa, ON K1N 6N5, Canada.		Longtin, Andre/D-2443-2009	Chacron, Maurice/0000-0002-3032-452X				BASTCHELET E, 1981, CIRCULAR STAT BIOL; Bastian J, 2002, J NEUROSCI, V22, P4577, DOI 10.1523/JNEUROSCI.22-11-04577.2002; BASTIAN J, 1981, J COMP PHYSIOL, V144, P465, DOI 10.1007/BF01326832; Berman NJ, 1999, J EXP BIOL, V202, P1243; Bialek W., 1996, SPIKES EXPLORING NEU; Borst A, 1999, NAT NEUROSCI, V2, P947, DOI 10.1038/14731; CARR CE, 1982, J COMP NEUROL, V211, P139, DOI 10.1002/cne.902110204; Crampton William G. R., 1998, Anais da Academia Brasileira de Ciencias, V70, P805; Doiron B, 2003, NATURE, V421, P539, DOI 10.1038/nature01360; Gabbiani F, 1996, NATURE, V384, P564, DOI 10.1038/384564a0; Gabbiani F, 1996, NETWORK-COMP NEURAL, V7, P61, DOI 10.1080/0954898X.1996.11978655; HEILIGENBERG W, 1982, J COMP PHYSIOL, V148, P287, DOI 10.1007/BF00679013; Heiligenberg W., 1991, NEURAL NETS ELECT FI; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; Machens CK, 2001, J NEUROSCI, V21, P3215, DOI 10.1523/JNEUROSCI.21-09-03215.2001; MacLeod K, 1996, SCIENCE, V274, P976, DOI 10.1126/science.274.5289.976; MAINEN ZF, 1995, SCIENCE, V268, P1503, DOI 10.1126/science.7770778; MALER L, 1994, J COMP NEUROL, V345, P224, DOI 10.1002/cne.903450206; MALER L, 1981, J COMP NEUROL, V195, P87, DOI 10.1002/cne.901950107; METZNER W, 1991, J COMP PHYSIOL A, V169, P135, DOI 10.1007/BF00215861; Metzner W, 1997, P NATL ACAD SCI USA, V94, P14798, DOI 10.1073/pnas.94.26.14798; Nelson ME, 1999, J EXP BIOL, V202, P1195; Rieke F, 1995, P ROY SOC B-BIOL SCI, V262, P259, DOI 10.1098/rspb.1995.0204; SILLITO AM, 1995, NATURE, V378, P492, DOI 10.1038/378492a0; Simoncelli EP, 2001, ANNU REV NEUROSCI, V24, P1193, DOI 10.1146/annurev.neuro.24.1.1193; vanSteveninck RRD, 1997, SCIENCE, V275, P1805, DOI 10.1126/science.275.5307.1805; Vinje WE, 2000, SCIENCE, V287, P1273, DOI 10.1126/science.287.5456.1273; VOSS RF, 1978, J ACOUST SOC AM, V63, P258, DOI 10.1121/1.381721; Zhang H, 1999, J COMP PHYSIOL A, V184, P85, DOI 10.1007/s003590050308; ZUPANC GKH, 1993, CAN J ZOOL, V71, P2301, DOI 10.1139/z93-323	30	143	144	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 1	2003	423	6935					77	81		10.1038/nature01590	http://dx.doi.org/10.1038/nature01590			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	673CG	12721628				2022-12-28	WOS:000182561600042
J	Ivanova, N; Sorokin, A; Anderson, I; Galleron, N; Candelon, B; Kapatral, V; Bhattacharyya, A; Reznik, G; Mikhailova, N; Lapidus, A; Chu, L; Mazur, M; Goltsman, E; Larsen, N; D'Souza, M; Walunas, T; Grechkin, Y; Pusch, G; Haselkorn, R; Fonstein, M; Ehrlich, SD; Overbeek, R; Kyrpides, N				Ivanova, N; Sorokin, A; Anderson, I; Galleron, N; Candelon, B; Kapatral, V; Bhattacharyya, A; Reznik, G; Mikhailova, N; Lapidus, A; Chu, L; Mazur, M; Goltsman, E; Larsen, N; D'Souza, M; Walunas, T; Grechkin, Y; Pusch, G; Haselkorn, R; Fonstein, M; Ehrlich, SD; Overbeek, R; Kyrpides, N			Genome sequence of Bacillus cereus and comparative analysis with Bacillus anthracis	NATURE			English	Article							PLCR REGULON; THURINGIENSIS; VIRULENCE; STRAINS; PATHOGENICITY; TRANSCRIPTION; MUTATION; INSECTS; TOXIN	Bacillus cereus is an opportunistic pathogen causing food poisoning manifested by diarrhoeal or emetic syndromes(1). It is closely related to the animal and human pathogen Bacillus anthracis and the insect pathogen Bacillus thuringiensis, the former being used as a biological weapon and the latter as a pesticide. B. anthracis and B. thuringiensis are readily distinguished from B. cereus by the presence of plasmid-borne specific toxins (B. anthracis and B. thuringiensis) and capsule (B. anthracis). But phylogenetic studies based on the analysis of chromosomal genes bring controversial results, and it is unclear whether B. cereus, B. anthracis and B. thuringiensis are varieties of the same species 2 or different species(3,4). Here we report the sequencing and analysis of the type strain B. cereus ATCC 14579. The complete genome sequence of B. cereus ATCC 14579 together with the gapped genome of B. anthracis A2012(5) enables us to perform comparative analysis, and hence to identify the genes that are conserved between B. cereus and B. anthracis, and the genes that are unique for each species. We use the former to clarify the phylogeny of the cereus group, and the latter to determine plasmid-independent species-specific markers.	Integrated Genom, Chicago, IL 60612 USA; INRA, Ctr Rech Jouy En Josas, F-78352 Jouy En Josas, France; IIT, Res Inst, Life Sci Operat, Chicago, IL 60616 USA	INRAE; UDICE-French Research Universities; Universite Paris Saclay; Illinois Institute of Technology	Ivanova, N (corresponding author), Integrated Genom, Chicago, IL 60612 USA.		Kyrpides, Nikos C./A-6305-2014; Lapidus, Alla L/I-4348-2013; Ehrlich, S./Y-2423-2019; Sorokin, Alexei/AAV-4666-2020	Kyrpides, Nikos C./0000-0002-6131-0462; Lapidus, Alla L/0000-0003-0427-8731; Ehrlich, S./0000-0002-7563-4046; Sorokin, Alexei/0000-0002-8653-9896; KAPATRAL, VINAYAK/0000-0002-0501-3738; Walunas, Theresa/0000-0002-7653-3650; Ivanova, Natalia/0000-0002-5802-9485				Agaisse H, 1999, MOL MICROBIOL, V32, P1043, DOI 10.1046/j.1365-2958.1999.01419.x; ANDERSON I, UNPUB J BACTERIOL; Bhattacharyya A, 2002, P NATL ACAD SCI USA, V99, P12403, DOI 10.1073/pnas.132393999; CARLSON CR, 1992, J BACTERIOL, V174, P3750, DOI 10.1128/JB.174.11.3750-3756.1992; Degnan BA, 2000, INFECT IMMUN, V68, P2441, DOI 10.1128/IAI.68.5.2441-2448.2000; Fedhila S, 2002, J BACTERIOL, V184, P3296, DOI 10.1128/JB.184.12.3296-3304.2002; Gohar M, 2002, PROTEOMICS, V2, P784, DOI 10.1002/1615-9861(200206)2:6<784::AID-PROT784>3.0.CO;2-R; GORDON VM, 1988, INFECT IMMUN, V56, P1066, DOI 10.1128/IAI.56.5.1066-1069.1988; Helgason E, 2000, APPL ENVIRON MICROB, V66, P2627, DOI 10.1128/AEM.66.6.2627-2630.2000; Johansen T, 1996, FEMS MICROBIOL LETT, V136, P325, DOI 10.1016/0378-1097(96)00031-6; Kapatral V, 2002, J BACTERIOL, V184, P2005, DOI 10.1128/JB.184.7.2005-2018.2002; Kotiranta A, 1998, INFECT IMMUN, V66, P4895, DOI 10.1128/IAI.66.10.4895-4902.1998; Kotiranta A, 2000, MICROBES INFECT, V2, P189, DOI 10.1016/S1286-4579(00)00269-0; Lechner S, 1998, INT J SYST BACTERIOL, V48, P1373, DOI 10.1099/00207713-48-4-1373; Lereclus D, 2000, INT J MED MICROBIOL, V290, P295, DOI 10.1016/S1438-4221(00)80024-7; Margulis L, 1998, P NATL ACAD SCI USA, V95, P1236, DOI 10.1073/pnas.95.3.1236; Maurelli AT, 1998, P NATL ACAD SCI USA, V95, P3943, DOI 10.1073/pnas.95.7.3943; McKenzie GJ, 2001, MOL CELL, V7, P571, DOI 10.1016/S1097-2765(01)00204-0; Mignot T, 2001, MOL MICROBIOL, V42, P1189, DOI 10.1046/j.1365-2958.2001.02692.x; Okstad OA, 1999, MICROBIOL-UK, V145, P3129, DOI 10.1099/00221287-145-11-3129; Peschel A, 2001, J EXP MED, V193, P1067, DOI 10.1084/jem.193.9.1067; Read TD, 2002, SCIENCE, V296, P2028, DOI 10.1126/science.1071837; Salamitou S, 2000, MICROBIOL-UK, V146, P2825, DOI 10.1099/00221287-146-11-2825; Slamti L, 2002, EMBO J, V21, P4550, DOI 10.1093/emboj/cdf450; Sorokin A, 1996, GENOME RES, V6, P448, DOI 10.1101/gr.6.5.448; Ticknor LO, 2001, APPL ENVIRON MICROB, V67, P4863, DOI 10.1128/AEM.67.10.4863-4873.2001; Turnbull PCB, 1999, J APPL MICROBIOL, V87, P237, DOI 10.1046/j.1365-2672.1999.00876.x; Vilas-Boas G, 2002, APPL ENVIRON MICROB, V68, P1414, DOI 10.1128/AEM.68.3.1414-1424.2002; Wang P, 1997, P NATL ACAD SCI USA, V94, P6977, DOI 10.1073/pnas.94.13.6977; Yoshida KI, 1997, J BACTERIOL, V179, P4591, DOI 10.1128/jb.179.14.4591-4598.1997	30	639	1348	5	102	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 1	2003	423	6935					87	91		10.1038/nature01582	http://dx.doi.org/10.1038/nature01582			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	673CG	12721630	hybrid			2022-12-28	WOS:000182561600044
J	Ruegg, C; Cavadini, N; Furrer, A; Gudel, HU; Kramer, K; Mutka, H; Habicht, AK; Vorderwisch, P; Wildes, A				Ruegg, C; Cavadini, N; Furrer, A; Gudel, HU; Kramer, K; Mutka, H; Habicht, AK; Vorderwisch, P; Wildes, A			Bose-Einstein condensation of the triplet states in the magnetic insulator TlCuCl3	NATURE			English	Article							GAP SYSTEM TLCUCL3; QUANTUM SPIN LIQUID; FIELD; EXCITATIONS; KCUCL3; CHAINS; ANTIFERROMAGNETS; DIMENSIONS; DYNAMICS; LADDERS	Bose-Einstein condensation denotes the formation of a collective quantum ground state of identical particles with integer spin or intrinsic angular momentum. In magnetic insulators, the magnetic properties are due to the unpaired shell electrons that have half-integer spin. However, in some such compounds (KCuCl3 and TlCuCl3), two Cu2+ ions are antiferromagnetically coupled(1) to form a dimer in a crystalline network: the dimer ground state is a spin singlet (total spin zero), separated by an energy gap from the excited triplet state (total spin one). In these dimer compounds, Bose-Einstein condensation becomes theoretically possible(2). At a critical external magnetic field, the energy of one of the Zeeman split triplet components (a type of boson) intersects the ground-state singlet, resulting in long-range magnetic order; this transition represents a quantum critical point at which Bose-Einstein condensation occurs. Here we report an experimental investigation of the excitation spectrum in such a field-induced magnetically ordered state, using inelastic neutron scattering measurements of TlCuCl3 single crystals. We verify unambiguously the theoretically predicted(3) gapless Goldstone mode characteristic of the Bose-Einstein condensation of the triplet states.	Swiss Fed Inst Technol, Neutron Scattering Lab, CH-5232 Villigen, Switzerland; Paul Scherrer Inst, CH-5232 Villigen, Switzerland; Univ Bern, Dept Chem & Biochem, CH-3000 Bern 9, Switzerland; Inst Max Von Laue Paul Langevin, F-38042 Grenoble 9, France; Hahn Meitner Inst Berlin GmbH, BENSC, D-14109 Berlin, Germany	Swiss Federal Institutes of Technology Domain; Paul Scherrer Institute; University of Bern; Institut Laue-Langevin (ILL); Helmholtz Association; Helmholtz-Zentrum fuer Materialien und Energie GmbH (HZB)	Ruegg, C (corresponding author), Swiss Fed Inst Technol, Neutron Scattering Lab, CH-5232 Villigen, Switzerland.	christian.rueegg@psi.ch	Rüegg, Christian/A-3476-2012; Vorderwisch, Peter/AAH-9366-2021; Krämer, Karl W/J-5021-2013; Habicht, Klaus/K-3636-2013	Rüegg, Christian/0000-0003-0139-7786; Krämer, Karl W/0000-0001-5524-7703; Habicht, Klaus/0000-0002-9915-7221; Wildes, Andrew/0000-0003-3957-2818				AFFLECK I, 1990, PHYS REV B, V41, P6697, DOI 10.1103/PhysRevB.41.6697; Anglin JR, 2002, NATURE, V416, P211, DOI 10.1038/416211a; BARDEEN J, 1957, PHYS REV, V108, P1175, DOI 10.1103/PhysRev.108.1175; Cavadini N, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.132415; Cavadini N, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.172414; Einstein A, 1924, SITZBER PREUSS AKAD, P261; Enderle M, 2000, PHYSICA B, V276, P560, DOI 10.1016/S0921-4526(99)01737-8; Giamarchi T, 1999, PHYS REV B, V59, P11398, DOI 10.1103/PhysRevB.59.11398; Kageyama H, 2000, PHYS REV LETT, V84, P5876, DOI 10.1103/PhysRevLett.84.5876; London F, 1938, NATURE, V141, P643, DOI 10.1038/141643a0; Matsumoto M, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.077203; Muller M, 2000, J PHYS-CONDENS MAT, V12, P7633, DOI 10.1088/0953-8984/12/34/309; Nikuni T, 2000, PHYS REV LETT, V84, P5868, DOI 10.1103/PhysRevLett.84.5868; Oosawa A, 1999, J PHYS-CONDENS MAT, V11, P265, DOI 10.1088/0953-8984/11/1/021; Oosawa A, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.104405; Oosawa A, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.094426; Oosawa A, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.134416; Rice TM, 2002, SCIENCE, V298, P760, DOI 10.1126/science.1078819; Ruegg C, 2002, APPL PHYS A-MATER, V74, pS840, DOI 10.1007/s003390101156; Sachdev S, 2000, SCIENCE, V288, P475, DOI 10.1126/science.288.5465.475; SACHDEV S, 1994, PHYS REV B, V50, P258, DOI 10.1103/PhysRevB.50.258; Saha-Dasgupta T, 2002, EUROPHYS LETT, V60, P309, DOI 10.1209/epl/i2002-00351-x; Schmidt S, 2001, EUROPHYS LETT, V53, P591, DOI 10.1209/epl/i2001-00193-6; Shiramura W, 1997, J PHYS SOC JPN, V66, P1900, DOI 10.1143/JPSJ.66.1900; Stone MB, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.064423; Tanaka H, 2001, J PHYS SOC JPN, V70, P939, DOI 10.1143/JPSJ.70.939; Wessel S, 2000, PHYS REV B, V62, P316, DOI 10.1103/PhysRevB.62.316; Xu GY, 2000, PHYS REV LETT, V84, P4465, DOI 10.1103/PhysRevLett.84.4465; ZHELUDEV A, UNPUB PHYS REV LETT	30	404	405	2	81	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 1	2003	423	6935					62	65		10.1038/nature01617	http://dx.doi.org/10.1038/nature01617			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	673CG	12721623				2022-12-28	WOS:000182561600037
J	Lim, BCB; Ariens, RAS; Carter, AM; Weisel, JW; Grant, PJ				Lim, BCB; Ariens, RAS; Carter, AM; Weisel, JW; Grant, PJ			Genetic regulation of fibrin structure and function: complex gene-environment interactions may modulate vascular risk	LANCET			English	Article							FACTOR-XIII GENE; COAGULATION-FACTOR-XIII; MYOCARDIAL-INFARCTION; THR312ALA POLYMORPHISM; VAL34LEU POLYMORPHISM; COMMON POLYMORPHISM; PLASMA-FIBRINOGEN; FXIII VAL34LEU; HEART-DISEASE; ASSOCIATION	Background Polymorphisms in the fibrinogen and factor XIII genes are associated with atherothrombotic risk, but clinical studies have produced inconsistent results and laboratory studies have not explained these findings. We aimed to investigate interactions between polymorphisms in the factor XIII and fibrinogen genes, fibrinogen concentrations, and other cardiovascular risk factors in relation to fibrin structure and function. Methods We used permeation analysis and electron microscopy to investigate interactions between fibrin structure, factor XIII Val34Leu, fibrinogen Aalpha Thr312Ala, fibrinogen 130 Arg448Lys, and fibrinogen concentrations in plasma and purified systems. Findings Increased fibrinogen concentrations were associated with decreases in permeability, with tighter clot structures in the presence of factor XIII 34Val alleles compared with those in the presence of 34Leu alleles. Findings were confirmed by scanning electron microscopy of fibrin. Similar changes in permeability were noted for Aalpha fibrinogen 312Ala compared with that for 312Thr. Interpretation Our results show interactions between coding polymorphisms in fibrinogen and factor XIII and fibrinogen concentrations that modify fibrin and explain the apparent paradox between epidemiological studies of factor XIII 34Leu and reported in-vitro effects on fibrin structure and function. We suggest a potential complexity of gene-gene and gene-environment interactions in determining cardiovascular risk.	Univ Leeds, Acad Unit Mol Vasc Med, Leeds, W Yorkshire, England; Univ Penn, Sch Med, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA	University of Leeds; University of Pennsylvania	Grant, PJ (corresponding author), Gen Infirm, Acad Unit Mol Vasc Med, G Floor,Martin Wing, Leeds LS1 3EX, W Yorkshire, England.	p.j.grant@leeds.ac.uk	Grant, Peter/HIR-3733-2022	Ariens, Robert/0000-0002-6310-5745	NHLBI NIH HHS [HL30954] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030954] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ariens RAS, 2000, BLOOD, V96, P988, DOI 10.1182/blood.V96.3.988.015k57_988_995; BAUMANN RE, 1993, BLOOD, V82, P2117; Behague I, 1996, CIRCULATION, V93, P440, DOI 10.1161/01.CIR.93.3.440; Bennett JS, 2001, ANN NY ACAD SCI, V936, P340; BLOMBACK B, 1989, BIOCHIM BIOPHYS ACTA, V997, P96, DOI 10.1016/0167-4838(89)90140-4; Carter AM, 2000, BLOOD, V96, P1177, DOI 10.1182/blood.V96.3.1177.015k25_1177_1179; Carter AM, 1999, CIRCULATION, V99, P2423, DOI 10.1161/01.CIR.99.18.2423; Carter AM, 1997, ARTERIOSCL THROM VAS, V17, P589, DOI 10.1161/01.ATV.17.3.589; Catto AJ, 1998, STROKE, V29, P813, DOI 10.1161/01.STR.29.4.813; Catto AJ, 1999, BLOOD, V93, P906, DOI 10.1182/blood.V93.3.906.403k24_906_908; COLLET JP, 1993, BLOOD, V82, P2462; Collet JP, 2000, ARTERIOSCL THROM VAS, V20, P1354, DOI 10.1161/01.ATV.20.5.1354; Corral J, 2000, HAEMATOLOGICA, V85, P293; Dotevall Annika, 1994, Annals of Epidemiology, V4, P369; Elbaz A, 2000, BLOOD, V95, P586, DOI 10.1182/blood.V95.2.586; FATAH K, 1992, THROMB HAEMOSTASIS, V68, P130; Fatah K, 1996, THROMB HAEMOSTASIS, V76, P535; Franco RF, 2000, HAEMATOLOGICA, V85, P67; Gemmati D, 2001, AM J HEMATOL, V67, P183, DOI 10.1002/ajh.1104; Hunter KA, 2001, CLIN SCI, V100, P459, DOI 10.1042/CS20000228; Kohler HP, 1998, THROMB HAEMOSTASIS, V79, P8, DOI 10.1055/s-0037-1614250; Lane DA, 2000, BLOOD, V95, P1517, DOI 10.1182/blood.V95.5.1517.005k48_1517_1532; Ma J, 1999, J AM COLL CARDIOL, V33, P1347, DOI 10.1016/S0735-1097(99)00007-8; MEADE TW, 1986, LANCET, V2, P533, DOI 10.1016/S0140-6736(86)90111-X; Tuut M, 2001, ANN EPIDEMIOL, V11, P232, DOI 10.1016/S1047-2797(00)00226-X; Warner D, 2001, THROMB HAEMOSTASIS, V85, P408; Wartiovaara U, 1999, ATHEROSCLEROSIS, V142, P295, DOI 10.1016/S0021-9150(98)00241-X; WEISEL JW, 1992, BIOPHYS J, V63, P111, DOI 10.1016/S0006-3495(92)81594-1; WILHELMSEN L, 1984, NEW ENGL J MED, V311, P501, DOI 10.1056/NEJM198408233110804; Woodhead JL, 1996, J BIOL CHEM, V271, P4946	30	169	171	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 26	2003	361	9367					1424	1431		10.1016/S0140-6736(03)13135-2	http://dx.doi.org/10.1016/S0140-6736(03)13135-2			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	672HZ	12727396				2022-12-28	WOS:000182516300011
J	Sowter, MC				Sowter, MC			New surgical treatments for menorrhagia	LANCET			English	Review							ENDOMETRIAL RESECTION; THERMAL BALLOON; ABLATION; HYSTERECTOMY; SYSTEM; TRIAL; MANAGEMENT; ROLLERBALL; RISK	Context Hysterectomy is a common and effective treatment for menorrhagia but is associated with substantial postoperative convalescence time and morbidity. In the early 1940s endometrial resection or ablation became a well-established day-case alternative for the surgical treatment of menorrhagia. Both endometrial resection and ablation require general anaesthesia, a high level of skill in. hysteroscopic surgery, and can be long procedures. More: recently, various new techniques have been developed that can be done in an outpatient setting under local anaesthesia and with a low risk of complications. The effectiveness of most new second-generation ablation technologies has not been confirmed in randomised trials and it is possible that I these techniques will not prove to be as effective or as safe: as originally thought. Starting Point Massimiliano Pellicano and colleagues (Am J Obstet Gynecol 2002; 1,87: 545-50) compared a second-generation ablation technique, thermal destruction of the endometrium with a heated-water-filled silicone balloon: with hysteroscopic endometrial resection. 82 women were:, randomised and followed up for 2 years. Thermal destruction! was quicker than hysteroscopic resection, and was associated with a similar level of postoperative satisfaction and reintervention rate. This study suggests, that thermal destruction is, as effective a technique as endometrial: resection. Where next? Many second-generation ablation techniques, are now available. Some may prove more effective than,others, but much larger studies are needed to address', safety. The development of progestagen-releasing intra-uterine devices, which provide effective treatment for menorrhagia and are also an effective and reversible form of contraception, may mean that the uptake of second-generation surgical ablation techniques is less widespread, than some proponents of these new technologies suggest.	Natl Womens Hosp, Dept Obstet & Gynaecol, Auckland, New Zealand		Sowter, MC (corresponding author), Natl Womens Hosp, Dept Obstet & Gynaecol, Auckland, New Zealand.	martinsowter@xtra.co.nz						Abbott JA, 2002, HUM REPROD UPDATE, V8, P68, DOI 10.1093/humupd/8.1.68; ANDERSSON K, 1994, CONTRACEPTION, V49, P56, DOI 10.1016/0010-7824(94)90109-0; Bain C, 2002, OBSTET GYNECOL, V99, P983, DOI 10.1016/S0029-7844(02)01663-0; Bhattacharya S, 1997, BRIT J OBSTET GYNAEC, V104, P601, DOI 10.1111/j.1471-0528.1997.tb11540.x; Bustos-Lopez, 1996, J Am Assoc Gynecol Laparosc, V3, pS5, DOI 10.1016/S1074-3804(96)80144-7; CAHAN WG, 1967, AM J OBSTET GYNECOL, V99, P138, DOI 10.1016/S0002-9378(16)34504-5; Cooper J, 2002, J AM ASSOC GYN LAP, V9, P418, DOI 10.1016/S1074-3804(05)60513-0; Cooper KG, 1999, BRIT J OBSTET GYNAEC, V106, P258, DOI 10.1111/j.1471-0528.1999.tb08240.x; Corson SL, 2001, J AM ASSOC GYN LAP, V8, P359, DOI 10.1016/S1074-3804(05)60331-3; Corson SL, 2000, J AM ASSOC GYN LAP, V7, P489, DOI 10.1016/S1074-3804(05)60361-1; Dobak JD, 2000, J AM ASSOC GYN LAP, V7, P95, DOI 10.1016/S1074-3804(00)80016-X; Donnez J, 2000, FERTIL STERIL, V74, P791, DOI 10.1016/S0015-0282(00)00715-9; DWYER N, 1993, BRIT J OBSTET GYNAEC, V100, P237, DOI 10.1111/j.1471-0528.1993.tb15237.x; Gannon MJ, 1999, BRIT J OBSTET GYNAEC, V106, P1246, DOI 10.1111/j.1471-0528.1999.tb08177.x; Garry R, 2002, GYNAECOL ENDOSC, V11, P5, DOI 10.1046/j.0962-1091.2002.00479.x; Garry R, 1997, BRIT J OBSTET GYNAEC, V104, P1329, DOI 10.1111/j.1471-0528.1997.tb10998.x; Grant A, 1999, BRIT J OBSTET GYNAEC, V106, P360; Hawe JA, 1999, BRIT J OBSTET GYNAEC, V106, P1143, DOI 10.1111/j.1471-0528.1999.tb08139.x; Hurskainen R, 2001, LANCET, V357, P273, DOI 10.1016/S0140-6736(00)03615-1; Kremer C, 2000, BRIT J OBSTET GYNAEC, V107, P1443, DOI 10.1111/j.1471-0528.2000.tb11667.x; LUUKKAINEN T, 1986, CONTRACEPTION, V33, P139, DOI 10.1016/0010-7824(86)90080-6; Meyer WR, 1998, OBSTET GYNECOL, V92, P98, DOI 10.1016/S0029-7844(98)00141-0; National Health Committee, 1998, GUID MAN HEAV MENSTR; NEUWIRTH RS, 1994, OBSTET GYNECOL, V83, P792; OConnor H, 1997, LANCET, V349, P897, DOI 10.1016/S0140-6736(96)07285-6; OConnor H, 1996, NEW ENGL J MED, V335, P151, DOI 10.1056/NEJM199607183350302; Overton C, 1997, BRIT J OBSTET GYNAEC, V104, P1351, DOI 10.1111/j.1471-0528.1997.tb11003.x; Parkin DE, 2000, GYNAECOL ENDOSC, V9, P1, DOI 10.1046/j.1365-2508.2000.00320.x; Peterson HB, 1996, AM J OBSTET GYNECOL, V174, P1161, DOI 10.1016/S0002-9378(96)70658-0; Phillips G, 1998, BRIT J OBSTET GYNAEC, V105, P897, DOI 10.1111/j.1471-0528.1998.tb10236.x; Rees M., 2000, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002126; *ROYAL COLL OBST G, 1999, GUID IN MAN MEN; Sculpher MJ, 1996, BRIT J OBSTET GYNAEC, V103, P142, DOI 10.1111/j.1471-0528.1996.tb09666.x; VESSEY MP, 1992, BRIT J OBSTET GYNAEC, V99, P402, DOI 10.1111/j.1471-0528.1992.tb13758.x	34	16	18	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 26	2003	361	9367					1456	1458		10.1016/S0140-6736(03)13140-6	http://dx.doi.org/10.1016/S0140-6736(03)13140-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	672HZ	12727413				2022-12-28	WOS:000182516300027
J	Spira, AM				Spira, AM			Assessment of travellers who return home ill	LANCET			English	Article							INFLAMMATORY-BOWEL-DISEASE; HEMORRHAGIC-FEVER; IMPORTED MALARIA; MYCOBACTERIUM-TUBERCULOSIS; ANTIBIOTIC-RESISTANCE; CLINICAL-FEATURES; RISK BEHAVIOR; DIARRHEA; EPIDEMIOLOGY; INFECTION	Every year, millions of people travel abroad, exposing themselves to various diseases. Advice on risk avoidance and on self-medication is not always successful; sometimes travellers return home ill or become unwell soon afterwards. There are many possible causes for such illnesses, and physicians should try to establish whether the disease is specifically associated with the recent journey. The approach to assessment of the ill traveller should make use not only of signs and symptoms, but also of geography and epidemiology. Travellers with fever need immediate attention to rule out serious and potentially life-threatening conditions. Faced with a difficult diagnosis, physicians should consult with experts in tropical and travel medicine.	Travel Med Ctr, Beverly Hills, CA 90211 USA		Spira, AM (corresponding author), Travel Med Ctr, 131 N Robertson Blvd, Beverly Hills, CA 90211 USA.	travelmed@earthlink.net	Franzeck, Fabian C/B-5055-2011					AFZALPURKAR RG, 1992, NEW ENGL J MED, V327, P1849, DOI 10.1056/NEJM199212243272605; Allos BM, 1997, J INFECT DIS, V176, pS125, DOI 10.1086/513783; Centers of Disease Control and Prevention, 2001, MMWR Recomm Rep, V50, P1, DOI 10.1103/PhysRevE.106.055304; [Anonymous], 2000, Wkly Epidemiol Rec, V75, P265; Ansdell VE, 1999, MED CLIN N AM, V83, P945; Astiz ME, 1998, LANCET, V351, P1501, DOI 10.1016/S0140-6736(98)01134-9; Baird JK, 1999, MED CLIN N AM, V83, P923; Bouchaud O, 2000, AM J TROP MED HYG, V63, P76, DOI 10.4269/ajtmh.2000.63.76; Brenier-Pinchart MP, 2000, AM J TROP MED HYG, V63, P150, DOI 10.4269/ajtmh.2000.63.150; BRYAN R, 1988, P 1 C INT TRAV MED 1, P385; Carlsson, 1996, J Travel Med, V3, P62, DOI 10.1111/j.1708-8305.1996.tb00700.x; CASTELLI F, 1995, CHEMOTHERAPY, V41, P20, DOI 10.1159/000239394; CAUMES E, 1995, CLIN INFECT DIS, V20, P542, DOI 10.1093/clinids/20.3.542; *CDCP, 2001, HLTH INF INT TRAV 20; Centers for Disease Control and Prevention (CDC), 1998, MMWR Morb Mortal Wkly Rep, V46, P1247; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P577; Centers for Disease Control and Prevention (CDC), 2002, MMWR Morb Mortal Wkly Rep, V51, P324; Centers for Disease Control and Prevention (CDC), 2001, MMWR Morb Mortal Wkly Rep, V50, P21; Centers for Disease Control and Prevention (CDC), 2001, MMWR Morb Mortal Wkly Rep, V50, P597; Centers for Disease Control (CDC), 1991, MMWR Morb Mortal Wkly Rep, V40, P108; Cobelens FGJ, 2000, LANCET, V356, P461, DOI 10.1016/S0140-6736(00)02554-X; Daniels NA, 2000, J INFECT DIS, V181, P1491, DOI 10.1086/315397; DAVIES HD, 1993, ARCH DERMATOL, V129, P588, DOI 10.1001/archderm.129.5.588; Desjeux P, 2001, T ROY SOC TROP MED H, V95, P239, DOI 10.1016/S0035-9203(01)90223-8; Doherty JF, 1996, BRIT MED J, V313, P1071, DOI 10.1136/bmj.313.7064.1071; DRIVER CR, 1994, JAMA-J AM MED ASSOC, V272, P1031, DOI 10.1001/jama.272.13.1031; DuPont HL, 1996, CLIN INFECT DIS, V22, P124, DOI 10.1093/clinids/22.1.124; Eisen DP, 2000, T ROY SOC TROP MED H, V94, P169, DOI 10.1016/S0035-9203(00)90262-1; ERICSSON CD, 1998, INFECT DIS CLIN N AM, V83, P85; FRYATT RJ, 1990, TROP GEOGR MED, V42, P119; Gagneux, 1996, J Travel Med, V3, P14, DOI 10.1111/j.1708-8305.1996.tb00690.x; GEAR JHS, 1982, S AFR MED J, V62, P576; GEAR JSS, 1975, BRIT MED J, V4, P489, DOI 10.1136/bmj.4.5995.489; GIANNELLA RA, 1986, REV INFECT DIS, V8, pS223; GILLIES P, 1992, AIDS, V6, P339, DOI 10.1097/00002030-199203000-00020; HAMSHEY R, 1996, J TRAVEL MED, V4, P17; HARRIES AD, 1985, BRIT MED J, V291, P1686, DOI 10.1136/bmj.291.6510.1686; HAWKES S, 1994, AIDS, V8, P247, DOI 10.1097/00002030-199402000-00013; Hill DR, 2000, AM J TROP MED HYG, V62, P585, DOI 10.4269/ajtmh.2000.62.585; Hoge CW, 1996, JAMA-J AM MED ASSOC, V275, P533, DOI 10.1001/jama.275.7.533; Isaacson M, 2001, CLIN INFECT DIS, V33, P1707, DOI 10.1086/322620; Isenbarger DW, 2002, EMERG INFECT DIS, V8, P175; Ison CA, 1998, LANCET, V351, P8; ISTRE GR, 1984, JAMA-J AM MED ASSOC, V251, P508, DOI 10.1001/jama.251.4.508; JACOBS MG, 1991, BRIT MED J, V302, P828, DOI 10.1136/bmj.302.6780.828; JELINEK T, 1994, CLIN INFECT DIS, V19, P1062, DOI 10.1093/clinids/19.6.1062; Jelinek T, 1997, ARCH INTERN MED, V157, P2367, DOI 10.1001/archinte.157.20.2367; Jelinek T, 2001, J TRAVEL MED, V8, P57, DOI 10.2310/7060.2001.24485; Joubert JJ, 2001, J TRAVEL MED, V8, P92, DOI 10.2310/7060.2001.24493; Kain KC, 1998, CLIN INFECT DIS, V27, P142, DOI 10.1086/514616; Kain KC, 1999, MED CLIN N AM, V83, P1077; Kain KC, 2001, CAN MED ASSOC J, V164, P654; KOZICKI M, 1985, INT J EPIDEMIOL, V14, P169, DOI 10.1093/ije/14.1.169; Magill AJ, 1998, INFECT DIS CLIN N AM, V12, P445, DOI 10.1016/S0891-5520(05)70013-1; Mahdy M S, 1979, CAN DIS WKLY REP, V5, P189; MAHLE WT, 1993, PEDIATR INFECT DIS J, V12, P627, DOI 10.1097/00006454-199308000-00001; MALONE JD, 1993, SEX TRANSM DIS, V20, P294, DOI 10.1097/00007435-199309000-00011; MARSCHANG A, 1995, INFECTION, V23, P94, DOI 10.1007/BF01833873; MATHIEU JJ, 1994, ARCH INTERN MED, V154, P1713, DOI 10.1001/archinte.154.15.1713; MCDONALD JC, 1988, AM J MED, V85, P799, DOI 10.1016/S0002-9343(88)80024-X; Memish ZA, 2002, CLIN INFECT DIS, V34, P84, DOI 10.1086/323403; Miller JM, 2000, CLIN INFECT DIS, V31, P433, DOI 10.1086/313974; MOLYNEUX M, 1993, BRIT MED J, V306, P1175, DOI 10.1136/bmj.306.6886.1175; MONTGOMERY RD, 1973, BMJ-BRIT MED J, V2, P265, DOI 10.1136/bmj.2.5861.265; Moore DAJ, 2002, EMERG INFECT DIS, V8, P74, DOI 10.3201/eid0801.010130; Muentener P, 1999, B WORLD HEALTH ORGAN, V77, P560; NIKLASSON B, 1979, SCAND J INFECT DIS, V11, P313, DOI 10.3109/inf.1979.11.issue-4.11; Oh MD, 2001, AM J TROP MED HYG, V65, P143, DOI 10.4269/ajtmh.2001.65.143; Pastoris MC, 1999, CLIN INFECT DIS, V28, P33, DOI 10.1086/515083; Pepin J, 2001, ADV PARASIT, V49, P71, DOI 10.1016/S0065-308X(01)49038-5; RAEBER PA, 1994, LANCET, V344, P331, DOI 10.1016/S0140-6736(94)91368-4; Reyburn H, 1998, TROP MED INT HEALTH, V3, P281, DOI 10.1046/j.1365-3156.1998.00222.x; Ripamonti D, 2002, CLIN INFECT DIS, V34, pE18, DOI 10.1086/338157; Schlagenhauf P, 2000, J TRAVEL MED, V7, P225, DOI 10.2310/7060.2000.00069; Schulte C, 2002, CLIN INFECT DIS, V34, P407, DOI 10.1086/338026; SCHUMACHER G, 1993, LANCET, V341, P241, DOI 10.1016/0140-6736(93)90105-P; Schwartz E, 2002, J TRAVEL MED, V9, P97, DOI 10.2310/7060.2002.21503; Schwartz E, 1996, AM J MED, V101, P516, DOI 10.1016/S0002-9343(96)00278-1; STEFFEN R, 1994, J WILDERNESS MED, V5, P56, DOI 10.1580/0953-9859-5.1.56; STEFFEN R, 1986, REV INFECT DIS, V8, pS122; STEFFEN R, 1991, T ROY SOC TROP MED H, V85, P156, DOI 10.1016/0035-9203(91)90005-J; STEFFEN R, 1987, J INFECT DIS, V156, P84, DOI 10.1093/infdis/156.1.84; STEFFEN R, 1983, JAMA-J AM MED ASSOC, V249, P1175; Strom H, 1997, INFECTION, V25, P317, DOI 10.1007/BF01720409; TAYLOR DN, 1988, JAMA-J AM MED ASSOC, V260, P1245, DOI 10.1001/jama.260.9.1245; Taylor DN, 1999, MED CLIN N AM, V83, P1033; Teichmann D, 1999, LANCET, V354, P1608, DOI 10.1016/S0140-6736(99)09233-8; VANCREVEL R, 1994, CLIN INFECT DIS, V19, P132, DOI 10.1093/clinids/19.1.132; VISSER LG, 1995, CLIN INFECT DIS, V20, P280, DOI 10.1093/clinids/20.2.280; White NJ, 1996, NEW ENGL J MED, V335, P800, DOI 10.1056/NEJM199609123351107; *WHO, 2001, WKLY EPIDEMIOL REC, V76, P365; *WHO EWGLI, 1998, WEEKLY EPIDEMIOLOGIC, V73, P257; Wilson ME, 1998, INFECT DIS CLIN N AM, V12, P471, DOI 10.1016/S0891-5520(05)70014-3; WOLFE M, 1992, INFECT DIS CLIN N AM, V6, P3; WOLFE MS, 1990, AM J MED, V88, pS34, DOI 10.1016/0002-9343(90)90275-I; Wongsrichanalai C, 2002, LANCET INFECT DIS, V2, P209, DOI 10.1016/S1473-3099(02)00239-6; World Health Organization, 1997, WORLD HLTH REP 1996, P1; *WORLD TOUR ORG, 2002, FACTS FIG 2001 DAT; Zaki SR, 1996, LANCET, V347, P535, DOI 10.1016/S0140-6736(96)91167-8	99	50	51	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 26	2003	361	9367					1459	1469		10.1016/S0140-6736(03)13141-8	http://dx.doi.org/10.1016/S0140-6736(03)13141-8			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	672HZ	12727414				2022-12-28	WOS:000182516300028
J	Check, E				Check, E			US debates future of Iraqi scientists	NATURE			English	News Item																			0	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 24	2003	422	6934					789	789		10.1038/422789b	http://dx.doi.org/10.1038/422789b			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	670WR	12712152	Bronze			2022-12-28	WOS:000182432600003
J	Hoag, H				Hoag, H			Atlantic cod meet icy death	NATURE			English	News Item																		Marsh R, 1999, FISH OCEANOGR, V8, P39, DOI 10.1046/j.1365-2419.1999.00092.x	1	18	18	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 24	2003	422	6934					792	792		10.1038/422792b	http://dx.doi.org/10.1038/422792b			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	670WR	12712158	Bronze			2022-12-28	WOS:000182432600009
J	Woolley, DE				Woolley, DE			The mast cell in inflammatory arthritis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RHEUMATOID LESION; ACTIVATION		Manchester Royal Infirm, Univ Dept Med, Manchester M13 9WL, Lancs, England	University of Manchester	Woolley, DE (corresponding author), Manchester Royal Infirm, Univ Dept Med, Oxford Rd, Manchester M13 9WL, Lancs, England.							Feldmann M, 2002, NAT REV IMMUNOL, V2, P364, DOI 10.1038/nri802; He SH, 2001, EUR J PHARMACOL, V412, P223, DOI 10.1016/S0014-2999(01)00734-8; Lee DM, 2002, SCIENCE, V297, P1689, DOI 10.1126/science.1073176; TETLOW LC, 1995, ANN RHEUM DIS, V54, P896, DOI 10.1136/ard.54.11.896; Woolley DE, 2000, ARTHRITIS RES, V2, P65, DOI 10.1186/ar70	5	109	117	0	4	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 24	2003	348	17					1709	1711		10.1056/NEJMcibr023206	http://dx.doi.org/10.1056/NEJMcibr023206			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	670PB	12711748				2022-12-28	WOS:000182416300013
J	Vlot, A				Vlot, A			The lost patient	LANCET			English	Editorial Material									Univ Med Ctr, Dept Haematol, NL-6500 HB Nijmegen, Netherlands	Radboud University Nijmegen	Vlot, A (corresponding author), Univ Med Ctr, Dept Haematol, NL-6500 HB Nijmegen, Netherlands.								0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 19	2003	361	9366					1367	1367		10.1016/S0140-6736(03)13074-7	http://dx.doi.org/10.1016/S0140-6736(03)13074-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	669HP	12711485				2022-12-28	WOS:000182346100026
J	Scholey, JM; Brust-Mascher, I; Mogilner, A				Scholey, JM; Brust-Mascher, I; Mogilner, A			Cell division	NATURE			English	Review							METAPHASE CHROMOSOME ALIGNMENT; MITOTIC SPINDLE; DIRECTIONAL INSTABILITY; CHECKPOINT PROTEINS; MICROTUBULE FLUX; MOTOR PROTEINS; KINETOCHORE; TENSION; CYTOKINESIS; DYNAMICS	In creating the mitotic spindle and the contractile ring, natural selection has engineered fascinating precision machines whose movements depend upon forces generated by ensembles of cytoskeletal proteins. These machines segregate chromosomes and divide the cell with high fidelity. Current research on the mechanisms and regulation of spindle morphogenesis, chromosome motility and cytokinesis emphasizes how ensembles of dynamic cytoskeletal polymers and multiple motors cooperate to generate the forces that guide the cell through mitosis and cytokinesis.	Univ Calif Davis, Ctr Genet & Dev, Lab Cell & Computat Biol, Davis, CA 95616 USA	University of California System; University of California Davis	Scholey, JM (corresponding author), Univ Calif Davis, Ctr Genet & Dev, Lab Cell & Computat Biol, Davis, CA 95616 USA.	jmscholey@ucdavis.edu	Mogilner, Alex/A-3135-2008		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055507] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM055507] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrieu A, 2000, CELL, V102, P817, DOI 10.1016/S0092-8674(00)00070-2; ALEXANDER SP, 1991, J CELL BIOL, V113, P805, DOI 10.1083/jcb.113.4.805; Beaudouin J, 2002, CELL, V108, P83, DOI 10.1016/S0092-8674(01)00627-4; Bi GQ, 1997, J CELL BIOL, V138, P999, DOI 10.1083/jcb.138.5.999; Bray D., 2001, CELL MOVEMENTS; Brust-Mascher I, 2002, MOL BIOL CELL, V13, P3967, DOI 10.1091/mbc.02-05-0069; CAO LG, 1990, J CELL BIOL, V110, P1089, DOI 10.1083/jcb.110.4.1089; Chan GKT, 2000, NAT CELL BIOL, V2, P944, DOI 10.1038/35046598; Cytrynbaum EN, 2003, BIOPHYS J, V84, P757, DOI 10.1016/S0006-3495(03)74895-4; Desai A, 1999, CELL, V96, P69, DOI 10.1016/S0092-8674(00)80960-5; Erickson HP, 2000, NAT CELL BIOL, V2, pE93, DOI 10.1038/35014084; Finger FP, 2002, CELL, V108, P727, DOI 10.1016/S0092-8674(02)00668-2; Funabiki H, 2000, CELL, V102, P411, DOI 10.1016/S0092-8674(00)00047-7; Glotzer M, 2001, ANNU REV CELL DEV BI, V17, P351, DOI 10.1146/annurev.cellbio.17.1.351; Gonczy P, 2000, NATURE, V408, P331, DOI 10.1038/35042526; Grill SW, 2001, NATURE, V409, P630, DOI 10.1038/35054572; Guertin DA, 2002, MICROBIOL MOL BIOL R, V66, P155, DOI 10.1128/MMBR.66.2.155-178.2002; Gunawardane RN, 2000, CURR TOP DEV BIOL, V49, P55; Harris H, 1999, BIRTH CELL; Heald R, 2000, NAT CELL BIOL, V2, pE11, DOI 10.1038/71394; Hoffman DB, 2001, MOL BIOL CELL, V12, P1995, DOI 10.1091/mbc.12.7.1995; HOLY TE, 1994, P NATL ACAD SCI USA, V91, P5682, DOI 10.1073/pnas.91.12.5682; Howard J., 2001, MECH MOTOR PROTEINS; Howell BJ, 2000, J CELL BIOL, V150, P1233, DOI 10.1083/jcb.150.6.1233; Howell BJ, 2001, J CELL BIOL, V155, P1159, DOI 10.1083/jcb.200105093; Joglekar AP, 2002, BIOPHYS J, V83, P42, DOI 10.1016/S0006-3495(02)75148-5; Kalab P, 2002, SCIENCE, V295, P2452, DOI 10.1126/science.1068798; Kapoor TM, 2002, J CELL BIOL, V157, P551, DOI 10.1083/jcb.200202073; Kapoor TM, 2001, J CELL BIOL, V154, P1125, DOI 10.1083/jcb.200106011; Karsenti E, 2001, SCIENCE, V294, P543, DOI 10.1126/science.1063488; Keating TJ, 2000, NAT CELL BIOL, V2, P352, DOI 10.1038/35014045; Kinoshita K, 2001, SCIENCE, V294, P1340, DOI 10.1126/science.1064629; Levesque AA, 2001, J CELL BIOL, V154, P1135, DOI 10.1083/jcb.200106093; Li XT, 1997, J CELL SCI, V110, P537; Liu B, 2001, J PLANT GROWTH REGUL, V20, P141, DOI 10.1007/s003440010012; Mack GJ, 2001, P NATL ACAD SCI USA, V98, P14434, DOI 10.1073/pnas.261371298; Maddox P, 2002, CURR BIOL, V12, P1670, DOI 10.1016/S0960-9822(02)01183-1; Maney T, 2000, INT REV CYTOL, V194, P67; Marshall WF, 2001, CURR BIOL, V11, P569, DOI 10.1016/S0960-9822(01)00180-4; McIntosh JR, 2002, ANNU REV CELL DEV BI, V18, P193, DOI 10.1146/annurev.cellbio.18.032002.132412; Mitchison TJ, 2001, NAT CELL BIOL, V3, pE17, DOI 10.1038/35050656; Moller-Jensen J, 2002, EMBO J, V21, P3119, DOI 10.1093/emboj/cdf320; Moritz M, 2000, NAT CELL BIOL, V2, P365, DOI 10.1038/35014058; Nasmyth K, 2000, SCIENCE, V288, P1379, DOI 10.1126/science.288.5470.1379; Nedelec F, 2002, J CELL BIOL, V158, P1005, DOI 10.1083/jcb.200202051; Nicklas RB, 2001, J CELL SCI, V114, P4173; NICKLAS RB, 1983, J CELL BIOL, V97, P542, DOI 10.1083/jcb.97.2.542; OSTERGREN G, 1951, HEREDITAS, V37, P85; Popov AV, 2002, CURR BIOL, V12, P1326, DOI 10.1016/S0960-9822(02)01033-3; PURCELL EM, 1977, AM J PHYS, V45, P3, DOI 10.1119/1.10903; RAPPAPORT R, 1967, SCIENCE, V156, P1241, DOI 10.1126/science.156.3779.1241; Rappaport R., 1996, CYTOKINESIS ANIMAL C; Reinsch S, 1998, J CELL SCI, V111, P2283; Robinson DN, 2002, BMC CELL BIOL, V3, DOI 10.1186/1471-2121-3-4; Robinson DN, 2000, TRENDS CELL BIOL, V10, P228, DOI 10.1016/S0962-8924(00)01747-5; SATTERWHITE L L, 1992, Current Opinion in Cell Biology, V4, P43, DOI 10.1016/0955-0674(92)90057-J; SCHOLEY JM, 2003, MOL MOTORS, P327; Severin F, 2001, J CELL BIOL, V153, P435, DOI 10.1083/jcb.153.2.435; Shah JV, 2000, CELL, V103, P997, DOI 10.1016/S0092-8674(00)00202-6; Shannon KB, 2002, MOL BIOL CELL, V13, P3706, DOI 10.1091/mbc.E02-03-0137; Sharp DJ, 2000, NATURE, V407, P41, DOI 10.1038/35024000; Sharp DJ, 2000, NAT CELL BIOL, V2, P922, DOI 10.1038/35046574; Shuster CB, 2002, P NATL ACAD SCI USA, V99, P3633, DOI 10.1073/pnas.052342699; SKIBBENS RV, 1993, J CELL BIOL, V122, P859, DOI 10.1083/jcb.122.4.859; Skoufias DA, 2001, P NATL ACAD SCI USA, V98, P4492, DOI 10.1073/pnas.081076898; Somma MP, 2002, MOL BIOL CELL, V13, P2448, DOI 10.1091/mbc.01-12-0589; Theurkauf WE, 2001, NAT CELL BIOL, V3, pE159, DOI 10.1038/35083110; Walczak CE, 1998, CURR BIOL, V8, P903, DOI 10.1016/S0960-9822(07)00370-3; Walczak CE, 2001, NAT CELL BIOL, V3, pE69, DOI 10.1038/35060144; Wang YL, 2001, CELL STRUCT FUNCT, V26, P633, DOI 10.1247/csf.26.633; Wells WA, 2001, J CELL BIOL, V154, P1102, DOI 10.1083/jcb.200108139; Wigge PA, 1998, J CELL BIOL, V141, P967, DOI 10.1083/jcb.141.4.967; Wittmann T, 2001, NAT CELL BIOL, V3, pE28, DOI 10.1038/35050669; Wojcik E, 2001, NAT CELL BIOL, V3, P1001, DOI 10.1038/ncb1101-1001; Wood Kenneth W., 2001, Current Opinion in Pharmacology, V1, P370, DOI 10.1016/S1471-4892(01)00064-9; Yucel JK, 2000, J CELL BIOL, V150, P1, DOI 10.1083/jcb.150.1.1; Zhou J, 2002, J BIOL CHEM, V277, P17200, DOI 10.1074/jbc.M110369200; Zhou J, 2002, J CELL SCI, V115, P3547, DOI 10.1242/jcs.00029	79	220	227	2	53	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 17	2003	422	6933					746	752		10.1038/nature01599	http://dx.doi.org/10.1038/nature01599			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	668CG	12700768				2022-12-28	WOS:000182272300048
J	Elley, CR; Kerse, N; Arroll, B; Robinson, E				Elley, CR; Kerse, N; Arroll, B; Robinson, E			Effectiveness of counselling patients on physical activity in general practice: cluster randomised controlled trial	BRITISH MEDICAL JOURNAL			English	Article							PRIMARY-CARE; BLOOD-PRESSURE; VALIDATION	Objective To assess the long term effectiveness of the "green prescription" programme, a clinician based initiative in general practice, that provides counselling on physical activity Design Cluster randomised controlled trial. Practices were randomised before systematic screening and recruitment of patients. Setting 42 rural and urban general practices in one region of New Zealand. Subjects All sedentary 40-79 year old patients visiting their general practitioner during the study's recruitment period. Intervention General practitioners were prompted by the patient to give oral and written advice on physical activity during usual consultations. Exercise specialists continued support by telephone and post. Control patients received usual care. Main outcome measures Change in physical activity, quality of life (as measured by the "short form 36". (SF-36) questionnaire), cardiovascular risk (Framingham and D'Agostino equations), and blood pressure over a 12 month period. Results 74% (117/159) of general practitioners and 66% (878/1322) of, screened eligible patients participated in the study. The, follow. up rate was 85% (750/878). Mean total energy expenditure increased by 9.4 kcal/kg/week (P=0.001) and leisure exercise by 2.7 kcal/kg/week (P=0.02) or 34 minutes/week more in the intervention group than in the, control group (P=0.04). The proportion of the intervention group undertaking 2.5 hours/week of leisure exercise increased by 9.7% (P=0.003) more than in the control group (number needed to treat=10). SF-36 measures of self rated "general health," "role physical," "vitality," and "bodily pain" improved significantly more in the intervention group (P < 0.05). A trend towards decreasing blood pressure became apparent but no significant difference in four year risk of coronary heart disease. Conclusion Counselling patients in general practice on exercise is effective in increasing physical activity and improving quality of life Over 12 months.	Univ Auckland, Dept Gen Practice & Primary Hlth Care, Auckland 1, New Zealand; Univ Auckland, Dept Community Hlth, Auckland 1, New Zealand	University of Auckland; University of Auckland	Elley, CR (corresponding author), Univ Auckland, Dept Gen Practice & Primary Hlth Care, Auckland 1, New Zealand.		Kerse, Ngaire/AFF-8119-2022					AINSWORTH BE, 1993, MED SCI SPORT EXER, V25, P71, DOI 10.1249/00005768-199301000-00011; ANDERSON KM, 1991, AM HEART J, V121, P293, DOI 10.1016/0002-8703(91)90861-B; Arroll B, 1991, Epidemiology, V2, P296, DOI 10.1097/00001648-199107000-00011; Campbell MK, 2000, FAM PRACT, V17, P192, DOI 10.1093/fampra/17.2.192; Centers for Disease Control and Prevention, 1996, PHYS ACT HLTH REP SU; COOK NR, 1995, ARCH INTERN MED, V155, P701, DOI 10.1001/archinte.155.7.701; D'Agostino RB, 2000, AM HEART J, V139, P272, DOI 10.1016/S0002-8703(00)90236-9; Halbert JA, 2000, MED J AUSTRALIA, V173, P84, DOI 10.5694/j.1326-5377.2000.tb139250.x; Halbert JA, 1997, J HUM HYPERTENS, V11, P641, DOI 10.1038/sj.jhh.1000509; Harland J, 1999, BRIT MED J, V319, P828, DOI 10.1136/bmj.319.7213.828; *INT MED STAT HLTH, 1999, GREEN PRESCR GEN PRA; Kerry SM, 1998, BRIT MED J, V316, P1455, DOI 10.1136/bmj.316.7142.1455; KERSE N, 1998, THESIS U MELBOURNE; Lamonte MJ, 2001, MED SCI SPORT EXER, V33, pS370, DOI 10.1097/00005768-200106001-00006; Lee IM, 2001, MED SCI SPORT EXER, V33, pS459, DOI 10.1097/00005768-200106001-00016; MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006; *MIN HLTH, 1998, TAK PULS 1996 97 NZ; Perneger TV, 1998, BRIT MED J, V316, P1236, DOI 10.1136/bmj.316.7139.1236; Philippaerts RM, 1999, INT J SPORTS MED, V20, P284, DOI 10.1055/s-2007-971132; Simons-Morton DG, 2001, JAMA-J AM MED ASSOC, V286, P677; Sobngwi E, 2001, INT J EPIDEMIOL, V30, P1361, DOI 10.1093/ije/30.6.1361; Spirduso WW, 2001, MED SCI SPORT EXER, V33, pS598, DOI 10.1097/00005768-200106001-00028; Stevens W, 1998, BRIT J SPORT MED, V32, P236, DOI 10.1136/bjsm.32.3.236; Whelton PK, 1997, ARCH INTERN MED, V157, P657, DOI 10.1001/archinte.157.6.657	24	361	364	0	32	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 12	2003	326	7393					793	796		10.1136/bmj.326.7393.793	http://dx.doi.org/10.1136/bmj.326.7393.793			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	670BE	12689976	Green Published, Bronze			2022-12-28	WOS:000182386700018
J	Helweg-Larsen, J				Helweg-Larsen, J			S-adenosylmethionine in plasma to test for Pneumocystis carinii pneumonia	LANCET			English	Editorial Material									Univ Copenhagen, Hvidovre Hosp, Dept Infect Dis, Copenhagen HIV Programme, DK-2650 Hvidovre, Copenhagen, Denmark	University of Copenhagen	Helweg-Larsen, J (corresponding author), Univ Copenhagen, Hvidovre Hosp, Dept Infect Dis, Copenhagen HIV Programme, DK-2650 Hvidovre, Copenhagen, Denmark.			Helweg-Larsen, Jannik/0000-0001-7192-0144				Benfield TL, 2001, CHEST, V119, P844, DOI 10.1378/chest.119.3.844; Fischer S, 2001, J INFECT DIS, V184, P1485, DOI 10.1086/324520; Kaplan JE, 2000, CLIN INFECT DIS, V30, pS5, DOI 10.1086/313843; Merali S, 2000, J BIOL CHEM, V275, P14958, DOI 10.1074/jbc.275.20.14958; Ruffini DD, 2002, AIDS, V16, P105, DOI 10.1097/00002030-200201040-00013; Sing A, 2000, J CLIN MICROBIOL, V38, P1461, DOI 10.1128/JCM.38.4.1461-1467.2000; Turner D, 2003, EUR RESPIR J, V21, P204, DOI 10.1183/09031936.03.00035303	7	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 12	2003	361	9365					1237	1237		10.1016/S0140-6736(03)13027-9	http://dx.doi.org/10.1016/S0140-6736(03)13027-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	666DM	12699946				2022-12-28	WOS:000182161600003
J	Tekkis, PP; McCulloch, P; Steger, AC; Benjamin, IS; Poloniecki, JD				Tekkis, PP; McCulloch, P; Steger, AC; Benjamin, IS; Poloniecki, JD			Mortality control charts for comparing performance of surgical units: validation study using hospital mortality data	BMJ-BRITISH MEDICAL JOURNAL			English	Article							LEAGUE TABLES; MORBIDITY; SURGERY; BRISTOL; VOLUME; CARE	Objective To design and validate a statistical method for evaluating the performance of surgical units that adjusts for case volume and case mix. Design Validation study using routinely collected data on in-hospital mortality. Data sources Two UK databases, the ASCOT prospective database and the risk scoring collaborative (RISC) database, covering 1042 patients undergoing surgery in 29 hospitals for gastro-oesophageal cancer between 1995 and 2000. Statistical analysis A two level hierarchical logistic regression model was used to adjust each unit's operative mortality for case mix. Crude or adjusted operative mortality was plotted on mortality control charts (a graphical representation of surgical performance) as a function of number of operations. Control limits defined as 90%, 95%, and 99% confidence intervals identified units whose performance diverged significantly from the mean. Results The mean in-hospital mortality was 12% (range 0% to 50%). The case volume of the units ranged from one to 55 cases a year. When crude figures were plotted on the mortality control chart, four units lay outside the 90% control limit, including two outside the 95% limit. When operative mortality was adjusted for risk, three units lay outside the 90% limit and one outside the 95% limit. The model fitted the data well and had adequate discrimination (area under the receiver operating characteristics curve 0.78). Conclusions The mortality control chart is art accurate, risk adjusted means of identifying units whose surgical performance, in terms of operative mortality, diverges significantly from the population mean. It gives an early warning of divergent performance. It could be adapted to monitor performance across various specialties.	Kings Coll Hosp London, Acad Dept Surg, London SE5 9RS, England; Univ Liverpool, Univ Hosp Aintree, Acad Surg Unit, Liverpool L9 7AL, Merseyside, England; Univ Hosp Lewisham, Dept Surg, London SE13 6LH, England; Univ London St Georges Hosp, Dept Publ Hlth Sci, London SW17 0QT, England	King's College Hospital NHS Foundation Trust; King's College Hospital; University of Liverpool; University of London; King's College London; St Georges University London	Tekkis, PP (corresponding author), Kings Coll Hosp London, Acad Dept Surg, Denmark Hill, London SE5 9RS, England.	ptekkis@blueyonder.co.uk		McCulloch, Peter/0000-0002-3210-8273				Adab P, 2002, BRIT MED J, V324, P95, DOI 10.1136/bmj.324.7329.95; [Anonymous], 1997, J CLIN PATHOL; Aylin P, 2001, LANCET, V358, P181, DOI 10.1016/S0140-6736(01)05404-6; Birkmeyer JD, 2002, NEW ENGL J MED, V346, P1128, DOI 10.1056/NEJMsa012337; COPELAND GP, 1991, BRIT J SURG, V78, P356; Cummins J, 2001, EUR J SURG ONCOL, V27, P709, DOI 10.1053/ejso.2001.1176; Daley J, 1997, J AM COLL SURGEONS, V185, P328, DOI 10.1016/S1072-7515(01)00939-5; *DEP HLTH, HOSP EP STAT MAIN OP; Gillison EW, 2002, BRIT J SURG, V89, P344, DOI 10.1046/j.0007-1323.2001.02015.x; Goldstein H, 1996, J ROY STAT SOC A STA, V159, P149, DOI 10.2307/2983475; Greenland S, 2000, INT J EPIDEMIOL, V29, P158, DOI 10.1093/ije/29.1.158; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4; Hosmer DW, 2000, APPL LOGISTIC REGRES, DOI 10.1002/0471722146; Lovegrove J, 1997, LANCET, V350, P1128, DOI 10.1016/S0140-6736(97)06507-0; MARSHALL EC, 2001, WILEY SER PROB STAT, P127; Marshall EG, 1998, BRIT MED J, V316, P1701, DOI 10.1136/bmj.316.7146.1701; Mohammed MA, 2001, LANCET, V357, P463, DOI 10.1016/S0140-6736(00)04019-8; Parry GJ, 1998, BRIT MED J, V316, P1931, DOI 10.1136/bmj.316.7149.1931; Poloniecki J, 1998, BRIT MED J, V316, P1697, DOI 10.1136/bmj.316.7146.1697; Schafer J, NORM MULTIPLE IMPUTA; Spiegelhalter DJ, 2002, J R STAT SOC A STAT, V165, P191, DOI 10.1111/1467-985X.02021; Stark J, 2000, LANCET, V355, P1004, DOI 10.1016/S0140-6736(00)90001-1; Swisher SG, 2000, J THORAC CARDIOV SUR, V119, P1126, DOI 10.1067/mtc.2000.105644	24	68	69	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 12	2003	326	7393					786	788A		10.1136/bmj.326.7393.786	http://dx.doi.org/10.1136/bmj.326.7393.786			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	670BE	12689973	Bronze, Green Published			2022-12-28	WOS:000182386700015
J	Schroder, R				Schroder, R			The genes orthodenticle and hunchback substitute for bicoid in the beetle Tribolium	NATURE			English	Article							DROSOPHILA EMBRYO; AXIS FORMATION; EXPRESSION; ANTERIOR; SEGMENTATION; INSECTS; RNA; PROTEIN; ELEGANS; PATTERN	In Drosophila, the morphogen Bicoid organizes anterior patterning in a concentration-dependent manner by activating the transcription of target genes such as orthodenticle (otd)(1) and hunchback (hb), and by repressing the translation of caudal(2),(3). Homologues of the bicoid gene have not been isolated in any organism apart from the higher Dipterans(4-7). In fact, head and thorax formation in other insects is poorly understood. To elucidate this process in a short-germband insect, I analysed the function of the conserved genes orthodenticle-1 (otd-1) and hb in the flour beetle Tribolium castaneum. Here I show that, in contrast to Drosophila, Tribolium otd-1 messenger RNA is maternally inherited by the embryo. Reduction of Tribolium otd-1 levels by RNA interference (RNAi) results in headless embryos. This shows that otd-1 is required for anterior patterning in Tribolium. As in Drosophila, Tribolium hb specifies posterior gnathal and thoracic segments. The head, thorax and the anterior abdomen fail to develop in otd-1/hb double-RNAi embryos. This phenotype is similar to that of strong bicoid mutants in Drosophila. I propose that otd-1 and hb are part of an ancestral anterior patterning system.	Univ Tubingen, Interfak Inst Zellbiol, Abt Genet Tiere, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen	Schroder, R (corresponding author), Univ Tubingen, Interfak Inst Zellbiol, Abt Genet Tiere, Morgenstelle 28, D-72076 Tubingen, Germany.			Schroder, Reinhard/0000-0002-3483-1916				Brown S, 2001, CURR BIOL, V11, pR43, DOI 10.1016/S0960-9822(01)00007-0; Brown SJ, 1999, EVOL DEV, V1, P11, DOI 10.1046/j.1525-142x.1999.99013.x; Bucher G, 2002, CURR BIOL, V12, pR85, DOI 10.1016/S0960-9822(02)00666-8; COHEN S, 1991, TRENDS GENET, V7, P267; Dearden P, 1999, CURR BIOL, V9, pR591, DOI 10.1016/S0960-9822(99)80381-9; Draper BW, 1996, CELL, V87, P205, DOI 10.1016/S0092-8674(00)81339-2; Dubnau J, 1996, NATURE, V379, P694, DOI 10.1038/379694a0; Falciani F, 1996, P NATL ACAD SCI USA, V93, P8479, DOI 10.1073/pnas.93.16.8479; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; FROHNHOFER HG, 1986, NATURE, V324, P120, DOI 10.1038/324120a0; Gamberi C, 2002, DEVELOPMENT, V129, P2699; Gao Q, 1998, DEVELOPMENT, V125, P4185; Isaacs HV, 1999, EVOL DEV, V1, P143, DOI 10.1046/j.1525-142x.1999.99020.x; Lall S, 2003, CURR BIOL, V13, P224, DOI 10.1016/S0960-9822(03)00045-9; Lall S, 2001, ANNU REV GENET, V35, P407, DOI 10.1146/annurev.genet.35.102401.090832; LEHMANN R, 1987, DEV BIOL, V119, P402, DOI 10.1016/0012-1606(87)90045-5; Li YB, 1996, DEV GENES EVOL, V206, P35, DOI 10.1007/s004270050028; Niessing D, 2000, MOL CELL, V5, P395, DOI 10.1016/S1097-2765(00)80434-7; Patel NH, 2001, DEVELOPMENT, V128, P3459; Pultz MA, 1999, DEVELOPMENT, V126, P701; RiveraPomar R, 1996, NATURE, V379, P746, DOI 10.1038/379746a0; SCHRODER R, 1993, ROUX ARCH DEV BIOL, V203, P34, DOI 10.1007/BF00539888; SIMPSONBROSE M, 1994, CELL, V78, P855, DOI 10.1016/S0092-8674(94)90622-X; SOMMER R, 1991, DEVELOPMENT, V113, P419; Stauber M, 1999, P NATL ACAD SCI USA, V96, P3786, DOI 10.1073/pnas.96.7.3786; Stauber M, 2002, P NATL ACAD SCI USA, V99, P274, DOI 10.1073/pnas.012292899; STJOHNSTON D, 1992, CELL, V68, P201; TAUTZ D, 1994, DEVELOPMENT, P193; Wimmer EA, 2000, SCIENCE, V287, P2476, DOI 10.1126/science.287.5462.2476; Wolff C, 1995, DEVELOPMENT, V121, P4227	30	141	148	1	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 10	2003	422	6932					621	625		10.1038/nature01536	http://dx.doi.org/10.1038/nature01536			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	665GN	12687002				2022-12-28	WOS:000182111400044
J	Korthals-de Bos, IBC; Hoving, JL; van Tulder, MW; Rutten-Van Molken, MPMH; Ader, HJ; de Vet, HCW; Koes, BW; Vondeling, H; Bouter, LM				Korthals-de Bos, IBC; Hoving, JL; van Tulder, MW; Rutten-Van Molken, MPMH; Ader, HJ; de Vet, HCW; Koes, BW; Vondeling, H; Bouter, LM			Cost effectiveness of physiotherapy, manual therapy, and general practitioner care for neck pain: economic evaluation alongside a randomised controlled trial	BRITISH MEDICAL JOURNAL			English	Article							DISABILITY INDEX; RATIOS	Objective To evaluate the cost effectiveness of physiotherapy, manual therapy, and care by a general practitioner for patients with neck pain. Design Economic evaluation alongside a randomised controlled trial. Setting Primary care. Participants 183 patients with neck pain for at least two weeks recruited by 42 general practitioners and randomly allocated to manual therapy (n = 60, spinal mobilisation), physiotherapy (n = 59, mainly exercise), or general practitioner care (n = 64, counselling, education, and drugs). Main outcome measures Clinical outcomes were perceived recovery, intensity of pain, functional disability, and quality of life. Direct and indirect costs were measured by means of cost diaries that were kept by patients for one year. Differences in mean costs between. groups, cost effectiveness, and cost utility ratios were evaluated by applying non-parametric bootstrapping techniques. Results The manual therapy group showed a faster improvement than the physiotherapy group and the general practitioner care group up to 26 weeks, but differences were negligible by follow up at 52 weeks. The total costs of manual therapy (C447; pound273; $402) were around one third of the costs of physiotherapy (C1297) and general practitioner care (C1379). These differences were significant: P < 0.01 for manual therapy versus physiotherapy and manual therapy versus general practitioner care and P = 0.55 for general practitioner care versus physiotherapy. The cost effectiveness ratios and the cost utility ratios showed that manual therapy was less costly and more effective than physiotherapy or general practitioner care. Conclusions Manual therapy (spinal mobilisation) is more effective and less costly for treating neck pain than physiotherapy or care by a general practitioner.	VU Univ, Inst Res Extramural Med, Med Ctr, NL-1081 BT Amsterdam, Netherlands; Erasmus Univ, Inst Med Technol Assessment, Rotterdam, Netherlands; Erasmus Med Ctr, Dept Gen Practice, Rotterdam, Netherlands	Vrije Universiteit Amsterdam; Erasmus University Rotterdam; Erasmus University Rotterdam; Erasmus MC	Korthals-de Bos, IBC (corresponding author), VU Univ, Inst Res Extramural Med, Med Ctr, Van Boechorststr 7, NL-1081 BT Amsterdam, Netherlands.		van Tulder, Maurits/AAB-9785-2022; Molken, Maureen Rutten-van/X-8712-2019; Koes, Bart w/K-4614-2016; Hoving, Jan/C-3744-2017; Hoving, Jan L/O-2235-2013; Molken, Maureen PMH Rutten-van/G-8481-2014	van Tulder, Maurits/0000-0002-7589-8471; Molken, Maureen Rutten-van/0000-0001-8706-3159; Koes, Bart w/0000-0002-0450-9969; Hoving, Jan L/0000-0002-0461-4013; Molken, Maureen PMH Rutten-van/0000-0001-8706-3159; Bouter, Lex/0000-0002-2659-5482				BORGHOUTS JA, 2000, THESIS WAGENINGEN; Borghouts JAJ, 1999, PAIN, V80, P629, DOI 10.1016/S0304-3959(98)00268-1; Chaudhary MA, 1996, STAT MED, V15, P1447; Dolan P, 1997, MED CARE, V35, P1095, DOI 10.1097/00005650-199711000-00002; *DUTCH CENTR ORG H, 1996, TAR MED SPEC EXCL PS; Efron B., 1994, MONOGRAPHS STAT APPL; Goossens MEJB, 2000, J CLIN EPIDEMIOL, V53, P688, DOI 10.1016/S0895-4356(99)00177-8; GROSS AR, 1996, ONLINE J CURR CLIN T; Hains F, 1998, J MANIP PHYSIOL THER, V21, P75; Harms-Ringdahl K, 2000, NECK BACK PAIN SCI E, P327; Hoving JL, 2002, ANN INTERN MED, V136, P713, DOI 10.7326/0003-4819-136-10-200205210-00006; Koopmanschap MA, 1996, PHARMACOECONOMICS, V10, P460, DOI 10.2165/00019053-199610050-00003; Lanser K, 1994, NEKKLACHTEN VOORKOME; LANSER K, 1994, NEKKLACHLEN WOORKOME; OOSTENBRINK JB, 2000, HANDLEIDING KOSTENUN; PICAVET HS, 2000, 266807002 RIVM NAT I; Skargren EI, 1998, SPINE, V23, P1875, DOI 10.1097/00007632-199809010-00016; Stinnett AA, 1998, MED DECIS MAKING, V18, pS68, DOI 10.1177/0272989X98018002S09; Stratford PW, 1999, PHYSIOTHER CANADA, V51, P107; VANHOUT BA, 1994, HEALTH ECON, V3, P309, DOI 10.1002/hec.4730030505; VANTULDER MW, 2000, NECK BACK PAIN SCI E, P339; VERNON H, 1991, J MANIP PHYSIOL THER, V14, P409; 2000, TAXE REPORT	23	171	173	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 26	2003	326	7395					911	914B						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	673WQ	12714472				2022-12-28	WOS:000182603600018
J	Fletcher, SW; Elmore, JG				Fletcher, SW; Elmore, JG			Mammographic screening for breast cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CARCINOMA IN-SITU; FALSE-POSITIVE MAMMOGRAMS; REPLACEMENT THERAPY; WOMEN; RISK; SENSITIVITY; DENSITY; VALIDATION; DISCOMFORT; PREDICTION		Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Boston, MA 02215 USA; Harvard Pilgrim Hlth Care, Boston, MA USA; Univ Washington, Dept Med, Seattle, WA USA	Harvard University; Harvard Medical School; Harvard Pilgrim Health Care; University of Washington; University of Washington Seattle	Fletcher, SW (corresponding author), Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, 6th Fl,133 Brookline Ave, Boston, MA 02215 USA.		Vaidya, Jayant S/A-7218-2008	Vaidya, Jayant S/0000-0003-1760-1278	NCI NIH HHS [R01 CA107623, K05 CA104699, R01 CA107623-04] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K05CA104699, R01CA107623] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON RN, 2002, NAT VITAL STAT REPOR, V50; Andrews F J, 2001, Australas Radiol, V45, P113, DOI 10.1046/j.1440-1673.2001.00889.x; Barton MB, 1999, ANN INTERN MED, V130, P651, DOI 10.7326/0003-4819-130-8-199904200-00005; Barton MB, 2001, J GEN INTERN MED, V16, P150, DOI 10.1111/j.1525-1497.2001.00329.x; BASINSKI A, 2000, ACP J CLUB, V133, P67; Bassett LW, 1994, AHCPR PUBLICATION; Berg AO, 2002, ANN INTERN MED, V137, P344, DOI 10.7326/0003-4819-137-5_Part_1-200209030-00011; Berry DA, 1998, JNCI-J NATL CANCER I, V90, P1431, DOI 10.1093/jnci/90.19.1431; Berry DA, 2002, J CLIN ONCOL, V20, P2701, DOI 10.1200/JCO.2002.05.121; BLACK WC, 1995, J NATL CANCER I, V87, P720, DOI 10.1093/jnci/87.10.720; Blackman D K, 1999, MMWR CDC Surveill Summ, V48, P1; BROWN ML, 1995, AM J ROENTGENOL, V165, P1373, DOI 10.2214/ajr.165.6.7484568; Burman ML, 1999, ANN INTERN MED, V131, P1, DOI 10.7326/0003-4819-131-1-199907060-00002; Christiansen CL, 2000, JNCI-J NATL CANCER I, V92, P1657, DOI 10.1093/jnci/92.20.1657; Clemons M, 2001, NEW ENGL J MED, V344, P276, DOI 10.1056/NEJM200101253440407; Dullum JR, 2000, RADIOLOGY, V214, P547, DOI 10.1148/radiology.214.2.r00fe23547; Edwards A, 2002, BMJ-BRIT MED J, V324, P827, DOI 10.1136/bmj.324.7341.827; Elmore G, 1998, NEW ENGL J MED, V338, P1089, DOI 10.1056/NEJM199804163381601; Ernster VL, 2000, ARCH INTERN MED, V160, P953, DOI 10.1001/archinte.160.7.953; Ernster VL, 1996, JAMA-J AM MED ASSOC, V275, P913, DOI 10.1001/jama.275.12.913; FAJARDO LL, 1988, INVEST RADIOL, V23, P505, DOI 10.1097/00004424-198807000-00004; Feig SA, 1996, CANCER, V77, P818, DOI 10.1002/(SICI)1097-0142(19960301)77:5<818::AID-CNCR2>3.3.CO;2-9; FEUER EJ, 1999, DEVCAN PROBABILITY D; FISHER B, 1993, NEW ENGL J MED, V328, P1581, DOI 10.1056/NEJM199306033282201; FLETCHER SW, 1993, J NATL CANCER I, V85, P1644, DOI 10.1093/jnci/85.20.1644; FLETCHER SW, 1997, MONOGR NATL CANC I, V22, P5; Gotzsche PC, 2000, LANCET, V355, P129, DOI 10.1016/S0140-6736(99)06065-1; Harvey JA, 1997, J NATL CANCER I, V89, P1623, DOI 10.1093/jnci/89.21.1623; HOLLAND R, 1983, CANCER, V52, P1810, DOI 10.1002/1097-0142(19831115)52:10<1810::AID-CNCR2820521009>3.0.CO;2-F; JOHNSON JD, 1992, J BEHAV MED, V15, P429, DOI 10.1007/BF00844940; *KAIS PERM, 1998, NGC0461 KAIS PERM; Keemers-Gels ME, 2000, BREAST CANCER RES TR, V60, P235, DOI 10.1023/A:1006457520996; Kerlikowske K, 1996, JAMA-J AM MED ASSOC, V276, P33, DOI 10.1001/jama.276.1.33; Kinsinger L., 1998, JGIM, V13, P98; Kornguth PJ, 1996, PAIN, V66, P187, DOI 10.1016/0304-3959(96)03057-6; Laya MB, 1996, J NATL CANCER I, V88, P643, DOI 10.1093/jnci/88.10.643; LAYA MB, 1995, RADIOLOGY, V196, P433, DOI 10.1148/radiology.196.2.7617857; LERMAN C, 1991, ANN INTERN MED, V114, P657, DOI 10.7326/0003-4819-114-8-657; MA L, 1992, J NATL CANCER I, V84, P781, DOI 10.1093/jnci/84.10.781; MILLER AB, 1993, CAN MED ASSOC J, V148, P718; *NAT CANC I, 2003, BREAST CANC PDQ SCRE; *NAT I HLTH CONS D, 1997, BREAST CANC SCREEN W, V15; Nystrom L, 2002, LANCET, V360, P724; Nystrom L, 2002, LANCET, V359, P909, DOI 10.1016/S0140-6736(02)08020-0; Offit K, 1996, J CLIN ONCOL, V14, P1730, DOI 10.1200/JCO.1996.14.5.1730; Olsen O, 2001, LANCET, V358, P1340, DOI 10.1016/S0140-6736(01)06449-2; Physician Insurers Association of America, 1995, BREAST CANC STUD; Pisano ED, 1998, RADIOLOGY, V208, P245, DOI 10.1148/radiology.208.1.9646820; Ries LA, 2002, SEER CANC STAT REV 1; RIES LAG, 1997, NIH PUBLICATION; Rockhill B, 2001, J NATL CANCER I, V93, P358, DOI 10.1093/jnci/93.5.358; RUTTER DR, 1992, BRIT MED J, V305, P443, DOI 10.1136/bmj.305.6851.443; Seidell JC, 2002, SIGNIFICANT TRENDS F; Silverman E, 2001, MED DECIS MAKING, V21, P231, DOI 10.1177/02729890122062523; Vainio H., 2002, BREAST CANC SCREENIN; VanDijck JAAM, 1996, INT J CANCER, V66, P727, DOI 10.1002/(SICI)1097-0215(19960611)66:6<727::AID-IJC3>3.0.CO;2-1; Welch HG, 1997, ANN INTERN MED, V127, P1023, DOI 10.7326/0003-4819-127-11-199712010-00014; White E, 1998, J NATL CANCER I, V90, P906, DOI 10.1093/jnci/90.12.906; 2000, LANCET, V355, P752; 2000, LANCET, V355, P747; 2001, LANCET, V358, P2164	61	249	257	0	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 24	2003	348	17					1672	1680		10.1056/NEJMcp021804	http://dx.doi.org/10.1056/NEJMcp021804			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	670PB	12711743	Green Accepted			2022-12-28	WOS:000182416300008
J	Ren, SX; Gang, F; Jiang, XG; Zeng, R; Miao, YG; Xu, H; Zhang, YX; Xiong, H; Lu, G; Lu, LF; Jiang, HQ; Jia, J; Tu, YF; Jiang, JX; Gu, WY; Zhang, YQ; Cai, Z; Sheng, HH; Yin, HF; Zhang, Y; Zhu, GF; Wan, M; Huang, HL; Qian, Z; Wang, SY; Ma, W; Yao, ZJ; Shen, Y; Qiang, BQ; Xia, QC; Guo, XK; Danchin, A; Saint Girons, I; Somerville, RL; Wen, YM; Shi, MH; Chen, Z; Xu, JG; Zhao, GP				Ren, SX; Gang, F; Jiang, XG; Zeng, R; Miao, YG; Xu, H; Zhang, YX; Xiong, H; Lu, G; Lu, LF; Jiang, HQ; Jia, J; Tu, YF; Jiang, JX; Gu, WY; Zhang, YQ; Cai, Z; Sheng, HH; Yin, HF; Zhang, Y; Zhu, GF; Wan, M; Huang, HL; Qian, Z; Wang, SY; Ma, W; Yao, ZJ; Shen, Y; Qiang, BQ; Xia, QC; Guo, XK; Danchin, A; Saint Girons, I; Somerville, RL; Wen, YM; Shi, MH; Chen, Z; Xu, JG; Zhao, GP			Unique physiological and pathogenic features of Leptospira interrogans revealed by whole-genome sequencing	NATURE			English	Article							PLATELET-ACTIVATING-FACTOR; GENE; MOTILITY; SYNTHASE	Leptospirosis is a widely spread disease of global concern. Infection causes flu-like episodes with frequent severe renal and hepatic damage, such as haemorrhage and jaundice. In more severe cases, massive pulmonary haemorrhages, including fatal sudden haemoptysis, can occur(1). Here we report the complete genomic sequence of a representative virulent serovar type strain (Lai)(2) of Leptospira interrogans serogroup Icterohaemorrhagiae consisting of a 4.33-megabase large chromosome and a 359-kilobase small chromosome, with a total of 4,768 predicted genes. In terms of the genetic determinants of physiological characteristics, the facultatively parasitic L. interrogans differs extensively from two other strictly parasitic pathogenic spirochaetes, Treponema pallidum(3) and Borrelia burgdorferi(4), although similarities exist in the genes that govern their unique morphological features. A comprehensive analysis of the L. interrogans genes for chemotaxis/motility and lipopolysaccharide synthesis provides a basis for in-depth studies of virulence and pathogenesis. The discovery of a series of genes possibly related to adhesion, invasion and the haematological changes that characterize leptospirosis has provided clues about how an environmental organism might evolve into an important human pathogen.	Chinese Natl Human Genome Ctr Shanghai, Shanghai 201203, Peoples R China; Chinese Acad Sci, Bioinformat Ctr, Inst Biochem & Cell Biol, Shanghai 200031, Peoples R China; Chinese Acad Sci, Inst Plant Physiol & Ecol, Biotechnol Res Ctr, Shanghai 200031, Peoples R China; Chinese Acad Sci, Shanghai Inst Biol Sci, Shanghai 200031, Peoples R China; Shanghai Med Univ 2, Rui Jin Hosp, Dept Microbiol & Parasitol, Shanghai 200025, Peoples R China; Chinese Ctr Dis Control & Prevent, Natl Inst Communicable Dis Control & Prevent, ICDC, China CDC, Beijing 102206, Peoples R China; Chinese Natl Human Genome Ctr, Beijing 100170, Peoples R China; Fudan Univ, Dept Mol Virol, Med Ctr, Shanghai 200032, Peoples R China; HKU, Pasteur Res Ctr, Hong Kong, Hong Kong, Peoples R China; Inst Pasteur, Unite Bacteriol Mol & Med, F-75724 Paris 15, France; Purdue Univ, Dept Biochem, W Lafayette, IN 47907 USA	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Shanghai Jiao Tong University; Chinese Center for Disease Control & Prevention; National Institute for Communicable Disease Control & Prevention, Chinese Center for Disease Control & Prevention; Fudan University; University of Hong Kong; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Zhao, GP (corresponding author), Chinese Natl Human Genome Ctr Shanghai, 250 Bi Bo Rd,Zhang Jiang High Tech Pk, Shanghai 201203, Peoples R China.	gpzhao@sibs.ac.cn	Ma, Wei/B-5999-2012; Yin, Haifeng/E-8787-2012	Zhao, Guo-Ping/0000-0002-7621-6620; Guo, Xiao-Kui/0000-0002-1595-9965; Danchin, Antoine/0000-0002-6350-5001				Arai H, 2002, J BIOCHEM, V131, P635, DOI 10.1093/oxfordjournals.jbchem.a003145; Bourhy P, 2000, FEMS MICROBIOL LETT, V191, P259, DOI 10.1016/S0378-1097(00)00393-1; Charon NW, 2002, ANNU REV GENET, V36, P47, DOI 10.1146/annurev.genet.36.041602.134359; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; Delcher AL, 1999, NUCLEIC ACIDS RES, V27, P4636, DOI 10.1093/nar/27.23.4636; Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186; Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175; Faine S, 1999, LEPTOSPIRA LEPTOSPIR, V2nd; Fraser CM, 1997, NATURE, V390, P580, DOI 10.1038/37551; Fraser CM, 1998, SCIENCE, V281, P375, DOI 10.1126/science.281.5375.375; Gordon D, 1998, GENOME RES, V8, P195, DOI 10.1101/gr.8.3.195; Heidelberg JF, 2000, NATURE, V406, P477, DOI 10.1038/35020000; Herter S, 2001, J BACTERIOL, V183, P4305, DOI 10.1128/JB.183.14.4305-4316.2001; Howell DM, 1999, J BACTERIOL, V181, P331, DOI 10.1128/JB.181.1.331-333.1999; Kmety E., 1993, CLASSIFICATION SPECI; KOHLHAW G, 1969, J BIOL CHEM, V244, P2218; Lowe TM, 1997, NUCLEIC ACIDS RES, V25, P955, DOI 10.1093/nar/25.5.955; Matsushita O, 1999, J BACTERIOL, V181, P923, DOI 10.1128/JB.181.3.923-933.1999; Motaleb MA, 2000, P NATL ACAD SCI USA, V97, P10899, DOI 10.1073/pnas.200221797; Ogata H, 1999, NUCLEIC ACIDS RES, V27, P29, DOI 10.1093/nar/27.1.29; Olendzenski L, 2000, J MOL EVOL, V51, P587, DOI 10.1007/s002390010122; Picardeau M, 2001, MOL MICROBIOL, V40, P189, DOI 10.1046/j.1365-2958.2001.02374.x; RILEY M, 1993, MICROBIOL REV, V57, P862, DOI 10.1128/MMBR.57.4.862-952.1993; Rodrigo L, 2001, BIOCHEM J, V354, P1, DOI 10.1042/0264-6021:3540001; SAIER M, 2001, SPIROCHETES MOL CELL; Tuckwell D, 1999, BIOCHEM SOC T, V27, P835, DOI 10.1042/bst0270835; Werts C, 2001, NAT IMMUNOL, V2, P346, DOI 10.1038/86354; Wolf YI, 2001, BMC EVOL BIOL, V1, DOI 10.1186/1471-2148-1-8; Zhang CT, 2000, NUCLEIC ACIDS RES, V28, P2804, DOI 10.1093/nar/28.14.2804	29	425	895	4	73	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	APR 24	2003	422	6934					888	893		10.1038/nature01597	http://dx.doi.org/10.1038/nature01597			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	670WR	12712204	hybrid			2022-12-28	WOS:000182432600054
J	Rohani, P; Green, CJ; Mantilla-Beniers, NB; Grenfell, BT				Rohani, P; Green, CJ; Mantilla-Beniers, NB; Grenfell, BT			Ecological interference between fatal diseases	NATURE			English	Article							POPULATION; DETERMINANTS; MEASLES; DENGUE	An important issue in population biology is the dynamic interaction between pathogens. Interest has focused mainly on the indirect interaction of pathogen strains, mediated by cross immunity(1-4). However, a mechanism has recently been proposed for 'ecological interference' between pathogens through the removal of individuals from the susceptible pool after an acute infection. To explore this possibility, we have analysed and modelled historical measles and whooping cough records. Here we show that ecological interference is particularly strong when fatal infections permanently remove susceptibles. Disease interference has substantial dynamical consequences, making multi-annual outbreaks of different infections characteristically out of phase. So, when disease prevalence is high and is associated with significant mortality, it might be impossible to understand epidemic patterns by studying pathogens in isolation. This new ecological null model has important consequences for understanding the multi-strain dynamics of pathogens such as dengue and echoviruses.	Univ Georgia, Inst Ecol, Athens, GA 30602 USA; Univ Cambridge, Dept Zool, Cambridge CB2 3EJ, England	University System of Georgia; University of Georgia; University of Cambridge	Rohani, P (corresponding author), Univ Georgia, Inst Ecol, Athens, GA 30602 USA.	rohani@uga.edu		rohani, pejman/0000-0002-7221-3801				ANDERSON R M, 1991; ANDERSON RM, 1982, SCIENCE, V215, P1053, DOI 10.1126/science.7063839; BARTLETT MS, 1957, J R STAT SOC SER A-G, V120, P48, DOI 10.2307/2342553; BEHRMAN RE, 1998, NELSON ESSENTIALS PE; Buonaccorsi JP, 2001, ECOLOGY, V82, P1668, DOI 10.1890/0012-9658(2001)082[1668:MATFSS]2.0.CO;2; Butler W, 1913, Proc R Soc Med, V6, P120; BUTLER W, 1947, P ROY SOC MED, V40, P384, DOI 10.1177/003591574704000710; Cherry JD, 1998, ANN INTERN MED, V128, P64, DOI 10.7326/0003-4819-128-1-199801010-00010; CREIGHTON C, 1994, HIST EPIDEMICS BRITA; DIETZ K, 1979, J MATH BIOL, V8, P291, DOI 10.1007/BF00276314; Earn DJD, 2000, SCIENCE, V287, P667, DOI 10.1126/science.287.5453.667; Focks DA, 2000, AM J TROP MED HYG, V62, P11, DOI 10.4269/ajtmh.2000.62.11; Gog JR, 2002, J MATH BIOL, V44, P169, DOI 10.1007/s002850100120; Gomes MGM, 2002, P ROY SOC B-BIOL SCI, V269, P227, DOI 10.1098/rspb.2001.1869; Grenfell BT, 2001, NATURE, V414, P716, DOI 10.1038/414716a; Gupta S, 1998, SCIENCE, V280, P912, DOI 10.1126/science.280.5365.912; Hales S, 2002, LANCET, V360, P830, DOI 10.1016/S0140-6736(02)09964-6; Kamo M, 2002, PHYSICA D, V165, P228, DOI 10.1016/S0167-2789(02)00389-5; Keeling MJ, 2001, PHYSICA D, V148, P317, DOI 10.1016/S0167-2789(00)00187-1; Kurane I., 1991, REV MED VIROL, V1, P211; LINNERT L, 1954, STAT REPORT MEASLES; MCLEAN AR, 1988, EPIDEMIOL INFECT, V100, P111, DOI 10.1017/S0950268800065614; Miller E, 1997, DEV BIOLOGICALS, V89, P15; RAND DA, 1991, P ROY SOC B-BIOL SCI, V246, P179, DOI 10.1098/rspb.1991.0142; Rohani P, 1999, SCIENCE, V286, P968, DOI 10.1126/science.286.5441.968; Rohani P, 1998, P ROY SOC B-BIOL SCI, V265, P2033, DOI 10.1098/rspb.1998.0537; Schenzle D, 1984, IMA J Math Appl Med Biol, V1, P169; Soper HE, 1929, J R STAT SOC, V92, P34, DOI 10.2307/2341437; Torrence C, 1998, B AM METEOROL SOC, V79, P61, DOI 10.1175/1520-0477(1998)079<0061:APGTWA>2.0.CO;2; WENJIE W, 1997, DENGUE B, V21	30	132	136	3	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 24	2003	422	6934					885	888		10.1038/nature01542	http://dx.doi.org/10.1038/nature01542			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	670WR	12712203				2022-12-28	WOS:000182432600053
J	Al-Khatib, SM; LaPointe, NMA; Kramer, JM; Califf, RM				Al-Khatib, SM; LaPointe, NMA; Kramer, JM; Califf, RM			What clinicians should know about the QT interval	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEART-RATE CORRECTION; T-WAVE PATTERNS; DRUG-THERAPY; ANTIARRHYTHMIC THERAPY; ANTIPSYCHOTIC-DRUGS; ARRHYTHMIC EVENTS; DE-POINTES; LONG; RISK; TORSADE	Context Of the several factors implicated in causing QT interval prolongation and torsades de pointes, errors in the use of medications that may prolong this interval deserve special attention. Objective To systematically summarize the available clinical data on the QT interval and to offer improved recommendations for the use of QT-prolonging medications. Data Sources We searched MEDLINE from 1966 through 2002 for all English-language articles related to the QT interval. Additional data sources included bibliographies of articles identified on MEDLINE, a survey of experts, and data presented at a meeting of experts on long QT syndrome. Study Selection We selected for review registries and case series examining clinical outcomes of patients,with prolonged QT interval and the effect of different methods of measurement of the QT interval on patient outcomes. Ten studies were identified, of which 6 were included in the analysis. Data Extraction Data quality was determined by publication in the peer-reviewed literature. Data Synthesis Optimal measurement of the QT interval is problematic because of lack of standardization and lack of data regarding the best way to adjust for heart rate. Reliable information on the proper use of QT-prolonging medications is scarce. Although a QT interval of at least 500 milliseconds generally has been shown to correlate with a higher risk of torsades de pointes, there is no established threshold below which prolongation of the QT interval is considered free of proarrhythmic risk. The risk of torsades de pointes should be assessed in patients who are about to begin taking a QT-prolonging medication. Although inadequate clinical studies preclude prediction of absolute risk for individual patients, particularly high-risk situations can be defined based on clinical variables. We propose recommendations on proper monitoring of the QT interval in patients receiving QT-prolonging medications. Conclusion Although the use of QT-prolonging medications can predispose to torsades de pointes, there is a relative paucity of information that can help clinicians and patients make optimal informed decisions about how best to minimize the risk of this serious complication.	Duke Clin Res Inst, Duke Ctr Educ & Res Therapeut, Durham, NC 27715 USA	Duke University	Al-Khatib, SM (corresponding author), Duke Clin Res Inst, Duke Ctr Educ & Res Therapeut, POB 17969, Durham, NC 27715 USA.	alkha001@mc.duke.edu		, Nancy/0000-0002-6390-8337	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [U18HS010548] Funding Source: NIH RePORTER; AHRQ HHS [U18HS10548] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		AHNVE S, 1985, EUR HEART J, V6, P85, DOI 10.1093/eurheartj/6.suppl_D.85; Anderson ME, 2001, J PHARMACOL EXP THER, V296, P806; Anderson ME, 2002, AM HEART J, V144, P769, DOI 10.1067/mhj.2002.125804; Aytemir K, 1999, PACE, V22, P1397, DOI 10.1111/j.1540-8159.1999.tb00635.x; Bednar MM, 2001, PROG CARDIOVASC DIS, V43, P1, DOI 10.1053/pcad.2001.21469; Chiang CE, 2000, J AM COLL CARDIOL, V36, P1, DOI 10.1016/S0735-1097(00)00716-6; Chung MK, 1998, J AM COLL CARDIOL, V32, P169, DOI 10.1016/S0735-1097(98)00189-2; COPLEN SE, 1990, CIRCULATION, V82, P1106, DOI 10.1161/01.CIR.82.4.1106; Curtis LH, 2003, AM J MED, V114, P135, DOI 10.1016/S0002-9343(02)01455-9; Demolis JL, 1996, CIRCULATION, V94, P1592, DOI 10.1161/01.CIR.94.7.1592; Donger C, 1997, CIRCULATION, V96, P2778, DOI 10.1161/01.CIR.96.9.2778; FUNCKBRENTANO C, 1993, AM J CARDIOL, V72, pB17, DOI 10.1016/0002-9149(93)90035-B; Glassman AH, 2001, AM J PSYCHIAT, V158, P1774, DOI 10.1176/appi.ajp.158.11.1774; HANSTEN PD, 2002, HANSTEN HORNS DRUG I; Hennessy S, 2002, BRIT MED J, V325, P1070, DOI 10.1136/bmj.325.7372.1070; Hnatkova K, 1999, PACE, V22, P1683, DOI 10.1111/j.1540-8159.1999.tb00390.x; KAY GN, 1983, J AM COLL CARDIOL, V2, P806; Khan IA, 2002, AM J MED, V112, P58, DOI 10.1016/S0002-9343(01)01011-7; LaPointe NMA, 2002, J AM COLL CARDIOL, V39, p125A; Locati EH, 1998, CIRCULATION, V97, P2237, DOI 10.1161/01.CIR.97.22.2237; Maisel WH, 1997, ANN INTERN MED, V127, P281, DOI 10.7326/0003-4819-127-4-199708150-00004; MAKKAR RR, 1993, JAMA-J AM MED ASSOC, V270, P2590, DOI 10.1001/jama.270.21.2590; Malik M, 2001, J CARDIOVASC ELECTR, V12, P411, DOI 10.1046/j.1540-8167.2001.00411.x; MILNE JR, 1982, PACE, V5, P352, DOI 10.1111/j.1540-8159.1982.tb02242.x; Molnar J, 1996, J AM COLL CARDIOL, V27, P76, DOI 10.1016/0735-1097(95)00426-2; MORGANROTH J, 1991, AM J CARDIOL, V67, P774, DOI 10.1016/0002-9149(91)90541-R; MORGANROTH J, 1991, CIRCULATION, V84, P1977, DOI 10.1161/01.CIR.84.5.1977; Moss AJ, 2002, CIRCULATION, V105, P794, DOI 10.1161/hc0702.105124; MOSS AJ, 1991, CIRCULATION, V84, P1136, DOI 10.1161/01.CIR.84.3.1136; MOSS AJ, 1995, CIRCULATION, V92, P2929, DOI 10.1161/01.CIR.92.10.2929; Pacifico A, 1999, NEW ENGL J MED, V340, P1855, DOI 10.1056/NEJM199906173402402; *PFIZ INC, 2000, DOF PROD MON CONF ED; Priori SG, 1999, CIRCULATION, V99, P529, DOI 10.1161/01.CIR.99.4.529; Ray WA, 2001, ARCH GEN PSYCHIAT, V58, P1161, DOI 10.1001/archpsyc.58.12.1161; Reardon M, 1996, CLIN CARDIOL, V19, P949, DOI 10.1002/clc.4960191209; Rebeiz AG, 2001, CLIN CARDIOL, V24, P750, DOI 10.1002/clc.4960241111; Reilly JG, 2000, LANCET, V355, P1048, DOI 10.1016/S0140-6736(00)02035-3; RODEN DM, 1994, NEW ENGL J MED, V331, P785; Roden DM, 1998, AM J CARDIOL, V82, p49I, DOI 10.1016/S0002-9149(98)00472-X; SCHWARTZ PJ, 1995, CIRCULATION, V92, P3381, DOI 10.1161/01.CIR.92.12.3381; Schwartz PJ, 2001, CIRCULATION, V103, P89; Simons GR, 1997, AM J CARDIOL, V80, P1551, DOI 10.1016/S0002-9149(97)00773-X; Smalley W, 2000, JAMA-J AM MED ASSOC, V284, P3036, DOI 10.1001/jama.284.23.3036; TATRO DS, 2002, DRUG INTERACTION FAC; *THOMS CORP, THOMS CORP HEALTHC S, V114; Torp-Pedersen C, 1999, NEW ENGL J MED, V341, P857, DOI 10.1056/NEJM199909163411201; *US FDA, 2001, ICHS7A SAF PHARM STU; *US FDA, 2002, ICHS7B SAF PHARM STU; *US FDA, 2000, FDA TALK PAP JANSS P; Viskin S, 1999, LANCET, V354, P1625, DOI 10.1016/S0140-6736(99)02107-8; Waldo AL, 1996, LANCET, V348, P7, DOI 10.1016/S0140-6736(96)02149-6; Wilde AAM, 1999, J AM COLL CARDIOL, V33, P327, DOI 10.1016/S0735-1097(98)00578-6; Zareba W, 1998, NEW ENGL J MED, V339, P960, DOI 10.1056/NEJM199810013391404; Zhang L, 2000, CIRCULATION, V102, P2849; CLIN EVALUATION QT Q	55	426	441	0	15	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 23	2003	289	16					2120	2127		10.1001/jama.289.16.2120	http://dx.doi.org/10.1001/jama.289.16.2120			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	669WW	12709470	Bronze			2022-12-28	WOS:000182374300028
J	Siderowf, A; Stern, M				Siderowf, A; Stern, M			Update on Parkinson disease	ANNALS OF INTERNAL MEDICINE			English	Review							ALPHA-SYNUCLEIN GENE; UBIQUITIN-PROTEIN LIGASE; L-DOPA; SUBTHALAMIC NUCLEUS; BODY FORMATION; LEWY-BODY; FOLLOW-UP; ASSOCIATION; MUTATIONS; LEVODOPA	This Update reviews developments in the pathophysiology and treatment of Parkinson disease during the past several years. In the area of pathophysiology, studies have addressed the contribution of environmental factors such as caffeine and pesticides. Large-scale epidemiologic studies have also expanded the role genetic factors are thought to play, Detailed studies of kindreds with familial Parkinson disease due to a-synuclein and parkin have catalyzed basic science investigations into the pathologic mechanisms of the disease. These studies have led to the development of a pathophysiologic model of Parkinson disease that emphasizes abnormal protein aggregation. Studies of treatment have clarified the relative roles Of L-dopa and dopamine agonists in early Parkinson disease and shown the potential for surgical interventions, particularly deep-brain stimulation, to relieve the symptoms of advanced, medically refractory disease.	Univ Penn, Parkinsons Dis & Movement Disorders Ctr, Philadelphia, PA 19107 USA	University of Pennsylvania; Pennsylvania Medicine	Siderowf, A (corresponding author), Univ Penn, Parkinsons Dis & Movement Disorders Ctr, 330 S 9th St, Philadelphia, PA 19107 USA.	adsiderowf@pahosp.com			AHRQ HHS [K-08 HS00004] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [K08HS000004] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ALBIN RL, 1992, NEUROLOGY, V42, P733, DOI 10.1212/WNL.42.4.733; Arawaka S, 1998, NEUROLOGY, V51, P887, DOI 10.1212/WNL.51.3.887; Baron MS, 1996, ANN NEUROL, V40, P355, DOI 10.1002/ana.410400305; Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834; Bonifati V, 2003, SCIENCE, V299, P256, DOI 10.1126/science.1077209; Chung KKK, 2001, NAT MED, V7, P1144, DOI 10.1038/nm1001-1144; Ciechanover A, 2001, NAT MED, V7, P1108, DOI 10.1038/nm1001-1108; Clarke CE, 2002, LANCET, V360, P1767, DOI 10.1016/S0140-6736(02)11668-0; COTZIAS GC, 1969, NEW ENGL J MED, V280, P337, DOI 10.1056/NEJM196902132800701; Fahn S, 1996, NEUROLOGY, V47, pS184, DOI 10.1212/WNL.47.6_Suppl_3.184S; FAHN S, 1974, NEUROLOGY, V24, P431, DOI 10.1212/WNL.24.5.431; Farrer M, 1999, HUM MOL GENET, V8, P81, DOI 10.1093/hmg/8.1.81; Feany MB, 2000, NATURE, V404, P394, DOI 10.1038/35006074; Fine J, 2000, NEW ENGL J MED, V342, P1708, DOI 10.1056/NEJM200006083422304; Freed CR, 2001, NEW ENGL J MED, V344, P710, DOI 10.1056/NEJM200103083441002; Freeman TB, 1999, NEW ENGL J MED, V341, P988, DOI 10.1056/NEJM199909233411311; Gasser T, 1998, NAT GENET, V18, P262, DOI 10.1038/ng0398-262; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Kumar R, 1998, NEUROLOGY, V51, P850, DOI 10.1212/WNL.51.3.850; LANGSTON JW, 1983, SCIENCE, V219, P979, DOI 10.1126/science.6823561; Leroy E, 1998, NATURE, V395, P451, DOI 10.1038/26652; Limousin P, 1998, NEW ENGL J MED, V339, P1105, DOI 10.1056/NEJM199810153391603; Lucking CB, 2000, NEW ENGL J MED, V342, P1560, DOI 10.1056/NEJM200005253422103; Macklin R, 1999, NEW ENGL J MED, V341, P992, DOI 10.1056/NEJM199909233411312; Marek K, 2002, JAMA-J AM MED ASSOC, V287, P1653; MAROTEAUX L, 1988, J NEUROSCI, V8, P2804; MARSDEN CD, 1994, BRAIN, V117, P877, DOI 10.1093/brain/117.4.877; MARTTILA RJ, 1988, NEUROLOGY, V38, P1217, DOI 10.1212/WNL.38.8.1217; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; MONTASTRUC JL, 1994, J NEUROL NEUROSUR PS, V57, P1034, DOI 10.1136/jnnp.57.9.1034; MORENS DM, 1995, NEUROLOGY, V45, P1041, DOI 10.1212/WNL.45.6.1041; Obeso JA, 2001, NEW ENGL J MED, V345, P956, DOI 10.1056/nejmoa000827; Parkinson Study Group, 2000, JAMA, V284, P1931; Pearce RKB, 1998, MOVEMENT DISORD, V13, P234, DOI 10.1002/mds.870130207; Piccini P, 1999, ANN NEUROL, V45, P577, DOI 10.1002/1531-8249(199905)45:5<577::AID-ANA5>3.0.CO;2-O; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Rascol O, 2000, NEW ENGL J MED, V342, P1484, DOI 10.1056/NEJM200005183422004; Ross GW, 2000, JAMA-J AM MED ASSOC, V283, P2674, DOI 10.1001/jama.283.20.2674; Scott WK, 2001, JAMA-J AM MED ASSOC, V286, P2239, DOI 10.1001/jama.286.18.2239; Scott WK, 1999, NEUROGENETICS, V2, P191, DOI 10.1007/s100480050083; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Sveinbjornsdottir S, 2000, NEW ENGL J MED, V343, P1765, DOI 10.1056/NEJM200012143432404; Tan EK, 2000, NEUROLOGY, V55, P533, DOI 10.1212/WNL.55.4.533; Tanner CM, 1996, NEUROL CLIN, V14, P317, DOI 10.1016/S0733-8619(05)70259-0; Tanner CM, 1999, JAMA-J AM MED ASSOC, V281, P341, DOI 10.1001/jama.281.4.341; Vaughan JR, 1998, HUM MOL GENET, V7, P751, DOI 10.1093/hmg/7.4.751; VIEREGGE P, 1992, NEUROLOGY, V42, P1453, DOI 10.1212/WNL.42.8.1453; WARD CD, 1983, NEUROLOGY, V33, P815, DOI 10.1212/WNL.33.7.815; Whone AL, 2002, NEUROLOGY, V58, pA82; Zhang Y, 2000, P NATL ACAD SCI USA, V97, P13354, DOI 10.1073/pnas.240347797; Zhang Y, 2000, NEUROBIOL DIS, V7, P240, DOI 10.1006/nbdi.2000.0319	52	105	115	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	2003	138	8					651	658		10.7326/0003-4819-138-8-200304150-00013	http://dx.doi.org/10.7326/0003-4819-138-8-200304150-00013			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	666JH	12693888				2022-12-28	WOS:000182173800008
J	Celesia, GG				Celesia, GG			Are the epilepsies disorders of ion channels?	LANCET			English	Editorial Material							GAMMA-2-SUBUNIT; SEIZURES; GENE		Loyola Univ, Stritch Sch Med, Dept Neurol, Maywood, IL 60153 USA	Loyola University Chicago	Celesia, GG (corresponding author), Loyola Univ, Stritch Sch Med, Dept Neurol, Maywood, IL 60153 USA.							Ashcroft F. M., 1999, ION CHANNELS DIS CHA; Baulac S, 2001, NAT GENET, V28, P46, DOI 10.1038/88254; BERKOVIC SF, 1908, CHANNELOPATHIES NERV; Celesia GG, 2001, CLIN NEUROPHYSIOL, V112, P2, DOI 10.1016/S1388-2457(00)00496-X; Escayg A, 2000, AM J HUM GENET, V66, P1531, DOI 10.1086/302909; Fujiwara T, 2003, BRAIN, V126, P531, DOI 10.1093/brain/awg053; Heron SE, 2002, LANCET, V360, P851, DOI 10.1016/S0140-6736(02)09968-3; Jackson J.H., 1870, ST ANDREWS MEDICAL G, P162; Lehmann-Horn F, 1999, PHYSIOL REV, V79, P1317, DOI 10.1152/physrev.1999.79.4.1317; Wallace RH, 2001, NAT GENET, V28, P49, DOI 10.1038/ng0501-49	10	4	6	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 12	2003	361	9365					1238	1239		10.1016/S0140-6736(03)13028-0	http://dx.doi.org/10.1016/S0140-6736(03)13028-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	666DM	12699947				2022-12-28	WOS:000182161600004
J	Malmstrom, PU				Malmstrom, PU			Time to abandon testing for microscopic haematuria in adults?	BRITISH MEDICAL JOURNAL			English	Article							BLADDER-CANCER; ASYMPTOMATIC MICROHEMATURIA; FLANK PAIN; HEMATURIA; MEN		Univ Uppsala Hosp, Dept Urol, SE-75185 Uppsala, Sweden	Uppsala University; Uppsala University Hospital	Malmstrom, PU (corresponding author), Univ Uppsala Hosp, Dept Urol, SE-75185 Uppsala, Sweden.							Bove P, 1999, J UROLOGY, V162, P685, DOI 10.1097/00005392-199909010-00013; BRITTON JP, 1989, BRIT MED J, V299, P1010, DOI 10.1136/bmj.299.6706.1010; CHOI BCK, 1990, J SOC OCCUP MED, V40, P47; Chong T. W., 1999, SMJ, V40, P578; Del Mar C, 2000, BRIT MED J, V320, P165, DOI 10.1136/bmj.320.7228.165; ElDin KE, 1996, EUR UROL, V30, P409; FRACCHIA JA, 1995, UROLOGY, V46, P484, DOI 10.1016/S0090-4295(99)80259-3; Grossfeld GD, 2001, AM FAM PHYSICIAN, V63, P1145; Hemstreet GP, 2001, JNCI-J NATL CANCER I, V93, P427, DOI 10.1093/jnci/93.6.427; HIATT RA, 1994, CANCER EPIDEM BIOMAR, V3, P439; Hock LM, 2002, J UROLOGY, V167, P57, DOI 10.1016/S0022-5347(05)65382-7; JimenezCruz JF, 1997, UROLOGY, V50, P529, DOI 10.1016/S0090-4295(97)00303-8; Johnston B, 1997, J UROLOGY, V158, P2098, DOI 10.1016/S0022-5347(01)68166-7; Kohler C, 1999, Lakartidningen, V96, P4911; MANSSON A, 1993, SCAND J UROL NEPHROL, V27, P363, DOI 10.3109/00365599309180448; McGregor DO, 1998, CLIN NEPHROL, V49, P345; MESSING EM, 1995, UROLOGY, V45, P387, DOI 10.1016/S0090-4295(99)80006-5; MESSING EM, 1995, J UROLOGY, V154, P57, DOI 10.1016/S0022-5347(01)67224-0; Mihara S, 1999, ULTRASOUND MED BIOL, V25, P1033, DOI 10.1016/S0301-5629(99)00070-8; MOHR DN, 1987, J GEN INTERN MED, V2, P318, DOI 10.1007/BF02596166; MULDERS PFA, 1994, BRIT J UROL, V73, P403, DOI 10.1111/j.1464-410X.1994.tb07604.x; MURAKAMI S, 1990, J UROLOGY, V144, P99, DOI 10.1016/S0022-5347(17)39379-5; PRESS SM, 1995, UROLOGY, V45, P753, DOI 10.1016/S0090-4295(99)80078-8; Ramakumar S, 1999, J UROLOGY, V161, P388, DOI 10.1016/S0022-5347(01)61899-8; SANDLER G, 1979, BRIT MED J, V2, P21, DOI 10.1136/bmj.2.6181.21; Schmetter BS, 1997, J UROLOGY, V158, P801, DOI 10.1016/S0022-5347(01)64321-0; Sultana SR, 1996, BRIT J UROL, V78, P691, DOI 10.1046/j.1464-410X.1996.01975.x; TSUKAMOTO T, 1991, European Urology, V19, P109	28	35	35	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 12	2003	326	7393					813	815		10.1136/bmj.326.7393.813	http://dx.doi.org/10.1136/bmj.326.7393.813			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	670BE	12689982	Green Published			2022-12-28	WOS:000182386700030
J	Simerly, C; Dominko, T; Navara, C; Payne, C; Capuano, S; Gosman, G; Chong, KY; Takahashi, D; Chace, C; Compton, D; Hewitson, L; Schatten, G				Simerly, C; Dominko, T; Navara, C; Payne, C; Capuano, S; Gosman, G; Chong, KY; Takahashi, D; Chace, C; Compton, D; Hewitson, L; Schatten, G			Molecular correlates of primate nuclear transfer failures	SCIENCE			English	Article							RHESUS-MONKEYS; FERTILIZATION; SPINDLE; EG5		Univ Pittsburgh, Sch Med, Dept Obstet Gynecol Reprod Sci, Magee Womens Res Inst,Pittsburgh Dev Ctr, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Cell Biol Physiol, Pittsburgh, PA 15213 USA; Dartmouth Coll, Sch Med, Dept Biochem, Hanover, NH 03755 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Dartmouth College	Schatten, G (corresponding author), Univ Pittsburgh, Sch Med, Dept Obstet Gynecol Reprod Sci, Magee Womens Res Inst,Pittsburgh Dev Ctr, Pittsburgh, PA 15213 USA.		Schatten, Gerald/B-3253-2009; simerly, Calvin/AAC-9564-2021; Navara, Christopher/C-2813-2011	Schatten, Gerald/0000-0001-5206-7782; Compton, Duane/0000-0002-4445-9118				Blangy A, 1995, CELL, V83, P1159, DOI 10.1016/0092-8674(95)90142-6; Dominko T, 1999, Cloning, V1, P143, DOI 10.1089/15204559950019906; Hewitson L, 1999, NAT MED, V5, P431, DOI 10.1038/7430; Meng L, 1997, BIOL REPROD, V57, P454, DOI 10.1095/biolreprod57.2.454; Mitalipov SM, 2002, BIOL REPROD, V66, P1367, DOI 10.1095/biolreprod66.5.1367; Mountain V, 1999, J CELL BIOL, V147, P351, DOI 10.1083/jcb.147.2.351; NAVARA CS, 1994, DEV BIOL, V162, P29, DOI 10.1006/dbio.1994.1064; SCHATTEN G, 1994, DEV BIOL, V165, P299, DOI 10.1006/dbio.1994.1256; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Wilmut I, 2002, NAT MED, V8, P215, DOI 10.1038/nm0302-215	10	187	216	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 11	2003	300	5617					297	297		10.1126/science.1082091	http://dx.doi.org/10.1126/science.1082091			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	665RQ	12690191				2022-12-28	WOS:000182135400047
J	Dalsgaard, T; Canfield, DE; Petersen, J; Thamdrup, B; Acuna-Gonzalez, J				Dalsgaard, T; Canfield, DE; Petersen, J; Thamdrup, B; Acuna-Gonzalez, J			N-2 production by the anammox reaction in the anoxic water column of Golfo Dulce, Costa Rica	NATURE			English	Article							ANAEROBIC AMMONIUM OXIDATION; OXYGEN-DEFICIENT CONDITIONS; SOUTH-PACIFIC OCEAN; MARINE-SEDIMENTS; NITRATE REDUCTION; ARABIAN SEA; DENITRIFICATION; NITROGEN; NITRIFICATION; MANGANESE	In oxygen-depleted zones of the open ocean, and in anoxic basins and fjords, denitrification (the bacterial reduction of nitrate to give N-2) is recognized as the only significant process converting fixed nitrogen to gaseous N-2. Primary production in the oceans is often limited by the availability of fixed nitrogen such as ammonium or nitrate(1), and nitrogen-removal processes consequently affect both ecosystem function and global biogeochemical cycles. It was recently discovered that the anaerobic oxidation of ammonium with nitrite-the 'anammox' reaction, performed by bacteria-was responsible for a significant fraction of N-2 production in some marine sediments(2). Here we show that this reaction is also important in the anoxic waters of Golfo Dulce, a 200-m-deep coastal bay in Costa Rica, where it accounts for 19-35% of the total N-2 formation in the water column. The water-column chemistry in Golfo Dulce is very similar to that in oxygen-depleted zones of the oceans-in which one-half to one-third of the global nitrogen removal is believed to occur(3,4). We therefore expect the anammox reaction to be a globally significant sink for oceanic nitrogen.	Natl Environm Res Inst, Dept Marine Ecol, DK-8600 Silkeborg, Denmark; Univ So Denmark, Inst Biol, Danish Ctr Earth Syst Sci, DK-5230 Odense M, Denmark; Univ Costa Rica, Ctr Invest Ciencias Mar & Limnol, CIMAR, San Jose, Costa Rica	Aarhus University; University of Southern Denmark; Universidad Costa Rica	Dalsgaard, T (corresponding author), Natl Environm Res Inst, Dept Marine Ecol, Vejlsovej 25,POB 314, DK-8600 Silkeborg, Denmark.		Thamdrup, Bo/F-3889-2016; Dalsgaard, Tage/B-5428-2008; Dalsgaard, Tage/J-6258-2014; Canfield, Don/C-1735-2012	Thamdrup, Bo/0000-0002-1221-7077; Dalsgaard, Tage/0000-0003-2604-6499; Dalsgaard, Tage/0000-0003-2604-6499; Canfield, Don/0000-0001-7602-8366				Bange HW, 2000, GLOBAL BIOGEOCHEM CY, V14, P1283, DOI 10.1029/1999GB001228; BRAMAN RS, 1989, ANAL CHEM, V61, P2715, DOI 10.1021/ac00199a007; CLINE JD, 1972, LIMNOL OCEANOGR, V17, P885, DOI 10.4319/lo.1972.17.6.0885; Codispoti LA, 2001, SCI MAR, V65, P85, DOI 10.3989/scimar.2001.65s285; CODISPOTI LA, 1985, MAR CHEM, V16, P277, DOI 10.1016/0304-4203(85)90051-9; Dalsgaard T, 2002, APPL ENVIRON MICROB, V68, P3802, DOI 10.1128/AEM.68.8.3802-3808.2002; Deutsch C, 2001, GLOBAL BIOGEOCHEM CY, V15, P483, DOI 10.1029/2000GB001291; Falkowski PG, 1998, SCIENCE, V281, P200, DOI 10.1126/science.281.5374.200; Gruber N, 1997, GLOBAL BIOGEOCHEM CY, V11, P235, DOI 10.1029/97GB00077; HALL PO, 1992, LIMNOL OCEANOGR, V37, P1113, DOI 10.4319/lo.1992.37.5.1113; Hansen H., 1983, METHODS SEAWATER ANA, P347; Hulth S, 1999, GEOCHIM COSMOCHIM AC, V63, P49, DOI 10.1016/S0016-7037(98)00285-3; KNOWLES R, 1982, MICROBIOL REV, V46, P43, DOI 10.1128/MMBR.46.1.43-70.1982; LIPSCHULTZ F, 1990, DEEP-SEA RES, V37, P1513, DOI 10.1016/0198-0149(90)90060-9; Luther GW, 1997, GEOCHIM COSMOCHIM AC, V61, P4043, DOI 10.1016/S0016-7037(97)00239-1; MURRAY JW, 1999, ENV DEGRADATION BLAC, P75; NAQVI SWA, 1987, J MAR RES, V45, P1049, DOI 10.1357/002224087788327118; NIELSEN LP, 1992, FEMS MICROBIOL ECOL, V86, P357, DOI 10.1016/0378-1097(92)90800-4; Otte S, 1999, APPL ENVIRON MICROB, V65, P3148; Richards F. A., 1965, CHEM OCEANOGR, V1, P611; RICHARDS FA, 1965, ADV WATER POLLUTION, P215; Thamdrup B, 2002, APPL ENVIRON MICROB, V68, P1312, DOI 10.1128/AEM.68.3.1312-1318.2002; Thamdrup B, 1996, REV BIOL TROP, V44, P19; Van Mooy BAS, 2002, GEOCHIM COSMOCHIM AC, V66, P457, DOI 10.1016/S0016-7037(01)00787-6; VANDEGRAAF AA, 1995, APPL ENVIRON MICROB, V61, P1246, DOI 10.1128/AEM.61.4.1246-1251.1995; Vargas JA, 1996, REV BIOL TROP, V44, pU1	26	503	590	6	372	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 10	2003	422	6932					606	608		10.1038/nature01526	http://dx.doi.org/10.1038/nature01526			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	665GN	12686998				2022-12-28	WOS:000182111400039
J	Gutknecht, DR				Gutknecht, DR			Hematoma of the rectus sheath	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Geisinger Med Ctr, Danville, PA 17822 USA	Geisinger Medical Center	Gutknecht, DR (corresponding author), Geisinger Med Ctr, Danville, PA 17822 USA.								0	3	3	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 10	2003	348	15					1455	1455		10.1056/NEJMicm010150	http://dx.doi.org/10.1056/NEJMicm010150			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	665CU	12686702				2022-12-28	WOS:000182102700006
J	Phillips, PEM; Stuber, GD; Heien, MLAV; Wightman, RM; Carelli, RM				Phillips, PEM; Stuber, GD; Heien, MLAV; Wightman, RM; Carelli, RM			Subsecond dopamine release promotes cocaine seeking	NATURE			English	Article							VENTRAL TEGMENTAL AREA; NUCLEUS-ACCUMBENS; EXTRACELLULAR DOPAMINE; DRUG-ADDICTION; NEURONS; REWARD; RATS; ACTIVATION; NEUROBIOLOGY; INTEGRATION	The dopamine-containing projection from the ventral tegmental area of the midbrain to the nucleus accumbens is critically involved in mediating the reinforcing properties of cocaine(1,2). Although neurons in this area respond to rewards on a subsecond timescale(3,4), neurochemical studies have only addressed the role of dopamine in drug addiction by examining changes in the tonic (minute-to-minute) levels of extracellular dopamine(5-9). To investigate the role of phasic (subsecond) dopamine signalling(10), we measured dopamine every 100 ms in the nucleus accumbens using electrochemical technology(11). Rapid changes in extracellular dopamine concentration were observed at key aspects of drug-taking behaviour in rats. Before lever presses for cocaine, there was an increase in dopamine that coincided with the initiation of drug-seeking behaviours. Notably, these behaviours could be reproduced by electrically evoking dopamine release on this timescale. After lever presses, there were further increases in dopamine concentration at the concurrent presentation of cocaine-related cues. These cues alone also elicited similar, rapid dopamine signalling, but only in animals where they had previously been paired to cocaine delivery. These findings reveal an unprecedented role for dopamine in the regulation of drug taking in real time.	Univ N Carolina, Dept Psychol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Chem, Chapel Hill, NC 27599 USA; Univ N Carolina, Ctr Neurosci, Chapel Hill, NC 27599 USA; Univ N Carolina, Curriculum Neurobiol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Carelli, RM (corresponding author), Univ N Carolina, Dept Psychol, Chapel Hill, NC 27599 USA.	rcarelli@unc.edu	Phillips, Paul/E-7813-2013; Phillips, Paul E. M./A-4463-2008; Stuber, Garret/E-1160-2011; Heien, Michael/A-4731-2009	Phillips, Paul/0000-0002-8749-7026; Phillips, Paul E. M./0000-0002-8749-7026; Heien, Michael/0000-0001-5164-9596; Stuber, Garret/0000-0003-1730-4855	NINDS NIH HHS [T32 NS007431] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [T32NS007431] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bradberry CW, 2000, J NEUROSCI, V20, P3874, DOI 10.1523/JNEUROSCI.20-10-03874.2000; Breiter HC, 1997, NEURON, V19, P591, DOI 10.1016/S0896-6273(00)80374-8; Carelli Regina M, 2002, Behav Cogn Neurosci Rev, V1, P281, DOI 10.1177/1534582302238338; Carelli RM, 2000, SYNAPSE, V35, P238, DOI 10.1002/(SICI)1098-2396(20000301)35:3<238::AID-SYN10>3.0.CO;2-Y; Carelli RM, 2000, J NEUROSCI, V20, P4255; CARELLI RM, 1993, BRAIN RES, V626, P14, DOI 10.1016/0006-8993(93)90557-4; Childress AR, 1999, AM J PSYCHIAT, V156, P11, DOI 10.1176/ajp.156.1.11; Di Chiara G, 1999, EUR J PHARMACOL, V375, P13, DOI 10.1016/S0014-2999(99)00372-6; EINHORN LC, 1988, J NEUROSCI, V8, P100; Garris PA, 1997, J NEUROCHEM, V68, P152; GRACE AA, 1991, NEUROSCIENCE, V41, P1, DOI 10.1016/0306-4522(91)90196-U; Hyland BI, 2002, NEUROSCIENCE, V114, P475, DOI 10.1016/S0306-4522(02)00267-1; Ito R, 2000, J NEUROSCI, V20, P7489; Kiyatkin EA, 1996, J NEUROPHYSIOL, V75, P142, DOI 10.1152/jn.1996.75.1.142; Koob GF, 1997, J NEUROPSYCH CLIN N, V9, P482; LACEY MG, 1990, BRIT J PHARMACOL, V99, P731, DOI 10.1111/j.1476-5381.1990.tb12998.x; MARSDEN CA, 1988, NEUROSCIENCE, V25, P389, DOI 10.1016/0306-4522(88)90247-3; MILLAR J, 1985, EUR J PHARMACOL, V109, P341, DOI 10.1016/0014-2999(85)90394-2; MOGENSON GJ, 1987, PROG PSYCHOB PHYSIOL, V12, P117; PENNARTZ CMA, 1994, PROG NEUROBIOL, V42, P719, DOI 10.1016/0301-0082(94)90025-6; PETTIT HO, 1989, PHARMACOL BIOCHEM BE, V34, P899, DOI 10.1016/0091-3057(89)90291-8; Schultz W, 1997, SCIENCE, V275, P1593, DOI 10.1126/science.275.5306.1593; Schultz W, 1998, J NEUROPHYSIOL, V80, P1, DOI 10.1152/jn.1998.80.1.1; SESACK SR, 1992, J COMP NEUROL, V320, P145, DOI 10.1002/cne.903200202; SESACK SR, 1990, BRAIN RES, V527, P266, DOI 10.1016/0006-8993(90)91146-8; Stamford JA, 1996, ANAL CHEM, V68, pA359, DOI 10.1021/ac961943a; Wightman RM, 2002, J NEUROCHEM, V82, P721, DOI 10.1046/j.1471-4159.2002.01005.x; Wise RA, 1996, CURR OPIN NEUROBIOL, V6, P243, DOI 10.1016/S0959-4388(96)80079-1; WISE RA, 1995, PSYCHOPHARMACOLOGY, V120, P10, DOI 10.1007/BF02246140; Wise RA, 1998, DRUG ALCOHOL DEPEN, V51, P13, DOI 10.1016/S0376-8716(98)00063-5	30	814	823	1	65	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 10	2003	422	6932					614	618		10.1038/nature01566	http://dx.doi.org/10.1038/nature01566			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	665GN	12687000				2022-12-28	WOS:000182111400042
J	Schwimmer, JB; Burwinkle, TM; Varni, JW				Schwimmer, JB; Burwinkle, TM; Varni, JW			Health-related quality of life of severely obese children and adolescents	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GENERIC CORE SCALES; BODY-MASS INDEX; PERCEIVED PHYSICAL APPEARANCE; SCHOOL PERFORMANCE; SOCIAL-ADJUSTMENT; PEDSQL(TM); VALIDITY; RELIABILITY; OVERWEIGHT; RESPONSIVENESS	Context One in 7 US children and adolescents is obese, yet little is known about their health-related quality of life (QOL). Objective To examine the health-related QOL of obese children and adolescents compared with children and adolescents who are healthy or those diagnosed as having cancer. Design, Setting, and Participants Cross-sectional study of 106 children and adolescents (57 males) between the ages of 5 and 18 years (mean [SD], 12.1 [3] years), who had been referred to an academic children's hospital for evaluation of obesity between January and June 2002. Children and adolescents had a mean (SD) body mass index (BMI) of 34.7 (9.3) and BMI z score of 2.6 (0.5). Main Outcome Measures Child self-report and parent proxy report using a pediatric QOL inventory generic core scale (range, 0-100). The inventory was administered by an interviewer for children aged 5 through 7 years. Scores were compared with previously published scores for healthy children and adolescents and children and adolescents diagnosed as having cancer. Results Compared with healthy children and adolescents, obese children and adolescents reported significantly (P<.001) lower health-related QOL in all domains (mean [SD] total score, 67 [16.3] for obese children and adolescents; 83 [14.8] for healthy children and adolescents). Obese children and adolescents were more likely to have impaired health-related QOL than healthy children and adolescents (odds ratio [OR], 5.5; 95% confidence interval [CI], 3.4-8.7) and were similar to children and adolescents diagnosed As having cancer (OR, 1.3; 95% CI, 0.8-2.3). Children and adolescents with obstructive sleep apnea reported a significantly lower health-related QOL total score (mean [SD], 53.8 [13.3]) than obese children and adolescents without obstructive sleep apnea (mean [SD], 67.9 [16.2]). For parent proxy report, the child or adolescent's. BMI z score was significantly inversely correlated with total score (r=-0.246; P=.01), physical functioning (r=-0.263; P<.01), social functioning (r=-0.347; P<001), and psychosocial functioning (r=-0.209; P=.03). Conclusions Severely obese children and adolescents have lower health-related QOL than children and adolescents who are healthy and similar QOL as those diagnosed as having cancer. Physicians, parents, and teachers need to be informed of the risk for impaired health-related QOL among obese children and adolescents to target interventions that could enhance health outcomes.	Univ Calif San Diego, Sch Med, Div Pediat Gastroenterol Hepatol & Nutr, San Diego, CA 92103 USA; Childrens Hosp & Hlth Ctr, Ctr Child Hlth Outcomes, San Diego, CA USA; Texas A&M Univ, Dept Architecture, College Stn, TX USA; Texas A&M Univ, Dept Med, College Stn, TX USA	University of California System; University of California San Diego; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station	Schwimmer, JB (corresponding author), Univ Calif San Diego, Sch Med, Div Pediat Gastroenterol Hepatol & Nutr, 200 W Arbor Dr, San Diego, CA 92103 USA.	jschwimmer@ucsd.edu	Fahimifar, Sepideh/M-5303-2019	Schwimmer, Jeffrey/0000-0001-8538-2877	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000827] Funding Source: NIH RePORTER	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BANIS HT, 1988, CHILD CARE HLTH DEV, V14, P157, DOI 10.1111/j.1365-2214.1988.tb00572.x; Barlow SE, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.3.e29; Birmaher B, 1996, J AM ACAD CHILD PSY, V35, P1427, DOI 10.1097/00004583-199611000-00011; *CDC, OV CHILDR AD 6 19 YE; Cohen J., 2013, STAT POWER ANAL BEHA, DOI DOI 10.4324/9780203771587; Diette GB, 2000, ARCH PEDIAT ADOL MED, V154, P923, DOI 10.1001/archpedi.154.9.923; Dietz WH, 1998, PEDIATRICS, V101, P518; Dietz WH, 1999, AM J CLIN NUTR, V70, p123S; Dietz WH, 1998, J PEDIATR-US, V132, P191; Doll HA, 2000, OBES RES, V8, P160, DOI 10.1038/oby.2000.17; EISER C, 2001, QUALITY LIFE CHILD A, P267; Epstein LH, 2000, OBES RES, V8, P575, DOI 10.1038/oby.2000.74; Fontaine KR, 1996, J FAM PRACTICE, V43, P265; Goodman E, 2002, PEDIATRICS, V110, P497, DOI 10.1542/peds.110.3.497; GORTMAKER SL, 1993, NEW ENGL J MED, V329, P1008, DOI 10.1056/NEJM199309303291406; Hollingshead A., 1975, 4 FACTOR INDEX SOCIA; Janicke DM, 2001, MED CARE, V39, P990, DOI 10.1097/00005650-200109000-00009; Jonides L, 2002, PEDIATRICS, V110, P215; KOLOTKIN RL, 1995, OBES RES, V3, P49, DOI 10.1002/j.1550-8528.1995.tb00120.x; Kolotkin RL, 2002, OBES RES, V10, P748, DOI 10.1038/oby.2002.102; MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006; MCHORNEY CA, 1992, MED CARE, V30, pMS253, DOI 10.1097/00005650-199205001-00025; Mo-Suwan L, 1999, INT J OBESITY, V23, P272, DOI 10.1038/sj.ijo.0800808; *NAT HEART LUNG BL, MORB MORT CHARTB; Nunnally J.C., 1978, PSYCHOMETRIC THEORY, DOI DOI 10.1037/018882; Ogden CL, 2002, JAMA-J AM MED ASSOC, V288, P1728, DOI 10.1001/jama.288.14.1728; Pedhazur EJ, 1991, MEASUREMENT DESIGN A; Ravens-Sieberer U, 2001, INT J OBESITY, V25, pS63, DOI 10.1038/sj.ijo.0801702; SPIRITO A, 1991, CLIN PSYCHOL REV, V11, P539, DOI 10.1016/0272-7358(91)90003-D; SPSS, 1998, SPSS VERS 8 0 WIND; Story MT, 2002, PEDIATRICS, V110, P210; SULLIVAN M, 1993, INT J OBESITY, V17, P503; UZARK K, IN PRESS PROGR PEDIA; VARNI JW, 1994, J DEV BEHAV PEDIATR, V15, P20, DOI 10.1097/00004703-199402000-00004; Varni JW, 2002, ARTHRITIS RHEUM-US, V46, P714, DOI 10.1002/art.10095; Varni JW, 2001, MED CARE, V39, P800, DOI 10.1097/00005650-200108000-00006; Varni JW, 1999, MED CARE, V37, P126, DOI 10.1097/00005650-199902000-00003; Varni JW, 2002, CANCER-AM CANCER SOC, V94, P2090, DOI 10.1002/cncr.10428; Varni JW, 2003, DIABETES CARE, V26, P631, DOI 10.2337/diacare.26.3.631; VARNI JW, 1995, J BEHAV MED, V18, P261, DOI 10.1007/BF01857873; Varni JW, 2002, J BEHAV MED, V25, P175, DOI 10.1023/A:1014836921812; VARNI JW, 1989, J DEV BEHAV PEDIATR, V10, P13; Varni JW, 1996, J CLIN CHILD PSYCHOL, V25, P201, DOI 10.1207/s15374424jccp2502_9; VARNI JW, 1992, AM J DIS CHILD, V146, P103, DOI 10.1001/archpedi.1992.02160130105030; Veale D, 2002, QUAL LIFE RES, V11, P389, DOI 10.1023/A:1015599326110; Vetiska J, 2000, DIABETES CARE, V23, P1706, DOI 10.2337/diacare.23.11.1706	46	1061	1078	2	73	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 9	2003	289	14					1813	1819		10.1001/jama.289.14.1813	http://dx.doi.org/10.1001/jama.289.14.1813			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	664ZJ	12684360	Bronze			2022-12-28	WOS:000182094900027
J	Clinton, WJ				Clinton, WJ			Turning the tide on the AIDS pandemic	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									William J Clinton Presidential Fdn, New York, NY USA		Clinton, WJ (corresponding author), William J Clinton Presidential Fdn, New York, NY USA.								0	31	32	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 1	2003	348	18					1800	1802		10.1056/NEJMsb023052	http://dx.doi.org/10.1056/NEJMsb023052			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	672VK	12724487				2022-12-28	WOS:000182543500010
J	Check, E				Check, E			National Academies launch grants for interdisciplinary work	NATURE			English	News Item																			0	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 24	2003	422	6934					791	791		10.1038/422791b	http://dx.doi.org/10.1038/422791b			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	670WR	12712156	Bronze			2022-12-28	WOS:000182432600007
J	Davis, ME				Davis, ME			Distinguishing the (almost) indistinguishable	SCIENCE			English	Editorial Material							ZEOLITE; MEMBRANES		CALTECH, Pasadena, CA 91125 USA	California Institute of Technology	Davis, ME (corresponding author), CALTECH, Pasadena, CA 91125 USA.							ALBERS EW, 1973, Patent No. 3730910; Beck LW, 1998, MICROPOR MESOPOR MAT, V22, P107, DOI 10.1016/S1387-1811(98)00096-1; DAVIS ME, 1991, IND ENG CHEM RES, V30, P1675, DOI 10.1021/ie00056a001; Davis ME, 2002, NATURE, V417, P813, DOI 10.1038/nature00785; GAVALAS G, IN PRESS MAT SCI MEM; Ha K, 2000, ADV MATER, V12, P1114, DOI 10.1002/1521-4095(200008)12:15<1114::AID-ADMA1114>3.0.CO;2-5; Lai ZP, 2003, SCIENCE, V300, P456, DOI 10.1126/science.1082169; Lewis JE, 1997, AICHE J, V43, P83, DOI 10.1002/aic.690430111; Lin YS, 2002, SEPAR PURIF METHOD, V31, P229, DOI 10.1081/SPM-120017009; Lu YF, 1997, NATURE, V389, P364, DOI 10.1038/38699; Okubo T, 2001, ANGEW CHEM INT EDIT, V40, P1069, DOI 10.1002/1521-3773(20010316)40:6<1069::AID-ANIE10690>3.0.CO;2-W; Tavolaro A, 1999, ADV MATER, V11, P975, DOI 10.1002/(SICI)1521-4095(199908)11:12<975::AID-ADMA975>3.0.CO;2-0; Yan YS, 1997, J MEMBRANE SCI, V123, P95, DOI 10.1016/S0376-7388(96)00206-2	13	29	29	2	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 18	2003	300	5618					438	439		10.1126/science.1083470	http://dx.doi.org/10.1126/science.1083470			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	668LR	12702861				2022-12-28	WOS:000182295900022
J	Sordella, R; Jiang, W; Chen, GC; Curto, M; Settleman, J				Sordella, R; Jiang, W; Chen, GC; Curto, M; Settleman, J			Modulation of rho GTPase signaling regulates a switch between adipogenesis and myogenesis	CELL			English	Article							INSULIN-RECEPTOR SUBSTRATE-1; AXON OUTGROWTH; P190 RHOGAP; DIFFERENTIATION; SHP-2; CELL; EXPRESSION; FAMILY; ACTIN; GENE	Mature adipocytes and myocytes are derived from a common mesenchymal precursor. While IGF-1 promotes the differentiation of both cell types, the signaling pathways that specify the distinct cell fates are largely unknown. Here, we show that the Rho GTPase and its regulator, p190-B RhoGAP, are components of a critical switch in the adipogenesis-myogenesis "decision." Cells derived from embryos lacking p190-B RhoGAP exhibit excessive Rho activity, are defective for adipogenesis, but undergo myogenesis in response to IGF-1 exposure. In vitro, activation of Rhokinase by Rho inhibits adipogenesis and is required for myogenesis. The activation state of Rho following IGF-1 signaling is determined by the tyrosine-phosphorylation status of p190-B RhoGAP and its resulting subcellular relocalization. Moreover, adjusting Rho activity is sufficient to alter the differentiation program of adipocyte and myocyte precursors. Together, these results identify the Rho GTPase as an essential modulator of IGF-1 signals that direct the adipogenesis-myogenesis cell fate decision.	Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA; Harvard Med Sch, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital	Settleman, J (corresponding author), Massachusetts Gen Hosp, Ctr Canc, 149 13th St, Charlestown, MA 02129 USA.		Chen, Guang-Chao/P-1262-2019	Chen, Guang-Chao/0000-0002-4980-4718	NCI NIH HHS [CA69498] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allen M, 2002, J MOL BIOL, V323, P411, DOI 10.1016/S0022-2836(02)00968-3; BAINS W, 1984, MOL CELL BIOL, V4, P1449, DOI 10.1128/MCB.4.8.1449; Begum N, 2002, J BIOL CHEM, V277, P6214, DOI 10.1074/jbc.M110508200; Bickel PE, 2002, AM J PHYSIOL-ENDOC M, V282, pE1, DOI 10.1152/ajpendo.2002.282.1.E1; Brouns MR, 2000, DEVELOPMENT, V127, P4891; Brouns MR, 2001, NAT CELL BIOL, V3, P361, DOI 10.1038/35070042; Burbelo PD, 1998, BBA-GENE STRUCT EXPR, V1443, P203, DOI 10.1016/S0167-4781(98)00207-3; Carnac G, 1998, MOL BIOL CELL, V9, P1891, DOI 10.1091/mbc.9.7.1891; Charrasse S, 2002, J CELL BIOL, V158, P953, DOI 10.1083/jcb.200202034; Fujisawa K, 1998, J BIOL CHEM, V273, P18943, DOI 10.1074/jbc.273.30.18943; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Henning SW, 1997, EMBO J, V16, P2397, DOI 10.1093/emboj/16.9.2397; Kontaridis MI, 2001, J CELL SCI, V114, P2187; Lacalle RA, 2002, J CELL BIOL, V157, P277, DOI 10.1083/jcb.200109031; Luo LQ, 1996, PERSPECT DEV NEUROBI, V4, P199; Maegawa H, 1999, J BIOL CHEM, V274, P30236, DOI 10.1074/jbc.274.42.30236; Marinissen MT, 2001, GENE DEV, V15, P535, DOI 10.1101/gad.855801; Miki H, 2001, MOL CELL BIOL, V21, P2521, DOI 10.1128/MCB.21.7.2521-2532.2001; O'Brien SP, 2000, P NATL ACAD SCI USA, V97, P12074, DOI 10.1073/pnas.97.22.12074; O'Reilly AM, 2000, MOL CELL BIOL, V20, P299, DOI 10.1128/MCB.20.1.299-311.2000; Reusch JEB, 2000, MOL CELL BIOL, V20, P1008, DOI 10.1128/MCB.20.3.1008-1020.2000; Rosen ED, 2000, ANNU REV CELL DEV BI, V16, P145, DOI 10.1146/annurev.cellbio.16.1.145; Settleman J, 1999, Prog Mol Subcell Biol, V22, P201; Sordella R, 2002, DEV CELL, V2, P553, DOI 10.1016/S1534-5807(02)00162-4; SUGAI M, 1992, J BIOL CHEM, V267, P2600; Symons M, 2000, TRENDS CELL BIOL, V10, P415, DOI 10.1016/S0962-8924(00)01832-8; Takano H, 1998, MOL CELL BIOL, V18, P1580, DOI 10.1128/MCB.18.3.1580; Taya S, 2001, J CELL BIOL, V155, P809, DOI 10.1083/jcb.200106139; Vincent S, 1999, EUR J CELL BIOL, V78, P539, DOI 10.1016/S0171-9335(99)80019-3; WILLIAMS IH, 1977, BIOCHEM BIOPH RES CO, V77, P175, DOI 10.1016/S0006-291X(77)80180-0; XU B, 1995, J BIOL CHEM, V270, P29825; Zhao M, 1999, MOL CELL BIOL, V19, P21	32	309	326	1	23	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 18	2003	113	2					147	158		10.1016/S0092-8674(03)00271-X	http://dx.doi.org/10.1016/S0092-8674(03)00271-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	672EP	12705864	Bronze			2022-12-28	WOS:000182508500005
J	Zhang, GY; Jiang, X; Wang, EG				Zhang, GY; Jiang, X; Wang, EG			Tubular graphite cones	SCIENCE			English	Article							CARBON NANOTUBES; PROBE MICROSCOPY; FIELD-EMISSION; CHEMISTRY	We report the synthesis of tubular graphite cones using a chemical vapor deposition method. The cones have nanometer-sized tips, micrometer-sized roots, and hollow interiors with a diameter ranging from about 2 to several tens of nanometers. The cones are composed of cylindrical graphite sheets; a continuous shortening of the graphite layers from the interior to the exterior makes them cone-shaped. All of the tubular graphite cones have a faceted morphology. The constituent graphite sheets have identical chiralities of a zigzag type across the entire diameter, imparting structural control to tubular-based carbon structures. The tubular graphite cones have potential for use as tips for scanning probe microscopy, but with greater rigidity and easier mounting than currently used carbon nanotubes.	Fraunhofer Inst Surface Engn & Thin Films, D-38108 Braunschweig, Germany; Chinese Acad Sci, Inst Phys, State Key Lab Surface Phys, Beijing 100080, Peoples R China; Chinese Acad Sci, Inst Phys, Int Ctr Quantum Struct, Beijing 100080, Peoples R China	Fraunhofer Gesellschaft; Chinese Academy of Sciences; Institute of Physics, CAS; Chinese Academy of Sciences; Institute of Physics, CAS	Jiang, X (corresponding author), Univ Siegen, Inst Mat Engn, Paul Bonartz Str 9, D-57068 Siegen, Germany.		Zhang, Guangyu/G-7892-2011					AJAYAN PM, 1993, NATURE, V361, P333, DOI 10.1038/361333a0; Dai HJ, 1996, NATURE, V384, P147, DOI 10.1038/384147a0; Fan SS, 1999, SCIENCE, V283, P512, DOI 10.1126/science.283.5401.512; Gogotsi Y, 2000, SCIENCE, V290, P317, DOI 10.1126/science.290.5490.317; Hafner JH, 1999, NATURE, V398, P761, DOI 10.1038/19658; HAMADA N, 1992, PHYS REV LETT, V68, P1579, DOI 10.1103/PhysRevLett.68.1579; Hummer G, 2001, NATURE, V414, P188, DOI 10.1038/35102535; Kim P, 1999, SCIENCE, V286, P2148, DOI 10.1126/science.286.5447.2148; Koga K, 2001, NATURE, V412, P802, DOI 10.1038/35090532; Krishnan A, 1997, NATURE, V388, P451, DOI 10.1038/41284; Libera J, 2001, CARBON, V39, P1307, DOI 10.1016/S0008-6223(00)00263-3; RINZLER AG, 1995, SCIENCE, V269, P1550, DOI 10.1126/science.269.5230.1550; SAITO Y, 1993, PHYS REV B, V48, P1907, DOI 10.1103/PhysRevB.48.1907; Saito Y, 1997, NATURE, V389, P554, DOI 10.1038/39221; Treacy MMJ, 1996, NATURE, V381, P678, DOI 10.1038/381678a0; TSANG SC, 1994, NATURE, V372, P159, DOI 10.1038/372159a0; Ugarte D, 1996, SCIENCE, V274, P1897, DOI 10.1126/science.274.5294.1897; Wong SS, 1998, NATURE, V394, P52, DOI 10.1038/27873	18	217	227	1	106	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 18	2003	300	5618					472	474		10.1126/science.1082264	http://dx.doi.org/10.1126/science.1082264			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	668LR	12702873				2022-12-28	WOS:000182295900035
J	Neff, BD				Neff, BD			Decisions about parental care in response to perceived paternity	NATURE			English	Article							BLUEGILL SUNFISH; LEPOMIS-MACROCHIRUS; EASTERN BLUEBIRDS; INVESTMENT; BEHAVIOR; CONFIDENCE; SUCCESS; SIZE	Evolutionary ecologists are attempting to explain how parents make behavioural decisions about how much care to provide to their young(1-4). Theory predicts that when genetic relatedness to young is decreased by cuckoldry, for example, parents should reduce their care in favour of alternative broods that provide greater reproductive success(5-7). Experimental manipulation of perceived paternity has been used to test the theory(8,9), but such studies have generated mixed results(10-13). Some manipulations can fail to alter a parent's perceived paternity(14), whereas others may directly affect parental behaviour when, for instance, the manipulation involves capturing the parent(15-18). No study has demonstrated parental care adjustment in a manner uncomplicated by experimental design or life history correlates. Here I test the theory using the fact that nest-tending parental male bluegill sunfish (Lepomis macrochirus) can assess their paternity using both the visual presence of parasitic cuckolder males during spawning(19), and olfactory cues released by newly hatched eggs(20,21). By manipulating both types of cues I show that parental males dynamically adjust their parental care, favouring broods that are apparently most closely related. These results confirm the importance of genetic relatedness in parental care decision-making.	Univ Western Ontario, Dept Biol, London, ON N6A 5B7, Canada	Western University (University of Western Ontario)	Neff, BD (corresponding author), Univ Western Ontario, Dept Biol, London, ON N6A 5B7, Canada.			Neff, Bryan/0000-0001-8499-250X				Brown GE, 1996, REV FISH BIOL FISHER, V6, P201; BURKE T, 1989, NATURE, V338, P249, DOI 10.1038/338249a0; Cargnelli LM, 1996, CAN J FISH AQUAT SCI, V53, P360, DOI 10.1139/cjfas-53-2-360; COLEMAN RM, 1991, ETHOLOGY, V87, P177, DOI 10.1111/j.1439-0310.1991.tb00245.x; DIXON A, 1994, NATURE, V371, P698, DOI 10.1038/371698a0; DOMINEY WJ, 1980, NATURE, V284, P546, DOI 10.1038/284546a0; Fu P, 2001, P ROY SOC B-BIOL SCI, V268, P1105, DOI 10.1098/rspb.2001.1625; GROSS MR, 1982, Z TIERPSYCHOL, V60, P1; Hunt J, 2002, J EVOLUTION BIOL, V15, P784, DOI 10.1046/j.1420-9101.2002.00442.x; Jamieson IG, 1997, AUK, V114, P291, DOI 10.2307/4089171; Kempenaers B, 1998, ANIM BEHAV, V55, P845, DOI 10.1006/anbe.1997.0667; Kempenaers B, 1997, ANIM BEHAV, V53, P423, DOI 10.1006/anbe.1996.0377; Kokko H, 1999, ECOL LETT, V2, P247, DOI 10.1046/j.1461-0248.1999.00075.x; Kokko H, 2000, TRENDS ECOL EVOL, V15, P440, DOI 10.1016/S0169-5347(00)01985-6; Lessells C.M., 1991, P32; MacDougall-Shackleton EA, 1998, BEHAV ECOL, V9, P201, DOI 10.1093/beheco/9.2.201; Neff BD, 2002, P ROY SOC B-BIOL SCI, V269, P1435, DOI 10.1098/rspb.2002.2028; Neff BD, 2001, J HERED, V92, P111, DOI 10.1093/jhered/92.2.111; Neff BD, 2001, P ROY SOC B-BIOL SCI, V268, P1559, DOI 10.1098/rspb.2001.1678; NEFF BD, UNPUB P R SOC LOND B; NEFF BD, IN PRESS ANIM COGN; Sargent R. C., 1993, BEHAV TELEOST FISHES, P275; Sheldon BC, 2002, PHILOS T R SOC B, V357, P341, DOI 10.1098/rstb.2001.0931; Sheldon BC, 1998, P ROY SOC B-BIOL SCI, V265, P1737, DOI 10.1098/rspb.1998.0496; Trivers R. L., 1972, SEXUAL SELECTION DES, P136, DOI DOI 10.1002/AJPA.1330400226; Westneat David F., 1996, Trends in Ecology and Evolution, V11, P87, DOI 10.1016/0169-5347(96)81049-4; WESTNEAT DF, 1993, BEHAV ECOL, V4, P66, DOI 10.1093/beheco/4.1.66; Wright J., 1998, SPERM COMPETITION SE, P117, DOI 10.1016/B978-012100543-6/50029-5	28	123	126	0	92	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 17	2003	422	6933					716	719		10.1038/nature01528	http://dx.doi.org/10.1038/nature01528			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	668CG	12700761				2022-12-28	WOS:000182272300040
J	Palella, FJ; Deloria-Knoll, M; Chmiel, JS; Moorman, AC; Wood, KC; Greenberg, AE; Holmberg, SD				Palella, FJ; Deloria-Knoll, M; Chmiel, JS; Moorman, AC; Wood, KC; Greenberg, AE; Holmberg, SD		HOPS	Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4(+) cell strata	ANNALS OF INTERNAL MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS-INFECTION; VIRAL LOAD; DISEASE; COUNT; MORTALITY; PANEL	Background: Optimal timing of antiretroviral therapy (ART) initiation for HIV-infected persons remains unclear. Objective: To assess survival benefit of initiating ART at different CD4(+) cell counts. Design: Prospective observational study. Setting: U.S. clinics in the HIV Outpatient Study (HOPS). Patients: HIV-infected patients with CD4(+) cell counts, plasma HIV RNA viral load, and ART use recorded from January 1994 through March 2002. Measurements: Before initiation of ART, patients were grouped by their CD4(+) cell counts into three subgroups: 0.201 to 0.350 x 10(9) cells/L (n = 399), 0.351 to 0.500 x 10(9) cells/L (n = 327), and 0.501 to 0.750 x 10(9) cells/L (n = 122). We compared mortality rates for each CD4(+) subgroup among patients who initiated ART and patients who delayed ART until reaching a lower CD4(+) subgroup. Results: Mortality rates for 340 patients who initiated ART and 59 who delayed ART in the CD4(+) subgroup of 0.201 to 0.350 x 10(9) cells/L were 15.4 and 56.4 deaths per 1000 person-years, respectively (rate ratio, 0.27 [95% Cl, 0.14 to 0.55]; P < 0.001). For the CD4(+) subgroup of 0.351 to 0.500 x 10(9) cells/L, mortality rates for 240 patients who initiated ART and 887 who delayed ART were 10.0 and 16.6 deaths per 1000 person-years, respectively (rate ratio, 0.61 [Cl, 0.22 to 1.67]; P = 0.17). For the CD4(+) subgroup of 0.501 to 0.750 x 109 cells/L, mortality rates in 55 patients who initiated ART and 67 who delayed ART were 7.5 and 3.1 deaths per 1000 person-years, respectively (rate ratio, 1.20 [Cl, 0.17 to 8.53]; P > 0.2). Patients in the 0.201 to 0.350 x 10(9) cells/L and 0.351 to 0.500 X 10(9) cells/L CD4(+) subgroups who initiated ART were more likely than those who delayed ART to achieve an undetectable HIV viral load (P = 0.03 and 0.04, respectively). Conclusions: Among HIV-infected persons with CD4(+) cell counts of 0.201 to 0.350 x 10(9) cells/L, initiating ART is associated with reduced mortality compared with delaying such therapy. Survival benefits of earlier ART initiation (at CD4(+) cell counts of 0.351 to 0.500 x 10(9) cells/L) are possible.	Northwestern Univ, Feinberg Sch Med, Div Infect Dis, Chicago, IL 60611 USA; Cerner Corp, APACHE Med Syst, Vienna, Austria; Ctr Dis Control & Prevent, Natl Ctr HIV STD & TB Prevent, Atlanta, GA USA	Northwestern University; Feinberg School of Medicine; Centers for Disease Control & Prevention - USA	Palella, FJ (corresponding author), Northwestern Univ, Feinberg Sch Med, Div Infect Dis, 676 N St Clair,Suite 200, Chicago, IL 60611 USA.	f-palella@northwestern.edu	Abrams, William R/A-5782-2008		PHS HHS [200-2001-00133] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Bica I, 2001, CLIN INFECT DIS, V32, P492, DOI 10.1086/318501; Burman WJ, 1998, JAMA-J AM MED ASSOC, V280, P93, DOI 10.1001/jama.280.1.93; COZZILEPRI A, 2000, 5 INT C DRUG THER HI; Dybul M, 2002, ANN INTERN MED, V137, P381, DOI 10.7326/0003-4819-137-5_Part_2-200209031-00001; Hogg RS, 2001, JAMA-J AM MED ASSOC, V286, P2568, DOI 10.1001/jama.286.20.2568; KAPLAN J, 2001, 8 C RETR OPP INF CHI; LANE C, 2000, 5 INT C DRUG THER HI; LEDERMAN M, 2000, 5 INT C DRUG THER HI; MONTANER J, 2000, 13 INT AIDS C DURB S; Moorman AC, 1999, ANN EPIDEMIOL, V9, P349, DOI 10.1016/S1047-2797(99)00005-8; Opravil M, 2002, AIDS, V16, P1371, DOI 10.1097/00002030-200207050-00009; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Phillips AN, 2001, JAMA-J AM MED ASSOC, V286, P2560, DOI 10.1001/jama.286.20.2560; PHILLIPS AN, 2000, 5 INT C DRUG THER HI; ROSNER B, 2000, FUNDAMENTALS BIOSTAT, P688; Schacker T, 2000, J INFECT DIS, V181, P354, DOI 10.1086/315178; *US DEP HHS, 2003, GUID US ANT AG HIV I; Von Bargen J, 1998, JAMA-J AM MED ASSOC, V280, P29, DOI 10.1001/jama.280.1.29; Walker BD, 1998, JAMA-J AM MED ASSOC, V280, P91, DOI 10.1001/jama.280.1.91; Yeni PG, 2002, JAMA-J AM MED ASSOC, V288, P222, DOI 10.1001/jama.288.2.222	20	334	345	2	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	2003	138	8					620	626		10.7326/0003-4819-138-8-200304150-00007	http://dx.doi.org/10.7326/0003-4819-138-8-200304150-00007			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	666JH	12693883				2022-12-28	WOS:000182173800002
J	Goldstein, LE; Muffat, JA; Cherny, RA; Moir, RD; Ericsson, MH; Huang, XD; Mavros, C; Coccia, JA; Faget, KY; Fitch, KA; Masters, CL; Tanzi, RE; Chylack, LT; Bush, AI				Goldstein, LE; Muffat, JA; Cherny, RA; Moir, RD; Ericsson, MH; Huang, XD; Mavros, C; Coccia, JA; Faget, KY; Fitch, KA; Masters, CL; Tanzi, RE; Chylack, LT; Bush, AI			Cytosolic beta-amyloid deposition and supranuclear cataracts in lenses from people with Alzheimer's disease	LANCET			English	Article							ALPHA-B-CRYSTALLIN; A-BETA; OXIDATIVE STRESS; PROTEIN; PRECURSOR; BRAIN; NEUROTOXICITY; TRANSPARENCY; ACCUMULATION; PEPTIDE	Background Pathological hallmarks of Alzheimer's disease include cerebral beta-amyloid (Abeta) deposition, amyloid accumulation, and neuritic plaque formation. We aimed to investigate the hypothesis that molecular pathological findings associated with Alzheimer's disease overlap in the lens and brain. Methods We obtained postmortem specimens of eyes and brain from nine individuals with Alzheimer's disease and eight controls without the disorder, and samples of primary aqueous humour from three people without the disorder who were undergoing cataract surgery. Dissected lenses were analysed by slit-lamp stereophotomicroscopy, western blot, tryptic-digest/mass spectrometry electrospray ionisation, and anti-Abeta surface-enhanced laser desorption ionisation (SELDI) mass spectrometry, immunohistochemistry, and immunogold electron microscopy. Aqueous humour was analysed by anti-Abeta SELDI mass spectrometry. We did binding and aggregation studies to investigate Abeta-lens protein interactions. Findings We identified Abeta1-40 and Abeta1-42 in lenses from people with and without Alzheimer's disease at concentrations comparable with brain, and Abeta1-40 in primary aqueous humour at concentrations comparable with cerebrospinal fluid. Abeta accumulated in lenses from individuals with Alzheimer's disease as electron-dense deposits located exclusively in the cytoplasm of supranuclear/cleep cortical lens fibre cells (n=4). We consistently saw equatorial supranuclear cataracts in lenses from people with Alzheimer's disease (n=9) but not in controls (n = 8). These supranuclear cataracts colocalised with enhanced Abeta immunoreactivity and birefringent Congo Red staining. Synthetic Abeta bound alphaB-crystallin, an abundant cytosolic lens protein. Abeta promoted lens protein aggregation that showed protofibrils, birefringent Congo Red staining, and Abeta/alphaB-crystallin coimmunoreactivity. Interpretation Abeta is present in the cytosol of lens fibre cells of people with Alzheimer's disease. Lens Abeta might promote regionally-specific lens protein aggregation, extracerebral amyloid formation, and supranuclear cataracts.	Massachusetts Gen Hosp, Genet & Aging Res Univ, Lab Oxidat Biol, Charlestown, MA 02129 USA; Brigham & Womens Hosp, Ctr Ophthalm Res, Boston, MA 02115 USA; Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Ecole Normale Super, Dept Bioengn, Cachan, France; Univ Melbourne, Dept Pathol, Parkville, Vic 3052, Australia; Univ Melbourne, Mental Hlth Res Inst Victoria, Parkville, Vic 3052, Australia; Harvard Univ, Sch Med, Electron Microscope Facil, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; UDICE-French Research Universities; Universite Paris Saclay; University of Melbourne; University of Melbourne; Harvard University; Harvard Medical School	Bush, AI (corresponding author), Massachusetts Gen Hosp, Genet & Aging Res Univ, Lab Oxidat Biol, Bldg 114,16th St, Charlestown, MA 02129 USA.		Bush, Ashley/Y-2457-2019; Bush, Ashley I/A-1186-2007; Tanzi, Rudolph/AAE-9622-2019; Muffat, Julien/P-2298-2014; Moir, Robert/M-7612-2017	Bush, Ashley/0000-0001-8259-9069; Bush, Ashley I/0000-0001-8259-9069; Tanzi, Rudolph/0000-0002-7032-1454; Sommerville, Christine/0000-0002-9226-1691; Muffat, Julien/0000-0003-1889-7023; Moir, Robert/0000-0001-5431-3553; Goldstein, Lee/0000-0001-8419-9800	NIA NIH HHS [AG005134-19, AG12686] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R29AG012686, P50AG005134, R01AG012686] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BENEDEK GB, 1971, APPL OPTICS, V10, P459, DOI 10.1364/AO.10.000459; Bush A I, 2001, Novartis Found Symp, V235, P26; Butterfield DA, 2002, FREE RADICAL BIO MED, V32, P1050, DOI 10.1016/S0891-5849(02)00794-3; Cherny RA, 1999, J BIOL CHEM, V274, P23223, DOI 10.1074/jbc.274.33.23223; CHYLACK LT, 1984, CIBA F SYMP, V106, P3; CHYLACK LT, 1984, INVEST OPHTH VIS SCI, V25, P166; Fonte V, 2002, P NATL ACAD SCI USA, V99, P9439, DOI 10.1073/pnas.152313999; Frederikse PH, 1996, J BIOL CHEM, V271, P10169, DOI 10.1074/jbc.271.17.10169; Glabe C, 2001, J MOL NEUROSCI, V17, P137, DOI 10.1385/JMN:17:2:137; Gouras GK, 2000, AM J PATHOL, V156, P15, DOI 10.1016/S0002-9440(10)64700-1; GRIFFITHS G, 1993, FINE STRUCTURE IMMUN; Hanson SRA, 2000, EXP EYE RES, V71, P195, DOI 10.1006/exer.2000.0868; Harding JJ, 1997, ALZ DIS ASSOC DIS, V11, P123, DOI 10.1097/00002093-199709000-00002; Hartley DM, 1999, J NEUROSCI, V19, P8876, DOI 10.1523/JNEUROSCI.19-20-08876.1999; Holton JL, 2002, J NEUROPATH EXP NEUR, V61, P254, DOI 10.1093/jnen/61.3.254; Horwitz J, 2000, SEMIN CELL DEV BIOL, V11, P53, DOI 10.1006/scdb.1999.0351; JOACHIM CL, 1989, NATURE, V341, P226, DOI 10.1038/341226a0; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Liang JJN, 2000, FEBS LETT, V484, P98, DOI 10.1016/S0014-5793(00)02136-0; LOWE J, 1992, NEUROPATH APPL NEURO, V18, P341, DOI 10.1111/j.1365-2990.1992.tb00796.x; LOWE RF, 1949, BRIT J OPHTHALMOL, V33, P131, DOI 10.1136/bjo.33.3.131; MIRRA SS, 1991, NEUROLOGY, V41, P479, DOI 10.1212/WNL.41.4.479; Moir RD, 1998, J BIOL CHEM, V273, P5013, DOI 10.1074/jbc.273.9.5013; Moir RD, 1999, BIOCHEMISTRY-US, V38, P4595, DOI 10.1021/bi982437d; Skovronsky DM, 1998, J CELL BIOL, V141, P1031, DOI 10.1083/jcb.141.4.1031; SPECTOR A, 1984, CIBA F SYMP, V106, P48; Stege GJJ, 1999, BIOCHEM BIOPH RES CO, V262, P152, DOI 10.1006/bbrc.1999.1167; Tanzi RE, 2001, NEURON, V32, P181, DOI 10.1016/S0896-6273(01)00476-7; VAEZY S, 1991, J MICROSC-OXFORD, V163, P85, DOI 10.1111/j.1365-2818.1991.tb03162.x	30	278	374	0	26	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 12	2003	361	9365					1258	1265		10.1016/S0140-6736(03)12981-9	http://dx.doi.org/10.1016/S0140-6736(03)12981-9			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	666DM	12699953				2022-12-28	WOS:000182161600010
J	Collins, FS; Morgan, M; Patrinos, A				Collins, FS; Morgan, M; Patrinos, A			The human genome project: Lessons from large-scale biology	SCIENCE			English	Article								The Human Genome Project has been the first major foray of the biological and medical research communities into "big science." In this Viewpoint, we present some of our experiences in organizing and managing such a complicated, publicly funded, international effort. We believe that many of the lessons we learned will be applicable to future large-scale projects in biology.	NHGRI, NIH, Bethesda, MD 20892 USA; Wellcome Trust Res Labs, London NW1 2BE, England; US DOE, Washington, DC 20585 USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); United States Department of Energy (DOE)	Collins, FS (corresponding author), NHGRI, NIH, Bldg 31,Room 4B09,9000 Rockville Pike, Bethesda, MD 20892 USA.							COLLINS F, 1993, SCIENCE, V262, P43, DOI 10.1126/science.8211127; Collins FS, 1998, SCIENCE, V282, P682, DOI 10.1126/science.282.5389.682; COLLINS FS, IN PRESS NATURE; Lambright W.H., 2002, MANAGING BIG SCI CAS; *NHGRI, 2002, NHGRI STAND QUAL HUM; *NHGRI, HAPL MAP; Olson MV, 2002, J MOL BIOL, V319, P931, DOI 10.1016/S0022-2836(02)00333-9; SULSTON J, 2002, COMMON THREAD STORY, P73; *US DEP HHS, 1990, UND OUR GEN INH US H; WATSON JD, 1990, SCIENCE, V248, P44, DOI 10.1126/science.2181665; WATSON JD, 1990, NY TIMES        0605, pC1; Wellcome Trust, 2003, SHAR DAT LARG SCAL B; 2003, GENOMES LIFE; 2003, ENCODE PROJECT ENCYC	14	651	714	3	132	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 11	2003	300	5617					286	290		10.1126/science.1084564	http://dx.doi.org/10.1126/science.1084564			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	665RQ	12690187	Green Submitted			2022-12-28	WOS:000182135400043
J	Walsh, PD; Abernethy, KA; Bermejo, M; Beyersk, R; De Wachter, P; Akou, ME; Huljbregis, B; Mambounga, DI; Toham, AK; Kilbourn, AM; Lahm, SA; Latour, S; Maisels, F; Mbina, C; Mihindou, Y; Obiang, SN; Effa, EN; Starkey, MP; Telfer, P; Thibault, M; Tutin, CEG; White, LJT; Wilkie, DS				Walsh, PD; Abernethy, KA; Bermejo, M; Beyersk, R; De Wachter, P; Akou, ME; Huljbregis, B; Mambounga, DI; Toham, AK; Kilbourn, AM; Lahm, SA; Latour, S; Maisels, F; Mbina, C; Mihindou, Y; Obiang, SN; Effa, EN; Starkey, MP; Telfer, P; Thibault, M; Tutin, CEG; White, LJT; Wilkie, DS			Catastrophic ape decline in western equatorial Africa	NATURE			English	Article							GORILLA-GORILLA; CONSERVATION; FOREST	Because rapidly expanding human populations have devastated gorilla (Gorilla gorilla) and common chimpanzee (Pan troglodytes) habitats in East and West Africa, the relatively intact forests of western equatorial Africa have been viewed as the last stronghold of African apes(1). Gabon and the Republic of Congo alone are thought to hold roughly 80% of the world's gorillas(2) and most of the common chimpanzees(1). Here we present survey results conservatively indicating that ape populations in Gabon declined by more than half between 1983 and 2000. The primary cause of the decline in ape numbers during this period was commercial hunting, facilitated by the rapid expansion of mechanized logging. Furthermore, Ebola haemorrhagic fever is currently spreading through ape populations in Gabon and Congo and now rivals hunting as a threat to apes. Gorillas and common chimpanzees should be elevated immediately to 'critically endangered' status. Without aggressive investments in law enforcement, protected area management and Ebola prevention, the next decade will see our closest relatives pushed to the brink of extinction.	Princeton Univ, Dept Ecol & Evolut Biol, Princeton, NJ 08540 USA; Ctr Int Rech Med Franceville, Franceville, Gabon; Univ Stirling, Dept Biol & Mol Sci, Stirling FK9 4LA, Scotland; Univ Barcelona, Fac Biol, Dept Biol Anim Vertebrados, E-08028 Barcelona, Spain; Wildlife Conservat Soc, Bronx, NY 10460 USA; WWF, Cent Africa Reg Program Off, Libreville, Gabon; Minist Econ Forestiere Eaux Peche Charge Environm, Direct Faune & Chasse, Libreville, Gabon; Inst Rech Ecol Trop, Libreville, Gabon; Univ Edinburgh, Inst Cell Anim & Populat Biol, Edinburgh EH9 3JT, Midlothian, Scotland; Univ Cambridge, Dept Geog, Cambridge CB2 3EN, England; NYU, Dept Anthropol, New York, NY 10003 USA	Princeton University; University of Stirling; University of Barcelona; Wildlife Conservation Society; World Wildlife Fund; University of Edinburgh; University of Cambridge; New York University	Walsh, PD (corresponding author), Princeton Univ, Dept Ecol & Evolut Biol, Guyot Hall, Princeton, NJ 08540 USA.	pwalsh@princeton.edu	Maisels, Fiona/E-7382-2015; Phillips, Paul/E-7813-2013	Maisels, Fiona/0000-0002-0778-0615; Phillips, Paul/0000-0002-8749-7026; Abernethy, Katharine/0000-0002-0393-9342				ANGOUE C, 2000, AVENIR PEUPLES FORET, V3; BARNES RFW, 1991, AFR J ECOL, V29, P54, DOI 10.1111/j.1365-2028.1991.tb00820.x; Bermejo M, 1999, ORYX, V33, P323, DOI 10.1017/S0030605300030726; BLOM A, 2001, J SUST TOURISM, V8, P175; Brugiere D, 2001, J ZOOL, V255, P251, DOI 10.1017/S0952836901001315; Buckland S. T., 1993, Distance sampling: estimating abundance of biological populations.; CHAMBERLIN C, 1978, INT J AFR HIST STUD, V11, P429, DOI 10.2307/217312; *DIR FAUN CHASS, 1999, RAPP ACT LUTT ANT LU; Georges AJ, 1999, J INFECT DIS, V179, pS65, DOI 10.1086/514290; Harcourt AH, 1996, BIOL CONSERV, V75, P165, DOI 10.1016/0006-3207(95)00059-3; Hedley Sharon L., 1999, Journal of Cetacean Research and Management, V1, P255; HUIJBREGTS B, IN PRESS ORYX; Kingdon J, 2011, KINGDON FIELD GUIDE, V4th; Lahm SA, 1993, ECOLOGY EC HUMAN WIL; Oates J.F., 1996, AFRICAN PRIMATES STA; POURTIER R., 1989, GABON ETAT DEVELOPPE, V2; ROBERTS L, 1998, WORLD RESOURCES, P292; TUTIN CEG, 1984, AM J PRIMATOL, V6, P313, DOI 10.1002/ajp.1350060403; Walsh PD, 1999, CONSERV BIOL, V13, P1194, DOI 10.1046/j.1523-1739.1999.98148.x; Wilkie D, 2000, CONSERV BIOL, V14, P1614, DOI 10.1046/j.1523-1739.2000.99102.x; Wilkie DS, 1999, ORYX, V33, P339, DOI 10.1017/S003060530003074X	22	393	416	0	198	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 10	2003	422	6932					611	614		10.1038/nature01566	http://dx.doi.org/10.1038/nature01566			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	665GN	12679788				2022-12-28	WOS:000182111400041
J	Berkowitz, RI; Wadden, TA; Tershakovec, AM; Cronquist, JL				Berkowitz, RI; Wadden, TA; Tershakovec, AM; Cronquist, JL			Behavior therapy and sibutramine for the treatment of adolescent obesity - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DEPENDENT DIABETES-MELLITUS; PLACEBO-CONTROLLED TRIAL; LIFE-STYLE MODIFICATION; WEIGHT-LOSS; PHARMACOLOGICAL TREATMENT; ENERGY-EXPENDITURE; ORLISTAT; MAINTENANCE; OVERWEIGHT; REDUCTION	Context Adolescent obesity is becoming a national public health problem. Weight-loss medications including sibutramine facilitate weight control in adults and could be used with obese adolescents in combination with behavior therapy (BT). Objective To examine whether increased weight loss in obese adolescents is induced when sibutramine is added to a family-based, behavioral weight control program. Design, Setting, and Participants Randomized, double-blind, placebo-controlled trial, consisting of 82 adolescents aged 13 to 17 years with a body mass index (BMI) of 32 to 44 conducted from March 1999 to August 2002 at a university-based clinic for 6 months, followed by open-label treatment during months 7 to 12. Interventions For the first 6 months, participants received either BT and sibutramine or BT and placebo. From months 7 to 12, all participants received sibutramine in open-label treatment. Main Outcome Measures Percentage change in BMI; systolic and diastolic blood pressure and pulse; and hunger. Results In intention-to-treat analysis at month 6, participants in the BT and sibutramine group lost a mean (SD) of 7.8 kg (6.3 kg) and had an 8.5% (6.8%) reduction in BMI, which was significantly more than weight loss of 3.2 kg (6.1 kg) and reduction in BMI of 4.00% (5.4%) in the BT and placebo group. Significantly greater reductions in hunger (P=.002) also were reported by participants who received BT and sibutramine. From months 7 to 12, adolescents initially treated with sibutramine gained 0.8 kg (10.5 kg) with continued use of the medication, whereas those who switched from placebo to sibutramine lost an additional 1.3 kg (5.4 kg). Medication. dose was reduced (n=23) or discontinued (n=10) to manage increases in blood-pressure, pulse rate, or other symptoms. Conclusions The addition of sibutramine to a comprehensive behavioral program induced significantly more weight loss than did BT and placebo. Until more extensive safety and efficacy data are available, medications for weight loss should be used only on an experimental basis in adolescents and children.	Univ Penn, Weight & Eating Disorders Program, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Dept Psychiat, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Dept Pediat, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Berkowitz, RI (corresponding author), Univ Penn, Weight & Eating Disorders Program, Sch Med, Dept Psychiat, 3535 Mkt St,Suite 3026, Philadelphia, PA 19104 USA.	rberk@mail.med.upenn.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000240] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054713] Funding Source: NIH RePORTER; NCRR NIH HHS [M01-RR00240] Funding Source: Medline; NIDDK NIH HHS [DK054713] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		*ABB LAB, 2002, MER SIB HYDR; Bray GA, 1996, OBES RES, V4, P263, DOI 10.1002/j.1550-8528.1996.tb00544.x; Callaway CW., 1988, ANTHROPOMETRIC STAND, P39; *CDCP, 2002, EP INF 2002 DAT STAT; Cohen J., 1998, STAT POWER ANAL BEHA; Davidson MH, 1999, JAMA-J AM MED ASSOC, V281, P235, DOI 10.1001/jama.281.3.235; *EUR AG EV MED PRO, 2002, COMM PROP MED PROD O; Glaser NS, 1998, WESTERN J MED, V168, P11; Goldfield G. S., 2002, Handbook of obesity treatment, P532; Haddock C. Keith, 1994, Annals of Behavioral Medicine, V16, P235; Haffner SM, 1996, DIABETES CARE, V19, P1138, DOI 10.2337/diacare.19.10.1138; Hansen DL, 1999, INT J OBESITY, V23, P1016, DOI 10.1038/sj.ijo.0801059; Hill JO, 1999, AM J CLIN NUTR, V69, P1108; Hollander PA, 1998, DIABETES CARE, V21, P1288, DOI 10.2337/diacare.21.8.1288; James WPT, 2000, LANCET, V356, P2119, DOI 10.1016/S0140-6736(00)03491-7; Kitagawa T, 1998, CLIN PEDIATR, V37, P111, DOI 10.1177/000992289803700208; LEAN MEJ, 1997, INT J OBESITY, V21, P30; LEIBEL RL, 1995, NEW ENGL J MED, V332, P621, DOI 10.1056/NEJM199503093321001; MUST A, 1992, NEW ENGL J MED, V327, P1350, DOI 10.1056/NEJM199211053271904; *NAT CTR HLTH STAT, 2002, OV US CHILDR AD NAT; Neufeld ND, 1998, DIABETES CARE, V21, P80, DOI 10.2337/diacare.21.1.80; NIETZ WH, 1994, OBES RES, V2, P54; Ogden CL, 2002, JAMA-J AM MED ASSOC, V288, P1728, DOI 10.1001/jama.288.14.1728; Phelan S, 2002, OBES RES, V10, P560, DOI 10.1038/oby.2002.77; Phillips DIW, 2000, INT J OBESITY, V24, P281, DOI 10.1038/sj.ijo.0801125; PinhasHamiel O, 1996, J PEDIATR-US, V128, P608, DOI 10.1016/S0022-3476(96)80124-7; Robinson TN, 1999, INT J OBESITY, V23, pS52, DOI 10.1038/sj.ijo.0800860; Rolls BJ, 1998, OBES RES, V6, P1; Rosenbloom A, 2000, PEDIATRICS, V105, P671; Rosenbloom AL, 1999, DIABETES CARE, V22, P345, DOI 10.2337/diacare.22.2.345; Sjostrom L, 1998, LANCET, V352, P167, DOI 10.1016/S0140-6736(97)11509-4; SMITH DE, 1991, HEALTH PSYCHOL, V10, P378, DOI 10.1037/0278-6133.10.6.378; STUNKARD AJ, 1985, J PSYCHOSOM RES, V29, P71, DOI 10.1016/0022-3999(85)90010-8; TRIOANA RP, 1995, ARCH PEDIAT ADOLESC, V149, P1085; Wadden T. A., 2002, Handbook of obesity treatment, P229; Wadden TA, 1997, OBES RES, V5, P218, DOI 10.1002/j.1550-8528.1997.tb00296.x; Wadden TA, 1999, OBES RES, V7, P170, DOI 10.1002/j.1550-8528.1999.tb00699.x; Wadden TA, 2001, ARCH INTERN MED, V161, P218, DOI 10.1001/archinte.161.2.218; WADDEN TA, 1990, PEDIATRICS, V85, P345; Wadden TA, 2001, WEIGHT REDUCTION PRI	40	248	256	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 9	2003	289	14					1805	1812		10.1001/jama.289.14.1805	http://dx.doi.org/10.1001/jama.289.14.1805			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	664ZJ	12684359	Bronze			2022-12-28	WOS:000182094900026
J	Egger, J; Grossmann, G; Auchterlonie, IA				Egger, J; Grossmann, G; Auchterlonie, IA			Lesson of the week - Benign sleep myoclonus in infancy mistaken for epilepsy	BRITISH MEDICAL JOURNAL			English	Review									Tech Univ Munich, Kinder & Poliklin, D-80804 Munich, Germany; Royal Aberdeen Childrens Hosp, Aberdeen AB25 2ZG, Scotland	Technical University of Munich; University of Aberdeen	Egger, J (corresponding author), Kinderspital Meran, Rossininstr 5, I-39012 Meran, Italy.							Coons S., 1987, SLEEP ITS DISORDERS; COULTER DL, 1982, ARCH NEUROL-CHICAGO, V39, P191, DOI 10.1001/archneur.1982.00510150061016; PARMELEE A, 1969, DEV MED CHILD NEUROL, V11, P764; RESNICK TJ, 1986, ARCH NEUROL-CHICAGO, V43, P266, DOI 10.1001/archneur.1986.00520030056014	4	21	25	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 3	2003	326	7396					975	976		10.1136/bmj.326.7396.975	http://dx.doi.org/10.1136/bmj.326.7396.975			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	676JC	12727774	Green Published			2022-12-28	WOS:000182746700022
J	Oyranoski, D				Oyranoski, D			Critics slam treatment for SARS as ineffective and perhaps dangerous	NATURE			English	News Item																			0	33	34	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 1	2003	423	6935					4	4		10.1038/423004a	http://dx.doi.org/10.1038/423004a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	673CG	12721587	Green Published, Bronze			2022-12-28	WOS:000182561600005
J	Schmidli, J; Carrel, T				Schmidli, J; Carrel, T			Cardiac compression by a ruptured aneurysm of the descending thoracic aorta	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Univ Hosp Bern, CH-3010 Bern, Switzerland	University of Bern; University Hospital of Bern	Schmidli, J (corresponding author), Univ Hosp Bern, CH-3010 Bern, Switzerland.								0	1	1	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 1	2003	348	18					1776	1776		10.1056/NEJMicm010016	http://dx.doi.org/10.1056/NEJMicm010016			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	672VK	12724483				2022-12-28	WOS:000182543500006
J	Groce, NE				Groce, NE			HIV/AIDS and people with disability	LANCET			English	Editorial Material							HIV; ADULTS; WOMEN		Yale Univ, Yale Sch Publ Hlth, Global Hlth Div, New Haven, CT 06520 USA	Yale University	Groce, NE (corresponding author), Yale Univ, Yale Sch Publ Hlth, Global Hlth Div, New Haven, CT 06520 USA.			Groce, Nora/0000-0002-7885-7042				ALTMAN B, 1997, J DISABIL POLICY STU, V8, P99; Blumberg SJ, 2003, JAIDS, V32, P77, DOI 10.1097/00126334-200301010-00011; Cambridge P, 1997, DISABIL SOC, V12, P427, DOI 10.1080/09687599727272; Chenoweth L., 1996, VIOLENCE AGAINST WOM, V2, P391, DOI [https://doi.org/10.1177/1077801296002004004, DOI 10.1177/1077801296002004004, 10.1177/1077801296002004004]; Collins PY, 2001, J URBAN HEALTH, V78, P162, DOI 10.1093/jurban/78.1.162; COURNOS F, 1990, HOSP COMMUNITY PSYCH, V41, P163; *EC SOC COMM AS PA, 1995, HIDD SIST WOM GIRLS; Gaskins S, 1999, J Assoc Nurses AIDS Care, V10, P75, DOI 10.1016/S1055-3290(06)60301-4; GASKINS S, 1999, J ASS NURSES AIDS CA, V35, P75; Helander E, 1993, PREJUDICE DIGNITY; Lishner DM, 1996, J RURAL HEALTH, V12, P45, DOI 10.1111/j.1748-0361.1996.tb00772.x; McGillivray JA, 1999, J APPL RES INTELLECT, V12, P113, DOI 10.1111/j.1468-3148.1999.tb00070.x; Moores DF, 1998, AM ANN DEAF, V143, P3, DOI 10.1353/aad.2012.0111; Nosek MA, 2001, VIOLENCE AGAINST WOM, V7, P477, DOI 10.1177/10778010122182569; ROBERTSON PE, 1991, J MENT DEFIC RES, V35, P475; *UNAIDS, 2002, REP GLOB HIV AIDS EP; *UNICEF, 1999, GLOB SURV AD DIS OV; Van Biema D, 1994, Time, V143, P76	18	65	67	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 26	2003	361	9367					1401	1402		10.1016/S0140-6736(03)13146-7	http://dx.doi.org/10.1016/S0140-6736(03)13146-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	672HZ	12727388				2022-12-28	WOS:000182516300003
J	Saunders, K; Bedford, ID; Yahara, T; Stanley, J				Saunders, K; Bedford, ID; Yahara, T; Stanley, J			The earliest recorded plant virus disease	NATURE			English	Article									John Innes Ctr Plant Sci Res, Dept Dis & Stress Biol, Norwich NR4 7UH, Norfolk, England; Kyushu Univ, Dept Biol, Fukuoka 8128581, Japan	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; Kyushu University	Saunders, K (corresponding author), John Innes Ctr Plant Sci Res, Dept Dis & Stress Biol, Norwich Res Pk, Norwich NR4 7UH, Norfolk, England.			Yahara, Tetsukazu/0000-0001-5105-7152; Saunders, Keith/0000-0002-5606-9627				Briddon RW, 2002, MOL BIOTECHNOL, V20, P315, DOI 10.1385/MB:20:3:315; Briddon RW, 2001, VIROLOGY, V285, P234, DOI 10.1006/viro.2001.0949; INOUYE T, 1980, Annals of the Phytopathological Society of Japan, V46, P49, DOI 10.3186/jjphytopath.46.49; KOCH R, 1884, MITTHEILUNGEN KAISER, V2; Mansoor S, 2003, TRENDS PLANT SCI, V8, P128, DOI 10.1016/S1360-1385(03)00007-4; Onuki Masatoshi, 2000, Journal of General Plant Pathology, V66, P176, DOI 10.1007/PL00012941; OSAKI T, 1979, Annals of the Phytopathological Society of Japan, V45, P62, DOI 10.3186/jjphytopath.45.62; Saunders K, 2001, VIROLOGY, V282, P38, DOI 10.1006/viro.2000.0832; Saunders K, 2000, P NATL ACAD SCI USA, V97, P6890, DOI 10.1073/pnas.97.12.6890; SUGA T, 1991, NANYOSHU COMPLETE EN; YAHARA T, 1993, OECOLOGIA, V96, P310, DOI 10.1007/BF00317499	11	84	94	1	10	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	APR 24	2003	422	6934					831	831		10.1038/422831a	http://dx.doi.org/10.1038/422831a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	670WR	12712190	Bronze			2022-12-28	WOS:000182432600038
J	Falsey, AR; Walsh, EE				Falsey, AR; Walsh, EE			Novel coronavirus and severe acute respiratory syndrome	LANCET			English	Editorial Material							SYNCYTIAL VIRUS; INFECTIONS; INFLUENZA; COMMUNITY		Univ Rochester, Sch Med & Dent, Rochester Gen Hosp, Rochester, NY USA	Rochester General Hospital; University of Rochester	Falsey, AR (corresponding author), Univ Rochester, Sch Med & Dent, Rochester Gen Hosp, Rochester, NY USA.							*CDCP, 2003, CDC TEL TRANSCR CDC; *CDCP, 2003, CDC LAB AN SUGG NEW; FALSEY AR, 1995, J INFECT DIS, V172, P389, DOI 10.1093/infdis/172.2.389; KASS EH, 1977, NEW ENGL J MED, V297, P1229, DOI 10.1056/NEJM197712012972209; Nicholson KG, 1997, BRIT MED J, V315, P1060, DOI 10.1136/bmj.315.7115.1060; Peret TCT, 2002, J INFECT DIS, V185, P1660, DOI 10.1086/340518; POUTANEN SM, 2003, N ENGL J MED    0331; TSANG KW, 2003, N ENGL J MED    0331; Zambon MC, 2001, LANCET, V358, P1410, DOI 10.1016/S0140-6736(01)06528-X	9	38	62	1	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 19	2003	361	9366					1312	1313		10.1016/S0140-6736(03)13084-X	http://dx.doi.org/10.1016/S0140-6736(03)13084-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	669HP	12711460	Bronze, Green Published			2022-12-28	WOS:000182346100002
J	Lassmann, H				Lassmann, H			Brain damage when multiple sclerosis is diagnosed clinically	LANCET			English	Editorial Material									Univ Vienna, Brain Res Inst, A-1090 Vienna, Austria	University of Vienna	Lassmann, H (corresponding author), Univ Vienna, Brain Res Inst, Waehringer Guertel 18, A-1090 Vienna, Austria.		Lassmann, Hans/Z-2269-2019	Lassmann, Hans/0000-0001-8617-5052				Aboul-Enein F, 2003, J NEUROPATH EXP NEUR, V62, P25, DOI 10.1093/jnen/62.1.25; BO L, 1994, J NEUROIMMUNOL, V51, P135, DOI 10.1016/0165-5728(94)90075-2; Dautry W, 2000, J CEREBR BLOOD F MET, V20, P789, DOI 10.1097/00004647-200005000-00005; Evangelou N, 2000, BRAIN, V123, P1845, DOI 10.1093/brain/123.9.1845; Filippi M, 2003, BRAIN, V126, P433, DOI 10.1093/brain/awg038; Kornek B, 1999, BRAIN PATHOL, V9, P651; Lassmann H, 1998, MCALPINES MULTIPLE S, P323; Smith KJ, 2002, LANCET NEUROL, V1, P232, DOI 10.1016/S1474-4422(02)00102-3	8	16	16	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 19	2003	361	9366					1317	1318		10.1016/S0140-6736(03)13088-7	http://dx.doi.org/10.1016/S0140-6736(03)13088-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	669HP	12711464				2022-12-28	WOS:000182346100006
J	Jain, S; Bates, FS				Jain, S; Bates, FS			On the origins of morphological complexity in block copolymer surfactants	SCIENCE			English	Article							MICROEMULSION NETWORKS; PHASE-SEPARATION; DIBLOCK COPOLYMERS; MICELLES; VESICLES; DILUTE; FLUIDS; WATER; MODEL	Amphiphilic compounds such as lipids and surfactants are fundamental building blocks of soft matter. We describe experiments with poly(1,2-butadiene-b-ethylene oxide) (PB-PEO) diblock copolymers, which form Y-junctions and three-dimensional networks in water at weight fractions of PEO intermediate to those associated with vesicle and wormlike micelle morphologies. Fragmentation of the network produces a nonergodic array of complex reticulated particles that have been imaged by cryogenic transmission electron microscopy. Data obtained with two sets of PB-PEO compounds indicate that this type of self-assembly appears above a critical molecular weight. These block copolymers represent versatile amphiphiles, mimicking certain low molecular weight three-component (surfactant/water/oil) microemulsions, without addition of a separate hydrophobe.	Univ Minnesota, Dept Chem Engn & Mat Sci, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Bates, FS (corresponding author), Univ Minnesota, Dept Chem Engn & Mat Sci, 421 Washington Ave SE, Minneapolis, MN 55455 USA.	bates@cems.umn.edu			NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R21EB000989] Funding Source: NIH RePORTER; NIBIB NIH HHS [1R21EB00989-01] Funding Source: Medline	NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))		Alexandridis P., 2000, AMPHIPHILIC BLOCK CO, DOI [10.1016/B978-0-444-82441-7.X5000-2, DOI 10.1016/B978-0-444-82441-7.X5000-2]; [Anonymous], 1992, INTERMOLECULAR SURFA; [Anonymous], 1980, VISCOELASTIC PROPERT; Bates FS, 1999, PHYS TODAY, V52, P32, DOI 10.1063/1.882522; Bernheim-Groswasser A, 1999, LANGMUIR, V15, P5448, DOI 10.1021/la990301q; Bernheim-Groswasser A, 2000, LANGMUIR, V16, P4131, DOI 10.1021/la991231q; Burke S, 2000, HIGH PERFORM POLYM, V12, P535, DOI 10.1088/0954-0083/12/4/308; Discher BM, 1999, SCIENCE, V284, P1143, DOI 10.1126/science.284.5417.1143; DRYE TJ, 1992, J CHEM PHYS, V96, P1367, DOI 10.1063/1.462172; EVANS DF, 1998, COLLOIDAL DOMAIN WHE; Gelbart WM, 1996, J PHYS CHEM-US, V100, P13169, DOI 10.1021/jp9606570; Hillmyer MA, 1996, MACROMOLECULES, V29, P6994, DOI 10.1021/ma960774t; KHATORY A, 1993, LANGMUIR, V9, P1456, DOI 10.1021/la00030a005; Kindt JT, 2002, J PHYS CHEM B, V106, P8223, DOI 10.1021/jp020670m; Krishnan K, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.098301; Kwon SY, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.258302; Panizza P, 1998, J PHYS-CONDENS MAT, V10, P11659, DOI 10.1088/0953-8984/10/50/006; PORTE G, 1986, J PHYS CHEM-US, V90, P5746, DOI 10.1021/j100280a055; Tlusty T, 2000, J PHYS-CONDENS MAT, V12, pA253, DOI 10.1088/0953-8984/12/8A/332; Tlusty T, 2000, SCIENCE, V290, P1328, DOI 10.1126/science.290.5495.1328; Tlusty T, 2000, PHYS REV LETT, V84, P1244, DOI 10.1103/PhysRevLett.84.1244; Won YY, 2000, J PHYS CHEM B, V104, P9054, DOI 10.1021/jp002934f; Won YY, 1999, SCIENCE, V283, P960, DOI 10.1126/science.283.5404.960; Won YY, 2003, MACROMOLECULES, V36, P953, DOI 10.1021/ma021439+; Won YY, 2002, J PHYS CHEM B, V106, P3354, DOI 10.1021/jp013639d; Yu K, 1996, LANGMUIR, V12, P5980, DOI 10.1021/la960894u; ZHANG LF, 1995, SCIENCE, V268, P1728, DOI 10.1126/science.268.5218.1728	27	1027	1043	17	602	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 18	2003	300	5618					460	464		10.1126/science.1082193	http://dx.doi.org/10.1126/science.1082193			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	668LR	12702869				2022-12-28	WOS:000182295900031
J	Walther, TC; Alves, A; Pickersgill, H; Loiodice, I; Hetzer, M; Galy, V; Hulsmann, BB; Kocher, T; Wilm, M; Allen, T; Mattaj, LW; Doye, V				Walther, TC; Alves, A; Pickersgill, H; Loiodice, I; Hetzer, M; Galy, V; Hulsmann, BB; Kocher, T; Wilm, M; Allen, T; Mattaj, LW; Doye, V			The conserved Nup107-160 complex is critical for nuclear pore complex assembly	CELL			English	Article							NUCLEOCYTOPLASMIC TRANSPORT; PROTEOMIC ANALYSIS; PROTEIN; NUCLEOPORINS; ENVELOPE; NUP98; STEPS; RECONSTITUTION; IDENTIFICATION; INTERFERENCE	Nuclear pore complexes (NPCs) are large multiprotein assemblies that allow traffic between the cytoplasm and the nucleus. During mitosis in higher eukaryotes, the Nuclear Envelope (NE) breaks down and NPCs disassemble. How NPCs reassemble and incorporate into the NE upon mitotic exit is poorly understood. We demonstrate a function for the conserved Nup1107-160 complex in this process. Partial in vivo depletion of Nup133 or Nup107 via RNAi in HeLa cells resulted in reduced levels of multiple nucleoporins and decreased NPC density in the NE. Immunodepletion of the entire Nup1107-160 complex from in vitro nuclear assembly reactions produced nuclei with a continuous NE but no NPCs. This phenotype was reversible only if Nup107-160 complex was readded before closed NE formation. Depletion also prevented association of FG-repeat nucleoporins with chromatin. We propose a stepwise model in which postmitotic NPC assembly initiates on chromatin via early recruitment of the Nup107-160 complex.	European Mol Biol Lab, D-69117 Heidelberg, Germany; Inst Curie, CNRS, UMR 144, F-75248 Paris 05, France; Christie Hosp NHS Trust, Paterson Inst Canc Res, CRC Dept Struct Cell Biol, Manchester M20 9BX, Lancs, England	European Molecular Biology Laboratory (EMBL); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research	Mattaj, LW (corresponding author), European Mol Biol Lab, Meyerhofstr 1, D-69117 Heidelberg, Germany.	mattaj@embl-heidelberg.de		Wilm, Matthias/0000-0002-5461-6834; Mattaj, Iain/0000-0002-5537-8284; Walther, Tobias/0000-0003-1442-1327; Koecher, Thomas/0000-0003-0827-1457				Allen NPC, 2001, J BIOL CHEM, V276, P29268, DOI 10.1074/jbc.M102629200; Allen TD, 1998, METHOD CELL BIOL, V53, P125; Bagley S, 2000, J CELL SCI, V113, P3885; Belgareh N, 2001, J CELL BIOL, V154, P1147, DOI 10.1083/jcb.200101081; Bodoor K, 1999, J CELL SCI, V112, P2253; CHAUDHARY N, 1993, J CELL BIOL, V122, P295, DOI 10.1083/jcb.122.2.295; Conti E, 2001, CURR OPIN CELL BIOL, V13, P310, DOI 10.1016/S0955-0674(00)00213-1; CORNINGS DE, 1970, EXP CELL RES, V62, P293; COURVALIN JC, 1990, J CLIN INVEST, V86, P279, DOI 10.1172/JCI114696; Cronshaw JA, 2002, J CELL BIOL, V158, P915, DOI 10.1083/jcb.200206106; DABAUVALLE MC, 1990, CHROMOSOMA, V100, P56, DOI 10.1007/BF00337603; Daigle N, 2001, J CELL BIOL, V154, P71, DOI 10.1083/jcb.200101089; DAVIS LI, 1986, CELL, V45, P699, DOI 10.1016/0092-8674(86)90784-1; Doye V, 1997, CURR OPIN CELL BIOL, V9, P401, DOI 10.1016/S0955-0674(97)80014-2; Drummond SP, 2002, J CELL BIOL, V158, P53, DOI 10.1083/jcb.200108145; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; FINLAY DR, 1991, J CELL BIOL, V114, P169, DOI 10.1083/jcb.114.1.169; FINLAY DR, 1990, CELL, V60, P17, DOI 10.1016/0092-8674(90)90712-N; Fontoura BMA, 1999, J CELL BIOL, V144, P1097, DOI 10.1083/jcb.144.6.1097; FORBES DJ, 1983, CELL, V34, P13, DOI 10.1016/0092-8674(83)90132-0; GOLDBERG MW, 1992, J STRUCT BIOL, V108, P257, DOI 10.1016/1047-8477(92)90026-7; Goldberg MW, 1997, J CELL SCI, V110, P409; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Grandi P, 1997, MOL BIOL CELL, V8, P2017, DOI 10.1091/mbc.8.10.2017; Haraguchi T, 2000, J CELL SCI, V113, P779; Hetzer M, 2000, MOL CELL, V5, P1013, DOI 10.1016/S1097-2765(00)80266-X; Hetzer M, 2001, NAT CELL BIOL, V3, P1086, DOI 10.1038/ncb1201-1086; Imreh G, 2000, EXP CELL RES, V259, P180, DOI 10.1006/excr.2000.4935; Jordan M, 1996, NUCLEIC ACIDS RES, V24, P596, DOI 10.1093/nar/24.4.596; Kuznetsov NV, 2002, CHROMOSOMA, V111, P236, DOI 10.1007/s00412-002-0208-2; LOHKA MJ, 1983, SCIENCE, V220, P719, DOI 10.1126/science.6601299; Lutzmann M, 2002, EMBO J, V21, P387, DOI 10.1093/emboj/21.3.387; Macaulay C, 1996, J CELL BIOL, V132, P5, DOI 10.1083/jcb.132.1.5; Marelli M, 2001, J CELL BIOL, V153, P709, DOI 10.1083/jcb.153.4.709; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; MAUL GG, 1977, J CELL BIOL, V74, P492, DOI 10.1083/jcb.74.2.492; NEWPORT J, 1987, CELL, V48, P205, DOI 10.1016/0092-8674(87)90424-7; Ohno M, 1998, CELL, V92, P327, DOI 10.1016/S0092-8674(00)80926-5; Palacios I, 1997, EMBO J, V16, P6783, DOI 10.1093/emboj/16.22.6783; Powers MA, 1997, J CELL BIOL, V136, P241, DOI 10.1083/jcb.136.2.241; RADU A, 1994, J BIOL CHEM, V269, P17600; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Rout MP, 2000, J CELL BIOL, V148, P635, DOI 10.1083/jcb.148.4.635; Shevchenko A, 1997, RAPID COMMUN MASS SP, V11, P1015, DOI 10.1002/(SICI)1097-0231(19970615)11:9<1015::AID-RCM958>3.0.CO;2-H; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Siniossoglou S, 1996, CELL, V84, P265, DOI 10.1016/S0092-8674(00)80981-2; Siniossoglou S, 2000, J CELL BIOL, V149, P41, DOI 10.1083/jcb.149.1.41; Stoffler D, 1999, CURR OPIN CELL BIOL, V11, P391, DOI 10.1016/S0955-0674(99)80055-6; Vasu S, 2001, J CELL BIOL, V155, P339, DOI 10.1083/jcb.200108007; Vasu SK, 2001, CURR OPIN CELL BIOL, V13, P363, DOI 10.1016/S0955-0674(00)00221-0; Walther TC, 2002, J CELL BIOL, V158, P63, DOI 10.1083/jcb.200202088; Walther TC, 2001, EMBO J, V20, P5703, DOI 10.1093/emboj/20.20.5703; Wiese C, 1997, J CELL SCI, V110, P1489; Wu XS, 2001, P NATL ACAD SCI USA, V98, P3191, DOI 10.1073/pnas.051631598	54	310	315	0	15	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 18	2003	113	2					195	206		10.1016/S0092-8674(03)00235-6	http://dx.doi.org/10.1016/S0092-8674(03)00235-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	672EP	12705868	Bronze			2022-12-28	WOS:000182508500009
J	Gandhi, TK; Weingart, SN; Borus, J; Seger, AC; Peterson, J; Burdick, E; Seger, DL; Shu, K; Federico, F; Leape, LL; Bates, DW				Gandhi, TK; Weingart, SN; Borus, J; Seger, AC; Peterson, J; Burdick, E; Seger, DL; Shu, K; Federico, F; Leape, LL; Bates, DW			Adverse drug events in ambulatory care	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HOSPITALIZED-PATIENTS; RISK-FACTORS; OUTPATIENTS; PREVENTION; COSTS	BACKGROUND: Adverse events related to drugs occur frequently among inpatients, and many of these events are preventable. However, few data are available on adverse drug events among outpatients. We conducted a study to determine the rates, types, severity, and preventability of such events among outpatients and to identify preventive strategies. METHODS: We performed a prospective cohort study, including a survey of patients and a chart review, at four adult primary care practices in Boston (two hospital-based and two community-based), involving a total of 1202 outpatients who received at least one prescription during a four-week period. Prescriptions were computerized at two of the practices and handwritten at the other two. RESULTS: Of the 661 patients who responded to the survey (response rate, 55 percent), 162 had adverse drug events (25 percent; 95 percent confidence interval, 20 to 29 percent), with a total of 181 events (27 per 100 patients). Twenty-four of the events (13 percent) were serious, 51 (28 percent) were ameliorable, and 20 (11 percent) were preventable. Of the 51 ameliorable events, 32 (63 percent) were attributed to the physician's failure to respond to medication-related symptoms and 19 (37 percent) to the patient's failure to inform the physician of the symptoms. The medication classes most frequently involved in adverse drug events were selective serotonin-reuptake inhibitors (10 percent), beta-blockers (9 percent), angiotensin-converting-enzyme inhibitors (8 percent), and nonsteroidal antiinflammatory agents (8 percent). On multivariate analysis, only the number of medications taken was significantly associated with adverse events. CONCLUSIONS: Adverse events related to drugs are common in primary care, and many are preventable or ameliorable. Monitoring for and acting on symptoms are important. Improving communication between outpatients and providers may help prevent adverse events related to drugs.	Brigham & Womens Hosp, Div Gen Internal Med, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, Boston, MA 02215 USA; Harvard Risk Management Fdn, Boston, MA USA; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard University; Harvard T.H. Chan School of Public Health	Gandhi, TK (corresponding author), Brigham & Womens Hosp, Div Gen Med, 75 Francis St, Boston, MA 02115 USA.	tgandhi@partners.org						Bates DW, 1999, ARCH INTERN MED, V159, P2553, DOI 10.1001/archinte.159.21.2553; BATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29, DOI 10.1001/jama.274.1.29; Bates DW, 1997, JAMA-J AM MED ASSOC, V277, P307, DOI 10.1001/jama.277.4.307; Borowitz SM, 1998, JAMA-J AM MED ASSOC, V280, P1321, DOI 10.1001/jama.280.15.1321; Classen DC, 1997, JAMA-J AM MED ASSOC, V277, P301, DOI 10.1001/jama.277.4.301; FOLLI HL, 1987, PEDIATRICS, V79, P718; Gandhi TK, 2000, J GEN INTERN MED, V15, P149, DOI 10.1046/j.1525-1497.2000.04199.x; Gurwitz JH, 2003, JAMA-J AM MED ASSOC, V289, P1107, DOI 10.1001/jama.289.9.1107; Hanlon JT, 1997, J AM GERIATR SOC, V45, P945, DOI 10.1111/j.1532-5415.1997.tb02964.x; HUTCHINSON TA, 1986, J CHRON DIS, V39, P533, DOI 10.1016/0021-9681(86)90198-0; Lazarou J, 1998, JAMA-J AM MED ASSOC, V279, P1200, DOI 10.1001/jama.279.15.1200; LEAPE LL, 1995, JAMA-J AM MED ASSOC, V274, P35, DOI 10.1001/jama.1995.03530010049034; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; Li YC, 2001, INT J MED INFORM, V61, P241, DOI 10.1016/S1386-5056(01)00146-0; ONEIL AC, 1993, ANN INTERN MED, V119, P370, DOI 10.7326/0003-4819-119-5-199309010-00004; SANDS DZ, 2001, HIMSS P, V3; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	17	912	934	1	30	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 17	2003	348	16					1556	1564		10.1056/NEJMsa020703	http://dx.doi.org/10.1056/NEJMsa020703			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	667TT	12700376	Bronze			2022-12-28	WOS:000182248900007
J	Pollard, TD				Pollard, TD			The cytoskeleton, cellular motility and the reductionist agenda	NATURE			English	Article							ACTIN; DYNAMICS; MECHANISMS; MICROSCOPY; MUTATIONS; LISTERIA; COMPLEX		Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA	Yale University	Pollard, TD (corresponding author), Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA.	thomas.pollard@yale.edu						Amann KJ, 2001, P NATL ACAD SCI USA, V98, P15009, DOI 10.1073/pnas.211556398; Berg JS, 2001, MOL BIOL CELL, V12, P780, DOI 10.1091/mbc.12.4.780; Bray D, 2002, P NATL ACAD SCI USA, V99, P7, DOI 10.1073/pnas.022641699; Burgess SA, 2003, NATURE, V421, P715, DOI 10.1038/nature01377; Fuchs E, 1998, SCIENCE, V279, P514, DOI 10.1126/science.279.5350.514; Gerbal F, 2000, BIOPHYS J, V79, P2259, DOI 10.1016/S0006-3495(00)76473-3; Gerull B, 2002, NAT GENET, V30, P201, DOI 10.1038/ng815; Hu AH, 2002, J BIOL CHEM, V277, P46512, DOI 10.1074/jbc.M208506200; Kim AS, 2000, NATURE, V404, P151, DOI 10.1038/35004513; Li HL, 2002, STRUCTURE, V10, P1317, DOI 10.1016/S0969-2126(02)00827-4; Loisel TP, 1999, NATURE, V401, P613, DOI 10.1038/44183; Mocz G, 2001, STRUCTURE, V9, P93, DOI 10.1016/S0969-2126(00)00557-8; Mogilner A, 2002, BIOPHYS J, V83, P1237, DOI 10.1016/S0006-3495(02)73897-6; Mohler PJ, 2003, NATURE, V421, P634, DOI 10.1038/nature01335; Moller-Jensen J, 2002, EMBO J, V21, P3119, DOI 10.1093/emboj/cdf320; Peterson JR, 2002, CHEM BIOL, V9, P1275, DOI 10.1016/S1074-5521(02)00284-3; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; Pollard TD, 2000, ANNU REV BIOPH BIOM, V29, P545, DOI 10.1146/annurev.biophys.29.1.545; Pollard TD, 2002, CELL BIOL; Roberts TM, 2000, J CELL BIOL, V149, P7, DOI 10.1083/jcb.149.1.7; Robinson RC, 2001, SCIENCE, V294, P1679, DOI 10.1126/science.1066333; Roy P, 2001, J CELL BIOL, V153, P1035, DOI 10.1083/jcb.153.5.1035; Tong AHY, 2001, SCIENCE, V294, P2364, DOI 10.1126/science.1065810; Tong AHY, 2002, SCIENCE, V295, P321, DOI 10.1126/science.1064987; Tyson JJ, 2001, NAT REV MOL CELL BIO, V2, P908, DOI 10.1038/35103078; Vale RD, 2000, SCIENCE, V288, P88, DOI 10.1126/science.288.5463.88; van den Ent F, 2001, CURR OPIN MICROBIOL, V4, P634, DOI 10.1016/S1369-5274(01)00262-4; Volkman BF, 2002, CELL, V111, P565, DOI 10.1016/S0092-8674(02)01076-0; WALKER RA, 1988, J CELL BIOL, V107, P1437, DOI 10.1083/jcb.107.4.1437; Wang L, 2001, MOL BIOL CELL, V12, P3257, DOI 10.1091/mbc.12.10.3257; Watanabe N, 2002, SCIENCE, V295, P1083, DOI 10.1126/science.1067470; Waterman-Storer CM, 1998, CURR BIOL, V8, P1227, DOI 10.1016/S0960-9822(07)00515-5	32	218	222	2	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 17	2003	422	6933					741	745		10.1038/nature01598	http://dx.doi.org/10.1038/nature01598			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	668CG	12700767				2022-12-28	WOS:000182272300047
J	Emanuel, EJ; Young-Xu, Y; Levinsky, NG; Gazelle, G; Saynina, O; Ash, AS				Emanuel, EJ; Young-Xu, Y; Levinsky, NG; Gazelle, G; Saynina, O; Ash, AS			Chemotherapy use among medicare beneficiaries at the end of life	ANNALS OF INTERNAL MEDICINE			English	Article							CELL LUNG-CANCER; QUALITY-OF-LIFE; RANDOMIZED-TRIAL; EXPECTATIONS; CISPLATIN; ATTITUDES; MITOMYCIN; SURVIVAL	Background: Although many observers believe that cancer chef motherapy is overused at the end of life, there are no published data on this. Objective: To determine the frequency and duration of chemotherapy use in the last 6 months of life stratified by type of cancer, age, and sex. Design: Retrospective cohort Analysis. Setting: Administrative databases from Massachusetts and California. Patients: All Medicare patients Who died of cancer in Massachusetts and 5% of Medicare cancer decedents in California in 1996. Measurements: Use of intravenous chemotherapy agents, chemotherapy administration, or medical evaluation for chemotherapy from Medicare billing data for each patient in 30-day periods from the date of death backward. Results: in Massachusetts, 33% of cancer decedents older than 65 years of age received chemotherapy in the last 6 months of life, 23% in the last 3 months, and 9% in the last month. In California, the percentages were 26%, 20%, and 9%, respectively. Chemotherapy use greatly declined with age. Chemotherapy use was similar for patients with breast, colon, and ovarian cancer and those with cancer generally considered unresponsive to chemotherapy, such as pancreatic, hepatocellular, or renal-cell cancer or melanoma. Patients with types of cancer that are unresponsive to chemotherapy had shorter duration of chemotherapy use. Conclusion: Among patients who died of cancer, chemotherapy was used frequently in the last 3 months of life. The cancer's responsiveness to chemotherapy does not seem to influence whether dying patients receive chemotherapy at the end of life.	NIH, Dept Clin Bioeth, Warren G Magnuson Clin Ctr, Bethesda, MD 20892 USA; Natl Bur Econ Res, Palo Alto, CA USA; Harvard Vanguard Associates, Boston, MA USA; Boston Univ, Sch Med, Boston, MA 02118 USA	National Institutes of Health (NIH) - USA; National Bureau of Economic Research; Harvard Vanguard Medical Associates; Boston University	Emanuel, EJ (corresponding author), NIH, Dept Clin Bioeth, Warren G Magnuson Clin Ctr, Bldg 10,Room 1C118, Bethesda, MD 20892 USA.		Ash, Arlene/AAG-2914-2019	Ash, Arlene/0000-0002-8448-0253	CLINICAL CENTER [Z01CL010508] Funding Source: NIH RePORTER	CLINICAL CENTER		ABELOFF DM, 2000, CLIN ONCOLOGY, P1681; Annas G J, 1992, Health Matrix Clevel, V2, P119; Burris HA, 1997, J CLIN ONCOL, V15, P2403, DOI 10.1200/JCO.1997.15.6.2403; Cullen MH, 1999, J CLIN ONCOL, V17, P3188, DOI 10.1200/JCO.1999.17.10.3188; Cullen M, 2001, LANCET ONCOL, V2, P173, DOI 10.1016/S1470-2045(00)00260-6; Cunningham D, 1998, LANCET, V352, P1413, DOI 10.1016/S0140-6736(98)02309-5; DEVITA WT, 2001, CANC PRINCIPLES PRAC, V1126, P1262; Doyle C, 2001, J CLIN ONCOL, V19, P1266, DOI 10.1200/JCO.2001.19.5.1266; Earle CC, 2000, CHEST, V117, P1239, DOI 10.1378/chest.117.5.1239; ELLIS PA, 1995, BRIT J CANCER, V71, P366, DOI 10.1038/bjc.1995.74; FIELD MJ, 1997, APPROACHING DEATH IM, P12; GOUGH IR, 1981, CLIN ONCOL, V7, P5; MCKHANN CF, 1999, TIME DIE, P1; Miller M, 2000, HASTINGS CENT REP, V30, P34, DOI 10.2307/3527646; Schrag D, 2001, J NATL CANCER I, V93, P850, DOI 10.1093/jnci/93.11.850; SLEVIN ML, 1990, BRIT MED J, V300, P1458, DOI 10.1136/bmj.300.6737.1458; SONTAG S, 1978, ILLNES METAPHOR; Wan GJ, 1997, PSYCHO-ONCOL, V6, P1; YELLEN SB, 1995, J CLIN ONCOL, V13, P1255, DOI 10.1200/JCO.1995.13.5.1255; 1997, CANC EC          MAR, P1	20	217	219	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	2003	138	8					639	643		10.7326/0003-4819-138-8-200304150-00011	http://dx.doi.org/10.7326/0003-4819-138-8-200304150-00011			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	666JH	12693886				2022-12-28	WOS:000182173800006
J	Rieseberg, LH; Livingstone, K				Rieseberg, LH; Livingstone, K			Evolution - Chromosomal speciation in primates	SCIENCE			English	Editorial Material							INVERSIONS		Indiana Univ, Dept Biol, Bloomington, IN 47405 USA	Indiana University System; Indiana University Bloomington	Rieseberg, LH (corresponding author), Indiana Univ, Dept Biol, Bloomington, IN 47405 USA.	lriesebe@indiana.edu	Rieseberg, Loren H/B-3591-2013	Rieseberg, Loren H/0000-0002-2712-2417				BAKER RJ, 1986, P NATL ACAD SCI USA, V83, P8245, DOI 10.1073/pnas.83.21.8245; Delneri D, 2003, NATURE, V422, P68, DOI 10.1038/nature01418; HALE DW, 1986, CHROMOSOMA, V94, P425, DOI 10.1007/BF00292751; Harrison RG, 1993, HYBRID ZONES EVOLUTI; Mayr E, 1942, ANIMAL SPECIES EVOLU; Navarro A, 2003, EVOLUTION, V57, P447, DOI 10.1554/0014-3820(2003)057[0447:APIGIP]2.0.CO;2; Navarro A, 2003, SCIENCE, V300, P321, DOI 10.1126/science.1080600; Noor MAF, 2001, P NATL ACAD SCI USA, V98, P12084, DOI 10.1073/pnas.221274498; Rieseberg LH, 2001, TRENDS ECOL EVOL, V16, P351, DOI 10.1016/S0169-5347(01)02187-5; STEBBINS GL, 1958, ADV GENET, V9, P147, DOI 10.1016/S0065-2660(08)60162-5; Via S, 2001, TRENDS ECOL EVOL, V16, P381, DOI 10.1016/S0169-5347(01)02188-7	11	39	40	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 11	2003	300	5617					267	268		10.1126/science.1084192	http://dx.doi.org/10.1126/science.1084192			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	665RQ	12690181				2022-12-28	WOS:000182135400037
J	Perin, I; Attaran, A				Perin, I; Attaran, A			Trading ideology for dialogue: an opportunity to fix international aid for health?	LANCET			English	Editorial Material									Harvard Univ, Carr Ctr Human Rights Policy, Cambridge, MA 02138 USA; Harvard Univ, John F Kennedy Sch Govt, Cambridge, MA 02138 USA; AXIOS Int, F-75001 Paris, France	Harvard University; Harvard University	Attaran, A (corresponding author), Harvard Univ, Carr Ctr Human Rights Policy, 79 JFK St, Cambridge, MA 02138 USA.							ARHINTENKORANG D, 2000, MOBILIZING RESOURCES; Attaran A, 2001, LANCET, V357, P57, DOI 10.1016/S0140-6736(00)03576-5; BELLAMY C, 1999, STATEMENT UNICEF EXE; BUSE K, 1994, HEALTH POLICY PLANN, V9, P95, DOI 10.1093/heapol/9.1.95; England S, 2001, PRACTICE POLICIES US; FEACHEM RGA, 2000, B WORLD HEALTH ORGAN, V78, P2; GRIBBLE JN, 1993, EPIDEMIOLOGICAL TRAN, P200; Gwatkin DR, 1999, LANCET, V354, P586, DOI 10.1016/S0140-6736(99)02108-X; HIBOU B, 1998, REV ESPRIT       AUG, P98; Kim J., 2000, DYING GROWTH; Knippenberg R, 1997, INT J HEALTH PLAN M, V12, pS9, DOI 10.1002/(SICI)1099-1751(199706)12:1+<S9::AID-HPM471>3.3.CO;2-U; Lee K, 1996, BRIT MED J, V312, P302; MICHAUD C, 1994, B WORLD HEALTH ORGAN, V72, P639; MURRAY CLJ, 1994, GLOBAL HLTH STAT COM; ROSS R, 1910, PREVENTION MALARIA, P295; RUFFIN JC, 1992, PIEGE HUMANITAIRE; SINDZINGRE A, 2000, REV ESPRIT       JUN, P116; Soucat A, 1997, INT J HEALTH PLAN M, V12, pS109, DOI 10.1002/(SICI)1099-1751(199706)12:1+<S109::AID-HPM468>3.3.CO;2-7; STIGLITZ J, 1998, N S I SEM RESP CRIS, P11; *UN, 2001, PI1380 UN; WANGOMBE JK, 1997, 365 WORLD BANK; *WHO, VACC COV TIM SER 197; *WHO, 1968, 2ND 10 YEARS WHO 195; *WHO COMM MACR HLT, 2001, 5 WHO COMM MACR HLTH; *WORLD BANK, 1996, INT ASS HLTH CAR FIN; *WORLD BANK, 1975, POL SER HLTH SECT PO, P29; *WORLD BANK GROUP, PROJ POL STRAT; 2001, LANCET, V358, P1827	28	20	21	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 5	2003	361	9364					1216	1219		10.1016/S0140-6736(03)12956-X	http://dx.doi.org/10.1016/S0140-6736(03)12956-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	664ZF	12686055				2022-12-28	WOS:000182094600025
J	Eriksson, M; Brown, WT; Gordon, LB; Glynn, MW; Singer, J; Scott, L; Erdos, MR; Robbins, CM; Moses, TY; Berglund, P; Dutra, A; Pak, E; Durkin, S; Csoka, AB; Boehnke, M; Glover, TW; Collins, FS				Eriksson, M; Brown, WT; Gordon, LB; Glynn, MW; Singer, J; Scott, L; Erdos, MR; Robbins, CM; Moses, TY; Berglund, P; Dutra, A; Pak, E; Durkin, S; Csoka, AB; Boehnke, M; Glover, TW; Collins, FS			Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome	NATURE			English	Article							NUCLEAR-ENVELOPE; UNIPARENTAL DISOMY; CHROMOSOME-1; HOMOZYGOSITY; PATIENT; LMNA	Hutchinson-Gilford progeria syndrome (HGPS) is a rare genetic disorder characterized by features reminiscent of marked premature ageing(1,2). Here, we present evidence of mutations in lamin A (LMNA) as the cause of this disorder. The HGPS gene was initially localized to chromosome 1q by observing two cases of uniparental isodisomy of 1q - the inheritance of both copies of this material from one parent - and one case with a 6-megabase paternal interstitial deletion. Sequencing of LMNA, located in this interval and previously implicated in several other heritable disorders(3,4), revealed that 18 out of 20 classical cases of HGPS harboured an identical de novo ( that is, newly arisen and not inherited) single-base substitution, G608G( GGC > GGT), within exon 11. One additional case was identified with a different substitution within the same codon. Both of these mutations result in activation of a cryptic splice site within exon 11, resulting in production of a protein product that deletes 50 amino acids near the carboxy terminus. Immunofluorescence of HGPS fibroblasts with antibodies directed against lamin A revealed that many cells show visible abnormalities of the nuclear membrane. The discovery of the molecular basis of this disease may shed light on the general phenomenon of human ageing.	NHGRI, NIH, Bethesda, MD 20892 USA; NIAID, Viral Dis Lab, NIH, Bethesda, MD 20892 USA; New York State Inst Basic Res Dev Disabil, Dept Human Genet, Staten Isl, NY 10314 USA; Tufts Univ, Sch Med, Dept Anat & Cellular Biol, Boston, MA 02111 USA; Rhode Isl Hosp, Dept Pediat, Providence, RI 02903 USA; Univ Michigan, Dept Human Genet, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biostat, Ann Arbor, MI 48109 USA; Brown Univ, Dept Biochem Mol Biol & Cell Biol, Providence, RI 02912 USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Institute for Basic Research in Developmental Disabilities; Tufts University; Lifespan Health Rhode Island; Rhode Island Hospital; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Brown University	Collins, FS (corresponding author), NHGRI, NIH, Bethesda, MD 20892 USA.	fc23a@nih.gov	Brown, William/GXN-2777-2022; Gordon, Leslie B./AAJ-5793-2021		NATIONAL HUMAN GENOME RESEARCH INSTITUTE [Z01HG200305] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000658] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007544] Funding Source: NIH RePORTER	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER PB, 1981, ARCH PATHOL LAB MED, V105, P384; Bergo MO, 2002, P NATL ACAD SCI USA, V99, P13049, DOI 10.1073/pnas.192460799; BROWN WT, 1979, MECH AGEING DEV, V9, P325; BROWN WT, 1992, AM J CLIN NUTR, V55, P1222; BROWN WT, 1990, GENETIC EFFECTS AGIN, V2, P521; Burke B, 2002, NAT REV MOL CELL BIO, V3, P575, DOI 10.1038/nrm879; Casper AM, 2002, CELL, V111, P779, DOI 10.1016/S0092-8674(02)01113-3; De Sandre-Giovannoli A, 2002, AM J HUM GENET, V70, P726, DOI 10.1086/339274; DEBUSK FL, 1972, J PEDIATR-US, V80, P697, DOI 10.1016/S0022-3476(72)80229-4; EGGERT M, 1993, EUR J BIOCHEM, V213, P659, DOI 10.1111/j.1432-1033.1993.tb17806.x; FISHER DZ, 1986, P NATL ACAD SCI USA, V83, P6450, DOI 10.1073/pnas.83.17.6450; Gelb BD, 1998, AM J HUM GENET, V62, P848, DOI 10.1086/301795; Genschel J, 2000, HUM MUTAT, V16, P451, DOI 10.1002/1098-1004(200012)16:6<451::AID-HUMU1>3.0.CO;2-9; HENNEKES H, 1994, J CELL SCI, V107, P1019; KHALIFA MM, 1989, CLIN GENET, V35, P125; LANDER ES, 1987, SCIENCE, V236, P1567, DOI 10.1126/science.2884728; LIN F, 1993, J BIOL CHEM, V268, P16321; Luengo WD, 2002, AM J MED GENET, V113, P298, DOI 10.1002/ajmg.10753; LUTZ RJ, 1992, P NATL ACAD SCI USA, V89, P3000, DOI 10.1073/pnas.89.7.3000; Pendas AM, 2002, NAT GENET, V31, P94, DOI 10.1038/ng871; Pulkkinen L, 1997, AM J HUM GENET, V61, P611, DOI 10.1086/515524; SHIANG R, 1994, CELL, V78, P335, DOI 10.1016/0092-8674(94)90302-6; SINENSKY M, 1994, J CELL SCI, V107, P61; SMITH AS, 1993, AM J NEURORADIOL, V14, P441; SMITH CAB, 1953, J R STAT SOC B, V15, P153; Speckman, 2000, AM J HUM GENET, V67, P775; Sullivan T, 1999, J CELL BIOL, V147, P913, DOI 10.1083/jcb.147.5.913; TREVASMACIEL A, 1988, AM J MED GENET, V31, P483	28	1478	1537	5	207	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 15	2003	423	6937					293	298		10.1038/nature01629	http://dx.doi.org/10.1038/nature01629			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678EX	12714972	Green Published			2022-12-28	WOS:000182853100044
J	Zile, MR; Gaasch, WH				Zile, MR; Gaasch, WH			Heart failure in aortic stenosis - Improving diagnosis and treatment	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Med Univ S Carolina, Gazes Cardiac Res Inst, Dept Med, Div Cardiol, Charleston, SC 29425 USA; Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC USA; Lahey Clin Fdn, Dept Cardiovasc Med, Burlington, MA USA	Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center; Lahey Hospital & Medical Center	Zile, MR (corresponding author), Med Univ S Carolina, Gazes Cardiac Res Inst, Dept Med, Div Cardiol, Charleston, SC 29425 USA.			Zile, Michael/0000-0001-7076-221X					0	19	19	0	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 1	2003	348	18					1735	1736		10.1056/NEJMp030035	http://dx.doi.org/10.1056/NEJMp030035			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	672VK	12724478				2022-12-28	WOS:000182543500001
J	Wood, ZA; Poole, LB; Karplus, PA				Wood, ZA; Poole, LB; Karplus, PA			Peroxiredoxin evolution and the regulation of hydrogen peroxide signaling	SCIENCE			English	Article							2-CYS PEROXIREDOXIN; MAMMALIAN PEROXIREDOXIN; THIOREDOXIN PEROXIDASE; ALKYL-HYDROPEROXIDE; CRYSTAL-STRUCTURE; OXIDATIVE STRESS; THIOL PEROXIDASE; SITE CYSTEINE; I EXPRESSION; NADH OXIDASE	Eukaryotic 2-Cys peroxiredoxins (2-Cys Prxs) not only act as antioxidants, but also appear to regulate hydrogen peroxide-mediated signal transduction. We show that bacterial 2-Cys Prxs are much less sensitive to oxidative inactivation than are eukaryotic 2-Cys Prxs. By identifying two sequence motifs unique to the sensitive 2-Cys Prxs and comparing the crystal structure of a bacterial 2-Cys Prx at 2.2 angstrom resolution with other Prx structures, we define the structural origins of sensitivity. We suggest this adaptation allows 2-Cys Prxs to act as floodgates, keeping resting levels of hydrogen peroxide low, while permitting higher levels during signal transduction.	Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97333 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Biochem, Winston Salem, NC 27157 USA	Oregon State University; Wake Forest University; Wake Forest Baptist Medical Center	Karplus, PA (corresponding author), Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97333 USA.	karplusp@ucs.orst.edu		Karplus, Paul/0000-0001-8725-6292	NIEHS NIH HHS [ES00210] Funding Source: Medline; NIGMS NIH HHS [R01 GM050389-10, GM50389, R01 GM050389] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000210] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050389] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen RG, 2000, FREE RADICAL BIO MED, V28, P463, DOI 10.1016/S0891-5849(99)00242-7; Alphey MS, 2000, J MOL BIOL, V300, P903, DOI 10.1006/jmbi.2000.3881; Bryk R, 2000, NATURE, V407, P211, DOI 10.1038/35025109; Carmody RJ, 2001, REDOX REP, V6, P77, DOI 10.1179/135100001101536085; Cha MK, 2000, BIOCHEMISTRY-US, V39, P6944, DOI 10.1021/bi000034j; Chae HZ, 1999, DIABETES RES CLIN PR, V45, P101, DOI 10.1016/S0168-8227(99)00037-6; Chang JW, 2001, BIOCHEM BIOPH RES CO, V289, P507, DOI 10.1006/bbrc.2001.5989; Chang TS, 2002, J BIOL CHEM, V277, P25370, DOI 10.1074/jbc.M110432200; Chung YM, 2001, ANTICANCER RES, V21, P1129; Claiborne A, 1999, BIOCHEMISTRY-US, V38, P15407, DOI 10.1021/bi992025k; Delaunay A, 2002, CELL, V111, P471, DOI 10.1016/S0092-8674(02)01048-6; Dietz KJ, 2002, J EXP BOT, V53, P1321, DOI 10.1093/jexbot/53.372.1321; Fujii J, 2002, REDOX REP, V7, P123, DOI 10.1179/135100002125000352; Hancock JT, 2001, BIOCHEM SOC T, V29, P345, DOI 10.1042/BST0290345; Hirotsu S, 1999, P NATL ACAD SCI USA, V96, P12333, DOI 10.1073/pnas.96.22.12333; Hofmann B, 2002, BIOL CHEM, V383, P347, DOI 10.1515/BC.2002.040; Jin DY, 1997, J BIOL CHEM, V272, P30952, DOI 10.1074/jbc.272.49.30952; Kang SW, 1998, J BIOL CHEM, V273, P6297, DOI 10.1074/jbc.273.11.6297; Kim H, 2000, J BIOL CHEM, V275, P18266, DOI 10.1074/jbc.275.24.18266; Kinnula VL, 2002, J PATHOL, V196, P316, DOI 10.1002/path.1042; Konig J, 2002, P NATL ACAD SCI USA, V99, P5738, DOI 10.1073/pnas.072644999; Koo KH, 2002, ARCH BIOCHEM BIOPHYS, V397, P312, DOI 10.1006/abbi.2001.2700; Mu ZM, 2002, J BIOL CHEM, V277, P43175, DOI 10.1074/jbc.M206066200; NIIMURA Y, 1995, J BIOL CHEM, V270, P25645, DOI 10.1074/jbc.270.43.25645; Noh DY, 2001, ANTICANCER RES, V21, P2085; Park SG, 2000, J BIOL CHEM, V275, P5723, DOI 10.1074/jbc.275.8.5723; Park SH, 2000, CLIN CANCER RES, V6, P4915; Poole LB, 2000, FREE RADICAL BIO MED, V28, P108, DOI 10.1016/S0891-5849(99)00218-X; Rabilloud T, 2002, J BIOL CHEM, V277, P19396, DOI 10.1074/jbc.M106585200; Rabilloud T, 2001, PROTEOMICS, V1, P1105, DOI 10.1002/1615-9861(200109)1:9<1105::AID-PROT1105>3.0.CO;2-M; Ritz D, 2001, SCIENCE, V294, P158, DOI 10.1126/science.1063143; Schroder E, 2000, STRUCTURE, V8, P605, DOI 10.1016/S0969-2126(00)00147-7; Wagner E, 2002, BIOCHEM J, V366, P777, DOI 10.1042/BJ20020525; Wong CM, 2000, ANTIOXID REDOX SIGN, V2, P507, DOI 10.1089/15230860050192288; Wonsey DR, 2002, P NATL ACAD SCI USA, V99, P6649, DOI 10.1073/pnas.102523299; Wood ZA, 2002, BIOCHEMISTRY-US, V41, P5493, DOI 10.1021/bi012173m; Wood ZA, 2003, TRENDS BIOCHEM SCI, V28, P32, DOI 10.1016/S0968-0004(02)00003-8; Yanagawa T, 2000, CANCER LETT, V156, P27, DOI 10.1016/S0304-3835(00)00434-1; Yanagawa T, 1999, CANCER LETT, V145, P127, DOI 10.1016/S0304-3835(99)00243-8; Yang KS, 2002, J BIOL CHEM, V277, P38029, DOI 10.1074/jbc.M206626200	40	1083	1133	5	135	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 25	2003	300	5619					650	653		10.1126/science.1080405	http://dx.doi.org/10.1126/science.1080405			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	671FB	12714747				2022-12-28	WOS:000182453700045
J	Judson, HF				Judson, HF			"The greatest surprise for everyone" - Notes on the 50th anniversary of the double helix	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									George Washington Univ, Ctr Hist Recent Sci, Washington, DC 20052 USA	George Washington University	Judson, HF (corresponding author), George Washington Univ, Ctr Hist Recent Sci, Washington, DC 20052 USA.							AVERY O, 1943, COMMUNICATION   0526; Avery OT, 1944, J EXP MED, V79, P137, DOI 10.1084/jem.79.2.137; Bergmann M, 1937, SCIENCE, V86, P187, DOI 10.1126/science.86.2226.187; CHARGAFF E, 1950, EXPERIENTIA, V6, P201, DOI 10.1007/BF02173653; CRICK F, 1974, NATURE, V248, P766, DOI 10.1038/248766a0; CRICK F H, 1958, Symp Soc Exp Biol, V12, P138; JUDSON HF, 1979, 8 DAY CREATION, P39; Judson HF., 1979, 8 DAY CREATION; SANGER F, 1949, BIOCHEM J, V44, P126, DOI 10.1042/bj0440126; SANGER F, 1949, COLD SPRING HARB SYM, V14, P153, DOI 10.1101/SQB.1950.014.01.019	10	4	4	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 24	2003	348	17					1712	1714		10.1056/NEJMon035356	http://dx.doi.org/10.1056/NEJMon035356			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	670PB	12711749				2022-12-28	WOS:000182416300014
J	Pearson, H				Pearson, H			Biotech firms pin hopes on defence	NATURE			English	News Item																		2003, NATURE, V421, P877	1	0	0	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 24	2003	422	6934					790	790		10.1038/422790b	http://dx.doi.org/10.1038/422790b			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	670WR	12712154	Bronze			2022-12-28	WOS:000182432600005
J	Barkai, G; Arbuzova, S; Berkenstadt, M; Heifetz, S; Cuckle, H				Barkai, G; Arbuzova, S; Berkenstadt, M; Heifetz, S; Cuckle, H			Frequency of Down's syndrome and neural-tube defects in the same family	LANCET			English	Article							MATERNAL RISK-FACTORS; METHYLENETETRAHYDROFOLATE REDUCTASE; FOLIC-ACID; PLASMA HOMOCYSTEINE; FOLATE METABOLISM; SPINA-BIFIDA; PREGNANCY; GENE; POLYMORPHISM; MUTATION	Background There is evidence that some mothers of infants with Down's syndrome have abnormal metabolism of folate and methyl, as well as mutations in folate genes, which are features that are also seen in neural-tube defects (NTD). We therefore investigated whether Down's syndrome and NTD arise more often in the same family than would be expected from the incidence of each disorder considered separately. Methods We studied two series of families using information obtained from medical records about maternal age, pregnancy outcome, congenital malformations, and karyotype: the first, 493 families from Israel who were at high risk of NTD (445 with a history of NTD and 48 with isolated hydrocephalus); and the second, 516 families from the Ukraine at high risk of Down's syndrome. Findings In the families at risk of NTD, there were a total of 11 pregnancies affected by Down's syndrome in 1492 at-risk pregnancies (compared with 1.87 expected on the basis of maternal age), which was a significant increase (p<0.00001). In the families at risk of Down's syndrome, there were seven NTD pregnancies in 1847 at risk, compared with 1.37 expected (p<0.001). Interpretation In this study, we provide direct evidence of a link between Down's syndrome and NTD. Folate supplementation before conception has the potential to reduce the frequency of Down's syndrome.	Chaim Sheba Med Ctr, Danek Gertner Inst Human Genet, IL-52621 Tel Hashomer, Israel; Tel Aviv Univ, Sackler Sch Med, IL-52621 Tel Aviv, Israel; Interreg Medicogenet Ctr, Donetsk, Ukraine; Univ Leeds, Leeds, W Yorkshire, England	Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine; University of Leeds	Barkai, G (corresponding author), Chaim Sheba Med Ctr, Danek Gertner Inst Human Genet, IL-52621 Tel Hashomer, Israel.		Arbuzova, Svetlana/W-5491-2018	Arbuzova, Svetlana/0000-0002-5846-1067				Arbuzova S, 2001, CLIN GENET, V60, P456, DOI 10.1034/j.1399-0004.2001.600609.x; ARBUZOVA S, 1998, DOWNS SYNDROME RES P, V5, P26; Ashfield-Watt PAL, 2002, AM J CLIN NUTR, V76, P180, DOI 10.1093/ajcn/76.1.180; Berry RJ, 1999, NEW ENGL J MED, V341, P1485, DOI 10.1056/NEJM199911113412001; Botto LD, 2000, AM J EPIDEMIOL, V151, P862; Brattstrom L, 1998, BMJ-BRIT MED J, V316, P894, DOI 10.1136/bmj.316.7135.894; Chadefaux-Vekemans B, 2002, PEDIATR RES, V51, P766, DOI 10.1203/01.PDR.0000017484.64723.43; Cuckle H, 1999, PRENATAL DIAG, V19, P1177, DOI 10.1002/(SICI)1097-0223(199912)19:12<1177::AID-PD714>3.0.CO;2-N; CUCKLE HS, 1987, BRIT J OBSTET GYNAEC, V94, P387, DOI 10.1111/j.1471-0528.1987.tb03115.x; Fenech M, 2001, MUTAT RES-FUND MOL M, V480, P51, DOI 10.1016/S0027-5107(01)00168-3; Hassold T, 2000, CLIN GENET, V57, P95, DOI 10.1034/j.1399-0004.2000.570201.x; Hobbs CA, 2000, AM J HUM GENET, V67, P623, DOI 10.1086/303055; Jacob RA, 1998, J NUTR, V128, P1204, DOI 10.1093/jn/128.7.1204; James SJ, 1999, AM J CLIN NUTR, V70, P495; KIRKE PN, 1993, Q J MED, V86, P703; Little J., 1992, EPIDEMIOLOGY CONTROL, P604; NANCE WE, 1969, NATURE, V224, P373, DOI 10.1038/224373a0; O'Leary VB, 2002, AM J MED GENET, V107, P151, DOI 10.1002/ajmg.10121; Petersen MB, 2001, AM J HUM GENET, V69, P323; Posey DL, 1996, LANCET, V347, P686, DOI 10.1016/S0140-6736(96)91236-2; PRYTKOV AN, 1978, GENETIKA+, V14, P1461; STEEGERSTHEUNISSEN RPM, 1994, METABOLISM, V43, P1475, DOI 10.1016/0026-0495(94)90004-3; Stuppia L, 2002, EUR J HUM GENET, V10, P388, DOI 10.1038/sj.ejhg.5200819; vanderPut NMJ, 1997, QJM-INT J MED, V90, P505, DOI 10.1093/qjmed/90.8.505; Vollset SE, 2000, AM J CLIN NUTR, V71, P962; WALD N, 1991, LANCET, V338, P131; Wald NJ, 2001, LANCET, V358, P2069, DOI 10.1016/S0140-6736(01)07104-5; Wilson A, 1999, MOL GENET METAB, V67, P317, DOI 10.1006/mgme.1999.2879; Zittoun J, 1998, METABOLISM, V47, P1413, DOI 10.1016/S0026-0495(98)90315-8	29	60	68	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 19	2003	361	9366					1331	1335		10.1016/S0140-6736(03)13080-2	http://dx.doi.org/10.1016/S0140-6736(03)13080-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	669HP	12711468				2022-12-28	WOS:000182346100010
J	El-Hashemite, N; Zhang, HB; Henske, EP; Kwiatkowski, DJ				El-Hashemite, N; Zhang, HB; Henske, EP; Kwiatkowski, DJ			Mutation in TSC2 and activation of mammalian target of rapamycin signalling pathway in renal angiomyolipoma	LANCET			English	Article							CELL-GROWTH; PROLIFERATION	Mutations that inactivate either TSC1 or TSC2 cause tuberous sclerosis. We have used immunoblotting and immunohistochemical analysis to see whether there is phosphorylation of p70 S6 kinase, and the ribosomal S6 protein in anglomyolipomas occurring in tuberous sclerosis. Hamartin (encoded by TSC1) and S6K was expressed in all samples. Tuberin (TSC2) was weak or absent in angiomyolipomas, but present in healthy kidney, whereas, phosphorylated p70 S6 kinase and p56 were present only in angiomyolipomas. Our results indicate activation of a mammalian target of rapamycin metabolic pathway in tuberous sclerosis lesions, which contributes to their growth. We suggest that treatment with rapamycin and its analogues could benefit such patients.	Brigham & Womens Hosp, Dept Med, Div Haematol, Boston, MA 02115 USA; Fox Chase Canc Ctr, Philadelphia, PA 19111 USA	Harvard University; Brigham & Women's Hospital; Fox Chase Cancer Center	Kwiatkowski, DJ (corresponding author), Brigham & Womens Hosp, Dept Med, Div Haematol, 75 Francis St, Boston, MA 02115 USA.							Gao XS, 2001, GENE DEV, V15, P1383, DOI 10.1101/gad.901101; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Kwiatkowski DJ, 2002, HUM MOL GENET, V11, P525, DOI 10.1093/hmg/11.5.525; Potter CJ, 2001, CELL, V105, P357, DOI 10.1016/S0092-8674(01)00333-6; Tapon N, 2001, CELL, V105, P345, DOI 10.1016/S0092-8674(01)00332-4	5	151	157	0	6	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 19	2003	361	9366					1348	1349		10.1016/S0140-6736(03)13044-9	http://dx.doi.org/10.1016/S0140-6736(03)13044-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	669HP	12711473				2022-12-28	WOS:000182346100015
J	Boshoff, HIM; Reed, MB; Barry, CE; Mizrahi, V				Boshoff, HIM; Reed, MB; Barry, CE; Mizrahi, V			DnaE2 polymerase contributes to in vivo survival and the emergence of drug resistance in Mycobacterium tuberculosis	CELL			English	Article							IRRADIATED ESCHERICHIA-COLI; POL-II; REPLICATION RESTART; DAMAGE INDUCTION; MUTATION-RATES; ERROR-PRONE; EXPRESSION; SMEGMATIS; REPAIR; GENES	The presence of multiple copies of the major replicative DNA polymerase (DnaE) in some organisms, including important pathogens and symbionts, has remained an unresolved enigma. We postulated that one copy might participate in error-prone DNA repair synthesis. We found that UV irradiation of Mycobacterium tuberculosis results in increased mutation frequency in the surviving fraction. We identified dnaE2 as a gene that is upregulated in vitro by several DNA damaging agents, as well as during infection of mice. Loss of this protein reduces both survival of the bacillus after UV irradiation and the virulence of the organism in mice. Our data suggest that DnaE2, and not a member of the Y family of error-prone DNA polymerases, is the primary mediator of survival through inducible mutagenesis and can contribute directly to the emergence of drug resistance in vivo. These results may indicate a potential new target for therapeutic intervention.	NIAID, TB Res Sect, Host Def Lab, NIH, Rockville, MD 20852 USA; Univ Witwatersrand, Sch Pathol, MRC, NHLS,WITS Mol Mycobacteriol Res Unit, Johannesburg, South Africa; Natl Hlth Lab Serv, Johannesburg, South Africa	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Health Laboratory Service; University of Witwatersrand; National Health Laboratory Service	Barry, CE (corresponding author), NIAID, TB Res Sect, Host Def Lab, NIH, Twinbrook 2,12441 Parklawn Dr, Rockville, MD 20852 USA.	clifton-barry@nih.gov; mizrahiv@pathology.wits.ac.za	Barry, Clifton E/ABE-7992-2020; Barry, III, Clifton/H-3839-2012	Barry, Clifton E/0000-0002-2927-270X; Barry, III, Clifton/0000-0002-2927-270X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000783, Z01AI000734] Funding Source: NIH RePORTER; Intramural NIH HHS [Z01 AI000783-11] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Bjorkholm B, 2001, P NATL ACAD SCI USA, V98, P14607, DOI 10.1073/pnas.241517298; Borden A, 2002, J BACTERIOL, V184, P2674, DOI 10.1128/JB.184.10.2674-2681.2002; Boshoff HIM, 2001, SCAND J INFECT DIS, V33, P101, DOI 10.1080/003655401753382567; Boshoff HIM, 2000, J BACTERIOL, V182, P5479, DOI 10.1128/JB.182.19.5479-5485.2000; Brooks PC, 2001, J BACTERIOL, V183, P4459, DOI 10.1128/JB.183.15.4459-4467.2001; Courcelle J, 2001, GENETICS, V158, P41; Dalrymple BP, 2001, P NATL ACAD SCI USA, V98, P11627, DOI 10.1073/pnas.191384398; Davis EO, 2002, MOL MICROBIOL, V46, P791, DOI 10.1046/j.1365-2958.2002.03199.x; Davis EO, 2002, J BACTERIOL, V184, P3287, DOI 10.1128/JB.184.12.3287-3295.2002; Dervyn E, 2001, SCIENCE, V294, P1716, DOI 10.1126/science.1066351; Durbach SI, 1997, MOL MICROBIOL, V26, P643, DOI 10.1046/j.1365-2958.1997.5731934.x; Dye C, 2002, SCIENCE, V295, P2042, DOI 10.1126/science.1063814; Espinal MA, 2000, JAMA-J AM MED ASSOC, V283, P2537, DOI 10.1001/jama.283.19.2537; Flynn JL, 2001, ANNU REV IMMUNOL, V19, P93, DOI 10.1146/annurev.immunol.19.1.93; Frischkorn K, 1998, MOL MICROBIOL, V29, P1203, DOI 10.1046/j.1365-2958.1998.01003.x; Gao DX, 2001, J BIOL CHEM, V276, P4441, DOI 10.1074/jbc.M009830200; Goodman MF, 2002, ANNU REV BIOCHEM, V71, P17, DOI 10.1146/annurev.biochem.71.083101.124707; Huang YP, 1999, J MOL EVOL, V48, P756, DOI 10.1007/PL00006520; Inoue R, 2001, MOL GENET GENOMICS, V266, P564, DOI 10.1007/s004380100564; ITO J, 1991, NUCLEIC ACIDS RES, V19, P4045, DOI 10.1093/nar/19.15.4045; Karunakaran P, 2000, J BACTERIOL, V182, P3331, DOI 10.1128/JB.182.12.3331-3335.2000; Khil PP, 2002, MOL MICROBIOL, V44, P89, DOI 10.1046/j.1365-2958.2002.02878.x; Luria SE, 1943, GENETICS, V28, P491; Makarova KS, 2002, NUCLEIC ACIDS RES, V30, P482, DOI 10.1093/nar/30.2.482; Manca C, 2001, P NATL ACAD SCI USA, V98, P5752, DOI 10.1073/pnas.091096998; Manganelli R, 1999, MOL MICROBIOL, V31, P715, DOI 10.1046/j.1365-2958.1999.01212.x; Maor-Shoshani A, 2000, P NATL ACAD SCI USA, V97, P565, DOI 10.1073/pnas.97.2.565; McKinney JD, 2000, NATURE, V406, P735, DOI 10.1038/35021074; Mdluli K, 1996, J INFECT DIS, V174, P1085, DOI 10.1093/infdis/174.5.1085; Metzgar D, 2000, CELL, V101, P581, DOI 10.1016/S0092-8674(00)80869-7; Mizrahi V, 2000, MOLECULAR GENETICS OF MYCOBACTERIA, P159; Morlock GP, 2000, ANTIMICROB AGENTS CH, V44, P3298, DOI 10.1128/AAC.44.12.3298-3301.2000; Napolitano R, 2000, EMBO J, V19, P6259, DOI 10.1093/emboj/19.22.6259; OGAORA P, 1997, MED PRIN PRACT, V6, P91; Oliver A, 2000, SCIENCE, V288, P1251, DOI 10.1126/science.288.5469.1251; Parish T, 2000, MICROBIOL-SGM, V146, P1969, DOI 10.1099/00221287-146-8-1969; Pham P, 2001, P NATL ACAD SCI USA, V98, P8350, DOI 10.1073/pnas.111007198; Ramaswamy S., 1998, Tubercle and Lung Disease, V79, P3, DOI 10.1054/tuld.1998.0002; Rangarajan S, 2002, MOL MICROBIOL, V43, P617, DOI 10.1046/j.1365-2958.2002.02747.x; Rangarajan S, 1999, P NATL ACAD SCI USA, V96, P9224, DOI 10.1073/pnas.96.16.9224; Rosche WA, 2000, METHODS, V20, P4, DOI 10.1006/meth.1999.0901; Russell DG, 2001, NAT REV MOL CELL BIO, V2, P569, DOI 10.1038/35085034; Schlosser-Silverman E, 2000, J BACTERIOL, V182, P5225, DOI 10.1128/JB.182.18.5225-5230.2000; Schoolnik GK, 2001, METHOD ENZYMOL, V336, P3, DOI 10.1016/S0076-6879(01)36573-4; Sherman DR, 2001, P NATL ACAD SCI USA, V98, P7534, DOI 10.1073/pnas.121172498; SNAPPER SB, 1990, MOL MICROBIOL, V4, P1911, DOI 10.1111/j.1365-2958.1990.tb02040.x; Sung HM, 2003, J BACTERIOL, V185, P2153, DOI 10.1128/JB.185.7.2153-2160.2003; Wilson W, 1999, P NATL ACAD SCI USA, V96, P12833, DOI 10.1073/pnas.96.22.12833	48	310	327	0	17	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 18	2003	113	2					183	193		10.1016/S0092-8674(03)00270-8	http://dx.doi.org/10.1016/S0092-8674(03)00270-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	672EP	12705867	Bronze			2022-12-28	WOS:000182508500008
J	Eden, A; Gaudet, F; Waghmare, A; Jaenisch, R				Eden, A; Gaudet, F; Waghmare, A; Jaenisch, R			Chromosomal instability and tumors promoted by DNA hypomethylation	SCIENCE			English	Article									MIT, Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02142 USA; Max Delbruck Ctr Mol Med, Berlin, Germany; Univ Munich, Dept Biol, Munich, Germany	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Helmholtz Association; Max Delbruck Center for Molecular Medicine; University of Munich	Jaenisch, R (corresponding author), MIT, Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	jaenisch@wi.mit.edu		Waghmare, Alpana/0000-0003-2268-9470	NATIONAL CANCER INSTITUTE [R01CA087869] Funding Source: NIH RePORTER; NCI NIH HHS [CA87869] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Cichowski K, 1999, SCIENCE, V286, P2172, DOI 10.1126/science.286.5447.2172; Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557; FEINBERG AP, 1998, CANCER RES, V48, P1149; KENDAL WS, 1988, CANCER RES, V48, P1060; Schulz WA, 2002, GENE CHROMOSOME CANC, V35, P58, DOI 10.1002/gcc.10092; Wong N, 2001, AM J PATHOL, V159, P465, DOI 10.1016/S0002-9440(10)61718-X	6	986	1040	2	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 18	2003	300	5618					455	455		10.1126/science.1083557	http://dx.doi.org/10.1126/science.1083557			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	668LR	12702868				2022-12-28	WOS:000182295900029
J	Magurran, AE; Henderson, PA				Magurran, AE; Henderson, PA			Explaining the excess of rare species in natural species abundance distributions	NATURE			English	Article							LOWER SEVERN ESTUARY; POPULATION STABILITY; DYNAMICS	The observation that a few species in ecological communities are exceptionally abundant, whereas most are rare, prompted the development of species abundance models(1-3). Nevertheless, despite the large literature on the commonness and rarity of species inspired by these pioneering studies, some widespread empirical patterns of species abundance resist easy explanation(4). Notable among these is the observation(5) that in large assemblages there are more rare species than the log normal model predicts(6,7). Here we use a long-term (21-year) data set, from an estuarine fish community, to show how an ecological community can be separated into two components. Core species, which are persistent, abundant and biologically associated with estuarine habitats, are log normally distributed. Occasional species occur infrequently in the record, are typically low in abundance and have different habitat requirements; they follow a log series distribution. These distributions are overlaid, producing the negative skew that characterizes real data sets.	Univ St Andrews, Sch Biol, Gatty Marine Lab, St Andrews KY16 8LB, Fife, Scotland; Pisces Conservat Ltd, Lymington SO41 8GN, Hants, England	University of St Andrews	Magurran, AE (corresponding author), Univ St Andrews, Sch Biol, Gatty Marine Lab, St Andrews KY16 8LB, Fife, Scotland.	aem1@st-andrews.ac.uk	Magurran, Anne E/D-7463-2013; Henderson, Peter Alan/Q-5145-2019	Henderson, Peter Alan/0000-0002-7461-1758; Magurran, Anne/0000-0002-0036-2795				Brown JH, 2001, SCIENCE, V293, P643, DOI 10.1126/science.293.5530.643; Brown JH, 2001, EVOLUTION, V55, P2137; Fisher RA, 1943, J ANIM ECOL, V12, P42, DOI 10.2307/1411; Gaston K.J., 2000, MACROECOLOGY; Harte J, 1999, SCIENCE, V284, P334, DOI 10.1126/science.284.5412.334; HENDERSON PA, 1990, J FISH BIOL, V37, P605; HENDERSON PA, 1994, NETH J SEA RES, V32, P321, DOI 10.1016/0077-7579(94)90009-4; Henderson PA, 1999, J FISH BIOL, V54, P1161, DOI 10.1111/j.1095-8649.1999.tb02046.x; Henderson PA, 1997, J FISH BIOL, V50, P280, DOI 10.1111/j.1095-8649.1997.tb01359.x; Henderson PA, 1998, J SEA RES, V40, P131, DOI 10.1016/S1385-1101(98)00020-3; HENDERSON PA, 1991, NETH J SEA RES, V27, P337, DOI 10.1016/0077-7579(91)90036-Z; Hubbell Stephen P., 2001, V32, pi; Krebs C.J., 1999, ECOLOGICAL METHODOLO; LYTHGOE J, 1971, FISHES SEA; Magurran A.E., 1988, ECOLOGICAL DIVERSITY; May R.M., 1975, P81; Motomura I., 1932, JPN J ZOOL, V44, P379; NEE S, 1991, P ROY SOC B-BIOL SCI, V243, P161, DOI 10.1098/rspb.1991.0026; PRESTON FW, 1948, ECOLOGY, V29, P254, DOI 10.2307/1930989; Rodrigues ASL, 2000, P ROY SOC B-BIOL SCI, V267, P897, DOI 10.1098/rspb.2000.1087; Southwood R., 2000, ECOLOGICAL METHODS; Southwood TRE, 1996, PHILOS T R SOC B, V351, P1113, DOI 10.1098/rstb.1996.0097; SUGIHARA G, 1980, AM NAT, V116, P770, DOI 10.1086/283669; TURNPENNY AWH, 1981, CEGB PUBLICATION; WHEELER A, 1969, FISHES BRIT ISLES	25	609	650	6	218	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	APR 17	2003	422	6933					714	716		10.1038/nature01547	http://dx.doi.org/10.1038/nature01547			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	668CG	12700760				2022-12-28	WOS:000182272300039
J	Martin, GS; Mannino, DM; Eaton, S; Moss, M				Martin, GS; Mannino, DM; Eaton, S; Moss, M			The epidemiology of sepsis in the United States from 1979 through 2000	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RESPIRATORY-DISTRESS-SYNDROME; INFLAMMATORY RESPONSE SYNDROME; GRAM-NEGATIVE SEPSIS; SEPTIC SHOCK; NATURAL-HISTORY; SIRS; POLYMORPHISM; MORTALITY; SUSCEPTIBILITY; DEFINITIONS	BACKGROUND: Sepsis represents a substantial health care burden, and there is limited epidemiologic information about the demography of sepsis or about the temporal changes in its incidence and outcome. We investigated the epidemiology of sepsis in the United States, with specific examination of race and sex, causative organisms, the disposition of patients, and the incidence and outcome. METHODS: We analyzed the occurrence of sepsis from 1979 through 2000 using a nationally representative sample of all nonfederal acute care hospitals in the United States. Data on new cases were obtained from hospital discharge records coded according to the International Classification of Diseases, Ninth Revision, Clinical Modification. RESULTS: Review of discharge data on approximately 750 million hospitalizations in the United States over the 22-year period identified 10,319,418 cases of sepsis. Sepsis was more common among men than among women (mean annual relative risk, 1.28 [95 percent confidence interval, 1.24 to 1.32]) and among nonwhite persons than among white persons (mean annual relative risk, 1.90 [95 percent confidence interval, 1.81 to 2.00]). Between 1979 and 2000, there was an annualized increase in the incidence of sepsis of 8.7 percent, from about 164,000 cases (82.7 per 100,000 population) to nearly 660,000 cases (240.4 per 100,000 population). The rate of sepsis due to fungal organisms increased by 207 percent, with gram-positive bacteria becoming the predominant pathogens after 1987. The total in-hospital mortality rate fell from 27.8 percent during the period from 1979 through 1984 to 17.9 percent during the period from 1995 through 2000, yet the total number of deaths continued to increase. Mortality was highest among black men. Organ failure contributed cumulatively to mortality, with temporal improvements in survival among patients with fewer than three failing organs. The average length of the hospital stay decreased, and the rate of discharge to nonacute care medical facilities increased. CONCLUSIONS: The incidence of sepsis and the number of sepsis-related deaths are increasing, although the overall mortality rate among patients with sepsis is declining. There are also disparities among races and between men and women in the incidence of sepsis. Gram-positive bacteria and fungal organisms are increasingly common causes of sepsis.	Emory Univ, Sch Med, Dept Med, Div Pulm Allergy & Crit Care, Atlanta, GA USA; Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA	Emory University; Centers for Disease Control & Prevention - USA	Martin, GS (corresponding author), Emory Univ, Grady Mem Hosp, Dept Med, Div Pulm Allergy & Crit Care, 69 Jesse Hill Jr Dr SE,Rm 2D-004, Atlanta, GA 30303 USA.	greg_martin@emory.org	Martin, Greg/B-4085-2009	Martin, Greg/0000-0002-9684-7593; Mannino, David/0000-0003-3646-7828; NOIRI, Eisei/0000-0002-9515-7582	NCRR NIH HHS [L30 RR020488, L30 RR020488-02] Funding Source: Medline; NHLBI NIH HHS [K23 HL067739-05, K23 HL067739, HL K23-67739] Funding Source: Medline; NIAAA NIH HHS [AA R01-11660] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K23HL067739] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA011660] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Abel SJC, 1998, THORAX, V53, P292, DOI 10.1136/thx.53.4.292; Abraham E, 2000, CRIT CARE MED, V28, P232, DOI 10.1097/00003246-200001000-00039; ADAMS WL, 1993, JAMA-J AM MED ASSOC, V270, P1222, DOI 10.1001/jama.270.10.1222; ADAMS WL, 1993, JAMA-J AM MED ASSOC, V270, P2055; Alberti C, 2002, INTENS CARE MED, V28, P108, DOI 10.1007/s00134-001-1143-z; Alberti C, 2002, INTENS CARE MED, V28, P525, DOI 10.1007/s00134-002-1284-8; Angus D C, 2001, Crit Care Med, V29, P1303, DOI 10.1097/00003246-200107000-00002; Angus DC, 2000, JAMA-J AM MED ASSOC, V283, P1723, DOI 10.1001/jama.283.13.1723; BECKSAGUE CM, 1993, J INFECT DIS, V167, P1247, DOI 10.1093/infdis/167.5.1247; Bernard GR, 2001, NEW ENGL J MED, V344, P699, DOI 10.1056/NEJM200103083441001; Bieler GS, 1997, ANAL SURVEY DATA USI; BONE RC, 1992, JAMA-J AM MED ASSOC, V268, P3452, DOI 10.1001/jama.268.24.3452; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; Brun-Buisson C, 2000, INTENS CARE MED, V26, pS64, DOI 10.1007/s001340051121; BRUNBUISSON C, 1995, JAMA-J AM MED ASSOC, V274, P968, DOI 10.1001/jama.274.12.968; Centers for Disease Control (CDC), 1990, MMWR Morb Mortal Wkly Rep, V39, P31; CHALFIN DB, 1993, JAMA-J AM MED ASSOC, V269, P249, DOI 10.1001/jama.269.2.249; Eaton S, 2002, AM J RESP CRIT CARE, V165, pA471; El-Serag HB, 1999, NEW ENGL J MED, V340, P745, DOI 10.1056/NEJM199903113401001; Fang XM, 1999, CRIT CARE MED, V27, P1330, DOI 10.1097/00003246-199907000-00024; Friedman G, 1998, CRIT CARE MED, V26, P2078, DOI 10.1097/00003246-199812000-00045; Heyland DK, 2000, CRIT CARE MED, V28, P3599, DOI 10.1097/00003246-200011000-00006; HOYERT DL, 2001, NATL VITAL STAT REPO, V8; HSIA DC, 1990, NEW ENGL J MED, V322, P1540; HSIA DC, 1988, NEW ENGL J MED, V318, P352, DOI 10.1056/NEJM198802113180604; Hubacek JA, 2001, CRIT CARE MED, V29, P557, DOI 10.1097/00003246-200103000-00015; Iezzoni LI, 1997, ANN INTERN MED, V127, P666, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00048; KIEFT H, 1993, ARCH INTERN MED, V153, P2241, DOI 10.1001/archinte.153.19.2241; MILBERG JA, 1995, JAMA-J AM MED ASSOC, V273, P306, DOI 10.1001/jama.273.4.306; Mira JP, 1999, JAMA-J AM MED ASSOC, V282, P561, DOI 10.1001/jama.282.6.561; *NAT CTR HLTH STAT, 2002, NAT HOSP DISCH SURV; Ollendorf DA, 2002, VALUE HEALTH, V5, P79, DOI 10.1046/j.1524-4733.2002.52013.x; PARRILLO JE, 1990, ANN INTERN MED, V113, P227, DOI 10.7326/0003-4819-113-3-227; PERL TM, 1995, JAMA-J AM MED ASSOC, V274, P338, DOI 10.1001/jama.274.4.338; PITTET D, 1995, INTENS CARE MED, V21, P302, DOI 10.1007/BF01705408; RANGELFRAUSTO MS, 1995, JAMA-J AM MED ASSOC, V273, P117, DOI 10.1001/jama.273.2.117; Rubenfeld GD, 1999, AM J RESP CRIT CARE, V160, P358, DOI 10.1164/ajrccm.160.1.9807118; SALVO I, 1995, INTENS CARE MED, V21, pS244, DOI 10.1007/BF01740762; Sands KE, 1997, JAMA-J AM MED ASSOC, V278, P234, DOI 10.1001/jama.278.3.234; Stuber F, 1996, CRIT CARE MED, V24, P381, DOI 10.1097/00003246-199603000-00004; Vincent JL, 1997, CRIT CARE MED, V25, P372, DOI 10.1097/00003246-199702000-00029; Warren BL, 2001, JAMA-J AM MED ASSOC, V286, P1869, DOI 10.1001/jama.286.15.1869; Warren BL, 2002, JAMA-J AM MED ASSOC, V287, P192; Wenzel RP, 2001, EMERG INFECT DIS, V7, P174, DOI 10.3201/eid0702.010203; Wenzel RP, 2001, CRIT CARE MED, V29, P1472, DOI 10.1097/00003246-200107000-00028; Wenzel RP, 2000, NEW ENGL J MED, V343, P1961, DOI 10.1056/NEJM200012283432610; Wheeler AP, 1999, NEW ENGL J MED, V340, P207, DOI 10.1056/NEJM199901213400307; WHITTLE J, 1993, NEW ENGL J MED, V329, P621, DOI 10.1056/NEJM199308263290907; Wong MD, 2002, NEW ENGL J MED, V347, P1585, DOI 10.1056/NEJMsa012979	49	4305	4777	6	256	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 17	2003	348	16					1546	1554		10.1056/NEJMoa022139	http://dx.doi.org/10.1056/NEJMoa022139			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	667TT	12700374	Bronze, Green Published			2022-12-28	WOS:000182248900005
J	Morrison, ED; Brandhagen, DJ; Phatak, PD; Barton, JC; Krawitt, EL; El-Serag, HB; Gordon, SC; Galan, MV; Tung, BY; Ioannou, GN; Kowdley, KV				Morrison, ED; Brandhagen, DJ; Phatak, PD; Barton, JC; Krawitt, EL; El-Serag, HB; Gordon, SC; Galan, MV; Tung, BY; Ioannou, GN; Kowdley, KV			Serum ferritin level predicts advanced hepatic fibrosis among US patients with phenotypic hemochromatosis	ANNALS OF INTERNAL MEDICINE			English	Article							HEREDITARY HEMOCHROMATOSIS; HOMOZYGOUS HEMOCHROMATOSIS; DIAGNOSIS; SURVIVAL	Background: DNA-based HFE gene testing can confirm hereditary hemochromatosis in most people of Northern European descent. However, liver biopsy is important to detect cirrhosis. Objective: To develop noninvasive criteria to predict the presence or absence of advanced hepatic fibrosis or cirrhosis in Americans with hemochromatosis. Design: Cross-sectional study. Setting: Six tertiary care referral clinics. Patients: 182 patients with phenotypically defined hemochromatosis. Measurements: Liver histopathology and serum ferritin, aspartate arninotransferase, and alanine arninotransferase levels. Multivariate logistic regression analysis was used to examine factors associated with cirrhosis (defined as bridging fibrosis or unequivocal cirrhosis on biopsy). Results: Cirrhosis was present in 40 of 182 (22%) patients in the overall group and in 35 of 147 (24%) of C282Y homozygotes. Only 1 of 93 patients with a serum ferritin level less than 1000 mug/L had cirrhosis compared with 39 of 89 patients with serum ferritin levels greater than 1000 mug/L (P < 0.001). No C282Y homozygotes or C282Y/H63D compound heterozygotes with serum ferritin levels less than 1000 mug/L had cirrhosis. Elevated serum aminotransferase levels (P = 0.001) and serum ferritin levels greater than 1000 mug/L (P = 0.001), but not age older than 40 years (P = 0.2), were independently associated with cirrhosis. In a multivariate model, the probability of cirrhosis was 7.4% among patients with serum ferritin levels less than 1000 mug/L compared with 72% among patients with serum ferritin levels greater than 1000 mug/L after adjustment for age and elevated serum liver enzyme levels. Conclusions: Patients with hemochromatosis and serum ferritin levels less than 1000 mug/L are unlikely to have cirrhosis. Liver biopsy to screen for cirrhosis may be unnecessary in such patients, regardless of age or serum liver enzyme levels.	Univ Washington, Div Gastroenterol Hepatol, Seattle, WA 98195 USA; William Beaumont Hosp, Royal Oak, MI 48072 USA; Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Serv, Seattle, WA USA; Baylor Coll Med, Vet Adm Med Ctr, Houston, TX 77030 USA; Univ Vermont, Burlington, VT USA; So Iron Disorders Ctr, Birmingham, AL USA; Univ Rochester, Rochester, NY USA; Rochester Gen Hosp, Rochester, NY 14621 USA; Mayo Clin, Rochester, MN USA	University of Washington; University of Washington Seattle; Beaumont Health; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Vermont; University of Rochester; Rochester General Hospital; Mayo Clinic	Kowdley, KV (corresponding author), Univ Washington, Div Gastroenterol Hepatol, 1959 NE Pacific St,Box 356174, Seattle, WA 98195 USA.	kkowdley@u.washington.edu	Kowdley, Kris/AAF-5202-2019	Barton, James/0000-0003-2876-8276	NIDDK NIH HHS [DK02957, DK 38215] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038215, K24DK002957] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS PC, 1991, GASTROENTEROLOGY, V101, P368, DOI 10.1016/0016-5085(91)90013-B; Bacon BR, 1999, ANN INTERN MED, V130, P953, DOI 10.7326/0003-4819-130-12-199906150-00002; BASSETT ML, 1986, HEPATOLOGY, V6, P24, DOI 10.1002/hep.1840060106; Beutler E, 2002, LANCET, V359, P211, DOI 10.1016/S0140-6736(02)07447-0; EDWARDS CQ, 1988, NEW ENGL J MED, V318, P1355, DOI 10.1056/NEJM198805263182103; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; Guyader D, 1998, GASTROENTEROLOGY, V115, P929, DOI 10.1016/S0016-5085(98)70265-3; Kowdley KV, 1997, GASTROENTEROLOGY, V113, P1270, DOI 10.1053/gast.1997.v113.pm9322522; LUDWIG J, 1993, MAYO CLIN PROC, V68, P263, DOI 10.1016/S0025-6196(12)60047-0; NIEDERAU C, 1985, NEW ENGL J MED, V313, P1256, DOI 10.1056/NEJM198511143132004; Powell LW, 1998, ANN INTERN MED, V129, P925, DOI 10.7326/0003-4819-129-11_Part_2-199812011-00002; Tavill AS, 2001, HEPATOLOGY, V33, P1321, DOI 10.1053/jhep.2001.24783	12	132	137	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	2003	138	8					627	633		10.7326/0003-4819-138-8-200304150-00008	http://dx.doi.org/10.7326/0003-4819-138-8-200304150-00008			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	666JH	12693884				2022-12-28	WOS:000182173800003
J	Sharma, L; Dunlop, DD; Song, J; Hayes, KW				Sharma, L; Dunlop, DD; Song, J; Hayes, KW			Quadriceps strength and osteoarthritis progression in maligned and lax knees	ANNALS OF INTERNAL MEDICINE			English	Article							EXERCISE; DISABILITY; RISK; PAIN; HIP	Background: Quadriceps muscle strengthening is a common goal in the management of knee osteoarthritis. In healthy knees, strength protects against new osteoarthritis. In arthritic knees, greater strength may protect joints and thereby delay osteoarthritis progression. Alternatively, in certain joint environments, such as malalignment or laxity, greater strength may, translate into damaging joint reaction forces. The relationship between quadriceps strength and progression of knee osteoarthritis may differ according to these factors. Objective: To determine whether greater quadriceps strength is associated with greater probability of tibiofemoral osteoarthritis progression in malaligned knees and in high-laxity knees. Design: Prospective, longitudinal cohort study. Setting: Academic medical center. Participants: 237 persons with primary knee osteoarthritis, definite tiblofemoral osteophytes, and at least some difficulty with knee-requiring activity. Two hundred thirty completed the 18-month evaluation. The current study primarily involved those without advanced osteoarthritis in either knee (n = 171). Measurements: Quadriceps strength, knee laxity and alignment, and osteoarthritis progression. Results: The predicted probability of tibiofemoral progression was 0.153 (95% Cl, 0.100 to 0.228) in high-strength knees and 0.098 (Cl, 0.061 to 0.155) in low-strength knees. In malaligned knees, high strength was associated with a significant increase (P = 0.03) in the likelihood of progression (predicted probability, 0.406 [Cl, 0.226 to 0.615] vs. 0.187 [Cl, 0.081 to 0.375] in high-strength vs. low-strength knees). Strength was also associated with increased likelihood of progression in high-laxity knees (P = 0.003 when high laxity was defined as greater than or equal to6.75 degrees). The probability of patellofemoral progression did not differ between high- and low-strength knees in the full sample or within subsets. Conclusions: Greater quadriceps strength at baseline was associated with increased likelihood of tibiofemoral osteoarthritis progression in malaligned knees and lax knees. Subset-specific approaches beyond strengthening exercises should be developed to enhance joint-protective muscle activity.	Northwestern Univ, Sch Med, Feinberg Sch Med, Div Rheumatol, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	Sharma, L (corresponding author), Northwestern Univ, Sch Med, Feinberg Sch Med, Div Rheumatol, 300 E Super Ave,Tarry Bldg 3-715, Chicago, IL 60611 USA.			Sharma, Leena/0000-0002-5571-1622	NCRR NIH HHS [RR-00048] Funding Source: Medline; NIAMS NIH HHS [AR-30692] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR030692] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Altman R, 1996, OSTEOARTHR CARTILAGE, V4, P217, DOI 10.1016/S1063-4584(05)80101-3; Altman RD, 2000, ARTHRITIS RHEUM-US, V43, P1905; ALTMAN RD, 1995, OSTEOARTHR CARTILAGE, V3, P3; Baker K, 2000, CURR OPIN RHEUMATOL, V12, P456, DOI 10.1097/00002281-200009000-00020; BRAGE ME, 1994, CLIN ORTHOPAEDICS, V304, P184; Brandt KD, 1999, J RHEUMATOL, V26, P2431; BUCKLANDWRIGHT C, 1995, OSTEOARTHR CARTILAGE, V3, P71; Chaisson CE, 1999, ARTHRITIS RHEUM-US, V42, P33, DOI 10.1002/1529-0131(199901)42:1<33::AID-ANR4>3.0.CO;2-I; CHAO EYS, 1994, ORTHOP CLIN N AM, V25, P379; Dieppe P, 1995, OSTEOARTHRITIC DISOR, P481; Ettinger WH, 1997, JAMA-J AM MED ASSOC, V277, P25, DOI 10.1001/jama.277.1.25; FISHER NM, 1991, ARCH PHYS MED REHAB, V72, P365; Gerber L.H., 2001, OSTEOARTHRITIS DIAGN, P413; GUCCIONE AA, 1994, AM J PUBLIC HEALTH, V84, P351, DOI 10.2105/AJPH.84.3.351; HSU RWW, 1990, CLIN ORTHOP RELAT R, V255, P215; KANNUS P, 1989, AM J SPORT MED, V17, P83, DOI 10.1177/036354658901700114; KANNUS P, 1988, CLIN ORTHOP RELAT R, V226, P103; LANKHORST GJ, 1985, SCAND J REHABIL MED, V17, P167; MARKOLF KL, 1981, J BONE JOINT SURG AM, V63, P570, DOI 10.2106/00004623-198163040-00007; MARKS R, 1994, J THEOR BIOL, V170, P283, DOI 10.1006/jtbi.1994.1189; MCALINDON TE, 1993, ANN RHEUM DIS, V52, P258, DOI 10.1136/ard.52.4.258; POTTENGER LA, 1990, ARTHRITIS RHEUM-US, V33, P853, DOI 10.1002/art.1780330612; Rejeski WJ, 1996, J GERONTOL B-PSYCHOL, V51, pP24, DOI 10.1093/geronb/51B.1.P24; SCHIPPLEIN OD, 1991, J ORTHOPAED RES, V9, P113, DOI 10.1002/jor.1100090114; Sharma L, 1999, ARTHRITIS RHEUM, V42, P861, DOI 10.1002/1529-0131(199905)42:5<861::AID-ANR4>3.0.CO;2-N; Sharma L, 1999, ARTHRITIS RHEUM-US, V42, P25, DOI 10.1002/1529-0131(199901)42:1<25::AID-ANR3>3.0.CO;2-G; Sharma L, 2001, JAMA-J AM MED ASSOC, V286, P188, DOI 10.1001/jama.286.2.188; Slemenda C, 1998, ARTHRITIS RHEUM, V41, P1951, DOI 10.1002/1529-0131(199811)41:11<1951::AID-ART9>3.0.CO;2-9; Solomonow M, 1994, KNEE, P107; TETSWORTH K, 1994, ORTHOP CLIN N AM, V25, P367; Van Baar ME, 1999, ARTHRITIS RHEUM-US, V42, P1361, DOI 10.1002/1529-0131(199907)42:7<1361::AID-ANR9>3.0.CO;2-9; van Baar ME, 1998, J RHEUMATOL, V25, P125; Wada M, 1996, BRIT J RHEUMATOL, V35, P560; WASHBURN RA, 1993, J CLIN EPIDEMIOL, V46, P153, DOI 10.1016/0895-4356(93)90053-4; WOO SL, 2001, OSTEOARTHRITIS DIAGN, P145	35	222	225	0	12	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	2003	138	8					613	619		10.7326/0003-4819-138-8-200304150-00006	http://dx.doi.org/10.7326/0003-4819-138-8-200304150-00006			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	666JH	12693882	Green Submitted			2022-12-28	WOS:000182173800001
J	Stirn, A				Stirn, A			Body piercing: medical consequences and psychological motivations	LANCET			English	Review							INFECTIOUS COMPLICATIONS; ENDOCARDITIS; ART; EAR; FASHION	Body piercing is increasing in popularity around the world. In this review, I describe the history, origins, and peculiarities of various forms of body piercing, and procedures involved, variations in healing time, legal aspects and regulations, and complications and side-effects. I have also included a discussion of the motivation for and psychological background behind body piercing. In presenting research results, I aim to raise awareness of the many risks associated with body piercing. In presenting psychological data, I intend to create an understanding of the multifaceted and often intense motivations associated with body piercing, and, thus, to diminish any prejudices held by health professionals against people with piercings.	Univ Frankfurt Klinikum, Klin Psychosomat Med & Psychotherapie, D-60528 Frankfurt, Germany	Goethe University Frankfurt; Goethe University Frankfurt Hospital	Stirn, A (corresponding author), Univ Frankfurt Klinikum, Klin Psychosomat Med & Psychotherapie, Heinrich Hoffmann Str 10, D-60528 Frankfurt, Germany.	stirn@em.uni-frankfurt.de						Akhondi H, 2002, EMERG INFECT DIS, V8, P850, DOI 10.3201/eid0808.010458; Alter MJ, 1999, J HEPATOL, V31, P88, DOI 10.1016/S0168-8278(99)80381-X; Altman JS, 1997, CUTIS, V60, P237; Armstrong M L, 1996, Pediatr Nurs, V22, P236; Armstrong M L, 1995, J Sch Nurs, V11, P20; Armstrong M L, 2001, J Sch Nurs, V17, P12; Armstrong ML, 1997, APPL NURS RES, V10, P181, DOI 10.1016/S0897-1897(97)80560-5; Armstrong ML, 2000, J ENVIRON HEALTH, V62, P25; ARMSTRONG ML, 1998, REG NURSE, V619, P26; ARMSTRONG ML, 1994, J SCH NURS, V101, P26; *ASS PROF PIERC, 1997, SAF SAN ATTR BOD PIE; Bassiouny MA, 2001, QUINTESSENCE INT, V32, P477; *BBC NEWS, 2002, PIERC PROBL 1 5; Braithwaite RL, 1999, J PUBLIC HEALTH POL, V20, P459, DOI 10.2307/3343131; Brown D, 1988, PENIS INSERTS SE ASI; BUCHWALD C, 1992, ORL J OTO-RHINO-LARY, V54, P108, DOI 10.1159/000276275; BUHRICH N, 1983, ARCH SEX BEHAV, V12, P167, DOI 10.1007/BF01541560; CATALANO J, 2000, APBNEWS COM     0317; CHRISTENSEN MH, POINT CONT BODY PIER; CHRISTENSEN W, 1989, MODERN PRIMITIVES IN, P79; de Man R A, 1999, Ned Tijdschr Geneeskd, V143, P2129; De Moor RJG, 2000, ENDOD DENT TRAUMATOL, V16, P232; DeMello Margo, 2000, BODIES INSCRIPTION C; *DEP HLTH, 1998, REG SKIN PIERC BUS; *DEP HLTH WELSH OF, 1996, REG SKIN PIERC CONS; Dyce O, 2000, HEAD NECK-J SCI SPEC, V22, P728, DOI 10.1002/1097-0347(200010)22:7<728::AID-HED14>3.3.CO;2-J; Favazza AR, 1998, J NERV MENT DIS, V186, P259, DOI 10.1097/00005053-199805000-00001; FEIGE M, 2001, PIERCING, V7, P64; Ferguson H, 1999, BRIT MED J, V319, P1627, DOI 10.1136/bmj.319.7225.1627; FIUMARA NJ, 1982, SEX TRANSM DIS, V9, P138, DOI 10.1097/00007435-198207000-00008; Folz BJ, 2000, ANN PLAS SURG, V45, P374, DOI 10.1097/00000637-200045040-00004; Greif J, 1999, Clin Nurs Res, V8, P368, DOI 10.1177/10547739922158368; *GROUP FRANC ET RE, 2002, GUID BONN PRAT PIERC; Guiard-Schmid JB, 2000, PRESSE MED, V29, P1948; Hadfield-Law L, 2001, Accid Emerg Nurs, V9, P14, DOI 10.1054/aaen.2000.0203; HAM P, 1999, BUDDHAS MOUNTAIN DES, P123; Han K, 1997, ORAL SURG ORAL MED O, V84, P28, DOI 10.1016/S1079-2104(97)90289-4; HARDEE PS, 2000, BR DENT J, V24, P57; Hayes MO, 2001, AM J INFECT CONTROL, V29, P271, DOI 10.1067/mic.2001.114402; HENDRICKS WM, 1991, CUTIS, V48, P386; Heudorf U, 2000, GESUNDHEITSWESEN, V62, P219, DOI 10.1055/s-2000-10860; Hewitt Kim, 1997, MUTILATING BODY IDEN; HIGGINS SP, 1995, INT J STD AIDS, V6, P54, DOI 10.1177/095646249500600113; Horle S, 2002, OPHTHALMOLOGE, V99, P200, DOI 10.1007/s003470100530; Javaid M, 1999, BRIT J PLAST SURG, V52, P676; Kaatz M, 2001, KOSMETISCHE MED, V4, P188; Kato Y, 1987, Hinyokika Kiyo, V33, P1672; Keogh IJ, 2001, J LARYNGOL OTOL, V115, P233; Khanna R, 1999, J ACCID EMERG MED, V16, P418; Koenig LM, 1999, J GEN INTERN MED, V14, P379, DOI 10.1046/j.1525-1497.1999.00357.x; Krause H, 2000, Mund Kiefer Gesichtschir, V4, P21, DOI 10.1007/s100060050006; Langford R, 1996, Nurs Times, V92, P46; LEVITON R, 1997, EMERGENCY, V2, P18; LONG GE, 1994, CLIN INFECT DIS, V18, P610, DOI 10.1093/clinids/18.4.610; LOTZ J, 1997, DECORATED SKIN WORLD, P234; Luksamijarulkul P, 1995, Asia Pac J Public Health, V8, P158; Makkai T, 2001, Commun Dis Intell Q Rep, V25, P67; MALLOY D, 1989, MODERN PRIMITIVES IN, P25; MANN RJ, 1983, CLIN EXP DERMATOL, V8, P199, DOI 10.1111/j.1365-2230.1983.tb01766.x; MARTINELLI RA, 2001, 39 ANN M INF DIS SOC; Masters W., 1995, HUMAN SEXUALITY; Mayers LB, 2002, MAYO CLIN PROC, V77, P29, DOI 10.4065/77.1.29; MCCANCE KL, 1994, PATHOPHYSIOLOGY BIOL; MCCARTHY VP, 1988, PEDIATR INFECT DIS J, V7, P741, DOI 10.1097/00006454-198810000-00020; MITTAL RR, 2002, INT J DERMATOL, V42, P109; Modest GA, 2002, NEW ENGL J MED, V347, P1626, DOI 10.1056/NEJM200211143472020; Muldoon K A, 1997, J Pediatr Health Care, V11, P298, DOI 10.1016/S0891-5245(97)90089-4; MYERS J, 1992, J CONTEMP ETHNOGR, V21, P267, DOI 10.1177/089124192021003001; Ochsenfahrt C, 2001, ANN THORAC SURG, V71, P1365, DOI 10.1016/S0003-4975(00)02273-6; Olsen JC, 2001, J EMERG MED, V20, P409, DOI 10.1016/S0736-4679(01)00307-9; Peate I, 2000, Br J Nurs, V9, P2163; Perkins CS, 1997, BRIT DENT J, V182, P147, DOI 10.1038/sj.bdj.4809327; Perkins K C, 1997, W V Med J, V93, P313; Peticolas T, 2000, J Contemp Dent Pract, V1, P30; Price SS, 1997, J AM DENT ASSOC, V128, P1017, DOI 10.14219/jada.archive.1997.0310; Ramage IJ, 1997, ARCH DIS CHILD, V77, P187; Sarnecki Judith Holland, 2001, AM ASS ANTHR J CONSC, V12.2, P35, DOI DOI 10.1525/ac.2001.12.2.35; SCULLY C, 1994, BRIT J ORAL MAX SURG, V32, P37, DOI 10.1016/0266-4356(94)90171-6; SIMPLOT TC, 2000, AM J OTOLARYNG, V19, P305; Slawik S, 1999, BJU INT, V84, P377; SPERRY K, 1992, AM J FOREN MED PATH, V13, P7, DOI 10.1097/00000433-199203000-00003; Stirn A., 2002, PSYCHOTRAUMATOLOGIE, V2, P45; Stirn A., 2002, PSYCHOTHER PSYCHOSOM, V52, P119; STIRN A, 2001, PSYCHOTHERAPIE SOZIA, V3, P283; STIRN A, 2002, INT CONV SOC PSYCH R; STOKES P, 1996, DAILY TELEGRAPH 0608, P8; Strom BL, 1998, ANN INTERN MED, V129, P761, DOI 10.7326/0003-4819-129-10-199811150-00002; Stuppy DJ, 1998, J ADV NURS, V27, P1165, DOI 10.1046/j.1365-2648.1998.00626.x; Sweetman, 1999, BODY SOC, V5, P51, DOI DOI 10.1177/1357034X99005002004; Tronel H, 2001, CLIN MICROBIOL INFEC, V7, P275, DOI 10.1046/j.1469-0691.2001.00241.x; Trupiano JK, 2001, CLIN INFECT DIS, V33, P131, DOI 10.1086/320885; TURKELTAUB SH, 1990, ANN PLAS SURG, V24, P279, DOI 10.1097/00000637-199003000-00015; Tweeten SSM, 1998, CLIN INFECT DIS, V26, P735, DOI 10.1086/514586; VALE V, 1989, MODERN PRIMITIVES IN, P35; WILLCOX RR, 1981, BRIT J VENER DIS, V57, P167; Willmott FE, 2001, INT J STD AIDS, V12, P358, DOI 10.1258/0956462011923282; Wright J, 1995, Nurs Stand, V10, P27; Zermann DH, 1997, SCAND J UROL NEPHROL, V31, P401; ZIEGLER B, 1997, BODY PIERCING, P12; Zolondek U, 1998, Gesundheitswesen, V60, P170; PERFORATIONS PARAPHI; 1994, BODY ART, V20, P39; SALAMANDER JEWELRY N; 2001, ARZTE ZEITUNG   0226; 1997, HARTFORD COURAN 0301, pF1; 1994, BODY ART, V19, P34	106	170	176	2	18	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 5	2003	361	9364					1205	1215		10.1016/S0140-6736(03)12955-8	http://dx.doi.org/10.1016/S0140-6736(03)12955-8			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	664ZF	12686054				2022-12-28	WOS:000182094600024
J	Greene, MJ; Gordon, DM				Greene, MJ; Gordon, DM			Social insects - Cuticular hydrocarbons inform task decisions	NATURE			English	Article							HARVESTER ANTS; COLONIES; DIVISION; DYNAMICS; LABOR		Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA	Stanford University	Greene, MJ (corresponding author), Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA.	greene@ants.stanford.edu						Gordon D. M., 2000, ANTS WORK INSECT SOC; GORDON DM, 1989, ANIM BEHAV, V38, P194, DOI 10.1016/S0003-3472(89)80082-X; Gordon DM, 2002, AM NAT, V159, P509, DOI 10.1086/339461; Gordon DM, 1996, NATURE, V380, P121, DOI 10.1038/380121a0; GORDON DM, 1987, ANIM BEHAV, V35, P833, DOI 10.1016/S0003-3472(87)80119-7; Gordon DM, 1999, BEHAV ECOL SOCIOBIOL, V45, P370, DOI 10.1007/s002650050573; Holldobler B., 1990, pi; NELSON DR, 1995, BIOCH WAXES, pCH1; ROBINSON GE, 1992, ANNU REV ENTOMOL, V37, P637, DOI 10.1146/annurev.en.37.010192.003225; Wagner D, 2001, J CHEM ECOL, V27, P1805, DOI 10.1023/A:1010408725464; Wagner D, 1998, J CHEM ECOL, V24, P2021, DOI 10.1023/A:1020781508889; WILSON EO, 1984, BEHAV ECOL SOCIOBIOL, V16, P89, DOI 10.1007/BF00293108; WINSTON ML, 1985, CAN J ZOOL, V63, P777, DOI 10.1139/z85-113	13	225	233	0	52	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 1	2003	423	6935					32	32		10.1038/423032a	http://dx.doi.org/10.1038/423032a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	673CG	12721617				2022-12-28	WOS:000182561600031
J	Tabar, L; Yen, MF; Vitak, B; Chen, HHT; Smith, RA; Duffy, SW				Tabar, L; Yen, MF; Vitak, B; Chen, HHT; Smith, RA; Duffy, SW			Mammography service screening and mortality in breast cancer patients: 20-year follow-up before and after introduction of screening	LANCET			English	Article							ALL-CAUSE MORTALITY; SWEDISH RANDOMIZED TRIALS; AGED 40-49 YEARS; CARCINOMA MORTALITY; 2 COUNTY; PROGRAM; UPDATE	Background The long term effect of mammographic service screening is not well established. We aimed to assess the long-term effect of mammographic screening on death from breast cancer, taking into account potential biases from self-selection, changes in breast cancer incidence, and classification of cause of death. Methods We compared deaths from breast cancer diagnosed in the 20 years before screening was introduced (1958-77) with those from breast cancer diagnosed in the 20 years after the introduction of screening (1978-97) in two Swedish counties, in 210 000 women aged 20-69 years. We also compared deaths from all cancers and from all causes in patients diagnosed with breast cancer in the 20 years before and after screening was introduced. In the analysis, data were stratified into age-groups invited for screening (40-69 years) and not invited (20-39 years), and by whether or not the women had actually received screening. We also analysed mortality for the 40-49-year age-group separately. Findings The unadjusted risk of death from breast cancer dropped significantly in the second screening period compared with the first in women aged 40-69 years (relative risk [RR] 0.77 [95% Cl 0.7-0.85]; p<0.0001). No such decline was seen in 20-39 year olds. After adjustment for age, self-selection bias, and changes in breast-cancer incidence in the 40-69 years age-group, breast-cancer mortality was reduced in women who were screened (0.56; 0.49-0.64 p<0.0001), in those who were not screened (0.84 [0.71-0.09]; p=0.03), and in screened and unscreened women combined (0.59 [0.53-0.66]; p<0.0001). After adjustment for age, self-selection bias, and changes in incidence in the 40-49-year age-group, deaths from breast cancer fell significantly in those who were screened (0.52 [0.4-0.67]; p<0.0001); and in all women, screened and unscreened combined (0.55 [0.44-0.7] p<0.0001) but not in unscreened women (p=0.2). In both 40-69-year and 40-49-year age-groups, reductions in deaths from all cancers and from all-causes in women with breast cancer were consistent with these results. Interpretation Taking account of potential biases, changes in clinical practice and changes in the incidence of breast cancer, mammography screening is contributing to substantial reductions in breast cancer mortality in these two Swedish counties.	Queen Mary Univ London, Wolfson Inst Prevent Med, Canc Res UK Dept Epidemiol Math & Stat, London EC1M 6BQ, England; Cent Hosp Falun, Dept Mammog, Falun, Sweden; UCL, Dept Stat Sci, London WC1E 6BT, England; Linkoping Univ Hosp, Dept Med Radiol, S-58185 Linkoping, Sweden; Natl Taiwan Univ, Grad Inst Prevent Med, Taipei 10764, Taiwan; Amer Canc Soc, Atlanta, GA 30329 USA	Cancer Research UK; University of London; Queen Mary University London; Falun Hospital; University of London; University College London; Linkoping University; National Taiwan University; American Cancer Society	Duffy, SW (corresponding author), Queen Mary Univ London, Wolfson Inst Prevent Med, Canc Res UK Dept Epidemiol Math & Stat, Charterhouse Sq, London EC1M 6BQ, England.	stephen.duffy@cancer.org.uk	Tabar, Laszlo Kornel/AGT-3287-2022	Chen, Hsiu-Hsi/0000-0002-5799-6705				Andersson I, 1997, J Natl Cancer Inst Monogr, P63; Antman K, 1999, JAMA-J AM MED ASSOC, V281, P1470, DOI 10.1001/jama.281.16.1470; Berry DA, 1998, BREAST IMAGING, P23, DOI 10.3233/BD-1998-103-405; Bjurstam N, 1997, CANCER, V80, P2091, DOI 10.1002/(SICI)1097-0142(19971201)80:11<2091::AID-CNCR8>3.0.CO;2-#; Black WC, 2002, JNCI-J NATL CANCER I, V94, P167, DOI 10.1093/jnci/94.3.167; Blanks RG, 2000, BRIT MED J, V321, P665, DOI 10.1136/bmj.321.7262.665; Breslow NE, 1987, STAT METHODS CANC RE; Chen HH, 1997, J EPIDEMIOL BIOSTAT, V2, P25; Chen T., 1997, J EPIDEMIOL BIOSTAT, P9; Church TR, 2002, J NATL CANCER I, V94, P861, DOI 10.1093/jnci/94.11.861; Dickersin K, 1999, LANCET, V353, P1896, DOI 10.1016/S0140-6736(99)90074-0; DUFFY SW, 1991, BRIT J CANCER, V64, P1133, DOI 10.1038/bjc.1991.477; Duffy SW, 2002, CANCER-AM CANCER SOC, V95, P458, DOI 10.1002/cncr.10765; Duffy SW, 2002, APPL STAT, V51, P234; Gail MH, 2002, J NATL CANCER I, V94, P862, DOI 10.1093/jnci/94.11.862; Hendrick R E, 1997, J Natl Cancer Inst Monogr, P87; Jonsson H, 2001, J MED SCREEN, V8, P152, DOI 10.1136/jms.8.3.152; Lagerlund M, 2000, EUR J CANCER PREV, V9, P25, DOI 10.1097/00008469-200002000-00004; Lenner P, 1997, J Med Screen, V4, P6; Nystrom L, 2002, LANCET, V359, P909, DOI 10.1016/S0140-6736(02)08020-0; NYSTROM L, 1993, LANCET, V341, P973, DOI 10.1016/0140-6736(93)91067-V; Olsen O, 2001, LANCET, V358, P1340, DOI 10.1016/S0140-6736(01)06449-2; Paci E, 2002, BRIT J CANCER, V87, P65, DOI 10.1038/sj.bjc.6600301; RINGASH J, 2001, CMAJ, V16, P469; Rostgaard K, 2001, STAT MED, V20, P47, DOI 10.1002/1097-0258(20010115)20:1<47::AID-SIM613>3.0.CO;2-5; Tabar L, 2000, RADIOL CLIN N AM, V38, P625, DOI 10.1016/S0033-8389(05)70191-3; TABAR L, 1992, RADIOL CLIN N AM, V30, P187; Tabar L, 2002, J MED SCREEN, V9, P159, DOI 10.1136/jms.9.4.159; TABAR L, 1989, J EPIDEMIOL COMMUN H, V43, P107, DOI 10.1136/jech.43.2.107; TABAR L, 1985, LANCET, V1, P829, DOI 10.1016/S0140-6736(85)92204-4; Tabar L, 2001, CANCER-AM CANCER SOC, V91, P1724, DOI 10.1002/1097-0142(20010501)91:9<1724::AID-CNCR1190>3.0.CO;2-V; Tornberg S, 1994, J Med Screen, V1, P184	32	500	517	0	21	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 26	2003	361	9367					1405	1410		10.1016/S0140-6736(03)13143-1	http://dx.doi.org/10.1016/S0140-6736(03)13143-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	672HZ	12727392				2022-12-28	WOS:000182516300007
J	Adami, HO; Trichopoulos, D				Adami, HO; Trichopoulos, D			Obesity and mortality from cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Karolinska Inst, Dept Med Epidemiol, Stockholm, Sweden; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA	Karolinska Institutet; Harvard University; Harvard T.H. Chan School of Public Health	Adami, HO (corresponding author), Karolinska Inst, Dept Med Epidemiol, Stockholm, Sweden.								0	52	58	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 24	2003	348	17					1623	1624		10.1056/NEJMp030029	http://dx.doi.org/10.1056/NEJMp030029			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	670PB	12711736				2022-12-28	WOS:000182416300001
J	Ben-Yosef, T; Ness, SL; Madeo, AC; Bar-Lev, A; Wolfman, JH; Ahmed, ZM; Desnick, RJ; Willner, JP; Avraham, KB; Ostrer, H; Oddoux, C; Griffith, AJ; Friedman, TB				Ben-Yosef, T; Ness, SL; Madeo, AC; Bar-Lev, A; Wolfman, JH; Ahmed, ZM; Desnick, RJ; Willner, JP; Avraham, KB; Ostrer, H; Oddoux, C; Griffith, AJ; Friedman, TB			Brief report - A mutation of PCDH15 among Ashkenazi Jews with the type 1 Usher syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RECESSIVE DEAFNESS; GENE; POPULATION; FREQUENCY; FAMILIES; PROFILE; DISEASE; CDH23; GJB2		NIDCD, Mol Genet Lab, NIH, Rockville, MD 20850 USA; CUNY Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA; Tel Aviv Univ, Sackler Sch Med, Dept Human Genet & Mol Med, IL-69978 Tel Aviv, Israel; NYU, Sch Med, Human Genet Program, New York, NY USA	National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Tel Aviv University; Sackler Faculty of Medicine; New York University	Friedman, TB (corresponding author), NIDCD, Mol Genet Lab, NIH, 5 Res Ct,Rm 2A15, Rockville, MD 20850 USA.	friedman@nidcd.nih.gov	Madeo, Anne/K-2880-2012; Madeo, Anne C/AAA-6186-2022	Avraham, Karen B/0000-0002-4913-251X; MADEO, ANNE/0000-0003-2048-9491	NCRR NIH HHS [RR-M01-00071] Funding Source: Medline; NIDCD NIH HHS [1 Z01 DC00060-01, 1 Z01 DC 00039-06] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000071] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [Z01DC000060, Z01DC000064, Z01DC000039] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Adato A, 1997, AM J HUM GENET, V61, P813, DOI 10.1086/514899; Ahmed ZM, 2001, AM J HUM GENET, V69, P25, DOI 10.1086/321277; Bach G, 2001, AM J MED GENET, V99, P70, DOI 10.1002/1096-8628(20010215)99:1<70::AID-AJMG1120>3.0.CO;2-0; Bitner-Glindzicz M, 2000, NAT GENET, V26, P56, DOI 10.1038/79178; Bolz H, 2001, NAT GENET, V27, P108, DOI 10.1038/83667; Bork JM, 2001, AM J HUM GENET, V68, P26, DOI 10.1086/316954; DAUSSET J, 1990, GENOMICS, V6, P575, DOI 10.1016/0888-7543(90)90491-C; HINDERINK JB, 1994, ANN OTO RHINOL LARYN, V103, P285, DOI 10.1177/000348949410300405; KRONN D, 1995, AM J HUM GENET, V57, P1250; Liebreich, 1861, DTSCH ARCH KLIN MED, V13, P53; LITTLE S, 1998, CURRENT PORTOCOLS HU, V2; MATOTH Y, 1987, AM J MED GENET, V27, P561; MEULENBELT I, 1995, AM J HUM GENET, V57, P1252; Morell RJ, 1998, NEW ENGL J MED, V339, P1500, DOI 10.1056/NEJM199811193392103; MORTON NE, 1991, ANN NY ACAD SCI, V630, P16, DOI 10.1111/j.1749-6632.1991.tb19572.x; Mustapha M, 2002, HUM GENET, V110, P348, DOI 10.1007/s00439-002-0690-x; Ostrer H, 2001, NAT REV GENET, V2, P891, DOI 10.1038/35098506; Petit C, 2001, ANNU REV GENOM HUM G, V2, P271, DOI 10.1146/annurev.genom.2.1.271; RISCH N, 1995, NAT GENET, V9, P152, DOI 10.1038/ng0295-152; SMITH RJH, 1994, AM J MED GENET, V50, P32, DOI 10.1002/ajmg.1320500107; Sobe T, 1999, AM J MED GENET, V86, P499, DOI 10.1002/(SICI)1096-8628(19991029)86:5<499::AID-AJMG19>3.3.CO;2-F; VERNON M, 1969, J CHRON DIS, V22, P133, DOI 10.1016/0021-9681(69)90055-1; Verpy E, 2000, NAT GENET, V26, P51, DOI 10.1038/79171; Weil D, 2003, HUM MOL GENET, V12, P463, DOI 10.1093/hmg/ddg051; WELL D, 1995, NATURE, V374, P60, DOI 10.1038/374060a0; Young N M, 1995, Ann Otol Rhinol Laryngol Suppl, V166, P342; Zlotogora J, 2000, MOL GENET METAB, V69, P169, DOI 10.1006/mgme.2000.2969	27	70	74	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 24	2003	348	17					1664	1670		10.1056/NEJMoa021502	http://dx.doi.org/10.1056/NEJMoa021502			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	670PB	12711741				2022-12-28	WOS:000182416300006
J	Lipshultz, SE; Sleeper, LA; Towbin, JA; Lowe, AM; Orav, EJ; Cox, GF; Lurie, PR; McCoy, KL; McDonald, MA; Messere, JE; Colan, SD				Lipshultz, SE; Sleeper, LA; Towbin, JA; Lowe, AM; Orav, EJ; Cox, GF; Lurie, PR; McCoy, KL; McDonald, MA; Messere, JE; Colan, SD			The incidence of pediatric cardiomyopathy in two regions of the United States	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IDIOPATHIC DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; CLINICAL PROFILE; NATURAL-HISTORY; FEMALE SEX; CHILDREN; INFANTS; HEART; EPIDEMIOLOGY; MORTALITY	Background: Population-based data on the incidence of pediatric cardiomyopathy are rare because of the lack of large, prospective studies. Methods: Since 1996 the Pediatric Cardiomyopathy Registry sponsored by the National Heart, Lung, and Blood Institute has collected data on all children with newly diagnosed cardiomyopathy in New England and the Central Southwest region (Texas, Oklahoma, and Arkansas) of the United States. We report on all children in these regions who received this diagnosis between 1996 and 1999. Results: We identified 467 cases of cardiomyopathy, for an overall annual incidence of 1.13 per 100,000 children (95 percent confidence interval, 1.03 to 1.23). The incidence was significantly higher among infants younger than 1 year old than among children and adolescents who were 1 to 18 years old (8.34 vs. 0.70 per 100,000, P<0.001). The annual incidence of cardiomyopathy was lower among white children (upper-bound estimate, 1.06 cases per 100,000) than among black children (lower-bound estimate, 1.47 per 100,000; P=0.02) and higher among boys than among girls (1.32 vs. 0.92 per 100,000, P<0.001). The incidence also varied significantly by region: 1.44 cases per 100,000 in New England and 0.98 per 100,000 in the Central Southwest region (P<0.001). When categorized according to type, dilated cardiomyopathy made up 51 percent of the cases, hypertrophic cardiomyopathy 42 percent, and restrictive or other types 3 percent; 4 percent were unspecified. There was no significant difference in the incidence rates according to the year. Conclusions: The estimated incidence of pediatric cardiomyopathy in two large regions of the United States is 1.13 cases per 100,000 children. Most cases are identified at an early age, and the incidence varies according to sex, region, and racial or ethnic origin.	Univ Rochester, Med Ctr, Div Pediat Cardiol, Rochester, NY 14642 USA; Golisano Childrens Hosp Strong, Div Pediat Cardiol, Rochester, NY USA; Univ Rochester, Sch Med & Dent, Dept Pediat, Rochester, NY 14642 USA; Childrens Hosp, Dept Cardiol, Boston, MA 02115 USA; Childrens Hosp, Div Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; New England Res Inst, Watertown, MA 02172 USA; Texas Childrens Hosp, Dept Pediat Cardiol Mol & Human Genet & Cardiovas, Houston, TX 77030 USA; Baylor Coll Med, Houston, TX 77030 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Genzyme Corp, Cambridge, MA USA; Albany Med Coll, Dept Pediat, Albany, NY 12208 USA	University of Rochester; University of Rochester; University of Rochester; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; HealthCore, Inc; Baylor College of Medicine; Baylor College of Medicine; Harvard University; Brigham & Women's Hospital; Sanofi-Aventis; Genzyme Corporation; Albany Medical College	Lipshultz, SE (corresponding author), Univ Rochester, Med Ctr, Div Pediat Cardiol, 601 Elmwood Ave,Box 631, Rochester, NY 14642 USA.		Towbin, Jeffrey A./J-5595-2019; Colan, Steven/ABB-4580-2020	Towbin, Jeffrey A./0000-0002-6585-714X; 	NATIONAL CANCER INSTITUTE [R01CA055576, P01CA068484, R01CA079060, R29CA055576] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053392] Funding Source: NIH RePORTER; NCI NIH HHS [CA79060, CA68484, CA55576] Funding Source: Medline; NHLBI NIH HHS [HL53392] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arola A, 1997, AM J EPIDEMIOL, V146, P385, DOI 10.1093/oxfordjournals.aje.a009291; Arola A, 1998, PEDIATRICS, V101, P369, DOI 10.1542/peds.101.3.369; BILGIC A, 1990, JPN HEART J, V31, P789; Boneva RS, 2001, CIRCULATION, V103, P2376; Boucek MM, 2001, J HEART LUNG TRANSPL, V20, P39, DOI 10.1016/S1053-2498(00)00243-6; CANNAN CR, 1995, CIRCULATION, V92, P2488, DOI 10.1161/01.CIR.92.9.2488; CARVALHO JS, 2002, PAEDIAT CARDIOLOGY, P1595; *CENS BUR, 1999, EST POP STAT AG SEX; Chang RKR, 2002, CIRCULATION, V106, P1514, DOI 10.1161/01.CIR.0000029104.94858.6F; CHEN SC, 1990, J AM COLL CARDIOL, V15, P189, DOI 10.1016/0735-1097(90)90199-Y; COLAN SD, 1992, J AM COLL CARDIOL, V19, P619, DOI 10.1016/S0735-1097(10)80282-7; CORREAVILLASENOR A, 1991, AM J EPIDEMIOL, V134, P393, DOI 10.1093/oxfordjournals.aje.a116101; COUGHLIN SS, 1993, J CLIN EPIDEMIOL, V46, P1003, DOI 10.1016/0895-4356(93)90167-Y; Cox GF, 2001, CIRCULATION, V104, P588; Evans Roger W, 1982, Heart Transplant, V1, P243; FERENCZ C, 1992, PEDIATR CARDIOL, V13, P65, DOI 10.1007/BF00798206; GILLUM RF, 1986, AM HEART J, V111, P752, DOI 10.1016/0002-8703(86)90111-0; GREENWOOD RD, 1976, AM HEART J, V92, P549, DOI 10.1016/S0002-8703(76)80074-9; Grenier MA, 2000, AM HEART J, V139, pS86, DOI 10.1067/mhj.2000.103933; GRIFFIN ML, 1988, J AM COLL CARDIOL, V11, P139, DOI 10.1016/0735-1097(88)90179-9; KUMAR K, IN PRESS INT J CARDI; Lipshultz, 2000, Prog Pediatr Cardiol, V12, P1, DOI 10.1016/S1058-9813(00)00076-X; Lipshultz SE, 2002, LANCET, V360, P368, DOI 10.1016/S0140-6736(02)09607-1; LIPSHULTZ SE, 1995, NEW ENGL J MED, V332, P1738, DOI 10.1056/NEJM199506293322602; MANOLIO TA, 1992, AM J CARDIOL, V69, P1458, DOI 10.1016/0002-9149(92)90901-A; MARON BJ, 1987, NEW ENGL J MED, V316, P780, DOI 10.1056/NEJM198703263161305; MARON BJ, 1981, PEDIAT CARDIOVASCULA, V11, P35; MARON BJ, 2001, MOSS ADAMS HEART DIS, V2, P1167; Nugent AW, 2003, NEW ENGL J MED, V348, P1639, DOI 10.1056/NEJMoa021737; PONGPANIGH B, 1985, JAP HEART J, V27, P11; SCHMALTZ AA, 1987, EUR HEART J, V8, P100, DOI 10.1093/oxfordjournals.eurheartj.a062236; Schwartz ML, 1996, CIRCULATION, V94, P2021, DOI 10.1161/01.CIR.94.8.2021; Simbre VC, 2002, PEDIATR RES, V51, p37A; STEIN H, 1964, ARCH DIS CHILD, V39, P610, DOI 10.1136/adc.39.208.610; TALIERCIO CP, 1985, J AM COLL CARDIOL, V6, P1126, DOI 10.1016/S0735-1097(85)80319-3; Towbin JA, 1999, CURR OPIN CARDIOL, V14, P250, DOI 10.1097/00001573-199905000-00010; TOWBIN JA, 2000, PEDIAT CARDIOVASCULA, P753; Tsirka AE, 2000, CIRCULATION, V102, P406	38	508	546	0	5	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 24	2003	348	17					1647	1655		10.1056/NEJMoa021715	http://dx.doi.org/10.1056/NEJMoa021715			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	670PB	12711739				2022-12-28	WOS:000182416300004
J	Takemaru, KI; Yamaguchi, S; Lee, YS; Zhang, Y; Carthew, RW; Moon, RT				Takemaru, KI; Yamaguchi, S; Lee, YS; Zhang, Y; Carthew, RW; Moon, RT			Chibby, a nuclear beta-catenin-associated antagonist of the Wnt/Wingless pathway	NATURE			English	Article							MAMMALIAN-CELLS; WINGLESS SIGNAL; XENOPUS EMBRYOS; DROSOPHILA; GENE; ARMADILLO; EXPRESSION; PROTEIN; LEF-1; INTERFERENCE	Inappropriate activation of downstream target genes by the oncoprotein beta-catenin is implicated in development of numerous human cancers(1,2). beta-catenin and its fruitfly counterpart Armadillo act as a coactivator in the canonical Wnt/Wingless pathway by binding to Tcf/Lef transcription factors(3-6). Here we report a conserved nuclear protein, named Chibby, which was identified in a screen for proteins that directly interact with the C-terminal region of beta-catenin. In mammalian cultured cells we demonstrate that Chibby inhibits beta-catenin-mediated transcriptional activation by competing with Lef-1 to bind to beta-catenin. Inhibition of Drosophila Chibby by RNA interference results in segment polarity defects that mimick a wingless gain-of-function phenotype, and overexpression of the wingless target genes engrailed and Ultrabithorax. In addition, epistasis experiments indicate that chibby acts downstream of wingless and upstream of armadillo.	Univ Washington, Ctr Dev Biol, Sch Med, Seattle, WA 98195 USA; Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA	University of Washington; University of Washington Seattle; Northwestern University	Moon, RT (corresponding author), Univ Washington, Howard Hughes Med Inst, Dept Pharmacol, Sch Med, Room K536C,Hlth Sci Bldg,Campus Box 357750, Seattle, WA 98195 USA.		Moon, Randall T/B-1743-2014; Moon, Randall/M-5605-2019	Moon, Randall T/0000-0002-9352-1408; Moon, Randall/0000-0002-9352-1408				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Broder YC, 1998, CURR BIOL, V8, P1121, DOI 10.1016/S0960-9822(98)70467-1; Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; CARTHEW RW, 2003, GENE SILENCING; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fukuchi T, 1998, CANCER RES, V58, P3526; Garcia-Rostan G, 2001, AM J PATHOL, V158, P987, DOI 10.1016/S0002-9440(10)64045-X; Hecht A, 1999, J BIOL CHEM, V274, P18017, DOI 10.1074/jbc.274.25.18017; Hsu SC, 1998, MOL CELL BIOL, V18, P4807, DOI 10.1128/MCB.18.8.4807; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; LEE YS, IN PRESS METHODS; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; NOORDERMEER J, 1992, DEVELOPMENT, V116, P711; PEIFER M, 1994, DEVELOPMENT, V120, P369; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; Polakis P, 2000, GENE DEV, V14, P1837; Sanson B, 1999, CELL, V98, P207, DOI 10.1016/S0092-8674(00)81015-6; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Yu X, 1996, DEVELOPMENT, V122, P849; Yu X, 1998, EMBO J, V17, P7021, DOI 10.1093/emboj/17.23.7021	29	227	253	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 24	2003	422	6934					905	909		10.1038/nature01570	http://dx.doi.org/10.1038/nature01570			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	670WR	12712206				2022-12-28	WOS:000182432600058
J	Samanta, J; Kendall, J; Samanta, A				Samanta, J; Kendall, J; Samanta, A			10-minute consultation - Polyarthralgia	BRITISH MEDICAL JOURNAL			English	Article									Leicester Royal Infirm, Dept Rheumatol, Leicester LE1 5WW, Leics, England	University of Leicester	Samanta, J (corresponding author), Leicester Royal Infirm, Dept Rheumatol, Leicester LE1 5WW, Leics, England.								0	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 19	2003	326	7394					859	859		10.1136/bmj.326.7394.859	http://dx.doi.org/10.1136/bmj.326.7394.859			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	670BF	12702621	Bronze, Green Published			2022-12-28	WOS:000182386800021
J	Fry, SN; Sayaman, R; Dickinson, MH				Fry, SN; Sayaman, R; Dickinson, MH			The aerodynamics of free-flight maneuvers in Drosophila	SCIENCE			English	Article							MUSCA-DOMESTICA; VISUAL CONTROL; FLY; ORIENTATION; BEHAVIOR	Using three-dimensional infrared high-speed video, we captured the wing and body kinematics of free-flying fruitflies as they performed rapid flight maneuvers. We then "replayed" the wing kinematics on a dynamically scaled robotic model to measure the aerodynamic forces produced by the wings. The results show that fly generates rapid turns with surprisingly subtle modifications in wing motion, which nonetheless generate sufficient torque for the fly to rotate its body through each turn. The magnitude and time course of the torque and body motion during rapid turns indicate that inertia, not friction, dominates the flight dynamics of insects.	CALTECH, Pasadena, CA 91125 USA; Univ Zurich, ETH Zurich, Inst Neuroinformat, CH-8057 Zurich, Switzerland	California Institute of Technology; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Zurich	Dickinson, MH (corresponding author), CALTECH, Pasadena, CA 91125 USA.		Sikandar, Usama/F-6586-2016	Sayaman, Rosalyn/0000-0003-1343-0619				COLLETT TS, 1975, J COMP PHYSIOL, V99, P1, DOI 10.1007/BF01464710; DAVID CT, 1978, PHYSIOL ENTOMOL, V3, P191, DOI 10.1111/j.1365-3032.1978.tb00148.x; GOTZ KG, 1968, KYBERNETIK, V4, P199, DOI 10.1007/BF00272517; REICHARDT W, 1973, NATURWISSENSCHAFTEN, V60, P122, DOI 10.1007/BF00594781; REICHARDT W, 1976, Q REV BIOPHYS, V9, P311, DOI 10.1017/S0033583500002523; Sane SP, 2001, J EXP BIOL, V204, P2607; Schilstra C, 1998, NATURE, V395, P654, DOI 10.1038/27114; Schilstra C, 1999, J EXP BIOL, V202, P1481; Tammero LF, 2002, J EXP BIOL, V205, P327; VOGEL S, 1966, J EXP BIOL, V44, P567; WAGNER H, 1986, PHILOS T ROY SOC B, V312, P527, DOI 10.1098/rstb.1986.0017	11	386	404	2	80	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 18	2003	300	5618					495	498		10.1126/science.1081944	http://dx.doi.org/10.1126/science.1081944			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	668LR	12702878				2022-12-28	WOS:000182295900043
J	Iglehart, JK				Iglehart, JK			Medicare and drug pricing	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							TRENDS											ALBERT H, 2001, COMMUNICATION   0620; *AM SOC CLIN ONC, 2002, AN WAYS MEANS STAFF; American Society of Clinical Oncology, 2001, REF MED PAYM METH CA; [Anonymous], 2001, GAO011118; BURTON TM, 2002, WALL STREET J   0313, pB1; CLOUD DJ, 2000, WALL STREET J   0927, pB1; *CTR MED MED SERV, 2003, DMEPOS COMP BIDD DEM; *DEP HLTH HUM SERV, 2000, OEI030000311 DEP HLT; *DEP HLTH HUM SERV, 2001, OEI030000310 DEP HLT; *DEP HLTH HUM SERV, 2000, OEI030000020 DEP HLT; *DEP HLTH HUM SERV, 1997, OEI039700290 DEP HLT; *DEP HLTH HUM SERV, 1998, OEI039700510 DEP HLT; *DEP HLTH HUM SERV, 1996, OEI039500420 DEP HLT; FREUDENHEIM M, 2002, NY TIMES        0513, pC5; FUHRMANS V, 2001, WALL STREET J   1213, pB4; FUHRMANS V, 2002, WALL STREET J   0607, P1; Gabel J, 2002, HEALTH AFFAIR, V21, P143, DOI 10.1377/hlthaff.21.5.143; *GEN ACC OFF, 2001, GAO0253; Gencarelli DM, 2002, AVERAGE WHOLESALE PR; Iglehart JK, 2002, NEW ENGL J MED, V347, P956, DOI 10.1056/NEJMhpr022143; Iglehart JK, 2002, NEW ENGL J MED, V346, P1924, DOI 10.1056/NEJMhpr020324; JAPSEN B, 2001, CHICAGO TRIBUNE 1122; KOWALCZYK L, 2001, BOSTON GLOBE    1221; Levit K, 2003, HEALTH AFFAIR, V22, P154, DOI 10.1377/hlthaff.22.1.154; MCGINLEY L, 2000, WALL STREET J   0602, pB6; NAIK G, 2002, WALL STREET J   1226, pA8; NICOLA TJ, 2001, REGULATORY LEGISLATI; Pear Robert, 2003, N Y Times Web, pA15; Pear Robert, 2002, NY TIMES        0517, pA1; STRUNK BC, 2001, HLTH AFFAIRS    0926; TAUZIN B, 2001, COMMUNICATION   1114; 2002, FED REG, V67, P79973	32	19	19	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 17	2003	348	16					1590	1597		10.1056/NEJMhpr035135	http://dx.doi.org/10.1056/NEJMhpr035135			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	667TT	12700381				2022-12-28	WOS:000182248900012
J	Baughman, RH				Baughman, RH			Materials science - Muscles made from metal	SCIENCE			English	Editorial Material							CARBON NANOTUBES		Univ Texas, NanoTech Inst, Richardson, TX 75083 USA	University of Texas System; University of Texas Dallas	Baughman, RH (corresponding author), Univ Texas, NanoTech Inst, Richardson, TX 75083 USA.	ray.baughman@utdallas.edu	Baughman, Ray/A-8628-2018	Baughman, Ray/0000-0001-5845-5137				Baughman RH, 1999, SCIENCE, V284, P1340, DOI 10.1126/science.284.5418.1340; Baughman RH, 2002, SCIENCE, V297, P787, DOI 10.1126/science.1060928; BAUGHMAN RH, UNPUB; BECK TR, 1979, J ELECTROCHEM SOC, V126, P252, DOI 10.1149/1.2129015; De Laurentis Kathryn J, 2002, Technol Health Care, V10, P91; MADDEN JD, UNPUB; Rinzler AG, 1998, APPL PHYS A-MATER, V67, P29, DOI 10.1007/s003390050734; Shahinpoor M, 1998, SMART MATER STRUCT, V7, pR15, DOI 10.1088/0964-1726/7/6/001; Vigolo B, 2000, SCIENCE, V290, P1331, DOI 10.1126/science.290.5495.1331; Weissmuller J, 2003, SCIENCE, V300, P312, DOI 10.1126/science.1081024; Zakhidov AA, 1998, SCIENCE, V282, P897, DOI 10.1126/science.282.5390.897; ZAKHIDOV AA, 2001, Patent No. 6261469	12	50	57	2	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 11	2003	300	5617					268	269		10.1126/science.1082270	http://dx.doi.org/10.1126/science.1082270			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	665RQ	12690182				2022-12-28	WOS:000182135400038
J	Joy, DA; Feng, XR; Mu, JB; Furuya, T; Chotivanich, K; Krettli, AU; Ho, M; Wang, A; White, NJ; Suh, E; Beerli, P; Su, XZ				Joy, DA; Feng, XR; Mu, JB; Furuya, T; Chotivanich, K; Krettli, AU; Ho, M; Wang, A; White, NJ; Suh, E; Beerli, P; Su, XZ			Early origin and recent expansion of Plasmodium falciparum	SCIENCE			English	Article							POPULATION-GROWTH; STATISTICAL TESTS; GENE TREES; MALARIA; DNA; NEUTRALITY; DIVERSITY; INFERENCE; EVOLUTION; HISTORY	The emergence of virulent Plasmodium falciparum in Africa within the past 6000 years as a result of a cascade of changes in human behavior and mosquito transmission has recently been hypothesized. Here, we provide genetic evidence for a sudden increase in the African malaria parasite population about 10,000 years ago, followed by migration to other regions on the basis of variation in 100 worldwide mitochondrial DNA sequences. However, both the world and some regional populations appear to be older (50,000 to 100,000 years old), suggesting an earlier wave of migration out of Africa, perhaps during the Pleistocene migration of human beings.	NIAID, Lab Malaria & Vector Res, NIH, Bethesda, MD 20892 USA; Mahidol Univ, Wellcome Trust Mahidol Univ Oxford Trop Med Res P, Bangkok 10400, Thailand; Fiocruz MS, Ctr Pesquisas Rene Rachou, Malaria Lab, BR-30190002 Belo Horizonte, MG, Brazil; Univ Calgary, Dept Microbiol & Infect Dis, Calgary, AB T2N 1N4, Canada; NIH, Ctr Informat Technol, Bethesda, MD 20892 USA; Florida State Univ, Dirac Sci Lib, Sch Computat Sci & Informat Technol, Tallahassee, FL 32306 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Mahidol University; Fundacao Oswaldo Cruz; University of Calgary; National Institutes of Health (NIH) - USA; NIH Center for Information Technology (CIT); State University System of Florida; Florida State University	Joy, DA (corresponding author), NIAID, Lab Malaria & Vector Res, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.	djoy@niaid.nih.gov	Furuya, Tetsuya/J-5916-2013; Beerli, Peter/HDN-6405-2022; White, Nicholas J/I-4629-2012; Beerli, Peter/A-3638-2009; White, Nick/AAC-6527-2019; feng, xiaorong/G-4811-2010	Furuya, Tetsuya/0000-0003-3979-7072; Beerli, Peter/0000-0003-0947-5451; White, Nick/0000-0002-1897-1978; feng, xiaorong/0000-0001-8410-3020; Su, Xinzhuan/0000-0003-3246-3248	CENTER FOR INFORMATION TECHNOLOGY [Z01CT000200, ZIHCT000200] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000892, ZIAAI000892] Funding Source: NIH RePORTER	CENTER FOR INFORMATION TECHNOLOGY(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Center for Information Technology (CIT)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Anderson TJC, 2000, MOL BIOL EVOL, V17, P1467, DOI 10.1093/oxfordjournals.molbev.a026247; Bahlo M, 2000, THEOR POPUL BIOL, V57, P79, DOI 10.1006/tpbi.1999.1447; Brunet M, 2002, NATURE, V418, P145, DOI 10.1038/nature00879; CANN RL, 1987, NATURE, V325, P31, DOI 10.1038/325031a0; CASTELLOE J, 1994, MOL PHYLOGENET EVOL, V3, P102, DOI 10.1006/mpev.1994.1013; Coluzzi M, 2002, SCIENCE, V298, P1415, DOI 10.1126/science.1077769; Coluzzi M, 1999, PARASSITOLOGIA, VOL 41, NOS 1-3, SEPTEMBER 1999, P277; Conway DJ, 2000, MOL BIOCHEM PARASIT, V111, P163, DOI 10.1016/S0166-6851(00)00313-3; Escalante AA, 1998, P NATL ACAD SCI USA, V95, P8124, DOI 10.1073/pnas.95.14.8124; Feagin JE, 2000, INT J PARASITOL, V30, P371, DOI 10.1016/S0020-7519(99)00190-3; FU YX, 1993, GENETICS, V133, P693; Fu YX, 1997, GENETICS, V147, P915; Hughes AL, 2001, P ROY SOC B-BIOL SCI, V268, P1855, DOI 10.1098/rspb.2001.1759; Ingman M, 2000, NATURE, V408, P708, DOI 10.1038/35047064; Kuhner MK, 1998, GENETICS, V149, P429; MCDONALD JH, 1991, NATURE, V351, P652, DOI 10.1038/351652a0; Mu JB, 2002, NATURE, V418, P323, DOI 10.1038/nature00836; NEI M, 1986, MOL BIOL EVOL, V3, P418; Pybus OG, 2000, GENETICS, V155, P1429; Rich SM, 1998, P NATL ACAD SCI USA, V95, P4425, DOI 10.1073/pnas.95.8.4425; ROGERS AR, 1992, MOL BIOL EVOL, V9, P552; SCHNEIDER S, 2000, ARLEQUIN SOFTWARE; TAJIMA F, 1989, GENETICS, V123, P585; Thomson R, 2000, P NATL ACAD SCI USA, V97, P7360, DOI 10.1073/pnas.97.13.7360; Underhill PA, 2000, NAT GENET, V26, P358, DOI 10.1038/81685; Volkman SK, 2001, SCIENCE, V293, P482, DOI 10.1126/science.1059878; Wootton JC, 2002, NATURE, V418, P320, DOI 10.1038/nature00813	27	280	291	0	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 11	2003	300	5617					318	321		10.1126/science.1081449	http://dx.doi.org/10.1126/science.1081449			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	665RQ	12690197				2022-12-28	WOS:000182135400054
J	Watkins, PJ				Watkins, PJ			ABC of diabetes - The diabetic foot	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Kings Coll Hosp London, Kings Diabet Ctr, London, England	King's College Hospital NHS Foundation Trust; King's College Hospital	Watkins, PJ (corresponding author), Kings Coll Hosp London, Kings Diabet Ctr, London, England.	peter.watkins1@virgin.net							0	41	44	0	14	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 3	2003	326	7396					977	979		10.1136/bmj.326.7396.977	http://dx.doi.org/10.1136/bmj.326.7396.977			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	676JC	12727775	Green Published			2022-12-28	WOS:000182746700023
J	Reynolds, SJ; Bartlett, JG; Quinn, TC; Beyrer, C; Bollinger, RC				Reynolds, SJ; Bartlett, JG; Quinn, TC; Beyrer, C; Bollinger, RC			Antiretroviral therapy where resources are limited	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							DRUG-RESISTANCE; POOR SETTINGS; COTE-DIVOIRE; HIV; ADULTS; TUBERCULOSIS; INFECTION; SURVIVAL; ABIDJAN; AFRICA		Johns Hopkins Univ, Sch Med, Div Infect Dis, Baltimore, MD 21205 USA; NIAID, NIH, Bethesda, MD 20892 USA; Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA	Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Reynolds, SJ (corresponding author), Johns Hopkins Univ, Sch Med, Div Infect Dis, Baltimore, MD 21205 USA.		safaiee, malihe/C-5045-2018; Zolfigol, Mohammad Ali/AAH-9281-2020; Habibi, Davood/AAH-3062-2020	Habibi, Davood/0000-0002-2386-8502; Bollinger, Robert/0000-0002-6798-6834; Reynolds, Steven/0000-0002-5403-2759	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000361, Z01AI000361] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adje C, 2001, J ACQ IMMUN DEF SYND, V26, P501, DOI 10.1097/00126334-200104150-00018; Anglaret X, 1999, LANCET, V353, P1463, DOI 10.1016/S0140-6736(98)07399-1; Attaran A, 2001, LANCET, V357, P57, DOI 10.1016/S0140-6736(00)03576-5; Badri M, 2002, LANCET, V359, P2059, DOI 10.1016/S0140-6736(02)08904-3; Bell JC, 1999, AIDS, V13, P1549, DOI 10.1097/00002030-199908200-00016; Brenner B, 2000, INT J ANTIMICROB AG, V16, P429, DOI 10.1016/S0924-8579(00)00270-3; *BRIT HIV ASS, 2002, GUID TREATM HIV INF; Casseb J, 1999, AIDS PATIENT CARE ST, V13, P213, DOI 10.1089/apc.1999.13.213; *DEP HLTH HUM SERV, 2002, GUID US ANT AG HIV I; Farmer P, 2001, LANCET, V358, P404, DOI 10.1016/S0140-6736(01)05550-7; *GLOB FUND FIGHT A, 2002, PROP COMP APPR FUND; Kam KM, 1998, CLIN IMMUNOL IMMUNOP, V89, P11, DOI 10.1006/clin.1998.4570; Kannangai R, 2000, J CLIN VIROL, V17, P101, DOI 10.1016/S1386-6532(00)00080-9; Kebba A, 2002, AIDS RES HUM RETROV, V18, P1181, DOI 10.1089/08892220260387922; Kitahata MM, 1996, NEW ENGL J MED, V334, P701, DOI 10.1056/NEJM199603143341106; Laurent C, 2002, AIDS, V16, P1363, DOI 10.1097/00002030-200207050-00008; Little SJ, 2002, NEW ENGL J MED, V347, P385, DOI 10.1056/NEJMoa013552; Mbewu A, 2001, B WORLD HEALTH ORGAN, V79, P1152; Porter K, 2001, BRIT MED J, V322, P1087, DOI 10.1136/bmj.322.7294.1087; Rabkin M, 2002, LANCET, V360, P1503, DOI 10.1016/S0140-6736(02)11478-4; Vergne L, 2002, J ACQ IMMUN DEF SYND, V29, P165, DOI 10.1097/00042560-200202010-00009; Weidle PJ, 2002, LANCET, V360, P34, DOI 10.1016/S0140-6736(02)09330-3; *WHO, 2002, SCAL ANT THER RES LI; *WHO UNAIDS, 2000, WHO UNAIDS HAIL CONS; Yeni PG, 2002, JAMA-J AM MED ASSOC, V288, P222, DOI 10.1001/jama.288.2.222	25	24	25	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 1	2003	348	18					1806	1809		10.1056/NEJMsb035366	http://dx.doi.org/10.1056/NEJMsb035366			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	672VK	12724489	Bronze			2022-12-28	WOS:000182543500012
J	Otto, SJ; Fracheboud, J; Looman, CWN; Broeders, MJM; Boer, R; Hendriks, JHCL; Verbeek, ALM; de Koning, HJ				Otto, SJ; Fracheboud, J; Looman, CWN; Broeders, MJM; Boer, R; Hendriks, JHCL; Verbeek, ALM; de Koning, HJ		Natl Evaluation Team Breast Canc S	Initiation of population-based mammography screening in Dutch municipalities and effect on breast-cancer mortality: a systematic review	LANCET			English	Review							SWEDISH RANDOMIZED TRIALS; CARCINOMA MORTALITY; COST-EFFECTIVENESS; NETHERLANDS; PROGRAM; ENGLAND; TRENDS; POLICY; IMPACT; SWEDEN	Background More than a decade ago, a mammography screening programme for women aged 50-69 years was initiated in the Netherlands. Our aim was to assess the effect of this programme on breast-cancer mortality rates. Methods We examined data for 27 948 women who died of breast-cancer aged 55-74 years between 1980 and 1999 (30 560 cases until 2001). We grouped individuals into 93 clusters, depending on where they lived, and analysed data by use of national population statistics. We analysed time trends in breast-cancer mortality, adjusting for gradual implementations at municipality level, taking as year 0 the month and year in which screening began in a particular municipality. We used a Poisson regression model to estimate the time at which the trend started to turn. We assessed indirectly whether this turning point was related to initiation of screening or adjuvant systemic therapy in four clusters defined according to when screening was implemented. Findings Compared with rates in 1986-88, breast-cancer mortality rates in women aged 55-74 years fell significantly in :199.7 and subsequent years as predicted, reaching -19.9% in 2001. Mortality rates had been increasing by an annual 0.3% until screening was introduced; thereafter we noted a decline of 1-7% per year (95% Cl 2.39-0.96) in women aged 55-74 years and of 1.2% in those aged 45-54 (2.40 to 0.07). The turning point in mortality trends arose at around year 0. Adjuvant systemic therapy is unlikely to be the cause of this turning point, since the mortality rates continued to rise up to 1 year after implementation in municipalities where screening began after 1995. Interpretation Routine mammography screening can reduce breast-cancer mortality rates in women aged 55-74 years.	Univ Med Ctr, Erasmus MC, Dept Publ Hlth, NL-3000 DR Rotterdam, Netherlands; Univ Med Ctr, Dept Epidemiol & Biostat, Nijmegen, Netherlands; Univ Med Ctr, Dept Radiol, Nijmegen, Netherlands; Natl Expert & Training Ctr Breast Canc Screening, Nijmegen, Netherlands	Erasmus University Rotterdam; Erasmus MC; Radboud University Nijmegen; Radboud University Nijmegen	de Koning, HJ (corresponding author), Univ Med Ctr, Erasmus MC, Dept Publ Hlth, POB 1738, NL-3000 DR Rotterdam, Netherlands.		de+Koning, Harry/AAF-9062-2019; Boer, Robert/AFM-0525-2022; Boer, Robert/AAH-2901-2022; Verbeek, A.L.M./H-8103-2014; Boer, Rob/E-6473-2015; Broeders, Mireille JM/C-8820-2015	de+Koning, Harry/0000-0003-4682-3646; Boer, Robert/0000-0003-0680-001X; Boer, Robert/0000-0003-0680-001X; Verbeek, A.L.M./0000-0002-2319-5002; Boer, Rob/0000-0003-0680-001X; Broeders, Mireille JM/0000-0002-8741-8148				Abe O, 1998, LANCET, V352, P930; Barchielli A, 2001, CANCER CAUSE CONTROL, V12, P249, DOI 10.1023/A:1011280204842; Blanks RG, 2000, BRIT MED J, V321, P665, DOI 10.1136/bmj.321.7262.665; Boer R, 1998, BRIT MED J, V317, P376; Bontenbal M, 2000, Ned Tijdschr Geneeskd, V144, P984; Broeders MJM, 2001, INT J CANCER, V92, P303, DOI 10.1002/1097-0215(200102)9999:9999&lt;::AID-IJC1186&gt;3.0.CO;2-B; Clarke M, 1998, LANCET, V351, P1451; de Koning H. J., 1990, KOSTEN EFFECTEN BEVO; DEKONING HJ, 1991, INT J CANCER, V49, P531, DOI 10.1002/ijc.2910490410; DEKONING HJ, 1995, JNCI-J NATL CANCER I, V87, P1217; DEKONING HJ, 1992, BRIT J CANCER, V65, P950, DOI 10.1038/bjc.1992.199; Duffy SW, 2002, CANCER-AM CANCER SOC, V95, P458, DOI 10.1002/cncr.10765; Fracheboud J, 1998, INT J CANCER, V75, P694, DOI 10.1002/(SICI)1097-0215(19980302)75:5<694::AID-IJC6>3.0.CO;2-U; Fracheboud J, 2001, BREAST, V10, P6, DOI 10.1054/brst.2000.0212; FRANCIS B, 1994, GLIM SYSTEM RELEASE; Garne JP, 1997, CANCER-AM CANCER SOC, V79, P69, DOI 10.1002/(SICI)1097-0142(19970101)79:1<69::AID-CNCR10>3.3.CO;2-2; Hakama M, 1997, BRIT MED J, V314, P864; Jonsson H, 2001, J MED SCREEN, V8, P152, DOI 10.1136/jms.8.3.152; Nystrom L, 2002, LANCET, V359, P909, DOI 10.1016/S0140-6736(02)08020-0; NYSTROM L, 1993, LANCET, V341, P973, DOI 10.1016/0140-6736(93)91067-V; QUINN M, 1995, BRIT MED J, V311, P1391, DOI 10.1136/bmj.311.7017.1391; Tabar L, 2001, CANCER-AM CANCER SOC, V91, P1724, DOI 10.1002/1097-0142(20010501)91:9<1724::AID-CNCR1190>3.0.CO;2-V; Tornberg S, 1994, J Med Screen, V1, P184; van den Akker-van Marle E, 1999, J MED SCREEN, V6, P30, DOI 10.1136/jms.6.1.30; VOOGD AC, 1994, ACTA ONCOL, V33, P753, DOI 10.3109/02841869409083944; Waterhouse J, 1976, CANC INCIDENCE 5 CON	26	255	261	0	16	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 26	2003	361	9367					1411	1417		10.1016/S0140-6736(03)13132-7	http://dx.doi.org/10.1016/S0140-6736(03)13132-7			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	672HZ	12727393				2022-12-28	WOS:000182516300008
J	Smyth, EF; Baker, RP; Wilken, BJ; Hartley, JE; White, TJ; Monson, JRT				Smyth, EF; Baker, RP; Wilken, BJ; Hartley, JE; White, TJ; Monson, JRT			Stapled versus excision haemorrhoidectomy: long-term follow up of a randomised controlled trial	LANCET			English	Article							HEMORRHOIDECTOMY	Advantages of the stapling procedure for haemorrhoids include reduced postoperative pain and shortened convalescence; however, there are few data with respect to functional and symptomatic outcome. At a dedicated clinic, we reviewed patients between Dec, 2001, and March, 2002, who had taken part in a randomised controlled trial undertaken at the unit in 1999, which compared outcomes after open or stapled haemorrhoidectomy. We noted the presence or absence of haemorrhoid specific symptoms, and assessed overall satisfaction, continence,. and quality of life. Rigid sigmoidoscopy and an anorectal examination were also used to examine symptomatic recurrence and disease activity. At minimum follow-up of 33 months since surgery, both techniques seem to be equally effective.	Univ Hull, Castle Hill Hosp, Acad Surg Unit, Cottingham HU16 5JQ, England	University of Hull	Monson, JRT (corresponding author), Univ Hull, Castle Hill Hosp, Acad Surg Unit, Castle Rd, Cottingham HU16 5JQ, England.							Cheetham MJ, 2000, LANCET, V356, P730, DOI 10.1016/S0140-6736(00)02632-5; Justin T, 1999, BRIT J SURG, V86, P60; Khalil KH, 2000, BRIT J SURG, V87, P1352, DOI 10.1046/j.1365-2168.2000.01624.x; Longo A., 1998, P 6 WORLD C END SURG; Mehigan BJ, 2000, LANCET, V355, P782, DOI 10.1016/S0140-6736(99)08362-2	5	72	75	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 26	2003	361	9367					1437	1438		10.1016/S0140-6736(03)13106-6	http://dx.doi.org/10.1016/S0140-6736(03)13106-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	672HZ	12727401				2022-12-28	WOS:000182516300016
J	Heisler, M; Moreno, A; DeMonner, S; Keller, A; Iacopino, V				Heisler, M; Moreno, A; DeMonner, S; Keller, A; Iacopino, V			Assessment of torture and ill treatment of detainees in Mexico - Attitudes and experiences of forensic physicians	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Context International and Mexican human rights organizations have documented torture of detainees (ie, those held and indicted but not sentenced) in all 31 states and the Federal District of Mexico, but little is known about the attitudes and experiences of forensic physicians examining detainees. Objective To assess forensic physicians' experiences with and attitudes toward the nature and extent of torture and ill treatment among detainees examined in the previous year. Design, Setting, and Participants With the support of the Mexican Office of the Federal Attorney General, as part of a larger initiative to implement governmental re-m forms to eradicate torture in Mexico, an anonymous, self-administered, written, 80-item survey designed to assess Correspondence of physician practices and attitudes with international standards on forensic investigation and documentation of torture was distributed to all federal forensic physicians (n=115) and a convenience sample of state forensic physicians (n=99) in Mexico in 2002. Main Outcome Measures Estimates of the numbers of federal detainees medically evaluated and numbers of cases of suspected, alleged, and documented torture or ill treatment among federal detainees; factors interfering with documentation of forensic evidence; physicians' attitudes toward torture; measures that would help them document torture; and recommendations for reform. Results Survey responses were received from 93 (81%) federal and 91 (92%) state forensic physicians. Forty-nine percent of federal physicians and 58% of state physicians reported that torture is a severe problem for detainees in Mexico. Federal physicians estimated that they had conducted 26445 to 30650 or more medical evaluations of the 13000 federal detainees in the past year and that between 1658 and 4850 of these detainees had alleged torture; these physicians also estimated that they had documented evidence of torture in a range of 285 to 1090 cases. Forty percent of respondents had suspected torture and/or ill treatment of detainees examined during the previous year, 64% had examined detainees who alleged these practices had occurred, and 49% had documented forensic evidence of torture among these detainees. Respondents reported that lack of photographic equipment and services (58%), inadequate monitoring and accuracy of medical examinations (36%), inadequate documentation of torture (29%), limitations in their training (28%), fear of reprisals for documenting torture (23%) and fear of coercion by police officials (18%) are factors that interfere with documentation of torture and ill treatment of detainees. Respondents further reported the need for additional training (98%), standardized protocols and documentation procedures for use in cases of alleged or suspected torture and/or ill treatment (81%), and monitoring to ensure the quality and accuracy of medical evaluations (95%). Conclusions Torture and ill treatment of detainees is a major problem in Mexico facilitated by multiple medical and legal factors. Mexican forensic physicians support measures to improve forensic documentation of torture and ill treatment of detainees.	Phys Human Rights, Boston, MA 02116 USA; Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI USA; Ann Arbor VEt Affairs Hlth Syst, Ann Arbor, MI USA; Boston Univ, Sch Publ Hlth, Hlth Law Dept, Boston, MA USA; Boston Med Ctr, Boston Ctr Refugee Hlth & Human Rights, Boston, MA USA; Brackenridge Hosp, Austin Med Educ Program, Austin, TX USA; NYU, Sch Med, Bellevue NYU Program Survivors Torture, New York, NY USA	University of Michigan System; University of Michigan; Boston University; Boston Medical Center; New York University	Iacopino, V (corresponding author), Phys Human Rights, 100 Boylston St,Suite 702, Boston, MA 02116 USA.		Heisler, Michele/B-5774-2015	Heisler, Michele/0000-0002-6889-2063				*AMN INT, 1994, PRINC MED ETH REL RO; *AMN INT, 2001, MEX JUST BETR TORT J; *AMN INT, 1994, ETH COD DECL REL HLT, P89; *AMN INT, 2001, MEX TORT CAS CALL OU; *AMN INT, 2002, AMN INT WORLD REP 20; World Medical Association, 2013, JAMA, V310, P2191, DOI 10.1001/jama.2013.281053; [Anonymous], 1917, POLITICAL CONSTITUTI; BASOGLU M, 1993, JAMA-J AM MED ASSOC, V270, P606, DOI 10.1001/jama.270.5.606; British Medical Association, 1992, MED BETR PART DOCT H; *BUR DEM HUM RIGHT, 2002, US DEP STAT COUNTR R; Human Rights Watch, 2002, HUM RIGHTS WATCH WOR; Iacopino V, 1996, JAMA-J AM MED ASSOC, V276, P396, DOI 10.1001/jama.276.5.396; Iacopino V, 1996, LANCET, V348, P1500, DOI 10.1016/S0140-6736(05)65892-8; Iacopino V, 1999, LANCET, V354, P1117; IACOPINO V, 1995, MED HLTH CARE 21 CEN, P376; Iacopino V, 2001, MANUAL EFFECTIVE INV; *LAW COMM HUM RIGH, 2001, LEG INJ MEX CRIM PRO; *MEX NAT COMM HUM, 2002, REP ACT NOV 16 2000; *OFF UN HIGH COMM, 2000, SIST INT PRES REP; *ORG ADM DESC PREV, 2002, DISTR POBL PEN FUER; Peel M., 2002, MED DOCUMENTATION TO; *STAT CORP, 2001, STATA COMP PROGR REL; *UN EC SOC COUNC, 1999, E19923 UN EC SOC COU; *UN EC SOC COUNC, 1999, ECN41999167 UN EC SO; *UN HIGH COMM HUM, 2000, ECN4RES200043 UN HIG; *UN HIGH COMM HUM, ECN4RES200032 UN HIG; *UN HIGH COMM HUM, 1998, ECN4199838ADD2 UN HI; *UN HIGH COMM HUM, 1987, CONV TORT OTH CRUEL; *WHO, WHO EST HLTH PERS; *WORLD MED ASS, 1975, WORLD MED ASS DECL G; 1991, J MED ETHICS S, V17, P1; [No title captured]	32	21	23	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 23	2003	289	16					2135	2143		10.1001/jama.289.16.2135	http://dx.doi.org/10.1001/jama.289.16.2135			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	669WW	12709474				2022-12-28	WOS:000182374300032
J	Wensing, M; Elwyn, G				Wensing, M; Elwyn, G			Improving the quality of health care - Methods for incorporating patients' views in health care	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE CARE; RESPONSE RATES; PREFERENCES; SATISFACTION		Univ Med Ctr St Radboud, Ctr Qual Care Res, NL-6500 HB Nijmegen, Netherlands; Univ Coll Swansea, Swansea Clin Sch, Primary Care Res Grp, Swansea SA2 8PP, W Glam, Wales	Radboud University Nijmegen; Swansea University	Wensing, M (corresponding author), Univ Med Ctr St Radboud, Ctr Qual Care Res, POB 9101, NL-6500 HB Nijmegen, Netherlands.		Elwyn, Glyn/B-4798-2009; Wensing, Michel/H-8113-2014; Elwyn, G./L-4292-2015; Wensing, Michel/D-3998-2009	Elwyn, Glyn/0000-0002-0917-6286; Wensing, Michel/0000-0001-6569-8137; 				Asch DA, 1997, J CLIN EPIDEMIOL, V50, P1129, DOI 10.1016/S0895-4356(97)00126-1; Baker R, 1997, QUAL HEALTH CARE, V6, P201, DOI 10.1136/qshc.6.4.201; BROWN JB, 1992, MED CARE, V30, P400, DOI 10.1097/00005650-199205000-00003; Edwards A, 2001, Health Expect, V4, P151, DOI 10.1046/j.1369-6513.2001.00116.x; Edwards P, 2002, BRIT MED J, V324, P1183, DOI 10.1136/bmj.324.7347.1183; Etter JF, 1997, J CLIN EPIDEMIOL, V50, P1123, DOI 10.1016/S0895-4356(97)00166-2; FROBERG DG, 1989, J CLIN EPIDEMIOL, V42, P345, DOI 10.1016/0895-4356(89)90039-5; *GEN PRACT COMM, 2002, YOUR CONTR YOUR FUT; Grol R, 1999, FAM PRACT, V16, P4, DOI 10.1093/fampra/16.1.4; GROL R, 2000, PATIENTS EVALUATE GE; Guadagnoli E, 1998, SOC SCI MED, V47, P329, DOI 10.1016/S0277-9536(98)00059-8; Jung HP, 2000, FAM PRACT, V17, P236, DOI 10.1093/fampra/17.3.236; Mullen Penelope M., 1999, Health Expect, V2, P222, DOI 10.1046/j.1369-6513.1999.00062.x; OBRIEN RM, 1995, QUAL QUANT, V29, P421, DOI 10.1007/BF01106066; Pascoe G C, 1983, Eval Program Plann, V6, P185, DOI 10.1016/0149-7189(83)90002-2; Rubin H R, 1990, Med Care Rev, V47, P267, DOI 10.1177/107755879004700302; Ryan M, 1999, SOC SCI MED, V48, P535, DOI 10.1016/S0277-9536(98)00374-8; Schers H, 2001, Spine (Phila Pa 1976), V26, pE348, DOI 10.1097/00007632-200108010-00013; Sitzia J, 1999, INT J QUAL HEALTH C, V11, P319, DOI 10.1093/intqhc/11.4.319; Sixma HJ, 2000, AGE AGEING, V29, P173, DOI 10.1093/ageing/29.2.173; Souchek J, 2000, MED CARE, V38, P1040, DOI 10.1097/00005650-200010000-00008; Streiner DL., 2001, HLTH MEASUREMENT SCA, V2nd; UHLMANN RF, 1984, MED CARE, V22, P681, DOI 10.1097/00005650-198407000-00011; WENSING M, 1994, SOC SCI MED, V38, P45, DOI 10.1016/0277-9536(94)90298-4; Wensing M, 2000, QUAL HEALTH CARE, V9, P200, DOI 10.1136/qhc.9.4.200; WILLIAMS B, 1994, SOC SCI MED, V38, P509, DOI 10.1016/0277-9536(94)90247-X	26	124	127	1	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 19	2003	326	7394					877	879		10.1136/bmj.326.7394.877	http://dx.doi.org/10.1136/bmj.326.7394.877			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	670BF	12702627	Green Published			2022-12-28	WOS:000182386800027
J	Haque, R; Huston, CD; Hughes, M; Houpt, E; Petri, WA				Haque, R; Huston, CD; Hughes, M; Houpt, E; Petri, WA			Amebiasis	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							PARASITE ENTAMOEBA-HISTOLYTICA; LIVER-ABSCESS; INTESTINAL AMEBIASIS; INVASIVE AMEBIASIS; ANTIGEN-DETECTION; UNITED-STATES; MOUSE MODEL; EPIDEMIOLOGY; INFECTION; LECTIN		Int Ctr Diarrhoeal Dis Res, Dhaka 1000, Bangladesh; Univ Vermont, Burlington, VT USA; Univ Virginia, Charlottesville, VA USA	International Centre for Diarrhoeal Disease Research (ICDDR); University of Vermont; University of Virginia	Petri, WA (corresponding author), Univ Virginia Hlth Syst, Div Infect Dis & Int Hlth, Rm 2115,MR4 Bldg,POB 801340, Charlottesville, VA 22908 USA.		Petri, William A./D-3639-2019; Petri, William/AAL-3642-2020; Ahuja, Vineet/N-1705-2019	Petri, William/0000-0002-7268-1218; Ahuja, Vineet/0000-0002-5474-9709	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043596] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI043596] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMS EB, 1977, MEDICINE, V56, P315, DOI 10.1097/00005792-197707000-00003; ADAMS EB, 1977, MEDICINE, V56, P325, DOI 10.1097/00005792-197707000-00004; ALI IKM, IN PRESS EMERG INFEC; Arellano J, 1996, PARASITE IMMUNOL, V18, P491, DOI 10.1046/j.1365-3024.1996.d01-16.x; ARISTIZABAL H, 1991, WORLD J SURG, V15, P216, DOI 10.1007/BF01659055; Barwick RS, 2002, AM J TROP MED HYG, V67, P623, DOI 10.4269/ajtmh.2002.67.623; Beck DL, 2002, EXP PARASITOL, V101, P157, DOI 10.1016/S0014-4894(02)00113-3; Blessmann J, 2002, NEW ENGL J MED, V347, P1384, DOI 10.1056/NEJM200210243471722; Blessmann J, 2002, AM J TROP MED HYG, V66, P578, DOI 10.4269/ajtmh.2002.66.578; BRAGA LL, 1992, J CLIN INVEST, V90, P1131, DOI 10.1172/JCI115931; Brandt H, 1970, Hum Pathol, V1, P351; CHADEE K, 1987, J CLIN INVEST, V80, P1245, DOI 10.1172/JCI113199; DENIS M, 1989, J LEUKOCYTE BIOL, V46, P270, DOI 10.1002/jlb.46.3.270; Dhar SK, 1996, MOL CELL BIOL, V16, P2314; DIAMOND LS, 1993, J EUKARYOT MICROBIOL, V40, P340, DOI 10.1111/j.1550-7408.1993.tb04926.x; ECKMANN L, 1995, J CLIN INVEST, V96, P1269, DOI 10.1172/JCI118161; Eichinger D, 2001, J EUKARYOT MICROBIOL, V48, P17, DOI 10.1111/j.1550-7408.2001.tb00411.x; ELLYSON JH, 1986, AM J SURG, V152, P21, DOI 10.1016/0002-9610(86)90131-5; Evangelopoulos A, 2001, PARASITOL INT, V50, P185, DOI 10.1016/S1383-5769(01)00078-2; Fontanet AL, 2000, ANN TROP MED PARASIT, V94, P269, DOI 10.1080/00034980050006456; Ghosh S, 2000, J CLIN MICROBIOL, V38, P3815, DOI 10.1128/JCM.38.10.3815-3821.2000; Haque R, 2000, J CLIN MICROBIOL, V38, P3235, DOI 10.1128/JCM.38.9.3235-3239.2000; Haque R, 1998, J CLIN MICROBIOL, V36, P449, DOI 10.1128/JCM.36.2.449-452.1998; Haque R, 2002, J INFECT DIS, V186, P547, DOI 10.1086/341566; Houpt ER, 2002, J IMMUNOL, V169, P4496, DOI 10.4049/jimmunol.169.8.4496; Huston CD, 2000, CELL MICROBIOL, V2, P617, DOI 10.1046/j.1462-5822.2000.00085.x; KATZENSTEIN D, 1982, MEDICINE, V61, P237, DOI 10.1097/00005792-198207000-00003; Kotloff KL, 1999, B WORLD HEALTH ORGAN, V77, P651; KROGSTAD DJ, 1978, ANN INTERN MED, V88, P89, DOI 10.7326/0003-4819-88-1-89; KRUPP IM, 1971, AM J TROP MED HYG, V20, P421, DOI 10.4269/ajtmh.1971.20.421; LEIPPE M, 1991, P NATL ACAD SCI USA, V88, P7659, DOI 10.1073/pnas.88.17.7659; Mai ZM, 1999, MOL CELL BIOL, V19, P2198; MCAULEY JB, 1992, CLIN INFECT DIS, V15, P464, DOI 10.1093/clind/15.3.464; MCAULEY JB, 1992, CLIN INFECT DIS, V15, P551, DOI 10.1093/clind/15.3.551; McCarthy JS, 2002, MED J AUSTRALIA, V177, P570, DOI 10.5694/j.1326-5377.2002.tb04957.x; Petri WA, 2000, PARASITOL TODAY, V16, P320, DOI 10.1016/S0169-4758(00)01730-0; Petri WA, 2002, ANNU REV MICROBIOL, V56, P39, DOI 10.1146/annurev.micro.56.012302.160959; Pillai DR, 1999, CLIN INFECT DIS, V29, P1315, DOI 10.1086/313433; POWELL SJ, 1966, LANCET, V2, P1329, DOI 10.1016/S0140-6736(66)92081-2; PRATHAP K, 1970, AM J PATHOL, V60, P229; REED SL, 1995, J IMMUNOL, V155, P266; Saito-Nakano Y, 2001, MOL BIOCHEM PARASIT, V116, P219, DOI 10.1016/S0166-6851(01)00318-8; SALATA RA, 1986, J IMMUNOL, V136, P2633; Seydel KB, 1998, GASTROENTEROLOGY, V115, P1446, DOI 10.1016/S0016-5085(98)70023-X; Singh U, 1997, P NATL ACAD SCI USA, V94, P8812, DOI 10.1073/pnas.94.16.8812; Tovar J, 1999, MOL MICROBIOL, V32, P1013, DOI 10.1046/j.1365-2958.1999.01414.x; VANSONNENBERG E, 1985, RADIOLOGY, V156, P631, DOI 10.1148/radiology.156.3.4023220; Willhoeft U, 1999, MOL BIOCHEM PARASIT, V99, P41, DOI 10.1016/S0166-6851(98)00178-9; Yan L, 2001, INFECT IMMUN, V69, P7911, DOI 10.1128/IAI.69.12.7911-7914.2001; Yi D, 1998, GLYCOBIOLOGY, V8, P1037, DOI 10.1093/glycob/8.10.1037	50	512	537	0	20	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 17	2003	348	16					1565	1573		10.1056/NEJMra022710	http://dx.doi.org/10.1056/NEJMra022710			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	667TT	12700377				2022-12-28	WOS:000182248900008
J	Portmann, O; Vaterlaus, A; Pescia, D				Portmann, O; Vaterlaus, A; Pescia, D			An inverse transition of magnetic domain patterns in ultrathin films	NATURE			English	Article							PHASE-DIAGRAM; FE/CU(100); INSTABILITY; SYSTEM	Inverse freezing and inverse melting are processes where a more symmetric phase is found at lower temperatures than at higher temperatures. Such inverse transitions are very rare(1). Here we report the existence of an inverse transition effect in ultrathin Fe films that are magnetized perpendicular to the film plane. The magnetization of these films is not uniform, but instead manifests itself as stripe domains with opposite perpendicular magnetization(2-4). Predictions relating to the disordering of this striped ground state in the limit of monolayer film thicknesses are controversial. Mean-field arguments(5-7) predict a continuous reduction of the stripe width when the temperature is increased; other studies(8-11) suggest that topological defects, such as dislocations and disclinations, might penetrate the system and induce geometrical phase transitions. We find, from scanning electron microscopy imaging, that when the temperature is increased, the low-temperature stripe domain structure transforms into a more symmetric, labyrinthine structure. However, at even higher temperatures and before the loss of magnetic order, a re-occurrence of the less symmetric stripe phase is found. Despite the widespread theoretical and experimental work on striped systems, this phase sequence and the microscopic instabilities driving it have not been observed before.	Swiss Fed Inst Technol, Festkorperphys Lab, CH-8093 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Portmann, O (corresponding author), Swiss Fed Inst Technol, Festkorperphys Lab, CH-8093 Zurich, Switzerland.							ABANOV A, 1995, PHYS REV B, V51, P1023, DOI 10.1103/PhysRevB.51.1023; CZECH R, 1989, J PHYS-CONDENS MAT, V1, P619, DOI 10.1088/0953-8984/1/3/013; De'Bell K, 2000, REV MOD PHYS, V72, P225, DOI 10.1103/RevModPhys.72.225; GAREL T, 1982, PHYS REV B, V26, P325, DOI 10.1103/PhysRevB.26.325; GEHRING GA, 1993, J PHYS-CONDENS MAT, V5, pL581, DOI 10.1088/0953-8984/5/44/007; Greer AL, 2000, NATURE, V404, P134, DOI 10.1038/35004689; Harrison C, 2000, SCIENCE, V290, P1558, DOI 10.1126/science.290.5496.1558; KASHUBA AB, 1993, PHYS REV B, V48, P10335, DOI 10.1103/PhysRevB.48.10335; Kirilyuk A, 1996, PHYS REV B, V54, P1050, DOI 10.1103/PhysRevB.54.1050; Kivelson SA, 1998, NATURE, V393, P550, DOI 10.1038/31177; Man KL, 2001, SURF SCI, V480, P163, DOI 10.1016/S0039-6028(01)00831-7; NELSON DR, 1980, FUNDAMENTAL PROBLEMS, V5, P53; Newell AC, 1996, PHYSICA D, V97, P185, DOI 10.1016/0167-2789(96)00073-5; PEARSON JE, 1993, SCIENCE, V261, P189, DOI 10.1126/science.261.5118.189; Pierce JP, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.224409; SEUL M, 1995, SCIENCE, V267, P476, DOI 10.1126/science.267.5197.476; SEUL M, 1992, PHYS REV LETT, V68, P2460, DOI 10.1103/PhysRevLett.68.2460; SORNETTE D, 1987, J PHYS-PARIS, V48, P151, DOI 10.1051/jphys:01987004801015100; STAMPANONI M, 1988, J APPL PHYS, V64, P5321, DOI 10.1063/1.342405; Stoycheva AD, 2000, PHYS REV LETT, V84, P4657, DOI 10.1103/PhysRevLett.84.4657; THOMASSEN J, 1992, PHYS REV LETT, V69, P3831, DOI 10.1103/PhysRevLett.69.3831; Vaterlaus A, 2000, PHYS REV LETT, V84, P2247, DOI 10.1103/PhysRevLett.84.2247; Yochelis A, 2002, SIAM J APPL DYN SYST, V1, P236, DOI 10.1137/S1111111101397111	23	140	141	0	47	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 17	2003	422	6933					701	704		10.1038/nature01538	http://dx.doi.org/10.1038/nature01538			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	668CG	12700756				2022-12-28	WOS:000182272300035
J	Moore, DAJ; Jennings, RM; Doherty, TF; Lockwood, DN; Chiodini, PL; Wright, SG; Whitty, CJM				Moore, DAJ; Jennings, RM; Doherty, TF; Lockwood, DN; Chiodini, PL; Wright, SG; Whitty, CJM			Lesson of the week - Assessing the severity of malaria	BRITISH MEDICAL JOURNAL			English	Review							FALCIPARUM; STAGE		Hosp Trop Dis, London WC1E 6AU, England	University College London Hospitals NHS Foundation Trust; University of London; London School of Hygiene & Tropical Medicine	Whitty, CJM (corresponding author), Hosp Trop Dis, London WC1E 6AU, England.		Whitty, Christopher/C-7740-2012	Whitty, Christopher/0000-0002-6076-5027				[Anonymous], 2000, T R SOC TROP MED S1, V94, pS1; D'Acremont V, 2002, BRIT MED J, V324, P875, DOI 10.1136/bmj.324.7342.875; Day NPJ, 2000, CRIT CARE MED, V28, P1833, DOI 10.1097/00003246-200006000-00025; Gaskell JF, 1920, Q J MED, V13, P381, DOI 10.1093/qjmed/os-13.52.381; MARSH K, 1995, NEW ENGL J MED, V332, P1399, DOI 10.1056/NEJM199505253322102; Silamut K, 1999, AM J PATHOL, V155, P395, DOI 10.1016/S0002-9440(10)65136-X; SILAMUT K, 1993, T ROY SOC TROP MED H, V87, P436, DOI 10.1016/0035-9203(93)90028-O; Skinner TS, 1996, INT J PARASITOL, V26, P519, DOI 10.1016/0020-7519(96)89380-5	8	15	15	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 12	2003	326	7393					808	809		10.1136/bmj.326.7393.808	http://dx.doi.org/10.1136/bmj.326.7393.808			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	670BE	12689980	Green Accepted, Green Published			2022-12-28	WOS:000182386700028
J	Shedlock, DJ; Shen, H				Shedlock, DJ; Shen, H			Requirement for CD4 T cell help in generating functional CD8 T cell memory	SCIENCE			English	Article							CD4-DEFICIENT MICE; VIRAL-INFECTION; VIRUS CHALLENGE; RESPONSES; IMMUNIZATION; LYMPHOCYTES	Although primary CD8 responses to acute infections are independent of CD4 help, it is unknown whether a similar situation applies to secondary responses. We show that depletion of CD4 cells during the recall response has minimal effect, whereas depletion during the priming phase leads to reduced responses by memory CD8 cells to reinfection. Memory CD8 cells generated in CD4(+/+) mice responded normally when transferred into CD4(-/-) hosts, whereas memory CD8 cells generated in CD4(-/-) mice mounted defective recall responses in CD4(-/-) adoptive hosts. These results demonstrate a previously undescribed role for CD4 help in the development of functional CD8 memory.	Univ Penn, Sch Med, Dept Microbiol, Philadelphia, PA 19104 USA	University of Pennsylvania	Shen, H (corresponding author), Univ Penn, Sch Med, Dept Microbiol, 3610 Hamilton Walk, Philadelphia, PA 19104 USA.			Shedlock, Devon/0000-0003-1018-7510	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045025] Funding Source: NIH RePORTER; NIAID NIH HHS [AI45025, AI07632] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Belz GT, 2000, P NATL ACAD SCI USA, V97, P2725, DOI 10.1073/pnas.040575197; Bennett SRM, 1998, NATURE, V393, P478, DOI 10.1038/30996; Bourgeois C, 2002, SCIENCE, V297, P2060, DOI 10.1126/science.1072615; den Haan JMM, 2000, P NATL ACAD SCI USA, V97, P12950, DOI 10.1073/pnas.97.24.12950; Foulds KE, 2002, J IMMUNOL, V168, P1528, DOI 10.4049/jimmunol.168.4.1528; Janssen EM, 2003, NATURE, V421, P852, DOI 10.1038/nature01441; Kaech SM, 2002, NAT REV IMMUNOL, V2, P251, DOI 10.1038/nri778; Liu HY, 2002, J IMMUNOL, V168, P3477, DOI 10.4049/jimmunol.168.7.3477; MATLOUBIAN M, 1994, J VIROL, V68, P8056, DOI 10.1128/JVI.68.12.8056-8063.1994; Murali-Krishna K, 1998, IMMUNITY, V8, P177, DOI 10.1016/S1074-7613(00)80470-7; RAHEMTULLA A, 1991, NATURE, V353, P180, DOI 10.1038/353180a0; Riberdy JM, 2000, J VIROL, V74, P9762, DOI 10.1128/JVI.74.20.9762-9765.2000; Ridge JP, 1998, NATURE, V393, P474, DOI 10.1038/30989; Schneider J, 1999, IMMUNOL REV, V170, P29, DOI 10.1111/j.1600-065X.1999.tb01326.x; Schoenberger SP, 1998, NATURE, V393, P480, DOI 10.1038/31002; Shedlock DJ, 2003, J IMMUNOL, V170, P2053, DOI 10.4049/jimmunol.170.4.2053; vonHerrath MG, 1996, J VIROL, V70, P1072, DOI 10.1128/JVI.70.2.1072-1079.1996; WHITTON JL, 1993, J VIROL, V67, P348, DOI 10.1128/JVI.67.1.348-352.1993; Zajac AJ, 1998, J EXP MED, V188, P2205, DOI 10.1084/jem.188.12.2205	20	1156	1204	2	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 11	2003	300	5617					337	339		10.1126/science.1082305	http://dx.doi.org/10.1126/science.1082305			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	665RQ	12690201				2022-12-28	WOS:000182135400059
J	Brumfiel, G				Brumfiel, G			French minister breaks diplomatic ice with visit to US	NATURE			English	News Item																		2003, NATURE, V421, P563	1	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 10	2003	422	6932					551	551		10.1038/422551b	http://dx.doi.org/10.1038/422551b			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	665GN	12686966	Bronze			2022-12-28	WOS:000182111400011
J	Kilbridge, P				Kilbridge, P			The cost of HIPAA compliance	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Kilbridge Associates, Cambridge, MA USA		Kilbridge, P (corresponding author), Kilbridge Associates, Cambridge, MA USA.								0	26	26	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 10	2003	348	15					1423	1424		10.1056/NEJMp030020	http://dx.doi.org/10.1056/NEJMp030020			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	665CU	12686698				2022-12-28	WOS:000182102700001
J	Li, XY; Qian, Q; Fu, ZM; Wang, YH; Xiong, GS; Zeng, DL; Wang, XQ; Liu, XF; Teng, S; Hiroshi, F; Yuan, M; Luo, D; Han, B; Li, JY				Li, XY; Qian, Q; Fu, ZM; Wang, YH; Xiong, GS; Zeng, DL; Wang, XQ; Liu, XF; Teng, S; Hiroshi, F; Yuan, M; Luo, D; Han, B; Li, JY			Control of tillering in rice	NATURE			English	Article							CELL-DIVISION; SIGNAL-TRANSDUCTION; ARABIDOPSIS ROOT; GENE ENCODES; PATHWAY; FAMILY; GRAS; EVOLUTION; PROTEIN; MEMBER	Tillering in rice (Oryza sativa L.) is an important agronomic trait for grain production, and also a model system for the study of branching in monocotyledonous plants. Rice tiller is a specialized grain-bearing branch that is formed on the unelongated basal internode and grows independently of the mother stem (culm) by means of its own adventitious roots(1). Rice tillering occurs in a two-stage process: the formation of an axillary bud at each leaf axil and its subsequent outgrowth(2). Although the morphology and histology(2,3) and some mutants of rice tillering(4) have been well described, the molecular mechanism of rice tillering remains to be elucidated. Here we report the isolation and characterization of MONOCULM 1 (MOC1), a gene that is important in the control of rice tillering. The moc1 mutant plants have only a main culm without any tillers owing to a defect in the formation of tiller buds. MOC1 encodes a putative GRAS family nuclear protein that is expressed mainly in the axillary buds and functions to initiate axillary buds and to promote their outgrowth.	Chinese Acad Sci, Inst Genet & Dev Biol, Beijing 100101, Peoples R China; Chinese Acad Agr Sci, China Natl Rice Res Inst, Hangzhou 310006, Zhejiang, Peoples R China; China Agr Univ, Beijing 100094, Peoples R China; Chinese Acad Sci, Inst Plant Physiol & Ecol, Shanghai 200032, Peoples R China; Chinese Acad Sci, Natl Ctr Gene Res, Shanghai 200233, Peoples R China	Chinese Academy of Sciences; Institute of Genetics & Developmental Biology, CAS; Chinese Academy of Agricultural Sciences; China National Rice Research Institute, CAAS; China Agricultural University; Chinese Academy of Sciences; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS	Li, JY (corresponding author), Chinese Acad Sci, Inst Genet & Dev Biol, Beijing 100101, Peoples R China.		qian, qian/AAH-8708-2021; Li, Jiayang/AAG-4377-2020	Li, Xueyong/0000-0002-8955-0345				[Anonymous], 1995, RICE GENET NEWSLETT; Bolle C, 2000, GENE DEV, V14, P1269; DiLaurenzio L, 1996, CELL, V86, P423, DOI 10.1016/S0092-8674(00)80115-4; Doebley J, 1997, NATURE, V386, P485, DOI 10.1038/386485a0; FOBERT PR, 1994, EMBO J, V13, P616, DOI 10.1002/j.1460-2075.1994.tb06299.x; Hanada K, 1993, SCI RICE PLANT, V1, P222; Hanada K., 1995, SCI RICE PLANT PHYSL, V2, P61; Harushima Y, 1998, GENETICS, V148, P479; Helariutta Y, 2000, CELL, V101, P555, DOI 10.1016/S0092-8674(00)80865-X; HIEI Y, 1994, PLANT J, V6, P271, DOI 10.1046/j.1365-313X.1994.6020271.x; Hu YX, 2000, PLANT J, V24, P693, DOI 10.1046/j.1365-313x.2000.00915.x; Hubbard L, 2002, GENETICS, V162, P1927; Itoh H, 2002, PLANT CELL, V14, P57, DOI 10.1105/tpc.010319; KATAYAMA TUKUDA, 1931, JOUR IMP AGRIC EXP STA [TOKYO] [NOJI SHIKEN JO IHO], V1, P327; Li YH, 1979, MORPHOLOGY ANATOMY G, P138; Lukens L, 2001, MOL BIOL EVOL, V18, P627, DOI 10.1093/oxfordjournals.molbev.a003843; Niwa Y, 1999, PLANT J, V18, P455, DOI 10.1046/j.1365-313X.1999.00464.x; Otsuga D, 2001, PLANT J, V25, P223, DOI 10.1046/j.1365-313x.2001.00959.x; Peng JR, 1997, GENE DEV, V11, P3194, DOI 10.1101/gad.11.23.3194; Peng JR, 1999, NATURE, V400, P256, DOI 10.1038/22307; Pysh LD, 1999, PLANT J, V18, P111, DOI 10.1046/j.1365-313X.1999.00431.x; Richards DE, 2000, BIOESSAYS, V22, P573, DOI 10.1002/(SICI)1521-1878(200006)22:6&lt;573::AID-BIES10&gt;3.0.CO;2-H; Sato Y, 1996, P NATL ACAD SCI USA, V93, P8117, DOI 10.1073/pnas.93.15.8117; Schmitz G, 2002, P NATL ACAD SCI USA, V99, P1064, DOI 10.1073/pnas.022516199; Schumacher K, 1999, P NATL ACAD SCI USA, V96, P290, DOI 10.1073/pnas.96.1.290; Silverstone AL, 1998, PLANT CELL, V10, P155, DOI 10.1105/tpc.10.2.155; Smith HMS, 1997, PLANT PHYSIOL, V114, P411, DOI 10.1104/pp.114.2.411; Stirnberg P, 2002, DEVELOPMENT, V129, P1131; Yan JQ, 1998, THEOR APPL GENET, V97, P267, DOI 10.1007/s001220050895	29	735	985	29	436	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 10	2003	422	6932					618	621		10.1038/nature01518	http://dx.doi.org/10.1038/nature01518			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	665GN	12687001				2022-12-28	WOS:000182111400043
J	Giacaman, R; Halileh, S				Giacaman, R; Halileh, S			Maintaining public health education in the West Bank	LANCET			English	Editorial Material									Birzeit Univ, Inst Community & Publ Hlth, Birzeit, West Bank, Israel	Birzeit University	Giacaman, R (corresponding author), Birzeit Univ, Inst Community & Publ Hlth, Box 14, Birzeit, West Bank, Israel.								0	5	5	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 5	2003	361	9364					1220	1221		10.1016/S0140-6736(03)12958-3	http://dx.doi.org/10.1016/S0140-6736(03)12958-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	664ZF	12686056				2022-12-28	WOS:000182094600026
J	Tomeoka, K; Kiriyama, K; Nakamura, K; Yamahana, Y; Sekine, T				Tomeoka, K; Kiriyama, K; Nakamura, K; Yamahana, Y; Sekine, T			Interplanetary dust from the explosive dispersal of hydratedasteroids by impacts	NATURE			English	Article							SHOCK METAMORPHISM; ATMOSPHERIC ENTRY; CARBONACEOUS CHONDRITES; ACCRETION RATE; MICROMETEORITES; MINERALOGY; ORIGIN	The Earth accretes about 30,000 tons of dust particles per year, with sizes in the range of 20-400 mum (refs 1, 2). Those particles collected at the Earth's surface-termed micrometeorites-are similar in chemistry and mineralogy to hydrated, porous meteorites (3-7), but such meteorites comprise only 2.8% of recovered falls(8). This large difference in relative abundances has been attributed to 'filtering' by the Earth's atmosphere(9), that is, the porous meteorites are considered to be so friable that they do not survive the impact with the atmosphere. Here we report shock-recovery experiments on two porous meteorites, one of which is hydrated and the other is anhydrous. The application of shock to the hydrated meteorite reduces it to minute particles and explosive expansion results upon release of the pressure, through a much broader range of pressures than for the anhydrous meteorite. Our results indicate that hydrated asteroids will produce dust particles during collisions at a much higher rate than anhydrous asteroids, which explains the different relative abundances of the hydrated material in micrometeorites and meteorites: the abundances are established before contact with the Earth's atmosphere.	Kobe Univ, Fac Sci, Dept Earth & Planetary Sci, Nada Ku, Kobe, Hyogo 6578501, Japan; Natl Inst Mat Sci, Tsukuba, Ibaraki 3050044, Japan	Kobe University; National Institute for Materials Science	Tomeoka, K (corresponding author), Kobe Univ, Fac Sci, Dept Earth & Planetary Sci, Nada Ku, Kobe, Hyogo 6578501, Japan.	tomeoka@kobe-u.ac.jp						BALDWIN B, 1971, J GEOPHYS RES, V76, P4653, DOI 10.1029/JA076i019p04653; Brownlee DE, 1997, METEORIT PLANET SCI, V32, P157, DOI 10.1111/j.1945-5100.1997.tb01257.x; Corrigan CM, 1997, METEORIT PLANET SCI, V32, P509, DOI 10.1111/j.1945-5100.1997.tb01296.x; Engrand C, 1998, METEORIT PLANET SCI, V33, P565, DOI 10.1111/j.1945-5100.1998.tb01665.x; FLYNN GJ, 1989, ICARUS, V77, P287, DOI 10.1016/0019-1035(89)90091-2; Fuchs L. H., 1973, SMITHSON CONTRIB EAR, V10, P1, DOI DOI 10.5479/SI.00810274.10.1; Gaffey M.J., 1989, ASTEROIDS, P98; Genge MJ, 1997, GEOCHIM COSMOCHIM AC, V61, P5149, DOI 10.1016/S0016-7037(97)00308-6; Greshake A, 1998, METEORIT PLANET SCI, V33, P267, DOI 10.1111/j.1945-5100.1998.tb01632.x; Housen KR, 1999, NATURE, V402, P155, DOI 10.1038/45985; Jessberger EK, 2001, ASTR AST LI, P253; JONES TD, 1990, ICARUS, V88, P172, DOI 10.1016/0019-1035(90)90184-B; KIEFFER SW, 1971, J GEOPHYS RES, V76, P5449, DOI 10.1029/JB076i023p05449; KURAT G, 1994, GEOCHIM COSMOCHIM AC, V58, P3879, DOI 10.1016/0016-7037(94)90369-7; LOVE SG, 1991, ICARUS, V89, P26, DOI 10.1016/0019-1035(91)90085-8; LOVE SG, 1993, SCIENCE, V262, P550, DOI 10.1126/science.262.5133.550; MCSWEEN HY, 1977, GEOCHIM COSMOCHIM AC, V41, P1777, DOI 10.1016/0016-7037(77)90210-1; MCSWEEN HY, 1979, GEOCHIM COSMOCHIM AC, V43, P1761, DOI 10.1016/0016-7037(79)90024-3; Nakamura T, 2001, GEOCHIM COSMOCHIM AC, V65, P4385, DOI 10.1016/S0016-7037(01)00722-0; NOGUCHI T, 2000, ANTARCTIC METEORITE, V13, P285; SCHAAL RB, 1979, P LUNAR PLANET SCI C, V10, P2547; Schmitt RT, 2000, METEORIT PLANET SCI, V35, P545, DOI 10.1111/j.1945-5100.2000.tb01435.x; SCOTT ERD, 1992, GEOCHIM COSMOCHIM AC, V56, P4281, DOI 10.1016/0016-7037(92)90268-N; Sears D.W.G., 1988, METEORITES EARLY SOL, P3; SEARS DWG, 1997, LUNAR PLANET SCI, V28, P1273; STOFFLER D, 1991, GEOCHIM COSMOCHIM AC, V55, P3845, DOI 10.1016/0016-7037(91)90078-J; Taylor S, 1998, NATURE, V392, P899, DOI 10.1038/31894; Tomeoka K, 1999, GEOCHIM COSMOCHIM AC, V63, P3683, DOI 10.1016/S0016-7037(99)00149-0; Toppani A, 2001, METEORIT PLANET SCI, V36, P1377, DOI 10.1111/j.1945-5100.2001.tb01831.x; Zolensky ME, 1996, METEORIT PLANET SCI, V31, P518, DOI 10.1111/j.1945-5100.1996.tb02093.x	30	50	50	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 1	2003	423	6935					60	62		10.1038/nature01567	http://dx.doi.org/10.1038/nature01567			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	673CG	12721622				2022-12-28	WOS:000182561600036
J	Kasahara, T; Kato, T				Kasahara, T; Kato, T			A new redox-cofactor vitamin for mammals	NATURE			English	Article							PYRROLOQUINOLINE QUINONE; ALPHA-AMINOADIPATE; LYSINE; BIOSYNTHESIS		RIKEN, Brain Sci Inst, Lab Mol Dynam Mental Disorders, Wako, Saitama 3510198, Japan	RIKEN	Kasahara, T (corresponding author), RIKEN, Brain Sci Inst, Lab Mol Dynam Mental Disorders, Wako, Saitama 3510198, Japan.		Kato, Tadafumi/J-3583-2014; Kasahara, Takaoki/AAJ-5367-2020	Kato, Tadafumi/0000-0001-7856-3952; Kasahara, Takaoki/0000-0002-0953-5146				BHATTACHARJEE JK, 1985, CRC CR REV MICROBIOL, V12, P131, DOI 10.3109/10408418509104427; Ehmann DE, 1999, BIOCHEMISTRY-US, V38, P6171, DOI 10.1021/bi9829940; FLUCKIGER R, 1988, BIOCHEM BIOPH RES CO, V153, P353, DOI 10.1016/S0006-291X(88)81230-0; HIGASHINO K, 1971, ARCH BIOCHEM BIOPHYS, V142, P606, DOI 10.1016/0003-9861(71)90525-X; KILLGORE J, 1989, SCIENCE, V245, P850, DOI 10.1126/science.2549636; KUMAZAWA T, 1992, BIOCHIM BIOPHYS ACTA, V1156, P62, DOI 10.1016/0304-4165(92)90096-D; MATHEWS FS, 1995, METHOD ENZYMOL, V258, P191; Praphanphoj V, 2001, MOL GENET METAB, V72, P336, DOI 10.1006/mgme.2000.3138; SALISBURY SA, 1979, NATURE, V280, P843, DOI 10.1038/280843a0; STEINBERG FM, 1994, J NUTR, V124, P744, DOI 10.1093/jn/124.5.744	10	157	188	1	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 24	2003	422	6934					832	832		10.1038/422832a	http://dx.doi.org/10.1038/422832a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	670WR	12712191				2022-12-28	WOS:000182432600039
J	Imai, Y; Parodo, J; Kajikawa, O; de Perrot, M; Fischer, S; Edwards, V; Cutz, E; Liu, MY; Keshavjee, S; Martin, TR; Marshall, JC; Ranieri, VM; Slutsky, AS				Imai, Y; Parodo, J; Kajikawa, O; de Perrot, M; Fischer, S; Edwards, V; Cutz, E; Liu, MY; Keshavjee, S; Martin, TR; Marshall, JC; Ranieri, VM; Slutsky, AS			Injurious mechanical ventilation and end-organ epithelial cell apoptosis and organ dysfunction in an experimental model of acute respiratory distress syndrome	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RENAL TUBULAR CELLS; INDUCED LUNG INJURY; SOLUBLE FAS-LIGAND; DEATH; FAILURE; SEPSIS; EXPRESSION; INDUCTION; CYTOKINES; ISCHEMIA	Context Recent clinical trials have demonstrated a decrease in multiple organ dysfunction syndrome (MODS) and mortality in patients with acute respiratory distress syndrome (ARDS) treated with a protective ventilatory strategy. Objective To examine the hypothesis that an injurious ventilatory strategy may lead to end-organ epithelial cell apoptosis and organ dysfunction. Design and Setting In vivo animals: 24 rabbits with acid-aspiration lung injury were ventilated with injurious or noninjurious ventilatory strategies. In vitro:,rabbit epithelial cells were exposed to plasma from in vivo rabbit studies. In vivo human: plasma samples from patients included in a previous randomized controlled trial examining a lung protective strategy were analyzed (lung protection group, n=9 and controls, n=11). Main Outcome Measures In vivo animals: biochemical markers of liver and renal dysfunction; apoptosis in end organs. In vitro: induction of apoptosis in LLC-RK1 renal tubular epithelial cells. In vivo human: correlation of plasma creatinine and soluble Fas ligand. Results The injurious ventilatory strategy led to increased rates of epithelial cell apoptosis in the kidney (mean [SE]: injurious, 10.9% [0.88%]; noninjurious, 1.86% [0.17%]; P<001) and small intestine villi (injurious, 6.7% [0.66%]; noninjurious, 0.97% [0.14%]; P<001), and led to the elevation of biochemical markers indicating renal dysfunction in vivo. Induction of apoptosis was increased in LLC-RK1 cells incubated with plasma from rabbits ventilated with injurious ventilatory strategy at 4 hours (P=.03) and 8 hours (P=.002). The Fas:Ig, a fusion protein that blocks soluble Fas ligand, attenuated induction of apoptosis in vitro. There was a significant correlation between changes in soluble Fas ligand and changes in creatinine in patients with ARDS (R=0.64, P=.002). Conclusions Mechanical ventilation can lead to epithelial cell apoptosis in the kidney and small intestine, Accompanied by biochemical evidence of organ dysfunction. This may partially explain the high rate of MODS observed in patients with ARDS and the decrease in morbidity and mortality in patients treated with a lung protective strategy.	Univ Toronto, St Michaels Hosp, Dept Crit Care, Toronto, ON M5B 1W8, Canada; Univ Hlth Network, Res Lab, Toronto, ON, Canada; Seattle Vet Adm Med Ctr, Seattle, WA USA; Hosp Sick Children, Res Inst, Dept Pediat Lab Med, Toronto, ON M5G 1X8, Canada; Univ Turin, Osped S Giovanni Battista, Sez Anestesiol & Rianimaz, Dipartimento Discipline Medicochirurg Div, Turin, Italy	University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); A.O.U. Citta della Salute e della Scienza di Torino; AOU San Giovanni Battista-Molinette; University of Turin	Slutsky, AS (corresponding author), Univ Toronto, St Michaels Hosp, Dept Crit Care, 30 Bond St,Queen Wing,Room 4-042, Toronto, ON M5B 1W8, Canada.	arthur.slutsky@utoronto.ca	Ranieri, Marco/AFX-8152-2022; Imai, Yumiko/GXW-1144-2022; Slutsky, Arthur/M-3325-2019; Slutsky, Arthur S/A-6013-2008	Slutsky, Arthur S/0000-0002-6063-3876; de Perrot, Marc/0000-0003-2000-9427; Liu, Mingyao/0000-0002-9188-8417; Keshavjee, Shaf/0000-0003-4547-8094				Amato MBP, 1998, NEW ENGL J MED, V338, P347, DOI 10.1056/NEJM199802053380602; [Anonymous], 1999, INTENS CARE MED, V25, P1444; BALK RA, 1995, JAMA-J AM MED ASSOC, V274, P127, DOI 10.1001/jama.1995.03530020045021; Belperio JA, 2002, J CLIN INVEST, V110, P1703, DOI 10.1172/JCI200215849; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; CARRICO CJ, 1986, ARCH SURG-CHICAGO, V121, P196; Coopersmith CM, 2002, JAMA-J AM MED ASSOC, V287, P1716, DOI 10.1001/jama.287.13.1716; Daemen MARC, 2001, TRANSPLANTATION, V71, P1007; de Perrot M, 2002, J THORAC CARDIOV SUR, V124, P1137, DOI 10.1067/mtc.2002.125056; Dreyfuss D, 1998, AM J RESP CRIT CARE, V157, P294, DOI 10.1164/ajrccm.157.1.9604014; Esteban A, 2002, JAMA-J AM MED ASSOC, V287, P345, DOI 10.1001/jama.287.3.345; Ferreira FL, 2001, JAMA-J AM MED ASSOC, V286, P1754, DOI 10.1001/jama.286.14.1754; Fink M P, 2000, Minerva Anestesiol, V66, P337; Fischer S, 2000, ANN SURG, V231, P424, DOI 10.1097/00000658-200003000-00016; Fry DE, 2000, AM SURGEON, V66, P126; Hashimoto S, 2000, AM J RESP CRIT CARE, V161, P237, DOI 10.1164/ajrccm.161.1.9810007; Healy E, 1998, KIDNEY INT, V54, P1955, DOI 10.1046/j.1523-1755.1998.00202.x; Hetts SW, 1998, JAMA-J AM MED ASSOC, V279, P300, DOI 10.1001/jama.279.4.300; Hiramatsu M, 1997, SHOCK, V7, P247, DOI 10.1097/00024382-199704000-00002; Hotchkiss RS, 2000, CRIT CARE MED, V28, P3207, DOI 10.1097/00003246-200009000-00016; Hotchkiss RS, 1999, CRIT CARE MED, V27, P1230, DOI 10.1097/00003246-199907000-00002; Hotchkiss RS, 1997, CRIT CARE MED, V25, P1298, DOI 10.1097/00003246-199708000-00015; Hudson LD, 1999, JAMA-J AM MED ASSOC, V282, P77, DOI 10.1001/jama.282.1.77; Imai Y, 2001, J APPL PHYSIOL, V91, P1836, DOI 10.1152/jappl.2001.91.4.1836; Iwama H, 2000, AM J EMERG MED, V18, P348, DOI 10.1016/S0735-6757(00)90141-4; Kajikawa O, 1997, J IMMUNOL METHODS, V205, P135, DOI 10.1016/S0022-1759(97)00066-5; Kajikawa O, 1996, J IMMUNOL METHODS, V197, P19, DOI 10.1016/0022-1759(96)00101-9; Koide N, 1996, FEMS IMMUNOL MED MIC, V16, P205, DOI 10.1111/j.1574-695X.1996.tb00137.x; Krammer P H, 1999, Adv Immunol, V71, P163; LeGall JR, 1996, JAMA-J AM MED ASSOC, V276, P802, DOI 10.1001/jama.276.10.802; MARSHALL JC, 1995, CRIT CARE MED, V23, P1638, DOI 10.1097/00003246-199510000-00007; Matute-Bello G, 1999, J IMMUNOL, V163, P2217; Matute-Bello G, 2001, AM J PHYSIOL-LUNG C, V281, pL328, DOI 10.1152/ajplung.2001.281.2.L328; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; OrtizArduan A, 1996, AM J PHYSIOL-RENAL, V271, pF1193; Papathanassoglou EDE, 2000, CRIT CARE MED, V28, P537, DOI 10.1097/00003246-200002000-00042; Perianayagam MC, 2000, J LAB CLIN MED, V136, P320, DOI 10.1067/mlc.2000.109318; Rana A, 2001, APOPTOSIS, V6, P83, DOI 10.1023/A:1009680229931; Ranieri VM, 2000, JAMA-J AM MED ASSOC, V284, P43, DOI 10.1001/jama.284.1.43; Ranieri VM, 1999, JAMA-J AM MED ASSOC, V282, P54, DOI 10.1001/jama.282.1.54; SCHUMER M, 1992, AM J PATHOL, V140, P831; Slutsky AS, 1998, AM J RESP CRIT CARE, V157, P1721, DOI 10.1164/ajrccm.157.6.9709092; Tesch GH, 1999, J CLIN INVEST, V103, P73, DOI 10.1172/JCI4876; Tremblay L, 1997, J CLIN INVEST, V99, P944, DOI 10.1172/JCI119259; Tremblay LN, 1998, P ASSOC AM PHYSICIAN, V110, P482; Ueda N, 1998, KIDNEY INT, V54, P399, DOI 10.1046/j.1523-1755.1998.00008.x; WARDLE EN, 1994, NEPHROL DIAL TRANSPL, V9, P104; Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806; Watson RWG, 1997, J IMMUNOL, V158, P945; Wyncoll DLA, 1999, LANCET, V354, P497, DOI 10.1016/S0140-6736(98)08129-X	51	446	488	2	25	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 23	2003	289	16					2104	2112		10.1001/jama.289.16.2104	http://dx.doi.org/10.1001/jama.289.16.2104			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	669WW	12709468	Bronze			2022-12-28	WOS:000182374300026
J	Olsen, JH; Winther, JF				Olsen, JH; Winther, JF			Down's syndrome and neural tube defects in the same families	LANCET			English	Editorial Material							2ND MALIGNANT NEOPLASMS; CHILDHOOD-CANCER; SURVIVORS; TUMORS		Danish Canc Soc, Inst Canc Epidemiol, DK-2100 Copenhagen, Denmark	Danish Cancer Society	Olsen, JH (corresponding author), Danish Canc Soc, Inst Canc Epidemiol, DK-2100 Copenhagen, Denmark.		Winther, Jeanette Falck/AAS-2754-2020	Winther, Jeanette Falck/0000-0002-3440-5108; Olsen, Jorgen Helge/0000-0001-9633-5662				HAWKINS MM, 1987, BRIT J CANCER, V56, P339, DOI 10.1038/bjc.1987.200; LI FP, 1975, CANCER, V35, P1230, DOI 10.1002/1097-0142(197504)35:4<1230::AID-CNCR2820350430>3.0.CO;2-Q; Neglia JP, 2001, J NATL CANCER I, V93, P618, DOI 10.1093/jnci/93.8.618; OLSEN JH, 1993, BRIT MED J, V307, P1030, DOI 10.1136/bmj.307.6911.1030; TUCKER MA, 1984, RAD CARCINOGENESIS E, P211	5	1	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 19	2003	361	9366					1316	1316		10.1016/S0140-6736(03)13086-3	http://dx.doi.org/10.1016/S0140-6736(03)13086-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	669HP	12711462				2022-12-28	WOS:000182346100004
J	Jones, CW				Jones, CW			Zeolites go organic	SCIENCE			English	Editorial Material									Georgia Inst Technol, Sch Chem Engn, Atlanta, GA 30332 USA	University System of Georgia; Georgia Institute of Technology	Jones, CW (corresponding author), Georgia Inst Technol, Sch Chem Engn, Atlanta, GA 30332 USA.							CARROTT PJM, 1986, CHEM IND, V786; Cauvel A, 1995, STUD SURF SCI CATAL, V94, P286; Inagaki S, 2002, NATURE, V416, P304, DOI 10.1038/416304a; Inagaki S, 1999, J AM CHEM SOC, V121, P9611, DOI 10.1021/ja9916658; Jones CW, 1998, NATURE, V393, P52, DOI 10.1038/29959; Lightfoot P, 2001, J MATER CHEM, V11, P212, DOI 10.1039/b002950p; MENTZEN BF, 1995, MATER RES BULL, V30, P373, DOI 10.1016/0025-5408(95)00003-8; Shea KJ, 1989, CHEM MATER, V1, P572, DOI 10.1021/cm00006a003; Yamamoto K, 2003, SCIENCE, V300, P470, DOI 10.1126/science.1081019	9	35	35	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 18	2003	300	5618					439	440		10.1126/science.1084030	http://dx.doi.org/10.1126/science.1084030			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	668LR	12702862				2022-12-28	WOS:000182295900023
J	Lengauer, C				Lengauer, C			An unstable liaison	SCIENCE			English	Editorial Material							DNA METHYLATION; CANCER; INSTABILITY; GENES; MUTATION; TUMORS; CELLS; MICE		Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Dept Oncol, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine	Lengauer, C (corresponding author), Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Dept Oncol, Baltimore, MD 21231 USA.	lengauer@jhmi.edu						Cahill DP, 1999, TRENDS CELL BIOL, V9, pM57, DOI 10.1016/S0962-8924(99)01661-X; Chen RZ, 1998, NATURE, V395, P89, DOI 10.1038/25779; Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557; Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558; JAENISCH R, COMMUNICATION; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Karpf AR, 2002, ONCOGENE, V21, P5496, DOI 10.1038/sj.onc.1205602; KAUTIAINEN TL, 1986, J BIOL CHEM, V261, P1594; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Lengauer C, 1997, P NATL ACAD SCI USA, V94, P2545, DOI 10.1073/pnas.94.6.2545; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6; Rhee I, 2000, NATURE, V404, P1003, DOI 10.1038/35010000; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Trinh BN, 2002, MOL CELL BIOL, V22, P2906, DOI 10.1128/MCB.22.9.2906-2917.2002; Vogel KS, 1999, SCIENCE, V286, P2176, DOI 10.1126/science.286.5447.2176; Xu GL, 1999, NATURE, V402, P187, DOI 10.1038/46052	20	38	39	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 18	2003	300	5618					442	443		10.1126/science.1084468	http://dx.doi.org/10.1126/science.1084468			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	668LR	12702865				2022-12-28	WOS:000182295900026
J	Rohwer, F				Rohwer, F			Global phage diversity	CELL			English	Editorial Material									San Diego State Univ, Dept Biol, San Diego, CA 92182 USA	California State University System; San Diego State University	Rohwer, F (corresponding author), San Diego State Univ, Dept Biol, San Diego, CA 92182 USA.		Rohwer, Forest/AAC-5315-2019	Rohwer, Forest/0000-0003-1548-5429				Breitbart M, 2002, P NATL ACAD SCI USA, V99, P14250, DOI 10.1073/pnas.202488399; BUCHENOSMOND C, 2002, ICTVDB U VIRUS DATAB; Cairns J., 1992, PHAGE ORIGINS MOL BI; CHAO A, 1984, SCAND J STAT, V11, P783; Curtis TP, 2002, P NATL ACAD SCI USA, V99, P10494, DOI 10.1073/pnas.142680199; Davis BM, 2002, MOBILE DNA-UK, P1040, DOI [10.1128/9781555817954.ch45, DOI 10.1128/9781555817954.CH45]; Novotny V, 2002, NATURE, V416, P841, DOI 10.1038/416841a; Pedulla ML, 2003, CELL, V113, P171, DOI 10.1016/S0092-8674(03)00233-2; SANGER F, 1977, NATURE, V265, P687, DOI 10.1038/265687a0	9	261	283	2	49	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 18	2003	113	2					141	141		10.1016/S0092-8674(03)00276-9	http://dx.doi.org/10.1016/S0092-8674(03)00276-9			1	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	672EP	12705861	Bronze			2022-12-28	WOS:000182508500002
J	Wolfe, CJ; Okubo, PG; Shearer, PM				Wolfe, CJ; Okubo, PG; Shearer, PM			Mantle fault zone beneath Kilauea volcano, Hawaii	SCIENCE			English	Article							SOUTH FLANK; CALIFORNIA; MICROEARTHQUAKES; DEFORMATION; SEISMICITY	Relocations and focal mechanism analyses of deep earthquakes (greater than or equal to13 kilometers) at Kilauea volcano demonstrate that seismicity is focused on an active fault zone at 30-kilometer depth, with seaward slip on a low-angle plane, and other smaller, distinct fault zones. The earthquakes we have analyzed predominantly reflect tectonic faulting in the brittle lithosphere rather than magma movement associated with volcanic activity. The tectonic earthquakes may be induced on preexisting faults by stresses of magmatic origin, although background stresses from volcano loading and lithospheric flexure may also contribute.	Univ Hawaii Manoa, Hawaii Inst Geophys & Planetol, Honolulu, HI 96822 USA; US Geol Survey, Hawaiian Volcano Observ, Hawaii Natl Pk, HI 96718 USA; Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA	University of Hawaii System; University of Hawaii Manoa; United States Department of the Interior; United States Geological Survey; University of California System; University of California San Diego; Scripps Institution of Oceanography	Wolfe, CJ (corresponding author), Univ Hawaii Manoa, Hawaii Inst Geophys & Planetol, Honolulu, HI 96822 USA.		Wolfe, Cecily/E-7874-2011; Shearer, Peter/K-5247-2012	Wolfe, Cecily/0000-0003-3144-5697; Shearer, Peter/0000-0002-2992-7630				Chouet BA, 1996, NATURE, V380, P309, DOI 10.1038/380309a0; DELANEY PT, 1990, SCIENCE, V247, P1311, DOI 10.1126/science.247.4948.1311; DZIEWONSKI AM, 1994, PHYS EARTH PLANET IN, V86, P253, DOI 10.1016/0031-9201(94)90124-4; Eaton J., 1987, US GEOL SURV PROF PA, V1350, P1307; EATON JP, 1960, SCIENCE, V132, P925, DOI 10.1126/science.132.3432.925; Gillard D, 1996, NATURE, V384, P343, DOI 10.1038/384343a0; GOT JL, 1994, J GEOPHYS RES-SOL EA, V99, P15375, DOI 10.1029/94JB00577; HILL DP, 1987, US GEOL SURV PROF PA, V1350, P903; Klein F.W., 1987, VOLCANISM HAWAII, P1019; Koyanagi R.Y., 1987, VOLCANISM HAWAII, P1221; NADEAU RM, 1995, SCIENCE, V267, P503, DOI 10.1126/science.267.5197.503; OWEN S, 1995, SCIENCE, V267, P1328, DOI 10.1126/science.267.5202.1328; POUPINET G, 1984, J GEOPHYS RES, V89, P5719, DOI 10.1029/JB089iB07p05719; Rubin AM, 1999, NATURE, V400, P635, DOI 10.1038/23196; RYAN MP, 1988, J GEOPHYS RES-SOLID, V93, P4213, DOI 10.1029/JB093iB05p04213; Shearer PM, 1997, J GEOPHYS RES-SOL EA, V102, P8269, DOI 10.1029/96JB03228; TILLING RI, 1993, NATURE, V363, P125, DOI 10.1038/363125a0; Waldhauser F, 2000, B SEISMOL SOC AM, V90, P1353, DOI 10.1785/0120000006	18	51	54	1	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 18	2003	300	5618					478	480		10.1126/science.1082205	http://dx.doi.org/10.1126/science.1082205			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	668LR	12702874				2022-12-28	WOS:000182295900037
J	Lebwohl, M				Lebwohl, M			Psoriasis	LANCET			English	Review							PLAQUE-TYPE PSORIASIS; FACTOR-ALPHA ANTIBODY; BAND UV-B; ANKYLOSING-SPONDYLITIS; THERAPY; ETANERCEPT; INFLIXIMAB; ARTHRITIS; DISEASE; EFFICACY	Recent breakthroughs in the treatment of psoriasis have led to improved understanding of the pathogenesis of this disease. Activation of T lymphocytes leading to release of cytokines results in proliferation of keratinocytes. Several new biological therapies have been developed, which target specific steps in the pathogenesis of psoriasis. With these new treatments, variable degrees of clearing occur. Initial data suggest improved safety over older agents such as methotrexate and ciclosporin, but long-term data are necessary. Enhancements in topical therapy and phototherapy have also increased the armamentarium of treatments available for this disorder.	CUNY Mt Sinai Sch Med, Dept Dermatol, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Lebwohl, M (corresponding author), CUNY Mt Sinai Sch Med, Dept Dermatol, New York, NY 10029 USA.	LebwohlL@aol.com						Abels DJ, 2000, J AM ACAD DERMATOL, V43, P325, DOI 10.1067/mjd.2000.106364; Abrams JR, 1999, J CLIN INVEST, V103, P1243, DOI 10.1172/JCI5857; Aithal GP, 2001, ALIMENT PHARM THERAP, V15, P1101, DOI 10.1046/j.1365-2036.2001.01023.x; Allen M, 2001, LAB INVEST, V81, P969, DOI 10.1038/labinvest.3780309; Asadullah K, 1998, J CLIN INVEST, V101, P783, DOI 10.1172/JCI1476; Asumalahti K, 2002, HUM MOL GENET, V11, P589, DOI 10.1093/hmg/11.5.589; Bagel J, 1998, J AM ACAD DERMATOL, V38, P938, DOI 10.1016/S0190-9622(98)70590-0; BARKER JNWN, 1991, LANCET, V338, P227, DOI 10.1016/0140-6736(91)90357-U; Barker JNWN, 2001, CLIN EXP DERMATOL, V26, P321, DOI 10.1046/j.1365-2230.2001.00830.x; Barthel HR, 2001, ARTHRIT RHEUM-ARTHR, V45, P404, DOI 10.1002/1529-0131(200108)45:4<404::AID-ART355>3.0.CO;2-X; Bhushan M, 2002, BRIT J DERMATOL, V146, P824, DOI 10.1046/j.1365-2133.2002.04743.x; Biondi Oriente C, 1989, Acta Derm Venereol Suppl (Stockh), V146, P69; BJERKE JR, 1978, J INVEST DERMATOL, V71, P340, DOI 10.1111/1523-1747.ep12529841; Bleumink GS, 2001, RHEUMATOLOGY, V40, P1317, DOI 10.1093/rheumatology/40.11.1317; BRANDRUP F, 1982, ACTA DERM-VENEREOL, V62, P229; Brandt J, 2000, ARTHRITIS RHEUM-US, V43, P1346, DOI 10.1002/1529-0131(200006)43:6<1346::AID-ANR18>3.0.CO;2-E; Brockbank J, 2000, EXPERT OPIN INV DRUG, V9, P1511, DOI 10.1517/13543784.9.7.1511; Callis KP, 2002, J INVEST DERMATOL, V119, P244; Cantini F, 2001, ARTHRITIS RHEUM, V44, P2933, DOI 10.1002/1529-0131(200112)44:12<2933::AID-ART482>3.0.CO;2-Y; Capon F, 2002, J INVEST DERMATOL, V118, P745, DOI 10.1046/j.1523-1747.2002.01749.x; Chaudhari U, 2001, LANCET, V357, P1842, DOI 10.1016/S0140-6736(00)04954-0; Chey WY, 2001, AM J GASTROENTEROL, V96, P2373, DOI 10.1111/j.1572-0241.2001.04039.x; Cohen RB, 2001, CAN J GASTROENTEROL, V15, P376, DOI 10.1155/2001/403102; Coven TR, 1997, ARCH DERMATOL, V133, P1514, DOI 10.1001/archderm.133.12.1514; DUFFY DL, 1993, J AM ACAD DERMATOL, V29, P428, DOI 10.1016/0190-9622(93)70206-9; DUHRA P, 1993, J AM ACAD DERMATOL, V28, P466, DOI 10.1016/0190-9622(93)70069-6; Ellis CN, 2001, NEW ENGL J MED, V345, P248, DOI 10.1056/NEJM200107263450403; Ferraccioli G, 2002, ANN RHEUM DIS, V61, P358, DOI 10.1136/ard.61.4.358; Friedrich M, 2002, J INVEST DERMATOL, V118, P672, DOI 10.1046/j.1523-1747.2002.01731.x; Gladman DD, 1998, ARTHRITIS RHEUM-US, V41, P1103, DOI 10.1002/1529-0131(199806)41:6<1103::AID-ART18>3.0.CO;2-N; GOECKERMAN WH, 1925, NW MED, V24, P15229; Goossens PH, 2001, ANN RHEUM DIS, V60, P637, DOI 10.1136/ard.60.6.637; Gottlieb A., 2000, Journal of Investigative Dermatology, V114, P840; GOTTLIEB A, 2002, 60 ANN M AM AC DERM; Gottlieb AB, 2002, J INVEST DERMATOL, V119, P234; Gottlieb AB, 2002, ARCH DERMATOL, V138, P591, DOI 10.1001/archderm.138.5.591; GOTTLIEB SL, 1995, NAT MED, V1, P442, DOI 10.1038/nm0595-442; Green MS, 1996, J AM ACAD DERMATOL, V34, P911, DOI 10.1016/S0190-9622(96)90078-X; Henter JI, 2001, NEW ENGL J MED, V345, P1577, DOI 10.1056/NEJM200111223452118; JONES SK, 1985, BRIT J DERMATOL, V113, P331, DOI 10.1111/j.1365-2133.1985.tb02086.x; Keane J, 2001, NEW ENGL J MED, V345, P1098, DOI 10.1056/NEJMoa011110; Kobbe G, 2001, BONE MARROW TRANSPL, V28, P47, DOI 10.1038/sj.bmt.1703094; Koo J, 1996, DERMATOL CLIN, V14, P485, DOI 10.1016/S0733-8635(05)70376-4; KOO J, 2002, 60 ANN M AM AC DERM; KROGH HK, 1979, ACTA DERM-VENEREOL, V21, P87; KRUEGER GG, 2002, 60 ANN M AM AC DERM; Krueger JG, 2000, J AM ACAD DERMATOL, V43, P448, DOI 10.1067/mjd.2000.106515; Krueger JG, 2002, J AM ACAD DERMATOL, V46, P1, DOI 10.1067/mjd.2002.120568; Langley R, 2001, J INVEST DERMATOL, V117, P817; LARKO O, 1989, ACTA DERM-VENEREOL, V69, P357; Lebwohl M, 1998, J AM ACAD DERMATOL, V38, P705, DOI 10.1016/S0190-9622(98)70594-8; Lebwohl M, 1999, J AM ACAD DERMATOL, V41, pS22, DOI 10.1016/S0190-9622(99)70362-2; LEBWOHL M, 2002, 60 ANN M AM AC DERM; LEONARDI C, 2002, 60 ANN M AM AC DERM; Lohner M., 1999, BRIT J DERMATOL, V141, P989; LOWE NJ, 2002, 60 ANN M AM AC DERM; Maini RN, 1998, ARTHRITIS RHEUM, V41, P1552, DOI 10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W; Margolis D, 2001, ARCH DERMATOL, V137, P778; Martin A, 2001, J AM ACAD DERMATOL, V45, P871, DOI 10.1067/mjd.2001.117852; Martinez F, 2001, INFLAMM BOWEL DIS, V7, P323, DOI 10.1097/00054725-200111000-00008; Mease PJ, 2000, LANCET, V356, P385, DOI 10.1016/S0140-6736(00)02530-7; *MED EC CO, 2002, PHYS DESK REF; *MED EC CO, 2002, REM PROD INF PHYS DE, P1181; MELSKI JW, 1977, J INVEST DERMATOL, V68, P328, DOI 10.1111/1523-1747.ep12496022; MENTER A, 1991, LANCET, V338, P231, DOI 10.1016/0140-6736(91)90358-V; MENTER A, 2002, 60 ANN M AM AC DERM; Mohan N, 2001, ARTHRITIS RHEUM-US, V44, P2862, DOI 10.1002/1529-0131(200112)44:12<2862::AID-ART474>3.0.CO;2-W; Moreland LW, 1999, ANN INTERN MED, V130, P478, DOI 10.7326/0003-4819-130-6-199903160-00004; Nagpal S, 2001, CURR MED CHEM, V8, P1661, DOI 10.2174/0929867013371950; *NAT PSOR FDN, 2000, BULLETIN, V31, P8; Nuijten MJC, 2001, PHARMACOECONOMICS, V19, P1051, DOI 10.2165/00019053-200119100-00006; Ogilvie ALJ, 2001, BRIT J DERMATOL, V144, P587, DOI 10.1046/j.1365-2133.2001.04089.x; Oh CJ, 2000, J AM ACAD DERMATOL, V42, P829, DOI 10.1067/mjd.2000.105948; Poikolainen K, 1999, ARCH DERMATOL, V135, P1490, DOI 10.1001/archderm.135.12.1490; Rappersberger K, 2002, J INVEST DERMATOL, V119, P876, DOI 10.1046/j.1523-1747.2002.00694.x; Ring J, 2001, BRIT J DERMATOL, V144, P495, DOI 10.1046/j.1365-2133.2001.04074.x; Roenigk HH, 1998, J AM ACAD DERMATOL, V38, P478, DOI 10.1016/S0190-9622(98)70508-0; Sacher C, 2002, J AM ACAD DERMATOL, V46, P113, DOI 10.1067/mjd.2001.119100; SCARPA R, 1984, BRIT J RHEUMATOL, V23, P246; SCHOPF RE, 1992, ARCH DERMATOL RES, V284, P227, DOI 10.1007/BF00375799; Schopf Rudolf E, 2002, Curr Opin Investig Drugs, V3, P720; Shakoor N, 2002, LANCET, V359, P579, DOI 10.1016/S0140-6736(02)07714-0; Shbeeb M, 2000, J RHEUMATOL, V27, P1247; Singri P, 2002, ARCH DERMATOL, V138, P657, DOI 10.1001/archderm.138.5.657; Snowden JA, 1997, BRIT J DERMATOL, V137, P130; Steinfeld SD, 2001, ARTHRITIS RHEUM, V44, P2371, DOI 10.1002/1529-0131(200110)44:10<2371::AID-ART401>3.0.CO;2-W; Stern RS, 1997, LANCET, V350, P349, DOI 10.1016/S0140-6736(97)05257-4; Stern RS, 1998, JNCI-J NATL CANCER I, V90, P1278, DOI 10.1093/jnci/90.17.1278; Stern RS, 1997, NEW ENGL J MED, V336, P1041, DOI 10.1056/NEJM199704103361501; Stone JH, 2001, ARTHRITIS RHEUM, V44, P1149, DOI 10.1002/1529-0131(200105)44:5<1149::AID-ANR197>3.3.CO;2-6; Takei S, 2001, J RHEUMATOL, V28, P1677; Tan MH, 2001, ARCH DERMATOL, V137, P930; Tanew A, 1999, ARCH DERMATOL, V135, P519, DOI 10.1001/archderm.135.5.519; THAM S N, 1988, Annals Academy of Medicine Singapore, V17, P482; Voigtlander C, 2001, ARCH DERMATOL, V137, P1571; Volden G, 1992, Acta Derm Venereol Suppl (Stockh), V172, P20; Zachariae H, 1997, BRIT J DERMATOL, V136, P531, DOI 10.1046/j.1365-2133.1997.6101586.x	97	498	541	3	68	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 5	2003	361	9364					1197	1204		10.1016/S0140-6736(03)12954-6	http://dx.doi.org/10.1016/S0140-6736(03)12954-6			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	664ZF	12686053				2022-12-28	WOS:000182094600023
J	Smith, JS; Green, J; Berrington de Gonzalez, A; Appleby, P; Peto, J; Plummer, M; Franceschi, S; Beral, V				Smith, JS; Green, J; Berrington de Gonzalez, A; Appleby, P; Peto, J; Plummer, M; Franceschi, S; Beral, V			Cervical cancer and use of hormonal contraceptives: a systematic review	LANCET			English	Review							DEPOT-MEDROXYPROGESTERONE ACETATE; CARCINOMA IN-SITU; HUMAN-PAPILLOMAVIRUS INFECTION; ORAL-CONTRACEPTIVES; RISK-FACTORS; INVASIVE ADENOCARCINOMAS; ADENOSQUAMOUS CARCINOMAS; NEOPLASIA; SMOKING; COLOMBIA	Background Human papillomavirus (HPV) is believed to be the most important cause of cervical cancer. Recent studies suggest that long duration use of oral contraceptives increases the risk of cervical cancer in HPV positive women. Methods Results from published studies were combined to examine the relationship between invasive and in situ cervical cancer and duration and recency of use of hormonal contraceptives, with particular attention to HPV infection. Findings 28 eligible studies were identified, together including 12 531 women with cervical cancer. Compared with never users of oral contraceptives, the relative risks of cervical cancer increased with increasing duration of use: for durations of approximately less than 5 years, 5-9 years, and 10 or more years, respectively, the summary relative risks were 1.1 (95% CI 1.1-1.2), 1.6 (1.4-1.7), and 2.2 (1.9-2.4) for all women; and 0.9 (0.7-1.2), 1.3 (1.0-1.9), and 2.5 (1.6-3.9) for HPV positive women. The results were broadly similar for invasive and in situ cervical cancers, for squamous cell and adenocarcinoma, and in studies that adjusted for HPV status, number of sexual partners, cervical screening, smoking, or use of barrier contraceptives. The limited available data suggest that the relative risk of cervical cancer may decrease after use of oral contraceptives ceases. However, study designs varied and there was some heterogeneity between study results. Interpretation Although long duration use of hormonal contraceptives is associated with an increased risk of cervical cancer, the public health implications of these findings depend largely on the extent to which the observed associations remain long after use of hormonal contraceptives has ceased, and this cannot be evaluated properly from published data.	Int Agcy Res Canc, F-69372 Lyon, France; Canc Res UK Epidemiol Unit, Oxford, England; Inst Canc Res, Surrey, England; London Sch Hyg & Trop Med, London WC1, England	World Health Organization; International Agency for Research on Cancer (IARC); Cancer Research UK; University of London; Institute of Cancer Research - UK; University of London; London School of Hygiene & Tropical Medicine	Beral, V (corresponding author), Radcliffe Infirm, Canc Res UK Epidemiol Unit, Gibson Bldg,Woodstock Rd, Oxford OX2 6HE, England.		de gonzalez, amy berrington/L-7017-2017; franceschi, silvia/M-2452-2014	de gonzalez, amy berrington/0000-0002-7332-8387; franceschi, silvia/0000-0003-4181-8071; Plummer, Martyn/0000-0001-5130-6497				[Anonymous], 1992, Contraception, V45, P299; BERAL V, 1988, LANCET, V2, P1331; Berrington A, 2002, LANCET, V360, P410, DOI 10.1016/S0140-6736(02)09578-8; BERRINGTON A, IN PRESS BIOSTATISTI; BERRY G, 1993, INT J CANCER, V55, P228; BOSCH FX, 1993, CANCER EPIDEM BIOMAR, V2, P415; BOSCH FX, 1992, INT J CANCER, V52, P750, DOI 10.1002/ijc.2910520514; BRINTON LA, 1986, INT J CANCER, V38, P339, DOI 10.1002/ijc.2910380307; BRINTON LA, 1990, INT J EPIDEMIOL, V19, P4, DOI 10.1093/ije/19.1.4; Calle EE, 1996, CONTRACEPTION, V54, pS1; Chaouki N, 1998, INT J CANCER, V75, P546, DOI 10.1002/(SICI)1097-0215(19980209)75:4&lt;546::AID-IJC9&gt;3.0.CO;2-T; Chichareon S, 1998, J NATL CANCER I, V90, P50, DOI 10.1093/jnci/90.1.50; COX DR, 1989, ANAL BINARY DATA, P60; Cuzick J, 1996, EUR J CANCER, V32A, P836, DOI 10.1016/0959-8049(95)00650-8; Daling JR, 1996, CANCER EPIDEM BIOMAR, V5, P541; Deacon JM, 2000, BRIT J CANCER, V83, P1565, DOI 10.1054/bjoc.2000.1523; EBELING K, 1987, INT J CANCER, V39, P427, DOI 10.1002/ijc.2910390402; ELUFNETO J, 1994, BRIT J CANCER, V69, P114, DOI 10.1038/bjc.1994.18; FERLAY J, 1998, GLOBOCAN, V1; GREEN J, IN PRESS BR J CANC; Hammerly C, 2022, LINGUIST INQ, V53, P823, DOI 10.1162/ling_a_00422; HERRERO R, 1990, INT J CANCER, V46, P5, DOI 10.1002/ijc.2910460103; Hildesheim A, 2001, BRIT J CANCER, V84, P1219, DOI 10.1054/bjoc.2001.1779; IARC, 1999, IARC MON EV CARC RIS, V72, P49; *IARC WORK GROUP E, 1999, IARC MONOGR EVAL CAR, V72, P339; IRWIN KL, 1988, JAMA-J AM MED ASSOC, V259, P59, DOI 10.1001/jama.259.1.59; JONES CJ, 1990, CANCER RES, V50, P3657; KJAER SK, 1993, CANCER CAUSE CONTROL, V4, P513, DOI 10.1007/BF00052426; Lacey JV, 1999, CANCER EPIDEM BIOMAR, V8, P1079; LAZCANOPONCE EC, 1995, REV INVEST CLIN, V47, P377; Madeleine MM, 2001, CANCER EPIDEM BIOMAR, V10, P171; Moreno V, 2002, LANCET, V359, P1085, DOI 10.1016/S0140-6736(02)08150-3; MUNOZ N, 1992, INT J CANCER, V52, P743, DOI 10.1002/ijc.2910520513; MUNOZ N, 1993, CANCER EPIDEM BIOMAR, V2, P423; Ngelangel C, 1998, JNCI-J NATL CANCER I, V90, P43, DOI 10.1093/jnci/90.1.43; OBERLE MW, 1988, INT J EPIDEMIOL, V17, P718, DOI 10.1093/ije/17.4.718; Parazzini F, 1998, EUR J CANCER, V34, P884, DOI 10.1016/S0959-8049(97)10139-3; PETERS RK, 1986, JNCI-J NATL CANCER I, V77, P1063; Rolon PA, 2000, INT J CANCER, V85, P486, DOI 10.1002/(SICI)1097-0215(20000215)85:4&lt;486::AID-IJC7&gt;3.0.CO;2-S; Santos C, 2001, BRIT J CANCER, V85, P966, DOI 10.1054/bjoc.2001.1948; Skegg DCG, 2002, LANCET, V359, P1080, DOI 10.1016/S0140-6736(02)08125-4; THOMAS DB, 1995, CONTRACEPTION, V52, P307, DOI 10.1016/0010-7824(95)00215-V; THOMAS DB, 1995, CONTRACEPTION, V51, P25, DOI 10.1016/0010-7824(94)00007-J; Thomas DB, 1996, AM J EPIDEMIOL, V144, P281, DOI 10.1093/oxfordjournals.aje.a008923; URSIN G, 1994, LANCET, V344, P1390, DOI 10.1016/S0140-6736(94)90567-3; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; YE Z, 1995, INT J EPIDEMIOL, V24, P19, DOI 10.1093/ije/24.1.19; Ylitalo N, 1999, INT J CANCER, V81, P357, DOI 10.1002/(SICI)1097-0215(19990505)81:3<357::AID-IJC8>3.3.CO;2-T; Zondervan KT, 1996, BRIT J CANCER, V73, P1291, DOI 10.1038/bjc.1996.247	49	275	298	0	19	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 5	2003	361	9364					1159	1167		10.1016/S0140-6736(03)12949-2	http://dx.doi.org/10.1016/S0140-6736(03)12949-2			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	664ZF	12686037				2022-12-28	WOS:000182094600008
J	Ayad, NG; Rankin, S; Murakami, M; Jebanathirajah, J; Gygi, S; Kirschner, MW				Ayad, NG; Rankin, S; Murakami, M; Jebanathirajah, J; Gygi, S; Kirschner, MW			Tome-1, a trigger of mitotic entry, is degraded during G1 via the APC	CELL			English	Article							SISTER-CHROMATID SEPARATION; ANAPHASE-PROMOTING COMPLEX; CELL-CYCLE; SUBSTRATE RECOGNITION; MITOSIS; KINASE; CDH1; DEGRADATION; PROTEOLYSIS; INHIBITOR	Entry into mitosis requires the activation of cdk1/ cyclin B, while mitotic exit is achieved when the same kinase activity decreases, as cyclin B is degraded. Cyclin B proteolysis is mediated by the anaphase promoting complex, or APC, an E3 ligase that is active at anaphase in mitosis through G1. We have identified a G1 substrate of the APC that we have termed Tome-1, for trigger of mitotic entry. Tome-1 is a cytosolic protein required for proper activation of cdk1/cyclin B and mitotic entry. Tome-1 associates with Skp-1 and is required for degradation of the cdk1 inhibitory tyrosine kinase wee1; Tome-1 therefore appears to be acting as part of an SCF-type E3 for wee1. Degradation of Tome-1 during G1 allows for wee 1 accumulation during interphase, thereby providing a critical link between the APC and SCF pathways in regulation of cclk1/cyclin B activity and thus mitotic entry and exit.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Taplin Biol Mass Spectrometry Facil, Boston, MA 02115 USA; NCI, Frederick, MD 21702 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Kirschner, MW (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, 200 Longwood Ave, Boston, MA 02115 USA.			Rankin, Susannah/0000-0002-4056-6610	NHGRI NIH HHS [HG00041] Funding Source: Medline	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; Fang CH, 1998, INT J MOL MED, V1, P163; Funabiki H, 2000, CELL, V102, P411, DOI 10.1016/S0092-8674(00)00047-7; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; Kawasaki H, 2001, EMBO J, V20, P4618, DOI 10.1093/emboj/20.16.4618; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Kotani S, 1999, J CELL BIOL, V146, P791, DOI 10.1083/jcb.146.4.791; Kramer ER, 2000, MOL BIOL CELL, V11, P1555, DOI 10.1091/mbc.11.5.1555; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Lorca T, 1998, EMBO J, V17, P3565, DOI 10.1093/emboj/17.13.3565; Lustig KD, 1997, METHOD ENZYMOL, V283, P83; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; Michael WM, 1998, SCIENCE, V282, P1886, DOI 10.1126/science.282.5395.1886; MUELLER PR, 1995, MOL BIOL CELL, V6, P119, DOI 10.1091/mbc.6.1.119; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; Peters JM, 1998, CURR OPIN CELL BIOL, V10, P759, DOI 10.1016/S0955-0674(98)80119-1; Peters JM, 1999, EXP CELL RES, V248, P339, DOI 10.1006/excr.1999.4443; Pfleger CM, 2000, GENE DEV, V14, P655; Pfleger CM, 2001, GENE DEV, V15, P2396, DOI 10.1101/gad.918201; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; Schlosser A, 2001, ANAL CHEM, V73, P170, DOI 10.1021/ac000826j; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SOLOMON MJ, 1991, COLD SH Q B, V56, P427; Stemmann O, 2001, CELL, V107, P715, DOI 10.1016/S0092-8674(01)00603-1; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; WATANABE N, 1995, EMBO J, V14, P1878, DOI 10.1002/j.1460-2075.1995.tb07180.x; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Winston JT, 1999, CURR BIOL, V9, P1180, DOI 10.1016/S0960-9822(00)80021-4; Zhou PB, 1998, MOL CELL, V2, P571, DOI 10.1016/S1097-2765(00)80156-2; Zou H, 1999, SCIENCE, V285, P418, DOI 10.1126/science.285.5426.418	32	141	150	0	7	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 4	2003	113	1					101	113		10.1016/S0092-8674(03)00232-0	http://dx.doi.org/10.1016/S0092-8674(03)00232-0			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	668GX	12679038	Bronze			2022-12-28	WOS:000182282900010
J	Drosten, C; Gunther, S; Preiser, W; van der Werf, S; Brodt, HR; Becker, S; Rabenau, H; Panning, M; Kolesnikova, L; Fouchier, RAM; Berger, A; Burguiere, AM; Cinatl, J; Eickmann, M; Escriou, N; Grywna, K; Kramme, S; Manuguerra, JC; Muller, S; Rickerts, V; Sturmer, M; Vieth, S; Klenk, HD; Osterhaus, ADME; Schmitz, H; Doerr, HW				Drosten, C; Gunther, S; Preiser, W; van der Werf, S; Brodt, HR; Becker, S; Rabenau, H; Panning, M; Kolesnikova, L; Fouchier, RAM; Berger, A; Burguiere, AM; Cinatl, J; Eickmann, M; Escriou, N; Grywna, K; Kramme, S; Manuguerra, JC; Muller, S; Rickerts, V; Sturmer, M; Vieth, S; Klenk, HD; Osterhaus, ADME; Schmitz, H; Doerr, HW			Identification of a novel coronavirus in patients with severe acute respiratory syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LASSA VIRUS; FEVER	BACKGROUND The severe acute respiratory syndrome (SARS) has recently been identified as a new clinical entity. SARS is thought to be caused by an unknown infectious agent. METHODS Clinical specimens from patients with SARS were searched for unknown viruses with the use of cell cultures and molecular techniques. RESULTS A novel coronavirus was identified in patients with SARS. The virus was isolated in cell culture, and a sequence 300 nucleotides in length was obtained by a polymerase-chain-reaction (PCR)-based random-amplification procedure. Genetic characterization indicated that the virus is only distantly related to known coronaviruses (identical in 50 to 60 percent of the nucleotide sequence). On the basis of the obtained sequence, conventional and real-time PCR assays for specific and sensitive detection of the novel virus were established. Virus was detected in a variety of clinical specimens from patients with SARS but not in controls. High concentrations of viral RNA of up to 100 million molecules per milliliter were found in sputum. Viral RNA was also detected at extremely low concentrations in plasma during the acute phase and in feces during the late convalescent phase. Infected patients showed seroconversion on the Vero cells in which the virus was isolated. CONCLUSIONS The novel coronavirus might have a role in causing SARS.	Bernhard Nocht Inst Trop Med, Dept Virol, Natl Reference Ctr Trop Infect Dis, D-20359 Hamburg, Germany; Goethe Univ Frankfurt, Inst Med Virol, D-6000 Frankfurt, Germany; Goethe Univ Frankfurt, Med Clin 3, D-6000 Frankfurt, Germany; Univ Marburg, Inst Virol, D-3550 Marburg, Germany; Inst Pasteur, Natl Influenza Ctr No France, Paris, France; Erasmus Univ, Inst Virol, Rotterdam, Netherlands	Bernhard Nocht Institut fur Tropenmedizin; Goethe University Frankfurt; Goethe University Frankfurt; Philipps University Marburg; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Erasmus University Rotterdam	Drosten, C (corresponding author), Bernhard Nocht Inst Trop Med, Dept Virol, Natl Reference Ctr Trop Infect Dis, Bernhard Nocht Str 74, D-20359 Hamburg, Germany.	drosten@bni-hamburg.de	Becker, Stefanie/AEM-2050-2022; Escriou, Nicolas/A-2392-2016; Panning, Marcus/I-7889-2016; Fouchier, Ron A/A-1911-2014; Becker, Stephan/A-1065-2010; Preiser, Wolfgang/J-4875-2016	Escriou, Nicolas/0000-0002-1224-6839; Fouchier, Ron A/0000-0001-8095-2869; Becker, Stephan/0000-0002-2794-5659; Preiser, Wolfgang/0000-0002-0254-7910; Gunther, Stephan/0000-0002-6562-0230; Osterhaus, Albert/0000-0002-6074-1172; van der WERF, Sylvie/0000-0002-1148-4456; Vieth, Simon/0000-0002-2765-1589; Sturmer, Martin/0000-0003-4300-9315				[Anonymous], 2003, Wkly Epidemiol Rec, V78, P73; [Anonymous], 2003, WKLY EPIDEMIOL REC, V78, P81; Cho KO, 2001, AM J VET RES, V62, P1436, DOI 10.2460/ajvr.2001.62.1436; Cossart Y, 1998, LANCET, V352, P164, DOI 10.1016/S0140-6736(05)77802-8; Drosten C, 2002, J CLIN MICROBIOL, V40, P2323, DOI 10.1128/JCM.40.7.2323-2330.2002; Felsenstein J., 2000, PHYLIP PHYLOGENY INF; Gunther S, 2000, EMERG INFECT DIS, V6, P466, DOI 10.3201/eid0605.000504; Kew MC, 1996, LANCET, V348, pSII10; Makela MJ, 1998, J CLIN MICROBIOL, V36, P539; Poutanen SM, 2003, NEW ENGL J MED, V348, P1995, DOI 10.1056/NEJMoa030634; Stephensen CB, 1999, VIRUS RES, V60, P181, DOI 10.1016/S0168-1702(99)00017-9; Tsang KW, 2003, NEW ENGL J MED, V348, P1977, DOI 10.1056/NEJMoa030666; WHO, 2003, CUM NUMB REP CAS SEV	13	2994	3382	9	434	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 15	2003	348	20					1967	1976		10.1056/NEJMoa030747	http://dx.doi.org/10.1056/NEJMoa030747			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	677TJ	12690091	Green Published, Bronze			2022-12-28	WOS:000182823400005
J	Carpenter, SJ; Erickson, JM; Holland, FD				Carpenter, SJ; Erickson, JM; Holland, FD			Migration of a Late Cretaceous fish	NATURE			English	Article							UNITED-STATES; OTOLITHS; CLIMATE	Late Cretaceous sediments from the Western Interior of North America yield exceptionally well preserved fossils(1,2) that serve as proxies for the rapidly changing climate preceding the Cretaceous/ Tertiary boundary (about 67-65 Myr ago)(3,4). Here we reconstruct the ontogenetic history of a Maastrichtian-age fish, Vorhisia vulpes(5), by using the carbon, oxygen and strontium isotope ratios of four aragonite otoliths collected from the Fox Hills Formation of South Dakota. Individuals of V. vulpes spawned in brackish water (about 70-80% seawater) and during their first year migrated to open marine waters of the Western Interior Seaway, where they remained for 3 years before returning to the estuary, presumably to spawn and die. The mean delta(18)O from the marine growth phase of V. vulpes yields a seawater temperature of 18 degreesC, which is consistent with leaf physiognomy and general-circulation-model temperature estimates for the Western Interior during the latest Maastrichtian(4,6,7).	Univ Iowa, Dept Geosci, Paul H Nelson Stable Isotope Lab, Iowa City, IA 52242 USA; Univ Iowa, Ctr Global & Reg Environm Res, Iowa City, IA 52242 USA; St Lawrence Univ, Dept Geol, Canton, NY 13617 USA; Univ N Dakota, Dept Geol & Geol Engn, Grand Forks, ND 58202 USA	University of Iowa; University of Iowa; Saint Lawrence University; University of North Dakota Grand Forks	Carpenter, SJ (corresponding author), Univ Iowa, Dept Geosci, Paul H Nelson Stable Isotope Lab, Iowa City, IA 52242 USA.	scott-j-carpenter@uiowa.edu						Andrus CFT, 2002, SCIENCE, V295, P1508, DOI 10.1126/science.1062004; Barrera E, 1999, GEOL S AM S, P245; BARRON EJ, 1993, PHILOS T R SOC B, V341, P307, DOI 10.1098/rstb.1993.0116; CARPENTER SJ, 1988, J SEDIMENT PETROL, V58, P706; CARPENTER SJ, 2002, GEOL SOC AM ABSTR, P31; Dettman DL, 2000, GEOLOGY, V28, P243, DOI 10.1130/0091-7613(2000)028<0243:OIEFHA>2.3.CO;2; Erickson J.M., 1999, N DAKOTA ACAD SCI P, V53, P124; Erickson J.M., 1992, N DAKOTA GEOLOGICAL, V76, P199; Frizzell D.L., 1965, COPEIA, V1965, P178, DOI DOI 10.2307/1440721; Healey MC, 1987, COMMON STRATEGIES AN, VI, P298; HUDDLESTON R W, 1983, Proceedings of the Biological Society of Washington, V96, P658; Ivany LC, 2000, NATURE, V407, P887, DOI 10.1038/35038044; MCARTHUR JM, 1994, PALAEOGEOGR PALAEOCL, V108, P95, DOI 10.1016/0031-0182(94)90024-8; McCormick S.D., 1987, AM FISH SOC S, V1, P211; Nolf Dirk, 1996, P433; Patterson WP, 1999, GEOLOGY, V27, P199, DOI 10.1130/0091-7613(1999)027<0199:OICFOP>2.3.CO;2; PATTERSON WP, 1993, CLIMATE CHANGE CONTI, P191; PETERSON BJ, 1987, ANNU REV ECOL SYST, V18, P293, DOI 10.1146/annurev.es.18.110187.001453; Randall R, 1987, AM FISHERIES SOC S, P27; Schwarcz HP, 1998, CAN J FISH AQUAT SCI, V55, P1798, DOI 10.1139/cjfas-55-8-1798; SHACKLETON NJ, 1975, INIT REP DSDP, V74, P761; Thorrold SR, 1997, GEOCHIM COSMOCHIM AC, V61, P2909, DOI 10.1016/S0016-7037(97)00141-5; URSIN E, 1979, S ZOOL SOC LOND, V44, P63; WAAGE KM, 1968, YALE U B, V27; Weidman CR, 2000, FISH RES, V46, P327, DOI 10.1016/S0165-7836(00)00157-0; Wilf P, 2003, P NATL ACAD SCI USA, V100, P599, DOI 10.1073/pnas.0234701100; WOLFE JA, 1987, PALAEOGEOGR PALAEOCL, V61, P33, DOI 10.1016/0031-0182(87)90040-X; Wurster CM, 2001, PALAEOGEOGR PALAEOCL, V170, P81, DOI 10.1016/S0031-0182(01)00229-2; WURSTER CM, IN PRESS PALEOBIOLOG	29	52	56	0	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 1	2003	423	6935					70	74		10.1038/nature01575	http://dx.doi.org/10.1038/nature01575			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	673CG	12721626				2022-12-28	WOS:000182561600040
J	Barry, PW; Pollard, AJ				Barry, PW; Pollard, AJ			Altitude illness	BRITISH MEDICAL JOURNAL			English	Review							ACUTE MOUNTAIN-SICKNESS; PULMONARY-EDEMA; CONTROLLED-TRIAL; PREVENTION; NIFEDIPINE; HEADACHE; CHILDREN; SOCIETY		Univ Leicester, Dept Child Hlth, Leicester LE2 7LX, Leics, England; Univ Oxford, John Radcliffe Hosp, Dept Paediat, Oxford OX3 9DU, England	University of Leicester; University of Oxford	Barry, PW (corresponding author), Univ Leicester, Dept Child Hlth, Leicester LE2 7LX, Leics, England.	pwb1@le.ac.uk						AUSTIN D, 1995, BRIT MED J, V311, P989; BARTSCH P, 1991, NEW ENGL J MED, V325, P1284, DOI 10.1056/NEJM199110313251805; BARTSCH P, 1993, BRIT MED J, V306, P1098, DOI 10.1136/bmj.306.6885.1098; Bartsch P, 2001, BRIT MED J, V322, P48; Bartsch P, 1997, RESPIRATION, V64, P435; BROOME JR, 1994, AVIAT SPACE ENVIR MD, V65, P19; Burtscher M, 1998, BRIT MED J, V316, P1057; Dumont L, 2000, BRIT MED J, V321, P267, DOI 10.1136/bmj.321.7256.267; *FDA, 1983, FDA DRUG B, V13, P27; Gertsch JH, 2002, HIGH ALT MED BIOL, V3, P29, DOI 10.1089/152702902753639522; Hackett PH, 2001, NEW ENGL J MED, V345, P107, DOI 10.1056/NEJM200107123450206; Hackett PH, 1999, ADV EXP MED BIOL, V474, P23; HORNBEIN TF, 2001, LUNG IOL HLTH DIS, V161; Hultgren HN, 1996, ANNU REV MED, V47, P267; Hultgren HN, 1996, WESTERN J MED, V164, P222; Mason D, 2000, SOCIOLOGY, V34, P1; MILLEDGE JS, 1991, EUR RESPIR J, V4, P1000; OELZ O, 1989, LANCET, V2, P1241; POLLARD A, 1988, LANCET, V1, P1277; Pollard AJ, 2001, HIGH ALT MED BIOL, V2, P389, DOI 10.1089/15270290152608561; Pollard AJ, 1998, BRIT MED J, V316, P874, DOI 10.1136/bmj.316.7135.874; ROACH R, 1992, ADV BIOSCI, V84, P266; ROACH R, 2002, BIBLIO HIGH ALTITUDE; Roach RC, 2000, J APPL PHYSIOL, V88, P581, DOI 10.1152/jappl.2000.88.2.581; ROACH RC, 1993, HYPOXIA AND MOLECULAR MEDICINE, P272; Sartori C, 2002, NEW ENGL J MED, V346, P1631, DOI 10.1056/NEJMoa013183; SCHNEIDER M, 2001, HIGH ALT MED BIOL, V2, P83; SHLIM DR, 1992, INT J SPORTS MED, V13, pS74, DOI 10.1055/s-2007-1024601; SINGH I, 1969, NEW ENGL J MED, V280, P175, DOI 10.1056/NEJM196901232800402; WARD MP, 1990, HIGH ALTITUDE MED PH; Woods DR, 2001, HIGH ALT MED BIOL, V2, P201, DOI 10.1089/152702901750265305	31	86	91	2	16	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 26	2003	326	7395					915	919		10.1136/bmj.326.7395.915	http://dx.doi.org/10.1136/bmj.326.7395.915			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	673WQ	12714473	Green Published			2022-12-28	WOS:000182603600020
J	Boccalandro, C; Lopez-Penabad, L; Boccalandro, F; Lavis, V				Boccalandro, C; Lopez-Penabad, L; Boccalandro, F; Lavis, V			Ventricular fibrillation in a young Asian man	LANCET			English	Editorial Material							THYROTOXIC PERIODIC PARALYSIS		Univ Texas, Sch Med, Div Endocrinol L, Houston, TX 77030 USA; Baylor Coll Med, Div Endocrinol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Endocrine Neoplasia & Hormonal Disorders, Houston, TX USA; Univ Texas, Sch Med, Div Cardiol, Houston, TX USA	University of Texas System; Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center; University of Texas System	Boccalandro, C (corresponding author), Univ Texas, Sch Med, Div Endocrinol L, 6431 Fannin St,MSB Suite 1-246, Houston, TX 77030 USA.			Lavis, Victor/0000-0002-1422-4764				CHIA BL, 1995, INT J CARDIOL, V47, P285, DOI 10.1016/0167-5273(94)02195-O; EE B, 1979, J ELECTROCARDIOL, V12, P263, DOI 10.1016/S0022-0736(79)80059-X; FISHER J, 1982, ARCH INTERN MED, V142, P1362, DOI 10.1001/archinte.142.7.1362; Manoukian MA, 1999, ARCH INTERN MED, V159, P601, DOI 10.1001/archinte.159.6.601; MCFADZEAN AJ, 1969, BRIT MED J, V538, P451	5	10	10	1	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 26	2003	361	9367					1432	1432		10.1016/S0140-6736(03)13137-6	http://dx.doi.org/10.1016/S0140-6736(03)13137-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	672HZ	12727398				2022-12-28	WOS:000182516300013
J	Stickler, DJ; Jones, GL; Russell, AD				Stickler, DJ; Jones, GL; Russell, AD			Control of encrustation and blockage of Foley catheters	LANCET			English	Article								Urinary catheters often become encrusted and blocked by crystalline Proteus mirabilis biofilms. Results of experiments In a laboratory model of a Foley catheterised bladder Infected with P mirabilis showed that when retention balloons were inflated with a solution of triclosan (10 g/L), the catheters drained freely for at least 7 days. Triclosan became impregnated throughout the silicone catheter material and completely Inhibited the formation of crystalline biofilm, whereas catheters inflated with water became blocked in 24 h. Our observations suggest a way to control a common complication in patients with long-term indwelling bladder catheters.	Cardiff Univ, Cardiff Sch Biosci, Cardiff CF10 3TL, S Glam, Wales; Cardiff Univ, Welsh Sch Pharm, Cardiff, S Glam, Wales	Cardiff University; Cardiff University	Stickler, DJ (corresponding author), Cardiff Univ, Cardiff Sch Biosci, Cardiff CF10 3TL, S Glam, Wales.							BIBBY JM, 1995, CELLS MAT, V2, P183; Jones RD, 2000, AM J INFECT CONTROL, V28, P184, DOI 10.1016/S0196-6553(00)90027-0; Kunin CM, 1997, URINARY TRACT INFECT, V5th, P226; Morris NS, 1997, BRIT J UROL, V80, P58, DOI 10.1046/j.1464-410X.1997.00185.x; Stickler DJ, 2002, J APPL MICROBIOL, V92, p163S, DOI 10.1046/j.1365-2672.92.5s1.6.x	5	59	70	1	10	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 26	2003	361	9367					1435	1437		10.1016/S0140-6736(03)13104-2	http://dx.doi.org/10.1016/S0140-6736(03)13104-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	672HZ	12727400				2022-12-28	WOS:000182516300015
J	Collet, E; Lemee-Cailleau, MH; Buron-Le Cointe, M; Cailleau, H; Wulff, M; Luty, T; Koshihara, SY; Meyer, M; Toupet, L; Rabiller, P; Techert, S				Collet, E; Lemee-Cailleau, MH; Buron-Le Cointe, M; Cailleau, H; Wulff, M; Luty, T; Koshihara, SY; Meyer, M; Toupet, L; Rabiller, P; Techert, S			Laser-induced ferroelectric structural order in an organic charge-transfer crystal	SCIENCE			English	Article							X-RAY-DIFFRACTION; TO-IONIC TRANSITION; PHASE-TRANSITION; TETRATHIAFULVALENE; CHLORANIL	We report the direct observation by x-ray diffraction of a photoinduced paraelectric-to-ferroelectric structural phase transition using monochromatic 100-picosecond synchrotron pulses. It occurs in tetrathiafulvalene-p-chloranil, a charge-transfer molecular material in which electronic and structural changes are strongly coupled. An optical 300-femtosecond laser pulse switches the material from a neutral to an ionic state on a 500-picosecond time scale and, by virtue of intrinsic cooperativity, generates self-organized long-range structural order. The x-ray data indicate a macroscopic ferroelectric reorganization after the laser irradiation. Refinement of the structures before and after laser irradiation indicates structural changes at the molecular level.	Univ Rennes 1, CNRS, UMR 6626, Grp Mat Condensee & Mat, F-35042 Rennes, France; CENS, Lab Leon Brillouin, F-91191 Gif Sur Yvette, France; European Synchrotron Radiat Facil, F-38043 Grenoble, France; Wroclaw Univ Technol, Inst Phys & Theoret Chem, PL-50370 Wroclaw, Poland; Tokyo Inst Technol, Dept Mat Sci, Meguro Ku, Tokyo 1528551, Japan; Kanagawa Acad Sci & Technol, Takatsu Ku, Kawasaki, Kanagawa 2130012, Japan; Oxford Diffract Poland Sp Zoo, PL-54440 Wroclaw, Poland; Max Planck Inst Biophys Chem, Dept 010, D-37070 Gottingen, Germany	Centre National de la Recherche Scientifique (CNRS); Universite de Rennes; CEA; Centre National de la Recherche Scientifique (CNRS); European Synchrotron Radiation Facility (ESRF); Wroclaw University of Science & Technology; Tokyo Institute of Technology; Kanagawa Academy Science & Technology; Max Planck Society	Collet, E (corresponding author), Univ Rennes 1, CNRS, UMR 6626, Grp Mat Condensee & Mat, F-35042 Rennes, France.	Eric.Collet@univ-rennes1.fr	Collet, Eric/O-9037-2019; Lemée-Cailleau, Marie-Hélène/M-6711-2013; TOUPET, Loic/N-7043-2014; RABILLER, Philippe/O-1623-2014; buron-le cointe, marylise/N-7592-2014; Koshihara, Shinya/ABA-1213-2021; Koshihara, Shinya/B-5095-2015	Collet, Eric/0000-0003-0810-7411; Techert, Simone/0000-0002-7549-7651; Koshihara, Shinya/0000-0002-7119-2017				Busse G, 2003, FARADAY DISCUSS, V122, P105, DOI 10.1039/b202831j; Cavalleri A, 2001, OPT PHOTONICS NEWS, V12, P28, DOI 10.1364/OPN.12.5.000028; Cavalleri A, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.237401; Iwai S, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.057402; JACOBSEN CS, 1983, J CHEM PHYS, V78, P112, DOI 10.1063/1.444530; Koshihara S, 1999, J PHYS CHEM B, V103, P2592, DOI 10.1021/jp984172i; LECOINTE M, 1995, PHYS REV B, V51, P3374, DOI 10.1103/PhysRevB.51.3374; LemeeCailleau MH, 1997, PHYS REV LETT, V79, P1690, DOI 10.1103/PhysRevLett.79.1690; Luty T, 2002, EUROPHYS LETT, V59, P619, DOI 10.1209/epl/i2002-00149-4; MAYERLE JJ, 1979, ACTA CRYSTALLOGR B, V35, P2988, DOI 10.1107/S0567740879011110; MEYER M, 2001, CRYSALIS SOFTWARE SY; NAGAOSA N, 1986, J PHYS SOC JPN, V55, P3488, DOI 10.1143/JPSJ.55.3488; Nasu K, 2001, J PHYS-CONDENS MAT, V13, pR693, DOI 10.1088/0953-8984/13/35/201; NASU K, 1997, RELAXATION EXCITED S; Nelson KA, 1999, SCIENCE, V286, P1310, DOI 10.1126/science.286.5443.1310; Rischel C, 1997, NATURE, V390, P490, DOI 10.1038/37317; Rousse A, 2001, REV MOD PHYS, V73, P17, DOI 10.1103/RevModPhys.73.17; Rousse A, 2001, NATURE, V410, P65, DOI 10.1038/35065045; Sheldrick G.M, 1997, SHELXL 97; Siders CW, 1999, SCIENCE, V286, P1340, DOI 10.1126/science.286.5443.1340; Srajer V, 1996, SCIENCE, V274, P1726, DOI 10.1126/science.274.5293.1726; Tanimura K, 2001, J LUMIN, V94, P483, DOI 10.1016/S0022-2313(01)00314-3; Techert S, 2001, PHYS REV LETT, V86, P2030, DOI 10.1103/PhysRevLett.86.2030; TORRANCE JB, 1981, PHYS REV LETT, V46, P253, DOI 10.1103/PhysRevLett.46.253; Wulff M, 1997, NUCL INSTRUM METH A, V398, P69, DOI 10.1016/S0168-9002(96)01226-0	25	367	369	7	158	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 25	2003	300	5619					612	615		10.1126/science.1082001	http://dx.doi.org/10.1126/science.1082001			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	671FB	12714737	Green Published			2022-12-28	WOS:000182453700033
J	Temeles, EJ; Kress, WJ				Temeles, EJ; Kress, WJ			Adaptation in a plant-hummingbird association	SCIENCE			English	Article							AGE-SEX CLASSES; RUFOUS HUMMINGBIRDS; DIMORPHISM; BEHAVIOR	Sexual dimorphism in bill morphology and body size of the Caribbean purple-throated carib hummingbird is associated with a reversal in. oral dimorphism of its Heliconia food plants. This hummingbird is the sole pollinator of H. caribaea and H. bihai, with flowers of the former corresponding to the short, straight bills of males, the larger sex, and flowers of the latter corresponding to the long, curved bills of females. On St. Lucia, H. bihai compensates for the rarity of H. caribaea by evolving a second color morph with flowers that match the bills of males, whereas on Dominica, H. caribaea evolves a second color morph with flowers that match the bills of females. The nectar rewards of all Heliconia morphs are consistent with each sex's choice of the morph that corresponds to its bill morphology and energy requirements, supporting the hypothesis that feeding preferences have driven their coadaptation.	Amherst Coll, Dept Biol, Amherst, MA 01002 USA; Smithsonian Inst, Natl Museum Nat Hist, US Natl Herbarium, MRC166, Washington, DC 20013 USA	Amherst College; Smithsonian Institution; Smithsonian National Museum of Natural History	Temeles, EJ (corresponding author), Amherst Coll, Dept Biol, Amherst, MA 01002 USA.		Temeles, Ethan J./AAD-7366-2021					[Anonymous], 1861, ORIGIN SPECIES MEANS; Bleiweiss R, 1999, P ROY SOC B-BIOL SCI, V266, P2491, DOI 10.1098/rspb.1999.0951; CARPENTER FL, 1993, BEHAV ECOL SOCIOBIOL, V33, P297; CARPENTER FL, 1993, BEHAV ECOL SOCIOBIOL, V33, P305; Colwell RK, 2000, AM NAT, V156, P495, DOI 10.1086/303406; Faegri K., 1966, PRINCIPLES POLLINATI; FEINSINGER P, 1982, ECOLOGY, V63, P1574, DOI 10.2307/1938881; FEINSINGER P, 1976, ECOL MONOGR, V46, P257, DOI 10.2307/1942255; Reznick David, 1996, P243; SCHEMSKE DW, 1984, SCIENCE, V225, P519, DOI 10.1126/science.225.4661.519; SELANDER RK, 1966, CONDOR, V68, P113, DOI 10.2307/1365712; TEMELES EJ, 1993, OECOLOGIA, V94, P87, DOI 10.1007/BF00317307; Temeles EJ, 2000, SCIENCE, V289, P441, DOI 10.1126/science.289.5478.441; Wallace Alfred R., 1871, CONTRIBUTIONS THEORY; WOLF LL, 1971, ECOLOGY, V52, P980, DOI 10.2307/1933803; WOLF LL, 1975, AUK, V92, P511, DOI 10.2307/4084604	16	137	140	0	88	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 25	2003	300	5619					630	633		10.1126/science.1080003	http://dx.doi.org/10.1126/science.1080003			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	671FB	12714743				2022-12-28	WOS:000182453700039
J	McKimm, J; Jollie, C; Cantillon, P				McKimm, J; Jollie, C; Cantillon, P			ABC of learning and teaching - Web based learning	BRITISH MEDICAL JOURNAL			English	Review									Imperial Coll Sch Med, Curriculum Dev, London, England; St Pancras Hosp, Camden Primary Care Trust, Skills Enhancement Project, London, England	Imperial College London	McKimm, J (corresponding author), Imperial Coll Sch Med, Curriculum Dev, London, England.			McKimm, Judy/0000-0002-8949-5067				Cook J., 2002, LTSN BIOSCIENCE B, V5; Forsyth I., 2001, TEACHING LEARNING MA; Jolliffe A., 2001, ONLINE LEARNING HDB	3	148	162	0	16	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 19	2003	326	7394					870	873		10.1136/bmj.326.7394.870	http://dx.doi.org/10.1136/bmj.326.7394.870			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	670BF	12702625	Green Published			2022-12-28	WOS:000182386800025
J	Brent, AE; Schweitzer, R; Tabin, CJ				Brent, AE; Schweitzer, R; Tabin, CJ			A somitic compartment of tendon progenitors	CELL			English	Article							GENE-EXPRESSION; CHICK; SCLERAXIS; ORIGIN; CHONDROGENESIS; MESODERM; MUSCLES; PATTERN; EMBRYO; FATE	We demonstrate that the tendons associated with the axial skeleton derive from a heretofore unappreciated, fourth compartment of the somites. Scleraxis (Scx), a bHLH transcription factor, marks this somitic tendon progenitor population at its inception, and is continuously expressed through differentiation into the mature tendons. Two earlier-formed somitic compartments, the sclerotome and myotome, interact to establish this fourth Scx-positive compartment. The tendon progenitors are induced at the sclerotome's edge, at the expense of skeletogenic Pax1 positive cells and in response to FGF signaling in the adjacent myotome. The tendon primordia thus form in a location abutting the two tissues that the mature tendons must ultimately connect. Tendon progenitor formation may reveal a general mechanism for the specification of other somitic subcompartments.	Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Oregon Hlth & Sci Univ, Dept Cell & Dev Biol, Portland, OR 97201 USA	Harvard University; Harvard Medical School; Oregon Health & Science University	Tabin, CJ (corresponding author), Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.	tabin@rascal.med.harvard.edu	Schweitzer, Ronen/AAY-2127-2020	Schweitzer, Ronen/0000-0002-7425-5028	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK056246] Funding Source: NIH RePORTER; NIDDK NIH HHS [P01 DK56246] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHRENS PB, 1977, DEV BIOL, V60, P69, DOI 10.1016/0012-1606(77)90110-5; BERESFORD B, 1983, J EMBRYOL EXP MORPH, V77, P99; Borycki AG, 2000, CURR TOP DEV BIOL, V48, P165; Brand-Saberi B, 2000, CURR TOP DEV BIOL, V48, P1; CHALEPAKIS G, 1991, CELL, V66, P873, DOI 10.1016/0092-8674(91)90434-Z; CHEVALLIER A, 1979, J EMBRYOL EXP MORPH, V49, P73; CHRIST B, 1983, ANAT EMBRYOL, V166, P87, DOI 10.1007/BF00317946; CSERJESI P, 1995, DEVELOPMENT, V121, P1099; Dietrich S, 1997, DEVELOPMENT, V124, P3895; Dockter JL, 1998, DEVELOPMENT, V125, P2113; Edom-Vovard F, 2002, DEV BIOL, V247, P351, DOI 10.1006/dbio.2002.0707; Fraidenraich D, 2000, DEV BIOL, V225, P392, DOI 10.1006/dbio.2000.9839; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; Huang RJ, 2000, ANAT EMBRYOL, V202, P195, DOI 10.1007/s004290000110; Huang RJ, 2000, DEVELOPMENT, V127, P527; HURLE JM, 1990, CELL DIFFER DEV, V30, P97, DOI 10.1016/0922-3371(90)90078-B; JOHNSON RL, 1994, CELL, V79, P1165, DOI 10.1016/0092-8674(94)90008-6; Kahane N, 2001, DEVELOPMENT, V128, P2187; Kiefer JC, 2001, DEV BIOL, V232, P77, DOI 10.1006/dbio.2000.0114; KIENY M, 1979, J EMBRYOL EXP MORPH, V49, P153; Logan M, 1998, METHODS, V14, P407, DOI 10.1006/meth.1998.0595; MARCELLE C, 1994, DEVELOPMENT, V120, P683; Monsoro-Burq AH, 2000, CURR TOP DEV BIOL, V48, P43; Morgan BA, 1996, METHOD CELL BIOL, V51, P185, DOI 10.1016/S0091-679X(08)60629-9; Murtaugh LC, 2001, DEV CELL, V1, P411, DOI 10.1016/S1534-5807(01)00039-9; Murtaugh LC, 1999, GENE DEV, V13, P225, DOI 10.1101/gad.13.2.225; ORDAHL CP, 1993, MOL BASIS MORPHOGENE, P165; Peters H, 1999, DEVELOPMENT, V126, P5399; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; Schweitzer R, 2001, DEVELOPMENT, V128, P3855; SEARLS RL, 1969, J EXP ZOOL, V170, P365, DOI 10.1002/jez.1401700313; Shellswell G., 1977, VERTEBRATE LIMB SOMI, P71; Stockdale FE, 2000, DEV DYNAM, V219, P304, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1057>3.0.CO;2-5; Stolte D, 2002, ANAT EMBRYOL, V205, P1, DOI 10.1007/s00429-002-0227-z; UENO H, 1992, J BIOL CHEM, V267, P1470; Williams BA, 1997, DEVELOPMENT, V124, P4983	36	394	411	0	15	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 18	2003	113	2					235	248		10.1016/S0092-8674(03)00268-X	http://dx.doi.org/10.1016/S0092-8674(03)00268-X			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	672EP	12705871	Bronze			2022-12-28	WOS:000182508500012
J	Kayed, R; Head, E; Thompson, JL; McIntire, TM; Milton, SC; Cotman, CW; Glabe, CG				Kayed, R; Head, E; Thompson, JL; McIntire, TM; Milton, SC; Cotman, CW; Glabe, CG			Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis	SCIENCE			English	Article							FLUORESCENCE CORRELATION SPECTROSCOPY; ALZHEIMERS-DISEASE; IN-VITRO; BETA; PEPTIDE; FIBRILS; PROTOFIBRILS; DETERMINANT; POTENT	Soluble oligomers are common to most amyloids and may represent the primary toxic species of amyloids, like the Abeta peptide in Alzheimer's disease (AD). Here we show that all of the soluble oligomers tested display a common conformation-dependent structure that is unique to soluble oligomers regardless of sequence. The in vitro toxicity of soluble oligomers is inhibited by oligomer-specific antibody. Soluble oligomers have a unique distribution in human AD brain that is distinct from fibrillar amyloid. These results indicate that different types of soluble amyloid oligomers have a common structure and suggest they share a common mechanism of toxicity.	Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA; Univ Calif Irvine, Inst Brain Aging & Dementia, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Chem, Irvine, CA 92697 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine	Glabe, CG (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA.				NIA NIH HHS [AG00538, AG16573] Funding Source: Medline; NINDS NIH HHS [NS31230] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P50AG016573] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Conway KA, 2000, BIOCHEMISTRY-US, V39, P2552, DOI 10.1021/bi991447r; El-Agnaf OMA, 2001, J MOL BIOL, V310, P157, DOI 10.1006/jmbi.2001.4743; Goldsbury C, 1999, J MOL BIOL, V285, P33, DOI 10.1006/jmbi.1998.2299; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Harper JD, 1999, BIOCHEMISTRY-US, V38, P8972, DOI 10.1021/bi9904149; Hartley DM, 1999, J NEUROSCI, V19, P8876, DOI 10.1523/JNEUROSCI.19-20-08876.1999; Kuo YM, 1996, J BIOL CHEM, V271, P4077; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Lashuel HA, 2002, NATURE, V418, P291, DOI 10.1038/418291a; LeVine H, 2002, ARCH BIOCHEM BIOPHYS, V404, P106; O'Nuallain B, 2002, P NATL ACAD SCI USA, V99, P1485, DOI 10.1073/pnas.022662599; Pitschke M, 1998, NAT MED, V4, P832, DOI 10.1038/nm0798-832; Serio TR, 2000, SCIENCE, V289, P1317, DOI 10.1126/science.289.5483.1317; SOREGHAN B, 1994, J BIOL CHEM, V269, P28551; Tjernberg LO, 1999, CHEM BIOL, V6, P53, DOI 10.1016/S1074-5521(99)80020-9	18	3299	3463	10	675	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 18	2003	300	5618					486	489		10.1126/science.1079469	http://dx.doi.org/10.1126/science.1079469			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	668LR	12702875				2022-12-28	WOS:000182295900040
J	Muller, B; Hartmann, B; Pyrowolakis, G; Affolter, M; Basler, K				Muller, B; Hartmann, B; Pyrowolakis, G; Affolter, M; Basler, K			Conversion of an extracellular Dpp/BMP morphogen gradient into an inverse transcriptional gradient	CELL			English	Article							DROSOPHILA WING DEVELOPMENT; SIGNAL-TRANSDUCTION; IMAGINAL DISCS; BINDING-SITES; DPP TARGETS; BRINKER; GENE; REPRESSION; SCHNURRI; ENCODES	Morphogen gradients control body pattern by differentially regulating cellular behavior. Here, we analyze the molecular events underlying the primary response to the Dpp/BMP morphogen in Drosophila. Throughout development, Dpp transduction causes the graded transcriptional downregulation of the brinker (brk) gene. We first provide significance for the brk expression gradient by showing that different Brk levels repress distinct combinations of wing genes expressed at different distances from Dpp-secreting cells. We then dissect the brk regulatory region and identify two separable elements with opposite properties, a constitutive enhancer and a Dpp morphogen-regulated silencer. Furthermore, we present genetic and biochemical evidence that the brk silencer serves as a direct target for a protein complex consisting of the Smad homologs Mad/Medea and the zinc finger protein Schnurri. Together, our results provide the molecular framework for a mechanism by which the extracellular Dpp/BMP morphogen establishes a finely tuned, graded read-out of transcriptional repression.	Univ Basel, Biozentrum, Abt Zellbiol, CH-4056 Basel, Switzerland; Univ Zurich, Inst Mol Biol, CH-8057 Zurich, Switzerland	University of Basel; University of Zurich	Affolter, M (corresponding author), Univ Basel, Biozentrum, Abt Zellbiol, Klingelbergstr 70, CH-4056 Basel, Switzerland.		Mueller, Bruno/E-9888-2017	Mueller, Bruno/0000-0003-2664-7219; Basler, Konrad/0000-0003-3534-1529; Affolter, Markus/0000-0002-5171-0016				Affolter M, 2001, EMBO J, V20, P3298, DOI 10.1093/emboj/20.13.3298; ARORA K, 1995, CELL, V81, P781, DOI 10.1016/0092-8674(95)90539-1; Ashe HL, 2000, DEVELOPMENT, V127, P3305; Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; Campbell G, 1999, CELL, V96, P553, DOI 10.1016/S0092-8674(00)80659-5; Chen CR, 2002, CELL, V110, P19, DOI 10.1016/S0092-8674(02)00801-2; DRIEVER W, 1989, NATURE, V340, P363, DOI 10.1038/340363a0; Entchev EV, 2000, CELL, V103, P981, DOI 10.1016/S0092-8674(00)00200-2; GRIEDER NC, 1995, CELL, V81, P791, DOI 10.1016/0092-8674(95)90540-5; Grimm S, 1996, SCIENCE, V271, P1601, DOI 10.1126/science.271.5255.1601; Gurdon JB, 1998, CELL, V95, P159, DOI 10.1016/S0092-8674(00)81747-X; Gurdon JB, 2001, NATURE, V413, P797, DOI 10.1038/35101500; Hasson P, 2001, EMBO J, V20, P5725, DOI 10.1093/emboj/20.20.5725; HOCH M, 1993, CURR OPIN GENET DEV, V3, P566, DOI 10.1016/0959-437X(93)90092-4; Holley SA, 1997, BIOESSAYS, V19, P281, DOI 10.1002/bies.950190404; Hudson JB, 1998, DEVELOPMENT, V125, P1407; Inoue H, 1998, MOL BIOL CELL, V9, P2145, DOI 10.1091/mbc.9.8.2145; Jazwinska A, 1999, DEVELOPMENT, V126, P3323; Jazwinska A, 1999, CELL, V96, P563, DOI 10.1016/S0092-8674(00)80660-1; JIANG J, 1993, CELL, V72, P741, DOI 10.1016/0092-8674(93)90402-C; Kim J, 1996, NATURE, V382, P133, DOI 10.1038/382133a0; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; Kirkpatrick H, 2001, J BIOL CHEM, V276, P18216, DOI 10.1074/jbc.M101365200; Lecuit T, 1996, NATURE, V381, P387, DOI 10.1038/381387a0; Lee KJ, 1999, ANNU REV NEUROSCI, V22, P261, DOI 10.1146/annurev.neuro.22.1.261; Marty T, 2000, NAT CELL BIOL, V2, P745, DOI 10.1038/35036383; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Minami M, 1999, NATURE, V398, P242, DOI 10.1038/18451; Morgan T.H., 1897, ROUX ARCH DEV BIOL, V5, P570; Muller B, 2000, DEVELOPMENT, V127, P2999; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; Raftery LA, 1999, DEV BIOL, V210, P251, DOI 10.1006/dbio.1999.9282; Ramirez-Weber FA, 1999, CELL, V97, P599, DOI 10.1016/S0092-8674(00)80771-0; Sakuta H, 2001, SCIENCE, V293, P111, DOI 10.1126/science.1058379; SEGALAT L, 1994, MECH DEVELOP, V47, P241, DOI 10.1016/0925-4773(94)90042-6; SMALL S, 1992, EMBO J, V11, P4047, DOI 10.1002/j.1460-2075.1992.tb05498.x; Strigini M, 1999, SEMIN CELL DEV BIOL, V10, P335, DOI 10.1006/scdb.1999.0293; STRUHL G, 1992, CELL, V69, P237, DOI 10.1016/0092-8674(92)90405-2; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; Sturtevant MA, 1997, DEVELOPMENT, V124, P21; Tabata T, 2001, NAT REV GENET, V2, P620, DOI 10.1038/35084577; Tanimoto H, 2000, MOL CELL, V5, P59, DOI 10.1016/S1097-2765(00)80403-7; Teleman AA, 2000, CELL, V103, P971, DOI 10.1016/S0092-8674(00)00199-9; Torres-Vazquez J, 2000, DEV BIOL, V227, P388, DOI 10.1006/dbio.2000.9900; Tsuneizumi K, 1997, NATURE, V389, P627, DOI 10.1038/39362; TURING AM, 1952, PHILOS T ROY SOC B, V237, P37, DOI 10.1098/rstb.1952.0012; Wisotzkey RG, 1998, DEVELOPMENT, V125, P1433; WOLPERT L, 1989, DEVELOPMENT, V107, P3	49	143	145	0	5	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 18	2003	113	2					221	233		10.1016/S0092-8674(03)00241-1	http://dx.doi.org/10.1016/S0092-8674(03)00241-1			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	672EP	12705870	Bronze, Green Accepted			2022-12-28	WOS:000182508500011
J	Song, JB; Wu, LL; Chen, Z; Kohanski, RA; Pick, L				Song, JB; Wu, LL; Chen, Z; Kohanski, RA; Pick, L			Axons guided by insulin receptor in Drosophila visual system	SCIENCE			English	Article							ADAPTER PROTEIN; EMBRYONIC-DEVELOPMENT; GUIDANCE; GROWTH; HOMOLOG; MEMORY; DOMAIN; BRAIN; PHOSPHORYLATION; SPECIFICITY	Insulin receptors are abundant in the central nervous system, but their roles remain elusive. Here we show that the insulin receptor functions in axon guidance. The Drosophila insulin receptor (DInR) is required for photoreceptor-cell (R-cell) axons to find their way from the retina to the brain during development of the visual system. DInR functions as a guidance receptor for the adapter protein Dock/Nck. This function is independent of Chico, the Drosophila insulin receptor substrate (IRS) homolog.	Mt Sinai Sch Med, Brookdale Dept Mol Cell & Dev Biol, New York, NY 10029 USA; Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21287 USA	Icahn School of Medicine at Mount Sinai; Johns Hopkins University; Johns Hopkins University	Pick, L (corresponding author), Mt Sinai Sch Med, Brookdale Dept Mol Cell & Dev Biol, 1 Gustave Levy Pl, New York, NY 10029 USA.							Ausubel FM, 1992, CURRENT PROTOCOLS MO; Baskin DG, 1999, BRAIN RES, V848, P114, DOI 10.1016/S0006-8993(99)01974-5; Bohni R, 1999, CELL, V97, P865, DOI 10.1016/S0092-8674(00)80799-0; Brogiolo W, 2001, CURR BIOL, V11, P213, DOI 10.1016/S0960-9822(01)00068-9; Chen C, 1996, ENDOCRINOLOGY, V137, P846, DOI 10.1210/en.137.3.846; Clandinin TR, 2002, NEURON, V35, P827, DOI 10.1016/S0896-6273(02)00876-0; Clemens JC, 1996, J BIOL CHEM, V271, P17002, DOI 10.1074/jbc.271.29.17002; Craft S, 1999, ARCH GEN PSYCHIAT, V56, P1135, DOI 10.1001/archpsyc.56.12.1135; FERNANDEZ R, 1995, EMBO J, V14, P3373, DOI 10.1002/j.1460-2075.1995.tb07343.x; FERNANDEZALMONACID R, 1987, MOL CELL BIOL, V7, P2718, DOI 10.1128/MCB.7.8.2718; Garrity PA, 1996, CELL, V85, P639, DOI 10.1016/S0092-8674(00)81231-3; Hing H, 1999, CELL, V97, P853, DOI 10.1016/S0092-8674(00)80798-9; KOHANSKI RA, UNPUB; Lannert H, 1998, BEHAV NEUROSCI, V112, P1199, DOI 10.1037/0735-7044.112.5.1199; Lee CH, 2001, NEURON, V30, P437, DOI 10.1016/S0896-6273(01)00291-4; Lee TM, 2001, TRENDS NEUROSCI, V24, P251, DOI 10.1016/S0166-2236(00)01791-4; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; Louvi A, 1997, DEV BIOL, V189, P33, DOI 10.1006/dbio.1997.8666; Meinertzhagen Ian A., 1993, P1363; Newsome TP, 2000, DEVELOPMENT, V127, P851; PETRUZZELLI L, 1985, J BIOL CHEM, V260, P6072; PETRUZZELLI L, 1986, P NATL ACAD SCI USA, V83, P4710, DOI 10.1073/pnas.83.13.4710; Rao Y, 1998, P NATL ACAD SCI USA, V95, P2077, DOI 10.1073/pnas.95.5.2077; RUAN YM, 1995, J BIOL CHEM, V270, P4236, DOI 10.1074/jbc.270.9.4236; Schmucker D, 2000, CELL, V101, P671, DOI 10.1016/S0092-8674(00)80878-8; Tatar M, 2001, SCIENCE, V292, P107, DOI 10.1126/science.1057987; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; Wickelgren I, 1998, SCIENCE, V280, P517, DOI 10.1126/science.280.5363.517; WOLFF T, 1997, MOL CELLULAR APPROAC, P474; WOLFF T, 1993, DEV DROSOPHILA MELAN, V2, P1277; Yenush L, 1996, MOL CELL BIOL, V16, P2509; Zaia A, 2000, MECH AGEING DEV, V113, P227, DOI 10.1016/S0047-6374(99)00118-9; Zhao WQ, 1999, J BIOL CHEM, V274, P34893, DOI 10.1074/jbc.274.49.34893	33	122	125	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 18	2003	300	5618					502	505		10.1126/science.1081203	http://dx.doi.org/10.1126/science.1081203			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	668LR	12702880				2022-12-28	WOS:000182295900045
J	Casolino, M; Bidoli, V; Morselli, A; Narici, L; DePascale, MP; Picozza, P; Reali, E; Sparvoli, R; Mazzenga, G; Ricci, M; Spillantini, P; Boezio, M; Bonvicini, V; Vacchi, A; Zampa, N; Castellini, G; Sannita, WG; Carlson, P; Galper, A; Korotkov, M; Popov, A; Vavilov, N; Avdeev, S; Fugelsang, C				Casolino, M; Bidoli, V; Morselli, A; Narici, L; DePascale, MP; Picozza, P; Reali, E; Sparvoli, R; Mazzenga, G; Ricci, M; Spillantini, P; Boezio, M; Bonvicini, V; Vacchi, A; Zampa, N; Castellini, G; Sannita, WG; Carlson, P; Galper, A; Korotkov, M; Popov, A; Vavilov, N; Avdeev, S; Fugelsang, C			Space travel - Dual origins of light flashes seen in space	NATURE			English	Article							STATION		Univ Roma Tor Vergata, Dept Phys, I-00133 Rome, Italy; Ist Nazl Fis Nucl, LNF, Rome, Italy; Univ Florence, Dept Phys, I-50121 Florence, Italy; Univ Trieste, Dept Phys, I-34127 Trieste, Italy; CNR, IROE, I-50127 Florence, Italy; Univ Genoa, DISMR, Genoa, Italy; SUNY Stony Brook, Dept Psychiat, Stony Brook, NY 11794 USA; Royal Inst Technol, Stockholm, Sweden; Moscow State Engn Phys Inst, Moscow, Russia; Russian Space Corp Energia Korolin, Moscow, Russia; European Astronaut Ctr, Cologne, Germany	University of Rome Tor Vergata; Istituto Nazionale di Fisica Nucleare (INFN); University of Florence; University of Trieste; Consiglio Nazionale delle Ricerche (CNR); University of Genoa; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Royal Institute of Technology; National Research Nuclear University MEPhI (Moscow Engineering Physics Institute); Roscosmos; United Rocket & Space Corporation; S.P. Korolev Rocket & Space Corporation - Energia; European Space Agency	Casolino, M (corresponding author), Univ Roma Tor Vergata, Dept Phys, I-00133 Rome, Italy.	casolino@roma2.infn.it	Vacchi, Andrea G/C-1291-2010; Casolino, Marco/ABI-1081-2020; Morselli, Aldo/G-6769-2011; Boezio, Mirko/ABC-4188-2020; Galper, Arkady M/M-9610-2015; Sparvoli, Roberta/H-8024-2018; Castellini, Guido/C-6716-2018	Vacchi, Andrea G/0000-0003-3855-5856; Morselli, Aldo/0000-0002-7704-9553; Boezio, Mirko/0000-0002-8015-2981; Sparvoli, Roberta/0000-0002-6314-6117; Bonvicini, Valter/0000-0003-1826-5843; Castellini, Guido/0000-0002-0177-0643; Picozza, Piergiorgio/0000-0002-7986-3321; casolino, marco/0000-0001-6067-5104				Avdeev S, 2002, ACTA ASTRONAUT, V50, P511, DOI 10.1016/S0094-5765(01)00190-4; Bidoli V, 2001, J PHYS G NUCL PARTIC, V27, P2051, DOI 10.1088/0954-3899/27/10/307; BUDINGER TF, 1977, SP412 NASA, P193; CHARMAN WN, 1971, NATURE, V230, P522, DOI 10.1038/230522a0; Hoffman RA, 1977, SP377 NASA, P127; HORNECK G, 1992, NUCL TRACKS RAD MEAS, V20, P185; MCNULTY PJ, 1978, SCIENCE, V201, P341, DOI 10.1126/science.663660; PINSKY LS, 1974, SCIENCE, V183, P957, DOI 10.1126/science.183.4128.957; TOBIAS C A, 1952, J Aviat Med, V23, P345	9	72	73	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 17	2003	422	6933					680	680		10.1038/422680a	http://dx.doi.org/10.1038/422680a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	668CG	12700751	Bronze			2022-12-28	WOS:000182272300030
J	de Chadarevian, S				de Chadarevian, S			Perceptions in science - The making of an icon credit	SCIENCE			English	Editorial Material							DEOXYRIBONUCLEIC-ACID		Univ Cambridge, Dept Hist & Philosophy Sci, Cambridge CB2 3RH, England	University of Cambridge	de Chadarevian, S (corresponding author), Univ Cambridge, Dept Hist & Philosophy Sci, Cambridge CB2 3RH, England.	sd10016@hermes.cam.ac.uk						BROWN AB, 1995, COMMUNICATION    JAN; CRICK F, 1988, COMMUNICATION   0105; CRICK F, 1997, COMMUNICATION   0602; CRICK F, 1998, COMMUNICATION   0105; CRICK FHC, 1954, PROC R SOC LON SER-A, V223, P80, DOI 10.1098/rspa.1954.0101; de Chadarevian S., 2002, DESIGNS LIFE MOL BIO; FRANKLIN RE, 1953, NATURE, V171, P740, DOI 10.1038/171740a0; HARGREAVES R, 1999, FACES CENTURY SAINSB, P7; OLBY R, 1994, PATH DOUBLE HELIX DI, P421; Roberts L, 2001, SCIENCE, V291, P1182; WATSON J, 1953, COMMUNICATION   0521; Watson J.D., 1968, DOUBLE HELIX PERSONA; WATSON JD, 1953, NATURE, V171, P964, DOI 10.1038/171964b0; WATSON JD, 1953, NATURE, V171, P737, DOI 10.1038/171737a0; WILKINS MHF, 1953, NATURE, V171, P738, DOI 10.1038/171738a0; 1953, VARSITY CAMBRID 0530, P1; 2003, ISIS, V94, P90	17	4	4	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 11	2003	300	5617					255	+						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	665RQ	12690175				2022-12-28	WOS:000182135400031
J	Baker, PJ; Wilson, JS				Baker, PJ; Wilson, JS			Coexistence of tropical tree species	NATURE			English	Article							FOREST		US Forest Serv, Inst Pacific Isl Forestry, Pacific SW Res Stn, USDA, Hilo, HI 96720 USA; Univ Maine, Dept Forest Management, Orono, ME 04469 USA	United States Department of Agriculture (USDA); United States Forest Service; University of Maine System; University of Maine Orono	Baker, PJ (corresponding author), US Forest Serv, Inst Pacific Isl Forestry, Pacific SW Res Stn, USDA, Hilo, HI 96720 USA.			Baker, Patrick/0000-0002-6560-7124				BORMANN FH, 1981, YALE U SCH FORESTRY, V94; BUSH MB, 1994, J BIOGEOGR, V21, P5, DOI 10.2307/2845600; CONDIT R, 1995, TRENDS ECOL EVOL, V10, P18, DOI 10.1016/S0169-5347(00)88955-7; Kelly CK, 2002, NATURE, V417, P437, DOI 10.1038/417437a; Oliver C.D., 1996, FOREST STAND DYNAMIC; Richards P.W., 1996, TROPICAL RAIN FOREST, VSecond edition	6	7	7	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 10	2003	422	6932					581	582		10.1038/422581a	http://dx.doi.org/10.1038/422581a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	665GN	12686991				2022-12-28	WOS:000182111400031
J	Siddiqui, A; Kerb, R; Weale, ME; Brinkmann, U; Smith, A; Goldstein, DB; Wood, NW; Sisodiya, SM				Siddiqui, A; Kerb, R; Weale, ME; Brinkmann, U; Smith, A; Goldstein, DB; Wood, NW; Sisodiya, SM			Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN GENOMIC DIVERSITY; P-GLYCOPROTEIN; MDR1 GENE; REFRACTORY EPILEPSY; EXPRESSION; BRAIN; CELLS	BACKGROUND: One third of patients with epilepsy have drug-resistant epilepsy, which is associated with an increased risk of death and debilitating psychosocial consequences. Because this form is resistant to multiple antiepileptic drugs, the mode of resistance must be nonspecific, involving drug-efflux transporters such as ATP-binding cassette sub-family B member 1 (ABCB1, also known as MDR1 and P-glycoprotein 170). We hypothesized that the CC genotype at the ABCB1 C3435T polymorphism, which is associated with increased expression of the protein, influences the response to antiepileptic-drug treatment. METHODS: ABCB1 3435 was genotyped in 315 patients with epilepsy, classified as drug-resistant in 200 and drug-responsive in 115, and 200 control subjects without epilepsy. Recently devised methods were used to control for population stratification, and linkage disequilibrium was calculated across the gene. RESULTS: As compared with patients with drug-responsive epilepsy, patients with drug-resistant epilepsy were more likely to have the CC genotype at ABCB1 3435 than the TT genotype (odds ratio, 2.66; 95 percent confidence interval, 1.32 to 5.38; P=0.006). There was no genetic stratification between the two groups of patients. The polymorphism fell within an extensive block of linkage disequilibrium spanning much or all of the gene, implying that the polymorphism may not itself be causal but rather may be linked with the causal variant. CONCLUSIONS: These pharmacogenomic results identify a genetic factor associated with resistance to antiepileptic drugs.	UCL, Inst Neurol, Dept Clin & Expt Epilepsy, London WC1N 3BG, England; UCL, Inst Neurol, Dept Mol Pathogenesis, London WC1N 3BG, England; UCL, Dept Biol, London WC1N 3BG, England; Epidauros Biotechnol, Pharmacogenet Lab, Bernried, Germany; Natl Neurol Inst, Singapore, Singapore	University of London; University College London; University of London; University College London; University of London; University College London	Sisodiya, SM (corresponding author), UCL, Inst Neurol, Dept Clin & Expt Epilepsy, London WC1N 3BG, England.	s.sisodiya@ion.ucl.ac.uk	Weale, Michael E/F-2587-2010; Brinkmann, Ulrich/AAF-8216-2019; Goldstein, David/AAY-8125-2020; Wood, Nicholas W/C-2505-2009	Weale, Michael E/0000-0003-4593-1186; Brinkmann, Ulrich/0000-0002-5558-0212; Wood, Nicholas W/0000-0002-9500-3348				Carroll ML, 2001, J MOL BIOL, V311, P17, DOI 10.1006/jmbi.2001.4847; Cascorbi I, 2001, CLIN PHARMACOL THER, V69, P169, DOI 10.1067/mcp.2001.114164; Casetta I, 1999, ACTA NEUROL SCAND, V99, P329, DOI 10.1111/j.1600-0404.1999.tb07360.x; Choo EF, 2000, DRUG METAB DISPOS, V28, P655; Daly MJ, 2001, NAT GENET, V29, P229, DOI 10.1038/ng1001-229; Dombrowski SM, 2001, EPILEPSIA, V42, P1501, DOI 10.1046/j.1528-1157.2001.12301.x; Drescher S, 2002, BRIT J CLIN PHARMACO, V53, P526, DOI 10.1046/j.1365-2125.2002.01591.x; Farrell RJ, 2000, GASTROENTEROLOGY, V118, P279, DOI 10.1016/S0016-5085(00)70210-1; Fellay J, 2002, LANCET, V359, P30, DOI 10.1016/S0140-6736(02)07276-8; Gelisse P, 2001, J NEUROL NEUROSUR PS, V70, P240, DOI 10.1136/jnnp.70.2.240; Goldstein DB, 2001, NAT GENET, V29, P109, DOI 10.1038/ng1001-109; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; Hitzl M, 2001, PHARMACOGENETICS, V11, P293, DOI 10.1097/00008571-200106000-00003; Hoffmeyer S, 2000, P NATL ACAD SCI USA, V97, P3473, DOI 10.1073/pnas.050585397; Kerb R., 2001, Pharmacogenomics Journal, V1, P204; Kim RB, 2001, CLIN PHARMACOL THER, V70, P189, DOI 10.1067/mcp.2001.117412; Lazarowski A, 1999, PEDIATR NEUROL, V21, P731, DOI 10.1016/S0887-8994(99)00074-0; Ling V, 1997, CANCER CHEMOTH PHARM, V40, pS3, DOI 10.1007/s002800051053; Llorente L, 2000, JOINT BONE SPINE, V67, P30; Loscher W, 2002, J PHARMACOL EXP THER, V301, P7, DOI 10.1124/jpet.301.1.7; MacDonald BK, 2001, ANN NEUROL, V50, P830; MacDonald BK, 2000, ANN NEUROL, V48, P833, DOI 10.1002/1531-8249(200012)48:6<833::AID-ANA3>3.0.CO;2-U; MACDONALD BK, 2001, ANN NEUROL, V49, P547; Reich DE, 2001, GENET EPIDEMIOL, V20, P4, DOI 10.1002/1098-2272(200101)20:1<4::AID-GEPI2>3.0.CO;2-T; Roy-Engel AM, 2001, GENETICS, V159, P279; Schinkel AH, 1999, ADV DRUG DELIVER REV, V36, P179, DOI 10.1016/S0169-409X(98)00085-4; Shapiro AB, 1998, ACTA PHYSIOL SCAND, V163, P227; Sisodiya SM, 2002, BRAIN, V125, P22, DOI 10.1093/brain/awf002; Sisodiya SM, 1999, NEUROREPORT, V10, P3437, DOI 10.1097/00001756-199911080-00032; Sisodiya SM, 2001, LANCET, V357, P42, DOI 10.1016/S0140-6736(00)03573-X; Tai HL, 2000, CURR OPIN MOL THER, V2, P459; Tanabe M, 2001, J PHARMACOL EXP THER, V297, P1137; TISHLER DM, 1995, EPILEPSIA, V36, P1, DOI 10.1111/j.1528-1157.1995.tb01657.x; Weir B.S., 1996, GENETIC DATA ANAL	34	509	556	0	25	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 10	2003	348	15					1442	1448		10.1056/NEJMoa021986	http://dx.doi.org/10.1056/NEJMoa021986			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	665CU	12686700	Green Published			2022-12-28	WOS:000182102700004
J	Druss, B; Mechanic, D				Druss, B; Mechanic, D			Should visit length be used as a quality indicator in primary care?	LANCET			English	Editorial Material							MANAGEMENT		Emory Univ, Rollins Sch Publ Hlth, Dept Hlth Policy & Management, Atlanta, GA 30322 USA; Rutgers State Univ, Inst Hlth Hlth Care Policy & Aging Res, New Brunswick, NJ 08903 USA	Emory University; Rollins School Public Health; Rutgers State University New Brunswick	Druss, B (corresponding author), Emory Univ, Rollins Sch Publ Hlth, Dept Hlth Policy & Management, Atlanta, GA 30322 USA.							CUTLER DM, 2001, HEALTH AFFAIR, V20, P11; *I MED, 2002, CROSS QUAL CHASM; Mechanic D, 2001, BRIT MED J, V323, P266, DOI 10.1136/bmj.323.7307.266; Mechanic D, 2001, NEW ENGL J MED, V344, P198, DOI 10.1056/NEJM200101183440307; *NCQA, 1998, DES ATTR HEDIS MEAS; Robinson JC, 2001, J HEALTH POLIT POLIC, V26, P1045, DOI 10.1215/03616878-26-5-1045; Rundall TG, 2002, BMJ-BRIT MED J, V325, P958, DOI 10.1136/bmj.325.7370.958; Safran DG, 1998, MED CARE, V36, P728, DOI 10.1097/00005650-199805000-00012; Shi LY, 2001, J FAM PRACTICE, V50, P161; Wagner EH, 2000, BMJ-BRIT MED J, V320, P569, DOI 10.1136/bmj.320.7234.569; Wilson A, 2002, BRIT J GEN PRACT, V52, P1012	11	11	12	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 5	2003	361	9364					1148	1148		10.1016/S0140-6736(03)12968-6	http://dx.doi.org/10.1016/S0140-6736(03)12968-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	664ZF	12686035				2022-12-28	WOS:000182094600006
J	Shauer, A; Ziv, H				Shauer, A; Ziv, H			Conflict and public health: report from Physicians for Human Rights-Israel	LANCET			English	Reprint									PHR Israel, IL-66020 Tel Aviv, Israel; Hadassa Hosp, Jerusalem, Israel		Shauer, A (corresponding author), PHR Israel, IL-66020 Tel Aviv, Israel.							GREENOUGH G, 2002, NUTR ASSESSMENT W BA; HASS A, 2000, HAARETZ         1019; OBRIEN L, 2002, OXFAM BRIEFING PAPER; *PAL RED CRESC SOC, TABL FIG	4	4	4	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 5	2003	361	9364					1221	1221		10.1016/S0140-6736(03)12957-1	http://dx.doi.org/10.1016/S0140-6736(03)12957-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	664ZF	12686057				2022-12-28	WOS:000182094600027
J	Shaw, SL; Kamyar, R; Ehrhardt, DW				Shaw, SL; Kamyar, R; Ehrhardt, DW			Sustained microtubule treadmilling in Arabidopsis cortical arrays	SCIENCE			English	Article							LIVING PLANT-CELLS; DYNAMIC INSTABILITY; GROWTH; TUBULIN; ORIENTATION; TURNOVER; SITES	Plant cells create highly structured microtubule arrays at the cell cortex without a central organizing center to anchor the microtubule ends. In vivo imaging of individual microtubules in Arabidopsis plants revealed that new microtubules are initiated at the cell cortex and exhibit dynamics at both ends. Polymerization-biased dynamic instability at one end and slow depolymerization at the other end result in sustained microtubule migration across the cell cortex by a hybrid treadmilling mechanism. This motility causes widespread microtubule repositioning and contributes to changes in array organization through microtubule reorientation and bundling.	Carnegie Inst Sci, Dept Plant Biol, Stanford, CA 94305 USA; Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA	Carnegie Institution for Science; Stanford University	Ehrhardt, DW (corresponding author), Carnegie Inst Sci, Dept Plant Biol, 290 Panama St, Stanford, CA 94305 USA.	ehrhardt@andrew2.stanford.edu		Shaw, Sidney/0000-0001-9195-6128				Baskin TI, 2001, PROTOPLASMA, V215, P150, DOI 10.1007/BF01280311; Bichet A, 2001, PLANT J, V25, P137, DOI 10.1046/j.1365-313x.2001.00946.x; Chan J, 1999, P NATL ACAD SCI USA, V96, P14931, DOI 10.1073/pnas.96.26.14931; CLAYTON L, 1985, J CELL BIOL, V101, P319, DOI 10.1083/jcb.101.1.319; CYR RJ, 1994, ANNU REV CELL BIOL, V10, P153, DOI 10.1146/annurev.cb.10.110194.001101; Erhardt M, 2002, J CELL SCI, V115, P2423; Granger CL, 2001, PROTOPLASMA, V216, P201, DOI 10.1007/BF02673872; GREEN PB, 1965, J CELL BIOL, V27, P343, DOI 10.1083/jcb.27.2.343; GUNNING BES, 1985, J CELL SCI, P157, DOI 10.1242/jcs.1985.Supplement_2.9; HARDHAM AR, 1978, J CELL BIOL, V77, P14, DOI 10.1083/jcb.77.1.14; HUSH JM, 1994, J CELL SCI, V107, P775; Keating TJ, 1997, P NATL ACAD SCI USA, V94, P5078, DOI 10.1073/pnas.94.10.5078; Lloyd C, 2002, PLANT CELL, V14, P2319, DOI 10.1105/tpc.141030; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; Rodionov V, 1999, P NATL ACAD SCI USA, V96, P115, DOI 10.1073/pnas.96.1.115; Rodionov VI, 1997, SCIENCE, V275, P215, DOI 10.1126/science.275.5297.215; SAXTON WM, 1984, J CELL BIOL, V99, P2175, DOI 10.1083/jcb.99.6.2175; SHIBAOKA H, 1991, CYTOSKELETAL BASIS P, P159; Thitamadee S, 2002, NATURE, V417, P193, DOI 10.1038/417193a; Vorobjev IA, 1999, J CELL SCI, V112, P2277; Wasteneys GO, 2002, J CELL SCI, V115, P1345; WatermanStorer CM, 1997, CURR BIOL, V7, pR369, DOI 10.1016/S0960-9822(06)00177-1; WatermanStorer CM, 1997, J CELL BIOL, V139, P417, DOI 10.1083/jcb.139.2.417; Whittington AT, 2001, NATURE, V411, P610, DOI 10.1038/35079128; WICK SM, 1985, CELL BIOL INT REP, V9, P357, DOI 10.1016/0309-1651(85)90031-1; YUAN M, 1994, P NATL ACAD SCI USA, V91, P6050, DOI 10.1073/pnas.91.13.6050; Yvon AMC, 1997, J CELL SCI, V110, P2391	27	346	353	1	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 13	2003	300	5626					1715	1718		10.1126/science.1083529	http://dx.doi.org/10.1126/science.1083529			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	688WF	12714675				2022-12-28	WOS:000183459700042
J	Mirabel, IF; Rodrigues, I				Mirabel, IF; Rodrigues, I			Formation of a black hole in the dark	SCIENCE			English	Article							INITIAL MASS FUNCTION; NORTHERN MILKY-WAY; OB ASSOCIATIONS; CYGNUS X-1; GALAXY; STATE; STARS	We show that the black hole in the x-ray binary Cygnus X-1 was formed in situ and did not receive an energetic trigger from a nearby supernova. The progenitor of the black hole had an initial mass greater than 40 solar masses, and during the collapse to form the similar to10-solar mass black hole of Cygnus X-1, the upper limit for the mass that could have been suddenly ejected is similar to1 solar mass, much less than the mass ejected in a supernova. The observations suggest that high-mass stellar black holes may form promptly, when massive stars disappear silently.	CEA Saclay, Serv Astrophys, F-91191 Gif Sur Yvette, France; Consejo Nacl Invest Cient & Tecn, Inst Astron & Fis Espacio, RA-1033 Buenos Aires, DF, Argentina	CEA; UDICE-French Research Universities; Universite Paris Saclay; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Instituto de Astronomia y Fisica del Espacio (IAFE)	Mirabel, IF (corresponding author), CEA Saclay, Serv Astrophys, F-91191 Gif Sur Yvette, France.		de Oliveira Filho, Irapuan Rodrigues/C-6834-2013	de Oliveira Filho, Irapuan Rodrigues/0000-0003-2141-9399				Beer ME, 2002, MON NOT R ASTRON SOC, V331, P351, DOI 10.1046/j.1365-8711.2002.05189.x; BLAAUW A, 1991, NATO ADV SCI I C-MAT, V342, P125; BLAHA C, 1989, ASTRON J, V98, P1598, DOI 10.1086/115244; BOWYER S, 1965, SCIENCE, V147, P394, DOI 10.1126/science.147.3656.394; Dambis AK, 2001, ASTRON LETT+, V27, P58, DOI 10.1134/1.1336863; Fryer CL, 2001, ASTROPHYS J, V554, P548, DOI 10.1086/321359; GARMANY CD, 1992, ASTRON ASTROPHYS SUP, V94, P211; Gierlinski M, 1999, MON NOT R ASTRON SOC, V309, P496, DOI 10.1046/j.1365-8711.1999.02875.x; Hamuy M, 2003, ASTROPHYS J, V582, P905, DOI 10.1086/344689; HERRERO A, 1995, ASTRON ASTROPHYS, V297, P556; Israelian G, 1999, NATURE, V401, P142, DOI 10.1038/43625; LaSala J, 1998, MON NOT R ASTRON SOC, V301, P285, DOI 10.1046/j.1365-8711.1998.02064.x; Lestrade JF, 1999, ASTRON ASTROPHYS, V344, P1014; MARGON B, 1973, ASTROPHYS J, V185, pL113, DOI 10.1086/181333; MASSEY P, 1995, ASTROPHYS J, V454, P151, DOI 10.1086/176474; Mel'nik AM, 2001, ASTRON LETT+, V27, P521, DOI 10.1134/1.1388920; Mirabel IF, 1998, NATURE, V392, P673, DOI 10.1038/33603; Nelemans G, 1999, ASTRON ASTROPHYS, V352, pL87; SCHALLER G, 1992, ASTRON ASTROPHYS SUP, V96, P269; Stirling AM, 2001, MON NOT R ASTRON SOC, V327, P1273, DOI 10.1046/j.1365-8711.2001.04821.x; WALBORN NR, 1973, ASTROPHYS J, V179, pL123, DOI 10.1086/181131	21	134	134	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 16	2003	300	5622					1119	1120		10.1126/science.1083451	http://dx.doi.org/10.1126/science.1083451			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678VC	12714674				2022-12-28	WOS:000182886500036
J	Ksiazek, TG; Erdman, D; Goldsmith, CS; Zaki, SR; Peret, T; Emery, S; Tong, SX; Urbani, C; Comer, JA; Lim, W; Rollin, PE; Dowell, SF; Ling, AE; Humphrey, CD; Shieh, WJ; Guarner, J; Paddock, CD; Rota, P; Fields, B; DeRisi, J; Yang, JY; Cox, N; Hughes, JM; LeDuc, JW; Bellini, WJ; Anderson, LJ				Ksiazek, TG; Erdman, D; Goldsmith, CS; Zaki, SR; Peret, T; Emery, S; Tong, SX; Urbani, C; Comer, JA; Lim, W; Rollin, PE; Dowell, SF; Ling, AE; Humphrey, CD; Shieh, WJ; Guarner, J; Paddock, CD; Rota, P; Fields, B; DeRisi, J; Yang, JY; Cox, N; Hughes, JM; LeDuc, JW; Bellini, WJ; Anderson, LJ		SARS Working Grp	A novel coronavirus associated with severe acute respiratory syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PORCINE EPIDEMIC DIARRHEA; ANTIGENIC RELATIONSHIPS; VIRUS-INFECTION; NIPAH VIRUS; PATHOGENESIS; PROPAGATION; ADAPTATION; DIAGNOSIS; GROWTH; FEVER	BACKGROUND A worldwide outbreak of severe acute respiratory syndrome (SARS) has been associated with exposures originating from a single ill health care worker from Guangdong Province, China. We conducted studies to identify the etiologic agent of this outbreak. METHODS We received clinical specimens from patients in seven countries and tested them, using virus-isolation techniques, electron-microscopical and histologic studies, and molecular and serologic assays, in an attempt to identify a wide range of potential pathogens. RESULTS None of the previously described respiratory pathogens were consistently identified. However, a novel coronavirus was isolated from patients who met the case definition of SARS. Cytopathological features were noted in Vero E6 cells inoculated with a throat-swab specimen. Electron-microscopical examination revealed ultrastructural features characteristic of coronaviruses. Immunohistochemical and immunofluorescence staining revealed reactivity with group I coronavirus polyclonal antibodies. Consensus coronavirus primers designed to amplify a fragment of the polymerase gene by reverse transcription-polymerase chain reaction (RT-PCR) were used to obtain a sequence that clearly identified the isolate as a unique coronavirus only distantly related to previously sequenced coronaviruses. With specific diagnostic RT-PCR primers we identified several identical nucleotide sequences in 12 patients from several locations, a finding consistent with a point-source outbreak. Indirect fluorescence antibody tests and enzyme-linked immunosorbent assays made with the new isolate have been used to demonstrate a virus-specific serologic response. This virus may never before have circulated in the U.S. population. CONCLUSIONS A novel coronavirus is associated with this outbreak, and the evidence indicates that this virus has an etiologic role in SARS. Because of the death of Dr. Carlo Urbani, we propose that our first isolate be named the Urbani strain of SARS-associated coronavirus.	Ctr Dis Control & Prevent, Special Pathogens Branch, Natl Ctr Infect Dis, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Resp & Enter Virus Brach, Natl Ctr Infect Dis, Atlanta, GA USA; Ctr Dis Control & Prevent, Infect Dis Pathol Act, Natl Ctr Infect Dis, Atlanta, GA USA; Ctr Dis Control & Prevent, Influenza Branch, Natl Ctr Infect Dis, Atlanta, GA USA; Ctr Dis Control & Prevent, Div Bacterial & Mycot Dis, Natl Ctr Infect Dis, Atlanta, GA USA; Ctr Dis Control & Prevent, Off Director, Div Viral & Rickettsial Dis, Natl Ctr Infect Dis, Atlanta, GA USA; WHO, Hanoi, Vietnam; Queen Mary Hosp, Govt Virus Unit, Hong Kong, Hong Kong, Peoples R China; Int Emerging Infect Dis Program, Bangkok, Thailand; Univ Calif San Francisco, San Francisco, CA 94143 USA; Singapore Gen Hosp, Dept Pathol, Singapore, Singapore; Ctr Dis Control, Dept Hlth, Taipei, Taiwan	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; World Health Organization; University of Hong Kong; University of California System; University of California San Francisco; Singapore General Hospital; Centers For Disease Control - Taiwan	Ksiazek, TG (corresponding author), Ctr Dis Control & Prevent, Special Pathogens Branch, Natl Ctr Infect Dis, Atlanta, GA 30333 USA.		Guarner, Jeannette/B-8273-2013	Guarner, Jeannette/0000-0001-5610-3541; Rollin, Pierre/0000-0002-4608-2641; Osborne, Jane/0000-0001-9529-7748				Becker W B, 1967, J Virol, V1, P1019; BOHLANDER SK, 1992, GENOMICS, V13, P1322, DOI 10.1016/0888-7543(92)90057-Y; BRADBURNE AF, 1970, ARCH GES VIRUSFORSCH, V31, P352, DOI 10.1007/BF01253769; BRADBURNE AF, 1972, J HYG-CAMB, V70, P235, DOI 10.1017/S0022172400022294; BRUCKOVA M, 1970, P SOC EXP BIOL MED, V135, P431; Chua KB, 2000, SCIENCE, V288, P1432, DOI 10.1126/science.288.5470.1432; Falsey AR, 2003, J INFECT DIS, V187, P785, DOI 10.1086/367901; Guarner J, 2000, AM J CLIN PATHOL, V114, P227, DOI 10.1309/HV74-N24T-2K2C-3E8Q; Hazelton PR, 2003, EMERG INFECT DIS, V9, P294, DOI 10.3201/eid0903.020327; HOFMANN M, 1988, J CLIN MICROBIOL, V26, P2235, DOI 10.1128/JCM.26.11.2235-2239.1988; JACOBSEGEELS HEL, 1983, J GEN VIROL, V64, P1859, DOI 10.1099/0022-1317-64-9-1859; JOHNSON KM, 1977, LANCET, V1, P569; Jonassen CM, 1998, J GEN VIROL, V79, P715, DOI 10.1099/0022-1317-79-4-715; Ksiazek TG, 1999, J INFECT DIS, V179, pS192, DOI 10.1086/514313; KUSANAGI K, 1992, J VET MED SCI, V54, P313, DOI 10.1292/jvms.54.313; Lavi E, 1996, VIROLOGY, V221, P325, DOI 10.1006/viro.1996.0382; Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685; Luby JP, 1999, J CLIN VIROL, V12, P43, DOI 10.1016/S0928-0197(98)00067-1; MCINTOSH K, 1969, J IMMUNOL, V102, P1109; MURRAY K, 1995, SCIENCE, V268, P94, DOI 10.1126/science.7701348; OSHIRO LS, 1971, J GEN VIROL, V12, P161, DOI 10.1099/0022-1317-12-2-161; PATTERSON S, 1982, J GEN VIROL, V60, P307, DOI 10.1099/0022-1317-60-2-307; Poutanen SM, 2003, NEW ENGL J MED, V348, P1995, DOI 10.1056/NEJMoa030634; Smolinsky M.S., 2003, MICROBIAL THREATS HL; Swofford D. L., 1999, PAUP 4 0 PHYLOGENETI; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tsang KW, 2003, NEW ENGL J MED, V348, P1977, DOI 10.1056/NEJMoa030666; Wang D, 2002, P NATL ACAD SCI USA, V99, P15687, DOI 10.1073/pnas.242579699; *WHO, 2003, AC RESP SYNDR CHIN U; Wong KT, 2002, AM J PATHOL, V161, P2153, DOI 10.1016/S0002-9440(10)64493-8; WULFF H, 1975, B WORLD HEALTH ORGAN, V52, P429; ZAKI SR, 1995, AM J PATHOL, V146, P552; 2003, MMWR MORB MORTAL WKL, V52, P241	33	2906	3379	9	797	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 15	2003	348	20					1953	1966		10.1056/NEJMoa030781	http://dx.doi.org/10.1056/NEJMoa030781			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	677TJ	12690092	Bronze			2022-12-28	WOS:000182823400004
J	Rosenbaum, P				Rosenbaum, P			Cerebral palsy: what parents and doctors want to know	BRITISH MEDICAL JOURNAL			English	Review							GROSS MOTOR FUNCTION; CHILDREN; HEALTH; METAANALYSIS; DISABILITIES; RELIABILITY; MAINSTREAM; PROGRAMS; SYSTEM; CARE	Cerebral palsy is a physical impairment that affects the development of movement. Impairment can vary considerably and no two people with cerebral palsy are affected in exactly the same way. The problems that children and adults with cerebral palsy face, including discrimination, are often similar.	McMaster Univ, CanChild Ctr Childhood Disabil Res, Hamilton, ON L8S 1C7, Canada	McMaster University	Rosenbaum, P (corresponding author), McMaster Univ, CanChild Ctr Childhood Disabil Res, Hamilton, ON L8S 1C7, Canada.		Rosenbaum, Peter/AAW-7913-2021	Rosenbaum, Peter/0000-0001-6751-5613				Bax M, 1999, DEV MED CHILD NEUROL, V41, P3, DOI 10.1017/S0012162299000018; BRESLAU N, 1981, MED CARE, V19, P741, DOI 10.1097/00005650-198107000-00005; Butler C, 2000, DEV MED CHILD NEUROL, V42, P634, DOI 10.1017/S0012162200001183; Butler C., 1991, PHYS MED REH CLIN N, V2, P801, DOI [10.1016/S1047-9651(18)30683-1, DOI 10.1016/S1047-9651(18)30683-1]; CADMAN D, 1987, PEDIATRICS, V79, P805; Cans C, 2000, DEV MED CHILD NEUROL, V42, P816, DOI 10.1111/j.1469-8749.2000.tb00695.x; CATHELS BA, 1993, MED J AUSTRALIA, V159, P444, DOI 10.5694/j.1326-5377.1993.tb137961.x; Collet JP, 2001, LANCET, V357, P582, DOI 10.1016/S0140-6736(00)04054-X; CUNNINGHAM CC, 1984, DEV MED CHILD NEUROL, V26, P33; Dodd KJ, 2002, ARCH PHYS MED REHAB, V83, P1157, DOI 10.1053/apmr.2002.34286; du Plessis AJ, 2002, CURR OPIN NEUROL, V15, P151, DOI 10.1097/00019052-200204000-00005; Edgar TS, 2001, J CHILD NEUROL, V16, P37, DOI 10.1177/088307380101600107; ESCOBAR GJ, 1991, ARCH DIS CHILD, V66, P204, DOI 10.1136/adc.66.2.204; Hetzel BS, 2000, J NUTR, V130, p493S, DOI 10.1093/jn/130.2.493S; Kennes J, 2002, DEV MED CHILD NEUROL, V44, P240, DOI 10.1017/S0012162201002018; Ketelaar M, 2001, PHYS THER, V81, P1534, DOI 10.1093/ptj/81.9.1534; King G, 1999, J PEDIATR PSYCHOL, V24, P41, DOI 10.1093/jpepsy/24.1.41; King SM, 1996, DEV MED CHILD NEUROL, V38, P757, DOI 10.1111/j.1469-8749.1996.tb15110.x; McLaughlin J, 2002, DEV MED CHILD NEUROL, V44, P17, DOI 10.1017/S0012162201001608; MUTCH L, 1992, DEV MED CHILD NEUROL, V34, P547; Nelson Karin B., 2000, Current Opinion in Neurology, V13, P133, DOI 10.1097/00019052-200004000-00004; NELSON KB, 1988, J PEDIATR-US, V112, P572, DOI 10.1016/S0022-3476(88)80169-0; NELSON KB, 1995, PAEDIATR PERINAT EP, V9, P135, DOI 10.1111/j.1365-3016.1995.tb00129.x; Palisano R, 1997, DEV MED CHILD NEUROL, V39, P214, DOI 10.1111/j.1469-8749.1997.tb07414.x; Reddihough DS, 1998, DEV MED CHILD NEUROL, V40, P763; Rosenbaum P, 2002, INFANT YOUNG CHILD, V15, P51, DOI 10.1097/00001163-200207000-00008; Rosenbaum P., 1998, FAMILY CENTRED SERVI, V18, P1, DOI [10.1080/J006v18n01, DOI 10.1080/J006V18N01, DOI 10.1080/J006v18n01_01]; Rosenbaum PL, 2002, JAMA-J AM MED ASSOC, V288, P1357, DOI 10.1001/jama.288.11.1357; ROSENBAUM PL, 2003, IN PRESS J PED NEURO; Stanley FJ, 2000, CEREBRAL PALSIES EPI; Wood E, 2000, DEV MED CHILD NEUROL, V42, P292, DOI 10.1017/S0012162200000529; World Health Organization, 2001, INT CLASS IMP ACT PA; Yude C, 1999, DEV MED CHILD NEUROL, V41, P4, DOI 10.1017/S001216229900002X	33	154	163	0	51	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 3	2003	326	7396					970	974		10.1136/bmj.326.7396.970	http://dx.doi.org/10.1136/bmj.326.7396.970			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	676JC	12727772	Green Published			2022-12-28	WOS:000182746700020
J	Souma, S; Machida, Y; Sato, T; Takahashi, T; Matsui, H; Wang, SC; Ding, H; Kaminski, A; Campuzano, JC; Sasaki, S; Kadowaki, K				Souma, S; Machida, Y; Sato, T; Takahashi, T; Matsui, H; Wang, SC; Ding, H; Kaminski, A; Campuzano, JC; Sasaki, S; Kadowaki, K			The origin of multiple superconducting gaps in MgB2	NATURE			English	Article								Magnesium diboride, MgB2, has the highest transition temperature (T-c = 39 K) of the known metallic superconductors(1). Whether the anomalously high T-c can be described within the conventional BCS (Bardeen-Cooper-Schrieffer) framework 2 has been debated. The key to understanding superconductivity lies with the 'superconducting energy gap' associated with the formation of the superconducting pairs. Recently, the existence of two kinds of superconducting gaps in MgB2 has been suggested by several experiments(3-9); this is in contrast to both conventional and high-T-c superconductors. A clear demonstration of two gaps has not yet been made because the previous experiments lacked the ability to resolve the momentum of the superconducting electrons. Here we report direct experimental evidence for the two-band superconductivity in MgB2, by separately observing the superconducting gaps of the sigma and pi bands (as well as a surface band). The gaps have distinctly different sizes, which unambiguously establishes MgB2 as a two-gap superconductor(10,11).	Tohoku Univ, Dept Phys, Sendai, Miyagi 9808578, Japan; Tokyo Inst Technol, Mat & Struct Lab, Yokohama, Kanagawa 2268503, Japan; Boston Coll, Dept Phys, Chestnut Hill, MA 02467 USA; Argonne Natl Lab, Div Mat Sci, Argonne, IL 60439 USA; Univ Illinois, Dept Phys, Chicago, IL 60607 USA; Univ Tsukuba, Inst Mat Sci, Tsukuba, Ibaraki 3058573, Japan	Tohoku University; Tokyo Institute of Technology; Boston College; United States Department of Energy (DOE); Argonne National Laboratory; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Tsukuba	Takahashi, T (corresponding author), Tohoku Univ, Dept Phys, Sendai, Miyagi 9808578, Japan.	t.takahashi@arpes.phys.tohoku.ac.jp	Takahashi, Takashi T/E-5080-2010; wang, shancai/J-1436-2017; Wang, Shancai/F-6162-2013; Sato, Takafumi/E-5094-2010; souma, seigo/A-4858-2010; Kadowaki, Kazuo/L-8660-2017; Matsui, Hiroaki/L-5595-2018; Sasaki, Satoshi/F-7627-2014; Campuzano, Juan Carlos/G-4358-2012; Tohoku, Arpes/A-4890-2010	wang, shancai/0000-0001-7564-9064; Sato, Takafumi/0000-0002-4544-5463; Kadowaki, Kazuo/0000-0002-9899-0094; Matsui, Hiroaki/0000-0002-6874-6154; Campuzano, Juan Carlos/0000-0002-2083-4884; Ding, Hong/0000-0003-4422-9248				BARDEEN J, 1957, PHYS REV, V108, P1175, DOI 10.1103/PhysRev.108.1175; Bouquet F, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.257001; Bouquet F, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.047001; Bud'ko SL, 2001, PHYS REV LETT, V86, P1877, DOI 10.1103/PhysRevLett.86.1877; Buzea C, 2001, SUPERCOND SCI TECH, V14, pR115, DOI 10.1088/0953-2048/14/11/201; Chen XB, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.012001; Choi HJ, 2002, NATURE, V418, P758, DOI 10.1038/nature00898; DING H, 1995, PHYS REV LETT, V74, P2784, DOI 10.1103/PhysRevLett.74.2784; Fedorov AV, 1999, PHYS REV LETT, V82, P2179, DOI 10.1103/PhysRevLett.82.2179; Gonnelli RS, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.247004; Joas C, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.132518; Karapetrov G, 2001, PHYS REV LETT, V86, P4374, DOI 10.1103/PhysRevLett.86.4374; Kortus J, 2001, PHYS REV LETT, V86, P4656, DOI 10.1103/PhysRevLett.86.4656; Kotegawa H, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.127001; Liu AY, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.087005; Machida Y, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.094507; MCMILLAN WL, 1968, PHYS REV, V175, P537, DOI 10.1103/PhysRev.175.537; Nagamatsu J, 2001, NATURE, V410, P63, DOI 10.1038/35065039; QUILTY JW, 2002, CONDMAT0206506; REINERT F, 2001, PHYS REV LETT, V87; Schmidt H, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.220504; Seneor P, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.012505; Takahashi T, 2001, PHYS REV LETT, V86, P4915, DOI 10.1103/PhysRevLett.86.4915; Tsuda S, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.177006; Uchiyama H, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.157002	26	205	212	1	60	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 1	2003	423	6935					65	67		10.1038/nature01619	http://dx.doi.org/10.1038/nature01619			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	673CG	12721624				2022-12-28	WOS:000182561600038
J	Bennett, DA; Jull, A				Bennett, DA; Jull, A			FDA: untapped source of unpublished trials	LANCET			English	Editorial Material							PUBLICATION BIAS; METAANALYSIS		Univ Auckland, Clin Trials Res Unit, Auckland 1, New Zealand	University of Auckland	Bennett, DA (corresponding author), Univ Auckland, Clin Trials Res Unit, Auckland 1, New Zealand.		Jull, Andrew/I-1737-2013	Jull, Andrew/0000-0002-8484-3771; Bennett, Derrick/0000-0002-9170-8447				Altman DG, 2001, ANN INTERN MED, V134, P663, DOI 10.7326/0003-4819-134-8-200104170-00012; Antes G, 2003, LANCET, V361, P978, DOI 10.1016/S0140-6736(03)12838-3; BEGG CB, 1988, J ROY STAT SOC A STA, V151, P419, DOI 10.2307/2982993; CHALMERS I, 1990, JAMA-J AM MED ASSOC, V263, P1405, DOI 10.1001/jama.263.10.1405; Egger M., 2008, SYSTEMATIC REV HLTH; Ioannidis JPA, 1998, JAMA-J AM MED ASSOC, V279, P281, DOI 10.1001/jama.279.4.281; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; MacLean CH, 2003, J CLIN EPIDEMIOL, V56, P44, DOI 10.1016/S0895-4356(02)00520-6; Pich J, 2003, LANCET, V361, P1015, DOI 10.1016/S0140-6736(03)12799-7; SCHERER RW, 2002, COCHRANE LIB; Stern JM, 1997, BMJ-BRIT MED J, V315, P640, DOI 10.1136/bmj.315.7109.640; Sterne JAC, 2001, BMJ-BRIT MED J, V323, P101, DOI 10.1136/bmj.323.7304.101; Sutton AJ, 2000, STAT METHODS MED RES, V9, P421, DOI 10.1191/096228000701555244	13	11	11	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 26	2003	361	9367					1402	1403		10.1016/S0140-6736(03)13147-9	http://dx.doi.org/10.1016/S0140-6736(03)13147-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	672HZ	12727389				2022-12-28	WOS:000182516300004
J	Euvrard, S; Kanitakis, J; Claudy, A				Euvrard, S; Kanitakis, J; Claudy, A			Medical progress - Skin cancers after organ transplantation	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							HUMAN-PAPILLOMAVIRUS DNA; PREVIOUS HUMAN-HERPESVIRUS-8 INFECTION; SQUAMOUS-CELL CARCINOMAS; KAPOSIS-SARCOMA; RENAL-TRANSPLANTATION; CLINICAL-COURSE; ATYPICAL FIBROXANTHOMA; RISK-FACTORS; RECIPIENTS; LESIONS		Hop Edouard Herriot, Dept Dermatol, F-69437 Lyon 03, France	CHU Lyon	Euvrard, S (corresponding author), Hop Edouard Herriot, Dept Dermatol, Pav R,Pl Arsonval, F-69437 Lyon 03, France.	sylvie.euvrard@numericable.fr	Kanitakis, Jean/Q-3450-2019	Kanitakis, Jean/0000-0003-0469-257X				Adamson R, 1998, TRANSPLANT P, V30, P1124, DOI 10.1016/S0041-1345(98)00178-X; ALKHADER AA, 1988, NEPHRON, V48, P165, DOI 10.1159/000184900; Allen UD, 2002, PEDIATR TRANSPLANT, V6, P187, DOI 10.1034/j.1399-3046.2002.02006.x; Arends MJ, 1997, BRIT J CANCER, V75, P722, DOI 10.1038/bjc.1997.128; Aseni P, 2001, LIVER TRANSPLANT, V7, P816, DOI 10.1053/jlts.2001.26925; Barete S, 2000, ARCH DERMATOL, V136, P1452, DOI 10.1001/archderm.136.12.1452; Bavinck JNB, 1997, J INVEST DERMATOL, V108, P708, DOI 10.1111/1523-1747.ep12292086; Bavinck JNB, 1996, TRANSPLANTATION, V61, P715, DOI 10.1097/00007890-199603150-00008; BAVINCK JNB, 1995, J CLIN ONCOL, V13, P1933, DOI 10.1200/JCO.1995.13.8.1933; BAVINCK JNB, 1993, BRIT J DERMATOL, V129, P242, DOI 10.1111/j.1365-2133.1993.tb11841.x; Berg D, 2002, J AM ACAD DERMATOL, V47, P1, DOI 10.1067/mjd.2002.125579; Berkhout RJM, 2000, J CLIN MICROBIOL, V38, P2087; BIRKELAND SA, 1995, INT J CANCER, V60, P183, DOI 10.1002/ijc.2910600209; Boshoff C, 2001, PHILOS T R SOC B, V356, P517, DOI 10.1098/rstb.2000.0778; Boxman ILA, 1997, J INVEST DERMATOL, V108, P712, DOI 10.1111/1523-1747.ep12292090; Butt A, 1997, LANCET, V349, P179, DOI 10.1016/S0140-6736(05)60981-6; Caforio ALP, 2000, CIRCULATION, V102, P222; Cairey-Remonnay S, 2002, J INVEST DERMATOL, V118, P1026, DOI 10.1046/j.1523-1747.2002.01787.x; Cattani P, 2001, J CLIN MICROBIOL, V39, P506, DOI 10.1128/JCM.39.2.506-508.2001; CHOCAIR PR, 1992, TRANSPLANTATION, V53, P1051, DOI 10.1097/00007890-199205000-00016; Cooper SM, 2002, CLIN EXP DERMATOL, V27, P436, DOI 10.1046/j.1365-2230.2002.01069.x; Cowen EW, 1999, J AM ACAD DERMATOL, V40, P697, DOI 10.1016/S0190-9622(99)70149-0; Dantal J, 1998, LANCET, V351, P623, DOI 10.1016/S0140-6736(97)08496-1; De Carlis L, 2001, TRANSPLANT P, V33, P2815, DOI 10.1016/S0041-1345(01)02201-1; De Hertog SAE, 2001, J CLIN ONCOL, V19, P231, DOI 10.1200/JCO.2001.19.1.231; de Jong-Tieben LM, 2000, TRANSPLANTATION, V69, P44, DOI 10.1097/00007890-200001150-00009; Ducloux D, 1998, TRANSPLANTATION, V65, P1270, DOI 10.1097/00007890-199805150-00022; Emond JP, 2002, J CLIN MICROBIOL, V40, P2217, DOI 10.1128/JCM.40.6.2217-2219.2002; Espana A, 2000, J INVEST DERMATOL, V115, P1158, DOI 10.1046/j.1523-1747.2000.0202a-3.x; EUVRARD S, 1993, CANCER, V72, P2198, DOI 10.1002/1097-0142(19931001)72:7<2198::AID-CNCR2820720722>3.0.CO;2-Q; EUVRARD S, 1995, J AM ACAD DERMATOL, V33, P222, DOI 10.1016/0190-9622(95)90239-2; EUVRARD S, 1995, TRANSPLANT P, V27, P1767; Euvrard S, 1997, BIODRUGS, V8, P176, DOI 10.2165/00063030-199708030-00003; Euvrard S, 1998, EJD BOOK SER, P175; Euvrard S, 2002, TRANSPLANTATION, V73, P297, DOI 10.1097/00007890-200201270-00025; Euvrard S, 2001, J AM ACAD DERMATOL, V44, P932, DOI 10.1067/mjd.2001.113465; EUVRARD S, 1992, NEW ENGL J MED, V327, P1924, DOI 10.1056/NEJM199212313272706; Euvrard S, 1997, ARCH DERMATOL, V133, P175, DOI 10.1001/archderm.133.2.175; Euvrard S, 2002, AM J CANCER, V1, P109; Farge D, 1993, Eur J Med, V2, P339; Frances C, 2000, TRANSPLANTATION, V69, P1776, DOI 10.1097/00007890-200005150-00008; Frezza EE, 1997, HEPATO-GASTROENTEROL, V44, P1172; Friedlaender MM, 2002, TRANSPLANTATION, V73, P1849, DOI 10.1097/00007890-200206150-00028; Guba M, 2002, NAT MED, V8, P128, DOI 10.1038/nm0202-128; HARTEVELT MM, 1990, TRANSPLANTATION, V49, P506, DOI 10.1097/00007890-199003000-00006; HARWOOD AR, 1979, AM J MED, V67, P759, DOI 10.1016/0002-9343(79)90731-9; Harwood CA, 2000, J MED VIROL, V61, P289, DOI 10.1002/1096-9071(200007)61:3&lt;289::AID-JMV2&gt;3.0.CO;2-Z; Hiesse C, 1997, TRANSPL P, V29, P831, DOI 10.1016/S0041-1345(96)00153-4; Ishikawa N, 2000, TRANSPLANT P, V32, P1907, DOI 10.1016/S0041-1345(00)01487-1; Jenkins FJ, 2002, J INFECT DIS, V185, P1238, DOI 10.1086/340237; Jensen P, 1999, J AM ACAD DERMATOL, V40, P177, DOI 10.1016/S0190-9622(99)70185-4; Kanitakis J, 1996, J AM ACAD DERMATOL, V35, P262, DOI 10.1016/S0190-9622(96)90346-1; Kapelushnik J, 2001, BRIT J HAEMATOL, V113, P425, DOI 10.1046/j.1365-2141.2001.02740.x; Leveque L, 2000, ANN DERMATOL VENER, V127, P160; LIDDINGTON M, 1989, BRIT J SURG, V76, P1002, DOI 10.1002/bjs.1800761005; Lindelof B, 2000, BRIT J DERMATOL, V143, P513, DOI 10.1046/j.1365-2133.2000.03703.x; LIPPMAN SM, 1992, J NATL CANCER I, V84, P235, DOI 10.1093/jnci/84.4.235; Luan FL, 2002, TRANSPLANTATION, V73, P1565, DOI 10.1097/00007890-200205270-00008; MAGNONE M, 1995, TRANSPLANTATION, V59, P1068, DOI 10.1097/00007890-199504150-00030; Marshall SE, 2000, KIDNEY INT, V58, P2186, DOI 10.1111/j.1523-1755.2000.00392.x; Marshall SE, 2000, TRANSPLANTATION, V69, P994; Martinez JC, 2003, ARCH DERMATOL, V139, P301, DOI 10.1001/archderm.139.3.301; McGregor JM, 1997, ONCOGENE, V15, P1737, DOI 10.1038/sj.onc.1201339; McGregor JM, 2002, J INVEST DERMATOL, V119, P84, DOI 10.1046/j.1523-1747.2002.01655.x; McKenna DB, 1999, BRIT J DERMATOL, V140, P656; Mehrany K, 2002, DERMATOL SURG, V28, P113, DOI 10.1046/j.1524-4725.2002.02901.x; Moore PS, 2000, NEW ENGL J MED, V343, P1411, DOI 10.1056/NEJM200011093431912; Mozzanica N, 1997, J HEART LUNG TRANSPL, V16, P964; Noel JC, 1997, TRANSPLANT INT, V10, P81, DOI 10.1111/j.1432-2277.1997.tb00543.x; O'Connor DP, 2001, J CLIN PATHOL-MOL PA, V54, P165, DOI 10.1136/mp.54.3.165; Otley CC, 2000, DERMATOL SURG, V26, P709, DOI 10.1046/j.1524-4725.2000.00091.x; Otley CC, 2001, ARCH DERMATOL, V137, P459; Ozen S, 1996, NEPHROL DIAL TRANSPL, V11, P1162; Paquet P, 1996, DERMATOLOGY, V192, P411, DOI 10.1159/000246435; Pellet C, 2002, J INFECT DIS, V186, P110, DOI 10.1086/341088; Penn I, 1998, Pediatr Transplant, V2, P56; Penn I, 1996, TRANSPLANTATION, V61, P274, DOI 10.1097/00007890-199601270-00019; PENN I, 1986, CANCER-AM CANCER SOC, V58, P611, DOI 10.1002/1097-0142(19860801)58:3<611::AID-CNCR2820580303>3.0.CO;2-M; Penn I, 1995, TRANSPLANTATION, V60, P1485, DOI 10.1097/00007890-199560120-00020; Penn I, 1997, TRANSPLANTATION, V64, P669, DOI 10.1097/00007890-199709150-00001; Penn I, 1999, TRANSPLANTATION, V68, P1717, DOI 10.1097/00007890-199912150-00015; Pollard JD, 2000, LARYNGOSCOPE, V110, P1257, DOI 10.1097/00005537-200008000-00006; QUNIBI W, 1988, AM J MED, V84, P225, DOI 10.1016/0002-9343(88)90418-4; Ramsay HM, 2002, BRIT J DERMATOL, V147, P950, DOI 10.1046/j.1365-2133.2002.04976.x; Ramsay HM, 2001, J INVEST DERMATOL, V117, P251, DOI 10.1046/j.0022-202x.2001.01357.x; Regamey N, 1998, NEW ENGL J MED, V339, P1358, DOI 10.1056/NEJM199811053391903; Rook AH, 2001, NEW ENGL J MED, V345, P296; ROOK AH, 1995, TRANSPLANTATION, V59, P714, DOI 10.1097/00007890-199503150-00013; Sanchez EQ, 2002, LIVER TRANSPLANT, V8, P285, DOI 10.1053/jlts.2002.29350; SHELL AGR, 1987, TRANSPLANT P, V19, P2214; Shepherd FA, 1997, J CLIN ONCOL, V15, P2371, DOI 10.1200/JCO.1997.15.6.2371; Sillman F H, 1997, Ann Transplant, V2, P59; Stockfleth E, 2002, RECENT RESULTS CANC, V160, P251; Storey A, 1998, NATURE, V393, P229, DOI 10.1038/30400; Tas S, 2000, ANN DERMATOL VENER, V127, P488; Veness MJ, 1999, CANCER, V85, P1758, DOI 10.1002/(SICI)1097-0142(19990415)85:8<1758::AID-CNCR16>3.0.CO;2-F; Webb MC, 1997, TRANSPL P, V29, P828, DOI 10.1016/S0041-1345(96)00152-2; Wehrli BM, 1998, AM J SURG PATHOL, V22, P1154, DOI 10.1097/00000478-199809000-00016; Winkelhorst JT, 2001, EUR J SURG ONCOL, V27, P409, DOI 10.1053/ejso.2001.1119; Woodle ES, 2001, TRANSPL P, V33, P3660, DOI 10.1016/S0041-1345(01)02577-5	100	1125	1159	0	22	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 24	2003	348	17					1681	1691		10.1056/NEJMra022137	http://dx.doi.org/10.1056/NEJMra022137			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	670PB	12711744				2022-12-28	WOS:000182416300009
J	Galagan, JE; Calvo, SE; Borkovich, KA; Selker, EU; Read, ND; Jaffe, D; FitzHugh, W; Ma, LJ; Smirnov, S; Purcell, S; Rehman, B; Elkins, T; Engels, R; Wang, SG; Nielsen, CB; Butler, J; Endrizzi, M; Qui, DY; Ianakiev, P; Pedersen, DB; Nelson, MA; Werner-Washburne, M; Selitrennikoff, CP; Kinsey, JA; Braun, EL; Zelter, A; Schulte, U; Kothe, GO; Jedd, G; Mewes, W; Staben, C; Marcotte, E; Greenberg, D; Roy, A; Foley, K; Naylor, J; Stabge-Thomann, N; Barrett, R; Gnerre, S; Kamal, M; Kamvysselis, M; Mauceli, E; Bielke, C; Rudd, S; Frishman, D; Krystofova, S; Rasmussen, C; Metzenberg, RL; Perkins, DD; Kroken, S; Cogoni, C; Macino, G; Catcheside, D; Li, WX; Pratt, RJ; Osmani, SA; DeSouza, CPC; Glass, L; Orbach, MJ; Berglund, JA; Voelker, R; Yarden, O; Plamann, M; Seiler, S; Dunlap, J; Radford, A; Aramayo, R; Natvig, DO; Alex, LA; Mannhaupt, G; Ebbole, DJ; Freitag, M; Paulsen, I; Sachs, MS; Lander, ES; Nusbaum, C; Birren, B				Galagan, JE; Calvo, SE; Borkovich, KA; Selker, EU; Read, ND; Jaffe, D; FitzHugh, W; Ma, LJ; Smirnov, S; Purcell, S; Rehman, B; Elkins, T; Engels, R; Wang, SG; Nielsen, CB; Butler, J; Endrizzi, M; Qui, DY; Ianakiev, P; Pedersen, DB; Nelson, MA; Werner-Washburne, M; Selitrennikoff, CP; Kinsey, JA; Braun, EL; Zelter, A; Schulte, U; Kothe, GO; Jedd, G; Mewes, W; Staben, C; Marcotte, E; Greenberg, D; Roy, A; Foley, K; Naylor, J; Stabge-Thomann, N; Barrett, R; Gnerre, S; Kamal, M; Kamvysselis, M; Mauceli, E; Bielke, C; Rudd, S; Frishman, D; Krystofova, S; Rasmussen, C; Metzenberg, RL; Perkins, DD; Kroken, S; Cogoni, C; Macino, G; Catcheside, D; Li, WX; Pratt, RJ; Osmani, SA; DeSouza, CPC; Glass, L; Orbach, MJ; Berglund, JA; Voelker, R; Yarden, O; Plamann, M; Seiler, S; Dunlap, J; Radford, A; Aramayo, R; Natvig, DO; Alex, LA; Mannhaupt, G; Ebbole, DJ; Freitag, M; Paulsen, I; Sachs, MS; Lander, ES; Nusbaum, C; Birren, B			The genome sequence of the filamentous fungus Neurospora crassa	NATURE			English	Article							INDUCED POINT MUTATION; YEAST SACCHAROMYCES-CEREVISIAE; DNA METHYLATION; MELANIN BIOSYNTHESIS; COLLETOTRICHUM-LAGENARIUM; SIGNAL-TRANSDUCTION; ADENYLYL-CYCLASE; SMALL RNAS; GENE; RIP	Neurospora crassa is a central organism in the history of twentieth-century genetics, biochemistry and molecular biology. Here, we report a high-quality draft sequence of the N. crassa genome. The approximately 40-megabase genome encodes about 10,000 protein-coding genes-more than twice as many as in the fission yeast Schizosaccharomyces pombe and only about 25% fewer than in the fruitfly Drosophila melanogaster. Analysis of the gene set yields insights into unexpected aspects of Neurospora biology including the identification of genes potentially associated with red light photobiology, genes implicated in secondary metabolism, and important differences in Ca2+ signalling as compared with plants and animals. Neurospora possesses the widest array of genome defence mechanisms known for any eukaryotic organism, including a process unique to fungi called repeat-induced point mutation (RIP). Genome analysis suggests that RIP has had a profound impact on genome evolution, greatly slowing the creation of new genes through genomic duplication and resulting in a genome with an unusually low proportion of closely related genes.	Whitehead Inst, Ctr Genome Res, Cambridge, MA 02141 USA; Univ Calif Riverside, Dept Plant Pathol, Riverside, CA 92521 USA; Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA; Univ Edinburgh, Inst Cell & Mol Biol, Edinburgh EH9 3JH, Midlothian, Scotland; Celara Genom, Rockville, MD 20850 USA; Texas A&M Univ, Dept Biol, College Stn, TX 77843 USA; Univ New Mexico, Dept Biol, Albuquerque, NM 87131 USA; Univ Colorado, Hlth Sci Ctr, Dept Cellular & Struct Biol, Denver, CO 80262 USA; Univ Kansas, Sch Med, Dept Microbiol, Kansas City, KS 66160 USA; Univ Florida, Dept Zool, Gainesville, FL 32611 USA; Hebrew Univ Jerusalem, Dept Plant Pathol & Microbiol, Fac Agr Food & Environm Qual Sci, IL-76100 Rehovot, Israel; Univ Dusseldorf, Inst Biochem, D-40225 Dusseldorf, Germany; Rockefeller Univ, Plant Mol Biol Lab, New York, NY 10021 USA; Tech Univ Munich, Dept Genome Oriented Bioinformat, Wissensch Zentrum Weihenstephan, D-85350 Freising Weihenstephan, Germany; GSF, Natl Res Ctr Environm & Hlth, Inst Bioinformat, D-85764 Neuherberg, Germany; Univ Kentucky, TH Morgan Sch Biol Sci, Lexington, KY 40506 USA; Univ Texas, Inst Cellular & Mol Biol, Austin, TX 78712 USA; Inst Genom Res, Rockville, MD 20878 USA; Univ Calif Berkeley, Dept Plant & Mol Biol, Berkeley, CA 94720 USA; Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Roma La Sapienza, Dipartimento Biotecnol Cellulari & Ematol, Rome, Italy; Flinders Univ S Australia, Sch Biol Sci, Adelaide, SA 5001, Australia; Ohio State Univ, Dept Mol Genet, Columbus, OH 43210 USA; Univ Arizona, Dept Plant Pathol, Tucson, AZ 85721 USA; Univ Missouri, Sch Biol Sci, Kansas City, MO 64110 USA; Dartmouth Coll, Sch Med, Dept Genet, Hanover, NH 03755 USA; Univ Leeds, Sch Biol, Leeds LS2 9JT, W Yorkshire, England; Calif State Polytech Univ Pomona, Dept Chem, Pomona, CA 91768 USA; Texas A&M Univ, Dept Plant Pathol & Microbiol, College Stn, TX 77843 USA; Oregon Hlth & Sci Univ, Dept Environm & Biomol Syst, OGI Sch Sci & Engn, Beaverton, OR 97006 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; Ohio State Univ, Dept Mol Genet, Columbus, OH 43211 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; University of California System; University of California Riverside; University of Oregon; University of Edinburgh; Texas A&M University System; Texas A&M University College Station; University of New Mexico; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Kansas; University of Kansas Medical Center; State University System of Florida; University of Florida; Hebrew University of Jerusalem; Heinrich Heine University Dusseldorf; Rockefeller University; Technical University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Kentucky; University of Texas System; University of Texas Austin; J. Craig Venter Institute; University of California System; University of California Berkeley; University of California System; University of California Los Angeles; Sapienza University Rome; Flinders University South Australia; University System of Ohio; Ohio State University; University of Arizona; University of Missouri System; University of Missouri Kansas City; Dartmouth College; University of Leeds; California State University System; California State Polytechnic University Pomona; Texas A&M University System; Texas A&M University College Station; Oregon Health & Science University; Massachusetts Institute of Technology (MIT); University System of Ohio; Ohio State University	Galagan, JE (corresponding author), Whitehead Inst, Ctr Genome Res, 320 Charles St, Cambridge, MA 02141 USA.	jgalag@mit.edu; bwb@genome.wi.mit.edu	Berglund, Andrew/AAS-1065-2021; Osmani, Stephen A./AAS-3904-2021; Kellis, Manolis/ABE-7385-2020; Bell-Pedersen, Deborah/H-8012-2016; Paulsen, Ian T/K-3832-2012; Frishman, Dmitrij/AAT-7815-2020; Rudd, Stephen A/A-6434-2013; krystofova, svetlana/AAU-8726-2020; Yarden, Oded/J-5988-2012; Ma, Li-Jun/AAG-2359-2020; Staben, Charles/C-1562-2013; Mewes, Hans-Werner/A-8204-2019	Kellis, Manolis/0000-0001-7113-9630; Bell-Pedersen, Deborah/0000-0002-1639-8215; Paulsen, Ian T/0000-0001-9015-9418; Rudd, Stephen A/0000-0002-0344-7487; Engels, Reinhard/0000-0003-0921-0736; , Oded/0000-0002-4722-535X; Sachs, Matthew/0000-0001-9891-9223; Marcotte, Edward/0000-0001-8808-180X; Galagan, James/0000-0003-0542-3291; Mewes, Hans-Werner/0000-0002-9713-6398; krystofova, svetlana/0000-0001-7631-2439; Braun, Edward/0000-0003-1643-5212; Catcheside, David/0000-0002-7101-6849; Aramayo, Rodolfo/0000-0001-9702-6204; Jedd, Gregory/0000-0002-5428-3873; Read, Nick/0000-0002-2286-2862; Ma, Li-Jun/0000-0002-2733-3708	NIGMS NIH HHS [R01 GM058770] Funding Source: Medline; NINDS NIH HHS [P01 NS039546] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058770] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS039546] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adams TH, 1998, MICROBIOL MOL BIOL R, V62, P35, DOI 10.1128/MMBR.62.1.35-54.1998; Aign V, 2001, GENETICS, V157, P1015; Aramayo R, 1996, CELL, V86, P103, DOI 10.1016/S0092-8674(00)80081-1; Aubry L, 1999, ANNU REV CELL DEV BI, V15, P469, DOI 10.1146/annurev.cellbio.15.1.469; Batzoglou S, 2002, GENOME RES, V12, P177, DOI 10.1101/gr.208902; Beadle GW, 1941, P NATL ACAD SCI USA, V27, P499, DOI 10.1073/pnas.27.11.499; Bootman MD, 2001, SEMIN CELL DEV BIOL, V12, P3, DOI 10.1006/scdb.2000.0211; CAMBARERI EB, 1991, GENETICS, V127, P699; CAMBARERI EB, 1989, SCIENCE, V244, P1571, DOI 10.1126/science.2544994; Catalanotto C, 2002, GENE DEV, V16, P790, DOI 10.1101/gad.222402; CORNELIUS G, 1989, BIOCHEM BIOPH RES CO, V162, P852, DOI 10.1016/0006-291X(89)92388-7; Davis R.H., 2000, NEUROSPORA CONTRIBUT; Davis RH, 2002, NAT REV GENET, V3, P397, DOI 10.1038/nrg797; Devlin PF, 2001, ANNU REV PHYSIOL, V63, P677, DOI 10.1146/annurev.physiol.63.1.677; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; Feng B, 2001, INFECT IMMUN, V69, P1781, DOI 10.1128/IAI.69.3.1781-1794.2001; FOSS HM, 1993, SCIENCE, V262, P1737, DOI 10.1126/science.7505062; FREE SJ, 1979, J BACTERIOL, V137, P1219, DOI 10.1128/JB.137.3.1219-1226.1979; Freitag M, 2002, P NATL ACAD SCI USA, V99, P8802, DOI 10.1073/pnas.132212899; Gadd G. M, 1994, GROWING FUNGUS, P183; GIMENO CJ, 1992, CELL, V68, P1077, DOI 10.1016/0092-8674(92)90079-R; Graia F, 2001, MOL MICROBIOL, V40, P586, DOI 10.1046/j.1365-2958.2001.02367.x; Gustin MC, 1998, MICROBIOL MOL BIOL R, V62, P1264, DOI 10.1128/MMBR.62.4.1264-1300.1998; Hutchison CA, 1999, SCIENCE, V286, P2165, DOI 10.1126/science.286.5447.2165; Hutvagner G, 2002, CURR OPIN GENET DEV, V12, P225, DOI 10.1016/S0959-437X(02)00290-3; Ikeda K, 2002, MOL MICROBIOL, V45, P1355, DOI 10.1046/j.1365-2958.2002.03101.x; IRELAN JT, 1994, GENETICS, V138, P1093; Ivey FD, 1999, FUNGAL GENET BIOL, V26, P48, DOI 10.1006/fgbi.1998.1101; Ivey FD, 2002, EUKARYOT CELL, V1, P634, DOI 10.1128/EC.1.4.634-642.2002; Josefsson LG, 1997, EUR J BIOCHEM, V249, P415, DOI 10.1111/j.1432-1033.1997.t01-1-00415.x; Kelkar HS, 2001, GENETICS, V157, P979; KLEIN PS, 1988, SCIENCE, V241, P1467, DOI 10.1126/science.3047871; Kouzminova E, 2001, EMBO J, V20, P4309, DOI 10.1093/emboj/20.15.4309; Kurosawa E., 1926, T NAT HIST SOC FORMO, V16, P213; LAKINTHOMAS PL, 1993, BIOCHEM J, V292, P805, DOI 10.1042/bj2920805; LEE DW, IN PRESS GENETICS; Lengeler KB, 2000, MICROBIOL MOL BIOL R, V64, P746, DOI 10.1128/MMBR.64.4.746-785.2000; Lindegren CC, 1936, J GENET, V32, P243, DOI 10.1007/BF02982680; Linden H, 1999, ADV GENET, V41, P35, DOI 10.1016/S0065-2660(08)60150-9; LU SW, 2001, FUNGAL GENET NEWS, V48, pA246; LUO ZG, 1995, MOL CELL BIOL, V15, P5235; Margolin BS, 1998, GENETICS, V149, P1787; Nelson MA, 1997, FUNGAL GENET BIOL, V21, P348, DOI 10.1006/fgbi.1997.0986; Ohno S., 1970, EVOLUTION GENE DUPLI; Payen A. de, 1843, ANN CHIM PHYS, V9, P5; Perkins D., 2001, NEUROSPORA COMPENDIU; Perkins DD, 1997, GENETICS, V147, P125; Pickford A, 2003, CURR GENET, V42, P220, DOI 10.1007/s00294-002-0351-6; Pott GB, 2000, FUNGAL GENET BIOL, V31, P55, DOI 10.1006/fgbi.2000.1225; Rountree MR, 1997, GENE DEV, V11, P2383, DOI 10.1101/gad.11.18.2383; RUSSELL PJ, 1987, J BACTERIOL, V169, P2902, DOI 10.1128/jb.169.6.2902-2905.1987; Schulte U, 2002, J BIOTECHNOL, V94, P3, DOI 10.1016/S0168-1656(01)00415-1; SELKER EU, 1981, CELL, V24, P819, DOI 10.1016/0092-8674(81)90107-0; SELKER EU, 1987, CELL, V51, P741, DOI 10.1016/0092-8674(87)90097-3; SELKER EU, 1993, SCIENCE, V262, P1724, DOI 10.1126/science.8259516; Selker EU, 2003, NATURE, V422, P893, DOI 10.1038/nature01564; SELKER EU, 1990, ANNU REV GENET, V24, P579, DOI 10.1146/annurev.ge.24.120190.003051; Shear CL, 1927, J AGRIC RES, V34, P1019; Shiu PKT, 2002, GENETICS, V161, P1483; Shiu PKT, 2001, CELL, V107, P905, DOI 10.1016/S0092-8674(01)00609-2; Silverman-Gavrila LB, 2001, EUR J CELL BIOL, V80, P379, DOI 10.1078/0171-9335-00175; SINGER MJ, 1995, MOL CELL BIOL, V15, P5586; TAKANO Y, 1995, MOL GEN GENET, V249, P162, DOI 10.1007/BF00290362; Takano Y, 1997, FUNGAL GENET BIOL, V21, P131, DOI 10.1006/fgbi.1997.0963; *TIDR, 2003, MICR DAT; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; VIGFUSSON NV, 1974, NATURE, V249, P383, DOI 10.1038/249383a0; Watters MK, 1999, GENETICS, V153, P705; Wolffe AP, 1999, SCIENCE, V286, P481, DOI 10.1126/science.286.5439.481; Yuan WM, 2001, J BACTERIOL, V183, P4040, DOI 10.1128/JB.183.13.4040-4051.2001; Zamore PD, 2002, SCIENCE, V296, P1265, DOI 10.1126/science.1072457; 2002, FUNGAL GENOME INITIA	72	1214	2171	0	207	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 24	2003	422	6934					859	868		10.1038/nature01554	http://dx.doi.org/10.1038/nature01554			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	670WR	12712197	Green Submitted, hybrid			2022-12-28	WOS:000182432600046
J	Griffith, SC; Montgomerie, R				Griffith, SC; Montgomerie, R			Why do birds engage in extra-pair copulation?	NATURE			English	Article							GENETIC SIMILARITY		Univ Oxford, Dept Zool, Edward Grey Inst, Oxford OX1 3PS, England; Queens Univ, Dept Biol, Kingston, ON K7L 3N6, Canada	University of Oxford; Queens University - Canada	Griffith, SC (corresponding author), Univ Oxford, Dept Zool, Edward Grey Inst, S Parks Rd, Oxford OX1 3PS, England.		Montgomerie, Robert D/C-6516-2008; Griffith, Simon/A-1996-2010; Griffith, Simon/AAH-3706-2021; Sandercock, Brett/L-1644-2016	Montgomerie, Robert D/0000-0003-4701-4525; Griffith, Simon/0000-0001-7612-4999; Griffith, Simon/0000-0001-7612-4999; Kis, Janos/0000-0001-9354-1292; Sandercock, Brett/0000-0002-9240-0268				Alves MAS, 1998, ANIM BEHAV, V56, P1323, DOI 10.1006/anbe.1998.0910; BENSCH S, 1994, EVOLUTION, V48, P317, DOI 10.1111/j.1558-5646.1994.tb01314.x; Blomqvist D, 2002, NATURE, V419, P613, DOI 10.1038/nature01104; Griffith SC, 2002, MOL ECOL, V11, P2195, DOI 10.1046/j.1365-294X.2002.01613.x; Keller LF, 1998, AM NAT, V152, P380, DOI 10.1086/286176; MEE A, IN PRESS ANIM BEHAV; Petrie M, 1999, NATURE, V401, P155, DOI 10.1038/43651; QUELLER DC, 1993, TRENDS ECOL EVOL, V8, P285, DOI 10.1016/0169-5347(93)90256-O; Reeve HK, 1992, MOL ECOL, V1, P223, DOI 10.1111/j.1365-294X.1992.tb00181.x	9	26	26	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 24	2003	422	6934					833	833		10.1038/422833b	http://dx.doi.org/10.1038/422833b			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	670WR	12712192				2022-12-28	WOS:000182432600040
J	Grant, CC; Roberts, M; Scragg, R; Stewart, J; Lennon, D; Kivell, D; Ford, R; Menzies, R				Grant, CC; Roberts, M; Scragg, R; Stewart, J; Lennon, D; Kivell, D; Ford, R; Menzies, R			Delayed immunisation and risk of pertussis in infants: unmatched case-control study	BRITISH MEDICAL JOURNAL			English	Article							IMMUNIZATION		Univ Auckland, Fac Med & Hlth Sci, Dept Paediat, Auckland 1, New Zealand; Univ Auckland, Fac Med & Hlth Sci, Dept Community Hlth, Auckland 1, New Zealand; S Auckland Hlth, Auckland, New Zealand; Canterbury Dist Hlth Board, Christchurch, New Zealand; Auckland Dist Hlth Board, Auckland, New Zealand	University of Auckland; University of Auckland; Auckland District Health Board	Grant, CC (corresponding author), Univ Auckland, Fac Med & Hlth Sci, Dept Paediat, Private Bag 92019, Auckland 1, New Zealand.			Scragg, Robert/0000-0003-0013-2620; Grant, Cameron/0000-0002-4032-7230				CRAMPTON P, 1998, NZ PUBLIC HLTH REPOR, V5, P81; DIETZ VJ, 1993, PEDIATR INFECT DIS J, V12, P353, DOI 10.1097/00006454-199304000-00022; Guris D, 1999, CLIN INFECT DIS, V28, P1230, DOI 10.1086/514776; POLLOCK TM, 1984, ARCH DIS CHILD, V59, P162, DOI 10.1136/adc.59.2.162; REID S, 1994, NEW ZEAL MED J, V107, P460	5	77	77	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 19	2003	326	7394					852	853		10.1136/bmj.326.7394.852	http://dx.doi.org/10.1136/bmj.326.7394.852			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	670BF	12702617	Green Published, Bronze			2022-12-28	WOS:000182386800017
J	Howard, J; Hyman, AA				Howard, J; Hyman, AA			Dynamics and mechanics of the microtubule plus end	NATURE			English	Review							SLOWLY HYDROLYZABLE ANALOG; XENOPUS EGG EXTRACTS; CENTROMERE-ASSOCIATED KINESIN; MITOTIC SPINDLE; GTP HYDROLYSIS; STRUCTURAL-CHANGES; FISSION YEAST; BUDDING YEAST; LIVING CELLS; IN-VIVO	An important function of microtubules is to move cellular structures such as chromosomes, mitotic spindles and other organelles around inside cells. This is achieved by attaching the ends of microtubules to cellular structures; as the microtubules grow and shrink, the structures are pushed or pulled around the cell. How do the ends of microtubules couple to cellular structures, and how does this coupling regulate the stability and distribution of the microtubules? It is now clear that there are at least three properties of a microtubule end: it has alternate structures; it has a biochemical transition defined by GTP hydrolysis; and it forms a distinct target for the binding of specific proteins. These different properties can be unified by thinking of the microtubule as a molecular machine, which switches between growing and shrinking modes. Each mode is associated with a specific end structure on which end-binding proteins can assemble to modulate dynamics and couple the dynamic properties of microtubules to the movement of cellular structures.	Max Planck Inst Mol Cell Biol & Genet, D-01307 Dresden, Germany	Max Planck Society	Howard, J (corresponding author), Max Planck Inst Mol Cell Biol & Genet, Pfotenhauerstr 108, D-01307 Dresden, Germany.		Howard, Jonathon/D-4229-2011; Howard, Jonathon/J-7492-2016; Hyman, Tony/F-1923-2011; Hyman, Anthony A/B-3917-2017	Howard, Jonathon/0000-0003-0086-1196; Howard, Jonathon/0000-0003-0086-1196; Hyman, Anthony A/0000-0003-3664-154X				Akhmanova A, 2001, CELL, V104, P923, DOI 10.1016/S0092-8674(01)00288-4; Andersen SSL, 2000, TRENDS CELL BIOL, V10, P261, DOI 10.1016/S0962-8924(00)01786-4; Arnal I, 2000, J CELL BIOL, V149, P767, DOI 10.1083/jcb.149.4.767; BELMONT LD, 1990, CELL, V62, P579, DOI 10.1016/0092-8674(90)90022-7; Brunner D, 2000, CELL, V102, P695, DOI 10.1016/S0092-8674(00)00091-X; Caplow M, 1996, MOL BIOL CELL, V7, P663, DOI 10.1091/mbc.7.4.663; CASSIMERIS L, 1988, J CELL BIOL, V107, P2223, DOI 10.1083/jcb.107.6.2223; CHRETIEN D, 1995, J CELL BIOL, V129, P1311, DOI 10.1083/jcb.129.5.1311; COUE M, 1991, J CELL BIOL, V112, P1165, DOI 10.1083/jcb.112.6.1165; Desai A, 1997, ANNU REV CELL DEV BI, V13, P83, DOI 10.1146/annurev.cellbio.13.1.83; Desai A, 1999, CELL, V96, P69, DOI 10.1016/S0092-8674(00)80960-5; Doe CQ, 2001, CURR OPIN CELL BIOL, V13, P68, DOI 10.1016/S0955-0674(00)00176-9; Dogterom M, 1997, SCIENCE, V278, P856, DOI 10.1126/science.278.5339.856; Doxsey S, 2001, NAT REV MOL CELL BIO, V2, P688, DOI 10.1038/35089575; DRECHSEL DN, 1995, CURR BIOL, V5, P215; ERICKSON HP, 1992, ANNU REV BIOPH BIOM, V21, P145, DOI 10.1146/annurev.bb.21.060192.001045; Faivre-Moskalenko C, 2002, P NATL ACAD SCI USA, V99, P16788, DOI 10.1073/pnas.252407099; Fygenson DK, 1997, PHYS REV LETT, V79, P4497, DOI 10.1103/PhysRevLett.79.4497; Geeves MA, 1999, ANNU REV BIOCHEM, V68, P687, DOI 10.1146/annurev.biochem.68.1.687; Gigant B, 2000, CELL, V102, P809, DOI 10.1016/S0092-8674(00)00069-6; Gonczy P, 2002, TRENDS CELL BIOL, V12, P332, DOI 10.1016/S0962-8924(02)02306-1; HAYDEN JH, 1990, J CELL BIOL, V111, P1039, DOI 10.1083/jcb.111.3.1039; He XW, 2001, CELL, V106, P195, DOI 10.1016/S0092-8674(01)00438-X; Hildebrandt ER, 2000, BBA-MOL CELL RES, V1496, P99, DOI 10.1016/S0167-4889(00)00012-4; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; Holy TE, 1997, P NATL ACAD SCI USA, V94, P6228, DOI 10.1073/pnas.94.12.6228; Howard J., 2001, MECH MOTOR PROTEINS; HUNTER AW, IN PRESS MOL CELL; Hyman AA, 1996, CELL, V84, P401, DOI 10.1016/S0092-8674(00)81285-4; HYMAN AA, 1992, MOL BIOL CELL, V3, P1155, DOI 10.1091/mbc.3.10.1155; HYMAN AA, 1995, J CELL BIOL, V128, P117, DOI 10.1083/jcb.128.1.117; INOUE S, 1995, MOL BIOL CELL, V6, P1619, DOI 10.1091/mbc.6.12.1619; Janosi IM, 2002, BIOPHYS J, V83, P1317, DOI 10.1016/S0006-3495(02)73902-7; Karsenti E, 1991, Semin Cell Biol, V2, P251; Karsenti E, 2001, SCIENCE, V294, P543, DOI 10.1126/science.1063488; Kim AJ, 2000, J CELL SCI, V113, P3681; Kinoshita K, 2002, TRENDS CELL BIOL, V12, P267, DOI 10.1016/S0962-8924(02)02295-X; Kinoshita K, 2001, SCIENCE, V294, P1340, DOI 10.1126/science.1064629; KIRSCHNER M, 1986, CELL, V45, P329, DOI 10.1016/0092-8674(86)90318-1; Komarova YA, 2002, J CELL BIOL, V159, P589, DOI 10.1083/jcb.200208058; Komarova YA, 2002, J CELL SCI, V115, P3527; Kusch J, 2002, GENE DEV, V16, P1627, DOI 10.1101/gad.222602; Lawrence CJ, 2002, J MOL EVOL, V54, P42, DOI 10.1007/s00239-001-0016-y; Lee L, 2000, SCIENCE, V287, P2260, DOI 10.1126/science.287.5461.2260; Liakopoulos D, 2003, CELL, V112, P561, DOI 10.1016/S0092-8674(03)00119-3; Lin HJ, 2001, J CELL BIOL, V155, P1173, DOI 10.1083/jcb.200108119; Loisel TP, 1999, NATURE, V401, P613, DOI 10.1038/44183; Maekawa H, 2003, EMBO J, V22, P438, DOI 10.1093/emboj/cdg063; MANDELKOW EM, 1991, J CELL BIOL, V114, P977, DOI 10.1083/jcb.114.5.977; Maney T, 1998, J CELL BIOL, V142, P787, DOI 10.1083/jcb.142.3.787; Maney T, 2001, J BIOL CHEM, V276, P34753, DOI 10.1074/jbc.M106626200; MEADS T, 1995, CELL MOTIL CYTOSKEL, V32, P273, DOI 10.1002/cm.970320404; MELKI R, 1989, BIOCHEMISTRY-US, V28, P9143, DOI 10.1021/bi00449a028; Mimori-Kiyosue Y, 2001, J CELL BIOL, V154, P1105, DOI 10.1083/jcb.200106113; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; MITCHISON TJ, 1993, SCIENCE, V261, P1044, DOI 10.1126/science.8102497; Moores CA, 2002, MOL CELL, V9, P903, DOI 10.1016/S1097-2765(02)00503-8; Muller-Reichert T, 1998, P NATL ACAD SCI USA, V95, P3661, DOI 10.1073/pnas.95.7.3661; Niederstrasser H, 2002, J MOL BIOL, V316, P817, DOI 10.1006/jmbi.2001.5360; Nogales E, 1999, CELL, V96, P79, DOI 10.1016/S0092-8674(00)80961-7; Perez F, 1999, CELL, V96, P517, DOI 10.1016/S0092-8674(00)80656-X; Rieder CL, 1998, TRENDS CELL BIOL, V8, P310, DOI 10.1016/S0962-8924(98)01299-9; SAMMAK PJ, 1988, NATURE, V332, P724, DOI 10.1038/332724a0; Sawin KE, 2000, CURR BIOL, V10, pR860, DOI 10.1016/S0960-9822(00)00819-8; Schroer TA, 2001, CURR OPIN CELL BIOL, V13, P92, DOI 10.1016/S0955-0674(00)00179-4; Schuyler SC, 2001, CELL, V105, P421, DOI 10.1016/S0092-8674(01)00364-6; Small JV, 2003, CURR OPIN CELL BIOL, V15, P40, DOI 10.1016/S0955-0674(02)00008-X; Tassin AM, 1999, BIOL CELL, V91, P343, DOI 10.1016/S0248-4900(99)80095-1; Tirnauer JS, 2000, J CELL BIOL, V149, P761, DOI 10.1083/jcb.149.4.761; Tirnauer JS, 2002, MOL BIOL CELL, V13, P3614, DOI 10.1091/mbc.E02-04-0210; Tournebize R, 2000, NAT CELL BIOL, V2, P13, DOI 10.1038/71330; Tran PT, 2001, J CELL BIOL, V153, P397, DOI 10.1083/jcb.153.2.397; Vale RD, 2000, SCIENCE, V288, P88, DOI 10.1126/science.288.5463.88; Valetti C, 1999, MOL BIOL CELL, V10, P4107, DOI 10.1091/mbc.10.12.4107; Vinh DBN, 2002, MOL BIOL CELL, V13, P1144, DOI 10.1091/mbc.02-01-0607; Walczak CE, 1996, CELL, V84, P37, DOI 10.1016/S0092-8674(00)80991-5; Yeh E, 2000, MOL BIOL CELL, V11, P3949, DOI 10.1091/mbc.11.11.3949	77	560	581	2	107	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 17	2003	422	6933					753	758		10.1038/nature01600	http://dx.doi.org/10.1038/nature01600			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	668CG	12700769				2022-12-28	WOS:000182272300049
J	Park, SJ; Shim, WH; Ho, DS; Raizner, AE; Park, SW; Hong, MK; Lee, CW; Choi, DH; Jang, YS; Lam, R; Weissman, NJ; Mintz, GS				Park, SJ; Shim, WH; Ho, DS; Raizner, AE; Park, SW; Hong, MK; Lee, CW; Choi, DH; Jang, YS; Lam, R; Weissman, NJ; Mintz, GS			A paclitaxel-eluting stent for the prevention of coronary restenosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ANGIOGRAPHIC FOLLOW-UP; INTRAVASCULAR ULTRASOUND; IN-VIVO; ANGIOPLASTY; CILOSTAZOL; DELIVERY; TAXOL; PROLIFERATION; HYPERPLASIA; TICLOPIDINE	BACKGROUND: Intimal hyperplasia and resulting restenosis limit the efficacy of coronary stenting. We studied a coronary stent coated with the antiproliferative agent paclitaxel as a means of preventing restenosis. METHODS: We conducted a multicenter, randomized, controlled, triple-blind study to evaluate the ability of a paclitaxel-eluting stent to inhibit restenosis. At three centers, 177 patients with discrete coronary lesions (<15 mm in length, 2.25 to 3.5 mm in diameter) underwent implantation of paclitaxel-eluting stents (low dose, 1.3 microg per square millimeter, or high dose, 3.1 microg per square millimeter) or control stents. Antiplatelet therapies included aspirin with ticlopidine (120 patients), clopidogrel (18 patients), or cilostazol (37 patients). Clinical follow-up was performed at one month and four to six months, and angiographic follow-up at four to six months. RESULTS: Technical success was achieved in 99 percent of the patients (176 of 177). At follow-up, the high-dose group, as compared with the control group, had significantly better results for the degree of stenosis (mean [+/-SD], 14+/-21 percent vs. 39+/-27 percent; P<0.001), late loss of luminal diameter (0.29+/-0.72 mm vs. 1.04+/-0.83 mm, P<0.001), and restenosis of more than 50 percent (4 percent vs. 27 percent, P<0.001). Intravascular ultrasound analysis demonstrated a dose-dependent reduction in the volume of intimal hyperplasia (31, 18, and 13 mm(sup 3), in the high-dose, low-dose, and control groups, respectively). There was a higher rate of major cardiac events in patients receiving cilostazol than in those receiving ticlopidine or clopidogrel. Among patients receiving ticlopidine or clopidogrel, event-free survival was 98 percent and 100 percent in the high-dose and control groups, respectively, at one month, and 96 percent in both at four to six months. CONCLUSIONS: Paclitaxel-eluting stents used with conventional antiplatelet therapy effectively inhibit restenosis and neointimal hyperplasia, with a safety profile similar to that of standard stents.	Asan Med Ctr, Div Cardiol, Seoul 138736, South Korea; Yonsei Med Ctr, Seoul, South Korea; Univ Hong Kong, Hong Kong, Hong Kong, Peoples R China; Cardiovasc Angiog Anal Lab, Houston, TX USA; Washington Hosp Ctr, Cardiovasc Res Inst, Washington, DC 20010 USA; Cardiovasc Res Fdn, New York, NY USA	University of Ulsan; Asan Medical Center; University of Hong Kong; MedStar Washington Hospital Center; Cardiovascular Research Foundation (CRF)	Park, SJ (corresponding author), Asan Med Ctr, Div Cardiol, 388-1 Poongnap Dong, Seoul 138736, South Korea.		Webb, Delores D/G-3047-2010	Choi, Donghoon/0000-0002-2009-9760; Jang, Yangsoo/0000-0002-2169-3112				Axel DI, 1997, CIRCULATION, V96, P636; Condado J A, 1999, Cardiovasc Radiat Med, V1, P30, DOI 10.1016/S1522-1865(98)00014-6; de Feyter PJ, 2000, Curr Interv Cardiol Rep, V2, P326; Farb A, 2001, CIRCULATION, V104, P473, DOI 10.1161/hc3001.092037; HANKE H, 1995, EUR HEART J, V16, P785, DOI 10.1093/oxfordjournals.eurheartj.a060997; Heldman AW, 2001, CIRCULATION, V103, P2289; Herdeg C, 2000, J AM COLL CARDIOL, V35, P1969, DOI 10.1016/S0735-1097(00)00614-8; Hermiller JB, 1996, AM J CARDIOL, V77, P247, DOI 10.1016/S0002-9149(97)89387-3; Hoffmann R, 1996, CIRCULATION, V94, P1247, DOI 10.1161/01.CIR.94.6.1247; Kimura T, 2002, CIRCULATION, V105, P2986, DOI 10.1161/01.CIR.0000019743.11941.3B; KUNTZ RE, 1992, CIRCULATION, V86, P1827, DOI 10.1161/01.CIR.86.6.1827; Lee JH, 2001, CLIN CARDIOL, V24, P551, DOI 10.1002/clc.4960240806; Lowe HC, 2002, J AM COLL CARDIOL, V39, P183, DOI 10.1016/S0735-1097(01)01742-9; Moreno PR, 1999, AM J CARDIOL, V84, P462, DOI 10.1016/S0002-9149(99)00334-3; Morice M, 2002, NEW ENGL J MED, V346, P1773, DOI 10.1056/NEJMoa012843; Ormiston JA, 1997, CIRCULATION, V96, P468; Park SW, 1999, AM J CARDIOL, V84, P511, DOI 10.1016/S0002-9149(99)00368-9; Park SW, 2000, AM J CARDIOL, V86, P499, DOI 10.1016/S0002-9149(00)01001-8; Rensing BJ, 2001, EUR HEART J, V22, P2125, DOI 10.1053/euhj.2001.2892; ROWINSKY EK, 1995, NEW ENGL J MED, V333, P75; ROWINSKY EK, 1993, SEMIN ONCOL, V20, P1; ROWINSKY EK, 1990, JNCI-J NATL CANCER I, V82, P1247, DOI 10.1093/jnci/82.15.1247; ROWINSKY EK, 1995, NEW ENGL J MED, V332, P1004, DOI 10.1056/NEJM199504133321507; SHIFF PB, 1979, NATURE, V277, P665; SOLLOTT SJ, 1995, J CLIN INVEST, V95, P1869, DOI 10.1172/JCI117867; Sousa JE, 2001, CIRCULATION, V104, P2007, DOI 10.1161/hc4201.098056; Teirstein PS, 2000, CIRCULATION, V101, P360, DOI 10.1161/01.CIR.101.4.360; Weissman NJ, 2001, AM J CARDIOL, V88, P248, DOI 10.1016/S0002-9149(01)01635-6; Yoon YS, 1999, AM J CARDIOL, V84, P1375, DOI 10.1016/S0002-9149(99)00579-2	29	333	364	1	18	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 17	2003	348	16					1537	1545		10.1056/NEJMoa021007	http://dx.doi.org/10.1056/NEJMoa021007			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	667TT	12700373	Green Published, Bronze			2022-12-28	WOS:000182248900004
J	Yueh, B; Shapiro, N; MacLean, CH; Shekelle, PG				Yueh, B; Shapiro, N; MacLean, CH; Shekelle, PG			Screening and management of adult hearing loss in primary care - Scientific review	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							QUALITY-OF-LIFE; COST-UTILITY; OTITIS-MEDIA; OLDER-ADULTS; COGNITIVE DYSFUNCTION; SYSTEMIC STEROIDS; COCHLEAR IMPLANT; IMPAIRMENT; OTOTOXICITY; PREVALENCE	Context Hearing loss is the third most prevalent chronic condition in older adults and has important effects on their physical and mental health. Despite these effects, most older patients are not assessed or treated for hearing loss. Objective To review the evidence on screening and management of hearing loss of older adults in the primary care setting. Data Sources and Study Selection We performed a search from 1985 to 2001 using MEDLINE, HealthSTAR, EMBASE, Ageline, and the National Guideline Clearinghouse for articles and practice guidelines about screening and management of hearing loss in older adults, as well as reviewed references in these articles and those suggested by experts in hearing impairment. Data Extraction We reviewed articles for the most clinically important information, emphasizing randomized clinical trials, where available, and identified 1595 articles. Data Synthesis Screening tests that reliably detect hearing loss are use of an audioscope, a hand-held combination otoscope and audiometer, and a self-administered questionnaire, the Hearing Handicap Inventory for the Elderly-Screening version. The value of routine screening for improving patient outcomes has not been evaluated in a randomized clinical trial. Screening is endorsed by most professional organizations, including the US Preventive Services Task Force. While most hearing loss in older adults is sensorineural and due to presbycusis, cerumen impaction and chronic otitis media may be present in up to 30% of elderly patients with hearing loss and can be treated by the primary care clinician. In randomized trials, hearing aids have been demonstrated to improve outcomes for patients with sensorineural hearing loss. Nonadherence to use of hearing aids is high. Prompt recognition of potentially reversible causes of hearing loss, such as sudden sensorineural hearing loss, is important to maximize the possibility of functional recovery. Conclusion While untested in a clinical trial, older adults can be screened for hearing loss using simple methods, and effective treatments exist and are available for many forms of hearing loss.	Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Dept Otolaryngol Head & Neck Surg, Seattle, WA 98108 USA; Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Dept Hlth Serv, Seattle, WA 98108 USA; RAND Hlth, Santa Monica, CA USA; Univ Calif Los Angeles, Div Head & Neck Surg, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Div Rheumatol, Los Angeles, CA 90024 USA; Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA USA	University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; RAND Corporation; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System	Yueh, B (corresponding author), Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Dept Otolaryngol Head & Neck Surg, 1660 S Columbian Way,Surg Sect 112OTO, Seattle, WA 98108 USA.	byueh@u.washington.edu		Yueh, Bevan/0000-0003-1380-1053				Alexiou C, 2001, ARCH OTOLARYNGOL, V127, P253, DOI 10.1001/archotol.127.3.253; [Anonymous], 1994, CAN GUID CLIN PREV H, VCanadian Task Force on the Periodic Health and Examination; Appollonio I, 1996, AGE AGEING, V25, P89, DOI 10.1093/ageing/25.2.89; Begg EJ, 2001, BRIT J CLIN PHARMACO, V52, p35S; BENTLER RA, IN PRESS EAR HEAR; Bichey BG, 2002, OTOL NEUROTOL, V23, P323, DOI 10.1097/00129492-200205000-00016; BRIEN JA, 1993, DRUG SAFETY, V9, P143, DOI 10.2165/00002018-199309020-00006; BRUMMETT RE, 1993, OTOLARYNG CLIN N AM, V26, P811; BRUMMETT RE, 1993, OTOLARYNG CLIN N AM, V26, P821; Butler CC, 2001, ARCH PEDIAT ADOL MED, V155, P641, DOI 10.1001/archpedi.155.6.641; CADMAN D, 1984, JAMA-J AM MED ASSOC, V251, P1580, DOI 10.1001/jama.251.12.1580; CAMPBELL KCM, 1993, OTOLARYNG CLIN N AM, V26, P903; CARABELLESE C, 1993, J AM GERIATR SOC, V41, P401, DOI 10.1111/j.1532-5415.1993.tb06948.x; Cheng AK, 1999, ARCH OTOLARYNGOL, V125, P1214, DOI 10.1001/archotol.125.11.1214; Cheng AK, 2000, JAMA-J AM MED ASSOC, V284, P850, DOI 10.1001/jama.284.7.850; CIURLIAGUY E, 1993, GERONTOLOGIST, V33, P644, DOI 10.1093/geront/33.5.644; DELBO M, 1987, LARYNGOSCOPE, V97, P1211; Eisenman DJ, 2000, ARCH OTOLARYNGOL, V126, P1161, DOI 10.1001/archotol.126.9.1161; FARRARIO F, 1997, ACTA OTORHINOLOARYNG, V17, P419; Friedman RA, 2001, OTOLARYNG HEAD NECK, V125, P544, DOI 10.1067/mhn.2001.119675; Garcia VP, 2001, ACTA OTO-LARYNGOL, V121, P569, DOI 10.1080/000164801316878836; Gates GA, 1996, ARCH OTOLARYNGOL, V122, P161; GATES GA, 1990, EAR HEARING, V11, P247, DOI 10.1097/00003446-199008000-00001; GUILD S, 1944, ANN OTOL, V53, P245; GURLAND B, 1977, INT J AGING HUM DEV, V8, P9, DOI 10.2190/CL3J-0E20-97XX-MV5L; Hashisaki GT, 2000, ARCH OTOLARYNGOL, V126, P1165, DOI 10.1001/archotol.126.9.1165; HENRICHSEN J, 1988, SCAND AUDIOL, V17, P209, DOI 10.3109/01050398809070706; HERBST KG, 1980, BMJ-BRIT MED J, V281, P903, DOI 10.1136/bmj.281.6245.903; Jerger J, 1996, EAR HEARING, V17, P490, DOI 10.1097/00003446-199612000-00005; JERGER J, 1995, J AM GERIATR SOC, V43, P928, DOI 10.1111/j.1532-5415.1995.tb05539.x; Kaplan H, 1996, J Am Acad Audiol, V7, P203; KAY DWK, 1964, BRIT J PSYCHIAT, V110, P668, DOI 10.1192/bjp.110.468.668; Kochkin S, 1997, HEARING J, V50, P31; Kochkin S., 2000, HEAR J, V53, P34, DOI [10.1097/00025572-200002000-00004, DOI 10.1097/00025572-200002000-00004]; Laforge R.G., 1992, J AGING HEALTH, V4, P126, DOI [10.1177/089826439200400108, DOI 10.1177/089826439200400108]; LEWISCULLINAN C, 1990, J ADV NURS, V15, P594, DOI 10.1111/j.1365-2648.1990.tb01859.x; LICHTENSTEIN MJ, 1988, JAMA-J AM MED ASSOC, V259, P2875, DOI 10.1001/jama.259.19.2875; LICHTENSTEIN MJ, 1988, EAR HEARING, V9, P208, DOI 10.1097/00003446-198808000-00006; Loovis CF, 1997, OTOLARYNG CLIN N AM, V30, P803; MACPHEE GJA, 1988, AGE AGEING, V17, P347, DOI 10.1093/ageing/17.5.347; Matteson M A, 1993, Geriatr Nurs, V14, P294, DOI 10.1016/S0197-4572(06)80053-4; MAY A E, 1990, British Journal of Audiology, V24, P301, DOI 10.3109/03005369009076570; MCBRIDE WS, 1994, AM J MED SCI, V307, P40, DOI 10.1097/00000441-199401000-00007; MOSCICKI EK, 1985, EAR HEARING, V6, P184, DOI 10.1097/00003446-198507000-00003; MULROW CD, 1990, ANN INTERN MED, V113, P188, DOI 10.7326/0003-4819-113-3-188; MULROW CD, 1990, J AM GERIATR SOC, V38, P45, DOI 10.1111/j.1532-5415.1990.tb01595.x; MULROW CD, 1992, J SPEECH HEAR RES, V35, P1402, DOI 10.1044/jshr.3506.1402; MULROW CD, 1990, EAR HEARING, V11, P176, DOI 10.1097/00003446-199006000-00002; MULROW CD, 1991, J GEN INTERN MED, V6, P249, DOI 10.1007/BF02598971; Nielsen C, 1999, MED CLIN N AM, V83, P1323, DOI 10.1016/S0025-7125(05)70169-3; OVEGARD A, 1994, SCAND AUDIOL, V23, P57, DOI 10.3109/01050399409047486; Palmer CS, 1999, ARCH OTOLARYNGOL, V125, P1221, DOI 10.1001/archotol.125.11.1221; PARVING A, 1991, AUDIOLOGY, V30, P61; Popelka MM, 1998, J AM GERIATR SOC, V46, P1075, DOI 10.1111/j.1532-5415.1998.tb06643.x; RAHKO T, 1985, ANN OTO RHINOL LARYN, V94, P140, DOI 10.1177/000348948509400208; Reuben DB, 1998, J AM GERIATR SOC, V46, P1008, DOI 10.1111/j.1532-5415.1998.tb02758.x; Ries P W, 1994, Vital Health Stat 10, P1; RINTELMANN WF, 1990, HEARING ASSESSMENT; ROSENFELD RM, 1991, ARCH OTOLARYNGOL, V117, P984; RYBAK LP, 1993, OTOLARYNG CLIN N AM, V26, P829; SAUNDERS JE, 1995, OTOLARYNG HEAD NECK, V113, P23, DOI 10.1016/S0194-5998(95)70140-0; SCHWEITZER VG, 1993, OTOLARYNG CLIN N AM, V26, P759; Stephens S D, 1990, Acta Otolaryngol Suppl, V476, P281; Stokroos RJ, 1998, ACTA OTO-LARYNGOL, V118, P488, DOI 10.1080/00016489850154603; STOOL SE, 1994, AHCPR PUBLICATION; TONNING F, 1991, SCAND AUDIOL, V20, P69, DOI 10.3109/01050399109070793; Tucci DL, 2000, ARCH OTOLARYNGOL, V126, P1164, DOI 10.1001/archotol.126.9.1164; Tucci DL, 2002, OTOL NEUROTOL, V23, P301, DOI 10.1097/00129492-200205000-00012; UHLMANN RF, 1989, JAMA-J AM MED ASSOC, V261, P1916, DOI 10.1001/jama.261.13.1916; UHLMANN RF, 1989, J GEN INTERN MED, V4, P90, DOI 10.1007/BF02602346; UPFOLD L J, 1990, British Journal of Audiology, V24, P311, DOI 10.3109/03005369009076571; *US DEP COMM, 1997, STAT ABSTR US; *US DEP HHS CDC NA, 1997, HLTH PEOPL 2000 REV; US Preventive Services Task Force, 1996, GUID CLIN PREV SERV, P18; Valente M, 1999, J AM ACAD AUDIOL, V10, P133; VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625; VARTIAINEN E, 1995, AM J OTOL, V16, P536; Ventry I M, 1983, ASHA, V25, P37; Wallhagen MI, 1997, AM J PUBLIC HEALTH, V87, P440, DOI 10.2105/AJPH.87.3.440; Weinstein B E, 1986, ASHA, V28, P41; WILLIAMS RL, 1993, JAMA-J AM MED ASSOC, V270, P1344, DOI 10.1001/jama.270.11.1344; Williamson Ian, 2002, Clin Evid, P469; WILSON WR, 1980, ARCH OTOLARYNGOL, V106, P772; Yueh B, 2000, ARCH OTOLARYNGOL, V126, P1394, DOI 10.1001/archotol.126.11.1394; Yueh B, 2001, ARCH OTOLARYNGOL, V127, P1197, DOI 10.1001/archotol.127.10.1197; YUEH B, 2001, SCREENING AUDITORY I; ZETTNER E, 1996, ASS RES OT FEBR 6 19; 1987, FED REG, V52, P44120	88	265	286	3	48	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 16	2003	289	15					1976	1985		10.1001/jama.289.15.1976	http://dx.doi.org/10.1001/jama.289.15.1976			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	667VC	12697801	Bronze			2022-12-28	WOS:000182253900031
J	Chen, J; Konstantinopoulos, PA; Satyal, S; Telonis, J; Blair, DC				Chen, J; Konstantinopoulos, PA; Satyal, S; Telonis, J; Blair, DC			Just another simple case of infectious mononucleosis?	LANCET			English	Article									SUNY Upstate Med Univ, Dept Med, Div Infect Dis, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Blair, DC (corresponding author), SUNY Upstate Med Univ, Dept Med, Div Infect Dis, 750 Adams St, Syracuse, NY 13210 USA.							Cohen JI, 2000, NEW ENGL J MED, V343, P481, DOI 10.1056/NEJM200008173430707; COLEBUNDERS R, 1983, ACTA CLIN BELG, V38, P189; Devereaux CE, 1999, AM J GASTROENTEROL, V94, P236, DOI 10.1111/j.1572-0241.1999.00806.x; GATHOF B S, 1991, Bildgebung, V58, P218	4	11	11	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 5	2003	361	9364					1182	1182		10.1016/S0140-6736(03)12953-4	http://dx.doi.org/10.1016/S0140-6736(03)12953-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	664ZF	12686041				2022-12-28	WOS:000182094600012
J	Read, TD; Peterson, SN; Tourasse, N; Baillie, LW; Paulsen, IT; Nelson, KE; Tettelin, H; Fouts, DE; Eisen, JA; Gill, SR; Holtzapple, EK; Okstad, OA; Helgason, E; Rilstone, J; Wu, M; Kolonay, JF; Beanan, MJ; Dodson, RJ; Brinkac, LM; Gwinn, M; DeBoy, RT; Madpu, R; Daugherty, SC; Durkin, AS; Haft, DH; Nelson, WC; Peterson, JD; Pop, M; Khouri, HM; Radune, D; Benton, JL; Mahamoud, Y; Jiang, LX; Hance, IR; Weidman, JF; Berry, KJ; Plaut, RD; Wolf, AM; Watkins, KL; Nierman, WC; Hazen, A; Cline, R; Redmond, C; Thwaite, JE; White, O; Salzberg, SL; Thomason, B; Friedlander, AM; Koehler, TM; Hanna, PC; Kolsto, AB; Fraser, CM				Read, TD; Peterson, SN; Tourasse, N; Baillie, LW; Paulsen, IT; Nelson, KE; Tettelin, H; Fouts, DE; Eisen, JA; Gill, SR; Holtzapple, EK; Okstad, OA; Helgason, E; Rilstone, J; Wu, M; Kolonay, JF; Beanan, MJ; Dodson, RJ; Brinkac, LM; Gwinn, M; DeBoy, RT; Madpu, R; Daugherty, SC; Durkin, AS; Haft, DH; Nelson, WC; Peterson, JD; Pop, M; Khouri, HM; Radune, D; Benton, JL; Mahamoud, Y; Jiang, LX; Hance, IR; Weidman, JF; Berry, KJ; Plaut, RD; Wolf, AM; Watkins, KL; Nierman, WC; Hazen, A; Cline, R; Redmond, C; Thwaite, JE; White, O; Salzberg, SL; Thomason, B; Friedlander, AM; Koehler, TM; Hanna, PC; Kolsto, AB; Fraser, CM			The genome sequence of Bacillus anthracis Ames and comparison to closely related bacteria	NATURE			English	Article							GENE; THURINGIENSIS; EXPRESSION; SUBTILIS; IDENTIFICATION; PROTEIN; CEREUS; PLCR; PXO1	Bacillus anthracis is an endospore-forming bacterium that causes inhalational anthrax(1). Key virulence genes are found on plasmids (extra-chromosomal, circular, double-stranded DNA molecules) pXO1 (ref. 2) and pXO2 (ref. 3). To identify additional genes that might contribute to virulence, we analysed the complete sequence of the chromosome of B. anthracis Ames (about 5.23 megabases). We found several chromosomally encoded proteins that may contribute to pathogenicity-including haemolysins, phospholipases and iron acquisition functions- and identified numerous surface proteins that might be important targets for vaccines and drugs. Almost all these putative chromosomal virulence and surface proteins have homologues in Bacillus cereus, highlighting the similarity of B. anthracis to near-neighbours that are not associated with anthrax(4). By performing a comparative genome hybridization of 19 B. cereus and Bacillus thuringiensis strains against a B. anthracis DNA microarray, we confirmed the general similarity of chromosomal genes among this group of close relatives. However, we found that the gene sequences of pXO1 and pXO2 were more variable between strains, suggesting plasmid mobility in the group. The complete sequence of B. anthracis is a step towards a better understanding of anthrax pathogenesis.	Inst Genom Res, Rockville, MD 20850 USA; Univ Maryland, Inst Biotechnol, Ctr Med Biotechnol, Baltimore, MD 21201 USA; George Washington Univ, Dept Biochem, Washington, DC 20052 USA; George Washington Univ, Dept Microbiol & Trop Med, Washington, DC 20052 USA; George Washington Univ, Dept Pharmacol, Washington, DC 20052 USA; Univ Oslo, Sch Pharm, N-0316 Oslo, Norway; Def Sci Technol Lab, Salisbury SP4 0JQ, Wilts, England; Johns Hopkins Univ, Baltimore, MD 21218 USA; Biotechnol Ctr Oslo, N-0317 Oslo, Norway; Univ Michigan, Sch Med, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA; USA, Med Res Inst Infect Dis, Frederick, MD 21702 USA; Univ Texas, Hlth Sci Ctr, Sch Med, Dept Microbiol & Mol Genet, Houston, TX 77225 USA	J. Craig Venter Institute; University System of Maryland; University of Maryland Baltimore; George Washington University; George Washington University; George Washington University; University of Oslo; Defence Science & Technology Laboratory; Johns Hopkins University; University of Michigan System; University of Michigan; University of Texas System; University of Texas Health Science Center Houston	Read, TD (corresponding author), Inst Genom Res, 9712 Med Ctr Dr, Rockville, MD 20850 USA.		Baillie, Les/AAG-7090-2020; Eisen, Jonathan A./H-2706-2019; Nelson, William C/E-9263-2016; Pop, Mihai/A-7987-2013; Read, Timothy/E-6240-2011; Plaut, Roger D./B-2340-2013; Okstad, Ole Andreas/ABE-4202-2020; Salzberg, Steven L/F-6162-2011; Salzberg, Steven/Q-6514-2019; Paulsen, Ian T/K-3832-2012	Eisen, Jonathan A./0000-0002-0159-2197; Nelson, William C/0000-0002-1873-3929; Pop, Mihai/0000-0001-9617-5304; Plaut, Roger D./0000-0002-0883-972X; Salzberg, Steven L/0000-0002-8859-7432; Salzberg, Steven/0000-0002-8859-7432; Paulsen, Ian T/0000-0001-9015-9418; Fraser, Claire/0000-0003-1462-2428; Read, Timothy/0000-0001-8966-9680; Okstad, Ole Andreas/0000-0001-9351-8535; Baillie, Les/0000-0002-8186-223X; Wu, Martin/0000-0003-3093-4077				Agaisse H, 1999, MOL MICROBIOL, V32, P1043, DOI 10.1046/j.1365-2958.1999.01419.x; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bellmann A, 2001, MICROBIOL-SGM, V147, P1765, DOI 10.1099/00221287-147-7-1765; Cossart P, 2002, INT J MED MICROBIOL, V291, P401; DeGroote MA, 1997, P NATL ACAD SCI USA, V94, P13997, DOI 10.1073/pnas.94.25.13997; Dixon TC, 1999, NEW ENGL J MED, V341, P815, DOI 10.1056/NEJM199909093411107; Glaser P, 2001, SCIENCE, V294, P849; Guttmann DM, 2000, FEMS MICROBIOL LETT, V188, P7, DOI 10.1111/j.1574-6968.2000.tb09160.x; Helgason E, 2000, APPL ENVIRON MICROB, V66, P2627, DOI 10.1128/AEM.66.6.2627-2630.2000; Keim P, 2000, J BACTERIOL, V182, P2928, DOI 10.1128/JB.182.10.2928-2936.2000; Ko M, 2002, J BACTERIOL, V184, P3917, DOI 10.1128/JB.184.14.3917-3922.2002; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; Lepore LS, 1996, J INVERTEBR PATHOL, V68, P131, DOI 10.1006/jipa.1996.0070; McCann KP, 1996, LETT APPL MICROBIOL, V23, P290, DOI 10.1111/j.1472-765X.1996.tb00192.x; Mignot T, 2001, MOL MICROBIOL, V42, P1189, DOI 10.1046/j.1365-2958.2001.02692.x; Nolling J, 2001, J BACTERIOL, V183, P4823, DOI 10.1128/JB.183.16.4823-4838.2001; Okinaka R, 1999, J APPL MICROBIOL, V87, P261, DOI 10.1046/j.1365-2672.1999.00883.x; Okinaka RT, 1999, J BACTERIOL, V181, P6509, DOI 10.1128/JB.181.20.6509-6515.1999; Pallen MJ, 2001, TRENDS MICROBIOL, V9, P97, DOI 10.1016/S0966-842X(01)01956-4; Pannucci J, 2002, J BACTERIOL, V184, P134, DOI 10.1128/JB.184.1.134-141.2002; Parkhill J, 2001, NATURE, V413, P523, DOI 10.1038/35097083; Read TD, 2002, SCIENCE, V296, P2028, DOI 10.1126/science.1071837; Salzberg SL, 1998, NUCLEIC ACIDS RES, V26, P544, DOI 10.1093/nar/26.2.544; Suyama M, 2001, TRENDS GENET, V17, P10, DOI 10.1016/S0168-9525(00)02159-4; Tettelin H, 2001, SCIENCE, V293, P498, DOI 10.1126/science.1061217; Thorne Curtis B., 1993, P113; Turnbull PCB, 1999, J APPL MICROBIOL, V87, P237, DOI 10.1046/j.1365-2672.1999.00876.x; West JT, 2000, J BACTERIOL, V182, P4841, DOI 10.1128/JB.182.17.4841-4848.2000	28	639	1350	3	112	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 1	2003	423	6935					81	86		10.1038/nature01586	http://dx.doi.org/10.1038/nature01586			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	673CG	12721629	Bronze, Green Published			2022-12-28	WOS:000182561600043
J	Sausville, EA				Sausville, EA			Imatinib for chronic myelogenous leukaemia: a 9 or 24 carat gold standard?	LANCET			English	Editorial Material							ABL TYROSINE KINASE; CHRONIC MYELOID-LEUKEMIA; PHILADELPHIA-CHROMOSOME; INHIBITOR; APOPTOSIS; MESYLATE; PATIENT; STI571; CELLS		NCI, Dev Therapeut Program, Rockville, MD 20852 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Sausville, EA (corresponding author), NCI, Dev Therapeut Program, Rockville, MD 20852 USA.							Cools J, 2003, NEW ENGL J MED, V348, P1201, DOI 10.1056/NEJMoa025217; Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Druker BJ, 2000, J CLIN INVEST, V105, P3, DOI 10.1172/JCI9083; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; HURON DR, IN PRESS CLIN CANC R; Joensuu H, 2001, NEW ENGL J MED, V344, P1052, DOI 10.1056/NEJM200104053441404; Kantarjian HM, 2002, CLIN CANCER RES, V8, P2167; Mow BMF, 2002, BLOOD, V99, P664, DOI 10.1182/blood.V99.2.664; Nimmanapalli R, 2001, CANCER RES, V61, P1799; O'Brien SG, 2003, NEW ENGL J MED, V348, P994, DOI 10.1056/NEJMoa022457; Peggs K, 2003, NEW ENGL J MED, V348, P1048, DOI 10.1056/NEJMe030009; Rubin BP, 2002, J CLIN ONCOL, V20, P3586, DOI 10.1200/JCO.2002.01.027; SILVER R, 2000, CANC MED, P1971; Yu CR, 2002, CLIN CANCER RES, V8, P2976	15	6	8	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 26	2003	361	9367					1400	1401		10.1016/S0140-6736(03)13145-5	http://dx.doi.org/10.1016/S0140-6736(03)13145-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	672HZ	12727387				2022-12-28	WOS:000182516300002
J	Nugent, AW; Daubeney, PEF; Chondros, P; Carlin, JB; Cheung, M; Wilkinson, LC; Davis, AM; Kahler, SG; Chow, CW; Wilkinson, JL; Weintraub, RG				Nugent, AW; Daubeney, PEF; Chondros, P; Carlin, JB; Cheung, M; Wilkinson, LC; Davis, AM; Kahler, SG; Chow, CW; Wilkinson, JL; Weintraub, RG		Natl Australian Childhood Cardiomy	The epidemiology of childhood cardiomyopathy in Australia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IDIOPATHIC DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; CARDIOVASCULAR-DISEASE; INTERNATIONAL-SOCIETY; SUDDEN-DEATH; CHILDREN; MYOCARDITIS; HEART; DETERMINANTS; CARDIOLOGY	Background: The incidence and age distribution of primary cardiomyopathy in children are not well defined. We undertook a population-based, retrospective cohort study in Australia to document the epidemiology of childhood cardiomyopathy. Methods: We analyzed all cases of primary cardiomyopathy in children who presented between 1987 and 1996 and who were younger than 10 years of age. Children were recruited from multiple sources, and cases of cardiomyopathy were classified according to World Health Organization guidelines. Results: Over the 10-year period, 314 new cases of primary cardiomyopathy were identified, for an annual incidence of 1.24 per 100,000 children younger than 10 years of age (95 percent confidence interval, 1.11 to 1.38). Dilated cardiomyopathy made up 58.6 percent of cases, hypertrophic cardiomyopathy 25.5 percent, restrictive cardiomyopathy 2.5 percent, and left ventricular noncompaction 9.2 percent of cases. The incidence of all types of cardiomyopathy except restrictive declined rapidly after infancy. In 11 cases (3.5 percent), sudden death was the first symptom. There was a male predominance among children with hypertrophic and unclassified cardiomyopathy. Indigenous children had a higher incidence of dilated cardiomyopathy than nonindigenous children (relative risk, 2.67; 95 percent confidence interval, 1.42 to 4.63) and a higher rate of death as the presenting symptom (16.7 percent vs. 2.6 percent, P=0.02). Lymphocytic myocarditis was present in 25 of 62 children with dilated cardiomyopathy (40.3 percent) who underwent cardiac histologic examination within two months after presentation. Conclusions: Lymphocytic myocarditis and left ventricular noncompaction are important causes of childhood cardiomyopathy in Australia. The timing and severity of presentation in children with cardiomyopathy are related to the type of cardiomyopathy, as well as to genetic and ethnic factors. .	Royal Childrens Hosp, Dept Cardiol, Melbourne, Vic, Australia; Royal Childrens Hosp, Dept Anat Pathol, Melbourne, Vic, Australia; Murdoch Childrens Res Inst, Clin Epidemiol & Biostat Unit, Melbourne, Vic, Australia; Univ Melbourne, Dept Gen Practice, Parkville, Vic 3052, Australia; Univ Melbourne, Dept Paediat, Parkville, Vic 3052, Australia	Royal Children's Hospital Melbourne; Royal Children's Hospital Melbourne; Murdoch Children's Research Institute; University of Melbourne; University of Melbourne	Weintraub, RG (corresponding author), Royal Childrens Hosp, Dept Cardiol, Flemington Rd, Parkville, Vic 3052, Australia.		Chondros, Patty/AAT-6426-2020; Carlin, John B/B-3492-2012; Carlin, John/AAG-4332-2020	Carlin, John B/0000-0002-2694-9463; Carlin, John/0000-0002-2694-9463; Davis, Andrew/0000-0003-2826-8562; Chondros, Patty/0000-0003-0393-8734				ADES LC, 1993, AM J MED GENET, V45, P327, DOI 10.1002/ajmg.1320450309; Aretz H T, 1987, Am J Cardiovasc Pathol, V1, P3; Arola A, 1997, AM J EPIDEMIOL, V146, P385, DOI 10.1093/oxfordjournals.aje.a009291; *AUSTR BUR STAT, 1994, 32300 AUSTR BUR STAT; *AUSTR BUR STAT, 1997, 32010 AUSTR BUR STAT; *AUSTR BUR STAT, 1993, 32010 AUSTR BUR STAT; *AUSTR BUR STAT, 1998, 32300 AUSTR BUR STAT; Boucek MM, 2001, J HEART LUNG TRANSPL, V20, P39, DOI 10.1016/S1053-2498(00)00243-6; Bowles NE, 2000, HERZ, V25, P168, DOI 10.1007/s000590050003; BURCH M, 1994, BRIT HEART J, V72, P246; Carapetis JR, 1999, AUST NZ J PUBL HEAL, V23, P159, DOI 10.1111/j.1467-842X.1999.tb01227.x; CHIN TK, 1990, CIRCULATION, V82, P507, DOI 10.1161/01.CIR.82.2.507; COLAN SD, 1992, J AM COLL CARDIOL, V19, P619, DOI 10.1016/S0735-1097(10)80282-7; FERENCZ C, 1992, PEDIATR CARDIOL, V13, P65, DOI 10.1007/BF00798206; Grenier MA, 2000, AM HEART J, V139, pS86, DOI 10.1067/mhj.2000.103933; Lipshultz SE, 2003, NEW ENGL J MED, V348, P1647, DOI 10.1056/NEJMoa021715; Maron BJ, 2002, JAMA-J AM MED ASSOC, V287, P1308, DOI 10.1001/jama.287.10.1308; Maron BJ, 1996, CIRCULATION, V94, P850, DOI 10.1161/01.CIR.94.4.850; MARTIN AB, 1994, CIRCULATION, V90, P330, DOI 10.1161/01.CIR.90.1.330; MASON JW, 1995, NEW ENGL J MED, V333, P269, DOI 10.1056/NEJM199508033330501; MATITIAU A, 1994, CIRCULATION, V90, P1310, DOI 10.1161/01.CIR.90.3.1310; MICHELS VV, 1992, NEW ENGL J MED, V326, P77, DOI 10.1056/NEJM199201093260201; Nugent AW, 2001, J HEART LUNG TRANSPL, V20, P1152, DOI 10.1016/S1053-2498(01)00334-5; Olson TM, 2002, CIRCULATION, V105, P2337, DOI 10.1161/01.CIR.0000018444.47798.94; Pauschinger M, 1999, CIRCULATION, V99, P1348, DOI 10.1161/01.CIR.99.10.1348; Richardson P, 1996, CIRCULATION, V93, P841, DOI 10.1161/01.CIR.93.5.841; Rivenes SM, 2000, CIRCULATION, V102, P876; SPIRITO P, 1989, NEW ENGL J MED, V320, P749, DOI 10.1056/NEJM198903233201201; *STAT CORP, 1999, STAT STAT SOFTW REL; Venugopalan P, 2001, INT J CARDIOL, V78, P135, DOI 10.1016/S0167-5273(00)00480-0; WILES HB, 1991, AM J CARDIOL, V68, P1372, DOI 10.1016/0002-9149(91)90248-J; Yetman AT, 1998, J AM COLL CARDIOL, V32, P1943, DOI 10.1016/S0735-1097(98)00493-8	32	471	528	0	9	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 24	2003	348	17					1639	1646		10.1056/NEJMoa021737	http://dx.doi.org/10.1056/NEJMoa021737			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	670PB	12711738				2022-12-28	WOS:000182416300003
J	Black, HR; Elliott, WJ; Grandits, G; Grambsch, P; Lucente, T; White, WB; Neaton, JD; Grimm, RH; Hansson, L; Lacourciere, Y; Muller, J; Sleight, P; Weber, MA; Williams, G; Wittes, J; Zanchetti, A; Anders, RJ				Black, HR; Elliott, WJ; Grandits, G; Grambsch, P; Lucente, T; White, WB; Neaton, JD; Grimm, RH; Hansson, L; Lacourciere, Y; Muller, J; Sleight, P; Weber, MA; Williams, G; Wittes, J; Zanchetti, A; Anders, RJ		CONVINCE Res Grp	Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BLOOD-PRESSURE; METAANALYSIS; DILTIAZEM; OUTCOMES; PLACEBO; STROKE; SYSTEM	Context Hypertensive patients are often given a calcium antagonist to reduce cardiovascular disease risk, but the benefit compared with other drug classes is controversial. Objective To determine whether initial therapy with controlled-onset extended-release (COER) verapamil is equivalent to a physician's choice of atenolol or hydrochlorothiazide in preventing cardiovascular disease. Design, Setting, and Participants Double-blind, randomized clinical trial conducted at 661 centers in 15 countries. A total of 16602 participants diagnosed as having hypertension and who had 1 or more additional risk factors for cardiovascular disease were enrolled between September 1996 and December 1998 and followed up until December 31, 2000. After a mean of 3 years of follow-up, the sponsor closed the study before unblinding the results. Intervention Initially, 8241 participants received 180 mg of COER Verapamil and 8361 received either 50 mg of atenolol or 12.5 mg of hydrochlorothiazide. Other drugs (eg, diuretic, beta-blocker, or an angiotensin-converting enzyme inhibitor) could be added in specified sequence if needed. Main Outcome Measures First occurrence of stroke, myocardial infarction, or cardiovascular disease-related death. Results Systolic and diastolic blood pressure were reduced by 13.6 mm Hg and 7.8 mm Hg for participants assigned to the COER verapamil group and by 13.5 and 7.1 mm Hg for partcipants assigned to the ateholol or hydrochlorothiazide group. There were 364 primary cardiovascular disease-related events that occurred in the COER verapamil group vs 365 in atenolol or hydrochlorothiazide group (hazard ratio [HR], 1.02; 95% confidence interval [CI], 0.88-1.18; P=.77). For fatal or nonfatal stroke, the HR was 1.15 (95% CI, 0.90-1.48); for fatal or nonfatal myocardial infarction, 0.82 (95% CI, 0.65-1.03); and for cardiovascular disease-related death, 1.09 (95% Cl, 0.87-1.37). The HR was 1.05 (95% CI, 0.95-1.16) for any prespecified cardiovascular disease-related event and 1.08 (95% CI, 0.93-1.26) for all-cause mortality. Non-stroke hemorrhage was more common with participants in the COER-verapamil group (n=118) compared with the atenolol or hydrochlorothiazide group (n=79) (HR, 1.54 [95% CI, 1.16-2.04]; P=.003). More cardiovascular disease-related events occurred between 6 AM and noon in both the COER verapamil (99/277) and atenolol or hydrochlorothiazide (88/274) groups; FIR, 1.15 (95% CI, 0.86-1.53). Conclusions The CONVINCE trial did not demonstrate equivalence of a COER verapamil-based antihypertensive regimen compared with a regimen beginning with a diuretic or beta-blocker. When considered in the context of other trials of calcium antagonists, these data indicate that the effectiveness of calcium-channel therapy in reducing cardiovascular disease is similar but not better than diuretic or beta-blocker treatment.	Rush Presbyterian St Lukes Med Ctr, Dept Prevent Med, Chicago, IL 60612 USA; Univ Minnesota, Div Biostat, Minneapolis, MN 55455 USA; Univ Minnesota, Ctr Evidence Based Med, Minneapolis, MN USA; Univ Connecticut, Sch Med, Dept Med, Sect Hypertens & Clin Pharmacol, Farmington, CT USA; Uppsala Univ, Dept Geriatr, Uppsala, Sweden; Ctr Hosp Univ Quebec, Quebec City, PQ, Canada; Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA; Univ Oxford, Dept Med, Oxford, England; John Radcliffe Hosp, Oxford OX3 9DU, England; SUNY, Dept Med, Brooklyn, NY USA; Brookdale Hosp, Brooklyn, NY USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; Stat Collaborat, Washington, DC USA; Osped Maggiore, I-20122 Milan, Italy; Ist Auxol Italiano, Milan, Italy; Univ Milan, Milan, Italy; Searle Labs, Clin Res, Skokie, IL USA	Rush University; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Connecticut; Uppsala University; Laval University; Harvard University; Massachusetts General Hospital; University of Oxford; University of Oxford; State University of New York (SUNY) System; SUNY Maritime College; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; IRCCS Istituto Auxologico Italiano; University of Milan; Pfizer	Black, HR (corresponding author), Rush Univ, Rush Med Coll, 1700 W Van Buren St,Suite 470, Chicago, IL 60612 USA.	hblack@rush.edu		zanchetti, alberto/0000-0003-4796-7959				ADDONIZIO VP, 1986, AM J PHYSIOL, V250, pH366, DOI 10.1152/ajpheart.1986.250.3.H366; Agodoa LY, 2001, JAMA-J AM MED ASSOC, V285, P2719, DOI 10.1001/jama.285.21.2719; Black HR, 1998, CONTROL CLIN TRIALS, V19, P370, DOI 10.1016/S0197-2456(98)00013-0; Black HR, 2001, HYPERTENSION, V37, P12, DOI 10.1161/01.HYP.37.1.12; Brenner BM, 2001, NEW ENGL J MED, V345, P861, DOI 10.1056/NEJMoa011161; Cohen MC, 1997, AM J CARDIOL, V79, P1512, DOI 10.1016/S0002-9149(97)00181-1; DING YA, 1994, J HUM HYPERTENS, V8, P273; Ellenberg SS, 2000, ANN INTERN MED, V133, P464, DOI 10.7326/0003-4819-133-6-200009190-00015; Elliott WJ, 1998, STROKE, V29, P992, DOI 10.1161/01.STR.29.5.992; Furberg CD, 2000, JAMA-J AM MED ASSOC, V283, P1967; Gomberg-Maitland M, 2001, ARCH INTERN MED, V161, P342, DOI 10.1001/archinte.161.3.342; GUPTA SK, 1995, J CLIN PHARMACOL, V35, P1083, DOI 10.1002/j.1552-4604.1995.tb04031.x; HANSEN JF, 1990, AM J CARDIOL, V66, P779; HANSEN JF, 1984, EUR HEART J, V5, P516; Hansson L, 2000, LANCET, V356, P359, DOI 10.1016/S0140-6736(00)02526-5; He J, 1998, JAMA-J AM MED ASSOC, V280, P1930, DOI 10.1001/jama.280.22.1930; Joint National Committee on Prevention Detection evaluation and treatment of high blood pressure, 1997, ARCH INTERN MED, V157, P2413, DOI DOI 10.1001/ARCHINTE.1997.00440420033005; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; Lewis EJ, 2001, NEW ENGL J MED, V345, P851, DOI 10.1056/NEJMoa011303; LLACOSTE L, 1994, CIRCULATION, V89, P630, DOI 10.1161/01.CIR.89.2.630; Neal B, 2000, LANCET, V356, P1955; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; PETO R, 1995, J CLIN EPIDEMIOL, V48, P23, DOI 10.1016/0895-4356(94)00150-O; Smolensky MH, 1999, AM HEART J, V137, pS14, DOI 10.1016/S0002-8703(99)70392-3; Staessen JA, 1997, LANCET, V350, P757, DOI 10.1016/S0140-6736(97)05381-6; The AO, 2002, JAMA-J AM MED ASSOC, V288, P2981, DOI DOI 10.1001/JAMA.288.23.2981; Therneau TM, 2000, MODELING SURVIVAL DA; White WB, 1998, AM J CARDIOL, V81, P424, DOI 10.1016/S0002-9149(97)00935-1; WHITE WB, 1995, AM J CARDIOL, V76, P375, DOI 10.1016/S0002-9149(99)80104-0; Yusuf S, 2000, NEW ENGL J MED, V342, P145	30	492	511	0	16	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 23	2003	289	16					2073	2082		10.1001/jama.289.16.2073	http://dx.doi.org/10.1001/jama.289.16.2073			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	669WW	12709465	Bronze			2022-12-28	WOS:000182374300023
J	Pedulla, ML; Ford, ME; Houtz, JM; Karthikeyan, T; Wadsworth, C; Lewis, JA; Jacobs-Sera, D; Falbo, J; Gross, J; Pannunzio, NR; Brucker, W; Kumar, V; Kandasamy, J; Keenan, L; Bardarov, S; Kriakov, J; Lawrence, JG; Jacobs, WR; Hendrix, RW; Hatfull, GF				Pedulla, ML; Ford, ME; Houtz, JM; Karthikeyan, T; Wadsworth, C; Lewis, JA; Jacobs-Sera, D; Falbo, J; Gross, J; Pannunzio, NR; Brucker, W; Kumar, V; Kandasamy, J; Keenan, L; Bardarov, S; Kriakov, J; Lawrence, JG; Jacobs, WR; Hendrix, RW; Hatfull, GF			Origins of highly mosaic mycobacteriophage genomes	CELL			English	Article							SYSTEMIC-LUPUS-ERYTHEMATOSUS; EVOLUTIONARY RELATIONSHIPS; NUCLEOTIDE-SEQUENCE; PHAGE GENOMICS; BACTERIOPHAGE; TUBERCULOSIS; PROTEIN; TAXONOMY; VIRUSES; RO	Bacteriophages are the most abundant organisms in the biosphere and play major roles in the ecological balance of microbial life. The genomic sequences of ten newly isolated mycobacteriophages suggest that the bacteriophage population as a whole is amazingly diverse and may represent the largest unexplored reservoir of sequence information in the biosphere. Genomic comparison of these mycobacteriophages contributes to our understanding of the mechanisms of viral evolution and provides compelling evidence for the role of illegitimate recombination in horizontal genetic exchange. The promiscuity of these recombination events results in the inclusion of many unexpected genes including those implicated in mycobacterial latency, the cellular and immune responses to mycobacterial infections, and autoimmune diseases such as human lupus. While the role of phages as vehicles of toxin genes is well established, these observations suggest a much broader involvement of phages in bacterial virulence and the host response to bacterial infections.	Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Pittsburgh Bacteriophage Inst, Pittsburgh, PA 15260 USA; Greater Latrobe High Sch, Latrobe, PA 15650 USA; ICMR, TB Res Ctr, Madras 600031, Tamil Nadu, India; Pelham Mem High Sch, Pelham, NY 10803 USA; Albert Einstein Coll Med, Dept Microbiol & Immunol, Howard Hughes Med Inst, Bronx, NY 10461 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Indian Council of Medical Research (ICMR); ICMR - National Institute for Research in Tuberculosis (NIRT); Howard Hughes Medical Institute; Yeshiva University; Albert Einstein College of Medicine	Hatfull, GF (corresponding author), Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA.	gfh@pitt.edu		Jacobs, William/0000-0003-3321-3080; Pannunzio, Nick/0000-0002-8290-8236	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI028927, R01AI028927, R37AI026170, R22AI026170, R01AI026170] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051975] Funding Source: NIH RePORTER; NIAID NIH HHS [AI28927, AI26170] Funding Source: Medline; NIGMS NIH HHS [GM5197508] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ackermann HW, 2001, ARCH VIROL, V146, P843, DOI 10.1007/s007050170120; ACKERMANN HW, 1987, MICROBIOL SCI, V4, P214; Bibb LA, 2002, MOL MICROBIOL, V45, P1515, DOI 10.1046/j.1365-2958.2002.03130.x; Boyd EF, 2001, TRENDS MICROBIOL, V9, P137, DOI 10.1016/S0966-842X(01)01960-6; Brussow H, 2002, CELL, V108, P13, DOI 10.1016/S0092-8674(01)00637-7; Brussow H, 2001, MOL MICROBIOL, V39, P213, DOI 10.1046/j.1365-2958.2001.02228.x; Brussow H, 2001, ANNU REV MICROBIOL, V55, P283, DOI 10.1146/annurev.micro.55.1.283; Chen XG, 2000, GENE DEV, V14, P777; Clark AJ, 2001, J MOL BIOL, V311, P657, DOI 10.1006/jmbi.2001.4868; Cole ST, 2001, NATURE, V409, P1007, DOI 10.1038/35059006; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Dobrindt U, 2000, INT J MED MICROBIOL, V290, P519; DOKE S, 1960, J KUMAMOTO MED SOC, V34, P1360; Eltringham IJ, 1999, J CLIN MICROBIOL, V37, P3528, DOI 10.1128/JCM.37.11.3528-3532.1999; Fessler BJ, 2002, BEST PRACT RES CL RH, V16, P281, DOI 10.1053/berh.2001.0226; Flynn JL, 2001, INFECT IMMUN, V69, P4195, DOI 10.1128/IAI.69.7.4195-4201.2001; Ford M. E., 1998, Tubercle and Lung Disease, V79, P63, DOI 10.1054/tuld.1998.0007; Ford ME, 1998, J MOL BIOL, V279, P143, DOI 10.1006/jmbi.1997.1610; FROMAN S, 1954, AM J PUBLIC HEALTH, V44, P1326, DOI 10.2105/AJPH.44.10.1326; Garza DR, 1998, MICROB ECOL, V36, P281, DOI 10.1007/s002489900115; Gordon D, 1998, GENOME RES, V8, P195, DOI 10.1101/gr.8.3.195; HARLEY JB, 1992, RHEUM DIS CLIN N AM, V18, P337; Hatfull GF, 2000, MOLECULAR GENETICS OF MYCOBACTERIA, P37; HATFULL GF, 1993, MOL MICROBIOL, V7, P395, DOI 10.1111/j.1365-2958.1993.tb01131.x; Hatfull Graham F., 1994, P165; Hendrix RW, 1999, P NATL ACAD SCI USA, V96, P2192, DOI 10.1073/pnas.96.5.2192; Hendrix RW, 2002, THEOR POPUL BIOL, V61, P471, DOI 10.1006/tpbi.2002.1590; JACOBS WR, 1993, SCIENCE, V260, P819, DOI 10.1126/science.8484123; JONES WD, 1990, AM REV RESPIR DIS, V142, P1000, DOI 10.1164/ajrccm/142.5.1000; Juhala RJ, 2000, J MOL BIOL, V299, P27, DOI 10.1006/jmbi.2000.3729; KATSURA I, 1987, NATURE, V327, P73, DOI 10.1038/327073a0; KATSURA I, 1984, CELL, V39, P691, DOI 10.1016/0092-8674(84)90476-8; Kell DB, 2000, CURR OPIN MICROBIOL, V3, P238, DOI 10.1016/S1369-5274(00)00082-5; LAAL S, 1991, P NATL ACAD SCI USA, V88, P1054, DOI 10.1073/pnas.88.3.1054; Labbe JC, 2000, P NATL ACAD SCI USA, V97, P13233, DOI 10.1073/pnas.230284297; Lawrence JG, 2002, J BACTERIOL, V184, P4891, DOI 10.1128/JB.184.17.4891-4905.2002; LEVIN ME, 1993, J MOL BIOL, V234, P124, DOI 10.1006/jmbi.1993.1568; MCCAULIFFE DP, 1989, J AUTOIMMUN, V2, P375, DOI 10.1016/0896-8411(89)90166-2; Mediavilla J, 2000, MOL MICROBIOL, V38, P955, DOI 10.1046/j.1365-2958.2000.02183.x; Mukamolova GV, 1998, P NATL ACAD SCI USA, V95, P8916, DOI 10.1073/pnas.95.15.8916; NESBIT CE, 1995, MOL MICROBIOL, V17, P1045, DOI 10.1111/j.1365-2958.1995.mmi_17061045.x; Ochman H, 2000, NATURE, V405, P299, DOI 10.1038/35012500; Recktenwald J, 2002, INFECT IMMUN, V70, P1896, DOI 10.1128/IAI.70.4.1896-1908.2002; ROESSNER CA, 1984, J BACTERIOL, V157, P165, DOI 10.1128/JB.157.1.165-170.1984; Rohwer F, 2000, LIMNOL OCEANOGR, V45, P408, DOI 10.4319/lo.2000.45.2.0408; Rohwer F, 2002, J BACTERIOL, V184, P4529, DOI 10.1128/JB.184.16.4529-4535.2002; Roman LJ, 2002, CHEM REV, V102, P1179, DOI 10.1021/cr000661e; Scanga CA, 2001, INFECT IMMUN, V69, P7711, DOI 10.1128/IAI.69.12.7711-7717.2001; Shi H, 1996, RNA, V2, P769; Shleeva MO, 2002, MICROBIOL-SGM, V148, P1581, DOI 10.1099/00221287-148-5-1581; Short SM, 1999, HYDROBIOLOGIA, V401, P19, DOI 10.1023/A:1003711115967; SIMON MN, 1971, BACTERIOPHAGE LAMBDA, P313; Smith MCM, 1999, NUCLEIC ACIDS RES, V27, P2145, DOI 10.1093/nar/27.10.2145; SONNHAMMER ELL, 1995, GENE-COMBIS, V167, P1; SUSSKIND MM, 1978, MICROBIOL REV, V42, P385, DOI 10.1128/MMBR.42.2.385-413.1978; TIMME TL, 1984, J GEN MICROBIOL, V130, P2059; Wagner PL, 2002, INFECT IMMUN, V70, P3985, DOI 10.1128/IAI.70.8.3985-3993.2002; WESTMORELAND BC, 1969, SCIENCE, V163, P1343, DOI 10.1126/science.163.3873.1343; Wilhelm SW, 1999, BIOSCIENCE, V49, P781, DOI 10.2307/1313569; Wommack KE, 2000, MICROBIOL MOL BIOL R, V64, P69, DOI 10.1128/MMBR.64.1.69-114.2000; XU J, 2000, THESIS U PITTSBURGH	61	469	500	0	50	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 18	2003	113	2					171	182		10.1016/S0092-8674(03)00233-2	http://dx.doi.org/10.1016/S0092-8674(03)00233-2			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	672EP	12705866	Bronze			2022-12-28	WOS:000182508500007
J	Tracey, WD; Wilson, RI; Laurent, G; Benzer, S				Tracey, WD; Wilson, RI; Laurent, G; Benzer, S			painless, a Drosophila gene essential for nociception	CELL			English	Article							CAPSAICIN-RECEPTOR; MECHANOSENSORY TRANSDUCTION; CATION CHANNEL; PROTEIN; IDENTIFICATION; MELANOGASTER; EXPRESSION; ELEGANS; THRESHOLD; NEURONS	We describe a paradigm for nociception in Drosophila. In response to the touch of a probe heated above 38degreesC, Drosophila larvae produce a stereotypical rolling behavior, unlike the response to an unheated probe. In a genetic screen for mutants defective in this noxious heat response, we identified the painless gene. Recordings from wild-type larval nerves identified neurons that initiated strong spiking above 38degreesC, and this activity was absent in the painless mutant. The painless mRNA encodes a protein of the transient receptor potential ion channel family. Painless is required for both thermal and mechanical nociception, but not for sensing light touch painless is expressed in peripheral neurons that extend multiple branched dendrites beneath the larval epidermis, similar to vertebrate pain receptors. An antibody to Painless binds to localized dendritic structures that we hypothesize are involved in nociceptive signaling.	CALTECH, Div Biol 156 29, Pasadena, CA 91125 USA; CALTECH, Div Biol 139 74, Pasadena, CA 91125 USA	California Institute of Technology; California Institute of Technology	Tracey, WD (corresponding author), CALTECH, Div Biol 156 29, Pasadena, CA 91125 USA.	tracey@caltech.edu; benzer@caltech.edu	Laurent, Gilles/A-4583-2012	Laurent, Gilles/0000-0002-2296-114X; Tracey, W. Daniel/0000-0003-4666-8199; Wilson, Rachel/0000-0001-8573-9266				Adams CM, 1998, J CELL BIOL, V140, P143, DOI 10.1083/jcb.140.1.143; Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; BECK PW, 1974, BRAIN RES, V67, P373, DOI 10.1016/0006-8993(74)90488-0; BESSOU P, 1969, J NEUROPHYSIOL, V32, P1025, DOI 10.1152/jn.1969.32.6.1025; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brembs B, 2000, LEARN MEMORY, V7, P104, DOI 10.1101/lm.7.2.104; Caterina MJ, 2000, SCIENCE, V288, P306, DOI 10.1126/science.288.5464.306; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Caterina MJ, 1999, NATURE, V398, P436, DOI 10.1038/18906; Chung YD, 2001, NEURON, V29, P415, DOI 10.1016/S0896-6273(01)00215-X; Colbert HA, 1997, J NEUROSCI, V17, P8259; Gao FB, 1999, GENE DEV, V13, P2549, DOI 10.1101/gad.13.19.2549; Grueber WB, 2002, DEVELOPMENT, V129, P2867; HARTENSTEIN V, 1988, DEVELOPMENT, V102, P869; Jaquemar D, 1999, J BIOL CHEM, V274, P7325, DOI 10.1074/jbc.274.11.7325; KERNAN M, 1994, NEURON, V12, P1195, DOI 10.1016/0896-6273(94)90437-5; Liu L, 2003, NAT NEUROSCI, V6, P267, DOI 10.1038/nn1009; MARIATH HA, 1985, J INSECT PHYSIOL, V31, P779, DOI 10.1016/0022-1910(85)90071-X; McKemy DD, 2002, NATURE, V416, P52, DOI 10.1038/nature719; MONTELL C, 1989, NEURON, V2, P1313, DOI 10.1016/0896-6273(89)90069-X; Montell C, 2002, MOL CELL, V9, P229, DOI 10.1016/S1097-2765(02)00448-3; Peier AM, 2002, SCIENCE, V296, P2046, DOI 10.1126/science.1073140; PHILLIPS AM, 1992, NEURON, V8, P631, DOI 10.1016/0896-6273(92)90085-R; Pouzat C, 2002, J NEUROSCI METH, V122, P43, DOI 10.1016/S0165-0270(02)00276-5; Roayaie K, 1998, NEURON, V20, P55, DOI 10.1016/S0896-6273(00)80434-1; Rorth P, 1998, DEVELOPMENT, V125, P1049; Sepp KJ, 1999, GENETICS, V151, P1093; Sherrington C, 1906, INTEGRATIVE ACTION N; Smith GD, 2002, NATURE, V418, P186, DOI 10.1038/nature00894; Story GM, 2003, CELL, V112, P819, DOI 10.1016/S0092-8674(03)00158-2; Strotmann R, 2000, NAT CELL BIOL, V2, P695, DOI 10.1038/35036318; SUN BH, 1995, J NEUROCHEM, V65, P434, DOI 10.1046/j.1471-4159.1995.65010434.x; SWEENEY ST, 1995, NEURON, V14, P341, DOI 10.1016/0896-6273(95)90290-2; TILLMAN DB, 1995, J PHYSIOL-LONDON, V485, P767, DOI 10.1113/jphysiol.1995.sp020767; Tobin DM, 2002, NEURON, V35, P307, DOI 10.1016/S0896-6273(02)00757-2; Tominaga M, 1998, NEURON, V21, P531, DOI 10.1016/S0896-6273(00)80564-4; VANHEES J, 1981, J NEUROL NEUROSUR PS, V44, P600, DOI 10.1136/jnnp.44.7.600; Walker RG, 2000, SCIENCE, V287, P2229, DOI 10.1126/science.287.5461.2229; Wittenburg N, 1999, P NATL ACAD SCI USA, V96, P10477, DOI 10.1073/pnas.96.18.10477; Xu HX, 2002, NATURE, V418, P181, DOI 10.1038/nature00882; Xu XZS, 2000, NEURON, V26, P647, DOI 10.1016/S0896-6273(00)81201-5; 2002, BDGP	42	501	525	4	90	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 18	2003	113	2					261	273		10.1016/S0092-8674(03)00272-1	http://dx.doi.org/10.1016/S0092-8674(03)00272-1			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	672EP	12705873	Bronze			2022-12-28	WOS:000182508500014
J	Yamamoto, K; Sakata, Y; Nohara, Y; Takahashi, Y; Tatsumi, T				Yamamoto, K; Sakata, Y; Nohara, Y; Takahashi, Y; Tatsumi, T			Organic-inorganic hybrid zeolites containing organic frameworks	SCIENCE			English	Article							FUNCTIONALIZED MOLECULAR-SIEVES; HOSTS; OFMSS	Organic-inorganic hybrid zeolite materials containing an organic framework have been synthesized by partially superseding a lattice oxygen atom by a methylene group. The use of methylene-bridged organosilane as a silicon source gives zeolite materials containing an organic group as lattice (ZOL), with several zeolitic phases such as the MFI and the LTA structures. Through various characterization methods, the presence of methylene frameworks (Si-CH2-Si) that replace siloxane bonds (Si-O-Si) has been verified, although the Si-C bonds are partly cleaved to give rise to terminal methyl groups. The shape-selective lipophilicity of a ZOL material indicates that it is not a physical mixture of conventional zeolite and amorphous organic-containing material but contains a genuine organic-inorganic hybrid zeolite.	Yokohama Natl Univ, Grad Sch Engn, Div Mat Sci & Chem Engn, Hodogaya Ku, Yokohama, Kanagawa 2408501, Japan; Univ Tokyo, Grad Sch Engn, Dept Appl Chem, Bunkyo Ku, Tokyo 1138656, Japan; CACs Inc, Yokohama Lab, Aoba Ku, Yokohama, Kanagawa 2270033, Japan	Yokohama National University; University of Tokyo	Tatsumi, T (corresponding author), Yokohama Natl Univ, Grad Sch Engn, Div Mat Sci & Chem Engn, Hodogaya Ku, 79-5 Tokiwadai, Yokohama, Kanagawa 2408501, Japan.							Asefa T, 1999, NATURE, V402, P867, DOI 10.1038/47229; Blasco T, 1996, CHEM COMMUN, P2367, DOI 10.1039/cc9960002367; CORRIU RJP, 1992, CHEM MATER, V4, P1217, DOI 10.1021/cm00024a020; COX SD, 1988, J AM CHEM SOC, V110, P2986, DOI 10.1021/ja00217a057; DAI FY, 1988, CHEM LETT, P869, DOI 10.1246/cl.1988.869; HERRON N, 1989, J AM CHEM SOC, V111, P530, DOI 10.1021/ja00184a021; Inagaki S, 1999, J AM CHEM SOC, V121, P9611, DOI 10.1021/ja9916658; Jones CW, 2001, MICROPOR MESOPOR MAT, V42, P21, DOI 10.1016/S1387-1811(00)00268-7; Jones CW, 1999, MICROPOR MESOPOR MAT, V33, P223, DOI 10.1016/S1387-1811(99)00141-9; Jones CW, 1998, NATURE, V393, P52, DOI 10.1038/29959; Lu YF, 2000, J AM CHEM SOC, V122, P5258, DOI 10.1021/ja9935862; Melde BJ, 1999, CHEM MATER, V11, P3302, DOI 10.1021/cm9903935; NOZUE Y, 1992, PHYS REV LETT, V68, P3789, DOI 10.1103/PhysRevLett.68.3789; ROBSON H, 2001, VERIFIED SYNTHESES Z, P179; Shea KJ, 1989, CHEM MATER, V1, P572, DOI 10.1021/cm00006a003; Simon U, 2000, MICROPOR MESOPOR MAT, V41, P1, DOI 10.1016/S1387-1811(00)00291-2; STUCKY GD, 1990, SCIENCE, V247, P669, DOI 10.1126/science.247.4943.669; TERASAKI O, 1992, SOLID STATE PHYS, V27, P601; Tsuji K, 1999, MICROPOR MESOPOR MAT, V29, P339, DOI 10.1016/S1387-1811(99)00003-7; Vietze U, 1998, PHYS REV LETT, V81, P4628, DOI 10.1103/PhysRevLett.81.4628; Wada Y, 2000, J AM CHEM SOC, V122, P8583, DOI 10.1021/ja0020557; YAMAMOTO K, 2001, STUD SURF SCI CATAL, V135, P299	22	173	176	5	94	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 18	2003	300	5618					470	472		10.1126/science.1081019	http://dx.doi.org/10.1126/science.1081019			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	668LR	12702872				2022-12-28	WOS:000182295900034
J	Rogan, WJ; Ware, JH				Rogan, WJ; Ware, JH			Exposure to lead in children - How low is low enough?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							LEVEL		NIEHS, Res Triangle Pk, NC 27709 USA; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Harvard University; Harvard T.H. Chan School of Public Health	Rogan, WJ (corresponding author), NIEHS, POB 12233, Res Triangle Pk, NC 27709 USA.		Rogan, Walter/I-6034-2012	Rogan, Walter/0000-0002-9302-0160	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES043011, ZIAES043011] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BELLINGER DC, 1992, PEDIATRICS, V90, P855; Centers for Disease Control, 1991, PREV LEAD POIS YOUNG; *DEP HLTH HUM SERV, 2000, HLTH PEOPL 2010 UND; Rogan WJ, 2001, NEW ENGL J MED, V344, P1421, DOI 10.1056/NEJM200105103441902; SCHWARTZ J, 1994, ENVIRON RES, V65, P42, DOI 10.1006/enrs.1994.1020	5	68	72	1	5	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 17	2003	348	16					1515	1516		10.1056/NEJMp030025	http://dx.doi.org/10.1056/NEJMp030025			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	667TT	12700370				2022-12-28	WOS:000182248900001
J	Bodenheimer, T				Bodenheimer, T			Primary care in the United States - Innovations in primary care in the United States	BRITISH MEDICAL JOURNAL			English	Article							IMPROVING PRIMARY-CARE; CHRONIC ILLNESS; CHRONIC DISEASE; HEALTH-CARE; MANAGEMENT; PHYSICIANS; ADHERENCE; VISITS		Univ Calif San Francisco, San Francisco Gen Hosp, Dept Family & Community Med, San Francisco, CA 94110 USA	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco	Bodenheimer, T (corresponding author), Univ Calif San Francisco, San Francisco Gen Hosp, Dept Family & Community Med, 1001 Potrero Ave, San Francisco, CA 94110 USA.							Anderson RM, 2000, DIABETES EDUCATOR, V26, P597, DOI 10.1177/014572170002600405; Baker A M, 2001, Jt Comm J Qual Improv, V27, P179; Beck A, 1997, J AM GERIATR SOC, V45, P543, DOI 10.1111/j.1532-5415.1997.tb03085.x; Black HR, 1997, ARCH INTERN MED, V157, P2413; Bodenheimer T, 2002, JAMA-J AM MED ASSOC, V288, P2469, DOI 10.1001/jama.288.19.2469; Bodenheimer T, 2002, JAMA-J AM MED ASSOC, V288, P1775, DOI 10.1001/jama.288.14.1775; Bodenheimer T, 2002, JAMA-J AM MED ASSOC, V288, P1909, DOI 10.1001/jama.288.15.1909; Burdi MD, 1999, HEALTH AFFAIR, V18, P134, DOI 10.1377/hlthaff.18.4.134; CLARK CM, 2000, JAMA-J AM MED ASSOC, V284, P863; DAVIS DA, 1995, JAMA-J AM MED ASSOC, V274, P700; Gotler RS, 2000, MED CARE, V38, P1200, DOI 10.1097/00005650-200012000-00007; Grumbach K, 2002, JAMA-J AM MED ASSOC, V288, P889, DOI 10.1001/jama.288.7.889; Grumbach K, 1999, NEW ENGL J MED, V341, P2008, DOI 10.1056/NEJM199912233412611; HUNT D, 1998, JAMA-J AM MED ASSOC, V280, P339; McBride P, 1998, ARCH INTERN MED, V158, P1238, DOI 10.1001/archinte.158.11.1238; Mitchell E, 2001, BMJ-BRIT MED J, V322, P279, DOI 10.1136/bmj.322.7281.279; Morrison I, 2000, BRIT MED J, V321, P1541, DOI 10.1136/bmj.321.7276.1541; Murray M, 2003, JAMA-J AM MED ASSOC, V289, P1035, DOI 10.1001/jama.289.8.1035; Sadur CN, 1999, DIABETES CARE, V22, P2011, DOI 10.2337/diacare.22.12.2011; Samsa GP, 2000, ARCH INTERN MED, V160, P967, DOI 10.1001/archinte.160.7.967; Sperl-Hillen J, 2000, Jt Comm J Qual Improv, V26, P615; St Peter RF, 1999, NEW ENGL J MED, V341, P1980, DOI 10.1056/NEJM199912233412606; STRUNK BC, 2002, TREADING WATER AM AC; Wagner EH, 2000, BMJ-BRIT MED J, V320, P569, DOI 10.1136/bmj.320.7234.569	24	39	39	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 12	2003	326	7393					796	798		10.1136/bmj.326.7393.796	http://dx.doi.org/10.1136/bmj.326.7393.796			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	670BE	12689977	Green Published, Bronze			2022-12-28	WOS:000182386700019
J	Schott, JM; Harkness, K; Barnes, J; della Rocchetta, AI; Vincent, A; Rossor, MN				Schott, JM; Harkness, K; Barnes, J; della Rocchetta, AI; Vincent, A; Rossor, MN			Amnesia, cerebral atrophy, and autoimmunity	LANCET			English	Editorial Material							ANTIBODIES		UCL, Inst Neurol, Dementia Res Grp, London WC1N 3BG, England; Natl Hosp Neurol & Neurosurg, Dept Neuropsychol, London WC1N 3BG, England; John Radcliffe Hosp, Inst Mol Med, Neurosci Grp, Oxford OX3 9DU, England	University of London; University College London; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; University of Oxford	Rossor, MN (corresponding author), UCL, Inst Neurol, Dementia Res Grp, London WC1N 3BG, England.	m.rossor@dementia.ion.ucl.ac.uk	Barnes, Josesphine/P-5698-2014; Schott, Jonathan M/A-9065-2011; Rossor, Martin/C-1598-2008	Schott, Jonathan M/0000-0003-2059-024X; Barnes, Josephine/0000-0003-3178-025X; Rossor, Martin/0000-0001-8215-3120				Buckley C, 2001, ANN NEUROL, V50, P73, DOI 10.1002/ana.1097; Liguori R, 2001, BRAIN, V124, P2417, DOI 10.1093/brain/124.12.2417; Morvan A, 1890, GAZETTE HEBDOMADAIRE, P173; Voltz R, 2002, LANCET NEUROL, V1, P294, DOI 10.1016/S1474-4422(02)00135-7	4	38	42	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	APR 12	2003	361	9365					1266	1266		10.1016/S0140-6736(03)12983-2	http://dx.doi.org/10.1016/S0140-6736(03)12983-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	666DM	12699955				2022-12-28	WOS:000182161600011
J	Wass, V; Roberts, C; Hoogenboom, R; Jones, R; Van der Vleuten, C				Wass, V; Roberts, C; Hoogenboom, R; Jones, R; Van der Vleuten, C			Effect of ethnicity on performance in a final objective structured clinical examination: qualitative and quantitative study	BRITISH MEDICAL JOURNAL			English	Article							MEDICAL-STUDENTS; MINORITIES; DOCTORS; MRCGP	Objective To assess the effect of ethnicity on Student performance in stations assessing communication, skills within an objective structured clinical examination. Design Quantitative and qualitative study Setting A final UK clinical examination consisting of a two day objective structured clinical examination with 22 stations. Participants 82 students from ethnic minorities and 97 white students. Main outcome measures Mean scores for stations (quantitative) and observations made using discourse analysis on selected communication stations (qualitative). Results Mean performance of students from ethnic minorities was significantly lower than that of white students for stations assessing communication skills on days 1 (67.0% (SD 6.8%) and 72.3% (7.6%); P=0.001) and 2 (65.2% (6.6%) and 69.5% (6.3%); P=0.003). No examples of overt discrimination were found in 309 video recordings. Transcriptions showed subtle differences in communication styles in some students from ethnic minorities who performed poorly. Examiners' assumptions about what is good communication may have contributed to differences in grading. Conclusions There was no evidence of explicit discrimination between students from ethnic minorities and white students in the objective structured clinical examination. A small group of male students from ethnic minorities used particularly poorly rated communicative styles, and some subtle problems in assessing communication skills may have introduced bias. Tests need to reflect issues of diversity to ensure that students from ethnic minorities are not disadvantaged.	Guys Kings & St Thomass Sch Med, Dept Gen Practice & Primary Care, London SE11 6SP, England; Kings Coll London, Dept Educ & Profess Studies, London SE11 6SP, England; Univ Maastricht, Dept Educ Dev & Res, Maastricht, Netherlands	University of London; King's College London; University of London; King's College London; Maastricht University	Wass, V (corresponding author), Guys Kings & St Thomass Sch Med, Dept Gen Practice & Primary Care, London SE11 6SP, England.	valerie.wass@kcl.ac.uk						ANGOFF WH, ED MEASUREMENT; ATKINSON P, 1995, MED TALK MED WORK LI; CATTO G, 2001, BMJ CLASSIFIED  0623, P2; COLLIVER JA, 1989, TEACH LEARN MED, V1, P31; DILLNER L, 1995, BRIT MED J, V310, P209, DOI 10.1136/bmj.310.6974.209; ERICKSON F, 1982, COUNSELLOR GATEKEEPE; Fowell SL, 2000, MED EDUC, V34, P1, DOI 10.1046/j.1365-2923.2000.0340s1001.x; GUMPERZ J, 1997, DISCUSSING COMMUNICA; JOLLY BC, 1988, P 27 ANN C ASS AM ME, P234; MCKENZIE KJ, 1995, BRIT MED J, V310, P478, DOI 10.1136/bmj.310.6978.478; McManus IC, 1998, BRIT MED J, V316, P345, DOI 10.1136/bmj.316.7128.345; McManus IC, 1996, MED EDUC, V30, P195, DOI 10.1111/j.1365-2923.1996.tb00742.x; Roberts C, 2000, BRIT MED J, V320, P370, DOI 10.1136/bmj.320.7231.370; ROBERTS C, 2003, IN PRESS MED ED; Skelton JR, 2001, MED EDUC, V35, P257, DOI 10.1046/j.1365-2923.2001.00873.x; SMITH R, 1987, BRIT MED J, V294, P328, DOI 10.1136/bmj.294.6568.328; van der Vleuten C.P., 1990, TEACH LEARN MED, V2, P58, DOI [https://doi.org/10.1080/10401339009539432, DOI 10.1080/10401339009539432]; WAKEFORD R, 1992, BRIT MED J, V305, P92, DOI 10.1136/bmj.305.6845.92; Wass V, 2001, LANCET, V357, P945, DOI 10.1016/S0140-6736(00)04221-5	19	75	75	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 12	2003	326	7393					800	803		10.1136/bmj.326.7393.800	http://dx.doi.org/10.1136/bmj.326.7393.800			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	670BE	12689978	Bronze, Green Published			2022-12-28	WOS:000182386700021
J	Boucher, P; Gotthardt, M; Li, WP; Anderson, RGW; Herz, J				Boucher, P; Gotthardt, M; Li, WP; Anderson, RGW; Herz, J			LRP: Role in vascular wall integrity and protection from atherosclerosis	SCIENCE			English	Article							RECEPTOR-RELATED PROTEIN; MUSCLE CELL-MIGRATION; APOLIPOPROTEIN-E; IN-VIVO; GENE; INACTIVATION; PROGRESSION; MICE	Vascular smooth muscle cell (SMC) proliferation and migration are important events in the development of atherosclerosis. The low-density lipoprotein receptor-related protein (LRP1) mediates suppression of SMC migration induced by platelet-derived growth factor (PDGF). Here we show that LRP1 forms a complex with the PDGF receptor (PDGFR). Inactivation of LRP1 in vascular SMCs of mice causes PDGFR overexpression and abnormal activation of PDGFR signaling, resulting in disruption of the elastic layer, SMC proliferation, aneurysm formation, and marked susceptibility to cholesterol-induced atherosclerosis. The development of these abnormalities was reduced by treatment with Gleevec, an inhibitor of PDGF signaling. Thus, LRP1 has a pivotal role in protecting vascular wall integrity and preventing atherosclerosis by controlling PDGFR activation.	Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Herz, J (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.		Gotthardt, Michael/ABE-8274-2021	Gotthardt, Michael/0000-0003-1788-3172; Boucher, Philippe/0000-0002-3928-9812	NHLBI NIH HHS [HL20948, R37 HL063762, HL63762] Funding Source: Medline; NIGMS NIH HHS [GM 52016] Funding Source: Medline; NINDS NIH HHS [NS43408] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948, R01HL063762, R37HL063762] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052016] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS043408] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Barnes H, 2001, J BIOL CHEM, V276, P19119, DOI 10.1074/jbc.M011437200; Boucher P, 2002, J BIOL CHEM, V277, P15507, DOI 10.1074/jbc.M200428200; Druker BJ, 2002, TRENDS MOL MED, V8, pS14, DOI 10.1016/S1471-4914(02)02305-5; Goodall S, 2001, CIRCULATION, V104, P304, DOI 10.1161/01.CIR.104.3.304; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; Holtwick R, 2002, P NATL ACAD SCI USA, V99, P7142, DOI 10.1073/pnas.102650499; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; Ishigami M, 1998, J BIOL CHEM, V273, P20156, DOI 10.1074/jbc.273.32.20156; Lee RT, 2000, ANN MED, V32, P233, DOI 10.3109/07853890009011765; Lijnen HR, 2002, BIOCHEM SOC T, V30, P163, DOI 10.1042/bst0300163; Loukinova E, 2002, J BIOL CHEM, V277, P15499, DOI 10.1074/jbc.M200427200; Nakamura T, 2002, NATURE, V415, P171, DOI 10.1038/415171a; Plenz GAM, 2003, ATHEROSCLEROSIS, V166, P1, DOI 10.1016/S0021-9150(01)00766-3; REDDICK RL, 1994, ARTERIOSCLER THROMB, V14, P141, DOI 10.1161/01.ATV.14.1.141; Rohlmann A, 1996, NAT BIOTECHNOL, V14, P1562, DOI 10.1038/nbt1196-1562; Rohlmann A, 1998, J CLIN INVEST, V101, P689, DOI 10.1172/JCI1240; ROSS R, 1993, TRANSPLANT P, V25, P2041; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Swertfeger DK, 2002, J BIOL CHEM, V277, P4141, DOI 10.1074/jbc.M109124200; Swertfeger DK, 2001, FRONT BIOSCI-LANDMRK, V6, pD526, DOI 10.2741/Swertfeg; Yanagisawa H, 2002, NATURE, V415, P168, DOI 10.1038/415168a	22	449	477	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 11	2003	300	5617					329	332		10.1126/science.1082095	http://dx.doi.org/10.1126/science.1082095			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	665RQ	12690199				2022-12-28	WOS:000182135400057
J	Strang, J; McCambridge, J; Best, D; Beswick, T; Bearn, J; Rees, S; Gossop, M				Strang, J; McCambridge, J; Best, D; Beswick, T; Bearn, J; Rees, S; Gossop, M			Loss of tolerance and overdose mortality after inpatient opiate detoxification: follow up study	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Inst Psychiat, Natl Addict Ctr, London SE5 8AF, England; Maudsley Hosp & Inst Psychiat, London SE5 8AF, England	University of London; King's College London; South London & Maudsley NHS Trust; University of London; King's College London	Strang, J (corresponding author), Inst Psychiat, Natl Addict Ctr, London SE5 8AF, England.	j.strang@iop.kcl.ac.uk	Strang, John/H-5460-2011	Strang, John/0000-0002-5413-2725; McCambridge, Jim/0000-0002-5461-7001; Best, David/0000-0002-6792-916X				Advisory Council on the Misuse of Drugs, 2000, RED DRUG REL DEATHS; Bird SM, 2003, ADDICTION, V98, P185, DOI 10.1046/j.1360-0443.2003.00264.x; Caplehorn JRM, 1998, DRUG ALCOHOL REV, V17, P9, DOI 10.1080/09595239800187551; Farrell M, 1996, ADDICTION, V91, P321, DOI 10.1111/j.1360-0443.1996.tb02282.x; OPPENHEIMER E, 1994, ADDICTION, V89, P1299, DOI 10.1111/j.1360-0443.1994.tb03309.x	5	207	211	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 3	2003	326	7396					959	960		10.1136/bmj.326.7396.959	http://dx.doi.org/10.1136/bmj.326.7396.959			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	676JC	12727768	Green Published, Bronze, Green Accepted			2022-12-28	WOS:000182746700016
J	Jiang, YX; Ruta, V; Chen, JY; Lee, A; MacKinnon, R				Jiang, YX; Ruta, V; Chen, JY; Lee, A; MacKinnon, R			The principle of gating charge movement in a voltage-dependent K+ channel	NATURE			English	Article							SHAKER POTASSIUM CHANNEL; TRANSMEMBRANE MOVEMENT; ESCHERICHIA-COLI; ION CHANNELS; S4 SEGMENT; WILD-TYPE; ACTIVATION; SENSOR; MUTANT; SITE	The steep dependence of channel opening on membrane voltage allows voltage-dependent K+ channels to turn on almost like a switch. Opening is driven by the movement of gating charges that originate from arginine residues on helical S4 segments of the protein. Each S4 segment forms half of a 'voltage-sensor paddle' on the channel's outer perimeter. Here we show that the voltage-sensor paddles are positioned inside the membrane, near the intracellular surface, when the channel is closed, and that the paddles move a large distance across the membrane from inside to outside when the channel opens. KvAP channels were reconstituted into planar lipid membranes and studied using monoclonal Fab fragments, a voltage-sensor toxin, and avidin binding to tethered biotin. Our findings lead us to conclude that the voltage-sensor paddles operate somewhat like hydrophobic cations attached to levers, enabling the membrane electric field to open and close the pore.	Rockefeller Univ, Howard Hughes Med Inst, Lab Mol Neurobiol & Biophys, New York, NY 10021 USA	Howard Hughes Medical Institute; Rockefeller University	MacKinnon, R (corresponding author), Rockefeller Univ, Howard Hughes Med Inst, Lab Mol Neurobiol & Biophys, 1230 York Ave, New York, NY 10021 USA.			Ruta, Vanessa/0000-0002-4963-2768				Aggarwal SK, 1996, NEURON, V16, P1169, DOI 10.1016/S0896-6273(00)80143-9; ARMSTRONG CM, 1974, J GEN PHYSIOL, V63, P533, DOI 10.1085/jgp.63.5.533; Aziz QH, 2002, J BIOL CHEM, V277, P42719, DOI 10.1074/jbc.M207258200; Baker OS, 1998, NEURON, V20, P1283, DOI 10.1016/S0896-6273(00)80507-3; Bass RB, 2002, SCIENCE, V298, P1582, DOI 10.1126/science.1077945; Bezanilla F, 2000, PHYSIOL REV, V80, P555, DOI 10.1152/physrev.2000.80.2.555; COLE KS, 1960, BIOPHYS J, V1, P1, DOI 10.1016/S0006-3495(60)86871-3; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Gonzalez C, 2001, P NATL ACAD SCI USA, V98, P9617, DOI 10.1073/pnas.171306298; Jiang YX, 2003, NATURE, V423, P33, DOI 10.1038/nature01580; Jiang YX, 2002, NATURE, V417, P523, DOI 10.1038/417523a; Laine M, 2002, BIOPHYS J, V82, p231A; Larsson HP, 1996, NEURON, V16, P387, DOI 10.1016/S0896-6273(00)80056-2; MARTINAC B, 1987, P NATL ACAD SCI USA, V84, P2297, DOI 10.1073/pnas.84.8.2297; Papazian DM, 2002, NOVART FDN SYMP, V245, P178; PAPAZIAN DM, 1995, NEURON, V14, P1293, DOI 10.1016/0896-6273(95)90276-7; PUGLIESE L, 1993, J MOL BIOL, V231, P698, DOI 10.1006/jmbi.1993.1321; Qiu XQ, 1996, J GEN PHYSIOL, V107, P313, DOI 10.1085/jgp.107.3.313; QIU XQ, 1994, J BIOL CHEM, V269, P7483; Ruta V, 2003, NATURE, V422, P180, DOI 10.1038/nature01473; Schoppa NE, 1998, J GEN PHYSIOL, V111, P313, DOI 10.1085/jgp.111.2.313; SCHOPPA NE, 1992, SCIENCE, V255, P1712, DOI 10.1126/science.1553560; Seoh SA, 1996, NEURON, V16, P1159, DOI 10.1016/S0896-6273(00)80142-7; SIGWORTH FJ, 1994, Q REV BIOPHYS, V27, P1, DOI 10.1017/S0033583500002894; SLATIN SL, 1994, NATURE, V371, P158, DOI 10.1038/371158a0; Starace DM, 1997, NEURON, V19, P1319, DOI 10.1016/S0896-6273(00)80422-5; Swartz KJ, 1997, NEURON, V18, P675, DOI 10.1016/S0896-6273(00)80307-4; Tiwari-Woodruff SK, 2000, J GEN PHYSIOL, V115, P123, DOI 10.1085/jgp.115.2.123; Wimley WC, 1996, BIOCHEMISTRY-US, V35, P5109, DOI 10.1021/bi9600153; Yifrach O, 2002, CELL, V111, P231, DOI 10.1016/S0092-8674(02)01013-9; Yusaf SP, 1996, PFLUG ARCH EUR J PHY, V433, P91, DOI 10.1007/s004240050253; ZAGOTTA WN, 1994, J GEN PHYSIOL, V103, P321, DOI 10.1085/jgp.103.2.321; ZAGOTTA WN, 1994, J GEN PHYSIOL, V103, P279, DOI 10.1085/jgp.103.2.279	33	656	685	1	99	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 1	2003	423	6935					42	48		10.1038/nature01581	http://dx.doi.org/10.1038/nature01581			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	673CG	12721619				2022-12-28	WOS:000182561600033
J	Giasson, BI; Forman, MS; Higuchi, M; Golbe, LI; Graves, CL; Kotzbauer, PT; Trojanowski, JQ; Lee, VMY				Giasson, BI; Forman, MS; Higuchi, M; Golbe, LI; Graves, CL; Kotzbauer, PT; Trojanowski, JQ; Lee, VMY			Initiation and synergistic fibrillization of tau and alpha-synuclein	SCIENCE			English	Article							PROTEIN-TAU; NEUROFIBRILLARY TANGLES; ALZHEIMERS-DISEASE; FILAMENTS; MUTANT; PHOSPHORYLATION; LOCALIZATION; DEMENTIA; RESIDUES; MISSENSE	Alpha-synuclein (alpha-syn) and tau polymerize into amyloid fibrils and form intraneuronal filamentous inclusions characteristic of neurodegenerative diseases. We demonstrate that alpha-syn induces fibrillization of tau and that coincubation of tau and alpha-syn synergistically promotes fibrillization of both proteins. The in vivo relevance of these findings is grounded in the co-occurrence of alpha-syn and tau filamentous amyloid inclusions in humans, in single transgenic mice that express A53T human alpha-syn in neurons, and in oligodendrocytes of bigenic mice that express wild-type human alpha-syn plus P301L mutant tau. This suggests that interactions between alpha-syn and tau can promote their fibrillization and drive the formation of pathological inclusions in human neurodegenerative diseases.	Univ Penn, Sch Med, Dept Pathol & Lab Med, Ctr Neurodegenerat Dis Res, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Inst Aging, Philadelphia, PA 19104 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Neurol, New Brunswick, NJ 08903 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Rutgers State University New Brunswick; Rutgers State University Medical Center	Lee, VMY (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, Ctr Neurodegenerat Dis Res, 3600 Spruce St, Philadelphia, PA 19104 USA.	vmylee@mail.med.upenn.edu						Arrasate M, 1999, FEBS LETT, V446, P199, DOI 10.1016/S0014-5793(99)00210-0; Buee L, 2000, BRAIN RES REV, V33, P95, DOI 10.1016/S0165-0173(00)00019-9; Cabin DE, 2002, J NEUROSCI, V22, P8797; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; CRYSTAL A, UNPUB; Duda JE, 2000, J NEUROSCI RES, V61, P121, DOI 10.1002/1097-4547(20000715)61:2<121::AID-JNR1>3.0.CO;2-4; Duda JE, 2002, ACTA NEUROPATHOL, V104, P7, DOI 10.1007/s00401-002-0563-3; Friedhoff P, 1998, P NATL ACAD SCI USA, V95, P15712, DOI 10.1073/pnas.95.26.15712; Giasson BI, 2002, NEURON, V34, P521, DOI 10.1016/S0896-6273(02)00682-7; Giasson BI, 1999, J BIOL CHEM, V274, P7619, DOI 10.1074/jbc.274.12.7619; Giasson BI, 2001, J BIOL CHEM, V276, P2380, DOI 10.1074/jbc.M008919200; Goedert M, 1998, BIOCHEM SOC T, V26, P463, DOI 10.1042/bst0260463; Goedert M, 1996, NATURE, V383, P550, DOI 10.1038/383550a0; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; HANSEN L, 1990, NEUROLOGY, V40, P1; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; Jensen PH, 1999, J BIOL CHEM, V274, P25481, DOI 10.1074/jbc.274.36.25481; KSIEZAKREDING H, 1991, NEURON, V6, P717, DOI 10.1016/0896-6273(91)90169-Z; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; Lewis J, 2000, NAT GENET, V25, P402, DOI 10.1038/78078; LOPRESTI P, 1995, P NATL ACAD SCI USA, V92, P10369, DOI 10.1073/pnas.92.22.10369; McKeith IG, 1996, NEUROLOGY, V47, P1113, DOI 10.1212/WNL.47.5.1113; Nacharaju P, 1999, FEBS LETT, V447, P195, DOI 10.1016/S0014-5793(99)00294-X; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Richter-Landsberg C, 2000, J NEUROSCI RES, V62, P9, DOI 10.1002/1097-4547(20001001)62:1<9::AID-JNR2>3.0.CO;2-U; SCHWEERS O, 1994, J BIOL CHEM, V269, P24290; Souza JM, 2000, FEBS LETT, V474, P116, DOI 10.1016/S0014-5793(00)01563-5; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n; Wood SJ, 1999, J BIOL CHEM, V274, P19509, DOI 10.1074/jbc.274.28.19509	29	645	671	2	41	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 25	2003	300	5619					636	640		10.1126/science.1082324	http://dx.doi.org/10.1126/science.1082324			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	671FB	12714745				2022-12-28	WOS:000182453700041
J	Partridge, TC; Granger, DE; Caffee, MW; Clarke, RJ				Partridge, TC; Granger, DE; Caffee, MW; Clarke, RJ			Lower Pliocene hominid remains from Sterkfontein	SCIENCE			English	Article							COSMOGENIC NUCLIDES; EROSION RATES; BE-10; RIVER; AGE; SKELETON; DECAY; AL-26	Cosmogenic aluminum-26 and beryllium-10 burial dates of low-lying fossiliferous breccia in the caves at Sterkfontein, South Africa, show that associated hominid fossils accumulated in the Lower Pliocene. These dates indicate that the skeleton StW 573 and newly discovered specimens from Jacovec Cavern have much the same age: approximately 4 million years. These specimens are thus of an age similar to Australopithecus anamensis from East Africa.	Univ Witwatersrand, Sterkfontein Res Unit, ZA-2050 Johannesburg, South Africa; Univ Witwatersrand, Climatol Res Grp, ZA-2050 Johannesburg, South Africa; Purdue Univ, Dept Earth & Atmospher Sci, W Lafayette, IN 47907 USA; Purdue Univ, Dept Phys, W Lafayette, IN 47907 USA; Univ Witwatersrand, Sch Med, Sterkfontein Res Unit, ZA-2193 Johannesburg, South Africa	University of Witwatersrand; University of Witwatersrand; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus; University of Witwatersrand	Partridge, TC (corresponding author), Univ Witwatersrand, Sterkfontein Res Unit, Private Bag 2, ZA-2050 Johannesburg, South Africa.	tcp@iafrica.com						Berger LR, 2002, AM J PHYS ANTHROPOL, V119, P192, DOI 10.1002/ajpa.10156; BROWN ET, 1995, EARTH PLANET SC LETT, V129, P193, DOI 10.1016/0012-821X(94)00249-X; CANDE SC, 1995, J GEOPHYS RES-SOL EA, V100, P6093, DOI 10.1029/94JB03098; CLARKE RJ, 1995, SCIENCE, V269, P521, DOI 10.1126/science.7624772; Clarke RJ, 2002, S AFR J SCI, V98, P415; Clarke RJ, 1998, S AFR J SCI, V94, P460; Granger DE, 1997, GEOLOGY, V25, P107, DOI 10.1130/0091-7613(1997)025<0107:QDROTN>2.3.CO;2; Granger DE, 1996, J GEOL, V104, P249, DOI 10.1086/629823; Granger DE, 2001, GEOL SOC AM BULL, V113, P825, DOI 10.1130/0016-7606(2001)113<0825:PPIOTG>2.0.CO;2; Granger DE, 2001, EARTH PLANET SC LETT, V188, P269, DOI 10.1016/S0012-821X(01)00309-0; Kibii J. M., 2000, THESIS U WITWATERSRA; Kuman K, 2000, J HUM EVOL, V38, P827, DOI 10.1006/jhev.1999.0392; LAL D, 1991, EARTH PLANET SC LETT, V104, P424, DOI 10.1016/0012-821X(91)90220-C; LAL D, 1985, P INDIAN AS-EARTH, V94, P1; MIDDLETON R, 1993, NUCL INSTRUM METH B, V82, P399, DOI 10.1016/0168-583X(93)95987-G; PARTRIDGE T C, 1991, Palaeontologia Africana, V28, P35; PARTRIDGE TC, 1978, NATURE, V275, P282, DOI 10.1038/275282a0; Partridge TC, 2000, OXFORD MGR GEOL GEOP, P100; Partridge TC, 1999, J QUATERNARY SCI, V14, P293, DOI 10.1002/(SICI)1099-1417(199907)14:4<293::AID-JQS471>3.0.CO;2-X; Riebe CS, 2000, GEOLOGY, V28, P803, DOI 10.1130/0091-7613(2000)028<0803:EEADIT>2.3.CO;2; Robinson J.T., 1972, EARLY HOMINID POSTUR; Schaller M, 2001, EARTH PLANET SC LETT, V188, P441, DOI 10.1016/S0012-821X(01)00320-X; SCHWARCZ HP, 1994, J HUM EVOL, V26, P175, DOI 10.1006/jhev.1994.1010; Tobias PV, 1996, SCIENCE, V271, P1301; Tobias PV, 2000, OXFORD MGR GEOL GEOP, P252; Turner A., 1997, Palaeontologia Africana, V34, P115; WILKINSON MJ, 1983, J ARCHAEOL SCI, V10, P515, DOI 10.1016/0305-4403(83)90034-1; WILKINSON MJ, 1973, THESIS U WITWATERSRA; Wilkinson MJ, 1985, HOMINID EVOLUTION PR, P165	29	147	163	0	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 25	2003	300	5619					607	612		10.1126/science.1081651	http://dx.doi.org/10.1126/science.1081651			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	671FB	12714736				2022-12-28	WOS:000182453700032
J	Reches, M; Gazit, E				Reches, M; Gazit, E			Casting metal nanowires within discrete self-assembled peptide nanotubes	SCIENCE			English	Article							AMYLOID FIBRIL FORMATION; PI-STACKING; PENTAPEPTIDE; MODEL	Tubular nanostructures are suggested to have a wide range of applications in nanotechnology. We report our observation of the self-assembly of a very short peptide, the Alzheimer's beta-amyloid diphenylalanine structural motif, into discrete and stiff nanotubes. Reduction of ionic silver within the nanotubes, followed by enzymatic degradation of the peptide backbone, resulted in the production of discrete nanowires with a long persistence length. The same dipeptide building block, made of D-phenylalanine, resulted in the production of enzymatically stable nanotubes.	Tel Aviv Univ, George S Wise Fac Life Sci, Dept Mol Microbiol & Biotechnol, IL-69978 Tel Aviv, Israel	Tel Aviv University	Gazit, E (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Mol Microbiol & Biotechnol, IL-69978 Tel Aviv, Israel.	ehudg@post.tau.ac.il	Gazit, Ehud/AHE-9332-2022; Gazit, Ehud/M-8026-2019; Gazit, Ehud/C-3715-2011; Reches, Meital/B-2348-2013	Gazit, Ehud/0000-0001-5764-1720; Gazit, Ehud/0000-0001-5764-1720; Reches, Meital/0000-0001-5652-9868				Azriel R, 2001, J BIOL CHEM, V276, P34156, DOI 10.1074/jbc.M102883200; Bong DT, 2001, ANGEW CHEM INT EDIT, V40, P988, DOI 10.1002/1521-3773(20010316)40:6<988::AID-ANIE9880>3.0.CO;2-N; Claessens CG, 1997, J PHYS ORG CHEM, V10, P254, DOI 10.1002/(SICI)1099-1395(199705)10:5<254::AID-POC875>3.0.CO;2-3; Dobson CM, 1999, TRENDS BIOCHEM SCI, V24, P329, DOI 10.1016/S0968-0004(99)01445-0; ENUSTUN BV, 1963, J AM CHEM SOC, V85, P3317, DOI 10.1021/ja00904a001; Findeis MA, 1999, BIOCHEMISTRY-US, V38, P6791, DOI 10.1021/bi982824n; Findeis Mark A., 2002, Current Topics in Medicinal Chemistry, V2, P417, DOI 10.2174/1568026024607508; Gazit E, 2002, FASEB J, V16, P77, DOI 10.1096/fj.01-0442hyp; Gazit E, 2002, ANGEW CHEM INT EDIT, V41, P257, DOI 10.1002/1521-3773(20020118)41:2<257::AID-ANIE257>3.0.CO;2-M; Gazit E, 2002, CURR MED CHEM, V9, P1725; GHADIRI MR, 1993, NATURE, V366, P324, DOI 10.1038/366324a0; Gorbitz CH, 2001, CHEM-EUR J, V7, P5153, DOI 10.1002/1521-3765(20011203)7:23<5153::AID-CHEM5153>3.0.CO;2-N; HARIS PI, 1995, BIOPOLYMERS, V37, P251, DOI 10.1002/bip.360370404; Harper JD, 1997, ANNU REV BIOCHEM, V66, P385, DOI 10.1146/annurev.biochem.66.1.385; Hartgerink JD, 1996, J AM CHEM SOC, V118, P43, DOI 10.1021/ja953070s; Henglein A, 1999, J PHYS CHEM B, V103, P9533, DOI 10.1021/jp9925334; Matsui H, 2000, J PHYS CHEM B, V104, P3383, DOI 10.1021/jp994117p; Mazor Y, 2002, J MOL BIOL, V322, P1013, DOI 10.1016/S0022-2836(02)00887-2; Perutz MF, 2002, P NATL ACAD SCI USA, V99, P5591, DOI 10.1073/pnas.042681399; Reches M, 2002, J BIOL CHEM, V277, P35475, DOI 10.1074/jbc.M206039200; Shetty AS, 1996, J AM CHEM SOC, V118, P1019, DOI 10.1021/ja9528893; Soto C, 1998, NAT MED, V4, P822, DOI 10.1038/nm0798-822; Sunde M, 1998, Q REV BIOPHYS, V31, P1, DOI 10.1017/S0033583598003400; Tjernberg LO, 1996, J BIOL CHEM, V271, P8545, DOI 10.1074/jbc.271.15.8545; Vauthey S, 2002, P NATL ACAD SCI USA, V99, P5355, DOI 10.1073/pnas.072089599; Waters ML, 2002, CURR OPIN CHEM BIOL, V6, P736, DOI 10.1016/S1367-5931(02)00359-9; Wickner RB, 2000, J STRUCT BIOL, V130, P310, DOI 10.1006/jsbi.2000.4250; Wolfe MS, 2002, NAT REV DRUG DISCOV, V1, P859, DOI 10.1038/nrd938; Zhang SG, 2002, CURR OPIN CHEM BIOL, V6, P865, DOI 10.1016/S1367-5931(02)00391-5	29	1995	2053	21	875	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 25	2003	300	5619					625	627		10.1126/science.1082387	http://dx.doi.org/10.1126/science.1082387			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	671FB	12714741				2022-12-28	WOS:000182453700037
J	Saltiel, AR				Saltiel, AR			Muscle or fat? Rho bridges the GAP	CELL			English	Editorial Material							INSULIN-RESISTANCE; PROTEIN-KINASE; OBESITY; SRC		Univ Michigan, Inst Life Sci, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Saltiel, AR (corresponding author), Univ Michigan, Inst Life Sci, Ann Arbor, MI 48109 USA.		Saltiel, Alan/L-3632-2019	Saltiel, Alan/0000-0002-9726-9828				Brouns MR, 2001, NAT CELL BIOL, V3, P361, DOI 10.1038/35070042; Coolican SA, 1997, J BIOL CHEM, V272, P6653, DOI 10.1074/jbc.272.10.6653; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hirosumi J, 2002, NATURE, V420, P333, DOI 10.1038/nature01137; Kahn BB, 2000, J CLIN INVEST, V106, P473, DOI 10.1172/JCI10842; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; Peterson JE, 1996, J BIOL CHEM, V271, P31562, DOI 10.1074/jbc.271.49.31562; Rosen ED, 2000, ANNU REV CELL DEV BI, V16, P145, DOI 10.1146/annurev.cellbio.16.1.145; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; Sordella R, 2003, CELL, V113, P147, DOI 10.1016/S0092-8674(03)00271-X; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187	11	4	4	0	4	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 18	2003	113	2					144	145		10.1016/S0092-8674(03)00277-0	http://dx.doi.org/10.1016/S0092-8674(03)00277-0			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	672EP	12705863	Bronze			2022-12-28	WOS:000182508500004
J	Bogardus, ST; Yueh, B; Shekelle, PG				Bogardus, ST; Yueh, B; Shekelle, PG			Screening and management of adult hearing loss in primary care - Clinical applications	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							QUALITY-OF-LIFE; COGNITIVE DYSFUNCTION; ELDERLY-PEOPLE; OLDER-ADULTS; IMPAIRMENT; PREVALENCE; AMPLIFICATION; EPIDEMIOLOGY; RATIONALE; COMMUNITY	Hearing loss is one of the most common chronic health conditions and has important implications for patient quality of life. However, hearing loss is substantially underdetected and undertreated. We present clinical cases to illustrate common situations in which primary care physicians may be called on to identify or to manage hearing loss. With the data reported in the companion scientific review as a guide, we present potential answers to important questions pertaining to hearing loss and suggest ways in which primary care physicians can improve the detection, evaluation, and treatment of hearing loss. The cases focus on screening for chronic hearing loss, evaluation of hearing loss, and treatment of patients with presbycusis.	Yale Univ, Sch Med, Dept Med, New Haven, CT 06504 USA; Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv Res Serv, Seattle, WA USA; Vet Affairs Puget Sound Hlth Care Syst, Dev Serv, Seattle, WA USA; Vet Affairs Puget Sound Hlth Care Syst, Surg Serv, Seattle, WA USA; Univ Washington, Dept Otolaryngol Head & Neck Surg, Seattle, WA 98195 USA; Univ Washington, Hlth Serv, Seattle, WA 98195 USA; RAND Hlth, Los Angeles, CA USA; Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA USA	Yale University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; RAND Corporation; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System	Bogardus, ST (corresponding author), Yale Univ, Sch Med, Dept Med, 20 York St,Tompkins 15, New Haven, CT 06504 USA.	bogardus@ynhh.org		Yueh, Bevan/0000-0003-1380-1053				[Anonymous], 1994, CAN GUID CLIN PREV H, VCanadian Task Force on the Periodic Health and Examination; Appollonio I, 1996, AGE AGEING, V25, P89, DOI 10.1093/ageing/25.2.89; Benson V, 1994, Vital Health Stat 10, P1; CARABELLESE C, 1993, J AM GERIATR SOC, V41, P401, DOI 10.1111/j.1532-5415.1993.tb06948.x; CIURLIAGUY E, 1993, GERONTOLOGIST, V33, P644, DOI 10.1093/geront/33.5.644; Gates GA, 1996, ARCH OTOLARYNGOL, V122, P161; GATES GA, 1990, EAR HEARING, V11, P247, DOI 10.1097/00003446-199008000-00001; GURLAND B, 1977, INT J AGING HUM DEV, V8, P9, DOI 10.2190/CL3J-0E20-97XX-MV5L; HERBST KG, 1980, BMJ-BRIT MED J, V281, P903, DOI 10.1136/bmj.281.6245.903; Jackson A L, 1968, Vital Health Stat 10, V10, P1; Jerger J, 1996, EAR HEARING, V17, P490, DOI 10.1097/00003446-199612000-00005; Kochkin S, 1997, HEARING J, V50, P31; Kochkin S., 2000, HEAR J, V53, P34, DOI [10.1097/00025572-200002000-00004, DOI 10.1097/00025572-200002000-00004]; Laforge R.G., 1992, J AGING HEALTH, V4, P126, DOI [10.1177/089826439200400108, DOI 10.1177/089826439200400108]; LEWISCULLINAN C, 1990, J ADV NURS, V15, P594, DOI 10.1111/j.1365-2648.1990.tb01859.x; LICHTENSTEIN MJ, 1988, JAMA-J AM MED ASSOC, V259, P2875, DOI 10.1001/jama.259.19.2875; LICHTENSTEIN MJ, 1988, EAR HEARING, V9, P208, DOI 10.1097/00003446-198808000-00006; MACPHEE GJA, 1988, AGE AGEING, V17, P347, DOI 10.1093/ageing/17.5.347; Matteson M A, 1993, Geriatr Nurs, V14, P294, DOI 10.1016/S0197-4572(06)80053-4; MCBRIDE WS, 1994, AM J MED SCI, V307, P40, DOI 10.1097/00000441-199401000-00007; MOSCICKI EK, 1985, EAR HEARING, V6, P184, DOI 10.1097/00003446-198507000-00003; MULROW CD, 1990, ANN INTERN MED, V113, P188, DOI 10.7326/0003-4819-113-3-188; MULROW CD, 1990, J AM GERIATR SOC, V38, P45, DOI 10.1111/j.1532-5415.1990.tb01595.x; MULROW CD, 1992, J SPEECH HEAR RES, V35, P1402, DOI 10.1044/jshr.3506.1402; MULROW CD, 1991, J GEN INTERN MED, V6, P249, DOI 10.1007/BF02598971; OVEGARD A, 1994, SCAND AUDIOL, V23, P57, DOI 10.3109/01050399409047486; Popelka MM, 1998, J AM GERIATR SOC, V46, P1075, DOI 10.1111/j.1532-5415.1998.tb06643.x; Prasher D, 1998, LANCET, V352, P1240, DOI 10.1016/S0140-6736(05)70483-9; Reuben DB, 1998, J AM GERIATR SOC, V46, P1008, DOI 10.1111/j.1532-5415.1998.tb02758.x; Ries P W, 1994, Vital Health Stat 10, P1; Smeeth L, 2002, LANCET, V359, P1466, DOI 10.1016/S0140-6736(02)08433-7; UHLMANN RF, 1989, JAMA-J AM MED ASSOC, V261, P1916, DOI 10.1001/jama.261.13.1916; *US DEP COMM, 1997, STAT ABSTR US; *US DEP HHS, 1997, HLTH PEOPL 2000 REV; VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625; Ventry I M, 1983, ASHA, V25, P37; Wallhagen MI, 1997, AM J PUBLIC HEALTH, V87, P440, DOI 10.2105/AJPH.87.3.440; Weinstein B E, 1986, ASHA, V28, P41; WILSON WR, 1980, ARCH OTOLARYNGOL, V106, P772; Yueh B, 2003, JAMA-J AM MED ASSOC, V289, P1976, DOI 10.1001/jama.289.15.1976; Yueh B, 2001, ARCH OTOLARYNGOL, V127, P1197, DOI 10.1001/archotol.127.10.1197	41	57	64	0	16	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 16	2003	289	15					1986	1990		10.1001/jama.289.15.1986	http://dx.doi.org/10.1001/jama.289.15.1986			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	667VC	12697802	Bronze			2022-12-28	WOS:000182253900032
J	Brat, DJ; Mapstone, TB				Brat, DJ; Mapstone, TB			Malignant glioma physiology: Cellular response to hypoxia and its role in tumor progression	ANNALS OF INTERNAL MEDICINE			English	Review							ENDOTHELIAL GROWTH-FACTOR; INDUCIBLE FACTOR 1-ALPHA; HUMAN GLIOBLASTOMA CELLS; WILD-TYPE P53; FACTOR-RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; FACTOR EXPRESSION; MICROVASCULAR PROLIFERATION; PROSTATE-CANCER; GENE-EXPRESSION		Emory Univ, Sch Med, Atlanta, GA USA	Emory University	Brat, DJ (corresponding author), Emory Univ Hosp, Dept Pathol & Lab Med, 1364 Clifton Rd NE,H-176, Atlanta, GA 30322 USA.	dbrat@emory.edu						An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Berdiev BK, 2001, J BIOL CHEM, V276, P38755, DOI 10.1074/jbc.M107266200; BERDIEV BK, 2003, IN PRESS J BIOL CHEM; BERNSTEIN M, 2001, NEUROONCOLOGY ESSENT; Bouvet M, 1998, CANCER RES, V58, P2288; Brat DJ, 2002, ADV ANAT PATHOL, V9, P24, DOI 10.1097/00125480-200201000-00004; Brat DJ, 2001, AM J PATHOL, V158, P789, DOI 10.1016/S0002-9440(10)64025-4; Bruger PC, 2002, SURG PATHOLOGY NERVO; Bubien JK, 1999, AM J PHYSIOL-CELL PH, V276, pC1405, DOI 10.1152/ajpcell.1999.276.6.C1405; Cairncross JG, 1998, J NATL CANCER I, V90, P1473, DOI 10.1093/jnci/90.19.1473; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; CAVENEE WK, 2000, PATHOLOGY GENETICS T, P10; Chen EY, 2001, CANCER RES, V61, P2429; Clarke K, 2001, BRIT J CANCER, V84, P1322, DOI 10.1054/bjoc.2001.1805; de Bono JS, 2002, TRENDS MOL MED, V8, pS19, DOI 10.1016/S1471-4914(02)02306-7; Dvorak HF, 2000, SEMIN PERINATOL, V24, P75, DOI 10.1016/S0146-0005(00)80061-0; FLEMING TP, 1992, CANCER RES, V52, P4550; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Frederick L, 2000, CANCER RES, V60, P1383; Fulci G, 1998, BRAIN PATHOL, V8, P599, DOI 10.1111/j.1750-3639.1998.tb00187.x; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hewitson KS, 2002, J BIOL CHEM, V277, P26351, DOI 10.1074/jbc.C200273200; Hirata A, 2002, CANCER RES, V62, P2554; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jiang BH, 2000, P NATL ACAD SCI USA, V97, P1749, DOI 10.1073/pnas.040560897; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Kerbel RS, 1998, MOL MED, V4, P286, DOI 10.1007/BF03401737; Lal A, 2001, JNCI-J NATL CANCER I, V93, P1337, DOI 10.1093/jnci/93.17.1337; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Mabjeesh NJ, 2002, CANCER RES, V62, P2478; Maher EA, 2001, GENE DEV, V15, P1311, DOI 10.1101/gad.891601; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; Maity A, 2000, CANCER RES, V60, P5879; Maxwell PH, 2001, CURR OPIN GENET DEV, V11, P293, DOI 10.1016/S0959-437X(00)00193-3; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Nakamura M, 2001, BRAIN PATHOL, V11, P159; Oosthuyse B, 2001, NAT GENET, V28, P131, DOI 10.1038/88842; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; Post DE, 2001, GENE THER, V8, P1801, DOI 10.1038/sj.gt.3301605; Ravi R, 2000, GENE DEV, V14, P34; REIFENBERGER G, 1993, CANCER RES, V53, P2736; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Semenza GL, 2001, TRENDS MOL MED, V7, P345, DOI 10.1016/S1471-4914(01)02090-1; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Takano S, 1996, CANCER RES, V56, P2185; VAN MEIR EG, 1994, CANCER RES, V54, P649; VONDEIMLING A, 1993, BRAIN PATHOL, V3, P19; Wang DG, 1999, CANCER RES, V59, P1464; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; WESSELING P, 1995, J NEUROPATH EXP NEUR, V54, P304, DOI 10.1097/00005072-199505000-00003; Zagzag D, 2000, CANCER-AM CANCER SOC, V88, P2606, DOI 10.1002/1097-0142(20000601)88:11<2606::AID-CNCR25>3.0.CO;2-W; Zundel W, 2000, GENE DEV, V14, P391; 2000, STAT REPORT PRIMARY	58	88	88	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	2003	138	8					659	668		10.7326/0003-4819-138-8-200304150-00014	http://dx.doi.org/10.7326/0003-4819-138-8-200304150-00014			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	666JH	12693889				2022-12-28	WOS:000182173800009
J	Swank, DJ; Swank-Bordewijk, SCG; Hop, WCJ; van Erp, WFM; Janssen, IMC; Bonjer, HJ; Jeekel, J				Swank, DJ; Swank-Bordewijk, SCG; Hop, WCJ; van Erp, WFM; Janssen, IMC; Bonjer, HJ; Jeekel, J			Laparoscopic adhesiolysis in patients with chronic abdominal pain: a blinded randomised controlled multi-centre trial	LANCET			English	Article							CHRONIC PELVIC PAIN; SURGERY	Background Laparoscopic adhesiolysis for chronic abdominal pain is controversial and is not evidence based. We aimed to test our hypothesis that laparoscopic adhesiolysis leads to substantial pain relief and improvement in quality of life in patients with adhesions and chronic abdominal pain. Methods Patients had diagnostic laparoscopy for chronic abdominal pain attributed to adhesions; other causes for their pain had been excluded. If adhesions were confirmed during diagnostic laparoscopy, patients were randomly assigned either to laparoscopic adhesiolysis or no treatment. Treatment allocation was concealed from patients, and assessors were unaware of patients' treatment and outcome. Pain was assessed for 1 year by visual analogue score (VAS) score (scale 0-100), pain change score, use of analgesics, and quality of life score. Analysis was by intention to treat. Findings Of 116 patients enrolled for diagnostic laparoscopy, 100 were randomly allocated either laparoscopic adhesiolysis (52) or no treatment (48). Both groups reported substantial pain relief and a significantly improved quality of life, but there was no difference between the groups (mean change from baseline of VAS score at 12 months: difference 3 points, p=0.53; 95% Cl -7 to 13). Interpretation Although laparoscopic adhesiolysis relieves chronic abdominal pain, it is not more beneficial than diagnostic laparoscopy alone. Therefore, laparoscopic adhesiolysis cannot be recommended as a treatment for adhesions in patients with chronic abdominal pain.	Groene Hart Hosp, Dept Surg, Gouda, Netherlands; Erasmus Univ, Med Ctr, Dept Epidemiol & Biostat, Rotterdam, Netherlands; Erasmus Univ, Med Ctr, Dept Surg, Rotterdam, Netherlands; Maxima Med Ctr, Dept Surg, Eindhoven, Netherlands; Rijnstate Hosp, Dept Surg, Arnhem, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Maxima Medical Center; Rijnstate Hospital	Swank, DJ (corresponding author), Kalmoes 10, NL-2811 EB Reeuwijk, Netherlands.			janssen, ignace/0000-0001-5666-754X				Bonjer HJ, 1997, BRIT J SURG, V84, P599, DOI 10.1002/bjs.1800840506; BRUXELLE J, 1994, REV PRATICIEN, V15, P1919; Chapron C, 1999, HUM REPROD, V14, P333, DOI 10.1093/humrep/14.2.333; Elcombe S, 1997, PSYCHOL MED, V27, P1041, DOI 10.1017/S0033291797004868; Ellis H, 1999, LANCET, V353, P1476, DOI 10.1016/S0140-6736(98)09337-4; ELLIS H, 1997, EUR J SURG S, V577, P5; HALLFELDT KKJ, 1995, ZBL CHIR, V120, P387; Hashizume M, 1997, SURG ENDOSC, V11, P1198, DOI 10.1007/s004649900568; HASSAON HM, 1971, AM J OBSTET GYNECOL, V110, P886, DOI 10.1016/0002-9378(71)90593-X; Howard F M, 1993, Obstet Gynecol Surv, V48, P357, DOI 10.1097/00006254-199306000-00001; Howard FM, 1996, J AM ASSOC GYN LAP, V4, P85, DOI 10.1016/S1074-3804(96)80116-2; IKARD RW, 1992, SOUTHERN MED J, V85, P939, DOI 10.1097/00007611-199210000-00002; Jeekel H, 1997, EUR J SURG, V163, P43; Klingensmith ME, 1996, SURG ENDOSC-ULTRAS, V10, P1085, DOI 10.1007/s004649900245; KOLMORGEN K, 1991, ZBL GYNAKOL, V113, P291; LAVONIUS M, 1999, SURG LAPARO ENDO PER, V10, P942; Linssen A C, 1991, Ned Tijdschr Geneeskd, V135, P557; Luijendijk RW, 1996, ANN SURG, V223, P242, DOI 10.1097/00000658-199603000-00003; MENZIES D, 1990, ANN ROY COLL SURG, V72, P60; Miller K, 1996, AM J SURG, V172, P353, DOI 10.1016/S0002-9610(96)00187-0; PETERS AAW, 1992, BRIT J OBSTET GYNAEC, V99, P59, DOI 10.1111/j.1471-0528.1992.tb14394.x; Salky BA, 1998, SURG ENDOSC-ULTRAS, V12, P911, DOI 10.1007/s004649900744; Schietroma M, 2001, Minerva Chir, V56, P461; STEEDMAN SM, 1992, CLIN J PAIN, V8, P204, DOI 10.1097/00002508-199209000-00004; Swank DJ, 2002, SURG ENDOSC, V16, P1468, DOI 10.1007/s00464-002-0008-z; TURNER JA, 1994, JAMA-J AM MED ASSOC, V271, P1609, DOI 10.1001/jama.271.20.1609; WARE JE, 1995, MED CARE S, V33, P64; ZUHLKE LEM, 1990, LANGENBECKS ARCH C S, V375, P1009	28	211	219	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 12	2003	361	9365					1247	1251		10.1016/S0140-6736(03)12979-0	http://dx.doi.org/10.1016/S0140-6736(03)12979-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	666DM	12699951				2022-12-28	WOS:000182161600008
J	Sun, JC; Bevan, MJ				Sun, JC; Bevan, MJ			Defective CD8 T cell memory following acute infection without CD4 T cell help	SCIENCE			English	Article							CHRONIC VIRAL-INFECTION; LISTERIA INFECTION; MICE; RESPONSES; LYMPHOCYTES; RESISTANCE	The CD8(+) cytotoxic T cell response to pathogens is thought to be CD4(+) helper T cell independent because infectious agents provide their own inflammatory signals. Mice that lack CD4(+) T cells mount a primary CD8 response to Listeria monocytogenes equal to that of wild-type mice and rapidly clear the infection. However, protective memory to a challenge is gradually lost in the former animals. Memory CD8(+) T cells from normal mice can respond rapidly, but memory CD8(+) T cells that are generated without CD4 help are defective in their ability to respond to secondary encounters with antigen. The results highlight a previously undescribed role for CD4 help in promoting protective CD8 memory development.	Univ Washington, Dept Immunol, Seattle, WA 98195 USA; Univ Washington, Howard Hughes Med Inst, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle	Bevan, MJ (corresponding author), Univ Washington, Dept Immunol, Seattle, WA 98195 USA.		Nogueira, Raquel Tayar/F-6475-2019	Nogueira, Raquel Tayar/0000-0002-0581-763X	Howard Hughes Medical Institute Funding Source: Medline; NIAID NIH HHS [AI 19335, R01 AI019335-19, R01 AI019335] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019335, R37AI019335] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BATTEGAY M, 1994, J VIROL, V68, P4700, DOI 10.1128/JVI.68.7.4700-4704.1994; Belz GT, 2002, J VIROL, V76, P12388, DOI 10.1128/JVI.76.23.12388-12393.2002; Bennett SRM, 1998, NATURE, V393, P478, DOI 10.1038/30996; Blattman JN, 2002, J EXP MED, V195, P657, DOI 10.1084/jem.20001021; Bourgeois C, 2002, EUR J IMMUNOL, V32, P2199, DOI 10.1002/1521-4141(200208)32:8<2199::AID-IMMU2199>3.0.CO;2-L; Bourgeois C, 2002, SCIENCE, V297, P2060, DOI 10.1126/science.1072615; CARDIN RD, 1996, J EXP MED, V184, P8056; Edelson BT, 1999, J IMMUNOL, V163, P4087; Edelson BT, 2000, CURR OPIN IMMUNOL, V12, P425, DOI 10.1016/S0952-7915(00)00112-6; Gordon S, 2002, CELL, V111, P927, DOI 10.1016/S0092-8674(02)01201-1; Janssen EM, 2003, NATURE, V421, P852, DOI 10.1038/nature01441; Kalams SA, 1998, J EXP MED, V188, P2199, DOI 10.1084/jem.188.12.2199; LADEL CH, 1994, J IMMUNOL, V153, P3116; Lauvau G, 2001, SCIENCE, V294, P1735, DOI 10.1126/science.1064571; Liu HY, 2002, J IMMUNOL, V168, P3477, DOI 10.4049/jimmunol.168.7.3477; MATLOUBIAN M, 1994, J VIROL, V68, P8056, DOI 10.1128/JVI.68.12.8056-8063.1994; RAHEMTULLA A, 1991, NATURE, V353, P180, DOI 10.1038/353180a0; Riberdy JM, 2000, J VIROL, V74, P9762, DOI 10.1128/JVI.74.20.9762-9765.2000; Ridge JP, 1998, NATURE, V393, P474, DOI 10.1038/30989; Schoenberger SP, 1998, NATURE, V393, P480, DOI 10.1038/31002; Shen H, 2003, J IMMUNOL, V170, P1443, DOI 10.4049/jimmunol.170.3.1443; vonHerrath MG, 1996, J VIROL, V70, P1072, DOI 10.1128/JVI.70.2.1072-1079.1996; Zajac AJ, 1998, CURR OPIN IMMUNOL, V10, P444, DOI 10.1016/S0952-7915(98)80119-2; Zajac AJ, 1998, J EXP MED, V188, P2205, DOI 10.1084/jem.188.12.2205	25	998	1033	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 11	2003	300	5617					339	342		10.1126/science.1083317	http://dx.doi.org/10.1126/science.1083317			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	665RQ	12690202	Green Accepted			2022-12-28	WOS:000182135400060
J	Zinner, E				Zinner, E			Planetary science - An isotopic view of the early solar system	SCIENCE			English	Editorial Material							ALUMINUM-RICH INCLUSIONS; SHORT-LIVED NUCLIDES; CHONDRITES; CHONDRULES; AL-26; RAYS		Washington Univ, Space Sci Lab, St Louis, MO 63130 USA; Washington Univ, Dept Phys, St Louis, MO 63130 USA	Washington University (WUSTL); Washington University (WUSTL)	Zinner, E (corresponding author), Washington Univ, Space Sci Lab, St Louis, MO 63130 USA.							Amelin Y, 2002, SCIENCE, V297, P1678, DOI 10.1126/science.1073950; CAMERON AGW, 1995, ASTROPHYS J, V447, pL53, DOI 10.1086/309554; CHAUSSIDON M, 2002, LUNAR PLANET SCI, V33; DESCH SJ, 2003, LUNAR PLANET SCI, V34; Gilmour J, 2002, SCIENCE, V297, P1658, DOI 10.1126/science.1075519; Goswami J. N., 2000, Protostars and planets 4, P963; Goswami JN, 2001, ASTROPHYS J, V549, P1151, DOI 10.1086/319434; Gounelle M, 2001, ASTROPHYS J, V548, P1051, DOI 10.1086/319019; Huss GR, 2001, METEORIT PLANET SCI, V36, P975, DOI 10.1111/j.1945-5100.2001.tb01934.x; Leya I, 2002, METEORIT PLANET SCI, V37, pA86; Marhas KK, 2002, SCIENCE, V298, P2182, DOI 10.1126/science.1078322; McKeegan KD, 2000, SCIENCE, V289, P1334, DOI 10.1126/science.289.5483.1334; MEYER BS, 2003, LUNAR PLANET SCI, V34; MOSTEFAOUI S, 2003, LUNAR PLANET SCI, V34; TACHIBANA S, 2003, LUNAR PLANET SCI, V34; WASSERBURG GJ, 1994, ASTROPHYS J, V424, P412, DOI 10.1086/173899; Zinner E, 2002, METEORIT PLANET SCI, V37, P1001, DOI 10.1111/j.1945-5100.2002.tb00872.x	18	28	32	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 11	2003	300	5617					265	267		10.1126/science.1080300	http://dx.doi.org/10.1126/science.1080300			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	665RQ	12690180				2022-12-28	WOS:000182135400036
J	Wiznitzer, M; Findling, RL				Wiznitzer, M; Findling, RL			Why do psychiatric drug research in children?	LANCET			English	Editorial Material							OBSESSIVE-COMPULSIVE DISORDER; MOOD DISORDERS; PSYCHOPHARMACOLOGY; ADOLESCENTS; PERSPECTIVE; DEPRESSION		Univ Hosp Cleveland, Dept Pediat, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Dept Psychiat, Cleveland, OH 44106 USA; Case Western Reserve Univ, Cleveland, OH 44106 USA	University Hospitals of Cleveland; University Hospitals of Cleveland; Case Western Reserve University	Wiznitzer, M (corresponding author), Univ Hosp Cleveland, Dept Pediat, Cleveland, OH 44106 USA.							Carrey N, 2001, CAN J PSYCHIAT, V46, P810, DOI 10.1177/070674370104600904; HAZELL P, 2002, COCHRANE DB SYST REV, V2, DOI DOI 10.1002/14651858.CD002317; Hyman SE, 2001, BIOL PSYCHIAT, V49, P962, DOI 10.1016/S0006-3223(01)01128-3; Jensen PS, 1999, ARCH GEN PSYCHIAT, V56, P1073; Kaufman J, 2001, BIOL PSYCHIAT, V49, P980, DOI 10.1016/S0006-3223(01)01127-1; Kessler RC, 2001, BIOL PSYCHIAT, V49, P1002, DOI 10.1016/S0006-3223(01)01129-5; March JS, 2001, J CLIN CHILD PSYCHOL, V30, P8, DOI 10.1207/S15374424JCCP3001_3; Michael KD, 2002, CLIN PSYCHOL REV, V22, P247, DOI 10.1016/S0272-7358(01)00089-7; Piacentini J, 2000, PSYCHIAT CLIN N AM, V23, P519, DOI 10.1016/S0193-953X(05)70178-7; *US FDA, 2003, FDA APPR PROZ PED US; Vitiello B, 2001, PEDIATRICS, V108, P983, DOI 10.1542/peds.108.4.983; Weintrob N, 2002, ARCH PEDIAT ADOL MED, V156, P696, DOI 10.1001/archpedi.156.7.696; Zito JM, 2003, ARCH PEDIAT ADOL MED, V157, P17, DOI 10.1001/archpedi.157.1.17	13	17	18	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 5	2003	361	9364					1147	1148		10.1016/S0140-6736(03)12967-4	http://dx.doi.org/10.1016/S0140-6736(03)12967-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	664ZF	12686034				2022-12-28	WOS:000182094600005
J	Ueda, H; Howson, JMM; Esposito, L; Heward, J; Snook, H; Chamberlain, G; Rainbow, DB; Hunter, KMD; Smith, AN; Di Genova, G; Herr, MH; Dahlman, I; Payne, F; Smyth, D; Lowe, C; Twells, RCJ; Howlett, S; Healy, B; Nutland, S; Rance, HE; Everett, V; Smink, LJ; Lam, AC; Cordell, HJ; Walker, NM; Bordin, C; Hulme, J; Motzo, C; Cucca, F; Hess, JF; Metzker, ML; Rogers, J; Gregory, S; Allahabadia, A; Nithiyananthan, R; Tuomilehto-Wolf, E; Tuomilehto, J; Bingley, P; Gillespie, KM; Undlien, DE; Ronningen, KS; Guja, C; Ionescu-Tirgoviste, C; Savage, DA; Maxwell, AP; Carson, DJ; Patterson, CC; Franklyn, JA; Clayton, DG; Peterson, LB; Wicker, LS; Todd, JA; Gough, SCL				Ueda, H; Howson, JMM; Esposito, L; Heward, J; Snook, H; Chamberlain, G; Rainbow, DB; Hunter, KMD; Smith, AN; Di Genova, G; Herr, MH; Dahlman, I; Payne, F; Smyth, D; Lowe, C; Twells, RCJ; Howlett, S; Healy, B; Nutland, S; Rance, HE; Everett, V; Smink, LJ; Lam, AC; Cordell, HJ; Walker, NM; Bordin, C; Hulme, J; Motzo, C; Cucca, F; Hess, JF; Metzker, ML; Rogers, J; Gregory, S; Allahabadia, A; Nithiyananthan, R; Tuomilehto-Wolf, E; Tuomilehto, J; Bingley, P; Gillespie, KM; Undlien, DE; Ronningen, KS; Guja, C; Ionescu-Tirgoviste, C; Savage, DA; Maxwell, AP; Carson, DJ; Patterson, CC; Franklyn, JA; Clayton, DG; Peterson, LB; Wicker, LS; Todd, JA; Gough, SCL			Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease	NATURE			English	Article							DEPENDENT DIABETES-MELLITUS; SOLUBLE FORM; CHROMOSOME 2Q33; GRAVES-DISEASE; CD28; POLYMORPHISM; REGION; EPIDEMIOLOGY; LYMPHOCYTES; REQUIRES	Genes and mechanisms involved in common complex diseases, such as the autoimmune disorders that affect approximately 5% of the population, remain obscure. Here we identify polymorphisms of the cytotoxic T lymphocyte antigen 4 gene (CTLA4)-which encodes a vital negative regulatory molecule of the immune system-as candidates for primary determinants of risk of the common autoimmune disorders Graves' disease, autoimmune hypothyroidism and type 1 diabetes. In humans, disease susceptibility was mapped to a non-coding 6.1 kb 30 region of CTLA4, the common allelic variation of which was correlated with lower messenger RNA levels of the soluble alternative splice form of CTLA4. In the mouse model of type 1 diabetes, susceptibility was also associated with variation in CTLA-4 gene splicing with reduced production of a splice form encoding a molecule lacking the CD80/CD86 ligand-binding domain. Genetic mapping of variants conferring a small disease risk can identify pathways in complex disorders, as exemplified by our discovery of inherited, quantitative alterations of CTLA4 contributing to autoimmune tissue destruction.	Univ Cambridge, Cambridge Inst Med Res, Juvenile Diabet Res Fdn, Wellcome Trust Diabet & Inflammat Lab, Cambridge CB2 2XY, England; Univ Birmingham, Div Med Sci, Birmingham B15 2TT, W Midlands, England; Univ Cagliari, Dipartimento Sci Biomed & Biotecnol, Cagliari, Italy; Merck Res Labs, W Point, PA 19486 USA; Wellsome Trust Sanger Inst, Cambridge CB10 1SA, England; Univ Helsinki, Natl Publ Hlth Inst, Diabet & Genet Epidemiol Unit, Helsinki, Finland; Univ Helsinki, Dept Publ Hlth, Helsinki, Finland; Univ Bristol, Div Med, Diabet & Metab Unit, Bristol BS10 5NG, Avon, England; Univ Oslo, Ulleval Univ Hosp, Inst Med Genet, Oslo, Norway; Rikshosp Univ Hosp, Inst Immunol, Oslo, Norway; Univ Oslo, Norwegian Inst Publ Hlth, Div Epidemiol, Lab Mol Epidemiol, Oslo, Norway; Inst Diabet Nutr & Metab Dis N Paulescu, Diabet Clin, Bucharest, Romania; Queens Univ Belfast, Belfast City Hosp, Dept Med Genet, Belfast BT9 7AB, Antrim, North Ireland; Belfast City Hosp, Reg Nephrol Unit, Belfast BT9 7AB, Antrim, North Ireland; Queens Univ Belfast, Dept Child Hlth, Belfast BT12 6BJ, Antrim, North Ireland; Queens Univ Belfast, Dept Epidemiol & Publ Hlth, Belfast BT12 6BJ, Antrim, North Ireland; Merck Res Labs, Dept Pharmacol, Rahway, NJ 07065 USA	University of Cambridge; University of Birmingham; University of Cagliari; Merck & Company; Wellcome Trust Sanger Institute; Finland National Institute for Health & Welfare; University of Helsinki; University of Helsinki; University of Bristol; University of Oslo; University of Oslo; National Hospital Norway; Norwegian Institute of Public Health (NIPH); University of Oslo; Belfast City Hospital; Queens University Belfast; Belfast City Hospital; Queens University Belfast; Queens University Belfast; Merck & Company	Todd, JA (corresponding author), Univ Cambridge, Cambridge Inst Med Res, Juvenile Diabet Res Fdn, Wellcome Trust Diabet & Inflammat Lab, Wellcome Trust MRC Bldg, Cambridge CB2 2XY, England.		Nithiyananthan, Ratnasingam/ABD-7859-2020; Payne, Felicity/GKF-2573-2022; Todd, John A/A-3542-2010; Wicker, Linda S/F-7384-2010; Guja, Cristian/K-2334-2019	Payne, Felicity/0000-0003-4228-581X; Todd, John A/0000-0003-2740-8148; smyth, deborah/0000-0002-6330-2669; Cordell, Heather/0000-0002-1879-5572; Dahlman, Ingrid/0000-0003-3819-5977; Gregory, Simon/0000-0002-7805-1743; CUCCA, Francesco/0000-0002-7414-1995; Walker, Neil/0000-0001-9796-7688; Howson, Joanna/0000-0001-7618-0050; Maxwell, Alexander P./0000-0002-6110-7253				Allahabadia A, 2001, LANCET, V358, P984, DOI 10.1016/S0140-6736(01)06125-6; Asano M, 1996, J EXP MED, V184, P387, DOI 10.1084/jem.184.2.387; BAIN SC, 1990, AUTOIMMUNITY, V7, P83, DOI 10.3109/08916939008993380; Chikuma S, 2003, J EXP MED, V197, P129, DOI 10.1084/jem.20021646; CLAYTON D, 2001, HDB STAT GENETICS, P519; Colucci F, 1997, P NATL ACAD SCI USA, V94, P8670, DOI 10.1073/pnas.94.16.8670; Cordell HJ, 2002, AM J HUM GENET, V70, P124, DOI 10.1086/338007; Dahlman I, 2002, NAT GENET, V30, P149, DOI 10.1038/ng825; Egen JG, 2002, NAT IMMUNOL, V3, P611, DOI 10.1038/ni0702-611; Finger EB, 2002, NAT IMMUNOL, V3, P1056, DOI 10.1038/ni1102-1056; Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424; Grohmann U, 2002, NAT IMMUNOL, V3, P1097, DOI 10.1038/ni846; Hanawa H, 2002, BLOOD, V99, P2138, DOI 10.1182/blood.V99.6.2138; Hill NJ, 2000, DIABETES, V49, P1744, DOI 10.2337/diabetes.49.10.1744; Howard TD, 2002, J ALLERGY CLIN IMMUN, V110, P743, DOI 10.1067/mai.2002.128723; Huang DR, 2000, J NEUROIMMUNOL, V105, P69, DOI 10.1016/S0165-5728(00)00191-0; Kaijzel EL, 2001, GENES IMMUN, V2, P135, DOI 10.1038/sj.gene.6363747; Kaufman KA, 1999, MOL HUM REPROD, V5, P84, DOI 10.1093/molehr/5.1.84; Kouki T, 2000, J IMMUNOL, V165, P6606, DOI 10.4049/jimmunol.165.11.6606; Kristiansen OP, 2000, GENES IMMUN, V1, P170, DOI 10.1038/sj.gene.6363655; Lamhamedi-Cherradi SE, 2001, DIABETES, V50, P2874, DOI 10.2337/diabetes.50.12.2874; LERNMARK A, 1990, AM J HUM GENET, V47, P1028; Lesage S, 2001, J EXP MED, V194, pF31, DOI 10.1084/jem.194.5.F31; Lin H, 1998, J EXP MED, V188, P199, DOI 10.1084/jem.188.1.199; Lohmueller KE, 2003, NAT GENET, V33, P177, DOI 10.1038/ng1071; Lynch KW, 2001, J BIOL CHEM, V276, P24341, DOI 10.1074/jbc.M102175200; Magistrelli G, 1999, BIOCHEM BIOPH RES CO, V259, P34, DOI 10.1006/bbrc.1999.0725; Magistrelli G, 1999, EUR J IMMUNOL, V29, P3596, DOI 10.1002/(SICI)1521-4141(199911)29:11<3596::AID-IMMU3596>3.0.CO;2-Y; Maloy KJ, 2003, J EXP MED, V197, P111, DOI 10.1084/jem.20021345; Manzotti CN, 2002, EUR J IMMUNOL, V32, P2888, DOI 10.1002/1521-4141(2002010)32:10<2888::AID-IMMU2888>3.0.CO;2-F; Marron MP, 2000, DIABETES, V49, P492, DOI 10.2337/diabetes.49.3.492; Maurer M, 2002, IMMUNOGENETICS, V54, P1, DOI 10.1007/s00251-002-0429-9; Mein CA, 2000, GENOME RES, V10, P330, DOI 10.1101/gr.10.3.330; Nistico L, 1996, HUM MOL GENET, V5, P1075, DOI 10.1093/hmg/5.7.1075; Oaks MK, 2000, CELL IMMUNOL, V201, P144, DOI 10.1006/cimm.2000.1649; Oaks MK, 2000, J IMMUNOL, V164, P5015, DOI 10.4049/jimmunol.164.10.5015; Olivier M, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf052; Pasare C, 2003, SCIENCE, V299, P1033, DOI 10.1126/science.1078231; Patterson CC, 1996, DIABETOLOGIA, V39, P1063, DOI 10.1007/BF00400655; Sakaguchi S, 2003, J EXP MED, V197, P397, DOI 10.1084/jem.20030012; Sharpe AH, 2002, NAT REV IMMUNOL, V2, P116, DOI 10.1038/nri727; SPIELMAN RS, 1993, AM J HUM GENET, V52, P506; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; TODD JA, 1991, DIABETIC MED, V8, P906, DOI 10.1111/j.1464-5491.1991.tb01528.x; TUOMILEHTO J, 1992, DIABETOLOGIA, V35, P70, DOI 10.1007/BF00400854; Zheng ZM, 1999, J VIROL, V73, P29, DOI 10.1128/JVI.73.1.29-36.1999	46	1690	1773	1	149	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 29	2003	423	6939					506	511		10.1038/nature01621	http://dx.doi.org/10.1038/nature01621			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	683RH	12724780	Green Published, Bronze			2022-12-28	WOS:000183162900035
J	Chen, MW; Ma, E; Hemker, KJ; Sheng, HW; Wang, YM; Cheng, XM				Chen, MW; Ma, E; Hemker, KJ; Sheng, HW; Wang, YM; Cheng, XM			Deformation twinning in nanocrystalline aluminum	SCIENCE			English	Article							MECHANICAL-BEHAVIOR; GRAIN-BOUNDARIES; DISLOCATIONS; COPPER	We report transmission electron microscope observations that provide evidence of deformation twinning in plastically deformed nanocrystalline aluminum. The presence of these twins is directly related to the nanocrystalline structure, because they are not observed in coarse-grained pure aluminum. We propose a dislocation-based model to explain the preference for deformation twins and stacking faults in nanocrystalline materials. These results underscore a transition from deformation mechanisms controlled by normal slip to those controlled by partial dislocation activity when grain size decreases to tens of nanometers, and they have implications for interpreting the unusual mechanical behavior of nanocrystalline materials.	Johns Hopkins Univ, Dept Mech Engn, Baltimore, MD 21218 USA; Johns Hopkins Univ, Dept Mat Sci & Engn, Baltimore, MD 21218 USA; Johns Hopkins Univ, Dept Phys & Astron, Baltimore, MD 21218 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Chen, MW (corresponding author), Johns Hopkins Univ, Dept Mech Engn, Baltimore, MD 21218 USA.		Chen, Ming/GVU-8412-2022; Ma, En/A-3232-2010; CHEN, Mingwei/A-4855-2010; Sheng, Howard/B-2033-2013; Cheng, Xuemei/D-2388-2010; Hemker, Kevin J/A-3315-2010; Chen, Mingwei/A-4855-2010; Wang, Yinmin (Morris)/F-2249-2010	CHEN, Mingwei/0000-0002-8274-3099; Cheng, Xuemei/0000-0001-6670-4316; Sheng, Howard/0000-0002-6134-0354; Chen, Mingwei/0000-0002-2850-8872; Wang, Yinmin (MORRIS)/0000-0003-0393-5154; Wang, Yinmin (Morris)/0000-0002-7161-2034				BLEWITT TH, 1957, J APPL PHYS, V28, P651, DOI 10.1063/1.1722824; Champion Y, 1998, NANOSTRUCT MATER, V10, P1097, DOI 10.1016/S0965-9773(98)00149-4; COHEN TB, 1963, ACTA METALL, V11, P996; Ebrahimi F, 1999, NANOSTRUCT MATER, V11, P343, DOI 10.1016/S0965-9773(99)00050-1; GRAY GT, 1991, MAT SCI ENG A-STRUCT, V145, P21, DOI 10.1016/0921-5093(91)90292-U; GRAY GT, 1988, ACTA METALL MATER, V36, P1745, DOI 10.1016/0001-6160(88)90242-8; Haque MA, 2002, SCRIPTA MATER, V47, P863, DOI 10.1016/S1359-6462(02)00306-8; Hirth IP, 1992, THEORY DISLOCATIONS; Huang JY, 1996, ACTA MATER, V44, P1211, DOI 10.1016/1359-6454(95)00231-6; Jacobsen KW, 2002, NAT MATER, V1, P15, DOI 10.1038/nmat718; Kumar KS, 2003, ACTA MATER, V51, P387, DOI 10.1016/S1359-6454(02)00421-4; Lagerlof KPD, 2002, PHILOS MAG A, V82, P2841, DOI 10.1080/01418610210157931; McFadden SX, 1999, NATURE, V398, P684, DOI 10.1038/19486; Murayama M, 2002, SCIENCE, V295, P2433, DOI 10.1126/science.1067430; Ovid'ko IA, 2002, SCIENCE, V295, P2386, DOI 10.1126/science.1071064; POND RC, 1981, I PHYS C SER, V61, P495; Schiotz J, 1998, NATURE, V391, P561, DOI 10.1038/35328; SHAMZUZZOHA M, 1991, PHILOS MAG A, V64, P245, DOI 10.1080/01418619108206138; Tadmor EB, 1999, J MATER RES, V14, P2233, DOI 10.1557/JMR.1999.0300; Van Swygenhoven H, 2002, SCIENCE, V296, P66; VAN SWYGENHOVEN H, 2002, PHYS REV B, V66; Venables, 1964, DEFORMATION TWINNING, P77; VENABLES JA, 1961, PHILOS MAG, V6, P379, DOI 10.1080/14786436108235892; Weertman JR, 1999, MRS BULL, V24, P44, DOI 10.1557/S088376940005154X; Yamakov V, 2002, ACTA MATER, V50, P5005, DOI 10.1016/S1359-6454(02)00318-X; Yamakov V, 2002, NAT MATER, V1, P45, DOI 10.1038/nmat700; Youngdahl CJ, 2001, SCRIPTA MATER, V44, P1475, DOI 10.1016/S1359-6462(01)00712-6	27	975	1005	27	684	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 23	2003	300	5623					1275	1277		10.1126/science.1083727	http://dx.doi.org/10.1126/science.1083727			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	681NN	12714676				2022-12-28	WOS:000183042400044
J	Kosten, TR; O'Connor, PG				Kosten, TR; O'Connor, PG			Management of drug and alcohol withdrawal	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							RAPID OPIATE DETOXIFICATION; DOUBLE-BLIND; OPIOID DETOXIFICATION; METHADONE-MAINTENANCE; COCAINE DEPENDENCE; CONTROLLED-TRIAL; CLONIDINE; CARBAMAZEPINE; PLACEBO; PROPRANOLOL		Vet Affairs Connecticut Healthcare Syst, West Haven, CT 06516 USA; Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA; Yale Univ, Sch Med, Dept Med, New Haven, CT 06510 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; Yale University; Yale University	Kosten, TR (corresponding author), Vet Affairs Connecticut Healthcare Syst, 950 Campbell Ave,Bldg 35, West Haven, CT 06516 USA.	thomas.kosten@yale.edu			NIDA NIH HHS [K05-DA 0454, P50-DA12762] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [K05DA000454, P50DA012762] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ADINOFF B, 1994, ALCOHOL CLIN EXP RES, V18, P873, DOI 10.1111/j.1530-0277.1994.tb00053.x; ALTERMAN AI, 1992, DRUG ALCOHOL DEPEN, V31, P19, DOI 10.1016/0376-8716(92)90004-V; BJORKQVIST SE, 1976, ACTA PSYCHIAT SCAND, V53, P333, DOI 10.1111/j.1600-0447.1976.tb00081.x; Carroll KM, 1996, EXP CLIN PSYCHOPHARM, V4, P46, DOI 10.1037/1064-1297.4.1.46; CHESKIN LJ, 1994, DRUG ALCOHOL DEPEN, V36, P115, DOI 10.1016/0376-8716(94)90093-0; CHU NS, 1979, NEUROLOGY, V29, P1397, DOI 10.1212/WNL.29.10.1397; CONNELL BJ, 1995, HISTOL HISTOPATHOL, V10, P255; Cornelius JR, 1997, ARCH GEN PSYCHIAT, V54, P700; Cucchia AT, 1998, DRUG ALCOHOL DEPEN, V52, P243, DOI 10.1016/S0376-8716(98)00100-8; Davis KM, 2001, J BIOMED SCI, V8, P7, DOI 10.1159/000054008; Fiellin DA, 2002, NEW ENGL J MED, V347, P817, DOI 10.1056/NEJMcp013579; Grabowski J, 1997, J CLIN PSYCHOPHARM, V17, P485, DOI 10.1097/00004714-199712000-00008; GRIFFITHS RR, 1990, J CLIN PSYCHOPHARM, V10, P237; HOBBS WR, 1996, GOODMAN GILMANS PHAR, P361; Holbrook AM, 1999, CAN MED ASSOC J, V160, P649; HORWITZ RI, 1989, ARCH INTERN MED, V149, P1089, DOI 10.1001/archinte.149.5.1089; JASINSKI DR, 1978, ARCH GEN PSYCHIAT, V35, P501; JASINSKI DR, 1985, ARCH GEN PSYCHIAT, V42, P1063; Jorenby DE, 1999, NEW ENGL J MED, V340, P685, DOI 10.1056/NEJM199903043400903; Kampman KM, 2001, DRUG ALCOHOL DEPEN, V63, P69, DOI 10.1016/S0376-8716(00)00193-9; Kleber H. D., 1999, TXB SUBSTANCE ABUSE, V2nd, P251; KLEBER HD, 1985, ARCH GEN PSYCHIAT, V42, P391; Kosten TR, 2002, EXPERT OPIN INV DRUG, V11, P491; KOSTEN TR, 1989, AM J PSYCHIAT, V146, P1349; KOSTEN TR, 1990, J NERV MENT DIS, V178, P217, DOI 10.1097/00005053-199004000-00001; Kosten TR, 2002, NEUROPSYCHOPHARMACOL, P1461; Lejoyeux M, 1998, ALCOHOL ALCOHOLISM, V33, P563, DOI 10.1093/alcalc/33.6.563; LOIMER N, 1991, AM J PSYCHIAT, V148, P933; Malcolm R, 2002, J GEN INTERN MED, V17, P349, DOI 10.1007/s11606-002-0038-1; Malcolm R, 2001, AM J ADDICTION, V10, P16, DOI 10.1080/10550490190942489; MALCOLM R, 1989, AM J PSYCHIAT, V146, P617; Malcolm R, 2000, DRUG ALCOHOL DEPEN, V60, P161, DOI 10.1016/S0376-8716(99)00151-9; Manwell LB, 1998, J ADDICT DIS, V17, P67, DOI 10.1300/J069v17n01_07; Markou A, 1998, NEUROPSYCHOPHARMACOL, V18, P135, DOI 10.1016/S0893-133X(97)00113-9; MAYOSMITH MF, 1995, ALCOHOL CLIN EXP RES, V19, P656, DOI 10.1111/j.1530-0277.1995.tb01563.x; MayoSmith MF, 1997, JAMA-J AM MED ASSOC, V278, P144, DOI 10.1001/jama.278.2.144; Mendelson JH, 1996, NEW ENGL J MED, V334, P965, DOI 10.1056/NEJM199604113341507; MOSCOVITZ H, 1993, J GEN INTERN MED, V8, P1, DOI 10.1007/BF02600283; Nutt D, 1999, BRIT J PSYCHIAT, V175, P114, DOI 10.1192/bjp.175.2.114; O'Connor PG, 2000, NEW ENGL J MED, V343, P1332, DOI 10.1056/NEJM200011023431809; O'Connor PG, 2000, ANN INTERN MED, V133, P40, DOI 10.7326/0003-4819-133-1-200007040-00008; O'Connor PG, 1998, NEW ENGL J MED, V338, P592, DOI 10.1056/NEJM199802263380907; O'Connor PG, 1998, JAMA-J AM MED ASSOC, V279, P229, DOI 10.1001/jama.279.3.229; OConnor PG, 1997, ANN INTERN MED, V127, P526, DOI 10.7326/0003-4819-127-7-199710010-00004; OCONNOR PG, 1994, AM J MED, V96, P551, DOI 10.1016/0002-9343(94)90096-5; Pages KP, 1998, AM J ADDICTION, V7, P198; PALESTINE ML, 1976, CURR THER RES CLIN E, V20, P289; Petry NM, 2000, DRUG ALCOHOL DEPEN, V58, P9, DOI 10.1016/S0376-8716(99)00071-X; Pfab R, 1999, J TOXICOL-CLIN TOXIC, V37, P43, DOI 10.1081/CLT-100102407; PRESSLICH O, 1989, J TOXICOL-CLIN TOXIC, V27, P263, DOI 10.3109/15563658908994422; Rabinowitz J, 1997, DRUG ALCOHOL DEPEN, V47, P77, DOI 10.1016/S0376-8716(97)00073-2; Reoux JP, 2000, AM J ADDICTION, V9, P135; Reoux JP, 2001, ALCOHOL CLIN EXP RES, V25, P1324, DOI 10.1097/00000374-200109000-00012; ROBINSON BJ, 1989, ALCOHOL CLIN EXP RES, V13, P95, DOI 10.1111/j.1530-0277.1989.tb00290.x; SAITZ R, 1994, JAMA-J AM MED ASSOC, V272, P519, DOI 10.1001/jama.272.7.519; SATEL SL, 1993, AM J PSYCHIAT, V150, P695; Scherbaum N, 1998, PHARMACOPSYCHIATRY, V31, P205, DOI 10.1055/s-2007-979329; Sees KL, 2000, JAMA-J AM MED ASSOC, V283, P1303, DOI 10.1001/jama.283.10.1303; SENAY EC, 1977, ARCH GEN PSYCHIAT, V34, P361; Smith D. E., 1999, AM PSYCHIAT PRESS TX, P239; Strang J, 1999, AM J ADDICTION, V8, P337, DOI 10.1080/105504999305749; STUPPAECK CH, 1992, ALCOHOL ALCOHOLISM, V27, P153; *SUBST AB MENT HLT, 1999, NAT HOUS SURV DRUG A; Tsai GC, 1998, ANNU REV MED, V49, P173; VINING E, 1988, BRIT J ADDICT, V83, P567; WORNER TM, 1994, AM J DRUG ALCOHOL AB, V20, P115, DOI 10.3109/00952999409084061; ZILM DH, 1980, ALCOHOL CLIN EXP RES, V4, P400, DOI 10.1111/j.1530-0277.1980.tb04839.x	67	339	347	0	24	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 1	2003	348	18					1786	1795		10.1056/NEJMra020617	http://dx.doi.org/10.1056/NEJMra020617			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	672VK	12724485				2022-12-28	WOS:000182543500008
J	Georgiou, G; Masip, L				Georgiou, G; Masip, L			An overoxidation journey with a return ticket	SCIENCE			English	Editorial Material							PEROXIREDOXINS; ACTIVATION; CYSTEINE; SWITCH; ACID		Univ Texas, Dept Chem Engn, Austin, TX 78712 USA; Univ Texas, Inst Cell & Mol Biol, Austin, TX 78712 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin	Georgiou, G (corresponding author), Univ Texas, Dept Chem Engn, Austin, TX 78712 USA.	gg@che.utexas.edu	Masip, Lluis/F-9919-2015	Masip, Lluis/0000-0002-3938-4633				Delaunay A, 2002, CELL, V111, P471, DOI 10.1016/S0092-8674(02)01048-6; Fu XY, 2001, J BIOL CHEM, V276, P41279, DOI 10.1074/jbc.M106958200; Georgiou G, 2002, CELL, V111, P607, DOI 10.1016/S0092-8674(02)01165-0; Hofmann B, 2002, BIOL CHEM, V383, P347, DOI 10.1515/BC.2002.040; Krapfenbauer K, 2003, BRAIN RES, V967, P152, DOI 10.1016/S0006-8993(02)04243-9; LEE TH, IN PRESS BLOOD; Mitsumoto A, 2001, FREE RADICAL BIO MED, V30, P625, DOI 10.1016/S0891-5849(00)00503-7; Woo HA, 2003, SCIENCE, V300, P653, DOI 10.1126/science.1080273; Wood ZA, 2003, SCIENCE, V300, P650, DOI 10.1126/science.1080405; Wood ZA, 2003, TRENDS BIOCHEM SCI, V28, P32, DOI 10.1016/S0968-0004(02)00003-8; Yang KS, 2002, J BIOL CHEM, V277, P38029, DOI 10.1074/jbc.M206626200; Yoo YD, 2002, EXP MOL MED, V34, P273, DOI 10.1038/emm.2002.38	12	96	98	1	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 25	2003	300	5619					592	594		10.1126/science.1084976	http://dx.doi.org/10.1126/science.1084976			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	671FB	12714731				2022-12-28	WOS:000182453700027
J	O'Brien, TG; Kinnaird, MF				O'Brien, TG; Kinnaird, MF			Caffeine and conservation	SCIENCE			English	Editorial Material									Wildlife Conservat Soc, Bogor, Indonesia	Wildlife Conservation Society - Indonesia	O'Brien, TG (corresponding author), Wildlife Conservat Soc, Jalan Pangrango 8, Bogor, Indonesia.							Kinnaird MF, 2003, CONSERV BIOL, V17, P245, DOI 10.1046/j.1523-1739.2003.02040.x; Mittermeier RA, 1998, CONSERV BIOL, V12, P516, DOI 10.1046/j.1523-1739.1998.012003516.x; RODEN C, 1999, COFFEE; Vandermeer J., 1995, BREAKFAST BIODIVERSI; VANDERNEER J, 2003, TROPICAL AGROECOSYST; Ward J., 1996, COFFEE CONSERVATION; 2001, LAMPUNG FIGURES; 2002, JAKARTA POST    0926, P13	8	67	67	1	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 25	2003	300	5619					587	587		10.1126/science.1082328	http://dx.doi.org/10.1126/science.1082328			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	671FB	12714727				2022-12-28	WOS:000182453700023
J	Melton, L				Melton, L			Crime busters	NATURE			English	Article																			0	22	23	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 24	2003	422	6934					917	917		10.1038/422917b	http://dx.doi.org/10.1038/422917b			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	670WR	12712209	Bronze			2022-12-28	WOS:000182432600061
J	Hoag, H				Hoag, H			Chemists' salaries turn south	NATURE			English	News Item																			0	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 17	2003	422	6933					650	650		10.1038/422650b	http://dx.doi.org/10.1038/422650b			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	668CG	12700723	Bronze			2022-12-28	WOS:000182272300005
J	Stellman, JM; Stellman, SD; Christian, R; Weber, T; Tomasallo, C				Stellman, JM; Stellman, SD; Christian, R; Weber, T; Tomasallo, C			The extent and patterns of usage of Agent Orange and other herbicides in Vietnam	NATURE			English	Article								Herbicides including Agent Orange were sprayed by United States forces for military purposes during the Vietnam War (1961-1971) at a rate more than an order of magnitude greater than for similar domestic weed control. In 1974, the US National Academy of Sciences published estimates of the extent and distribution of herbicides sprayed. Here we present revised estimates, developed using more-complete data. The spray inventory is expanded by more than seven million litres, in particular with heavily dioxin-contaminated herbicides. Estimates for the amount of dioxin sprayed are almost doubled. Hamlet census data reveal that millions of Vietnamese were likely to have been sprayed upon directly. Our identification of specific military herbicide targets has led to a more coherent understanding of spraying. Common errors in earlier interpretations of the spray data are also discussed.	Columbia Univ, Dept Hlth Policy & Management, New York, NY 10032 USA; Columbia Univ, Dept Epidemiol, New York, NY 10032 USA; Inst Canc Prevent, Valhalla, NY 10595 USA	Columbia University; Columbia University	Stellman, JM (corresponding author), Columbia Univ, Dept Hlth Policy & Management, 600 W 168th St, New York, NY 10032 USA.	jms13@columbia.edu						*ABL SOFTW CORP, 2000, R2V SOFTW; BLACKMAN GE, 1974, EFFECTS HERBICIDES B; BROWN JW, 1962, VEGETATIONAL SPRAY T; Buckingham Jr Wil- liam, 1982, OPERATION RANCH HAND; Cecil Paul Frederick, 1986, HERBICIDAL WARFARE R; CECIL PF, 1984, THESIS TEXAS A M U; COLLINS CV, 1967, 670020 DTEC CHECO DI; *COMM ASS WART EXP, 1997, CHAR EXP VET AG OR O; COURTNEY KD, 1970, SCIENCE, V168, P864, DOI 10.1126/science.168.3933.864; CRAIG DA, 1975, USE HERBICIDES SE AS; Cyranoski D, 2002, NATURE, V416, P252, DOI 10.1038/416252a; DARROW RA, 1969, HERBICIDES USED SE A; DARROW RA, 1966, OCONUS DEFOLIATION T; DASHIELL TR, 1973, P KUNSTADTERS COMPAR; *DAT MAN AG, 1970, DARU07 HERBS US MIL; Dwernychuk LW, 2002, CHEMOSPHERE, V47, P117, DOI 10.1016/S0045-6535(01)00300-9; HARRIGAN ET, 1970, ADTCTR7036 AFB ARM D; HAY A, 1982, CHEM SCYTHE LESSONS, P187; Heizer JR., 1971, MTR5105 MITR CORP; HUDDLE FP, 1969, TECHNOLOGY ASSESSMEN; Institute of Medicine; Committee to Review the Health Effects in Vietnam Veterans of Exposure to Herbicides; Division of Health Promotion and Disease Prevention, 1994, VET AG OR HLTH EFF H; *MIL ASS COMM, 202 COMM LIST 202 TA; MOSELEY WT, 1967, COMMUNICATION   0510; *NAT RES COUNC COM, 1974, EFF HERB S VIET A; OLENCHUK PG, 1963, EVALUATION HERBICIDE; ORIANS GH, 1970, SCIENCE, V169, P1030, DOI 10.1126/science.169.3950.1030; *PAN HERB PRES SCI, 1971, REP 2 4 5 T; SMITH C, 1981, VIETNAM MAP BOOK SEL; Stellman JM, 2003, ENVIRON HEALTH PERSP, V111, P321, DOI 10.1289/ehp.5755; THAYER TC, 1985, SPECIAL STUDIES MILI; *US DEP DEF, 1950, REC US FORC SE AS 19; *US DEP DEF, 1965, HERB FIL 1965 1970; *US DEP DEF, 1967, HAML EV SYST; *US DEP DEF, REC US FORC SE AS HE; *US MIL ASS COMM V, 1969, 74 MACV APO; WIERSMA GB, 1970, 16223 ACN US ARM COM; Young A. L., 1988, AGENT ORANGE ITS ASS; YOUNG AL, 1974, ECOLOGICAL STUDIES H; YOUNG AL, 1978, OEHLTR7892 AFB	39	236	246	2	75	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 17	2003	422	6933					681	687		10.1038/nature01537	http://dx.doi.org/10.1038/nature01537			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	668CG	12700752	Green Published			2022-12-28	WOS:000182272300031
J	Fergusson, D; Hebert, PC; Lee, SK; Walker, CR; Barrington, KJ; Joseph, L; Blajchman, MA; Shapiro, S				Fergusson, D; Hebert, PC; Lee, SK; Walker, CR; Barrington, KJ; Joseph, L; Blajchman, MA; Shapiro, S			Clinical outcomes following institution of universal leukoreduction of blood transfusions for premature infants	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RISK-FACTORS; RED-CELLS; IRON; IMMUNOMODULATION; RETINOPATHY; HEMORRHAGE	Context Leukocytes present in stored blood products can have a variety of biological effects, including depression of immune function, thereby increasing nosocomial infections and possibly resulting in organ failure and death. Premature infants, given their immature immune state, may be uniquely predisposed to the effects of transfused leukocytes. Objective To evaluate the clinical outcomes following implementation of a universal prestorage red blood cell (RBC) leukoreduction program in premature infants admitted to neonatal intensive care units (NICUs). Design and Setting Retrospective before-and-after study conducted in 3 Canadian tertiary care NICUs from January 1998 to December 2000. Patients A total of 515 premature infants weighing less than 1250 g who were admitted to the NICU, received at least 1 RBC transfusion, and survived at least 48 hours were enrolled. The intervention group consisted of infants admitted in the 18-month period following the introduction of universal leukoreduction (n=247) and the control group consisted of infants admitted during the 18 months prior to the introduction of universal leukoreduction (n=268). Main Outcome Measures Primary outcomes were nosocomial bacteremia and NICU mortality, compared before and after implementation of universal leukoreduction using multivariate regression. Secondary outcomes included bronchopulmonary dysplasia, retinopathy of prematurity, necrotizing enterocolitis, and intraventricular hemorrhage. Results The proportion of infants who acquired bacteremia after an RBC transfusion was 79/267 (29.6%) in the nonleukoreduction period and 63/246 (25.6%) in the leukoreduction period. For NICU mortality, there were 45 deaths (16.8%) in the nonleukoreduction period and 44 deaths (17.8%) in the leukoreduction period. The adjusted odds ratio (OR) for bacteremia was 0.59 (95% confidence interval [CI], 0.34-1.01) and for mortality was 1.22 (95% Cl, 0.59-2.50). The adjusted ORs for bronchopulmonary dysplasia and retinopathy of prematurity were 0.42 (95% Cl, 0.25-0.70) and 0.56 (95% Cl, 0.33-0.93), respectively. The adjusted ORs for necrotizing enterocolitis and grade 3 or 4 intraventricular hemorrhage were 0.39 (95% Cl, 0.17-0.90) and 0.65 (95% Cl, 0.35-1.19), respectively. The adjusted OR for a composite measure of any major neonatal morbidity was 0.31 (95% Cl, 0.17-0.56). Crude and adjusted rates for all secondary outcomes suggest that leukoreduction was associated with improved outcomes. Conclusion Implementation of universal prestorage leukoreduction was not associated with significant reductions in NICU mortality or bacteremia but was associated with improvement in several clinical outcomes in premature infants requiring RBC transfusions.	Univ Ottawa, Ctr Transfus Res, Ottawa Hosp, Ottawa, ON K1H 8L6, Canada; Univ Ottawa, Ottawa Hlth Res Inst, Clin Epidemiol Unit, Ottawa, ON K1H 8L6, Canada; Univ Ottawa, Dept Pediat, Ottawa, ON K1H 8L6, Canada; McGill Univ, Dept Epidemiol & Biostat, Montreal, PQ, Canada; McGill Univ, Dept Pediat, Montreal, PQ, Canada; Univ British Columbia, Dept Pediat, Vancouver, BC V6T 1W5, Canada; McMaster Univ, Med Ctr, Dept Pathol, Hamilton, ON L8N 3Z5, Canada; Canadian Blood Serv, Hamilton, ON, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; McGill University; McGill University; University of British Columbia; McMaster University; Canadian Blood Services	Fergusson, D (corresponding author), Univ Ottawa, Ctr Transfus Res, Ottawa Hosp, 501 Smyth Rd,Box 201, Ottawa, ON K1H 8L6, Canada.		Lee, Shoo K/P-3016-2015	Barrington, Keith/0000-0001-9669-5094; Fergusson, Dean/0000-0002-3389-2485				BELL MJ, 1978, ANN SURG, V187, P1, DOI 10.1097/00000658-197801000-00001; Blajchman MA, 1997, TRANSFUSION, V37, P121, DOI 10.1046/j.1537-2995.1997.37297203512.x; Buonocore G, 1998, ACTA PAEDIATR, V87, P77, DOI 10.1080/08035259850157912; *CAN BLOOD SERV, 2001, REP CAN 2000 2001; Chien LY, 2002, OBSTET GYNECOL, V99, P401, DOI 10.1016/S0029-7844(01)01732-X; Dani C, 2001, EARLY HUM DEV, V62, P57, DOI 10.1016/S0378-3782(01)00115-3; Englert J A, 2001, J Perinatol, V21, P21, DOI 10.1038/sj.jp.7200511; Fergusson D, 2002, TRANSFUSION, V42, P159, DOI 10.1046/j.1537-2995.2002.00022.x; Hirano K, 2001, ARCH DIS CHILD-FETAL, V84, pF188, DOI 10.1136/fn.84.3.F188; Korhonen P, 1999, EARLY HUM DEV, V54, P245, DOI 10.1016/S0378-3782(98)00101-7; Lackmann GM, 1996, FREE RADICAL BIO MED, V20, P407, DOI 10.1016/0891-5849(95)00209-X; Lee SK, 2000, PEDIATRICS, V106, P1070, DOI 10.1542/peds.106.5.1070; Little R. J. A., 1987, STAT ANAL MISSING DA; McAlister FA, 1998, BRIT J SURG, V85, P171; Muller-Steinhardt M, 1997, TRANSFUSION, V37, P1137, DOI 10.1046/j.1537-2995.1997.37111298088042.x; PAPILE LA, 1978, J PEDIATR-US, V92, P529, DOI 10.1016/S0022-3476(78)80282-0; Sankaran K, 2002, CAN MED ASSOC J, V166, P173; Seiberth V, 2000, OPHTHALMOLOGICA, V214, P131, DOI 10.1159/000027482; Silvers KM, 1998, ARCH DIS CHILD-FETAL, V78, pF214, DOI 10.1136/fn.78.3.F214; Strauss RG, 1997, AM J CLIN PATHOL, V107, pS57; Vamvakas EC, 2001, BLOOD, V97, P1180, DOI 10.1182/blood.V97.5.1180; VAMVAKAS EC, 1999, IMMUNOMODULATORY EFF	22	69	73	1	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 16	2003	289	15					1950	1956		10.1001/jama.289.15.1950	http://dx.doi.org/10.1001/jama.289.15.1950			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	667VC	12697797	Bronze			2022-12-28	WOS:000182253900027
J	Hasbun, R; Vikram, HR; Barakat, LA; Buenconsejo, J; Quagliarello, VJ				Hasbun, R; Vikram, HR; Barakat, LA; Buenconsejo, J; Quagliarello, VJ			Complicated left-sided native valve endocarditis in adults - Risk classification for mortality	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NATIONAL-DEATH-INDEX; INFECTIVE ENDOCARDITIS; BACTERIAL-ENDOCARDITIS; VITAL STATUS; SURGERY; MANAGEMENT; DIAGNOSIS	Context Complicated left-sided native valve endocarditis causes significant morbidity and mortality in adults. Lack of valid data regarding estimation of prognosis makes management of this condition difficult. Objective To derive and externally validate a prognostic classification system for adults with complicated left-sided native valve endocarditis. Design, Setting, and Patients Retrospective observational cohort study conducted from January 1990 to January 2000 at 7 Connecticut hospitals among 513 patients older than 16,years who experienced complicated left-sided native valve endocarditis and who were divided into derivation (n=259) and validation (n=254) cohorts. Main Outcome Measure All-cause mortality at 6 months after baseline. Results In the derivation and validation cohorts, the 6-month mortality rates were 25% and 26%, respectively. Five baseline features were independently associated with 6-month mortality (comorbidity [P=.03], abnormal mental status [P=.02], moderate to severe congestive heart failure [P=.01], bacterial etiology other than viridans streptococci [P<.001 except Staphylococus aureus, P=.004], and medical therapy without valve surgery [P=.002]) and were used to create a prognostic classification system. In the derivation cohort, patients were classified into 4 groups with increasing risk for 6-month mortality: 5%, 15%, 31%, and 59% (P<.001). In the validation cohort, a similar risk among the 4 groups was observed: 7%, 19%, 32%, and 69% (P<.001). Conclusions Adults with complicated left-sided native valve endocarditis can be accurately risk stratified using baseline features into 4 groups of prognostic severity. This prognostic classification system might be useful for facilitating management decisions.	Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06520 USA; Yale Univ, Sch Epidemiol & Publ Hlth, New Haven, CT 06520 USA; Griffin Hosp, Derby, CT USA; Hosp St Raphael, Infect Dis Sect, New Haven, CT USA; Tulane Univ, Sch Med, Infect Dis Sect, New Orleans, LA 70112 USA	Yale University; Yale University; Hospital Saint Raphael; Tulane University	Hasbun, R (corresponding author), Yale Univ, Sch Med, Dept Internal Med, POB 208022,800 LCI, New Haven, CT 06520 USA.							Alexiou C, 2000, ANN THORAC SURG, V69, P1448, DOI 10.1016/S0003-4975(00)01139-5; Bayer AS, 1998, CIRCULATION, V98, P2936, DOI 10.1161/01.CIR.98.25.2936; Bishara J, 2001, CLIN INFECT DIS, V33, P1636, DOI 10.1086/323785; Braitman LE, 1996, ANN INTERN MED, V125, P406, DOI 10.7326/0003-4819-125-5-199609010-00008; CARPENTER JL, 1991, REV INFECT DIS, V13, P127; CATES JE, 1951, Q J MED, V20, P93; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; CONCATO J, 1993, ANN INTERN MED, V118, P201, DOI 10.7326/0003-4819-118-3-199302010-00009; CROFT CH, 1983, AM J CARDIOL, V51, P1650, DOI 10.1016/0002-9149(83)90203-5; DINUBILE MJ, 1982, ANN INTERN MED, V96, P650, DOI 10.7326/0003-4819-96-5-650; DURACK DT, 1994, AM J MED, V96, P200, DOI 10.1016/0002-9343(94)90143-0; Feinstein AR, 1985, CLIN EPIDEMIOLOGY AR; GRIFFIN FM, 1972, ANN INTERN MED, V76, P23, DOI 10.7326/0003-4819-76-1-23; Gum PA, 2001, JAMA-J AM MED ASSOC, V286, P1187, DOI 10.1001/jama.286.10.1187; Joffe MM, 1999, AM J EPIDEMIOL, V150, P327; KARALIS DG, 1991, AM J MED, V90, P193; KIMOSE HH, 1990, SCAND J THORAC CARD, V24, P111, DOI 10.3109/14017439009098053; Lash TL, 2001, EPIDEMIOLOGY, V12, P259, DOI 10.1097/00001648-200103000-00021; MCANULTY JH, 1979, JAMA-J AM MED ASSOC, V242, P77, DOI 10.1001/jama.242.1.77; MIDDLEMOST S, 1991, J AM COLL CARDIOL, V18, P663, DOI 10.1016/0735-1097(91)90785-8; MUGGE A, 1993, INFECT DIS CLIN N AM, V7, P877; Mylonakis E, 2001, NEW ENGL J MED, V345, P1318, DOI 10.1056/NEJMra010082; PELLETIER LL, 1977, MEDICINE, V56, P287, DOI 10.1097/00005792-197707000-00002; PRUITT AA, 1978, MEDICINE, V57, P329, DOI 10.1097/00005792-197807000-00004; RICHARDSON JV, 1978, CIRCULATION, V58, P589, DOI 10.1161/01.CIR.58.4.589; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; STECKELBERG JM, 1991, ANN INTERN MED, V114, P635, DOI 10.7326/0003-4819-114-8-635; VONREYN CF, 1981, ANN INTERN MED, V94, P505, DOI 10.7326/0003-4819-94-4-505; WALLACE AG, 1965, CIRCULATION, V31, P450, DOI 10.1161/01.CIR.31.3.450; WENTWORTH DN, 1983, AM J PUBLIC HEALTH, V73, P1270, DOI 10.2105/AJPH.73.11.1270; WILSON WR, 1982, MAYO CLIN PROC, V57, P162; WILSON WR, 1978, CIRCULATION, V58, P585, DOI 10.1161/01.CIR.58.4.585; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690	33	236	246	1	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 16	2003	289	15					1933	1940		10.1001/jama.289.15.1933	http://dx.doi.org/10.1001/jama.289.15.1933			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	667VC	12697795				2022-12-28	WOS:000182253900025
J	Hebert, PC; Fergusson, D; Blajchman, MA; Wells, GA; Kmetic, A; Coyle, D; Heddle, N; Germain, M; Goldman, M; Toye, B; Schweitzer, I; vanWalraven, C; Devine, D; Sher, GD				Hebert, PC; Fergusson, D; Blajchman, MA; Wells, GA; Kmetic, A; Coyle, D; Heddle, N; Germain, M; Goldman, M; Toye, B; Schweitzer, I; vanWalraven, C; Devine, D; Sher, GD		Leukoreduction Study Investigators	Clinical outcomes following institution of the Canadian universal leukoreduction program for red blood cell transfusions	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HIGH-RISK PATIENTS; WBC REDUCTION; COLORECTAL-CANCER; CDC DEFINITIONS; INFECTIONS; SURGERY; TRIAL; COMPLICATIONS; METAANALYSIS; SEPSIS	Context A number of countries have implemented a policy of universal leukoreduction of their blood supply, but the potential role of leukoreduction in decreasing postoperative mortality and infection is unclear. Objective To evaluate clinical outcomes following adoption of a national universal prestorage leukoreduction program for blood transfusions. Design, Setting, and Population Retrospective before-and-after cohort study conducted from August 1998 to August 2000 in 23 academic and community hospitals throughout Canada, enrolling 14786 patients who received red blood cell transfusions following cardiac surgery or repair of hip fracture, or who required intensive care following a surgical intervention or multiple trauma. Intervention Universal prestorage leukoreduction program introduced by 2 Canadian blood agencies. A total of 6982 patients were enrolled during the control period and 7804 patients were enrolled following prestorage leukoreduction. Main Outcome Measures All-cause in-hospital mortality and serious nosocomial infections (pneumonia, bacteremia, septic shock, all surgical site infections) occurring after first transfusion and at least 2 days after index procedure or intensive care unit admission. Secondary outcomes included rates of posttransfusion fever and antibiotic use. Results Unadjusted in-hospital mortality rates were significantly lower following the introduction of leukoreduction compared with the control period (6.19% vs 7.03%, respectively; P=.04). Compared with the control period, the adjusted odds of death following leukoreduction were reduced (odds ratio [OR], 0.87; 95% confidence interval [Cl], 0.75-0.99), but serious nosocomial infections did not decrease (adjusted OR, 0.97; 95% Cl, 0.87-1.09). The frequency of posttransfusion fevers decreased significantly following leukoreduction (adjusted OR, 0.86; 95% Cl, 0.79-0.94), as did antibiotic use (adjusted OR, 0.90; 95% Cl, 0.82-0.99). Conclusion A national universal leukoreduction program is potentially associated with decreased mortality as well as decreased fever episodes and antibiotic use after red blood cell transfusion in high-risk patients.	Univ Ottawa, Ctr Transfus Res, Ottawa Hlth Res Inst, Clin Epidemiol Program, Ottawa, ON K1H 8L6, Canada; McMaster Univ, Dept Pathol, Hamilton, ON, Canada; Canadian Blood Serv, Hamilton, ON, Canada; Univ Ottawa, Dept Med, Ottawa, ON, Canada; McMaster Univ, Dept Med, Hamilton, ON L8S 4L8, Canada; Hema Quebec, Quebec City, PQ, Canada; Univ Ottawa, Dept Pathol & Lab Med, Ottawa, ON K1N 6N5, Canada; Canadian Blood Serv, Vancouver, BC, Canada; Canadian Blood Serv, Ottawa, ON, Canada	University of Ottawa; Ottawa Hospital Research Institute; McMaster University; Canadian Blood Services; University of Ottawa; McMaster University; Hema-Quebec; University of Ottawa; Canadian Blood Services; Canadian Blood Services	Hebert, PC (corresponding author), Univ Ottawa, Ctr Transfus Res, Ottawa Hlth Res Inst, Clin Epidemiol Program, 501 Smyth Rd,Box 201, Ottawa, ON K1H 8L6, Canada.		Wells, George A/M-4549-2017	Wells, George A/0000-0002-2289-9139; Fergusson, Dean/0000-0002-3389-2485; Coyle, Doug/0000-0003-3492-2268				Baron JF, 2002, ANESTH ANALG, V94, P529, DOI 10.1097/00000539-200203000-00010; Bilgin YM, 2001, BLOOD, V98, p828A; Blajchman MA, 1997, TRANSFUSION, V37, P121, DOI 10.1046/j.1537-2995.1997.37297203512.x; BONE RC, 1992, CRIT CARE MED, V20, P864, DOI 10.1097/00003246-199206000-00025; BRUNBUISSON C, 1995, JAMA-J AM MED ASSOC, V274, P968, DOI 10.1001/jama.274.12.968; *CAN BLOOD SERV, 2002, CIRC INF US HUM BLOO; Chiavetta JA, 1996, TRANSFUSION, V36, P699, DOI 10.1046/j.1537-2995.1996.36896374373.x; Dzik WH, 2002, TRANSFUSION, V42, P1114, DOI 10.1046/j.1537-2995.2002.00182.x; Fergusson D, 2002, TRANSFUS MED REV, V16, P296, DOI 10.1053/tmrv.2002.35211; GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3; Hebert PC, 1997, AM J RESP CRIT CARE, V155, P1618, DOI 10.1164/ajrccm.155.5.9154866; HORAN TC, 1992, INFECT CONT HOSP EP, V13, P606; HOUBIERS JGA, 1994, LANCET, V344, P573, DOI 10.1016/S0140-6736(94)91965-8; Jensen LS, 1996, LANCET, V348, P841, DOI 10.1016/S0140-6736(96)06168-5; JOHANSON WG, 1972, ANN INTERN MED, V77, P701, DOI 10.7326/0003-4819-77-5-701; KNAUS WA, 1992, CHEST, V101, P1656, DOI 10.1378/chest.101.6.1656; McAlister FA, 1998, BRIT J SURG, V85, P171; Moore FA, 1997, ARCH SURG-CHICAGO, V132, P620; OPELZ G, 1973, TRANSPLANT P, V5, P253; *PALL MED BLOOD PR, 2002, PALL MED LEUK WB CPD; Shanwell A, 1997, TRANSFUSION, V37, P678, DOI 10.1046/j.1537-2995.1997.37797369441.x; SHERERTZ RJ, 1992, INFECT CONT HOSP EP, V13, P599; Thurer RL, 2000, TRANSFUSION, V40, P751, DOI 10.1046/j.1537-2995.2000.40060751.x; TOEWS GB, 1987, CLIN CHEST MED, V8, P467; VAMVAKAS E, 1993, TRANSFUSION, V33, P754, DOI 10.1046/j.1537-2995.1993.33994025027.x; Vamvakas EC, 2001, TRANSFUSION, V41, P691, DOI 10.1046/j.1537-2995.2001.41050691.x; van de Watering LMG, 1998, CIRCULATION, V97, P562; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; WELBOURN CRB, 1991, BRIT J SURG, V78, P651, DOI 10.1002/bjs.1800780607; Yusuf S, 2000, NEW ENGL J MED, V342, P145	30	255	262	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 16	2003	289	15					1941	1949		10.1001/jama.289.15.1941	http://dx.doi.org/10.1001/jama.289.15.1941			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	667VC	12697796	Bronze			2022-12-28	WOS:000182253900026
J	Wilcox, RA; Whitham, EM				Wilcox, RA; Whitham, EM			The symbol of modern medicine: Why one snake is more than two	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							CADUCEUS	Today, two serpent motifs are commonly used to symbolize the practice and profession of medicine. Internationally, the most popular symbol of medicine is the single serpent-entwined staff of Asklepios (Latin, Aesculapius), the ancient Greco-Roman god of medicine. However, in the United States, the staff of Asklepios (the Asklepian) and a double serpent-entwined staff with surmounting wings (the caduceus) are both popular medical symbols. The latter symbol is often designated as the "medical caduceus" and is equated with the ancient caduceus, the double serpent-entwined staff of the Greco-Roman god Hermes (Latin, Mercury). Many physicians would be surprised to learn that the medical caduceus has a quite modern origin: Its design is derived not from the ancient caduceus of Hermes but from the printer's mark of a popular 19th-century medical publisher. Furthermore, this modern caduceus became a popular medical symbol only after its adoption by the U.S. Army Medical Corps at the beginning of the 20th century. This paper describes the ancient origin of the Asklepian and, how a misunderstanding of ancient mythology and iconography seems to have led to the inappropriate popularization of the modern caduceus as a medical symbol.	Flinders Med Ctr, Dept Med Biochem, Bedford Pk, SA 5042, Australia	Flinders Medical Centre	Wilcox, RA (corresponding author), Flinders Med Ctr, Dept Med Biochem, Bedford Pk, SA 5042, Australia.		Wilcox, Robert A/A-3135-2014					ARNOLD HL, 1937, J MICHIGAN STATE MED, V36, P157; Bailey JE, 1996, ANN INTERN MED, V125, P254, DOI 10.7326/0003-4819-125-3-199608010-00023; Bailey JE, 1996, ANN INTERN MED, V124, P257, DOI 10.7326/0003-4819-124-2-199601150-00011; BREMER JL, 1958, NEW ENGL J MED, V258, P334, DOI 10.1056/NEJM195802132580707; CARLYLE T, 2003, SARTOR RESARTUS LIFE; Dillemann G, 1965, Prod Probl Pharm, V20, P452; *ED DEP, 1902, J ASS MILITARY SURG, V11, P70; Edelstein Emma J, 1998, ASCLEPIUS COLLECTION, V1; ELY T, 1891, OLYMPOS TALES GODS G; FREY EF, 1978, TEX REP BIOL MED, V36, P1; Friedlander Walter J., 1992, GOLDEN WAND MED HIST; GERHARD FH, 1909, JAMA-J AM MED ASSOC, V52, P1325; GERHARD SP, 1919, JAMA-J AM MED ASSOC, V72, P1243; GLUCKMAN I, 1965, NZ MED J, V64, P156; Gluckman L, 1998, NEW ZEAL MED J, V111, P281; Grant M.A., 1960, MYTH HYGINUS FABULAE; Harrison Jane Ellen, 1912, THEMIS STUDY SOCIAL; HART GD, 2000, ASCLEPIUS GOD MED, V94; HOMER, 1991, ILIAD; Jackson Ralph, 1988, DOCTORS DIS ROMAN EM; Kellie SM, 1999, LANCET, V354, P1038, DOI 10.1016/S0140-6736(05)76654-X; KERENYI C, 1959, ASKLEPIOS ARCHETPAL; MCCULLOCH CC, 1917, MIL SURG, V41, P137; Newman Art, 1988, ILLUSTRATED TREASURY; Nutton V, 1973, Class Q, V23, P158; NYLANDER C, 1963, ANTIQUITY, V37, P6, DOI 10.1017/S0003598X00036954; PARADA C, 1994, GENEALOGICAL GUIDE G; Penn RG, 1994, MED ANCIENT GREEK RO; RAKEL RE, 1985, JAMA-J AM MED ASSOC, V253, P2369; ROSENTHAL F, 1990, SCI MED ISLAM COLLEC, P53; Schouten Jan, 1967, ROD SERPENT AESCULAP; SOZINSKY TS, 1884, MED SURG REPORTER, V50, P33; SOZINSKY TS, 1891, MED SYMBOLISM; STEPHENSON FB, 1892, BOSTON MED SURG J, V127, P308; Tyson SL, 1932, SCI MON, V34, P492; VonStaden H, 1996, J HIST MED ALL SCI, V51, P404; WALTON A, 1894, CORNELL STUDIES CLAS	37	33	33	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	2003	138	8					673	677		10.7326/0003-4819-138-8-200304150-00016	http://dx.doi.org/10.7326/0003-4819-138-8-200304150-00016			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	666JH	12693891				2022-12-28	WOS:000182173800011
J	Jimenez-Sanchez, G				Jimenez-Sanchez, G			Developing a platform for genomic medicine in Mexico	SCIENCE			English	Article							GENETIC-STRUCTURE	Mexico is preparing to develop a genomic medicine program focused on national health problems. Modern Mexicans result from an admixture of more than 65 native Indian groups with Spaniards, leading to a unique genetic makeup and a characteristic set of disease susceptibilities. Since 1999, more than 100 experts from different fields have joined efforts with government, academia, and industry to identify priorities and goals for genomic medicine in Mexico. The plan includes establishment of an Institute of Genomic Medicine with strong intramural and extramural programs. This project is expected to ease the social and financial burden of health problems in Mexico.	Consortium Inst Genom Med Mexico, Mexico City 14210, DF, Mexico; Johns Hopkins Univ, McKusick Nathans Inst Genet Med, Baltimore, MD 21205 USA	Instituto Nacional de Medicina Genomica; Johns Hopkins University	Jimenez-Sanchez, G (corresponding author), Consortium Inst Genom Med Mexico, Camino Ajusco 130-101,Col Jardines Montana, Mexico City 14210, DF, Mexico.							Arredondo A, 2001, REV INVEST CLIN, V53, P422; FRENK J, 2002, SALUD MEXICO 2001; FRENK J, 2001, PROGRAMA NACL SALUD; Gorodezky C, 2001, HUM IMMUNOL, V62, P979, DOI 10.1016/S0198-8859(01)00296-8; Jimenez-Sanchez Gerardo, 2002, Gac Med Mex, V138, P291; JIMENEZSANCHEZ G, 2002, ESTE PAIS, V141, P50; JIMENEZSANCHEZ G, 2002, ESTE PAIS, V139, P17; JIMENEZSANCHEZ G, 2002, HACIA I NACL MED GEN; Lisker R, 1996, HUM BIOL, V68, P395; *MIN HLTH GOV MEX, 2001, PROGR ACC INV SAL; *SECR SAL, 2001, EST EV PRINC CAUS MU	11	23	24	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 11	2003	300	5617					295	296		10.1126/science.1084059	http://dx.doi.org/10.1126/science.1084059			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	665RQ	12690190				2022-12-28	WOS:000182135400046
J	Goldberger, J; He, RR; Zhang, YF; Lee, SW; Yan, HQ; Choi, HJ; Yang, PD				Goldberger, J; He, RR; Zhang, YF; Lee, SW; Yan, HQ; Choi, HJ; Yang, PD			Single-crystal gallium nitride nanotubes	NATURE			English	Article							MOLECULAR-BEAM EPITAXY; GAN NANOTUBES; NANOWIRES; NANOTECHNOLOGY; ZNO	Since the discovery of carbon nanotubes in 1991 (ref. 1), there have been significant research efforts to synthesize nanometre-scale tubular forms of various solids(2-10). The formation of tubular nanostructure generally requires a layered or anisotropic crystal structure(2-4). There are reports(5,6,11) of nanotubes made from silica, alumina, silicon and metals that do not have a layered crystal structure; they are synthesized by using carbon nanotubes and porous membranes as templates, or by thin-film rolling. These nanotubes, however, are either amorphous, polycrystalline or exist only in ultrahigh vacuum(8). The growth of single-crystal semiconductor hollow nanotubes would be advantageous in potential nanoscale electronics, optoelectronics and biochemical-sensing applications. Here we report an 'epitaxial casting' approach for the synthesis of single-crystal GaN nanotubes with inner diameters of 30-200 nm and wall thicknesses of 5-50 nm. Hexagonal ZnO nanowires were used as templates for the epitaxial overgrowth of thin GaN layers in a chemical vapour deposition system. The ZnO nanowire templates were subsequently removed by thermal reduction and evaporation, resulting in ordered arrays of GaN nanotubes on the substrates. This templating process should be applicable to many other semiconductor systems.	Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Mat Sci, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Yang, PD (corresponding author), Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA.		Goldberger, Joshua/N-8963-2016; Choi, Heon-Jin/G-7450-2012; Goldberger, Joshua/F-5484-2011	Goldberger, Joshua/0000-0003-4284-604X; Goldberger, Joshua/0000-0003-4284-604X				AJAYAN PM, 1995, NATURE, V375, P564, DOI 10.1038/375564a0; Caruso RA, 2001, CHEM MATER, V13, P3272, DOI 10.1021/cm001257z; Hamdani F, 1998, J APPL PHYS, V83, P983, DOI 10.1063/1.366786; Hamdani F, 1997, APPL PHYS LETT, V71, P3111, DOI 10.1063/1.120262; He RR, 2002, NANO LETT, V2, P1109, DOI 10.1021/n10257216; Huang MH, 2001, SCIENCE, V292, P1897, DOI 10.1126/science.1060367; Huang Y, 2002, NANO LETT, V2, P101, DOI 10.1021/nl015667d; IIJIMA S, 1991, NATURE, V354, P56, DOI 10.1038/354056a0; Kim JR, 2002, APPL PHYS LETT, V80, P3548, DOI 10.1063/1.1478158; Kondo Y, 2000, SCIENCE, V289, P606, DOI 10.1126/science.289.5479.606; Lauhon LJ, 2002, NATURE, V420, P57, DOI 10.1038/nature01141; Lee SM, 1999, PHYS REV B, V60, P7788, DOI 10.1103/PhysRevB.60.7788; Li JY, 2001, J MATER SCI LETT, V20, P1987, DOI 10.1023/A:1013155323435; Li YD, 2001, J AM CHEM SOC, V123, P9904, DOI 10.1021/ja016435j; MARTIN CR, 1994, SCIENCE, V266, P1961, DOI 10.1126/science.266.5193.1961; Patzke GR, 2002, ANGEW CHEM INT EDIT, V41, P2446, DOI 10.1002/1521-3773(20020715)41:14<2446::AID-ANIE2446>3.0.CO;2-K; Schmidt OG, 2001, NATURE, V410, P168, DOI 10.1038/35065525; Schoning MJ, 2002, ANALYST, V127, P1137, DOI 10.1039/b204444g; Tenne R, 2001, TOP APPL PHYS, V80, P81; Tenne R, 2001, PROG INORG CHEM, V50, P269; Vayssieres L, 2001, CHEM MATER, V13, P4395, DOI 10.1021/cm011160s; Wu YY, 2001, ADV MATER, V13, P520, DOI 10.1002/1521-4095(200104)13:7<520::AID-ADMA520>3.0.CO;2-W; Yang SM, 1999, ADV MATER, V11, P1427, DOI 10.1002/(SICI)1521-4095(199912)11:17<1427::AID-ADMA1427>3.0.CO;2-3	23	1163	1188	15	783	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 10	2003	422	6932					599	602		10.1038/nature01551	http://dx.doi.org/10.1038/nature01551			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	665GN	12686996				2022-12-28	WOS:000182111400037
J	Ross, AM; Anupindi, SA; Kleinman, RE; Ryan, DP; Balis, UJ				Ross, AM; Anupindi, SA; Kleinman, RE; Ryan, DP; Balis, UJ			A 14-year-old boy with ulcerative colitis, primary sclerosing cholangitis, and partial duodenal obstruction - Cholangiocarcinoma, with duodenal stricture	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CHRONIC-PANCREATITIS; SURGICAL-TREATMENT; DISEASE; CHILDREN; COMPLICATION; POPULATION; CARCINOMA; SURVIVAL; RISK		Hasbro Childrens Hosp, Dept Pediat, Providence, RI USA; Brown Univ, Sch Med, Dept Pediat, Providence, RI USA; Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA	Hasbro Children's Hospital; Brown University; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Ross, AM (corresponding author), Hasbro Childrens Hosp, Dept Pediat, Providence, RI USA.			Balis, Ulysses/0000-0002-4168-1477				Androulakis J, 2000, SURG CLIN N AM, V80, P171, DOI 10.1016/S0039-6109(05)70401-1; Angulo P, 1999, HEPATOLOGY, V30, P325, DOI 10.1002/hep.510300101; ARANHA GV, 1984, ARCH SURG-CHICAGO, V119, P833; Azarow K, 1996, J PEDIATR SURG, V31, P750, DOI 10.1016/S0022-3468(96)90122-0; Bank S, 1999, GASTROENTEROL CLIN N, V28, P571, DOI 10.1016/S0889-8553(05)70074-1; Bergquist A, 1998, HEPATOLOGY, V27, P311, DOI 10.1002/hep.510270201; Bergquist A, 1998, Clin Liver Dis, V2, P283, DOI 10.1016/S1089-3261(05)70008-8; BRADLEY EL, 1981, ANN SURG, V193, P638, DOI 10.1097/00000658-198105000-00015; COOPER SG, 1987, JAMA-J AM MED ASSOC, V258, P226, DOI 10.1001/jama.258.2.226; DEBRAY D, 1994, J PEDIATR-US, V124, P49, DOI 10.1016/S0022-3476(94)70253-5; Dohil R, 2000, BEST PRACT RES CL GA, V14, P53, DOI 10.1053/bega.1999.0059; Feretis C, 1997, GASTROINTEST ENDOSC, V46, P161, DOI 10.1016/S0016-5107(97)70066-X; FERRI FF, 2000, FERRIS CLIN ADVISOR, P643; Floreani A, 1999, LIVER, V19, P228, DOI 10.1111/j.1478-3231.1999.tb00040.x; FREY CF, 1990, WORLD J SURG, V14, P59, DOI 10.1007/BF01670547; Hanau LH, 2000, INFECT DIS CLIN N AM, V14, P521, DOI 10.1016/S0891-5520(05)70119-7; Izbicki JR, 1999, SURG CLIN N AM, V79, P913, DOI 10.1016/S0039-6109(05)70051-7; Komuro H, 2000, J PEDIATR SURG, V35, P1259, DOI 10.1053/jpsu.2000.8768; Kornfeld D, 1997, SCAND J GASTROENTERO, V32, P1042, DOI 10.3109/00365529709011222; MAKRAUER FL, 1982, DIGEST DIS SCI, V27, P525, DOI 10.1007/BF01296732; Noel JM, 1997, J PEDIATR GASTR NUTR, V24, P594, DOI 10.1097/00005176-199705000-00018; PEETZ ME, 1989, AM SURGEON, V55, P474; Pietzak M M, 2000, Pediatr Rev, V21, P406; Ponsioen CY, 2002, GUT, V51, P562, DOI 10.1136/gut.51.4.562; RAI R, 1998, SLEISENGER FORDTRANS, V2, P1771; Reynolds HL, 2001, SURG CLIN N AM, V81, P117, DOI 10.1016/S0039-6109(05)70276-0; SATAKE K, 1984, AM SURGEON, V50, P534; Schweiger GD, 1998, ABDOM IMAGING, V23, P347, DOI 10.1007/s002619900358; SEROUR F, 1992, J SURG ONCOL, V49, P29, DOI 10.1002/jso.2930490108; Soll AH, 1998, SLEISENGER FORDTRANS, P620; TAYLOR SM, 1991, SOUTHERN MED J, V84, P338; TROTT A, 1998, EMERGENCY MED CONCEP, V2, P1888; Tsakayannis DE, 1996, J PEDIATR SURG, V31, P127, DOI 10.1016/S0022-3468(96)90334-6; WILCHANSKI M, 1995, HEPATOLOGY, V22, P1415; Yamamoto T, 1999, SCAND J GASTROENTERO, V34, P1019	35	6	6	0	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 10	2003	348	15					1464	1476		10.1056/NEJMcpc030004	http://dx.doi.org/10.1056/NEJMcpc030004			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	665CU	12686704				2022-12-28	WOS:000182102700008
J	Warren, SM; Brunet, LJ; Harland, RM; Economides, AN; Longaker, MT				Warren, SM; Brunet, LJ; Harland, RM; Economides, AN; Longaker, MT			The BMP antagonist noggin regulates cranial suture fusion	NATURE			English	Article							IN-VITRO; BONE-FORMATION; EXPRESSION; PROTEIN; BIOLOGY; GROWTH; VIVO; OSTEOBLASTS; MECHANISMS; MUTATIONS	During skull development, the cranial connective tissue framework undergoes intramembranous ossification to form skull bones (calvaria). As the calvarial bones advance to envelop the brain, fibrous sutures form between the calvarial plates(1). Expansion of the brain is coupled with calvarial growth through a series of tissue interactions within the cranial suture complex(2). Craniosynostosis, or premature cranial suture fusion, results in an abnormal skull shape, blindness and mental retardation(3). Recent studies have demonstrated that gain-of-function mutations in fibroblast growth factor receptors (fgfr) are associated with syndromic forms of craniosynostosis(4,5). Noggin, an antagonist of bone morphogenetic proteins (BMPs), is required for embryonic neural tube, somites and skeleton patterning(6-8). Here we show that noggin is expressed postnatally in the suture mesenchyme of patent, but not fusing, cranial sutures, and that noggin expression is suppressed by FGF2 and syndromic fgfr signalling. Since noggin misexpression prevents cranial suture fusion in vitro and in vivo, we suggest that syndromic fgfr-mediated craniosynostoses may be the result of inappropriate downregulation of noggin expression.	Stanford Univ, Dept Surg, Sch Med, Stanford, CA 94305 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Div Biochem & Mol Biol, Berkeley, CA 94720 USA; Regeneron Pharmaceut Inc, Tarrytown, NY 10591 USA	Stanford University; University of California System; University of California Berkeley; Regeneron	Longaker, MT (corresponding author), Stanford Univ, Dept Surg, Sch Med, Stanford, CA 94305 USA.			Economides, Aris/0000-0002-6508-8942				Albrecht U, 1997, MOL CELLULAR METHODS, P23; Bradley JP, 1996, CLEFT PALATE-CRAN J, V33, P150, DOI 10.1597/1545-1569(1996)033<0150:SICSBV>2.3.CO;2; Bradley JP, 1996, PLAST RECONSTR SURG, V98, P1039, DOI 10.1097/00006534-199611000-00018; Brunet LJ, 1998, SCIENCE, V280, P1455, DOI 10.1126/science.280.5368.1455; Brunkow ME, 2001, AM J HUM GENET, V68, P577, DOI 10.1086/318811; Capdevila J, 1999, MOL CELL, V4, P839, DOI 10.1016/S1097-2765(00)80393-7; Capdevila J, 1998, DEV BIOL, V197, P205, DOI 10.1006/dbio.1997.8824; COHEN MM, 1995, AM J MED GENET, V56, P334, DOI 10.1002/ajmg.1320560327; Dixon ME, 2001, GENET MED, V3, P349, DOI 10.1097/00125817-200109000-00004; Gazzerro E, 1998, J CLIN INVEST, V102, P2106, DOI 10.1172/JCI3459; Greenwald JA, 2001, AM J PATHOL, V158, P441, DOI 10.1016/S0002-9440(10)63987-9; Greenwald JA, 2000, J BONE MINER RES, V15, P2413, DOI 10.1359/jbmr.2000.15.12.2413; Hsu DR, 1998, MOL CELL, V1, P673, DOI 10.1016/S1097-2765(00)80067-2; Mansukhani A, 2000, J CELL BIOL, V149, P1297, DOI 10.1083/jcb.149.6.1297; McCarthy JG, 1990, PLASTIC SURG, P3013; McMahon JA, 1998, GENE DEV, V12, P1438, DOI 10.1101/gad.12.10.1438; Minabe-Saegusa C, 1998, DEV GROWTH DIFFER, V40, P343; Moore R, 2002, DEV BIOL, V243, P99, DOI 10.1006/dbio.2001.0533; Opperman LA, 1997, J BONE MINER RES, V12, P301, DOI 10.1359/jbmr.1997.12.3.301; Paine-Saunders S, 2002, J BIOL CHEM, V277, P2089, DOI 10.1074/jbc.M109151200; Roth DA, 1997, J BONE MINER RES, V12, P311, DOI 10.1359/jbmr.1997.12.3.311; Slavkin HC, 1979, DEV CRANIOFACIAL BIO; THILANDER B, 1995, ACTA ODONTOL SCAND, V53, P144, DOI 10.3109/00016359509005964; WANG EA, 1990, P NATL ACAD SCI USA, V87, P2220, DOI 10.1073/pnas.87.6.2220; Warren SM, 2001, PLAST RECONSTR SURG, V107, P523, DOI 10.1097/00006534-200102000-00034; Wilkie AOM, 1997, HUM MOL GENET, V6, P1647, DOI 10.1093/hmg/6.10.1647; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6	28	259	272	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 10	2003	422	6932					625	629		10.1038/nature01545	http://dx.doi.org/10.1038/nature01545			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	665GN	12687003				2022-12-28	WOS:000182111400045
J	Bravata, DM; Sanders, L; Huang, J; Krumholz, HM; Olkin, I; Gardner, CD; Bravata, DM				Bravata, DM; Sanders, L; Huang, J; Krumholz, HM; Olkin, I; Gardner, CD; Bravata, DM			Efficacy and safety of low-carbohydrate diets - A systematic review	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							LOW-CALORIE DIET; RESTING METABOLIC-RATE; LOW-FAT DIET; DEPENDENT DIABETES-MELLITUS; RANDOMIZED CONTROLLED TRIAL; CARDIOVASCULAR RISK-FACTORS; ENERGY-RESTRICTED DIETS; WEIGHT-LOSS; BODY-COMPOSITION; MONOUNSATURATED FAT	Context Low-carbohydrate diets have been popularized without detailed evidence of their efficacy or safety. The literature has no clear consensus as to what amount of carbohydrates per day constitutes a low-carbohydrate diet. Objective To evaluate changes in weight, serum lipids, fasting serum glucose, and fasting serum insulin levels, and blood pressure among adults using low-carbohydrate diets in the outpatient setting. Data Sources We performed MEDLINE and bibliographic searches for English-language studies published between January 1, 1966, and February 15, 2003, with key words such as low carbohydrate, ketogenic, and diet. Study Selection We included articles describing adult, outpatient recipients of low-carbohydrate diets of 4 days or more in duration and 500 kcal/d or more, and which reported both carbohydrate content and total calories consumed. Literature searches identified 2609 potentially relevant articles of low-carbohydrate diets. We included 107 articles describing 94 dietary interventions reporting data for 3268 participants; 663 participants received diets of 60 g/d or less of carbohydrates-of whom only 71 received 20 g/d or less of carbohydrates. Study variables (eg, number of participants, design of dietary evaluation), participant variables (eg, age, sex, baseline weight, fasting serum glucose level), diet variables (eg, carbohydrate content, caloric content, duration) were abstracted from each study. Data Extraction Two authors independently reviewed articles meeting inclusion criteria and abstracted data onto pretested abstraction forms. Data Synthesis The included studies were highly heterogeneous with respect to design, carbohydrate content (range, 0-901 g/d), total caloric content (range, 5254629 kcal/d), diet duration (range, 4-365 days), and participant characteristics (eg, baseline weight range, 57-217 kg). No study evaluated diets of 60 g/d or less of carbohydrates in participants with a mean age older than 53.1 years. Only 5 studies (non-randomized and no comparison groups) evaluated these diets for more than 90 days. Among obese patients, weight loss was associated with longer diet duration (P=.002), restriction of calorie intake (P=.03), but not with reduced carbohydrate content (P=.90). Low-carbohydrate diets had no significant adverse effect on serum lipid, fasting serum glucose, and fasting serum insulin levels, or blood pressure. Conclusions There is insufficient evidence to make recommendations for or against the use of low-carbohydrate diets, particularly among participants older than age 50 years, for use longer than 90 days, or for diets of 20 g/d or less of carbohydrates. Among the published studies, participant,weight loss while using low-carbohydrate diets was principally associated with decreased caloric intake and increased diet duration but not with reduced carbohydrate content.	Stanford Univ, Sch Med, Ctr Primary Care & Outcomes Res, Stanford, CA 94305 USA; Stanford Univ, Sch Educ, Dept Stat, Stanford, CA 94305 USA; Stanford Univ, Stanford Ctr Res Dis Prevent, Stanford, CA 94305 USA; Calif Pacific Med Ctr, San Francisco, CA USA; Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA; Yale Univ, Sch Med, Robert Wood Johnson Clin Scholars Program, New Haven, CT 06510 USA; Vet Affairs Connecticut Healthcare Syst, Clin Epidemiol Res Ctr, West Haven, CT USA	Stanford University; Stanford University; Stanford University; California Pacific Medical Center; Yale University; Yale University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System	Bravata, DM (corresponding author), Stanford Univ, Sch Med, Ctr Primary Care & Outcomes Res, 117 Encina Commons, Stanford, CA 94305 USA.	bravata@healthpolicy.stanford.edu	, Harlan/AAI-2875-2020; Biguzzi, Felipe A/E-4724-2015					ALFORD BB, 1990, J AM DIET ASSOC, V90, P534; *AM HEART ASS, HIGH PROT DIETS AHA; *AM HEART ASS, 2002, SCI SESS AM HEART AS; APFELBAUM M, 1981, INT J OBESITY, V5, P117; Atkins RC, 1998, ATKINS NEW DIET REVO; Banting W., 1863, LETT CORPULENCE ADDR; BARON JA, 1986, AM J PUBLIC HEALTH, V76, P1293, DOI 10.2105/AJPH.76.11.1293; BENOIT FL, 1965, ANN INTERN MED, V63, P604, DOI 10.7326/0003-4819-63-4-604; BETTENS C, 1989, INT J OBESITY, V13, P113; BIALKOWSKA M, 1977, Materia Medica Polona, V9, P244; BONANOME A, 1991, AM J CLIN NUTR, V54, P586, DOI 10.1093/ajcn/54.3.586; Brown RC, 2000, MED SCI SPORT EXER, V32, P690, DOI 10.1097/00005768-200003000-00021; BRUSSAARD JH, 1982, ATHEROSCLEROSIS, V42, P205, DOI 10.1016/0021-9150(82)90151-4; Buffenstein R, 2000, PHYSIOL BEHAV, V68, P439, DOI 10.1016/S0031-9384(99)00222-X; CALLEPASCUAL AL, 1995, HORM METAB RES, V27, P499, DOI 10.1055/s-2007-980011; CANGIANO C, 1992, AM J CLIN NUTR, V56, P863, DOI 10.1093/ajcn/56.5.863; Carey AL, 2001, J APPL PHYSIOL, V91, P115, DOI 10.1152/jappl.2001.91.1.115; CATTRAN DC, 1980, CLIN NEPHROL, V13, P177; COMI D, 1995, EUR J CLIN NUTR, V49, pS242; CORDERA R, 1985, DIABETES METAB, V11, P137; Coyle EF, 2001, AM J PHYSIOL-ENDOC M, V280, pE391, DOI 10.1152/ajpendo.2001.280.3.E391; De Lorenzo A, 2001, DIABETES NUTR METAB, V14, P181; DONNELLY JE, 1991, AM J CLIN NUTR, V54, P56, DOI 10.1093/ajcn/54.1.56; EKSTEDT B, 1991, SCAND J CLIN LAB INV, V51, P437, DOI 10.3109/00365519109091637; Engelhart M, 1996, CLIN EXP RHEUMATOL, V14, P289; EVANS E, 1974, NUTR METAB, V17, P360; FAGERBERG B, 1984, INT J OBESITY, V8, P237; FERY F, 1982, DIABETES METAB, V8, P299; Flegal KM, 1998, INT J OBESITY, V22, P39, DOI 10.1038/sj.ijo.0800541; Flegal KM, 2002, JAMA-J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723; Fleming Richard M, 2002, Prev Cardiol, V5, P110, DOI 10.1111/j.1520-037X.2002.01231.x; FOSTER GD, 1992, AM J CLIN NUTR, V55, P811, DOI 10.1093/ajcn/55.4.811; FOSTER GD, 1990, AM J CLIN NUTR, V51, P167, DOI 10.1093/ajcn/51.2.167; GAFFNEY T, 1981, MED J AUSTRALIA, V1, P237; Gleser L.J., 1994, HDB RES SYNTHESIS, P339, DOI DOI 10.7758/9781610448864.16; Golay A, 1996, INT J OBESITY, V20, P1067; Grande F, 1967, Nutr Rev, V25, P189; GREENHAFF PL, 1988, EUR J APPL PHYSIOL, V57, P531, DOI 10.1007/BF00418458; GREENHAFF PL, 1988, EUR J APPL PHYSIOL, V57, P583, DOI 10.1007/BF00418466; Gumbiner B, 1998, DIABETES CARE, V21, P9, DOI 10.2337/diacare.21.1.9; HALLAK MH, 1988, AM J CLIN NUTR, V48, P1197, DOI 10.1093/ajcn/48.5.1197; HAMMER RL, 1989, AM J CLIN NUTR, V49, P77, DOI 10.1093/ajcn/49.1.77; HARVEY J, 1993, APPETITE, V21, P105, DOI 10.1016/0195-6663(93)90003-3; Haulrik N, 2002, AM J CLIN NUTR, V76, P1202, DOI 10.1093/ajcn/76.6.1202; HEDGES L, 1985, STAT METHODS METAANA, V1; Heilbronn LK, 1999, DIABETES CARE, V22, P889, DOI 10.2337/diacare.22.6.889; Heilbronn LK, 2002, J AM COLL NUTR, V21, P120, DOI 10.1080/07315724.2002.10719204; Helge JW, 2002, INT J OBESITY, V26, P1118, DOI 10.1038/sj.ijo.0802058; HELLER RF, 1993, CARBOHYDRATE ADDICTS; HOCKADAY TDR, 1978, BRIT J NUTR, V39, P357, DOI 10.1079/BJN19780045; Holmback U, 2002, J NUTR, V132, P1892, DOI 10.1093/jn/132.7.1892; HULLEY SB, 1972, LANCET, V2, P551; IRELAND P, 1992, DIABETES CARE, V15, P1499, DOI 10.2337/diacare.15.11.1499; Jenkins DJA, 2001, AM J CLIN NUTR, V74, P57; Jeor STS, 2001, CIRCULATION, V104, P1869, DOI 10.1161/hc4001.096152; KIRBY R K, 1985, Carle Selected Papers, V37, P14; KOGON MM, 1994, AM J CLIN NUTR, V60, P488, DOI 10.1093/ajcn/60.4.488; Kratz M, 2002, J CLIN ENDOCR METAB, V87, P5008, DOI 10.1210/jc.2002-020496; KROTKIEWSKI M, 1990, AM J CLIN NUTR, V51, P321, DOI 10.1093/ajcn/51.3.321; KWAN RMF, 1986, J NUTR, V116, P2393, DOI 10.1093/jn/116.12.2393; LAROSA JC, 1980, J AM DIET ASSOC, V77, P264; Lean MEJ, 1997, EUR J CLIN NUTR, V51, P243, DOI 10.1038/sj.ejcn.1600391; Lousley S E, 1984, Diabet Med, V1, P21; Low CC, 1996, DIABETES, V45, P569, DOI 10.2337/diabetes.45.5.569; LUNTZ GRWN, 1975, POSTGRAD MED J, V51, P133; Luscombe ND, 2002, DIABETES CARE, V25, P652, DOI 10.2337/diacare.25.4.652; Luscombe ND, 1999, EUR J CLIN NUTR, V53, P473, DOI 10.1038/sj.ejcn.1600779; MARSOOBIAN V, 1990, 74 ANN M FED AM SOC; MATHIESON RA, 1986, METABOLISM, V35, P394, DOI 10.1016/0026-0495(86)90126-5; Mezzano D, 2001, EUR J CLIN NUTR, V55, P444, DOI 10.1038/sj.ejcn.1601202; Miller ER, 2002, HYPERTENSION, V40, P612, DOI 10.1161/01.HYP.0000037217.96002.8E; Mogul H R, 2001, Heart Dis, V3, P285; Mokdad AH, 1999, JAMA-J AM MED ASSOC, V282, P1519, DOI 10.1001/jama.282.16.1519; Muller H, 2003, J NUTR, V133, P78, DOI 10.1093/jn/133.1.78; NAGY R, 1974, VA MED, V101, P383; NOBELS F, 1989, NETH J MED, V35, P295; ODEA K, 1989, J AM DIET ASSOC, V89, P1076; Parker B, 2002, DIABETES CARE, V25, P425, DOI 10.2337/diacare.25.3.425; PETERSON CM, 1995, J AM COLL NUTR, V14, P369; Pieke B, 2000, INT J OBESITY, V24, P1286, DOI 10.1038/sj.ijo.0801440; POMERLEAU J, 1993, DIABETOLOGIA, V36, P829, DOI 10.1007/BF00400358; RABAST U, 1978, MED KLIN, V73, P55; RACETTE SB, 1995, AM J CLIN NUTR, V61, P486, DOI 10.1093/ajcn/61.3.486; ROSEN JC, 1985, AM J CLIN NUTR, V42, P371, DOI 10.1093/ajcn/42.3.371; Saltzman E, 2001, J AM COLL NUTR, V20, P50, DOI 10.1080/07315724.2001.10719014; Saltzman E, 2001, J NUTR, V131, P1465, DOI 10.1093/jn/131.5.1465; SCHLUNDT DG, 1993, INT J OBESITY, V17, P623; SCOTT CB, 1992, MED SCI SPORT EXER, V24, P814; Sears B., 1995, ZONE DIETARY ROAD MA; Serdula MK, 1999, JAMA-J AM MED ASSOC, V282, P1353, DOI 10.1001/jama.282.14.1353; SEROG P, 1982, AM J CLIN NUTR, V35, P24, DOI 10.1093/ajcn/35.1.24; SHAH M, 1994, AM J CLIN NUTR, V59, P980, DOI 10.1093/ajcn/59.5.980; Sharman MJ, 2002, J NUTR, V132, P1879, DOI 10.1093/jn/132.7.1879; SIMONYI J, 1969, Cor et Vasa, V11, P251; SIMPSON RW, 1979, BRIT MED J, V1, P1753, DOI 10.1136/bmj.1.6180.1753; Skov AR, 1999, INT J OBESITY, V23, P1170, DOI 10.1038/sj.ijo.0801048; Skov AR, 2002, OBES RES, V10, P432, DOI 10.1038/oby.2002.60; SKOV R, 1999, INT J OBES RELAT MET, V23, P528; SPAULDING SW, 1976, J CLIN ENDOCR METAB, V42, P197, DOI 10.1210/jcem-42-1-197; SPILLER GA, 1992, J AM COLL NUTR, V11, P126; Staudacher HM, 2001, INT J SPORT NUTR EXE, V11, P273, DOI 10.1123/ijsnem.11.3.273; Stein K, 2000, J AM DIET ASSOC, V100, P760, DOI 10.1016/S0002-8223(00)00219-4; Straznicky NE, 1999, HYPERTENSION, V34, P580, DOI 10.1161/01.HYP.34.4.580; THOMPSON PD, 1984, METABOLISM, V33, P1003, DOI 10.1016/0026-0495(84)90228-2; VANSTRATUM P, 1978, AM J CLIN NUTR, V31, P206, DOI 10.1093/ajcn/31.2.206; VASWANI AN, 1983, J AM COLL NUTR, V2, P123; Vessby B, 2001, DIABETOLOGIA, V44, P312, DOI 10.1007/s001250051620; Volek JS, 2002, METABOLISM, V51, P864, DOI 10.1053/meta.2002.32037; Volek JS, 2001, METABOLISM, V50, P1351, DOI 10.1053/meta.2001.25648; Volek JS, 2000, J AM COLL NUTR, V19, P383, DOI 10.1080/07315724.2000.10718935; WADDEN TA, 1990, JAMA-J AM MED ASSOC, V264, P707, DOI 10.1001/jama.264.6.707; WALBERG JL, 1988, MED SCI SPORT EXER, V20, P34, DOI 10.1249/00005768-198802000-00005; WEINSIER RL, 1974, ANN INTERN MED, V80, P332, DOI 10.7326/0003-4819-80-3-332; Westman EC, 2002, AM J MED, V113, P30, DOI 10.1016/S0002-9343(02)01129-4; Whitehead JM, 1996, INT J OBESITY, V20, P727; Wolever TMS, 2002, BRIT J NUTR, V87, P477, DOI 10.1079/BJN2002568; WOLFE BM, 1991, METABOLISM, V40, P338, DOI 10.1016/0026-0495(91)90142-J; Wolfe BMJ, 1999, CLIN INVEST MED, V22, P140; YOUNG CM, 1971, AM J CLIN NUTR, V24, P290; 2000, MED LETT DRUGS THER, V42, P52; 1966, NUTR REV, V24, P133	121	366	374	3	151	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 9	2003	289	14					1837	1850		10.1001/jama.289.14.1837	http://dx.doi.org/10.1001/jama.289.14.1837			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	664ZJ	12684364				2022-12-28	WOS:000182094900031
J	Lilford, RJ				Lilford, RJ			Ethics of clinical trials from a Bayesian and decision analytic perspective: whose equipoise is it anyway?	BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED TRIALS; MEDICINE	Should the equipoise of the patient, or that of the doctor, determine whether a patient enters a clinical trial? People asking patients to consent to trials are glossing over the ethical complexities. Choices should be based both on probabilities of events (which experts might know) and on the value that a patient places on those events (which only the patient can know).	Univ Birmingham, Dept Publ Hlth & Epidemiol, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Lilford, RJ (corresponding author), Univ Birmingham, Dept Publ Hlth & Epidemiol, Publ Hlth Bldg, Birmingham B15 2TT, W Midlands, England.							Ashby D, 2000, STAT MED, V19, P3291, DOI 10.1002/1097-0258(20001215)19:23<3291::AID-SIM627>3.0.CO;2-T; Braunholtz DA, 2001, J CLIN EPIDEMIOL, V54, P217, DOI 10.1016/S0895-4356(00)00305-X; *CENTR OFF RES ETH, 2002, COREC GUID RES PAT I; Collins R, 1996, OXFORD TXB MED, V1, P21; Donovan J, 2002, BMJ-BRIT MED J, V325, P766, DOI 10.1136/bmj.325.7367.766; Edwards SJ., 1998, HEALTH TECHNOL ASSES, V2, P1; Lilford RJ, 1995, BMJ-BRIT MED J, V311, P1621, DOI 10.1136/bmj.311.7020.1621; Lilford RJ, 1995, J ROY SOC MED, V88, P552; PAUKER SP, 1977, YALE J BIOL MED, V50, P275; SPIEGELHALTER DJ, 1994, J R STAT SOC A STAT, V157, P357, DOI 10.2307/2983527; THORNTON JG, 1992, BRIT MED J, V304, P1099, DOI 10.1136/bmj.304.6834.1099; Weinstein MC, 1980, CLIN DECISION ANAL; Wragg JA, 2000, SOC SCI MED, V51, P453, DOI 10.1016/S0277-9536(99)00477-3	13	67	67	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 3	2003	326	7396					980	981		10.1136/bmj.326.7396.980	http://dx.doi.org/10.1136/bmj.326.7396.980			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	676JC	12727776	Green Published			2022-12-28	WOS:000182746700024
J	Spruck, CH; de Miguel, MP; Smith, APL; Ryan, A; Stein, P; Schultz, RM; Lincoln, AJ; Donovan, PJ; Reed, SI				Spruck, CH; de Miguel, MP; Smith, APL; Ryan, A; Stein, P; Schultz, RM; Lincoln, AJ; Donovan, PJ; Reed, SI			Requirement of Cks2 for the first metaphase/anaphase transition of mammalian meiosis	SCIENCE			English	Article							CELL-CYCLE; PROTEIN; ARREST; DISRUPTION; XE-P9; MLH1	We generated mice lacking Cks2, one of two mammalian homologs of the yeast Cdk1-binding proteins, Suc1 and Cks1, and found them to be viable but sterile in both sexes. Sterility is due to failure of both male and female germ cells to progress past the first meiotic metaphase. The chromosomal events up through the end of prophase I are normal in both CKS2(-/-) males and females, suggesting that the phenotype is due directly to failure to enter anaphase and not a consequence of a checkpoint-mediated metaphase I arrest.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Univ Calif San Diego, Sch Med, Dept Med, La Jolla, CA 92093 USA; Univ Penn, Dept Biol, Philadelphia, PA 19104 USA	Scripps Research Institute; Jefferson University; University of California System; University of California San Diego; University of Pennsylvania	Reed, SI (corresponding author), Scripps Res Inst, Dept Mol Biol, MB-7,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	sreed@scripps.edu	Stein, Paula/ABE-9388-2020	Stein, Paula/0000-0002-2040-4593; Smith, Adrian/0000-0001-9732-1422	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD022681] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD022681, R01HD038252] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA074224] Funding Source: NIH RePORTER; NCI NIH HHS [CA74224] Funding Source: Medline; NICHD NIH HHS [HD22681, HD38252] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Baker SM, 1996, NAT GENET, V13, P336, DOI 10.1038/ng0796-336; Barlow C, 1998, DEVELOPMENT, V125, P4007; Dix DJ, 1996, P NATL ACAD SCI USA, V93, P3264, DOI 10.1073/pnas.93.8.3264; Ganoth D, 2001, NAT CELL BIOL, V3, P321, DOI 10.1038/35060126; Hirao Y, 1997, DEVELOPMENT, V124, P5107; Lee JY, 2001, ANNU REV CELL DEV BI, V17, P753, DOI 10.1146/annurev.cellbio.17.1.753; Lipkin SM, 2002, NAT GENET, V31, P385, DOI 10.1038/ng931; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; Nasmyth K, 2002, SCIENCE, V297, P559, DOI 10.1126/science.1074757; Orr-Weaver TL, 1999, SCIENCE, V285, P344; Patra D, 1996, GENE DEV, V10, P1503, DOI 10.1101/gad.10.12.1503; Patra D, 1998, GENE DEV, V12, P2549, DOI 10.1101/gad.12.16.2549; Pittman DL, 1998, MOL CELL, V1, P697, DOI 10.1016/S1097-2765(00)80069-6; RICHARDSON HE, 1990, GENE DEV, V4, P1332, DOI 10.1101/gad.4.8.1332; Spruck C, 2001, MOL CELL, V7, P639, DOI 10.1016/S1097-2765(01)00210-6; TANG Y, 1993, GENE DEV, V7, P822, DOI 10.1101/gad.7.5.822; Watson ML, 1998, P NATL ACAD SCI USA, V95, P14361, DOI 10.1073/pnas.95.24.14361; Woods LM, 1999, J CELL BIOL, V145, P1395, DOI 10.1083/jcb.145.7.1395	18	100	102	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 25	2003	300	5619					647	650		10.1126/science.1084149	http://dx.doi.org/10.1126/science.1084149			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	671FB	12714746				2022-12-28	WOS:000182453700044
J	Schneider, R; Ferrara, A; Salvaterra, R; Omukai, K; Bromm, V				Schneider, R; Ferrara, A; Salvaterra, R; Omukai, K; Bromm, V			Low-mass relics of early star formation	NATURE			English	Article							NUCLEOSYNTHESIS	The earliest stars to form in the Universe were the first sources of light, heat and metals after the Big Bang. The products of their evolution will have had a profound impact on subsequent generations of stars. Recent studies(1-7) of primordial star formation have shown that, in the absence of metals (elements heavier than helium), the formation of stars with masses 100 times that of the Sun would have been strongly favoured, and that low-mass stars could not have formed before a minimum level of metal enrichment had been reached. The value of this minimum level is very uncertain, but is likely to be between 10(-6) and 10(-4) that of the Sun(6,8). Here we show that the recent discovery(9) of the most iron-poor star known indicates the presence of dust in extremely low-metallicity gas, and that this dust is crucial for the formation of lower-mass second-generation stars that could survive until today. The dust provides a pathway for cooling the gas that leads to fragmentation of the precursor molecular cloud into smaller clumps, which become the lower-mass stars.	Osserv Astrofis Arcetri, I-50125 Florence, Italy; Enrico Fermi Ctr, I-00184 Rome, Italy; Scuola Int Super Studi Avanzati, SSISA, I-34100 Trieste, Italy; Natl Astron Observ, Div Theoret Astrophys, Tokyo 1818588, Japan; Harvard Smithsonian Ctr Astrophys, Cambridge, MA 02138 USA	Istituto Nazionale Astrofisica (INAF); International School for Advanced Studies (SISSA); National Institutes of Natural Sciences (NINS) - Japan; National Astronomical Observatory of Japan (NAOJ); Harvard University; Smithsonian Astrophysical Observatory; Smithsonian Institution	Schneider, R (corresponding author), Osserv Astrofis Arcetri, Largo Enrico Fermi 5, I-50125 Florence, Italy.	raffa@arcetri.astro.it	Schneider, Raffaella/E-4216-2017; Ferrara, Andrea/A-4357-2011	Schneider, Raffaella/0000-0001-9317-2888; Salvaterra, Ruben/0000-0002-9393-8078				Abel T, 2002, SCIENCE, V295, P93, DOI 10.1126/science.1063991; Bromm V, 2002, ASTROPHYS J, V564, P23, DOI 10.1086/323947; Bromm V, 2001, MON NOT R ASTRON SOC, V328, P969, DOI 10.1046/j.1365-8711.2001.04915.x; Heger A, 2002, ASTROPHYS J, V567, P532, DOI 10.1086/338487; Mackey J, 2003, ASTROPHYS J, V586, P1, DOI 10.1086/367613; Nakamura F, 2002, ASTROPHYS J, V569, P549, DOI 10.1086/339392; Omukai K, 1998, ASTROPHYS J, V508, P141, DOI 10.1086/306395; OMUKAI K, UNPUB ASTROPHYS J; Qian YZ, 2002, ASTROPHYS J, V567, P515, DOI 10.1086/338277; Ripamonti E, 2002, MON NOT R ASTRON SOC, V334, P401, DOI 10.1046/j.1365-8711.2002.05516.x; Schneider R, 2002, ASTROPHYS J, V571, P30, DOI 10.1086/339917; Siess L, 2002, ASTROPHYS J, V570, P329, DOI 10.1086/339733; Truran JW, 2002, PUBL ASTRON SOC PAC, V114, P1293, DOI 10.1086/344585	14	203	204	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 24	2003	422	6934					869	871		10.1038/nature01579	http://dx.doi.org/10.1038/nature01579			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	670WR	12712198	Green Submitted			2022-12-28	WOS:000182432600047
J	Peiris, JSM; Lai, ST; Poon, LLM; Guan, Y; Yam, LYC; Lim, W; Nicholls, J; Yee, WKS; Yan, WW; Cheung, MT; Cheng, VCC; Chan, KH; Tsang, DNC; Yung, RWH; Ng, TK; Yuen, KY				Peiris, JSM; Lai, ST; Poon, LLM; Guan, Y; Yam, LYC; Lim, W; Nicholls, J; Yee, WKS; Yan, WW; Cheung, MT; Cheng, VCC; Chan, KH; Tsang, DNC; Yung, RWH; Ng, TK; Yuen, KY		SARS Study Grp	Coronavirus as a possible cause of severe acute respiratory syndrome	LANCET			English	Article							HUMAN-DISEASE; VIRUS; INFECTIONS; DIAGNOSIS	Background An outbreak of severe acute respiratory syndrome (SARS) has been reported in Hong Kong. We investigated the viral cause and clinical presentation among 50 patients. Methods We analysed case notes and microbiological findings for 50 patients with SARS, representing more than five separate epidemiologically linked transmission clusters. We defined the clinical presentation and risk factors associated with severe disease and investigated the causal agents by chest radiography and laboratory testing of nasopharyngeal aspirates and sera samples. We compared the laboratory findings with those submitted for microbiological investigation of other diseases from patients whose identity was masked. Findings Patients, age ranged from 23 to 74 years. Fever, chills, myalgia, and cough were the most frequent complaints. When compared with chest radiographic changes, respiratory symptoms and auscultatory findings were disproportionally mild. Patients who were household contacts of other infected people and had older age, lymphopenia, and liver dysfunction were associated with severe disease. A virus belonging to the family Coronaviridae was isolated from two patients. By use of serological and reverse-transcriptase PCR specific for this virus, 45 of 50 patients with SARS, but no controls, had evidence of infection with this virus. Interpretation A coronavirus was isolated from patients with SARS that might be the primary agent associated with this disease. Serological and molecular tests specific for the virus permitted a definitive laboratory diagnosis to be made and allowed further investigation to define whether other cofactors play a part in disease progression.	Univ Hong Kong, Queen Mary Hosp, Dept Pathol & Microbiol, Hong Kong, Hong Kong, Peoples R China; Princess Margaret Hosp, Dept Med Intens Care & Pathol, Hong Kong, Hong Kong, Peoples R China; Dept Hlth, Govt Virus Unit, Hong Kong, Hong Kong, Peoples R China; Pamela Youde Nethersole Eastern Hosp, Dept Pathol & Med, Hong Kong, Hong Kong, Peoples R China; Kwong Wah Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China; Queen Elizabeth Hosp, Dept Pathol, Kowloon, Hong Kong, Peoples R China	University of Hong Kong; Pamela Youde Nethersole Eastern Hospital; Kwong Wah Hospital	Peiris, JSM (corresponding author), Univ Hong Kong, Queen Mary Hosp, Dept Microbiol, Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China.		Yuen, Kwok Yung/C-4465-2009; Chan, Kwok Hung/ABD-5399-2021; Poon, Leo Lit Man/C-4382-2009; Poon, Leo/AAP-6887-2020; Peiris, Joseph Sriyal Malik/C-4380-2009; Nicholls, John Malcolm/C-4375-2009	Poon, Leo Lit Man/0000-0002-9101-7953; Peiris, Joseph Sriyal Malik/0000-0001-8217-5995; Guan, Yi/0000-0001-6057-9243; Nicholls, John Malcolm/0000-0001-7217-7444; Yuen, Kwok-yung/0000-0002-2083-1552; CHENG, Vincent Chi-Chung/0000-0003-1765-7706	PHS HHS [A195357] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		CAUL EO, 1977, ARCH VIROL, V54, P107, DOI 10.1007/BF01314383; Chan KH, 2002, J CLIN MICROBIOL, V40, P1675, DOI 10.1128/JCM.40.5.1675-1680.2002; Cheung CY, 2002, LANCET, V360, P1831, DOI 10.1016/S0140-6736(02)11772-7; El-Sahly HM, 2000, CLIN INFECT DIS, V31, P96, DOI 10.1086/313937; FOTZ RJ, 1999, CHEST, V115, P901; Fouchier RAM, 2000, J CLIN MICROBIOL, V38, P4096, DOI 10.1128/JCM.38.11.4096-4101.2000; Knipe D, 2001, FIELDS VIROLOGY, P1187; McINTOSH K., 1974, Current Topics in Microbiology and Immunology, P85; MCINTOSH K, 1970, AM J EPIDEMIOL, V91, P585, DOI 10.1093/oxfordjournals.aje.a121171; TALBOT PJ, IN PRESS ADV EXP MED; WENZEL RP, 1974, AM REV RESPIR DIS, V109, P621; *WHO, 2003, WKLY EPIDEMIOL REC, V78, P86; *WHO, 2003, WKLY EPIDEMIOL REC, V78, P81; Wiedbrauk DL, 1993, MANUAL CLIN VIROLOGY; Yuen KY, 1998, LANCET, V351, P467, DOI 10.1016/S0140-6736(98)01182-9	15	2011	2316	4	363	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 19	2003	361	9366					1319	1325		10.1016/S0140-6736(03)13077-2	http://dx.doi.org/10.1016/S0140-6736(03)13077-2			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	669HP	12711465	Green Published, Bronze			2022-12-28	WOS:000182346100007
J	Gruenheid, S; Finlay, BB				Gruenheid, S; Finlay, BB			Microbial pathogenesis and cytoskeletal function	NATURE			English	Review							RECEPTOR-MEDIATED PHAGOCYTOSIS; LYSOSOMAL MEMBRANE-GLYCOPROTEINS; III SECRETED EFFECTOR; ACTIN-BASED MOTILITY; SALMONELLA-TYPHIMURIUM; FILAMENTOUS STRUCTURES; BACTERIAL PATHOGENS; TIGHT JUNCTION; CELL INVASION; PROTEIN	Pathogenic microbes subvert normal host-cell processes to create a specialized niche, which enhances their survival. A common and recurring target of pathogens is the host cell's cytoskeleton, which is utilized by these microbes for purposes that include attachment, entry into cells, movement within and between cells, vacuole formation and remodelling, and avoidance of phagocytosis. Our increased understanding of these processes in recent years has not only contributed to a greater comprehension of the molecular causes of infectious diseases, but has also revealed fundamental insights into normal functions of the cytoskeleton. From the use of bacterial toxins to investigate Rho family GTPases to in vitro studies of actin polymerization using Listeria and Shigella, the study of pathogenesis has provided important tools to probe cytoskeletal function.	Univ British Columbia, Biotechnol Lab, Vancouver, BC V6T 1Z3, Canada	University of British Columbia	Gruenheid, S (corresponding author), Univ British Columbia, Biotechnol Lab, Vancouver, BC V6T 1Z3, Canada.	bfinlay@interchange.ubc.ca		Gruenheid, Samantha/0000-0002-0908-6715				Allen LAH, 1996, J EXP MED, V184, P627, DOI 10.1084/jem.184.2.627; Amyere M, 2002, INT J MED MICROBIOL, V291, P487; Andor A, 2001, CELL MICROBIOL, V3, P301, DOI 10.1046/j.1462-5822.2001.00114.x; Beuzon CR, 2000, EMBO J, V19, P3235, DOI 10.1093/emboj/19.13.3235; Black DS, 2000, MOL MICROBIOL, V37, P515, DOI 10.1046/j.1365-2958.2000.02021.x; Brodsky FM, 2002, TRAFFIC, V3, P1, DOI 10.1034/j.1600-0854.2002.30101.x; Bruce-Staskal PJ, 2002, J CELL SCI, V115, P2689; Brumell JH, 2002, TRAFFIC, V3, P407, DOI 10.1034/j.1600-0854.2002.30604.x; Brumell JH, 2001, CELL MICROBIOL, V3, P75, DOI 10.1046/j.1462-5822.2001.00087.x; Buchwald G, 2002, EMBO J, V21, P3286, DOI 10.1093/emboj/cdf329; Carlson SA, 2002, LIFE SCI, V70, P1415, DOI 10.1016/S0024-3205(01)01512-0; Caron E, 2002, CURR OPIN CELL BIOL, V14, P82, DOI 10.1016/S0955-0674(01)00298-8; Catron DM, 2002, CELL MICROBIOL, V4, P315, DOI 10.1046/j.1462-5822.2002.00198.x; Celli J, 2002, TRENDS MICROBIOL, V10, P232, DOI 10.1016/S0966-842X(02)02343-0; Coppolino MG, 2001, J CELL SCI, V114, P4307; Cornelis GR, 2002, J CELL BIOL, V158, P401, DOI 10.1083/jcb.200205077; Cowman AF, 2002, SCIENCE, V298, P126, DOI 10.1126/science.1078169; Elliott DA, 2001, INFECT IMMUN, V69, P5940, DOI 10.1128/IAI.69.9.5940-5942.2001; FALLMAN M, 1995, INFECT IMMUN, V63, P3117; Ferrari G, 1999, CELL, V97, P435, DOI 10.1016/S0092-8674(00)80754-0; Frischknecht F, 1999, NATURE, V401, P926, DOI 10.1038/44860; Frishknecht F, 2001, TRENDS CELL BIOL, V11, P30, DOI 10.1016/S0962-8924(00)01871-7; Fu YX, 1999, NATURE, V401, P293, DOI 10.1038/45829; GARCIADELPORTILLO F, 1993, P NATL ACAD SCI USA, V90, P10544, DOI 10.1073/pnas.90.22.10544; Goldberg MB, 2001, MICROBIOL MOL BIOL R, V65, P595, DOI 10.1128/MMBR.65.4.595-626.2001; Goosney DL, 2001, INFECT IMMUN, V69, P3315, DOI 10.1128/IAI.69.5.3315-3322.2001; Gouin E, 1999, J CELL SCI, V112, P1697; GREENBERG S, 1994, J BIOL CHEM, V269, P3897; Griffiths EK, 2002, CURR OPIN IMMUNOL, V14, P317, DOI 10.1016/S0952-7915(02)00334-5; Grosdent N, 2002, INFECT IMMUN, V70, P4165, DOI 10.1128/IAI.70.8.4165-4176.2002; Gruenheid S, 2001, NAT CELL BIOL, V3, P856, DOI 10.1038/ncb0901-856; Guerin I, 2000, EUR J CELL BIOL, V79, P735, DOI 10.1078/0171-9335-00092; Guerin I, 2000, INFECT IMMUN, V68, P2655, DOI 10.1128/IAI.68.5.2655-2662.2000; Hueck CJ, 1998, MICROBIOL MOL BIOL R, V62, P379, DOI 10.1128/MMBR.62.2.379-433.1998; Lesnick ML, 2001, MOL MICROBIOL, V39, P1464, DOI 10.1046/j.1365-2958.2001.02360.x; May RC, 2001, J CELL SCI, V114, P1061; McGee K, 2001, FEBS LETT, V509, P59, DOI 10.1016/S0014-5793(01)03139-8; McNamara BP, 2001, J CLIN INVEST, V107, P621, DOI 10.1172/JCI11138; Meresse S, 2001, CELL MICROBIOL, V3, P567, DOI 10.1046/j.1462-5822.2001.00141.x; Meresse S, 1999, NAT CELL BIOL, V1, pE183, DOI 10.1038/15620; Moss B, 2001, NAT CELL BIOL, V3, pE245, DOI 10.1038/ncb1101-e245; MUALLEM S, 1995, J CELL BIOL, V128, P589, DOI 10.1083/jcb.128.4.589; Murli S, 2001, CELL MICROBIOL, V3, P795, DOI 10.1046/j.1462-5822.2001.00158.x; Nemerow GR, 2002, NAT CELL BIOL, V4, pE69, DOI 10.1038/ncb0402-e69; Niebuhr K, 2002, EMBO J, V21, P5069, DOI 10.1093/emboj/cdf522; Pelkmans L, 2001, NAT CELL BIOL, V3, P473, DOI 10.1038/35074539; Philpott DJ, 1996, AM J PHYSIOL-GASTR L, V270, pG634, DOI 10.1152/ajpgi.1996.270.4.G634; Raucher D, 2000, CELL, V100, P221, DOI 10.1016/S0092-8674(00)81560-3; Rozelle AL, 2000, CURR BIOL, V10, P311, DOI 10.1016/S0960-9822(00)00384-5; Russell DG, 2002, J CELL BIOL, V158, P421, DOI 10.1083/jcb.200205034; RUTZALBERT J, 2002, MOL MICROBIOL, V44, P645; Sandvig K, 2002, ANNU REV CELL DEV BI, V18, P1, DOI 10.1146/annurev.cellbio.18.011502.142107; Sears CL, 2000, AM J PHYSIOL-GASTR L, V279, pG1129, DOI 10.1152/ajpgi.2000.279.6.G1129; Shao F, 2002, CELL, V109, P575, DOI 10.1016/S0092-8674(02)00766-3; Sibley LD, 2000, TRAFFIC, V1, P100, DOI 10.1034/j.1600-0854.2000.010202.x; Simonovic I, 2001, INFECT IMMUN, V69, P5679, DOI 10.1128/IAI.69.9.5679-5688.2001; Simonovic I, 2000, CELL MICROBIOL, V2, P305, DOI 10.1046/j.1462-5822.2000.00055.x; Smith GA, 2002, ANNU REV CELL DEV BI, V18, P135, DOI 10.1146/annurev.cellbio.18.012502.105920; Speck O, 2003, NATURE, V421, P83, DOI 10.1038/nature01295; Steele-Mortimer O, 2000, TRAFFIC, V1, P107, DOI 10.1034/j.1600-0854.2000.010203.x; Stein MA, 1996, MOL MICROBIOL, V20, P151, DOI 10.1111/j.1365-2958.1996.tb02497.x; Tan H, 2002, TRENDS PARASITOL, V18, P427, DOI 10.1016/S1471-4922(02)02368-1; Taunton J, 2001, CURR OPIN CELL BIOL, V13, P85, DOI 10.1016/S0955-0674(00)00178-2; Terebiznik MR, 2002, NAT CELL BIOL, V4, P766, DOI 10.1038/ncb854; Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088; van der Goot FG, 2001, SEMIN IMMUNOL, V13, P89, DOI 10.1006/smim.2000.0300; VANNHIEU GT, 2000, CELL MICROBIOL, V2, P187, DOI DOI 10.1046/J.1462-5822.2000.00046.X; Vazquez-Torres A, 2000, SCIENCE, V287, P1655, DOI 10.1126/science.287.5458.1655; Waterman-Storer CM, 1999, NAT CELL BIOL, V1, P45, DOI 10.1038/9018; Yoshida S, 2002, EMBO J, V21, P2923, DOI 10.1093/emboj/cdf319; Yuhan R, 1997, GASTROENTEROLOGY, V113, P1873, DOI 10.1016/S0016-5085(97)70006-4; ZHANG ZY, 1992, J BIOL CHEM, V267, P23759; Zhou DG, 2001, MICROBES INFECT, V3, P1293, DOI 10.1016/S1286-4579(01)01489-7	73	245	253	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 17	2003	422	6933					775	781		10.1038/nature01603	http://dx.doi.org/10.1038/nature01603			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	668CG	12700772				2022-12-28	WOS:000182272300052
J	Walker, PR; Worobey, M; Rambaut, A; Holmes, EC; Pybus, OG				Walker, PR; Worobey, M; Rambaut, A; Holmes, EC; Pybus, OG			Sexual transmission of HIV in Africa - Other routes of infection are not the dominant contributor to the African epidemic.	NATURE			English	Article							HEPATITIS-C VIRUS		Univ Oxford, Dept Zool, Oxford OX1 3PS, England	University of Oxford	Walker, PR (corresponding author), Univ Oxford, Dept Zool, S Parks Rd, Oxford OX1 3PS, England.		Holmes, Edward/Y-2789-2019; Pybus, Oliver G/B-2640-2012; Holmes, Edward/GVR-9499-2022; Rambaut, Andrew/B-2481-2009	Holmes, Edward/0000-0001-9596-3552; Pybus, Oliver G/0000-0002-8797-2667; Rambaut, Andrew/0000-0003-4337-3707; Walker, Polly/0000-0003-1969-0059				Gisselquist D, 2003, INT J STD AIDS, V14, P162, DOI 10.1258/095646203762869160; Goldmann DA, 2002, J ALLERGY CLIN IMMUN, V110, pS21, DOI 10.1067/mai.2002.125337; Pybus OG, 2001, SCIENCE, V292, P2323, DOI 10.1126/science.1058321; Smith DB, 1997, J GEN VIROL, V78, P321, DOI 10.1099/0022-1317-78-2-321; *UNAIDS, 2002, REP GLOB HIV AIDS EP	5	40	42	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 17	2003	422	6933					679	679		10.1038/422679a	http://dx.doi.org/10.1038/422679a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	668CG	12700750	Bronze			2022-12-28	WOS:000182272300029
J	Berwick, DM				Berwick, DM			Disseminating innovations in health care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							QUALITY; MEDICINE	Health care is rich in evidence-based innovations, yet even when such innovations are implemented successfully in one location, they often disseminate slowly-if at all. Diffusion of innovations is a major challenge in all industries including health care. This article examines the theory and research on the dissemination of innovations and suggests applications of that theory to health care. It explores in detail 3 clusters of influence on the rate of diffusion of innovations within an organization: the perceptions of the innovation, the characteristics of the individuals who may adopt the change, and contextual and managerial factors within the organization. This theory makes plausible at least 7 recommendations for health care executives who want to accelerate the rate of diffusion of innovations within their organizations: find sound innovations, find and, support "innovators, " invest in "early adopters, " make early adopter activity observable, trust and enable reinvention create slack for change, and lead by example.	Inst Healthcare Improvement, Boston, MA 02215 USA	Institute for Healthcare Improvement	Berwick, DM (corresponding author), Inst Healthcare Improvement, 375 Longwood Ave,4th Floor, Boston, MA 02215 USA.	dberwick@ihi.org	Young, Alexander/A-1523-2009; Greiver, Michelle/N-8764-2015	Young, Alexander/0000-0002-9367-9213; Greiver, Michelle/0000-0001-8957-0285				[Anonymous], 1986, AGRIBUSINESS, DOI DOI 10.1002/1520-6297(198624)2:43.0.CO;2-G; Bergstrom N, 2002, NURS RES, V51, P400; Berman S, 1997, PEDIATRICS, V100, P585, DOI 10.1542/peds.100.4.585; BERNSTEIN SJ, 1998, MR5922AHCPR RAND; Blendon RJ, 1995, HEALTH AFFAIR, V14, P220, DOI 10.1377/hlthaff.14.4.220; Casalino L, 2003, JAMA-J AM MED ASSOC, V289, P434, DOI 10.1001/jama.289.4.434; *CDCP, 1998, MMWR-MORBID MORTAL W, V47, P797; Chassin MR, 1998, JAMA-J AM MED ASSOC, V280, P1000, DOI 10.1001/jama.280.11.1000; Collins B A, 2000, Manag Care, V9, P56; COVELL DG, 1985, ANN INTERN MED, V103, P596, DOI 10.7326/0003-4819-103-4-596; Davidoff F, 2000, ANN INTERN MED, V132, P996, DOI 10.7326/0003-4819-132-12-200006200-00012; DEMOTT RK, 1990, AM J OBSTET GYNECOL, V162, P1593, DOI 10.1016/0002-9378(90)90925-W; Eberhardt MS, 2001, URBAN RURAL HLTH CHA; ELLIS J, 1995, LANCET, V346, P407, DOI 10.1016/S0140-6736(95)92781-6; Ely JW, 2002, BRIT MED J, V324, P710, DOI 10.1136/bmj.324.7339.710; FLAMM B, 1997, REDUCING CESAREAN SE; Flamm BL, 1997, OBSTET GYNECOL, V90, P312, DOI 10.1016/S0029-7844(97)00263-9; GRANOVETTER MS, 1973, AM J SOCIOL, V78, P1360, DOI 10.1086/225469; Horbar J D, 1999, Pediatrics, V103, P350; Institute of Medicine (US) Committee, 2001, CROSSING QUALITY CHA, P1, DOI [DOI 10.17226/10027, 10.17226/10027]; Jencks SF, 2000, JAMA-J AM MED ASSOC, V284, P1670, DOI 10.1001/jama.284.13.1670; Jewkes J.., 1969, SOURCES INVENTION; JURAN JM, 1981, JURAN QUALITY IMPROV, P14; Leape L L, 1993, QRB Qual Rev Bull, V19, P144; LIND J, 1953, TREATISE SCURVY 1753; MOSTELLER F, 1981, SCIENCE, V211, P881, DOI 10.1126/science.6781066; NADLER G, 1995, CREATIVE SOLUTION FI; Nugent W.C., 1999, IMPROVING OUTCOMES R; Paine Anthony, 1997, ENLIGHTENMENT EXPLOR, P176; Pinker S, 1994, LANGUAGE INSTINCT NE; *PROF BOOKS LTD, 2001, EC POCK WORLD FIG, P74; Rogers E., 2003, DIFFUSION INNOVATION, VFifth; Ryan B, 1943, RURAL SOCIOL, V8, P15; Sobel D., 1996, LONGITUDE TRUE STORY; Soumerai SB, 1998, JAMA-J AM MED ASSOC, V279, P1358, DOI 10.1001/jama.279.17.1358; *US AG HLTH RES QU, 1992, AHCPR PUBL; WEISS KB, 1997, IMPROVING ASTHMA CAR	37	1148	1153	2	138	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 16	2003	289	15					1969	1975		10.1001/jama.289.15.1969	http://dx.doi.org/10.1001/jama.289.15.1969			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	667VC	12697800				2022-12-28	WOS:000182253900030
J	Buchan, I; Hooper, L; McElduff, P; Freemantle, N; Martin, D				Buchan, I; Hooper, L; McElduff, P; Freemantle, N; Martin, D			Primary coronary angioplasty versus thrombolysis for acute myocardial infarction	LANCET			English	Letter							METAANALYSIS		Univ Manchester, Evidence Populat Hlth Unit, Manchester M13 9PT, Lancs, England; Cleveland Clin Fdn, Cleveland, OH 44195 USA; Univ Birmingham, Birmingham, W Midlands, England	University of Manchester; Cleveland Clinic Foundation; University of Birmingham	Buchan, I (corresponding author), Univ Manchester, Evidence Populat Hlth Unit, Manchester M13 9PT, Lancs, England.		Hooper, Lee/D-2795-2009; Buchan, Iain E/H-5767-2013	Hooper, Lee/0000-0002-7904-3331; Buchan, Iain E/0000-0003-3392-1650; Freemantle, Nick/0000-0001-5807-5740				Egger M, 2003, Health Technol Assess, V7, P1; Gavaghan DJ, 2000, PAIN, V85, P415, DOI 10.1016/S0304-3959(99)00302-4; Keeley EC, 2003, LANCET, V361, P13, DOI 10.1016/S0140-6736(03)12113-7; Martin DO, 2000, EPIDEMIOLOGY, V11, P255, DOI 10.1097/00001648-200005000-00005; Sterne JAC, 2001, J CLIN EPIDEMIOL, V54, P1046, DOI 10.1016/S0895-4356(01)00377-8	5	0	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 12	2003	361	9365					1304	1304		10.1016/S0140-6736(03)13012-7	http://dx.doi.org/10.1016/S0140-6736(03)13012-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	666DM	12699991				2022-12-28	WOS:000182161600046
J	Dehant, V				Dehant, V			Planetary science - A liquid core for Mars?	SCIENCE			English	Editorial Material									Observ Royal Belgique, B-1180 Brussels, Belgium		Dehant, V (corresponding author), Observ Royal Belgique, B-1180 Brussels, Belgium.	veronique.dehant@oma.be						Acuna MH, 1998, SCIENCE, V279, P1676, DOI 10.1126/science.279.5357.1676; Folkner WM, 1997, J GEOPHYS RES-PLANET, V102, P4057, DOI 10.1029/96JE02125; Lognonne P, 2000, PLANET SPACE SCI, V48, P1289, DOI 10.1016/S0032-0633(00)00110-0; Longhi J., 1992, MARS, V1, P184, DOI [10.2307/j.ctt207g59v.10, DOI 10.2307/J.CTT207G59V.10]; SCHUBERT G, 1990, J GEOPHYS RES-SOLID, V95, P14095, DOI 10.1029/JB095iB09p14095; Smith DE, 2001, SCIENCE, V294, P2141, DOI 10.1126/science.1066556; Sohl F, 1997, J GEOPHYS RES-PLANET, V102, P1613, DOI 10.1029/96JE03419; Van Hoolst T, 2003, ICARUS, V161, P281, DOI 10.1016/S0019-1035(02)00045-3; Yoder CF, 1997, J GEOPHYS RES-PLANET, V102, P4065, DOI 10.1029/96JE03642; Yoder CF, 2003, SCIENCE, V300, P299, DOI 10.1126/science.1079645	10	0	0	1	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 11	2003	300	5617					260	261		10.1126/science.1083626	http://dx.doi.org/10.1126/science.1083626			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	665RQ	12690177				2022-12-28	WOS:000182135400033
J	Montcouquiol, M; Rachel, RA; Lanford, PJ; Copeland, NG; Jenkins, NA; Kelley, MW				Montcouquiol, M; Rachel, RA; Lanford, PJ; Copeland, NG; Jenkins, NA; Kelley, MW			Identification of Vangl2 and Scrb1 as planar polarity genes in mammals	NATURE			English	Article							NEURAL-TUBE DEFECTS; DROSOPHILA TISSUE POLARITY; CELL FATE; MOUSE; STRABISMUS; CIRCLETAIL; MUTANT; LOCALIZATION; EXTENSION; MUTATION	In mammals, an example of planar cell polarity (PCP) is the uniform orientation of the hair cell stereociliary bundles within the cochlea. The PCP pathway of Drosophila(1-4) refers to a conserved signalling pathway that regulates the coordinated orientation of cells or structures within the plane of an epithelium. Here we show that a mutation in Vangl2, a mammalian homologue of the Drosophila PCP gene Strabismus/Van Gogh, results in significant disruptions in the polarization of stereociliary bundles in mouse cochlea as a result of defects in the direction of movement and/or anchoring of the kinocilium within each hair cell. Similar, but less severe, defects are observed in animals containing a mutation in the LAP protein family gene Scrb1 (homologous with Drosophila scribble). Polarization defects in animals heterozygous for Vangl2 and Scrb1 are comparable with Vangl2 homozygotes, demonstrating genetic interactions between these genes in the regulation of PCP in mammals. These results demonstrate a role for the PCP pathway in planar polarization in mammals, and identify Scrb1 as a PCP gene.	NIDCD, Sect Dev Neurosci, NIH, Rockville, MD 20850 USA; NCI, Mouse Canc Genet Program, Frederick, MD 21702 USA; Univ Maryland, College Pk, MD 20742 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University System of Maryland; University of Maryland College Park	Montcouquiol, M (corresponding author), NIDCD, Sect Dev Neurosci, NIH, Rockville, MD 20850 USA.	montcouq@nidcd.nih.gov	montcouquiol, mireille/L-6199-2017	montcouquiol, mireille/0000-0001-8739-6519	DIVISION OF BASIC SCIENCES - NCI [Z01BC010394, Z01BC010556] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [Z01DC000059, ZIADC000059] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Adler PN, 2002, DEV CELL, V2, P525, DOI 10.1016/S1534-5807(02)00176-4; Adler PN, 2001, CURR OPIN CELL BIOL, V13, P635, DOI 10.1016/S0955-0674(00)00263-5; Bilder D, 2000, NATURE, V403, P676, DOI 10.1038/35001108; Chen P, 2002, DEVELOPMENT, V129, P2495; COPP AJ, 1994, DEV BIOL, V165, P20, DOI 10.1006/dbio.1994.1230; Darken RS, 2002, EMBO J, V21, P976, DOI 10.1093/emboj/21.5.976; Goto T, 2002, DEV BIOL, V247, P165, DOI 10.1006/dbio.2002.0673; Hamblet NS, 2002, DEVELOPMENT, V129, P5827, DOI 10.1242/dev.00164; HUDSPETH AJ, 1979, P NATL ACAD SCI USA, V76, P1506, DOI 10.1073/pnas.76.3.1506; Hung AY, 2002, J BIOL CHEM, V277, P5699, DOI 10.1074/jbc.R100065200; Kibar Z, 2001, NAT GENET, V28, P251, DOI 10.1038/90081; Lanford PJ, 1999, NAT GENET, V21, P289, DOI 10.1038/6804; Mlodzik M, 2002, TRENDS GENET, V18, P564, DOI 10.1016/S0168-9525(02)02770-1; Mueller KL, 2002, J NEUROSCI, V22, P9368; Murdoch JN, 2003, HUM MOL GENET, V12, P87, DOI 10.1093/hmg/ddg014; Murdoch JN, 2001, HUM MOL GENET, V10, P2593, DOI 10.1093/hmg/10.22.2593; Murdoch JN, 2001, GENOMICS, V78, P55, DOI 10.1006/geno.2001.6638; Park M, 2002, NAT CELL BIOL, V4, P20, DOI 10.1038/ncb716; Rachel RA, 2002, GENESIS, V33, P55, DOI 10.1002/gene.10088; Rachel RA, 2000, GENESIS, V27, P32, DOI 10.1002/1526-968X(200005)27:1<32::AID-GENE50>3.0.CO;2-T; Rubel E. W, 1978, HDB SENSORY PHYSL, VIX, P135; STRONG LC, 1949, J HERED, V40, P329, DOI 10.1093/oxfordjournals.jhered.a105976; Taylor J, 1998, GENETICS, V150, P199; Wolff T, 1998, DEVELOPMENT, V125, P1149; Wu DK, 1996, J NEUROSCI, V16, P6454	25	539	555	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 8	2003	423	6936					173	177		10.1038/nature01618	http://dx.doi.org/10.1038/nature01618			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	675MR	12724779				2022-12-28	WOS:000182699600047
J	Car, J; Sheikh, A				Car, J; Sheikh, A			Telephone consultations	BMJ-BRITISH MEDICAL JOURNAL			English	Review							RANDOMIZED CONTROLLED TRIAL; HOURS PRIMARY-CARE; NURSE FOLLOW-UP; GENERAL-PRACTITIONERS; AUTOMATED CALLS; CLINICAL-PRACTICE; TRACT INFECTIONS; CANCER-PATIENTS; FAMILY-PRACTICE; NHS DIRECT	Delivery of clinical care by telephone is still somewhat controversial. What evidence exists to clarify its potential role, and how can the quality and safety of care be ensured?	Univ London Imperial Coll Sci Technol & Med, Dept Primary Hlth Care & Gen Practice, London SW7 2AZ, England; Univ London St Georges Hosp, Sch Med, Dept Publ Hlth Sci, London, England	Imperial College London; St Georges University London	Car, J (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Primary Hlth Care & Gen Practice, London SW7 2AZ, England.	josip.car@imperial.ac.uk	Car, Josip/H-6755-2015	Car, Josip/0000-0001-8969-371X; Sheikh, Aziz/0000-0001-7022-3056				Andrews JK, 2002, J PAEDIATR CHILD H, V38, P23, DOI 10.1046/j.1440-1754.2002.00718.x; Anie KA, 1996, J CLIN EPIDEMIOL, V49, P653, DOI 10.1016/0895-4356(95)00583-8; ANTMAN EM, 1986, AM J CARDIOL, V58, P1021, DOI 10.1016/S0002-9149(86)80031-5; Austin JS, 1996, ARTHRIT CARE RES, V9, P391, DOI 10.1002/1529-0131(199610)9:5<391::AID-ANR1790090508>3.0.CO;2-V; Balas EA, 1997, JAMA-J AM MED ASSOC, V278, P152, DOI 10.1001/jama.278.2.152; Barry HC, 2001, J FAM PRACTICE, V50, P589; BHAT K, 1985, ANN ALLERGY, V54, P109; Blackmore K, 1999, BRIT MED J, V318, P1137; Bowman G S, 1994, J Clin Nurs, V3, P369, DOI 10.1111/j.1365-2702.1994.tb00414.x; BRIMBERRY R, 1988, J FAM PRACTICE, V26, P397; Brough RJ, 1996, BRIT J UROL, V78, P401, DOI 10.1046/j.1464-410X.1996.00087.x; Cartmill M, 2001, BRIT J NEUROSURG, V15, P453, DOI 10.1080/713653837; CASEY R, 1985, CLIN PEDIATR, V24, P149, DOI 10.1177/000992288502400307; Christensen A A, 2001, Pediatr Dent, V23, P495; CHWALOW AJ, 1989, DIABETES METAB, V15, P157; COHEN AJ, 1980, J PUBLIC HEALTH DENT, V40, P64, DOI 10.1111/j.1752-7325.1980.tb01850.x; Cooper HM, 2000, OPHTHALMIC PLAST REC, V16, P231, DOI 10.1097/00002341-200005000-00011; Cukor P, 1998, TELEMED J, V4, P313, DOI 10.1089/tmj.1.1998.4.313; Culbertson VL, 1999, ANN PHARMACOTHER, V33, P541, DOI 10.1345/aph.18266; Curren J R, 2001, Int J Palliat Nurs, V7, P331; Dale J, 1995, Nurs Stand, V9, P28; De Leo D, 2002, BRIT J PSYCHIAT, V181, P226, DOI 10.1192/bjp.181.3.226; Delichatsios H, 1998, J GEN INTERN MED, V13, P579, DOI 10.1046/j.1525-1497.1998.00179.x; Delichatsios HK, 2001, AM J HEALTH PROMOT, V15, P215, DOI 10.4278/0890-1171-15.4.215; DINI EF, 1995, ARCH PEDIAT ADOL MED, V149, P902, DOI 10.1001/archpedi.1995.02170210076013; *DOCT PAT PARTN, 2002, GP APP WAST YOUNG; Donnelly JM, 2000, PSYCHO-ONCOL, V9, P44, DOI 10.1002/(SICI)1099-1611(200001/02)9:1<44::AID-PON431>3.3.CO;2-M; Dudas V, 2002, DM-DIS MON, V48, P239, DOI 10.1016/S0011-5029(02)90031-3; EISENBERG MS, 1985, AM J PUBLIC HEALTH, V75, P47, DOI 10.2105/AJPH.75.1.47; EVANS RJ, 1993, ARCH EMERG MED, V10, P216; Fallis WM, 2001, CAN J SURG, V44, P39; Fatovich DM, 1998, MED J AUSTRALIA, V169, P143, DOI 10.5694/j.1326-5377.1998.tb116015.x; Fazili J, 2001, AM J GASTROENTEROL, V96, P2086, DOI 10.1016/S0002-9270(01)02530-8; Foster J, 1999, BRIT J GEN PRACT, V49, P111; Fulmer T T, 1999, J Gerontol Nurs, V25, P6; Gallagher M, 1998, BRIT J GEN PRACT, V48, P1141; Gold DB, 2000, AM J HEALTH PROMOT, V15, P97, DOI 10.4278/0890-1171-15.2.97; HALLAM L, 1992, BRIT J GEN PRACT, V42, P186; HALLAM L, 1993, BRIT J GEN PRACT, V43, P331; Hamadeh G, 1989, Fam Med, V21, P305; Hannis MD, 1996, J GEN INTERN MED, V11, P678, DOI 10.1007/BF02600159; HANNIS MD, 1994, AM J MED SCI, V308, P349, DOI 10.1097/00000441-199412000-00007; Hardy KJ, 2001, BRIT MED J, V323, P1298, DOI 10.1136/bmj.323.7324.1298; Hartford K, 2002, HEART LUNG, V31, P199, DOI 10.1067/mhl.2002.122942; Hashim M J, 2001, J Am Board Fam Pract, V14, P193; HEAGARTY MC, 1978, AM J PUBLIC HEALTH, V68, P14, DOI 10.2105/AJPH.68.1.14; Hull S, 2002, BRIT J GEN PRACT, V52, P712; Hunter E F, 2000, Home Healthc Nurse, V18, P172, DOI 10.1097/00004045-200003000-00008; INTAGLIATA J, 1976, J STUD ALCOHOL, V37, P1330, DOI 10.15288/jsa.1976.37.1330; JEPSON S, 1994, WESTERN J MED, V160, P529; Jiwa M, 2002, BRIT J GEN PRACT, V52, P390; Jones JS, 1997, ACAD EMERG MED, V4, P1147, DOI 10.1111/j.1553-2712.1997.tb03698.x; KEELING AW, 1995, HEART LUNG, V24, P45, DOI 10.1016/S0147-9563(05)80094-9; Kelly D F, 1999, Can Oncol Nurs J, V9, P175; Koepsell TD, 1996, AM J EPIDEMIOL, V144, P704; Lattimer V, 1998, BMJ-BRIT MED J, V317, P1054; Lattimer V, 2000, BMJ-BRIT MED J, V320, P1053, DOI 10.1136/bmj.320.7241.1053; Lieu TA, 1998, PEDIATRICS, V101, DOI 10.1542/peds.101.4.e3; LINKINS RW, 1994, ARCH PEDIAT ADOL MED, V148, P908, DOI 10.1001/archpedi.1994.02170090022002; Little Mary, 2002, Lippincotts Case Manag, V7, P103, DOI 10.1097/00129234-200205000-00004; Lynch DJ, 1997, J FAM PRACTICE, V44, P293; MacDonald J, 2000, PSYCHIAT SERV, V51, P812, DOI 10.1176/appi.ps.51.6.812; Maguire P, 2002, BRIT MED J, V325, P697, DOI 10.1136/bmj.325.7366.697; MANNICHE C, 1994, PAIN, V57, P317, DOI 10.1016/0304-3959(94)90007-8; Marcantonio ER, 1998, J GEN INTERN MED, V13, P621, DOI 10.1046/j.1525-1497.1998.00185.x; McBride CM, 1999, PATIENT EDUC COUNS, V37, P3, DOI 10.1016/S0738-3991(98)00098-6; McDoniels-Silvers AL, 2001, EXP LUNG RES, V27, P297, DOI 10.1080/019021401300054064; MCDOWELL I, 1989, J FAM PRACTICE, V28, P420; McKinstry B, 2002, BRIT J GEN PRACT, V52, P306; Mehrabian A., 1981, SILENT MESSAGES IMPL, V2nd; MERMELSTEIN HT, 1991, PSYCHOSOMATICS, V32, P407, DOI 10.1016/S0033-3182(91)72042-2; Mohr DC, 2000, J CONSULT CLIN PSYCH, V68, P356, DOI 10.1037//0022-006X.68.2.356; Munro J, 2000, BRIT MED J, V321, P150, DOI 10.1136/bmj.321.7254.150; Nelson JR, 2001, AM J MED, V111, P43, DOI 10.1016/S0002-9343(01)00970-6; O'Brien G, 1998, PEDIATRICS, V101, DOI 10.1542/peds.101.6.e6; O'Cathain A, 2000, BRIT MED J, V320, P1035, DOI 10.1136/bmj.320.7241.1035; Oldham J, 2002, BRIT MED J, V325, P547, DOI 10.1136/bmj.325.7363.547; Ottolini MC, 1998, PEDIATRICS, V101, DOI 10.1542/peds.101.3.e2; PAULSEN AS, 1988, ARCH GEN PSYCHIAT, V45, P62; Payne F, 2001, FAM PRACT, V18, P156, DOI 10.1093/fampra/18.2.156; Peres R, 2001, AUST NZ J OBSTET GYN, V41, P82, DOI 10.1111/j.1479-828X.2001.tb01300.x; Piette JD, 1999, AM J PREV MED, V17, P138, DOI 10.1016/S0749-3797(99)00061-6; Piette JD, 2000, MED CARE, V38, P218, DOI 10.1097/00005650-200002000-00011; Piette JD, 2000, AM J MED, V108, P20, DOI 10.1016/S0002-9343(99)00298-3; Riegel B, 2002, ARCH INTERN MED, V162, P705, DOI 10.1001/archinte.162.6.705; Ritchie PD, 2000, AUST NZ J MED, V30, P585, DOI 10.1111/j.1445-5994.2000.tb00860.x; Rosbe KW, 2000, ARCH OTOLARYNGOL, V126, P718, DOI 10.1001/archotol.126.6.718; Saint S, 1999, AM J MED, V106, P636, DOI 10.1016/S0002-9343(99)00122-9; Sawyer SM, 2002, J PAEDIATR CHILD H, V38, P79, DOI 10.1046/j.1440-1754.2002.00766.x; Simon GE, 2000, BRIT MED J, V320, P550, DOI 10.1136/bmj.320.7234.550; Stead LF, 2001, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002850.PUB2; Stoddard AM, 2002, PREV MED, V34, P90, DOI 10.1006/pmed.2001.0960; Swingler GH, 2000, J CLIN EPIDEMIOL, V53, P331, DOI 10.1016/S0895-4356(99)00166-3; THOMPSON RS, 1986, MED CARE, V24, P904, DOI 10.1097/00005650-198610000-00004; Toon PD, 2002, BRIT MED J, V324, P1230, DOI 10.1136/bmj.324.7348.1230; Touyz LZG, 1998, J OROFAC PAIN, V12, P219; Turner D, 1996, Br J Nurs, V5, P1361; VANELDERENVANKEMENADE T, 1994, BRIT J CLIN PSYCHOL, V33, P367, DOI 10.1111/j.2044-8260.1994.tb01133.x; WASSON J, 1992, JAMA-J AM MED ASSOC, V267, P1788, DOI 10.1001/jama.267.13.1788; Waterman AD, 2001, J GEN INTERN MED, V16, P460, DOI 10.1046/j.1525-1497.2001.016007460.x; WEINBERGER M, 1993, ARTHRITIS RHEUM, V36, P243, DOI 10.1002/art.1780360216; Welch H G, 2000, Eff Clin Pract, V3, P123; WOOD PR, 1989, PEDIATRICS, V83, P925; Zhu SH, 2002, NEW ENGL J MED, V347, P1087, DOI 10.1056/NEJMsa020660	104	174	178	0	22	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 3	2003	326	7396					966	969		10.1136/bmj.326.7396.966	http://dx.doi.org/10.1136/bmj.326.7396.966			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	676JC	12727771	Green Published, Bronze			2022-12-28	WOS:000182746700019
J	Moore, J				Moore, J			Stealth ship sets sail for a quiet life fishing for data	NATURE			English	News Item																			0	2	2	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 1	2003	423	6935					7	7		10.1038/423007b	http://dx.doi.org/10.1038/423007b			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	673CG	12721594	Bronze			2022-12-28	WOS:000182561600012
J	Altshuler, DL; Clark, CJ				Altshuler, DL; Clark, CJ			Darwin's hummingbirds	SCIENCE			English	Editorial Material							DIMORPHISM; BIRDS; SIZE		CALTECH, Dept Bioengn, Pasadena, CA 91125 USA; Univ Calif Berkeley, Dept Integrat Biol, Berkeley, CA 94720 USA	California Institute of Technology; University of California System; University of California Berkeley	Altshuler, DL (corresponding author), CALTECH, Dept Bioengn, Pasadena, CA 91125 USA.		Altshuler, Douglas L./E-5786-2011	Altshuler, Douglas L./0000-0002-1364-3617				Bleiweiss R, 1999, P ROY SOC B-BIOL SCI, V266, P2491, DOI 10.1098/rspb.1999.0951; Bleiweiss R, 1997, EVOL ECOL, V11, P217, DOI 10.1023/A:1018456017643; BROWN JH, 1978, AM ZOOL, V18, P687; Campbell DR, 1996, ECOLOGY, V77, P1463, DOI 10.2307/2265543; Colwell RK, 2000, AM NAT, V156, P495, DOI 10.1086/303406; Darwin C., 1871, P475; ENDLER JA, 1995, TRENDS ECOL EVOL, V10, P22, DOI 10.1016/S0169-5347(00)88956-9; Grant P. R., 1986, ECOLOGY EVOLUTION DA; Schuchmann K.-L., 1999, HDB BIRDS WORLD, P468; STILES FG, 1995, CONDOR, V97, P853, DOI 10.2307/1369527; Temeles EJ, 2000, SCIENCE, V289, P441, DOI 10.1126/science.289.5478.441; Temeles EJ, 2003, SCIENCE, V300, P630, DOI 10.1126/science.1080003; Wiens JJ, 2001, TRENDS ECOL EVOL, V16, P517, DOI 10.1016/S0169-5347(01)02217-0	13	17	17	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 25	2003	300	5619					588	589		10.1126/science.1084477	http://dx.doi.org/10.1126/science.1084477			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	671FB	12714728				2022-12-28	WOS:000182453700024
J	Butler, D				Butler, D			Agent Orange health investigation stuck at square one	NATURE			English	News Item																		2003, NATURE, V422, P649; 2002, NATURE, V416, P252	2	1	1	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 24	2003	422	6934					793	793		10.1038/422793b	http://dx.doi.org/10.1038/422793b			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	670WR	12712159	Bronze			2022-12-28	WOS:000182432600011
J	Counter, CM; Press, W; Compton, CC				Counter, CM; Press, W; Compton, CC			Telomere shortening in cultured autografts of patients with burns	LANCET			English	Article							CELLS	In extensive third-degree burns, donor sites for conventional split thickness skin grafts are limited. In such cases, cultured epithelial (keratinocyte) grafts are prepared from small samples of the patient's own skin and expanded In tissue culture, a process that may incur very many cell divisions. Telomeres shorten with each cell division, and are markers of cellular proliferative history. We therefore measured telomere length In healed cultured epithelial autografts from four patients with burns, and noted that their telomeres were shorter than those in non-cultured skin from the same Individuals, and than those in skin of healthy donors older than 80 years. Such great loss of telomeric DNA suggests that engrafted cells might have a shortened lifespan, which could have negative repercussions on the long-term viability of these grafts.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Dept Radiat Oncol, Durham, NC 27710 USA; Harvard Inst Med, Harvard Gene Therapy Initiat, Boston, MA USA; McGill Univ, Dept Pathol, Montreal, PQ H3A 2T5, Canada	Duke University; Harvard University; Harvard Medical School; McGill University	Counter, CM (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Dept Radiat Oncol, Durham, NC 27710 USA.			Counter, Christopher M/0000-0003-0748-3079	NATIONAL CANCER INSTITUTE [R01CA082481] Funding Source: NIH RePORTER; NCI NIH HHS [CA82481] Funding Source: Medline; PHS HHS [R01-35242] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Armbruster BN, 2001, MOL CELL BIOL, V21, P7775, DOI 10.1128/MCB.21.22.7775-7786.2001; Collins K, 2002, ONCOGENE, V21, P564, DOI 10.1038/sj.onc.1205083; GALLICO GG, 1984, NEW ENGL J MED, V311, P448, DOI 10.1056/NEJM198408163110706; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Pellegrini G, 1999, TRANSPLANTATION, V68, P868, DOI 10.1097/00007890-199909270-00021	5	23	24	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 19	2003	361	9366					1345	1346		10.1016/S0140-6736(03)13042-5	http://dx.doi.org/10.1016/S0140-6736(03)13042-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	669HP	12711471				2022-12-28	WOS:000182346100013
J	Morrison-Griffiths, S; Walley, TJ; Park, BK; Breckenridge, AM; Pirmohamed, M				Morrison-Griffiths, S; Walley, TJ; Park, BK; Breckenridge, AM; Pirmohamed, M			Reporting of adverse drug reactions by nurses	LANCET			English	Article								Schemes for spontaneous reporting of adverse drug reactions are Important to post-marketing safety surveillance worldwide. In the UK, doctors, dentists, coroners, and pharmacists are allowed to report through the yellow card scheme, but nurses were not until October, 2002. We used a similar programme to assess the role of community and hospital nurses in reporting of adverse drug reactions. The proportion and quality of reports received from nurses was similar to that of those received from doctors: we received reports from one in seven nurses eligible to report, compared with one In eight doctors; 137 of 1.77 nurse reports and 676 of 984 doctor reports were judged to be appropriate according to regulatory authority criteria (95% CI for difference between proportions 1.4-15.0, z=2.3, p=0.02). Our findings suggest that nurses, who form the largest proportion of healthcare staff in the UK, can play a valuable part in improvement of pharmacovigilance.	Univ Liverpool, Dept Pharmacol & Therapeut, Liverpool L69 3GE, Merseyside, England	University of Liverpool	Pirmohamed, M (corresponding author), Univ Liverpool, Dept Pharmacol & Therapeut, Ashton St, Liverpool L69 3GE, Merseyside, England.		Pirmohamed, Munir/H-6004-2011	Pirmohamed, Munir/0000-0002-7534-7266; Morrison-Griffiths, Sally/0000-0002-0250-9076				HALL M, 1995, BRIT J CLIN PHARMACO, V40, P173, DOI 10.1111/j.1365-2125.1995.tb05774.x; Morrison-Griffiths S, 1998, Nurs Times, V94, P52; NARANJO CA, 1981, CLIN PHARMACOL THER, V30, P239, DOI 10.1038/clpt.1981.154; RAWLINS MD, 1995, J ROY COLL PHYS LOND, V29, P41; *UK DEP HLTH, EXT IND NURS PRESCR	5	51	54	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 19	2003	361	9366					1347	1348		10.1016/S0140-6736(03)13043-7	http://dx.doi.org/10.1016/S0140-6736(03)13043-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	669HP	12711472				2022-12-28	WOS:000182346100014
J	Kumar, R				Kumar, R			Another tie that binds the MTA family to breast cancer	CELL			English	Editorial Material							ESTROGEN-RECEPTOR; EXPRESSION		Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Kumar, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Biol, 1515 Holcombe Blvd, Houston, TX 77030 USA.							Chen YH, 2001, FOOD BIOPROD PROCESS, V79, P35, DOI 10.1205/09603080151123344; Kumar R, 2002, NATURE, V418, P654, DOI 10.1038/nature00889; Mazumdar A, 2001, NAT CELL BIOL, V3, P30, DOI 10.1038/35050532; MISHRA SK, 2003, IN PRESS J BIOL 0314; Simpson A, 2001, GENE, V273, P29, DOI 10.1016/S0378-1119(01)00563-7; Talukder AH, 2003, J BIOL CHEM, V278, P11676, DOI 10.1074/jbc.M209570200; TOH Y, 1994, J BIOL CHEM, V269, P22958; Wang RA, 2003, IDENTITIES OF MEMBRANE STEROID RECEPTORS -- AND OTHER PROTEINS MEDIATING NONGENOMIC STEROID ACTION, P119; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3	9	49	53	0	0	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 18	2003	113	2					142	143		10.1016/S0092-8674(03)00274-5	http://dx.doi.org/10.1016/S0092-8674(03)00274-5			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	672EP	12705862	Bronze			2022-12-28	WOS:000182508500003
J	Shiflet, G				Shiflet, G			The more elements, the merrier	SCIENCE			English	Editorial Material									Univ Virginia, Dept Mat Sci & Engn, Charlottesville, VA 22904 USA	University of Virginia	Shiflet, G (corresponding author), Univ Virginia, Dept Mat Sci & Engn, Charlottesville, VA 22904 USA.							Davis J.R., 1990, ASM HDB, V2, P889; GRIMVALL G, 1986, THERMOPHYSICAL PROPE, P205; HE Y, 1988, SCIENCE, V241, P1640, DOI 10.1126/science.241.4873.1640; Kaufman L., 1970, COMPUTER CALCULATION; *NAT RES COUNC, 2003, MAT RES M 21 CENT DE; OLSEN GB, 1997, SCIENCE, V277, P1237; Pecker A., 1993, APPL PHYS LETT, V63, P2342; RHINES F, 1956, PHASE DIAGRAMS METAL, P220; Saito T, 2003, SCIENCE, V300, P464, DOI 10.1126/science.1081957; WRIGHT W, 1901, J W SOC ENG      DEC	10	8	9	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 18	2003	300	5618					443	444		10.1126/science.1083759	http://dx.doi.org/10.1126/science.1083759			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	668LR	12702866				2022-12-28	WOS:000182295900027
J	Wolfe, SM				Wolfe, SM			Ephedra - Scientific evidence versus money/politics	SCIENCE			English	Editorial Material							ALKALOIDS		Publ Citizens Hlth Res Grp, Washington, DC 20009 USA		Wolfe, SM (corresponding author), Publ Citizens Hlth Res Grp, Washington, DC 20009 USA.							CRABTREE P, 2003, SAN DIEGO UNION 0123, pC1; EVANS D, 2002, BLOOMBERG NEWS  0411; Haller CA, 2000, NEW ENGL J MED, V343, P1833, DOI 10.1056/NEJM200012213432502; Haller CA, 2002, CLIN PHARMACOL THER, V71, P421, DOI 10.1067/mcp.2002.124523; HEATH M, COMMUNICATION; ROAN S, 2002, LOS ANGELES TIM 1209, pF1; Weintraub A, 2002, BUS WEEK, P40; WEISSKOPF M, 2000, TIME            0522, pR20; Willman D., 2001, LOS ANGELES TIM 0311, pA1	9	9	11	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 18	2003	300	5618					437	437		10.1126/science.1081910	http://dx.doi.org/10.1126/science.1081910			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	668LR	12702860				2022-12-28	WOS:000182295900021
J	Lodwig, EM; Hosie, AHF; Bordes, A; Findlay, K; Allaway, D; Karunakaran, R; Downie, JA; Poole, PS				Lodwig, EM; Hosie, AHF; Bordes, A; Findlay, K; Allaway, D; Karunakaran, R; Downie, JA; Poole, PS			Amino-acid cycling drives nitrogen fixation in the legume - Rhizobium symbiosis	NATURE			English	Article							PEA ROOT-NODULES; PERIBACTEROID MEMBRANE; TRANSPORT MUTANTS; LEGUMINOSARUM; METABOLISM; IDENTIFICATION; BACTEROIDS; PERMEASE; SHUTTLE; CARBON	The biological reduction of atmospheric N-2 to ammonium (nitrogen fixation) provides about 65% of the biosphere's available nitrogen. Most of this ammonium is contributed by legume rhizobia symbioses(1), which are initiated by the infection of legume hosts by bacteria (rhizobia), resulting in formation of root nodules. Within the nodules, rhizobia are found as bacteroids, which perform the nitrogen fixation: to do this, they obtain sources of carbon and energy from the plant, in the form of dicarboxylic acids(2,3). It has been thought that, in return, bacteroids simply provide the plant with ammonium. But here we show that a more complex amino-acid cycle is essential for symbiotic nitrogen fixation by Rhizobium in pea nodules. The plant provides amino acids to the bacteroids, enabling them to shut down their ammonium assimilation. In return, bacteroids act like plant organelles to cycle amino acids back to the plant for asparagine synthesis. The mutual dependence of this exchange prevents the symbiosis being dominated by the plant, and provides a selective pressure for the evolution of mutualism.	Univ Reading, Sch Anim & Microbial Sci, Reading RG6 6AJ, Berks, England; John Innes Ctr Plant Sci Res, Norwich NR4 7UH, Norfolk, England	University of Reading; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Poole, PS (corresponding author), Univ Reading, Sch Anim & Microbial Sci, POB 228, Reading RG6 6AJ, Berks, England.		Downie, Allan/I-3487-2012; Hosie, Arthur/J-9615-2012	Hosie, Arthur/0000-0002-1327-7901; Findlay, Kim/0000-0002-1556-0532; Allaway, David/0000-0003-4602-8933; Ramakrishnan, Karunakaran/0000-0002-6450-1299; Lodwig, Emma/0000-0001-6941-7996; Downie, Allan/0000-0003-1011-4960				Allaway D, 2000, MOL MICROBIOL, V36, P508, DOI 10.1046/j.1365-2958.2000.01884.x; APPELS MA, 1991, PLANT PHYSIOL, V95, P740, DOI 10.1104/pp.95.3.740; BERINGER JE, 1977, J GEN MICROBIOL, V98, P339, DOI 10.1099/00221287-98-2-339; Craig J, 1999, PLANT J, V17, P353, DOI 10.1046/j.1365-313X.1999.00382.x; FINAN TM, 1983, J BACTERIOL, V154, P1403, DOI 10.1128/JB.154.3.1403-1413.1983; Hosie AHF, 2002, J BACTERIOL, V184, P4071, DOI 10.1128/JB.184.15.4071-4080.2002; Hosie AHF, 2001, MOL MICROBIOL, V40, P1449, DOI 10.1046/j.1365-2958.2001.02497.x; INDIVERI C, 1987, J BIOL CHEM, V262, P15979; Kahn M. L., 1985, Nitrogen fixation research progress. Proceedings of the 6th International Symposium on Nitrogen Fixation, Corvallis, OR, USA, August 4-10. 1985., P193; Mouritzen P, 1997, PLANT PHYSIOL, V115, P519, DOI 10.1104/pp.115.2.519; NEWTON WE, 2000, NITROGEN FIXATION MO, P3; Parsons R, 1996, J EXP BOT, V47, P421, DOI 10.1093/jxb/47.3.421; Patriarca EJ, 2002, MICROBIOL MOL BIOL R, V66, P203, DOI 10.1128/MMBR.66.2.203-222.2002; Poole P, 2000, ADV MICROB PHYSIOL, V43, P117, DOI 10.1016/S0065-2911(00)43004-3; Prell J, 2002, MICROBIOL-SGM, V148, P615, DOI 10.1099/00221287-148-2-615; RONSON CW, 1981, P NATL ACAD SCI-BIOL, V78, P4284, DOI 10.1073/pnas.78.7.4284; ROSENDAHL L, 1992, J PLANT PHYSIOL, V139, P635, DOI 10.1016/S0176-1617(11)80385-8; Rosendahl L, 2001, PLANT SOIL, V230, P31, DOI 10.1023/A:1004628217418; Saalbach G, 2002, PROTEOMICS, V2, P325, DOI 10.1002/1615-9861(200203)2:3<325::AID-PROT325>3.0.CO;2-W; Udvardi M. K., 1988, Molecular Plant-Microbe Interactions, V1, P250, DOI 10.1094/MPMI-1-250; UDVARDI MK, 1988, FEBS LETT, V231, P36, DOI 10.1016/0014-5793(88)80697-5; Vance CP, 2000, PROKARYOTIC NITROGEN FIXATION, P589; Walshaw DL, 1996, MOL MICROBIOL, V21, P1239, DOI 10.1046/j.1365-2958.1996.00078.x; WATSON RJ, 1993, J BACTERIOL, V175, P1919, DOI 10.1128/JB.175.7.1919-1928.1993	24	333	358	11	137	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 17	2003	422	6933					722	726		10.1038/nature01527	http://dx.doi.org/10.1038/nature01527			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	668CG	12700763				2022-12-28	WOS:000182272300042
J	Davis, N; Pohlman, A; Gehlbach, B; Kress, JP; McAtee, J; Herlitz, J; Hall, J				Davis, N; Pohlman, A; Gehlbach, B; Kress, JP; McAtee, J; Herlitz, J; Hall, J			Improving the process of informed consent in the critically ill	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONFUSION ASSESSMENT METHOD; UNIT CAM-ICU; DELIRIUM	Context Invasive procedures are often performed emergently in the intensive care unit (ICU), and patients or their proxies may not be available to provide informed consent. Little is known about the effectiveness of intensivists in obtaining informed consent. Objectives To describe the nature of informed consent in the ICU and to determine if simple interventions could enhance the process. Design, Setting, and Patients Prospective study of 2 cohorts of consecutively admitted patients (N=270) in a 16-bed ICU at a university hospital. All patients admitted to the ICU during the baseline period from November 1, 2001, to December 31, 2001, and during the intervention period from March 1, 2002, to April 30, 2002, were included. Intervention A hospital-approved universal consent form for 8 commonly performed procedures (arterial catheter, central venous catheter, pulmonary artery catheter, or peripherally inserted central catheter placement; lumbar puncture; thoracentesis; paracentesis; and intubation/mechanical ventilation) was administered to patients or proxies. Handouts describing each procedure were available in the ICU waiting area. Physicians and nurses were introduced to the universal consent form during orientation to the ICU. Main Outcome Measures Incidence of informed consent for invasive procedures at baseline and after intervention; whether the patient or proxy provided informed consent; and understanding by the consenter of the procedure as determined by the responses on a questionnaire. Results Fifty-three percent of procedures (155/292) were performed after consent had been obtained during the baseline period compared with 90% (308/340) during the intervention period (absolute difference, 37.4%; P<.001). During baseline, the majority (71.6%; 111/155) of consents were provided by proxies. This was also the case during the intervention period in which 65.6% (202/308) of consents were provided by proxies (absolute difference, 6.0%; P=.23). Comprehension by consenters of indications for and risks of the procedures was high and not different between the 2 periods (P=.75). Conclusions Invasive procedures are frequent in the ICU and consent for them is often obtained by proxy. Providing a universal consent form to patients, proxies, and health care clinicians significantly increased the frequency with which consent was obtained without compromising comprehension of the process by the consenter.	Univ Chicago Hosp & Clin, Pritzker Sch Med, Pulm & Crit Care Med Sect, Chicago, IL 60637 USA; Univ Chicago Hosp & Clin, Off Risk Management, Chicago, IL 60637 USA	University of Chicago; University of Illinois System; University of Chicago; University of Illinois System	Hall, J (corresponding author), Univ Chicago Hosp & Clin, Pritzker Sch Med, Pulm & Crit Care Med Sect, MC 6076,5841 S Maryland Ave, Chicago, IL 60637 USA.			Gehlbach, Brian/0000-0003-3160-1741	PHS HHS [K236M63906] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Azoulay E, 2000, CRIT CARE MED, V28, P3044, DOI 10.1097/00003246-200008000-00061; BLACKHALL LJ, 1995, JAMA-J AM MED ASSOC, V274, P820, DOI 10.1001/jama.274.10.820; *CRIT CAR ASS AM T, 2002, PRIM CRIT CAR PAT TH; Dyson M, 1999, J CLIN NURS, V8, P284, DOI 10.1046/j.1365-2702.1999.00265.x; Ely EW, 2001, JAMA-J AM MED ASSOC, V286, P2703, DOI 10.1001/jama.286.21.2703; Ely EW, 2001, CRIT CARE MED, V29, P1370, DOI 10.1097/00003246-200107000-00012; ETHELLS E, 1996, CMAJ, V155, P177; HALL JA, 1988, MED CARE, V26, P657, DOI 10.1097/00005650-198807000-00002; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Levine R J, 1991, Law Med Health Care, V19, P207; Shelly MP, 1999, INTENS CARE MED, V25, P137, DOI 10.1007/s001340050805; SULMASY DP, 1994, AM J MED, V96, P432, DOI 10.1016/0002-9343(94)90170-8; *U CHIC, 2001, U CHIC HOSP POL PROC	13	51	52	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 16	2003	289	15					1963	1968		10.1001/jama.289.15.1963	http://dx.doi.org/10.1001/jama.289.15.1963			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	667VC	12697799	Bronze			2022-12-28	WOS:000182253900029
J	Omran, H; Schmidt, H; Hackenbroch, M; Illien, S; Bernhardt, P; von der Recke, G; Fimmers, R; Flacke, S; Layer, G; Pohl, C; Luderitz, B; Schild, H; Sommer, T				Omran, H; Schmidt, H; Hackenbroch, M; Illien, S; Bernhardt, P; von der Recke, G; Fimmers, R; Flacke, S; Layer, G; Pohl, C; Luderitz, B; Schild, H; Sommer, T			Silent and apparent cerebral embolism after retrograde catheterisation of the aortic valve in valvular stenosis: a prospective, randomised study	LANCET			English	Article							INTERNAL ATRIAL DEFIBRILLATION; CARDIAC-CATHETERIZATION; ECHOCARDIOGRAPHY; STROKE; BRAIN	Background In most patients, severity of valvular aortic stenosis can be accurately assessed non-invasively by echocardiography. However, retrograde catheterisation of the aortic valve is often undertaken. This procedure has a potential risk of neurological complications, with an unknown incidence of clinically silent embolism. We aimed to establish the frequency of clinically apparent and silent cerebral embolism after this procedure. Methods We prospectively randomised 152 consecutive patients with valvular aortic stenosis at a German university hospital to receive either cardiac catheterisation with (n=101) or without (n=51) passage through the aortic valve. Patients underwent cranial MRI and neurological assessment within 48 h before and after the procedure to assess cerebral embolism. Controls were 32 patients without valvular aortic stenosis who underwent coronary angiography and laevocardiography. Findings 22 of 101 patients (22%) who underwent retrograde catheterisation of the aortic valve had focal diffusion-imaging abnormalities in a pattern consistent with acute cerebral embolic events after the procedure; three of these patients (3%) had clinically apparent neurological deficits. By contrast, none of the patients without passage of the valve, or any of the controls, had evidence of cerebral embolism as assessed by MRI. Interpretation Patients with valvular aortic stenosis who undergo retrograde catheterisation of the aortic valve have a substantial risk of clinically apparent cerebral embolism, and frequently have silent ischaemic brain lesions. Patients should be informed about these risks, and this procedure should be used only in patients with unclear echocardiographical findings when additional information is necessary for clinical management.	Univ Bonn, Dept Med Cardiol, D-53105 Bonn, Germany; Univ Bonn, Dept Radiol, D-53105 Bonn, Germany; Univ Bonn, Dept Neurol, D-53105 Bonn, Germany; Univ Bonn, Dept Stat & Biometr, D-53105 Bonn, Germany	University of Bonn; University of Bonn; University of Bonn; University of Bonn	Omran, H (corresponding author), Univ Bonn, Dept Med Cardiol, Sigmund Freud Str 25, D-53105 Bonn, Germany.							Barth A, 2000, STROKE, V31, P1824, DOI 10.1161/01.STR.31.8.1824; Bartsch B, 1999, Z KARDIOL, V88, P255, DOI 10.1007/s003920050284; Bendszus M, 1999, LANCET, V354, P1594, DOI 10.1016/S0140-6736(99)07083-X; Feiwell RJ, 2001, AM J NEURORADIOL, V22, P646; GORLIN R, 1951, AM HEART J, V41, P1, DOI 10.1016/0002-8703(51)90002-6; Grossman W, 1991, CARDIAC CATHETERIZAT; HENRY WL, 1980, CIRCULATION, V62, P212, DOI 10.1161/01.CIR.62.2.212; Hoffmann R, 1993, J AM COLL CARDIOL, V22, P529, DOI 10.1016/0735-1097(93)90060-E; KAPILA A, 1986, STROKE, V17, P619, DOI 10.1161/01.STR.17.4.619; Landwehr P, 2001, EUR RADIOL, V11, P1521, DOI 10.1007/s003300100963; MOSELEY ME, 1990, AM J NEURORADIOL, V11, P423; Omran H, 1998, AM J CARDIOL, V81, P1446, DOI 10.1016/S0002-9149(98)00212-4; Omran H, 1997, J AM COLL CARDIOL, V29, P131, DOI 10.1016/S0735-1097(96)00439-1; Otto CM, 1999, ECHOCARDIOGR-J CARD, V16, P675, DOI 10.1111/j.1540-8175.1999.tb00124.x; Rordorf G, 2001, AM J NEURORADIOL, V22, P5; Schaefer PW, 2000, RADIOLOGY, V217, P331, DOI 10.1148/radiology.217.2.r00nv24331; Tardif JC, 1997, J AM COLL CARDIOL, V29, P1296, DOI 10.1016/S0735-1097(97)00060-0; WARACH S, 1995, ANN NEUROL, V37, P231, DOI 10.1002/ana.410370214; YEAGER M, 1986, AM J CARDIOL, V57, P644, DOI 10.1016/0002-9149(86)90851-9	19	292	297	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 12	2003	361	9365					1241	1246		10.1016/S0140-6736(03)12978-9	http://dx.doi.org/10.1016/S0140-6736(03)12978-9			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	666DM	12699950				2022-12-28	WOS:000182161600007
J	Calle, EE; Rodriguez, C; Walker-Thurmond, K; Thun, MJ				Calle, EE; Rodriguez, C; Walker-Thurmond, K; Thun, MJ			Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BODY-MASS INDEX; OVARIAN-CANCER; RISK-FACTORS; BREAST-CANCER; GALLBLADDER CANCER; PANCREATIC-CANCER; PHYSICAL-ACTIVITY; PROSTATE-CANCER; GASTRIC CARDIA; WEIGHT	Background: The influence of excess body weight on the risk of death from cancer has not been fully characterized. Methods: In a prospectively studied population of more than 900,000 U.S. adults (404,576 men and 495,477 women) who were free of cancer at enrollment in 1982, there were 57,145 deaths from cancer during 16 years of follow-up. We examined the relation in men and women between the body-mass index in 1982 and the risk of death from all cancers and from cancers at individual sites, while controlling for other risk factors in multivariate proportional-hazards models. We calculated the proportion of all deaths from cancer that was attributable to overweight and obesity in the U.S. population on the basis of risk estimates from the current study and national estimates of the prevalence of overweight and obesity in the U.S. adult population. Results: The heaviest members of this cohort (those with a body-mass index [the weight in kilograms divided by the square of the height in meters] of at least 40) had death rates from all cancers combined that were 52 percent higher (for men) and 62 percent higher (for women) than the rates in men and women of normal weight. For men, the relative risk of death was 1.52 (95 percent confidence interval, 1.13 to 2.05); for women, the relative risk was 1.62 (95 percent confidence interval, 1.40 to 1.87). In both men and women, body-mass index was also significantly associated with higher rates of death due to cancer of the esophagus, colon and rectum, liver, gallbladder, pancreas, and kidney; the same was true for death due to non-Hodgkin's lymphoma and multiple myeloma. Significant trends of increasing risk with higher body-mass-index values were observed for death from cancers of the stomach and prostate in men and for death from cancers of the breast, uterus, cervix, and ovary in women. On the basis of associations observed in this study, we estimate that current patterns of overweight and obesity in the United States could account for 14 percent of all deaths from cancer in men and 20 percent of those in women. Conclusions: Increased body weight was associated with increased death rates for all cancers combined and for cancers at multiple specific sites.	Amer Canc Soc, Dept Epidemiol & Surveillance Res, Atlanta, GA 30329 USA	American Cancer Society	Calle, EE (corresponding author), Amer Canc Soc, Dept Epidemiol & Surveillance Res, 1599 Clifton Rd NE, Atlanta, GA 30329 USA.	jcalle@cancer.org						Allison DB, 1999, JAMA-J AM MED ASSOC, V282, P1530, DOI 10.1001/jama.282.16.1530; Andersson SO, 1997, JNCI-J NATL CANCER I, V89, P385, DOI 10.1093/jnci/89.5.385; Bergstrom A, 2001, INT J CANCER, V91, P421, DOI 10.1002/1097-0215(200002)9999:9999&lt;::AID-IJC1053&gt;3.0.CO;2-T; Bergstrom A, 2001, INT J CANCER, V92, P927, DOI 10.1002/ijc.1285; BOYD NF, 1981, JNCI-J NATL CANCER I, V67, P785; Calle EE, 1999, NEW ENGL J MED, V341, P1097, DOI 10.1056/NEJM199910073411501; CALLE EE, 1993, AM J EPIDEMIOL, V137, P235, DOI 10.1093/oxfordjournals.aje.a116664; Calle EE, 2000, AM J EPIDEMIOL, V151, P550, DOI 10.1093/oxfordjournals.aje.a010242; Carroll KK, 1998, LIPIDS, V33, P1055, DOI 10.1007/s11745-998-0305-8; Centers for Disease Control and Prevention (CDC) National Center for Health Statistics (NCHS), 2002, NAT HLTH NUTR EX SUR; Chow WH, 1998, JNCI-J NATL CANCER I, V90, P150, DOI 10.1093/jnci/90.2.150; Cox D. R., 1984, ANAL SURVIVAL DATA; COX DR, 1972, J R STAT SOC B, V34, P187; CRAMER DW, 1984, OBSTET GYNECOL, V63, P833; FARROW DC, 1989, AM J EPIDEMIOL, V129, P1300, DOI 10.1093/oxfordjournals.aje.a115249; FerroLuzzi A, 1995, WHO TECH REP SER, V854, P1; FLANDERS WD, 1984, J CHRON DIS, V37, P449, DOI 10.1016/0021-9681(84)90028-6; Gapstur SM, 2000, JAMA-J AM MED ASSOC, V283, P2552, DOI 10.1001/jama.283.19.2552; Garfinkel L, 1985, Natl Cancer Inst Monogr, V67, P49; Giovannucci E, 1997, CANCER EPIDEM BIOMAR, V6, P557; Henley SJ, 2002, EPIDEMIOLOGY, V13, P268, DOI 10.1097/00001648-200205000-00006; Hill HA, 1996, CANCER CAUSE CONTROL, V7, P19, DOI 10.1007/BF00115635; Holly EA, 1999, AM J EPIDEMIOL, V150, P375, DOI 10.1093/oxfordjournals.aje.a010017; Hunter DJ, 1996, CANCER CAUSE CONTROL, V7, P56, DOI 10.1007/BF00115638; International Agency for Research on Cancer, 2002, IARC HDB CANC PREV, V6; Ji BT, 1997, CANCER EPIDEM BIOMAR, V6, P481; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES PR, P163; Kolonel LN, 1996, CANCER CAUSE CONTROL, V7, P83, DOI 10.1007/BF00115640; Kopelman PG, 2000, NATURE, V404, P635, DOI 10.1038/35007508; Kuczmarski RJ, 1997, OBES RES, V5, P542, DOI 10.1002/j.1550-8528.1997.tb00575.x; LEW EA, 1979, J CHRON DIS, V32, P563, DOI 10.1016/0021-9681(79)90119-X; Lindsted KD, 1998, INT J OBESITY, V22, P544, DOI 10.1038/sj.ijo.0800623; MANSON JE, 1995, NEW ENGL J MED, V333, P677, DOI 10.1056/NEJM199509143331101; Michaud DS, 2001, JAMA-J AM MED ASSOC, V286, P921, DOI 10.1001/jama.286.8.921; Mink PJ, 1996, EPIDEMIOLOGY, V7, P38, DOI 10.1097/00001648-199601000-00008; MOLLER H, 1994, EUR J CANCER, V30A, P344, DOI 10.1016/0959-8049(94)90254-2; Nomura AM, 2001, EPIDEMIOL REV, V23, P126, DOI 10.1093/oxfordjournals.epirev.a000777; PALTA M, 1982, AM J EPIDEMIOL, V115, P223, DOI 10.1093/oxfordjournals.aje.a113294; Peto J, 2001, NATURE, V411, P390, DOI 10.1038/35077256; Petrelli JM, 2002, CANCER CAUSE CONTROL, V13, P325, DOI 10.1023/A:1015288615472; Potter JD, 1996, CANCER CAUSE CONTROL, V7, P127, DOI 10.1007/BF00115644; Purdie DM, 2001, CANCER CAUSE CONTROL, V12, P855, DOI 10.1023/A:1012267619561; Reeves MJ, 1996, CANCER, V77, P301, DOI 10.1002/(SICI)1097-0142(19960115)77:2<301::AID-CNCR12>3.0.CO;2-5; Rockhill B, 1998, AM J PUBLIC HEALTH, V88, P15, DOI 10.2105/AJPH.88.1.15; Rodriguez C, 2001, CANCER EPIDEM BIOMAR, V10, P345; Rothman K., 1998, MODERN EPIDEMIOLOGY; Silverman DT, 1998, JNCI-J NATL CANCER I, V90, P1710, DOI 10.1093/jnci/90.22.1710; SLATTERY ML, 1989, AM J EPIDEMIOL, V130, P497, DOI 10.1093/oxfordjournals.aje.a115363; STELLMAN SD, 1986, JNCI-J NATL CANCER I, V76, P1057; STEVENS J, 1990, AM J EPIDEMIOL, V132, P1156, DOI 10.1093/oxfordjournals.aje.a115758; Stevens J, 1998, OBES RES, V6, P268, DOI 10.1002/j.1550-8528.1998.tb00349.x; STEWART AW, 1987, AM J EPIDEMIOL, V125, P122, DOI 10.1093/oxfordjournals.aje.a114494; STROM BL, 1995, CANCER, V76, P1747, DOI 10.1002/1097-0142(19951115)76:10<1747::AID-CNCR2820761011>3.0.CO;2-L; THUN MJ, 1992, JNCI-J NATL CANCER I, V84, P1491, DOI 10.1093/jnci/84.19.1491; VAUGHAN TL, 1995, CANCER EPIDEM BIOMAR, V4, P85; WALTER SD, 1976, BIOMETRICS, V32, P829, DOI 10.2307/2529268; Wee CC, 2000, ANN INTERN MED, V132, P697, DOI 10.7326/0003-4819-132-9-200005020-00003; *WHO, 1977, INT CLASS DIS MAN IN, V1; Willett W., 2012, NUTR EPIDEMIOLOGY; WILLETT WC, 1995, JAMA-J AM MED ASSOC, V273, P461, DOI 10.1001/jama.273.6.461; Willett WC, 1999, NEW ENGL J MED, V341, P427, DOI 10.1056/NEJM199908053410607; Wolk A, 1996, CANCER CAUSE CONTROL, V7, P5, DOI 10.1007/BF00115634; Wolk A, 2001, CANCER CAUSE CONTROL, V12, P13, DOI 10.1023/A:1008995217664; World Cancer Research Fund, 1997, FOOD NUTR PREV CANC, P371; Zatonski WA, 1997, JNCI-J NATL CANCER I, V89, P1132, DOI 10.1093/jnci/89.15.1132	65	5284	5437	23	574	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 24	2003	348	17					1625	1638		10.1056/NEJMoa021423	http://dx.doi.org/10.1056/NEJMoa021423			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	670PB	12711737				2022-12-28	WOS:000182416300002
J	Maskell, NA; Gleeson, FV; Davies, RJ				Maskell, NA; Gleeson, FV; Davies, RJ			Standard pleural biopsy versus CT-guided cutting-needle biopsy for diagnosis of malignant disease in pleural effusions: a randomised controlled trial	LANCET			English	Article							CYTOLOGIC EVALUATION; MESOTHELIOMA; THORACOSCOPY; FLUID; EFFICACY; VALUES	Background Over 200 000 pleural effusions are attributable to cancer in the UK and USA every year. Cytological examination of pleural fluid classifies about 60% of malignant effusions. Pleural biopsy needs to be done in the remaining cases. We aimed to assess whether CT-guided biopsy is an improvement over standard pleural biopsy in this setting. Methods 50 consecutive patients with cytologically negative suspected malignant pleural effusions were recruited. All had a contrast-enhanced thoracic CT scan to assess pleural thickening. Patients were randomly allocated, stratified by baseline pleural thickening, to either Abrams' pleural biopsy (standard care; n=25) or CT-guided cutting needle biopsy (n=25). Sensitivity for pleural malignancy from the biopsy specimen was the primary endpoint, with the patient's clinical outcome after 1 year being the diagnostic gold standard. Analysis was per protocol. Findings Three patients did not undergo biopsy. Abrams' biopsy correctly diagnosed malignancy in eight of 17 patients (sensitivity 47%, specificity 100%, negative predictive value 44%, positive predictive value 100%). CT-guided biopsy correctly diagnosed malignancy in 13 of 15 (sensitivity 87%, specificity 100%, negative predictive value 80%, positive predictive value 100%; difference in sensitivity between Abrams' and CT-guided 40%, 95% CI 10-69, p=0.02). Diagnostic advantage was similar in patients proving to have mesothelioma. Interpretation Primary use of CT-guided biopsy would avoid doing at least one Abrams' biopsy for every 2.5 CT-guided biopsies undertaken. In cytology-negative suspected malignant pleural effusions, CT-guided pleural biopsy is a better diagnostic test than Abrams' pleural biopsy.	Churchill Hosp, Oxford Radcliffe NHS Trust, Oxford Ctr Resp Med, Resp Trials Unit, Oxford OX3 7LJ, England; Churchill Hosp, Oxford Radcliffe NHS Trust, Oxford OX3 7LJ, England	University of Oxford; University of Oxford	Maskell, NA (corresponding author), Churchill Hosp, Oxford Radcliffe NHS Trust, Oxford Ctr Resp Med, Resp Trials Unit, Oxford OX3 7LJ, England.			maskell, nick/0000-0002-1276-6500				ABRAMS L D, 1958, Lancet, V1, P30; Adams RF, 2001, CHEST, V120, P1798, DOI 10.1378/chest.120.6.1798; Adams RF, 2001, RADIOLOGY, V219, P510, DOI 10.1148/radiology.219.2.r01ma07510; BOUTIN C, 1993, CANCER, V72, P389, DOI 10.1002/1097-0142(19930715)72:2<389::AID-CNCR2820720213>3.0.CO;2-V; Boutin C, 1998, CLIN CHEST MED, V19, P295, DOI 10.1016/S0272-5231(05)70078-2; BOUTIN C, 1995, CHEST, V108, P754, DOI 10.1378/chest.108.3.754; CANTO A, 1983, CHEST, V84, P176, DOI 10.1378/chest.84.2.176; CHANG DB, 1991, CHEST, V100, P1328, DOI 10.1378/chest.100.5.1328; DEFRANCIS N, 1955, NEW ENGL J MED, V252, P948, DOI 10.1056/NEJM195506022522206; Escudero BC, 1990, ARCH INTERN MED, V150, P1190, DOI 10.1001/archinte.150.6.1190; FRIST B, 1979, AM J CLIN PATHOL, V72, P48; GLEESON F, 1990, CLIN RADIOL, V41, P199, DOI 10.1016/S0009-9260(05)80968-7; HARRIS RJ, 1995, CHEST, V108, P828, DOI 10.1378/chest.108.3.828; MAREL M, 1993, CHEST, V104, P1486, DOI 10.1378/chest.104.5.1486; MESTITZ P, 1958, LANCET, V2, P1349; NANCE KV, 1991, MODERN PATHOL, V4, P320; PAGE RD, 1989, ANN THORAC SURG, V48, P66, DOI 10.1016/0003-4975(89)90179-3; PETO J, 1995, LANCET, V345, P535, DOI 10.1016/S0140-6736(95)90462-X; Peto J, 1999, BRIT J CANCER, V79, P666, DOI 10.1038/sj.bjc.6690105; POE RH, 1984, ARCH INTERN MED, V144, P325, DOI 10.1001/archinte.144.2.325; PRAKASH UBS, 1985, MAYO CLIN PROC, V60, P158, DOI 10.1016/S0025-6196(12)60212-2; Renshaw AA, 1997, CHEST, V111, P106, DOI 10.1378/chest.111.1.106; RUFFIE P, 1989, J CLIN ONCOL, V7, P1157, DOI 10.1200/JCO.1989.7.8.1157; SALYER WR, 1975, CHEST, V67, P536, DOI 10.1378/chest.67.5.536; SCERBO J, 1971, J AMER MED ASSOC, V218, P377, DOI 10.1001/jama.218.3.377; SCOTT EM, 1995, RADIOLOGY, V194, P867, DOI 10.1148/radiology.194.3.7862993; Screaton NJ, 2000, RADIOL CLIN N AM, V38, P293, DOI 10.1016/S0033-8389(05)70164-0; TOMLINSON JR, 1987, SEMIN RESPIR MED, V9, P30, DOI 10.1055/s-2007-1012685; Wiggins J, 2001, THORAX, V56, P250	29	240	248	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 19	2003	361	9366					1326	1330		10.1016/S0140-6736(03)13079-6	http://dx.doi.org/10.1016/S0140-6736(03)13079-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	669HP	12711467				2022-12-28	WOS:000182346100009
J	Pluchino, S; Quattrini, A; Brambilla, E; Gritti, A; Salani, G; Dina, G; Galli, R; Del Carro, U; Amadio, S; Bergami, A; Furlan, R; Comi, G; Vescovi, AL; Martino, G				Pluchino, S; Quattrini, A; Brambilla, E; Gritti, A; Salani, G; Dina, G; Galli, R; Del Carro, U; Amadio, S; Bergami, A; Furlan, R; Comi, G; Vescovi, AL; Martino, G			Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosis	NATURE			English	Article							CENTRAL-NERVOUS-SYSTEM; STEM-CELLS; TRANSPLANTATION; REMYELINATION; ENCEPHALOMYELITIS; REGENERATION; PROGENITORS; ANTIBODIES; LESIONS; REPAIR	Widespread demyelination and axonal loss are the pathological hallmarks of multiple sclerosis. The multifocal nature of this chronic inflammatory disease of the central nervous system complicates cellular therapy and puts emphasis on both the donor cell origin and the route of cell transplantation. We established syngenic adult neural stem cell cultures and injected them into an animal model of multiple sclerosis-experimental autoimmune encephalomyelitis (EAE) in the mouse-either intravenously or intracerebroventricularly. In both cases, significant numbers of donor cells entered into demyelinating areas of the central nervous system and differentiated into mature brain cells. Within these areas, oligodendrocyte progenitors markedly increased, with many of them being of donor origin and actively remyelinating axons. Furthermore, a significant reduction of astrogliosis and a marked decrease in the extent of demyelination and axonal loss were observed in transplanted animals. The functional impairment caused by EAE was almost abolished in transplanted mice, both clinically and neurophysiologically. Thus, adult neural precursor cells promote multifocal remyelination and functional recovery after intravenous or intrathecal injection in a chronic model of multiple sclerosis.	Hosp San Raffaele, DIBIT, Neuroimmunol Unit, I-20132 Milan, Italy; Hosp San Raffaele, Stem Cell Res Inst, I-20132 Milan, Italy; Hosp San Raffaele, Dept Neurol & Neurophysiol, I-20132 Milan, Italy	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Martino, G (corresponding author), Hosp San Raffaele, DIBIT, Neuroimmunol Unit, Via Olgettina 58, I-20132 Milan, Italy.	vescovi@tin.it; martino.gianvito@hsr.it	Gritti, Angela/K-2729-2016; Del Carro, Ubaldo/AAO-3457-2020; Vescovi, Angelo Luigi/A-4919-2015; Messier, Claude/A-2322-2008; BRAMBILLA, ELENA/AAN-3742-2020; Galli, Rossella/AAI-8028-2020; Pluchino, Stefano/AAE-9037-2019; martino, gianvito/AAL-2682-2020; dina, giorgia/AAN-3770-2020; Quattrini, Angelo/J-8373-2018	Gritti, Angela/0000-0002-9845-0370; Del Carro, Ubaldo/0000-0003-3301-5412; Vescovi, Angelo Luigi/0000-0002-1742-4112; Messier, Claude/0000-0002-4791-1763; BRAMBILLA, ELENA/0000-0003-1399-2128; Galli, Rossella/0000-0001-9023-7033; Pluchino, Stefano/0000-0002-6267-9472; martino, gianvito/0000-0003-1295-9131; dina, giorgia/0000-0002-9684-2143; Quattrini, Angelo/0000-0002-8226-8320				Aboody KS, 2000, P NATL ACAD SCI USA, V97, P12846, DOI 10.1073/pnas.97.23.12846; Alexander JS, 2002, J ANAT, V200, P561, DOI 10.1046/j.1469-7580.2002.00057.x; Archer DR, 1997, NAT MED, V3, P54, DOI 10.1038/nm0197-54; BLAKEMORE WF, 1977, NATURE, V266, P68, DOI 10.1038/266068a0; Brocke S, 1999, P NATL ACAD SCI USA, V96, P6896, DOI 10.1073/pnas.96.12.6896; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; Chen JL, 2001, J NEUROL SCI, V189, P49, DOI 10.1016/S0022-510X(01)00557-3; Chopp M, 2002, LANCET NEUROL, V1, P92, DOI 10.1016/S1474-4422(02)00040-6; Clarke D, 2001, CURR OPIN GENET DEV, V11, P575, DOI 10.1016/S0959-437X(00)00235-5; DECKERTSCHLUTER M, 1994, J NEUROPATH EXP NEUR, V53, P457, DOI 10.1097/00005072-199409000-00005; Del Maschio A, 1999, J EXP MED, V190, P1351, DOI 10.1084/jem.190.9.1351; Eclancher F, 1996, BRAIN RES, V737, P201, DOI 10.1016/0006-8993(96)00732-9; Feltri ML, 2002, J CELL BIOL, V156, P199, DOI 10.1083/jcb.200109021; Follenzi A, 2000, NAT GENET, V25, P217, DOI 10.1038/76095; Franklin RJM, 1997, MULT SCLER, V3, P84, DOI 10.1177/135245859700300205; Franklin RJM, 2002, NAT REV NEUROSCI, V3, P705, DOI 10.1038/nrn917; Furlan R, 2001, J IMMUNOL, V167, P1821, DOI 10.4049/jimmunol.167.3.1821; Galli R, 2002, DEVELOPMENT, V129, P1633; Gensert JM, 1997, NEURON, V19, P197, DOI 10.1016/S0896-6273(00)80359-1; Gritti A, 1999, J NEUROSCI, V19, P3287; GROVES AK, 1993, NATURE, V362, P453, DOI 10.1038/362453a0; Hemmer B, 2002, NAT REV NEUROSCI, V3, P291, DOI 10.1038/nrn784; Horner PJ, 2000, NATURE, V407, P963, DOI 10.1038/35039559; Imaizumi T, 2000, NAT BIOTECHNOL, V18, P949, DOI 10.1038/79432; Jefferson S, 1997, MULT SCLER, V3, P162, DOI 10.1177/135245859700300220; Kim JH, 2002, NATURE, V418, P50, DOI 10.1038/nature00900; Learish RD, 1999, ANN NEUROL, V46, P716, DOI 10.1002/1531-8249(199911)46:5<716::AID-ANA6>3.0.CO;2-M; Linker RA, 2002, NAT MED, V8, P620, DOI 10.1038/nm0602-620; Lucchinetti C, 2000, ANN NEUROL, V47, P707, DOI 10.1002/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q; Moon LDF, 2001, EUR J NEUROSCI, V14, P1667, DOI 10.1046/j.0953-816x.2001.01795.x; Temple S, 2001, NATURE, V414, P112, DOI 10.1038/35102174; Teng YD, 2002, P NATL ACAD SCI USA, V99, P3024, DOI 10.1073/pnas.052678899	32	850	923	0	56	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 17	2003	422	6933					688	694		10.1038/nature01552	http://dx.doi.org/10.1038/nature01552			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	668CG	12700753				2022-12-28	WOS:000182272300032
J	Kuypers, MMM; Sliekers, AO; Lavik, G; Schmid, M; Jorgensen, BB; Kuenen, JG; Damste, JSS; Strous, M; Jetten, MSM				Kuypers, MMM; Sliekers, AO; Lavik, G; Schmid, M; Jorgensen, BB; Kuenen, JG; Damste, JSS; Strous, M; Jetten, MSM			Anaerobic ammonium oxidation by anammox bacteria in the Black Sea	NATURE			English	Article							TARGETED OLIGONUCLEOTIDE PROBES; IN-SITU DETECTION; OXIDIZING BACTERIA; MARINE-SEDIMENTS; DIVERSITY; NITROGEN; OCEAN	The availability of fixed inorganic nitrogen (nitrate, nitrite and ammonium) limits primary productivity in many oceanic regions(1). The conversion of nitrate to N(2) by heterotrophic bacteria (denitrification) is believed to be the only important sink for fixed inorganic nitrogen in the ocean(2). Here we provide evidence for bacteria that anaerobically oxidize ammonium with nitrite to N(2) in the world's largest anoxic basin, the Black Sea. Phylogenetic analysis of 16S ribosomal RNA gene sequences shows that these bacteria are related to members of the order Planctomycetales performing the anammox (anaerobic ammonium oxidation) process in ammonium-removing bioreactors(3). Nutrient profiles, fluorescently labelled RNA probes, (15)N tracer experiments and the distribution of specific 'ladderane' membrane lipids(4) indicate that ammonium diffusing upwards from the anoxic deep water is consumed by anammox bacteria below the oxic zone. This is the first time that anammox bacteria have been identified and directly linked to the removal of fixed inorganic nitrogen in the environment. The widespread occurrence of ammonium consumption in suboxic marine settings(5-7) indicates that anammox might be important in the oceanic nitrogen cycle.	Max Planck Inst Marine Microbiol, Dept Biogeochem, D-28359 Bremen, Germany; Delft Univ Technol, Dept Microbiol, NL-2628 BC Delft, Netherlands; Royal Netherlands Inst Sea Res NIOZ, Dept Marine Biogeochem & Toxicol, NL-1790 AB Den Burg, Netherlands; Univ Nijmegen, Dept Microbiol, NL-6526 ED Nijmegen, Netherlands	Max Planck Society; Delft University of Technology; Utrecht University; Royal Netherlands Institute for Sea Research (NIOZ); Radboud University Nijmegen	Kuypers, MMM (corresponding author), Max Planck Inst Marine Microbiol, Dept Biogeochem, Celsiusstr 1, D-28359 Bremen, Germany.	mkuypers@mpi-bremen.de	Jetten, Mike/B-8834-2011; Lavik, Gaute/F-6578-2013; Damste, Jaap S Sinninghe/F-6128-2011; Schmid, Markus C/D-2669-2012; Jorgensen, Bo B/C-2214-2013; Strous, Marc/B-4064-2017	Jetten, Mike/0000-0002-4691-7039; Damste, Jaap S Sinninghe/0000-0002-8683-1854; Jorgensen, Bo B/0000-0001-9398-8027; Strous, Marc/0000-0001-9600-3828; Sliekers, Olav/0000-0002-8109-2431				AMANN RI, 1990, APPL ENVIRON MICROB, V56, P1919, DOI 10.1128/AEM.56.6.1919-1925.1990; BENDER M, 1989, GEOCHIM COSMOCHIM AC, V53, P685, DOI 10.1016/0016-7037(89)90011-2; Berg P, 1998, LIMNOL OCEANOGR, V43, P1500, DOI 10.4319/lo.1998.43.7.1500; Codispoti L.A., 1991, DEEP-SEA RES, V38, P691, DOI 10.1016/S0198-0149(10)80004-4; CODISPOTI LA, 1985, MAR CHEM, V16, P277, DOI 10.1016/0304-4203(85)90051-9; Dalsgaard T, 2002, APPL ENVIRON MICROB, V68, P3802, DOI 10.1128/AEM.68.8.3802-3808.2002; Damste JSS, 2002, NATURE, V419, P708, DOI 10.1038/nature01128; Falkowski PG, 1997, NATURE, V387, P272, DOI 10.1038/387272a0; FROELICH PN, 1979, GEOCHIM COSMOCHIM AC, V43, P1075, DOI 10.1016/0016-7037(79)90095-4; Kuenen JG, 2001, ASM NEWS, V67, P456; LEWIS BL, 1991, DEEP SEA RES S2, V38, P773; Li LN, 1999, BIODIVERS CONSERV, V8, P659, DOI 10.1023/A:1008848203739; MULDER A, 1995, FEMS MICROBIOL ECOL, V16, P177, DOI 10.1111/j.1574-6941.1995.tb00281.x; MURRAY JW, 1995, ADV CHEM SER, V244, P157, DOI 10.1021/ba-1995-0244.ch007; Neef A, 1998, MICROBIOL-UK, V144, P3257, DOI 10.1099/00221287-144-12-3257; Oguz T, 2001, DEEP-SEA RES PT I, V48, P761, DOI 10.1016/S0967-0637(00)00054-6; Pernthaler J, 2001, METHOD MICROBIOL, V30, P207, DOI 10.1016/S0580-9517(01)30046-6; Redfield A. C, 1963, SEA, P26, DOI DOI 10.1016/J.ORGGEOCHEM.2014.06.002; Richards F.A., 1965, CHEM OCEANOGRAPHY, P611; Schmid M, 2000, SYST APPL MICROBIOL, V23, P93, DOI 10.1016/S0723-2020(00)80050-8; Schmid M, 2001, ENVIRON MICROBIOL, V3, P450, DOI 10.1046/j.1462-2920.2001.00211.x; Sorokin YI., 2002, BIO INL WAT; Strous M, 1999, NATURE, V400, P446, DOI 10.1038/22749; Thamdrup B, 2002, APPL ENVIRON MICROB, V68, P1312, DOI 10.1128/AEM.68.3.1312-1318.2002; WARD BB, 1991, NATO ADV SCI I C-MAT, V351, P111; [No title captured]	26	880	1032	30	810	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 10	2003	422	6932					608	611		10.1038/nature01472	http://dx.doi.org/10.1038/nature01472			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	665GN	12686999				2022-12-28	WOS:000182111400040
J	Schechter, AN; Gladwin, MT				Schechter, AN; Gladwin, MT			Hemoglobin and the paracrine and endocrine functions of nitric oxide	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							BIOAVAILABILITY		NIDDK, Biol Chem Lab, NIH, Bethesda, MD 20892 USA; NIH, Warren Grant Magnuson Clin Ctr, Dept Crit Care Med, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA	Schechter, AN (corresponding author), NIDDK, Biol Chem Lab, NIH, Bldg 10,Rm 9N-307, Bethesda, MD 20892 USA.			Schechter, Alan N/0000-0002-5235-9408	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK025093, Z01DK025093] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Gladwin MT, 2002, J BIOL CHEM, V277, P27818, DOI 10.1074/jbc.M203236200; Huang KT, 2001, P NATL ACAD SCI USA, V98, P11771, DOI 10.1073/pnas.201276698; Joshi MS, 2002, P NATL ACAD SCI USA, V99, P10341, DOI 10.1073/pnas.152149699; McMahon TJ, 2002, NAT MED, V8, P711, DOI 10.1038/nm718; Rassaf T, 2002, J CLIN INVEST, V109, P1241, DOI 10.1172/JCI200214995; Reiter CD, 2002, NAT MED, V8, P1383, DOI 10.1038/nm799	6	177	187	1	12	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 10	2003	348	15					1483	1485		10.1056/NEJMcibr023045	http://dx.doi.org/10.1056/NEJMcibr023045			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	665CU	12686706				2022-12-28	WOS:000182102700011
J	Seki, K; Hirahara, M; Hoshino, M; Terasawa, T; Elphic, RC; Saito, Y; Mukai, T; Hayakawa, H; Kojima, H; Matsumoto, H				Seki, K; Hirahara, M; Hoshino, M; Terasawa, T; Elphic, RC; Saito, Y; Mukai, T; Hayakawa, H; Kojima, H; Matsumoto, H			Cold ions in the hot plasma sheet of Earth's magnetotail	NATURE			English	Article							MAGNETIC RECONNECTION; GEOTAIL	Most visible matter in the Universe exists as plasma. How this plasma is heated, and especially how the initial non-equilibrium plasma distributions relax to thermal equilibrium (as predicted by Maxwell-Boltzman statistics), is a fundamental question in studies of astrophysical(1-3) and laboratory plasmas(4,5). Astrophysical plasmas are often so tenuous that binary collisions(2,3) can be ignored, and it is not clear how thermal equilibrium develops for these 'collisionless' plasmas. One example of a collisionless plasma is the Earth's plasma sheet(6), where thermalized hot plasma with ion temperatures of about 5 x 10(7) K has been observed(7). Here we report direct observations of a plasma distribution function during a solar eclipse, revealing cold ions in the Earth's plasma sheet in coexistence with thermalized hot ions. This cold component cannot be detected by plasma sensors on satellites that are positively charged in sunlight, but our observations in the Earth's shadow show that the density of the cold ions is comparable to that of hot ions. This high density is difficult to explain within existing theories(8-10), as it requires a mechanism that permits half of the source plasma to remain cold upon entry into the hot turbulent plasma sheet.	Nagoya Univ, Solar Terr Environm Lab, Aichi 4428507, Japan; Rikkyo Univ, Dept Phys, Tokyo 1718501, Japan; Univ Tokyo, Dept Earth & Planetary Sci, Tokyo 1130033, Japan; Los Alamos Natl Lab, Los Alamos, NM 87545 USA; Inst Space & Astronaut Sci, Kanagawa 2298510, Japan; Kyoto Univ, Radio Sci Ctr Space & Atmosphere, Kyoto 6110011, Japan	Nagoya University; Rikkyo University; University of Tokyo; United States Department of Energy (DOE); Los Alamos National Laboratory; Japan Aerospace Exploration Agency (JAXA); Institute of Space & Astronautical Science (ISAS); Kyoto University	Seki, K (corresponding author), Nagoya Univ, Solar Terr Environm Lab, Honohara 3-13, Aichi 4428507, Japan.	seki@stelab.nagoya-u.ac.jp	Hoshino, Masahiro/A-1837-2009; Kojima, Hirotsugu/O-2087-2018	Hoshino, Masahiro/0000-0002-1818-9927; Saito, Yoshifumi/0000-0002-1354-3544; Seki, Kanako/0000-0001-5557-9062; Terasawa, Toshio/0000-0003-2507-9803				Abe T, 1996, J GEOMAGN GEOELECTR, V48, P319, DOI 10.5636/jgg.48.319; Arzner K, 2001, J GEOPHYS RES-SPACE, V106, P3827, DOI 10.1029/2000JA000179; BAUMJOHANN W, 1989, J GEOPHYS RES, V94, P6597, DOI 10.1029/JA094iA06p06597; DELCOURT DC, 1994, J GEOPHYS RES-SPACE, V99, P5681, DOI 10.1029/93JA02770; GARY SP, 1991, SPACE SCI REV, V56, P373, DOI 10.1007/BF00196632; HIRAHARA M, 1994, GEOPHYS RES LETT, V21, P3003, DOI 10.1029/94GL02109; Hoshino M, 1998, J GEOPHYS RES-SPACE, V103, P4509, DOI 10.1029/97JA01785; Kodama R, 2001, NATURE, V412, P798, DOI 10.1038/35090525; Lakhina GS, 2000, J GEOPHYS RES-SPACE, V105, P27791, DOI 10.1029/2000JA900054; MOSES RW, 1993, J GEOPHYS RES-SPACE, V98, P4013, DOI 10.1029/92JA02267; Nishida A, 1998, J GEOPHYS RES-SPACE, V103, P4409, DOI 10.1029/97JA01617; Ono Y, 1997, PHYS PLASMAS, V4, P1953, DOI 10.1063/1.872337; Priest ER, 1998, NATURE, V393, P545, DOI 10.1038/31166; SAITO Y, 1995, J GEOPHYS RES-SPACE, V100, P23567, DOI 10.1029/95JA01675; SCUDDER JD, 1992, ASTROPHYS J, V398, P299, DOI 10.1086/171858; Seki K, 2001, SCIENCE, V291, P1939, DOI 10.1126/science.1058913	16	68	68	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 10	2003	422	6932					589	592		10.1038/nature01502	http://dx.doi.org/10.1038/nature01502			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	665GN	12686993				2022-12-28	WOS:000182111400034
J	Willert, K; Brown, JD; Danenberg, E; Duncan, AW; Weissman, IL; Reya, T; Yates, JR; Nusse, R				Willert, K; Brown, JD; Danenberg, E; Duncan, AW; Weissman, IL; Reya, T; Yates, JR; Nusse, R			Wnt proteins are lipid-modified and can act as stem cell growth factors	NATURE			English	Article							SIGNALING PATHWAY; C-ELEGANS; DROSOPHILA; WINGLESS; IDENTIFICATION; EXPRESSION; CANCER; FORM	Wnt signalling is involved in numerous events in animal development(1), including the proliferation of stem cells(2) and the specification of the neural crest(3). Wnt proteins are potentially important reagents in expanding specific cell types, but in contrast to other developmental signalling molecules such as hedgehog proteins and the bone morphogenetic proteins, Wnt proteins have never been isolated in an active form. Although Wnt proteins are secreted from cells(4-7), secretion is usually inefficient(8) and previous attempts to characterize Wnt proteins have been hampered by their high degree of insolubility. Here we have isolated active Wnt molecules, including the product of the mouse Wnt3a gene. By mass spectrometry, we found the proteins to be palmitoylated on a conserved cysteine. Enzymatic removal of the palmitate or site-directed and natural mutations of the modified cysteine result in loss of activity, and indicate that the lipid is important for signalling. The purified Wnt3a protein induces self-renewal of haematopoietic stem cells, signifying its potential use in tissue engineering.	Stanford Univ, Sch Med, Howard Hughes Med Inst, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Dev Biol, Stanford, CA 94305 USA; Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	Howard Hughes Medical Institute; Stanford University; Stanford University; Duke University; Stanford University; Scripps Research Institute	Nusse, R (corresponding author), Stanford Univ, Sch Med, Howard Hughes Med Inst, Stanford, CA 94305 USA.			Danenberg, Esther/0000-0002-1799-4457; Duncan, Andrew/0000-0003-4962-4191				BORDIER C, 1981, J BIOL CHEM, V256, P1604; BRADLEY RS, 1995, MOL CELL BIOL, V15, P4616; Brannon M, 1996, DEV BIOL, V180, P344, DOI 10.1006/dbio.1996.0306; BURRUS LW, 1995, EXP CELL RES, V220, P363, DOI 10.1006/excr.1995.1327; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; COUSO JP, 1994, CELL, V79, P259, DOI 10.1016/0092-8674(94)90195-3; Domen J, 2000, J EXP MED, V192, P1707, DOI 10.1084/jem.192.12.1707; Duncan JA, 1998, J BIOL CHEM, V273, P15830, DOI 10.1074/jbc.273.25.15830; Garcia-Castro MI, 2002, SCIENCE, V297, P848, DOI 10.1126/science.1070824; Hofmann K, 2000, TRENDS BIOCHEM SCI, V25, P111, DOI 10.1016/S0968-0004(99)01539-X; Hsieh JC, 1999, P NATL ACAD SCI USA, V96, P3546, DOI 10.1073/pnas.96.7.3546; Kadowaki T, 1996, GENE DEV, V10, P3116, DOI 10.1101/gad.10.24.3116; MacCoss MJ, 2002, P NATL ACAD SCI USA, V99, P7900, DOI 10.1073/pnas.122231399; Maloof JN, 1999, DEVELOPMENT, V126, P37; MASON JO, 1992, MOL BIOL CELL, V3, P521, DOI 10.1091/mbc.3.5.521; McKendry R, 1997, DEV BIOL, V192, P420, DOI 10.1006/dbio.1997.8797; NOORDERMEER J, 1994, NATURE, V367, P80, DOI 10.1038/367080a0; PAPKOFF J, 1990, MOL CELL BIOL, V10, P2723, DOI 10.1128/MCB.10.6.2723; Pepinsky RB, 1998, J BIOL CHEM, V273, P14037, DOI 10.1074/jbc.273.22.14037; Polakis P, 2000, GENE DEV, V14, P1837; REYA T, 2003, NATURE          0427; Rocheleau CE, 1997, CELL, V90, P707, DOI 10.1016/S0092-8674(00)80531-0; ROELINK H, 1991, GENE DEV, V5, P381, DOI 10.1101/gad.5.3.381; Shibamoto S, 1998, GENES CELLS, V3, P659; Tabb DL, 2002, J PROTEOME RES, V1, P21, DOI 10.1021/pr015504q; Tanaka K, 2002, J BIOL CHEM, V277, P12816, DOI 10.1074/jbc.M200187200; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; VANLEEUWEN F, 1994, NATURE, V368, P342, DOI 10.1038/368342a0; Washburn MP, 2001, NAT BIOTECHNOL, V19, P242, DOI 10.1038/85686; Wu CH, 2002, J BIOL CHEM, V277, P41762, DOI 10.1074/jbc.M207850200	30	1673	1827	4	216	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 22	2003	423	6938					448	452		10.1038/nature01611	http://dx.doi.org/10.1038/nature01611			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	681AJ	12717451				2022-12-28	WOS:000183012000044
J	Lessard, J; Sauvageau, G				Lessard, J; Sauvageau, G			Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells	NATURE			English	Article							ACUTE MYELOID-LEUKEMIA; BONE-MARROW CELLS; ACUTE MYELOGENOUS LEUKEMIA; POLYCOMB-GROUP GENES; HEMATOPOIETIC-CELL; EXPRESSION; HOXA9; T(7-11)(P15-P15); TRANSFORMATION; OVEREXPRESSION	An emerging concept in the field of cancer biology is that a rare population of 'tumour stem cells' exists among the heterogeneous group of cells that constitute a tumour. This concept, best described with human leukaemia, indicates that stem cell function ( whether normal or neoplastic) might be defined by a common set of critical genes. Here we show that the Polycomb group gene Bmi-1 has a key role in regulating the proliferative activity of normal stem and progenitor cells. Most importantly, we provide evidence that the proliferative potential of leukaemic stem and progenitor cells lacking Bmi-1 is compromised because they eventually undergo proliferation arrest and show signs of differentiation and apoptosis, leading to transplant failure of the leukaemia. Complementation studies showed that Bmi-1 completely rescues these proliferative defects. These studies therefore indicate that Bmi-1 has an essential role in regulating the proliferative activity of both normal and leukaemic stem cells.	Clin Res Inst Montreal, Lab Mol Genet Hemopoiet Stem Cells, Montreal, PQ H2W 1R7, Canada; Univ Montreal, Hosp Maisonneuve Rosemont, Dept Med, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Hosp Maisonneuve Rosemont, Div Hematol, Montreal, PQ H3C 3J7, Canada	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Universite de Montreal; Universite de Montreal	Sauvageau, G (corresponding author), Clin Res Inst Montreal, Lab Mol Genet Hemopoiet Stem Cells, 110 Pine Ave W, Montreal, PQ H2W 1R7, Canada.	sauvagg@ircm.qc.ca		Sauvageau, Guy/0000-0002-4333-7266				Appelbaum F R, 2001, Hematology Am Soc Hematol Educ Program, P62; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Borrow J, 1996, NAT GENET, V12, P159, DOI 10.1038/ng0296-159; BRADY G, 1990, Methods in Molecular and Cellular Biology, V2, P17; Dimri GP, 2002, CANCER RES, V62, P4736; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Jordan CT, 2000, LEUKEMIA, V14, P1777, DOI 10.1038/sj.leu.2401903; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kroon E, 1998, EMBO J, V17, P3714, DOI 10.1093/emboj/17.13.3714; Krosl J, 1998, ONCOGENE, V16, P3403, DOI 10.1038/sj.onc.1201883; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Lessard J, 1999, GENE DEV, V13, P2691, DOI 10.1101/gad.13.20.2691; Lessard J, 1998, BLOOD, V91, P1216, DOI 10.1182/blood.V91.4.1216; Nakamura T, 1996, NAT GENET, V12, P154, DOI 10.1038/ng0296-154; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Park IK, 2002, BLOOD, V99, P488, DOI 10.1182/blood.V99.2.488; Porcher C, 1996, CELL, V86, P47, DOI 10.1016/S0092-8674(00)80076-8; SAUVAGEAU G, 1995, GENE DEV, V9, P1753, DOI 10.1101/gad.9.14.1753; Sauvageau G, 1997, IMMUNITY, V6, P13, DOI 10.1016/S1074-7613(00)80238-1; Testa U, 2002, BLOOD, V100, P2980, DOI 10.1182/blood-2002-03-0852; Thorsteinsdottir U, 2002, BLOOD, V99, P121, DOI 10.1182/blood.V99.1.121; VANDERLUGT NMT, 1994, GENE DEV, V8, P757, DOI 10.1101/gad.8.7.757; Vonlanthen S, 2001, BRIT J CANCER, V84, P1372, DOI 10.1054/bjoc.2001.1791; Weber HO, 2002, ONCOGENE, V21, P3207, DOI 10.1038/sj.onc.1205429	24	1177	1298	3	54	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 15	2003	423	6937					255	260		10.1038/nature01572	http://dx.doi.org/10.1038/nature01572			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678EX	12714970				2022-12-28	WOS:000182853100034
J	Bush, J; White, M; Kai, J; Rankin, J; Bhopal, R				Bush, J; White, M; Kai, J; Rankin, J; Bhopal, R			Understanding influences on smoking in Bangladeshi and Pakistani adults: community based, qualitative study	BRITISH MEDICAL JOURNAL			English	Article							POPULATIONS; DRINKING; RISK	Objective To gain detailed understanding of influences on smoking behaviour in Bangladeshi and Pakistani communities in the United Kingdom to inform the development of effective and culturally acceptable smoking cessation interventions. Design Qualitative study using community participatory methods, purposeful sampling, one to one interviews, focus groups, and a grounded approach to data generation and analysis. Setting Newcastle upon Tyne, during 2000-2. Participants 87 men and 54 women aged 18-80 years, smokers and non-smokers, from the Bangladeshi and Pakistani communities. Results Four dominant, highly inter-related themes had an important influence on smoking attitudes and behaviour: gender, age, religion, and tradition. Smoking was a widely accepted practice in Pakistani, and particularly Bangladeshi, men and was associated with socialising, sharing, and male identity. Among women, smoking was associated with stigma and shame. Smoking in women is often hidden from family members. Peer pressure was an important influence on smoking behaviour in younger people, who tended to hide their smoking from elders. There were varied and conflicting interpretations of how acceptable smoking is within the Muslim religion. Tradition, culture, and the family played an important role in nurturing and cultivating norms and values around smoking. Conclusion Although there are some culturally specific contexts for smoking behaviour in Bangladeshi and Pakistani adults-notably the influence of gender and religion-there are also strong similarities with white people, particularly among younger adults. Themes identified should help to inform the development and appropriate targeting of smoking cessation interventions.	Univ Newcastle Upon Tyne, Sch Populat & Hlth Sci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ Nottingham, Sch Med, Sch Community Hlth Sci, Div Primary Care, Nottingham NG7 2UH, England; Univ Edinburgh, Sch Med, Div Community Hlth Sci, Publ Hlth Sci Sect, Edinburgh EH8 9AG, Midlothian, Scotland	Newcastle University - UK; University of Nottingham; University of Edinburgh	Bush, J (corresponding author), Univ Newcastle Upon Tyne, Sch Populat & Hlth Sci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.		White, Martin J. R./G-2410-2010	Kai, Joe/0000-0001-9040-9384				Bahl V, 1996, BRIT J CANCER, V74, pS2; BALARAJAN R, 1986, COMMUNITY MED, V8, P237; Bhopal R, 1999, BRIT MED J, V319, P215, DOI 10.1136/bmj.319.7204.215; Bhopal R. S., 1993, RACE HLTH CONT BRIT, P137; Bhopal RS, 1996, BRIT J CANCER, V74, pS22; BURGESS RG, 1991, FIELD INTRO FIELD RE; Butler CC, 1998, BMJ-BRIT MED J, V316, P1878; Cook PA, 2001, PUBLIC HEALTH, V115, P54, DOI 10.1038/sj.ph.1900728; Department of Health, 1999, HLTH SURV ENGL; DOUGLAS J, 1998, HLTH ED J, V57, P329; Farren C, 1996, BRIT J CANCER, V74, pS78; Glaser B.G., 1965, AWARENESS DYING; Hiller, 1996, RES CULTURAL DIFFERE, P220; *HLTH DEV AG, 2000, TOB ENGL ETHN MIN RE; *HLTH ED AUTH, 2000, BLACK MIN ETHN GROUP; Kai Joe, 1999, Health Expect, V2, P7, DOI 10.1046/j.1369-6513.1999.00033.x; KOHLI HS, 1989, PUBLIC HEALTH, V103, P433, DOI 10.1016/S0033-3506(89)80053-8; Modood T., 1997, ETHNIC MINORITIES BR; POORANSINGH S, 2001, BMJ; RAW M, 1998, THORAX 2 S5, V53; Strauss A., 1990, BASICS QUALITATIVE R; West R, 2000, THORAX, V55, P987, DOI 10.1136/thorax.55.12.987; WHITE M, 2002, STUDY EXPLORE FEASIB	23	100	101	0	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 3	2003	326	7396					962	965		10.1136/bmj.326.7396.962	http://dx.doi.org/10.1136/bmj.326.7396.962			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	676JC	12727770	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000182746700018
J	Liu, YF; Hong, X; Kappler, J; Jiang, L; Zhang, RG; Xu, LG; Pan, CH; Martin, WE; Murphy, RC; Shu, HB; Dai, SD; Zhang, GY				Liu, YF; Hong, X; Kappler, J; Jiang, L; Zhang, RG; Xu, LG; Pan, CH; Martin, WE; Murphy, RC; Shu, HB; Dai, SD; Zhang, GY			Ligand-receptor binding revealed by the TNF family member TALL-1	NATURE			English	Article							TUMOR-NECROSIS-FACTOR; B-CELL MATURATION; CRYSTAL-STRUCTURE; AUTOIMMUNE-DISEASE; LYMPHOCYTE STIMULATOR; BAFF; TACI; BLYS; APRIL; BCMA	The tumour necrosis factor (TNF) ligand TALL-1 and its cognate receptors, BCMA, TACI and BAFF-R, were recently identified as members of the TNF superfamily, which are essential factors contributing to B-cell maturation. The functional, soluble fragment of TALL-1 (sTALL-1) forms a virus-like assembly for its proper function. Here we determine the crystal structures of sTALL-1 complexed with the extracellular domains of BCMA and BAFF-R at 2.6 and 2.5 Angstrom, respectively. The single cysteine-rich domain of BCMA and BAFF-R both have saddle-like architectures, which sit on the horseback-like surface formed by four coil regions on each individual sTALL-1 monomer. Three novel structural modules, D2, X2 and N, were revealed from the current structures. Sequence alignments, structural modelling and mutagenesis revealed that one disulphide bridge in BAFF-R is critical for determining the binding specificity of the extracellular domain eBAFF-R to TALL-1 instead of APRIL, a closely related ligand of TALL-1, which was confirmed by binding experiments in vitro.	Univ Colorado, Hlth Sci Ctr, Sch Med, Natl Jewish Med & Res Ctr,Integrated Dept Immunol, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Sch Med, Howard Hughes Med Inst, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Sch Med, Dept Pharmacol,Biomol Struct Program, Denver, CO 80206 USA; Peking Univ, Coll Life Sci, Dept Cell Biol & Genet, Beijing 100871, Peoples R China; Argonne Natl Lab, Struct Biol Sect, Argonne, IL 60439 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Howard Hughes Medical Institute; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Peking University; United States Department of Energy (DOE); Argonne National Laboratory	Zhang, GY (corresponding author), Univ Colorado, Hlth Sci Ctr, Sch Med, Natl Jewish Med & Res Ctr,Integrated Dept Immunol, 1400 Jackson St, Denver, CO 80206 USA.	zhangg@njc.org		Xu, Liangguo/0000-0003-1991-2889				BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; Bodmer JL, 2002, TRENDS BIOCHEM SCI, V27, P19, DOI 10.1016/S0968-0004(01)01995-8; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; Cha SS, 1999, IMMUNITY, V11, P253, DOI 10.1016/S1074-7613(00)80100-4; ECK MJ, 1992, J BIOL CHEM, V267, P2119; ECK MJ, 1989, J BIOL CHEM, V264, P17595; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Gross JA, 2000, NATURE, V404, P995, DOI 10.1038/35010115; Gross JA, 2001, IMMUNITY, V15, P289, DOI 10.1016/S1074-7613(01)00183-2; Hahne M, 1998, J EXP MED, V188, P1185, DOI 10.1084/jem.188.6.1185; Hymowitz SG, 1999, MOL CELL, V4, P563, DOI 10.1016/S1097-2765(00)80207-5; JONES EY, 1989, NATURE, V338, P225, DOI 10.1038/338225a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KARPUSAS M, 1995, STRUCTURE, V3, P1031, DOI 10.1016/S0969-2126(01)00239-8; Karpusas M, 2002, J MOL BIOL, V315, P1145, DOI 10.1006/jmbi.2001.5296; Kayagaki N, 2002, IMMUNITY, V17, P515, DOI 10.1016/S1074-7613(02)00425-9; Khare SD, 2000, P NATL ACAD SCI USA, V97, P3370, DOI 10.1073/pnas.050580697; Lam J, 2001, J CLIN INVEST, V108, P971, DOI 10.1172/JCI13890; Liu YF, 2002, CELL, V108, P383, DOI 10.1016/S0092-8674(02)00631-1; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Mackay F, 1999, J EXP MED, V190, P1697, DOI 10.1084/jem.190.11.1697; Mackay F, 2002, TRENDS IMMUNOL, V23, P113, DOI 10.1016/S1471-4906(01)02159-7; Marsters SA, 2000, CURR BIOL, V10, P785, DOI 10.1016/S0960-9822(00)00566-2; Mongkolsapaya J, 1999, NAT STRUCT BIOL, V6, P1048; Moore PA, 1999, SCIENCE, V285, P260, DOI 10.1126/science.285.5425.260; Mukhopadhyay A, 1999, J BIOL CHEM, V274, P15978, DOI 10.1074/jbc.274.23.15978; Naismith JH, 1998, TRENDS BIOCHEM SCI, V23, P74, DOI 10.1016/S0968-0004(97)01164-X; Oren DA, 2002, NAT STRUCT BIOL, V9, P288, DOI 10.1038/nsb769; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Roschke V, 2002, J IMMUNOL, V169, P4314, DOI 10.4049/jimmunol.169.8.4314; Schiemann B, 2001, SCIENCE, V293, P2111, DOI 10.1126/science.1061964; Schneider P, 1999, J EXP MED, V189, P1747, DOI 10.1084/jem.189.11.1747; Schneider P, 2001, J EXP MED, V194, P1691, DOI 10.1084/jem.194.11.1691; Shu HB, 2000, P NATL ACAD SCI USA, V97, P9156, DOI 10.1073/pnas.160213497; Shu HB, 1999, J LEUKOCYTE BIOL, V65, P680, DOI 10.1002/jlb.65.5.680; Thompson JS, 2000, J EXP MED, V192, P129, DOI 10.1084/jem.192.1.129; Thompson JS, 2001, SCIENCE, V293, P2108, DOI 10.1126/science.1061965; von Bulow GU, 2001, IMMUNITY, V14, P573, DOI 10.1016/S1074-7613(01)00130-3; Ware CF, 2000, J EXP MED, V192, pF35, DOI 10.1084/jem.192.11.F35; Xia XZ, 2000, J EXP MED, V192, P137, DOI 10.1084/jem.192.1.137; Xu SL, 2001, MOL CELL BIOL, V21, P4067, DOI 10.1128/MCB.21.12.4067-4074.2001; Yan MH, 2000, NAT IMMUNOL, V1, P37, DOI 10.1038/76889; Yan MH, 2001, CURR BIOL, V11, P1547, DOI 10.1016/S0960-9822(01)00481-X; Yu G, 2000, NAT IMMUNOL, V1, P252, DOI 10.1038/79802	45	103	122	1	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 1	2003	423	6935					49	56		10.1038/nature01543	http://dx.doi.org/10.1038/nature01543			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	673CG	12721620				2022-12-28	WOS:000182561600034
J	Prochaska, JX; Howk, JC; Wolfe, AM				Prochaska, JX; Howk, JC; Wolfe, AM			The elemental abundance pattern in a galaxy at z=2.626	NATURE			English	Article							LYMAN-BREAK GALAXIES; LY-ALPHA SYSTEMS; NUCLEOSYNTHESIS; ABSORPTION; EVOLUTION; RATIOS; STARS	The discovery of metal-poor stars(1,2) (where metal is any element more massive than helium) has enabled astronomers to probe the chemical enrichment history of the Milky Way(3,4). More recently, element abundances in gas inside high-redshift galaxies has been probed through the absorption lines imprinted on the spectra of background quasars(5-8), but these have typically yielded measurements of only a few elements. Furthermore, interpretation of these abundances is complicated by the fact that differential incorporation of metals into dust can produce an abundance pattern similar to that expected from nucleosynthesis by massive stars(9). Here we report the observation of over 25 elements in a galaxy at redshift z = 2.626. With these data, we can examine nucleosynthetic processes independent of the uncertainty arising from depletion. We find that the galaxy was enriched mainly by massive stars (M > 15 solar masses) and propose that it is the progenitor of a massive elliptical galaxy. The detailed abundance patterns suggest that boron is produced through processes that act independently of metallicity, and may require alternative mechanisms for the nucleosynthesis of germanium.	Univ Calif Santa Cruz, Univ Calif Observ, Lick Observ, Santa Cruz, CA 95064 USA; Univ Calif San Diego, Dept Phys, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Astrophys & Space Sci, La Jolla, CA 92093 USA	University of California System; University of California Santa Cruz; University of California System; University of California San Diego; University of California System; University of California San Diego	Prochaska, JX (corresponding author), Univ Calif Santa Cruz, Univ Calif Observ, Lick Observ, Santa Cruz, CA 95064 USA.		Howk, Jay/D-2577-2013	Prochaska, J. Xavier/0000-0002-7738-6875; Howk, J. Christopher/0000-0002-2591-3792				BURBIDGE EM, 1957, REV MOD PHYS, V29, P547, DOI 10.1103/RevModPhys.29.547; Busso M, 1999, ANNU REV ASTRON ASTR, V37, P239, DOI 10.1146/annurev.astro.37.1.239; CASSE M, 1995, NATURE, V373, P318, DOI 10.1038/373318a0; CHAMBERLAIN JW, 1951, ASTROPHYS J, V114, P52, DOI 10.1086/145451; Fields BD, 1999, ASTROPHYS J, V516, P797, DOI 10.1086/307145; HELFER HL, 1959, ASTROPHYS J, V129, P700, DOI 10.1086/146668; Hoffman RD, 1996, ASTROPHYS J, V460, P478, DOI 10.1086/176986; JURA M, 1978, ASTROPHYS J, V219, P861, DOI 10.1086/155847; Lu LM, 1996, ASTROPHYS J SUPPL S, V107, P475, DOI 10.1086/192373; MCWILLIAM A, 1995, ASTRON J, V109, P2757, DOI 10.1086/117486; Molaro P, 2000, ASTROPHYS J, V541, P54, DOI 10.1086/309439; Pettini M, 2000, ASTROPHYS J, V532, P65, DOI 10.1086/308562; Pettini M, 2000, ASTROPHYS J, V528, P96, DOI 10.1086/308176; Prochaska JX, 2002, ASTROPHYS J, V566, P68, DOI 10.1086/338080; PROCHASKA JX, UNPUB ASTROPHYS J SU; Saglia RP, 2002, ASTROPHYS J, V579, pL13, DOI 10.1086/344742; Savage BD, 1996, ANNU REV ASTRON ASTR, V34, P279, DOI 10.1146/annurev.astro.34.1.279; Schramm DN, 1998, REV MOD PHYS, V70, P303, DOI 10.1103/RevModPhys.70.303; Sheinis AI, 2002, PUBL ASTRON SOC PAC, V114, P851, DOI 10.1086/341706; TINSLEY BM, 1979, ASTROPHYS J, V229, P1046, DOI 10.1086/157039; Trager SC, 2000, ASTRON J, V119, P1645, DOI 10.1086/301299; Vladilo G, 2002, ASTRON ASTROPHYS, V391, P407, DOI 10.1051/0004-6361:20020822; VOGT SS, 1994, SPIE, V2198, P362; WHEELER JC, 1989, ANNU REV ASTRON ASTR, V27, P279; White RL, 2000, ASTROPHYS J SUPPL S, V126, P133, DOI 10.1086/313300; WOLFE AM, 1986, ASTROPHYS J SUPPL S, V61, P249, DOI 10.1086/191114; WOLFE AM, UNPUB ASTROPHYS J; WOOSLEY SE, 1995, ASTROPHYS J SUPPL S, V101, P181, DOI 10.1086/192237; WOOSLEY SE, 1990, ASTROPHYS J, V356, P272, DOI 10.1086/168839	30	72	72	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 1	2003	423	6935					57	59		10.1038/nature01524	http://dx.doi.org/10.1038/nature01524			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	673CG	12721621	Green Submitted			2022-12-28	WOS:000182561600035
J	Diamond, J; Bellwood, P				Diamond, J; Bellwood, P			Farmers and their languages: The first expansions	SCIENCE			English	Review							ORIGINS; MTDNA; PREHISTORY; HOMELAND; SUPPORT	The largest movements and replacements of human populations since the end of the Ice Ages resulted from the geographically uneven rise of food production around the world. The first farming societies thereby gained great advantages over hunter-gatherer societies. But most of those resulting shifts of populations and languages are complex, controversial, or both. We discuss the main complications and specific examples involving 15 language families. Further progress will depend on interdisciplinary research that combines archaeology, crop and livestock studies, physical anthropology, genetics, and linguistics.	Univ Calif Los Angeles, Dept Geog, Los Angeles, CA 90095 USA; Australian Natl Univ, Sch Archaeol & Anthropol, Canberra, ACT 0200, Australia; Australian Natl Univ, Res Sch Pacific Studies, Canberra, ACT 0200, Australia	University of California System; University of California Los Angeles; Australian National University; Australian National University	Diamond, J (corresponding author), Univ Calif Los Angeles, Dept Geog, Los Angeles, CA 90095 USA.	jdiamond@geog.ucla.edu; peter.bellwood@anu.edu.au						ADAMS REW, 2000, CAMBRIDGE HIST NAT 1, V2; AIKHENVALD A, 1999, AMAZONIAN LANGAUGES, P75; AMMERMAN AJ, 1984, NEOLITHIC TRANSITION; [Anonymous], 1989, PRODIGIOUS BIRDS; [Anonymous], 1997, GUNS GERMS STEEL; ANTHONY DW, 1995, ANTIQUITY, V69, P554, DOI 10.1017/S0003598X00081941; BARYOSEF O, 1998, REV ARCHAEOL, V19; Bell-wood Peter, 1995, ARCHAEOLOGY SE ASIA, P11; Bellwood P, 2001, ANNU REV ANTHROPOL, V30, P181, DOI 10.1146/annurev.anthro.30.1.181; BELLWOOD P, 2001, AREAL DIFFUSION GENE, P27; BELLWOOD P, 1997, POLYNESIANS; Bellwood P., 2003, EXAMINING LANGUAGE F; Bellwood Peter, 1997, PREHISTORY INDOMALAY; Bellwood Peter, 2000, TIME DEPTH HIST LING, V109, P127; BLAZEK V, 1998, ARCHAEOLOGY LANGUAGE, V4, P48; BLUST R, 1995, J WORLD PREHIST, V9, P453, DOI 10.1007/BF02221119; Bousman C. B., 1998, AFR ARCHAEOL REV, V15, P133, DOI DOI 10.1023/A:1022110818616; Campbell Lyle, 1997, AM INDIAN LANGUAGES; Cavalli-Sforza L. L., 1994, HIST GEOGRAPHY HUMAN; Cavalli-Sforza LL, 1995, GREAT HUMAN DIASPORA; Chikhi L, 2002, P NATL ACAD SCI USA, V99, P11008, DOI 10.1073/pnas.162158799; Collet D. P., 1982, ARCHAEOLOGICAL LINGU, P182198; Damania A, 1998, ORIGINS AGR CROP DOM; Diakonoff I, 1998, J SEMITIC STUD, V43, P209, DOI 10.1093/jss/43.2.209; Diamond J, 2002, NATURE, V418, P700, DOI 10.1038/nature01019; Dolgopolsky Aron, 1993, MEDITERRANEAN LANGUA, V6-7, P230; Downs J. F., 1964, ANIMAL HUSBANDRY NAV; DREWS R, 2001, INDOEUROPEAN STUDIES, V38; Dumond Don, 1987, ESKIMOS ALEUTS; EHRET C, 1979, J AFR HIST, V20, P161, DOI 10.1017/S002185370001700X; EHRET C, 1995, RECONSTRUCTING PROTO; Ehret Christopher, 1998, AFRICAN CLASSICAL AG; *ENCY BRIT, 1987, ENCY BRIT, V22; Fortescue Michael, 1998, LANGUAGE RELATIONS B; FULLER D, 2003, EXAMINING LANGUAGE F, pCH16; GIMBUTAS M, 1985, J INDO-EUR STUD, V13, P185; Golson J., 1977, SUNDA SAHUL PREHISTO, P601; Greenberg J. H, 1987, LANGUAGE AM; Haberle S., 2000, ENV HIST, V6, P349; HAGELBERG E, 2001, ARCHAEOLOGY LAPITA D, P167; Harris DR, 1996, ORIGINS SPREAD AGR P; Higham C., 1996, BRONZE AGE SE ASIA; Hill EW, 2000, NATURE, V404, P351, DOI 10.1038/35006158; HILL J, 2003, EXAMINING LANGUAGE F, pCH26; Hill JH, 2001, AM ANTHROPOL, V103, P913, DOI 10.1525/aa.2001.103.4.913; Horai S, 1996, AM J HUM GENET, V59, P579; HUDSON M, 1999, RUINS IDENTITY; Hurles ME, 2002, GENETICS, V160, P289; Janhunen Juha Antero, 1996, MANCHURIA ETHNIC HIS; Kaufman Terence, 1990, AMAZONIAN LINGUISTIC, P13; KING VT, 1933, PEOPLES BORNEO; KRANTZ GS, 1988, GEOGRAPHICAL DEV EUR; Levine M., 1999, LATE PREHISTORIC EXP, P5; Mallory J. P., 1997, ARCHAEOLOGY LANGUAGE, V27, P93; MALLORY JP, 1989, SEARCH INDOEUROPEAN; MATSON RG, 2003, EXAMINING LANGUAGE F, pCH27; Melton T, 1998, AM J HUM GENET, V63, P1807, DOI 10.1086/302131; MILITAREV A, 2003, EXAMINING LANGUAGE F, pCH12; NETTLE DANIEL, 1999, LINGUISTIC DIVERSITY; Omoto K, 1997, AM J PHYS ANTHROPOL, V102, P437; Oppenheimer SJ, 2001, NATURE, V410, P166, DOI 10.1038/35065520; PAWLEY AK, 2003, EXAMINING LANGUAGE F, pCH20; PAWLEY AK, 1998, PERSPECTIVES BIRDS H, P684; PHILLIPSON D, 2003, EXAMINING LANGUAGE F, pCH15; Piperno D.R., 1998, ORIGINS AGR LOWLAND; REID L, 1994, LANGUAGE CONTACT CHA, P443; Renfrew C, 2000, CAMB ARCHAEOL J, V10, P7, DOI 10.1017/S0959774300000019; Renfrew C, 1999, J INDO-EUR STUD, V27, P257; Renfrew C., 1996, ORIGINS SPREAD AGR P, P70; RENFREW C, 1987, ARCHAEOLOGY LANGUAGE; Richards M, 2000, AM J HUM GENET, V67, P1251, DOI 10.1016/S0002-9297(07)62954-1; Ross Malcolm., 1997, ARCHAEOLOGY LANGUAGE, P209; Rouse I., 1992, TAINOS; RUHLEN M, 1987, GUIDE WORLDS LANGUAG, V1; SHERRATT A, 1988, ANTIQUITY, V62, P584; Simoni L, 2000, AM J HUM GENET, V66, P262, DOI 10.1086/302706; SMITH B, 1998, P NATL ACAD SCI USA, V98, P1324; Smith B.D., 1995, EMERGENCE AGR; Snow D., 1991, FARMERS HUNTERS COLO, P71; SPRIGGS M, 1996, ORIGINS SPREAD AGR P, P524; Underhill PA, 2001, ANN HUM GENET, V65, P43, DOI 10.1046/j.1469-1809.2001.6510043.x; van der Veen M., 1999, EXPLOITATION PLANT R; VANDRIEM G, 1999, B INDOPACIFIC PREHIS, V18, P43; Vinton Kirch P., 2017, ROAD WINDS; Watkins Calvert, 1985, AM HERITAGE DICT IND; Whittle A., 1996, EUROPE NEOLITHIC; Williamson K., 2000, AFRICAN LANGUAGES IN, P11; Zohary D, 2000, DOMESTICATION PLANTS, DOI DOI 10.1006/ANBO.2001.1505; [No title captured]	89	526	559	1	137	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 25	2003	300	5619					597	603		10.1126/science.1078208	http://dx.doi.org/10.1126/science.1078208			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	671FB	12714734	Green Submitted			2022-12-28	WOS:000182453700030
J	Lilley, MD; Butterfield, DA; Lupton, JE; Olson, EJ				Lilley, MD; Butterfield, DA; Lupton, JE; Olson, EJ			Magmatic events can produce rapid changes in hydrothermal vent chemistry	NATURE			English	Article							DE-FUCA RIDGE; EAST PACIFIC RISE; MIDOCEAN RIDGE; SPREADING CENTERS; CRUSTAL STRUCTURE; FLUIDS; JUAN; FIELD; EVOLUTION; SEAMOUNT	The Endeavour segment of the Juan de Fuca ridge is host to one of the most vigorous hydrothermal areas found on the global mid-ocean-ridge system, with five separate vent fields located within 15 km along the top of the ridge segment(1). Over the past decade, the largest of these vent fields(2), the 'Main Endeavour Field', has exhibited a constant spatial gradient in temperature and chloride concentration in its vent fluids, apparently driven by differences in the nature and extent of subsurface phase separation(3). This stable situation was disturbed on 8 June 1999 by an earthquake swarm(4). Owing to the nature of the seismic signals and the lack of new lava flows observed in the area during subsequent dives of the Alvin and Jason submersibles (August-September 1999), the event was interpreted to be tectonic in nature(4). Here we show that chemical data from hydrothermal fluid samples collected in September 1999 and June 2000 strongly suggest that the event was instead volcanic in origin. Volatile data from this event and an earlier one at 9degreesN on the East Pacific Rise show that such magmatic events can have profound and rapid effects on fluid-mineral equilibria, phase separation, He-3/heat ratios and fluxes of volatiles from submarine hydrothermal systems.	Univ Washington, Sch Oceanog, Seattle, WA 98195 USA; Univ Washington, NOAA, Pacific Marine Environm Lab, Joint Inst Study Atmosphere & Ocean, Seattle, WA 98195 USA; NOAA, Pacific Marine Environm Lab, Newport, OR 97365 USA	University of Washington; University of Washington Seattle; National Oceanic Atmospheric Admin (NOAA) - USA; University of Washington; University of Washington Seattle; National Oceanic Atmospheric Admin (NOAA) - USA	Lilley, MD (corresponding author), Univ Washington, Sch Oceanog, Seattle, WA 98195 USA.		Butterfield, David/H-3815-2016	Butterfield, David/0000-0002-1595-9279				[Anonymous], 1995, GEOPHYS MONOGR SER; Bohnenstiehl DR, 2002, TECTONOPHYSICS, V354, P49, DOI 10.1016/S0040-1951(02)00289-5; BUTTERFIELD DA, 1990, J GEOPHYS RES-SOLID, V95, P12895, DOI 10.1029/JB095iB08p12895; BUTTERFIELD DA, 1994, J GEOPHYS RES-SOL EA, V99, P9561, DOI 10.1029/93JB03132; Davis EE, 2001, J GEOPHYS RES-SOL EA, V106, P21953, DOI 10.1029/2000JB000040; DELANEY JR, 1992, J GEOPHYS RES-SOL EA, V97, P19663, DOI 10.1029/92JB00174; DETRICK RS, 2002, EOS, V83, pF1353; Ding K, 2001, EARTH PLANET SC LETT, V186, P417, DOI 10.1016/S0012-821X(01)00257-6; Dixon JE, 1995, J PETROL, V36, P1607; DIXON JE, 1988, EARTH PLANET SC LETT, V90, P87, DOI 10.1016/0012-821X(88)90114-8; Johnson HP, 2000, NATURE, V407, P174, DOI 10.1038/35025040; Kadko D, 1998, GEOCHIM COSMOCHIM AC, V62, P1521, DOI 10.1016/S0016-7037(98)00088-X; KAPPEL ES, 1986, J GEOPHYS RES-SOLID, V91, P13925, DOI 10.1029/JB091iB14p13925; Kelley DS, 2002, ANNU REV EARTH PL SC, V30, P385, DOI 10.1146/annurev.earth.30.091201.141331; LILLEY MD, 1993, NATURE, V364, P45, DOI 10.1038/364045a0; LILLEY MD, 1991, EOS T AM GEOPHYS UN, V72, P481; LISTER CRB, 1983, HYDROTHERMAL PROCESS, P141, DOI DOI 10.1007/978-1-4899-0402-7_7; LOWELL RP, 1994, J GEOPHYS RES-SOL EA, V99, P565, DOI 10.1029/93JB02568; Lupton J. E., 1991, EOS T AM GEOPHYS UN, V72, P481; Lupton JE, 1999, EARTH PLANET SC LETT, V171, P343, DOI 10.1016/S0012-821X(99)00149-1; ROHR KMM, 1988, GEOLOGY, V16, P533, DOI 10.1130/0091-7613(1988)016<0533:ADCSAT>2.3.CO;2; SEDWICK PN, 1992, GEOCHIM COSMOCHIM AC, V56, P3643, DOI 10.1016/0016-7037(92)90159-G; SEEWALD JS, 2001, EOS, V82, pF615; Sohn RA, 1998, NATURE, V396, P159, DOI 10.1038/24146; Stuart FM, 1998, CHEM GEOL, V147, P77, DOI 10.1016/S0009-2541(97)00173-3; Von Damm KL, 2000, J GEOPHYS RES-SOL EA, V105, P11203, DOI 10.1029/1999JB900414; VONDAMM KL, 1995, NATURE, V375, P47, DOI 10.1038/375047a0; WHITE DJ, 1990, GEOPHYS J INT, V100, P349, DOI 10.1111/j.1365-246X.1990.tb00690.x; WILCOCK WDS, 2002, J GEOPHYS RES B, V107; Wilcock WSD, 1996, EARTH PLANET SC LETT, V145, P49, DOI 10.1016/S0012-821X(96)00195-1	30	185	191	0	40	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 24	2003	422	6934					878	881		10.1038/nature01569	http://dx.doi.org/10.1038/nature01569			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	670WR	12712202	Bronze			2022-12-28	WOS:000182432600051
J	Melton, L				Melton, L			On the trail of SNPs	NATURE			English	Article									Novartis Fdn, London, England	Novartis	Melton, L (corresponding author), Novartis Fdn, London, England.								0	22	23	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 24	2003	422	6934					917	923		10.1038/422917a	http://dx.doi.org/10.1038/422917a			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	670WR	12712209	Bronze			2022-12-28	WOS:000182432600060
J	Moss, AJ				Moss, AJ			Long QT syndrome	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							T-WAVE PATTERNS; GENETIC VARIABLES; CARDIAC EVENTS; REPOLARIZATION; THERAPY; MUTATIONS; GENOTYPE; SPECTRUM; SCN5A; HERG		Univ Rochester, Med Ctr, Heart Res Follow Up Program, Dept Med,Cardiol Unit, Rochester, NY 14642 USA	University of Rochester	Moss, AJ (corresponding author), Univ Rochester, Med Ctr, Heart Res Follow Up Program, Dept Med,Cardiol Unit, Box 653, Rochester, NY 14642 USA.				NHLBI NIH HHS [HL-51648, HL-33843] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051648, R01HL033843] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ali RHH, 2000, AM J CARDIOL, V85, P457, DOI 10.1016/S0002-9149(99)90772-5; Compton SJ, 1996, CIRCULATION, V94, P1018, DOI 10.1161/01.CIR.94.5.1018; Dorostkar PC, 1999, CIRCULATION, V100, P2431, DOI 10.1161/01.CIR.100.24.2431; JERVELL A, 1957, AM HEART J, V54, P59, DOI 10.1016/0002-8703(57)90079-0; Moss AJ, 1999, AM J CARDIOL, V84, P876, DOI 10.1016/S0002-9149(99)00458-0; MOSS AJ, 1991, CIRCULATION, V84, P1136, DOI 10.1161/01.CIR.84.3.1136; Moss AJ, 2000, CIRCULATION, V101, P616, DOI 10.1161/01.CIR.101.6.616; MOSS AJ, 1995, CIRCULATION, V92, P2929, DOI 10.1161/01.CIR.92.10.2929; MOSS AJ, 1971, NEW ENGL J MED, V285, P903, DOI 10.1056/NEJM197110142851607; MOSS AJ, 1992, TRENDS CARDIOVAS MED, V2, P81, DOI 10.1016/1050-1738(92)90010-P; Moss AJ., 1993, AM J CARDIOL, V72, p23B; SCHWARTZ PJ, 1995, CIRCULATION, V92, P3381, DOI 10.1161/01.CIR.92.12.3381; Schwartz PJ, 2001, CIRCULATION, V103, P89; SCHWARTZ PJ, 1993, CIRCULATION, V88, P782, DOI 10.1161/01.CIR.88.2.782; Splawski I, 2000, CIRCULATION, V102, P1178, DOI 10.1161/01.CIR.102.10.1178; Windle JR, 2001, ANN NONINVAS ELECTRO, V6, P153, DOI 10.1111/j.1542-474X.2001.tb00100.x; Zareba W, 1998, NEW ENGL J MED, V339, P960, DOI 10.1056/NEJM199810013391404; ZAREBA W, IN PRESS J CARDIOVAS; Zhang L, 2000, CIRCULATION, V102, P2849	19	176	186	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 23	2003	289	16					2041	2044		10.1001/jama.289.16.2041	http://dx.doi.org/10.1001/jama.289.16.2041			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	669WW	12709446				2022-12-28	WOS:000182374300002
J	Mitsui, T; Rose, MK; Fomin, E; Ogletree, DF; Salmeron, M				Mitsui, T; Rose, MK; Fomin, E; Ogletree, DF; Salmeron, M			Dissociative hydrogen adsorption on palladium requires aggregates of three or more vacancies	NATURE			English	Article								During reaction, a catalyst surface usually interacts with a constantly fluctuating mix of reactants, products, 'spectators' that do not participate in the reaction, and species that either promote or inhibit the activity of the catalyst. How molecules adsorb and dissociate under such dynamic conditions is often poorly understood. For example, the dissociative adsorption of the diatomic molecule H-2-a central step in many industrially important catalytic processes-is generally assumed(1) to require at least two adjacent and empty atomic adsorption sites (or vacancies). The creation of active sites for H-2 dissociation will thus involve the formation of individual vacancies and their subsequent diffusion and aggregation(2-6), with the coupling between these events determining the activity of the catalyst surface. But even though active sites are the central component of most reaction models, the processes controlling their formation, and hence the activity of a catalyst surface, have never been captured experimentally. Here we report scanning tunnelling microscopy observations of the transient formation of active sites for the dissociative adsorption of H-2 molecules on a palladium (111) surface. We find, contrary to conventional thinking(1), that two-vacancy sites seem inactive, and that aggregates of three or more hydrogen vacancies are required for efficient H-2 dissociation.	Univ Calif Berkeley, Lawrence Berkeley Lab, Div Mat Sci, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Salmeron, M (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Div Mat Sci, Berkeley, CA 94720 USA.		Ogletree, D Frank F/D-9833-2016	Ogletree, D Frank F/0000-0002-8159-0182; Mitsui, Toshiyuki/0000-0002-5465-4742				Behler S, 1997, REV SCI INSTRUM, V68, P2479, DOI 10.1063/1.1148172; BOUDART M, 1969, AM SCI, V57, P97; CONRAD H, 1974, SURF SCI, V41, P435, DOI 10.1016/0039-6028(74)90060-0; FELTER TE, 1989, PHYS REV B, V40, P891, DOI 10.1103/PhysRevB.40.891; Lovvik OM, 1998, PHYS REV B, V58, P10890, DOI 10.1103/PhysRevB.58.10890; MITSUI T, UNPUB SURF SCI; Paul JF, 1996, PHYS REV B, V53, P8015, DOI 10.1103/PhysRevB.53.8015; PONEC V, 1972, J CATAL, V24, P250, DOI 10.1016/0021-9517(72)90069-3; Sinfelt J. H., 1983, BIMETALLIC CATALYSTS; Somorjai G.A., 2010, INTRO SURFACE CHEM C; Taylor HS, 1925, P R SOC LOND A-CONTA, V108, P105, DOI 10.1098/rspa.1925.0061	11	276	280	7	135	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 17	2003	422	6933					705	707		10.1038/nature01557	http://dx.doi.org/10.1038/nature01557			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	668CG	12700757	Green Published			2022-12-28	WOS:000182272300036
J	Bruins, HJ; van der Plicht, J; Mazar, A				Bruins, HJ; van der Plicht, J; Mazar, A			C-14 dates from Tel Rehov: Iron-age chronology, pharaohs, and Hebrew kings	SCIENCE			English	Article							RADIOCARBON TIME SCALE; PRECISION DECADAL CALIBRATION; BIBLICAL ARCHAEOLOGY; BRONZE-AGE; BC; ISRAEL	Stratified radiocarbon dates provide an independent chronological link between archaeological layers and historical data. The invasion by Pharaoh Shoshenq I (Shishak) is a key historical synchronism, similar to 925 B. C. E., mentioned in both Egyptian inscriptions and the Hebrew Bible. The list of places raided by Shoshenq, mentioned at Karnak ( Egypt), includes Rehov ( Israel). The site yielded a consistent series of radiocarbon dates from the 12th to 9th century B. C. E. Our results (i) suggest a revised Iron-Age chronology; (ii) date an archaeological stratum to Shoshenq's campaign; (iii) indicate the similarity of "Solomonic" and "Omride" pottery; and (iv) provide correlation with Greece and Cyprus.	Ben Gurion Univ Negev, Jacob Blaustein Inst Desert Res, Dept Man Desert, IL-84990 Sede Boqer, Israel; Univ Groningen, Ctr Isotope Res, NL-9747 AG Groningen, Netherlands; Hebrew Univ Jerusalem, Inst Archaeol, IL-91904 Jerusalem, Israel	Ben Gurion University; University of Groningen; Hebrew University of Jerusalem	Bruins, HJ (corresponding author), Ben Gurion Univ Negev, Jacob Blaustein Inst Desert Res, Dept Man Desert, Sede Boker Campus, IL-84990 Sede Boqer, Israel.		van der Plicht, Johannes/B-9994-2013					Balter M, 2000, SCIENCE, V287, P31, DOI 10.1126/science.287.5450.31; Ben-Tor A., 2000, B AM SCH ORIENT RES, V317, P9, DOI DOI 10.2307/1357481; BRUINS HJ, 1989, RADIOCARBON, V31, P1019; BRUINS HJ, 2001, RADIOCARBON, V43; COLDSTREAM N, IN PRESS ISR EXPLOR; Finkelstein I, 1999, NEAR EAST ARCHAEOL, V62, P35, DOI 10.2307/3210721; Finkelstein I., 1998, TEL AVIV, V25, P208, DOI DOI 10.1179/tav.1998.1998.2.208; Finkelstein Israel, 1996, LEVANT, V28, P177, DOI DOI 10.1179/LEV.1996.28.1.177; Gilboa A, 2001, RADIOCARBON, V43, P1343; GITIN S, 1998, MEDITERRANEAN PEOPLE; Kitchen K. A, 1986, 3 INTERMEDIATE PERIO; Kitchen K. A., 2000, SYNCHRONISATION CIVI, P39; Manning SW, 2001, SCIENCE, V294, P2532, DOI 10.1126/science.1066112; MANNING SW, 1992, ANTIQUITY, V66, P636, DOI 10.1017/S0003598X00039351; Mazar A, 1999, ISRAEL EXPLOR J, V49, P1; Mazar A, 2001, RADIOCARBON, V43, P1333; Mazar A., 1997, LEVANT, V29, P157, DOI [10.1179/lev.1997.29.1.157, DOI 10.1179/LEV.1997.29.1.157]; MILLER MJ, 1986, HIST ANCIENT ISRAEL; PEARSON GW, 1986, RADIOCARBON, V28, P839, DOI 10.1017/S0033822200060173; Ramsey CB, 1995, RADIOCARBON, V37, P425, DOI 10.1017/S0033822200030903; Rast W.E., 1978, STUDIES IRON AGE POT; Smith J. C., UNPUB; STUIVER M, 1993, RADIOCARBON, V35, P35, DOI 10.1017/S0033822200013801; STUIVER M, 1986, RADIOCARBON, V28, P863, DOI 10.1017/S0033822200060185; Stuiver M., 1998, RADIOCARBON, V40; van der Plicht J, 2001, RADIOCARBON, V43, P1155; WEINSTEIN JM, 1984, RADIOCARBON, V26, P297, DOI 10.1017/S0033822200006731; Weninger B, 1995, RADIOCARBON, V37, P443, DOI 10.1017/S0033822200030927	28	51	51	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 11	2003	300	5617					315	318		10.1126/science.1082776	http://dx.doi.org/10.1126/science.1082776			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	Science & Technology - Other Topics	665RQ	12690196				2022-12-28	WOS:000182135400053
J	Hu, FB; Li, TY; Colditz, GA; Willett, WC; Manson, JE				Hu, FB; Li, TY; Colditz, GA; Willett, WC; Manson, JE			Television watching and other sedentary behaviors in relation to risk of obesity and type 2 diabetes mellitus in women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PHYSICAL-ACTIVITY; UNITED-STATES; MEN; WEIGHT; CHILDREN; HEALTH	Context Current public health campaigns to reduce obesity and type 2 diabetes have largely focused on increasing exercise, but have paid little attention to the reduction of sedentary behaviors. Objective To examine the-relationship between various sedentary behaviors, especially prolonged television (TV) watching, and risk of obesity and type 2 diabetes in women. Design, Setting, and Participants Prospective cohort study conducted from 1992 to 1998 among women from 11 states in the Nurses' Health Study. The obesity analysis included 50277 women who had a body mass index (BMI) of less than 30 and were free from diagnosed cardiovascular disease, diabetes, or cancer and completed questions on physical activity and sedentary behaviors at baseline. The diabetes analysis included 68497 women who at baseline were free from diagnosed diabetes mellitus, cardiovascular disease, or cancer. Main Outcome Measures Onset of obesity and type 2 diabetes mellitus. Results During 6 years of follow-up, 3757 (7.5%) of 50277 women who had a BMI of less than 30 in 1992 became obese (13MI greater than or equal to30). Overall, we documented 1515 new cases of type 2 diabetes. Time spent watching TV was positively associated with risk of obesity and type 2 diabetes. In the multivariate analyses adjusting for age, smoking, exercise levels, dietary factors, and other covariates, each 2-h/d increment in TV watching was associated with a 23% (95% confidence interval [CI], 17%-30%) increase in obesity and a 14% (95% CI, 5%-23%) increase in risk of diabetes; each 2-h/d increment in sitting at work was associated with a 5% (95% CI, 0%-10%) increase in obesity and a 7% (95% CI, 0%-1.6%) increase in diabetes. In contrast, standing or walking around at home (2 h/d) was associated with a 9% (95% CI, 6%-12%) reduction in obesity and a 12% (95% CI, 7%-16%) reduction in diabetes. Each 1 hour per day of brisk walking was associated with a 24% (95% CI, 19%-29%) reduction in obesity and a 34% (95% CI, 27%-41%) reduction in diabetes We estimated that in our cohort, 30% (95% CI, 24%-36%) of new cases of obesity and 43% (95% CI, 32%-52%) of new cases of diabetes could be prevented by adopting a relatively active lifestyle (<10 h/wk of TV watching and &GE;30 min/d of brisk walking). Conclusions Independent of exercise levels, sedentary behaviors, especially TV watching, were associated with significantly elevated risk of obesity and type 2 diabetes, whereas even light to moderate activity was associated with substantially lower risk. This study emphasize's the importance of reducing prolonged TV watching and other sedentary behaviors for preventing obesity and diabetes.	Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Channing Labs, Boston, MA USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Div Prevent Med, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Hu, FB (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Nutr, 665 Huntington Ave, Boston, MA 02115 USA.		Colditz, Graham/A-3963-2009; Hu, Frank/C-1919-2013	Colditz, Graham/0000-0002-7307-0291; 	NATIONAL CANCER INSTITUTE [P01CA087969] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058845] Funding Source: NIH RePORTER; NCI NIH HHS [CA87969] Funding Source: Medline; NIDDK NIH HHS [DK58845] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AINSWORTH BE, 1993, MED SCI SPORT EXER, V25, P71, DOI 10.1249/00005768-199301000-00011; Andersen RE, 1998, JAMA-J AM MED ASSOC, V279, P938, DOI 10.1001/jama.279.12.938; BURCHFIEL CM, 1995, AM J EPIDEMIOL, V141, P360, DOI 10.1093/aje/141.4.360; Ching PLYH, 1996, AM J PUBLIC HEALTH, V86, P25, DOI 10.2105/AJPH.86.1.25; Coakley EH, 1998, INT J OBESITY, V22, P89, DOI 10.1038/sj.ijo.0800549; COLDITZ GA, 1990, AM J EPIDEMIOL, V132, P501, DOI 10.1093/oxfordjournals.aje.a115686; DIETZ WH, 1985, PEDIATRICS, V75, P807; FALCIGLIA GA, 1980, J NUTR EDUC, V12, P196; Field AE, 2001, ARCH INTERN MED, V161, P1581, DOI 10.1001/archinte.161.13.1581; Flegal KM, 2002, JAMA-J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723; Fung TT, 2000, AM J EPIDEMIOL, V152, P1171, DOI 10.1093/aje/152.12.1171; Gortmaker SL, 1996, ARCH PEDIAT ADOL MED, V150, P356, DOI 10.1001/archpedi.1996.02170290022003; GURWITZ JH, 1994, J AM GERIATR SOC, V42, P1235, DOI 10.1111/j.1532-5415.1994.tb06503.x; HARRIS M, 1979, DIABETES, V28, P1039; HELMRICH SP, 1991, NEW ENGL J MED, V325, P147, DOI 10.1056/NEJM199107183250302; Hu FB, 2001, NEW ENGL J MED, V345, P790, DOI 10.1056/NEJMoa010492; Hu FB, 1999, JAMA-J AM MED ASSOC, V282, P1433, DOI 10.1001/jama.282.15.1433; Hu FB, 2001, ARCH INTERN MED, V161, P1542, DOI 10.1001/archinte.161.12.1542; JACOBS DR, 1993, MED SCI SPORT EXER, V25, P81, DOI 10.1249/00005768-199301000-00012; Lank N H, 1992, J Community Health, V17, P377, DOI 10.1007/BF01323999; Lynch J, 1996, ARCH INTERN MED, V156, P1307, DOI 10.1001/archinte.156.12.1307; MANSON JE, 1992, JAMA-J AM MED ASSOC, V268, P63, DOI 10.1001/jama.268.1.63; MANSON JE, 1991, LANCET, V338, P774, DOI 10.1016/0140-6736(91)90664-B; *NIELS MED RES, 1998, NIELS REP TEL; PERRY IJ, 1995, BRIT MED J, V310, P560, DOI 10.1136/bmj.310.6979.560; Robinson TN, 2001, PEDIATR CLIN N AM, V48, P1017, DOI 10.1016/S0031-3955(05)70354-0; Robinson TN, 1999, JAMA-J AM MED ASSOC, V282, P1561, DOI 10.1001/jama.282.16.1561; TUCKER LA, 1989, AM J PUBLIC HEALTH, V79, P516, DOI 10.2105/AJPH.79.4.516; TUCKER LA, 1991, AM J PUBLIC HEALTH, V81, P908, DOI 10.2105/AJPH.81.7.908; van Dam RM, 2002, ANN INTERN MED, V136, P201, DOI 10.7326/0003-4819-136-3-200202050-00008; WACHOLDER S, 1994, AM J EPIDEMIOL, V140, P303, DOI 10.1093/oxfordjournals.aje.a117252; WACHOLDER S, 1994, AM J EPIDEMIOL, V140, P668; WILLETT W, 1983, AM J EPIDEMIOL, V117, P651, DOI 10.1093/oxfordjournals.aje.a113598; WOLF AM, 1994, INT J EPIDEMIOL, V23, P991, DOI 10.1093/ije/23.5.991	34	1163	1203	7	162	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 9	2003	289	14					1785	1791		10.1001/jama.289.14.1785	http://dx.doi.org/10.1001/jama.289.14.1785			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	664ZJ	12684356	Bronze			2022-12-28	WOS:000182094900023
J	Reya, T; Duncan, AW; Ailles, L; Domen, J; Scherer, DC; Willert, K; Hintz, L; Nusse, R; Weissman, IL				Reya, T; Duncan, AW; Ailles, L; Domen, J; Scherer, DC; Willert, K; Hintz, L; Nusse, R; Weissman, IL			A role for Wnt signalling in self-renewal of haematopoietic stem cells	NATURE			English	Article							HAIR FOLLICLE MORPHOGENESIS; BETA-CATENIN; AXIS FORMATION; GENE FAMILY; PROLIFERATION; TRANSCRIPTION; EXPANSION; PATHWAY; COMPLEX; MICE	Haematopoietic stem cells (HSCs) have the ability to renew themselves and to give rise to all lineages of the blood; however, the signals that regulate HSC self-renewal remain unclear. Here we show that the Wnt signalling pathway has an important role in this process. Overexpression of activated beta-catenin expands the pool of HSCs in long-term cultures by both phenotype and function. Furthermore, HSCs in their normal microenvironment activate a LEF-1/TCF reporter, which indicates that HCSs respond to Wnt signalling in vivo. To demonstrate the physiological significance of this pathway for HSC proliferation we show that the ectopic expression of axin or a frizzled ligand-binding domain, inhibitors of the Wnt signalling pathway, leads to inhibition of HSC growth in vitro and reduced reconstitution in vivo. Furthermore, activation of Wnt signalling in HSCs induces increased expression of HoxB4 and Notch1, genes previously implicated in self-renewal of HSCs. We conclude that the Wnt signalling pathway is critical for normal HSC homeostasis in vitro and in vivo, and provide insight into a potential molecular hierarchy of regulation of HSC development.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94035 USA; Stanford Univ, Sch Med, Dept Dev Biol, Stanford, CA 94035 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Immunol, Durham, NC 27710 USA; Stanford Univ, Sch Med, Howard Hughes Med Inst, Stanford, CA 94035 USA	Duke University; Stanford University; Stanford University; Duke University; Duke University; Howard Hughes Medical Institute; Stanford University	Reya, T (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA.	t.reya@duke.edu		Duncan, Andrew/0000-0003-4962-4191				Antonchuk J, 2002, CELL, V109, P39, DOI 10.1016/S0092-8674(02)00697-9; Audet J, 1998, CURR OPIN BIOTECH, V9, P146, DOI 10.1016/S0958-1669(98)80107-9; Austin TW, 1997, BLOOD, V89, P3624, DOI 10.1182/blood.V89.10.3624.3624_3624_3635; Barth AIM, 1999, P NATL ACAD SCI USA, V96, P4947, DOI 10.1073/pnas.96.9.4947; Bhardwaj G, 2001, NAT IMMUNOL, V2, P172, DOI 10.1038/84282; Cadigan KM, 1998, CELL, V93, P767, DOI 10.1016/S0092-8674(00)81438-5; Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804; Chenn A, 2002, SCIENCE, V297, P365, DOI 10.1126/science.1074192; Cheshier SP, 1999, P NATL ACAD SCI USA, V96, P3120, DOI 10.1073/pnas.96.6.3120; Domen J, 2000, J EXP MED, V191, P253, DOI 10.1084/jem.191.2.253; Domen J, 2000, J EXP MED, V192, P1707, DOI 10.1084/jem.192.12.1707; Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463-8471.1998; Gat U, 1998, CELL, V95, P605, DOI 10.1016/S0092-8674(00)81631-1; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; HAWLEY RG, 1992, J EXP MED, V176, P1149, DOI 10.1084/jem.176.4.1149; HING HK, 1994, MECH DEVELOP, V47, P261, DOI 10.1016/0925-4773(94)90044-2; HOOPER JE, 1994, NATURE, V372, P461, DOI 10.1038/372461a0; Hsieh JC, 1999, P NATL ACAD SCI USA, V96, P3546, DOI 10.1073/pnas.96.7.3546; Huelsken J, 2001, CELL, V105, P533, DOI 10.1016/S0092-8674(01)00336-1; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; INGHAM PW, 1993, DEVELOPMENT, V117, P283; Ivanova NB, 2002, SCIENCE, V298, P601, DOI 10.1126/science.1073823; Kielman MF, 2002, NAT GENET, V32, P594, DOI 10.1038/ng1045; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; Maloof JN, 1999, DEVELOPMENT, V126, P37; Miller CL, 1997, P NATL ACAD SCI USA, V94, P13648, DOI 10.1073/pnas.94.25.13648; MORRISON SJ, 1994, IMMUNITY, V1, P661, DOI 10.1016/1074-7613(94)90037-X; MORRISON SJ, 1995, P NATL ACAD SCI USA, V92, P10302, DOI 10.1073/pnas.92.22.10302; Randall TD, 1997, BLOOD, V89, P3596, DOI 10.1182/blood.V89.10.3596.3596_3596_3606; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Reya T, 2000, IMMUNITY, V13, P15, DOI 10.1016/S1074-7613(00)00004-2; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; SPANGRUDE GJ, 1989, SCIENCE, V244, P1030; UCHIDA N, 1992, J EXP MED, V175, P175, DOI 10.1084/jem.175.1.175; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Van den Berg DJ, 1998, BLOOD, V92, P3189, DOI 10.1182/blood.V92.9.3189.421k45_3189_3202; Varnum-Finney B, 2000, NAT MED, V6, P1278, DOI 10.1038/81390; Wang E, 2000, NAT BIOTECHNOL, V18, P457, DOI 10.1038/74546; Weissman IL, 2000, CELL, V100, P157, DOI 10.1016/S0092-8674(00)81692-X; WILLERT K, 2003, NATURE          0427, DOI DOI 10.1038/NATURE01611; Yamamoto H, 1998, MOL CELL BIOL, V18, P2867, DOI 10.1128/MCB.18.5.2867; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4; Zhu AJ, 1999, DEVELOPMENT, V126, P2285	44	1622	1767	2	107	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 22	2003	423	6938					409	414		10.1038/nature01593	http://dx.doi.org/10.1038/nature01593			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	681AJ	12717450				2022-12-28	WOS:000183012000034
J	Winston, DJ; Maziarz, RT; Chandrasekar, PH; Lazarus, HM; Goldman, M; Blumer, JL; Leitz, GJ; Territo, MC				Winston, DJ; Maziarz, RT; Chandrasekar, PH; Lazarus, HM; Goldman, M; Blumer, JL; Leitz, GJ; Territo, MC			Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients - A multicenter, randomized trial	ANNALS OF INTERNAL MEDICINE			English	Article							INVASIVE FUNGAL-INFECTIONS; BONE-MARROW-TRANSPLANTATION; DOSE AMPHOTERICIN-B; VERSUS-HOST-DISEASE; DOUBLE-BLIND; ASPERGILLUS INFECTIONS; NEUTROPENIC PATIENTS; RISK-FACTORS; MOLD INFECTIONS; PLACEBO	Background: Allogeneic hematopoietic stem-cell transplant recipients often receive fluconazole or an amphotericin B preparation for antifungal prophylaxis. Because of concerns about fungal resistance with fluconazole and toxicity with amphotericin B, alternative prophylactic regimens have become necessary. Objective: To compare the efficacy and safety of intravenous and oral itraconazole with the efficacy and safety of intravenous and oral fluconazole for long-term prophylaxis of fungal infections. Design: Open-label, multicenter, randomized trial. Setting: Five transplantation centers in the United States. Patients: 140 patients undergoing allogeneic hematopoietic stem-cell transplantation. Intervention: Itraconazole (200 mg intravenously every 12 hours for 2 days followed by 200 mg intravenously every 24 hours or a 200-mg oral solution every 12 hours) or fluconazole (400 mg intravenously or orally every 24 hours) from day 1 until day 100 after transplantation. Measurements: Proven invasive or superficial fungal infection, drug-related side effects, mortality from fungal infection, and overall mortality. Results: Proven invasive fungal infections occurred in 6 of 71 itraconazole recipients (9%) and in, 17 of 67 fluconazole recipients (25%) during the first 180 days after transplantation (difference, -16 percentage points [95% Cl, -29.2 to -4.7 percentage points]; P = 0.01). Superficial fungal infections occurred in 3 of 71 itraconazole recipients (4%) and in 2 of 67 fluconazole recipients (3%). In a multivariable analysis using factors known to affect the risk for invasive fungal infection after hematopoietic stem-cell transplantation, prophylaxis with itraconazole was still associated with fewer invasive fungal infections (odds ratio, 0.300 [Cl, 0.111 to 0.814]; P = 0.02) caused by either yeasts or molds. More fungal pathogens were found to be resistant to fluconazole than to itraconazole. Except for more frequent gastrointestinal side effects (nausea, vomiting, diarrhea, or abdominal pain) in patients given itraconazole (24% vs. 9%; difference, 15 percentage points [Cl, 2.9 to 27.0 percentage points]; P = 0.02), both itraconazole and fluconazole were well tolerated. The overall mortality rate was similar in each group (32 of 71 patients in the itraconazole group [45%] vs. 28 of 67 patients in the fluconazole group [42%]; difference, 3 percentage points [Cl, -13.2 to 19.8 percentage points]; P > 0.2), but fewer deaths were related to fungal infection in patients given itraconazole (6 of 71 [9%]) than in patients given fluconazole (12 of 67 [18%]) (difference, 9 percentage points [Cl, -20.6 to 1.8 percentage points]; P = 0.13). Conclusion: Itraconazole is more effective than fluconazole for long-term prophylaxis of invasive fungal infections after allogeneic hematopoietic stem-cell transplantation. Except for gastrointestinal side effects, itraconazole is well tolerated.	Univ Calif Los Angeles, Ctr Med, Dept Med, Los Angeles, CA 90095 USA; Oregon Hlth & Sci Univ, Portland, OR 97201 USA; Wayne State Univ, Harper Hosp, Detroit, MI USA; Univ Hosp Cleveland, Ireland Canc Ctr, Cleveland, OH 44106 USA; Indiana Univ Hosp, Indianapolis, IN 46202 USA; Ortho Biotech, Raritan, NJ USA	University of California System; University of California Los Angeles; Oregon Health & Science University; Wayne State University; University Hospitals of Cleveland; Indiana University System	Winston, DJ (corresponding author), Univ Calif Los Angeles, Ctr Med, Dept Med, Room 42-121 CHS,10833 Conte Ave, Los Angeles, CA 90095 USA.	dwinston@mednet.ucla.edu						Ascioglu S, 2002, CLIN INFECT DIS, V34, P7, DOI 10.1086/323335; BACK DJ, 1991, BRIT J CLIN PHARMACO, V32, P624, DOI 10.1111/j.1365-2125.1991.tb03963.x; Baddley JW, 2001, CLIN INFECT DIS, V32, P1319, DOI 10.1086/319985; BLACKWELDER WC, 1982, CONTROL CLIN TRIALS, V3, P345, DOI 10.1016/0197-2456(82)90024-1; Boogaerts M, 2001, ANN INTERN MED, V135, P412, DOI 10.7326/0003-4819-135-6-200109180-00010; CRIPPA F, 2000, 40 INT C ANT AG CHEM, V25; DeBeule K, 1996, INT J ANTIMICROB AG, V6, P175, DOI 10.1016/0924-8579(95)00043-7; Dykewicz CA, 2001, CLIN INFECT DIS, V33, P139, DOI 10.1086/321805; EspinelIngroff A, 1997, J CLIN MICROBIOL, V35, P139, DOI 10.1128/JCM.35.1.139-143.1997; GLASMACHER A, 2000, 40 INT C ANT AG CHEM, V363; GOODMAN JL, 1992, NEW ENGL J MED, V326, P845, DOI 10.1056/NEJM199203263261301; GOODRICH JM, 1991, J INFECT DIS, V164, P731, DOI 10.1093/infdis/164.4.731; Harousseau JL, 2000, ANTIMICROB AGENTS CH, V44, P1887, DOI 10.1128/AAC.44.7.1887-1893.2000; HUANG WY, 1987, AM J CLIN PATHOL, V87, P528, DOI 10.1093/ajcp/87.4.528; Jantunen E, 1997, BONE MARROW TRANSPL, V19, P801, DOI 10.1038/sj.bmt.1700737; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kelsey SM, 1999, BONE MARROW TRANSPL, V23, P163, DOI 10.1038/sj.bmt.1701543; Leather HL, 2000, BLOOD, V96, p390A; Marr KA, 2000, BLOOD, V96, P2055; Marr KA, 2000, J INFECT DIS, V181, P309, DOI 10.1086/315193; Marr KA, 2002, CLIN INFECT DIS, V34, P909, DOI 10.1086/339202; Menichetti F, 1999, CLIN INFECT DIS, V28, P250, DOI 10.1086/515129; MEUNIER F, 1987, REV INFECT DIS, V9, P408; Morgenstern GR, 1999, BRIT J HAEMATOL, V105, P901, DOI 10.1046/j.1365-2141.1999.01465.x; ODONNELL MR, 1994, J CLIN ONCOL, V12, P827, DOI 10.1200/JCO.1994.12.4.827; RILEY DK, 1994, AM J MED, V97, P509, DOI 10.1016/0002-9343(94)90345-X; ROSENBAUM PR, 1984, J AM STAT ASSOC, V79, P516, DOI 10.2307/2288398; *SAS I INC, 1996, US MAN SAS VERS 6 12; SAYER HG, 1994, BLOOD, V84, P1328; Schmidt U, 1991, Mycoses, V34 Suppl 1, P33; Schwartz S, 1999, BLOOD, V93, P3654; Sheehan DJ, 1999, CLIN MICROBIOL REV, V12, P40, DOI 10.1128/CMR.12.1.40; SLAVIN MA, 1995, J INFECT DIS, V171, P1545, DOI 10.1093/infdis/171.6.1545; SULLIVAN KM, 1981, BLOOD, V57, P267, DOI 10.1182/blood.V57.2.267.267; The National Committee for Clinical Laboratory Standard, 1997, M27A NCCLS; THOMAS ED, 1975, NEW ENGL J MED, V292, P895, DOI 10.1056/NEJM197504242921706; TOLLEMAR J, 1993, BONE MARROW TRANSPL, V12, P577; van Burik JAH, 1998, MEDICINE, V77, P246, DOI 10.1097/00005792-199807000-00003; Wald A, 1997, J INFECT DIS, V175, P1459, DOI 10.1086/516480; WARNOCK DW, 1988, J ANTIMICROB CHEMOTH, V21, P93, DOI 10.1093/jac/21.1.93; Wingard J R, 1999, Biol Blood Marrow Transplant, V5, P55, DOI 10.1053/bbmt.1999.v5.pm10371357; WINGARD JR, 1987, BONE MARROW TRANSPL, V2, P175; WINGARD JR, 1993, ANTIMICROB AGENTS CH, V37, P1847, DOI 10.1128/AAC.37.9.1847; WINGARD JR, 1991, NEW ENGL J MED, V325, P1274, DOI 10.1056/NEJM199110313251803; Wolff SN, 2000, BONE MARROW TRANSPL, V25, P853, DOI 10.1038/sj.bmt.1702233	45	285	304	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 6	2003	138	9					705	713		10.7326/0003-4819-138-9-200305060-00006	http://dx.doi.org/10.7326/0003-4819-138-9-200305060-00006			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	674XA	12729424				2022-12-28	WOS:000182661400002
J	Farrow, R				Farrow, R			ABC of learning and teaching in medicine - Creating teaching materials	BMJ-BRITISH MEDICAL JOURNAL			English	Review									Univ Exeter, Peninsula Med Sch, Exeter EX4 4QJ, Devon, England; Univ Plymouth, Peninsula Med Sch, Plymouth, Devon, England	University of Exeter; University of Plymouth	Farrow, R (corresponding author), Univ Exeter, Peninsula Med Sch, Exeter EX4 4QJ, Devon, England.							CANNON R, 1999, HDB TEACHERS U COLLE; HARTLEY J, 1994, DESIGNING INSTRUCTIO; Kemp J. E., 1985, PLANNING PRODUCING I; Newble DI, 2001, HDB MED TEACHERS	4	7	7	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 26	2003	326	7395					921	923		10.1136/bmj.326.7395.921	http://dx.doi.org/10.1136/bmj.326.7395.921			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	673WQ	12714475	Green Published			2022-12-28	WOS:000182603600022
J	Lee, SS; Kennedy, S; Tolonen, AC; Ruvkun, G				Lee, SS; Kennedy, S; Tolonen, AC; Ruvkun, G			DAF-16 target genes that control C-elegans life-span and metabolism	SCIENCE			English	Article							INSULIN-RECEPTOR; OXIDATIVE STRESS; LONGEVITY; EXPRESSION; RESISTANCE	Signaling from the DAF-2/insulin receptor to the DAF-16/FOXO transcription factor controls longevity, metabolism, and development in disparate phyla. To identify genes that mediate the conserved biological outputs of daf-2/insulin-like signaling, we used comparative genomics to identify 17 orthologous genes from Caenorhabditis and Drosophila, each of which bears a DAF-16 binding site in the promoter region. One-third of these DAF-16 downstream candidate genes were regulated by daf-2/insulin-like signaling in C. elegans, and RNA interference inactivation of the candidates showed that many of these genes mediate distinct aspects of daf-16 function, including longevity, metabolism, and development.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Mol Biol,Dept Genet, Boston, MA 02114 USA; MIT, Dept Biol, Cambridge, MA 02139 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Massachusetts Institute of Technology (MIT)	Ruvkun, G (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Mol Biol,Dept Genet, 50 Blossom St, Boston, MA 02114 USA.	ruvkun@molbio.mgh.harvard.edu		Kennedy, Scott/0000-0002-7974-8155; Tolonen, Andrew/0000-0001-5907-4504				Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Ashrafi K, 2003, NATURE, V421, P268, DOI 10.1038/nature01279; Birkenkamp KU, 2003, BIOCHEM SOC T, V31, P292, DOI 10.1042/bst0310292; Bluher M, 2003, SCIENCE, V299, P572, DOI 10.1126/science.1078223; Chan SW, 2001, J BIOL CHEM, V276, P28402, DOI 10.1074/jbc.M100313200; Coghlan A, 2002, GENOME RES, V12, P857, DOI 10.1101/gr.172702; DEAN M, 2002, HUMAN ATP BINDING CA; Finch CE, 2001, ANNU REV GENOM HUM G, V2, P435, DOI 10.1146/annurev.genom.2.1.435; FRIEDMAN DB, 1988, GENETICS, V118, P75; Furuyama T, 2000, BIOCHEM J, V349, P629, DOI 10.1042/0264-6021:3490629; Garofalo RS, 2002, TRENDS ENDOCRIN MET, V13, P156, DOI 10.1016/S1043-2760(01)00548-3; Gildea JJ, 2000, GENETICS, V156, P645; Guarente L, 2001, TRENDS GENET, V17, P391, DOI 10.1016/S0168-9525(01)02339-3; Holzenberger M, 2003, NATURE, V421, P182, DOI 10.1038/nature01298; Honda Y, 1999, FASEB J, V13, P1385, DOI 10.1096/fasebj.13.11.1385; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; Knauf F, 2002, P NATL ACAD SCI USA, V99, P14315, DOI 10.1073/pnas.222531899; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Lee RYN, 2001, CURR BIOL, V11, P1950, DOI 10.1016/S0960-9822(01)00595-4; Lee S. A., UNPUB; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; Nakai J, 2002, NAT GENET, V32, P245, DOI 10.1038/ng890; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Rogina B, 2000, SCIENCE, V290, P2137, DOI 10.1126/science.290.5499.2137; Simmer F, 2002, CURR BIOL, V12, P1317, DOI 10.1016/S0960-9822(02)01041-2; Tan PB, 1998, CELL, V93, P569, DOI 10.1016/S0092-8674(00)81186-1; Timmons L, 1998, NATURE, V395, P854, DOI 10.1038/27579; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; WADSWORTH WG, 1989, DEV BIOL, V132, P167, DOI 10.1016/0012-1606(89)90214-5; Wolkow CA, 2000, SCIENCE, V290, P147, DOI 10.1126/science.290.5489.147; Yu H, 2001, J MOL BIOL, V314, P1017, DOI 10.1006/jmbi.2000.5210	32	504	525	2	57	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 25	2003	300	5619					644	647		10.1126/science.1083614	http://dx.doi.org/10.1126/science.1083614			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	671FB	12690206				2022-12-28	WOS:000182453700043
J	van Geen, A; Zheng, Y; Stute, M; Ahmed, KM				van Geen, A; Zheng, Y; Stute, M; Ahmed, KM			Comment on "Arsenic mobility and groundwater extraction in Bangladesh" (II)	SCIENCE			English	Editorial Material									Columbia Univ, Lamont Doherty Earth Observ, Palisades, NY 10964 USA; CUNY Queens Coll, Flushing, NY 11367 USA; Columbia Univ Barnard Coll, New York, NY 10027 USA; Univ Dhaka, Dept Geol, Dhaka 1000, Bangladesh	Columbia University; City University of New York (CUNY) System; Queens College NY (CUNY); Columbia University; University of Dhaka	van Geen, A (corresponding author), Columbia Univ, Lamont Doherty Earth Observ, Palisades, NY 10964 USA.		yang, zheng/HGC-7753-2022	Ahmed, Kazi Matin/0000-0001-5188-4385; ZHENG, Yan/0000-0001-5256-9395	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES010349] Funding Source: NIH RePORTER; NIEHS NIH HHS [P42ES10349] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aggarwal P. K, 2000, BGD8016 IAEA TC; Harvey CF, 2002, SCIENCE, V298, P1602, DOI 10.1126/science.1076978; Kinniburgh D.G., 2000, ARSENIC CONTAMINATIO; LEVIN I, 1985, RADIOCARBON, V27, P1, DOI 10.1017/S0033822200006895; McArthur JM, 2001, WATER RESOUR RES, V37, P109, DOI 10.1029/2000WR900270; Nickson R, 1998, NATURE, V395, P338, DOI 10.1038/26387; STUTE M, 2001, GROUNDWATER CONTAMIN, P109; STUTE M, UNPUB; WEISS W, 1979, EVIDENCE PULSED DISC, P17; ZHENG Y, IN PRESS APPL GEOCHE	10	43	43	3	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 25	2003	300	5619					584C	584C		10.1126/science.1081057	http://dx.doi.org/10.1126/science.1081057			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	671FB	12714725				2022-12-28	WOS:000182453700019
J	Strasser, BJ				Strasser, BJ			Who cares about the double helix?	NATURE			English	Editorial Material									Univ Geneva, CMU, Inst Hist Med & Hlth, CH-1211 Geneva 4, Switzerland	University of Geneva	Strasser, BJ (corresponding author), Univ Geneva, CMU, Inst Hist Med & Hlth, CH-1211 Geneva 4, Switzerland.		Strasser, Bruno J/E-9337-2012	Strasser, Bruno J./0000-0002-2773-6670				Abir-Am P, 1985, Hist Sci, V23, P73; ABIRAM PG, 2000, COMMOMORATIVE PRACTI; ANKER S, 2003, IN PRESS MOL GAZE AR; Collins FS, 1998, SCIENCE, V282, P682, DOI 10.1126/science.282.5389.682; de Chadarevian S., 2002, DESIGNS LIFE MOL BIO; Harris T, 2001, TRENDS MOL MED, V7, P492, DOI 10.1016/S1471-4914(01)02170-0; KERNP M, 2003, NATURE, V421, P416; Miska D, 2003, NAT REV DRUG DISCOV, V2, P231, DOI 10.1038/nrd1036; Morange Michel, 1998, HIST MOL BIOL; Olby R, 2003, NATURE, V421, P402, DOI 10.1038/nature01397; Roberts L, 2001, SCIENCE, V291, P1182; Strasser BJ, 2002, AM J MED GENET, V115, P83, DOI 10.1002/ajmg.10542; WATSON JD, 1953, NATURE, V171, P737, DOI 10.1038/171737a0; Wood EJ, 2001, NAT REV MOL CELL BIO, V2, P217, DOI 10.1038/35056600; 2001, NATURE GENET, V27, P227	15	23	24	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 24	2003	422	6934					803	804		10.1038/422803a	http://dx.doi.org/10.1038/422803a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	670WR	12712169				2022-12-28	WOS:000182432600019
J	Friedberg, EC; Fischhaber, PL				Friedberg, EC; Fischhaber, PL			TB or not TB: How Mycobacterium tuberculosis may evade drug treatment	CELL			English	Editorial Material							DNA-POLYMERASES; IDENTIFICATION; REPLICATION		Univ Texas, SW Med Ctr, Dept Pathol, Lab Mol Pathol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Friedberg, EC (corresponding author), Univ Texas, SW Med Ctr, Dept Pathol, Lab Mol Pathol, Dallas, TX 75390 USA.							Boshoff HIM, 2003, CELL, V113, P183, DOI 10.1016/S0092-8674(03)00270-8; Dervyn E, 2001, SCIENCE, V294, P1716, DOI 10.1126/science.1066351; Friedberg EC, 2002, SCIENCE, V296, P1627, DOI 10.1126/science.1070236; Giraud A, 2001, SCIENCE, V291, P2606, DOI 10.1126/science.1056421; Goodman MF, 2002, ANNU REV BIOCHEM, V71, P17, DOI 10.1146/annurev.biochem.71.083101.124707; Inoue R, 2001, MOL GENET GENOMICS, V266, P564, DOI 10.1007/s004380100564; Mizrahi V, 2000, MOLECULAR GENETICS OF MYCOBACTERIA, P159; WELCH MM, 1982, J BACTERIOL, V152, P351	8	5	7	0	3	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 18	2003	113	2					139	140		10.1016/S0092-8674(03)00275-7	http://dx.doi.org/10.1016/S0092-8674(03)00275-7			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	672EP	12705860	Bronze			2022-12-28	WOS:000182508500001
J	Brandenburg, VM; Schubert, H				Brandenburg, VM; Schubert, H			Pulmonary alveolar microlithiasis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Univ Hosp, D-52057 Aachen, Germany	RWTH Aachen University; RWTH Aachen University Hospital	Brandenburg, VM (corresponding author), Univ Hosp, D-52057 Aachen, Germany.								0	4	5	0	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 17	2003	348	16					1555	1555		10.1056/NEJMicm020034	http://dx.doi.org/10.1056/NEJMicm020034			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	667TT	12700375				2022-12-28	WOS:000182248900006
J	Hayama, R; Yokoi, S; Tamaki, S; Yano, M; Shimamoto, K				Hayama, R; Yokoi, S; Tamaki, S; Yano, M; Shimamoto, K			Adaptation of photoperiodic control pathways produces short-day flowering in rice	NATURE			English	Article							CIRCADIAN CLOCK; ARABIDOPSIS; GENE; CONSTANS; TIME; FT; EXPRESSION; GIGANTEA; ORTHOLOG; ENCODES	The photoperiodic control of flowering is one of the important developmental processes of plants because it is directly related to successful reproduction(1). Although the molecular genetic analysis of Arabidopsis thaliana, a long-day (LD) plant, has provided models to explain the control of flowering time in this species(2-4), very little is known about its molecular mechanisms for short-day (SD) plants. Here we show how the photoperiodic control of flowering is regulated in rice, a SD plant. Overexpression of OsGI(5), an orthologue of the Arabidopsis GIGANTEA (GI) gene(6,7) in transgenic rice, caused late flowering under both SD and LD conditions. Expression of the rice orthologue(8) of the Arabidopsis CONSTANS (CO) gene(9) was increased in the transgenic rice, whereas expression of the rice orthologue(10) of FLOWERING LOCUS T (FT)(11,12) was suppressed. Our results indicate that three key regulatory genes for the photoperiodic control of flowering are conserved between Arabidopsis, a LD plant, and rice, a SD plant, but regulation of the FT gene by CO was reversed, resulting in the suppression of flowering in rice under LD conditions.	Nara Inst Sci & Technol, Plant Mol Genet Lab, Ikoma 6300101, Japan; Natl Inst Agrobiol Sci, Tsukuba, Ibaraki 3058602, Japan	Nara Institute of Science & Technology; National Institute of Agrobiological Sciences - Japan	Shimamoto, K (corresponding author), Nara Inst Sci & Technol, Plant Mol Genet Lab, 8916-5 Takayama, Ikoma 6300101, Japan.		Yano, Masahiro/AAC-5441-2019; Yokoi, Shuji/B-4102-2012; Yokoi, Shuji/L-3988-2019	Yokoi, Shuji/0000-0001-9358-1876; Yano, Masahiro/0000-0003-1510-4622				ARAKI T, 1993, PLANT J, V3, P231, DOI 10.1046/j.1365-313X.1993.t01-15-00999.x; CHRISTENSEN AH, 1992, PLANT MOL BIOL, V18, P675, DOI 10.1007/BF00020010; Fowler S, 1999, EMBO J, V18, P4679, DOI 10.1093/emboj/18.17.4679; Hayama R, 2002, PLANT CELL PHYSIOL, V43, P494, DOI 10.1093/pcp/pcf059; HIEI Y, 1994, PLANT J, V6, P271, DOI 10.1046/j.1365-313X.1994.6020271.x; Izawa T, 2000, PLANT J, V22, P391, DOI 10.1046/j.1365-313X.2000.00753.x; Izawa T, 2002, GENE DEV, V16, P2006, DOI 10.1101/gad.999202; Kardailsky I, 1999, SCIENCE, V286, P1962, DOI 10.1126/science.286.5446.1962; Kobayashi Y, 1999, SCIENCE, V286, P1960, DOI 10.1126/science.286.5446.1960; Kojima S, 2002, PLANT CELL PHYSIOL, V43, P1096, DOI 10.1093/pcp/pcf156; Koornneef M, 1998, ANNU REV PLANT PHYS, V49, P345, DOI 10.1146/annurev.arplant.49.1.345; Liu JY, 2001, PLANT PHYSIOL, V125, P1821, DOI 10.1104/pp.125.4.1821; Martinez-Garcia JF, 2002, P NATL ACAD SCI USA, V99, P15211, DOI 10.1073/pnas.222390599; Mouradov A, 2002, PLANT CELL, V14, pS111, DOI 10.1105/tpc.001362; Park DH, 1999, SCIENCE, V285, P1579, DOI 10.1126/science.285.5433.1579; PUTTERILL J, 1995, CELL, V80, P847, DOI 10.1016/0092-8674(95)90288-0; Samach A, 2000, SCIENCE, V288, P1613, DOI 10.1126/science.288.5471.1613; Simpson GG, 2002, SCIENCE, V296, P285, DOI 10.1126/science.296.5566.285; Suarez-Lopez P, 2001, NATURE, V410, P1116, DOI 10.1038/35074138; TANAKA A, 1990, NUCLEIC ACIDS RES, V18, P6767, DOI 10.1093/nar/18.23.6767; THOMAS B, 1998, PHOTOPERIODISM PLANT; Yano M, 2000, PLANT CELL, V12, P2473, DOI 10.1105/tpc.12.12.2473; Yanovsky MJ, 2002, NATURE, V419, P308, DOI 10.1038/nature00996	23	526	600	9	133	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 17	2003	422	6933					719	722		10.1038/nature01549	http://dx.doi.org/10.1038/nature01549			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	668CG	12700762				2022-12-28	WOS:000182272300041
J	Nelson, WJ				Nelson, WJ			Adaptation of core mechanisms to generate cell polarity	NATURE			English	Review							BUD-SITE SELECTION; YEAST SACCHAROMYCES-CEREVISIAE; CANINE KIDNEY-CELLS; PROTEIN-KINASE-C; FISSION YEAST; PLASMA-MEMBRANE; ACTIN CYTOSKELETON; EPITHELIAL-CELLS; CAENORHABDITIS-ELEGANS; ADHERENS JUNCTIONS	Cell polarity is defined as asymmetry in cell shape, protein distributions and cell functions. It is characteristic of single-cell organisms, including yeast and bacteria, and cells in tissues of multi-cell organisms such as epithelia in worms, flies and mammals. This diversity raises several questions: do different cell types use different mechanisms to generate polarity, how is polarity signalled, how do cells react to that signal, and how is structural polarity translated into specialized functions? Analysis of evolutionarily diverse cell types reveals that cell-surface landmarks adapt core pathways for cytoskeleton assembly and protein transport to generate cell polarity.	Stanford Univ, Beckman Ctr Mol & Genet Med, Sch Med, Dept Cellular & Mol Physiol, Stanford, CA 94305 USA	Stanford University	Nelson, WJ (corresponding author), Stanford Univ, Beckman Ctr Mol & Genet Med, Sch Med, Dept Cellular & Mol Physiol, Stanford, CA 94305 USA.				NIGMS NIH HHS [R01 GM035527] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035527] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; Amberg DC, 1997, MOL BIOL CELL, V8, P729, DOI 10.1091/mbc.8.4.729; AROETI B, 1993, J CELL BIOL, V123, P1149, DOI 10.1083/jcb.123.5.1149; Bagnat M, 2001, MOL BIOL CELL, V12, P4129, DOI 10.1091/mbc.12.12.4129; Balda MS, 2003, J CELL BIOL, V160, P423, DOI 10.1083/jcb.200210020; BARTLES JR, 1987, J CELL BIOL, V105, P1241, DOI 10.1083/jcb.105.3.1241; Beinhauer JD, 1997, J CELL BIOL, V139, P717, DOI 10.1083/jcb.139.3.717; BENDER A, 1989, P NATL ACAD SCI USA, V86, P9976, DOI 10.1073/pnas.86.24.9976; Bilder D, 2003, NAT CELL BIOL, V5, P53, DOI 10.1038/ncb897; Bilder D, 2000, NATURE, V403, P676, DOI 10.1038/35001108; Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; Bossinger O, 2001, DEV BIOL, V230, P29, DOI 10.1006/dbio.2000.0113; BRENNWALD P, 1994, CELL, V79, P245, DOI 10.1016/0092-8674(94)90194-5; Brunner D, 2000, CELL, V102, P695, DOI 10.1016/S0092-8674(00)00091-X; Carminati JL, 1997, J CELL BIOL, V138, P629, DOI 10.1083/jcb.138.3.629; Chang F, 2001, TRENDS GENET, V17, P273, DOI 10.1016/S0168-9525(01)02279-X; CHANT J, 1991, CELL, V65, P1203, DOI 10.1016/0092-8674(91)90015-Q; Chant T, 1999, ANNU REV CELL DEV BI, V15, P365, DOI 10.1146/annurev.cellbio.15.1.365; Cohen D, 2001, TRAFFIC, V2, P556, DOI 10.1034/j.1600-0854.2001.20805.x; Cox RT, 1996, J CELL BIOL, V134, P133, DOI 10.1083/jcb.134.1.133; Dimitratos SD, 1999, BIOESSAYS, V21, P912, DOI 10.1002/(SICI)1521-1878(199911)21:11<912::AID-BIES3>3.0.CO;2-Z; Dubreuil RR, 2000, J CELL BIOL, V149, P647, DOI 10.1083/jcb.149.3.647; Eby JJ, 1998, CURR BIOL, V8, P967, DOI 10.1016/S0960-9822(98)00398-4; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Evangelista M, 2002, NAT CELL BIOL, V4, P32, DOI 10.1038/ncb718; Evangelista M, 2000, J CELL BIOL, V148, P353, DOI 10.1083/jcb.148.2.353; Evangelista M, 1997, SCIENCE, V276, P118, DOI 10.1126/science.276.5309.118; Feierbach B, 2001, CURR BIOL, V11, P1656, DOI 10.1016/S0960-9822(01)00525-5; FOE VE, 1993, DEV DROSOPHILA MELAN, V1, P149; Fukata M, 2001, NAT REV MOL CELL BIO, V2, P887, DOI 10.1038/35103068; Gao L, 2002, CURR BIOL, V12, P221, DOI 10.1016/S0960-9822(01)00663-7; Glynn JM, 2001, CURR BIOL, V11, P836, DOI 10.1016/S0960-9822(01)00235-4; Grindstaff KK, 1998, CELL, V93, P731, DOI 10.1016/S0092-8674(00)81435-X; Hunter C, 2000, J CELL BIOL, V150, P391, DOI 10.1083/jcb.150.2.391; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; Hurd TW, 2003, NAT CELL BIOL, V5, P137, DOI 10.1038/ncb923; Imamura H, 1997, EMBO J, V16, P2745, DOI 10.1093/emboj/16.10.2745; Izumi Y, 1998, J CELL BIOL, V143, P95, DOI 10.1083/jcb.143.1.95; Joberty G, 2000, NAT CELL BIOL, V2, P531, DOI 10.1038/35019573; Kang PJ, 2001, SCIENCE, V292, P1376, DOI 10.1126/science.1060360; Karpova TS, 2000, MOL BIOL CELL, V11, P1727, DOI 10.1091/mbc.11.5.1727; Knust E, 2002, SCIENCE, V298, P1955, DOI 10.1126/science.1072161; Kohno H, 1996, EMBO J, V15, P6060, DOI 10.1002/j.1460-2075.1996.tb00994.x; Kreitzer G, 2000, NAT CELL BIOL, V2, P125, DOI 10.1038/35000081; Kreitzer G, 2003, NAT CELL BIOL, V5, P126, DOI 10.1038/ncb917; LAFONT F, 1994, NATURE, V372, P801; Lechler T, 2001, J CELL BIOL, V155, P261, DOI 10.1083/jcb.200104094; Lecuit T, 2000, J CELL BIOL, V150, P849, DOI 10.1083/jcb.150.4.849; Lecuit T, 2002, DEV CELL, V2, P425, DOI 10.1016/S1534-5807(02)00141-7; Lee WL, 2000, J CELL BIOL, V151, P789, DOI 10.1083/jcb.151.4.789; Legouis R, 2000, NAT CELL BIOL, V2, P415, DOI 10.1038/35017046; Lehman K, 1999, J CELL BIOL, V146, P125, DOI 10.1083/jcb.146.1.125; Liakopoulos D, 2003, CELL, V112, P561, DOI 10.1016/S0092-8674(03)00119-3; Ligon LA, 2001, NAT CELL BIOL, V3, P913, DOI 10.1038/ncb1001-913; Lin D, 2000, NAT CELL BIOL, V2, P540, DOI 10.1038/35019582; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; Low SH, 1996, MOL BIOL CELL, V7, P2007, DOI 10.1091/mbc.7.12.2007; Marston AL, 2001, CURR BIOL, V11, P803, DOI 10.1016/S0960-9822(01)00230-5; Mata J, 1997, CELL, V89, P939, DOI 10.1016/S0092-8674(00)80279-2; Medina E, 2002, J CELL BIOL, V158, P941, DOI 10.1083/jcb.200203080; Mohler PJ, 2002, J CELL SCI, V115, P1565; Mostov KE, 2000, CURR OPIN CELL BIOL, V12, P483, DOI 10.1016/S0955-0674(00)00120-4; MOSTOV KE, 1986, CELL, V46, P613, DOI 10.1016/0092-8674(86)90887-1; Muller HAJ, 1996, J CELL BIOL, V134, P149, DOI 10.1083/jcb.134.1.149; Musch A, 2002, MOL BIOL CELL, V13, P158, DOI 10.1091/mbc.01-10-0496; NELSON WJ, 1987, NATURE, V328, P533, DOI 10.1038/328533a0; Novick P, 2002, TRENDS CELL BIOL, V12, P247, DOI 10.1016/S0962-8924(02)02293-6; O'Brien LE, 2002, NAT REV MOL CELL BIO, V3, P531, DOI 10.1038/nrm859; Park HO, 1999, GENE DEV, V13, P1912, DOI 10.1101/gad.13.15.1912; Pelham RJ, 2001, NAT CELL BIOL, V3, P235, DOI 10.1038/35060020; Perez-Moreno M, 2003, CELL, V112, P535, DOI 10.1016/S0092-8674(03)00108-9; Petronczki M, 2001, NAT CELL BIOL, V3, P43, DOI 10.1038/35050550; Pfeffer S, 2003, CELL, V112, P507, DOI 10.1016/S0092-8674(03)00118-1; Pruyne D, 2002, SCIENCE, V297, P612, DOI 10.1126/science.1072309; Pruyne D, 2000, J CELL SCI, V113, P365; Pruyne D, 2000, J CELL SCI, V113, P571; Sagot I, 2002, NAT CELL BIOL, V4, P626, DOI 10.1038/ncb834; Sagot I, 2002, NAT CELL BIOL, V4, P42, DOI 10.1038/ncb719; Sawin KE, 1999, CURR BIOL, V9, P1335, DOI 10.1016/S0960-9822(00)80058-5; SCHEJTER ED, 1993, CELL, V75, P373, DOI 10.1016/0092-8674(93)80078-S; Schott D, 1999, J CELL BIOL, V147, P791, DOI 10.1083/jcb.147.4.791; Sheu YJ, 1998, MOL CELL BIOL, V18, P4053, DOI 10.1128/MCB.18.7.4053; Suzuki A, 2002, J CELL SCI, V115, P3565, DOI 10.1242/jcs.00032; Tanentzapf G, 2003, NAT CELL BIOL, V5, P46, DOI 10.1038/ncb896; Tepass U, 2001, ANNU REV GENET, V35, P747, DOI 10.1146/annurev.genet.35.102401.091415; TEPASS U, 1993, DEV BIOL, V159, P311, DOI 10.1006/dbio.1993.1243; TerBush DR, 1996, EMBO J, V15, P6483, DOI 10.1002/j.1460-2075.1996.tb01039.x; Tran PT, 2001, J CELL BIOL, V153, P397, DOI 10.1083/jcb.153.2.397; Tsukita S, 1999, CURR OPIN CELL BIOL, V11, P628, DOI 10.1016/S0955-0674(99)00016-2; VEGASALAS DE, 1987, J CELL BIOL, V104, P905, DOI 10.1083/jcb.104.4.905; WANG AZ, 1990, J CELL SCI, V95, P137; Wang HY, 2002, MOL BIOL CELL, V13, P515, DOI 10.1091/mbc.01-11-0542; Wedlich-Soldner R, 2003, SCIENCE, V299, P1231, DOI 10.1126/science.1080944; Wodarz A, 2000, J CELL BIOL, V150, P1361, DOI 10.1083/jcb.150.6.1361; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; Wu C, 1997, J BIOL CHEM, V272, P30623, DOI 10.1074/jbc.272.49.30623; Yeaman C, 1999, PHYSIOL REV, V79, P73, DOI 10.1152/physrev.1999.79.1.73; Yoshimori T, 1996, J CELL BIOL, V133, P247, DOI 10.1083/jcb.133.2.247; Zahner JE, 1996, MOL CELL BIOL, V16, P1857; ZHENG Y, 1995, J BIOL CHEM, V270, P626, DOI 10.1074/jbc.270.2.626	100	536	546	1	49	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 17	2003	422	6933					766	774		10.1038/nature01602	http://dx.doi.org/10.1038/nature01602			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	668CG	12700771	Green Accepted			2022-12-28	WOS:000182272300051
J	Duggen, S; Hoernle, K; van den Bogaard, P; Rupke, L; Morgan, JP				Duggen, S; Hoernle, K; van den Bogaard, P; Rupke, L; Morgan, JP			Deep roots of the Messinian salinity crisis	NATURE			English	Article							LATE MIOCENE; SUBDUCTION; EVOLUTION; MOROCCO; SEQUENCES; MANTLE; DELAMINATION; LITHOSPHERE; CHRONOLOGY; MAGMATISM	The Messinian salinity crisis-the desiccation of the Mediterranean Sea between 5.96 and 5.33 million years (Myr) ago(1)-was one of the most dramatic events on Earth during the Cenozoic era(2). It resulted from the closure of marine gateways between the Atlantic Ocean and the Mediterranean Sea, the causes of which remain enigmatic. Here we use the age and composition of volcanic rocks to reconstruct the geodynamic evolution of the westernmost Mediterranean from the Middle Miocene epoch to the Pleistocene epoch (about 12.1-0.65 Myr ago). Our data show that a marked shift in the geochemistry of mantle-derived volcanic rocks, reflecting a change from subduction-related to intraplate-type volcanism, occurred between 6.3 and 4.8 Myr ago, largely synchronous with the Messinian salinity crisis. Using a thermomechanical model, we show that westward roll back of subducted Tethys oceanic lithosphere and associated asthenospheric upwelling provides a plausible mechanism for producing the shift in magma chemistry and the necessary uplift (similar to1 km) along the African and Iberian continental margins to close the Miocene marine gateways, thereby causing the Messinian salinity crisis.	GEOMAR Res Ctr Marine Geosci, D-24148 Kiel, Germany	Helmholtz Association; GEOMAR Helmholtz Center for Ocean Research Kiel	Duggen, S (corresponding author), Univ London, Dept Geol, Egham TW20 0EX, Surrey, England.	s.duggen@gl.rhul.ac.uk	Ruepke, Lars/AAA-4099-2020; Zhang, Junyuan/P-9292-2018; Ruepke, Lars/B-8597-2015; Hoernle, Kaj/AAF-9500-2021	Ruepke, Lars/0000-0001-7025-4362; Ruepke, Lars/0000-0001-7025-4362; Morgan, Jason/0000-0002-3100-0877				ADAMS CG, 1977, NATURE, V269, P383, DOI 10.1038/269383a0; ALLEGRE CJ, 1981, EARTH PLANET SC LETT, V52, P85, DOI 10.1016/0012-821X(81)90210-7; Benito R, 1999, LITHOS, V46, P773, DOI 10.1016/S0024-4937(99)00003-1; Calvert A, 2000, J GEOPHYS RES-SOL EA, V105, P10871, DOI 10.1029/2000JB900024; COMAS M. C., 1999, P OCEAN DRILL PROGRA, V161, P555, DOI [DOI 10.2973/ODP.PROC.SR.161.262.1999, DOI 10.2973/ODP.PROC]; El Bakkali S, 1998, LITHOS, V45, P523, DOI 10.1016/S0024-4937(98)00048-6; ELLAM RM, 1989, J GEOPHYS RES-SOLID, V94, P4589, DOI 10.1029/JB094iB04p04589; ELLAM RM, 1988, B VOLCANOL, V50, P386, DOI 10.1007/BF01050638; Esteban Mateu, 1996, Concepts in Sedimentology and Paleontology, V5, P55; Garces M, 1998, EARTH PLANET SC LETT, V163, P69, DOI 10.1016/S0012-821X(98)00176-9; Girbacea R, 1998, GEOLOGY, V26, P611, DOI 10.1130/0091-7613(1998)026<0611:SITWPL>2.3.CO;2; Gutscher MA, 2002, GEOLOGY, V30, P1071, DOI 10.1130/0091-7613(2002)030<1071:EFASBG>2.0.CO;2; HODELL DA, 1986, NATURE, V320, P411, DOI 10.1038/320411a0; Hodell DA, 2001, PALEOCEANOGRAPHY, V16, P164, DOI 10.1029/1999PA000487; Hodell DA, 1989, PALEOCEANOGRAPHY, V4, P467, DOI 10.1029/PA004i004p00467; Hoernle K., 1999, P OCEAN DRILLING PRO, V161, P357, DOI [10.2973/odp.proc.sr.161.264.1999, DOI 10.2973/ODP.PROC.SR.181.273.1999, DOI 10.2973/ODP.PROC.SR.161.264.1999]; HOFMANN AW, 1988, EARTH PLANET SC LETT, V90, P297, DOI 10.1016/0012-821X(88)90132-X; Hsii K.J., 1978, INITIAL REPORTS DE 1, V42, P1053, DOI DOI 10.2973/DSDP.PROC.42-1.1978; HSU KJ, 1973, NATURE, V242, P240, DOI 10.1038/242240a0; JAMES DE, 1981, ANNU REV EARTH PL SC, V9, P311, DOI 10.1146/annurev.ea.09.050181.001523; KAY RW, 1993, TECTONOPHYSICS, V219, P177, DOI 10.1016/0040-1951(93)90295-U; Krijgsman W, 1999, NATURE, V400, P652, DOI 10.1038/23231; Krijgsman W, 1999, MAR GEOL, V153, P147, DOI 10.1016/S0025-3227(98)00084-X; Martinez-Ruiz F., 1999, P OCEAN DRILLING PRO, V161, P21; PLATT JP, 1989, GEOLOGY, V17, P540, DOI 10.1130/0091-7613(1989)017<0540:ECOTCL>2.3.CO;2; Roger S, 2000, EARTH PLANET SC LETT, V179, P101, DOI 10.1016/S0012-821X(00)00094-7; Rupke LH, 2002, GEOLOGY, V30, P1035, DOI 10.1130/0091-7613(2002)030<1035:ATRVIC>2.0.CO;2; TAYLOR HP, 1986, REV MINERAL, V16, P227; Taylor RN, 1998, EARTH PLANET SC LETT, V164, P79, DOI 10.1016/S0012-821X(98)00182-4; Turner SP, 1999, J PETROL, V40, P1011, DOI 10.1093/petrology/40.6.1011; WEIJERMARS R, 1988, TECTONOPHYSICS, V148, P211, DOI 10.1016/0040-1951(88)90129-1; ZHONG SJ, 1994, J GEOPHYS RES-SOL EA, V99, P15683, DOI 10.1029/94JB00809	32	438	443	0	125	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 10	2003	422	6932					602	606		10.1038/nature01553	http://dx.doi.org/10.1038/nature01553			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	665GN	12686997				2022-12-28	WOS:000182111400038
J	Nakata, T; Shimamoto, K				Nakata, T; Shimamoto, K			Cardiac denervation in amyloid polyneuropathy	LANCET			English	Editorial Material									Sapporo Med Univ, Sch Med, Grad Sch Med Cardiovasc & Renal Med, Sapporo, Hokkaido, Japan	Sapporo Medical University	Nakata, T (corresponding author), Sapporo Med Univ, Sch Med, Grad Sch Med Cardiovasc & Renal Med, Sapporo, Hokkaido, Japan.								0	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 5	2003	361	9364					1181	1181		10.1016/S0140-6736(03)12952-2	http://dx.doi.org/10.1016/S0140-6736(03)12952-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	664ZF	12686040	Bronze			2022-12-28	WOS:000182094600011
J	Dalton, R				Dalton, R			Arizona institute names leader	NATURE			English	News Item																			0	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 1	2003	423	6935					6	6		10.1038/423006c	http://dx.doi.org/10.1038/423006c			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	673CG	12721592	Bronze			2022-12-28	WOS:000182561600010
J	Jackson, LA; Neuzil, KM; Yu, OC; Benson, P; Barlow, WE; Adams, AL; Hanson, CA; Mahoney, LD; Shay, DK; Thompson, WW				Jackson, LA; Neuzil, KM; Yu, OC; Benson, P; Barlow, WE; Adams, AL; Hanson, CA; Mahoney, LD; Shay, DK; Thompson, WW		Vaccine Safety Datalink	Effectiveness of pneumococcal polysaccharide vaccine in older adults	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COMMUNITY-ACQUIRED PNEUMONIA; STREPTOCOCCUS-PNEUMONIAE; REQUIRING HOSPITALIZATION; ELDERLY PEOPLE; UNITED-STATES; EFFICACY; DISEASE; TRIAL; INFECTION; METAANALYSIS	BACKGROUND: Streptococcus pneumoniae is the chief cause of pneumonia in older adults, but it remains unclear whether use of the pneumococcal polysaccharide vaccine alters the overall risk of community-acquired pneumonia. In a large population of older adults, we assessed the effectiveness of the pneumococcal vaccine. METHODS: In this retrospective cohort study, 47,365 Group Health Cooperative members 65 years of age or older were assessed over a three-year period. The primary outcomes were hospitalization because of community-acquired pneumonia (validated by chart review), pneumonia in patients who were not hospitalized (``outpatient pneumonia,'' determined from administrative data sources), and pneumococcal bacteremia. The association between pneumococcal vaccination and the risk of each outcome was evaluated by means of multivariate Cox proportional-hazards models, with adjustment for age, sex, nursing-home residence or nonresidence, smoking status, medical conditions, and receipt or nonreceipt of influenza vaccine. RESULTS: During the study period, 1428 cohort members were hospitalized with community-acquired pneumonia, 3061 were assigned a diagnosis of outpatient pneumonia, and 61 had pneumococcal bacteremia. Receipt of the pneumococcal vaccine was associated with a significant reduction in the risk of pneumococcal bacteremia (hazard ratio, 0.56; 95 percent confidence interval, 0.33 to 0.93) but a slightly increased risk of hospitalization for pneumonia (hazard ratio, 1.14; 95 percent confidence interval, 1.02 to 1.28). Pneumococcal vaccination did not alter the risk of outpatient pneumonia (hazard ratio, 1.04; 95 percent confidence interval, 0.96 to 1.13) or of any case of community-acquired pneumonia, whether or not it required hospitalization (hazard ratio, 1.07; 95 percent confidence interval, 0.99 to 1.14). CONCLUSIONS: These findings support the effectiveness of the pneumococcal polysaccharide vaccine for the prevention of bacteremia, but they suggest that alternative strategies are needed to prevent nonbacteremic pneumonia, which is a more common manifestation of pneumococcal infection in elderly persons.	Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98101 USA; Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA USA; Univ Washington, Dept Biostat, Seattle, WA 98195 USA; Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA; Ctr Dis Control & Prevent, Natl Immunizat Program, Atlanta, GA USA	Group Health Cooperative; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; Centers for Disease Control & Prevention - USA	Jackson, LA (corresponding author), Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, 1730 Minor Ave,Suite 1600, Seattle, WA 98101 USA.			Shay, David/0000-0001-9619-4820				*ADM COMM IMM PRAC, 1997, MMWR-MORBID MORTAL W, V46, P1; BARTLETT JG, 1995, NEW ENGL J MED, V333, P1618, DOI 10.1056/NEJM199512143332408; Black SB, 2002, PEDIATR INFECT DIS J, V21, P810, DOI 10.1097/00006454-200209000-00005; Breiman RF, 2000, ARCH INTERN MED, V160, P2633, DOI 10.1001/archinte.160.17.2633; Briles DE, 2000, VACCINE, V18, P1707, DOI 10.1016/S0264-410X(99)00511-3; Briles DE, 2000, J INFECT DIS, V182, P1694, DOI 10.1086/317602; Centers for Disease Control and Prevention, 2000, ACT BACT COR SURV AB; Cornu C, 2001, VACCINE, V19, P4780, DOI 10.1016/S0264-410X(01)00217-1; DAVIS AL, 1987, CHEST, V92, P204, DOI 10.1378/chest.92.2.204; *DEP HLTH HUM SERV, 1980, DHHS PUBL PHS; Dworkin MS, 2001, CLIN INFECT DIS, V32, P794, DOI 10.1086/319218; Feikin DR, 2000, AM J PUBLIC HEALTH, V90, P223, DOI 10.2105/AJPH.90.2.223; FINE MJ, 1994, ARCH INTERN MED, V154, P2666, DOI 10.1001/archinte.1994.00420230051007; Fisher LD, 1999, ANNU REV PUBL HEALTH, V20, P145, DOI 10.1146/annurev.publhealth.20.1.145; French N, 2000, LANCET, V355, P2106, DOI 10.1016/S0140-6736(00)02377-1; GAILLAT J, 1985, REV EPIDEMIOL SANTE, V33, P437; Honkanen PO, 1999, VACCINE, V17, P2493, DOI 10.1016/S0264-410X(99)00069-9; HOYERT DL, 2001, NATL VITAL STAT REPO, V8; Kaplan V, 2002, AM J RESP CRIT CARE, V165, P766, DOI 10.1164/ajrccm.165.6.2103038; Koivula I, 1997, AM J MED, V103, P281, DOI 10.1016/S0002-9343(97)00149-6; MARRIE TJ, 1989, REV INFECT DIS, V11, P586; Marston BJ, 1997, ARCH INTERN MED, V157, P1709, DOI 10.1001/archinte.157.15.1709; McAfee Tim, 2002, Nicotine Tob Res, V4 Suppl 1, pS31; Moore R A, 2000, BMC Fam Pract, V1, P1, DOI 10.1186/1471-2296-1-1; Newcomer R, 1999, J AM GERIATR SOC, V47, P215, DOI 10.1111/j.1532-5415.1999.tb04580.x; Newschaffer CJ, 1997, J CLIN EPIDEMIOL, V50, P725, DOI 10.1016/S0895-4356(97)00050-4; Nichol KL, 1999, ARCH INTERN MED, V159, P2437, DOI 10.1001/archinte.159.20.2437; Ortqvist A, 1998, LANCET, V351, P399, DOI 10.1016/S0140-6736(97)07358-3; Ruiz-Gonzalez A, 1999, AM J MED, V106, P385, DOI 10.1016/S0002-9343(99)00050-9; SHAPIRO ED, 1991, NEW ENGL J MED, V325, P1453, DOI 10.1056/NEJM199111213252101; SIMBERKOFF MS, 1986, NEW ENGL J MED, V315, P1318, DOI 10.1056/NEJM198611203152104; Sisk JE, 1997, JAMA-J AM MED ASSOC, V278, P1333, DOI 10.1001/jama.278.16.1333; Sisk JE, 2000, JAMA-J AM MED ASSOC, V283, P341; Watson L, 2002, VACCINE, V20, P2166, DOI 10.1016/S0264-410X(02)00112-3; Whitney CG, 2000, NEW ENGL J MED, V343, P1917, DOI 10.1056/NEJM200012283432603; 1998, MMWR MORB MORTAL WKL, V47, P280; 2000, MMWR MORB MORTAL WKL, V49, P375; 2001, MMWR MORB MORTAL WKL, V50, P466; 1999, MMWR MORB MORTAL WKL, V48, P374	39	426	447	1	25	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 1	2003	348	18					1747	1755		10.1056/NEJMoa022678	http://dx.doi.org/10.1056/NEJMoa022678			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	672VK	12724480				2022-12-28	WOS:000182543500003
J	Burns, KH; Viveiros, MM; Ren, YS; Wang, P; DeMayo, FJ; Frail, DE; Eppig, JJ; Matzuk, MM				Burns, KH; Viveiros, MM; Ren, YS; Wang, P; DeMayo, FJ; Frail, DE; Eppig, JJ; Matzuk, MM			Roles of NPM2 in chromatin and nucleolar organization in oocytes and embryos	SCIENCE			English	Article							SPERM NUCLEI; EGG CYTOPLASM; NUCLEOPLASMIN; MOUSE; GENE; DECONDENSATION; SEQUENCE; NUCLEOPHOSMIN; ACQUISITION; EXPRESSION	Upon fertilization, remodeling of condensed maternal and paternal gamete DNA occurs to form the diploid genome. In Xenopus laevis, nucleoplasmin 2 (NPM2) decondenses sperm DNA in vitro. To study chromatin remodeling in vivo, we isolated mammalian NPM2 orthologs. Mouse NPM2 accumulates in oocyte nuclei and persists in preimplantation embryos. Npm2 knockout females have fertility defects owing to failed preimplantation embryo development. Although sperm DNA decondensation proceeds without NPM2, abnormalities are evident in oocyte and early embryonic nuclei. These defects include an absence of coalesced nucleolar structures and loss of heterochromatin and deacetylated histone H3 that normally circumscribe nucleoli in oocytes and early embryos, respectively. Thus, Npm2 is a maternal effect gene critical for nuclear and nucleolar organization and embryonic development.	Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Dept Human Mol Genet, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Jackson Lab, Bar Harbor, ME 04609 USA; Wyeth Ayerst Res, Collegeville, PA 19426 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Jackson Laboratory; Pfizer	Matzuk, MM (corresponding author), Baylor Coll Med, Dept Pathol, 1 Baylor Plaza, Houston, TX 77030 USA.	mmatzuk@bcm.tmc.edu	Burns, Kathleen/A-3360-2011; Viveiros, Maria/P-4120-2015; DeMayo, Francesco/C-6255-2019	DeMayo, Francesco/0000-0002-9480-7336; Wang, Pei/0000-0003-2373-7315	NICHD NIH HHS [HD33438, HD07495, HD21970, HD42500] Funding Source: Medline; NIGMS NIH HHS [T32GM07330] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD033438] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U01HD021970, R37HD033438, P30HD007495, R01HD042500, R37HD021970] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007330] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bouniol-Baly C, 1999, BIOL REPROD, V60, P580, DOI 10.1095/biolreprod60.3.580; BURGLIN TR, 1987, GENE DEV, V1, P97, DOI 10.1101/gad.1.1.97; CAPECCHI MR, 1994, SCI AM, V270, P52, DOI 10.1038/scientificamerican0394-52; CHAN WY, 1989, BIOCHEMISTRY-US, V28, P1033, DOI 10.1021/bi00429a017; Christians E, 2000, NATURE, V407, P693, DOI 10.1038/35037669; DILWORTH SM, 1987, CELL, V51, P1009, DOI 10.1016/0092-8674(87)90587-3; DINGWALL C, 1987, EMBO J, V6, P69, DOI 10.1002/j.1460-2075.1987.tb04720.x; Gillespie PJ, 2000, NUCLEIC ACIDS RES, V28, P472, DOI 10.1093/nar/28.2.472; Gurtu VE, 2002, GENETICS, V160, P271; Howell CY, 2001, CELL, V104, P829, DOI 10.1016/S0092-8674(01)00280-X; Hunt PA, 2002, SCIENCE, V296, P2181, DOI 10.1126/science.1071907; LATHAM KE, 1992, DEV BIOL, V149, P457, DOI 10.1016/0012-1606(92)90300-6; Ma J, 2001, BIOL REPROD, V64, P1713, DOI 10.1095/biolreprod64.6.1713; MacArthur CA, 1997, GENOMICS, V42, P137, DOI 10.1006/geno.1997.4353; Maeda Y, 1998, ZYGOTE, V6, P39, DOI 10.1017/S0967199400005062; MATTSON BA, 1990, MOL REPROD DEV, V25, P374, DOI 10.1002/mrd.1080250411; Matzuk MM, 2002, SCIENCE, V296, P2178, DOI 10.1126/science.1071965; Meric F, 1997, J BIOL CHEM, V272, P12840, DOI 10.1074/jbc.272.19.12840; OHSUMI K, 1991, DEV BIOL, V148, P295, DOI 10.1016/0012-1606(91)90338-4; PERREAULT SD, 1992, MUTAT RES, V296, P43, DOI 10.1016/0165-1110(92)90031-4; PHILPOTT A, 1991, CELL, V65, P569, DOI 10.1016/0092-8674(91)90089-H; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; SCHMIDTZACHMANN MS, 1988, CHROMOSOMA, V96, P417, DOI 10.1007/BF00303035; Tong ZB, 2000, NAT GENET, V26, P267, DOI 10.1038/81547; USUI N, 1976, J ULTRA MOL STRUCT R, V57, P276, DOI 10.1016/S0022-5320(76)80117-7; WICKRAMASINGHE D, 1991, DEV BIOL, V143, P162, DOI 10.1016/0012-1606(91)90063-9; Wu XM, 2003, NAT GENET, V33, P187, DOI 10.1038/ng1079; Zuccotti M, 1998, BIOL REPROD, V58, P700, DOI 10.1095/biolreprod58.3.700	28	277	291	1	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 25	2003	300	5619					633	636		10.1126/science.1081813	http://dx.doi.org/10.1126/science.1081813			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	671FB	12714744				2022-12-28	WOS:000182453700040
J	Steptoe, A; Perkins-Porras, L; McKay, C; Rink, E; Hilton, S; Cappuccio, FP				Steptoe, A; Perkins-Porras, L; McKay, C; Rink, E; Hilton, S; Cappuccio, FP			Behavioural counselling to increase consumption of fruit and vegetables in low income adults: randomised trial	BRITISH MEDICAL JOURNAL			English	Article							VITAMIN-C; INTERVENTIONS; DISEASE; WOMEN; MEN	Objective To measure the effect of brief behavioural counselling in general practice on patients' consumption of fruit and vegetables in adults from a low income population. Design Parallel group randomised controlled trial. Setting Primary health centre in a deprived, ethnically mixed inner city area. Participants 271 patients aged 18-70 years without serious illness. Intervention Brief individual behavioural counselling based on the stage of change model; time matched nutrition education counselling. Main outcome measures-Self reported number of portions of fruit and vegetables eaten per day, plasma beta carotene, alpha tocopherol, and ascorbic acid concentrations, and 24 hour urinary potassium excretion. Assessment at baseline, eight weeks, and 12 months. Results Consumption of fruit and vegetables increased from baseline to 12 months by 1.5 and 0.9 portions per day in the behavioural and nutrition groups (mean difference 0.6 portions, 95% confidence interval 0.1 to 1.1). The proportion of participants eating five or more portions a day increased by 42% and 27% in the two groups (mean difference 15%, 3% to 28%). Plasma beta carotene and alpha tocopherol concentrations increased in both groups, but the rise in beta carotene was greater in the behavioural group (mean difference 0.16 mumol/1,0.001 mumol/l to 1.34 mumol/l). There were no changes in plasma ascorbic acid concentrations or urinary potassium excretion. Differences were maintained when analysis was restricted to the 177 participants with incomes less than or equal to pound400 ((sic)596, $640) a week. Conclusions Brief individual counselling in primary care can elicit sustained increases in consumption of fruit and vegetables in low income adults in the general population.	UCL, Dept Epidemiol & Publ Hlth, London WC1E 6BT, England; St George Hosp, Sch Med, Dept Gen Practice & Primary Care, London SW17 0RE, England	University of London; University College London; St Georges University London	Steptoe, A (corresponding author), UCL, Dept Epidemiol & Publ Hlth, Mortimer St, London WC1E 6BT, England.	a.steptoe@ucl.ac.uk	Steptoe, Andrew/Y-2440-2019; Cappuccio, Francesco Paolo/ABF-1094-2020; Cappuccio, Francesco/D-3028-2009; Perkins-Porras, Linda/S-5220-2019	Cappuccio, Francesco Paolo/0000-0002-7842-5493; Perkins-Porras, Linda/0000-0001-9433-0235; Steptoe, Andrew/0000-0001-7808-4943				Ammerman AS, 2002, PREV MED, V35, P25, DOI 10.1006/pmed.2002.1028; Armstrong NC, 1997, FREE RADICAL RES, V27, P207, DOI 10.3109/10715769709097853; Bowen DJ, 2002, ANNU REV PUBL HEALTH, V23, P255, DOI 10.1146/annurev.publhealth.23.100901.140555; CAPPUCCIO FP, IN PRESS NUTR METAB; *COI COMM FOOD STA, 2001, CONS ATT FOOD STAND; *DEP HLTH, 5 A DAY PROGR; *DEP HLTH, 1999, SAV LIV HLTH NAT; Down D., 2000, FAMILY SPENDING REPO; John JH, 2002, LANCET, V359, P1969, DOI 10.1016/S0140-6736(02)98858-6; Khaw KT, 2001, LANCET, V357, P657, DOI 10.1016/S0140-6736(00)04128-3; *MIN AGR FOOD FISH, 2000, NAT FOOD SURV 1999; Ness AR, 1997, INT J EPIDEMIOL, V26, P1, DOI 10.1093/ije/26.1.1; Ness AR, 1999, INT J EPIDEMIOL, V28, P450, DOI 10.1093/ije/28.3.450; Prochaska JO, 1997, AM J HEALTH PROMOT, V12, P38, DOI 10.4278/0890-1171-12.1.38; ROE L, 1994, FAM PRACT, V11, P375, DOI 10.1093/fampra/11.4.375; Treasure T, 1998, BRIT MED J, V317, P362; *USDA, USA NUTR DAT STAND R; VUILLEUMIER JP, 1989, J MICRONUTR ANAL, V5, P25; Wardle J, 2000, APPETITE, V34, P269, DOI 10.1006/appe.1999.0311; *WORK GROUP DIET C, 1998, NUTR ASP DEV CANC, V48	20	109	115	0	10	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 19	2003	326	7394					855	858A		10.1136/bmj.326.7394.855	http://dx.doi.org/10.1136/bmj.326.7394.855			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	670BF	12702620	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000182386800020
J	Gaudet, F; Hodgson, JG; Eden, A; Jackson-Grusby, L; Dausman, J; Gray, JW; Leonhardt, H; Jaenisch, R				Gaudet, F; Hodgson, JG; Eden, A; Jackson-Grusby, L; Dausman, J; Gray, JW; Leonhardt, H; Jaenisch, R			Induction of tumors in mice by genomic hypomethylation	SCIENCE			English	Article							GERM-LINE; 5-METHYLCYTOSINE CONTENT; RETROVIRAL GENOMES; DNA METHYLATION; C-MYC; EXPRESSION; INSTABILITY; CANCER; TRANSMISSION; INTEGRATION	Genome-wide DNA hypomethylation occurs in many human cancers, but whether this epigenetic change is a cause or consequence of tumorigenesis has been unclear. To explore this phenomenon, we generated mice carrying a hypomorphic DNA methyltransferase 1 (Dnmt1) allele, which reduces Dnmt1 expression to 10% of wild-type levels and results in substantial genome-wide hypomethylation in all tissues. The mutant mice were runted at birth, and at 4 to 8 months of age they developed aggressive T cell lymphomas that displayed a high frequency of chromosome 15 trisomy. These results indicate that DNA hypomethylation plays a causal role in tumor formation, possibly by promoting chromosomal instability.	MIT, Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02142 USA; Univ Munich, Dept Biol 2, D-80336 Munich, Germany; Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany; Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94143 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); University of Munich; Helmholtz Association; Max Delbruck Center for Molecular Medicine; University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center	Jaenisch, R (corresponding author), MIT, Whitehead Inst Biomed Res, Cambridge, MA 02142 USA.	jaenisch@wi.mit.edu	jia, xu/A-8386-2016; Leonhardt, Heinrich/B-2791-2014		NCI NIH HHS [CA87869] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA087869] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Chen RZ, 1998, NATURE, V395, P89, DOI 10.1038/25779; Cory S, 1999, CANCER RES, V59, p1685S; Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557; Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; GAMASOSA MA, 1983, NUCLEIC ACIDS RES, V11, P6883, DOI 10.1093/nar/11.19.6883; Gaudet F, 1998, J BIOL CHEM, V273, P32725, DOI 10.1074/jbc.273.49.32725; GAUDET F, UNPUB; Hodgson G, 2001, NAT GENET, V29, P459, DOI 10.1038/ng771; Jackson-Grusby L, 2001, NAT GENET, V27, P31, DOI 10.1038/83730; JAENISCH R, 1976, P NATL ACAD SCI USA, V73, P1260, DOI 10.1073/pnas.73.4.1260; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; JAENISCH R, 1985, P NATL ACAD SCI USA, V82, P1451, DOI 10.1073/pnas.82.5.1451; JAHNER D, 1980, NATURE, V287, P456, DOI 10.1038/287456a0; JEANPIERRE M, 1993, HUM MOL GENET, V2, P731, DOI 10.1093/hmg/2.6.731; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Karpf AR, 2002, ONCOGENE, V21, P5496, DOI 10.1038/sj.onc.1205602; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; LAPEYRE JN, 1979, BIOCHEM BIOPH RES CO, V87, P698, DOI 10.1016/0006-291X(79)92015-1; Lei H, 1996, DEVELOPMENT, V122, P3195; Lengauer C, 1997, P NATL ACAD SCI USA, V94, P2545, DOI 10.1073/pnas.94.6.2545; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MACLEOD AR, 1995, J BIOL CHEM, V270, P8037, DOI 10.1074/jbc.270.14.8037; Muto M, 1996, JPN J CANCER RES, V87, P247, DOI 10.1111/j.1349-7006.1996.tb00213.x; Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6; SELTEN G, 1984, EMBO J, V3, P3215, DOI 10.1002/j.1460-2075.1984.tb02281.x; STEWART C, 1983, SCIENCE, V221, P760, DOI 10.1126/science.6683871; Trinh BN, 2002, MOL CELL BIOL, V22, P2906, DOI 10.1128/MCB.22.9.2906-2917.2002; Tucker KL, 1996, GENE DEV, V10, P1008, DOI 10.1101/gad.10.8.1008; WAINFAN E, 1992, CANCER RES, V52, pS2071; Walsh CP, 1998, NAT GENET, V20, P116, DOI 10.1038/2413; Whitehurst CE, 1999, IMMUNITY, V10, P313, DOI 10.1016/S1074-7613(00)80031-X; WIRSCHUBSKY Z, 1986, INT J CANCER, V38, P739, DOI 10.1002/ijc.2910380518; Xu GL, 1999, NATURE, V402, P187, DOI 10.1038/46052; ZAGONEL V, 1993, LEUKEMIA, V7, P30	35	1135	1195	1	68	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 18	2003	300	5618					489	492		10.1126/science.1083558	http://dx.doi.org/10.1126/science.1083558			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	668LR	12702876				2022-12-28	WOS:000182295900041
J	Kljuic, A; Bazzi, H; Sundberg, JP; Martinez-Mir, A; O'Shaughnessy, R; Mahoney, MG; Levy, M; Montagutelli, X; Ahmad, W; Alta, VM; Gordon, D; Uitto, J; Whiting, D; Ott, J; Fischer, S; Gilliam, TC; Jahoda, CAB; Morris, RJ; Panteleyev, AA; Nguyen, VT; Christiano, AM				Kljuic, A; Bazzi, H; Sundberg, JP; Martinez-Mir, A; O'Shaughnessy, R; Mahoney, MG; Levy, M; Montagutelli, X; Ahmad, W; Alta, VM; Gordon, D; Uitto, J; Whiting, D; Ott, J; Fischer, S; Gilliam, TC; Jahoda, CAB; Morris, RJ; Panteleyev, AA; Nguyen, VT; Christiano, AM			Desmoglein 4 in hair follicle differentiation and epidermal adhesion: Evidence from inherited hypotrichosis and acquired pemphigus vulgaris	CELL			English	Article							SUPRABASAL INTEGRIN EXPRESSION; PALMOPLANTAR KERATODERMA; DESMOSOMAL CADHERINS; CELL-ADHESION; GROWTH-FACTOR; WOOLLY HAIR; KERATINOCYTE; PHENOTYPE; MUTATION; DISEASE	Cell adhesion and communication are interdependent aspects of cell behavior that are critical for morphogenesis and tissue architecture. In the skin, epidermal adhesion is mediated in part by specialized cell-cell junctions known as desmosomes, which are characterized by the presence of desmosomal cadherins, known as desmogleins and desmocollins. We identified a cadherin family member, desmoglein 4, which is expressed in the suprabasal epidermis and hair follicle. The essential role of desmoglein 4 in skin was established by identifying mutations in families with inherited hypotrichosis, as well as in the lanceolate hair mouse. We also show that DSG4 is an autoantigen in pemphigus vulgaris. Characterization of the phenotype of naturally occurring mutant mice revealed disruption of desmosomal adhesion and perturbations in keratinocyte behavior. We provide evidence that desmoglein 4 is a key mediator of keratinocyte cell adhesion in the hair follicle, where it coordinates the transition from proliferation to differentiation.	Columbia Univ, Dept Genet & Dev, New York, NY 10032 USA; Columbia Univ, Dept Dermatol, New York, NY 10032 USA; Columbia Univ, Columbia Genome Ctr, New York, NY 10032 USA; Jackson Lab, Bar Harbor, ME 04609 USA; Thomas Jefferson Univ, Jefferson Med Coll, Dept Dermatol & Cutaneous Biol, Philadelphia, PA 19107 USA; Baylor Coll Med, Houston, TX 77030 USA; Inst Pasteur, Unite Genet Mammiferes, F-75724 Paris, France; Dallas associated Dermatologists, Dallas, TX 75246 USA; Rockefeller Univ, Lab Stat Genet, New York, NY 10021 USA; Univ Durham, Durham DH1 3LE, England; Univ Calif Davis, Dept Dermatol, Sacramento, CA 95817 USA	Columbia University; Columbia University; Columbia University; Jackson Laboratory; Jefferson University; Baylor College of Medicine; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Rockefeller University; Durham University; University of California System; University of California Davis	Christiano, AM (corresponding author), Columbia Univ, Dept Genet & Dev, New York, NY 10032 USA.		Bazzi, Hisham/AAA-6584-2021; Ahmad, Wasim/E-9713-2015; Mahoney, My/A-2716-2009; IBIS, NEUROGENETICA/P-2947-2015; Martinez-Mir, Amalia/K-7715-2018; Ahmad, Wasim/GSD-8904-2022; Panteleyev, Andrey A/R-9151-2016	Bazzi, Hisham/0000-0001-8388-4005; Martinez-Mir, Amalia/0000-0002-1628-8972; Panteleyev, Andrey A/0000-0002-8733-9183; O'Shaughnessy, Ryan/0000-0002-3701-0267; Jahoda, Colin/0000-0002-1762-1220; Nguyen, Vu/0000-0002-1142-6352	NCRR NIH HHS [K26-RR173] Funding Source: Medline; NIAMS NIH HHS [R03 AR47938, P01 AR38923] Funding Source: Medline; PHS HHS [R01-44924] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R03AR047938, P01AR038923] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ahmad W, 1998, SCIENCE, V279, P720, DOI 10.1126/science.279.5351.720; AUBER L., 1952, TRANS ROY SOC EDINBURGH, V62, P191; BULLOUGH W. S., 1958, BIOLOGY HAIR GROWTH, P171; BUXTON RS, 1993, J CELL BIOL, V121, P481, DOI 10.1083/jcb.121.3.481; CARROLL JM, 1995, CELL, V83, P957, DOI 10.1016/0092-8674(95)90211-2; Chidgey M, 2001, J CELL BIOL, V155, P821, DOI 10.1083/jcb.200105009; Eshkind L, 2002, EUR J CELL BIOL, V81, P592, DOI 10.1078/0171-9335-00278; Frank J, 1999, NATURE, V398, P473, DOI 10.1038/18997; Freedberg IM, 2001, J INVEST DERMATOL, V116, P633, DOI 10.1046/j.1523-1747.2001.01327.x; FRESHNEY RI, 1987, ANIMAL CELLS MANUAL; Frischmeyer PA, 1999, HUM MOL GENET, V8, P1893, DOI 10.1093/hmg/8.10.1893; Garrod DR, 2002, CURR OPIN CELL BIOL, V14, P537, DOI 10.1016/S0955-0674(02)00366-6; Green KJ, 2000, NAT REV MOL CELL BIO, V1, P208, DOI 10.1038/35043032; GRINNELL F, 1990, J TRAUMA, V30, pS144; HARDY MH, 1992, TRENDS GENET, V8, P55, DOI 10.1016/0168-9525(92)90350-D; HARLOW E, 1998, USING ANTIBODIES LAB; Hudson LG, 1998, MICROSC RES TECHNIQ, V43, P444, DOI 10.1002/(SICI)1097-0029(19981201)43:5<444::AID-JEMT10>3.0.CO;2-C; Hunt DM, 2001, EUR J HUM GENET, V9, P197, DOI 10.1038/sj.ejhg.5200605; Jamora C, 2002, NAT CELL BIOL, V4, pE101, DOI 10.1038/ncb0402-e101; JIANG CK, 1993, P NATL ACAD SCI USA, V90, P6786, DOI 10.1073/pnas.90.14.6786; Keith D, 1999, HUM MOL GENET, V8, P143, DOI 10.1093/hmg/8.1.143; Kljuic A, 2003, EXP DERMATOL, V12, P20, DOI 10.1034/j.1600-0625.2003.120103.x; KLJUIC A, IN PRESS EXP DERMATO; Koch PJ, 1997, J CELL BIOL, V137, P1091, DOI 10.1083/jcb.137.5.1091; Kulessa H, 2000, EMBO J, V19, P6664, DOI 10.1093/emboj/19.24.6664; Kurose K, 2000, J DERMATOL SCI, V24, P184, DOI 10.1016/S0923-1811(00)00100-6; Kurzen H, 1998, DIFFERENTIATION, V63, P295, DOI 10.1046/j.1432-0436.1998.6350295.x; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; McGrath JA, 1997, NAT GENET, V17, P240, DOI 10.1038/ng1097-240; McKoy G, 2000, LANCET, V355, P2119, DOI 10.1016/S0140-6736(00)02379-5; McMillan JR, 2001, J DERMATOL, V28, P291, DOI 10.1111/j.1346-8138.2001.tb00136.x; Mendelsohn C, 1999, DEVELOPMENT, V126, P1139; Montagutelli X, 1997, J INVEST DERMATOL, V109, P324, DOI 10.1111/1523-1747.ep12335844; Montagutelli X, 1996, J INVEST DERMATOL, V107, P20, DOI 10.1111/1523-1747.ep12297438; MORRIS RJ, 1994, CELL PROLIFERAT, V27, P279, DOI 10.1111/j.1365-2184.1994.tb01425.x; Nguyen VT, 2000, J CLIN INVEST, V106, P1467, DOI 10.1172/JCI10305; Norgett EE, 2000, HUM MOL GENET, V9, P2761, DOI 10.1093/hmg/9.18.2761; Orwin D F, 1979, Int Rev Cytol, V60, P331, DOI 10.1016/S0074-7696(08)61266-8; Paine-Saunders S, 2002, J BIOL CHEM, V277, P2089, DOI 10.1074/jbc.M109151200; Pulkkinen L, 2003, EXP DERMATOL, V12, P11, DOI 10.1034/j.1600-0625.2003.120102.x; Pulkkinen L, 2002, J INVEST DERMATOL, V119, P1237, DOI 10.1046/j.1523-1747.2002.19645.x; Rikimaru K, 1997, EXP DERMATOL, V6, P214, DOI 10.1111/j.1600-0625.1997.tb00165.x; ROTH SI, 1964, J ULTRA MOL STRUCT R, V11, P33, DOI 10.1016/S0022-5320(64)80091-5; Sambrook J., 2002, MOL CLONING LAB MANU; Sobel E, 1996, AM J HUM GENET, V58, P1323; Sundberg JP, 2000, EXP DERMATOL, V9, P206, DOI 10.1034/j.1600-0625.2000.009003206.x; Thompson JD, 1999, NUCLEIC ACIDS RES, V27, P2682, DOI 10.1093/nar/27.13.2682; Tong XM, 2003, TRENDS MOL MED, V9, P79, DOI 10.1016/S1471-4914(02)00025-4; VANSCOTT EJ, 1963, J INVEST DERMATOL, V41, P269, DOI 10.1038/jid.1963.110	49	243	253	0	9	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 18	2003	113	2					249	260		10.1016/S0092-8674(03)00273-3	http://dx.doi.org/10.1016/S0092-8674(03)00273-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	672EP	12705872	Bronze			2022-12-28	WOS:000182508500013
J	Adu, D; Cockwell, P; Ives, NJ; Shaw, J; Wheatly, K				Adu, D; Cockwell, P; Ives, NJ; Shaw, J; Wheatly, K			Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomised trials	BRITISH MEDICAL JOURNAL			English	Article							ACUTE CELLULAR REJECTION; PREVENT ACUTE REJECTION; ALLOGRAFT RECIPIENTS; DOUBLE-BLIND; BASILIXIMAB; DACLIZUMAB; REDUCTION; SURVIVAL; THERAPY; PLACEBO	Objective To study the effect of interleukin-2 receptor monoclonal antibodies on acute rejection episodes, graft loss, deaths, and rate of infection and malignancy in patients with renal transplants. Design Meta-analysis of published data. Data sources Medline, Embase, and Cochrane library for years 1996-2003 plus search of medical editors' trial amnesty and contact, with manufacturers of the antibodies. Selection of studies Randomised controlled trials comparing interleukin-2 receptor antibodies with placebo or no additional treatment in patients with renal transplants receiving ciclosporin based immunosuppression. Results Eight randomised controlled trials involving 1871 patients met the selection criteria (although only 1858 patients were analysed). Interleukin-2 receptor antibodies significantly reduced the risk of acute rejection (odds ratio 0.51, 95% confidence interval 0.42 to 0.63). There were no significant differences in the rate of graft loss (0.78, 0.58 to 1.04), mortality (0.75, 0.46 to 1.23), overall incidence of infections (0.97, 0.77 to 1.24), incidence of cytomegalovirus infections (0.81, 0.62 to 1.04), or risk of malignancies at one year (0.82, 0.39 to 1.70). The different antibodies had a similar sized effect on acute rejection (test for heterogeneity P=0.7): anti-Tac (0.37, 0.16 to 0.89), BT563 (0.37, 0.1 to 1.38), basiliximab (0.56, 0.44 to 0.72), and daclizumab (0.46, 0.32 to 0.67). The reduction in acute rejections was,similar for all ciclosporin based immunosuppression regimens (test for heterogeneity P=1.0). Conclusions Adding interleukin-2 receptor antibodies to ciclosporin based immunosuppression reduces episodes of acute rejection at six months by 49%. There is no evidence of an increased risk of infective complications. Longer follow up studies are needed to confirm whether interleukin-2 receptor antibodies improve long term graft and patient survival.	Queen Elizabeth Hosp, Dept Nephrol, Birmingham B15 2TH, W Midlands, England; Birmingham Clin Trials Unit, Birmingham B15 2RR, W Midlands, England	University of Birmingham; University of Birmingham	Adu, D (corresponding author), Queen Elizabeth Hosp, Dept Nephrol, Birmingham B15 2TH, W Midlands, England.			Cockwell, Paul/0000-0003-1975-266X; Ives, Natalie/0000-0002-1664-7541				Early Breast Cancer Trialists' Collaborative Group, 1990, TREATM EARL BREAST C; Hariharan S, 2000, NEW ENGL J MED, V342, P605, DOI 10.1056/NEJM200003023420901; Jamil B, 1999, TRANSPLANTATION, V68, P1597, DOI 10.1097/00007890-199911270-00027; Kahan BD, 1999, TRANSPLANTATION, V67, P276, DOI 10.1097/00007890-199901270-00016; KAMEL O, 2001, AM J TRANSPLANT S1, V1, P353; KIRKMAN RL, 1991, TRANSPLANTATION, V51, P107, DOI 10.1097/00007890-199101000-00016; Knoll GA, 1999, BRIT MED J, V318, P1104, DOI 10.1136/bmj.318.7191.1104; Lawen JG, 2003, TRANSPLANTATION, V75, P37, DOI 10.1097/00007890-200301150-00007; MATAS AJ, 1994, TRANSPLANTATION, V57, P857, DOI 10.1097/00007890-199403270-00015; MORGAN DA, 1976, SCIENCE, V193, P1007, DOI 10.1126/science.181845; Nashan B, 1997, LANCET, V350, P1193, DOI 10.1016/S0140-6736(97)09278-7; Nashan B, 1999, TRANSPLANTATION, V67, P110, DOI 10.1097/00007890-199901150-00019; Ponticelli C, 2001, TRANSPLANTATION, V72, P1261, DOI 10.1097/00007890-200110150-00014; ROBB R, 1984, J EXP MED, V162, P358; VANGELDER T, 1995, TRANSPLANTATION, V60, P248; Vincenti F, 1998, NEW ENGL J MED, V338, P161, DOI 10.1056/NEJM199801153380304	16	98	103	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 12	2003	326	7393					789	791		10.1136/bmj.326.7393.789	http://dx.doi.org/10.1136/bmj.326.7393.789			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	670BE	12689974	Green Published, Bronze			2022-12-28	WOS:000182386700016
J	Alberio, R; Campbell, KHS				Alberio, R; Campbell, KHS			Epigenetics and nuclear transfer	LANCET			English	Editorial Material							CLONED MICE; SOMATIC-CELLS		Univ Nottingham, Sch Biosci, Loughborough LE12 5RD, Leics, England	University of Nottingham	Campbell, KHS (corresponding author), Univ Nottingham, Sch Biosci, Loughborough LE12 5RD, Leics, England.		Alberio, Ramiro/G-5955-2011	Alberio, Ramiro/0000-0001-6560-3919				Alberio R., 2003, Theriogenology, V59, P318; Bordignon V, 2001, DEV BIOL, V233, P192, DOI 10.1006/dbio.2001.0215; Chavatte-Palmer P, 2002, BIOL REPROD, V66, P1596, DOI 10.1095/biolreprod66.6.1596; Humpherys D, 2001, SCIENCE, V293, P95, DOI 10.1126/science.1061402; Humphreys D, 2002, P NATL ACAD SCI USA, V99, P12889, DOI 10.1073/pnas.192433399; Lai LX, 2002, SCIENCE, V295, P1089, DOI 10.1126/science.1068228; Lanza RP, 2001, SCIENCE, V294, P1893, DOI 10.1126/science.1063440; Ogonuki N, 2002, NAT GENET, V30, P253, DOI 10.1038/ng841; Ogura A, 2003, THERIOGENOLOGY, V59, P87, DOI 10.1016/S0093-691X(02)01276-1; Tamashiro KLK, 2002, NAT MED, V8, P262, DOI 10.1038/nm0302-262	10	9	9	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 12	2003	361	9365					1239	1240		10.1016/S0140-6736(03)13029-2	http://dx.doi.org/10.1016/S0140-6736(03)13029-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	666DM	12699948				2022-12-28	WOS:000182161600005
J	Navarro, A; Barton, NH				Navarro, A; Barton, NH			Chromosomal speciation and molecular divergence - Accelerated evolution in rearranged chromosomes	SCIENCE			English	Article							UPPER MIOCENE; GENES; RECOMBINATION; SELECTION; HISTORY; HOMINID; HUMANS; RATES	Humans and their closest evolutionary relatives, the chimpanzees, differ in similar to1.24% of their genomic DNA sequences. The fraction of these changes accumulated during the speciation processes that have separated the two lineages may be of special relevance in understanding the basis of their differences. We analyzed human and chimpanzee sequence data to search for the patterns of divergence and polymorphism predicted by a theoretical model of speciation. According to the model, positively selected changes should accumulate in chromosomes that present. fixed structural differences, such as inversions, between the two species. Protein evolution was more than 2.2 times faster in chromosomes that had undergone structural rearrangements compared with colinear chromosomes. Also, nucleotide variability is slightly lower in rearranged chromosomes. These patterns of divergence and polymorphism may be, at least in part, the molecular footprint of speciation events in the human and chimpanzee lineages.	Univ Pompeu Fabra, Dept Ciencies Expt & Salut, Barcelona 08003, Catalonia, Spain; Univ Edinburgh, Inst Cell Anim & Populat Biol, Edinburgh EH9 3JT, Midlothian, Scotland	Pompeu Fabra University; University of Edinburgh	Navarro, A (corresponding author), Univ Pompeu Fabra, Dept Ciencies Expt & Salut, Doctor Aiguader 80, Barcelona 08003, Catalonia, Spain.	arcadi.navarro@cexs.upf.es	Navarro, Arcadi/F-1592-2011	Navarro, Arcadi/0000-0003-2162-8246				Andolfatto P, 2001, GENET RES, V77, P1, DOI 10.1017/S0016672301004955; Bernardi G, 2000, GENE, V241, P3, DOI 10.1016/S0378-1119(99)00485-0; Brunet M, 2002, NATURE, V418, P145, DOI 10.1038/nature00879; Castresana J, 2002, NUCLEIC ACIDS RES, V30, P1751, DOI 10.1093/nar/30.8.1751; Chen FC, 2001, AM J HUM GENET, V68, P444, DOI 10.1086/318206; Consigliere S, 1996, CHROMOSOME RES, V4, P264, DOI 10.1007/BF02263675; Ebersberger I, 2002, AM J HUM GENET, V70, P1490, DOI 10.1086/340787; EYREWALKER A, 1993, P ROY SOC B-BIOL SCI, V252, P237, DOI 10.1098/rspb.1993.0071; FITCH WM, 1971, BIOCHEM GENET, V5, P231, DOI 10.1007/BF00485794; Haig D, 1999, PHILOS T R SOC B, V354, P1447, DOI 10.1098/rstb.1999.0490; Hudson R.R., 1990, Oxford Surveys in Evolutionary Biology, V7, P1; JANCZEWSKI DN, 1990, J HERED, V81, P375; Johnson T, 2002, GENETICS, V162, P395; Kimura M., 1983, NEUTRAL THEORY MOL E; KING M, 1993, SPECIES EVOLUTION; Kong A, 2002, NAT GENET, V31, P241, DOI 10.1038/ng917; Lercher MJ, 2001, MOL BIOL EVOL, V18, P2032, DOI 10.1093/oxfordjournals.molbev.a003744; LI WH, 1993, J MOL EVOL, V36, P96, DOI 10.1007/BF02407308; Lopez P, 2002, MOL BIOL EVOL, V19, P1; Machado CA, 2002, MOL BIOL EVOL, V19, P472, DOI 10.1093/oxfordjournals.molbev.a004103; Navarro A, 2003, EVOLUTION, V57, P447, DOI 10.1554/0014-3820(2003)057[0447:APIGIP]2.0.CO;2; Noor MAF, 2001, P NATL ACAD SCI USA, V98, P12084, DOI 10.1073/pnas.221274498; Orr HA, 1996, GENETICS, V144, P1331; Ortiz-Barrientos D, 2002, GENETICA, V116, P167, DOI 10.1023/A:1021296829109; Przeworski M, 2000, TRENDS GENET, V16, P296, DOI 10.1016/S0168-9525(00)02030-8; Rieseberg LH, 2001, TRENDS ECOL EVOL, V16, P351, DOI 10.1016/S0169-5347(01)02187-5; Rozas J, 1999, BIOINFORMATICS, V15, P174, DOI 10.1093/bioinformatics/15.2.174; Spirito F, 1998, ENDLESS FORMS, P320; Stephens JC, 2001, SCIENCE, V293, P489, DOI 10.1126/science.1059431; Van Doorn GS, 2001, P ROY SOC B-BIOL SCI, V268, P2155, DOI 10.1098/rspb.2001.1780; Vieira J, 2001, GENETICS, V158, P279; Vignaud P, 2002, NATURE, V418, P152, DOI 10.1038/nature00880; Wallis M, 2001, J MOL EVOL, V53, P10, DOI 10.1007/s002390010187; Williams EJB, 2000, NATURE, V407, P900, DOI 10.1038/35038066; Williams EJB, 2002, MOL BIOL EVOL, V19, P1395, DOI 10.1093/oxfordjournals.molbev.a004202; Xia X, 2001, J HERED, V92, P371, DOI 10.1093/jhered/92.4.371; YANG Z, 2002, PHYLOGENETIC ANAL MA; Yi SJ, 2002, MOL BIOL EVOL, V19, P2191, DOI 10.1093/oxfordjournals.molbev.a004043; YUNIS JJ, 1982, SCIENCE, V215, P1525, DOI 10.1126/science.7063861	39	304	314	2	51	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 11	2003	300	5617					321	324		10.1126/science.1080600	http://dx.doi.org/10.1126/science.1080600			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	665RQ	12690198	Green Submitted			2022-12-28	WOS:000182135400055
J	Savolainen, C; Hovi, T				Savolainen, C; Hovi, T			Caveat: poliovirus may be hiding under other labels	LANCET			English	Editorial Material									Natl Publ Hlth Inst, Dept Microbiol, WHO Collaborating Ctr Poliovirus Reference & Res, Enterovirus Lab, SF-00300 Helsinki, Finland	Finland National Institute for Health & Welfare	Savolainen, C (corresponding author), Natl Publ Hlth Inst, Dept Microbiol, WHO Collaborating Ctr Poliovirus Reference & Res, Enterovirus Lab, Mannerheimintie 166, SF-00300 Helsinki, Finland.							Dove AW, 1997, SCIENCE, V277, P779, DOI 10.1126/science.277.5327.779; Minor PD, 2001, LANCET, V358, P166, DOI 10.1016/S0140-6736(01)05399-5; *WHO OMS, POL ER; YOON JW, 1979, NEW ENGL J MED, V300, P1173, DOI 10.1056/NEJM197905243002102; 2002, WHO GLOBAL ACTION PL	5	11	13	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 5	2003	361	9364					1145	1146		10.1016/S0140-6736(03)12965-0	http://dx.doi.org/10.1016/S0140-6736(03)12965-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	664ZF	12686032				2022-12-28	WOS:000182094600003
J	De Sandre-Giovannoli, A; Bernard, R; Cau, P; Navarro, C; Amiel, J; Boccaccio, I; Lyonnet, S; Stewart, CL; Munnich, A; Le Merrer, M; Levy, N				De Sandre-Giovannoli, A; Bernard, R; Cau, P; Navarro, C; Amiel, J; Boccaccio, I; Lyonnet, S; Stewart, CL; Munnich, A; Le Merrer, M; Levy, N			Lamin A truncation in Hutchinson-Gilford progeria	SCIENCE			English	Article							DISEASE		Fac Med Timone, INSERM, U491, Marseille, France; Hop La Timone, Dept Med Genet, Marseille, France; Hop Necker Enfants Malad, INSERM, U393, Paris, France; Hop Conception, Biol Cellulaire Lab, Marseille, France; NCI, Can & Dev Biol Lab, Frederick, MD 21702 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Levy, N (corresponding author), Fac Med Timone, INSERM, U491, Marseille, France.		De Sandre-Giovannoli, Annachiara/AAJ-6992-2020; amiel, jeanne/AGX-1124-2022; Cau, Pierre/M-3541-2016; LEVY, Nicolas/J-1632-2014; amiel, jeanne/H-3501-2017; De Sandre-Giovannoli, Annachiara/L-5759-2016; Lyonnet, Stanislas/H-5483-2017; Navarro, Claire/V-8774-2017	De Sandre-Giovannoli, Annachiara/0000-0002-2324-2462; LEVY, Nicolas/0000-0001-5171-6365; amiel, jeanne/0000-0001-5973-4728; De Sandre-Giovannoli, Annachiara/0000-0002-2324-2462; Lyonnet, Stanislas/0000-0001-5426-9417; Navarro, Claire/0000-0001-9490-2643	NATIONAL CANCER INSTITUTE [Z01BC010377] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Burke B, 2002, NAT REV MOL CELL BIO, V3, P575, DOI 10.1038/nrm879; Novelli G, 2002, AM J HUM GENET, V71, P426, DOI 10.1086/341908; Worman HJ, 2002, TRENDS CELL BIOL, V12, P591, DOI 10.1016/S0962-8924(02)02401-7	3	1004	1042	2	97	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 27	2003	300	5628					2055	2055		10.1126/science.1084125	http://dx.doi.org/10.1126/science.1084125			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	694KZ	12702809				2022-12-28	WOS:000183774900035
J	Lee, N; Hui, D; Wu, A; Chan, P; Cameron, P; Joynt, GM; Ahuja, A; Yung, MY; Leung, CB; To, KF; Lui, SF; Szeto, CC; Chung, S; Sung, JJY				Lee, N; Hui, D; Wu, A; Chan, P; Cameron, P; Joynt, GM; Ahuja, A; Yung, MY; Leung, CB; To, KF; Lui, SF; Szeto, CC; Chung, S; Sung, JJY			A major outbreak of severe acute respiratory syndrome in Hong Kong	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							OBLITERANS ORGANIZING PNEUMONIA; BRONCHIOLITIS	BACKGROUND There has been an outbreak of the severe acute respiratory syndrome (SARS) worldwide. We report the clinical, laboratory, and radiologic features of 138 cases of suspected SARS during a hospital outbreak in Hong Kong. METHODS From March 11 to 25, 2003, all patients with suspected SARS after exposure to an index patient or ward were admitted to the isolation wards of the Prince of Wales Hospital. Their demographic, clinical, laboratory, and radiologic characteristics were analyzed. Clinical end points included the need for intensive care and death. Univariate and multivariate analyses were performed. RESULTS There were 66 male patients and 72 female patients in this cohort, 69 of whom were health care workers. The most common symptoms included fever (in 100 percent of the patients); chills, rigors, or both (73.2 percent); and myalgia (60.9 percent). Cough and headache were also reported in more than 50 percent of the patients. Other common findings were lymphopenia (in 69.6 percent), thrombocytopenia (44.8 percent), and elevated lactate dehydrogenase and creatine kinase levels (71.0 percent and 32.1 percent, respectively). Peripheral air-space consolidation was commonly observed on thoracic computed tomographic scanning. A total of 32 patients (23.2 percent) were admitted to the intensive care unit; 5 patients died, all of whom had coexisting conditions. In a multivariate analysis, the independent predictors of an adverse outcome were advanced age (odds ratio per decade of life, 1.80; 95 percent confidence interval, 1.16 to 2.81; P=0.009), a high peak lactate dehydrogenase level (odds ratio per 100 U per liter, 2.09; 95 percent confidence interval, 1.28 to 3.42; P=0.003), and an absolute neutrophil count that exceeded the upper limit of the normal range on presentation (odds ratio, 1.60; 95 percent confidence interval, 1.03 to 2.50; P=0.04). CONCLUSIONS SARS is a serious respiratory illness that led to significant morbidity and mortality in our cohort.	Chinese Univ Hong Kong, Dept Med & Therapeut, Hong Kong, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Dept Emergency Med, Hong Kong, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Dept Anesthesia & Intens Care, Hong Kong, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Dept Diagnost Radiol & Organ Imaging, Hong Kong, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Dept Surg, Hong Kong, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Dept Anat & Cellular Pathol, Hong Kong, Hong Kong, Peoples R China	Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong	Sung, JJY (corresponding author), Prince Wales Hosp, Dept Med & Therapeut, Shatin, Hong Kong, Peoples R China.		Chan, Paul KS/J-9360-2013; Ahuja, Anil T/H-4031-2017; Szeto, Cheuk Chun/N-4954-2015; Joynt, Gavin M/C-7606-2009; Sung, Joseph J. Y./R-3203-2018; Hui, David Shu-Cheong/O-2754-2015; Lee, Nelson/B-6418-2008	Chan, Paul KS/0000-0002-6360-4608; Ahuja, Anil T/0000-0002-0726-5402; Szeto, Cheuk Chun/0000-0002-8898-8505; Joynt, Gavin M/0000-0002-5823-3435; Sung, Joseph J. Y./0000-0003-3125-5199; Hui, David Shu-Cheong/0000-0003-4382-2445; Lee, Nelson/0000-0002-0783-6607; Cameron, Peter/0000-0002-1443-557X				Bartlett John G., 2000, Clinical Infectious Diseases, V31, P347, DOI 10.1086/313954; *CDCP, UPD INT DOM INF CONT; Centers for Disease Control and Prevention, SEV AC RESP SYNDR SA; Epler GR, 2001, ARCH INTERN MED, V161, P158, DOI 10.1001/archinte.161.2.158; MULLER NL, 1990, AM J ROENTGENOL, V154, P983; Niederman MS, 2001, AM J RESP CRIT CARE, V163, P1730, DOI 10.1164/ajrccm.163.7.at1010; *WHO, 2003, CUM NUMB REP CAS SAR; 2003, MMWR MORB MORTAL WKL, V52, P255; 2003, MMWR MORB MORTAL WKL, V52, P241	9	1570	1828	1	134	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 15	2003	348	20					1986	1994		10.1056/NEJMoa030685	http://dx.doi.org/10.1056/NEJMoa030685			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	677TJ	12682352	Bronze			2022-12-28	WOS:000182823400007
J	Wormser, GP; Ramanathan, R; Nowakowski, J; McKenna, D; Holmgren, D; Visintainer, P; Dornbush, R; Singh, B; Nadelman, RB				Wormser, GP; Ramanathan, R; Nowakowski, J; McKenna, D; Holmgren, D; Visintainer, P; Dornbush, R; Singh, B; Nadelman, RB			Duration of antibiotic therapy for early Lyme disease - A randomized, double-blind, placebo-controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							ERYTHEMA MIGRANS; BORRELIA-BURGDORFERI; CEFUROXIME AXETIL; DOXYCYCLINE; INFECTION	Background: Treatment of patients with early Lyme disease has trended toward longer duration despite the absence of supporting clinical trials. Objective: To evaluate different durations of oral doxycycline treatment and the combination of oral doxycycline and a single intravenous dose of ceftriaxone for treatment of patients with early Lyme disease. Design: Randomized, double-blind, placebo-controlled trial. Setting: Single-center university hospital. Patients: 180 patients with erythema migrans. Intervention: Ten days of oral doxycycline, with or without a single intravenous dose of ceftriaxone, or 20 days of oral doxycycline. Measurements: Outcome was based on clinical observations and neurocognitive testing. Efficacy was assessed at 20 days, 3 months, 12 months, and 30 months. Results: At all time points, the complete response rate was similar for the three treatment groups in both on-study and intention-to-treat analyses. In the on-study analysis, the complete response rate at 30 months was 83.9% in the 20-day doxycycline group, 90.3% in the 10-day doxycycline group, and 86.5% in the doxycycline-ceftriaxone group (P > 0.2). The only patient with treatment failure (10-day doxycycline group) developed meningitis on day 18. There were no significant differences in the results of neurocognitive testing among the three treatment groups and a separate control group without Lyme disease. Diarrhea occurred significantly more often in the doxycycline-ceftriaxone group (35%) than in either of the other two groups (P < 0.001). Conclusions: Extending treatment with doxycycline from 10 to 20 days or adding one dose of ceftriaxone to the beginning of a 10-day course of doxycycline did not enhance therapeutic efficacy in patients with erythema migrans. Regardless of regimen, objective evidence of treatment failure was extremely rare.	New York Med Coll, Div Infect Dis, Valhalla, NY 10595 USA	New York Medical College	Wormser, GP (corresponding author), New York Med Coll, Div Infect Dis, Room 245,Munger Pavil, Valhalla, NY 10595 USA.		Ahluwalia, Brij/E-4614-2013	Visintainer, Paul/0000-0002-2491-1242	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041508] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01-AR41508] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Beck A., 1993, BECK DEPRESSION INVE; BUTLER T, 1978, J INFECT DIS, V137, P573, DOI 10.1093/infdis/137.5.573; Centers for Disease Control and Prevention (CDC), 2001, MMWR Morb Mortal Wkly Rep, V50, P800; Dattwyler RJ, 1997, NEW ENGL J MED, V337, P289, DOI 10.1056/NEJM199707313370501; DEFILIPPIS WA, 1979, BOOKLET CATEGORY TES; Delis DC., 2000, CALIFORNIA VERBAL LE; Derogatis LR.., 1992, SCL 90 R ADM SCORING; FEKETY FR, 1990, AM J MED, V88, pS38, DOI 10.1016/0002-9343(90)90326-9; Fleiss J. L., 1981, STAT METHODS RATES P, V2; Goodglass H., 1983, BOSTON NAMING TEST; Heaton RK, 1991, COMPREHENSIVE NORMS; Klempner MS, 2001, NEW ENGL J MED, V345, P85, DOI 10.1056/NEJM200107123450202; Luft BJ, 1996, ANN INTERN MED, V124, P785, DOI 10.7326/0003-4819-124-9-199605010-00002; LUFT BJ, 1992, JAMA-J AM MED ASSOC, V267, P1364, DOI 10.1001/jama.267.10.1364; LUGER SW, 1995, ANTIMICROB AGENTS CH, V39, P661, DOI 10.1128/AAC.39.3.661; NADELMAN RB, 1992, ANN INTERN MED, V117, P273, DOI 10.7326/0003-4819-117-4-273; NOWAKOWSKI J, 1995, J AM ACAD DERMATOL, V32, P223, DOI 10.1016/0190-9622(95)90130-2; Smith A., 1982, SYMBOL DIGIT MODALIT; STEERE AC, 1983, ANN INTERN MED, V99, P22, DOI 10.7326/0003-4819-99-1-22; STEERE AC, 2000, MANDELL DOUGLAS BENN, P2504; Strle F, 1999, ANN INTERN MED, V130, P32, DOI 10.7326/0003-4819-130-1-199901050-00006; Wechsler D, 1974, WECHSLER MEMORY SCAL; Wechsler D., 2008, WECHSLER ADULT INTEL, P257; Wormser GP, 1999, J INFECT DIS, V180, P720, DOI 10.1086/314922; WORMSER GP, 1995, MT SINAI J MED, V62, P188; 2001, MMWR MORB MORTAL WKL, V50, P181; 1997, MMWR MORB MO SRR10, V46, P20	27	167	173	0	18	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 6	2003	138	9					697	704		10.7326/0003-4819-138-9-200305060-00005	http://dx.doi.org/10.7326/0003-4819-138-9-200305060-00005			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	674XA	12729423				2022-12-28	WOS:000182661400001
J	Crespo, M; Bosch, F; Villamor, N; Bellosillo, B; Colomer, D; Rozman, M; Marce, S; Lopez-Guillermo, A; Campo, E; Montserrat, E				Crespo, M; Bosch, F; Villamor, N; Bellosillo, B; Colomer, D; Rozman, M; Marce, S; Lopez-Guillermo, A; Campo, E; Montserrat, E			ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							70-KDA TYROSINE PHOSPHOPROTEIN; V-H GENES; CD38 EXPRESSION; GENOMIC ABERRATIONS; ZETA-CHAIN; B-CELLS; REPERTOIRE; PHENOTYPE; PATHOGENESIS; SURVIVAL	BACKGROUND: The mutational status of immunoglobulin heavy-chain variable-region (IgV(sub H)) genes in the leukemic cells of chronic lymphocytic leukemia (CLL) is an important prognostic factor in the disease. We investigated whether the expression of ZAP-70 by CLL cells correlated with the IgV(sub H) mutational status, disease progression, and survival. METHODS: The expression of ZAP-70 was analyzed in T-cell and B-cell lines and in peripheral-blood samples from 56 patients with CLL with the use of flow cytometry, Western blotting, and immunohistochemistry. The results were correlated with the IgV(sub H) mutational status and clinical outcome. RESULTS: ZAP-70 was detected by flow-cytometric analysis in cells of T-cell lineage and in leukemic cells from 32 of 56 patients with CLL. In all patients in whom at least 20 percent of the leukemic cells were positive for ZAP-70, IgV(sub H) was unmutated, whereas IgV(sub H) mutations were found in 21 of 24 patients in whom less than 20 percent of the leukemic cells were positive for ZAP-70 (P<0.001). Concordant results were obtained when ZAP-70 expression was assessed by immunohistochemistry or Western blotting. The level of ZAP-70 expression did not change over time (median, 37 months) in sequential samples from 30 patients with CLL. Patients with Binet stage A CLL who had at least 20 percent ZAP-70-positive leukemic cells had more rapid progression and poorer survival than those with less than 20 percent ZAP-70-positive cells. CONCLUSIONS: Among patients with CLL, expression of ZAP-70, as detected by flow-cytometric analysis, correlated with IgV(sub H) mutational status, disease progression, and survival.	Hosp Clin Barcelona, Inst Invest Biomed August Pi & Sunyer, Dept Hematol, E-08036 Barcelona, Spain; Hosp Clin Barcelona, Inst Invest Biomed August Pi & Sunyer, Hematopathol Unit, E-08036 Barcelona, Spain	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Bosch, F (corresponding author), Hosp Clin Barcelona, Inst Invest Biomed August Pi & Sunyer, Dept Hematol, Villarroel 170, E-08036 Barcelona, Spain.	fbosch@clinic.ub.es	COLOMER, DOLORS/ABG-6894-2020; MARCE, Silvia/J-6651-2017; Campo, Elias/AAC-5593-2019; Bosch, Francesc/AAE-7052-2019	MARCE, Silvia/0000-0001-9128-6822; Campo, Elias/0000-0001-9850-9793; Bosch, Francesc/0000-0001-9241-2886; Crespo, Marta/0000-0002-7732-7808; Rozman, Maria/0000-0002-2641-1110; COLOMER, DOLORS/0000-0001-7486-8484				Bellosillo B, 2002, BLOOD, V100, P1810, DOI 10.1182/blood-2001-12-0327; BINET JL, 1981, CANCER-AM CANCER SOC, V48, P198, DOI 10.1002/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V; Caligaris-Cappio F, 1999, J CLIN ONCOL, V17, P399, DOI 10.1200/JCO.1999.17.1.399; CAMPBELL MJ, 1992, MOL IMMUNOL, V29, P193, DOI 10.1016/0161-5890(92)90100-C; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; Chen LG, 2002, BLOOD, V100, P4609, DOI 10.1182/blood-2002-06-1683; COOK GP, 1995, IMMUNOL TODAY, V16, P237, DOI 10.1016/0167-5699(95)80166-9; Damle RN, 1999, BLOOD, V94, P1840, DOI 10.1182/blood.V94.6.1840; DEANE M, 1990, EUR J IMMUNOL, V20, P2209, DOI 10.1002/eji.1830201009; Del Poeta G, 2001, BLOOD, V98, P2633, DOI 10.1182/blood.V98.9.2633; Dohner H, 2000, NEW ENGL J MED, V343, P1910, DOI 10.1056/NEJM200012283432602; Fais F, 1998, J CLIN INVEST, V102, P1515, DOI 10.1172/JCI3009; Hamblin BJ, 2000, BLOOD, V95, P2455, DOI 10.1182/blood.V95.7.2455.007a43c_2455_2457; Hamblin TJ, 1999, BLOOD, V94, P1848, DOI 10.1182/blood.V94.6.1848; Ibrahim S, 2001, BLOOD, V98, P181, DOI 10.1182/blood.V98.1.181; ISAKOV N, 1995, J EXP MED, V181, P375, DOI 10.1084/jem.181.1.375; Klein U, 2001, J EXP MED, V194, P1625, DOI 10.1084/jem.194.11.1625; Latour S, 2001, CURR OPIN IMMUNOL, V13, P299, DOI 10.1016/S0952-7915(00)00219-3; Lin K, 2002, BLOOD, V100, P1404, DOI 10.1182/blood-2001-11-0066; Lin K, 2002, BLOOD, V100, P2291; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Montserrat Emili, 2002, Hematol J, V3, P7; Muller-Hermelink, 2001, PATHOLOGY GENETICS T, P168; Oscier DG, 2002, BLOOD, V100, P1177, DOI 10.1182/blood.V100.4.1177.h81602001177_1177_1184; Oscier DG, 1997, BLOOD, V89, P4153, DOI 10.1182/blood.V89.11.4153; RAI KR, 1975, BLOOD, V46, P219, DOI 10.1182/blood.V46.2.219.219; Rajewsky K, 1996, NATURE, V381, P751, DOI 10.1038/381751a0; Rosenwald A, 2001, J EXP MED, V194, P1639, DOI 10.1084/jem.194.11.1639; ROZMAN C, 1995, NEW ENGL J MED, V333, P1515; SCHROEDER HW, 1994, IMMUNOL TODAY, V15, P288, DOI 10.1016/0167-5699(94)90009-4; *SPSS, 1999, SPSS ADV STAT VERS 1; Stilgenbauer S, 2002, LEUKEMIA, V16, P993, DOI 10.1038/sj.leu.2402537; VIVIER E, 1993, EUR J IMMUNOL, V23, P1872, DOI 10.1002/eji.1830230821; ZWEIG MH, 1993, CLIN CHEM, V39, P1589	35	1019	1067	0	31	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 1	2003	348	18					1764	1775		10.1056/NEJMoa023143	http://dx.doi.org/10.1056/NEJMoa023143			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	672VK	12724482				2022-12-28	WOS:000182543500005
J	Hirotsune, S; Yoshida, N; Chen, A; Garrett, L; Sugiyama, F; Takahashi, S; Yagami, K; Wynshaw-Boris, A; Yoshiki, A				Hirotsune, S; Yoshida, N; Chen, A; Garrett, L; Sugiyama, F; Takahashi, S; Yagami, K; Wynshaw-Boris, A; Yoshiki, A			An expressed pseudogene regulates the messenger-RNA stability of its homologous coding gene	NATURE			English	Article								A pseudogene is a gene copy that does not produce a functional, full-length protein(1). The human genome is estimated to contain up to 20,000 pseudogenes(2,3). Although much effort has been devoted to understanding the function of pseudogenes, their biological roles remain largely unknown. Here we report the role of an expressed pseudogene-regulation of messenger-RNA stability-in a transgene-insertion mouse mutant exhibiting polycystic kidneys and bone deformity. The transgene was integrated into the vicinity of the expressing pseudogene of Makorin1, called Makorin1-p1. This insertion reduced transcription of Makorin1-p1, resulting in destabilization of Makorin1 mRNA in trans by way of a cis-acting RNA decay element within the 5' region of Makorin1 that is homologous between Makorin1 and Makorin1-p1. Either Makorin1 or Makorin1-p1 transgenes could rescue these phenotypes. Our findings demonstrate a specific regulatory role of an expressed pseudogene, and point to the functional significance of non-coding RNAs.	Saitama Med Sch, Res Ctr Genom Med, Div Neurosci, Hidaka, Saitama 3501241, Japan; Japan Sci & Technol Corp, PRESTO, Kawaguchi, Saitama, Japan; NHGRI, Genet Dis Res Branch, NIH, Bethesda, MD 20892 USA; Univ Tsukuba, Inst Basic Med Sci, Tsukuba, Ibaraki 3058575, Japan; Univ Tsukuba, Lab Anim Resource Ctr, Tsukuba, Ibaraki 3058575, Japan; Univ Calif San Diego, Sch Med, Ctr Canc, Dept Pediat, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Ctr Canc, Dept Med, La Jolla, CA 92093 USA; RIKEN Tsukuba Inst, Bioresource Ctr, Dept Biol Syst, Expt Anim Div, Tsukuba, Ibaraki 3050074, Japan	Saitama Medical University; Japan Science & Technology Agency (JST); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University of Tsukuba; University of Tsukuba; University of California System; University of California San Diego; University of California System; University of California San Diego; RIKEN	Hirotsune, S (corresponding author), Saitama Med Sch, Res Ctr Genom Med, Div Neurosci, Yamane 1397-1, Hidaka, Saitama 3501241, Japan.		Yoshiki, Atsushi/O-6162-2019	Yoshiki, Atsushi/0000-0002-9450-5151				Goncalves I, 2000, GENOME RES, V10, P672, DOI 10.1101/gr.10.5.672; GRAY TA, 2000, GENOMICS, V25, P14430; Greally JM, 1999, P NATL ACAD SCI USA, V96, P14430, DOI 10.1073/pnas.96.25.14430; Harrison PM, 2002, GENOME RES, V12, P272, DOI 10.1101/gr.207102; Mighell AJ, 2000, FEBS LETT, V468, P109, DOI 10.1016/S0014-5793(00)01199-6; Nagai Y, 1998, J BONE MINER RES, V13, P664, DOI 10.1359/jbmr.1998.13.4.664; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; VANIN EF, 1985, ANNU REV GENET, V19, P253, DOI 10.1146/annurev.genet.19.1.253	8	320	354	1	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 1	2003	423	6935					91	96		10.1038/nature01535	http://dx.doi.org/10.1038/nature01535			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	673CG	12721631				2022-12-28	WOS:000182561600045
J	Schulze, DJ; Harte, B; Valley, JW; Brenan, JM; Channer, DMD				Schulze, DJ; Harte, B; Valley, JW; Brenan, JM; Channer, DMD			Extreme crustal oxygen isotope signatures preserved in coesite in diamond	NATURE			English	Article							HYDROTHERMAL ALTERATION; OCEANIC-CRUST; FLUID-FLOW; ECLOGITES; INCLUSIONS; OPHIOLITE; GEOCHEMISTRY; KIMBERLITES; VENEZUELA; PRESSURE	The anomalously high and low oxygen isotope values observed in eclogite xenoliths from the upper mantle beneath cratons have been interpreted as indicating that the parent rock of the eclogites experienced alteration on the ancient sea floor(1). Recognition of this genetic lineage has provided the foundation for a model of the evolution of the continents whereby imbricated slabs of oceanic lithosphere underpin and promote stabilization of early cratons(2). Early crustal growth is thought to have been enhanced by the addition of slab-derived magmas, leaving an eclogite residuum in the upper mantle beneath the cratons(3). But the oxygen isotope anomalies observed in eclogite xenoliths are small relative to those in altered ocean-floor basalt and intermediate-stage subduction-zone eclogites, and this has hindered acceptance of the hypothesis that the eclogite xenoliths represent subducted and metamorphosed ocean-floor basalts. We present here the oxygen isotope composition of eclogitic mineral inclusions, analysed in situ in diamonds using an ion microprobe/ secondary ion mass spectrometer. The oxygen isotope values of coesite (a polymorph of SiO2) inclusions are substantially higher than previously reported for xenoliths from the subcratonic mantle, but are typical of subduction-zone meta-basalts, and accordingly provide strong support for the link between altered ocean-floor basalts and mantle eclogite xenoliths.	Univ Toronto, Erindale Coll, Dept Geol, Mississauga, ON L5L 1C6, Canada; Univ Edinburgh, Dept Geol & Geophys, Edinburgh EH9 3JW, Midlothian, Scotland; Univ Wisconsin, Dept Geol & Geophys, Madison, WI 53706 USA; Univ Toronto, Dept Geol, Toronto, ON M5S 3B1, Canada; Guaniamo Min Co, Ctr Mohedano, Caracas 1060, Venezuela	University of Toronto; University Toronto Mississauga; University of Edinburgh; University of Wisconsin System; University of Wisconsin Madison; University of Toronto	Schulze, DJ (corresponding author), Univ Toronto, Erindale Coll, Dept Geol, Mississauga, ON L5L 1C6, Canada.		Facility, Edinburgh Ion Microprobe/AAD-8512-2020; Valley, John W./B-3466-2011	Facility, Edinburgh Ion Microprobe/0000-0001-6248-6657; Valley, John W./0000-0003-3530-2722				Cartigny P, 1999, P 7 INT KIMB C CAP T, P117; CLAYTON RN, 1975, GEOCHIM COSMOCHIM AC, V39, P1197, DOI 10.1016/0016-7037(75)90062-9; COCKER JD, 1982, EARTH PLANET SC LETT, V61, P112, DOI 10.1016/0012-821X(82)90043-7; DEINES P, 1991, GEOCHIM COSMOCHIM AC, V55, P515, DOI 10.1016/0016-7037(91)90009-T; Eiler JM, 1997, CHEM GEOL, V138, P221, DOI 10.1016/S0009-2541(97)00015-6; Farquhar J, 2002, SCIENCE, V298, P2369, DOI 10.1126/science.1078617; GARLICK GD, 1971, SCIENCE, V172, P1025, DOI 10.1126/science.172.3987.1025; GURNEY JJ, 1989, KIMBERLITES RELATED, V2, P935; Haggerty SE, 1999, SCIENCE, V285, P851, DOI 10.1126/science.285.5429.851; HELMSTAEDT H, 1989, KIMBERLITES RELATED, V1, P358; ITO E, 1987, CHEM GEOL, V62, P157, DOI 10.1016/0009-2541(87)90083-0; JACOB D, 1994, GEOCHIM COSMOCHIM AC, V58, P5191, DOI 10.1016/0016-7037(94)90304-2; JAGOUTZ E, 1984, LUNAR PLANET SCI, V15, P395; Kaminsky FV, 2000, CAN MINERAL, V38, P1347, DOI 10.2113/gscanmin.38.6.1347; Leech ML, 2000, LITHOS, V52, P235, DOI 10.1016/S0024-4937(99)00093-6; Lowry D, 1999, GEOCHIM COSMOCHIM AC, V63, P1825, DOI 10.1016/S0016-7037(99)00120-9; MACGREGOR ID, 1986, J GEOPHYS RES-SOLID, V91, P14063, DOI 10.1029/JB091iB14p14063; Mattey D. P, 1994, MINERAL MAG A, P573; Miller JA, 2001, CHEM GEOL, V178, P43, DOI 10.1016/S0009-2541(00)00428-9; MUEHLENBACHS K, 1980, INITIAL REPORTS DE 2, V51, P1159; PEARSON DG, 1991, EARTH PLANET SC LETT, V102, P289, DOI 10.1016/0012-821X(91)90024-C; Rollinson H, 1997, NATURE, V389, P173, DOI 10.1038/38266; SCHIFFMAN P, 1984, EARTH PLANET SC LETT, V70, P207, DOI 10.1016/0012-821X(84)90006-2; SHARP ZD, 1992, CONTRIB MINERAL PETR, V112, P358, DOI 10.1007/BF00310466; Sobolev NV, 1998, GEOLOGY, V26, P971, DOI 10.1130/0091-7613(1998)026<0971:UUMBGG>2.3.CO;2; Spicuzza MJ, 1998, CHEM GEOL, V144, P195, DOI 10.1016/S0009-2541(97)00131-9; STAUDIGEL H, 1981, CONTRIB MINERAL PETR, V77, P150, DOI 10.1007/BF00636518; VALLEY JW, 1986, REV MINERAL, V16, P445; Valley JW, 1996, CONTRIB MINERAL PETR, V124, P225, DOI 10.1007/s004100050188; VALLEY JW, IN PRESS GEOCHIM COS; [No title captured]	31	88	93	0	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 1	2003	423	6935					68	70		10.1038/nature01615	http://dx.doi.org/10.1038/nature01615			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	673CG	12721625				2022-12-28	WOS:000182561600039
J	Hubbell, JA				Hubbell, JA			Enhancing drug function	SCIENCE			English	Editorial Material							COPOLYMER MICELLES; DELIVERY; TRANSDUCTION; CELLS; GENE		Swiss Fed Inst Technol, Inst Biomed Engn, CH-8044 Zurich, Switzerland; Swiss Fed Inst Technol, Dept Mat Sci, CH-8044 Zurich, Switzerland; Univ Zurich, CH-8044 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Zurich	Hubbell, JA (corresponding author), Swiss Fed Inst Technol, Inst Biomed Engn, Moussonstr 18, CH-8044 Zurich, Switzerland.		Hubbell, Jeffrey A/A-9266-2008	Hubbell, Jeffrey A/0000-0003-0276-5456				BADER H, 1984, ANGEW MAKROMOL CHEM, V123, P457, DOI 10.1002/apmc.1984.051230121; Discher DE, 2002, SCIENCE, V297, P967, DOI 10.1126/science.1074972; Jensen KD, 2003, J CONTROL RELEASE, V87, P89, DOI 10.1016/S0168-3659(02)00352-8; Kabanov AV, 2003, ADV DRUG DELIVER REV, V55, P151, DOI 10.1016/S0169-409X(02)00176-X; Kakizawa Y, 2002, ADV DRUG DELIVER REV, V54, P203, DOI 10.1016/S0169-409X(02)00017-0; Liu JQ, 2001, BIOMACROMOLECULES, V2, P362, DOI 10.1021/bm015515c; Luo LB, 2002, BIOCONJUGATE CHEM, V13, P1259, DOI 10.1021/bc025524y; MATSUMURA Y, 1986, CANCER RES, V46, P6387; Otsuka H, 2003, ADV DRUG DELIVER REV, V55, P403, DOI 10.1016/S0169-409X(02)00226-0; Rapoport N, 2002, J PHARM SCI, V91, P157, DOI 10.1002/jps.10006; Savic R, 2003, SCIENCE, V300, P615, DOI 10.1126/science.1078192; Schwarze SR, 2000, TRENDS CELL BIOL, V10, P290, DOI 10.1016/S0962-8924(00)01771-2; Wagner E, 1999, ADV DRUG DELIVER REV, V38, P279, DOI 10.1016/S0169-409X(99)00033-2; Zastre J, 2002, EUR J PHARM BIOPHARM, V54, P299, DOI 10.1016/S0939-6411(02)00119-4; Zuber G, 2001, ADV DRUG DELIVER REV, V52, P245, DOI 10.1016/S0169-409X(01)00213-7	15	162	167	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 25	2003	300	5619					595	596		10.1126/science.1083625	http://dx.doi.org/10.1126/science.1083625			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	671FB	12714733				2022-12-28	WOS:000182453700029
J	Mead, S; Stumpf, MPH; Whitfield, J; Beck, JA; Poulter, M; Campbell, T; Uphill, JB; Goldstein, D; Alpers, M; Fisher, EMC; Collinge, J				Mead, S; Stumpf, MPH; Whitfield, J; Beck, JA; Poulter, M; Campbell, T; Uphill, JB; Goldstein, D; Alpers, M; Fisher, EMC; Collinge, J			Balancing selection at the prion protein gene consistent with prehistoric kurulike epidemics	SCIENCE			English	Article							CREUTZFELDT-JAKOB-DISEASE; LINKAGE DISEQUILIBRIUM; VARIANT; POLYMORPHISM; CANNIBALISM; GENOTYPE; SCRAPIE; FRANCE; PRNP	Kuru is an acquired prion disease largely restricted to the Fore linguistic group of the Papua New Guinea Highlands, which was transmitted during endocannibalistic feasts. Heterozygosity for a common polymorphism in the human prion protein gene (PRNP) confers relative resistance to prion diseases. Elderly survivors of the kuru epidemic, who had multiple exposures at mortuary feasts, are, in marked contrast to younger unexposed Fore, predominantly PRNP 129 heterozygotes. Kuru imposed strong balancing selection on the Fore, essentially eliminating PRNP 129 homozygotes. Worldwide PRNP haplotype diversity and coding allele frequencies suggest that strong balancing selection at this locus occurred during the evolution of modern humans.	Univ Coll, Inst Neurol, MRC, Prion Unit, London WC1N 3BG, England; Univ Coll, Inst Neurol, Dept Neurodegenerat Dis, London WC1N 3BG, England; UCL, Dept Biol, Galton Lab, London WC1E 6BT, England; Inst Med Res, Goroka, EHP, Papua N Guinea; Curtin Univ Technol, Perth, WA 6001, Australia	University of London; University College London; University of London; University College London; University of London; University College London; PNG Institute Of Medical Research; Curtin University	Collinge, J (corresponding author), Univ Coll, Inst Neurol, MRC, Prion Unit, Queen Sq, London WC1N 3BG, England.	j.collinge@prion.ucl.ac.uk	Fisher, Elizabeth MC/C-2168-2008; Mead, Simon/E-9414-2011	Fisher, Elizabeth MC/0000-0003-2850-9936; Mead, Simon/0000-0002-4326-1468				ALPERS M, 1971, Proceedings of the Australian Association of Neurologists, V8, P7; Berr C, 1998, NEUROLOGY, V51, P734, DOI 10.1212/WNL.51.3.734; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; Cervenakova L, 1998, P NATL ACAD SCI USA, V95, P13239, DOI 10.1073/pnas.95.22.13239; COLLINGE J, 1991, LANCET, V337, P1441, DOI 10.1016/0140-6736(91)93128-V; Collinge J, 1996, LANCET, V348, P56, DOI 10.1016/S0140-6736(05)64378-4; Combarros O, 2000, NEUROLOGY, V55, P593, DOI 10.1212/WNL.55.4.593; d'Aignaux JH, 1999, NEUROLOGY, V53, P1197, DOI 10.1212/WNL.53.6.1197; Defleur A, 1999, SCIENCE, V286, P128, DOI 10.1126/science.286.5437.128; DICKINSON AG, 1975, NATURE, V256, P732, DOI 10.1038/256732a0; GAJDUSEK DC, 1966, NATURE, V209, P794, DOI 10.1038/209794a0; Harpending H, 2000, ANNU REV GENOM HUM G, V1, P361, DOI 10.1146/annurev.genom.1.1.361; Hill AF, 2000, P NATL ACAD SCI USA, V97, P10248, DOI 10.1073/pnas.97.18.10248; HUGHES AL, 1999, ADAPTIVE EVOLUTION G, P1; Marlar RA, 2000, NATURE, V407, P74, DOI 10.1038/35024064; MCDONALD JH, 1991, NATURE, V351, P652, DOI 10.1038/351652a0; Mead S, 2001, AM J HUM GENET, V69, P1225, DOI 10.1086/324710; PALMER MS, 1991, NATURE, V352, P340, DOI 10.1038/352340a0; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; Schatzl HM, 1997, J MOL BIOL, V265, P257, DOI 10.1006/jmbi.1996.0791; Shibuya S, 1998, ANN NEUROL, V43, P826, DOI 10.1002/ana.410430618; Stephens JC, 2001, SCIENCE, V293, P489, DOI 10.1126/science.1059431; Tishkoff SA, 2001, SCIENCE, V293, P455, DOI 10.1126/science.1061573; WHITFIELD JF, UNPUB	24	278	292	0	52	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 25	2003	300	5619					640	643		10.1126/science.1083320	http://dx.doi.org/10.1126/science.1083320			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	671FB	12690204				2022-12-28	WOS:000182453700042
J	Selker, EU; Tountas, NA; Cross, SH; Margolin, BS; Murphy, JG; Bird, AP; Freitag, M				Selker, EU; Tountas, NA; Cross, SH; Margolin, BS; Murphy, JG; Bird, AP; Freitag, M			The methylated component of the Neurospora crassa genome	NATURE			English	Article							INDUCED POINT MUTATION; DNA METHYLATION; CYTOSINE METHYLATION; GENE; TRANSPOSONS; ELEMENT; RETROTRANSPOSON; PROTEIN; ISLANDS; REGION	Cytosine methylation is common, but not ubiquitous, in eukaryotes. Mammals(1) and the fungus Neurospora crassa(2,3) have about 2-3% of cytosines methylated. In mammals, methylation is almost exclusively in the under-represented CpG dinucleotides, and most CpGs are methylated(1) whereas in Neurospora, methylation is not preferentially in CpG dinucleotides and the bulk of the genome is unmethylated(4). DNA methylation is essential in mammals(5) but is dispensable in Neurospora(3,6), making this simple eukaryote a favoured organism in which to study methylation. Recent studies indicate that DNA methylation in Neurospora depends on one DNA methyltransferase, DIM-2 (ref. 6), directed by a histone H3 methyltransferase, DIM-5 (ref. 7), but little is known about its cellular and evolutionary functions. As only four methylated sequences have been reported previously in N. crassa, we used methyl-binding-domain agarose chromatography(8) to isolate the methylated component of the genome. DNA sequence analysis shows that the methylated component of the genome consists almost exclusively of relics of transposons that were subject to repeat-induced point mutation-a genome defence system that mutates duplicated sequences(9).	Univ Oregon, Dept Biol, Eugene, OR 97403 USA; Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA; Univ Edinburgh, Inst Cell & Mol Biol, Edinburgh EH9 3JR, Midlothian, Scotland	University of Oregon; University of Oregon; University of Edinburgh	Selker, EU (corresponding author), Univ Oregon, Dept Biol, Eugene, OR 97403 USA.		Murphy, Jonathan/AAD-6655-2019	Murphy, Jonathan/0000-0001-6485-5727; Cross, Sally/0000-0001-6518-6449; Bird, Adrian/0000-0002-8600-0372				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bibbins M, 1998, MOL GEN GENET, V258, P431, DOI 10.1007/s004380050752; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; Cambareri EB, 1998, MOL CELL BIOL, V18, P5465, DOI 10.1128/MCB.18.9.5465; CAMBARERI EB, 1994, MOL GEN GENET, V242, P658, DOI 10.1007/BF00283420; CROSS SH, 1994, NAT GENET, V6, P236, DOI 10.1038/ng0394-236; FOSS HM, 1993, SCIENCE, V262, P1737, DOI 10.1126/science.7505062; Foss HM, 1998, MOL GEN GENET, V259, P60, DOI 10.1007/s004380050789; Galagan JE, 2003, NATURE, V422, P859, DOI 10.1038/nature01554; Kempken F, 2001, CHROMOSOMA, V110, P1, DOI 10.1007/s004120000118; Kouzminova E, 2001, EMBO J, V20, P4309, DOI 10.1093/emboj/20.15.4309; KRUMLAUF R, 1980, J BIOL CHEM, V255, P1138; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Margolin BS, 1998, GENETICS, V149, P1787; MEEHAN RR, 1992, NUCLEIC ACIDS RES, V20, P5085, DOI 10.1093/nar/20.19.5085; METZENBERG RL, 1985, P NATL ACAD SCI USA, V82, P2067, DOI 10.1073/pnas.82.7.2067; Miao VPW, 2000, J MOL BIOL, V300, P249, DOI 10.1006/jmbi.2000.3864; Miura A, 2001, NATURE, V411, P212, DOI 10.1038/35075612; Paszkowski J, 2001, CURR OPIN PLANT BIOL, V4, P123, DOI 10.1016/S1369-5266(00)00147-3; Plasterk RHA, 1999, TRENDS GENET, V15, P326, DOI 10.1016/S0168-9525(99)01777-1; RUSSELL PJ, 1985, MOL GENETICS FILAMEN, P321; SELKER EU, 1993, SCIENCE, V262, P1724, DOI 10.1126/science.8259516; Selker EU, 2002, ADV GENET, V46, P439; Selker EU, 1998, P NATL ACAD SCI USA, V95, P9430, DOI 10.1073/pnas.95.16.9430; Singer T, 2001, GENE DEV, V15, P591, DOI 10.1101/gad.193701; Tamaru H, 2001, NATURE, V414, P277, DOI 10.1038/35104508; Tompa R, 2002, CURR BIOL, V12, P65, DOI 10.1016/S0960-9822(01)00622-4; Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5; Zhou Y, 2001, MOL GENET GENOMICS, V265, P748, DOI 10.1007/s004380100472	30	170	181	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 24	2003	422	6934					893	897		10.1038/nature01564	http://dx.doi.org/10.1038/nature01564			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	670WR	12712205	Green Published			2022-12-28	WOS:000182432600055
J	Ho, W				Ho, W			Guideline on management of severe acute respiratory syndrome (SARS)	LANCET			English	Editorial Material											Ho, W (corresponding author), Hosp Authr Bldg, Kowloon, Hong Kong, Peoples R China.								0	47	61	0	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 19	2003	361	9366					1313	1315		10.1016/S0140-6736(03)13085-1	http://dx.doi.org/10.1016/S0140-6736(03)13085-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	669HP	12711461	Bronze, Green Published			2022-12-28	WOS:000182346100003
J	Alff, L; Krockenberger, Y; Welter, B; Schonecke, M; Gross, R; Manske, D; Naito, M				Alff, L; Krockenberger, Y; Welter, B; Schonecke, M; Gross, R; Manske, D; Naito, M			A hidden pseudogap under the 'dome' of superconductivity in electron-doped high-temperature superconductors	NATURE			English	Article							DOPING DEPENDENCE; STATE; PHASE; ORDER; GAP	The ground state of superconductors is characterized by the long-range order of condensed Cooper pairs: this is the only order present in conventional superconductors. The high-transition-temperature (high-T-c) superconductors, in contrast, exhibit more complex phase behaviour, which might indicate the presence of other competing ground states. For example, the pseudogap(1,2)-a suppression of the accessible electronic states at the Fermi level in the normal state of high-T-c superconductors has been interpreted as either a precursor to superconductivity(3,4) or as tracer of a nearby ground state that can be separated from the superconducting state by a quantum critical point(5,6). Here we report the existence of a second order parameter(7) hidden within the superconducting phase of the underdoped (electron-doped) high-T-c superconductor Pr2-xCexCuO4-y and the newly synthesized electron-doped material La2-xCexCuO4-y (ref. 8). The existence of a pseudogap when superconductivity is suppressed excludes precursor superconductivity as its origin. Our observation is consistent with the presence of a (quantum) phase transition at T = 0, which may be a key to understanding high-T-c superconductivity. This supports the picture that the physics of high-T-c superconductors is determined by the interplay between competing and coexisting ground states.	Bayer Akad Wissensch, Walther Meissner Inst, D-85748 Garching, Germany; Free Univ Berlin, Inst Theoret Phys, D-14195 Berlin, Germany; NTT Corp, Basic Res Labs, Kanagawa 243, Japan	Free University of Berlin; Nippon Telegraph & Telephone Corporation	Alff, L (corresponding author), Bayer Akad Wissensch, Walther Meissner Inst, D-85748 Garching, Germany.	lambert.alff@wmi.badw.de	Alff, Lambert/O-9715-2019; Gross, Rudolf/A-6227-2012; Naito, Michio/E-7427-2013; Alff, Lambert/N-9981-2017; Krockenberger, Yoshiharu/M-8161-2018	Gross, Rudolf/0000-0003-4524-7552; Naito, Michio/0000-0002-7581-889X; 				Alff L, 1999, PHYS REV LETT, V83, P2644, DOI 10.1103/PhysRevLett.83.2644; Alff L, 1998, PHYS REV B, V58, P11197, DOI 10.1103/PhysRevB.58.11197; ANDERGASSEN S, 2001, PHYS REV LETT, V87; ANDO Y, 1995, PHYS REV LETT, V75, P4662, DOI 10.1103/PhysRevLett.75.4662; Armitage NP, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.147003; Biswas A, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.104519; Chakravarty S, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.094503; Chandra P, 2002, NATURE, V417, P831, DOI 10.1038/nature00795; Fournier P, 1998, PHYS REV LETT, V81, P4720, DOI 10.1103/PhysRevLett.81.4720; Gollnik F, 1998, PHYS REV B, V58, P11734, DOI 10.1103/PhysRevB.58.11734; Kaminski A, 2002, NATURE, V416, P610, DOI 10.1038/416610a; Kleefisch S, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.100507; Krasnov VM, 2000, PHYS REV LETT, V84, P5860, DOI 10.1103/PhysRevLett.84.5860; Lake B, 2002, NATURE, V415, P299, DOI 10.1038/415299a; Mannhart J, 1996, PHYS REV LETT, V77, P2782, DOI 10.1103/PhysRevLett.77.2782; Manske D, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.144520; Mook HA, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.012502; Naito M, 2000, JPN J APPL PHYS 2, V39, pL485, DOI 10.1143/JJAP.39.L485; Nguyen HK, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.180519; Onose Y, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.217001; Renner C, 1998, PHYS REV LETT, V80, P149, DOI 10.1103/PhysRevLett.80.149; Sachdev S, 2000, SCIENCE, V288, P475, DOI 10.1126/science.288.5465.475; Singley EJ, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.224503; Skinta JA, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.207005; Tallon JL, 2001, PHYSICA C, V349, P53, DOI 10.1016/S0921-4534(00)01524-0; Timusk T, 1999, REP PROG PHYS, V62, P61, DOI 10.1088/0034-4885/62/1/002; Varma CM, 1999, PHYS REV LETT, V83, P3538, DOI 10.1103/PhysRevLett.83.3538; Varma CM, 2000, PHYS REV B, V61, pR3804, DOI 10.1103/PhysRevB.61.R3804; Xu ZA, 2000, NATURE, V406, P486, DOI 10.1038/35020016	30	107	111	1	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 17	2003	422	6933					698	701		10.1038/nature01488	http://dx.doi.org/10.1038/nature01488			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	668CG	12700755				2022-12-28	WOS:000182272300034
J	Selevan, SG; Rice, DC; Hogan, KA; Euling, SY; Pfahles-Hutchens, A; Bethel, J				Selevan, SG; Rice, DC; Hogan, KA; Euling, SY; Pfahles-Hutchens, A; Bethel, J			Blood lead concentration and delayed puberty in girls	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NUTRITION EXAMINATION SURVEY; 3RD NATIONAL-HEALTH; ETHNIC-DIFFERENCES; POSTMENARCHEAL PERIOD; AFRICAN-AMERICAN; GROWTH; EXPOSURE; RAT; MATURATION; MENARCHE	BACKGROUND: Environmental lead exposure has been linked to alterations in growth and endocrine function. It is not known whether such exposure affects pubertal development. METHODS: We analyzed the relations between blood lead concentration and pubertal development among girls (defined as females 8 to 18 years of age) who were enrolled in a cross-sectional study (the third National Health and Nutrition Examination Survey) in which race was self-reported or proxy-reported: 600 were non-Hispanic white, 805 were non-Hispanic African-American, and 781 were Mexican-American girls. Puberty was measured on the basis of the age at menarche and Tanner stage for pubic-hair and breast development. RESULTS: Geometric mean lead concentrations were less than 3 microg per deciliter (0.144 micromol per liter) in all three groups. As compared with concentrations of 1 microg per deciliter (0.048 micromol per liter), lead concentrations of 3 microg per deciliter were associated with decreased height (P<0.001), after adjustment for age, race, and other factors, but not with body-mass index or weight. Blood lead concentrations of 3 microg per deciliter were associated with significant delays in breast and pubic-hair development in African-American and Mexican-American girls. The delays were most marked among African-American girls; in this group, the delays in reaching Tanner stages 2, 3, 4, and 5 associated with a lead concentration of 3 microg per deciliter as compared with 1 microg per deciliter were 3.8, 5.3, 5.8, and 2.1 months, respectively, for breast development and 4.0, 5.5, 6.0, and 2.2 months, respectively, for pubic-hair development; the associated delay in age at menarche was 3.6 months. In white girls, there were nonsignificant delays in all pubertal measures in association with a lead concentration of 3 microg per deciliter. CONCLUSIONS: These data suggest that environmental exposure to lead may delay growth and pubertal development in girls, although confirmation is warranted in prospective studies.	US EPA, Natl Ctr Environm Assessment, Off Res & Dev, Washington, DC 20460 USA; US EPA, Off Pollut Prevent Pesticides & Tox Subst, Washington, DC 20460 USA; WESTAT Corp, Rockville, MD 20850 USA	United States Environmental Protection Agency; United States Environmental Protection Agency; Westat	Selevan, SG (corresponding author), US EPA, Natl Ctr Environm Assessment, Off Res & Dev, 8623D, Washington, DC 20460 USA.							Agency for Toxic Substances and Disease Registry, 1999, TOX PROF LEAD; [Anonymous], 1998, MMWR MORB MORTAL WKL, V47, P1; Ballew C, 1999, J PEDIATR-US, V134, P623, DOI 10.1016/S0022-3476(99)70250-7; BELLINGER D, 1991, ENVIRON RES, V54, P151, DOI 10.1016/S0013-9351(05)80097-0; Biro FM, 2001, J PEDIATR-US, V138, P636, DOI 10.1067/mpd.2001.114476; Blanck HM, 2000, EPIDEMIOLOGY, V11, P641, DOI 10.1097/00001648-200011000-00005; Centers for Disease Control, 1991, PREV LEAD POIS YOUNG; Dearth RK, 2002, REPROD TOXICOL, V16, P343, DOI 10.1016/S0890-6238(02)00037-0; Den Hond E, 2002, ENVIRON HEALTH PERSP, V110, P771, DOI 10.1289/ehp.02110771; *ENV PROT AG, 1997, EXP FACT HDB, V1, P4; FRISANCHO AR, 1991, AM J CLIN NUTR, V54, P516, DOI 10.1093/ajcn/54.3.516; Harlow SD, 1997, AM J EPIDEMIOL, V146, P572; Harlow SD, 1996, AM J EPIDEMIOL, V144, P980; HermanGiddens ME, 1997, PEDIATRICS, V99, P505, DOI 10.1542/peds.99.4.505; Kaplowitz PB, 2001, PEDIATRICS, V108, P347, DOI 10.1542/peds.108.2.347; Kim D, 2000, BRAIN BEHAV IMMUN, V14, P305, DOI 10.1006/brbi.2000.0609; KIMMEL CA, 1980, TOXICOL APPL PHARM, V56, P28, DOI 10.1016/0041-008X(80)90129-5; Krstevska-Konstantinova M, 2001, HUM REPROD, V16, P1020, DOI 10.1093/humrep/16.5.1020; Magarey AM, 1999, ACTA PAEDIATR, V88, P139, DOI 10.1080/08035259950170286; MARSHALL WA, 1969, ARCH DIS CHILD, V44, P291, DOI 10.1136/adc.44.235.291; Mood Alexander McFarlane, 1950, INTRO THEORY STAT, P1; *NAT HLTH NUTR EX, 1997, NHANE 3 SERIES 1A, V2; National Center for Health Statistics, 1994, VIT HLTH STAT, V94-1308; PATTERSON CC, 1983, LEAD VERSUS HLTH, P17; POUNDS JG, 1991, ENVIRON HEALTH PERSP, V91, P17, DOI 10.2307/3430978; Prikle JL, 1994, JAMA-J AM MED ASSOC, V272, P284; Ronis MJJ, 1998, J TOXICOL ENV HEAL A, V54, P101, DOI 10.1080/009841098158944; Ronis MJJ, 1998, J TOXICOL ENV HEAL A, V53, P327, DOI 10.1080/009841098159312; Ronis MJJ, 1998, J TOXICOL ENV HEAL A, V54, P77, DOI 10.1080/009841098158935; RUBIN K, 1993, J PEDIATR-US, V123, P863, DOI 10.1016/S0022-3476(05)80381-6; Russell DL, 2001, J PEDIATR-US, V139, P844, DOI 10.1067/mpd.2001.119446; SCHWARTZ J, 1986, PEDIATRICS, V77, P281; SELVIN S, 1991, STAT ANAL EPIDEMIOLO; SHUKLA R, 1991, PEDIATRICS, V88, P886; Vizmanos B, 2000, EUR J CLIN NUTR, V54, P203, DOI 10.1038/sj.ejcn.1600920; Wattigney Wendy A., 1999, Ethnicity and Disease, V9, P181; Wu TJ, 2002, PEDIATRICS, V110, P752, DOI 10.1542/peds.110.4.752; Yanovski JA, 2000, J CLIN ENDOCR METAB, V85, P2660, DOI 10.1210/jc.85.8.2660	38	185	190	0	18	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 17	2003	348	16					1527	1536		10.1056/NEJMoa020880	http://dx.doi.org/10.1056/NEJMoa020880			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	667TT	12700372				2022-12-28	WOS:000182248900003
J	Leonidas, JC; Guelfguat, M; Valderrama, E				Leonidas, JC; Guelfguat, M; Valderrama, E			Langerhans' cell histiocytosis	LANCET			English	Editorial Material									Northshore LIJ Hlth Syst, Schneider Childrens Hosp, Div Pediat Radiol, New Hyde Pk, NY 11040 USA; Northshore LIJ Hlth Syst, Schneider Childrens Hosp, Div Pediat Pathol, New Hyde Pk, NY 11040 USA; Albert Einstein Coll Med, New York, NY USA	Northwell Health; North Shore University Hospital; Steven & Alexandra Cohen Children's Medical Center of New York; Northwell Health; North Shore University Hospital; Steven & Alexandra Cohen Children's Medical Center of New York; Yeshiva University	Leonidas, JC (corresponding author), Northshore LIJ Hlth Syst, Schneider Childrens Hosp, Div Pediat Radiol, 270-05 76th Ave, New Hyde Pk, NY 11040 USA.	leonidas@lij.edu						[Anonymous], 1987, Lancet, V1, P208; Christian HA, 1920, MED CLIN N AM, V3, P849; Conter V, 1996, HAEMATOLOGICA, V81, P468; Coppes-Zantinga A, 2002, BRIT J HAEMATOL, V116, P3, DOI 10.1046/j.1365-2141.2002.03232.x; De Graaf Jan H., 1997, Current Opinion in Pediatrics, V9, P46, DOI 10.1097/00008480-199702000-00011; EGELER RM, 1994, MED PEDIATR ONCOL, V22, P129, DOI 10.1002/mpo.2950220213; EGELER RM, 1992, J PEDIATR, V127, P1; FIRKIN BG, 1996, DICT MED EPONYMS, P166; Hand A, 1921, AM J MED SCI, V162, P509, DOI 10.1097/00000441-192110000-00004; Hand. A., 1893, ARCH PEDIAT, V10, P673; Lampert F, 1998, HEMATOL ONCOL CLIN N, V12, P213, DOI 10.1016/S0889-8588(05)70506-2; Nagarajan R, 2001, J PEDIAT HEMATOL ONC, V23, P629, DOI 10.1097/00043426-200112000-00017; Schindler E, 1997, AM J NEURORADIOL, V18, P1297; Schueller A, 1915, FORTSCHR ROENTGENSTR, V23, P12	14	48	58	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 12	2003	361	9365					1293	1295		10.1016/S0140-6736(03)12990-X	http://dx.doi.org/10.1016/S0140-6736(03)12990-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	666DM	12699969				2022-12-28	WOS:000182161600024
J	Catherall, AT; Eaves, L; King, PJ; Booth, SR				Catherall, AT; Eaves, L; King, PJ; Booth, SR			Floating gold in cryogenic oxygen	NATURE			English	Article									Univ Nottingham, Sch Phys & Astron, Nottingham NG7 2RD, England	University of Nottingham	Catherall, AT (corresponding author), Univ Nottingham, Sch Phys & Astron, Nottingham NG7 2RD, England.			Eaves, Laurence/0000-0002-5334-0987				COWLEY MD, 1967, J FLUID MECH, V30, P671, DOI 10.1017/S0022112067001697; Geim AK, 1999, NATURE, V400, P323, DOI 10.1038/22444; Ikezoe Y, 1998, NATURE, V393, P749, DOI 10.1038/31619	3	60	69	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 10	2003	422	6932					579	579		10.1038/422579a	http://dx.doi.org/10.1038/422579a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	665GN	12686988				2022-12-28	WOS:000182111400028
J	Verlinsky, Y; Rechitsky, S; Verlinsky, O; Ozen, S; Sharapova, T; Masciangelo, C; Morris, R; Kuliev, A				Verlinsky, Y; Rechitsky, S; Verlinsky, O; Ozen, S; Sharapova, T; Masciangelo, C; Morris, R; Kuliev, A			Preimplantation diagnosis for sonic hedgehog mutation causing familial holoprosencephaly	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GENETIC DIAGNOSIS; BIRTH		Inst Reprod Genet, Chicago, IL USA		Kuliev, A (corresponding author), 2825 N Halsted St, Chicago, IL 60657 USA.	anverkuliev@hotmail.com	OZEN, SEZA/I-9096-2013; Kuliev, Anver/P-5666-2018	Kuliev, Anver/0000-0002-2486-9339				Abou-Sleiman PM, 2002, MOL HUM REPROD, V8, P304, DOI 10.1093/molehr/8.3.304; Gianaroli L, 1999, FERTIL STERIL, V72, P837, DOI 10.1016/S0015-0282(99)00377-5; HANDYSIDE AH, 1990, NATURE, V344, P768, DOI 10.1038/344768a0; HANDYSIDE AH, 1992, NEW ENGL J MED, V327, P905, DOI 10.1056/NEJM199209243271301; Kuliev A, 1998, J ASSIST REPROD GEN, V15, P219, DOI 10.1023/A:1022571822585; Kuliev Anver, 2002, Reprod Biomed Online, V5, P294; MUENKE M, 1994, P NATL ACAD SCI USA, V91, P8102, DOI 10.1073/pnas.91.17.8102; Munne S, 1999, HUM REPROD, V14, P2191, DOI 10.1093/humrep/14.9.2191; Nanni L, 1999, HUM MOL GENET, V8, P2479, DOI 10.1093/hmg/8.13.2479; Rechitsky S, 1998, J ASSIST REPROD GEN, V15, P253, DOI 10.1023/A:1022532108472; RECHITSKY S, 2000, FETAL CELLS MATERNAL, P8; Rechitsky Svetlana, 2002, Reprod Biomed Online, V5, P148; Sermon K, 1997, PRENATAL DIAG, V17, P925, DOI 10.1002/(SICI)1097-0223(199710)17:10<925::AID-PD178>3.0.CO;2-4; Verlinsky Y, 2002, JAMA-J AM MED ASSOC, V287, P1018, DOI 10.1001/jama.287.8.1018; VERLINSKY Y, 1990, HUM REPROD, V5, P826, DOI 10.1093/oxfordjournals.humrep.a137192; VERLINSKY Y, 2000, ATLAS PREIMPLANTATIO; Wilton L, 2001, NEW ENGL J MED, V345, P1537, DOI 10.1056/NEJMoa011052; Xu KP, 1999, JAMA-J AM MED ASSOC, V281, P1701, DOI 10.1001/jama.281.18.1701	18	17	20	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 10	2003	348	15					1449	1454		10.1056/NEJMoa022652	http://dx.doi.org/10.1056/NEJMoa022652			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	665CU	12686701				2022-12-28	WOS:000182102700005
J	Kagey, MH; Melhuish, TA; Wotton, D				Kagey, MH; Melhuish, TA; Wotton, D			The polycomb protein Pc2 is a SUMO E3	CELL			English	Article							UBIQUITIN-LIKE PROTEIN; HISTONE METHYLTRANSFERASE ACTIVITY; TRITHORAX GROUP PROTEINS; CELLULAR PHOSPHOPROTEIN; PROMYELOCYTIC LEUKEMIA; MULTIPROTEIN COMPLEX; NEGATIVE MODULATION; CONJUGATING ENZYME; NUCLEAR-BODIES; HUMAN HOMOLOG	Polycomb group (PcG) proteins form large multimeric complexes (PcG bodies) which are involved in the stable repression of gene expression. The human PcG protein, Pc2, has been shown to recruit the transcriptional corepressor, CtBP, to PcG bodies. We show that CtBP is sumoylated at a single lysine. In vitro, CtBP sumoylation minimally requires the SUMO E1 and E2 (Ubc9) and SUMO-1. However, Pc2 dramatically enhances CtBP sumoylation. In vivo, this is likely due to the ability of Pc2 to recruit both CtBP and Ubc9 to PcG bodies, thereby bringing together substrate and E2, and stimulating the transfer of SUMO to CtBP. These results demonstrate that Pc2 is a SUMO E3, and suggest that PcG bodies may be sumoylation centers.	Univ Virginia, Ctr Cell Signaling, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA	University of Virginia	Wotton, D (corresponding author), Univ Virginia, Ctr Cell Signaling, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA.	dw2p@virginia.edu		Wotton, David/0000-0002-4652-5350	NICHD NIH HHS [HD 39926] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Bernier-Villamor V, 2002, CELL, V108, P345, DOI 10.1016/S0092-8674(02)00630-X; Boddy MN, 1996, ONCOGENE, V13, P971; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; Brock HW, 2001, CURR OPIN GENET DEV, V11, P175, DOI 10.1016/S0959-437X(00)00176-3; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Cavalli G, 1998, CURR OPIN CELL BIOL, V10, P354, DOI 10.1016/S0955-0674(98)80011-2; Chinnadurai G, 2002, MOL CELL, V9, P213, DOI 10.1016/S1097-2765(02)00443-4; Criqui-Filipe P, 1999, EMBO J, V18, P3392, DOI 10.1093/emboj/18.12.3392; Czermin B, 2002, CELL, V111, P185, DOI 10.1016/S0092-8674(02)00975-3; Dahiya A, 2001, MOL CELL, V8, P557, DOI 10.1016/S1097-2765(01)00346-X; Desterro JMP, 1997, FEBS LETT, V417, P297, DOI 10.1016/S0014-5793(97)01305-7; DOHMEN RJ, 1995, J BIOL CHEM, V270, P18099, DOI 10.1074/jbc.270.30.18099; Espinas ML, 2000, EMBO REP, V1, P253, DOI 10.1093/embo-reports/kvd046; Francis NJ, 2001, MOL CELL, V8, P545, DOI 10.1016/S1097-2765(01)00316-1; Gerasimova TI, 1998, CELL, V92, P511, DOI 10.1016/S0092-8674(00)80944-7; Gunster MJ, 2001, J CELL BIOCHEM, P129, DOI 10.1002/jcb.1093; Gunster MJ, 1997, MOL CELL BIOL, V17, P2326, DOI 10.1128/MCB.17.4.2326; Hay RT, 2001, TRENDS BIOCHEM SCI, V26, P332, DOI 10.1016/S0968-0004(01)01849-7; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hochstrasser M, 2001, CELL, V107, P5, DOI 10.1016/S0092-8674(01)00519-0; Jackson PK, 2000, TRENDS CELL BIOL, V10, P429, DOI 10.1016/S0962-8924(00)01834-1; Jackson PK, 2001, GENE DEV, V15, P3053, DOI 10.1101/gad.955501; Jacobs JJL, 2002, BBA-REV CANCER, V1602, P151, DOI 10.1016/S0304-419X(02)00052-5; Jentsch S, 2000, TRENDS CELL BIOL, V10, P335, DOI 10.1016/S0962-8924(00)01785-2; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; Johnson EW, 1997, J BACK MUSCULOSKELET, V9, P3, DOI 10.3233/BMR-1997-9102; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Kennison JA, 1995, ANNU REV GENET, V29, P289, DOI 10.1146/annurev.ge.29.120195.001445; Kirsh O, 2002, EMBO J, V21, P2682, DOI 10.1093/emboj/21.11.2682; Kuzmichev A, 2002, GENE DEV, V16, P2893, DOI 10.1101/gad.1035902; Lallemand-Breitenbach V, 2001, J EXP MED, V193, P1361, DOI 10.1084/jem.193.12.1361; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Lapenta V, 1997, GENOMICS, V40, P362, DOI 10.1006/geno.1996.4556; Mannen H, 1996, BIOCHEM BIOPH RES CO, V222, P178, DOI 10.1006/bbrc.1996.0717; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; Mayer RJ, 1998, FOLD DES, V3, pR97, DOI 10.1016/S1359-0278(98)00047-9; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Muller J, 2002, CELL, V111, P197, DOI 10.1016/S0092-8674(02)00976-5; MULLER J, 1995, EMBO J, V14, P1209, DOI 10.1002/j.1460-2075.1995.tb07104.x; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Ogawa H, 2002, SCIENCE, V296, P1132, DOI 10.1126/science.1069861; Okura T, 1996, J IMMUNOL, V157, P4277; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Pirrotta V, 1998, CELL, V93, P333, DOI 10.1016/S0092-8674(00)81162-9; Poux S, 2001, DEVELOPMENT, V128, P75; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Ross S, 2002, MOL CELL, V10, P831, DOI 10.1016/S1097-2765(02)00682-2; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Sampson DA, 2001, J BIOL CHEM, V276, P21664, DOI 10.1074/jbc.M100006200; Sapetschnig A, 2002, EMBO J, V21, P5206, DOI 10.1093/emboj/cdf510; Satijn DPE, 2001, MOL CELL BIOL, V21, P1360, DOI 10.1128/MCB.21.4.1360-1369.2001; Saurin AJ, 1998, J CELL BIOL, V142, P887, DOI 10.1083/jcb.142.4.887; Schaeper U, 1998, J BIOL CHEM, V273, P8549, DOI 10.1074/jbc.273.15.8549; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; Schmidt D, 2002, P NATL ACAD SCI USA, V99, P2872, DOI 10.1073/pnas.052559499; Schumacher A, 1997, TRENDS GENET, V13, P167, DOI 10.1016/S0168-9525(97)01133-5; Sewalt RGAB, 1999, MOL CELL BIOL, V19, P777; Sewalt RGAB, 2002, MOL CELL BIOL, V22, P5539, DOI 10.1128/MCB.22.15.5539-5553.2002; Sewalt RGAB, 1998, MOL CELL BIOL, V18, P3586, DOI 10.1128/MCB.18.6.3586; Shen ZY, 1996, GENOMICS, V36, P271, DOI 10.1006/geno.1996.0462; SIMON J, 1995, CURR OPIN CELL BIOL, V7, P376, DOI 10.1016/0955-0674(95)80093-X; Simon JA, 2002, CURR OPIN GENET DEV, V12, P210, DOI 10.1016/S0959-437X(02)00288-5; Sternsdorf T, 1997, J CELL BIOL, V139, P1621, DOI 10.1083/jcb.139.7.1621; Takahashi Y, 2001, J BIOL CHEM, V276, P48973, DOI 10.1074/jbc.M109295200; Turner J, 1998, EMBO J, V17, P5129, DOI 10.1093/emboj/17.17.5129; Turner J, 2001, BIOESSAYS, V23, P683, DOI 10.1002/bies.1097; van der Vlag J, 1999, NAT GENET, V23, P474, DOI 10.1038/70602; Weigert R, 1999, NATURE, V402, P429, DOI 10.1038/46587; WU J, 1995, J BIOL CHEM, V270, P14209, DOI 10.1074/jbc.270.23.14209	71	443	466	1	22	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 4	2003	113	1					127	137		10.1016/S0092-8674(03)00159-4	http://dx.doi.org/10.1016/S0092-8674(03)00159-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	668GX	12679040	Bronze			2022-12-28	WOS:000182282900012
J	Plant, PK; Owen, JL; Parrott, S; Elliott, MW				Plant, PK; Owen, JL; Parrott, S; Elliott, MW			Cost effectiveness of ward based non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease: economic analysis of randomised controlled trial	BRITISH MEDICAL JOURNAL			English	Article							POSITIVE PRESSURE VENTILATION; ACUTE RESPIRATORY-FAILURE; NONINVASIVE VENTILATION	Objective To evaluate the cost effectiveness of standard treatment with and without the addition of ward based non-invasive ventilation in patients admitted to hospital with all acute exacerbation of chronic obstructive pulmonary disease. Design Incremental cost effectiveness analysis of a randomised controlled trial. Setting Medical wards in 14 hospitals in the United Kingdom. Participants The trial comprised 236 patients admitted to hospital with an acute exacerbation of chronic obstructive pulmonary disease and mild to moderate acidosis (pH 7.25-7.35) secondary to respiratory failure. The economic analysis Compared the costs of treatment that these patients received after randomisation. Main outcome measure Incremental cost per in-hospital death. Results 24/118 died in the group receiving standard treatment and 12/118 in the group receiving non-invasive ventilation (P=0.05). Allocation to the group receiving non-invasive ventilation was associated with a reduction in costs of pound49362 ($78741; C73 109), mainly through reduced use of intensive care units. The incremental cost effectiveness ratio was -pound645 per death avoided (95% confidence interval -pound2310 to pound386), indicating a dominant (more effective and less costly) strategy. Modelling of these data indicates that a typical UK hospital providing a non-invasive ventilation service will avoid six deaths and three to nine admissions to intensive care units per year, with an associated cost reduction of pound112000-53000 per year. Conclusions Non-invasive ventilation is a highly cost, effective treatment that both reduced total costs and improved mortality in hospital.	St James Univ Hosp, Dept Resp Med, Leeds LS9 7TF, W Yorkshire, England; Univ York, Ctr Hlth Econ, York YO10 5DD, N Yorkshire, England	Saint James's University Hospital; University of York - UK	Plant, PK (corresponding author), St James Univ Hosp, Dept Resp Med, Leeds LS9 7TF, W Yorkshire, England.			Parrott, Steven James/0000-0002-0165-1150				Altman DG, 1991, PRACTICAL STAT MED R, P48; BOTT J, 1993, LANCET, V341, P1555, DOI 10.1016/0140-6736(93)90696-E; BROCHARD L, 1995, NEW ENGL J MED, V333, P817, DOI 10.1056/NEJM199509283331301; Celikel T, 1998, CHEST, V114, P1636, DOI 10.1378/chest.114.6.1636; DRUMMOND MF, 1987, METHODS EC EVALUATIO, P74; DRUMMOND MF, 1987, METHODS EC EVALUATIO, P39; Keenan SP, 2000, CRIT CARE MED, V28, P2094, DOI 10.1097/00003246-200006000-00072; Kollef MH, 2000, LANCET, V356, P956, DOI 10.1016/S0140-6736(00)02708-2; KRAMER N, 1995, AM J RESP CRIT CARE, V151, P1799, DOI 10.1164/ajrccm.151.6.7767523; Martin TJ, 2000, AM J RESP CRIT CARE, V161, P807, DOI 10.1164/ajrccm.161.3.9808143; Plant PK, 2000, THORAX, V55, P550, DOI 10.1136/thorax.55.7.550; Plant PK, 2000, LANCET, V355, P1931, DOI 10.1016/S0140-6736(00)02323-0	12	85	87	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 3	2003	326	7396					956	959		10.1136/bmj.326.7396.956	http://dx.doi.org/10.1136/bmj.326.7396.956			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	676JC	12727767	Bronze, Green Accepted, Green Published			2022-12-28	WOS:000182746700015
J	Willerslev, E; Hansen, AJ; Binladen, J; Brand, TB; Gilbert, MTP; Shapiro, B; Bunce, M; Wiuf, C; Gilichinsky, DA; Cooper, A				Willerslev, E; Hansen, AJ; Binladen, J; Brand, TB; Gilbert, MTP; Shapiro, B; Bunce, M; Wiuf, C; Gilichinsky, DA; Cooper, A			Diverse plant and animal genetic records from Holocene and Pleistocene sediments	SCIENCE			English	Article							ANCIENT DNA; MITOCHONDRIAL; TUNDRA; EVOLUTION; SEQUENCES; ALASKA; STEPPE; ORIGIN	Genetic analyses of permafrost and temperate sediments reveal that plant and animal DNA may be preserved for long periods, even in the absence of obvious macrofossils. In Siberia, five permafrost cores ranging from 400,000 to 10,000 years old contained at least 19 different plant taxa, including the oldest authenticated ancient DNA sequences known, and megafaunal sequences including mammoth, bison, and horse. The genetic data record a number of dramatic changes in the taxonomic diversity and composition of Beringian vegetation and fauna. Temperate cave sediments in New Zealand also yielded DNA sequences of extinct biota, including two species of ratite moa, and 29 plant taxa characteristic of the prehuman environment. Therefore, many sedimentary deposits may contain unique, and widespread, genetic records of paleoenvironments.	Univ Copenhagen, Inst Zool, Dept Evolutionary Biol, DK-2100 Copenhagen O, Denmark; Univ Oxford, Dept Zool, Henry Wellcome Ancient Biomol Ctr, Oxford OX1 3PS, England; Univ Oxford, Dept Stat, Oxford OX1 3TG, England; Russian Acad Sci, Inst Physicochem & Biol Problems Soil Sci, Soil Cryol Lab, Pushchino 142290, Moscow Region, Russia	University of Copenhagen; University of Oxford; University of Oxford; Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Physicohemical & Biological Problems of Soil Science	Hansen, AJ (corresponding author), Univ Copenhagen, Inst Zool, Dept Evolutionary Biol, Univ Pk 15, DK-2100 Copenhagen O, Denmark.		Willerslev, Eske/AAA-5686-2019; Willerslev, Eske/A-9619-2011; Hansen, Anders Johannes/A-5608-2013; Cooper, Alan/E-8171-2012; Wiuf, Carsten/H-6320-2011; Gilbert, Marcus TP/A-8936-2013	Willerslev, Eske/0000-0002-7081-6748; Hansen, Anders Johannes/0000-0002-1890-2702; Cooper, Alan/0000-0002-7738-7851; Wiuf, Carsten/0000-0002-1302-4445; Gilbert, Marcus TP/0000-0002-5805-7195; Bunce, Michael/0000-0002-0302-4206				ANDERSON PM, 1994, QUATERNARY RES, V41, P306, DOI 10.1006/qres.1994.1035; Barnes I, 2002, SCIENCE, V295, P2267, DOI 10.1126/science.1067814; BIRKY CW, 1995, P NATL ACAD SCI USA, V92, P11331, DOI 10.1073/pnas.92.25.11331; BLANCHARD JL, 1995, J MOL EVOL, V41, P397, DOI 10.1007/BF00160310; Colinvaux P, 1996, NATURE, V382, P21, DOI 10.1038/382021a0; Colinvaux P.A., 1984, Q REV ARCHAEOLOGY, V5, P10; Cooper A, 2000, SCIENCE, V289, P1139; Cooper A, 2001, NATURE, V409, P704, DOI 10.1038/35055536; COOPER AJL, UNPUB; CWYNAR LC, 1980, SCIENCE, V208, P1375, DOI 10.1126/science.208.4450.1375; Endicott P, 2003, AM J HUM GENET, V72, P178, DOI 10.1086/345487; Gilbert MTP, 2003, AM J HUM GENET, V72, P32, DOI 10.1086/345378; Goetcheus VG, 2001, QUATERNARY SCI REV, V20, P135, DOI 10.1016/S0277-3791(00)00127-X; Guthrie R.D., 1990, FROZEN FAUNA MAMMOTH; Hansen AJ, 2001, MOL BIOL EVOL, V18, P262, DOI 10.1093/oxfordjournals.molbev.a003800; Hofreiter M, 2001, NAT REV GENET, V2, P353, DOI 10.1038/35072071; HOPKINS M, 1982, PALEOECOLOGY BERINGI; Jackson RB, 1997, P NATL ACAD SCI USA, V94, P7362, DOI 10.1073/pnas.94.14.7362; Krings M, 1997, CELL, V90, P19, DOI 10.1016/S0092-8674(00)80310-4; McGlone MS, 2001, NEW ZEAL J ECOL, V25, P1; Poinar HN, 1998, SCIENCE, V281, P402, DOI 10.1126/science.281.5375.402; Richards M, 1996, AM J HUM GENET, V59, P185; Stewart JR, 2001, TRENDS ECOL EVOL, V16, P608, DOI 10.1016/S0169-5347(01)02338-2; Volk T, 2001, ROOT DYNAMICS WILLOW; Waits LP, 1998, CONSERV BIOL, V12, P408, DOI 10.1046/j.1523-1739.1998.96351.x; Willerslev E, 1999, P NATL ACAD SCI USA, V96, P8017, DOI 10.1073/pnas.96.14.8017; WILLERSLEV E, UNPUB; Yurtsev BA, 2001, QUATERNARY SCI REV, V20, P165, DOI 10.1016/S0277-3791(00)00125-6	28	393	433	8	203	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 2	2003	300	5620					791	795		10.1126/science.1084114	http://dx.doi.org/10.1126/science.1084114			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	673KH	12702808				2022-12-28	WOS:000182579800049
J	Jiang, YX; Lee, A; Chen, JY; Ruta, V; Cadene, M; Chait, BT; MacKinnon, R				Jiang, YX; Lee, A; Chen, JY; Ruta, V; Cadene, M; Chait, BT; MacKinnon, R			X-ray structure of a voltage-dependent K+ channel	NATURE			English	Article							POTASSIUM CHANNEL; GATING CHARGE; TRANSMEMBRANE MOVEMENT; S4 SEGMENT; PERSPECTIVE; SEQUENCE; PROTEIN; ACTIVATION; CONDUCTION; HANATOXIN	Voltage-dependent K+ channels are members of the family of voltage-dependent cation (K+, Na+ and Ca2+) channels that open and allow ion conduction in response to changes in cell membrane voltage. This form of gating underlies the generation of nerve and muscle action potentials, among other processes. Here we present the structure of KvAP, a voltage-dependent K+ channel from Aeropyrum pernix. We have determined a crystal structure of the full-length channel at a resolution of 3.2 Angstrom, and of the isolated voltage-sensor domain at 1.9 Angstrom, both in complex with monoclonal Fab fragments. The channel contains a central ion-conduction pore surrounded by voltage sensors, which form what we call 'voltage-sensor paddles'-hydrophobic, cationic, helix-turn-helix structures on the channel's outer perimeter. Flexible hinges suggest that the voltage-sensor paddles move in response to membrane voltage changes, carrying their positive charge across the membrane.	Rockefeller Univ, Howard Hughes Med Inst, Lab Mol Neurobiol & Biophys, Lab Mass Spectrometry & Gaseous Ion Chem, New York, NY 10021 USA	Howard Hughes Medical Institute; Rockefeller University	MacKinnon, R (corresponding author), Rockefeller Univ, Howard Hughes Med Inst, Lab Mol Neurobiol & Biophys, Lab Mass Spectrometry & Gaseous Ion Chem, 1230 York Ave, New York, NY 10021 USA.	mackinn@rockvax.rockefeller.edu		Ruta, Vanessa/0000-0002-4963-2768; Cadene, Martine/0000-0003-4936-2662				Aggarwal SK, 1996, NEURON, V16, P1169, DOI 10.1016/S0896-6273(00)80143-9; ARMSTRONG CM, 1974, J GEN PHYSIOL, V63, P533, DOI 10.1085/jgp.63.5.533; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baker OS, 1998, NEURON, V20, P1283, DOI 10.1016/S0896-6273(00)80507-3; Bezanilla F, 2000, PHYSIOL REV, V80, P555, DOI 10.1152/physrev.2000.80.2.555; Bezanilla F, 2002, J GEN PHYSIOL, V120, P465, DOI 10.1085/jgp.20028660; Blaustein RO, 2000, NAT STRUCT BIOL, V7, P309; BRUNGER AT, 1991, J MOL BIOL, V221, P239, DOI 10.1016/0022-2836(91)90817-P; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; Cha A, 1997, NEURON, V19, P1127, DOI 10.1016/S0896-6273(00)80403-1; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Gandhi CS, 2002, J GEN PHYSIOL, V120, P455, DOI 10.1085/jgp.20028678; Harlow E., 1989, ANTIBODIES LAB MANUA; Heginbotham L, 1999, J GEN PHYSIOL, V114, P551, DOI 10.1085/jgp.114.4.551; Hille B., 2001, ION CHANNELS EXCITAB, V3rd Edn; HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764; Horn R, 2002, J GEN PHYSIOL, V120, P449, DOI 10.1085/jgp.20028658; Jiang YX, 2003, NATURE, V423, P42, DOI 10.1038/nature01581; Jiang YX, 2002, NATURE, V417, P515, DOI 10.1038/417515a; Jiang YX, 2002, NATURE, V417, P523, DOI 10.1038/417523a; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Larsson HP, 1996, NEURON, V16, P387, DOI 10.1016/S0896-6273(00)80056-2; Lu Z, 2001, NATURE, V413, P809, DOI 10.1038/35101535; Mannuzzu LM, 1996, SCIENCE, V271, P213, DOI 10.1126/science.271.5246.213; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NODA M, 1984, NATURE, V312, P121, DOI 10.1038/312121a0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Qiu XQ, 1996, J GEN PHYSIOL, V107, P313, DOI 10.1085/jgp.107.3.313; Ruta V, 2003, NATURE, V422, P180, DOI 10.1038/nature01473; SANTACRUZTOLOZA L, 1994, BIOCHEMISTRY-US, V33, P5607, DOI 10.1021/bi00184a033; SCHOPPA NE, 1992, SCIENCE, V255, P1712, DOI 10.1126/science.1553560; Seoh SA, 1996, NEURON, V16, P1159, DOI 10.1016/S0896-6273(00)80142-7; SIGWORTH FJ, 1994, Q REV BIOPHYS, V27, P1, DOI 10.1017/S0033583500002894; SLATIN SL, 1994, NATURE, V371, P158, DOI 10.1038/371158a0; Swartz KJ, 1997, NEURON, V18, P675, DOI 10.1016/S0896-6273(00)80307-4; Swartz KJ, 1997, NEURON, V18, P665, DOI 10.1016/S0896-6273(00)80306-2; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TEMPEL BL, 1987, SCIENCE, V237, P770, DOI 10.1126/science.2441471; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; YANG NB, 1995, NEURON, V15, P213, DOI 10.1016/0896-6273(95)90078-0; Yusaf SP, 1996, PFLUG ARCH EUR J PHY, V433, P91, DOI 10.1007/s004240050253; Zhou YF, 2001, NATURE, V414, P43, DOI 10.1038/35102009	43	1527	1601	7	228	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 1	2003	423	6935					33	41		10.1038/nature01580	http://dx.doi.org/10.1038/nature01580			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	673CG	12721618				2022-12-28	WOS:000182561600032
J	Bhandari, N; Bahl, R; Mazumdar, S; Martines, J; Black, RE; Bhan, MK				Bhandari, N; Bahl, R; Mazumdar, S; Martines, J; Black, RE; Bhan, MK		Infant Feeding Study Grp	Effect of community-based promotion of exclusive breastfeeding on diarrhoeal illness and growth: a cluster randomised controlled trial	LANCET			English	Article							COMPLEMENTARY FOODS; FED INFANTS; INTERVENTION; PNEUMONIA; HONDURAS; HEALTH; AGE	Background Exclusive breastfeeding is recommended until age 6 months. We assessed the feasibility, effectiveness, and safety of an educational intervention to promote exclusive breastfeeding for this length of time in India. Methods We developed the intervention through formative research, pair-matched eight communities on their baseline characteristics, and randomised one of each pair to receive the intervention and the other to no specific intervention. We trained health and nutrition workers in the intervention communities to counsel mothers for exclusive breastfeeding at multiple opportunities. We enrolled 1115 infants born in the 9 months after training-552 in the intervention and 473 in the control communities. Feeding at age 3 months, and anthropometry and of diarrhoea prevalence at age 3 months and 6 months were assessed. All analyses were by intention to treat. Findings We assessed 483 and 412 individuals at 3 months in the intervention and control groups, respectively, and 468 and 412 at 6 months. At 3 months, exclusive breastfeeding rates were 79% (381) in the intervention and 48% (197) in the control communities (odds ratio 4.02, 95% Cl 3.01-5.38, p<0.0001). The 7-day diarrhoea prevalence was lower in the intervention than in the control communities at 3 months (0.64, 0.44-0.95, p=0.028) and 6 months (0.85, 0.72-0.99, p=0.04). The mean weights and lengths, and the proportion with weight-for-height or height-for-age Z scores of 2 or less, at age 3 months and 6 months did not differ much between groups. Intervention effect on exclusive breastfeeding, diarrhoeal morbidity, and anthropometry at age 6 months in the low-birthweight subgroup was similar to that for all births. Interpretation Promotion of exclusive breastfeeding until age 6 months in a developing country through existing primary health-care services is feasible, reduces the risk of diarrhoea, and does not lead to growth faltering.	All India Inst Med Sci, Dept Paediat, New Delhi 110029, India; WHO, Dept Child & Adolescent Hlth & Dev, CH-1211 Geneva, Switzerland; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Bloomberg Sch Publ Hlth, Baltimore, MD USA	All India Institute of Medical Sciences (AIIMS) New Delhi; University of Geneva; World Health Organization; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Bhan, MK (corresponding author), All India Inst Med Sci, Dept Paediat, Ansari Nagar, New Delhi 110029, India.	community.research@cih.uib.no	Sandall, Jane/D-4146-2009	Sandall, Jane/0000-0003-2000-743X; Black, Robert/0000-0001-9926-7984				BEAUDRY M, 1995, J PEDIATR-US, V126, P191, DOI 10.1016/S0022-3476(95)70544-9; Cesar JA, 1999, BRIT MED J, V318, P1316, DOI 10.1136/bmj.318.7194.1316; COHEN RJ, 1994, LANCET, V344, P288, DOI 10.1016/S0140-6736(94)91337-4; CUNNINGHAM AS, 1991, J PEDIATR-US, V118, P659, DOI 10.1016/S0022-3476(05)80023-X; Dewey KG, 1999, AM J CLIN NUTR, V69, P679; DEWEY KG, 1995, J PEDIATR-US, V126, P696, DOI 10.1016/S0022-3476(95)70395-0; DONNER A, 1981, AM J EPIDEMIOL, V114, P906, DOI 10.1093/oxfordjournals.aje.a113261; Froozani MD, 1999, B WORLD HEALTH ORGAN, V77, P381; Grummer-Strawn L M, 1997, Matern Child Health J, V1, P35, DOI 10.1023/A:1026224402712; Haider R, 2000, LANCET, V356, P1643, DOI 10.1016/S0140-6736(00)03159-7; HOWIE PW, 1990, BRIT MED J, V300, P11, DOI 10.1136/bmj.300.6716.11; *INT I POP SCI ORC, 2000, 2 NFHS; Kramer MS, 2001, JAMA-J AM MED ASSOC, V285, P413, DOI 10.1001/jama.285.4.413; Morrow AL, 1999, LANCET, V353, P1226, DOI 10.1016/S0140-6736(98)08037-4; Oddy W H, 2001, Breastfeed Rev, V9, P11; Raisler J, 1999, AM J PUBLIC HEALTH, V89, P25, DOI 10.2105/AJPH.89.1.25; Smith P. G., 1996, FIELD TRIALS HLTH IN; Valdes V, 2000, J TROP PEDIATRICS, V46, P149, DOI 10.1093/tropej/46.3.149; Victora CG, 1999, AM J CLIN NUTR, V70, P309; *WHO DIV CHILD HLT, 1997, INT MAN CHILDH ILLN; *WHO DIV CHILD HLT, 1997, WHOCHD973F; World Health Organisation, 2009, WORLD HLTH ORG GEN; World Health Organization Division of Child Health and Development, 1991, IND ASS BREASTF PRAC; 1982, INTEGRATED CHILD DEV	24	242	245	1	23	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 26	2003	361	9367					1418	1423		10.1016/S0140-6736(03)13134-0	http://dx.doi.org/10.1016/S0140-6736(03)13134-0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	672HZ	12727395				2022-12-28	WOS:000182516300010
J	Viskin, S				Viskin, S			Shooting at ambulances in Israel: a cardiologist's viewpoint	LANCET			English	Editorial Material									Tel Aviv Univ, Sackler Sch Med, Tel Aviv Med Ctr, Dept Cardiol, IL-64239 Tel Aviv, Israel	Tel Aviv University; Sackler Faculty of Medicine	Viskin, S (corresponding author), Tel Aviv Univ, Sackler Sch Med, Tel Aviv Med Ctr, Dept Cardiol, IL-64239 Tel Aviv, Israel.							[Anonymous], 2002, LANCET, V359, P1261; Blachar Y, 2002, LANCET, V359, P1859, DOI 10.1016/S0140-6736(02)08682-8; CHRISTIANO R, 2002, COVERAGE OCTOBER 12; DORON AI, 2002, UNFORTUNATE TRUTH PA; HAREL D, 2002, INAPPROPRIATE USE AM; *ISR MIN FOR AFF, PASS SUIC BOMB PARK; *ISR MIN FOR AFF, 1993, FAT TERR ATT ISR DEC; REES M, 2002, TIME	8	4	4	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 26	2003	361	9367					1470	1471		10.1016/S0140-6736(03)13142-X	http://dx.doi.org/10.1016/S0140-6736(03)13142-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	672HZ	12727415				2022-12-28	WOS:000182516300029
J	Maller, JL				Maller, JL			Fishing at the cell surface	SCIENCE			English	Editorial Material							PROGESTERONE-RECEPTOR; OOCYTE; PROTEIN; MATURATION; ARREST		Univ Colorado, Sch Med, Howard Hughes Med Inst, Denver, CO 80262 USA; Univ Colorado, Sch Med, Dept Pharmacol, Denver, CO 80262 USA	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Maller, JL (corresponding author), Univ Colorado, Sch Med, Howard Hughes Med Inst, Denver, CO 80262 USA.							Bayaa M, 2000, P NATL ACAD SCI USA, V97, P12607, DOI 10.1073/pnas.220302597; Boonyaratanakornkit V, 2001, MOL CELL, V8, P269, DOI 10.1016/S1097-2765(01)00304-5; Duckworth BC, 2002, P NATL ACAD SCI USA, V99, P16794, DOI 10.1073/pnas.222661299; Losel R, 2003, NAT REV MOL CELL BIO, V4, P46, DOI 10.1038/nrm1009; Maller JL, 2001, P NATL ACAD SCI USA, V98, P8, DOI 10.1073/pnas.98.1.8; Mehlmann LM, 2002, SCIENCE, V297, P1343, DOI 10.1126/science.1073978; Schmitt A, 2002, P NATL ACAD SCI USA, V99, P4361, DOI 10.1073/pnas.022056399; Sheng YL, 2001, CURR BIOL, V11, P405, DOI 10.1016/S0960-9822(01)00123-3; Tian JD, 2000, P NATL ACAD SCI USA, V97, P14358, DOI 10.1073/pnas.250492197; YONG Z, 2003, P NATL ACAD SCI USA, V100, P2237; Zhu Y, 2003, P NATL ACAD SCI USA, V100, P2231, DOI 10.1073/pnas.0336132100	11	37	38	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 25	2003	300	5619					594	595		10.1126/science.1083725	http://dx.doi.org/10.1126/science.1083725			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	671FB	12714732				2022-12-28	WOS:000182453700028
J	Savic, R; Luo, LB; Eisenberg, A; Maysinger, D				Savic, R; Luo, LB; Eisenberg, A; Maysinger, D			Micellar nanocontainers distribute to defined cytoplasmic organelles	SCIENCE			English	Article							BLOCK-COPOLYMER MICELLES; DRUG-DELIVERY; CELLS; NANOPARTICLES; DIBLOCK; TARGET; NERVE	Block copolymer micelles are water-soluble biocompatible nanocontainers with great potential for delivering hydrophobic drugs. An understanding of their cellular distribution is essential to achieving selective delivery of drugs at the subcellular level. Triple-labeling confocal microscopy in live cells revealed the localization of micelles in several cytoplasmic organelles, including mitochondria, but not in the nucleus. Moreover, micelles change the cellular distribution of and increase the amount of the agent delivered to the cells. These micelles may thus be worth exploring for their potential to selectively deliver drugs to specified subcellular targets.	McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Chem, Montreal, PQ H3A 2K6, Canada	McGill University; McGill University	Maysinger, D (corresponding author), McGill Univ, Dept Pharmacol & Therapeut, 3655 Drummond St, Montreal, PQ H3G 1Y6, Canada.		Maysinger, Dusica/GYU-6332-2022; Eisenberg, Adi/B-8676-2008					Allen C, 2000, DRUG DELIV, V7, P139; De Jaeghere F, 2000, J DRUG TARGET, V8, P143, DOI 10.3109/10611860008996860; Discher DE, 2002, SCIENCE, V297, P967, DOI 10.1126/science.1074972; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Haughland R.P., 1996, HDB FLUORESCENT PROB; Kabanov AV, 2002, CRIT REV THER DRUG, V19, P1, DOI 10.1615/CritRevTherDrugCarrierSyst.v19.i1.10; Kakizawa Y, 2002, ADV DRUG DELIVER REV, V54, P203, DOI 10.1016/S0169-409X(02)00017-0; Kataoka K, 2001, ADV DRUG DELIVER REV, V47, P113, DOI 10.1016/S0169-409X(00)00124-1; Langer R, 2001, SCIENCE, V293, P58, DOI 10.1126/science.1063273; LASIC DD, 1995, SCIENCE, V267, P1275, DOI 10.1126/science.7871422; Liaw J, 1999, PHARM RES-DORDR, V16, P213, DOI 10.1023/A:1012157906528; Liu JQ, 2001, BIOMACROMOLECULES, V2, P362, DOI 10.1021/bm015515c; Luo LB, 2002, BIOCONJUGATE CHEM, V13, P1259, DOI 10.1021/bc025524y; MAYSINGER D, 2002, POLYM BIOMATERIALS, pCH42; Moghimi SM, 2001, PHARMACOL REV, V53, P283; Rapoport N, 2002, J PHARM SCI, V91, P157, DOI 10.1002/jps.10006; Saltzman W. M., 2001, DRUG DELIVERY ENG PR; Szleifer I, 1997, CURR OPIN SOLID ST M, V2, P337, DOI 10.1016/S1359-0286(97)80125-8; Torchilin VP, 2002, ADV DRUG DELIVER REV, V54, P235, DOI 10.1016/S0169-409X(02)00019-4; Vaudry D, 2002, SCIENCE, V296, P1648, DOI 10.1126/science.1071552; Webb RH, 1999, METHOD ENZYMOL, V307, P3; YOKOYAMA M, 1998, BIORELATED POLYM GEL, pCH6; Zhang LF, 1996, SCIENCE, V272, P1777, DOI 10.1126/science.272.5269.1777	23	978	1026	7	240	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 25	2003	300	5619					615	618		10.1126/science.1078192	http://dx.doi.org/10.1126/science.1078192			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	671FB	12714738				2022-12-28	WOS:000182453700034
J	Bonifacio, P; Limongi, M; Chieffi, A				Bonifacio, P; Limongi, M; Chieffi, A			How did the metals in a giant star originate?	NATURE			English	Article							CHEMICAL-COMPOSITION; POOR STARS; SUPERNOVAE		Osserv Astron Trieste, Ist Nazl Astrofis, I-34131 Trieste, Italy; Osserv Astron Roma, Ist Nazl Astrofis, I-00040 Rome, Italy; CNR, Ist Astrofis Spaziale, I-00133 Rome, Italy	Istituto Nazionale Astrofisica (INAF); Istituto Nazionale Astrofisica (INAF); Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale Astrofisica (INAF)	Bonifacio, P (corresponding author), Osserv Astron Trieste, Ist Nazl Astrofis, I-34131 Trieste, Italy.	bonifaci@ts.astro.it						Aoki W, 2002, ASTROPHYS J, V576, pL141, DOI 10.1086/343761; Chieffi A, 2002, ASTROPHYS J, V577, P281, DOI 10.1086/342170; Chieffi A, 2002, ASTROPHYS SPACE SC L, V274, P47; Depagne E, 2002, ASTRON ASTROPHYS, V390, P187, DOI 10.1051/0004-6361:20020687	5	19	19	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 24	2003	422	6934					834	834		10.1038/422834a	http://dx.doi.org/10.1038/422834a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	670WR	12712194	Bronze, Green Submitted			2022-12-28	WOS:000182432600042
J	Carroll, SB				Carroll, SB			Genetics and the making of Homo sapiens	NATURE			English	Review							PLANUM TEMPORALE; BRISTLE NUMBER; MODERN HUMANS; GREAT APES; ENDOCRANIAL CAPACITY; POSITIVE SELECTION; RAPID EVOLUTION; MIDDLE AWASH; HUMAN GENOME; HOMINID	Understanding the genetic basis of the physical and behavioural traits that distinguish humans from other primates presents one of the great new challenges in biology. Of the millions of base-pair differences between humans and chimpanzees, which particular changes contributed to the evolution of human features after the separation of the Pan and Homo lineages 5-7 million years ago? How can we identify the 'smoking guns' of human genetic evolution from neutral ticks of the molecular evolutionary clock? The magnitude and rate of morphological evolution in hominids suggests that many independent and incremental developmental changes have occurred that, on the basis of recent findings in model animals, are expected to be polygenic and regulatory in nature. Comparative genomics, population genetics, gene-expression analyses and medical genetics have begun to make complementary inroads into the complex genetic architecture of human evolution.	Univ Wisconsin, Howard Hughes Med Inst, Madison, WI 53706 USA; Univ Wisconsin, Mol Biol Lab, Madison, WI 53706 USA	Howard Hughes Medical Institute; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Carroll, SB (corresponding author), Univ Wisconsin, Howard Hughes Med Inst, 1525 Linden Dr, Madison, WI 53706 USA.	sbcarrol@facstaff.wisc.edu						Andolfatto P, 2001, CURR OPIN GENET DEV, V11, P635, DOI 10.1016/S0959-437X(00)00246-X; Asfaw B, 2002, NATURE, V416, P317, DOI 10.1038/416317a; ATCHLEY WR, 1985, GENETICS, V111, P579; Atchley WR, 1997, GENETICS, V147, P765; Brakefield PM, 1996, NATURE, V384, P236, DOI 10.1038/384236a0; Britten RJ, 2002, P NATL ACAD SCI USA, V99, P13633, DOI 10.1073/pnas.172510699; Brodmann Karl, 1912, Anatomischer Anzeiger, V41; Brunet M, 2002, NATURE, V418, P145, DOI 10.1038/nature00879; Buxhoeveden DR, 2001, BRAIN BEHAV EVOLUT, V57, P349, DOI 10.1159/000047253; Cantalupo C, 2001, NATURE, V414, P505, DOI 10.1038/35107134; Carroll S. B., 2001, DNA DIVERSITY MOL GE; CHARLESWORTH B, 1982, EVOLUTION, V36, P474, DOI 10.1111/j.1558-5646.1982.tb05068.x; Chen FC, 2001, AM J HUM GENET, V68, P444, DOI 10.1086/318206; Conroy GC, 2000, AM J PHYS ANTHROPOL, V113, P111; Conroy GC, 1998, SCIENCE, V280, P1730, DOI 10.1126/science.280.5370.1730; Coyne JA, 2002, NATURE, V418, P19, DOI 10.1038/418019a; Davidson E. H., 2001, DEV EVOLUTION; de Leon MSP, 2001, NATURE, V412, P534, DOI 10.1038/35087573; Dean C, 2001, NATURE, V414, P628, DOI 10.1038/414628a; Diller KC, 2002, MOL BIOL EVOL, V19, P2342, DOI 10.1093/oxfordjournals.molbev.a004061; DOEBLEY J, 1993, GENETICS, V134, P559; Enard W, 2002, NATURE, V418, P869, DOI 10.1038/nature01025; Enard W, 2002, SCIENCE, V296, P340, DOI 10.1126/science.1068996; Fay JC, 2001, GENETICS, V158, P1227; Fujiyama A, 2002, SCIENCE, V295, P131, DOI 10.1126/science.1065199; Gannon PJ, 1998, SCIENCE, V279, P220, DOI 10.1126/science.279.5348.220; Gibson G, 1999, GENETICS, V151, P1081; GINGERICH PD, 1983, SCIENCE, V222, P159, DOI 10.1126/science.222.4620.159; Gingerich PD, 2001, GENETICA, V112, P127, DOI 10.1023/A:1013311015886; Goldschmidt R., 1940, MAT BASIS EVOLUTION; Gould S. J., 1977, ONTOGENY PHYLOGENY; Groves C.P., 1986, P187; Hacia JG, 2001, TRENDS GENET, V17, P637, DOI 10.1016/S0168-9525(01)02494-5; Haile-Selassie Y, 2001, NATURE, V412, P178, DOI 10.1038/35084063; Hof PR, 2001, NEUROSCI LETT, V307, P139, DOI 10.1016/S0304-3940(01)01964-4; HOLLOWAY RL, 1980, AM J PHYS ANTHROPOL, V53, P285, DOI 10.1002/ajpa.1330530213; Hopkins WD, 1998, J COMP PSYCHOL, V112, P95, DOI 10.1037/0735-7036.112.1.95; Hopkins WD, 1998, NEUROREPORT, V9, P2913, DOI 10.1097/00001756-199808240-00043; Hughes A.L., 1999, ADAPTIVE EVOLUTION G; Johnson ME, 2001, NATURE, V413, P514, DOI 10.1038/35097067; KIMBEL WH, 1994, NATURE, V368, P449, DOI 10.1038/368449a0; KING MC, 1975, SCIENCE, V188, P107, DOI 10.1126/science.1090005; KLEIN J, 2002, WHERE DO WE COME FRO; Klein RG, 2000, EVOL ANTHROPOL, V9, P17, DOI 10.1002/(SICI)1520-6505(2000)9:1<17::AID-EVAN3>3.0.CO;2-A; Kreitman M, 2000, ANNU REV GENOM HUM G, V1, P539, DOI 10.1146/annurev.genom.1.1.539; LAI CG, 1994, SCIENCE, V266, P1697, DOI 10.1126/science.7992053; Lai CSL, 2001, NATURE, V413, P519, DOI 10.1038/35097076; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lauter N, 2002, GENETICS, V160, P333; Leakey MG, 2001, NATURE, V410, P433, DOI 10.1038/35068500; Li W. H, 1997, MOL EVOLUTION; Lieberman DE, 2002, P NATL ACAD SCI USA, V99, P1134, DOI 10.1073/pnas.022440799; Livshits G, 2002, ANN HUM BIOL, V29, P271, DOI 10.1080/03014460110085322; Long AD, 2000, GENETICS, V154, P1255; Long AD, 1998, GENETICS, V149, P999; MACFADDEN BJ, 1986, PALEOBIOLOGY, V12, P355, DOI 10.1017/S0094837300003109; Mackay TFC, 2001, NAT REV GENET, V2, P11, DOI 10.1038/35047544; McCollum MA, 2001, BIOESSAYS, V23, P481, DOI 10.1002/bies.1068; MCDONALD JH, 1991, NATURE, V351, P652, DOI 10.1038/351652a0; Moggi-Cecchi J, 2001, NATURE, V414, P595, DOI 10.1038/414595a; Nachman MW, 2001, TRENDS GENET, V17, P481, DOI 10.1016/S0168-9525(01)02409-X; Nimchinsky EA, 1999, P NATL ACAD SCI USA, V96, P5268, DOI 10.1073/pnas.96.9.5268; Nuzhdin SV, 2000, HEREDITY, V84, P97, DOI 10.1046/j.1365-2540.2000.00640.x; Ohta T, 2002, P NATL ACAD SCI USA, V99, P16134, DOI 10.1073/pnas.252626899; Penin X, 2002, AM J PHYS ANTHROPOL, V118, P50, DOI 10.1002/ajpa.10044; Pinker S, 2001, NATURE, V413, P465, DOI 10.1038/35097173; Polaczyk PJ, 1998, DEV GENES EVOL, V207, P462, DOI 10.1007/s004270050137; Ptak SE, 2002, TRENDS GENET, V18, P559, DOI 10.1016/S0168-9525(02)02781-6; RELETHFORD JH, 2001, GENETICS SEARCH MODE; Rice SH, 2002, HUMAN EVOLUTION THROUGH DEVELOPMENTAL CHANGE, P154; Richmond BG, 2002, J HUM EVOL, V43, P529, DOI 10.1006/jhev.2002.0594; Ruff CB, 1997, NATURE, V387, P173, DOI 10.1038/387173a0; Rutherford SL, 1998, NATURE, V396, P336, DOI 10.1038/24550; Sabeti PC, 2002, NATURE, V419, P832, DOI 10.1038/nature01140; Schwartz JH, 1999, ANAT RECORD, V257, P15; Semendeferi K, 2002, NAT NEUROSCI, V5, P272, DOI 10.1038/nn814; Semendeferi K, 2001, AM J PHYS ANTHROPOL, V114, P224, DOI 10.1002/1096-8644(200103)114:3<224::AID-AJPA1022>3.3.CO;2-9; SHUBIN N, 1995, EVOLUTION, V49, P874, DOI 10.1111/j.1558-5646.1995.tb02323.x; Stam LF, 1996, GENETICS, V144, P1559; Swanson WJ, 2002, NAT REV GENET, V3, P137, DOI 10.1038/nrg733; TAJIMA F, 1989, GENETICS, V123, P585; True JR, 1997, EVOLUTION, V51, P816, DOI [10.2307/2411157, 10.1111/j.1558-5646.1997.tb03664.x]; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Wang RL, 1999, NATURE, V398, P236, DOI 10.1038/18435; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; Wilkins A.S., 2002, EVOLUTION DEV PATHWA; Williams FL, 2002, HUMAN EVOLUTION THROUGH DEVELOPMENTAL CHANGE, P405; Wolpoff MH, 2002, NATURE, V419, P581, DOI 10.1038/419581a; Wood B, 1999, SCIENCE, V284, P65, DOI 10.1126/science.284.5411.65; Wood B, 2002, NATURE, V418, P133, DOI 10.1038/418133a; Wyckoff GJ, 2000, NATURE, V403, P304, DOI 10.1038/35002070; Yan H, 2002, SCIENCE, V297, P1143, DOI 10.1126/science.1072545	92	194	202	1	89	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 24	2003	422	6934					849	857		10.1038/nature01495	http://dx.doi.org/10.1038/nature01495			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	670WR	12712196				2022-12-28	WOS:000182432600045
J	Alexandroff, AB; Hazleman, BL; Matthewson, M; Black, CM; Rytina, E; Crawford, R; Burrows, NP				Alexandroff, AB; Hazleman, BL; Matthewson, M; Black, CM; Rytina, E; Crawford, R; Burrows, NP			Woody hands	LANCET			English	Editorial Material							PALMAR FASCIITIS; POLYARTHRITIS; CARCINOMA		Addenbrookes Hosp, Dept Dermatol, Cambridge CB2 2SP, England; Addenbrookes Hosp, Dept Rheumatol, Cambridge CB2 2SP, England; Addenbrookes Hosp, Dept Orthopaed Surg, Cambridge CB2 2SP, England; Addenbrookes Hosp, Dept Pathol, Cambridge CB2 2SP, England; Addenbrookes Hosp, Dept Gynaecol Oncol, Cambridge CB2 2SP, England; Royal Free Hosp, Dept Rheumatol, London, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	Burrows, NP (corresponding author), Addenbrookes Hosp, Dept Dermatol, Cambridge CB2 2SP, England.							CHAMPION GD, 1987, J RHEUMATOL, V14, P1196; Cox NH, 1996, BRIT J DERMATOL, V135, P995, DOI 10.1046/j.1365-2133.1996.d01-1110.x; Enomoto M, 2000, INTERNAL MED, V39, P754, DOI 10.2169/internalmedicine.39.754; PFINSGRAFF J, 1986, SEMIN ARTHRITIS RHEU, V16, P118, DOI 10.1016/0049-0172(86)90045-4; SEAMAN JM, 1985, ARTHRITIS RHEUM, V28, P1179, DOI 10.1002/art.1780281017	5	17	17	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 19	2003	361	9366					1344	1344		10.1016/S0140-6736(03)13082-6	http://dx.doi.org/10.1016/S0140-6736(03)13082-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	669HP	12711470				2022-12-28	WOS:000182346100012
J	Chan-Yeung, M; Yu, WC				Chan-Yeung, M; Yu, WC			Outbreak of severe acute respiratory syndrome in Hong kong special administrative region: case report	BRITISH MEDICAL JOURNAL			English	Article								Objective To describe the outbreak of severe acute respiratory syndrome in Hong Kong. Design Descriptive case series. Setting Hong Kong, Special Administrative Region, China Results The outbreak started with a visitor from southern China on 21 February At the hospitals where the first cases were treated the disease spread quickly among healthcare workers, and then out into the community as family members became infected. By 1 April, 685 cases had been reported with 16 deaths. Symptoms include high fever and one or more respiratory symptoms (including cough, shortness of breath, and difficulty breathing,). Changes in lung tissue suggest that part of the lung damage is due to cytokines induced by the microbial agent, which has led to empirical treatment with corticosteroids, broad spectrum antiviral agent, and antibacterial cover. There is strong evidence that a novel coronavirus is the pathogen. Precautions for droplet infection should be instituted, including the wearing of masks and rigorous disinfection and hygiene procedures. On 27 March the Department of Health announced drastic measures, including vigorous contact tracing and examination, quarantine of contacts in their homes, and closure of all schools and universities. Conclusion The rapidity of the spread of the disease and the morbidity indicate that the agent responsible is highly infectious and virulent. Strict infection control measures for droplet and contact transmission by healthcare workers, a vigilant healthcare profession, and public education are essential for disease prevention.	Univ Hong Kong, Queen Mary Hosp, Div Resp & Crit Care Med, Hong Kong, Hong Kong, Peoples R China; Princess Margaret Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong	Chan-Yeung, M (corresponding author), Univ Hong Kong, Queen Mary Hosp, Div Resp & Crit Care Med, 4-F,Professorial Block, Hong Kong, Hong Kong, Peoples R China.							Centers for Disease Control and Prevention, SEV AC RESP SYNDR SA; *GOV HONG KONG SPE, ATYP PNEUM; *HOSP AUTH, 2003, SEV AC RESP SYNDR CL; LEE N, 2003, N ENGL J MED, V7; PERIRIS JSM, 2003, LANCET, V8; TSANG KW, 2003, N ENGL J MED    0401; *WHO, 2003, SEV AC RESP SYNDR	7	79	95	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 19	2003	326	7394					850	+		10.1136/bmj.326.7394.850	http://dx.doi.org/10.1136/bmj.326.7394.850			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	670BF	12702616	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000182386800016
J	Middleton, E; Baker, D				Middleton, E; Baker, D			Comparison of social distribution of immunisation with measles, mumps, and rubella vaccine, England, 1991-2001	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Univ Manchester, Natl Primary Care Res & Dev Ctr, Manchester M13 9PL, Lancs, England	University of Manchester	Baker, D (corresponding author), Univ Manchester, Natl Primary Care Res & Dev Ctr, Manchester M13 9PL, Lancs, England.	d.j.baker@salford.ac.uk						Baker D, 1998, BRIT MED J, V317, P1659; *COMM DIS SURV CTR, 1999, COMMUN DIS REP CDR W, V9, P37; Marshall H, 2001, Trends Immunol, V22, P14, DOI 10.1016/S1471-4906(00)01846-9; TONSEND P, 1985, INT J HEALTH SERV, V15, P637, DOI 10.2190/AN09-8R52-UE6B-VWUU; Victora CG, 2000, LANCET, V356, P1093, DOI 10.1016/S0140-6736(00)02741-0	5	45	45	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 19	2003	326	7394					854	854		10.1136/bmj.326.7394.854	http://dx.doi.org/10.1136/bmj.326.7394.854			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	670BF	12702619	Green Published, Bronze			2022-12-28	WOS:000182386800019
J	Brochard-Wyart, F; de Gennes, PG				Brochard-Wyart, F; de Gennes, PG			How soft skin wrinkles	SCIENCE			English	Editorial Material									Inst Curie, Sect Rech, F-75231 Paris 05, France; Coll France, F-75231 Paris, France	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; College de France	Brochard-Wyart, F (corresponding author), Inst Curie, Sect Rech, 11 Rue Pierre & Marie Curie, F-75231 Paris 05, France.							Cerda E, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.074302; DEGENNES PG, 1993, PHYSICS LIQUID CRYST; LOBKOVSKY A, 1995, SCIENCE, V270, P1482, DOI 10.1126/science.270.5241.1482; THOMPSON DW, 1942, GROWTH FORM NEW EDIT	4	21	22	0	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 18	2003	300	5618					441	441		10.1126/science.300.5618.441	http://dx.doi.org/10.1126/science.300.5618.441			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	668LR	12702864				2022-12-28	WOS:000182295900025
J	Chang, EF; Merzenich, MM				Chang, EF; Merzenich, MM			Environmental noise retards auditory cortical development	SCIENCE			English	Article							PLASTICITY; CORTEX; MATURATION; EXPERIENCE; CATS; SENSITIVITY; PERIODS; RAT; MAP	The mammalian auditory cortex normally undergoes rapid and progressive functional maturation. Here we show that rearing infant rat pups in continuous, moderate-level noise delayed the emergence of adultlike topographic representational order and the refinement of response selectivity in the primary auditory cortex (A1) long beyond normal developmental benchmarks. When those noise-reared adult rats were subsequently exposed to a pulsed pure-tone stimulus, A1 rapidly reorganized, demonstrating that exposure-driven plasticity characteristic of the critical period was still ongoing. These results demonstrate that A1 organization is shaped by a young animal's exposure to salient, structured acoustic inputs-and implicate noise as a risk factor for abnormal child development.	Univ Calif San Francisco, WM Keck Ctr Integrat Neurosci, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Chang, EF (corresponding author), Univ Calif San Francisco, WM Keck Ctr Integrat Neurosci, San Francisco, CA 94143 USA.	echang@itsa.ucsf.edu			NINDS NIH HHS [NS-38416, NS-10414] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AHISSAR E, 1992, SCIENCE, V257, P1412, DOI 10.1126/science.1529342; Bao SW, 2001, NATURE, V412, P79, DOI 10.1038/35083586; CASTREN E, 1992, P NATL ACAD SCI USA, V89, P9444, DOI 10.1073/pnas.89.20.9444; COSTALUPES JA, 1984, J NEUROPHYSIOL, V51, P1326, DOI 10.1152/jn.1984.51.6.1326; CYNADER M, 1980, J NEUROPHYSIOL, V43, P1026, DOI 10.1152/jn.1980.43.4.1026; EDELINE JM, 1993, BEHAV NEUROSCI, V107, P539, DOI 10.1037/0735-7044.107.4.539; Ehret G, 2000, HEARING RES, V141, P107, DOI 10.1016/S0378-5955(99)00213-0; Etzel RA, 1997, PEDIATRICS, V100, P724; Hanover JL, 1999, J NEUROSCI, V19, part. no.; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; Iyengar S, 2002, J NEUROSCI, V22, P946, DOI 10.1523/JNEUROSCI.22-03-00946.2002; Kilgard MP, 1998, SCIENCE, V279, P1714, DOI 10.1126/science.279.5357.1714; Klinke R, 1999, SCIENCE, V285, P1729, DOI 10.1126/science.285.5434.1729; Kral A, 2001, AUDIOL NEURO-OTOL, V6, P346, DOI 10.1159/000046845; KUHL PK, 1992, SCIENCE, V255, P606, DOI 10.1126/science.1736364; MARLER P, 1973, P NATL ACAD SCI USA, V70, P1393, DOI 10.1073/pnas.70.5.1393; MOORE DR, 1985, ACTA OTO-LARYNGOL, P19; MOWER GD, 1981, BRAIN RES, V220, P255, DOI 10.1016/0006-8993(81)91216-6; PHILBIN MK, 1994, DEV PSYCHOBIOL, V27, P11; PHILLIPS DP, 1985, HEARING RES, V18, P87, DOI 10.1016/0378-5955(85)90112-1; Ponton CW, 1996, NEUROREPORT, V8, P61, DOI 10.1097/00001756-199612200-00013; SALLY SL, 1988, J NEUROPHYSIOL, V59, P1627, DOI 10.1152/jn.1988.59.5.1627; SANES DH, 1983, SCIENCE, V221, P1183, DOI 10.1126/science.6612332; Shepherd RK, 1997, ACTA OTO-LARYNGOL, P28; Stanton SG, 1996, AUDIT NEUROSCI, V2, P97; White LE, 2001, NATURE, V411, P1049, DOI 10.1038/35082568; WITHINGTONWRAY DJ, 1990, EUR J NEUROSCI, V2, P693, DOI 10.1111/j.1460-9568.1990.tb00459.x; Zhang LI, 2001, NAT NEUROSCI, V4, P1123, DOI 10.1038/nn745; Zhang LI, 2002, P NATL ACAD SCI USA, V99, P2309, DOI 10.1073/pnas.261707398	29	383	392	1	66	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 18	2003	300	5618					498	502		10.1126/science.1082163	http://dx.doi.org/10.1126/science.1082163			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	668LR	12702879				2022-12-28	WOS:000182295900044
J	Pawson, T; Nash, P				Pawson, T; Nash, P			Assembly of cell regulatory systems through protein interaction domains	SCIENCE			English	Review							PUMILIO-HOMOLOGY DOMAIN; ABL TYROSINE KINASE; TGF-BETA RECEPTOR; SRC SH2 DOMAIN; STRUCTURAL BASIS; CRYSTAL-STRUCTURE; UBIQUITIN LIGASE; SACCHAROMYCES-CEREVISIAE; PEPTIDE RECOGNITION; SIGNAL-TRANSDUCTION	The sequencing of complete genomes provides a list that includes the proteins responsible for cellular regulation. However, this does not immediately reveal what these proteins do, nor how they are assembled into the molecular machines and functional networks that control cellular behavior. The regulation of many different cellular processes requires the use of protein interaction domains to direct the association of polypeptides with one another and with phospholipids, small molecules, or nucleic acids. The modular nature of these domains, and the flexibility of their binding properties, have likely facilitated the evolution of cellular pathways. Conversely, aberrant interactions can induce abnormal cellular behavior and disease. The fundamental properties of protein interaction domains are discussed in this review and in detailed reviews on individual domains at Science's STKE at http://www.sciencemag.org/cgi/content/full/300/5618/445/DC1.	Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON M5S 1A8, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto	Pawson, T (corresponding author), Mt Sinai Hosp, Samuel Lunenfeld Res Inst, 600 Univ Ave, Toronto, ON M5G 1X5, Canada.	pawson@mshri.on.ca	Pawson, Tony J/E-4578-2013					Aarts M, 2002, SCIENCE, V298, P846, DOI 10.1126/science.1072873; Agalioti T, 2002, CELL, V111, P381, DOI 10.1016/S0092-8674(02)01077-2; Albert R, 2000, NATURE, V406, P378, DOI 10.1038/35019019; Apic G, 2001, Bioinformatics, V17 Suppl 1, pS83; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Aurandt J, 2002, P NATL ACAD SCI USA, V99, P12085, DOI 10.1073/pnas.142433199; Bader GD, 2002, NAT BIOTECHNOL, V20, P991, DOI 10.1038/nbt1002-991; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Bashaw GJ, 2000, CELL, V101, P703, DOI 10.1016/S0092-8674(00)80883-1; Bear JE, 2002, CELL, V109, P509, DOI 10.1016/S0092-8674(02)00731-6; Betschinger J, 2003, NATURE, V422, P326, DOI 10.1038/nature01486; Bilder D, 2003, NAT CELL BIOL, V5, P53, DOI 10.1038/ncb897; Blomberg N, 1999, TRENDS BIOCHEM SCI, V24, P441, DOI 10.1016/S0968-0004(99)01472-3; Bradley JR, 2001, ONCOGENE, V20, P6482, DOI 10.1038/sj.onc.1204788; Bradshaw JM, 2000, J MOL BIOL, V299, P521; Chan B, 2003, NAT CELL BIOL, V5, P155, DOI 10.1038/ncb920; Choi JW, 1996, SCIENCE, V273, P239, DOI 10.1126/science.273.5272.239; Cochran AG, 2000, CHEM BIOL, V7, pR85, DOI 10.1016/S1074-5521(00)00106-X; Copley RR, 2002, FEBS LETT, V513, P129, DOI 10.1016/S0014-5793(01)03289-6; Cullen PJ, 2001, CURR BIOL, V11, pR882, DOI 10.1016/S0960-9822(01)00523-1; Dajani R, 2003, EMBO J, V22, P494, DOI 10.1093/emboj/cdg068; Dikic I, 2002, FEBS LETT, V529, P110, DOI 10.1016/S0014-5793(02)03188-5; Dodge KL, 2001, EMBO J, V20, P1921, DOI 10.1093/emboj/20.8.1921; Donaldson LW, 2002, P NATL ACAD SCI USA, V99, P14053, DOI 10.1073/pnas.212518799; Doray B, 2002, P NATL ACAD SCI USA, V99, P8072, DOI 10.1073/pnas.082235699; Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; Durocher D, 2000, MOL CELL, V6, P1169, DOI 10.1016/S1097-2765(00)00114-3; Ebnet K, 2001, EMBO J, V20, P3738, DOI 10.1093/emboj/20.14.3738; Edwards TA, 2001, CELL, V105, P281, DOI 10.1016/S0092-8674(01)00318-X; Fambrough D, 1999, CELL, V97, P727, DOI 10.1016/S0092-8674(00)80785-0; Ficarro SB, 2002, NAT BIOTECHNOL, V20, P301, DOI 10.1038/nbt0302-301; Garcia CK, 2001, SCIENCE, V292, P1394, DOI 10.1126/science.1060458; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Ghose R, 2001, NAT STRUCT BIOL, V8, P998, DOI 10.1038/nsb1101-998; Graham TA, 2002, MOL CELL, V10, P563, DOI 10.1016/S1097-2765(02)00637-8; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; Groves MR, 1999, CURR OPIN STRUC BIOL, V9, P383, DOI 10.1016/S0959-440X(99)80052-9; Gruenheid S, 2001, NAT CELL BIOL, V3, P856, DOI 10.1038/ncb0901-856; Hamada K, 2003, EMBO J, V22, P502, DOI 10.1093/emboj/cdg039; Harris K, 2001, CURR BIOL, V11, P1815, DOI 10.1016/S0960-9822(01)00567-X; Hassan AH, 2002, CELL, V111, P369, DOI 10.1016/S0092-8674(02)01005-X; He GC, 2002, J BIOL CHEM, V277, P44044, DOI 10.1074/jbc.M208539200; He YP, 2002, BLOOD, V99, P2957, DOI 10.1182/blood.V99.8.2957; Hillier BJ, 1999, SCIENCE, V284, P812, DOI 10.1126/science.284.5415.812; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Hofmann K, 1999, CELL MOL LIFE SCI, V55, P1113, DOI 10.1007/s000180050361; Hon WC, 2002, NATURE, V417, P975, DOI 10.1038/nature00767; Huang X, 2000, NAT STRUCT BIOL, V7, P634, DOI 10.1038/77923; Huber AH, 2001, CELL, V105, P391, DOI 10.1016/S0092-8674(01)00330-0; Hurd TW, 2003, NAT CELL BIOL, V5, P137, DOI 10.1038/ncb923; Huse M, 2001, MOL CELL, V8, P671, DOI 10.1016/S1097-2765(01)00332-X; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jacobs SA, 2002, SCIENCE, V295, P2080, DOI 10.1126/science.1069473; Jacobson RH, 2000, SCIENCE, V288, P1422, DOI 10.1126/science.288.5470.1422; JENVWEIN T, 2001, SCIENCE, V203, P1074; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Joberty G, 2000, NAT CELL BIOL, V2, P531, DOI 10.1038/35019573; Jogl G, 2002, EMBO J, V21, P4785, DOI 10.1093/emboj/cdf502; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Kemphues K, 2000, CELL, V101, P345, DOI 10.1016/S0092-8674(00)80844-2; Kessels HWHG, 2002, P NATL ACAD SCI USA, V99, P8524, DOI 10.1073/pnas.142224499; Kim CA, 2002, NAT STRUCT BIOL, V9, P453, DOI 10.1038/nsb802; Kimber MS, 2000, MOL CELL, V5, P1043, DOI 10.1016/S1097-2765(00)80269-5; Knoblich JA, 2001, NAT REV MOL CELL BIO, V2, P11, DOI 10.1038/35048085; Kuriyan J, 1997, ANNU REV BIOPH BIOM, V26, P259, DOI 10.1146/annurev.biophys.26.1.259; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LASKO P, 2003, SCI STKE, pRE6; Latour S, 2003, NAT CELL BIOL, V5, P149, DOI 10.1038/ncb919; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Li JJ, 2002, MOL CELL, V9, P1045, DOI 10.1016/S1097-2765(02)00527-0; Li SC, 1999, CURR BIOL, V9, P1355, DOI 10.1016/S0960-9822(00)80080-9; Lin D, 2000, NAT CELL BIOL, V2, P540, DOI 10.1038/35019582; Liu Q, 2003, MOL CELL, V11, P471, DOI 10.1016/S1097-2765(03)00046-7; Lock LS, 2000, J BIOL CHEM, V275, P31536, DOI 10.1074/jbc.M003597200; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Mayer BJ, 2001, J CELL SCI, V114, P1253; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; Migaud M, 1998, NATURE, V396, P433, DOI 10.1038/24790; Min JH, 2002, SCIENCE, V296, P1886, DOI 10.1126/science.1073440; Misra S, 2002, NATURE, V415, P933, DOI 10.1038/415933a; Mujtaba S, 2002, MOL CELL, V9, P575, DOI 10.1016/S1097-2765(02)00483-5; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; Nagar B, 2003, CELL, V112, P859, DOI 10.1016/S0092-8674(03)00194-6; Nash P, 2001, NATURE, V414, P514, DOI 10.1038/35107009; NASH P, UNPUB; Nguyen JT, 1998, SCIENCE, V282, P2088, DOI 10.1126/science.282.5396.2088; Nielsen PR, 2002, NATURE, V416, P103, DOI 10.1038/nature722; Nourry Claire, 2003, Sci STKE, V2003, pRE7; Ohno S, 2001, CURR OPIN CELL BIOL, V13, P641, DOI 10.1016/S0955-0674(00)00264-7; Orlicky S, 2003, CELL, V112, P243, DOI 10.1016/S0092-8674(03)00034-5; Owen DJ, 2000, EMBO J, V19, P6141, DOI 10.1093/emboj/19.22.6141; Pallen M, 2002, TRENDS MICROBIOL, V10, P556, DOI 10.1016/S0966-842X(02)02476-9; Park SH, 2003, SCIENCE, V299, P1061, DOI 10.1126/science.1076979; Park YC, 2000, CELL, V101, P777, DOI 10.1016/S0092-8674(00)80889-2; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Pawson T, 2000, GENE DEV, V14, P1027; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Perrot V, 2002, J BIOL CHEM, V277, P43115, DOI 10.1074/jbc.M206005200; Petrelli A, 2002, NATURE, V416, P187, DOI 10.1038/416187a; Plant PJ, 2003, NAT CELL BIOL, V5, P301, DOI 10.1038/ncb948; Polo S, 2002, NATURE, V416, P451, DOI 10.1038/416451a; Poy F, 2001, NAT STRUCT BIOL, V8, P1053, DOI 10.1038/nsb720; Puertollano R, 2001, SCIENCE, V292, P1712, DOI 10.1126/science.1060750; Qiu RG, 2000, CURR BIOL, V10, P697, DOI 10.1016/S0960-9822(00)00535-2; Rhee J, 2002, NAT CELL BIOL, V4, P798, DOI 10.1038/ncb858; Salomon AR, 2003, P NATL ACAD SCI USA, V100, P443, DOI 10.1073/pnas.2436191100; Sawyer TK, 2002, MINI-REV MED CHEM, V2, P475, DOI 10.2174/1389557023405765; Sayos J, 1998, NATURE, V395, P462, DOI 10.1038/26683; Scaplehorn N, 2002, CURR BIOL, V12, P740, DOI 10.1016/S0960-9822(02)00812-6; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; Schreiber SL, 2002, CELL, V111, P771, DOI 10.1016/S0092-8674(02)01196-0; Schwartz MF, 2002, MOL CELL, V9, P1055, DOI 10.1016/S1097-2765(02)00532-4; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Sheng M, 2002, SCIENCE, V298, P776, DOI 10.1126/science.1075333; Shiba T, 2002, NATURE, V415, P937, DOI 10.1038/415937a; SICHERI F, 1997, NATURE, V385, P582; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Soubeyran P, 2002, NATURE, V416, P183, DOI 10.1038/416183a; Spink KE, 2001, EMBO J, V20, P6203, DOI 10.1093/emboj/20.22.6203; Swiercz JM, 2002, NEURON, V35, P51, DOI 10.1016/S0896-6273(02)00750-X; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Tanentzapf G, 2003, NAT CELL BIOL, V5, P46, DOI 10.1038/ncb896; Tartaglia M, 2001, NAT GENET, V29, P465, DOI 10.1038/ng772; Tong AHY, 2002, SCIENCE, V295, P321, DOI 10.1126/science.1064987; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Verdecia MA, 2000, NAT STRUCT BIOL, V7, P639, DOI 10.1038/77929; von Mering C, 2002, NATURE, V417, P399, DOI 10.1038/nature750; Wajant H, 2001, CELL SIGNAL, V13, P389, DOI 10.1016/S0898-6568(01)00160-7; Wang XQ, 2002, CELL, V110, P501, DOI 10.1016/S0092-8674(02)00873-5; Wang XQ, 2001, MOL CELL, V7, P855, DOI 10.1016/S1097-2765(01)00229-5; Willems AR, 1999, PHILOS T ROY SOC B, V354, P1533, DOI 10.1098/rstb.1999.0497; Wong K, 2001, CELL, V107, P209, DOI 10.1016/S0092-8674(01)00530-X; Wu JW, 2001, MOL CELL, V8, P1277, DOI 10.1016/S1097-2765(01)00421-X; Wurtele M, 2003, EMBO J, V22, P987, DOI 10.1093/emboj/cdg104; Wybenga-Groot LE, 2001, CELL, V106, P745, DOI 10.1016/S0092-8674(01)00496-2; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737; Yaffe MB, 2002, NAT REV MOL CELL BIO, V3, P177, DOI 10.1038/nrm759; Yaffe MB, 2001, CURR OPIN CELL BIOL, V13, P131, DOI 10.1016/S0955-0674(00)00189-7; Ye H, 1999, MOL CELL, V4, P321, DOI 10.1016/S1097-2765(00)80334-2; Zarrinpar Ali, 2003, Sci STKE, V2003, pRE8, DOI 10.1126/stke.2003.179.re8; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; Zhu YX, 2001, SCIENCE, V292, P1716, DOI 10.1126/science.1060896	148	1081	1269	2	162	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 18	2003	300	5618					445	452		10.1126/science.1083653	http://dx.doi.org/10.1126/science.1083653			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	668LR	12702867				2022-12-28	WOS:000182295900028
J	Gung, YC; Panning, M; Romanowicz, B				Gung, YC; Panning, M; Romanowicz, B			Global anisotropy and the thickness of continents	NATURE			English	Article							UPPER-MANTLE; LEHMANN DISCONTINUITY; BENEATH CONTINENTS; SEISMIC ANISOTROPY; VELOCITY STRUCTURE; LITHOSPHERE; INVERSION; SHIELD; MODEL	For decades there has been a vigorous debate about the depth extent of continental roots(1,2). The analysis of heat-flow(3), mantle-xenolith(4) and electrical-conductivity(5) data all indicate that the coherent, conductive part of continental roots (the 'tectosphere') is at most 200-250 km thick. Some global seismic tomographic models agree with this estimate, but others suggest that a much thicker zone of high velocities lies beneath continental shields(6-9), reaching a depth of at least 400 km. Here we show that this disagreement can be reconciled by taking into account seismic anisotropy. We show that significant radial anisotropy, with horizontally polarized shear waves travelling faster than those that are vertically polarized, is present under most cratons in the depth range 250-400 km-similar to that found under ocean basins(9,10) at shallower depths of 80-250 km. We propose that, in both cases, the anisotropy is related to shear in a low-viscosity asthenospheric channel, located at different depths under continents and oceans. The seismically defined 'tectosphere' is then at most 200-250 km thick under old continents. The 'Lehmann discontinuity', observed mostly under continents at about 200-250 km, and the 'Gutenberg discontinuity', observed under oceans at depths of about 60-80 km, may both be associated with the bottom of the lithosphere, marking a transition to flow-induced asthenospheric anisotropy.	Univ Calif Berkeley, Berkeley Seismol Lab, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Earth & Planetary Sci, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley	Romanowicz, B (corresponding author), Univ Calif Berkeley, Berkeley Seismol Lab, Berkeley, CA 94720 USA.		Panning, Mark P/B-3805-2011; Romanowicz, barbara A/H-6726-2017	Panning, Mark P/0000-0002-2041-3190; Romanowicz, barbara A/0000-0002-6208-6044; Gung, Yuancheng/0000-0001-7550-4025				ANDERSON DL, 1979, J GEOPHYS RES, V84, P7555, DOI 10.1029/JB084iB13p07555; Babuska V, 1998, PURE APPL GEOPHYS, V151, P257, DOI 10.1007/s000240050114; Bokelmann GHR, 2002, GEOLOGY, V30, P1027, DOI 10.1130/0091-7613(2002)030<1027:WFDNA>2.0.CO;2; Debayle E, 2000, EARTH PLANET SC LETT, V184, P339, DOI 10.1016/S0012-821X(00)00314-9; DZIEWONSKI AM, 1981, PHYS EARTH PLANET IN, V25, P297, DOI 10.1016/0031-9201(81)90046-7; Ekstrom G, 1998, NATURE, V394, P168, DOI 10.1038/28148; Fouch MJ, 2000, J GEOPHYS RES-SOL EA, V105, P6255, DOI 10.1029/1999JB900372; GAHERTY JB, 1995, SCIENCE, V268, P1468, DOI 10.1126/science.268.5216.1468; Gu YJ, 2001, GEOPHYS RES LETT, V28, P4655, DOI 10.1029/2001GL013679; Hirth G., 2000, GEOCHEM GEOPHY GEOSY, V1, DOI [10.1029/2000GC000048, DOI 10.1029/2000GC000048]; Jaupart C, 1998, J GEOPHYS RES-SOL EA, V103, P15269, DOI 10.1029/98JB01395; JORDAN TH, 1975, REV GEOPHYS, V13, P1, DOI 10.1029/RG013i003p00001; KARATO S, 1992, GEOPHYS RES LETT, V19, P2255, DOI 10.1029/92GL02603; LEVEN JH, 1981, NATURE, V289, P234, DOI 10.1038/289234a0; Levin V, 1999, J GEOPHYS RES-SOL EA, V104, P17975, DOI 10.1029/1999JB900168; Levin V, 2000, TECTONOPHYSICS, V323, P131, DOI 10.1016/S0040-1951(00)00105-0; LI XD, 1995, GEOPHYS J INT, V121, P695, DOI 10.1111/j.1365-246X.1995.tb06432.x; Masters G, 1996, PHILOS T R SOC A, V354, P1385, DOI 10.1098/rsta.1996.0054; Megnin C, 2000, GEOPHYS J INT, V143, P709, DOI 10.1046/j.1365-246X.2000.00298.x; Montagner JP, 2002, EARTH PLANET SC LETT, V202, P263, DOI 10.1016/S0012-821X(02)00791-4; MONTAGNER JP, 1989, PHYS EARTH PLANET IN, V54, P82, DOI 10.1016/0031-9201(89)90189-1; MONTAGNER JP, 1994, REV GEOPHYS, V32, P135; REVENAUGH J, 1991, J GEOPHYS RES-SOL EA, V96, P19781, DOI 10.1029/91JB01487; Ritsema J, 1999, SCIENCE, V286, P1925, DOI 10.1126/science.286.5446.1925; Romanowicz B, 2002, SCIENCE, V296, P513, DOI 10.1126/science.1069404; Rudnick RL, 1998, CHEM GEOL, V145, P395, DOI 10.1016/S0009-2541(97)00151-4; SHEARER PM, 1990, NATURE, V344, P121, DOI 10.1038/344121a0; Silver PG, 1996, ANNU REV EARTH PL SC, V24, P385, DOI 10.1146/annurev.earth.24.1.385; TONG C, 1994, J GEOPHYS RES-SOL EA, V99, P15783, DOI 10.1029/94JB00460; VINNIK LP, 1992, GEOPHYS J INT, V111, P433, DOI 10.1111/j.1365-246X.1992.tb02102.x	30	346	358	5	43	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 17	2003	422	6933					707	711		10.1038/nature01559	http://dx.doi.org/10.1038/nature01559			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	668CG	12700758				2022-12-28	WOS:000182272300037
J	Frazier, ME; Johnson, GM; Thomassen, DG; Oliver, CE; Patrinos, A				Frazier, ME; Johnson, GM; Thomassen, DG; Oliver, CE; Patrinos, A			Realizing the potential of the genome revolution: The Genomes to Life program	SCIENCE			English	Article								The systems biology revolution is proceeding along multiple pathways as different science agencies and the private sector have adopted strategies suited to their particular needs and cultures. To meet this challenge, the U. S. Department of Energy has developed the Genomes to Life (GTL) program. A central focus of GTL is environmental microbial biology as a way to approach global environmental problems, and its key goal is to achieve, over the next 10 to 20 years, a basic understanding of thousands of microbes and microbial systems in their native environments. This focus demands that we address huge gaps in knowledge, technology, computing, data storage and manipulation, and systems-level integration.	US DOE, Off Sci, Off Biol & Environm Res, Washington, DC 20585 USA; US DOE, Off Adv Sci Comp Res, Washington, DC 20585 USA	United States Department of Energy (DOE); United States Department of Energy (DOE)	Thomassen, DG (corresponding author), US DOE, Off Sci, Off Biol & Environm Res, SC-70,Germantown Bldg,1000 Independence Ave SW, Washington, DC 20585 USA.	david.thomassen@science.doe.gov						[Anonymous], COMMUNICATION; BUSH GW, 2001, COMMUNICATIOPN  0611; Copley J, 2002, NATURE, V415, P572, DOI 10.1038/415572a; *DOE, 1995, DOEEM0230; *OFF SCI TECHN POL, 2002, FY 2004 INT RES DEV; Tiedje JM, 2002, NAT BIOTECHNOL, V20, P1093, DOI 10.1038/nbt1102-1093; WATSON JD, 1953, NATURE, V171, P737, DOI 10.1038/171737a0; Whitman WB, 1998, P NATL ACAD SCI USA, V95, P6578, DOI 10.1073/pnas.95.12.6578; 2002, USER FACILITIES 21 C; GENOMES LIFE; GENOMES LIFE ACCELER	11	43	51	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 11	2003	300	5617					290	293		10.1126/science.1084566	http://dx.doi.org/10.1126/science.1084566			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	665RQ	12690188				2022-12-28	WOS:000182135400044
J	Notholt, J; Kuang, ZM; Rinsland, CP; Toon, GC; Rex, M; Jones, N; Albrecht, T; Deckelmann, H; Krieg, J; Weinzierl, C; Bingemer, H; Weller, R; Schrems, O				Notholt, J; Kuang, ZM; Rinsland, CP; Toon, GC; Rex, M; Jones, N; Albrecht, T; Deckelmann, H; Krieg, J; Weinzierl, C; Bingemer, H; Weller, R; Schrems, O			Enhanced upper tropical tropospheric COS: Impact on the stratospheric aerosol layer	SCIENCE			English	Article							CARBONYL SULFIDE; ATMOSPHERIC CHEMISTRY; TRANSPORT; EMISSION; PACIFIC; PROJECT; GASES; OZONE; MODEL; NO	Carbonyl sulfide (COS) is considered to be a major source of the stratospheric sulfate aerosol during periods of volcanic quiescence. We measured COS at the tropical tropopause and find mixing ratios to be 20 to 50% larger than are assumed in models. The enhanced COS levels are correlated with high concentrations of biomass-burning pollutants like carbon monoxide ( CO) and hydrogen cyanide (HCN). The analysis of backward trajectories and global maps of. re statistics suggest that biomass-burning emissions transported upward by deep convection are the source of the enhanced COS in the upper tropical troposphere.	Univ Bremen, D-28334 Bremen, Germany; CALTECH, Pasadena, CA 91125 USA; NASA, Langley Res Ctr, Hampton, VA 23681 USA; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; Alfred Wegener Inst Polar & Marine Res, D-14473 Potsdam, Germany; Univ Wollongong, Wollongong, NSW 2522, Australia; Goethe Univ Frankfurt, D-60325 Frankfurt, Germany; Alfred Wegener Inst Polar & Marine Res, D-27568 Bremerhaven, Germany	University of Bremen; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Langley Research Center; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); Helmholtz Association; Alfred Wegener Institute, Helmholtz Centre for Polar & Marine Research; University of Wollongong; Goethe University Frankfurt; Helmholtz Association; Alfred Wegener Institute, Helmholtz Centre for Polar & Marine Research	Notholt, J (corresponding author), Univ Bremen, D-28334 Bremen, Germany.	jnotholt@iup.physik.uni-bremen.de	Jones, Nicholas/AFU-3135-2022; Rex, Markus/A-6054-2009; Notholt, Justus/P-4520-2016; Jones, Nicholas B/G-5575-2011	Jones, Nicholas/0000-0002-0111-2368; Rex, Markus/0000-0001-7847-8221; Notholt, Justus/0000-0002-3324-885X; Jones, Nicholas B/0000-0002-0111-2368				Andreae MO, 1997, SCIENCE, V276, P1052, DOI 10.1126/science.276.5315.1052; Andreae MO, 1996, J GEOPHYS RES-ATMOS, V101, P23519, DOI 10.1029/96JD01786; Andreae MO, 2001, GLOBAL BIOGEOCHEM CY, V15, P955, DOI 10.1029/2000GB001382; BROWN LR, 1992, SPECTROSCOPY EARTHS, P97; CHIN M, 1995, J GEOPHYS RES-ATMOS, V100, P8993, DOI 10.1029/95JD00275; CRUTZEN PJ, 1990, SCIENCE, V250, P1669, DOI 10.1126/science.250.4988.1669; CRUTZEN PJ, 1976, GEOPHYS RES LETT, V3, P73, DOI 10.1029/GL003i002p00073; CRUTZEN PJ, 1979, NATURE, V282, P253, DOI 10.1038/282253a0; European Space Agency, ATSR WORLD FIR ATL; Folkins I, 1997, GEOPHYS RES LETT, V24, P3185, DOI 10.1029/97GL03047; Gerbig C, 1999, J GEOPHYS RES-ATMOS, V104, P1699, DOI 10.1029/1998JD100031; Griffith DWT, 2000, GEOPHYS RES LETT, V27, P2485, DOI 10.1029/2000GL011797; Gunson MR, 1996, GEOPHYS RES LETT, V23, P2333, DOI 10.1029/96GL01569; Hoell JM, 1997, J GEOPHYS RES-ATMOS, V102, P28223, DOI 10.1029/97JD02581; Hoell JM, 1999, J GEOPHYS RES-ATMOS, V104, P5567, DOI 10.1029/1998JD100074; Holton JR, 2001, GEOPHYS RES LETT, V28, P2799, DOI 10.1029/2001GL013148; Intergovernmental Panel on Climate Change Working Group III, 2000, EMISSIONS SCENARIOS; JOHNSON JE, 1993, J GEOPHYS RES-ATMOS, V98, P23443, DOI 10.1029/92JD01911; Kettle AJ, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2002JD002187; Kjellstrom E, 1998, J ATMOS CHEM, V29, P151, DOI 10.1023/A:1005976511096; LEIFER R, 1989, J GEOPHYS RES-ATMOS, V94, P5173, DOI 10.1029/JD094iD04p05173; Leung FYT, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2001GL013955; Pitari G, 2002, J ATMOS SCI, V59, P414, DOI 10.1175/1520-0469(2002)059<0414:IOFCAE>2.0.CO;2; RINSLAND CP, 2002, J GEOPHYS RES, V107, P22; Rothman LS, 1998, J QUANT SPECTROSC RA, V60, P665, DOI 10.1016/S0022-4073(98)00078-8; Sherwood SC, 2000, GEOPHYS RES LETT, V27, P2513, DOI 10.1029/2000GL011438; Smyth S, 1996, J GEOPHYS RES-ATMOS, V101, P1743, DOI 10.1029/95JD02861; Thomason LW, 1997, J GEOPHYS RES-ATMOS, V102, P3611, DOI 10.1029/96JD02960; Thornton DC, 1996, J GEOPHYS RES-ATMOS, V101, P1873, DOI 10.1029/95JD00617; Tyndall G.S., 1999, ATMOSPHERIC CHEM GLO; Weisenstein DK, 1997, J GEOPHYS RES-ATMOS, V102, P13019, DOI 10.1029/97JD00901	32	75	76	4	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 11	2003	300	5617					307	310		10.1126/science.1080320	http://dx.doi.org/10.1126/science.1080320			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	665RQ	12690193	Green Submitted			2022-12-28	WOS:000182135400050
J	Inoue, M; Chang, L; Hwang, J; Chiang, SH; Saltiel, AR				Inoue, M; Chang, L; Hwang, J; Chiang, SH; Saltiel, AR			The exocyst complex is required for targeting of Glut4 to the plasma membrane by insulin	NATURE			English	Article							3T3-L1 ADIPOCYTES; 3T3L1 ADIPOCYTES; RHO; TRANSLOCATION; GLUCOSE; TRANSPORT; PROTEINS; TC10; RAB4; GLUCOSE-TRANSPORTER-4	Insulin stimulates glucose transport by promoting exocytosis of the glucose transporter Glut4 (refs 1, 2). The dynamic processes involved in the trafficking of Glut4-containing vesicles, and in their targeting, docking and fusion at the plasma membrane, as well as the signalling processes that govern these events, are not well understood. We recently described tyrosine-phosphorylation events restricted to subdomains of the plasma membrane that result in activation of the G protein TC10 (refs 3, 4). Here we show that TC10 interacts with one of the components of the exocyst complex, Exo70. Exo70 translocates to the plasma membrane in response to insulin through the activation of TC10, where it assembles a multiprotein complex that includes Sec6 and Sec8. Overexpression of an Exo70 mutant blocked insulin-stimulated glucose uptake, but not the trafficking of Glut4 to the plasma membrane. However, this mutant did block the extracellular exposure of the Glut4 protein. So, the exocyst might have a crucial role in the targeting of the Glut4 vesicle to the plasma membrane, perhaps directing the vesicle to the precise site of fusion.	Univ Michigan, Med Ctr, Inst Life Sci, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Inst Life Sci, Dept Physiol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Saltiel, AR (corresponding author), Univ Michigan, Med Ctr, Inst Life Sci, Dept Internal Med, 1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.		Saltiel, Alan/L-3632-2019	Chang, Louise/0000-0001-5501-4774; Saltiel, Alan/0000-0002-9726-9828				Bryant NJ, 2002, NAT REV MOL CELL BIO, V3, P267, DOI 10.1038/nrm782; Chamberlain LH, 2002, J BIOL CHEM, V277, P49750, DOI 10.1074/jbc.M206936200; Chang L, 2002, P NATL ACAD SCI USA, V99, P12835, DOI 10.1073/pnas.202495599; Cheatham B, 2000, TRENDS ENDOCRIN MET, V11, P356, DOI 10.1016/S1043-2760(00)00308-8; Chiang SH, 2002, J BIOL CHEM, V277, P13067, DOI 10.1074/jbc.M109471200; Chiang SH, 2001, NATURE, V410, P944, DOI 10.1038/35073608; Cormont M, 1996, MOL CELL BIOL, V16, P6879; Dawson K, 2001, BIOCHEM BIOPH RES CO, V287, P445, DOI 10.1006/bbrc.2001.5620; Guo W, 2000, TRENDS CELL BIOL, V10, P251, DOI 10.1016/S0962-8924(00)01754-2; Hsu SC, 1999, TRENDS CELL BIOL, V9, P150, DOI 10.1016/S0962-8924(99)01516-0; Hwang JB, 1999, J BIOL CHEM, V274, P22813, DOI 10.1074/jbc.274.32.22813; Kee Y, 1997, P NATL ACAD SCI USA, V94, P14438, DOI 10.1073/pnas.94.26.14438; Kimura A, 2001, P NATL ACAD SCI USA, V98, P9098, DOI 10.1073/pnas.151252898; Lin D, 2000, NAT CELL BIOL, V2, P540, DOI 10.1038/35019582; Lipschutz JH, 2002, CURR BIOL, V12, pR212, DOI 10.1016/S0960-9822(02)00753-4; Liu J, 2002, MOL CELL BIOL, V22, P3599, DOI 10.1128/MCB.22.11.3599-3609.2002; Millar CA, 1999, MOL BIOL CELL, V10, P3675, DOI 10.1091/mbc.10.11.3675; Neudauer CL, 1998, CURR BIOL, V8, P1151, DOI 10.1016/S0960-9822(07)00486-1; Novick P, 2002, TRENDS CELL BIOL, V12, P247, DOI 10.1016/S0962-8924(02)02293-6; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; Sherman LA, 1996, ENDOCRINOLOGY, V137, P266, DOI 10.1210/en.137.1.266; Shisheva A, 1997, BIOCHEMISTRY-US, V36, P6564, DOI 10.1021/bi970202g; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; TerBush DR, 1996, EMBO J, V15, P6483, DOI 10.1002/j.1460-2075.1996.tb01039.x; Thurmond DC, 1998, J BIOL CHEM, V273, P33876, DOI 10.1074/jbc.273.50.33876; TING AE, 1995, P NATL ACAD SCI USA, V92, P9613, DOI 10.1073/pnas.92.21.9613; VAN AL, 1997, GENE DEV, V11, P2295; Yeaman C, 2001, J CELL BIOL, V155, P593, DOI 10.1083/jcb.200107088	29	264	279	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 10	2003	422	6932					629	633		10.1038/nature01533	http://dx.doi.org/10.1038/nature01533			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	665GN	12687004	Green Published			2022-12-28	WOS:000182111400046
J	Serdula, MK; Khan, LK; Dietz, WH				Serdula, MK; Khan, LK; Dietz, WH			Weight-loss Counseling revisited	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									CDCP, Div Nutr & Phys Act, Chron Dis Nutr Branch, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA	Centers for Disease Control & Prevention - USA	Serdula, MK (corresponding author), CDCP, Div Nutr & Phys Act, Chron Dis Nutr Branch, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy NE,Mailstop K26, Atlanta, GA 30341 USA.	mks1@cdc.gov						Anderson DA, 1999, ARCH FAM MED, V8, P156, DOI 10.1001/archfami.8.2.156; Brolin RE, 2002, JAMA-J AM MED ASSOC, V288, P2793, DOI 10.1001/jama.288.22.2793; FIORE MC, 2000, TREATING TOBACCO USE; Freedman MR, 2001, OBES RES, V9, p1S, DOI 10.1038/oby.2001.113; Galuska DA, 1999, JAMA-J AM MED ASSOC, V282, P1576, DOI 10.1001/jama.282.16.1576; Jakicic JM, 2001, MED SCI SPORT EXER, V33, P2145, DOI 10.1097/00005768-200112000-00026; Jeffery RW, 2000, HEALTH PSYCHOL, V19, P5, DOI 10.1037/0278-6133.19.Suppl1.5; *NIH, 2003, PRACT GUID ID EV TRE; *PARTN HLTH WEIGH, 2003, VOL GUID PROV WEIGHT; Pi-Sunyer FX, 1998, OBES RES, V6, p51S; Simkin-Silverman LR, 1997, OBES RES, V5, P603, DOI 10.1002/j.1550-8528.1997.tb00582.x; SIMKINSILVERMAN LR, 2002, OBES RES, V346, P591; Thomas PR, 1995, COMMITTEE DEV CRITER, DOI 10.1037/10510-000; Wadden T, 1993, OBESITY THEORY THERA, P197; Wadden TA, 2000, MED CLIN N AM, V84, P441, DOI 10.1016/j.psc.2004.09.008; WILLIAMSON DF, 1990, ARCH INTERN MED, V150, P665, DOI 10.1001/archinte.150.3.665; Wing RR, 2001, ANNU REV NUTR, V21, P323, DOI 10.1146/annurev.nutr.21.1.323; Yanovski S Z, 1993, Arch Fam Med, V2, P309, DOI 10.1001/archfami.2.3.309; Yanovski SZ, 2002, NEW ENGL J MED, V346, P591, DOI 10.1056/NEJMra012586; [No title captured]	20	73	77	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 9	2003	289	14					1747	1750		10.1001/jama.289.14.1747	http://dx.doi.org/10.1001/jama.289.14.1747			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	664ZJ	12684339				2022-12-28	WOS:000182094900001
J	Davies, M; Bruce, C; Bewley, K; Outlaw, M; Mioulet, V; Lloyd, G; Clegg, C				Davies, M; Bruce, C; Bewley, K; Outlaw, M; Mioulet, V; Lloyd, G; Clegg, C			Pollovirus type 1 in working stocks of typed human rhinoviruses	LANCET			English	Article							WILD	After eradication of circulating polioviruses, reintroduction might arise from cultured laboratory stocks, or from collections of patients' or environmental samples. In an example of a further class of risk, we recorded poliovirus type 1 in at least four working stocks of what had been identified as various serotypes; of human rhinovirus. This finding emphasises the need to urgently assess the possibility of presence of poliovirus, even in apparently well-characterised stocks of other viruses, to screen for the virus where necessary, and to destroy materials in which risk outweighs potential benefit.	Publ Hlth Lab Serv, Ctr Appl Microbiol & Res, Natl Collect Pathogen Viruses, Salisbury SP4 0JG, Wilts, England		Clegg, C (corresponding author), Publ Hlth Lab Serv, Ctr Appl Microbiol & Res, Natl Collect Pathogen Viruses, Porton Down, Salisbury SP4 0JG, Wilts, England.			Bewley, Kevin/0000-0002-9078-6734				Dove AW, 1997, SCIENCE, V277, P779, DOI 10.1126/science.277.5327.779; Minor PD, 2001, LANCET, V358, P166, DOI 10.1016/S0140-6736(01)05399-5; MULDERS MN, 1995, J INFECT DIS, V171, P1399, DOI 10.1093/infdis/171.6.1399; Savolainen C, 2002, J GEN VIROL, V83, P333, DOI 10.1099/0022-1317-83-2-333; *WHO DEP VACC BIOL, 1999, WHOVB9932 DEP VACC B	5	15	17	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 5	2003	361	9364					1187	1188		10.1016/S0140-6736(03)12919-4	http://dx.doi.org/10.1016/S0140-6736(03)12919-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	664ZF	12686044				2022-12-28	WOS:000182094600015
J	Roper, C; Pearce, R; Bredenkamp, B; Gumede, J; Drakeley, C; Mosha, F; Chandramohan, D; Sharp, B				Roper, C; Pearce, R; Bredenkamp, B; Gumede, J; Drakeley, C; Mosha, F; Chandramohan, D; Sharp, B			Antifolate antimalarial resistance in southeast Africa: a population-based analysis	LANCET			English	Article							PLASMODIUM-FALCIPARUM MALARIA; DIHYDROPTEROATE SYNTHASE; DIHYDROFOLATE-REDUCTASE; SULFADOXINE-PYRIMETHAMINE; POINT MUTATION; SYNTHETASE; FAILURE; MARKERS	Background Sulfadoxine-pyrimethamine was first introduced for treatment of malaria in Africa during the early 1980s for cases when chloroquine treatment failed, and has since become the first-line treatment in many countries. Resistance to sulfadoxine-pyrimethamine is now increasing, especially in southeast Africa. Methods We characterised genetic change in dhfr and dhps genes in the Plasmodium falciparum population of KwaZulu-Natal, South Africa, during 1995-99, a period of rapid deterioration of the effectiveness of sulfadoxine-pyrimethamine. We assessed the evolutionary origin of the resistance by analysing polymorphic microsatellite repeats in the flanking region of the dhfr and dhps genes, which show whether resistance alleles originated through shared or independent ancestral mutation events. We then assessed the current extent of dispersal of dhfr and dhps resistance alleles by doing the same analysis in P falciparum sampled from communities in the Kilimanjaro region of northern Tanzania in 2001. Findings The large genetic change during 1995-99 in KwaZulu-Natal, South Africa, in both the health facility and the wider community surveys, was at the dhps locus, apparently because resistance at dhfr was established before 1995. The allelic determinants of resistance in this province share a common evolutionary origin with those found in Kilimanjaro, Tanzania, even though the two sites are 4000 km apart. Interpretation Three resistant dhfr alleles, and one resistant dhps allele, each derived from independent ancestral lineages, have been driven through through southeast Africa. The movement by the dhfr alleles (pyrimethamine resistance) preceded that of the dhps allele (sulfadoxine resistance). Our findings emphasise that gene flow rather than new mutations has been the most common originator of resistance in African countries.	Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Med, London WC1E 7HT, England; MRC, Malaria Res Lead Programme, ZA-4067 Durban, South Africa; Dept Hlth, Malaria Control Programme, Kwa Zulu, South Africa; Kilimanjaro Christian Med Ctr, Joint Malaria Programme, Moshi, Tanzania	University of London; London School of Hygiene & Tropical Medicine; Kilimanjaro Christian Medical Centre	Roper, C (corresponding author), Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Med, Keppel St, London WC1E 7HT, England.	Cally.Roper@lshtm.ac.uk	Roper, Cally/K-2989-2013	Roper, Cally/0000-0002-6545-309X				Bahl A, 2002, NUCLEIC ACIDS RES, V30, P87, DOI 10.1093/nar/30.1.87; Bredenkamp BLF, 2001, SAMJ S AFR MED J, V91, P970; Clyde David F, 1967, MALARIA TANZANIA; Cortese JF, 2002, J INFECT DIS, V186, P999, DOI 10.1086/342946; COWMAN AF, 1988, P NATL ACAD SCI USA, V85, P9109, DOI 10.1073/pnas.85.23.9109; Curtis J, 1998, J INFECT DIS, V177, P1429, DOI 10.1086/517831; HARTL DL, 1997, PRINCIPLES POPULATIO, P430; Hastings IM, 2002, PHILOS T ROY SOC B, V357, P505, DOI 10.1098/rstb.2001.1036; JONES AS, 1958, T R SOC TROP MED HYG, V52, P547; Kublin JG, 1998, LANCET, V351, P1629, DOI 10.1016/S0140-6736(98)24022-0; Kublin JG, 2002, J INFECT DIS, V185, P380, DOI 10.1086/338566; Marsh K, 1998, LANCET, V352, P924, DOI 10.1016/S0140-6736(05)61510-3; Mberu EK, 2000, AM J TROP MED HYG, V62, P396, DOI 10.4269/ajtmh.2000.62.396; Nzila AM, 2000, J INFECT DIS, V181, P2023, DOI 10.1086/315520; Omar SA, 2001, T ROY SOC TROP MED H, V95, P315, DOI 10.1016/S0035-9203(01)90250-0; Paget-McNicol S, 2001, PARASITOLOGY, V122, P497, DOI 10.1017/S0031182001007739; PAYNE D, 1988, PARASITOL TODAY, V4, P112, DOI 10.1016/0169-4758(88)90042-7; Pearce RJ, 2003, ANTIMICROB AGENTS CH, V47, P1347, DOI 10.1128/AAC.47.4.1347-1354.2003; PETERSON DS, 1988, P NATL ACAD SCI USA, V85, P9114, DOI 10.1073/pnas.85.23.9114; Plowe CV, 1997, J INFECT DIS, V176, P1590, DOI 10.1086/514159; Sims P, 1998, PARASITOL TODAY, V14, P136, DOI 10.1016/S0169-4758(97)01203-9; Su XZ, 1996, GENOMICS, V33, P430, DOI 10.1006/geno.1996.0218; Su XZ, 1997, CELL, V91, P593, DOI 10.1016/S0092-8674(00)80447-X; Triglia T, 1997, P NATL ACAD SCI USA, V94, P13944, DOI 10.1073/pnas.94.25.13944; Triglia T, 1998, EMBO J, V17, P3807, DOI 10.1093/emboj/17.14.3807; Wang P, 1997, MOL BIOCHEM PARASIT, V89, P161, DOI 10.1016/S0166-6851(97)00114-X; White NJ, 1999, LANCET, V353, P1965, DOI 10.1016/S0140-6736(98)07367-X; Wootton JC, 2002, NATURE, V418, P320, DOI 10.1038/nature00813; Wu YM, 1996, P NATL ACAD SCI USA, V93, P1130, DOI 10.1073/pnas.93.3.1130	29	243	244	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 5	2003	361	9364					1174	1181		10.1016/S0140-6736(03)12951-0	http://dx.doi.org/10.1016/S0140-6736(03)12951-0			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	664ZF	12686039				2022-12-28	WOS:000182094600010
J	Yamaguchi, R; Newport, J				Yamaguchi, R; Newport, J			RETRACTED: A role for Ran-GTP and Crm1 in blocking re-replication (Retracted Article. See vol 119, pg 145, 2004)	CELL			English	Article; Retracted Publication							ORIGIN RECOGNITION COMPLEX; DNA-REPLICATION; CELL-CYCLE; XENOPUS-LAEVIS; NUCLEAR EXPORT; EGG EXTRACTS; S-PHASE; CHROMATIN ASSOCIATION; MULTIPLE MECHANISMS; KINASE-ACTIVITY	All eukaryotic cells have regulatory mechanisms that limit genomic replication to a single round each cell cycle. These systems function by blocking formation of prereplication complexes. The regulatory mechanisms in the yeast S. cerevisiae have been identified, but these do not appear to be conserved in metazoans. Using Xenopus egg extracts, we have identified a metazoan-specific regulatory system that limits replication to a single round. We show that during S phase, soluble MCM helicase, an essential initiation factor, is inactivated when it associates with exportin-1/Crm1. Formation of this complex is dependent on both high Ran-GTP and cdk2 kinase activity. Lowering Ran-GTP within nuclei or nuclear extracts allows MCM to reassociate with chromatin during S phase and induces re-replication. Importantly, prevention of re-replication requires MCM-Crm1 complex formation, but it does not require export of MCM from the nucleus. Therefore, in metazoans, Crm1 functions in both nuclear export and blocking of re-replication.	Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Newport, J (corresponding author), Univ Calif San Diego, Dept Biol, 9500 Gilman Dr, La Jolla, CA 92093 USA.	jnewport@ucsd.edu		Yamaguchi, Ryuji/0000-0002-1706-7063	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033523] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM33523] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; BISCHOFF FR, 1995, EMBO J, V14, P705, DOI 10.1002/j.1460-2075.1995.tb07049.x; BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0; Clarke PR, 2001, TRENDS CELL BIOL, V11, P366, DOI 10.1016/S0962-8924(01)02071-2; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; Delmolino LM, 2001, J BIOL CHEM, V276, P26947, DOI 10.1074/jbc.M101870200; Findeisen M, 1999, EUR J BIOCHEM, V264, P415, DOI 10.1046/j.1432-1327.1999.00613.x; Gruss OJ, 2001, CELL, V104, P83, DOI 10.1016/S0092-8674(01)00193-3; Hodgson B, 2002, CURR BIOL, V12, P678, DOI 10.1016/S0960-9822(02)00778-9; Hua XH, 1997, J CELL BIOL, V137, P183, DOI 10.1083/jcb.137.1.183; Hua XQH, 1998, J CELL BIOL, V140, P271, DOI 10.1083/jcb.140.2.271; Hughes M, 1998, J CELL SCI, V111, P3017; Jiang W, 1999, P NATL ACAD SCI USA, V96, P6193, DOI 10.1073/pnas.96.11.6193; Kalab P, 2002, SCIENCE, V295, P2452, DOI 10.1126/science.1068798; Kehlenbach RH, 1999, J CELL BIOL, V145, P645, DOI 10.1083/jcb.145.4.645; Kutay U, 1998, MOL CELL, V1, P359, DOI 10.1016/S1097-2765(00)80036-2; Labib K, 1999, NAT CELL BIOL, V1, P415, DOI 10.1038/15649; Lee SH, 2002, J BIOL CHEM, V277, P23358, DOI 10.1074/jbc.M111559200; Lei M, 2001, J CELL SCI, V114, P1447; Lounsbury KM, 1997, J BIOL CHEM, V272, P551; Maiorano D, 2000, NATURE, V404, P622, DOI 10.1038/35007104; McGarry TJ, 2002, MOL BIOL CELL, V13, P3662, DOI 10.1091/mbc.E02-04-0199; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; Mendez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000; Nguyen VQ, 2001, NATURE, V411, P1068, DOI 10.1038/35082600; Nilsson J, 2001, J MOL BIOL, V305, P231, DOI 10.1006/jmbi.2000.4313; Nishitani H, 2002, GENES CELLS, V7, P523, DOI 10.1046/j.1365-2443.2002.00544.x; Nishitani H, 2001, J BIOL CHEM, V276, P44905, DOI 10.1074/jbc.M105406200; Okuno Y, 2001, EMBO J, V20, P4263, DOI 10.1093/emboj/20.15.4263; Pelizon C, 2000, GENE DEV, V14, P2526, DOI 10.1101/gad.176300; Piatti S, 1996, GENE DEV, V10, P1516, DOI 10.1101/gad.10.12.1516; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Quinn LM, 2001, GENE DEV, V15, P2741, DOI 10.1101/gad.916201; SMYTHE C, 1991, METHOD CELL BIOL, V35, P449; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Walter J, 1998, MOL CELL, V1, P519, DOI 10.1016/S1097-2765(00)80052-0; Wohlschlegel JA, 2000, SCIENCE, V290, P2309, DOI 10.1126/science.290.5500.2309; Yanagi K, 2002, J BIOL CHEM, V277, P40871, DOI 10.1074/jbc.M206202200; Yanow SK, 2001, EMBO J, V20, P4648, DOI 10.1093/emboj/20.17.4648	41	35	38	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 4	2003	113	1					115	125		10.1016/S0092-8674(03)00200-9	http://dx.doi.org/10.1016/S0092-8674(03)00200-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	668GX	12679039	Bronze			2022-12-28	WOS:000182282900011
J	Scherer, SW; Cheung, J; MacDonald, JR; Osborne, LR; Nakabayashi, K; Herbrick, JA; Carson, AR; Parker-Katiraee, L; Skaug, J; Khaja, R; Zhang, JJ; Hudek, AK; Li, M; Haddad, M; Duggan, GE; Fernandez, BA; Kanematsu, E; Gentles, S; Christopoulos, CC; Choufani, S; Kwasnicka, D; Zheng, XQH; Lai, ZW; Nusskern, D; Zhang, Q; Gu, ZP; Lu, F; Zeesman, S; Nowaczyk, MJ; Teshima, I; Chitayat, D; Shuman, C; Weksberg, R; Zackai, EH; Grebe, TA; Cox, SR; Kirkpatrick, SJ; Rahman, N; Friedman, JM; Heng, HHQ; Pelicci, PG; Lo-Coco, F; Belloni, E; Shaffer, LG; Pober, B; Morton, CC; Gusella, JF; Bruns, GAP; Korf, BR; Quade, BJ; Ligon, AH; Ferguson, H; Higgins, AW; Leach, NT; Herrick, SR; Lemyre, E; Farra, CG; Kim, HG; Summers, AM; Gripp, KW; Roberts, W; Szatmari, P; Winsor, EJT; Grzeschik, KH; Teebi, A; Minassian, BA; Kere, J; Armengol, L; Pujana, MA; Estivill, X; Wilson, MD; Koop, BF; Tosi, S; Moore, GE; Boright, AP; Zlotorynski, E; Kerem, B; Kroisel, PM; Petek, E; Oscier, DG; Mould, SJ; Dohner, H; Dohner, K; Rommens, JM; Vincent, JB; Venter, JC; Li, PW; Mural, RJ; Adams, MD; Tsui, LC				Scherer, SW; Cheung, J; MacDonald, JR; Osborne, LR; Nakabayashi, K; Herbrick, JA; Carson, AR; Parker-Katiraee, L; Skaug, J; Khaja, R; Zhang, JJ; Hudek, AK; Li, M; Haddad, M; Duggan, GE; Fernandez, BA; Kanematsu, E; Gentles, S; Christopoulos, CC; Choufani, S; Kwasnicka, D; Zheng, XQH; Lai, ZW; Nusskern, D; Zhang, Q; Gu, ZP; Lu, F; Zeesman, S; Nowaczyk, MJ; Teshima, I; Chitayat, D; Shuman, C; Weksberg, R; Zackai, EH; Grebe, TA; Cox, SR; Kirkpatrick, SJ; Rahman, N; Friedman, JM; Heng, HHQ; Pelicci, PG; Lo-Coco, F; Belloni, E; Shaffer, LG; Pober, B; Morton, CC; Gusella, JF; Bruns, GAP; Korf, BR; Quade, BJ; Ligon, AH; Ferguson, H; Higgins, AW; Leach, NT; Herrick, SR; Lemyre, E; Farra, CG; Kim, HG; Summers, AM; Gripp, KW; Roberts, W; Szatmari, P; Winsor, EJT; Grzeschik, KH; Teebi, A; Minassian, BA; Kere, J; Armengol, L; Pujana, MA; Estivill, X; Wilson, MD; Koop, BF; Tosi, S; Moore, GE; Boright, AP; Zlotorynski, E; Kerem, B; Kroisel, PM; Petek, E; Oscier, DG; Mould, SJ; Dohner, H; Dohner, K; Rommens, JM; Vincent, JB; Venter, JC; Li, PW; Mural, RJ; Adams, MD; Tsui, LC			Human chromosome 7: DNA sequence and biology	SCIENCE			English	Article							SEGMENTAL DUPLICATIONS; REGION; MAP; LOCALIZATION; SPEECH; GENES	DNA sequence and annotation of the entire human chromosome 7, encompassing nearly 158 million nucleotides of DNA and 1917 gene structures, are presented. To generate a higher order description, additional structural features such as imprinted genes, fragile sites, and segmental duplications were integrated at the level of the DNA sequence with medical genetic data, including 440 chromosome rearrangement breakpoints associated with disease. This approach enabled the discovery of candidate genes for developmental diseases including autism.	Hosp Sick Children, Dept Genet & Genom Biol, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Div Clin & Metab Genet, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Child Dev Ctr, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Dept Paediat, Div Neurol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Med, Toronto, ON M5S 1A8, Canada; Mem Univ Newfoundland, Fac Med, Discipline Genet, St John, NF A1B 3V6, Canada; Celera Genom, Rockville, MD 20850 USA; Hamilton Hlth Sci Ctr, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Dept Psychiat & Behav Neurosci, Hamilton, ON L8N 3Z5, Canada; Univ Toronto, Dept Pediat, Toronto, ON M5G 1X8, Canada; Childrens Hosp Philadelphia, Div Human Genet & Mol Biol, Philadelphia, PA 19104 USA; Univ Phoenix Genet Program, Phoenix, AZ 85016 USA; Univ Wisconsin, Dept Med Genet, Madison, WI 53706 USA; Inst Canc Res, Sect Canc Genet, Sutton SM2 5NG, Surrey, England; Univ British Columbia, Dept Med Genet, Vancouver, BC V6H 3N1, Canada; Wayne State Univ, Sch Med, Detroit, MI 48202 USA; European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy; Firc Inst Mol Oncol, Canc Genet Unit, I-20134 Milan, Italy; Univ Roma Tor Vergata, Dipartimento Biopatol & Diagnost Immagini, I-00133 Rome, Italy; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Yale Univ, Sch Med, Dept Genet, New Haven, CT 06520 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Obstet Gynecol & Reprod Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Neurol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Harvard Partners Ctr Genet & Genom, Boston, MA 02115 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Mol Neurogenet Lab, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Childrens Hosp, Dept Pediat, Boston, MA 02115 USA; N York Gen Hosp, Dept Genet, Toronto, ON M2K 1E1, Canada; Alfred I DuPont Hosp Children, Div Med Genet, Wilmington, DE 19899 USA; Univ Toronto, Univ Hlth Network, Prenatal Diag Program, Toronto, ON M5G 1X5, Canada; Univ Toronto, Univ Hlth Network, Dept Lab Med & Pathobiol, Toronto, ON M5G 1X5, Canada; Univ Marburg, Med Zentrum Humangenet, D-35037 Marburg, Germany; Karolinska Inst, Novum, Dept Biosci, S-14157 Stockholm, Sweden; Huddinge Univ Hosp, Clin Res Ctr, S-14157 Stockholm, Sweden; Ctr Genom Regulat, Program Genes & Dis, Barcelona 08003, Catalonia, Spain; Univ Victoria, Dept Biol, Victoria, BC V8W 3N5, Canada; John Radcliffe Hosp, Inst Mol Med, MRC, Mol Haematol Unit, Oxford OX3 9DS, England; Univ London Imperial Coll Sci Technol & Med, Fac Med, Inst Reprod & Dev Biol, Dept Fetal & Maternal Med, London W12 0NN, England; Univ Toronto, Univ Hlth Network, Dept Med, Div Endocrinol, Toronto, ON M5G 2C4, Canada; Hebrew Univ Jerusalem, Inst Life Sci, Dept Genet, IL-91904 Jerusalem, Israel; Karl Franzens Univ Graz, Inst Med Biol & Human Genet, A-8010 Graz, Austria; Royal Bournemouth Hosp, Dept Haematol, Bournemouth BH7 7DW, Dorset, England; Univ Hosp Ulm, Dept Internal Med 3, D-89081 Ulm, Germany; Univ Toronto, Clark Inst, Ctr Addict & Mental Hlth, Toronto, ON M5T 1R8, Canada; Univ Toronto, Dept Psychiat, Toronto, ON M5T 1R8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; Memorial University Newfoundland; McMaster University; McMaster University; University of Toronto; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Wisconsin System; University of Wisconsin Madison; University of London; Institute of Cancer Research - UK; University of British Columbia; Wayne State University; IRCCS European Institute of Oncology (IEO); IFOM - FIRC Institute of Molecular Oncology; University of Rome Tor Vergata; Baylor College of Medicine; Yale University; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Boston Children's Hospital; Harvard Medical School; University of Toronto; University Toronto Affiliates; North York General Hospital; Nemours Alfred I. duPont Hospital for Children; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Philipps University Marburg; Karolinska Institutet; Karolinska Institutet; Barcelona Institute of Science & Technology; Pompeu Fabra University; Centre de Regulacio Genomica (CRG); University of Victoria; University of Oxford; Imperial College London; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Hebrew University of Jerusalem; University of Graz; Ulm University; University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada; University of Toronto	Scherer, SW (corresponding author), Hosp Sick Children, Dept Genet & Genom Biol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	steve@genet.sickkids.on.ca	Rommens, Johanna/AAT-7465-2021; Koop, Ben F./A-8151-2008; MacDonald, Jeffrey Robert/GLU-2255-2022; Choufani, Sanaa/GWC-1820-2022; belloni, elena/H-9909-2013; Kere, Juha/A-9179-2008; Pujana, Miquel Angel/N-3127-2014; Moore, Gudrun/A-2092-2009; Estivill, Xavier/A-3125-2013; Wilson, Michael D/K-6294-2014; Döhner, Hartmut/C-8933-2016; Tsui, Lap-chee/A-1081-2010; Korf, Bruce R/H-4882-2012; Kere, Juha/AAX-9117-2021; Estivill, Xavier/E-2957-2012; Pelicci, Pier Giuseppe/AAL-6572-2020; Tosi, Sabrina/AAA-7199-2022; Scherer, Stephen W./B-3785-2013; Rahman, Nazneen/B-8890-2012; Rahman, Nazneen/D-2802-2013	Koop, Ben F./0000-0003-0045-5200; Choufani, Sanaa/0000-0002-5241-2213; Kere, Juha/0000-0003-1974-0271; Pujana, Miquel Angel/0000-0003-3222-4044; Estivill, Xavier/0000-0002-0723-2256; Wilson, Michael D/0000-0002-4015-3066; Döhner, Hartmut/0000-0003-2116-5536; Kere, Juha/0000-0003-1974-0271; Tosi, Sabrina/0000-0002-0036-0191; Scherer, Stephen W./0000-0002-8326-1999; Cheung, Joseph/0000-0002-1222-7603; Rahman, Nazneen/0000-0003-4376-0440; Friedman, Jan/0000-0002-7482-9570; MacDonald, Jeffrey/0000-0001-5058-2393; Belloni, Elena/0000-0003-3214-0780; Moore, Gudrun/0000-0002-2099-3420; Zheng Bradley, Xiangqun/0000-0002-9324-2708	Canadian Institutes of Health Research [38103] Funding Source: Medline; NIGMS NIH HHS [P01 GM061354] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM061354] Funding Source: NIH RePORTER	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bailey JA, 2002, SCIENCE, V297, P1003, DOI 10.1126/science.1072047; Boocock GRB, 2003, NAT GENET, V33, P97, DOI 10.1038/ng1062; Bouffard GG, 1997, GENOME RES, V7, P59, DOI 10.1101/gr.7.1.59; Cheung J, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-4-r25; de la Puente A, 1998, CYTOGENET CELL GENET, V83, P176, DOI 10.1159/000015175; Deloukas P, 2001, NATURE, V414, P865, DOI 10.1038/414865a; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; Dunham I, 1999, NATURE, V402, P489, DOI 10.1038/990031; *FANT CONS, 2002, NATURE, V420, P523; Hattori M, 2000, NATURE, V405, P311, DOI 10.1038/35012518; Heilig R, 2003, NATURE, V421, P601, DOI 10.1038/nature01348; HILLIER LW, IN PRESS NATURE; *INT MOL GEN STUD, 1998, HUM MOL GENET, V3, P571; KOBAYASHI K, 1999, ANTURE GENET, V2, P159; KUNZ J, 1994, GENOMICS, V22, P439, DOI 10.1006/geno.1994.1407; Lai CSL, 2001, NATURE, V413, P519, DOI 10.1038/35097076; Lai CSL, 2000, AM J HUM GENET, V67, P357, DOI 10.1086/303011; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Ma B, 2002, BIOINFORMATICS, V18, P440, DOI 10.1093/bioinformatics/18.3.440; Merlo GR, 2002, GENESIS, V33, P97, DOI 10.1002/gene.10098; Mural RJ, 2002, SCIENCE, V296, P1661, DOI 10.1126/science.1069193; Osborne LR, 2001, NAT GENET, V29, P321, DOI 10.1038/ng753; Osborne LR, 1997, GENOMICS, V45, P402, DOI 10.1006/geno.1997.4923; Pevzner P, 2003, GENOME RES, V13, P37, DOI 10.1101/gr.757503; Robledo RF, 2002, GENE DEV, V16, P1089, DOI 10.1101/gad.988402; SCHERER SW, 1994, HUM MOL GENET, V3, P1345; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; Stein LD, 2002, GENOME RES, V12, P1599, DOI 10.1101/gr.403602; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; WEVRICK R, 1991, NUCLEIC ACIDS RES, V19, P2295, DOI 10.1093/nar/19.9.2295	31	152	526	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 2	2003	300	5620					767	772		10.1126/science.1083423	http://dx.doi.org/10.1126/science.1083423			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	673KH	12690205	Green Accepted			2022-12-28	WOS:000182579800041
J	Tian, D; Traw, MB; Chen, JQ; Kreitman, M; Bergelson, J				Tian, D; Traw, MB; Chen, JQ; Kreitman, M; Bergelson, J			Fitness costs of R-gene-mediated resistance in Arabidopsis thaliana	NATURE			English	Article							NUCLEOTIDE-BINDING SITE; DISEASE-RESISTANCE; PSEUDOMONAS-SYRINGAE; DEFENSE RESPONSES; NATURAL-SELECTION; PLANT-RESISTANCE; PATHOGENS; RPS2; POLYMORPHISM; SPECIFICITY	Resistance genes (R-genes) act as an immune system in plants by recognizing pathogens and inducing defensive pathways. Many R-gene loci are present in plant genomes, presumably reflecting the need to maintain a large repertoire of resistance alleles. These loci also often segregate for resistance and susceptibility alleles that natural selection has maintained as polymorphisms within a species for millions of years(1-5). Given the obvious advantage to an individual of being disease resistant, what prevents these resistance alleles from being driven to fixation by natural selection? A cost of resistance(6) is one potential explanation; most models require a lower fitness of resistant individuals in the absence of pathogens for long-term persistence of susceptibility alleles(7). Here we test for the presence of a cost of resistance at the RPM1 locus of Arabidopsis thaliana. Results of a field experiment comparing the fitness of isogenic strains that differ in the presence or absence of RPM1 and its natural promoter reveal a large cost of RPM1, providing the first evidence that costs contribute to the maintenance of an ancient R-gene polymorphism.	Univ Chicago, Dept Ecol & Evolut, Chicago, IL 60637 USA; Nanjing Univ, Dept Biol, Nanjing 210093, Peoples R China	University of Chicago; Nanjing University	Bergelson, J (corresponding author), Univ Chicago, Dept Ecol & Evolut, 1101 E 57th St, Chicago, IL 60637 USA.	jbergels@midway.uchicago.edu	Traw, Milton Brian/ABD-3275-2020; Bruening, Stefan/B-8505-2011	Traw, Milton Brian/0000-0002-3148-2108; Chen, Jian-Qun/0000-0003-4376-5655; Bergelson, Joy/0000-0001-7893-7387	NIGMS NIH HHS [R01 GM057994, R01 GM062504] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057994, R01GM062504] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bergelson J, 2001, ANNU REV GENET, V35, P469, DOI 10.1146/annurev.genet.35.102401.090954; Bergelson J, 1996, AM NAT, V148, P536, DOI 10.1086/285938; BISGROVE SR, 1994, PLANT CELL, V6, P927, DOI 10.1105/tpc.6.7.927; Boyes DC, 1998, P NATL ACAD SCI USA, V95, P15849, DOI 10.1073/pnas.95.26.15849; Brown JKM, 2002, CURR OPIN PLANT BIOL, V5, P339, DOI 10.1016/S1369-5266(02)00270-4; Caicedo AL, 1999, P NATL ACAD SCI USA, V96, P302, DOI 10.1073/pnas.96.1.302; Dangl JL, 2001, NATURE, V411, P826, DOI 10.1038/35081161; Dewdney J, 2000, PLANT J, V24, P205, DOI 10.1046/j.1365-313x.2000.00870.x; GILLESPIE JH, 1975, ECOLOGY, V56, P493, DOI 10.2307/1934983; Grant MR, 1998, P NATL ACAD SCI USA, V95, P15843, DOI 10.1073/pnas.95.26.15843; GRANT MR, 1995, SCIENCE, V269, P843, DOI 10.1126/science.7638602; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Holt BF, 2002, DEV CELL, V2, P807, DOI 10.1016/S1534-5807(02)00174-0; HOWE C, 1995, GENE CLONING MANIPUL; Jakob K, 2002, MOL PLANT MICROBE IN, V15, P1195, DOI 10.1094/MPMI.2002.15.12.1195; JORGENSEN JH, 1990, NORSK LANDBRUKSFOR S, V9, P125; KLEMENT Z, 1963, NATURE, V199, P299, DOI 10.1038/199299b0; Mackey D, 2003, CELL, V112, P379, DOI 10.1016/S0092-8674(03)00040-0; Mackey D, 2002, CELL, V108, P743, DOI 10.1016/S0092-8674(02)00661-X; Mauricio R, 2003, GENETICS, V163, P735; MINDRINOS M, 1994, CELL, V78, P1089, DOI 10.1016/0092-8674(94)90282-8; Moore ERB, 1996, SYST APPL MICROBIOL, V19, P478, DOI 10.1016/S0723-2020(96)80021-X; Oldroyd GED, 1998, P NATL ACAD SCI USA, V95, P10300, DOI 10.1073/pnas.95.17.10300; OW DW, 1995, CRIT REV PLANT SCI, V14, P239, DOI 10.1080/713608117; Rausher MD, 2001, NATURE, V411, P857, DOI 10.1038/35081193; REDEI GP, 1975, ANNU REV GENET, V9, P111, DOI 10.1146/annurev.ge.09.120175.000551; SIMMS EL, 1987, AM NAT, V130, P570, DOI 10.1086/284731; Stahl EA, 1999, NATURE, V400, P667, DOI 10.1038/23260; Stuiver MH, 2001, NATURE, V411, P865, DOI 10.1038/35081200; Tang XY, 1999, PLANT CELL, V11, P15, DOI 10.1105/tpc.11.1.15; Tao Y, 2000, PLANT CELL, V12, P2541, DOI 10.1105/tpc.12.12.2541; Tian DC, 2002, P NATL ACAD SCI USA, V99, P11525, DOI 10.1073/pnas.172203599; Traw MB, 2003, MOL ECOL, V12, P1125, DOI 10.1046/j.1365-294X.2003.01815.x; van der Biezen EA, 1998, TRENDS BIOCHEM SCI, V23, P454, DOI 10.1016/S0968-0004(98)01311-5; Wang ZX, 2001, PLANT MOL BIOL, V47, P653, DOI 10.1023/A:1012457113700; WHALEN MC, 1991, PLANT CELL, V3, P49, DOI 10.1105/tpc.3.1.49	36	551	571	3	143	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 1	2003	423	6935					74	77		10.1038/nature01588	http://dx.doi.org/10.1038/nature01588			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	673CG	12721627				2022-12-28	WOS:000182561600041
J	Sharp, D				Sharp, D			Chateau resveratrol	LANCET			English	Editorial Material							FRENCH PARADOX; WINE; MORTALITY; DISEASE		The Lancet, London NW1 7BY, England		Sharp, D (corresponding author), The Lancet, London NW1 7BY, England.							de Lorgeril M, 2002, CARDIOVASC RES, V54, P503, DOI 10.1016/S0008-6363(01)00545-4; Klatsky AL, 2003, SCI AM, V288, P74, DOI 10.1038/scientificamerican0203-74; Laatikainen T, 2003, J EPIDEMIOL COMMUN H, V57, P379, DOI 10.1136/jech.57.5.379; Lindsay J, 2002, AM J EPIDEMIOL, V156, P445, DOI 10.1093/aje/kwf074; MCMICHAEL J, 1979, LANCET, V1, P1186; Mukamal KJ, 2003, NEW ENGL J MED, V348, P109, DOI 10.1056/NEJMoa022095; Rosenkranz S, 2002, FASEB J, V16, P1958, DOI 10.1096/fj.02-0207fje; Simini B, 2000, LANCET, V355, P48, DOI 10.1016/S0140-6736(05)71990-5; STLEGER AS, 1979, LANCET, V1, P1017, DOI 10.1016/S0140-6736(79)92765-X; Waterhouse AL, 2002, ANN NY ACAD SCI, V957, P21, DOI 10.1111/j.1749-6632.2002.tb02903.x; 2003, WINE SCI EXPLORATION, P320	11	4	4	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 26	2003	361	9367					1404	1404		10.1016/S0140-6736(03)13149-2	http://dx.doi.org/10.1016/S0140-6736(03)13149-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	672HZ	12727391				2022-12-28	WOS:000182516300006
J	Van Hove, JLK; Grunewald, S; Jaeken, J; Demaerel, P; Declercq, PE; Bourdoux, P; Niezen-Koning, K; Deanfeld, JE; Leonard, JV				Van Hove, JLK; Grunewald, S; Jaeken, J; Demaerel, P; Declercq, PE; Bourdoux, P; Niezen-Koning, K; Deanfeld, JE; Leonard, JV			D,L-3-hydroxybutyrate treatment of multiple acyl-CoA dehydrogenase deficiency (MADD)	LANCET			English	Article								Cardiomyopathy and leukodystrophy are life-threatening complications of multiple acyl-CoA dehydrogenase deficiency (MADD). A 2-year-old boy with this disorder developed rapidly progressive leukodystrophy resulting in complete paralysis within 4 months. Within a week of starting sodium-D,L-3-hydroxybutyrate he had improved. After 2 years, neurological function returned, including walking independently, with progressive improvement of brain MRI. Two additional infants with MADD developed life-threatening cardiomyopathy unresponsive to conventional treatment. On sodium-D,L-3-hydroxybutyrate treatment their cardiac contractility showed progressive and sustained improvement. D,L-3-hydroxybutyrate is a therapeutic option for cerebral and cardiac complications in severe fatty acid oxidation defects.	Katholieke Univ Leuven, Univ Hosp Gasthuisberg, Dept Paediat, B-3000 Louvain, Belgium; Katholieke Univ Leuven, Univ Hosp Gasthuisberg, Dept Radiol, Louvain, Belgium; Katholieke Univ Leuven, Univ Hosp Gasthuisberg, Dept Lab Med, Louvain, Belgium; Great Ormond St Hosp Sick Children, Metab Unit, London WC1N 3JH, England; Inst Child Hlth, Biochem Endocrinol & Metab Unit, London, England; Inst Child Hlth, Vasc Physiol Unit, London, England; ULB Lab Paediat, Brussels, Belgium; Univ Groningen Hosp, Dept Paediat, Groningen, Netherlands; Univ Groningen, Inst Drug Explorat, Groningen, Netherlands	KU Leuven; University Hospital Leuven; KU Leuven; University Hospital Leuven; KU Leuven; University Hospital Leuven; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London; University of London; University College London; University of Groningen; University of Groningen	Van Hove, JLK (corresponding author), Katholieke Univ Leuven, Univ Hosp Gasthuisberg, Dept Paediat, B-3000 Louvain, Belgium.	Johan.Vanhove@uz.kuleuven.ac.be		Niezen-Koning, Klary E/0000-0002-9384-4354				al-Essa M A, 2000, J Perinatol, V20, P120, DOI 10.1038/sj.jp.7200325; Bonham JR, 1999, J INHERIT METAB DIS, V22, P174, DOI 10.1023/A:1005406205548; Frerman F. E., 2001, METABOLIC MOL BASES, P2357, DOI DOI 10.1036/OMMBID.131; SWIATEK KR, 1984, BIOCHEM MED METAB B, V31, P332, DOI 10.1016/0006-2944(84)90089-9; Uziel G, 1995, PEDIATR NEUROL, V13, P333, DOI 10.1016/0887-8994(95)00187-5	5	72	73	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 26	2003	361	9367					1433	1435		10.1016/S0140-6736(03)13105-4	http://dx.doi.org/10.1016/S0140-6736(03)13105-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	672HZ	12727399				2022-12-28	WOS:000182516300014
J	Kuznetsov, AE; Birch, KA; Boldyrev, AI; Li, X; Zhai, HJ; Wang, LS				Kuznetsov, AE; Birch, KA; Boldyrev, AI; Li, X; Zhai, HJ; Wang, LS			All-metal antiaromatic molecule: Rectangular Al-4(4-) in the Li3Al4- anion	SCIENCE			English	Article							AROMATIC-MOLECULES; AL-4(2-); CLUSTERS	We report the experimental and theoretical characterization of antiaromaticity in an all-metal system, Li3Al4-, which we produced by laser vaporization and studied with the use of photoelectron spectroscopy and ab initio calculations. The most stable structure of Li3Al4- found theoretically contained a rectangular Al-4(4-) tetraanion stabilized by the three Li+ ions in a capped octahedral arrangement. Molecular orbital analyses reveal that the rectangular Al-4(4-) tetraanion has four pi electrons, consistent with the 4n Huckel rule for antiaromaticity.	Washington State Univ, Dept Phys, Richland, WA 99352 USA; Utah State Univ, Dept Chem & Biochem, Logan, UT 84322 USA; Pacific NW Natl Lab, WR Wiley Environm Mol Sci Lab, Richland, WA 99352 USA	Washington State University; Utah System of Higher Education; Utah State University; United States Department of Energy (DOE); Pacific Northwest National Laboratory	Wang, LS (corresponding author), Washington State Univ, Dept Phys, 2710 Univ Dr, Richland, WA 99352 USA.		Boldyrev, Alexander I./C-5940-2009; Zhai, Hua-Jin/E-8715-2011; Kuznetsov, Aleksey E/F-1345-2010	Boldyrev, Alexander I./0000-0002-8277-3669; Zhai, Hua-Jin/0000-0002-1592-0534; Kuznetsov, Aleksey/0000-0001-8857-3118				[Anonymous], 2001, CHEM REV, V101; BRESLOW R, 1973, ACCOUNTS CHEM RES, V6, P393, DOI 10.1021/ar50072a001; Breslow R., 1970, J AM CHEM SOC, V92, P2165, DOI 10.1021/ja00710a077; CHASKO S, 2001, PHYS REV B, V64, DOI UNSP 155409; Fowler PW, 2001, CHEM PHYS LETT, V342, P85, DOI 10.1016/S0009-2614(01)00559-0; Frisch M.J., 2016, GAUSSIAN 16 REVISION; Juselius J, 2001, J PHYS CHEM A, V105, P9939, DOI 10.1021/jp012346h; Kuznetsov AE, 2001, ANGEW CHEM INT EDIT, V40, P3369, DOI 10.1002/1521-3773(20010917)40:18<3369::AID-ANIE3369>3.0.CO;2-Z; Li X, 2001, SCIENCE, V291, P859, DOI 10.1126/science.291.5505.859; Schaftenaar G., 1998, MOLDEN3 4; Wang LS, 1998, ADV MET SEM, V4, P299; WANG LS, 1995, J CHEM PHYS, V102, P9480, DOI 10.1063/1.468817; Zhan CG, 2002, J AM CHEM SOC, V124, P14795, DOI 10.1021/ja021026o	13	203	206	0	56	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 25	2003	300	5619					622	625		10.1126/science.1082477	http://dx.doi.org/10.1126/science.1082477			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	671FB	12714740				2022-12-28	WOS:000182453700036
J	Cohen, LM; Germain, MJ; Poppel, DM				Cohen, LM; Germain, MJ; Poppel, DM			Practical considerations in dialysis withdrawal "To have that option is a blessing"	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							QUALITY-OF-LIFE; SERIOUSLY ILL PATIENTS; STAGE RENAL-DISEASE; LONG-TERM DIALYSIS; PALLIATIVE CARE; SUPPORT TREATMENT; DECISION-MAKING; TERMINALLY ILL; END; DEPRESSION	Cessation of life-support treatment is an appropriate option for situations in which the burdens of therapy substantially outweigh the benefits. Decisions to withdraw dialysis now precede 1 in 4 deaths of patients who have end-stage renal disease. Guidelines have been recently published to assist clinicians in making these complex and emotionally charged determinations, and they include: relying on shared decision making by all participants, obtaining informed consent, estimating the prognosis on dialysis, adopting a systematic approach for conflict resolution of disagreements, honoring advance directives, and ensuring the provision of palliative care. These principles are discussed in relation to an elderly man with dementia whose family decided to terminate maintenance hemodialysis.	Baystate Med Ctr, Dept Psychiat, Springfield, MA 01199 USA; Baystate Med Ctr, Dept Med, Springfield, MA 01199 USA; Western New England Renal & Transplantat Associat, W Springfield, MA USA	Baystate Medical Center; Baystate Medical Center	Cohen, LM (corresponding author), Baystate Med Ctr, Dept Psychiat, 759 Chestnut St,S2669, Springfield, MA 01199 USA.							ALEXANDER S, 1962, LIFE            1109, P102; Beck DA, 1998, CLIN GERIATR MED, V14, P765; Breitbart W, 2000, JAMA-J AM MED ASSOC, V284, P2907, DOI 10.1001/jama.284.22.2907; BUCKMAN R, 1992, HOW BREAK BADS NEWS; Cassell EJ, 1999, ANN INTERN MED, V131, P531, DOI 10.7326/0003-4819-131-7-199910050-00009; Chochinov HM, 2002, JAMA-J AM MED ASSOC, V287, P2253, DOI 10.1001/jama.287.17.2253; CHOCHINOV HM, 1994, AM J PSYCHIAT, V151, P537; Cohen L M, 2001, J Palliat Med, V4, P167, DOI 10.1089/109662101750290209; COHEN LM, 1995, ARCH INTERN MED, V155, P42, DOI 10.1001/archinte.155.1.42; Cohen LM, 2002, PSYCHOSOM MED, V64, P889, DOI 10.1097/01.PSY.0000028828.64279.84; Cohen LM, 2000, ARCH INTERN MED, V160, P2513, DOI 10.1001/archinte.160.16.2513; Cohen LM, 2000, PSYCHOSOMATICS, V41, P195, DOI 10.1176/appi.psy.41.3.195; Cohen LM, 1998, ARCH INTERN MED, V158, P1973, DOI 10.1001/archinte.158.18.1973; Cohen LM, 2000, AM J KIDNEY DIS, V36, P140, DOI 10.1053/ajkd.2000.8286; COHEN LM, 2001, OXFORD TXB PALLIATIV, P103; COHEN LM, 2003, GERIATRIC PALLIATIVE, P192; COHEN LM, 2002, TXB CONSULTATION LIA, P537; COHEN LM, 2003, THERAPY NEPHROLOGY H, P753; COHEN LM, 2003, THERAPY NEPHROLOGY H, P731; Cotler M, 2000, HASTINGS CENT REP, V30, P24, DOI 10.2307/3528449; Coulehan JL, 2001, ANN INTERN MED, V135, P221, DOI 10.7326/0003-4819-135-3-200108070-00022; Crawley LM, 2002, ANN INTERN MED, V136, P673, DOI 10.7326/0003-4819-136-9-200205070-00010; CUMMINGS NB, 2001, DIS KIDNEY URINARY T, V3, P3007; Darrah J B, 1987, ASAIO Trans, V33, P791; Davison SN, 2002, SEMIN DIALYSIS, V15, P41, DOI 10.1046/j.1525-139x.2002.00015.x; DESSNER GH, 1986, NEW ENGL J MED, V314, P1449; Eiser AR, 1996, AM J KIDNEY DIS, V27, P451, DOI 10.1016/S0272-6386(96)90373-X; *END STAG REN DIS, REC FIELD; *ESRD NETW NEW ENG, 2002, 2001 ANN REP CTR MED, P60; FISHER SH, 1986, NEW ENGL J MED, V314, P1449; Fried TR, 2002, NEW ENGL J MED, V346, P1061, DOI 10.1056/NEJMsa012528; FRIEDMAN EA, 1987, ASAIO T, V33, P794; Galla JH, 2000, J AM SOC NEPHROL, V11, P1340, DOI 10.1681/ASN.V1171340; HIRSCH DJ, 1994, AM J KIDNEY DIS, V23, P463, DOI 10.1016/S0272-6386(12)81012-2; HOLLEY JL, 1991, J AM SOC NEPHROL, V1, P1284; Holley JL, 1997, AM J KIDNEY DIS, V30, P356, DOI 10.1016/S0272-6386(97)90279-1; Holley JL, 1999, AM J KIDNEY DIS, V33, P688, DOI 10.1016/S0272-6386(99)70220-9; Jansen LA, 2002, ANN INTERN MED, V136, P845, DOI 10.7326/0003-4819-136-11-200206040-00014; Kagawa-Singer M, 2001, JAMA-J AM MED ASSOC, V286, P2993, DOI 10.1001/jama.286.23.2993; Karlawish JHT, 1999, ANN INTERN MED, V130, P835, DOI 10.7326/0003-4819-130-10-199905180-00018; KAYE M, 1992, ETHICAL PROBLEMS DIA, P117; Leeman CP, 1999, GEN HOSP PSYCHIAT, V21, P112, DOI 10.1016/S0163-8343(98)00069-3; Leggat J E Jr, 1997, Adv Ren Replace Ther, V4, P22; Levinson W, 2001, ANN INTERN MED, V135, P386, DOI 10.7326/0003-4819-135-5-200109040-00027; Levy NB, 2001, TXB NEPHROLOGY, P1279; LOWANCE DC, 1993, AM J KIDNEY DIS, V21, P679, DOI 10.1016/S0272-6386(12)80045-X; LOWANCE DC, 1988, KIDNEY INT, V34, P124, DOI 10.1038/ki.1988.155; MCBRIDE P, 1990, CLIN DIALYSIS, P20; Meier DE, 2002, NEW ENGL J MED, V346, P1087, DOI 10.1056/NEJM200204043461413; Merkus MP, 1999, NEPHROL DIAL TRANSPL, V14, P1163, DOI 10.1093/ndt/14.5.1163; Moss A H, 2000, J Palliat Med, V3, P253, DOI 10.1089/jpm.2000.3.253; MOSS AH, 1993, J AM SOC NEPHROL, V4, P229; *NAT KIDN FDN, 1996, IN WITHDR DIAL END S; NEU S, 1986, NEW ENGL J MED, V314, P14, DOI 10.1056/NEJM198601023140103; Quill TE, 2000, JAMA-J AM MED ASSOC, V284, P2502, DOI 10.1001/jama.284.19.2502; RABETOY CP, IN PRESS EDTNA ERCA; *REN PHYS ASS AM S, 2000, SHAR DEC MAK APPR IN, V2; Rettig RA, 1991, KIDNEY FAILURE FEDER; Ries LAG, 2002, SEER CANC STAT REV; Saunders C, 1989, TXB PAIN, P624; Sekkarie MA, 1998, AM J KIDNEY DIS, V31, P464, DOI 10.1053/ajkd.1998.v31.pm9506683; Shidler NR, 1998, AM J KIDNEY DIS, V32, P557, DOI 10.1016/S0272-6386(98)70017-4; Shuster JL, 1999, PSYCHOSOMATICS, V40, P1; Singer PA, 1999, AM J KIDNEY DIS, V33, P980; SINGER PA, 1992, J AM SOC NEPHROL, V2, P1235; SULLIVAN MD, 1994, AM J PSYCHIAT, V151, P971; *US REN DAT SYST, 2002, USRDS 2002 ANN DAT R; *US REN DAT SYST, 1999, AM J KIDNEY DIS S, V34, pS1; *US REN DAT SYST, 2001, USRDS 2001 ANN DAT R; Valderrabano F, 2001, AM J KIDNEY DIS, V38, P443, DOI 10.1053/ajkd.2001.26824; Weisbord SD, 2002, J AM SOC NEPHROL, V13, p706A; WEISBORD SD, IN PRESS NEPHROL DIA; Woods A, 1999, J NEPHROL SOCIAL WOR, V19, P9; World Health Organization, 1996, CANC PAIN REL; Zaubler TS, 2000, PSYCHOSOMATICS, V41, P193, DOI 10.1176/appi.psy.41.3.193	75	78	81	0	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 23	2003	289	16					2113	2119		10.1001/jama.289.16.2113	http://dx.doi.org/10.1001/jama.289.16.2113			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	669WW	12709469				2022-12-28	WOS:000182374300027
J	Berger, A				Berger, A			Science commentary: Pertussis immunisation	BRITISH MEDICAL JOURNAL			English	Editorial Material							REACTOGENICITY; VACCINES											Miller E, 1997, VACCINE, V15, P51, DOI 10.1016/S0264-410X(96)00112-0; Miller E, 2001, VACCINE, V19, P3904, DOI 10.1016/S0264-410X(01)00123-2; MILLER E, 1995, VACCINE, V13, P1183, DOI 10.1016/0264-410X(95)00061-5; Van Buynder PG, 1999, EPIDEMIOL INFECT, V123, P403, DOI 10.1017/S0950268899003052	4	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 19	2003	326	7394					853	853		10.1136/bmj.326.7394.853	http://dx.doi.org/10.1136/bmj.326.7394.853			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	670BF	12702618	Green Published, Bronze			2022-12-28	WOS:000182386800018
J	Herbison, P; Hay-Smith, J; Ellis, G; Moore, K				Herbison, P; Hay-Smith, J; Ellis, G; Moore, K			Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DOUBLE-BLIND; URINARY-INCONTINENCE; DETRUSOR INSTABILITY; EMEPRONIUM BROMIDE; URGE INCONTINENCE; TROSPIUM CHLORIDE; PROPIVERIN-HYDROCHLORIDE; FLAVOXATE HYDROCHLORIDE; OXYBUTININ CHLORIDE; OXYBUTYNIN CHLORIDE	Objective To determine the effectiveness of anticholinergic drugs for the treatment of overactive bladder syndrome. Design Systematic review of randomised controlled trials. Data sources Published papers and abstracts. Study selection Randomised controlled trials with anticholinergic drug treatment in one arm and placebo in another. Data extraction Primary outcomes of interest were patient perceived cure or improvement in symptoms, differences in number of incontinent episodes and number of voids in 24 hours, and side effects. Secondary outcomes of interest were urodynamic measures of bladder function (volume at first contraction, maximum cystometric capacity, and residual volume) and adverse events. Data synthesis 32 trials were included, totalling 6800 participants. Most trials were described as double blind but were variable in other aspects of quality. At the end of treatment, cure or improvement (relative risk 1.41, 95% confidence interval 1.29 to 1.54), differences in incontinent episodes in 24 hours (estimated mean difference 0.6, 0.4 to 0.8), number of voids in 24 hours (0.6,0.4 to 0.8), maximum cystometric capacity (54 ml, 43 ml to 66 ml), and volume at first contraction (52 ml, 37 ml to 67 ml), were significantly in favour of anticholinergics (P < 0.0001 for all). Anticholinergics were associated with significantly higher residual volumes (4 ml, 1 ml to 7 ml; P=0.02) mid an increased rate of dry mouth (relative risk 2.56, 2.24 to 2.92; P < 0.0001). Sensitivity analysis, although affected by small numbers of studies, showed little likelihood of an effect of age, sex, diagnosis, or choice of drug. Conclusions Although statistically significant, the differences between anticholinergic drugs and placebo were small, apart from the increased rate of dry mouth in patients receiving active treatment. For many of the outcomes studied, the observed difference between anticholinergics and placebo may be of questionable clinical significance. None of these studies provided data on long term outcome.	Univ Otago, Dept Prevent & Social Med, Dunedin, New Zealand; Univ Otago, Dept Womens & Childrens Hlth, Dunedin, New Zealand; St George Hosp, Dept Urogynaecol, Kogarah, NSW 2217, Australia	University of Otago; University of Otago; St George Hospital	Herbison, P (corresponding author), Univ Otago, Dept Prevent & Social Med, POB 913, Dunedin, New Zealand.	peter.herbison@otago.ac.nz		Herbison, Graham Peter/0000-0002-5684-024X; Moore, Kate/0000-0001-6947-9839				Abrams P, 1998, BRIT J UROL, V81, P801; Abrams P, 1996, P INT CONT SOC 26 AN, P276; ABRAMS P, 2001, P INT CONT SOC 32 AN; Alloussi S, 1998, J CLIN RES, V1, P439; ANDERSEN JR, 1988, BRIT J UROL, V61, P310, DOI 10.1111/j.1464-410X.1988.tb13964.x; Appell RA, 1997, UROLOGY, V50, P90, DOI 10.1016/S0090-4295(97)00599-2; BAGGER PV, 1985, SCAND J UROL NEPHROL, V19, P31, DOI 10.3109/00365598509180219; Bono AV, 1982, UROLOGIA, V49, P764; BROCKLEHURST J C, 1972, Age and Ageing, V1, P152, DOI 10.1093/ageing/1.3.152; Brown JS, 1999, OBSTET GYNECOL, V94, P66, DOI 10.1016/S0029-7844(99)00263-X; BROWN MM, 1999, CEREBROVASC DIS, V9, P66; Burgio KL, 1998, JAMA-J AM MED ASSOC, V280, P1995, DOI 10.1001/jama.280.23.1995; Cardozo L, 2000, BJU INT, V85, P659, DOI 10.1046/j.1464-410x.2000.00575.x; CHALIHA C, 1998, BR J OBSTET GYNA S17, V105, P276; Clarke GM, 2000, CONSERV BIOL SER, V4, P1; Davila GW, 2001, J UROLOGY, V166, P140, DOI 10.1016/S0022-5347(05)66095-8; DAVILA GW, 2001, INT UROGYNECOLOGY S3, V12, pS43; Di Stasi SM, 2001, J UROLOGY, V165, P491, DOI 10.1097/00005392-200102000-00032; Dorschner W, 2000, EUR UROL, V37, P702, DOI 10.1159/000020221; Drutz H P, 1999, Int Urogynecol J Pelvic Floor Dysfunct, V10, P283, DOI 10.1007/s001929970003; DuBeau C. E., 2000, Neurourology and Urodynamics, V19, P492; Elbourne DR, 2002, INT J EPIDEMIOL, V31, P140, DOI 10.1093/ije/31.1.140; ENZELSBERGER H, 1995, BRIT J OBSTET GYNAEC, V102, P929, DOI 10.1111/j.1471-0528.1995.tb10885.x; Frohlich G, 1998, ARZNEIMITTEL-FORSCH, V48, P486; GRANT AM, 2002, COCHRANE LIB; GRIEBENOW R, 1994, NEUROUROL URODYNAM, V13, P430; HALASKA M, 1994, NEUROUROL URODYNAM, V13, P428; HAYSMITH J, 2002, COCHRANE LIB; Hennessey A, 1999, J NEUROL, V246, P1027, DOI 10.1007/s004150050508; Herzog AR., 2001, INT UROGYNAECOL J, V12, pS66; Jackson S, 1997, UROLOGY, V50, P18, DOI 10.1016/S0090-4295(97)00580-3; Jacquetin B, 2001, EUR J OBSTET GYN R B, V98, P97, DOI 10.1016/S0301-2115(00)00561-3; Jonas U, 1997, WORLD J UROL, V15, P144, DOI 10.1007/BF02201987; Junemann KP, 1999, NEUROUROL URODYNAM, V18, P375; Junemann KP, 2000, NEUROUROL URODYNAM, V19, P488; KIRSCHNERHERMAN.R, 1997, P INT CONT SOC 27 AN, P149; Kobelt G, 1997, UROLOGY, V50, P100, DOI 10.1016/S0090-4295(97)00602-X; KRAMER AEJL, 1987, TGO-TIJDSCHR THER GE, V12, P256; Krishnan KR, 1996, NEUROUROL URODYNAM, V15, P674; Larsson G, 1999, UROLOGY, V53, P990, DOI 10.1016/S0090-4295(98)00629-3; Madersbacher H, 1999, BJU INT, V84, P646; Malone-Lee JG, 2001, J AM GERIATR SOC, V49, P700, DOI 10.1046/j.1532-5415.2001.49144.x; MASSEY JA, 1986, BRIT J UROL, V58, P125, DOI 10.1111/j.1464-410X.1986.tb09010.x; Mattiasson A, 1998, NEUROUROL URODYNAM, V17, P249, DOI 10.1002/(SICI)1520-6777(1998)17:3<249::AID-NAU9>3.3.CO;2-I; MEYHOFF HH, 1983, BRIT J UROL, V55, P34, DOI 10.1111/j.1464-410X.1983.tb07075.x; Millard R, 1999, J UROLOGY, V161, P1551, DOI 10.1016/S0022-5347(05)68951-3; Milsom I, 2001, BJU INT, V87, P760, DOI 10.1046/j.1464-410x.2001.02228.x; MOISEY CU, 1980, BRIT J UROL, V52, P472, DOI 10.1111/j.1464-410X.1980.tb03093.x; Moller LA, 2000, ACTA OBSTET GYN SCAN, V79, P298, DOI 10.1080/j.1600-0412.2000.079004298.x; MOORE KH, 1990, BRIT J UROL, V66, P479, DOI 10.1111/j.1464-410X.1990.tb14992.x; Murray KHA, 1984, P 14 ANN M INT CONT, P454; OBRINK A, 1978, SCAND J UROL NEPHROL, V12, P215; OUSLANDER JG, 1995, J AM GERIATR SOC, V43, P610, DOI 10.1111/j.1532-5415.1995.tb07193.x; Rentzhog L, 1998, BRIT J UROL, V81, P42; Riva D, 1984, Clin Exp Obstet Gynecol, V11, P37; ROBINSON JM, 1983, BRIT J UROL, V55, P371, DOI 10.1111/j.1464-410X.1983.tb03325.x; ROE B, 2002, COCHRANE LIB; Roland M, 1998, BRIT MED J, V316, P285, DOI 10.1136/bmj.316.7127.285; Rosario DJ, 1999, NEUROUROL URODYNAM, V18, P223, DOI 10.1002/(SICI)1520-6777(1999)18:3<223::AID-NAU9>3.0.CO;2-6; ROSARIO DJ, 1995, NEUROUROL URODYNAM, V14, P464; ROSARIO DJ, 1995, P 25 ANN M INT CONT, P223; Serrano Brambila EA, 2000, GINECOL OBSTET MEX, V68, P174; Smith R, 1998, BMJ-BRIT MED J, V317, P291, DOI 10.1136/bmj.317.7154.291; Stohrer M, 1999, SPINAL CORD, V37, P196, DOI 10.1038/sj.sc.3100750; STOHRER M, 1991, UROL INT, V47, P138; SZONYI G, 1995, AGE AGEING, V24, P287, DOI 10.1093/ageing/24.4.287; TAGO K, 1990, NEUROUROL URODYNAM, V9, P337; TAPP AJS, 1990, BRIT J OBSTET GYNAEC, V97, P521, DOI 10.1111/j.1471-0528.1990.tb02523.x; THUROFF JW, 1991, J UROLOGY, V145, P813, DOI 10.1016/S0022-5347(17)38459-8; Ueda T, 2000, INT J UROL, V7, P95, DOI 10.1046/j.1442-2042.2000.00147.x; Ulshofer B, 2001, CLIN DRUG INVEST, V21, P563, DOI 10.2165/00044011-200121080-00005; Van Kerrebroeck P, 2001, UROLOGY, V57, P414, DOI 10.1016/S0090-4295(00)01113-4; Van Kerrebroeck PEVA, 1998, NEUROUROL URODYNAM, V17, P499, DOI 10.1002/(SICI)1520-6777(1998)17:5<499::AID-NAU6>3.0.CO;2-8; WALTER S, 1982, BRIT J UROL, V54, P249, DOI 10.1111/j.1464-410X.1982.tb06968.x; WEHNERT J, 1992, AKTUEL UROL, V23, P7, DOI 10.1055/s-2008-1060401; WEHNERT J, 1989, Z UROL NEPHROL, V82, P259; WEIN A J, 1978, Urology, V12, P184, DOI 10.1016/0090-4295(78)90329-1; WEIN AJ, 1999, INT UROGYNECOLOGY S1, V10, pS150; WHITEHEAD JA, 1967, GERIATRICS, V22, P154; WILLIAMS AJ, 1981, PHARMATHERAPEUTICA, V2, P539; Yaphe J, 2001, FAM PRACT, V18, P565, DOI 10.1093/fampra/18.6.565; ZEEGERS AGM, 1987, WORLD J UROL, V5, P57, DOI 10.1007/BF00326777; ZORZITTO ML, 1989, AGE AGEING, V18, P195, DOI 10.1093/ageing/18.3.195	83	212	224	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 19	2003	326	7394					841	844J		10.1136/bmj.326.7394.841	http://dx.doi.org/10.1136/bmj.326.7394.841			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	670BF	12702614	Bronze, Green Published			2022-12-28	WOS:000182386800014
J	Navsaria, HA; Rugg, EL				Navsaria, HA; Rugg, EL			Telomere shortening: significant for keratinocyte grafting?	LANCET			English	Editorial Material							EPIDERMAL STEM-CELLS		Univ London, Queen Marys Sch Med & Dent, Barts & London, Ctr Cutaneous Res, London E1 2AT, England	University of London; Queen Mary University London	Navsaria, HA (corresponding author), Univ London, Queen Marys Sch Med & Dent, Barts & London, Ctr Cutaneous Res, London E1 2AT, England.							BARRANDON Y, 1987, P NATL ACAD SCI USA, V84, P2302, DOI 10.1073/pnas.84.8.2302; Bickenbach JR, 1999, P ASSOC AM PHYSICIAN, V111, P184, DOI 10.1046/j.1525-1381.1999.99222.x; Collins K, 2002, ONCOGENE, V21, P564, DOI 10.1038/sj.onc.1205083; CUONO C, 1986, LANCET, V1, P1123, DOI 10.1016/S0140-6736(86)91838-6; Gonzalez-Suarez E, 2001, EMBO J, V20, P2619, DOI 10.1093/emboj/20.11.2619; Morrison SJ, 1997, CELL, V88, P287, DOI 10.1016/S0092-8674(00)81867-X; MUNSTER AM, 1997, BURNS, V23, P1; NAVSARIA HA, 1994, BURNS S1, V20, P57; Pellegrini G, 1999, TRANSPLANTATION, V68, P868, DOI 10.1097/00007890-199909270-00021; Rheinwald JG, 2002, MOL CELL BIOL, V22, P5157, DOI 10.1128/MCB.22.14.5157-5172.2002	10	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 19	2003	361	9366					1316	1317		10.1016/S0140-6736(03)13087-5	http://dx.doi.org/10.1016/S0140-6736(03)13087-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	669HP	12711463				2022-12-28	WOS:000182346100005
J	Mickelson, W; Aloni, S; Han, WQ; Cumings, J; Zettl, A				Mickelson, W; Aloni, S; Han, WQ; Cumings, J; Zettl, A			Packing C-60 in boron nitride nanotubes	SCIENCE			English	Article							CARBON NANOTUBES; BN NANOTUBES; NANOWIRES	We have created insulated C-60 nanowire by packing C-60 molecules into the interior of insulating boron nitride nanotubes (BNNTs). For small-diameter BNNTs, the wire consists of a linear chain of C-60 molecules. With increasing BNNT inner diameter, unusual C-60 stacking configurations are obtained (including helical, hollow core, and incommensurate) that are unknown for bulk or thin-film forms of C-60. C-60 in BNNTs thus presents a model system for studying the properties of dimensionally constrained "silo" crystal structures. For the linear-chain case, we have fused the C-60 molecules to form a single-walled carbon nanotube inside the insulating BNNT.	Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Sci Mat, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Zettl, A (corresponding author), Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA.		Han, Wei-Qiang/E-2818-2013; Mickelson, Willi/D-8813-2013; Zettl, Alex K/O-4925-2016; Cumings, John/A-3595-2012; Han, Weiqiang/AAJ-7738-2020	Han, Wei-Qiang/0000-0001-5525-8277; Mickelson, Willi/0000-0002-6398-6212; Zettl, Alex K/0000-0001-6330-136X; 				BLASE X, 1994, EUROPHYS LETT, V28, P3085; CHANG KJ, 1985, PHYS REV LETT, V54, P2375, DOI 10.1103/PhysRevLett.54.2375; CHOPRA NG, 1995, SCIENCE, V269, P966, DOI 10.1126/science.269.5226.966; Cumings J, 2000, CHEM PHYS LETT, V316, P211, DOI 10.1016/S0009-2614(99)01277-4; ERICKSON RO, 1973, SCIENCE, V181, P705, DOI 10.1126/science.181.4101.705; Girifalco LA, 2000, PHYS REV B, V62, P13104, DOI 10.1103/PhysRevB.62.13104; Gulseren O, 1998, PHYS REV LETT, V80, P3775, DOI 10.1103/PhysRevLett.80.3775; Han WQ, 2002, APPL PHYS LETT, V81, P1110, DOI 10.1063/1.1498494; Jamneala T, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.256804; Kondo Y, 2000, SCIENCE, V289, P606, DOI 10.1126/science.289.5479.606; Luzzi DE, 2000, CARBON, V38, P1751, DOI 10.1016/S0008-6223(00)00088-9; Okada S, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.201303; Pickett GT, 2000, PHYS REV LETT, V85, P3652, DOI 10.1103/PhysRevLett.85.3652; RUBIO A, 1994, PHYS REV B, V49, P5081, DOI 10.1103/PhysRevB.49.5081; Schmidt M, 1997, PHYS REV E, V55, P7228, DOI 10.1103/PhysRevE.55.7228; Smith BW, 1998, NATURE, V396, P323, DOI 10.1038/24521	16	275	290	1	113	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 18	2003	300	5618					467	469		10.1126/science.1082346	http://dx.doi.org/10.1126/science.1082346			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	668LR	12702871				2022-12-28	WOS:000182295900033
J	Saito, T; Furuta, T; Hwang, JH; Kuramoto, S; Nishino, K; Suzuki, N; Chen, R; Yamada, A; Ito, K; Seno, Y; Nonaka, T; Ikehata, H; Nagasako, N; Iwamoto, C; Ikuhara, Y; Sakuma, T				Saito, T; Furuta, T; Hwang, JH; Kuramoto, S; Nishino, K; Suzuki, N; Chen, R; Yamada, A; Ito, K; Seno, Y; Nonaka, T; Ikehata, H; Nagasako, N; Iwamoto, C; Ikuhara, Y; Sakuma, T			Multifunctional alloys obtained via a dislocation-free plastic deformation mechanism	SCIENCE			English	Article							INVAR PROBLEM; PSEUDOPOTENTIALS	We describe a group of alloys that exhibit "super" properties, such as ultralow elastic modulus, ultrahigh strength, super elasticity, and super plasticity, at room temperature and that show Elinvar and Invar behavior. These "super" properties are attributable to a dislocation-free plastic deformation mechanism. In cold-worked alloys, this mechanism forms elastic strain fields of hierarchical structure that range in size from the nanometer scale to several tens of micrometers. The resultant elastic strain energy leads to a number of enhanced material properties.	Toyota Cent Res & Dev Labs Inc, Nagakute, Aichi 4801192, Japan; Univ Tokyo, Inst Engn Innovat, Bunkyo Ku, Tokyo 1138656, Japan; Univ Tokyo, Grad Sch Frontier Sci, Bunkyo Ku, Tokyo 1130033, Japan	Toyota Central R&D Labs Inc; University of Tokyo; University of Tokyo	Saito, T (corresponding author), Toyota Cent Res & Dev Labs Inc, Nagakute, Aichi 4801192, Japan.	saito@mosk.tytlabs.co.jp	Ikuhara, Yuichi/F-3066-2010; Ikuhara, Yuichi/N-1001-2015	Ikuhara, Yuichi/0000-0003-3886-005X; KURAMOTO, Shigeru/0000-0002-9007-0605				AVERILL FW, 1973, J CHEM PHYS, V59, P6412, DOI 10.1063/1.1680020; Baker C., 1971, Metal Science Journal, V5, P92; Duerig TW., 1994, MAT PROP HDB TIT ALL, P1035; Egerton RF, 1986, ELECT ENERGY LOSS SP, DOI [10.1007/978-1-4419-9583-4, DOI 10.1007/978-1-4419-9583-4]; Guillaume CE., 1919, P PHYS SOC LOND, V191, P374; HOHENBERG P, 1964, PHYS REV B, V136, pB864, DOI 10.1103/PhysRevB.7.1912; Kainuma R, 2002, APPL PHYS LETT, V80, P4348, DOI 10.1063/1.1485118; Kitamura H, 1998, J SYNCHROTRON RADIAT, V5, P184, DOI 10.1107/S0909049597018724; KOHN W, 1965, PHYS REV, V140, P1133, DOI 10.1103/PhysRev.140.A1133; Krenn CR, 2001, MAT SCI ENG A-STRUCT, V319, P111, DOI 10.1016/S0921-5093(01)00998-4; LAASONEN K, 1993, PHYS REV B, V47, P10142, DOI 10.1103/PhysRevB.47.10142; MORINAGA M, 1989, 6 WORLD C TIT SOC FR, P1373; NAKAMURA Y, 1976, IEEE T MAGN, V12, P278, DOI 10.1109/TMAG.1976.1059049; SLATER JC, 1979, CALCULATION MOL ORBI; Teo, 1986, EXAFS BASIC PRINCIPL; VANDERBILT D, 1990, PHYS REV B, V41, P7892, DOI 10.1103/PhysRevB.41.7892; WOHLFARTH EP, 1975, IEEE T MAGN, V11, P1638, DOI 10.1109/TMAG.1975.1058962	17	731	766	29	324	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 18	2003	300	5618					464	467		10.1126/science.1081957	http://dx.doi.org/10.1126/science.1081957			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	668LR	12702870	Green Submitted			2022-12-28	WOS:000182295900032
J	Saad, EB; Marrouche, NF; Saad, CP; Ha, E; Bash, D; White, RD; Rhodes, J; Prieto, L; Martin, DO; Saliba, WI; Schweikert, RA; Natale, A				Saad, EB; Marrouche, NF; Saad, CP; Ha, E; Bash, D; White, RD; Rhodes, J; Prieto, L; Martin, DO; Saliba, WI; Schweikert, RA; Natale, A			Pulmonary vein stenosis after catheter ablation of atrial fibrillation. Emergence of a new clinical syndrome	ANNALS OF INTERNAL MEDICINE			English	Article							ECTOPIC BEATS; RADIOFREQUENCY ABLATION; INITIATION; SYSTEM	Background: Pulmonary vein isolation is a new, effective curative procedure for selected patients with atrial fibrillation. Pulmonary vein stenosis is a potential complication and may lead to symptoms that are often underrecognized. Objective: To describe the clinical course and symptoms associated with pulmonary vein stenosis developing after ablation in the pulmonary veins. Design: Retrospective study. Setting: Tertiary care referral center. Patients: 335 patients referred for catheter ablation of drug-refractory atrial fibrillation. Intervention: Pulmonary vein electrical isolation using radiofrequency catheter ablation. Measurements: Three months after ablation, patients underwent routine screening for pulmonary vein stenosis with spiral computed tomography. Screening was considered earlier if symptoms suggestive of stenosis developed and was repeated at 6 and 12 months if any pulmonary vein narrowing was observed. Pulmonary vein angiography and dilatation were offered to patients with severe (>70%) stenosis. Results: Severe pulmonary vein stenosis was detected in 18 patients (5% [95% Cl, 3.2% to 8.4%]) a mean (+SD) of 5.2 +/- 2.6 months after ablation. Eight of these 18 patients (44%) were asymptomatic, but 8 (44%) reported shortness of breath, 7 (39%) reported cough, and 5 (28%) reported hemoptysis. Radiologic abnormalities were present in 9 patients (50%) and led to diagnoses of pneumonia (4 patients), lung cancer (1 patient), and pulmonary embolism (2 patients). Pulmonary vein stenosis was not considered in any patient during the initial work-up. Dilatation of the affected vein was performed in 12 patients. Postintervention lung perfusion scans revealed significant improvement in lung flow. Conclusions: Severe pulmonary vein stenosis after catheter ablation of atrial fibrillation is associated with respiritory symptoms that frequently mimic more common diseases, often leading to erroneous diagnostic and therapeutic procedures. Awareness of this syndrome is important for proper and prompt management.	Cleveland Clin Fdn, Dept Cardiovasc Med, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Natale, A (corresponding author), Cleveland Clin Fdn, Dept Cardiovasc Med, 9500 Euclid Ave,Desk F15, Cleveland, OH 44195 USA.	natalea@cce.org		White, Richard D./0000-0002-1133-7819				Chen SA, 2000, J CARDIOVASC ELECTR, V11, P218; Chen SA, 1999, CIRCULATION, V100, P1879, DOI 10.1161/01.CIR.100.18.1879; Cole CR, 2001, CIRCULATION, V104, P567; Cooper JM, 2001, CIRCULATION, V104, P3010, DOI 10.1161/hc5001.101503; Haissaguerre M, 2000, CIRCULATION, V101, P1409, DOI 10.1161/01.CIR.101.12.1409; Haissaguerre M, 1998, NEW ENGL J MED, V339, P659, DOI 10.1056/NEJM199809033391003; Kanagaratnam L, 2001, PACE, V24, P1774, DOI 10.1046/j.1460-9592.2001.01774.x; Lin WS, 2000, CIRCULATION, V101, P1274, DOI 10.1161/01.CIR.101.11.1274; Marrouche NF, 2002, J AM COLL CARDIOL, V40, P464, DOI 10.1016/S0735-1097(02)01972-1; Natale A, 2000, CIRCULATION, V102, P1879, DOI 10.1161/01.CIR.102.16.1879; Natale A, 1999, PACE, V22, P1634, DOI 10.1111/j.1540-8159.1999.tb00383.x; Oral H, 2002, CIRCULATION, V105, P1077, DOI 10.1161/hc0902.104712; Robbins IM, 1998, CIRCULATION, V98, P1769, DOI 10.1161/01.CIR.98.17.1769; Scanavacca MI, 2000, J CARDIOVASC ELECTR, V11, P677, DOI 10.1111/j.1540-8167.2000.tb00030.x; Yang M, 2001, J COMPUT ASSIST TOMO, V25, P34, DOI 10.1097/00004728-200101000-00006; Yu WC, 2001, J CARDIOVASC ELECTR, V12, P887, DOI 10.1046/j.1540-8167.2001.00887.x	16	167	177	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	2003	138	8					634	638		10.7326/0003-4819-138-8-200304150-00010	http://dx.doi.org/10.7326/0003-4819-138-8-200304150-00010			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	666JH	12693885				2022-12-28	WOS:000182173800005
J	Foell, D; Ichida, F; Vogl, T; Yu, XY; Chen, R; Miyawaki, T; Sorg, C; Roth, J				Foell, D; Ichida, F; Vogl, T; Yu, XY; Chen, R; Miyawaki, T; Sorg, C; Roth, J			S100A12 (EN-RAGE) in monitoring Kawasaki disease	LANCET			English	Article							RECEPTOR	The calcium-binding protein S100A12 causes inflammation through interaction with the multiligand receptor for advanced glycation end products (RAGE). Blocking of S100A12 showed promising therapeutic effects in mice. We investigated 31 individuals with Kawasaki disease, and recorded an association between expression of S100A12 and activity of Kawasaki disease. Serum concentrations of S100A12 decreased quickly in 28 patients who responded to treatment with gammaglobulin (from 463 mug/L [SD 316] to 184 mug/L [147] within 24 h, p<0.0001). Since the interaction of S100A12 with multiligand receptors has a key role in inflammatory responses, this protein could serve as a novel target for future therapeutic interventions in inflammatory disorders.	Univ Hosp Munster, Dept Paediat, D-48149 Munster, Germany; Univ Hosp Munster, Inst Expt Dermatol, D-48149 Munster, Germany; Toyama Med & Pharmaceut Univ, Dept Paediat, Toyama, Japan	University of Munster; University of Munster; University of Toyama	Foell, D (corresponding author), Univ Hosp Munster, Dept Paediat, Von Esmarch Str 58, D-48149 Munster, Germany.							Brogan PA, 2002, ARCH DIS CHILD, V86, P286, DOI 10.1136/adc.86.4.286; Hofmann MA, 1999, CELL, V97, P889, DOI 10.1016/S0092-8674(00)80801-6; Schmidt AM, 2001, J CLIN INVEST, V108, P949, DOI 10.1172/JCI200114002; Vogl T, 1999, J BIOL CHEM, V274, P25291, DOI 10.1074/jbc.274.36.25291	4	109	117	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 12	2003	361	9365					1270	1272		10.1016/S0140-6736(03)12986-8	http://dx.doi.org/10.1016/S0140-6736(03)12986-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	666DM	12699958				2022-12-28	WOS:000182161600014
J	Blake, WJ; Kaern, M; Cantor, CR; Collins, JJ				Blake, WJ; Kaern, M; Cantor, CR; Collins, JJ			Noise in eukaryotic gene expression	NATURE			English	Article							RNA-POLYMERASE-II; TRANSCRIPTIONAL ACTIVATION; IN-VIVO; SINGLE-CELL; DIFFERENTIATION; STOCHASTICITY; REINITIATION; PROBABILITY; RECRUITMENT; INITIATION	Transcription in eukaryotic cells has been described as quantal(1), with pulses of messenger RNA produced in a probabilistic manner(2,3). This description reflects the inherently stochastic nature(4-9) of gene expression, known to be a major factor in the heterogeneous response of individual cells within a clonal population to an inducing stimulus(10-16). Here we show in Saccharomyces cerevisiae that stochasticity (noise) arising from transcription contributes significantly to the level of heterogeneity within a eukaryotic clonal population, in contrast to observations in prokaryotes(15), and that such noise can be modulated at the translational level. We use a stochastic model of transcription initiation specific to eukaryotes to show that pulsatile mRNA production, through reinitiation, is crucial for the dependence of noise on transcriptional efficiency, highlighting a key difference between eukaryotic and prokaryotic sources of noise. Furthermore, we explore the propagation of noise in a gene cascade network and demonstrate experimentally that increased noise in the transcription of a regulatory protein leads to increased cell-cell variability in the target gene output, resulting in prolonged bistable expression states. This result has implications for the role of noise in phenotypic variation and cellular differentiation.	Boston Univ, Ctr Biodynam, Boston, MA 02215 USA; Boston Univ, Ctr Adv Biotechnol, Bioinformat Program, Boston, MA 02215 USA; Boston Univ, Dept Biomed Engn, Boston, MA 02215 USA	Boston University; Boston University; Boston University	Collins, JJ (corresponding author), Boston Univ, Ctr Biodynam, 44 Cummington St, Boston, MA 02215 USA.		Kaern, Mads/GVU-6867-2022	Kaern, Mads/0000-0002-9371-666X				Becskei A, 2001, EMBO J, V20, P2528, DOI 10.1093/emboj/20.10.2528; Bhaumik SR, 2001, GENE DEV, V15, P1935, DOI 10.1101/gad.911401; Biggar SR, 2001, EMBO J, V20, P3167, DOI 10.1093/emboj/20.12.3167; CHATTERJEE S, 1995, NATURE, V374, P820, DOI 10.1038/374820a0; Elowitz MB, 2002, SCIENCE, V297, P1183, DOI 10.1126/science.1070919; FIERING S, 1990, GENE DEV, V4, P1823, DOI 10.1101/gad.4.10.1823; Hahn S, 1998, COLD SPRING HARB SYM, V63, P181, DOI 10.1101/sqb.1998.63.181; Hasty J, 2000, P NATL ACAD SCI USA, V97, P2075, DOI 10.1073/pnas.040411297; Hume DA, 2000, BLOOD, V96, P2323, DOI 10.1182/blood.V96.7.2323.h8002323_2323_2328; Kemkemer R, 2002, P NATL ACAD SCI USA, V99, P13783, DOI 10.1073/pnas.212386999; Kepler TB, 2001, BIOPHYS J, V81, P3116, DOI 10.1016/S0006-3495(01)75949-8; KLAGES N, 1995, NATURE, V374, P822, DOI 10.1038/374822a0; KO MSH, 1991, J THEOR BIOL, V153, P181, DOI 10.1016/S0022-5193(05)80421-7; KO MSH, 1990, EMBO J, V9, P2835, DOI 10.1002/j.1460-2075.1990.tb07472.x; Larschan E, 2001, GENE DEV, V15, P1946, DOI 10.1101/gad.911501; McAdams HH, 1997, P NATL ACAD SCI USA, V94, P814, DOI 10.1073/pnas.94.3.814; NOVICK A, 1957, P NATL ACAD SCI USA, V43, P553, DOI 10.1073/pnas.43.7.553; Ozbudak EM, 2002, NAT GENET, V31, P69, DOI 10.1038/ng869; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; ROSS IL, 1994, IMMUNOL CELL BIOL, V72, P177, DOI 10.1038/icb.1994.26; Rossi FMV, 2000, MOL CELL, V6, P723, DOI 10.1016/S1097-2765(00)00070-8; SHARP PM, 1987, NUCLEIC ACIDS RES, V15, P1281, DOI 10.1093/nar/15.3.1281; Stewart JJ, 2001, J BIOL CHEM, V276, P30078, DOI 10.1074/jbc.M105276200; Struhl K, 1996, CELL, V84, P179, DOI 10.1016/S0092-8674(00)80970-8; Swain PS, 2002, P NATL ACAD SCI USA, V99, P12795, DOI 10.1073/pnas.162041399; Thattai M, 2001, P NATL ACAD SCI USA, V98, P8614, DOI 10.1073/pnas.151588598; Thattai M, 2002, BIOPHYS J, V82, P2943, DOI 10.1016/S0006-3495(02)75635-X; VANROON MA, 1989, DEV BIOL, V136, P508, DOI 10.1016/0012-1606(89)90276-5; WALTERS MC, 1995, P NATL ACAD SCI USA, V92, P7125, DOI 10.1073/pnas.92.15.7125; Yean D, 1997, MOL CELL BIOL, V17, P3809, DOI 10.1128/MCB.17.7.3809	30	1212	1243	1	133	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 10	2003	422	6932					633	637		10.1038/nature01546	http://dx.doi.org/10.1038/nature01546			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	665GN	12687005				2022-12-28	WOS:000182111400047
J	McElroy, K; Simmonds, RW; Hoffman, JE; Lee, DH; Orenstein, J; Eisaki, H; Uchida, S; Davis, JC				McElroy, K; Simmonds, RW; Hoffman, JE; Lee, DH; Orenstein, J; Eisaki, H; Uchida, S; Davis, JC			Relating atomic-scale electronic phenomena to wave-like quasiparticle states in superconducting Bi2Sr2CaCu2O8+delta	NATURE			English	Article							GAP ANISOTROPY; DENSITY	The electronic structure of simple crystalline solids can be completely described in terms either of local quantum states in real space (r-space), or of wave-like states defined in momentum-space (k-space). However, in the copper oxide superconductors, neither of these descriptions alone may be sufficient. Indeed, comparisons between r-space(1-5) and k-space(6-13) studies of Bi2Sr2CaCu2O8+delta (Bi-2212) reveal numerous unexplained phenomena and apparent contradictions. Here, to explore these issues, we report Fourier transform studies of atomic-scale spatial modulations in the Bi-2212 density of states. When analysed as arising from quasiparticle interference(14-16), the modulations yield elements of the Fermi-surface and energy gap in agreement with photoemission experiments(12,13). The consistency of numerous sets of dispersing modulations with the quasiparticle interference model shows that no additional order parameter is required. We also explore the momentum-space structure of the unoccupied states that are inaccessible to photoemission, and find strong similarities to the structure of the occupied states. The copper oxide quasiparticles therefore apparently exhibit particle-hole mixing similar to that of conventional superconductors. Near the energy gap maximum, the modulations become intense, commensurate with the crystal, and bounded by nanometre-scale domains(4). Scattering of the antinodal quasiparticles is therefore strongly influenced by nanometre-scale disorder.	Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Mat Sci, Berkeley, CA 94720 USA; Tsinghua Univ, Ctr Adv Study, Beijing 100084, Peoples R China; AIST, Tsukuba, Ibaraki 3058568, Japan; Univ Tokyo, Dept Phys, Bunkyo Ku, Tokyo 1138656, Japan; Cornell Univ, Dept Phys, LASSP, Ithaca, NY 14850 USA	University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Tsinghua University; National Institute of Advanced Industrial Science & Technology (AIST); University of Tokyo; Cornell University	Davis, JC (corresponding author), Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA.	jcdavis@ccmr.cornell.edu	mcelroy, kyle/D-1816-2013; Orenstein, Joseph W/I-3451-2015; Hoffman, Jennifer E/H-4334-2011; Eisaki, Hiroshi/F-6317-2018	Hoffman, Jennifer E/0000-0003-2752-5379; Eisaki, Hiroshi/0000-0002-8299-6416; Simmonds, Raymond/0000-0003-2217-2965; McElroy, Kyle/0000-0003-4799-2820				AEBI P, 1994, PHYS REV LETT, V72, P2757, DOI 10.1103/PhysRevLett.72.2757; BYERS JM, 1993, PHYS REV LETT, V71, P3363, DOI 10.1103/PhysRevLett.71.3363; CAMPUZANO JC, 1990, PHYS REV LETT, V64, P2308, DOI 10.1103/PhysRevLett.64.2308; Campuzano JC, 1996, PHYS REV B, V53, P14737, DOI 10.1103/PhysRevB.53.R14737; CAMPUZANO JC, 2002, ARXIVORGCONDMAT02094; Cren T, 2001, EUROPHYS LETT, V54, P84, DOI 10.1209/epl/i2001-00232-4; CROMMIE MF, 1993, NATURE, V363, P524, DOI 10.1038/363524a0; DAMASCELLI A, 2002, ARXIVORGCONDMAT02085; DESSAU DS, 1993, PHYS REV LETT, V71, P2781, DOI 10.1103/PhysRevLett.71.2781; Ding H, 1996, PHYS REV B, V54, pR9678, DOI 10.1103/PhysRevB.54.R9678; Ding H, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.227001; Fedorov AV, 1999, PHYS REV LETT, V82, P2179, DOI 10.1103/PhysRevLett.82.2179; Feng DL, 2000, SCIENCE, V289, P277, DOI 10.1126/science.289.5477.277; Hoffman JE, 2002, SCIENCE, V295, P466, DOI 10.1126/science.1066974; Hoffman JE, 2002, SCIENCE, V297, P1148, DOI 10.1126/science.1072640; Howald C, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.014533; Howald C, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.100504; HOWALD C, 2002, ARXIVORGCONDMAT02015; Johnson PD, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.177007; KIVELSON SA, 2002, ARXIVORGCONDMAT02106; Lang KM, 2002, NATURE, V415, P412, DOI 10.1038/415412a; Lanzara A, 2001, NATURE, V412, P510, DOI 10.1038/35087518; Pan SH, 2001, NATURE, V413, P282, DOI 10.1038/35095012; PODOLSKY D, 2002, ARXIVORGCONDMAT02040; POLKOVNIKOV A, 2002, ARXIVORGCONDMAT02083; SHEN ZX, 1993, PHYS REV LETT, V70, P1553, DOI 10.1103/PhysRevLett.70.1553; SHEN ZX, 1995, SCIENCE, V267, P343, DOI 10.1126/science.267.5196.343; Valla T, 1999, SCIENCE, V285, P2110, DOI 10.1126/science.285.5436.2110; Wang QH, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.020511; Zhang DG, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.100506	30	396	398	2	184	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 10	2003	422	6932					592	596		10.1038/nature01496	http://dx.doi.org/10.1038/nature01496			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	665GN	12686994				2022-12-28	WOS:000182111400035
J	Ettinger, MP; Littlejohn, TW; Schwartz, SL; Weiss, SR; McIlwain, HH; Heymsfield, SB; Bray, GA; Roberts, WG; Heyman, ER; Stambler, N; Heshka, S; Vicary, C; Guler, HP				Ettinger, MP; Littlejohn, TW; Schwartz, SL; Weiss, SR; McIlwain, HH; Heymsfield, SB; Bray, GA; Roberts, WG; Heyman, ER; Stambler, N; Heshka, S; Vicary, C; Guler, HP			Recombinant variant of ciliary neurotrophic factor for weight loss in obese adults - A randomized, dose-ranging study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LEPTIN; RESISTANCE; SIBUTRAMINE; PROTEIN; TRIAL; GENE	Context Obese individuals tend to resist the weight-regulating effects of exogenously administered leptin. A genetically engineered recombinant human variant ciliary neurotrophic factor (rhvCNTF) that signals through leptinlike pathways in the hypothalamus has been shown to bypass leptin resistance in animal models of obesity. Objective To identify a safe and well-tolerated dose of rhvCNTF that causes weight loss in obese adults. Design, Setting, and Patients Twelve-week, double-blind, randomized, parallel-group, dose-ranging, multicenter clinical trial conducted at 2 university obesity clinics and at 5 independent clinical research clinics from March 2000 to August 2001, and including 173 nondiabetic obese adults, 82.6% of whom were women, with a mean (SD) body mass index of 41.1 (4.1). Interventions Patients were randomly assigned to receive daily for 12 weeks subcutaneous injections of placebo (n = 32) or 0.3 mug/kg (n = 32), 1.0 mug/kg (n = 38), or 2.0 mug/kg (n=33) of rhvCNTF. Another group received 1.0 mug/kg for 8 weeks and placebo for 4 weeks (n=38), but they were not included in the primary analysis. All participants received instructions for a reduced-calorie diet (World Health Organization formula minus 500 kcal/d). Main Outcome Measures Change in weight during the 12-week double-blind treatment period and proportion of patients who achieved a weight loss of at least 5%. Results Of the 173 randomized patients, 123 (71%) completed the double-blind dosing period. Mean (SEM) changes in kilograms from baseline body weights were 0.1 (0.6) for placebo and -1.5 (0.6) for the 0.3, -4.1 (0.6) for the 1.0, and -3.4 (0.7) for the 2.0 mug/kg of rhvCNTF dosage groups (P<.001, test for trend). Two patients (8.7%) in the placebo and 2 (8.3%) in the 0.3-&mu;g/kg, 8 (29.6%) in the 1.0-&mu;g/kg, and 5 (26%) in the 2.0-&mu;g/kg treatment groups achieved a weight loss of at least 5%. Recombinant human variant CNTF was generally well tolerated although adverse events occurred in 75% of patients receiving placebo and 78% to 93% of patients receiving rhvCNTF, in a dose-related fashion, with mild injection site reactions as the most frequently reported adverse event. Conclusions In this initial, dose-ranging, 12-week study, treatment with rhvCNTF resulted in more weight loss than placebo. These preliminary findings require confirmation in large prospective clinical trials.	Regeneron Pharmaceut Inc, Tarrytown, NY 10591 USA; Radiat Res, Stuart, FL USA; Piedmont Med Res Associates, Winston Salem, NC USA; Diabet & Glandular Dis Clin, San Antonio, TX USA; Radiant Res, San Diego, CA USA; Tampa Med Grp Res, Tampa, FL USA; St Lukes Roosevelt Hosp, New York, NY 10025 USA; Pennington Biomed Res Ctr, Baton Rouge, LA USA; Celeris Corp, Rockville, MD USA	Regeneron; Mount Sinai St. Luke's; Mount Sinai West; Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center	Guler, HP (corresponding author), Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA.		Heymsfield, Steven B/N-1968-2017	Heymsfield, Steven B/0000-0003-1127-9425				Bray GA, 1999, OBES RES, V7, P189, DOI 10.1002/j.1550-8528.1999.tb00701.x; Buchanan TA, 2002, DIABETES, V51, P2796, DOI 10.2337/diabetes.51.9.2796; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Gloaguen I, 1997, P NATL ACAD SCI USA, V94, P6456, DOI 10.1073/pnas.94.12.6456; Guler H. P., 2000, International Journal of Obesity, V24, pS102; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Heymsfield SB, 1999, JAMA-J AM MED ASSOC, V282, P1568, DOI 10.1001/jama.282.16.1568; Hudson K D, 1977, J R Coll Gen Pract, V27, P497; Ip Nancy Y., 1992, Progress in Growth Factor Research, V4, P139, DOI 10.1016/0955-2235(92)90028-G; Kalra SP, 2001, P NATL ACAD SCI USA, V98, P4279, DOI 10.1073/pnas.091101498; Lambert PD, 2001, P NATL ACAD SCI USA, V98, P4652, DOI 10.1073/pnas.061034298; Lotz B, 1996, NEUROLOGY, V46, P1244; Mantzoros CS, 2000, J CLIN ENDOCR METAB, V85, P4000, DOI 10.1210/jc.85.11.4000; PANYATATOS N, 1993, J BIOL CHEM, V268, P19000; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Rosenbaum M, 1997, NEW ENGL J MED, V337, P396, DOI 10.1056/NEJM199708073370606; Schofield W N, 1985, Hum Nutr Clin Nutr, V39 Suppl 1, P5; SENDTNER M, 1994, J NEUROBIOL, V25, P1436, DOI 10.1002/neu.480251110; WEINTRAUB M, 1992, CLIN PHARMACOL THER, V51, P642, DOI 10.1038/clpt.1992.76; Wirth A, 2001, JAMA-J AM MED ASSOC, V286, P1331, DOI 10.1001/jama.286.11.1331; Xu B, 1998, ENDOCRINOLOGY, V139, P466, DOI 10.1210/en.139.2.466; Yanovski SZ, 2002, NEW ENGL J MED, V346, P591, DOI 10.1056/NEJMra012586	22	157	165	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 9	2003	289	14					1826	1832		10.1001/jama.289.14.1826	http://dx.doi.org/10.1001/jama.289.14.1826			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	664ZJ	12684362				2022-12-28	WOS:000182094900029
J	Tate, DF; Jackvony, EH; Wing, RR				Tate, DF; Jackvony, EH; Wing, RR			Effects of Internet behavioral counseling on weight loss in adults at risk for type 2 diabetes - A randomized trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PHYSICAL-ACTIVITY	Context Weight loss programs on the Internet appear promising for short-term weight loss but have not been studied for weight loss in individuals at risk of type 2 diabetes; thus, the longer-term efficacy is unknown. Objective To compare the effects of an Internet weight loss program alone vs with the addition of behavioral counseling via e-mail provided for 1 year to individuals at risk of type 2 diabetes. Design, Setting, and Participants A single-center randomized controlled trial conducted from September 2001 to September 2002 in Providence, RI, of 92 overweight adults whose mean (SD) age was 48.5 (9.4) years and body mass index, 33.1 (3.8). Interventions Participants were randomized to a basic Internet (n=46) or to an Internet plus behavioral e-counseling program (n=46). Both groups received 1 face-to-face counseling session and the same core Internet programs and were instructed to submit weekly weights. Participants in e-counseling submitted calorie and exercise information and received weekly e-mail behavioral counseling and feedback from a counselor. Main Outcome Measures Measured weight and waist circumference at 0 and 12 months. Results Intent-to-treat analyses showed the behavioral e-counseling group lost more mean (SD) weight at 12 months than the basic Internet group (-4.4 [6.2] vs -2.0 [5.7] kg; P=.04), and had greater decreases in percentage of initial body weight (4.8% vs 2.2%; P=.03), body mass index (-1.6 [2.2] vs -0.8 [2.1]; P=.03), and waist circumference (-7.2 [7.5] vs -4.4 [5.7] cm; P=.05). Conclusion Adding e-mail counseling to a basic Internet weight loss intervention program significantly improved weight loss in adults at risk of diabetes.	Brown Univ, Miriam Hosp, Sch Med, Weight Control & Diabet Res Ctr, Providence, RI 02906 USA	Brown University; Lifespan Health Rhode Island; Miriam Hospital	Tate, DF (corresponding author), Brown Univ, Miriam Hosp, Sch Med, Weight Control & Diabet Res Ctr, 14 3rd St,RISE Bldg, Providence, RI 02906 USA.	dtate@lifespan.org						BLOCK G, 1986, AM J EPIDEMIOL, V124, P453, DOI 10.1093/oxfordjournals.aje.a114416; Feil EG, 2000, DIABETES EDUCATOR, V26, P806; Glasgow RE, 2000, MED CARE, V38, P1062, DOI 10.1097/00005650-200011000-00002; Glasgow RE, 1999, ANN BEHAV MED, V21, P159, DOI 10.1007/BF02908297; Glasgow RE, 2001, DIABETES SPECTRUM, V14, P99, DOI [DOI 10.2337/DIASPECT.14.2.99, 10.2337/diaspect.14.2.99]; GROUP DPP, 2002, NEW ENGL J MED, V346, P393; Harvey-Berino J, 2002, INT J OBESITY, V26, P1254, DOI 10.1038/sj.ijo.0802051; *HUM KIN, 1988, ANTHR STAND REF MAN; Jeffery RW, 1998, J CONSULT CLIN PSYCH, V66, P777, DOI 10.1037/0022-006X.66.5.777; McKay HG, 1998, DIABETES EDUCATOR, V24, P174; PAFFENBARGER RS, 1978, AM J EPIDEMIOL, V108, P161, DOI 10.1093/oxfordjournals.aje.a112608; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Sherwin RS, 2002, DIABETES CARE, V25, P742; Sherwood NE, 1998, AM J HEALTH PROMOT, V13, P12, DOI 10.4278/0890-1171-13.1.12; Tate DF, 2001, JAMA-J AM MED ASSOC, V285, P1172, DOI 10.1001/jama.285.9.1172; THOMAS S, 1992, CAN J SPORT SCI, V17, P338; Tuomilehto J, 2001, NEW ENGL J MED, V344, P1343, DOI 10.1056/NEJM200105033441801; Wing R. R., 1998, HDB OBESITY, P855	18	494	499	1	30	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 9	2003	289	14					1833	1836		10.1001/jama.289.14.1833	http://dx.doi.org/10.1001/jama.289.14.1833			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	664ZJ	12684363				2022-12-28	WOS:000182094900030
J	Leventhal, A; Melville, L; Berry, EM				Leventhal, A; Melville, L; Berry, EM			Public health education in a conflict area: a report from Israel	LANCET			English	Editorial Material									Minist Hlth, Publ Hlth Serv, IL-91010 Jerusalem, Israel; Minist Hlth, Dept Hlth Promot & Hlth Educ, IL-91010 Jerusalem, Israel; Hebrew Univ Jerusalem, Hadassah Med Sch, Braun Sch Publ Hlth, IL-91010 Jerusalem, Israel	Hebrew University of Jerusalem	Leventhal, A (corresponding author), Minist Hlth, Publ Hlth Serv, IL-91010 Jerusalem, Israel.							BARNEA T, 2000, ISRAELIPALESTINIAN C	1	4	4	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 5	2003	361	9364					1222	1222		10.1016/S0140-6736(03)12959-5	http://dx.doi.org/10.1016/S0140-6736(03)12959-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	664ZF	12686058				2022-12-28	WOS:000182094600028
J	Abbott, A; Oyranoski, D				Abbott, A; Oyranoski, D			Biologists seek to head off future sources of infection	NATURE			English	News Item																			0	7	8	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 1	2003	423	6935					3	3		10.1038/423003b	http://dx.doi.org/10.1038/423003b			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	673CG	12721586	Green Published, Bronze			2022-12-28	WOS:000182561600004
J	Gayle, HD				Gayle, HD			Curbing the global AIDS epidemic	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							TRANSMISSION; HIV-1		Bill & Melinda Gates Fdn, Seattle, WA USA	Bill & Melinda Gates Foundation	Gayle, HD (corresponding author), Bill & Melinda Gates Fdn, Seattle, WA USA.							Blower S, 2001, AIDS, V15, P1309, DOI 10.1097/00002030-200107060-00014; Coates TJ, 2000, LANCET, V356, P103, DOI 10.1016/S0140-6736(00)02446-6; de Ven PV, 1999, AIDS, V13, P2289, DOI 10.1097/00002030-199911120-00011; DESJARLAIS DC, 1995, JAMA-J AM MED ASSOC, V274, P1226, DOI 10.1001/jama.274.15.1226; Ford K, 1996, AIDS, V10, P213, DOI 10.1097/00002030-199602000-00013; *GLOB HIV PREV WOR, 2002, GLOB MOB HIV PREV BL; Gray RH, 2001, LANCET, V357, P1149, DOI 10.1016/S0140-6736(00)04331-2; GROSSKURTH H, 1995, LANCET, V346, P530, DOI 10.1016/S0140-6736(95)91380-7; Guay LA, 1999, LANCET, V354, P795, DOI 10.1016/S0140-6736(99)80008-7; Jha P, 2002, SCIENCE, V295, P2036, DOI 10.1126/science.295.5562.2036; *NAT INT COUNC, 2002, NIC PUBL ICA; *PROGR COORD BOARD, 2002, REP PROGR COORD BOAR; Stover J, 2002, LANCET, V360, P73, DOI 10.1016/S0140-6736(02)09339-X; *UNAIDS, 2002, REP GLOB HIV AIDS EP; WHO, 2002, SCAL ANT THER RES LI	15	17	17	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 1	2003	348	18					1802	1805		10.1056/NEJMsb030352	http://dx.doi.org/10.1056/NEJMsb030352			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	672VK	12724488				2022-12-28	WOS:000182543500011
J	Traversi, E; Tramarin, R				Traversi, E; Tramarin, R			Intracoronary imaging with multislice spiral computed tomography	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									IRCCS, Fdn Salvatore Maugeri, I-27100 Pavia, Italy	Istituti Clinici Scientifici Maugeri IRCCS; University of Pavia	Traversi, E (corresponding author), IRCCS, Fdn Salvatore Maugeri, I-27100 Pavia, Italy.		Traversi, Egidio/E-6304-2019; Tramarin, Roberto/AAY-6223-2020	Traversi, Egidio/0000-0002-1517-6303; Tramarin, Roberto/0000-0001-5203-2969					0	0	0	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 1	2003	348	18					E5	E5		10.1056/ENEJMicm020443	http://dx.doi.org/10.1056/ENEJMicm020443			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	672VK	12724498				2022-12-28	WOS:000182543500037
J	Balague, F; Dudler, J; Nordin, M				Balague, F; Dudler, J; Nordin, M			Low-back pain in children	LANCET			English	Editorial Material									Hop Cantonal Fribourg, Serv Rhumatol Med Phys & Rehabil, CH-1708 Fribourg, Switzerland; CHU Vaudois, Serv Rhumatol Med Phys & Rehabil, CH-1011 Lausanne, Switzerland; NYU Med Ctr, Hosp Joint Dis, Occupat & Ind Orthoped Ctr, New York, NY 10016 USA	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); New York University; NYU Langone Medical Center; Hospital for Joint Disease NYULMC	Balague, F (corresponding author), Hop Cantonal Fribourg, Serv Rhumatol Med Phys & Rehabil, CH-1708 Fribourg, Switzerland.			Dudler, Jean/0000-0001-8533-5800				Chambers CT, 1997, ARCH PEDIAT ADOL MED, V151, P449, DOI 10.1001/archpedi.1997.02170420019003; de Inocencio J, 1998, PEDIATRICS, V102, part. no., DOI 10.1542/peds.102.6.e63; KING AJC, 1992, HLTH CANADAS YOUTH V; Roese I, 1996, Rehabilitation (Stuttg), V35, P103; Silman A., 2001, EPIDEMIOLOGY RHEUMAT, V2nd; Waddell G, 2002, BACK PAIN INCAPACITY; Watson KD, 2003, ARCH DIS CHILD, V88, P12, DOI 10.1136/adc.88.1.12; Watson KD, 2002, PAIN, V97, P87, DOI 10.1016/S0304-3959(02)00008-8	8	54	55	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 26	2003	361	9367					1403	1404		10.1016/S0140-6736(03)13148-0	http://dx.doi.org/10.1016/S0140-6736(03)13148-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	672HZ	12727390				2022-12-28	WOS:000182516300005
J	Thami, GP; Bhalla, M				Thami, GP; Bhalla, M			Erythromelalgia induced by possible calcium channel blockade by ciclosporin	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Govt Med Coll & Hosp, Dept Dermatol & Venerol, Chandigarh 160047, India		Thami, GP (corresponding author), Govt Med Coll & Hosp, Dept Dermatol & Venerol, Sector 32B, Chandigarh 160047, India.	thamigp@yahoo.com						COLOMBANI PM, 1985, SCIENCE, V228, P337, DOI 10.1126/science.3885394; KANITAKIS J, 1990, ARCH DERMATOL, V126, P369, DOI 10.1001/archderm.126.3.369; LEVESQUE H, 1989, BRIT MED J, V298, P1252, DOI 10.1136/bmj.298.6682.1252-b; SANCHEZ EN, 1994, CLIN EXP RHEUMATOL, V12, P653; von Vigier RO, 2002, BRIT J CLIN PHARMACO, V54, P334, DOI 10.1046/j.1365-2125.2002.01622.x	5	8	8	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 26	2003	326	7395					910	910		10.1136/bmj.326.7395.910	http://dx.doi.org/10.1136/bmj.326.7395.910			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	673WQ	12714471	Green Published, Bronze			2022-12-28	WOS:000182603600017
J	Usmani, GN; Westra, SJ; Younes, S; Russell, GJ; Harris, NL; Grabowski, EE; Younes, S				Usmani, GN; Westra, SJ; Younes, S; Russell, GJ; Harris, NL; Grabowski, EE; Younes, S			A 14-month-old boy with hepatomegaly, perianal lesions, and a bony lump on the forehead - Langerhans'-cell histiocytosis.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							ORBITAL RHABDOMYOSARCOMA; MALIGNANT HISTIOCYTOSIS; CHILDREN; CLASSIFICATION; SARCOIDOSIS; LYMPHOMA; DISEASE		Univ Massachusetts, Sch Med, Dept Pediat, Div Pediat Hematol & Oncol, Worcester, MA 01605 USA; UMass Mem Healthcare, Childrens Med Ctr, Worcester, MA USA; Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Usmani, GN (corresponding author), Univ Massachusetts, Sch Med, Dept Pediat, Div Pediat Hematol & Oncol, Worcester, MA 01605 USA.							Baldassano RN, 1999, GASTROENTEROL CLIN N, V28, P445, DOI 10.1016/S0889-8553(05)70064-9; BROADBENT V, 1989, MED PEDIATR ONCOL, V17, P492, DOI 10.1002/mpo.2950170527; Brodeur GM, 1993, PRINCIPLES PRACTICE, P739; Brunning RD, 1999, BRIT J HAEMATOL, V107, P679, DOI 10.1046/j.1365-2141.1999.01822.x; Chhem RK, 2001, RADIOL CLIN N AM, V39, P357, DOI 10.1016/S0033-8389(05)70282-7; EGELER RM, 1995, J PEDIATR-US, V127, P1, DOI 10.1016/S0022-3476(95)70248-2; Favara BE, 2002, PEDIATR DEVEL PATHOL, V5, P130, DOI 10.1007/s10024-001-0159-2; Favara BE, 1997, MED PEDIATR ONCOL, V29, P157, DOI 10.1002/(SICI)1096-911X(199709)29:3<157::AID-MPO1>3.0.CO;2-C; FINK CW, 1997, J RHEUMATOL, V24, P172; Goldberg S H, 1997, Curr Opin Ophthalmol, V8, P51, DOI 10.1097/00055735-199710000-00011; HETHERINGTON S, 1982, AM J DIS CHILD, V136, P13, DOI 10.1001/archpedi.1982.03970370015002; Jaffe R, 1999, CLIN LAB MED, V19, P135; JOHNSON TE, 2000, OPHTHALMOL CLIN N AM, V23, P643; LUCARELLI M, 2000, ARCH OPHTHALMOL-CHIC, V118, P302; MELDRUM ML, 1999, OPHTHALMOL CLIN N AM, V12, P279; Oberlin O, 2001, J CLIN ONCOL, V19, P197, DOI 10.1200/JCO.2001.19.1.197; Pileri SA, 2002, HISTOPATHOLOGY, V41, P1, DOI 10.1046/j.1365-2559.2002.01418.x; Reinhardt D, 2000, BRIT J HAEMATOL, V110, P863, DOI 10.1046/j.1365-2141.2000.02290.x; ROSAI J, 1969, ARCH PATHOL, V87, P63; Sandlund JT, 1996, NEW ENGL J MED, V334, P1238, DOI 10.1056/NEJM199605093341906; Schmidt D, 2001, CURR OPIN HEMATOL, V8, P1, DOI 10.1097/00062752-200101000-00001; Schmitz L, 1998, HEMATOL ONCOL CLIN N, V12, P221, DOI 10.1016/S0889-8588(05)70507-4; Shetty AK, 1998, CLIN PEDIATR, V37, P707, DOI 10.1177/000992289803701201; Sohaib SA, 1998, CLIN RADIOL, V53, P357, DOI 10.1016/S0009-9260(98)80009-3; WEISS L, 2001, WHO CLASSIFICATION T, V3, P280; WILLMAN CL, 1994, NEW ENGL J MED, V331, P154, DOI 10.1056/NEJM199407213310303	26	8	11	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 24	2003	348	17					1692	1701		10.1056/NEJMcpc030006	http://dx.doi.org/10.1056/NEJMcpc030006			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	670PB	12711745				2022-12-28	WOS:000182416300010
J	Basaria, S; Braga, M				Basaria, S; Braga, M			Pagetic skull	LANCET			English	Editorial Material									Johns Hopkins Univ, Bayview Med Ctr, Div Endocrinol, Baltimore, MD 21218 USA; Univ Fed Parana, Div Endocrinol, BR-80060000 Curitiba, Parana, Brazil	Johns Hopkins University; Universidade Federal do Parana	Basaria, S (corresponding author), Johns Hopkins Univ, Bayview Med Ctr, Div Endocrinol, Baltimore, MD 21218 USA.			Basaria, Shehzad/0000-0002-8533-2383; Basaria, Shehzad/0000-0003-1749-8549					0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 19	2003	361	9366					1325	1325		10.1016/S0140-6736(03)13078-4	http://dx.doi.org/10.1016/S0140-6736(03)13078-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	669HP	12711466				2022-12-28	WOS:000182346100008
J	Littlejohns, P; Wyatt, JC; Garvican, L				Littlejohns, P; Wyatt, JC; Garvican, L			Evaluating computerised health information systems: hard lessons still to be learnt	BRITISH MEDICAL JOURNAL			English	Article									Natl Inst Clin Excellence, London WC2N 5HR, England; UCL, Sch Publ Policy, Knowledge Management Ctr, London WC1H 9E2, England; St George Hosp, Sch Med, London SW17 0RE, England	National Institute for Health & Care Excellence; University of London; University College London; St Georges University London	Littlejohns, P (corresponding author), Natl Inst Clin Excellence, London WC2N 5HR, England.	p.littlejohns@nice.nhs.uk	Wyatt, Jeremy/F-8160-2010	Wyatt, Jeremy/0000-0001-7008-1473				*AUD COMM, 1995, YOUR INF STUD INF MA; Friedman C.P., 1997, EVALUATION METHODS M, P41; GIBBS W, 1997, SCI AM, V278, P64; Herbst K, 1999, J PUBLIC HEALTH MED, V21, P305, DOI 10.1093/pubmed/21.3.305; *HLTH SYST TRUST, EV HOSP INF SYST NO; Kaplan B, 1988, J Health Hum Resour Adm, V11, P9; *NAT AUD OFF, 1999, 1992 1998 IM T STRAT; Willcocks L., 1993, EVALUATING FEASIBILI	8	188	190	0	10	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 19	2003	326	7394					860	863		10.1136/bmj.326.7394.860	http://dx.doi.org/10.1136/bmj.326.7394.860			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	670BF	12702622	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000182386800022
J	Watkins, PJ				Watkins, PJ			ABC of diabetes - Cardiovascular disease, hypertension, and lipids	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Kings Coll Hosp London, Kings Diabet Ctr, London, England	King's College Hospital NHS Foundation Trust; King's College Hospital	Watkins, PJ (corresponding author), Kings Coll Hosp London, Kings Diabet Ctr, London, England.	peter.watkins1@virgin.net							0	33	46	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 19	2003	326	7394					874	876		10.1136/bmj.326.7394.874	http://dx.doi.org/10.1136/bmj.326.7394.874			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	670BF	12702626	Green Published			2022-12-28	WOS:000182386800026
J	van Schoor, NM; Smit, JH; Twisk, JWR; Bouter, LM; Lips, P				van Schoor, NM; Smit, JH; Twisk, JWR; Bouter, LM; Lips, P			Prevention of hip fractures by external hip protectors - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ELDERLY PEOPLE; CARE FACILITIES; HOME RESIDENTS; NURSING-HOMES; FALLS; AGE	Context Several randomized controlled trials have been performed to examine the effectiveness of external hip protectors in reducing the incidence of hip fractures, but the results are controversial. Objective To examine the effectiveness of hip protectors in reducing the incidence of hip fractures in an elderly high-risk population. Design, Setting, and Participants Randomized controlled trial of elderly persons aged 70 years or older, who have low bone density, and are at high risk for falls. Participants lived in apartment houses for the elderly, homes for the elderly, and nursing homes in Amsterdam and surrounding areas in the Netherlands. They were enrolled in the study between March 1999 and March 2001; the mean follow-up was 69.6 weeks. Of the 830 persons who were screened, 561 persons were enrolled. Intervention External hip protector. Both groups received written information on bone health and risk factors for falls. Main Outcome Measure Time to first hip fracture. Survival analysis was used to include all participants for the time they participated. Results In the intervention group, 18 hip fractures occurred vs 20 in the control group. Four hip fractures in the intervention group occurred while an individual was wearing a hip protector. At least 4 hip fractures in the intervention group occurred late at night or early in the morning. Both in univariate analysis (log-rank P=.86) and in multivariate analysis (hazard ratio [HR], 1.05; 95% confidence interval [CI], 0.55-2.03), no statistically significant difference between the intervention group and control group. was found with regard to time to first hip fracture. In addition, the per protocol analysis in compliant participants did not show a statistically significant difference between the groups (HR, 0.77; 95% Cl, 0.25-2.38). Conclusion The hip protector studied was not effective in preventing hip fractures.	Vrije Univ Amsterdam, Med Ctr, Dept Endocrinol, NL-1007 MB Amsterdam, Netherlands; Vrije Univ Amsterdam, Med Ctr, Inst Res Extramural Med, NL-1007 MB Amsterdam, Netherlands; Vrije Univ Amsterdam, Med Ctr, Dept Sociol & Social Gerontol, NL-1007 MB Amsterdam, Netherlands; Vrije Univ Amsterdam, Med Ctr, Dept Clin Epidemiol & Biostat, NL-1007 MB Amsterdam, Netherlands	Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam	Lips, P (corresponding author), Vrije Univ Amsterdam, Med Ctr, Dept Endocrinol, POB 7057, NL-1007 MB Amsterdam, Netherlands.			Bouter, Lex/0000-0002-2659-5482				BOEREBOOM FTJ, 1991, NETH J MED, V38, P51; Cameron ID, 2001, AGE AGEING, V30, P477, DOI 10.1093/ageing/30.6.477; Chan DK, 2000, ARCH GERONTOL GERIAT, V30, P25, DOI 10.1016/S0167-4943(99)00048-5; COOPER C, 1992, OSTEOPOROSIS INT, V2, P285, DOI 10.1007/BF01623184; Ekman A, 1997, LANCET, V350, P563, DOI 10.1016/S0140-6736(05)63140-6; Graafmans WC, 1996, AM J EPIDEMIOL, V143, P1129; Harada A, 2001, OSTEOPOROSIS INT, V12, P215, DOI 10.1007/s001980170132; HILDRETH R, 2001, OSTEOPOROSIS INT, V12, pS13; Hubacher M, 2001, OSTEOPOROSIS INT, V12, P794, DOI 10.1007/s001980170057; JANTTI PO, 1993, PUBLIC HEALTH, V107, P89, DOI 10.1016/S0033-3506(05)80404-4; Jantti PO, 1998, AGE AGEING, V27, P758, DOI 10.1093/ageing/27.6.758; Jensen J, 2002, ANN INTERN MED, V136, P733, DOI 10.7326/0003-4819-136-10-200205210-00008; JOHNELL O, 1984, ACTA ORTHOP SCAND, V55, P290, DOI 10.3109/17453678408992358; Kannus P, 2000, NEW ENGL J MED, V343, P1506, DOI 10.1056/NEJM200011233432101; Kannus P, 1996, BONE, V18, pS57, DOI 10.1016/8756-3282(95)00381-9; KANNUS P, 1995, LANCET, V346, P50, DOI 10.1016/S0140-6736(95)92679-8; LAURITZEN JB, 1993, LANCET, V341, P11, DOI 10.1016/0140-6736(93)92480-H; LAURITZEN JB, 1996, COCHRANE DATABASE SY; Lips P, 1991, Osteoporos Int, V1, P218; LIPS P, 1990, BONE MINER, V9, P49, DOI 10.1016/0169-6009(90)90099-2; Lips Paul, 1997, American Journal of Medicine, V103, p3S, DOI 10.1016/S0002-9343(97)90021-8; Magaziner J, 2000, J GERONTOL A-BIOL, V55, pM498, DOI 10.1093/gerona/55.9.M498; Meyer G, 2003, BRIT MED J, V326, P76, DOI 10.1136/bmj.326.7380.76; OOMS ME, 1994, OSTEOPOROSIS INT, V4, P6, DOI 10.1007/BF02352254; PARKER MJ, 2002, COCHRANE LIB; Pluijm SMF, 1999, OSTEOPOROSIS INT, V9, P550, DOI 10.1007/s001980050275; PLUIJM SMF, 2001, THESIS VRIJE U; TOMBAUGH TN, 1992, J AM GERIATR SOC, V40, P922, DOI 10.1111/j.1532-5415.1992.tb01992.x; Tromp AM, 1998, J BONE MINER RES, V13, P1932, DOI 10.1359/jbmr.1998.13.12.1932; VANSCHOOR NM, IN PRESS OSTEOPOROS; Villar MTA, 1998, AGE AGEING, V27, P195, DOI 10.1093/ageing/27.2.195; Zohman G L, 1995, Am J Orthop (Belle Mead NJ), V24, P666	32	96	97	0	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 16	2003	289	15					1957	1962		10.1001/jama.289.15.1957	http://dx.doi.org/10.1001/jama.289.15.1957			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	667VC	12697798	Bronze, Green Published			2022-12-28	WOS:000182253900028
J	Hutchinson, L				Hutchinson, L			ABC of learning and teaching - Educational environment	BRITISH MEDICAL JOURNAL			English	Review									Univ Hosp Lewisham, London, England	University of London; King's College London	Hutchinson, L (corresponding author), Univ Hosp Lewisham, London, England.							DENT JA, 2001, PRACTICAL GUIDE MED; Eraut Michael, 1994, DEV PROFESSIONAL KNO; NEWBLE DI, 1994, HDB MED TEACHERS; NORMAN GR, 1992, ACAD MED, V67, P557, DOI 10.1097/00001888-199209000-00002; Welsh I., 2002, PARTNERS LEARNING GU	5	159	166	0	18	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 12	2003	326	7393					810	812		10.1136/bmj.326.7393.810	http://dx.doi.org/10.1136/bmj.326.7393.810			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	670BE	12689981	Green Published			2022-12-28	WOS:000182386700029
J	Grossman, SR; Deato, ME; Brignone, C; Chan, HM; Kung, AL; Tagami, H; Nakatani, Y; Livingston, DM				Grossman, SR; Deato, ME; Brignone, C; Chan, HM; Kung, AL; Tagami, H; Nakatani, Y; Livingston, DM			Polyubiquitination of p53 by a ubiquitin ligase activity of p300	SCIENCE			English	Article							PROTEASOME-MEDIATED DEGRADATION; PROTEIN; BINDING; MDM2; COMPLEXES; PROMOTES	Rapid turnover of the tumor suppressor protein p53 requires the MDM2 ubiquitin ligase, and both interact with p300-CREB-binding protein transcriptional coactivator proteins. p53 is stabilized by the binding of p300 to the oncoprotein E1A, suggesting that p300 regulates p53 degradation. Purified p300 exhibited intrinsic ubiquitin ligase activity that was inhibited by E1A. In vitro, p300 with MDM2 catalyzed p53 polyubiquitination, whereas MDM2 catalyzed p53 monoubiquitination. E1A expression caused a decrease in polyubiquitinated but not monoubiquitinated p53 in cells. Thus, generation of the polyubiquitinated forms of p53 that are targeted for proteasome degradation requires the intrinsic ubiquitin ligase activities of MDM2 and p300.	Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Livingston, DM (corresponding author), Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA.		Kung, Andrew/AAL-2384-2020; Kung, Andrew L/AEU-0826-2022	Kung, Andrew L/0000-0002-9091-488X	NATIONAL CANCER INSTITUTE [R01CA015751, R37CA015751] Funding Source: NIH RePORTER; NCI NIH HHS [CA15751] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Chiou SK, 1997, J VIROL, V71, P3515, DOI 10.1128/JVI.71.5.3515-3525.1997; Conaway RC, 2002, SCIENCE, V296, P1254, DOI 10.1126/science.1067466; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Grossman SR, 2001, EUR J BIOCHEM, V268, P2773, DOI 10.1046/j.1432-1327.2001.02226.x; Hatakeyama S, 2001, J BIOL CHEM, V276, P33111, DOI 10.1074/jbc.M102755200; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hochstrasser M, 2000, NAT CELL BIOL, V2, pE153, DOI 10.1038/35019643; Ito A, 2002, EMBO J, V21, P6236, DOI 10.1093/emboj/cdf616; Koegl M, 1999, CELL, V96, P635, DOI 10.1016/S0092-8674(00)80574-7; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kurokawa R, 1998, SCIENCE, V279, P700, DOI 10.1126/science.279.5351.700; Lai ZH, 2001, J BIOL CHEM, V276, P31357, DOI 10.1074/jbc.M011517200; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Maki CG, 1996, CANCER RES, V56, P2649; Pickart CM, 2000, TRENDS BIOCHEM SCI, V25, P544, DOI 10.1016/S0968-0004(00)01681-9; Prives C, 1999, J PATHOL, V187, P112; Querido E, 1997, J VIROL, V71, P3526, DOI 10.1128/JVI.71.5.3526-3533.1997; Rodriguez MS, 2000, MOL CELL BIOL, V20, P8458, DOI 10.1128/MCB.20.22.8458-8467.2000; Zhu QZ, 2001, CANCER RES, V61, P64; Zhu QZ, 2001, J BIOL CHEM, V276, P29695, DOI 10.1074/jbc.M102634200	20	373	386	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 11	2003	300	5617					342	344		10.1126/science.1080386	http://dx.doi.org/10.1126/science.1080386			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	665RQ	12690203				2022-12-28	WOS:000182135400061
J	Heshka, S; Anderson, JW; Atkinson, RL; Greenway, FL; Hill, JO; Phinney, SD; Kolotkin, RL; Miller-Kovach, K; Pi-Sunyer, FX				Heshka, S; Anderson, JW; Atkinson, RL; Greenway, FL; Hill, JO; Phinney, SD; Kolotkin, RL; Miller-Kovach, K; Pi-Sunyer, FX			Weight loss with self-help compared with a structured commercial program - A randomized trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							QUALITY-OF-LIFE; BLOOD-PRESSURE; OBESITY; OVERWEIGHT; REDUCTION; ADULTS; RISK	Context Although commercial weight loss programs provide treatment to millions of clients, their efficacy has not been evaluated in rigorous long-term trials. Objective To compare weight loss and health benefits achieved and maintained through self-help weight loss vs with a structured commercial program. Design and Setting A 2-year, multicenter randomized clinical trial with clinic visits at 12, 26, 52, 78, and 104 weeks conducted at 6 academic research centers in the United States between January 1998 and January 2001. Participants Overweight and obese men (n=65) and women (n=358) (body mass index, 27-40) aged 18 to 65 years. Intervention Random assignment to either a self-help program (n=212) consisting of two 20-minute counseling sessions with a nutritionist and provision of self-help resources or to a commercial weight loss program (n=211) consisting of a food plan, an activity plan, and a cognitive restructuring behavior modification plan, delivered at weekly meetings. Main Outcome Measures Weight change was the primary outcome measure. Secondary outcomes included waist circumference, body mass index, blood pressure, serum lipids, glucose, and insulin levels. Results At 2 years, 150 participants (71%)in the commercial group and 159 (75%) in the self-help group completed the study. In the intent-to-treat analysis, mean (SD) weight loss of participants in the commercial group was greater than in the self-help group at 1 year (-4.3 [6.1] kg vs -1.3 [6.1] kg, respectively; P<.001) and at 2 years (-2.9 [6.5] kg vs -0.2 [6.5] kg, respectively; P<.001). Waist circumference (P=.003) and body mass index (P<.001) decreased more in the commercial group. Changes in blood pressure, lipids, glucose, and insulin levels were related to changes in weight in both groups, but between group differences in biological parameters were mainly nonsignificant by year 2. Conclusion The structured commercial weight loss program provided modest weight loss but more than self-help over a 2-year period.	St Lukes Roosevelt Hosp, New York Obes Res Ctr, New York, NY 10025 USA; Columbia Univ, New York, NY USA; VA Med Ctr, Lexington, KY USA; Univ Kentucky, Lexington, KY 40506 USA; Univ Wisconsin, Madison, WI USA; Louisiana State Univ, Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA; Univ Colorado, Boulder, CO 80309 USA; Univ Calif Davis, Dept Med, Davis, CA 95616 USA; Obes & Qual Life Consulting, Durham, NC USA; Weight Watchers Int, Woodbury, NY USA	Mount Sinai St. Luke's; Mount Sinai West; Columbia University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Lexington VA Medical Center; University of Kentucky; University of Wisconsin System; University of Wisconsin Madison; Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center; University of Colorado System; University of Colorado Boulder; University of California System; University of California Davis	Heshka, S (corresponding author), St Lukes Roosevelt Hosp, 1090 Amsterdam Ave,14C, New York, NY 10025 USA.		Atkinson, Richard/AAK-4953-2021; Greenway, Frank/N-1966-2017	Greenway, Frank/0000-0002-1766-6111; Kolotkin, Ronette/0000-0002-1300-2131; Atkinson, Richard L./0000-0003-1745-5645; phinney, stephen/0000-0002-3322-3978				Anderson JW, 2001, OBES RES, V9, p326S, DOI 10.1038/oby.2001.138; Ashley JM, 2001, OBES RES, V9, p312S, DOI 10.1038/oby.2001.136; DATTILO AM, 1992, AM J CLIN NUTR, V56, P320, DOI 10.1093/ajcn/56.2.320; Department of Health and Human Services. National Heart Lung and Blood Institute, 1998, CLIN GUID ID EV TREA; Gandek, 1997, SF 36 HLTH SURVEY MA; GOLDSTEIN DJ, 1992, INT J OBESITY, V16, P397; HEO M, IN PRESS STAT MED; Heshka S, 2000, AM J MED, V109, P282, DOI 10.1016/S0002-9343(00)00494-0; Janssen I, 2002, ARCH INTERN MED, V162, P2074, DOI 10.1001/archinte.162.18.2074; KANNEL WB, 1991, J CLIN EPIDEMIOL, V44, P183, DOI 10.1016/0895-4356(91)90265-B; Khaodhiar L., 2001, International textbook of obesity, P413; Klein S, 2001, OBES RES, V9, p354S, DOI 10.1038/oby.2001.142; Kolotkin RL, 2001, OBES RES, V9, P102, DOI 10.1038/oby.2001.13; LEVY AS, 1993, ANN INTERN MED, V119, P661, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00007; Lowe MR, 1999, OBES RES, V7, P51, DOI 10.1002/j.1550-8528.1999.tb00390.x; Lowe MR, 2001, INT J OBESITY, V25, P325, DOI 10.1038/sj.ijo.0801521; *MARK ENT INC, 2001, US WEIGHT LOSS DIET; Mertens IL, 2000, OBES RES, V8, P270, DOI 10.1038/oby.2000.32; *NAT AC SCI AC ADV, 1978, PREV SERV WELL POP; *NAT CATTL BEEF AS, 1996, EAT SMART; *NAT CATTL BEEF AS, 1996, FITT FITN; *NIH, 1995, PHYS ACT CARD HLTH; PERRI MG, 1989, J CONSULT CLIN PSYCH, V57, P450, DOI 10.1037/0022-006X.57.3.450; Rippe JM, 1998, OBES RES, V6, P208, DOI 10.1002/j.1550-8528.1998.tb00339.x; SERDULA MK, 1993, ANN INTERN MED, V119, P667, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00008; Serdula MK, 1999, JAMA-J AM MED ASSOC, V282, P1353, DOI 10.1001/jama.282.14.1353; Stevens VJ, 2001, ANN INTERN MED, V134, P1, DOI 10.7326/0003-4819-134-1-200101020-00007; TAYLOR CB, 1993, OBESITY THEORY THERA, P335; Thomas PR, 1995, WEIGHING OPTIONS CRI; WADDEN TA, 1992, ARCH INTERN MED, V152, P961, DOI 10.1001/archinte.152.5.961	30	310	310	0	24	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 9	2003	289	14					1792	1798		10.1001/jama.289.14.1792	http://dx.doi.org/10.1001/jama.289.14.1792			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	664ZJ	12684357	Bronze			2022-12-28	WOS:000182094900024
J	Sharma, S; tenOever, BR; Grandvaux, N; Zhou, GP; Lin, RT; Hiscott, J				Sharma, S; tenOever, BR; Grandvaux, N; Zhou, GP; Lin, RT; Hiscott, J			Triggering the interferon antiviral response through an IKK-related pathway	SCIENCE			English	Article							KAPPA-B KINASE; REGULATORY FACTOR-3; TRANSCRIPTION FACTORS; VIRUS-INFECTION; ACTIVATION; PHOSPHORYLATION; DISTINCT; COMPLEX; IRF-3; ASSOCIATION	Rapid induction of type I interferon expression, a central event in establishing the innate antiviral response, requires cooperative activation of numerous transcription factors. Although signaling pathways that activate the transcription factors nuclear factor kappaB and ATF-2/c-Jun have been well characterized, activation of the interferon regulatory factors IRF-3 and IRF-7 has remained a critical missing link in understanding interferon signaling. We report here that the IkappaB kinase (IKK)-related kinases IKKepsilon and TANK-binding kinase 1 are components of the virus-activated kinase that phosphorylate IRF-3 and IRF-7. These studies illustrate an essential role for an IKK-related kinase pathway in triggering the host antiviral response to viral infection.	McGill Univ, Jewish Gen Hosp, Lady Davis Inst Med Res, Dept Microbiol & Immunol, Montreal, PQ H3T 1E2, Canada; McGill Univ, Jewish Gen Hosp, Lady Davis Inst Med Res, Dept Med, Montreal, PQ H3T 1E2, Canada	Lady Davis Institute; McGill University; Lady Davis Institute; McGill University	Lin, RT (corresponding author), McGill Univ, Jewish Gen Hosp, Lady Davis Inst Med Res, Dept Microbiol & Immunol, 3755 Cote St Catherine, Montreal, PQ H3T 1E2, Canada.		Lin, Rongtuan/A-1442-2008	Lin, Rongtuan/0000-0002-2238-3503				Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Bonnard M, 2000, EMBO J, V19, P4976, DOI 10.1093/emboj/19.18.4976; Chariot A, 2002, J BIOL CHEM, V277, P37029, DOI 10.1074/jbc.M205069200; Huang Q, 2001, SCIENCE, V294, P870, DOI 10.1126/science.294.5543.870; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Lin RT, 1998, MOL CELL BIOL, V18, P2986, DOI 10.1128/MCB.18.5.2986; Lin RT, 2000, MOL CELL BIOL, V20, P6342, DOI 10.1128/MCB.20.17.6342-6353.2000; Marie I, 1998, EMBO J, V17, P6660, DOI 10.1093/emboj/17.22.6660; Nomura F, 2000, GENES CELLS, V5, P191; Peters RT, 2000, MOL CELL, V5, P513, DOI 10.1016/S1097-2765(00)80445-1; Peters RT, 2001, BBA-REV CANCER, V1471, pM57, DOI 10.1016/S0304-419X(00)00024-X; Pomerantz JL, 1999, EMBO J, V18, P6694, DOI 10.1093/emboj/18.23.6694; Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001; Sato M, 2000, IMMUNITY, V13, P539, DOI 10.1016/S1074-7613(00)00053-4; Sen GC, 2001, ANNU REV MICROBIOL, V55, P255, DOI 10.1146/annurev.micro.55.1.255; Servant MJ, 2003, J BIOL CHEM, V278, P9441, DOI 10.1074/jbc.M209851200; Servant MJ, 2001, J BIOL CHEM, V276, P355, DOI 10.1074/jbc.M007790200; Shimada T, 1999, INT IMMUNOL, V11, P1357, DOI 10.1093/intimm/11.8.1357; Smith EJ, 2001, J BIOL CHEM, V276, P8951, DOI 10.1074/jbc.M008717200; tenOever BR, 2002, J VIROL, V76, P3659, DOI 10.1128/JVI.76.8.3659-3669.2002; Tojima Y, 2000, NATURE, V404, P778, DOI 10.1038/35008109; Wathelet MG, 1998, MOL CELL, V1, P507, DOI 10.1016/S1097-2765(00)80051-9; Weaver BK, 1998, MOL CELL BIOL, V18, P1359, DOI 10.1128/MCB.18.3.1359; Yoneyama M, 1998, EMBO J, V17, P1087, DOI 10.1093/emboj/17.4.1087	24	1296	1362	1	63	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 16	2003	300	5622					1148	1151		10.1126/science.1081315	http://dx.doi.org/10.1126/science.1081315			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678VC	12702806				2022-12-28	WOS:000182886500047
J	Parham, P				Parham, P			The unsung heroes	NATURE			English	Editorial Material							CELLS		Stanford Univ, Sch Med, Stanford, CA 94305 USA	Stanford University	Parham, P (corresponding author), Stanford Univ, Sch Med, 300 Pasteur Dr, Stanford, CA 94305 USA.							Martin MP, 2002, NAT GENET, V31, P429, DOI 10.1038/ng934; Moretta A, 2002, NAT REV IMMUNOL, V2, P957, DOI 10.1038/nri956; Parham P, 1999, IMMUNOL REV, V167, P5, DOI 10.1111/j.1600-065X.1999.tb01378.x; Scalzo AA, 2002, TRENDS MICROBIOL, V10, P470, DOI 10.1016/S0966-842X(02)02441-1	4	40	41	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 1	2003	423	6935					20	20		10.1038/423020a	http://dx.doi.org/10.1038/423020a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	673CG	12721604	Bronze			2022-12-28	WOS:000182561600020
J	Watkins, PJ				Watkins, PJ			ABC of diabetes - Retinopathy	BRITISH MEDICAL JOURNAL			English	Article									Kings Coll Hosp, Ctr Diabet, London, England	King's College Hospital NHS Foundation Trust; King's College Hospital	Watkins, PJ (corresponding author), Kings Coll Hosp, Ctr Diabet, London, England.								0	83	88	1	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 26	2003	326	7395					924	926		10.1136/bmj.326.7395.924	http://dx.doi.org/10.1136/bmj.326.7395.924			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	673WQ	12714476	Green Published			2022-12-28	WOS:000182603600023
J	Trenberth, KE; Otto-Bliesner, BL				Trenberth, KE; Otto-Bliesner, BL			Toward integrated reconstruction of past climates	SCIENCE			English	Editorial Material							SYSTEM MODEL; TEMPERATURES; VARIABILITY		Natl Ctr Atmospher Res, Boulder, CO 80307 USA	National Center Atmospheric Research (NCAR) - USA	Trenberth, KE (corresponding author), Natl Ctr Atmospher Res, POB 3000, Boulder, CO 80307 USA.		Otto-Bliesner, Bette/AAY-7691-2020; Trenberth, Kevin Edward/A-5683-2012	Trenberth, Kevin Edward/0000-0002-1445-1000				[Anonymous], [No title captured]; Blackmon M, 2001, B AM METEOROL SOC, V82, P2357, DOI 10.1175/1520-0477(2001)082<2357:TCCSM>2.3.CO;2; BRADLEY RS, 2003, GEOPHYS RES LETT, V30; Cole JE, 1999, J GEOPHYS RES-ATMOS, V104, P14223, DOI 10.1029/1999JD900182; FAIRBANKS RG, 1982, NATURE, V298, P841, DOI 10.1038/298841a0; Huber M, 2003, SCIENCE, V299, P877, DOI 10.1126/science.1078766; Koutavas A, 2002, SCIENCE, V297, P226, DOI 10.1126/science.1072376; Mann ME, 1999, GEOPHYS RES LETT, V26, P759, DOI 10.1029/1999GL900070; Otto-Bliesner BL, 2001, J CLIMATE, V14, P3587, DOI 10.1175/1520-0442(2001)014<3587:TPVITN>2.0.CO;2; Stott L, 2002, SCIENCE, V297, P222, DOI 10.1126/science.1071627; Thompson LG, 2002, SCIENCE, V298, P589, DOI 10.1126/science.1073198; Trenberth KE, 1998, J GEOPHYS RES-OCEANS, V103, P14291, DOI 10.1029/97JC01444; Werner M, 2000, GEOPHYS RES LETT, V27, P723, DOI 10.1029/1999GL006075; WERNER M, 2002, J GEOPHYS RES, V107	14	26	26	1	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 25	2003	300	5619					589	591		10.1126/science.1083122	http://dx.doi.org/10.1126/science.1083122			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	671FB	12714729				2022-12-28	WOS:000182453700025
J	Woo, HA; Chae, HZ; Hwang, SC; Yang, KS; Kang, SW; Kim, K; Rhee, SG				Woo, HA; Chae, HZ; Hwang, SC; Yang, KS; Kang, SW; Kim, K; Rhee, SG			Reversing the inactivation of peroxiredoxins caused by cysteine sulfinic acid formation	SCIENCE			English	Article							THIOL-SPECIFIC ANTIOXIDANT; THIOREDOXIN PEROXIDASE; 2-CYS PEROXIREDOXIN; HYDROGEN-PEROXIDE; CRYSTAL-STRUCTURE; OXIDATION; PROTEINS; ACTIVATION; REDUCTASE; CATALYSIS	The active-site cysteine of peroxiredoxins is selectively oxidized to cysteine sulfinic acid during catalysis, which leads to inactivation of peroxidase activity. This oxidation was thought to be irreversible. However, by metabolic labeling of mammalian cells with S-35, we show that the sulfinic form of peroxiredoxin I, produced during the exposure of cells to H2O2, is rapidly reduced to the catalytically active thiol form. The mammalian cells' ability to reduce protein sulfinic acid might serve as a mechanism to repair oxidatively damaged proteins or represent a new type of cyclic modification by which the function of various proteins is regulated.	NHLBI, Lab Cell Signaling, NIH, Bethesda, MD 20892 USA; Ewha Womans Univ, Ctr Cell Signaling Res, Seoul 120750, South Korea; Ewha Womans Univ, Div Mol Life Sci, Seoul 120750, South Korea	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Ewha Womans University; Ewha Womans University	Rhee, SG (corresponding author), NHLBI, Lab Cell Signaling, NIH, Bldg 10, Bethesda, MD 20892 USA.		Woo, Hyun Ae/AAT-9586-2021	Hwang, Sung Chul/0000-0003-2401-619X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL005506] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7017, DOI 10.1073/pnas.91.15.7017; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7022, DOI 10.1073/pnas.91.15.7022; Claiborne A, 1999, BIOCHEMISTRY-US, V38, P15407, DOI 10.1021/bi992025k; Eichhorn E, 1999, J BIOL CHEM, V274, P26639, DOI 10.1074/jbc.274.38.26639; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; Fu XY, 2001, J BIOL CHEM, V276, P41279, DOI 10.1074/jbc.M106958200; Hamann M, 2002, METHOD ENZYMOL, V348, P146, DOI 10.1016/S0076-6879(02)48634-X; Hirotsu S, 1999, P NATL ACAD SCI USA, V96, P12333, DOI 10.1073/pnas.96.22.12333; Hofmann B, 2002, BIOL CHEM, V383, P347, DOI 10.1515/BC.2002.040; Jin DY, 1997, J BIOL CHEM, V272, P30952, DOI 10.1074/jbc.272.49.30952; Kang SW, 1998, J BIOL CHEM, V273, P6297, DOI 10.1074/jbc.273.11.6297; KICE JL, 1980, ADV PHYS ORG CHEM, V17, P65; Kim JR, 2000, ANAL BIOCHEM, V283, P214, DOI 10.1006/abio.2000.4623; Levine RL, 2000, IUBMB LIFE, V50, P301, DOI 10.1080/15216540051081056; Mitsumoto A, 2001, FREE RADICAL BIO MED, V30, P625, DOI 10.1016/S0891-5849(00)00503-7; Murakami T, 2000, PROTEIN SCI, V9, P1024, DOI 10.1110/ps.9.5.1024; Rabilloud T, 2002, J BIOL CHEM, V277, P19396, DOI 10.1074/jbc.M106585200; Rhee S.G., 2000, SCI STKE; Rhee SG, 2001, IUBMB LIFE, V52, P35, DOI 10.1080/15216540252774748; Schroder E, 2000, STRUCTURE, V8, P605, DOI 10.1016/S0969-2126(00)00147-7; Shen HM, 2002, FREE RADICAL BIO MED, V33, P552, DOI 10.1016/S0891-5849(02)00918-8; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616; YANG KC, UNPUB; Yang KS, 2002, J BIOL CHEM, V277, P38029, DOI 10.1074/jbc.M206626200; Zhang P, 1997, J BIOL CHEM, V272, P30615, DOI 10.1074/jbc.272.49.30615	26	445	466	1	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 25	2003	300	5619					653	656		10.1126/science.1080273	http://dx.doi.org/10.1126/science.1080273			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	671FB	12714748				2022-12-28	WOS:000182453700046
J	Dheer, S; Chang, R				Dheer, S; Chang, R			"Corkscrew" esophagus	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Thomas Jefferson Univ Hosp, Philadelphia, PA 19107 USA	Jefferson University	Dheer, S (corresponding author), Thomas Jefferson Univ Hosp, Philadelphia, PA 19107 USA.								0	1	1	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 24	2003	348	17					1671	1671		10.1056/NEJMicm020564	http://dx.doi.org/10.1056/NEJMicm020564			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	670PB	12711742				2022-12-28	WOS:000182416300007
J	Wilson, JF				Wilson, JF			Advancing the war on malaria	ANNALS OF INTERNAL MEDICINE			English	News Item													Wilson, Jennifer/Q-3623-2019	Wilson, Jennifer/0000-0003-4025-3136					0	1	2	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	2003	138	8					693	696		10.7326/0003-4819-138-8-200304150-00039	http://dx.doi.org/10.7326/0003-4819-138-8-200304150-00039			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	666JH	12693913				2022-12-28	WOS:000182173800032
J	Champion, Y; Langlois, C; Guerin-Mailly, S; Langlois, P; Bonnentien, JL; Hytch, MJ				Champion, Y; Langlois, C; Guerin-Mailly, S; Langlois, P; Bonnentien, JL; Hytch, MJ			Near-perfect elastoplasticity in pure nanocrystalline copper	SCIENCE			English	Article							DEFORMATION-BEHAVIOR	Ductile metals and alloys undergo plastic yielding at room temperature, during which they exhibit work-hardening and the generation of surface instabilities that lead to necking and failure. We show that pure nanocrystalline copper behaves differently, displaying near-perfect elastoplastic behavior characterized by Newtonian flow and the absence of both work-hardening and neck formation. We observed this behavior in tensile tests on fully dense large-scale bulk nanocrystalline samples. The experimental results further our understanding of the unique mechanical properties of nanocrystalline materials and also provide a basis for commercial technologies for the plastic ( and superplastic) formation of such materials.	CNRS, Ctr Etud Chim Met, F-94407 Vitry Sur Seine, France; Univ Paris 13, CNRS, Lab Ingn Mat & Hautes Press, F-93430 Villetaneuse, France	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); Universite Paris 13	Champion, Y (corresponding author), CNRS, Ctr Etud Chim Met, 15 Rue Georges Urbain, F-94407 Vitry Sur Seine, France.	yannick.champion@glvt-cnrs.fr	Langlois, Cyril/C-7722-2011; Hytch, Martin/N-6911-2019					Arzt E, 1998, ACTA MATER, V46, P5611, DOI 10.1016/S1359-6454(98)00231-6; Ashby MF., 1980, ENG MAT INTRO THEIR; Champion Y, 1996, SCRIPTA MATER, V35, P517, DOI 10.1016/1359-6462(96)00170-4; Champion Y, 2001, SCRIPTA MATER, V44, P1609, DOI 10.1016/S1359-6462(01)00782-5; Cheggour N, 1996, PHYSICA C, V258, P21, DOI 10.1016/0921-4534(95)00703-2; Cottrell A. H., 1953, DISLOCATIONS PLASTIC; Dominguez O, 1998, METALL MATER TRANS A, V29, P2941, DOI 10.1007/s11661-998-0201-3; Fedorov AA, 2002, SCRIPTA MATER, V47, P51, DOI 10.1016/S1359-6462(02)00096-9; Jia D, 2001, APPL PHYS LETT, V79, P611, DOI 10.1063/1.1384000; KARCH J, 1987, NATURE, V330, P556, DOI 10.1038/330556a0; Kim HS, 2000, ACTA MATER, V48, P493, DOI 10.1016/S1359-6454(99)00353-5; Lu L, 2000, SCIENCE, V287, P1463, DOI 10.1126/science.287.5457.1463; Masumura RA, 1998, ACTA MATER, V46, P4527, DOI 10.1016/S1359-6454(98)00150-5; McFadden SX, 1999, NATURE, V398, P684, DOI 10.1038/19486; Mukherjee AK, 2002, MAT SCI ENG A-STRUCT, V322, P1, DOI 10.1016/S0921-5093(01)01115-7; Murayama M, 2002, SCIENCE, V295, P2433, DOI 10.1126/science.1067430; NIEH TG, 1991, SCRIPTA METALL MATER, V25, P955, DOI 10.1016/0956-716X(91)90256-Z; Schiotz J, 1998, NATURE, V391, P561, DOI 10.1038/35328; Van Swygenhoven H, 1999, PHYS REV B, V60, P22, DOI 10.1103/PhysRevB.60.22; Wang YM, 2002, NATURE, V419, P912, DOI 10.1038/nature01133; Wei Q, 2002, APPL PHYS LETT, V81, P1240, DOI 10.1063/1.1501158; Zghal S, 2002, ACTA MATER, V50, P4695, DOI 10.1016/S1359-6454(02)00285-9	22	221	228	1	102	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 11	2003	300	5617					310	311		10.1126/science.1081042	http://dx.doi.org/10.1126/science.1081042			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	665RQ	12690194				2022-12-28	WOS:000182135400051
J	Brumfiel, G				Brumfiel, G			High-voltage shock sparks fusion from X-ray crush	NATURE			English	News Item																			0	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 10	2003	422	6932					549	549		10.1038/422549b	http://dx.doi.org/10.1038/422549b			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	665GN	12686962	Bronze			2022-12-28	WOS:000182111400007
J	Prandoni, P; Bilora, F; Marchiori, A; Bernardi, E; Petrobelli, F; Lensing, AWA; Prins, MH; Girolami, A				Prandoni, P; Bilora, F; Marchiori, A; Bernardi, E; Petrobelli, F; Lensing, AWA; Prins, MH; Girolami, A			An association between atherosclerosis and venous thrombosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DEEP-VEIN THROMBOSIS; RISK-FACTORS; PULMONARY-EMBOLISM; D-DIMER; CAROTID ATHEROSCLEROSIS; GENERAL-POPULATION; THROMBOEMBOLISM; DISEASE; THROMBOPHILIA; MECHANISMS	BACKGROUND: In about a third of patients with venous thromboembolism, the cause of the disorder is unexplained. In patients with atherosclerosis, activation of both platelets and blood coagulation and an increase in fibrin turnover are detectable, which may lead to thrombotic complications. Whether atherosclerosis is associated with an increased risk of venous thrombosis is unknown. METHODS: We performed ultrasonography of the carotid arteries in 299 unselected patients who had deep venous thrombosis of the legs without symptomatic atherosclerosis and in 150 control subjects. Patients with spontaneous thrombosis, patients with secondary thrombosis from acquired risk factors, and control subjects were assessed for plaques. RESULTS: At least one carotid plaque was detected in 72 of the 153 patients with spontaneous thrombosis (47.1 percent; 95 percent confidence interval, 39.1 to 55.0), 40 of the 146 with secondary thrombosis (27.4 percent; 95 percent confidence interval, 20.2 to 34.6), and 48 of the 150 control subjects (32.0 percent; 95 percent confidence interval, 24.5 to 39.5). The odds ratios for carotid plaques in patients with spontaneous thrombosis, as compared with patients with secondary thrombosis and with controls, were 2.3 (95 percent confidence interval, 1.4 to 3.7) and 1.8 (95 percent confidence interval, 1.1 to 2.9), respectively. In a multivariate analysis that accounted for risk factors for atherosclerosis, the strength of this association did not change. CONCLUSIONS: There is an association between atherosclerotic disease and spontaneous venous thrombosis. Atherosclerosis may induce venous thrombosis, or the two conditions may share common risk factors.	Univ Padua, Chair Internal Med 2, Dept Med & Surg Sci, Sch Med, I-35128 Padua, Italy; Univ Amsterdam, Acad Med Ctr, Ctr Vasc Med, NL-1105 AZ Amsterdam, Netherlands; Univ Maastricht, Dept Clin Epidemiol, Maastricht, Netherlands	University of Padua; University of Amsterdam; Academic Medical Center Amsterdam; Maastricht University	Prandoni, P (corresponding author), Univ Padua, Chair Internal Med 2, Dept Med & Surg Sci, Sch Med, Via Osped Civile 105, I-35128 Padua, Italy.	paoprand@tin.it						ANDERSON FA, 1991, ARCH INTERN MED, V151, P933, DOI 10.1001/archinte.151.5.933; Andreescu ACM, 2002, THROMB HAEMOSTASIS, V87, P47, DOI 10.1055/s-0037-1612942; Bauer KA, 2001, ANN INTERN MED, V135, P367, DOI 10.7326/0003-4819-135-5-200109040-00013; BERNSTEIN EF, 1993, CEREBRAL REVASCULARI, P73; Binaghi F, 1998, Minerva Cardioangiol, V46, P217; COGO A, 1994, ARCH INTERN MED, V154, P164, DOI 10.1001/archinte.154.2.164; Drouet L, 1998, ARCH MAL COEUR VAISS, V91, P41; Ebrahim S, 1999, STROKE, V30, P841, DOI 10.1161/01.STR.30.4.841; EIKELBOOM BC, 1993, CEREBRAL REVASCULARI, P451; FitzGerald GA, 1997, THROMB HAEMOSTASIS, V78, P280; Foley P W, 1997, Cardiovasc Surg, V5, P157; Gaustadnes M, 1999, BLOOD COAGUL FIBRIN, V10, P251, DOI 10.1097/00001721-199907000-00006; Goldhaber SZ, 1997, JAMA-J AM MED ASSOC, V277, P642, DOI 10.1001/jama.277.8.642; Grady D, 2000, ANN INTERN MED, V132, P689, DOI 10.7326/0003-4819-132-9-200005020-00002; Hansson PO, 1997, ARCH INTERN MED, V157, P1665, DOI 10.1001/archinte.157.15.1665; Heit JA, 2002, SEMIN THROMB HEMOST, V28, P3, DOI 10.1055/s-2002-32312; Hollander M, 2002, CIRCULATION, V105, P2872, DOI 10.1161/01.CIR.0000018650.58984.75; Holvoet P, 1997, CURR OPIN LIPIDOL, V8, P320, DOI 10.1097/00041433-199710000-00012; Joakimsen O, 1999, ARTERIOSCL THROM VAS, V19, P3007, DOI 10.1161/01.ATV.19.12.3007; Kearon C, 2000, HEMOSTASIS THROMBOSI, V4th, P1153; Koenig W, 2001, ARTERIOSCL THROM VAS, V21, P1701, DOI 10.1161/hq1001.097020; Lensing AWA, 1999, LANCET, V353, P479, DOI 10.1016/S0140-6736(98)04298-6; Libby P, 2000, CLIN CARDIOL, V23, P3, DOI 10.1002/clc.4960231103; Libby P, 2000, HEMOSTASIS THROMBOSI, P743; Libertiny G, 1999, BRIT J SURG, V86, P907, DOI 10.1046/j.1365-2168.1999.01129.x; MARDER VJ, 2000, HEMOSTASIS THROMBOSI, P1243; NORDSTROM M, 1992, J INTERN MED, V232, P155, DOI 10.1111/j.1365-2796.1992.tb00565.x; Oger E, 2000, THROMB HAEMOSTASIS, V83, P657; Palareti G, 2002, THROMB HAEMOSTASIS, V87, P7; PRANDONI P, 1992, NEW ENGL J MED, V327, P1128, DOI 10.1056/NEJM199210153271604; Prandoni P, 1996, ANN INTERN MED, V125, P1, DOI 10.7326/0003-4819-125-1-199607010-00001; PRANDONI P, 1999, PULMONARY EMBOLISM, P2; PRATI P, 1992, STROKE, V23, P1705, DOI 10.1161/01.STR.23.12.1705; PRINS MH, 1991, ARCH INTERN MED, V151, P1721, DOI 10.1001/archinte.151.9.1721; Ray JG, 2001, CURR CONTR TRIALS C, V2, P165, DOI 10.1186/CVM-2-4-165; Ray JG, 2001, ARCH INTERN MED, V161, P1405, DOI 10.1001/archinte.161.11.1405; Silverstein MD, 1998, ARCH INTERN MED, V158, P585, DOI 10.1001/archinte.158.6.585; Simioni P, 1997, NEW ENGL J MED, V336, P399, DOI 10.1056/NEJM199702063360602; Simioni P, 1996, THROMB HAEMOSTASIS, V76, P187; Simioni P, 1999, THROMB HAEMOSTASIS, V81, P198, DOI 10.1055/s-0037-1614442; Simioni P, 1996, THROMB HAEMOSTASIS, V76, P883; Simioni P, 2000, BLOOD, V96, P3329; Sueishi K, 1998, SEMIN THROMB HEMOST, V24, P255, DOI 10.1055/s-2007-995851; Tierney L. M., 2000, CURRENT MED DIAGNOSI, V39th; TRIPLETT DA, 2001, HEMOSTASIS NEWS, V6, P1; Vaya A, 2002, BRIT J HAEMATOL, V118, P255, DOI 10.1046/j.1365-2141.2002.03563.x; ZIERLER RE, 1993, VASCULAR DIAGNOSIS, P328	47	484	507	0	15	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 10	2003	348	15					1435	1441		10.1056/NEJMoa022157	http://dx.doi.org/10.1056/NEJMoa022157			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	665CU	12686699	Bronze, Green Published			2022-12-28	WOS:000182102700003
J	Park, IK; Qian, DL; Kiel, M; Becker, MW; Pihalja, M; Weissman, IL; Morrison, SJ; Clarke, MF				Park, IK; Qian, DL; Kiel, M; Becker, MW; Pihalja, M; Weissman, IL; Morrison, SJ; Clarke, MF			Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells	NATURE			English	Article							GENE-EXPRESSION; POLYCOMB; MICE; DEFECTS; REGULATOR; DELETION; LOCUS; MDM2; P53	A central issue in stem cell biology is to understand the mechanisms that regulate the self-renewal of haematopoietic stem cells (HSCs), which are required for haematopoiesis to persist for the lifetime of the animal(1). We found that adult and fetal mouse and adult human HSCs express the proto-oncogene Bmi-1. The number of HSCs in the fetal liver of Bmi-1(-/-) mice(2) was normal. In postnatal Bmi-1(-/-) mice, the number of HSCs was markedly reduced. Transplanted fetal liver and bone marrow cells obtained from Bmi-1(-/-) mice were able to contribute only transiently to haematopoiesis. There was no detectable self-renewal of adult HSCs, indicating a cell autonomous defect in Bmi-1(-/-) mice. A gene expression analysis revealed that the expression of stem cell associated genes(3), cell survival genes, transcription factors, and genes modulating proliferation including p16(Ink4a) and p19(Arf) was altered in bone marrow cells of the Bmi-1(-/-) mice. Expression of p16(Ink4a) and p19(Arf) in normal HSCs resulted in proliferative arrest and p53-dependent cell death, respectively. Our results indicate that Bmi-1 is essential for the generation of self-renewing adult HSCs.	Univ Michigan, Div Hematol Oncol, Ann Arbor, MI 48109 USA; Univ Michigan, Howard Hughes Med Inst, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Cell & Dev Biol, Ann Arbor, MI 48109 USA; Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA	University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Stanford University	Clarke, MF (corresponding author), Univ Michigan, Div Hematol Oncol, Ann Arbor, MI 48109 USA.		Morrison, Sean/ABD-5326-2021	Becker, Michael/0000-0001-9890-8815; Morrison, Sean/0000-0003-1587-8329				Akashi K, 2003, BLOOD, V101, P383, DOI 10.1182/blood-2002-06-1780; Antonchuk J, 2002, CELL, V109, P39, DOI 10.1016/S0092-8674(02)00697-9; Antonchuk J, 2001, EXP HEMATOL, V29, P1125, DOI 10.1016/S0301-472X(01)00681-6; Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804; Christensen JL, 2001, P NATL ACAD SCI USA, V98, P14541, DOI 10.1073/pnas.261562798; COTTA C, 2001, RETROVIRAL TRANSDUCT, P243; Domen J, 2000, J EXP MED, V191, P253, DOI 10.1084/jem.191.2.253; Fisher RC, 1999, BLOOD, V94, P1283, DOI 10.1182/blood.V94.4.1283.416k16_1283_1290; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Lawrence HJ, 1997, BLOOD, V89, P1922, DOI 10.1182/blood.V89.6.1922; Lessard J, 1998, BLOOD, V91, P1216, DOI 10.1182/blood.V91.4.1216; LESSARD J, 2003, NATURE          0420; Mahmoudi T, 2001, ONCOGENE, V20, P3055, DOI 10.1038/sj.onc.1204330; MORRISON SJ, 1994, IMMUNITY, V1, P661, DOI 10.1016/1074-7613(94)90037-X; MORRISON SJ, 1995, P NATL ACAD SCI USA, V92, P10302, DOI 10.1073/pnas.92.22.10302; Nichogiannopoulou A, 1999, J EXP MED, V190, P1201, DOI 10.1084/jem.190.9.1201; Ohta H, 2002, J EXP MED, V195, P759, DOI 10.1084/jem.20011911; Park IK, 2002, BLOOD, V99, P488, DOI 10.1182/blood.V99.2.488; Parks IK, 2001, J BIOL CHEM, V276, P915, DOI 10.1074/jbc.M005947200; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Porcher C, 1996, CELL, V86, P47, DOI 10.1016/S0092-8674(00)80076-8; QUELLE DE, 1995, CELL, V83, P993; Ramalho-Santos M, 2002, SCIENCE, V298, P597, DOI 10.1126/science.1072530; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; vanderLugt NMT, 1996, MECH DEVELOP, V58, P153, DOI 10.1016/S0925-4773(96)00570-9; VANDERLUGT NMT, 1994, GENE DEV, V8, P757, DOI 10.1101/gad.8.7.757; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Wright DE, 2002, J EXP MED, V195, P1145, DOI 10.1084/jem.20011284; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	30	1486	1605	2	71	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 15	2003	423	6937					302	305		10.1038/nature01587	http://dx.doi.org/10.1038/nature01587			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678EX	12714971	Green Published			2022-12-28	WOS:000182853100046
J	Raschke, R; Hirsh, J; Guidry, JR				Raschke, R; Hirsh, J; Guidry, JR			Suboptimal monitoring and dosing of unfractionated heparin in comparative studies with low-molecular-weight heparin	ANNALS OF INTERNAL MEDICINE			English	Article							CONTINUOUS INTRAVENOUS HEPARIN; DAILY SUBCUTANEOUS DALTEPARIN; DEEP VENOUS THROMBOSIS; THERAPEUTIC RANGE; INITIAL TREATMENT; HOME	Background: Site-specific validation of the activated partial thromboplastin time (aPTT) therapeutic range is required to ensure administration of the optimal dose of unfractionated heparin. Therapeutic ranges of 1.5 to 2.5 times the control value are subtherapeutic for most modern aPTT reagents. Purpose: To audit the appropriateness of aPTT monitoring in clinical trials comparing unfractionated heparin and low-molecular-weight heparin in patients with venous thromboembolism. Data Sources: Search of PubMed database from 1984 to 2001. Study Selection: Randomized, controlled trials that compared unfractionated and low-molecular-weight heparin for the treatment of venous thromboembolism. Data Extraction: Use of unvalidated and potentially suboptimal therapeutic ranges for aPTT in patients assigned to receive unfractionated heparin. Data Synthesis: Fifteen studies met inclusion criteria. Only 3 studies used a validated aPTT therapeutic range, and 11 studies used a range that included aPTT values 1.5 times the control value. Ten studies reported unfractionated heparin doses, and 7 of these documented a reduction to less than 30 000 U/d in response to aPTT results. Conclusions: Most studies monitored unfractionated heparin inappropriately. This shortcoming could be responsible for the reduced efficacy of unfractionated heparin in clinical trials.	Good Samaritan Reg Med Ctr, Phoenix, AZ 85006 USA; Henderson Civ Hosp Res Ctr, Hamilton, ON, Canada; Desert Samaritan Med Ctr, Mesa, AZ USA		Raschke, R (corresponding author), Good Samaritan Reg Med Ctr, 1111 E McDowell Rd, Phoenix, AZ 85006 USA.	robertraschke@bannerhealth.com		Raschke, Robert/0000-0003-3495-7065				Bates SM, 2001, ARCH INTERN MED, V161, P385, DOI 10.1001/archinte.161.3.385; Belcaro G, 1999, ANGIOLOGY, V50, P781; Breddin HK, 2001, NEW ENGL J MED, V344, P626, DOI 10.1056/NEJM200103013440902; BRILLEDWARDS P, 1993, ANN INTERN MED, V119, P104, DOI 10.7326/0003-4819-119-2-199307150-00002; DUROUX P, 1991, THROMB HAEMOSTASIS, V65, P251; Fiessinger JN, 1996, THROMB HAEMOSTASIS, V76, P195; Harenberg J, 2000, THROMB HAEMOSTASIS, V83, P652; HULL RD, 1992, NEW ENGL J MED, V326, P975, DOI 10.1056/NEJM199204093261502; Hyers TM, 2001, CHEST, V119, p176S, DOI 10.1378/chest.119.1_suppl.176S; Koopman MMW, 1996, NEW ENGL J MED, V334, P682, DOI 10.1056/NEJM199603143341102; LENSING AWA, 1995, ARCH INTERN MED, V155, P601, DOI 10.1001/archinte.155.6.601; Levine M, 1996, NEW ENGL J MED, V334, P677, DOI 10.1056/NEJM199603143341101; LINDMARKER P, 1994, THROMB HAEMOSTASIS, V72, P186; Luomanmaki K, 1996, J INTERN MED, V240, P85, DOI 10.1046/j.1365-2796.1996.18845000.x; Merli G, 2001, ANN INTERN MED, V134, P191, DOI 10.7326/0003-4819-134-3-200102060-00009; Olson JD, 1998, ARCH PATHOL LAB MED, V122, P782; PRANDONI P, 1992, LANCET, V339, P441, DOI 10.1016/0140-6736(92)91054-C; Rocha E, 2000, HAEMATOLOGICA, V85, P935; Simonneau G, 1997, NEW ENGL J MED, V337, P663, DOI 10.1056/NEJM199709043371002; SIMONNEAU G, 1993, ARCH INTERN MED, V153, P1541, DOI 10.1001/archinte.153.13.1541; tenCate JW, 1997, NEW ENGL J MED, V337, P657	21	52	54	2	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 6	2003	138	9					720	723		10.7326/0003-4819-138-9-200305060-00008	http://dx.doi.org/10.7326/0003-4819-138-9-200305060-00008			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	674XA	12729426				2022-12-28	WOS:000182661400004
J	Raffle, AE; Alden, B; Quinn, M; Babb, PJ; Brett, MT				Raffle, AE; Alden, B; Quinn, M; Babb, PJ; Brett, MT			Outcomes of screening to prevent cancer: analysis of cumulative incidence of cervical abnormality and modelling of cases and deaths prevented	BRITISH MEDICAL JOURNAL			English	Article							INTRAEPITHELIAL NEOPLASIA; NATURAL-HISTORY; PROGRESSION; MORTALITY; CYTOLOGY; CONSENT; ENGLAND; TRENDS; WOMEN	Objective To determine the frequency of different outcomes in women participating in cervical screening. Design Analysis of screening records from 348 419 women, and modelling of cases of cervical cancer and deaths with and without screening. Setting Cervical screening programme in Bristol. Results For every 10 000 women screened from 1976 to 1996,1564 had abnormal cytology, 818 were investigated, and 543 had abnormal histology. One hundred and seventy six had persistent abnormality for two years or more. In the absence of screening 80 women would be expected to develop cancer of the cervix by 2011, of whom 25 would die. With screening 10 of these deaths would be avoided. Comparison of cumulative abnormality rates with numbers expected to develop cancer in the absence of screening suggests that at least 80% of high grade dyskaryosis and of high grade dysplasia would not progress to cancer. The lifetime risk of having abnormal cytology detected could be as high as 40% for women born since 1960. Conclusions Screening is labour and resource intensive. It involves treatment for many women not destined to develop invasive cancer. The increased intervention rate for cervical abnormality in England is due to change in practice, not a cohort effect, and is probably the reason for the marked fall in incidence and mortality during the 1990s. For other cancers there is scope for major iatrogenic harm from screening because of invasive tests and treatments.	Avon Hlth Author, Bristol BS2 8EE, Avon, England; Off Natl Stat, Natl Canc Intelligence Ctr, London SW1V 2QQ, England; Southmead Gen Hosp, Dept Cellular Pathol, Bristol BS10 5NB, Avon, England	Southmead Hospital	Raffle, AE (corresponding author), Avon Hlth Author, King Sq House, Bristol BS2 8EE, Avon, England.							Anderson CM, 1999, CYTOPATHOLOGY, V10, P221, DOI 10.1046/j.1365-2303.1999.00198.x; Bos AB, 1997, BRIT J CANCER, V75, P124, DOI 10.1038/bjc.1997.20; Dillner J, 2000, J CLIN VIROL, V19, P7, DOI 10.1016/S1386-6532(00)00126-8; EVANS DMD, 1986, J CLIN PATHOL, V39, P933, DOI 10.1136/jcp.39.9.933; Foster P, 1998, J MED ETHICS, V24, P151, DOI 10.1136/jme.24.3.151; Frable WJ, 1998, ACTA CYTOL, V42, P76, DOI 10.1159/000331537; Furber SE, 1997, AUST NZ J OBSTET GYN, V37, P107, DOI 10.1111/j.1479-828X.1997.tb02230.x; General Medical Council (UK), 1998, SEEK PAT CONS ETH CO; Holowaty P, 1999, JNCI-J NATL CANCER I, V91, P252, DOI 10.1093/jnci/91.3.252; MARTEAU TM, 1990, BRIT J OBSTET GYNAEC, V97, P859, DOI 10.1111/j.1471-0528.1990.tb02586.x; OSTOR AG, 1993, INT J GYNECOL PATHOL, V12, P186; Quinn M, 1999, BRIT MED J, V318, P904, DOI 10.1136/bmj.318.7188.904; Quinn M, 2001, CANC TRENDS ENGLAND; Raffle A E, 2001, Health Expect, V4, P92, DOI 10.1046/j.1369-6513.2001.00138.x; Raffle AE, 1999, LANCET, V354, P431, DOI 10.1016/S0140-6736(05)75855-4; RAFFLE AE, 1995, LANCET, V345, P1469, DOI 10.1016/S0140-6736(95)91036-0; Sasieni P, 1999, BRIT MED J, V318, P1244; Slater D, 1998, LANCET, V351, P1130, DOI 10.1016/S0140-6736(05)79410-1; Slater DN, 2000, CYTOPATHOLOGY, V11, P166, DOI 10.1046/j.1365-2303.2000.00248.x; *UK NAT SCREEN COM, 2000, 2 REP	20	87	88	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 26	2003	326	7395					901	904A		10.1136/bmj.326.7395.901	http://dx.doi.org/10.1136/bmj.326.7395.901			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	673WQ	12714468	Green Published, Bronze			2022-12-28	WOS:000182603600014
J	Jonsson, KB; Zahradnik, R; Larsson, T; White, KE; Sugimoto, T; Imanishi, Y; Yamamoto, T; Hampson, G; Koshiyama, H; Ljunggren, O; Oba, K; Yang, IM; Miyauchi, A; Econs, MJ; Lavigne, J; Juppner, H				Jonsson, KB; Zahradnik, R; Larsson, T; White, KE; Sugimoto, T; Imanishi, Y; Yamamoto, T; Hampson, G; Koshiyama, H; Ljunggren, O; Oba, K; Yang, IM; Miyauchi, A; Econs, MJ; Lavigne, J; Juppner, H			Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TUMOR-INDUCED OSTEOMALACIA; RICKETS; FGF-23; GENE	Background: Mutations in fibroblast growth factor 23 (FGF-23) cause autosomal dominant hypophosphatemic rickets. Clinical and laboratory findings in this disorder are similar to those in oncogenic osteomalacia, in which tumors abundantly express FGF-23 messenger RNA, and to those in X-linked hypophosphatemia, which is caused by inactivating mutations in a phosphate-regulating endopeptidase called PHEX. Recombinant FGF-23 induces phosphaturia and hypophosphatemia in vivo, suggesting that it has a role in phosphate regulation. To determine whether FGF-23 circulates in healthy persons and whether it is elevated in those with oncogenic osteomalacia or X-linked hypophosphatemia, an immunometric assay was developed to measure it. Methods: Using affinity-purified, polyclonal antibodies against [Tyr223]FGF-23(206-222)amide and [Tyr224]FGF-23(225-244)amide, we developed a two-site enzyme-linked immunosorbent assay that detects equivalently recombinant human FGF-23, the mutant form in which glutamine is substituted for arginine at position 179 (R179Q), and synthetic human FGF-23(207-244)amide. Plasma or serum samples from 147 healthy adults (mean [+/-SD] age, 48.4+/-19.6 years) and 26 healthy children (mean age, 10.9+/-5.5 years) and from 17 patients with oncogenic osteomalacia (mean age, 43.0+/-13.3 years) and 21 patients with X-linked hypophosphatemia (mean age, 34.9+/-17.2 years) were studied. Results: Mean FGF-23 concentrations in the healthy adults and children were 55+/-50 and 69+/-36 reference units (RU) per milliliter, respectively. Four patients with oncogenic osteomalacia had concentrations ranging from 426 to 7970 RU per milliliter, which normalized after tumor resection. FGF-23 concentrations were 481+/-528 RU per milliliter in those with suspected oncogenic osteomalacia and 353+/-510 RU per milliliter (range, 31 to 2335) in those with X-linked hypophosphatemia. Conclusions: FGF-23 is readily detectable in the plasma or serum of healthy persons and can be markedly elevated in those with oncogenic osteomalacia or X-linked hypophosphatemia, suggesting that this growth factor has a role in phosphate homeostasis. FGF-23 measurements might improve the management of phosphate-wasting disorders.	Massachusetts Gen Hosp, Dept Med, Endocrine Unit, Boston, MA 02114 USA; Massachusetts Gen Hosp, MassGen Hosp Children, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA; Uppsala Univ, Dept Surg Sci, Uppsala, Sweden; Uppsala Univ, Dept Med Sci, Uppsala, Sweden; Immutopics, San Clemente, CA USA; Indiana Univ, Sch Med, Dept Med, Indianapolis, IN USA; Indiana Univ, Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA; Kobe Univ, Grad Sch Med, Dept Clin Mol Med, Div Endocrinol & Metab, Kobe, Hyogo 657, Japan; Osaka City Univ, Grad Sch Med, Dept Metab Endocrinol & Mol Med, Osaka 558, Japan; Minoh City Hosp, Dept Pediat, Osaka, Japan; Osaka Univ, Grad Sch Med, Dept Pediat, Osaka, Japan; St Thomas Hosp, Dept Chem Pathol, London, England; Hyogo Kenritsu Amagasaki Hosp, Dept Med, Div Endocrinol & Metab, Amagasaki, Hyogo, Japan; Kyushu Univ, Grad Sch Med Sci, Dept Med & Bioregulatory Sci, Fukuoka 812, Japan; Aso Iizuka Hosp, Fukuoka, Japan; Kuyunghee Univ, Dept Internal Med, Seoul, South Korea; Natl Hyogo Chuo Hosp, Sanda, Hyogo, Japan	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Uppsala University; Uppsala University; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Kobe University; Osaka Metropolitan University; Osaka University; Guy's & St Thomas' NHS Foundation Trust; Kyushu University; Kyung Hee University	Juppner, H (corresponding author), Massachusetts Gen Hosp, Dept Med, Endocrine Unit, Wellman 5, Boston, MA 02114 USA.		Koshiyama, Hiroyuki/H-3877-2011; , kenneth/GPF-8006-2022; Miyauchi, Akimitsu/GYU-7403-2022	Econs, Michael/0000-0003-0940-1911	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K24AR002095, R01AR042228, R29AR042228] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK063934, R01DK046718, R37DK046718] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR42228, K24-AR02095] Funding Source: Medline; NIDDK NIH HHS [DK063934-01, DK46718] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bai XY, 2003, J BIOL CHEM, V278, P9843, DOI 10.1074/jbc.M210490200; Bowe AE, 2001, BIOCHEM BIOPH RES CO, V284, P977, DOI 10.1006/bbrc.2001.5084; De Beur SMJ, 2002, J BONE MINER RES, V17, P1102, DOI 10.1359/jbmr.2002.17.6.1102; Holm IA, 1997, AM J HUM GENET, V60, P790; NUSSBAUM SR, 1987, CLIN CHEM, V33, P1364; SABBAGH Y, PHEX LOCUS DATA BASE; Seufert J, 2001, NEW ENGL J MED, V345, P1883, DOI 10.1056/NEJMoa010839; Shimada T, 2001, P NATL ACAD SCI USA, V98, P6500, DOI 10.1073/pnas.101545198; Shimada T, 2002, ENDOCRINOLOGY, V143, P3179, DOI 10.1210/en.143.8.3179; Shimada T, 2001, J BONE MINER RES, V16, pS151; White KE, 2001, J CLIN ENDOCR METAB, V86, P497, DOI 10.1210/jc.86.2.497; White KE, 2001, KIDNEY INT, V60, P2079, DOI 10.1046/j.1523-1755.2001.00064.x; White KE, 2000, NAT GENET, V26, P345, DOI 10.1038/81664; Yamashita T, 2000, BIOCHEM BIOPH RES CO, V277, P494, DOI 10.1006/bbrc.2000.3696; Yang In Myung, 1997, Korean Journal of Internal Medicine (English Edition), V12, P89	15	644	675	0	13	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 24	2003	348	17					1656	1663		10.1056/NEJMoa020881	http://dx.doi.org/10.1056/NEJMoa020881			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	670PB	12711740				2022-12-28	WOS:000182416300005
J	Markham, R; Smith, A				Markham, R; Smith, A			Limits to patient choice: example from anaesthesia	BRITISH MEDICAL JOURNAL			English	Article									Royal Lancaster Infirm, Dept Anaesthesia, Lancaster LA1 4RP, England		Smith, A (corresponding author), Royal Lancaster Infirm, Dept Anaesthesia, Lancaster LA1 4RP, England.		Smith, Andrew F/C-5384-2012					Coulter A, 2002, BMJ-BRIT MED J, V324, P648, DOI 10.1136/bmj.324.7338.648; Department of Health, 2001, GOOD PRACT CONS IMPL; LACK JA, PATIENT INFORMATION; Smith R, 2002, BRIT MED J, V324, P497, DOI 10.1136/bmj.324.7336.497; Warner MA, 1999, ANESTHESIOLOGY, V90, P896	5	12	10	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 19	2003	326	7394					863	864		10.1136/bmj.326.7394.863	http://dx.doi.org/10.1136/bmj.326.7394.863			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	670BF	12702623	Bronze, Green Published			2022-12-28	WOS:000182386800023
J	Wang, YX; Lee, CH; Tiep, S; Yu, RT; Ham, JY; Kang, HJ; Evans, RM				Wang, YX; Lee, CH; Tiep, S; Yu, RT; Ham, JY; Kang, HJ; Evans, RM			Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity	CELL			English	Article							INSULIN-RESISTANCE; PPAR-GAMMA; ADAPTIVE THERMOGENESIS; CHOLESTEROL EFFLUX; NUCLEAR RECEPTORS; LEPTIN RECEPTOR; ADIPOSE-TISSUE; DB/DB MICE; MACROPHAGES; MECHANISMS	In contrast to the well-established roles of PPARgamma and PPARalpha in lipid metabolism, little is known for PPARdelta in this process. We show here that targeted activation of PPARdelta in adipose tissue specifically induces expression of genes required for fatty acid oxidation and energy dissipation, which in turn leads to improved lipid profiles and reduced adiposity. Importantly, these animals are completely resistant to both high-fat diet-induced and genetically predisposed (Lepr(db/db)) obesity. As predicted, acute treatment of Lepr(db/db) mice with a PPARdelta agonist depletes lipid accumulation. In parallel, PPARdelta-deficient mice challenged with high-fat diet show reduced energy uncoupling and are prone to obesity. In vitro, activation of PPARdelta in adipocytes and skeletal muscle cells promotes fatty acid oxidation and utilization. Our findings suggest that PPARdelta serves as a widespread regulator of fat burning and identify PPARdelta as a potential target in treatment of obesity and its associated disorders.	Salk Inst Biol Studies, Gene Express Lab, La Jolla, CA 92037 USA; Salk Inst Biol Studies, Howard Hughes Med Inst, La Jolla, CA 92037 USA; Seoul Natl Univ, Sch Earth & Environm Sci, Oceanog Program, Marine Biotechnol Lab, Seoul 151747, South Korea	Salk Institute; Howard Hughes Medical Institute; Salk Institute; Seoul National University (SNU)	Evans, RM (corresponding author), Salk Inst Biol Studies, Gene Express Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Evans, Ronald/AAF-4001-2019	Evans, Ronald/0000-0002-9986-5965; Yu, Ruth/0000-0002-9527-9627				Akiyama TE, 2002, MOL CELL BIOL, V22, P2607, DOI 10.1128/MCB.22.8.2607-2619.2002; Barak Y, 2002, P NATL ACAD SCI USA, V99, P303, DOI 10.1073/pnas.012610299; Barak Y, 1999, MOL CELL, V4, P585, DOI 10.1016/S1097-2765(00)80209-9; Berg AH, 2001, NAT MED, V7, P947, DOI 10.1038/90992; Berger J, 2002, ANNU REV MED, V53, P409, DOI 10.1146/annurev.med.53.082901.104018; Blough E, 1999, BIOTECHNIQUES, V26, P202, DOI 10.2144/99262bm05; Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866; Chawla A, 2001, MOL CELL, V7, P161, DOI 10.1016/S1097-2765(01)00164-2; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; Hamm JK, 2001, J BIOL CHEM, V276, P18464, DOI 10.1074/jbc.M100797200; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Kersten S, 2000, NATURE, V405, P421, DOI 10.1038/35013000; Kopecky J, 1996, AM J PHYSIOL-ENDOC M, V270, pE768, DOI 10.1152/ajpendo.1996.270.5.E768; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; Leibowitz MD, 2000, FEBS LETT, V473, P333, DOI 10.1016/S0014-5793(00)01554-4; Li AC, 2000, J CLIN INVEST, V106, P523, DOI 10.1172/JCI10370; Lowell BB, 2000, NATURE, V404, P652, DOI 10.1038/35007527; Michalik L, 2001, J CELL BIOL, V154, P799, DOI 10.1083/jcb.200011148; Moitra J, 1998, GENE DEV, V12, P3168, DOI 10.1101/gad.12.20.3168; Oliver WR, 2001, P NATL ACAD SCI USA, V98, P5306, DOI 10.1073/pnas.091021198; Peters JM, 2000, MOL CELL BIOL, V20, P5119, DOI 10.1128/MCB.20.14.5119-5128.2000; Picard F, 2002, CELL, V111, P931, DOI 10.1016/S0092-8674(02)01169-8; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Reddy JK, 2001, ANNU REV NUTR, V21, P193, DOI 10.1146/annurev.nutr.21.1.193; Rosen ED, 2001, J BIOL CHEM, V276, P37731, DOI 10.1074/jbc.R100034200; ROSS SR, 1990, P NATL ACAD SCI USA, V87, P9590, DOI 10.1073/pnas.87.24.9590; Shimomura I, 1998, GENE DEV, V12, P3182, DOI 10.1101/gad.12.20.3182; Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9; Steppan CM, 2001, NATURE, V409, P307, DOI 10.1038/35053000; Tan NS, 2001, GENE DEV, V15, P3263, DOI 10.1101/gad.207501; Vosper H, 2001, J BIOL CHEM, V276, P44258, DOI 10.1074/jbc.M108482200; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Yamauchi T, 2001, J BIOL CHEM, V276, P41245, DOI 10.1074/jbc.M103241200; Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984	35	1053	1138	1	95	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 18	2003	113	2					159	170		10.1016/S0092-8674(03)00269-1	http://dx.doi.org/10.1016/S0092-8674(03)00269-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	672EP	12705865	Bronze			2022-12-28	WOS:000182508500006
J	De Deyn, GB; Raaijmakers, CE; Zoomer, HR; Berg, MP; de Ruiter, PC; Verhoef, HA; Bezemer, TM; van der Putten, WH				De Deyn, GB; Raaijmakers, CE; Zoomer, HR; Berg, MP; de Ruiter, PC; Verhoef, HA; Bezemer, TM; van der Putten, WH			Soil invertebrate fauna enhances grassland succession and diversity	NATURE			English	Article							PLANT; COMMUNITY; HERBIVORY; FEEDBACK; MYCORRHIZAE; DYNAMICS; MOSAICS; BIOTA	One of the most important areas in ecology is to elucidate the factors that drive succession in ecosystems and thus influence the diversity of species in natural vegetation. Significant mechanisms in this process are known to be resource limitation(1-3) and the effects of aboveground vertebrate herbivores(4,5). More recently, symbiotic and pathogenic soil microbes have been shown to exert a profound effect on the composition of vegetation(6-9) and changes therein(10,11). However, the influence of invertebrate soil fauna on succession has so far received little attention(12,13). Here we report that invertebrate soil fauna might enhance both secondary succession and local plant species diversity. Soil fauna from a series of secondary grassland succession stages selectively suppress early successional dominant(14) plant species, thereby enhancing the relative abundance of subordinate(14) species and also that of species from later succession stages. Soil fauna from the mid-succession stage had the strongest effect. Our results clearly show that soil fauna strongly affects the composition of natural vegetation and we suggest that this knowledge might improve the restoration and conservation of plant species diversity.	Netherlands Inst Ecol, NIOO, KNAW, Ctr Terr Ecol,Dept Multitrop Interact, NL-6666 ZG Heteren, Netherlands; Vrije Univ Amsterdam, Inst Ecol Sci, Dept Anim Ecol, NL-1081 HV Amsterdam, Netherlands; Univ Utrecht, Copernicus Res Inst Sustainable Dev & Innovat, Dept Environm Sci, NL-3508 TC Utrecht, Netherlands	Royal Netherlands Academy of Arts & Sciences; Netherlands Institute of Ecology (NIOO-KNAW); Vrije Universiteit Amsterdam; Utrecht University	De Deyn, GB (corresponding author), Netherlands Inst Ecol, NIOO, KNAW, Ctr Terr Ecol,Dept Multitrop Interact, POB 40, NL-6666 ZG Heteren, Netherlands.	g.dedeyn@nioo.knaw.nl	De Deyn, Gerlinde/AFI-8702-2022; De Deyn, Gerlinde B/C-1593-2009; Bezemer, Martijn/A-4068-2009; De Deyn, Gerlinde/F-7080-2017; van der Putten, Wim H/C-3707-2011	De Deyn, Gerlinde/0000-0003-4823-6912; De Deyn, Gerlinde B/0000-0003-4823-6912; Bezemer, Martijn/0000-0002-2878-3479; De Deyn, Gerlinde/0000-0003-4823-6912; van der Putten, Wim H/0000-0002-9341-4442; Berg, Matty P./0000-0001-8442-8503				ALMUFTI MM, 1977, J ECOL, V65, P759, DOI 10.2307/2259378; Bever JD, 1997, J ECOL, V85, P561, DOI 10.2307/2960528; BEVER JD, 1994, ECOLOGY, V75, P1965, DOI 10.2307/1941601; Blomqvist MM, 2000, OIKOS, V90, P582, DOI 10.1034/j.1600-0706.2000.900316.x; Bradford MA, 2002, SCIENCE, V298, P615, DOI 10.1126/science.1075805; BROWN VK, 1989, OIKOS, V54, P67, DOI 10.2307/3565898; BROWN VK, 1992, VEGETATIO, V101, P3, DOI 10.1007/BF00031910; Carson WP, 2000, ECOL MONOGR, V70, P73, DOI 10.1890/0012-9615(2000)070[0073:HAPSCC]2.0.CO;2; Clements F.E., 1916, PLANT SUCCESSION ANA; Crawley MJ, 1997, PLANT ECOL; Grime JP, 1998, J ECOL, V86, P902, DOI 10.1046/j.1365-2745.1998.00306.x; Hartnett DC, 1999, ECOLOGY, V80, P1187, DOI 10.1890/0012-9658(1999)080[1187:MIPCSA]2.0.CO;2; JOHNSON NC, 1991, OECOLOGIA, V86, P349, DOI 10.1007/BF00317600; Klironomos JN, 2002, NATURE, V417, P67, DOI 10.1038/417067a; MARRS RH, 1993, ADV ECOL RES, V24, P241, DOI 10.1016/S0065-2504(08)60044-6; Olff H, 2000, OECOLOGIA, V125, P45, DOI 10.1007/PL00008890; Olff H, 1998, TRENDS ECOL EVOL, V13, P261, DOI 10.1016/S0169-5347(98)01364-0; Oostenbrink I.C., 1960, NEMATOLOGY, P439; Packer A, 2000, NATURE, V404, P278, DOI 10.1038/35005072; PETERS JH, 1988, CANCER LETT, V39, P287, DOI 10.1016/0304-3835(88)90072-9; SIMPSON EH, 1949, NATURE, V163, P688, DOI 10.1038/163688a0; Tilman D., 1982, Monographs in Population Biology, pi; van der Heijden MGA, 1998, NATURE, V396, P69, DOI 10.1038/23932; VANDERPUTTEN WH, 1993, NATURE, V362, P53; VANSTRAALEN NM, 1982, PEDOBIOLOGIA, V24, P197; Wardle DA, 1997, OIKOS, V80, P470, DOI 10.2307/3546620; YEATES GW, 1993, J NEMATOL, V25, P315	27	409	433	20	398	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 17	2003	422	6933					711	713		10.1038/nature01548	http://dx.doi.org/10.1038/nature01548			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	668CG	12700759				2022-12-28	WOS:000182272300038
J	Han, AD; Pan, F; Stroud, JC; Youn, HD; Liu, JO; Chen, L				Han, AD; Pan, F; Stroud, JC; Youn, HD; Liu, JO; Chen, L			Sequence-specific recruitment of transcriptional co-repressor Cabin1 by myocyte enhancer factor-2	NATURE			English	Article							HISTONE DEACETYLASES; CRYSTAL-STRUCTURE; TERNARY COMPLEX; FACTOR MEF2; MADS-BOX; ACTIVATION; DNA; APOPTOSIS; DIFFERENTIATION; CALCINEURIN	The myocyte enhancer factor-2 (MEF2) family of transcription factors has important roles in the development and function of T cells, neuronal cells and muscle cells(1-3). MEF2 is capable of repressing or activating transcription by association with a variety of co-repressors or co-activators in a calcium-dependent manner(1,4,5). Transcriptional repression by MEF2 has attracted particular attention because of its potential role in hypertrophic responses of cardiomyocytes(6). Several MEF2 co-repressors, such as Cabin1/Cain and class II histone deacetylases (HDACs), have been identified(7-12). However, the molecular mechanism of their recruitment to specific promoters by MEF2 remains largely unknown. Here we report a crystal structure of the MADS-box/MEF2S domain of human MEF2B bound to a motif of the transcriptional co-repressor Cabin1 and DNA at 2.2 Angstrom resolution. The crystal structure reveals a stably folded MEF2S domain on the surface of the MADS box. Cabin1 adopts an amphipathic alpha-helix to bind a hydrophobic groove on the MEF2S domain, forming a triple-helical interaction. Our studies of the ternary Cabin1/MEF2/DNA complex show a general mechanism by which MEF2 recruits transcriptional co-repressor Cabin1 and class II HDACs to specific DNA sites.	Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA	University of Colorado System; University of Colorado Boulder; Johns Hopkins University; Johns Hopkins University	Chen, L (corresponding author), Univ Colorado, Dept Chem & Biochem, Campus Box 215, Boulder, CO 80309 USA.		Stroud, James C/B-3230-2012; chen, Lin/A-3392-2008; Youn, Hong-Duk/J-2774-2012	Stroud, James C/0000-0003-0850-4812; chen, Lin/0000-0003-4798-6199; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL076334] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI049905] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL076334] Funding Source: Medline; NIAID NIH HHS [R21 AI049905] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; Black BL, 1998, ANNU REV CELL DEV BI, V14, P167, DOI 10.1146/annurev.cellbio.14.1.167; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Hassler M, 2001, EMBO J, V20, P3018, DOI 10.1093/emboj/20.12.3018; Huang K, 2000, EMBO J, V19, P2615, DOI 10.1093/emboj/19.11.2615; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Lai MM, 1998, J BIOL CHEM, V273, P18325, DOI 10.1074/jbc.273.29.18325; Lemercier C, 2000, J BIOL CHEM, V275, P15594, DOI 10.1074/jbc.M908437199; Lu JR, 2000, MOL CELL, V6, P233, DOI 10.1016/S1097-2765(00)00025-3; Lu JR, 2000, P NATL ACAD SCI USA, V97, P4070, DOI 10.1073/pnas.080064097; Mao ZX, 1999, SCIENCE, V286, P785, DOI 10.1126/science.286.5440.785; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; McKinsey TA, 2002, TRENDS BIOCHEM SCI, V27, P40, DOI 10.1016/S0968-0004(01)02031-X; Miska EA, 1999, EMBO J, V18, P5099, DOI 10.1093/emboj/18.18.5099; Molkentin JD, 1996, MOL CELL BIOL, V16, P2627; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; PELLEGRINI L, 1995, NATURE, V376, P490, DOI 10.1038/376490a0; Santelli E, 2000, J MOL BIOL, V297, P437, DOI 10.1006/jmbi.2000.3568; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; Sparrow DB, 1999, EMBO J, V18, P5085, DOI 10.1093/emboj/18.18.5085; Sun L, 1998, IMMUNITY, V8, P703, DOI 10.1016/S1074-7613(00)80575-0; Tan S, 1998, NATURE, V391, P660, DOI 10.1038/35563; WORONICZ JD, 1995, MOL CELL BIOL, V15, P6364; Youn HD, 2000, J BIOL CHEM, V275, P22563, DOI 10.1074/jbc.C000304200; Youn HD, 1999, SCIENCE, V286, P790, DOI 10.1126/science.286.5440.790; Youn HD, 2000, IMMUNITY, V13, P85, DOI 10.1016/S1074-7613(00)00010-8; Zhang CL, 2002, CELL, V110, P479, DOI 10.1016/S0092-8674(02)00861-9	30	81	93	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 17	2003	422	6933					730	734		10.1038/nature01555	http://dx.doi.org/10.1038/nature01555			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	668CG	12700764				2022-12-28	WOS:000182272300044
J	Schliwa, M; Woehlke, G				Schliwa, M; Woehlke, G			Molecular motors	NATURE			English	Review							MESSENGER-RNA LOCALIZATION; KINESIN-LIKE PROTEIN; LEFT-RIGHT ASYMMETRY; ACTIN-BASED MOTOR; CYTOPLASMIC DYNEIN; AXONAL-TRANSPORT; MYOSIN-V; PROCESSIVE KINESIN; VESICLE TRANSPORT; DIMERIC KINESIN	Life implies movement. Most forms of movement in the living world are powered by tiny protein machines known as molecular motors. Among the best known are motors that use sophisticated intramolecular amplification mechanisms to take nanometre steps along protein tracks in the cytoplasm. These motors transport a wide variety of cargo, power cell locomotion, drive cell division and, when combined in large ensembles, allow organisms to move. Motor defects can lead to severe diseases or may even be lethal. Basic principles of motor design and mechanism have now been derived, and an understanding of their complex cellular roles is emerging.	Univ Munich, Adolf Butenandt Inst, D-80336 Munich, Germany	University of Munich	Schliwa, M (corresponding author), Univ Munich, Adolf Butenandt Inst, Schillerstr 42, D-80336 Munich, Germany.	schliwa@bio.med.uni-muenchen.de		Woehlke, Gunther/0000-0001-8462-9962				Addinall SG, 2001, J BIOL CHEM, V276, P15939, DOI 10.1074/jbc.M011628200; Askham JM, 2002, MOL BIOL CELL, V13, P3627, DOI 10.1091/mbc.E02-01-0061; AVRAHAM KB, 2002, E SCHERING RES FDN W, V36, P271; Bowman AB, 2000, CELL, V103, P583, DOI 10.1016/S0092-8674(00)00162-8; Brendza RP, 2000, SCIENCE, V289, P2120, DOI 10.1126/science.289.5487.2120; Bridgman PC, 1999, J CELL BIOL, V146, P1045, DOI 10.1083/jcb.146.5.1045; Brown SS, 1999, ANNU REV CELL DEV BI, V15, P63, DOI 10.1146/annurev.cellbio.15.1.63; Burgess SA, 2003, NATURE, V421, P715, DOI 10.1038/nature01377; Cha BJ, 2001, CELL, V106, P35, DOI 10.1016/S0092-8674(01)00419-6; Coy DL, 1999, NAT CELL BIOL, V1, P288, DOI 10.1038/13001; Day IS, 2000, J BIOL CHEM, V275, P13737, DOI 10.1074/jbc.275.18.13737; De La Cruz EM, 1999, P NATL ACAD SCI USA, V96, P13726, DOI 10.1073/pnas.96.24.13726; Dohner K, 2002, MOL BIOL CELL, V13, P2795, DOI 10.1091/mbc.01-07-0348; Dujardin DL, 2002, CURR OPIN CELL BIOL, V14, P44, DOI 10.1016/S0955-0674(01)00292-7; Endow SA, 2000, NATURE, V406, P913, DOI 10.1038/35022617; Endow SA, 1999, NAT CELL BIOL, V1, pE163, DOI 10.1038/14113; Espindola FS, 2000, CELL MOTIL CYTOSKEL, V47, P269, DOI 10.1002/1097-0169(200012)47:4<269::AID-CM2>3.3.CO;2-7; Friedman DS, 1999, NAT CELL BIOL, V1, P293, DOI 10.1038/13008; Geeves MA, 1999, ANNU REV BIOCHEM, V68, P687, DOI 10.1146/annurev.biochem.68.1.687; Gross SP, 2002, J CELL BIOL, V156, P855, DOI 10.1083/jcb.200105055; Gunawardena S, 2001, NEURON, V32, P389, DOI 10.1016/S0896-6273(01)00496-2; Hackney DD, 2000, NAT CELL BIOL, V2, P257, DOI 10.1038/35010525; HACKNEY DD, 1995, NATURE, V377, P448, DOI 10.1038/377448a0; Hammer JA, 2002, CURR OPIN CELL BIOL, V14, P69, DOI 10.1016/S0955-0674(01)00296-4; Helfand BT, 2002, J CELL BIOL, V157, P795, DOI 10.1083/jcb.200202027; Holleran EA, 1998, INT REV CYTOL, V182, P69, DOI 10.1016/S0074-7696(08)62168-3; Homma K, 2001, NATURE, V412, P831, DOI 10.1038/35090597; Houdusse A, 2000, P NATL ACAD SCI USA, V97, P11238, DOI 10.1073/pnas.200376897; Howard J., 2001, MECH MOTOR PROTEINS; Hua W, 2002, SCIENCE, V295, P844, DOI 10.1126/science.1063089; Huang JD, 1999, NATURE, V397, P267, DOI 10.1038/16722; Humphrey D, 2002, NATURE, V416, P413, DOI 10.1038/416413; Inoue A, 2002, NAT CELL BIOL, V4, P302, DOI 10.1038/ncb774; Jansen RP, 2001, NAT REV MOL CELL BIO, V2, P247, DOI 10.1038/35067016; Jimbo T, 2002, NAT CELL BIOL, V4, P323, DOI 10.1038/ncb779; Kallipolitou A, 2001, EMBO J, V20, P6226, DOI 10.1093/emboj/20.22.6226; Kamal A, 2001, NATURE, V414, P643, DOI 10.1038/414643a; Karcher RL, 2001, SCIENCE, V293, P1317, DOI 10.1126/science.1061086; Karki S, 2002, MOL BIOL CELL, V13, P1722, DOI 10.1091/mbc.02-02-0011; Kiebler MA, 2000, NEURON, V25, P19, DOI 10.1016/S0896-6273(00)80868-5; Kikkawa M, 2000, CELL, V100, P241, DOI 10.1016/S0092-8674(00)81562-7; Klopfenstein DR, 2002, CELL, V109, P347, DOI 10.1016/S0092-8674(02)00708-0; Koonce MP, 2000, MOL BIOL CELL, V11, P523, DOI 10.1091/mbc.11.2.523; Kosztin I, 2002, P NATL ACAD SCI USA, V99, P3575, DOI 10.1073/pnas.052209199; Kozielski F, 1997, CELL, V91, P985, DOI 10.1016/S0092-8674(00)80489-4; Kuriyama R, 2002, J CELL BIOL, V156, P783, DOI 10.1083/jcb.200109090; LaMonte BH, 2002, NEURON, V34, P715, DOI 10.1016/S0896-6273(02)00696-7; Lang MJ, 2002, BIOPHYS J, V83, P491, DOI 10.1016/S0006-3495(02)75185-0; Lantz VA, 1998, J CELL BIOL, V140, P897, DOI 10.1083/jcb.140.4.897; Marszalek JR, 1999, P NATL ACAD SCI USA, V96, P5043, DOI 10.1073/pnas.96.9.5043; Marszalek JR, 2000, CELL, V102, P175, DOI 10.1016/S0092-8674(00)00023-4; Morfini G, 2002, EMBO J, V21, P281, DOI 10.1093/emboj/21.3.281; Muresan V, 2001, MOL CELL, V7, P173, DOI 10.1016/S1097-2765(01)00165-4; Murphy CT, 2001, NAT CELL BIOL, V3, P311, DOI 10.1038/35060110; Nonaka S, 1998, CELL, V95, P829, DOI 10.1016/S0092-8674(00)81705-5; Nonaka S, 2002, NATURE, V418, P96, DOI 10.1038/nature00849; Okada Y, 2000, P NATL ACAD SCI USA, V97, P640, DOI 10.1073/pnas.97.2.640; Okada Y, 1999, SCIENCE, V283, P1152, DOI 10.1126/science.283.5405.1152; Olbrich H, 2002, NAT GENET, V30, P143, DOI 10.1038/ng817; Oppenheimer J. R., 1953, SCI COMMON UNDERSTAN; Piddini E, 2001, EMBO J, V20, P4076, DOI 10.1093/emboj/20.15.4076; Qin HM, 2001, CURR BIOL, V11, P457, DOI 10.1016/S0960-9822(01)00122-1; Rice S, 1999, NATURE, V402, P778, DOI 10.1038/45483; Rief M, 2000, P NATL ACAD SCI USA, V97, P9482, DOI 10.1073/pnas.97.17.9482; Rietdorf J, 2001, NAT CELL BIOL, V3, P992, DOI 10.1038/ncb1101-992; Rock RS, 2001, P NATL ACAD SCI USA, V98, P13655, DOI 10.1073/pnas.191512398; Rogers KR, 2001, EMBO J, V20, P5101, DOI 10.1093/emboj/20.18.5101; Ruff C, 2001, NAT STRUCT BIOL, V8, P226, DOI 10.1038/84962; Sablin EP, 1998, NATURE, V395, P813, DOI 10.1038/27463; Sakakibara H, 1999, NATURE, V400, P586, DOI 10.1038/23066; SCHLIWA M, 2003, MOL MOTORS; Schnitzer MJ, 2000, NAT CELL BIOL, V2, P718, DOI 10.1038/35036345; Schnorrer F, 2000, NAT CELL BIOL, V2, P185, DOI 10.1038/35008601; Schott DH, 2002, J CELL BIOL, V156, P35, DOI 10.1083/jcb.200110086; Seidman JG, 2001, CELL, V104, P557, DOI 10.1016/S0092-8674(01)00242-2; Seiler S, 2000, NAT CELL BIOL, V2, P333, DOI 10.1038/35014022; Shea TB, 2001, TRENDS NEUROSCI, V24, P644, DOI 10.1016/S0166-2236(00)01919-6; Spudich JA, 2001, NAT REV MOL CELL BIO, V2, P387, DOI 10.1038/35073086; Stebbings H, 2001, INT REV CYTOL, V211, P1, DOI 10.1016/S0074-7696(01)11016-8; Supp DM, 1997, NATURE, V389, P963, DOI 10.1038/40140; Surrey T, 2001, SCIENCE, V292, P1167, DOI 10.1126/science.1059758; Tai AW, 1999, CELL, V97, P877, DOI 10.1016/S0092-8674(00)80800-4; TANG N, 2002, J BIOL CHEM; Terada S, 2000, CURR OPIN NEUROBIOL, V10, P566, DOI 10.1016/S0959-4388(00)00129-X; Thorn KS, 2000, J CELL BIOL, V151, P1093, DOI 10.1083/jcb.151.5.1093; Tomishige M, 2000, J CELL BIOL, V151, P1081, DOI 10.1083/jcb.151.5.1081; Tomishige M, 2002, SCIENCE, V297, P2263, DOI 10.1126/science.1073386; Vale RD, 2000, SCIENCE, V288, P88, DOI 10.1126/science.288.5463.88; Vale RD, 1996, J CELL BIOL, V135, P291, DOI 10.1083/jcb.135.2.291; Vallee RB, 2001, TRENDS CELL BIOL, V11, P155, DOI 10.1016/S0962-8924(01)01956-0; Veigel C, 2002, NAT CELL BIOL, V4, P59, DOI 10.1038/ncb732; Verhey KJ, 2001, J CELL BIOL, V152, P959, DOI 10.1083/jcb.152.5.959; Walker ML, 2000, NATURE, V405, P804, DOI 10.1038/35015592; Watters JW, 2001, CURR BIOL, V11, P1503, DOI 10.1016/S0960-9822(01)00476-6; Wells AL, 1999, NATURE, V401, P505, DOI 10.1038/46835; Westbroek W, 2001, PIGM CELL RES, V14, P320, DOI 10.1034/j.1600-0749.2001.140503.x; Wu XFS, 2002, NAT CELL BIOL, V4, P271, DOI 10.1038/ncb760; Yun MY, 2001, EMBO J, V20, P2611, DOI 10.1093/emboj/20.11.2611; Zhao C, 2001, CELL, V105, P587, DOI 10.1016/S0092-8674(01)00363-4; Zimmerman W, 2000, TRAFFIC, V1, P927, DOI 10.1034/j.1600-0854.2000.011202.x	100	803	821	5	264	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 17	2003	422	6933					759	765		10.1038/nature01601	http://dx.doi.org/10.1038/nature01601			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	668CG	12700770				2022-12-28	WOS:000182272300050
J	Edwards, IR				Edwards, IR			Withdrawing drugs: nefazodone, the start of the latest saga	LANCET			English	Editorial Material									Uppsala Monitoring Ctr, S-75320 Uppsala, Sweden		Edwards, IR (corresponding author), Uppsala Monitoring Ctr, S-75320 Uppsala, Sweden.							Abraham J, 2003, DRUG SAFETY, V26, P135, DOI 10.2165/00002018-200326030-00001; BISCARINI L, 2000, MEYLERS SIDE EFFECTS, P266; Edwards IR, 1997, DRUG SAFETY, V17, P216, DOI 10.2165/00002018-199717040-00002; Graham DJ, 2001, JAMA-J AM MED ASSOC, V286, P831, DOI 10.1001/jama.286.7.831; *PUBL CIT, 2003, HRG PUBL, V1657; *PUBL CIT, 2003, PUBL CIT CALLS FDA B; SANJAY AP, 2003, LANCET, V361, P1136; Smalley W, 2000, JAMA-J AM MED ASSOC, V284, P3036, DOI 10.1001/jama.284.23.3036; van Grootheest ACK, 2002, DRUG SAFETY, V25, P1051, DOI 10.2165/00002018-200225150-00001	9	11	13	1	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 12	2003	361	9365					1240	1240		10.1016/S0140-6736(03)13030-9	http://dx.doi.org/10.1016/S0140-6736(03)13030-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	666DM	12699949				2022-12-28	WOS:000182161600006
J	Roizen, NJ; Patterson, D				Roizen, NJ; Patterson, D			Down's syndrome	LANCET			English	Review							CELIAC-DISEASE; PRENATAL-DIAGNOSIS; ATLANTOAXIAL INSTABILITY; THYROID-FUNCTION; METABOLIC-RATE; HEARING-LOSS; TS65DN MICE; CHILDREN; PREVALENCE; DISORDERS	The sequencing of chromosome 21 and the use of models of Down's syndrome in mice have allowed us to relate genes and sets of genes to the neuropathogenesis of this syndrome, and to better understand its phenotype. Research in prenatal screening and diagnosis aims to find methods to identify fetuses with Down's syndrome, and reduce or eliminate the need for amniocentesis. Other areas of active research and clinical interest include the association of Down's syndrome with coeliac disease and Alzheimer's disease, and improved median age of death. Medical management of the syndrome requires an organised approach of assessment, monitoring, prevention, and vigilance. Improvements in quality of life of individuals with Down's syndrome have resulted from improvements in medical care, identification and treatment of psychiatric disorders (such as depression, disruptive behaviour disorders, and autism), and early educational interventions with support in typical educational settings. Approaches and outcomes differ throughout the world.	SUNY Upstate Med Univ, Dept Pediat, 750 E Adams St, Syracuse, NY 13210 USA; Eleanor Roosevelt Inst Denver, Denver, CO USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Roizen, NJ (corresponding author), SUNY Upstate Med Univ, Dept Pediat, 750 E Adams St, Syracuse, NY 13210 USA.	roizenn@upstate.edu						ALLISON DB, 1995, INT J OBESITY, V19, P858; Ani C, 2000, DEV MED CHILD NEUROL, V42, P207, DOI 10.1017/S0012162200000359; Anwar AJ, 1998, DIABETIC MED, V15, P160, DOI 10.1002/(SICI)1096-9136(199802)15:2<160::AID-DIA537>3.0.CO;2-J; BALKANY TJ, 1979, CLIN PEDIATR, V18, P116, DOI 10.1177/000992287901800207; Bianchi DW, 1999, BRIT J HAEMATOL, V105, P574, DOI 10.1046/j.1365-2141.1999.01383.x; Blake D, 1999, MOL HUM REPROD, V5, P1166, DOI 10.1093/molehr/5.12.1166; Bonamico M, 2001, J PEDIATR GASTR NUTR, V33, P139, DOI 10.1097/00005176-200108000-00008; Book L, 2001, AM J MED GENET, V98, P70, DOI 10.1002/1096-8628(20010101)98:1<70::AID-AJMG1002>3.0.CO;2-G; Bourc'his D, 2001, SCIENCE, V294, P2536, DOI 10.1126/science.1065848; BOVICELLI L, 1982, OBSTET GYNECOL, V59, pS13; Brown F R 3rd, 1990, Pediatrics, V85, P450; Bruni M., 1998, FINE MOTOR SKILLS CH; Busciglio J, 2002, NEURON, V33, P677, DOI 10.1016/S0896-6273(02)00604-9; Capone G, 2002, LIFE SCI, V70, P2885, DOI 10.1016/S0024-3205(02)01538-2; Capone GT, 2001, J DEV BEHAV PEDIATR, V22, P40, DOI 10.1097/00004703-200102000-00007; CAPUTO AR, 1989, CLIN PEDIATR, V28, P355, DOI 10.1177/000992288902800804; Carlsson AK, 2001, PEDIATRICS, V107, P42, DOI 10.1542/peds.107.1.42; Carnicer J, 2001, EUR J GASTROEN HEPAT, V13, P263, DOI 10.1097/00042737-200103000-00008; CASELLI MA, 1991, J AM PODIAT MED ASSN, V81, P119, DOI 10.7547/87507315-81-3-119; CATALANO RA, 1990, SURV OPHTHALMOL, V34, P385, DOI 10.1016/0039-6257(90)90116-D; Chapman RS, 1998, J SPEECH LANG HEAR R, V41, P861, DOI 10.1044/jslhr.4104.861; Cheffins T, 2000, BRIT J OBSTET GYNAEC, V107, P1453, DOI 10.1111/j.1471-0528.2000.tb11668.x; Cohen W. I., 1999, DOWN SYNDROME Q, V4, P1, DOI DOI 10.1002/0471227579.CH17; Cohen WI, 1998, ARCH PEDIAT ADOL MED, V152, P119; COOPER SA, 1994, BRIT J PSYCHIAT, V165, P399, DOI 10.1192/bjp.165.3.399; CREMERS MJG, 1993, LANCET, V342, P511, DOI 10.1016/0140-6736(93)91644-2; CRONK C, 1988, PEDIATRICS, V81, P102; Cunniff C, 2001, PEDIATRICS, V107, P442; daCunha RP, 1996, AM J OPHTHALMOL, V122, P236, DOI 10.1016/S0002-9394(14)72015-X; DAHLE AJ, 1988, J MENT DEFIC RES, V32, P333; DALTON AJ, 1986, PSYCHIAT CLIN N AM, V9, P659; Davisson MT, 2001, GENOMICS, V78, P99, DOI 10.1006/geno.2001.6639; Doolin MT, 2002, AM J HUM GENET, V71, P1222, DOI 10.1086/344209; Doyle JS, 1996, SPINE, V21, P1223, DOI 10.1097/00007632-199605150-00016; ELKINS TE, 1990, J REPROD MED, V35, P745; Ercis M, 1996, CLIN GENET, V50, P317; EYMAN RK, 1991, AM J MENT RETARD, V95, P603; FORT P, 1984, J PEDIATR-US, V104, P545, DOI 10.1016/S0022-3476(84)80544-2; Freeman SB, 1998, AM J MED GENET, V80, P213, DOI 10.1002/(SICI)1096-8628(19981116)80:3<213::AID-AJMG6>3.0.CO;2-8; Fujiura GT, 1997, RES DEV DISABIL, V18, P261, DOI 10.1016/S0891-4222(97)00008-5; GEGGEL RL, 1993, J PEDIATR-US, V122, P821, DOI 10.1016/S0022-3476(06)80036-3; Goldberg-Stern H, 2001, BRAIN DEV-JPN, V23, P375, DOI 10.1016/S0387-7604(01)00239-X; GOLDSTEIN H, 1988, EUR J OBSTET GYN R B, V27, P343, DOI 10.1016/0028-2243(88)90048-2; HANSON MJ, 1987, TEACHING INFANT DOWN; Hasle H, 2000, LANCET, V355, P165, DOI 10.1016/S0140-6736(99)05264-2; Hassold T, 2000, CLIN GENET, V57, P95, DOI 10.1034/j.1399-0004.2000.570201.x; HASSOLD TJ, 1998, DOWN SYNDROME PROMIS; Hattori M, 2000, NATURE, V405, P311, DOI 10.1038/35012518; Hennequin M, 1999, DEV MED CHILD NEUROL, V41, P275, DOI 10.1017/S0012162299000596; Hobbs CA, 2000, AM J HUM GENET, V67, P623, DOI 10.1086/303055; Howlin P., 1995, DEV MED CHILD NEUROL, V37, P398, DOI [10.1111/j.1469-8749.1995.tb12023.x, DOI 10.1111/J.1469-8749.1995.TB12023.X]; Hunter AGW, 2001, MANAGEMENT GENETIC S, P103; Hyde LA, 2001, BEHAV NEUROSCI, V115, P1239, DOI 10.1037//0735-7044.115.6.1239; Hyde LA, 2001, BEHAV BRAIN RES, V118, P53, DOI 10.1016/S0166-4328(00)00313-2; IHNAT DHK, 1993, J RHEUMATOL, V20, P742; ILNO Y, 1999, INT J PEDIATR OTORHI, V49, P143; JULIANREYNIER C, 1995, J MED GENET, V32, P597, DOI 10.1136/jmg.32.8.597; Kamatani N, 1996, ANN RHEUM DIS, V55, P649, DOI 10.1136/ard.55.9.649; Kapranov P, 2002, SCIENCE, V296, P916, DOI 10.1126/science.1068597; Karlsson B, 1998, ARCH DIS CHILD, V79, P242, DOI 10.1136/adc.79.3.242; Katsanis N, 1997, MAMM GENOME, V8, P526, DOI 10.1007/s003359900491; KENNEDY RL, 1992, CLIN ENDOCRINOL, V37, P471, DOI 10.1111/j.1365-2265.1992.tb01475.x; Kent L, 1999, DEV MED CHILD NEUROL, V41, P153, DOI 10.1017/S001216229900033X; Kivivuori SM, 1996, CLIN GENET, V49, P15; Kraus JP, 1999, HUM MUTAT, V13, P362; Kumin, 2003, EARLY COMMUNICATION; Lai F. M., 2002, SMJ Singapore Medical Journal, V43, P070; Lange B, 2000, BRIT J HAEMATOL, V110, P512, DOI 10.1046/j.1365-2141.2000.02027.x; LEJEUNE J, 1959, CR HEBD ACAD SCI, V248, P1721; Leonard S, 2000, PAEDIATR PERINAT EP, V14, P163; Lobaugh NJ, 2001, ARCH PEDIAT ADOL MED, V155, P442, DOI 10.1001/archpedi.155.4.442; LUKE A, 1994, J PEDIATR-US, V125, P829, DOI 10.1016/S0022-3476(06)80193-9; Marino B, 2001, PEDIATRICS, V108, P1384; McAloon J, 2000, J ROY COLL PHYS LOND, V34, P587; Merrick J, 2000, ISRAEL MED ASSOC J, V2, P25; Miller J., 1999, IMPROVING COMMUNICAT; Morris JK, 2002, J MED SCREEN, V9, P2, DOI 10.1136/jms.9.1.2; MOSCOW JA, 1995, CANCER RES, V55, P3790; MYERS BA, 1991, J NERV MENT DIS, V179, P609, DOI 10.1097/00005053-199110000-00004; Noble SE, 2000, ARCH DIS CHILD, V82, P27, DOI 10.1136/adc.82.1.27; O'Leary VB, 2002, AM J MED GENET, V107, P151, DOI 10.1002/ajmg.10121; OELWEIN P, 1997, TEACHING READING CHI; Olsen CL, 1997, PRENATAL DIAG, V17, P1113, DOI 10.1002/(SICI)1097-0223(199712)17:12<1113::AID-PD200>3.0.CO;2-7; OLSON JC, 1990, PEDIATRICS, V86, P931; PANT SS, 1968, J CLIN ENDOCR METAB, V28, P472, DOI 10.1210/jcem-28-4-472; PUESCHEL SM, 1991, ARCH NEUROL-CHICAGO, V48, P318, DOI 10.1001/archneur.1991.00530150088024; Pueschel SM, 1998, ARCH PEDIAT ADOL MED, V152, P123; PUESCHEL SM, 1992, PEDIATRICS, V89, P1194; PUESCHEL SM, 1985, AM J DIS CHILD, V139, P236, DOI 10.1001/archpedi.1985.02140050030014; PUESCHEL SM, 1990, AM J MED GENET, P52; PUESCHEL SM, 1996, MENT RETARD DEV D R, V2, P90; PUESCHEL SM, 1988, YOUNG PERSON DOWN SY; Rasmussen P, 2001, DEV MED CHILD NEUROL, V43, P750, DOI 10.1017/S0012162201001372; REEVES RH, 1995, NAT GENET, V11, P177, DOI 10.1038/ng1095-177; Richtsmeier JT, 2000, DEV DYNAM, V217, P137, DOI 10.1002/(SICI)1097-0177(200002)217:2<137::AID-DVDY1>3.0.CO;2-N; RISSER WL, 1995, PEDIATRICS, V96, P151; Roizen N., 2002, CHILDREN DISABILITIE, P307; Roizen Nancy J, 2002, Adolesc Med, V13, P345; ROIZEN NJ, 1993, AM J MED GENET, V46, P510, DOI 10.1002/ajmg.1320460509; ROIZEN NJ, 1994, DEV MED CHILD NEUROL, V36, P594; Roizen NJ, 2001, MENT RETARD DEV D R, V7, P38, DOI 10.1002/1098-2779(200102)7:1<38::AID-MRDD1006>3.0.CO;2-C; ROIZEN NJ, 1993, J PEDIATR-US, V123, pS9, DOI 10.1016/S0022-3476(05)81588-4; ROIZEN NJ, 2001, YOUR CHILD DISABILIT, P217; Rosch C, 2000, EUR J EPIDEMIOL, V16, P627, DOI 10.1023/A:1007693025935; Rubin SS, 1998, MENT RETARD, V36, P175, DOI 10.1352/0047-6765(1998)036<0175:OPIPWD>2.0.CO;2; SCHERBENSKE JM, 1990, J AM ACAD DERMATOL, V22, P933, DOI 10.1016/0190-9622(90)70129-6; Schupf N, 2002, BRIT J PSYCHIAT, V180, P405, DOI 10.1192/bjp.180.5.405; Schupf N, 1997, J INTELL DISABIL RES, V41, P264, DOI 10.1111/j.1365-2788.1997.tb00706.x; SELBY KA, 1991, ARCH DIS CHILD, V66, P876, DOI 10.1136/adc.66.7.876; SELIKOWITZ M, 1993, DEV MED CHILD NEUROL, V35, P511; SELIKOWITZ M, 1993, DEV MED CHILD NEUROL, V35, P396; SEPULVEDA D, 1995, AM J MENT RETARD, V100, P109; SHERIDAN R, 1989, J MED GENET, V26, P294, DOI 10.1136/jmg.26.5.294; Shott SR, 2001, INT J PEDIATR OTORHI, V61, P199, DOI 10.1016/S0165-5876(01)00572-9; SHOTT SR, 2000, DOWN SYNDROME Q, V5, P1; Smith DS, 2001, AM FAM PHYSICIAN, V64, P1031; Smith-Bindman R, 2001, JAMA-J AM MED ASSOC, V285, P1044, DOI 10.1001/jama.285.8.1044; Solans A, 2000, CYTOGENET CELL GENET, V88, P43, DOI 10.1159/000015483; STAFSTROM CE, 1994, DEV MED CHILD NEUROL, V36, P576; STRAYGUNDERSEN K, 1995, BABIES DOWN SYNDROME; Taggard DA, 2000, J NEUROSURG, V93, P205, DOI 10.3171/spi.2000.93.2.0205; TURNBULL AP, 1985, J ADOLESCENT HEALTH, V6, P108, DOI 10.1016/S0197-0070(85)80035-8; WINDERS PC, 1997, GROSS MOTOR SKILLS C; WISHART JG, 1995, ETIOLOGY PATHOGENESI, P57; Yang QH, 2002, LANCET, V359, P1019, DOI 10.1016/S0140-6736(02)08092-3; Yaron Y, 2001, CLIN PERINATOL, V28, P321, DOI 10.1016/S0095-5108(05)70086-5; Zachor DA, 2000, J PEDIATR GASTR NUTR, V31, P275, DOI 10.1097/00005176-200009000-00014	127	759	801	4	222	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 12	2003	361	9365					1281	1289		10.1016/S0140-6736(03)12987-X	http://dx.doi.org/10.1016/S0140-6736(03)12987-X			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	666DM	12699967				2022-12-28	WOS:000182161600022
J	Slijper, FME				Slijper, FME			Clitoral surgery and sexual outcome in intersex conditions	LANCET			English	Editorial Material							CONGENITAL ADRENAL-HYPERPLASIA; CHILDREN; HYPOSPADIAS; INDIVIDUALS; FEMALE		Sophia Childrens Univ Hosp, Erasmus MC, Gender Team, NL-3000 DR Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus MC - Sophia Children's Hospital	Slijper, FME (corresponding author), Sophia Childrens Univ Hosp, Erasmus MC, Gender Team, NL-3000 DR Rotterdam, Netherlands.							Berenbaum S, 2002, HORM RES, V58, P188; Berenbaum SA, 2000, J CLIN ENDOCR METAB, V85, P727, DOI 10.1210/jc.85.2.727; KUHNLE U, 1995, EUR J PEDIATR, V154, P708, DOI 10.1007/BF02276713; Migeon CJ, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.3.e31; MUREAU MAM, 1995, J UROLOGY, V154, P1902, DOI 10.1016/S0022-5347(01)66823-X; Slijper F, 1992, J SEX EDUC THER, V18, P200, DOI [10.1080/01614576.1992.110, DOI 10.1080/01614576.1992.110]; Slijper FME, 1998, ARCH SEX BEHAV, V27, P125, DOI 10.1023/A:1018670129611; Wisniewski AB, 2001, HORM RES, V56, P3, DOI 10.1159/000048083	8	6	7	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 12	2003	361	9365					1236	1237		10.1016/S0140-6736(03)13026-7	http://dx.doi.org/10.1016/S0140-6736(03)13026-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	666DM	12699945				2022-12-28	WOS:000182161600002
J	Moore, B; Zhou, L; Rolland, F; Hall, Q; Cheng, WH; Liu, YX; Hwang, I; Jones, T; Sheen, J				Moore, B; Zhou, L; Rolland, F; Hall, Q; Cheng, WH; Liu, YX; Hwang, I; Jones, T; Sheen, J			Role of the Arabidopsis glucose sensor HXK1 in nutrient, light, and hormonal signaling	SCIENCE			English	Article							GENE-EXPRESSION; HEXOKINASE	Glucose modulates many vital processes in photosynthetic plants. Analyses of Arabidopsis glucose insensitive2 (gin2) mutants de. ne the physiological functions of a specific hexokinase (HXK1) in the plant glucose-signaling network. HXK1 coordinates intrinsic signals with extrinsic light intensity. HXK1 mutants lacking catalytic activity still support various signaling functions in gene expression, cell proliferation, root and in florescence growth, and leaf expansion and senescence, thus demonstrating the uncoupling of glucose signaling from glucose metabolism. The gin2 mutants are also insensitive to auxin and hypersensitive to cytokinin. Plants use HXK as a glucose sensor to interrelate nutrient, light, and hormone signaling networks for controlling growth and development in response to the changing environment.	Harvard Univ, Sch Med, Dept Genet, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital	Sheen, J (corresponding author), Harvard Univ, Sch Med, Dept Genet, Boston, MA 02114 USA.	sheen@molbio.mgh.harvard.edu	Cheng, Wan-Hsing/ABH-1421-2020	Cheng, Wan-Hsing/0000-0003-4924-7429; Rolland, Filip/0000-0003-2601-0752				Dai N, 1999, PLANT CELL, V11, P1253, DOI 10.1105/tpc.11.7.1253; Gray WM, 2001, NATURE, V414, P271, DOI 10.1038/35104500; Hwang I, 2001, NATURE, V413, P383, DOI 10.1038/35096500; JANG JC, 1994, PLANT CELL, V6, P1665, DOI 10.1105/tpc.6.11.1665; Jang JC, 1997, PLANT CELL, V9, P5, DOI 10.1105/tpc.9.1.5; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; Koch KE, 1996, ANNU REV PLANT PHYS, V47, P509, DOI 10.1146/annurev.arplant.47.1.509; KOPCZAK SD, 1992, PLANT CELL, V4, P539, DOI 10.1105/tpc.4.5.539; Kraakman LS, 1999, BIOCHEM J, V343, P159, DOI 10.1042/0264-6021:3430159; Lee CK, 1999, SCIENCE, V285, P1390, DOI 10.1126/science.285.5432.1390; Li JM, 1996, SCIENCE, V272, P398, DOI 10.1126/science.272.5260.398; Lin SJ, 2002, NATURE, V418, P344, DOI 10.1038/nature00829; MA H, 1989, MOL CELL BIOL, V9, P5630, DOI 10.1128/MCB.9.12.5630; Pego JV, 2000, TRENDS PLANT SCI, V5, P531, DOI 10.1016/S1360-1385(00)01783-0; Quirino BF, 2000, TRENDS PLANT SCI, V5, P278, DOI 10.1016/S1360-1385(00)01655-1; Rolland F, 2002, PLANT CELL, V14, pS185, DOI 10.1105/tpc.010455; Rolland F, 2001, TRENDS BIOCHEM SCI, V26, P310, DOI 10.1016/S0968-0004(01)01805-9; SHEEN J, UNPUB; Stitt M, 1999, PLANT CELL ENVIRON, V22, P583, DOI 10.1046/j.1365-3040.1999.00386.x; Stulke J, 1999, CURR OPIN MICROBIOL, V2, P195, DOI 10.1016/S1369-5274(99)80034-4; SUN TP, 1992, PLANT CELL, V4, P119, DOI 10.1105/tpc.4.2.119; Vaulont S, 2000, J BIOL CHEM, V275, P31555, DOI 10.1074/jbc.R000016200; Wang KLC, 2002, PLANT CELL, V14, pS131, DOI 10.1105/tpc.001768; WINTERMANS JF, 1965, BIOCHIM BIOPHYS ACTA, V109, P448, DOI 10.1016/0926-6585(65)90170-6; Zhou L, 1998, P NATL ACAD SCI USA, V95, P10294, DOI 10.1073/pnas.95.17.10294; Zinke I, 2002, EMBO J, V21, P6162, DOI 10.1093/emboj/cdf600	26	828	888	17	218	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 11	2003	300	5617					332	336		10.1126/science.1080585	http://dx.doi.org/10.1126/science.1080585			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	665RQ	12690200				2022-12-28	WOS:000182135400058
J	Strausberg, RL; Schreiber, SL				Strausberg, RL; Schreiber, SL			From knowing to controlling: A path from Genomics to drugs using small molecule probes	SCIENCE			English	Article							STOCK SOLUTION APPROACH; CHEMICAL GENETICS; ONE-BEAD	The National Cancer Institute Initiative in Chemical Genetics is designed to encourage the development of small molecular probes. The probes are useful for activating or inactivating protein functions, thereby providing resources that help discern the functions of gene products in normal and disease cells, as well as in tissues. This initiative includes "ChemBank," a suite of informatics tools and databases aimed at promoting the development and use of chemical genetics by scientists worldwide. The information generated with such tools should provide a critical link from genomic discovery to drug development.	NCI, Canc Genom Off, Bethesda, MD 20892 USA; Harvard Univ, Dept Chem & Biol Chem, Howard Hughes Med Inst, Cambridge, MA 02115 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Center for Cancer Genomics (CCG); Harvard University; Howard Hughes Medical Institute	Strausberg, RL (corresponding author), NCI, Canc Genom Off, 31 Ctr Dr, Bethesda, MD 20892 USA.							Blackwell HE, 2001, CHEM BIOL, V8, P1167, DOI 10.1016/S1074-5521(01)00085-0; Clemons PA, 2001, CHEM BIOL, V8, P1183, DOI 10.1016/S1074-5521(01)00086-2; Mayer TU, 1999, SCIENCE, V286, P971, DOI 10.1126/science.286.5441.971; Riggins GJ, 2001, HUM MOL GENET, V10, P663, DOI 10.1093/hmg/10.7.663; Schreiber SL, 2003, CHEM ENG NEWS, V81, P51, DOI 10.1021/cen-v081n009.p051; Schreiber SL, 2000, SCIENCE, V287, P1964, DOI 10.1126/science.287.5460.1964; Shuey DJ, 2002, DRUG DISCOV TODAY, V7, P1040, DOI 10.1016/S1359-6446(02)02474-1; Straight AF, 2003, SCIENCE, V299, P1743, DOI 10.1126/science.1081412; Van Dyke T, 2002, CELL, V108, P135, DOI 10.1016/S0092-8674(02)00621-9	9	229	237	2	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 11	2003	300	5617					294	295		10.1126/science.1083395	http://dx.doi.org/10.1126/science.1083395			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	665RQ	12690189	Green Published			2022-12-28	WOS:000182135400045
J	Weissmuller, J; Viswanath, RN; Kramer, D; Zimmer, P; Wurschum, R; Gleiter, H				Weissmuller, J; Viswanath, RN; Kramer, D; Zimmer, P; Wurschum, R; Gleiter, H			Charge-induced reversible strain in a metal	SCIENCE			English	Article							SURFACE STRESS; AU(111); INTERFACE; ELECTRODES; RELAXATION; BEHAVIOR; SOLIDS	Dimension changes on the order of 0.1% or above in response to an applied voltage have been reported for many types of materials, including ceramics, polymers, and carbon nanostructures, but not, so far, for metals. We show that reversible strain amplitudes comparable to those of commercial piezoceramics can be induced in metals by introducing a continuous network of nanometersized pores with a high surface area and by controlling the surface electronic charge density through an applied potential relative to an electrolyte impregnating the pores.	Forschungszentrum Karlsruhe, Inst Nanotechnol, D-76021 Karlsruhe, Germany; Univ Saarland, Fachrichtung Tech Phys, D-6600 Saarbrucken, Germany; Graz Tech Univ, Inst Tech Phys, A-8010 Graz, Austria	Helmholtz Association; Karlsruhe Institute of Technology; Saarland University; Graz University of Technology	Weissmuller, J (corresponding author), Forschungszentrum Karlsruhe, Inst Nanotechnol, D-76021 Karlsruhe, Germany.		Weissmüller, Jörg/C-3967-2009; Kramer, Dominik/O-8771-2014	Weissmüller, Jörg/0000-0002-8958-4414; Wurschum, Roland/0000-0003-4624-4433; Kramer, Dominik/0000-0002-9761-0627; R. N., Viswanath/0000-0002-6772-7672; VISWANATH, R/0000-0002-5376-0834				Baughman RH, 1999, SCIENCE, V284, P1340, DOI 10.1126/science.284.5418.1340; Baughman RH, 1996, SYNTHETIC MET, V78, P339, DOI 10.1016/0379-6779(96)80158-5; BENESH GA, 1990, J PHYS-CONDENS MAT, V2, P9065, DOI 10.1088/0953-8984/2/46/007; Berlincourt D., 1971, ULTRASONIC TRANSDUCE, P63; CHRISTENSEN NE, 1985, PHYS REV B, V32, P6145, DOI 10.1103/PhysRevB.32.6145; Erlebacher J, 2001, NATURE, V410, P450, DOI 10.1038/35068529; Gleiter H, 2001, ACTA MATER, V49, P737, DOI 10.1016/S1359-6454(00)00221-4; Gurtin ME, 1998, PHILOS MAG A, V78, P1093, DOI 10.1080/01418619808239977; Haiss W, 1998, J ELECTROANAL CHEM, V452, P199, DOI 10.1016/S0022-0728(98)00137-5; Haiss W, 1996, LANGMUIR, V12, P4311, DOI 10.1021/la9602224; Ibach H., 1997, Surface Science Reports, V29, P193, DOI 10.1016/S0167-5729(97)00010-1; Ibach H, 1997, SURF SCI, V375, P107, DOI 10.1016/S0039-6028(96)01252-6; Lucas CA, 2002, ELECTROCHIM ACTA, V47, P3065, DOI 10.1016/S0013-4686(02)00225-6; Luth H, 1995, SURFACES INTERFACES; MACFARLANE RE, 1965, PHYS LETT, V18, P91, DOI 10.1016/0031-9163(65)90659-1; Nagy Z, 2002, ELECTROCHIM ACTA, V47, P3037, DOI 10.1016/S0013-4686(02)00223-2; Nichols RJ, 2002, SURF SCI, V513, P263, DOI 10.1016/S0039-6028(02)01510-8; Ogawa T, 2002, JPN J APPL PHYS 2, V41, pL55, DOI 10.1143/JJAP.41.L55; Park SE, 1997, J APPL PHYS, V82, P1804, DOI 10.1063/1.365983; Schmickler W, 1998, J ELECTROANAL CHEM, V453, P61, DOI 10.1016/S0022-0728(98)00133-8; Uchino K., 1997, PIEZOELECTRIC ACTUAT, P106; Weissmuller J, 1997, ACTA MATER, V45, P1899, DOI 10.1016/S1359-6454(96)00314-X; Zhang QM, 1998, SCIENCE, V280, P2101, DOI 10.1126/science.280.5372.2101	23	443	454	5	199	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 11	2003	300	5617					312	315		10.1126/science.1081024	http://dx.doi.org/10.1126/science.1081024			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	665RQ	12690195				2022-12-28	WOS:000182135400052
J	Charlson, ME; Isom, OW				Charlson, ME; Isom, OW			Care after coronary-artery bypass surgery	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AMERICAN-HEART-ASSOCIATION; QUALITY-OF-LIFE; FOLLOW-UP; CARDIAC REHABILITATION; COGNITIVE FUNCTION; ELDERLY-PATIENTS; OLDER-ADULTS; RISK-FACTOR; GRAFT; OUTCOMES		Cornell Univ, Weill Med Coll, Div Gen Internal Med, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Ctr Complementary & Integrat Med, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Cardiothorac Surg, New York, NY 10021 USA	Cornell University; Cornell University; Cornell University	Charlson, ME (corresponding author), Cornell Univ, Weill Med Coll, Div Gen Internal Med, 525 E 68th St,Box 46, New York, NY 10021 USA.	mecharl@med.cornell.edu						Alderman EL, 1997, JAMA-J AM MED ASSOC, V277, P715; Alexopoulos GS, 1997, AM J PSYCHIAT, V154, P562; Balady GJ, 2000, CIRCULATION, V102, P1069, DOI 10.1161/01.CIR.102.9.1069; Benowitz NL, 1997, J AM COLL CARDIOL, V29, P1422, DOI 10.1016/S0735-1097(97)00079-X; Berks G, 2001, COMPUT MED IMAG GRAP, V25, P1, DOI 10.1016/S0895-6111(00)00038-0; Blumenthal JA, 1997, ARCH INTERN MED, V157, P2213, DOI 10.1001/archinte.157.19.2213; Campeau L, 1999, CIRCULATION, V99, P3241, DOI 10.1161/01.CIR.99.25.3241; Campeau L, 1997, NEW ENGL J MED, V336, P153; CAVENDER JB, 1992, J AM COLL CARDIOL, V20, P287, DOI 10.1016/0735-1097(92)90092-2; Charlson M, 1999, P ASSOC AM PHYSICIAN, V111, P622, DOI 10.1046/j.1525-1381.1999.99130.x; Chen J, 2000, ARCH INTERN MED, V160, P947, DOI 10.1001/archinte.160.7.947; De Giorgio L, 2000, NEW ENGL J MED, V342, P1376; Detre KM, 2000, NEW ENGL J MED, V342, P989, DOI 10.1056/NEJM200004063421401; Domanski MJ, 2000, J AM COLL CARDIOL, V36, P1877, DOI 10.1016/S0735-1097(00)00973-6; Dressler FA, 1998, J AM COLL CARDIOL, V31, P134, DOI 10.1016/S0735-1097(97)00449-X; DUBACH P, 1989, AM J CARDIOL, V63, P530, DOI 10.1016/0002-9149(89)90894-1; Eagle KA, 1999, J AM COLL CARDIOL, V34, P1262, DOI 10.1016/S0735-1097(99)00389-7; Eikelboom JW, 1999, ANN INTERN MED, V131, P363, DOI 10.7326/0003-4819-131-5-199909070-00008; Flaker GC, 1999, J AM COLL CARDIOL, V34, P106, DOI 10.1016/S0735-1097(99)00145-X; FRASURESMITH N, 1994, JAMA-J AM MED ASSOC, V271, P1082; FRASURESMITH N, 1993, JAMA-J AM MED ASSOC, V270, P1819, DOI 10.1001/jama.270.15.1819; Glassman AH, 2002, JAMA-J AM MED ASSOC, V288, P701, DOI 10.1001/jama.288.6.701; GOLD JP, 1995, J THORAC CARDIOV SUR, V110, P1302, DOI 10.1016/S0022-5223(95)70053-6; GOLDMAN S, 1994, CIRCULATION, V89, P1138, DOI 10.1161/01.CIR.89.3.1138; Graham IM, 1997, JAMA-J AM MED ASSOC, V277, P1775, DOI 10.1001/jama.277.22.1775; Hartman GS, 1996, ANESTH ANALG, V83, P701, DOI 10.1097/00000539-199610000-00007; Hedback B, 2001, J CARDIOVASC RISK, V8, P153, DOI 10.1097/00043798-200106000-00006; Herlitz J, 1995, EUR HEART J, V16, P1825; Hlatky MA, 1997, CIRCULATION, V96, P11; Hlatky MA, 1997, NEW ENGL J MED, V336, P92, DOI 10.1056/NEJM199701093360203; Hongo RH, 2002, J AM COLL CARDIOL, V40, P231, DOI 10.1016/S0735-1097(02)01954-X; Hoogwerf BJ, 1999, DIABETES, V48, P1289, DOI 10.2337/diabetes.48.6.1289; KATZ ES, 1992, J AM COLL CARDIOL, V20, P70, DOI 10.1016/0735-1097(92)90139-E; Khatri P, 1999, HEALTH PSYCHOL, V18, P301, DOI 10.1037/0278-6133.18.3.301; LOOP FD, 1986, NEW ENGL J MED, V314, P1, DOI 10.1056/NEJM198601023140101; Mahanna EP, 1996, ANN THORAC SURG, V61, P1342, DOI 10.1016/0003-4975(95)01095-5; Milani RV, 1998, AM J CARDIOL, V81, P1233, DOI 10.1016/S0002-9149(98)00121-0; Moller JT, 1998, LANCET, V351, P1742; Moller JT, 1998, LANCET, V351, P857, DOI 10.1016/S0140-6736(97)07382-0; Newman MF, 2001, NEW ENGL J MED, V344, P395, DOI 10.1056/NEJM200102083440601; NEWMAN S, 1989, J PSYCHOSOM RES, V33, P227, DOI 10.1016/0022-3999(89)90050-0; Oosterga M, 2001, AM J CARDIOL, V87, P542, DOI 10.1016/S0002-9149(00)01428-4; Oxman TE, 1997, J GERONTOL B-PSYCHOL, V52, pP1, DOI 10.1093/geronb/52B.1.P1; Pasternak RC, 2002, CIRCULATION, V106, P1024, DOI 10.1161/01.CIR.0000032466.44170.44; PEARSON T, 1994, CIRCULATION, V90, P3125, DOI 10.1161/01.CIR.90.6.3125; PEDERSEN TR, 1994, LANCET, V344, P1383; Peterson JC, 2002, AM J GERIAT PSYCHIAT, V10, P192, DOI 10.1176/appi.ajgp.10.2.192; Pirraglia PA, 1999, INT J GERIATR PSYCH, V14, P668, DOI 10.1002/(SICI)1099-1166(199908)14:8<668::AID-GPS988>3.0.CO;2-9; Pocock SJ, 1996, CIRCULATION, V94, P135, DOI 10.1161/01.CIR.94.2.135; *POST COR ART BYP, 1997, NEW ENGL J MED, V337, P1859; Selnes OA, 1999, ANN THORAC SURG, V67, P1669, DOI 10.1016/S0003-4975(99)00258-1; SMITH SC, 1995, J AM COLL CARDIOL, V26, P292, DOI 10.1016/0735-1097(95)90846-G; Stern A, 1999, AM HEART J, V138, P746, DOI 10.1016/S0002-8703(99)70191-2; van Domburg RT, 2000, J AM COLL CARDIOL, V36, P878, DOI 10.1016/S0735-1097(00)00810-X; Voors AA, 1996, CIRCULATION, V93, P42, DOI 10.1161/01.CIR.93.1.42; WassertheilSmoller S, 1996, ARCH INTERN MED, V156, P553, DOI 10.1001/archinte.156.5.553; Wenger NK, 1995, AHCPR PUBLICATION; Wenger NK, 1995, AHCPR PUBLICATION, P1; WILLIAMSRUSSO P, 1995, JAMA-J AM MED ASSOC, V274, P44, DOI 10.1001/jama.274.1.44; Yusuf S, 2000, NEW ENGL J MED, V342, P145; [No title captured]	61	27	31	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 10	2003	348	15					1456	1463		10.1056/NEJMcp010691	http://dx.doi.org/10.1056/NEJMcp010691			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	665CU	12686703				2022-12-28	WOS:000182102700007
J	Decosas, J				Decosas, J			HIV prevention and treatment in South Africa: affordable and desirable	LANCET			English	Editorial Material									Plan Ghana, Plan W Africa Reg Off, Accra, Ghana		Decosas, J (corresponding author), Plan Ghana, Plan W Africa Reg Off, PMB Osu Main PO, Accra, Ghana.							*ACT SOC S AFR, 2002, AIDS DEM MOD ACT SOC; FASSIN D, 2003, BRIT MED J, V320, P495; Galvao J, 2002, LANCET, V360, P1862, DOI 10.1016/S0140-6736(02)11775-2; GEFFEN N, 2003, 28 CSSR U CAP TOWN; *HLTH SYST TRUST, 2002, INT FIND PMTCT PIL S; Meda N, 2002, AIDS, V16, P2323, DOI 10.1097/00002030-200211220-00013; World Health Organization, 2002, WORLD HLTH REPORT 20	7	5	5	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 5	2003	361	9364					1146	1147		10.1016/S0140-6736(03)12966-2	http://dx.doi.org/10.1016/S0140-6736(03)12966-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	664ZF	12686033				2022-12-28	WOS:000182094600004
J	Michalek, J; Collins, RH; Hill, BJ; Brenchley, JM; Douek, DC				Michalek, J; Collins, RH; Hill, BJ; Brenchley, JM; Douek, DC			Identification and monitoring of graft-versus-host specific T-cell clone in stem cell transplantation	LANCET			English	Article							DISEASE	Allogeneic haemopoietic stem cell transplantation can be complicated by acute graft-versus-host disease (GVHD). If the alloreactive T-cell clones responsible for this disorder could be identified before stem cell transplantation, they could be quantitatively monitored afterwards to allow initiation of immunosuppression before GVHD becomes apparent. We identified an alloreactive CD4(+) T-cell clone from a donor before stem cell transplantation, and then monitored its frequency in the recipient's peripheral blood after transplantation by use of clonotypic quantitative real-time PCR. Greatly increased concentrations of this clone (nearly 100% of circulating CD4(+) T cells) preceded and closely correlated with the onset of clinical GVHD, suggesting that a sole alloreactive T-cell clone was responsible for initiation of this disease in vivo. This simple identification and monitoring of potentially GVHD-causing clones can be undertaken before stem cell transplantation with no previous knowledge of the alloantigen responsible, and could allow earlier diagnosis and intervention in GVHD.	NIAID, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA; Univ Texas, SW Med Ctr, Ctr Canc Immunobiol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Bone Marrow Transplant Unit, Dallas, TX USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Douek, DC (corresponding author), NIAID, Vaccine Res Ctr, NIH, 40 Convent Dr, Bethesda, MD 20892 USA.		Brenchley, Jason/AAC-5085-2019	Brenchley, Jason/0000-0001-8357-2984				Andre-Schmutz I, 2002, LANCET, V360, P130, DOI 10.1016/S0140-6736(02)09413-8; Dickinson AM, 2002, NAT MED, V8, P410, DOI 10.1038/nm0402-410; Douek DC, 2002, J IMMUNOL, V168, P3099, DOI 10.4049/jimmunol.168.6.3099; Murphy WJ, 1999, CURR OPIN IMMUNOL, V11, P509, DOI 10.1016/S0952-7915(99)00002-3; Mutis T, 1999, NAT MED, V5, P839, DOI 10.1038/10563	5	66	93	0	6	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 5	2003	361	9364					1183	1185		10.1016/S0140-6736(03)12917-0	http://dx.doi.org/10.1016/S0140-6736(03)12917-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	664ZF	12781582				2022-12-28	WOS:000182094600013
J	Butler, D				Butler, D			French researchers demand radical overhaul of funding	NATURE			English	News Item																			0	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 1	2003	423	6935					6	6		10.1038/423006b	http://dx.doi.org/10.1038/423006b			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	673CG	12721591	Bronze			2022-12-28	WOS:000182561600009
J	Butler, D				Butler, D			Commission lays foundations for rise in research spending	NATURE			English	News Item																			0	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 1	2003	423	6935					6	6		10.1038/423006a	http://dx.doi.org/10.1038/423006a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	673CG	12721591	Bronze			2022-12-28	WOS:000182561600008
